Page last updated: 2024-10-20

uric acid and Gout

uric acid has been researched along with Gout in 4404 studies

Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.

Gout: Metabolic disorder characterized by recurrent acute arthritis, hyperuricemia and deposition of sodium urate in and around the joints, sometimes with formation of URIC ACID calculi.

Research Excerpts

ExcerptRelevanceReference
"To assess efficacy, safety, pharmacokinetics, and immunogenicity of pegloticase plus methotrexate (MTX) versus pegloticase plus placebo cotreatment for uncontrolled gout in a randomized, placebo-controlled, double-blind trial."9.69A Randomized, Placebo-Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings. ( Botson, JK; Chamberlain, J; Grewal, S; La, D; LaMoreaux, B; LoCicero, K; Majjhoo, A; Obermeyer, K; Ong, S; Parikh, N; Peterson, J; Saag, K; Sainati, S; Tesser, JRP; Verma, S; Weinblatt, ME; Xin, Y, 2023)
"To determine whether placebo is non-inferior to low-dose colchicine for reducing gout flares during the first 6 months of allopurinol using the 'start-low go-slow' dose approach."9.69Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial. ( Chapman, PT; Dalbeth, N; Drake, J; Frampton, C; Haslett, J; Horne, A; Mihov, B; Stamp, L, 2023)
"To investigate whether serum urate levels, number of gout flares, and tophi burden are related to death from cardiovascular (CV) causes after treatment with febuxostat or allopurinol in patients with gout from the Cardiovascular Safety of Febuxostat or Allopurinol in Patients With Gout and Cardiovascular Comorbidities (CARES) trial."9.51Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial. ( Becker, MA; Borer, JS; Castillo, M; Gorelick, PB; Gunawardhana, L; Hunt, B; Saag, KG; Whelton, A; White, WB, 2022)
"The predominant mechanism driving hyperuricemia in gout is renal uric acid underexcretion; however, the standard urate-lowering therapy (ULT) recommendation is first-line xanthine oxidase inhibitor (XOI), irrespective of the cause of hyperuricemia."9.51Superiority of Low-Dose Benzbromarone to Low-Dose Febuxostat in a Prospective, Randomized Comparative Effectiveness Trial in Gout Patients With Renal Uric Acid Underexcretion. ( Chen, Y; Cheng, X; Cui, L; Dalbeth, N; He, Y; Hu, S; Ji, A; Li, C; Li, H; Liu, Z; Lu, J; Ma, L; Qi, H; Ran, Z; Sun, M; Terkeltaub, R; Wang, C; Xue, X; Yan, F; Yu, Q; Yuan, X, 2022)
"The present study compared the efficacy and safety of low-dose febuxostat versus allopurinol in chronic kidney disease (CKD) patients complicated with hyperuricemia (HUA)."9.51Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study. ( Cao, B; Yang, N, 2022)
" One hundred and ninety-seven adults with gout and SUA levels ≥8 mg/dL were randomized to febuxostat or allopurinol in a 1:1 ratio for 36 weeks."9.51Effects of intensive urate lowering therapy with febuxostat in comparison with allopurinol on pulse wave velocity in patients with gout and increased cardiovascular risk: the FORWARD study. ( Borghi, C; Desideri, G; Gerritsen, M; Giannattasio, C; Nurmohamed, MT; Rajzer, M; Tausche, AK, 2022)
"Early allopurinol initiation during an acute gout flare did not lead to significant changes in time to resolution, flare recurrence, and inflammatory markers."9.51Early versus Late Allopurinol Initiation in Acute Gout Flare (ELAG): a randomized controlled trial. ( Manavathongchai, S; Pongsittisak, W; Satpanich, P, 2022)
"Gout is common in patients with heart failure (HF), and sodium-glucose cotransporter 2 inhibitors, a foundational treatment for HF, reduce uric acid levels."9.41Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER. ( Butt, JH; Claggett, BL; de Boer, RA; Desai, AS; Docherty, KF; Hernandez, AF; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Lam, CSP; Langkilde, AM; Martinez, FA; McMurray, JJV; Petersson, M; Ponikowski, P; Sabatine, MS; Shah, SJ; Solomon, SD; Vaduganathan, M, 2023)
"Thirty-nine subjects with persistent hyperuricemia were randomized to receive curcumin (500-mg capsules twice daily, 20 subjects) or placebo (19 subjects)."9.41Effect of Curcumin on Serum Urate in Asymptomatic Hyperuricemia: A Randomized Placebo-Controlled Trial. ( Asavatanabodee, P; Bupparenoo, P; Chaiamnuay, S; Narongroeknawin, P; Pakchotanon, R, 2021)
"To examine the efficacy and safety of pegloticase in combination with methotrexate (MTX) in patients with uncontrolled gout in an exploratory, open-label clinical trial (ClinicalTrials."9.41Pegloticase in Combination With Methotrexate in Patients With Uncontrolled Gout: A Multicenter, Open-label Study (MIRROR). ( Bennett, R; Botson, JK; Kenney, HM; LaMoreaux, B; Obermeyer, K; Peloso, PM; Peterson, J; Tesser, JRP; Weinblatt, ME, 2021)
"Our objective was to determine whether initiation of febuxostat during an acute gout flare prolongs the current episode."9.41Initiation of febuxostat for acute gout flare does not prolong the current episode: a randomized clinical trial. ( Cui, X; Geng, H; Jia, E; Jiang, Y; Li, B; Ma, W; Qiu, X; Wei, J; Xiao, M; Xiao, Y; Xie, J; Yao, X; Zhang, J; Zhang, Y; Zhong, L, 2021)
" We evaluated the efficacy and safety of dotinurad versus febuxostat, a widely used drug in Japan, in hyperuricemic Japanese patients with or without gout."9.34A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout. ( Furuno, K; Hosoya, T; Kanda, S, 2020)
"Dotinurad 2 mg was verified to have a non-inferior serum uric acid lowering effect compared with benzbromarone 50 mg, in Japanese hyperuricemic patients with or without gout."9.34Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study. ( Fushimi, M; Hosoya, T; Ohashi, T; Sano, T; Sasaki, T, 2020)
"Febuxostat and allopurinol are urate-lowering therapies used to treat patients with gout."9.34Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. ( De Caterina, R; Findlay, E; Ford, I; Hallas, J; Hawkey, CJ; MacDonald, TM; Mackenzie, IS; McMurray, JJV; Nuki, G; Perez-Ruiz, F; Ralston, SH; Robertson, M; Walters, M; Webster, J, 2020)
"To compare the efficacy and safety of low-dose febuxostat with low-dose benzbromarone in patients with primary gout, a randomized controlled, open-label trial was performed among male patients with primary gout for urate-lowering therapy (ULT) in a dedicated gout clinic in China."9.30Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort. ( Cheng, X; Cui, L; He, Y; Ji, A; Li, C; Li, H; Liang, N; Ma, L; Sun, M; Sun, R; Sun, W; Wang, C; Wu, X; Xu, T; Xue, X; Yuan, X; Zhang, H, 2019)
"To assess the efficacy and safety of febuxostat extended release (XR) and immediate release (IR) in patients with gout and normal or impaired renal function."9.30Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study. ( Becker, MA; Castillo, M; Gunawardhana, L; Hunt, B; Kisfalvi, K; Saag, KG; Whelton, A, 2019)
"To examine whether allopurinol dose escalation to achieve serum urate (SU) target can influence bone erosion or monosodium urate (MSU) crystal deposition, as measured by dual-energy computed tomography (DECT) in patients with gout."9.30Effects of Allopurinol Dose Escalation on Bone Erosion and Urate Volume in Gout: A Dual-Energy Computed Tomography Imaging Study Within a Randomized, Controlled Trial. ( Aati, O; Allan, J; Billington, K; Dalbeth, N; Doyle, A; Drake, J; Frampton, C; Horne, A; Stamp, LK; Tan, P, 2019)
"To determine whether febuxostat with stepwise dose increase is as useful as colchicine prophylaxis in reducing gout flares during the initial introduction of urate-lowering therapy in patients with gout in comparison with febuxostat with no dose titration."9.27Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study. ( Fujimori, S; Hidaka, Y; Ide, Y; Inoue, K; Kim, H; Sugimoto, M; Tamaki, S; Taniguchi, A; Yamamoto, T; Yamanaka, H, 2018)
" We did a post-hoc analysis of recorded on-study gout attacks and plasma uric acid concentrations according to treatment allocation."9.27Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study. ( Ansquer, JC; Best, JD; Buizen, L; d'Emden, MC; Davis, TME; Feher, MD; Flack, J; Foucher, C; Gebski, V; Hedley, J; Jenkins, AJ; Keech, AC; Kesaniemi, YA; Li, L; McGill, N; Scott, RS; Sullivan, DR; Waldman, B, 2018)
"Gout patients do not routinely achieve optimal outcomes related in part to suboptimal administration of urate lowering therapy (ULT) including first-line xanthine oxidase inhibitors allopurinol or febuxostat."9.27Design and Rationale for the Veterans Affairs "Cooperative Study Program 594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat" Trial. ( Brittan, K; Brophy, M; Davis-Karim, A; Henrie, AM; Mikuls, TR; Neogi, T; Newcomb, J; O'Dell, JR; Palevsky, PM; Pillinger, MH; Pittman, D; Taylor, TH; Timilsina, S; Wu, H, 2018)
"The objective of the study was to evaluate the effect of lesinurad, a selective uric acid uptake inhibitor, alone and in combination with the xanthine oxidase inhibitor allopurinol, on serum uric acid and urinary urate excretion in patients with gout and hyperuricemia."9.27The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout. ( Baumgartner, S; Kerr, B; Manhard, K; Quart, B; Shen, Z; Yeh, LT, 2018)
"Verinurad (RDEA3170) is a selective uric acid reabsorption inhibitor in clinical development for treatment of hyperuricemia and gout."9.27Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout. ( Clauson, V; Gillen, M; Hall, J; Kankam, M; Lee, C; Liu, S; Miner, JN; Nguyen, M; Shen, Z; Walker, S; Wilson, D; Yang, X, 2018)
"Japanese male subjects aged 21-65 years with gout (n = 37) or asymptomatic hyperuricaemia (n = 35) and serum urate (sUA) ⩾8 mg/dl were randomized to febuxostat (10, 20, 40 mg) in combination with verinurad (2."9.27Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study. ( Gillen, M; Hall, J; Ito, Y; Liu, S; Shen, Z; Shiramoto, M; Yamamoto, A; Yan, X, 2018)
"The aim of this research work was to observe and analyze the efficacy of febuxostat and allopurinol in the treatment of gout with hyperuricemia."9.27The efficacy of febuxostat and allopurinol in the treatment of gout with hyperuricemia. ( Wang, S, 2018)
"This multicenter, open-label study evaluated the efficacy and safety of long-term twice-daily oral topiroxostat administration in patients with or  without gout."9.27Multicenter, Open-Label Study of Long-Term Topiroxostat (FYX-051) Administration in Japanese Hyperuricemic Patients with or Without Gout. ( Hosoya, T; Ishikawa, T; Ogawa, Y; Ohashi, T; Sakamoto, R, 2018)
"To examine the relationship among canakinumab, a monoclonal antibody targeting IL-1β; serum uric acid levels; and the incidence of gout attacks."9.27Relationship of Interleukin-1β Blockade With Incident Gout and Serum Uric Acid Levels: Exploratory Analysis of a Randomized Controlled Trial. ( Everett, BM; Glynn, RJ; Libby, P; MacFadyen, JG; Ridker, PM; Solomon, DH; Thuren, T, 2018)
" People with gout receiving at least creatinine clearance (CrCL)-based allopurinol dose for ≥1 month and SU ≥6 mg/dL were recruited."9.24A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. ( Barclay, ML; Chapman, PT; Dalbeth, N; Drake, J; Frampton, C; Horne, A; Stamp, LK; Tan, P, 2017)
"To investigate the efficacy and safety of lesinurad in combination with febuxostat in a 12-month phase III trial in patients with tophaceous gout."9.24Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial. ( Adler, S; Baumgartner, S; Bhakta, N; Dalbeth, N; Fung, M; Jones, G; Khanna, D; Kopicko, J; Perez-Ruiz, F; Storgard, C; Terkeltaub, R, 2017)
"There is little evidence guiding selection of nondiuretic, antihypertensive agents with a goal of lowering uric acid (SUA) and minimizing gout risk."9.24Metoprolol Increases Uric Acid and Risk of Gout in African Americans With Chronic Kidney Disease Attributed to Hypertension. ( Appel, LJ; Juraschek, SP; Miller, ER, 2017)
"In this double-blind, placebo-controlled study, 314 subjects with hyperuricemia (serum uric acid [UA] level of ≥7."9.24Effects of Febuxostat in Early Gout: A Randomized, Double-Blind, Placebo-Controlled Study. ( Choi, HK; Dalbeth, N; Gunawardhana, L; Hunt, B; MacDonald, PA; Palmer, WE; Saag, KG; Thienel, U, 2017)
"Our objectives were to determine whether a change in serum uric acid (sUA) resulted in a corresponding change in the fractional excretion of uric acid (FEUA) and whether the renal response was different in patients with gout versus healthy subjects."9.24Patients with gout differ from healthy subjects in renal response to changes in serum uric acid. ( Liu, S; Miner, JN; Perez-Ruiz, F, 2017)
"Lesinurad added to allopurinol demonstrated superior sUA lowering versus allopurinol-alone therapy and lesinurad 200 mg was generally well tolerated in patients with gout warranting additional therapy."9.24Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). ( Adler, S; Bardin, T; Baumgartner, S; Bhakta, N; Fung, M; Keenan, RT; Khanna, PP; Kopicko, J; So, A; Storgard, C, 2017)
"Topiroxostat, a selective xanthine oxidoreductase inhibitor, is used in Japan for the treatment of hyperuricemic patients with or without gout."9.24Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: a randomized, double-blinded, controlled phase 2b study. ( Hosoya, T; Ohashi, T; Sasaki, T, 2017)
" Cox proportional hazard ratio was used to compare the risk of CAD in gout patients taking allopurinol or/and benzbromarone with those taking neither drug."9.24Allopurinol, benzbromarone and risk of coronary heart disease in gout patients: A population-based study. ( Chiang, SJ; Daimon, M; Ho, Y; Lin, HC; Uang, YS; Wang, CH; Wang, LH, 2017)
"We aimed to assess the relative efficacy and safety of dotinurad (2 mg), benzbromarone (50 mg), and febuxostat (40 mg) in hyperuricemic patients with or without gout."9.22Comparative efficacy and safety of dotinurad, febuxostat, and benzbromarone in hyperuricemic patients with or without gout: A network meta-analysis of randomized controlled trials. ( Lee, YH; Song, GG, 2022)
"We aimed to assess the relative efficacy and safety of topiroxostat at different dosages in hyperuricemic patients with or without gout."9.22Comparative efficacy and safety of topiroxostat at different dosages in hyperuricemic patients with or without gout: A network meta-analysis of randomized controlled trials. ( Lee, YH; Song, GG, 2022)
"Increased serum uric acid (SUA) levels are commonly seen in patients with metabolic syndrome and are widely accepted as risk factors for hypertension, gout, non-alcoholic fatty liver disease, chronic kidney disease (CKD), and cardiovascular diseases."9.22Uric acid in metabolic syndrome: Does uric acid have a definitive role? ( Copur, S; Demiray, A; Kanbay, M, 2022)
"Uric acid (UA) is the final product of purine metabolism in the human body, and impaired purine metabolism can increase the uric acid in serum, finally resulting in hyperuricemia (HUA)."9.22Excess Uric Acid Induces Gouty Nephropathy Through Crystal Formation: A Review of Recent Insights. ( Dong, B; Geng, Z; Mei, Y; Xu, L, 2022)
"This phase IIIB study compared the efficacy and safety of febuxostat and allopurinol in gout patients with or without tophi who were HLA-B*5801 negative."9.22Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study. ( Chen, CJ; Chen, DY; Hsu, PN; Lai, JH; Lin, HY; Yu, KH, 2016)
"Control of serum uric acid (sUA) levels is very important during chemotherapy in patients with malignant tumors, as the risks of tumor lysis syndrome (TLS) and renal events are increased with increasing levels of sUA."9.22Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol. ( Fujimaki, K; Fujisaki, T; Gemba, K; Goto, T; Kaneko, M; Kawai, Y; Kiguchi, T; Kirito, K; Maemondo, M; Nakajima, A; Okamoto, M; Takeda, K; Tamura, K; Ueda, T, 2016)
"In Japan, although topiroxostat, a selective xanthine oxidoreductase inhibitor, has been used for the treatment of patients with hyperuricemia including gout, no published randomized controlled studies evaluating the dose-dependent relationship with respect to the serum urate-lowering efficacy have been reported."9.22Clinical efficacy and safety of topiroxostat in Japanese male hyperuricemic patients with or without gout: an exploratory, phase 2a, multicentre, randomized, double-blind, placebo-controlled study. ( Hashimoto, H; Hosoya, T; Ohashi, T; Sakamoto, R; Sasaki, T, 2016)
" Patients who had inadequate serum urate levels (a gout patient: serum urate level ≥416·4 μmol/L; an asymptomatic hyperuricemic patient with specific complications (urinary lithiasis, hypertension, hyperlipidemia and/or diabetes): serum urate level ≥475·8 μmol/L; and an asymptomatic hyperuricemic patient with no specific complications: serum urate level ≥535·3 μmol/L) were randomized to topiroxostat 120 mg/day or allopurinol 200 mg/day, with an equal allocation ratio, for 16 weeks."9.22Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study. ( Hashimoto, H; Hosoya, T; Ogawa, Y; Ohashi, T; Sakamoto, R, 2016)
"To determine whether a pharmacist-staffed gout management program is more effective than usual care in achieving target serum uric acid (sUA) levels in gout patients."9.22A Pharmacist-Staffed, Virtual Gout Management Clinic for Achieving Target Serum Uric Acid Levels: A Randomized Clinical Trial. ( Avins, A; Goldfien, R; Jacobson, A; Ng, M; Pressman, A, 2016)
"Excess body burden of uric acid promotes gout."9.22Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. ( Girardet, JL; Hagerty, DT; Hyndman, D; Iverson, C; Liu, S; Manhard, K; Miner, JN; Nanavati, P; Quart, B; Shen, Z; Tan, PK; Terkeltaub, R; Yeh, LT, 2016)
"Traditionally, allopurinol is not initiated during an acute gout attack to avoid prolonging the painful arthritis."9.20Does starting allopurinol prolong acute treated gout? A randomized clinical trial. ( Collamer, A; Higgs, J; Hill, EM; Sit, M; Sky, K, 2015)
"To compare the efficiency and safety of febuxostat with those of allopurinol in Chinese patients with gout and hyperuricemia."9.20A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia. ( Chen, S; Ji, H; Ji, Q; Lin, J; Liu, B; Liu, H; Liu, P; Liu, X; Lu, Y; Ming, J; Peng, Y; Wang, J; Wang, Y; Xu, S; Zhang, Y, 2015)
"Allopurinol is the most widely prescribed serum uric acid-lowering therapy (ULT) in gout."9.20An open-label, 6-month study of allopurinol safety in gout: The LASSO study. ( Baumgartner, S; Becker, MA; Choi, HK; Cravets, M; Dalbeth, N; Fitz-Patrick, D; Storgard, C, 2015)
"We prospectively evaluated whether an effective 12-month uric acid-lowering therapy (ULT) with the available xanthine oxidase (XO) inhibitors allopurinol and febuxostat in patients with chronic tophaceous gout has an impact on oxidative stress and/or vascular function."9.19As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout. ( Aringer, M; Bielitz, C; Christoph, M; Forkmann, M; Kopprasch, S; Richter, U; Tausche, AK; Wunderlich, C, 2014)
"Topiroxostat, a selective xanthine oxidase inhibitor, shows effective reduction in the serum urate level in hyperuricemic patients with or without gout."9.19Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout. ( Fujimori, S; Hara, S; Hisatome, I; Hosoya, T; Nomura, S; Ohno, I; Uchida, S; Yamamoto, T, 2014)
"Gout patients (n = 512) with serum uric acid (sUA) concentrations of at least 8."9.19An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia. ( Bao, C; Du, H; Gu, J; Huang, A; Huang, X; Jiang, L; Li, J; Li, X; Li, Z; Liu, Y; Zhang, Y; Zhang, Z; Zhao, D; Zhu, P; Zuo, X, 2014)
"The aim of this study was to evaluate the pharmacodynamics (PDs), pharmacokinetics (PKs) and safety of lesinurad (selective uric acid reabsorption inhibitor) in combination with febuxostat (xanthine oxidase inhibitor) in patients with gout."9.19Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia. ( Baumgartner, S; Fleischmann, R; Hingorani, V; Kerr, B; Manhard, K; Miner, JN; Polvent, E; Quart, B; Shen, Z; Suster, M; Yeh, LT, 2014)
"The aims of this study were to establish whether, in patients with gout, MPO is released from neutrophils and urate is oxidized to allantoin and if these effects are attenuated by allopurinol."9.19Myeloperoxidase and oxidation of uric acid in gout: implications for the clinical consequences of hyperuricaemia. ( Drake, J; Forbes, LV; Kettle, AJ; Khalilova, IS; Stamp, LK; Turner, R; Zhang, M, 2014)
"To evaluate the efficacy and safety of IL-1 inhibitor rilonacept (IL-1 Trap) for gout flare (GF) prevention during initiation of uric acid-lowering therapy (ULT) with allopurinol in a multiregional phase 3 clinical trial."9.17Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. ( Evans, RR; Fouche, L; King-Davis, S; Luo, SF; Mitha, E; Schumacher, HR; Wang, J; Weinstein, SP; Yancopoulos, GD, 2013)
"Assess the impact of urate-lowering therapy on renal function in subjects with gout who were treated with febuxostat for ≤ 48 months."9.17Preservation of renal function during gout treatment with febuxostat: a quantitative study. ( Chefo, S; Gunawardhana, L; MacDonald, PA; Whelton, A, 2013)
"To compare the characteristics of female versus male gout patients and assess urate-lowering efficacy and safety of febuxostat or allopurinol treatment in women with gout."9.16Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. ( Becker, MA; Chefo, S; Chohan, S; Jackson, RL; MacDonald, PA, 2012)
"0 mg/dL) gout subjects were enrolled in the 6-month, double-blind, randomized, comparative CONFIRMS trial and randomized, 1:1:1, to receive febuxostat, 40 mg or 80 mg, or allopurinol (200 mg or 300 mg based on renal function) once daily."9.16The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age. ( Hunt, B; Jackson, RL; MacDonald, PA, 2012)
"To evaluate the efficacy and safety of the interleukin-1 inhibitor rilonacept (interleukin-1 Trap) for gout flare prevention during initiation of uric acid-lowering therapy (ULT)."9.16Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. ( Clower, J; Evans, RR; Jennings, W; Saag, KG; Schumacher, HR; Terkeltaub, R; Wang, J; Weinstein, SP; Yancopoulos, GD, 2012)
"To determine the efficacy and safety of increasing the allopurinol dose above the proposed creatinine clearance-based dose in patients with gout."9.15Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. ( Barclay, ML; Chapman, PT; Frampton, C; James, J; O'Donnell, JL; Stamp, LK; Zhang, M, 2011)
"To investigate the pharmacokinetic and pharmacodynamic interaction between probenecid and oxypurinol (the active metabolite of allopurinol) in patients with gout."9.15Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. ( Day, RO; Graham, GG; McLachlan, AJ; Stocker, SL; Williams, KM, 2011)
"Hyperuricemia of gout can arise due to either overproduction or underexcretion of uric acid."9.15Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors. ( Goldfarb, DS; Gunawardhana, L; Hunt, B; MacDonald, PA, 2011)
"Febuxostat or allopurinol was administered to patients with hyperuricemia including gout for 8 weeks to compare the efficacy and safety of these drugs."9.15An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: p ( Fujimori, S; Hada, T; Hosoya, T; Kamatani, N; Kohri, K; Matsuzawa, Y; Nakamura, T; Ueda, T; Yamamoto, T; Yamanaka, H, 2011)
": A multicenter study with randomized, placebo-controlled, double-blind, parallel-group comparison was carried out to evaluate the efficacy and safety of febuxostat in 103 patients with hyperuricemia (including patients with gout) in Japan."9.15Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. ( Fujimori, S; Hada, T; Hisashi, Y; Hosoya, T; Kamatani, N; Kenjiro, K; Kohri, K; Matsuzawa, Y; Nakamura, T; Naoyuki, K; Shin, F; Takanori, U; Tatsuo, H; Tetsuya, Y; Toshikazu, H; Toshitaka, N; Ueda, T; Yamamoto, T; Yamanaka, H; Yuji, M, 2011)
"A multicenter study with randomized, placebo-controlled, double-blind, parallel, intergroup comparison was carried out to evaluate the dose-response relationship, efficacy, and safety of febuxostat in 202 patients with hyperuricemia (including patients with gout) in Japan."9.15Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study. ( Fujimori, S; Hada, T; Hisashi, Y; Hosoya, T; Kamatani, N; Kenjiro, K; Kohri, K; Matsuzawa, Y; Nakamura, T; Naoyuki, K; Shin, F; Takanori, U; Tatsuo, H; Tetsuya, Y; Toshikazu, H; Toshitaka, N; Ueda, T; Yamamoto, T; Yamanaka, H; Yuji, M, 2011)
"Febuxostat was administered to patients with hyperuricemia including gout in Japan to compare its efficacy and safety with those of allopurinol."9.15An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phas ( Fujimori, S; Hada, T; Hisashi, Y; Hosoya, T; Kamatani, N; Kenjiro, K; Kohri, K; Matsuzawa, Y; Nakamura, T; Naoyuki, K; Shin, F; Takanori, U; Tatsuo, H; Tetsuya, Y; Toshikazu, H; Toshitaka, N; Ueda, T; Yamamoto, T; Yamanaka, H; Yuji, M, 2011)
"In previous clinical studies of hyperuricemia including gout, although serum uric acid (sUA) levels reduced to 6."9.15Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout. ( Fujimori, S; Hada, T; Hosoya, T; Kamatani, N; Kohri, K; Matsuzawa, Y; Nakamura, T; Ueda, T; Yamamoto, T; Yamanaka, H, 2011)
"This 5-yr study assessed urate-lowering and clinical efficacy and safety of long-term febuxostat therapy in subjects with gout."9.14Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. ( Becker, MA; Lademacher, C; Lloyd, E; MacDonald, PA; Schumacher, HR, 2009)
"The purpose of this study was to compare urate-lowering (UL) efficacy and safety of daily febuxostat and allopurinol in subjects with gout and serum urate (sUA) > or = 8."9.14The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. ( Becker, MA; Espinoza, LR; Lademacher, C; Lloyd, E; MacDonald, P; Schumacher, HR; Wells, AF, 2010)
"To establish a benchmark for gout control using the proportion of patients with serum uric acid (SUA) < 0."9.14More allopurinol is needed to get gout patients < 0.36 mmol/l: a gout audit in the form of a before-after trial. ( Arroll, B; Ben, C; Bennett, M; Dalbeth, N; Hettiarachchi, D; Shelling, G, 2009)
"To investigate the efficacy and tolerability of allopurinol as the first-choice antihyperuricaemic treatment for gout, and compare the efficacy and tolerability of benzbromarone and probenecid as second-choice treatment."9.14Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. ( Brouwers, JR; Delsing, J; Griep, EN; Hoekstra, M; Jansen, TL; Reinders, MK; van de Laar, MA; van Roon, EN, 2009)
"To compare the urate-lowering efficacy and safety of febuxostat, allopurinol, and placebo in a large group of subjects with hyperuricemia and gout, including persons with impaired renal function."9.13Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. ( Becker, MA; Hunt, B; Joseph-Ridge, N; Lademacher, C; Macdonald, PA; Schumacher, HR; Streit, J; Wortmann, RL, 2008)
"To evaluate the major cardiovascular (CV) events of febuxostat compared to allopurinol for the treatment of gout or asymptomatic hyperuricemia."9.12The major cardiovascular events of febuxostat versus allopurinol in treating gout or asymptomatic hyperuricemia: a systematic review and meta-analysis. ( Li, H; Sun, J; Wang, M; Wen, C; Xie, Z; Zhang, M; Zhang, Y; Zhao, T, 2021)
" Elevated uric acid levels are risk factors for gout, hypertension, and chronic kidney diseases."9.12Uric Acid in Inflammation and the Pathogenesis of Atherosclerosis. ( Kimura, Y; Kono, H; Tsukui, D, 2021)
"The description of gout dates back almost 5000 years, and scientific interest in uric acid increased when it was found to be involved in the pathogenesis of gout."9.12The Impact of Uric Acid and Hyperuricemia on Cardiovascular and Renal Systems. ( Agnoletti, D; Borghi, C; Cicero, AFG, 2021)
"Benzbromarone is effective in lowering uric acid levels and in reducing the number of acute attacks of gout in patients who have failed optimal treatment."9.11Benzbromarone therapy in management of refractory gout. ( Gow, P; Kumar, S; Ng, J, 2005)
"Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, is a potential alternative to allopurinol for patients with hyperuricemia and gout."9.11Febuxostat compared with allopurinol in patients with hyperuricemia and gout. ( Becker, MA; Eustace, D; Joseph-Ridge, N; MacDonald, PA; Palo, WA; Schumacher, HR; Streit, J; Wortmann, RL, 2005)
"To evaluate metformin efficacy and safety in patients with gout and insulin resistance (IR)."9.11[Use of metformin (siofor) in patients with gout and insulin resistance (pilot 6-month results)]. ( Barskova, VG; Eliseev, MS; Iakunina, IA; Il'inykh, EV; Kudaeva, FM; Nasonov, EL; Tsapina, TN; Volkov, AV; Zilov, AV, 2005)
"To assess the short-term urate-lowering effect of fenofibrate in men on long-term allopurinol therapy for hyperuricaemia and gout."9.10Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. ( Ball, SG; Feher, MD; Hepburn, AL; Hogarth, MB; Kaye, SA, 2003)
"Uric acid overexcretion in patients with gout is frequently assessed by the measurement of 24 hour urinary uric acid excretion, which is cumbersome with ambulatory patients, and requires accurate timing and complete collection of the specimen."9.09Spot urine uric acid to creatinine ratio used in the estimation of uric acid excretion in primary gout. ( Hada, T; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamakita, J; Yamamoto, T, 2001)
"It is known that chronic renal insufficiency (CRI) patients with gout may have subtle lead poisoning."9.09Lead chelation therapy and urate excretion in patients with chronic renal diseases and gout. ( Ho, HH; Lin, JL; Lin-Tan, DT; Yu, CC, 2001)
"To study the efficacy of allopurinol and benzbromarone to reduce serum urate concentrations in patients with primary chronic gout."9.08Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. ( Alonso-Ruiz, A; Calabozo, M; García-Erauskin, G; Herrero-Beites, A; Perez-Ruiz, F; Ruiz-Lucea, E, 1998)
"The objectives of this study were to establish if, and to what extent, benzbromarone affects allopurinol/oxypurinol kinetics, and to compare the uric acid lowering capabilities of Allomaron (allopurinol 100 mg plus benzbromarone 20 mg) with the effects of allopurinol alone in patients with confirmed gout."9.07The effect of benzbromarone on allopurinol/oxypurinol kinetics in patients with gout. ( Groenewoud, G; Hundt, HK; Müller, FO; Schall, R; van der Merwe, JC; van Dyk, M, 1993)
"This study compared the effects of azapropazone and indomethacin plus allopurinol in the management of acute gout and hyperuricaemia."9.06Comparative trial of azapropazone and indomethacin plus allopurinol in acute gout and hyperuricaemia. ( Davis, RH; Fraser, RC; Walker, FS, 1987)
"The antihyperuricemic properties of amflutizole were investigated in studies designed to determine its efficacy and mechanisms of action in individuals with gout and hyperuricemia."9.05Antihyperuricemic properties of amflutizole in gout. ( Fox, IH; Lightfoot, RW; Ridolfo, AS; Wortmann, RL, 1985)
"The effect of daily administration of a single 300-mg tablet of allopurinol on serum urate levels was compared with the effect of divided doses of the drug (100 mg three times a day) in an open-labeled crossover trial of 20 patients with hyperuricemia and gout."9.04Allopurinol and gouty hyperuricemia. Efficacy of a single daily dose. ( Elion, GB; Robin, JA; Rodnan, GP; Tolchin, SF, 1975)
"Gout is characterized by high serum uric acid (SUA) levels and arthritis."9.01Impact of bariatric surgery on serum uric acid levels and the incidence of gout-A meta-analysis. ( Kaushal, S; Koura, A; Lim, B; Oo, AM; Rao, J; Syn, N; Yeo, C; Yeo, D, 2019)
"Concerns about the cardiovascular safety of febuxostat lead to reconsideration of the place of febuxostat in the management of gout."9.01The role of febuxostat in gout. ( Bardin, T; Richette, P, 2019)
"Previous epidemiological investigations have evaluated the association between gout, serum uric acid levels, and obstructive sleep apnea syndrome (OSAS), but with inconsistent results."9.01A meta-analysis of the association between gout, serum uric acid level, and obstructive sleep apnea. ( Cheng, C; Liang, M; Min, M; Rizeq, FK; Shi, T; Sun, C; Sun, Y; Zhang, Y, 2019)
"We aimed to assess the relative efficacy and safety of once-daily administration of lesinurad in combination with xanthine oxidase inhibitor (XOI) in hyperuricemic patients with gout."9.01Comparative efficacy and safety of lesinurad 200 mg and 400 mg combined with a xanthine oxidase inhibitor in hyperuricemic patients with gout: A Bayesian network meta-analysis of randomized controlled trials
. ( Lee, YH; Song, GG, 2019)
"This study aimed to examine whether the uric acid level or gout is causally associated with bone mineral density (BMD)."9.01Uric acid level, gout and bone mineral density: A Mendelian randomization study. ( Lee, YH; Song, GG, 2019)
" allopurinol was associated with the improved safety outcome and have comparable mortality and net clinical outcome in patients with hyperuricemia."9.01The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis. ( Chang, WC; Chen, TC; Hsu, FS; Hwang, JJ; Lee, CC; Liu, CW; Lo, C; Shau, WY; Wang, ML, 2019)
"Gout develops in four stages beginning with an asymptomatic increase in blood levels of uric acid."8.98Crystal arthritides - gout and calcium pyrophosphate arthritis : Part 2: clinical features, diagnosis and differential diagnostics. ( Bertsch, T; Bollheimer, LC; Härle, P; Schlee, S; Sieber, CC, 2018)
"Gout and calcium pyrophosphate deposition disease (CPPD, pseudogout) are still the most frequent inflammatory arthritides in multimorbid elderly patients."8.98Crystal arthritides - gout and calcium pyrophosphate arthritis : Part 1: Epidemiology and pathophysiology. ( Bertsch, T; Bollheimer, LC; Härle, P; Schlee, S; Sieber, CC, 2018)
"This was a pooled analysis of phase III trials on allopurinol and febuxostat, including 4101 patients with gout and hyperuricemia."8.95Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol. ( Cimmino, MA; Cutolo, M; Perez-Ruiz, F, 2017)
"The research progress of puerarin and its derivatives in anti-inflammatory and anti-gout activities was reviewed in this paper."8.95[Research progress of puerarin and its derivatives on anti-inflammatory and anti-gout activities]. ( Li, XP; Ma, YC; Xing, ZH; Zhang, B; Zhang, MD, 2017)
"Lowering serum uric acid (SUA) levels can essentially cure gout; however, this is not widely practiced."8.95Serum Uric Acid and the Risk of Incident and Recurrent Gout: A Systematic Review. ( Bolzani, A; Cheung, A; Choi, HK; Shiozawa, A; Szabo, SM, 2017)
"The aim of this study was to examine the associations of tea consumption with the serum uric acid (SUA) level, hyperuricemia (HU) and the risk of gout."8.95Is tea consumption associated with the serum uric acid level, hyperuricemia or the risk of gout? A systematic review and meta-analysis. ( Cui, Y; Deng, YH; Huang, YZ; Lei, GH; Li, LJ; Li, XA; Xie, X; Zeng, C; Zhang, Y, 2017)
"Recent evidence would indicate that high serum uric acid (SUA) levels can be a significant and independent risk factor for hypertension and cardiovascular diseases, such as ischemic heart disease and heart failure."8.93Uric acid lowering therapy in cardiovascular diseases. ( Iellamo, F; Romeo, F; Sposato, B; Volterrani, M, 2016)
" It is caused by factors that elevate the concentration of serum uric acid (sUA), leading to hyperuricemia (sUA >6."8.93Overview of Serum Uric Acid Treatment Targets in Gout: Why Less Than 6 mg/dL? ( Edwards, NL; Ruoff, G, 2016)
" Chondrocalcinosis is a radiographic entity characterized by deposits of calcium pyrophosphate crystals (CPP) within the fibrocartilage or hyalin cartilage."8.91[Gout and and calcium pyrophosphate crystal arthropathies: pathophysiology]. ( Albert, JD; Coiffier, G, 2015)
"Our review found low- to moderate-quality evidence indicating similar effects on withdrawals due to AEs and SAEs and incidence of acute gout attacks when allopurinol (100 to 600 mg daily) was compared with placebo, benzbromarone (100 to 200 mg daily) or febuxostat (80 mg daily)."8.90Allopurinol for chronic gout. ( Bombardier, C; Buchbinder, R; Edwards, CJ; Kydd, AS; Seth, R, 2014)
"This study aims to compare the urate-lowering response rate of febuxostat and allopurinol in gout patient using a model-based meta-analysis."8.90[A model-based meta-analysis to compare urate-lowering response rate of febuxostat and allopurinol in gout patient]. ( Li, L; Lu, W; Sun, Y; Zhou, TY, 2014)
"To evaluate the safety and efficacy of febuxostat compared to allopurinol for the treatment of chronic gout."8.89A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout. ( Ehteshami-Afshar, A; Faruque, LI; Homik, J; Tjosvold, L; Tonelli, M; Wiebe, N, 2013)
" Concordantly, recent studies have revived the controversy over the role of circulating uric acid, hyperuricemia, and gout as an independent prognostic factor for cardiovascular morbidity and mortality."8.89Chronic hyperuricemia, uric acid deposit and cardiovascular risk. ( Cheli, P; Del Pinto, R; Desideri, G; Di Giosia, P; Ferri, C; Ferri, L; Grassi, D; Properzi, G, 2013)
"Febuxostat has been approved for the treatment of hyperuricemia in patients with/without gout."8.89Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis. ( Chen, S; Cheng, Q; Li, Q; Liu, L; Luo, T; Lv, Q; Mei, M; Yang, S; Ye, P; Zhang, W, 2013)
"Many patients with acute gout (11%-49%) have normal serum uric acid (SUA) levels."8.87Clinical inquiry. Are serum uric acid levels always elevated in acute gout? ( Fletcher, A; Leiszler, M; Poddar, S, 2011)
"Febuxostat, a nonpurine selective inhibitor of both the oxidized and reduced forms of xanthine oxidase, was approved in February 2009 by the US Food and Drug Administration for the management of hyperuricemia in adults with gout."8.85Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout. ( Ernst, ME; Fravel, MA, 2009)
"Uric acid nephrolithiasis is typically found in individuals with a low urine pH and a normal concentration of urinary uric acid."8.84Uric acid nephrolithiasis. ( Bushinsky, DA; Liebman, SE; Taylor, JG, 2007)
"Impaired renal uric acid excretion is the major mechanism of hyperuricemia in patients with primary gout."8.84Control of renal uric acid excretion and gout. ( Kamatani, N; Taniguchi, A, 2008)
" Recently it has been identified that hypertension are frequently associated with myogenic hyperuricemia converted from overproduced hypoxanthine in the skeletal muscles."8.84[Idiopathic hyperuricemia with overproduction of uric acid]. ( Hisatome, I; Igawa, O; Mizuta, E, 2008)
"Although allopurinol has been available for approximately 50 years, hyperuricemia and its sequelae are not only prevalent, but the incidence and costs associated with this disorder continue to increase."8.82Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase. ( Bomalaski, JS; Clark, MA, 2004)
"Benzbromarone1 is a benzofuran derivative which lowers serum urate and increases urinary urate excretion in normal, hyperuricaemic and gouty subjects."8.75Benzbromarone: a review of its pharmacological properties and therapeutic use in gout and hyperuricaemia. ( Avery, GS; Brogden, RN; Heel, RC; Speight, TM, 1977)
"The occurrence of gout attacks at the start of uric acid lowering treatment worsens compliance."8.31A retrospective observational study of the appropriate starting dose of febuxostat in patients with gout. ( Ghang, B; Jeong, W; Kim, J; Lee, J, 2023)
" Reducing uric acid and inhibiting inflammation are the focused areas of drug research and development on gout."8.31Rutin ameliorates gout via reducing XOD activity, inhibiting ROS production and NLRP3 inflammasome activation in quail. ( Huang, J; Li, Y; Lin, Z; Wang, Y; Wu, H; Zhang, B, 2023)
"Poor adherence to allopurinol among people with gout contributes to suboptimal gout management."8.31Optimizing adherence to allopurinol for gout: patients' perspectives. ( Aslani, P; Chan, JS; Coleshill, MJ; Day, RO; Michael, TJF; Spragg, JCJ; Stocker, SL, 2023)
" This research aimed to study the relation of ischemic cerebrovascular disease with benzbromarone use among persons with gout-related disorders."8.31The risk of ischemic cerebrovascular disease associated with benzbromarone use in gout people: A retrospective cohort study in Taiwan. ( Hwang, BF; Kuo, YH; Lai, SW; Liao, KF; Liu, CS, 2023)
"Correlation influence factor analysis of gout patients' serum uric acid (SUA) levels, their examination fees, and various complications were explored."8.31Association between serum uric acid levels of patients with gout and their complications and examination fees: A cross-sectional analysis. ( Dang, W; Liu, J; Wang, J; Xu, D; You, L; Zhao, L, 2023)
"To explore pro-inflammatory cytokines status in the tear fluid of patients with hyperuricemia and gout and its association with uric acid level."8.31Uric acid is independently associated with interleukin-1β levels in tear fluid of hyperuricemia and gout patients. ( Hu, X; Liu, C; Lu, H; Lu, T; Wu, M, 2023)
"Spontaneous serum uric acid (SUA) decrease has been found in many patients during acute gout attacks, but its mechanism remains unclear."8.31Intestinal uric acid excretion contributes to serum uric acid decrease during acute gout attack. ( Cao, L; Du, X; Lin, C; Wan, W; Xu, R; Yang, X; Zhao, T; Zhou, M; Zhu, X; Zou, H, 2023)
"We investigated the appropriate duration of colchicine prophylaxis to maximize the persistence of xanthine oxidase inhibitors (XOIs) as first-line urate-lowering therapy (ULT) in patients with gout."8.31Analysis of appropriate duration of colchicine prophylaxis to maximize the persistence of xanthine oxidase inhibitors as the first-line urate-lowering therapy in patients with gout using the Korean Health Insurance Review and Assessment Service database. ( Kim, AR; Lee, SG; So, MW, 2023)
" It suppressed liver xanthine oxidase activity to decrease uric acid synthesis and modulated renal urate transporters to stimulate uric acid excretion, alleviating kidney damage caused by hyperuricemia."8.31Paeonia × suffruticosa Andrews leaf extract and its main component apigenin 7-O-glucoside ameliorate hyperuricemia by inhibiting xanthine oxidase activity and regulating renal urate transporters. ( An, J; Li, C; Li, Y; Lin, F; Ma, S; Wang, S; Xie, Y; Xu, L; Zhang, Y; Zhao, Y, 2023)
"Higher serum uric acid (SUA) can cause gout, which is principally characterized by arthritis due to monosodium urate crystal deposition in the lower extremities."8.31Association between serum uric acid levels and peripheral artery disease in Chinese adults with hypertension. ( Bao, H; Cheng, X; Han, F; Hu, F; Huang, X; Wang, T; Yu, C; Zhou, W; Zhu, L, 2023)
"To determine the risk of adverse events associated with colchicine or non-steroidal anti-inflammatory drug (NSAID) prophylaxis when initiating allopurinol for gout."8.31Safety of colchicine and NSAID prophylaxis when initiating urate-lowering therapy for gout: propensity score-matched cohort studies in the UK Clinical Practice Research Datalink. ( Bajpai, R; Clarson, LE; Forrester, H; Mallen, CD; Muller, S; Padmanabhan, N; Partington, RJ; Roddy, E; Whittle, R, 2023)
" Thus, we aimed to investigate diurnal variations in serum levels of UA and plasma levels of xanthine, hypoxanthine, and xanthine oxidoreductase (XOR) activity, which were measured at 18:00, 6:00, and 12:00 in male patients with coronary artery disease."8.31Diurnal Variations in Serum Uric Acid, Xanthine, and Xanthine Oxidoreductase Activity in Male Patients with Coronary Artery Disease. ( Hiki, M; Ishiwata, S; Kasai, T; Kato, T; Kuwabara, M; Matsumoto, H; Murase, T; Murata, A; Naito, R; Nakamura, T; Sato, A; Shimizu, M; Shitara, J; Suda, S; Yatsu, S, 2023)
"Achieving target serum uric acid (SUA) levels is important in gout management."8.31Factors for achieving target serum uric acid levels after initiating urate-lowering therapy in patients with gout: results from the ULTRA registry. ( Ahn, JK; Choi, B; Choi, HJ; Choi, SR; Do, H; Kim, HO; Kim, JH; Kim, MJ; Kim, SH; Lee, CH; Lee, SG; Lee, SW; Moon, KW; Shin, K; Son, CN; Son, KM; Song, R, 2023)
" The averaged serum uric acid levels in patients with gout reduced after WMT (p = 0."8.12Effects of Washed Microbiota Transplantation on Serum Uric Acid Levels, Symptoms, and Intestinal Barrier Function in Patients with Acute and Recurrent Gout: A Pilot Study. ( Cai, JY; Deng, ZH; He, XX; Kong, LP; Wu, LH; Xia, HH; Xie, WR; Yang, XY; Zhang, R; Zheng, YM, 2022)
"Sixty-nine men with gout attending rheumatology clinics, all prescribed allopurinol for ≥ 6 months, completed the Intentional Non-Adherence Scale (INAS)."8.12Why Do Patients With Gout Not Take Allopurinol? ( Chalder, T; Dalbeth, N; Emad, Y; Petrie, KJ; Weinman, J, 2022)
"Characterized by an excessively increased uric acid (UA) level in serum, hyperuricemia induces gout and also poses a great threat to renal and cardiovascular systems."8.12Noninvasive and Individual-Centered Monitoring of Uric Acid for Precaution of Hyperuricemia via Optical Supramolecular Sensing. ( Chai, S; Chai, X; Geng, WC; Guo, DS; Li, JJ; Wang, L; Wang, Y; Yu, H; Yue, YX; Zhang, Y, 2022)
" These physiological characteristics have promoted the study of poly-gallic acid (PGAL), a poly-oxidized form of gallic acid reported to be effective in in vitro models of inflammation."8.12Anti-inflammatory and Antioxidant Effect of Poly-gallic Acid (PGAL) in an In Vitro Model of Synovitis Induced by Monosodium Urate Crystals. ( Fernández-Torres, J; Gimeno, M; Luján-Juárez, IA; Martínez-Flores, K; Martínez-López, V; Montaño-Armendariz, N; Sánchez-Sánchez, R; Zamudio-Cuevas, Y, 2022)
" In this study, the xanthine oxidase (XO) inhibition and uric acid-lowering effect of corni fructus extract (CFE) were evaluated in mice with potassium oxonate-induced hyperuricemia."8.12Protective effects of corni fructus extract in mice with potassium oxonate-induced hyperuricemia. ( Chen, C; Chen, FA; Chen, HC; Chiu, PY; Li, YL; Wang, CC, 2022)
" Ongoing research is examining the association of obesity, dietary patterns, and blood pressure (BP) with serum uric acid (sUA)."8.12Correlation of obesity, dietary patterns, and blood pressure with uric acid: data from the NHANES 2017-2018. ( Fan, GJ; Lin, YP; Lu, QY; Yao, J; Zhang, Y; Zhao, J, 2022)
"Pegloticase + methotrexate co-therapy was well-tolerated over 12 months, with sustained SU lowering, progressive gout flare reduction, and no new safety concerns."8.12A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an ( Bennett, R; Botson, JK; Chamberlain, J; Kenney, HM; LaMoreaux, B; Obermeyer, K; Peloso, PM; Peterson, J; Ramanathan, S; Song, Y; Tesser, JRP; Weinblatt, ME; Xin, Y; Zhao, L, 2022)
"Multiple observational studies have reported the close associations of obstructive sleep apnea (OSA) with serum uric acid (SUA) levels and gout."8.12Assessing the causal associations of obstructive sleep apnea with serum uric acid levels and gout: a bidirectional two-sample Mendelian randomization study. ( Cen, H; Ding, C; He, W; Huang, L; Jin, T; Ni, J; Xie, Y; Zeng, Z; Zhang, L, 2022)
"To investigate the efficacy and tolerability of febuxostat in gout patients on dialysis."8.02Efficacy and tolerability of febuxostat in gout patients on dialysis. ( Choi, SW; Choi, SY; Lee, S; Lim, DH; Oh, JS; So, MW, 2021)
"The objectives of our study were to compare the efficacy of febuxostat with allopurinol in Thai subjects with gout, as well as to determine the predictive factors of responsiveness to urate-lowering agents and to evaluate the safety of febuxostat in a real-world setting."8.02Efficacy of febuxostat versus allopurinol and the predictors of achieving target serum urate in a cohort of Thai people with gout. ( Jatuworapruk, K; Lertnawapan, R, 2021)
"This is a single-center, prospective cohort study conducted in one adult Arthritis Clinic at the University of the Philippines-Philippine General Hospital which included 138 patients with gout (1977 ACR criteria), SUA ≥ 6 mg/dl prior to ULT, initiated on ULT (allopurinol or febuxostat), with six months minimum follow-up and with SUA determination post-treatment."8.02Achievement of the target serum urate level among patients with gout treated with allopurinol or febuxostat in an arthritis clinic in the Philippines. ( Penserga, EG; Quilisadio, JEC; Salido, EO, 2021)
"The coexistence of calcium pyrophosphate dihydrate (CPPD) and monosodium urate monohydrate crystals in gouty tophi has rarely been reported."8.02Calcium Pyrophosphate Dihydrate Crystal Deposition in Gouty Tophi. ( Bardin, T; Bazin, D; Cohen-Solal, M; Ea, HK; Frochot, V; Gauffenic, A; Laredo, JD; Le, NH; Marty, C; Nguyen, QD; Olivier, O; Ostertag, A; Pham, NG; Richette, P, 2021)
"This study assessed factors associated with achieving target serum uric acid (sUA) level and occurrence of gouty arthritis in Japanese clinical practice."8.02Factors associated with achieving target serum uric acid level and occurrence of gouty arthritis: A retrospective observational study of Japanese health insurance claims data. ( Horiuchi, H; Koto, R; Nakajima, A; Yamanaka, H, 2021)
"In this nonrandomized, open-label, single-arm trial, we administered topiroxostat 40-160 mg/day to HFpEF patients with hyperuricemia or gout to achieve a target uric acid level of 6."8.02Effect of Topiroxostat on Brain Natriuretic Peptide Level in Patients with Heart Failure with Preserved Ejection Fraction: A Pilot Study. ( Asai, K; Koen, M; Kubota, Y; Shimizu, W; Wakita, M, 2021)
"Gout is a type of inflammatory arthritis caused by the deposition of monosodium uric acid (MSU) crystals in tissues."8.02Loganin Alleviates Gout Inflammation by Suppressing NLRP3 Inflammasome Activation and Mitochondrial Damage. ( Cho, YY; Choi, N; Jang, JH; Kang, HC; Lee, HS; Lee, JY; Yang, G, 2021)
"To investigate the incidence and potential risk factors for development of fenofibrate-associated nephrotoxicity in gout patients."8.02Effects of fenofibrate therapy on renal function in primary gout patients. ( Chen, Y; Cheng, X; Cui, L; Han, L; He, Y; Ji, A; Ji, X; Li, C; Li, H; Li, X; Liu, Z; Lu, J; Ma, L; Merriman, TR; Ren, W; Sun, W; Wang, C; Wang, X; Yuan, X; Zhang, H, 2021)
"The aim of this study was to identify the effects of melatonin on acute gouty inflammation and to investigate the underlying mechanisms."8.02Melatonin Alleviates Acute Gouty Inflammation In Vivo and In Vitro. ( Cao, L; Xiao, WZ; Zhao, L; Zhu, XX; Zou, HJ, 2021)
"In patients with gout, treating to target serum uric acid levels (sUA) of ≤6."8.02Serum uric acid control for prevention of gout flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance claims and medical check-up data in Japan. ( Horiuchi, H; Koto, R; Nakajima, A; Yamanaka, H, 2021)
"To analyse the antinociceptive interaction between quercetin (QUER) and diclofenac (DIC) in experimental arthritic gout-pain."8.02Quercetin decreases the antinociceptive effect of diclofenac in an arthritic gout-pain model in rats. ( Ángeles-López, GE; Aviles-Herrera, J; Bustamante-Marquina, A; Déciga-Campos, M; González-Trujano, ME; Navarrete-Vázquez, G; Ventura-Martínez, R, 2021)
" In this study, the differences between gout with cerebral infarction (gout+CI) and gout with coronary heart disease (gout+CHD) and related factors that affect serum uric acid (sUA) levels in gout+CI were investigated by a cross-sectional study."8.02Factors Influencing the Serum Uric Acid in Gout with Cerebral Infarction. ( Duan, L; Li, Y; Tian, Y; Yang, H, 2021)
"To assess factors associated with the ability to achieve and maintain target serum urate (SU) with allopurinol in patients with gout."7.96Factors Influencing the Effectiveness of Allopurinol in Achieving and Sustaining Target Serum Urate in a US Veterans Affairs Gout Cohort. ( Saag, KG; Singh, JA; Yang, S, 2020)
"Eucalyptol alleviates MSU-induced pain and inflammation via mechanisms possibly involving anti-oxidative effect."7.96Eucalyptol alleviates inflammation and pain responses in a mouse model of gout arthritis. ( Li, X; Li, Y; Liu, B; Tai, Y; Wang, C; Wang, P; Yin, C; Zheng, X, 2020)
" Our study was to discover different lipid levels of gout and asymptomatic hyperuricemia and the predictors of sUA (serum uric acid) levels."7.96The comparison of dyslipidemia and serum uric acid in patients with gout and asymptomatic hyperuricemia: a cross-sectional study. ( Gu, J; Huang, Y; Jiang, Y; Li, X; Liang, J; Ou, J; Song, W; Wei, Q, 2020)
"The 24-hour uric acid excretion measurement is important in assessing disease status and helping to select the appropriate uric acid-lowering agent for patients with gout, however, it is inconvenient."7.96The Utility of the Random Urine Uric Acid-to-Creatinine Ratio for Patients with Gout Who Need Uricosuric Agents: Retrospective Cross-Sectional Study. ( Choi, ST; Kim, CH; Kim, SJ; Moon, SJ; Song, JS, 2020)
"Lifelong urate-lowering therapy (ULT) with xanthine oxidase inhibitors (XOIs), such as allopurinol and febuxostat, is the cornerstone of gout treatment."7.96Comparison of persistence rates between allopurinol and febuxostat as first-line urate-lowering therapy in patients with gout: an 8-year retrospective cohort study. ( Ahn, E; Kim, A; Kim, GT; Kim, Y; Lee, SG; So, MW, 2020)
"Topiroxostat, a selective xanthine oxidoreductase inhibitor, is used for the management of hyperuricemic patients with or without gout in Japan."7.96Long-Term Safety and Effectiveness of the Xanthine Oxidoreductase Inhibitor, Topiroxostat in Japanese Hyperuricemic Patients with or Without Gout: A 54-week Open-label, Multicenter, Post-marketing Observational Study. ( Hashimoto, T; Ichikawa, K; Ishikawa, T; Kanno, Y; Maeda, T; Nakagawa, T; Sato, Y, 2020)
"To investigate the effects of serum uric acid (SUA) level and its fluctuation on renal dysfunction in gout patients."7.96Uric acid fluctuation had no effect on renal function among gout patients. ( Fu, Y; Mo, M; Shao, B; Shen, J; Shen, Y; Si, S; Wang, S; Wu, H; Xin, X; Yu, Y; Zhu, J, 2020)
"To assess the impact of allopurinol on diabetes in a retrospective cohort of Veterans' Affairs patients with gout."7.96Allopurinol use and type 2 diabetes incidence among patients with gout: A VA retrospective cohort study. ( Crittenden, DB; Greenberg, J; Pike, VC; Pillinger, MH; Qian, Y; Slobodnick, A; Toprover, M; Zhong, H, 2020)
" Herein we aimed to investigate whether procyanidin B2 (PCB2), a natural dietary compound, can suppress MSU crystals-stimulated gouty inflammation."7.96Management of Gout-associated MSU crystals-induced NLRP3 inflammasome activation by procyanidin B2: targeting IL-1β and Cathepsin B in macrophages. ( Jiang, M; Jiao, JY; Li, Y; Lian, LH; Lin, YC; Liu, J; Nan, JX; Piao, MH; Qiao, CY; Shang, Y; Sun, RH; Wu, YL; Ye, H; Zhan, ZY; Zhang, ZH, 2020)
"12 a week-long combined therapy of the allopurinol-reducing drug with the anti-inflammatory dose movalis prevents the exacerbation of the articular syndrome and improves the quality of life of patients with gout."7.96[Evaluation of a 12-week allopurinol-lowering therapy in combination with the non-steroidal anti-inflammatory drug meloxicam in patients with gout]. ( Gromova, MA; Kislyak, OA; Malysheva, NV; Tsurko, VV, 2020)
" Serum uric acid levels and estimated glomerular filtration rate (eGFR) of patients with gouty arthritis were collected at baseline and 1 year after febuxostat administration."7.96Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4-5 chronic kidney disease not yet on dialysis. ( Kim, JM; Kim, SH; Lee, SY; Son, CN, 2020)
"EATP lowered the serum uric acid level and increased the urine uric acid level through excretion, which is useful in the treatment of gout."7.91Therapeutic potential of ethyl acetate fraction of Tephrosia purpurea Linn. leaves in a rat model of gout. ( Nipate, SS; Yelmar, PS, 2019)
"Lesinurad (LESU) is a selective urate reabsorption inhibitor approved at 200 mg daily for use with a xanthine oxidase inhibitor (XOI) to treat hyperuricaemia in gout patients failing to achieve target serum urate on XOI."7.91Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout. ( Baumgartner, S; Goldfarb, DS; Jalal, D; Pillinger, M; Saag, KG; Schechter, BM; Terkeltaub, R; Valiyil, R; White, WB, 2019)
"To further explore the possibility of xanthine and hypoxanthine to be gout biomarkers as substitutes for uric acid."7.91Study on the diagnosis of gout with xanthine and hypoxanthine. ( Deng, B; Deng, M; Fei, X; Huang, Z; Wang, Y; Ye, L, 2019)
" The RSGE treatment dose-dependently reduced PO- and MSU-induced paw edema, serum TNF-α, IL-1β, IL-6, IL-12, uric acid, and BUN, while significantly elevated serum IL-10, urinary uric acid and creatinine levels as compared with the respective values in the hyperuricemic and gouty mice group (vehicle group)."7.91Protective effects of Rhizoma smilacis glabrae extracts on potassium oxonate- and monosodium urate-induced hyperuricemia and gout in mice. ( Chang, Y; Liang, C; Liang, G; Nie, Y; Xiao, D; Zeng, S; Zhan, S; Zheng, Q; Zheng, X, 2019)
"Gout patients with chronic kidney disease (CKD) accumulate the active allopurinol metabolite oxypurinol, suggesting that allopurinol may promote greater serum urate (sU) lowering in CKD patients."7.91Low-Dose Allopurinol Promotes Greater Serum Urate Lowering in Gout Patients with Chronic Kidney Disease Compared with Normal Kidney Function. ( Crittenden, DB; Fisher, MC; Keenan, RT; Krasnokutsky, S; Modjinou, DV; Oh, C; Pillinger, MH; Toprover, M, 2019)
" We investigated whether epigallocatechin-3-gallate (EGCG) suppresses the activation of the NLRP3 inflammasome, thereby effectively preventing gouty inflammation."7.91Epigallocatechin-3-Gallate Prevents Acute Gout by Suppressing NLRP3 Inflammasome Activation and Mitochondrial DNA Synthesis. ( Cho, YY; Kang, HC; Lee, HE; Lee, HS; Lee, JY; Park, YB; Yang, G, 2019)
"To investigate the effects on hypercholesterolemia and hypertriglyceridemia in gouty patients receiving uric acid-lowering therapy (UALT)."7.91Efficacy of uric acid-lowering therapy on hypercholesterolemia and hypertriglyceridemia in gouty patients. ( Deng, JX; Jie, LG; Qu, Y; Wu, J; Yu, QH; Zhang, YP, 2019)
"In patients with gout, maintaining too low serum uric acid (SUA) level with urate-lowering therapy is a concern because uric acid is thought to be neuroprotective."7.88Uric acid and incident dementia over 12 years of follow-up: a population-based cohort study. ( Bardin, T; Debette, S; Latourte, A; Perez-Ruiz, F; Richette, P; Soumaré, A, 2018)
" The PKPD model was used to simulate mono and dual-ULT in gout patients with either under-excretion (lowered clearance) or overproduction of uric acid, with suboptimal adherence modelled as either a single drug holiday of increasing duration or doses taken at random."7.88Impact of non-adherence on the safety and efficacy of uric acid-lowering therapies in the treatment of gout. ( Hill-McManus, D; Hughes, D; Lane, S; Marshall, S; Soto, E, 2018)
"Uric acid is best known for its role in gout-the most prevalent inflammatory arthritis in humans-that is also described as an unusual complication of anorexia nervosa (AN)."7.88Anorexia nervosa and uric acid beyond gout: An idea worth researching. ( Maas, J; Simeunovic Ostojic, M, 2018)
"The aetiology of gout is closely linked to the deposition of monosodium uric acid (MSU) crystals and the consequent activation of the NOD-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome."7.88Suppression of NLRP3 inflammasome by oral treatment with sulforaphane alleviates acute gouty inflammation. ( Cho, YY; Kang, HC; Lee, HE; Lee, HS; Lee, JY; Yang, G; Yeon, SH, 2018)
"This narrative review aims to highlight recent findings on the relation between uric acid level and cognitive decline or dementia."7.88Uric acid and cognitive decline: a double-edge sword? ( Bardin, T; Latourte, A; Richette, P, 2018)
"Numerous epidemiological studies have shown that male patients with uric acid nephrolithiasis outnumber female patients."7.88Mediators of the Effects of Gender on Uric Acid Nephrolithiasis: A Novel Application of Structural Equation Modeling. ( Chang, YY; Chen, HW; Chen, YC; Chou, YH; Li, CC; Wu, WJ; Yang, FM, 2018)
"A retrospective data analysis was performed within the UK Clinical Practice Research Datalink (1987-2014) among incident gout patients, aged ⩾40 years and starting allopurinol (n = 48 280)."7.88Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD). ( Arts, ICW; Boonen, A; Burden, AM; de Vries, F; Scheepers, LEJM; Souverein, P; Spaetgens, B, 2018)
"To retrospectively analyze the efficacy and safety of febuxostat on gout patients with low serum uric acid level."7.88Febuxostat in the treatment of gout patients with low serum uric acid level: 1-year finding of efficacy and safety study. ( Chen, X; Gu, B; Li, C; Qian, K; Ren, Q; Shen, M; Su, D; Wang, X; Xu, W; Yang, L; Yuan, H; Zhang, J, 2018)
" SUA was downregulated during acute gouty arthritis, which might be associated with increased urinary excretion of uric acid."7.88Renal excretion is a cause of decreased serum uric acid during acute gout. ( Cao, L; Guo, M; Lv, X; Wan, W; Xue, Y; Zhao, T; Zheng, S; Zhu, X; Zou, H, 2018)
"Procyanidins significantly attenuated gout pain and suppressed ankle swelling."7.85Grape seed-derived procyanidins alleviate gout pain via NLRP3 inflammasome suppression. ( Fan, YX; Gui, X; Han, Y; Hu, L; Jiang, CY; Liu, BQ; Liu, HJ; Liu, WT; Pan, XX; Tang, YL, 2017)
"Studies have suggested a relationship between higher baseline serum uric acid (sUA) levels and an elevated risk of subsequent ischemic cardiovascular outcomes among acute coronary syndrome (ACS) patients; this relationship may be modified by a clinical history of gout and has not been studied in large patient cohorts."7.85An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome. ( Akerblom, A; Clare, RM; Held, C; Hess, CN; James, S; Keenan, RT; Klein, AB; Mahaffey, KW; Pagidipati, NJ; Roe, MT; Tricoci, P; Wallentin, L; Wojdyla, D, 2017)
"Patient and provider factors, including allopurinol medication adherence, affect gout treatment outcomes."7.85Allopurinol Medication Adherence as a Mediator of Optimal Outcomes in Gout Management. ( Bendlin, KA; Coburn, BW; Meza, J; Mikuls, TR; Russell, CL; Sayles, H, 2017)
"Serum uric acid (sUA) levels are causally associated with the risk of gout flares."7.85Serum uric acid levels and the risk of flares among gout patients in a US managed care setting. ( Buysman, EK; Korrer, S; Shiozawa, A, 2017)
"We aimed to investigate the effects of febuxostat on IR and the expression of high-sensitivity C-reactive protein (hs-CRP) in patients with primary gout."7.85Effects of febuxostat on insulin resistance and expression of high-sensitivity C-reactive protein in patients with primary gout. ( Li, Y; Lu, Y; Meng, J; Yuan, X, 2017)
"To evaluate and compare the safety and efficacy of three urate lowering agents: febuxostat, allopurinol, and benzbromarone, when used to treat Chinese gout patients."7.85A study comparing the safety and efficacy of febuxostat, allopurinol, and benzbromarone in Chinese gout patients: a retrospective cohort study
. ( Chen, X; Su, J; Tian, J; Zhou, Q; Zhou, T; Zhu, J, 2017)
"The aim of this study was to evaluate relationships between serum uric acid (SUA) and newly emergent acute myocardial infarction (AMI), congestive heart failure (CHF), coronary artery disease (CAD), composite cardiovascular (CV) events (AMI, CHF, CAD), hypertension, hyperlipidemia, and renal disease in gout patients."7.85Evaluation of the Relationship Between Serum Uric Acid Levels and Cardiovascular Events in Patients With Gout: A Retrospective Analysis Using Electronic Medical Record Data. ( Bienen, EJ; Essex, MN; Hopps, M; Makinson, GT; Mardekian, J; Udall, M, 2017)
"A population analysis was conducted in nonmem using oxypurinol and urate plasma concentrations from 133 gout patients."7.83Predicting allopurinol response in patients with gout. ( Barclay, ML; Dalbeth, N; Duffull, SB; Merriman, TR; Stamp, LK; Wright, DF, 2016)
" Model flow based on guideline and real-world treatment paradigms incorporated gout flare, serum uric acid (sUA) testing, treatment titration, discontinuation, and adverse events, chronic kidney disease (CKD) incidence and progression, and type 2 diabetes mellitus (T2DM) incidence."7.83Febuxostat in the management of gout: a cost-effectiveness analysis. ( Gahn, JC; Mitri, G; Shiozawa, A; Smolen, LJ, 2016)
"Psoriasis has been reported to be associated with raised serum uric acid levels and gout, and uric acid has been demonstrated to mediate inflammatory pathways via secretion of pro-inflammatory chemokines."7.83Psoriasis and uric acid: a population-based cross-sectional study. ( Lai, YC; Yew, YW, 2016)
"Gout is a chronic disease characterized by the deposition of urate crystals in the joints and throughout the body, caused by an excess burden of serum uric acid (sUA)."7.83The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed Care Pharmacy and Medical Costs Perspective. ( Gahn, JC; Mitri, G; Shiozawa, A; Smolen, LJ, 2016)
" Whether gout, the most common rheumatologic inflammatory arthritis, or its cause, elevated serum uric acid (SUA), is associated with VTE incidence is unknown."7.83Serum uric acid, gout, and venous thromboembolism: The atherosclerosis risk in communities study. ( Folsom, AR; Kubota, Y; McAdams-DeMarco, M, 2016)
"Benzbromarone provides useful urate-lowering efficacy and does not appear unsafe in patients with gout."7.83The safety and efficacy of benzbromarone in gout in Aotearoa New Zealand. ( Cathro, A; Corkill, M; Dalbeth, N; Frampton, C; Gardner, D; Grainger, R; Haslett, J; Kain, T; Kumar, R; Kumar, S; Metcalfe, S; Porter, D; Stamp, LK; Stebbings, S; Taylor, G; White, D; Wyeth, J, 2016)
"Gouty arthritis is caused by the deposition of uric acid crystals, which induce the activation of NOD-like receptor family, pyrin domain containing 3(NLRP3) inflammasome."7.83Targeting ASC in NLRP3 inflammasome by caffeic acid phenethyl ester: a novel strategy to treat acute gout. ( Choi, JY; Jeong, S; Jung, Y; Kim, ND; Lee, HE; Lee, JY; Park, HH; Yang, G, 2016)
"There is very limited information on the association between arsenic and serum uric acid levels or gout."7.81Arsenic exposure, hyperuricemia, and gout in US adults. ( Fadrowski, JJ; Guallar, E; Kuo, CC; Lin, YS; Navas-Acien, A; Weaver, V, 2015)
"To identify modifiable patient and provider factors associated with allopurinol adherence and the achievement of a serum urate acid (SUA) goal in gout."7.81Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system. ( Cheetham, TC; Coburn, BW; Curtis, JR; Mikuls, TR; Rashid, N; Saag, KG; Wu, YL, 2015)
"To quantify the risk of non-fatal acute myocardial infarction (AMI) among users of allopurinol."7.81Allopurinol use and risk of non-fatal acute myocardial infarction. ( Álvarez, A; Bryant, V; de Abajo, FJ; García-Poza, P; García-Rodríguez, LA; Gil, MJ; Rodríguez, A, 2015)
"To evaluate the cost-effectiveness of allopurinol versus febuxostat in adult patients with gout over a 5-year time period from a U."7.81Cost-effectiveness analysis of allopurinol versus febuxostat in chronic gout patients: a U.S. payer perspective. ( Bottorff, MB; Gandhi, PK; Gentry, WM; Ma, Q, 2015)
"Allopurinol is used as long-term therapy to reduce the occurrence of gout flares."7.81Allopurinol adherence among patients with gout: an Italian general practice database study. ( Antonioli, L; Blandizzi, C; Capogrosso-Sansone, A; Convertino, I; Cricelli, C; Cricelli, I; Fornai, M; Lapi, F; Mantarro, S; Montagnani, S; Pecchioli, S; Tuccori, M, 2015)
"Inefficient renal excretion of uric acid is the main pathophysiological mechanism for hyperuricemia in gout patients."7.81Renal clearance of uric acid is linked to insulin resistance and lower excretion of sodium in gout patients. ( Aniel-Quiroga, MA; Chinchilla, SP; Erauskin, GG; Herrero-Beites, AM; Merriman, T; Perez-Ruiz, F, 2015)
" Study patients had at least one medical claim with a diagnosis of gout, at least one filled prescription for febuxostat or allopurinol and at least one sUA measurement post-index prescription."7.81Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort. ( Akhras, KS; Shiozawa, A; Singh, JA, 2015)
"Our objective was to evaluate data on the cost-effectiveness of febuxostat compared with standard clinical practice with allopurinol in patients with gout that was presented to the Scottish Medicines Consortium (SMC) in 2010."7.80Cost-effectiveness of febuxostat in chronic gout. ( Beard, SM; Nuki, G; Pearson, IV; von Scheele, BG, 2014)
"American College of Rheumatology and European League Against Rheumatism guidelines recommend colchicine to prevent gout flares in patients initiating and increasing uric acid–lowering therapy until serum uric acid is maintained at ≤6 mg/dl."7.80Evaluating appropriate use of prophylactic colchicine for gout flare prevention. ( George, M; Hussain, F; Pullman-Mooar, S; Schumacher, HR, 2014)
"The object of this study was to evaluate the effect of uric acid lowering therapy in reducing the new development of comorbidities and the frequency of acute attacks in gout patients."7.80Prevention of comorbidity and acute attack of gout by uric acid lowering therapy. ( Joo, H; Joo, K; Jung, KH; Kwon, SR; Lim, MJ; Park, W, 2014)
"Hyperhomocysteinemia is one of the important factors of the cardiovascular disease, and gout is well known to be associated with cardiovascular disease."7.80Elevated serum homocysteine levels were not correlated with serum uric acid levels, but with decreased renal function in gouty patients. ( Choi, ST; Kim, JS; Song, JS, 2014)
"To assess the feasibility and diagnostic value of detecting uric acid depositing among patients with tophaceous gout using a dual energy CT based Gemstone spectral imaging (GSI) technology for qualitative analysis of uric acid."7.80Detection of uric acid depositing in tophaceous gout using a new dual energy spectral CT technology. ( Cai, J; Ding, Q; Li, X; Liu, B; Luo, L; Wang, J; Wang, W; Wang, X; Xia, L; Yu, Y; Zhang, C, 2014)
"Gout with uric acid underexcretion is associated with transporter gene SNP related mainly to tubular reabsorption, whereas uric acid normoexcretion is associated only with tubular secretion SNP."7.80Tubular urate transporter gene polymorphisms differentiate patients with gout who have normal and decreased urinary uric acid excretion. ( Bailén, R; Banegas, JR; de Miguel, E; Puig, JG; Torres, RJ, 2014)
"While the prevalence of gout was calculated by counting patients with this diagnosis hyperuricemia was inferred in patients taking allopurinol at hospital admission or discharge, on the assumption that this drug was only prescribed owing to the finding of high serum levels of uric acid."7.80Gout, allopurinol intake and clinical outcomes in the hospitalized multimorbid elderly. ( Conca, A; Corrao, S; Djade, CD; Franchi, C; Mannucci, PM; Marcucci, M; Marengoni, A; Nobili, A; Pasina, L; Salerno, F; Tettamanti, M, 2014)
"Probenecid is recommended as urate-lowering therapy (ULT) in patients with gout where xanthine oxidase inhibitors are ineffective, not tolerated, or contraindicated."7.79Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population. ( Dalbeth, N; Gow, PJ; Pui, K, 2013)
"A loss-of-function mutation (Q141K, rs2231142) in the ATP-binding cassette, subfamily G, member 2 gene (ABCG2) has been shown to be associated with serum uric acid levels and gout in Asians, Europeans, and European and African Americans; however, less is known about these associations in other populations."7.79Association of functional polymorphism rs2231142 (Q141K) in the ABCG2 gene with serum uric acid and gout in 4 US populations: the PAGE Study. ( Best, LG; Brown-Gentry, KD; Cole, SA; Crawford, DC; Deelman, E; Fornage, M; Franceschini, N; Gaffo, AL; Glenn, KR; Heiss, G; Jenny, NS; Jorgensen, NW; Kao, WH; Kottgen, A; Li, Q; Liu, K; Matise, TC; North, KE; Spencer, KL; Umans, JG; Voruganti, VS; Zhang, L, 2013)
"Acute gout is associated with a decrease in serum uric acid (SUA) that is considered to be in response to acute inflammation but it may be a feature of gout itself."7.79The effect of the systemic inflammatory response, as provoked by elective orthopaedic surgery, on serum uric acid in patients without gout: a prospective study. ( Ashby, HL; Chugh, S; Deshpande, S; Ford, C; Gama, R; Razavi, C; Thomas, OL; Waldron, JL, 2013)
"Although hyperuricemia is suggested to increase allantoin production in both pro- and antioxidant manners, it remains undetermined whether it increases the serum concentration of allantoin."7.78Relationship between serum allantoin and urate in healthy subjects and effects of benzbromarone in gout patients. ( Koga, M; Koyama, H; Kurajoh, M; Moriwaki, Y; Shoji, T; Sumida, C; Tsutsumi, Z; Yamamoto, A; Yamamoto, T, 2012)
"Allopurinol is the most commonly used urate-lowering therapy in gout."7.78Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. ( Dalbeth, N; Dockerty, JL; Drake, J; Frampton, C; Jones, PB; Stamp, LK; Taylor, WJ, 2012)
"In this hypothesis-generating study, gout patients who took colchicine had a significantly lower prevalence of MI and exhibited trends toward reduced all-cause mortality and lower CRP level versus those who did not take colchicine."7.78Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. ( Crittenden, DB; Cronstein, BN; Greenberg, JD; Keenan, RT; Lehmann, RA; Pillinger, MH; Schneck, L; Sedlis, SP; Shah, B, 2012)
"Blood lead levels in the range currently considered acceptable are associated with increased prevalence of gout and hyperuricemia."7.78Low-level lead exposure and the prevalence of gout: an observational study. ( Bhalla, V; Krishnan, E; Lingala, B, 2012)
" We present a case of tophaceous gout with uric acid levels that did not respond to prescription of very high doses of allopurinol or uricosuric agents."7.77Febuxostat efficacy in allopurinol-resistant tophaceous gout. ( Reid, G; Uh, M, 2011)
"Allopurinol, a purine base analog inhibitor of xanthine oxidase (XO) activity, remains the standard for pharmacologic urate-lowering management of gout."7.77Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. ( Chohan, S, 2011)
"The treatment of gout requires a lowering of serum urate (SU) levels, and allopurinol is the drug that is most commonly used for this purpose."7.77Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level. ( Barclay, ML; Chapman, PT; Drake, J; Frampton, C; O'Donnell, JL; Stamp, LK; Zhang, M, 2011)
"Urate-lowering therapy (ULT), adjusted to achieve and maintain a serum uric acid (SUA) of <6 mg/dl, remains the standard of care for the chronic management of gout."7.77Improving the use of allopurinol in chronic gout: monitoring oxypurinol levels to guide therapy. ( Gilliland, WR; Keith, MP, 2011)
"To identify factors associated with acute gout attacks in normouricaemic gout patients receiving allopurinol."7.77Factors associated with acute gout attacks in normouricaemic gout patients receiving allopurinol: a retrospective study. ( Kim, YG; Lee, CK; Lee, SG; So, MW; Yoo, B, 2011)
"We tested 16 million SNPs, identified through whole-genome sequencing of 457 Icelanders, for association with gout and serum uric acid levels."7.77Identification of low-frequency variants associated with gout and serum uric acid levels. ( Andreassen, OA; Besenbacher, S; Bjornsdottir, G; de Visser, MC; Eyjolfsson, GI; Geirsson, AJ; Gudbjartsson, DF; Gudjonsson, SA; Gylfason, A; Helgadottir, HT; Helgason, A; Hjartarson, E; Holm, H; Jonasdottir, A; Jonsdottir, I; Jonsson, H; Karason, A; Kiemeney, LA; Kong, A; Magnusson, G; Magnusson, OT; Masson, G; Olafsson, I; Pack, AI; Pedersen, JH; Rafnar, T; Saemundsdottir, J; Stefansson, H; Stefansson, K; Sulem, P; Thorsteinsdottir, U; Walters, GB; Zanon, C, 2011)
"Recent genome-wide association and functional studies have shown that the ABCG2 gene encodes for a urate transporter, and a common causal ABCG2 variant, rs2231142, leads to elevated uric acid levels and prevalent gout among Whites and Blacks."7.76The rs2231142 variant of the ABCG2 gene is associated with uric acid levels and gout among Japanese people. ( Folsom, AR; Iso, H; Kitamura, A; Köttgen, A; Tanigawa, T; Yamagishi, K, 2010)
"Published evidence in the literature, regulatory status, and relative costs of colchicine and nonsteroidal anti-inflammatory drugs (NSAIDs) for prophylaxis of gouty flares during early urate-lowering therapy are reviewed."7.76Nonsteroidal anti-inflammatory drugs and colchicine to prevent gout flare during early urate-lowering therapy: perspectives on alternative therapies and costs. ( Peterson, DM, 2010)
"To assess the value of dual energy computed tomography (DECT) for the detection of uric acid (UA) deposition in patients with gout."7.76[Application of dual-energy computed tomography for detecting uric acid deposition in patients with gout]. ( Chen, Y; Jin, ZY; Liu, W; Sun, H; Wang, X; Xu, K; Xue, HD; Zeng, XJ; Zhang, YQ, 2010)
"In this article we describe a gouty caucasian male patient who had high levels of serum uric acid since 1970s."7.75Persistent normalization of serum levels of uric acid in a gouty patient after administration of cyproterone acetate. ( D'Angelo, S; Olivieri, I; Palazzi, C; Pennese, E, 2009)
"To determine longterm urate-lowering efficacy and clinical benefits and safety of therapy with febuxostat or allopurinol in subjects with gout."7.75Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. ( Becker, MA; Lademacher, C; Lloyd, E; MacDonald, PA; Schumacher, HR, 2009)
"We examined the association between serum uric acid (SUA) level and the frequency, risk, and cost of gout flares among the elderly."7.75Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter? ( Cahill, KE; Krishnan, E; Mody, RR; Patel, PA; Tang, J; Wu, EQ; Yu, AP, 2009)
"The aim of this prospective study was to evaluate results of metformin (MF) therapy during 1 year of uric acid (UA) metabolism and the clinical course of gout with insulin resistance (IR)."7.75[Effect of metformin on the clinical course of gout and insulin resistance]. ( Aleksandrova, EN; Barskova, VG; Eliseev, MS; Kudaeva, FM; Nasonov, EL; Nasonova, VA; Volkov, AV, 2009)
"Gout is well known to be produced by increased uric acid level in blood."7.75Calcium oxalate stone and gout. ( Marickar, YM, 2009)
"We identified three genetic loci associated with uric acid concentration and gout."7.74Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. ( Astor, BC; Benjamin, EJ; Boerwinkle, E; Coresh, J; Dehghan, A; Fox, CS; Hofman, A; Hwang, SJ; Kao, WL; Köttgen, A; Levy, D; Rivadeneira, F; van Duijn, CM; Witteman, JC; Yang, Q, 2008)
"2 mg/kg (monthly vs daily) in patients with tophaceous gout not treatable by allopurinol."7.74Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study. ( Bardin, T; Brière, C; Hoenen-Clavert, V; Loeuille, D; Richette, P, 2007)
"To evaluate haemoglobin A1c (HbA1c), fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels in a nationally representative sample of men and women."7.74Haemoglobin A1c, fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels--the Third National Health and Nutrition Examination Survey. ( Choi, HK; Ford, ES, 2008)
"Cross-sectional studies indicate metabolic syndrome is a risk factor for elevated serum uric acid."7.74Impact of childhood metabolic syndrome components on the risk of elevated uric acid in adulthood: the Bogalusa Heart Study. ( Berenson, G; Chen, W; Menke, A; Muntner, P; Patel, DA; Srinivasan, S, 2008)
"We determined why calcium oxalate stones instead of uric acid stones form in some patients with gouty diathesis."7.73Physicochemical metabolic characteristics for calcium oxalate stone formation in patients with gouty diathesis. ( Moe, OW; Pak, CY; Peterson, RD; Poindexter, JR; Sakhaee, K, 2005)
"Patients with system lupus erythematosus, rheumatic arthritis, chronic active hepatitis and gout were found to have considerable hyperuricemia and be decreased in aminoacides content, which are the predecessors of purine."7.73[Hyperuricemia and disorders in content of amino acids-purine precursors in patients with autoimmune diseases and gout]. ( Anan'eva, MN; Dubiaga, VV; Nikolenko, IuI; Nikolenko, VIu; Shchukin, IN; Siniachenko, OV, 2005)
"Development of the acute and chronic inflammatory responses known as gout and pseudogout are associated with the deposition of monosodium urate (MSU) or calcium pyrophosphate dihydrate (CPPD) crystals, respectively, in joints and periarticular tissues."7.73Gout-associated uric acid crystals activate the NALP3 inflammasome. ( Martinon, F; Mayor, A; Pétrilli, V; Tardivel, A; Tschopp, J, 2006)
"Adherence to published allopurinol dosing guidelines led to suboptimal control of hyperuricemia in this population of patients with gout."7.73Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. ( Dalbeth, N; Gow, P; Kumar, S; Stamp, L, 2006)
"To assess the efficacy of fenofibrate treatment in combination with urate lowering agents in patients with gout."7.73Effect of fenofibrate in combination with urate lowering agents in patients with gout. ( Lee, CH; Lee, J; Lee, YH, 2006)
"The clinical manifestations of gout result from the formation and deposition of uric acid (UA) crystals."7.72Determination of uric acid in human saliva by capillary electrophoresis with electrochemical detection: potential application in fast diagnosis of gout. ( Chu, Q; Guan, Y; Ye, J, 2004)
"The effect of Tofu (bean curd) ingestion on uric acid metabolism was examined in 8 healthy and 10 gout subjects."7.70Effect of Tofu (bean curd) ingestion and on uric acid metabolism in healthy and gouty subjects. ( Higashino, K; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamakita, J; Yamamoto, T, 1998)
"To investigate the incidence of gout and the interaction between uric acid level and other risk factors in the development of gout."7.70The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. ( Chou, P; Lin, HY; Lin, KC, 2000)
" We examined the development of gout and an increased uric acid level in relation to lead, adjusting for other known risk factors."7.70Effect of low level lead exposure on hyperuricemia and gout among middle aged and elderly men: the normative aging study. ( Hu, H; Kim, R; Liang, MH; Shadick, NA; Sparrow, D; Weiss, S, 2000)
"We compared gouty diathesis with uric acid versus calcium stones."7.69Clinical and biochemical presentation of gouty diathesis: comparison of uric acid versus pure calcium stone formation. ( Adams-Huet, B; Khatchadourian, J; Pak, CY; Preminger, GM; Whitson, PA, 1995)
"Ten women with crystal-proved primary gout and normal serum creatinine levels (below 116 mmol/L) were studied while they were on a purine-restricted diet and taking no medications known to influence uric acid metabolism."7.69Purine metabolism in women with primary gout. ( de Miguel, E; Gil, AA; Mateos, FA; Miranda, ME; Pérez de Ayala, C; Puig, JG; Torres, RJ, 1994)
"Primary gout is characterized by increased plasma and decreased urinary concentrations of hypoxanthine, xanthine and uric acid."7.69Purine metabolism in patients with gout: the role of lead. ( Herrero, E; Mateos, FA; Miranda-Carús, E; Puig, JG; Ramos, T; Sanz, AG, 1997)
"Hyperuricemia and gout have been associated with cyclosporine A (CyA) therapy in transplant recipients."7.68Tophaceous gout in patients with renal transplants treated with cyclosporine A. ( Baethge, BA; Landreneau, MD; McDonald, JC; Work, J, 1993)
"Lasting normalisation of uric acid levels after treatment of patients with gout and hyperuricaemia with a combination of 300 mg allopurinol and 60 mg benzbromarone A total of 210 patients (163 men, 47 women) with gout and hyperuricaemia was treated for three months with daily doses of 300 mg allopurinol and 60 mg benzbromarone."7.68[Long lasting normalization of uric acid after combination therapy with 300 mg allopurinol and 60 mg benzbromarone in patients with gout and hyperuricemia]. ( Matzkies, F, 1992)
"To determine the frequency and characteristics of hyperuricemia and gouty arthritis among cyclosporine-treated heart transplant recipients."7.68Hyperuricemia and gout among heart transplant recipients receiving cyclosporine. ( Burack, DA; Griffith, BP; Kahl, LE; Thompson, ME, 1992)
"We reviewed the clinical features and uric acid metabolism in 37 female patients with gout."7.68Female gout. Clinical spectrum and uric acid metabolism. ( Capitán, CF; de Miguel, E; Gijón, JB; Jiménez, ML; Mateos, FA; Michán, AD; Pérez de Ayala, C; Puig, JG, 1991)
"Ten patients with gout, hypertension, and mild to moderate renal insufficiency were studied for possible lead nephropathy by measuring stimulated urinary lead excretion."7.67Occult lead intoxication in patients with gout and kidney disease. ( Cecere, FA; Saylor, RP; Wright, LF, 1984)
"Sixteen hyperuricemic gouty patients were treated with diflunisal, a novel salicylate, 500 mg BID."7.67Hypouricemic action of diflunisal in gouty patients: in vitro and in vivo studies. ( Ambanelli, U; Ferraccioli, G; Spisni, A, 1984)
"The behavior of plasma and urine oxypurines (hypoxanthine and xanthine) and of uric acid has been studied in normal subjects and in gout patients."7.67[Analysis of uric acid and oxypurines in normal subjects and in gout patients]. ( Di Stefano, A; Leoncini, R; Marinello, E; Pizzichini, M; Porcelli, B; Taddeo, A, 1989)
"The clearance of uric acid, hypoxanthine and xanthine has been examined in gout patients and in normal subjects compared to creatinine, after a purine-free diet."7.67[Clearance of oxypurines in normal subjects and in gout patients subjected to a purine-free diet. Effects of allopurinol]. ( Di Stefano, A; Leoncini, R; Marinello, E; Pizzichini, M; Porcelli, B; Taddeo, A, 1989)
"The relationship between uric acid metabolism and lipid levels was analyzed in 148 male subjects with primary gout."7.67Relationship between hypertriglyceridemia and uric acid production in primary gout. ( Jiao, S; Kubo, M; Matsubara, K; Matsuzawa, Y; Takama, T; Tarui, S, 1989)
"Two members of a Spanish family were studied: an eight-year-old boy (Patient 1) with tophaceous gout, purine nucleotide and uric acid overproduction, and sensorineural deafness, and his 27-year-old mother (Patient 2), who had gout."7.67Inherited superactivity of phosphoribosylpyrophosphate synthetase: association of uric acid overproduction and sensorineural deafness. ( Becker, MA; Jimenez, ML; Kim, M; Mateos, FA; Puig, JG; Simmonds, HA, 1988)
"A patient with coexistent Klinefelter's syndrome, systemic lupus erythematosus (SLE) and chronic tophaceous gouty arthritis developed allopurinol hypersensitivity."7.67Allopurinol hypersensitivity in a patient with coexistent systemic lupus erythematosus and tophaceous gout. ( Fam, AG; McDonald, J; Paton, T; Senn, J, 1988)
"The renal excretion of uric acid is usually diminished in primary gout with respect to increased serum urate levels."7.67Renal excretion of hypoxanthine and xanthine in primary gout. ( Jiménez, ML; Mateos, FA; Puig, JG; Ramos, TH, 1988)
"Uric acid concentration in the serum was investigated 3 times a day using the uricase method in 15 gout inpatients on a hypopurine diet with age- and sex-adjusted caloric content."7.67[Circadian rhythm of uric acid levels of the serum in gout]. ( Atanasov, NA; Karastanev, II; Kereziev, IK; Kuzmanova, SI; Solakov, PTs, 1987)
"In an open trial 15 patients with acute gout attacks were treated with Tolmetin."7.66[Treatment of acute gout attacks with tolmetin (author's transl)]. ( Gaismayer, K; Petera, P; Tausch, G, 1982)
"The incorporation of 15N-glycine into urinary uric acid was studied in three gouty patients, repeating a study carried out 13 to 27 years ago."7.66Long-term follow-up of incorporation of 15N from glycine into uric acid in gout. ( Roboz, J; Yu, TF, 1981)
"The results over 10 years in 200 patients (103 with gout and 97 with hyperuricaemia) treated with benzbromarone 75 - 120 mg/d are reported."7.66Ten years' experience with benzbromarone in the management of gout and hyperuricaemia. ( Giudicelli, CP; Masbernard, A, 1981)
"We describe three patients in whom severe, life-threatening hyperkalemia and renal insufficiency developed after treatment of acute gouty arthritis with indomethacin."7.66Indomethacin-induced hyperkalemia in three patients with gouty arthritis. ( Beckstrom, D; Findling, JW; Itskovitz, H; Kozin, F; Rawsthorne, L, 1980)
"A patient with intractable tophaceous gout and advanced renal failure responded favorably to treatment by long-term hemodialysis and administration of allopurinol."7.66Chronic gouty nephropathy treated by long-term hemodialysis and allopurinol. ( Johnson, WJ; O'Duffy, JD, 1979)
"Chronic lead nephtropathy, secondary gout (lead-gout) and porphyrinuria may develop after long lasting professional exposure to lead."7.65[Chronic lead poisoning: Lead gout with giant tophi on the skin, nephrophathy and porphyrinopathy]. ( Künzig, M; Orfanos, CE, 1975)
"Chickens genetically selected for high incidence of articular gout and hyperuricemia were used to determine the site of defective uric acid (UA) transport in gout."7.65Localization of renal tubular uric acid transport defect in gouty chickens. ( Quebbemann, AJ; Zmuda, MJ, 1975)
"THE CONCEPT OF AN ABNORMALITY OF GLUTAMINE METABOLISM IN PRIMARY GOUT WAS FIRST PROPOSED ON THE BASIS OF ISOTOPE DATA: when [(15)N]glycine was administered to gouty subjects, there was disproportionately great enrichment of N-(3 + 9) of uric acid, which derive from the amide-N of glutamine."7.65The kinetics of intramolecular distribution of 15N in uric acid after administration of (15N) glycine. A reappraisal of the significance of preferential labeling of N-(3+9) of uric acid in primary gout. ( Sperling, O; Starmer, CF; Wyngaarden, JB, 1973)
" Serum uric acid levels may rise slightly, but no clinical gout was seen in this study."7.64TREATMENT OF CONGESTIVE HEART FAILURE WITH TRIAMTERENE. ( FRIEDMAN, R; SCHUCHER, R; WENER, J, 1965)
"Adenine inhibited the de novo synthesis of purines in both normal and gouty man as shown by inhibition of the incorporation of glycine-(15)N into urinary uric acid without altering the incorporation of glycine-(15)N into urinary creatinine."7.64Suppression of glycine-15N incorporation into urinary uric acid by adenine-8-13C in normal and gouty subjects. ( Klinenberg, JR; Miller, J; Seegmiller, JE; Watts, RW, 1968)
" The MGH Acupuncture Sensation Scale and adverse events related to acupuncture will be measured after each treatment."7.30Evaluating the effectiveness and safety of acupuncture on serum uric acid in asymptomatic hyperuricemia population: a randomized controlled clinical trial study protocol. ( Chen, Z; Fang, MY; Huang, Y; Li, CN; Lin, FP; Liu, WH; Ma, Y; Tu, SH; Wang, B; Wang, Y; Xie, WX; Yu, LL; Zhang, RY; Zheng, CH, 2023)
"To determine the long-term use of and adherence to urate-lowering therapy (ULT), serum urate (SU) control, and self-reported flares in participants from a randomized controlled trial of allopurinol dose escalation, in order to achieve target SU concentration (< 0."7.11Long-Term Follow-up of a Randomized Controlled Trial of Allopurinol Dose Escalation to Achieve Target Serum Urate in People With Gout. ( Coleman, GB; Dalbeth, N; Drake, J; Frampton, C; Haslett, J; Horne, AM; Stamp, LK; Su, I, 2022)
"Gout is a multifactorial metabolic and inflammatory disease that occurs when increased uric acid (UA) induce HU resulting in monosodium urate (MSU) crystal deposition in joints."7.01Uric acid en route to gout. ( Zhang, WZ, 2023)
" The primary endpoint was safety, assessed by adverse events (AE) and laboratory values."6.79Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study. ( Evans, RR; King-Davis, S; Kivitz, A; Schumacher, HR; Sundy, JS; Weinstein, SP; Wu, R, 2014)
"Despite an increasing incidence of gout in older age patients with multiple metabolic and cardiovascular comorbidities, there are limited data addressing whether currently available urate-lowering therapy is comparably effective and safe in older (≥65 years of age) versus younger (<65 years of age) patients."6.76Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects. ( Becker, MA; Gunawardhana, L; Hunt, B; MacDonald, PA, 2011)
"Treatment with benzbromarone monotherapy (range: 100-200 mg/day; mean 138 mg/day) resulted in 92% of patients reaching target levels sUr 6.73Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. ( Brouwers, JR; Houtman, PM; Jansen, TL; Reinders, MK; van Roon, EN, 2007)
"Treatment with febuxostat resulted in a significant reduction of sUA levels at all dosages."6.71Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. ( Becker, MA; Eustace, D; Joseph-Ridge, N; MacDonald, PA; Palo, WA; Schumacher, HR; Vernillet, L; Wortmann, RL, 2005)
"Losartan has been shown to increase urinary uric acid excretion and hence to lower serum uric acid levels."6.70Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. ( Brunner, HR; Burnier, M; Chiolero, A; Fallab-Stubi, CL; Gerster, JC; Maillard, M; Würzner, G, 2001)
"The treatment of gout is based on several principles."6.58Crystal arthritides - gout and calcium pyrophosphate arthritis : Part 3: Treatment. ( Bertsch, T; Bollheimer, LC; Härle, P; Schlee, S; Sieber, CC, 2018)
"Gout is a clinical disorder that is characterized by the deposition of monosodium urate crystals (MSU) in joints and tendons, usually in the presence of prolonged hyperuricaemia."6.55Review of the ophthalmic manifestations of gout and uric acid crystal deposition. ( Ao, J; Casson, RJ; Goldblatt, F, 2017)
"Allopurinol is a safe option, slightly better than other ULDs."6.52Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis. ( Carmona, L; Castrejon, I; Loza, E; Pérez-Ruiz, F; Rosario, MP; Toledano, E, 2015)
"Uric acid has a stimulating effect on the cerebral cortex, and this could have allowed humans, compared with other animals, to develop higher brain mass volume, better intellectual performances, and maybe evolutionary supremacy."6.52Uric acid: friend or foe? Uric acid and cognitive function "Gout kills more wise men than simple". ( De Giorgi, A; Fabbian, F; Manfredini, R; Misurati, E; Pala, M; Parisi, C; Tiseo, R, 2015)
"Gout is one of the most common forms of arthritis."6.50Impaired response or insufficient dosage? Examining the potential causes of "inadequate response" to allopurinol in the treatment of gout. ( Barclay, ML; Dalbeth, N; Merriman, TR; Roberts, RL; Singh, JA; Stamp, LK; Wright, DF, 2014)
"Uric acid is a waste product of purine catabolism."6.49Uric acid as a danger signal in gout and its comorbidities. ( Kataoka, H; Lai, JJ; Rock, KL, 2013)
"Uric acid has been identified as an endogenous adjuvant that drives immune responses in the absence of microbial stimulation."6.47The role of uric acid as an endogenous danger signal in immunity and inflammation. ( Ghaemi-Oskouie, F; Shi, Y, 2011)
"Uric acid is a weak acid that exists largely as MSU, the ionized form, in urate pool at physiologic pH."6.44[Physiology and dynamics of uric acid in hyperuricemia]. ( Nakamura, T; Takagi, K; Ueda, T, 2008)
"Dimethyl fumarate (DMF) has shown anti-inflammatory and antioxidant activities."5.91Dimethyl fumarate attenuates MSU-induced gouty arthritis by inhibiting NLRP3 inflammasome activation and oxidative stress. ( Cao, Y; Hu, Y; Jin, XF; Liu, Y; Zou, JM, 2023)
"Uric acid has antioxidant and neuroprotective properties."5.91[The influence of uric acid on the course of amyotrophic lateral sclerosis]. ( Areprintseva, DK; Kutlubaev, MA; Pervushina, EV, 2023)
"Uric acid (UA) is an important antioxidant that has been positively associated with muscle strength in older adults."5.91Association between serum uric acid and muscle strength in older adults with or without gout diagnosis: NHANES 2011-2014. ( de Oliveira, EP; Nahas, PC; Nehme, R, 2023)
"The gouty ulcers were not completely healed by Day 14 compared with those in the PBS controls."5.72Gout-associated uric acid crystals induce tophi ulcerations and impair wound healing in a novel gouty ulcer model. ( Bao, W; Cheng, X; Jia, C; Su, Y; Wang, P; Xue, Y; Yin, B, 2022)
"Melatonin (MLT) is a powerful endogenous anti-inflammatory agent and effective in reducing cellular damage."5.72Influence of Pinealectomy and Long-term Melatonin Administration on Inflammation and Oxidative Stress in Experimental Gouty Arthritis. ( Altinoz, E; Ballur, AFH; Bicer, Y; Demir, M; Elbe, H; Karayakali, M; Onal, MO; Yigitturk, G, 2022)
"Gout is a chronic disease caused by monosodium urate (MSU) crystal deposition in the joints and surrounding tissues."5.72Taxifolin blocks monosodium urate crystal-induced gouty inflammation by regulating phagocytosis and autophagy. ( Jiang, YJ; Lian, LH; Nan, JX; Piao, MH; Wang, H; Wu, YL, 2022)
"Gout is a painful form of inflammatory arthritis characterized by the deposition of monosodium urate (MSU) crystals in the joints."5.72The Therapeutic Effect of Phosphopeptide P140 Attenuates Inflammation Induced by Uric Acid Crystals in Gout Arthritis Mouse Model. ( Aganetti, M; Amaral, FA; Braga, AD; de Faria, AMC; de Oliveira, VLS; Galvão, I; Georgel, P; Martins, VD; Mastrippolito, D; Mendes, V; Muller, S; Rocha, V; Talamini, L; Verdot, C; Vieira, AT, 2022)
"To assess efficacy, safety, pharmacokinetics, and immunogenicity of pegloticase plus methotrexate (MTX) versus pegloticase plus placebo cotreatment for uncontrolled gout in a randomized, placebo-controlled, double-blind trial."5.69A Randomized, Placebo-Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings. ( Botson, JK; Chamberlain, J; Grewal, S; La, D; LaMoreaux, B; LoCicero, K; Majjhoo, A; Obermeyer, K; Ong, S; Parikh, N; Peterson, J; Saag, K; Sainati, S; Tesser, JRP; Verma, S; Weinblatt, ME; Xin, Y, 2023)
"No significant increase was noted in acute gout flare severity or duration among GA patients treated with early aggressive control of hyperuricemia using probenecid plus colchicine."5.69Early urate-lowering therapy in gouty arthritis with acute flares: a double-blind placebo controlled clinical trial. ( Chen, HC; Wei, JC; Yang, DH, 2023)
"To determine whether placebo is non-inferior to low-dose colchicine for reducing gout flares during the first 6 months of allopurinol using the 'start-low go-slow' dose approach."5.69Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial. ( Chapman, PT; Dalbeth, N; Drake, J; Frampton, C; Haslett, J; Horne, A; Mihov, B; Stamp, L, 2023)
"This study aimed to investigate the efficacy and safety of tart cherry supplementary citrate (TaCCi) mixture on urine pH, serum urate (sUA), C-reactive protein (CRP), and gout flares in gout patients initiating urate-lowering therapy (ULT), in comparison to citrate mixture and sodium bicarbonate."5.69Efficacy and safety of tart cherry supplementary citrate mixture on gout patients: a prospective, randomized, controlled study. ( Cui, L; Dalbeth, N; Han, L; He, Y; Ji, A; Ji, X; Li, C; Li, X; Liu, Z; Sun, M; Sun, W; Wang, C; Wang, X; Wang, Z; Xue, X, 2023)
"Thus, hyperuricemia is associated with impaired endothelial function."5.62Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease - Japanese Guideline on the Management of Asymptomatic Hyperuricemia. ( Bahrudin, U; Hisatome, I; Kuwabara, M; Li, P; Maharani, N; Mahati, E; Miake, J; Ninomiya, H; Taufiq, F; Utami, SB, 2021)
"Patients with hyperuricemia are among the high-risk group of postoperative gout attacks."5.62Factors Influencing Early Serum Uric Acid Fluctuation After Bariatric Surgery in Patients with Hyperuricemia. ( Fu, L; Liu, Y; Wen, J; Xu, C; Yan, T; Yang, H; You, Y; Yu, J; Zhan, D; Zhang, T, 2021)
"To investigate whether serum urate levels, number of gout flares, and tophi burden are related to death from cardiovascular (CV) causes after treatment with febuxostat or allopurinol in patients with gout from the Cardiovascular Safety of Febuxostat or Allopurinol in Patients With Gout and Cardiovascular Comorbidities (CARES) trial."5.51Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial. ( Becker, MA; Borer, JS; Castillo, M; Gorelick, PB; Gunawardhana, L; Hunt, B; Saag, KG; Whelton, A; White, WB, 2022)
"Calcium supplementation (770 mg/d from dairy or calcium citrate) reduced serum urate concentrations, suggesting that the gout-protective effect of low-fat dairy consumption is at least partly due to a urate-lowering effect of calcium."5.51Urate-lowering effect of calcium supplementation: Analyses of a randomized controlled trial. ( Alfenas, RCG; Alves, RDM; Bittencourt, JM; Cândido, FG; Freitas, DMO; Rocha, DMUP, 2022)
"The predominant mechanism driving hyperuricemia in gout is renal uric acid underexcretion; however, the standard urate-lowering therapy (ULT) recommendation is first-line xanthine oxidase inhibitor (XOI), irrespective of the cause of hyperuricemia."5.51Superiority of Low-Dose Benzbromarone to Low-Dose Febuxostat in a Prospective, Randomized Comparative Effectiveness Trial in Gout Patients With Renal Uric Acid Underexcretion. ( Chen, Y; Cheng, X; Cui, L; Dalbeth, N; He, Y; Hu, S; Ji, A; Li, C; Li, H; Liu, Z; Lu, J; Ma, L; Qi, H; Ran, Z; Sun, M; Terkeltaub, R; Wang, C; Xue, X; Yan, F; Yu, Q; Yuan, X, 2022)
"Allopurinol is a urate-lowering therapy used to treat patients with gout."5.51Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial. ( Avery, AJ; Barr, RJ; Begg, AG; Duce, SL; Dumbleton, JS; Ford, I; Greenlaw, N; Hawkey, CJ; MacDonald, TM; Mackenzie, IS; Pigazzani, F; Ritchie, LD; Rogers, A; Rooke, ED; Struthers, AD; Taggar, JS; Townend, JN; Walker, A; Wei, L, 2022)
"The present study compared the efficacy and safety of low-dose febuxostat versus allopurinol in chronic kidney disease (CKD) patients complicated with hyperuricemia (HUA)."5.51Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study. ( Cao, B; Yang, N, 2022)
" One hundred and ninety-seven adults with gout and SUA levels ≥8 mg/dL were randomized to febuxostat or allopurinol in a 1:1 ratio for 36 weeks."5.51Effects of intensive urate lowering therapy with febuxostat in comparison with allopurinol on pulse wave velocity in patients with gout and increased cardiovascular risk: the FORWARD study. ( Borghi, C; Desideri, G; Gerritsen, M; Giannattasio, C; Nurmohamed, MT; Rajzer, M; Tausche, AK, 2022)
"Early allopurinol initiation during an acute gout flare did not lead to significant changes in time to resolution, flare recurrence, and inflammatory markers."5.51Early versus Late Allopurinol Initiation in Acute Gout Flare (ELAG): a randomized controlled trial. ( Manavathongchai, S; Pongsittisak, W; Satpanich, P, 2022)
"Gout is the most common inflammatory arthritis worldwide, and patients experience a heavy burden of cardiovascular and metabolic diseases."5.51mTOR inhibition by metformin impacts monosodium urate crystal-induced inflammation and cell death in gout: a prelude to a new add-on therapy? ( Broen, JCA; Jansen, M; Merriman, T; Ottria, A; Phipps-Green, A; Radstake, TRDJ; Schuiveling, M; van der Linden, M; van Lochem, E; Vazirpanah, N; Wichers, CGK; Zimmermann, M, 2019)
"Gout is a chronic disease associated with deposition of monosodium urate crystals and accompanied by diabetes, hypertension, and dyslipidemia."5.48Effect of fenofibrate on uric acid level in patients with gout. ( Choi, Y; Jung, JY; Kim, HA; Suh, CH; Yoon, D, 2018)
"Gout is a painful disorder which does not have an efficient delivery system for its treatment."5.46Oral delivery of allopurinol niosomes in treatment of gout in animal model. ( Kaithwas, G; Kanoujia, J; Parashar, P; Saraf, SA; Singh, N; Tripathi, CB, 2017)
"This network meta-analysis demonstrated an important absolute benefit of dotinurad 4 mg once daily to achieve target serum uric acid and low risk of adverse events for drug treatment of gout or hyperuricemia patients."5.41Comparative efficacy and safety of uricosuric agents in the treatment of gout or hyperuricemia: a systematic review and network meta-analysis. ( Chen, LR; Guo, Y; He, GH; Jiang, FF; Li, YJ; Qian, K; Wang, P; Yang, M; Yang, ZL; Yin, SJ, 2023)
" Gout is the most common inflammatory arthritis worldwide and starts with the crystallization of uric acid within the joints and soft tissues."5.41Amyloid A amyloidosis on medullary sponge kidney in a 28-year-old male with gout: A case report and literature review. ( Acikalin, MF; Kasifoglu, T; Yilmaz, F, 2023)
"Gout is common in patients with heart failure (HF), and sodium-glucose cotransporter 2 inhibitors, a foundational treatment for HF, reduce uric acid levels."5.41Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER. ( Butt, JH; Claggett, BL; de Boer, RA; Desai, AS; Docherty, KF; Hernandez, AF; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Lam, CSP; Langkilde, AM; Martinez, FA; McMurray, JJV; Petersson, M; Ponikowski, P; Sabatine, MS; Shah, SJ; Solomon, SD; Vaduganathan, M, 2023)
"Theaflavins exert anti-gout effects by down regulating the gene and protein expression of glucose transporter 9 (GLUT9) and uric acid transporter 1 (URAT1), while upregulating the mRNA expression levels of organic anion transporter 1 (OAT1), organic cation transporter N1 (OCTN1), organic cation transporters 1/2 (Oct1/2), and organic anion transporter 2 (OAT2)."5.41Mechanisms of theaflavins against gout and strategies for improving the bioavailability. ( Chen, J; Gong, S; Hu, J; Li, X; Ma, L; Yu, H; Zheng, Y; Zheng, Z, 2023)
"Gout is a common inflammatory arthritis caused by increased serum uric acid levels."5.41The Chinese patent medicine Tongfengding capsule for gout in adults: a systematic review of safety and effectiveness. ( Hua, Q; Lin, Y; Liu, X; Luo, Y; Xia, A; Yang, Q; Zheng, K, 2023)
"Xanthine oxidase inhibitors such as allopurinol and febuxostat have been the mainstay urate-lowering therapy (ULT) for treating hyperuricaemia in patients with gout."5.41Mechanisms and rationale for uricase use in patients with gout. ( Lioté, F; Pérez-Ruiz, F; Schlesinger, N, 2023)
"Gout is a common inflammatory arthritis caused by persistently elevated uric acid levels."5.41Gout therapeutics and drug delivery. ( Boucetta, H; Chen, Z; He, W; Lai, Y; Li, X; Peng, X; Sosnik, A; Xie, B, 2023)
" This review article focuses on the relationship between uric acid and thirteen specific domains: transporters, genetic factors, diet, lifestyle, gout, diabetes mellitus, metabolic syndrome, atherosclerosis, hypertension, kidney diseases, cardiovascular diseases, neurological diseases, and malignancies."5.41Exploring the Multifaceted Nexus of Uric Acid and Health: A Review of Recent Studies on Diverse Diseases. ( Abe, K; Akashi, N; Aoki, Y; Fukuuchi, T; Hisatome, I; Ichida, K; Kurajoh, M; Kuwabara, M; Maruhashi, T; Miyata, H; Mizuta, E; Morikawa, N; Morita, M; Nishimiya, K; Ogino, K; Otani, N; Ouchi, M; Takada, T; Tanaka, A; Tanaka, Y; Tsutani, H, 2023)
"Thirty-nine subjects with persistent hyperuricemia were randomized to receive curcumin (500-mg capsules twice daily, 20 subjects) or placebo (19 subjects)."5.41Effect of Curcumin on Serum Urate in Asymptomatic Hyperuricemia: A Randomized Placebo-Controlled Trial. ( Asavatanabodee, P; Bupparenoo, P; Chaiamnuay, S; Narongroeknawin, P; Pakchotanon, R, 2021)
"To examine the efficacy and safety of pegloticase in combination with methotrexate (MTX) in patients with uncontrolled gout in an exploratory, open-label clinical trial (ClinicalTrials."5.41Pegloticase in Combination With Methotrexate in Patients With Uncontrolled Gout: A Multicenter, Open-label Study (MIRROR). ( Bennett, R; Botson, JK; Kenney, HM; LaMoreaux, B; Obermeyer, K; Peloso, PM; Peterson, J; Tesser, JRP; Weinblatt, ME, 2021)
"Our objective was to determine whether initiation of febuxostat during an acute gout flare prolongs the current episode."5.41Initiation of febuxostat for acute gout flare does not prolong the current episode: a randomized clinical trial. ( Cui, X; Geng, H; Jia, E; Jiang, Y; Li, B; Ma, W; Qiu, X; Wei, J; Xiao, M; Xiao, Y; Xie, J; Yao, X; Zhang, J; Zhang, Y; Zhong, L, 2021)
"Urate crystal gout arthritis and calcium pyrophosphate deposition disease (CPPD) are crystalline arthropathies seen in middle age to elderly patients, but are also seen in the active duty military population."5.4120 Years of Radiographic Imaging: Crystalline Deposits Causing Severe Arthropathy and Erosions. ( Babb, S; Breighner, C; Goldstein, E; Mank, VMF; Meghpara, S; Roberts, J, 2023)
"Hip fractures were not significantly associated with UA."5.40Association of serum uric acid and incident nonspine fractures in elderly men: the Osteoporotic Fractures in Men (MrOS) study. ( Cawthon, PM; Lane, NE; Lay, YA; Lui, LY; Orwoll, E; Parimi, N; Wise, BL; Yao, W, 2014)
"Gout is a metabolic disorder associated with hyperuricemia resulting in the deposition of monosodium urate (MSU) crystals in joints and tissues."5.40Study on the anti-gout activity of chlorogenic acid: improvement on hyperuricemia and gouty inflammation. ( Cao, L; Ding, G; Guo, CR; Huang, WZ; Meng, ZQ; Tang, ZH; Wang, KD; Wang, ZZ; Xiao, W; Yan, YX; Yang, ZL, 2014)
"Because refractory gout is associated with high oxidative stress in spite of high PUA, and profoundly depleting uric acid did not increase lipid or protein oxidation, we conclude that urate is not a major factor controlling oxidative stress in vivo."5.36Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo. ( Ganson, NJ; Hershfield, MS; Jaggers, D; Kelly, SJ; Roberts, LJ; Santisteban, I; Scarlett, E; Sundy, JS, 2010)
"Dotinurad, a novel selective urate reabsorption inhibitor (SURI) that has a future potential for the treatment of hyperuricemia, reduces serum uric acid levels by selectively inhibiting urate transporter 1 (URAT1)."5.34Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 stu ( Fushimi, M; Hosoya, T; Ohashi, T; Sano, T; Sasaki, T, 2020)
"Dotinurad, a novel selective urate reabsorption inhibitor (SURI), reduces serum uric acid levels by selectively inhibiting urate transporter 1 (URAT1) for the treatment of hyperuricemia with or without gout."5.34Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study. ( Fushimi, M; Hosoya, T; Ohashi, T; Sano, T; Sasaki, T, 2020)
"Dotinurad at doses of 2-4-mg sufficiently reduced serum uric acid levels in hyperuricemic patients with or without gout, and its efficacy and safety were verified for long-term administration."5.34Open-label study of long-term administration of dotinurad in Japanese hyperuricemic patients with or without gout. ( Fushimi, M; Hosoya, T; Ohashi, T; Okui, D; Sasaki, T, 2020)
" We evaluated the efficacy and safety of dotinurad versus febuxostat, a widely used drug in Japan, in hyperuricemic Japanese patients with or without gout."5.34A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout. ( Furuno, K; Hosoya, T; Kanda, S, 2020)
"Dotinurad 2 mg was verified to have a non-inferior serum uric acid lowering effect compared with benzbromarone 50 mg, in Japanese hyperuricemic patients with or without gout."5.34Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study. ( Fushimi, M; Hosoya, T; Ohashi, T; Sano, T; Sasaki, T, 2020)
"Febuxostat and allopurinol are urate-lowering therapies used to treat patients with gout."5.34Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. ( De Caterina, R; Findlay, E; Ford, I; Hallas, J; Hawkey, CJ; MacDonald, TM; Mackenzie, IS; McMurray, JJV; Nuki, G; Perez-Ruiz, F; Ralston, SH; Robertson, M; Walters, M; Webster, J, 2020)
"Gout is a metabolic disorder that results in hyperuricemia and the deposition of positively birefringent monosodium urate crystals in various parts of the body."5.33Gout induced by intoxication of sodium bicarbonate in Korean native broilers. ( Ejaz, S; Kim, BS; Lim, CW, 2005)
"Episodes of gout are common in the setting of renal transplantation."5.31Tacrolimus for the treatment of gout in renal transplantation: two case reports and review of the literature. ( Dittmer, I; Faire, B; Pilmore, HL, 2001)
"To compare the efficacy and safety of low-dose febuxostat with low-dose benzbromarone in patients with primary gout, a randomized controlled, open-label trial was performed among male patients with primary gout for urate-lowering therapy (ULT) in a dedicated gout clinic in China."5.30Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort. ( Cheng, X; Cui, L; He, Y; Ji, A; Li, C; Li, H; Liang, N; Ma, L; Sun, M; Sun, R; Sun, W; Wang, C; Wu, X; Xu, T; Xue, X; Yuan, X; Zhang, H, 2019)
"To assess the efficacy and safety of febuxostat extended release (XR) and immediate release (IR) in patients with gout and normal or impaired renal function."5.30Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study. ( Becker, MA; Castillo, M; Gunawardhana, L; Hunt, B; Kisfalvi, K; Saag, KG; Whelton, A, 2019)
"Lesinurad [Zurampic; 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)], a selective inhibitor of uric acid reabsorption transporters approved for the treatment of gout, is a racemate of two atropisomers."5.30Characterization of Stereoselective Metabolism, Inhibitory Effect on Uric Acid Uptake Transporters, and Pharmacokinetics of Lesinurad Atropisomers. ( Girardet, JL; Lee, CA; Miner, JN; Renner, M; Shen, Z; Wilson, DM; Yang, C; Zhou, D, 2019)
"We conducted a site-randomized trial (n=1463 patients) comparing a 1-year, pharmacist-led intervention to usual care in patients with gout initiating allopurinol."5.30Adherence and Outcomes with Urate-Lowering Therapy: A Site-Randomized Trial. ( Cheetham, TC; Chen, L; Coburn, BW; Curtis, JR; Foster, PJ; Kerimian, A; Levy, GD; Low, KJ; Mikuls, TR; Rashid, N; Redden, DT; Saag, KG, 2019)
"URC102, a novel and potent inhibitor of human uric acid transporter 1 (hURAT1), is currently under clinical development to treat patients with gout."5.30URC102, a potent and selective inhibitor of hURAT1, reduced serum uric acid in healthy volunteers. ( Ahn, Y; Lee, H; Lee, HA; Onohara, M; Park, SI; Yoon, S; Yu, KS, 2019)
"To examine whether allopurinol dose escalation to achieve serum urate (SU) target can influence bone erosion or monosodium urate (MSU) crystal deposition, as measured by dual-energy computed tomography (DECT) in patients with gout."5.30Effects of Allopurinol Dose Escalation on Bone Erosion and Urate Volume in Gout: A Dual-Energy Computed Tomography Imaging Study Within a Randomized, Controlled Trial. ( Aati, O; Allan, J; Billington, K; Dalbeth, N; Doyle, A; Drake, J; Frampton, C; Horne, A; Stamp, LK; Tan, P, 2019)
"Gout is an acute rheumatic disorder that occurs in connection with the deposition of monosodium urate (MSU) crystals in the joints."5.30Altered arachidonic acid metabolism in urate crystal induced inflammation. ( Duffin, KL; Gregory, SA; Isakson, PC; Margalit, A; Shaffer, AF, 1997)
"To determine whether febuxostat with stepwise dose increase is as useful as colchicine prophylaxis in reducing gout flares during the initial introduction of urate-lowering therapy in patients with gout in comparison with febuxostat with no dose titration."5.27Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study. ( Fujimori, S; Hidaka, Y; Ide, Y; Inoue, K; Kim, H; Sugimoto, M; Tamaki, S; Taniguchi, A; Yamamoto, T; Yamanaka, H, 2018)
"6 years) with hyperuricemia (fasting serum uric acid ≥0."5.27Ultrasonographic assessment of joint pathology in type 2 diabetes and hyperuricemia: The Fremantle Diabetes Study Phase II. ( Davis, TME; Davis, WA; Drinkwater, JJ; Keen, HI; Latkovic, E; Nossent, J, 2018)
" We did a post-hoc analysis of recorded on-study gout attacks and plasma uric acid concentrations according to treatment allocation."5.27Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study. ( Ansquer, JC; Best, JD; Buizen, L; d'Emden, MC; Davis, TME; Feher, MD; Flack, J; Foucher, C; Gebski, V; Hedley, J; Jenkins, AJ; Keech, AC; Kesaniemi, YA; Li, L; McGill, N; Scott, RS; Sullivan, DR; Waldman, B, 2018)
"Gout patients do not routinely achieve optimal outcomes related in part to suboptimal administration of urate lowering therapy (ULT) including first-line xanthine oxidase inhibitors allopurinol or febuxostat."5.27Design and Rationale for the Veterans Affairs "Cooperative Study Program 594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat" Trial. ( Brittan, K; Brophy, M; Davis-Karim, A; Henrie, AM; Mikuls, TR; Neogi, T; Newcomb, J; O'Dell, JR; Palevsky, PM; Pillinger, MH; Pittman, D; Taylor, TH; Timilsina, S; Wu, H, 2018)
"The objective of the study was to evaluate the effect of lesinurad, a selective uric acid uptake inhibitor, alone and in combination with the xanthine oxidase inhibitor allopurinol, on serum uric acid and urinary urate excretion in patients with gout and hyperuricemia."5.27The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout. ( Baumgartner, S; Kerr, B; Manhard, K; Quart, B; Shen, Z; Yeh, LT, 2018)
"Verinurad (RDEA3170) is a selective uric acid reabsorption inhibitor in clinical development for treatment of hyperuricemia and gout."5.27Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout. ( Clauson, V; Gillen, M; Hall, J; Kankam, M; Lee, C; Liu, S; Miner, JN; Nguyen, M; Shen, Z; Walker, S; Wilson, D; Yang, X, 2018)
"Japanese male subjects aged 21-65 years with gout (n = 37) or asymptomatic hyperuricaemia (n = 35) and serum urate (sUA) ⩾8 mg/dl were randomized to febuxostat (10, 20, 40 mg) in combination with verinurad (2."5.27Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study. ( Gillen, M; Hall, J; Ito, Y; Liu, S; Shen, Z; Shiramoto, M; Yamamoto, A; Yan, X, 2018)
"To determine factors that predict inadequate serum urate (SU) lowering response in a randomized controlled trial of allopurinol dose escalation (DE) in gout."5.27Can we predict inadequate response to allopurinol dose escalation? Analysis of a randomised controlled trial. ( Barclay, M; Chapman, PT; Dalbeth, N; Drake, J; Frampton, C; Horne, A; Stamp, LK; Tan, P, 2018)
"The aim of this research work was to observe and analyze the efficacy of febuxostat and allopurinol in the treatment of gout with hyperuricemia."5.27The efficacy of febuxostat and allopurinol in the treatment of gout with hyperuricemia. ( Wang, S, 2018)
"This multicenter, open-label study evaluated the efficacy and safety of long-term twice-daily oral topiroxostat administration in patients with or  without gout."5.27Multicenter, Open-Label Study of Long-Term Topiroxostat (FYX-051) Administration in Japanese Hyperuricemic Patients with or Without Gout. ( Hosoya, T; Ishikawa, T; Ogawa, Y; Ohashi, T; Sakamoto, R, 2018)
"Gout is principally a disease of middle-aged men."5.26Uric acid crystal-induced nephropathy: evidence for a specific renal lesion in a gouty family. ( Cameron, JS; Dillon, MJ; Farebrother, DA; Pincott, JR; Simmons, HA; Warren, DJ, 1981)
" People with gout receiving at least creatinine clearance (CrCL)-based allopurinol dose for ≥1 month and SU ≥6 mg/dL were recruited."5.24A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. ( Barclay, ML; Chapman, PT; Dalbeth, N; Drake, J; Frampton, C; Horne, A; Stamp, LK; Tan, P, 2017)
"To investigate the efficacy and safety of lesinurad in combination with febuxostat in a 12-month phase III trial in patients with tophaceous gout."5.24Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial. ( Adler, S; Baumgartner, S; Bhakta, N; Dalbeth, N; Fung, M; Jones, G; Khanna, D; Kopicko, J; Perez-Ruiz, F; Storgard, C; Terkeltaub, R, 2017)
"There is little evidence guiding selection of nondiuretic, antihypertensive agents with a goal of lowering uric acid (SUA) and minimizing gout risk."5.24Metoprolol Increases Uric Acid and Risk of Gout in African Americans With Chronic Kidney Disease Attributed to Hypertension. ( Appel, LJ; Juraschek, SP; Miller, ER, 2017)
"To determine the long-term safety and efficacy of allopurinol dose escalation (DE) to achieve target serum urate (SU) in gout."5.24Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension study. ( Barclay, M; Chapman, PT; Dalbeth, N; Drake, J; Frampton, C; Horne, A; Stamp, LK; Tan, P, 2017)
"In this double-blind, placebo-controlled study, 314 subjects with hyperuricemia (serum uric acid [UA] level of ≥7."5.24Effects of Febuxostat in Early Gout: A Randomized, Double-Blind, Placebo-Controlled Study. ( Choi, HK; Dalbeth, N; Gunawardhana, L; Hunt, B; MacDonald, PA; Palmer, WE; Saag, KG; Thienel, U, 2017)
"The use of allopurinol in people with chronic kidney disease (CKD) remains one of the most controversial areas in gout management."5.24The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial. ( Barclay, M; Chapman, PT; Dalbeth, N; Drake, J; Frampton, C; Horne, A; Stamp, LK; Tan, P, 2017)
"Our objectives were to determine whether a change in serum uric acid (sUA) resulted in a corresponding change in the fractional excretion of uric acid (FEUA) and whether the renal response was different in patients with gout versus healthy subjects."5.24Patients with gout differ from healthy subjects in renal response to changes in serum uric acid. ( Liu, S; Miner, JN; Perez-Ruiz, F, 2017)
"Lesinurad added to allopurinol demonstrated superior sUA lowering versus allopurinol-alone therapy and lesinurad 200 mg was generally well tolerated in patients with gout warranting additional therapy."5.24Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). ( Adler, S; Bardin, T; Baumgartner, S; Bhakta, N; Fung, M; Keenan, RT; Khanna, PP; Kopicko, J; So, A; Storgard, C, 2017)
"Topiroxostat, a selective xanthine oxidoreductase inhibitor, is used in Japan for the treatment of hyperuricemic patients with or without gout."5.24Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: a randomized, double-blinded, controlled phase 2b study. ( Hosoya, T; Ohashi, T; Sasaki, T, 2017)
" Cox proportional hazard ratio was used to compare the risk of CAD in gout patients taking allopurinol or/and benzbromarone with those taking neither drug."5.24Allopurinol, benzbromarone and risk of coronary heart disease in gout patients: A population-based study. ( Chiang, SJ; Daimon, M; Ho, Y; Lin, HC; Uang, YS; Wang, CH; Wang, LH, 2017)
"In the double-blind, randomized, controlled trial, we aimed to evaluate the effects of compound tufuling oral liquid (CoTOL) on serum uric acid (sUA) levels and recurrence of acute gouty arthritis in intercritical and chronic gout treatment."5.24Hypouricemic and arthritis relapse-reducing effects of compound tufuling oral-liquid in intercritical and chronic gout: A double-blind, placebo-controlled, multicenter randomized trial. ( Fan, Y; Gao, X; Han, Y; Jing, X; Li, X; Li, Y; Sun, J; Tang, X; Wen, C; Wu, H; Xie, Z, 2017)
"Allopurinol has been universally successful in lowering the serum uric acid concentration and uric acid excretion to normal levels, while not significantly affecting the clearance of urate or other aspects of renal function."5.24The treatment of gout and disorders of uric acid metabolism with allopurinol. ( Houpt, JB; Ogryzlo, MA; Urowitz, MB; Weber, HM, 1966)
"We aimed to assess the relative efficacy and safety of dotinurad (2 mg), benzbromarone (50 mg), and febuxostat (40 mg) in hyperuricemic patients with or without gout."5.22Comparative efficacy and safety of dotinurad, febuxostat, and benzbromarone in hyperuricemic patients with or without gout: A network meta-analysis of randomized controlled trials. ( Lee, YH; Song, GG, 2022)
"We aimed to assess the relative efficacy and safety of topiroxostat at different dosages in hyperuricemic patients with or without gout."5.22Comparative efficacy and safety of topiroxostat at different dosages in hyperuricemic patients with or without gout: A network meta-analysis of randomized controlled trials. ( Lee, YH; Song, GG, 2022)
"Refractory, or uncontrolled, gout is a chronic, progressive, inflammatory arthropathy resulting from continued urate deposition after failed attempts to lower serum uric acid below the therapeutic threshold with oral urate-lowering therapies such as allopurinol and febuxostat."5.22Enhancing the Response Rate to Recombinant Uricases in Patients with Gout. ( LaMoreaux, B; Padnick-Silver, L; Schlesinger, N, 2022)
"Increased serum uric acid (SUA) levels are commonly seen in patients with metabolic syndrome and are widely accepted as risk factors for hypertension, gout, non-alcoholic fatty liver disease, chronic kidney disease (CKD), and cardiovascular diseases."5.22Uric acid in metabolic syndrome: Does uric acid have a definitive role? ( Copur, S; Demiray, A; Kanbay, M, 2022)
"We thoroughly searched five electronic resource databases for randomized controlled trials (RCTs) that compared the efficacy and safety of allopurinol versus conventional treatment or placebo for the treatment of patients with diabetes mellitus."5.22Effects of allopurinol on renal function in patients with diabetes: a systematic review and meta-analysis. ( Cai, Y; Liu, WJ; Liu, Y; Luo, Q; Tian, L; Zhao, Q, 2022)
"Uric acid (UA) is the final product of purine metabolism in the human body, and impaired purine metabolism can increase the uric acid in serum, finally resulting in hyperuricemia (HUA)."5.22Excess Uric Acid Induces Gouty Nephropathy Through Crystal Formation: A Review of Recent Insights. ( Dong, B; Geng, Z; Mei, Y; Xu, L, 2022)
"Gout is well known as an inflammatory rheumatic disease presenting with arthritis and abnormal metabolism of uric acid."5.22Gout and Diet: A Comprehensive Review of Mechanisms and Management. ( Chen, S; Xu, H; Xu, Y; Yuan, M; Zhang, Y, 2022)
"Alcohol is recognized a risk factor for increased uric acid and gout flare."5.22The role of alcohol consumption in pathogenesis of gout. ( Nieradko-Iwanicka, B, 2022)
"This phase IIIB study compared the efficacy and safety of febuxostat and allopurinol in gout patients with or without tophi who were HLA-B*5801 negative."5.22Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study. ( Chen, CJ; Chen, DY; Hsu, PN; Lai, JH; Lin, HY; Yu, KH, 2016)
"Control of serum uric acid (sUA) levels is very important during chemotherapy in patients with malignant tumors, as the risks of tumor lysis syndrome (TLS) and renal events are increased with increasing levels of sUA."5.22Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol. ( Fujimaki, K; Fujisaki, T; Gemba, K; Goto, T; Kaneko, M; Kawai, Y; Kiguchi, T; Kirito, K; Maemondo, M; Nakajima, A; Okamoto, M; Takeda, K; Tamura, K; Ueda, T, 2016)
"In Japan, although topiroxostat, a selective xanthine oxidoreductase inhibitor, has been used for the treatment of patients with hyperuricemia including gout, no published randomized controlled studies evaluating the dose-dependent relationship with respect to the serum urate-lowering efficacy have been reported."5.22Clinical efficacy and safety of topiroxostat in Japanese male hyperuricemic patients with or without gout: an exploratory, phase 2a, multicentre, randomized, double-blind, placebo-controlled study. ( Hashimoto, H; Hosoya, T; Ohashi, T; Sakamoto, R; Sasaki, T, 2016)
" Patients who had inadequate serum urate levels (a gout patient: serum urate level ≥416·4 μmol/L; an asymptomatic hyperuricemic patient with specific complications (urinary lithiasis, hypertension, hyperlipidemia and/or diabetes): serum urate level ≥475·8 μmol/L; and an asymptomatic hyperuricemic patient with no specific complications: serum urate level ≥535·3 μmol/L) were randomized to topiroxostat 120 mg/day or allopurinol 200 mg/day, with an equal allocation ratio, for 16 weeks."5.22Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study. ( Hashimoto, H; Hosoya, T; Ogawa, Y; Ohashi, T; Sakamoto, R, 2016)
" This is a large pragmatic cluster-randomized trial designed to assess a highly automated, pharmacist-led intervention to optimize allopurinol treatment in gout."5.22Rationale and design of the randomized evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-UP) Study. ( Bridges, SL; Chang, JM; Cheetham, TC; Coburn, BW; Curtis, JR; Kerimian, A; Levy, GD; Low, KJ; Mikuls, TR; Rashid, N; Redden, DT; Saag, KG, 2016)
"Excess body burden of uric acid promotes gout."5.22Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. ( Girardet, JL; Hagerty, DT; Hyndman, D; Iverson, C; Liu, S; Manhard, K; Miner, JN; Nanavati, P; Quart, B; Shen, Z; Tan, PK; Terkeltaub, R; Yeh, LT, 2016)
"Traditionally, allopurinol is not initiated during an acute gout attack to avoid prolonging the painful arthritis."5.20Does starting allopurinol prolong acute treated gout? A randomized clinical trial. ( Collamer, A; Higgs, J; Hill, EM; Sit, M; Sky, K, 2015)
"To compare the efficiency and safety of febuxostat with those of allopurinol in Chinese patients with gout and hyperuricemia."5.20A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia. ( Chen, S; Ji, H; Ji, Q; Lin, J; Liu, B; Liu, H; Liu, P; Liu, X; Lu, Y; Ming, J; Peng, Y; Wang, J; Wang, Y; Xu, S; Zhang, Y, 2015)
"Allopurinol is the most widely prescribed serum uric acid-lowering therapy (ULT) in gout."5.20An open-label, 6-month study of allopurinol safety in gout: The LASSO study. ( Baumgartner, S; Becker, MA; Choi, HK; Cravets, M; Dalbeth, N; Fitz-Patrick, D; Storgard, C, 2015)
"We prospectively evaluated whether an effective 12-month uric acid-lowering therapy (ULT) with the available xanthine oxidase (XO) inhibitors allopurinol and febuxostat in patients with chronic tophaceous gout has an impact on oxidative stress and/or vascular function."5.19As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout. ( Aringer, M; Bielitz, C; Christoph, M; Forkmann, M; Kopprasch, S; Richter, U; Tausche, AK; Wunderlich, C, 2014)
"Topiroxostat, a selective xanthine oxidase inhibitor, shows effective reduction in the serum urate level in hyperuricemic patients with or without gout."5.19Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout. ( Fujimori, S; Hara, S; Hisatome, I; Hosoya, T; Nomura, S; Ohno, I; Uchida, S; Yamamoto, T, 2014)
"Gout patients (n = 512) with serum uric acid (sUA) concentrations of at least 8."5.19An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia. ( Bao, C; Du, H; Gu, J; Huang, A; Huang, X; Jiang, L; Li, J; Li, X; Li, Z; Liu, Y; Zhang, Y; Zhang, Z; Zhao, D; Zhu, P; Zuo, X, 2014)
"The aim of this study was to evaluate the pharmacodynamics (PDs), pharmacokinetics (PKs) and safety of lesinurad (selective uric acid reabsorption inhibitor) in combination with febuxostat (xanthine oxidase inhibitor) in patients with gout."5.19Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia. ( Baumgartner, S; Fleischmann, R; Hingorani, V; Kerr, B; Manhard, K; Miner, JN; Polvent, E; Quart, B; Shen, Z; Suster, M; Yeh, LT, 2014)
"The aims of this study were to establish whether, in patients with gout, MPO is released from neutrophils and urate is oxidized to allantoin and if these effects are attenuated by allopurinol."5.19Myeloperoxidase and oxidation of uric acid in gout: implications for the clinical consequences of hyperuricaemia. ( Drake, J; Forbes, LV; Kettle, AJ; Khalilova, IS; Stamp, LK; Turner, R; Zhang, M, 2014)
"To evaluate the efficacy and safety of IL-1 inhibitor rilonacept (IL-1 Trap) for gout flare (GF) prevention during initiation of uric acid-lowering therapy (ULT) with allopurinol in a multiregional phase 3 clinical trial."5.17Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. ( Evans, RR; Fouche, L; King-Davis, S; Luo, SF; Mitha, E; Schumacher, HR; Wang, J; Weinstein, SP; Yancopoulos, GD, 2013)
"Assess the impact of urate-lowering therapy on renal function in subjects with gout who were treated with febuxostat for ≤ 48 months."5.17Preservation of renal function during gout treatment with febuxostat: a quantitative study. ( Chefo, S; Gunawardhana, L; MacDonald, PA; Whelton, A, 2013)
"To compare the characteristics of female versus male gout patients and assess urate-lowering efficacy and safety of febuxostat or allopurinol treatment in women with gout."5.16Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. ( Becker, MA; Chefo, S; Chohan, S; Jackson, RL; MacDonald, PA, 2012)
"0 mg/dL) gout subjects were enrolled in the 6-month, double-blind, randomized, comparative CONFIRMS trial and randomized, 1:1:1, to receive febuxostat, 40 mg or 80 mg, or allopurinol (200 mg or 300 mg based on renal function) once daily."5.16The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age. ( Hunt, B; Jackson, RL; MacDonald, PA, 2012)
"Twenty-three cases with gout receiving furosemide and allopurinol were recruited."5.16Furosemide increases plasma oxypurinol without lowering serum urate--a complex drug interaction: implications for clinical practice. ( Barclay, ML; Chapman, PT; Drake, J; Frampton, C; O'Donnell, JL; Stamp, LK; Zhang, M, 2012)
"To evaluate the efficacy and safety of the interleukin-1 inhibitor rilonacept (interleukin-1 Trap) for gout flare prevention during initiation of uric acid-lowering therapy (ULT)."5.16Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. ( Clower, J; Evans, RR; Jennings, W; Saag, KG; Schumacher, HR; Terkeltaub, R; Wang, J; Weinstein, SP; Yancopoulos, GD, 2012)
"To determine the efficacy and safety of increasing the allopurinol dose above the proposed creatinine clearance-based dose in patients with gout."5.15Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. ( Barclay, ML; Chapman, PT; Frampton, C; James, J; O'Donnell, JL; Stamp, LK; Zhang, M, 2011)
"To investigate the pharmacokinetic and pharmacodynamic interaction between probenecid and oxypurinol (the active metabolite of allopurinol) in patients with gout."5.15Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. ( Day, RO; Graham, GG; McLachlan, AJ; Stocker, SL; Williams, KM, 2011)
"Hyperuricemia of gout can arise due to either overproduction or underexcretion of uric acid."5.15Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors. ( Goldfarb, DS; Gunawardhana, L; Hunt, B; MacDonald, PA, 2011)
"Febuxostat or allopurinol was administered to patients with hyperuricemia including gout for 8 weeks to compare the efficacy and safety of these drugs."5.15An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: p ( Fujimori, S; Hada, T; Hosoya, T; Kamatani, N; Kohri, K; Matsuzawa, Y; Nakamura, T; Ueda, T; Yamamoto, T; Yamanaka, H, 2011)
": A multicenter study with randomized, placebo-controlled, double-blind, parallel-group comparison was carried out to evaluate the efficacy and safety of febuxostat in 103 patients with hyperuricemia (including patients with gout) in Japan."5.15Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. ( Fujimori, S; Hada, T; Hisashi, Y; Hosoya, T; Kamatani, N; Kenjiro, K; Kohri, K; Matsuzawa, Y; Nakamura, T; Naoyuki, K; Shin, F; Takanori, U; Tatsuo, H; Tetsuya, Y; Toshikazu, H; Toshitaka, N; Ueda, T; Yamamoto, T; Yamanaka, H; Yuji, M, 2011)
"A multicenter study with randomized, placebo-controlled, double-blind, parallel, intergroup comparison was carried out to evaluate the dose-response relationship, efficacy, and safety of febuxostat in 202 patients with hyperuricemia (including patients with gout) in Japan."5.15Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study. ( Fujimori, S; Hada, T; Hisashi, Y; Hosoya, T; Kamatani, N; Kenjiro, K; Kohri, K; Matsuzawa, Y; Nakamura, T; Naoyuki, K; Shin, F; Takanori, U; Tatsuo, H; Tetsuya, Y; Toshikazu, H; Toshitaka, N; Ueda, T; Yamamoto, T; Yamanaka, H; Yuji, M, 2011)
"Febuxostat was administered to patients with hyperuricemia including gout in Japan to compare its efficacy and safety with those of allopurinol."5.15An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phas ( Fujimori, S; Hada, T; Hisashi, Y; Hosoya, T; Kamatani, N; Kenjiro, K; Kohri, K; Matsuzawa, Y; Nakamura, T; Naoyuki, K; Shin, F; Takanori, U; Tatsuo, H; Tetsuya, Y; Toshikazu, H; Toshitaka, N; Ueda, T; Yamamoto, T; Yamanaka, H; Yuji, M, 2011)
"In previous clinical studies of hyperuricemia including gout, although serum uric acid (sUA) levels reduced to 6."5.15Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout. ( Fujimori, S; Hada, T; Hosoya, T; Kamatani, N; Kohri, K; Matsuzawa, Y; Nakamura, T; Ueda, T; Yamamoto, T; Yamanaka, H, 2011)
"Two replicate, randomized, double-blind, placebo-controlled trials (C0405 and C0406) were conducted between June 2006 and October 2007 at 56 rheumatology practices in the United States, Canada, and Mexico in patients with severe gout, allopurinol intolerance or refractoriness, and serum uric acid concentration of 8."5.15Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. ( Baraf, HS; Becker, MA; Edwards, NL; Gutierrez-Urena, SR; Hamburger, SA; Horowitz, Z; Huang, W; Lipsky, PE; Maroli, AN; Sundy, JS; Treadwell, EL; Vázquez-Mellado, J; Waltrip, RW; White, WB; Yood, RA, 2011)
"This 5-yr study assessed urate-lowering and clinical efficacy and safety of long-term febuxostat therapy in subjects with gout."5.14Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. ( Becker, MA; Lademacher, C; Lloyd, E; MacDonald, PA; Schumacher, HR, 2009)
"Data collected from 2 randomized controlled clinical trials assessing the efficacy of etoricoxib or indomethacin for 7 days in acute gout were used to assess SU levels during acute gouty attacks."5.14Serum urate during acute gout. ( Norquist, JM; Schlesinger, N; Watson, DJ, 2009)
"The purpose of this study was to compare urate-lowering (UL) efficacy and safety of daily febuxostat and allopurinol in subjects with gout and serum urate (sUA) > or = 8."5.14The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. ( Becker, MA; Espinoza, LR; Lademacher, C; Lloyd, E; MacDonald, P; Schumacher, HR; Wells, AF, 2010)
"To establish a benchmark for gout control using the proportion of patients with serum uric acid (SUA) < 0."5.14More allopurinol is needed to get gout patients < 0.36 mmol/l: a gout audit in the form of a before-after trial. ( Arroll, B; Ben, C; Bennett, M; Dalbeth, N; Hettiarachchi, D; Shelling, G, 2009)
"Use of urate-lowering therapy (ULT), such as febuxostat or allopurinol, is recommended for the long-term management of hyperuricemia in patients with gout to reduce the incidence of acute flares."5.14Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. ( Hunt, B; Jackson, RL; Macdonald, PA; Wortmann, RL, 2010)
"To investigate the efficacy and tolerability of allopurinol as the first-choice antihyperuricaemic treatment for gout, and compare the efficacy and tolerability of benzbromarone and probenecid as second-choice treatment."5.14Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. ( Brouwers, JR; Delsing, J; Griep, EN; Hoekstra, M; Jansen, TL; Reinders, MK; van de Laar, MA; van Roon, EN, 2009)
"To compare the urate-lowering efficacy and safety of febuxostat, allopurinol, and placebo in a large group of subjects with hyperuricemia and gout, including persons with impaired renal function."5.13Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. ( Becker, MA; Hunt, B; Joseph-Ridge, N; Lademacher, C; Macdonald, PA; Schumacher, HR; Streit, J; Wortmann, RL, 2008)
"Lower dosages of allopurinol are recommended to avoid toxicity in gout patients with impaired renal function."5.13Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease. ( Angthararak, S; Panomvana, D; Sripradit, S, 2008)
"To evaluate the major cardiovascular (CV) events of febuxostat compared to allopurinol for the treatment of gout or asymptomatic hyperuricemia."5.12The major cardiovascular events of febuxostat versus allopurinol in treating gout or asymptomatic hyperuricemia: a systematic review and meta-analysis. ( Li, H; Sun, J; Wang, M; Wen, C; Xie, Z; Zhang, M; Zhang, Y; Zhao, T, 2021)
" Elevated uric acid levels are risk factors for gout, hypertension, and chronic kidney diseases."5.12Uric Acid in Inflammation and the Pathogenesis of Atherosclerosis. ( Kimura, Y; Kono, H; Tsukui, D, 2021)
"This review aims to summarize recent evidence regarding the complex relationship between uric acid (UA), gout, and brain diseases."5.12Hyperuricemia, Gout, and the Brain-an Update. ( Dumurgier, J; Latourte, A; Paquet, C; Richette, P, 2021)
" Gout is a form of inflammatory arthritis which is characterized by an increase in the serum uric acid deposits in and around the joints of the extremities, the so called tophi."5.12Renal disorders in rheumatologic diseases: the spectrum is changing (part 2. Arthridides). ( Doria, A; Moroni, G; Ponticelli, C, 2021)
"To assess the efficacy and safety of the commonly used urate-lowering therapies (ULTs): febuxostat, allopurinol, and lesinurad in hyperuricemic patients with gout."5.12Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials. ( Fan, M; Gu, J; Li, X; Liu, J; Schlesinger, N; Wu, X; Zhao, B, 2021)
"Uric acid, the end-product of purine metabolism in humans, is not only a cause of gout, but also may play roles in developing cardiovascular diseases such as hypertension, atrial fibrillation, chronic kidney disease, heart failure, coronary artery disease, and cardiovascular death."5.12Uric acid and cardiovascular disease: A clinical review. ( Kobayashi, Y; Node, K; Saito, Y; Tanaka, A, 2021)
"The treatment of gout with allopurinol is effective at reducing urate levels and the frequency of flares."5.12Effectiveness of Allopurinol in Reducing Mortality: Time-Related Biases in Observational Studies. ( Hudson, M; Suissa, K; Suissa, S, 2021)
" It is noninferior to benzbromarone or febuxostat in reducing serum urate levels in hyperuricemic patients with or without gout."5.12Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout. ( Hosoya, T; Ishikawa, T; Takahashi, T; Taniguchi, T, 2021)
"The description of gout dates back almost 5000 years, and scientific interest in uric acid increased when it was found to be involved in the pathogenesis of gout."5.12The Impact of Uric Acid and Hyperuricemia on Cardiovascular and Renal Systems. ( Agnoletti, D; Borghi, C; Cicero, AFG, 2021)
" Twenty-five patients with acute gout arthritis were randomized into two groups and treated over 5 days: group A, diclofenac 75 mg orally, twice a day; and group B, laser irradiation once a day."5.12Photobiomodulation of pain and inflammation in microcrystalline arthropathies: experimental and clinical results. ( Campana, V; Gavotto, A; Moya, M; Palma, J; Simes, J; Soriano, F; Soriano, M; Soriano, R; Spitale, L, 2006)
"Uric acid is a strong scavenger of reactive oxygen species, which are known to contribute to the development of atherosclerosis, while the incidence of atherosclerotic diseases is rather high in patients with gout."5.11Oxidized low-density lipoprotein autoantibodies in patients with primary gout: effect of urate-lowering therapy. ( Ka, T; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamamoto, T, 2004)
"72 cases of gouty renal damage were randomly divided into a treatment group of 42 cases and a control group of 30 cases to observe the therapeutic effects and the changes in 24-hour urinary protein content, blood creatinine, uric acid and urea nitrogen in blood before treatment and one month after treatment."5.11Clinical analysis for the acupuncture treatment in 42 cases of gouty renal damage. ( Ma, X, 2004)
"Benzbromarone is effective in lowering uric acid levels and in reducing the number of acute attacks of gout in patients who have failed optimal treatment."5.11Benzbromarone therapy in management of refractory gout. ( Gow, P; Kumar, S; Ng, J, 2005)
"Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, is a potential alternative to allopurinol for patients with hyperuricemia and gout."5.11Febuxostat compared with allopurinol in patients with hyperuricemia and gout. ( Becker, MA; Eustace, D; Joseph-Ridge, N; MacDonald, PA; Palo, WA; Schumacher, HR; Streit, J; Wortmann, RL, 2005)
"To evaluate metformin efficacy and safety in patients with gout and insulin resistance (IR)."5.11[Use of metformin (siofor) in patients with gout and insulin resistance (pilot 6-month results)]. ( Barskova, VG; Eliseev, MS; Iakunina, IA; Il'inykh, EV; Kudaeva, FM; Nasonov, EL; Tsapina, TN; Volkov, AV; Zilov, AV, 2005)
"Sixty-three patients with crystal-confirmed tophaceous gout were treated with allopurinol, benzbromarone, or combined therapy to achieve serum uric acid levels less than the threshold for saturation of urate in tissues."5.10Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. ( Calabozo, M; Herrero-Beites, AM; Perez-Ruiz, F; Pijoan, JI; Ruibal, A, 2002)
"Chronic occupational exposure to lead is related to low urate excretion and a high incidence of gout in lead workers."5.10Environmental lead exposure and urate excretion in the general population. ( Ho, HH; Lin, JL; Tan, DT; Yu, CC, 2002)
"To assess the short-term urate-lowering effect of fenofibrate in men on long-term allopurinol therapy for hyperuricaemia and gout."5.10Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. ( Ball, SG; Feher, MD; Hepburn, AL; Hogarth, MB; Kaye, SA, 2003)
"We performed the present study to determine the degree of visceral fat accumulation and incidence of visceral fat obesity in 138 gout patients who were classified as overexcretion type (n = 53) and underexcretion type (n = 85) by their levels of uric acid clearance and urinary uric acid excretion."5.09Increased visceral fat accumulation further aggravates the risks of insulin resistance in gout. ( Hada, T; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamakita , J; Yamamoto, T, 2001)
"To determine if lowering of serum uric acid (SUA) concentrations below 6 mg/dl or longer duration of lowered SUA will result in depletion of urate crystals from the knee joints and prevent further attacks of gout."5.09Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? ( Beutler, A; Clayburne, G; Eisner, E; Li-Yu, J; Rull, M; Schumacher, HR; Sieck, M, 2001)
"Uric acid overexcretion in patients with gout is frequently assessed by the measurement of 24 hour urinary uric acid excretion, which is cumbersome with ambulatory patients, and requires accurate timing and complete collection of the specimen."5.09Spot urine uric acid to creatinine ratio used in the estimation of uric acid excretion in primary gout. ( Hada, T; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamakita, J; Yamamoto, T, 2001)
"It is known that chronic renal insufficiency (CRI) patients with gout may have subtle lead poisoning."5.09Lead chelation therapy and urate excretion in patients with chronic renal diseases and gout. ( Ho, HH; Lin, JL; Lin-Tan, DT; Yu, CC, 2001)
"To investigate whether allopurinol and benzbromarone affect the concentration of uridine in plasma, allopurinol or benzbromarone were administered to patients with gout for 3 to 6 months."5.08Effect of allopurinol and benzbromarone on the concentration of uridine in plasma. ( Higashino, K; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamakita, J; Yamamoto, T, 1997)
"The uric acid concentration in blood has been widely accepted as a diagnostic indicator of hyperuricemia and gout, and its assay method is well established."5.08Determination of uric acid in scalp hair for non-invasive evaluation of uricemic controls in hyperuricemia. ( Isaka, Y; Kobayashi, K; Morioka, Y; Tozawa, T, 1998)
"To study the efficacy of allopurinol and benzbromarone to reduce serum urate concentrations in patients with primary chronic gout."5.08Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. ( Alonso-Ruiz, A; Calabozo, M; García-Erauskin, G; Herrero-Beites, A; Perez-Ruiz, F; Ruiz-Lucea, E, 1998)
"The objectives of this study were to establish if, and to what extent, benzbromarone affects allopurinol/oxypurinol kinetics, and to compare the uric acid lowering capabilities of Allomaron (allopurinol 100 mg plus benzbromarone 20 mg) with the effects of allopurinol alone in patients with confirmed gout."5.07The effect of benzbromarone on allopurinol/oxypurinol kinetics in patients with gout. ( Groenewoud, G; Hundt, HK; Müller, FO; Schall, R; van der Merwe, JC; van Dyk, M, 1993)
"Fifty patients with gout were randomly allocated to one of 2 groups receiving allopurinol, either continuously or for 2 months every year."5.06Intermittent control of hyperuricemia in the treatment of gout. ( Bull, PW; Scott, JT, 1989)
"This study compared the effects of azapropazone and indomethacin plus allopurinol in the management of acute gout and hyperuricaemia."5.06Comparative trial of azapropazone and indomethacin plus allopurinol in acute gout and hyperuricaemia. ( Davis, RH; Fraser, RC; Walker, FS, 1987)
"Uric acid, the metabolic mediator of gout and urate renal stones, is associated with increased cardiovascular risk burden."5.05Hyperuricemia: a novel old disorder-relationship and potential mechanisms in heart failure. ( Borghi, C; Cosentino, E; Landolfo, M; Palazzuoli, A, 2020)
" Uric acid has anti-oxidant properties, but high levels predispose to gout and may play a role in metabolic syndrome."5.05Management of hyperuricemia in asymptomatic patients: A critical appraisal. ( Brucato, A; Carnovale, C; Cianci, F, 2020)
"Increased serum uric acid (SUA) levels cause gout and are associated with multiple diseases, including chronic kidney disease."5.05Polygenic analysis of the effect of common and low-frequency genetic variants on serum uric acid levels in Korean individuals. ( Chang, Y; Cho, SK; Kim, B; Kim, HL; Kim, HN; Kuo, PH; Myung, W; Ryu, S; Winkler, CA; Won, HH, 2020)
" While uric acid is usually discussed in the context of gout, hyperuricaemia is also associated with hypertension, chronic kidney disease, hypertriglyceridaemia, obesity, atherosclerotic heart disease, metabolic syndrome, and type 2 diabetes."5.05Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. ( Agabiti-Rosei, E; Borghi, C; Johnson, RJ; Kielstein, JT; Lurbe, E; Mancia, G; Redon, J; Stack, AG; Tsioufis, KP, 2020)
" Based on the patent literature of last five years, we can expect a burst of novel alternate compounds in the near future which could have the ability to reduce the uric acid level, by inhibiting XO enzyme in patients, which at the moment are striving hard to fight against the dreadful disease condition like gout."5.05Xanthine oxidase inhibitors: patent landscape and clinical development (2015-2020). ( Bedi, PMS; Sharma, S; Singh, H; Singh, JV, 2020)
"Hyperuricemia is a state in which the serum levels of uric acid are elevated."5.05Hyperuricemia, the heart, and the kidneys - to treat or not to treat? ( Bevc, S; Ekart, R; Hojs, R; Petreski, T, 2020)
" Here, we also review the clinical importance of altered ABCG2 expression and function in general drug metabolism, cancer multidrug resistance, and impaired uric acid excretion, leading to gout."5.05The ABCG2/BCRP transporter and its variants - from structure to pathology. ( Hegedűs, T; Homolya, L; Sarkadi, B, 2020)
"Uric acid, the end product of purine metabolism, plays a key role in the pathogenesis of gout and other disease processes."5.05Molecular Pathophysiology of Uric Acid Homeostasis. ( Estiverne, C; Mandal, AK; Mount, DB, 2020)
"The antihyperuricemic properties of amflutizole were investigated in studies designed to determine its efficacy and mechanisms of action in individuals with gout and hyperuricemia."5.05Antihyperuricemic properties of amflutizole in gout. ( Fox, IH; Lightfoot, RW; Ridolfo, AS; Wortmann, RL, 1985)
"Allopurinol was administered to seven patients with gout to compare the effects of three different methods of administration."5.04Single daily dose of allopurinol. ( Brewis, I; Ellis, RM; Scott, JT, 1975)
"The effect of daily administration of a single 300-mg tablet of allopurinol on serum urate levels was compared with the effect of divided doses of the drug (100 mg three times a day) in an open-labeled crossover trial of 20 patients with hyperuricemia and gout."5.04Allopurinol and gouty hyperuricemia. Efficacy of a single daily dose. ( Elion, GB; Robin, JA; Rodnan, GP; Tolchin, SF, 1975)
"Gout is characterized by high serum uric acid (SUA) levels and arthritis."5.01Impact of bariatric surgery on serum uric acid levels and the incidence of gout-A meta-analysis. ( Kaushal, S; Koura, A; Lim, B; Oo, AM; Rao, J; Syn, N; Yeo, C; Yeo, D, 2019)
"Gout is a systemic disease, characterized by the formation and deposition of crystals in tissues (mainly in and around the joints) of individuals with elevated serum uric acid levels."5.01Gout and arrhythmias: In search for causation beyond association. ( Angelidis, C; Deftereos, S; Giannopoulos, G, 2019)
"Efficacy was assessed by changes in serum urate (sUA), urinary uric acid, gout flare rates, and /or tophi."5.01Combination urate-lowering therapy in the treatment of gout: What is the evidence? ( Dalbeth, N; Perez-Ruiz, F, 2019)
"Advances in gout genetics have provided important molecular insights into disease pathogenesis, better characterized the pharmacogenetics of allopurinol, and raised the possibility of using genetic testing to provide personalized treatment for patients."5.01Genetic advances in gout: potential applications in clinical practice. ( Dalbeth, N; Merriman, TR; Tai, V, 2019)
"Pegloticase is a PEGylated uric acid specific enzyme indicated for the treatment of refractory gout."5.01Recapture and improved outcome of pegloticase response with methotrexate-A report of two cases and review of the literature. ( Bessen, MY; Bessen, SY; Yung, CM, 2019)
"Concerns about the cardiovascular safety of febuxostat lead to reconsideration of the place of febuxostat in the management of gout."5.01The role of febuxostat in gout. ( Bardin, T; Richette, P, 2019)
"Gout is a disease characterized by abnormal metabolism of the uric acid, leading to undesired buildup of monosodium urate crystals affecting mainly the first metatarsal-phalangeal joint of the foot and less commonly other joints or the soft tissues of the body."5.01Rare Manifestation of Gout: Gouty Tophi in the Nose. ( IIliev, G; Ivanova, PP; Nedev, P; Popov, H, 2019)
" Cardioprotective benefits of allopurinol, a first-line agent for the treatment of gout, have been demonstrated to potentially prevent myocardial infarction, stroke, atrial fibrillation, and other cardiovascular diseases in observational studies in select populations."5.01Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy. ( Gupta, MK; Singh, JA, 2019)
"Previous epidemiological investigations have evaluated the association between gout, serum uric acid levels, and obstructive sleep apnea syndrome (OSAS), but with inconsistent results."5.01A meta-analysis of the association between gout, serum uric acid level, and obstructive sleep apnea. ( Cheng, C; Liang, M; Min, M; Rizeq, FK; Shi, T; Sun, C; Sun, Y; Zhang, Y, 2019)
"Purine metabolism in the circulatory system yields uric acid as its final oxidation product, which is believed to be linked to the development of gout and kidney stones."5.01Hyperuricemia and Cardiovascular Disease. ( Cheng, J; Huangfu, N; Wang, Y; Xu, Z; Zhang, D; Zhang, F; Zhang, S; Zhao, R; Zheng, W, 2019)
"We aimed to assess the relative efficacy and safety of once-daily administration of lesinurad in combination with xanthine oxidase inhibitor (XOI) in hyperuricemic patients with gout."5.01Comparative efficacy and safety of lesinurad 200 mg and 400 mg combined with a xanthine oxidase inhibitor in hyperuricemic patients with gout: A Bayesian network meta-analysis of randomized controlled trials
. ( Lee, YH; Song, GG, 2019)
"This study aimed to examine whether the uric acid level or gout is causally associated with bone mineral density (BMD)."5.01Uric acid level, gout and bone mineral density: A Mendelian randomization study. ( Lee, YH; Song, GG, 2019)
" allopurinol was associated with the improved safety outcome and have comparable mortality and net clinical outcome in patients with hyperuricemia."5.01The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis. ( Chang, WC; Chen, TC; Hsu, FS; Hwang, JJ; Lee, CC; Liu, CW; Lo, C; Shau, WY; Wang, ML, 2019)
"Lesinurad provides an additional option for people with gout unable to achieve target serum uric acid with XOI alone."4.98New urate-lowing therapies. ( Abhishek, A, 2018)
"Hyperuricemia (chronically elevated serum uric acid) is the main pathology underlying the development of gout, the most common inflammatory arthropathy."4.98ABCG2 as a therapeutic target candidate for gout. ( Fujita, K; Ichida, K, 2018)
"Gout develops in four stages beginning with an asymptomatic increase in blood levels of uric acid."4.98Crystal arthritides - gout and calcium pyrophosphate arthritis : Part 2: clinical features, diagnosis and differential diagnostics. ( Bertsch, T; Bollheimer, LC; Härle, P; Schlee, S; Sieber, CC, 2018)
"Gout and calcium pyrophosphate deposition disease (CPPD, pseudogout) are still the most frequent inflammatory arthritides in multimorbid elderly patients."4.98Crystal arthritides - gout and calcium pyrophosphate arthritis : Part 1: Epidemiology and pathophysiology. ( Bertsch, T; Bollheimer, LC; Härle, P; Schlee, S; Sieber, CC, 2018)
" It arises through the deposition of uric acid crystals in joints as a result of hyperuricemia."4.95Treatment Options for Gout. ( Bleckwenn, M; Engel, B; Just, J; Weckbecker, K, 2017)
"Gout is a rheumatologic condition associated with elevated serum uric acid levels and deposition of monosodium urate crystals in joints and soft tissues."4.95Updates on the treatment of gout, including a review of updated treatment guidelines and use of small molecule therapies for difficult-to-treat gout and gout flares. ( Abazia, DT; Bridgeman, MB; Soskind, R, 2017)
"Gout is the most common form of inflammatory arthropathy and is caused by an excess of uric acid in the blood (hyperuricemia)."4.95Change gout: the need for a new approach. ( Punzi, L, 2017)
"This was a pooled analysis of phase III trials on allopurinol and febuxostat, including 4101 patients with gout and hyperuricemia."4.95Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol. ( Cimmino, MA; Cutolo, M; Perez-Ruiz, F, 2017)
"The research progress of puerarin and its derivatives in anti-inflammatory and anti-gout activities was reviewed in this paper."4.95[Research progress of puerarin and its derivatives on anti-inflammatory and anti-gout activities]. ( Li, XP; Ma, YC; Xing, ZH; Zhang, B; Zhang, MD, 2017)
" In addition to education and a non-pharmacological management approach, urate-lowering therapy (ULT) should be considered from the first presentation of the disease, and serum uric acid (SUA) levels should be maintained at<6 mg/dL (360 µmol/L) and <5 mg/dL (300 µmol/L) in those with severe gout."4.952016 updated EULAR evidence-based recommendations for the management of gout. ( Bardin, T; Barskova, V; Becce, F; Castañeda-Sanabria, J; Coyfish, M; Doherty, M; Guillo, S; Jansen, TL; Janssens, H; Lioté, F; Mallen, C; Nuki, G; Pascual, E; Perez-Ruiz, F; Pimentao, J; Punzi, L; Pywell, T; Richette, P; So, A; Tausche, AK; Tubach, F; Uhlig, T; Zavada, J; Zhang, W, 2017)
"It appears that soluble uric acid has a much larger role to play than just being a risk factor for gout."4.95Factors modulating the inflammatory response in acute gouty arthritis. ( Cleophas, MC; Crişan, TO; Joosten, LA, 2017)
"[PubMed and Google Scholar databases] were search for all articles and trials published before 2016, using the key terms [hyperuricemia, gout, tophi, joint erosion, joint damage, treatment guidelines, American College of Rheumatology (ACR), European League Against Rheumatism (EULAR), flare, comorbidity, epidemiology, adherence, serum uric acid (sUA), monosodium urate (MSU), <6 mg/dL, MSU crystal formation, as well as individual drug names and classes of treatments of interest (allopurinol, febuxostat, colchicine, non-steroidal anti-inflammatories (NSAIDs)]."4.95Limitations of the Current Standards of Care for Treating Gout and Crystal Deposition in the Primary Care Setting: A Review. ( Keenan, RT, 2017)
"Lowering serum uric acid (SUA) levels can essentially cure gout; however, this is not widely practiced."4.95Serum Uric Acid and the Risk of Incident and Recurrent Gout: A Systematic Review. ( Bolzani, A; Cheung, A; Choi, HK; Shiozawa, A; Szabo, SM, 2017)
"Recent evidence would indicate that high serum uric acid (SUA) levels can be a significant and independent risk factor for hypertension and cardiovascular diseases, such as ischemic heart disease and heart failure."4.93Uric acid lowering therapy in cardiovascular diseases. ( Iellamo, F; Romeo, F; Sposato, B; Volterrani, M, 2016)
"In patients with gout, serum uric acid (sUA) concentrations should be lowered at least below the target of 6 mg/dL (even below 5 mg/dL in patients with severe gout)."4.93Urate lowering therapies in the treatment of gout: a systematic review and meta-analysis. ( Borghi, C; Perez-Ruiz, F, 2016)
"Besides the well accepted need to treat hyperuricemia associated with gout, some large observational studies and small prospective therapeutic trials have suggested that treating asymptomatic hyperuricemia, especially by xanthine oxidase inhibition, the enzyme producing uric acid, could be beneficial for cardiovascular and renal risk prevention."4.93[HYPERURICEMIA AND POTENTIAL RISK OF CARDIOVASCULAR AND RENAL DISEASES]. ( Krzesinski, JM; Schils, R, 2016)
"Hyperuricemia (elevated serum uric acid) is prevalent, and an important mediator of gout, an increasingly common condition."4.93Hyperuricemia, the kidneys, and the spectrum of associated diseases: a narrative review. ( Jalal, DI, 2016)
" It is caused by factors that elevate the concentration of serum uric acid (sUA), leading to hyperuricemia (sUA >6."4.93Overview of Serum Uric Acid Treatment Targets in Gout: Why Less Than 6 mg/dL? ( Edwards, NL; Ruoff, G, 2016)
" In gout, inflammation arises from precipitation of uric acid in the form of needle-shaped monosodium urate crystals."4.91How neutrophil extracellular traps orchestrate the local immune response in gout. ( Hahn, J; Herrmann, M; Hoffmann, MH; Kienhöfer, D; Manger, B; Maueröder, C; Schauer, C; Schett, G, 2015)
"The goal of emerging therapies is to address the unsatisfactory control of serum uric acid in patients with symptomatic hyperuricemia such as those with gout, to provide better tolerability compared to traditional agents and minimize the risk of adverse events, especially in patients with comorbidities and the elderly."4.91Investigational drugs for hyperuricemia. ( Shahid, H; Singh, JA, 2015)
" Chondrocalcinosis is a radiographic entity characterized by deposits of calcium pyrophosphate crystals (CPP) within the fibrocartilage or hyalin cartilage."4.91[Gout and and calcium pyrophosphate crystal arthropathies: pathophysiology]. ( Albert, JD; Coiffier, G, 2015)
"In gouty patients, urate lowering therapies (ULTs) are recommended to bring serum uric acid (SUA) levels below 6."4.91Why focus on uric acid? ( Johnson, RJ, 2015)
" MSU nucleation was found to be increased by a number of factors, including sodium ions, uric acid binding antibodies, and synovial fluid or serum from patients with gout."4.91Factors influencing the crystallization of monosodium urate: a systematic literature review. ( Chhana, A; Dalbeth, N; Lee, G, 2015)
" Better understanding of the transporters URAT1 and ABCG2 in particular would appear to provide opportunities for more selective, better tolerated agents to increase the renal clearance of uric acid and thereby control hyperuricemia."4.90Uricosuric drugs: the once and future therapy for hyperuricemia? ( Bach, MH; Simkin, PA, 2014)
" The results of the meta-analysis showed that when gout had progressed to the stage of acute arthritis, there was no significant difference in clinical efficacy between Chinese herbal decoctions and traditional Western medicine, as indicated based on the following parameters: serum uric acid (standardized mean difference (SMD):0."4.90Systematic review and meta-analysis of the clinical efficacy and adverse effects of Chinese herbal decoction for the treatment of gout. ( Chen, P; Cheng, D; Liu, L; Liu, X; Pettigrew, JC; Wu, Y; Yi, D; Zhang, Y; Zhou, L, 2014)
" The search terms were 'gout', 'gouty arthritis', 'hyperuricemia', 'uric acid', 'xanthine oxidase (XO) inhibitor', 'uricosuric', 'urate transporter 1(URAT1)' and 'glucose transporter 9 (GLUT9)'."4.90A review of phytotherapy of gout: perspective of new pharmacological treatments. ( Bochu, W; Ling, X, 2014)
" Most items showed a positive likelihood ratio (LR+) < 3, except for the following: response of arthritis to colchicine (LR+ 4."4.90Diagnostic value of clinical, laboratory, and imaging findings in patients with a clinical suspicion of gout: a systematic literature review. ( Andrès, M; Carmona, L; Falzon, L; Sivera, F; van der Heijde, DM, 2014)
"To systematically review the validity of serum uric acid (SUA) as a treatment target for patients with gout, and the clinimetric properties of the potential tools for monitoring these patients."4.90Treatment target and followup measures for patients with gout: a systematic literature review. ( Andrés, M; Carmona, L; Falzon, L; Sivera, F; van der Heijde, DM, 2014)
"Our review found low- to moderate-quality evidence indicating similar effects on withdrawals due to AEs and SAEs and incidence of acute gout attacks when allopurinol (100 to 600 mg daily) was compared with placebo, benzbromarone (100 to 200 mg daily) or febuxostat (80 mg daily)."4.90Allopurinol for chronic gout. ( Bombardier, C; Buchbinder, R; Edwards, CJ; Kydd, AS; Seth, R, 2014)
"We considered all randomised controlled trials (RCTs) or quasi-randomised controlled trials (controlled clinical trials (CCTs)) that compared uricosuric medications (benzbromarone, probenecid or sulphinpyrazone) alone or in combination with another therapy (placebo or other active uric acid-lowering medication, or non-pharmacological treatment) in adults with chronic gout for inclusion."4.90Uricosuric medications for chronic gout. ( Bombardier, C; Buchbinder, R; Edwards, CJ; Kydd, AS; Seth, R, 2014)
"This study aims to compare the urate-lowering response rate of febuxostat and allopurinol in gout patient using a model-based meta-analysis."4.90[A model-based meta-analysis to compare urate-lowering response rate of febuxostat and allopurinol in gout patient]. ( Li, L; Lu, W; Sun, Y; Zhou, TY, 2014)
" Twenty-five out of 41 trials, involving 23 different herbal prescriptions, found statistical significance in lowering serum uric acid level, and the overall effect from Chinese herbal medicine in inflammation relief is better than conventional therapies in 19 trials with 17 different prescriptions."4.89Chinese herbal medicine for gout: a systematic review of randomized clinical trials. ( Han, M; Li, XX; Liu, JP; Wang, YY, 2013)
"To evaluate the safety and efficacy of febuxostat compared to allopurinol for the treatment of chronic gout."4.89A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout. ( Ehteshami-Afshar, A; Faruque, LI; Homik, J; Tjosvold, L; Tonelli, M; Wiebe, N, 2013)
"Traditionally, serum uric acid (SUA) has been implicated in acute gouty arthritis or chronic gouty arthropathy."4.89Hyperuricaemia: more than just a cause of gout? ( Athyros, VG; Karagiannis, A; Katsiki, N; Mikhailidis, DP, 2013)
" Concordantly, recent studies have revived the controversy over the role of circulating uric acid, hyperuricemia, and gout as an independent prognostic factor for cardiovascular morbidity and mortality."4.89Chronic hyperuricemia, uric acid deposit and cardiovascular risk. ( Cheli, P; Del Pinto, R; Desideri, G; Di Giosia, P; Ferri, C; Ferri, L; Grassi, D; Properzi, G, 2013)
"Febuxostat has been approved for the treatment of hyperuricemia in patients with/without gout."4.89Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis. ( Chen, S; Cheng, Q; Li, Q; Liu, L; Luo, T; Lv, Q; Mei, M; Yang, S; Ye, P; Zhang, W, 2013)
"(a) To examine the latest information about renal tubular handling of uric acid, its genetic background and contribution to the causation of hyperuricemia."4.88Hyperuricemia, gout and the kidney. ( Gibson, T, 2012)
" The relationship between hyperuricemia and gout was first documented in the nineteenth century by Alfred Baring Garrod, who demonstrated deposits of uric acid crystals on a linen thread held dipped in acidified blood (the so-called "thread method")."4.88Some historical remarks on microcrystalline arthritis (gout and chondrocalcinosis). ( Marson, P; Pasero, G, 2012)
"A number of epidemiological studies have reported an association between serum uric acid levels and a wide variety of high-risk conditions including hypertension, insulin resistance, and kidney and cerebro-cardiovascular disease."4.88Cardiovascular and renal effects of hyperuricaemia and gout. ( Leoncini, G; Pontremoli, R; Viazzi, F, 2012)
"Gout is a metabolic disorder of excess uric acid accumulation that manifests clinically as inflammatory arthritis, chronic arthropathy and the formation of deposits of uric acid known as tophi."4.88Pegloticase for treating refractory chronic gout. ( George, RL; Sundy, JS, 2012)
"In addition to its role as a metabolic waste product, uric acid has been proposed to be an important molecule with multiple functions in human physiologic and pathophysiologic processes and may be linked to human diseases beyond nephrolithiasis and gout."4.88Renal transport of uric acid: evolving concepts and uncertainties. ( Bobulescu, IA; Moe, OW, 2012)
"Gout is a metabolic disorder of purine metabolism and uric acid elimination."4.88Safety of urate-lowering therapies: managing the risks to gain the benefits. ( Keenan, RT, 2012)
"The approval of febuxostat, a non-purine-analogue inhibitor of xanthine oxidase, by the European Medicines Agency and the US Food and Drug Administration heralds a new era in the treatment of gout."4.87Gout therapeutics: new drugs for an old disease. ( Burns, CM; Wortmann, RL, 2011)
" Recent findings support the notion that the physiological function of ABCG2 is involved in the elimination of uric acid resulting in higher risk for developing gout in male patients harboring genetic variants."4.87In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2). ( Kroemer, HK; Meyer zu Schwabedissen, HE, 2011)
" Identifying monosodium urate (MSU) and calcium pyrophosphate dehydrate (CPPD) crystals allows a quick and definitive diagnosis of both gout and CPPD arthritis, and remains the accepted gold standard."4.87Synovial fluid analysis for crystals. ( Andrés, M; Pascual, E; Sivera, F, 2011)
"Through the use of a systematic computer-based literature analysis, this pharmacoeconomic review evaluated costs, risks, and benefits of Colcrys (colchicine) compared with other treatments for gout in the US."4.87A new perspective on the pharmacoeconomics of colchicine. ( Davis, MW; Lauterio, TJ; Wertheimer, AI, 2011)
"In France, colchicine remains the standard treatment for the acute flare of gout."4.87[Treatment of gout]. ( Dubost, JJ; Mathieu, S; Soubrier, M, 2011)
"High uric acid (UA) levels can cause gout, urolithiasis and acute and chronic nephropathy, all of which are due to the deposit of urate crystals."4.87Is there anything good in uric acid? ( Alvarez-Lario, B; Macarrón-Vicente, J, 2011)
"Many patients with acute gout (11%-49%) have normal serum uric acid (SUA) levels."4.87Clinical inquiry. Are serum uric acid levels always elevated in acute gout? ( Fletcher, A; Leiszler, M; Poddar, S, 2011)
"During the past few decades, the mean serum uric acid levels and the prevalence of hyperuricemia in the general population appear to have increased."4.87The epidemiology of uric acid and fructose. ( Choi, HK; Rho, YH; Zhu, Y, 2011)
"Gout is a common metabolic disorder characterized by elevated uric acid leading to the formation and accumulation of uric acid crystals in synovial fluids."4.86Update on biology: uric acid and the activation of immune and inflammatory cells. ( Martinon, F, 2010)
"Uric acid crystals, the causative agent of gout, have recently gained widespread attention due to their role as a natural endogenous adjuvant."4.86Recent developments in immune activation by uric acid crystals. ( Chau, EM; Ng, G; Shi, Y, 2010)
" Chronic hyperuricemia (uric acid serum levels >6."4.86Crystal arthropathies: recognizing and treating "the gouch". ( Quillen, DM, 2010)
"Uric acid has historically been viewed as a purine metabolic waste product excreted by the kidney and gut that is relatively unimportant other than its penchant to crystallize in joints to cause the disease gout."4.85Lessons from comparative physiology: could uric acid represent a physiologic alarm signal gone awry in western society? ( Benner, SA; Gabriela Sanchez-Lozada, L; Johnson, RJ; Mu, W; Nakagawa, T; Oliver, WJ; Rodriguez-Iturbe, B; Roncal, C; Sautin, YY, 2009)
" However, detection of SF monosodium urate and calcium pyrophosphate dihydrate crystals, even from un-inflamed joints during intercritical periods, allow a precise diagnosis of gout and of calcium pyrophosphate crystal-related arthritis."4.85Joint aspiration and injection and synovial fluid analysis. ( Courtney, P; Doherty, M, 2009)
"Elevated serum uric acid levels cause gout and are a risk factor for cardiovascular disease and diabetes."4.85Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. ( Adamski, J; Albrecht, E; Aulchenko, Y; Beckmann, JS; Bergmann, S; Bochud, M; Brown, M; Campbell, H; Caulfield, M; Connell, J; Doering, A; Dominiczak, A; Farrall, M; Gieger, C; Gyllensten, U; Homuth, G; Illig, T; Johansson, A; Johnson, T; Kolz, M; Lamina, C; Mangino, M; McCarthy, MI; Meitinger, T; Mooser, V; Munroe, P; Nagaraja, R; Nauck, M; Nyholt, DR; Peden, J; Peltonen, L; Perola, M; Pramstaller, P; Prokisch, H; Rudan, I; Salo, P; Salomaa, V; Samani, NJ; Sanna, S; Schlessinger, D; Spector, TD; Teumer, A; Uda, M; Vitart, V; Völker, U; Vollenweider, P; Völzke, H; Waeber, G; Wallace, C; Wang-Sattler, R; Waterworth, D; Watkins, H; Whitfield, JB; Wichmann, HE; Wilson, JF; Wright, AF, 2009)
"Gout is a common rheumatic disease in humans which is characterized by elevation in serum uric acid levels, and deposition of uric acid crystals in the joint."4.85Recent insights into the pathogenesis of hyperuricaemia and gout. ( Ralston, SH; Riches, PL; Wright, AF, 2009)
"Febuxostat, a nonpurine selective inhibitor of both the oxidized and reduced forms of xanthine oxidase, was approved in February 2009 by the US Food and Drug Administration for the management of hyperuricemia in adults with gout."4.85Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout. ( Ernst, ME; Fravel, MA, 2009)
"*Febuxostat is an orally administered, non-purine, selective inhibitor of xanthine oxidase approved for the management of chronic hyperuricaemia in patients with gout."4.84Febuxostat. ( Hair, PI; Keating, GM; McCormack, PL, 2008)
" A rapid and massive raise of uric acid, during tumor lysis syndrome (TLS), and also a lower and chronic hyperuricemia, as in gout, mainly damage the kidney."4.84Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout. ( Cammalleri, L; Malaguarnera, M, 2007)
"Uric acid nephrolithiasis is typically found in individuals with a low urine pH and a normal concentration of urinary uric acid."4.84Uric acid nephrolithiasis. ( Bushinsky, DA; Liebman, SE; Taylor, JG, 2007)
" While physicians have understood for at least a century that uric acid causes gout, we are now beginning to address the question of why hyperuricemia exists and the mechanisms by which uric acid acts to stimulate inflammation."4.84Hyperuricemia and gout: new insights into pathogenesis and treatment. ( Abeles, AM; Pillinger, MH; Rosenthal, P, 2007)
" Specifically, we review newly discovered mechanisms of uric acid-induced inflammation, uric acid's putative role as a "danger signal" in innate immunity, the possible link between hyperuricemia and cardiovascular disease, and evolutionary evidence suggesting that hyperuricemia conferred a survival advantage in primates (when the gene for uricase was lost) several million years ago."4.84Update on gout: pathophysiology and potential treatments. ( Abeles, AM; Cronstein, BN; Park, JY; Pillinger, MH, 2007)
"Impaired renal uric acid excretion is the major mechanism of hyperuricemia in patients with primary gout."4.84Control of renal uric acid excretion and gout. ( Kamatani, N; Taniguchi, A, 2008)
" Recently it has been identified that hypertension are frequently associated with myogenic hyperuricemia converted from overproduced hypoxanthine in the skeletal muscles."4.84[Idiopathic hyperuricemia with overproduction of uric acid]. ( Hisatome, I; Igawa, O; Mizuta, E, 2008)
" A syndrome of increased activity of PRPP synthetase, an X-linked dominant-inherited disorder, is one of the models of gout caused by increased production of uric acid."4.84[Increased activity of PRPP synthetase]. ( Iizasa, T, 2008)
"Urate lowering treatment is indicated in patients with recurrent acute attacks, tophi, gouty arthropathy, radiographic changes of gout, multiple joint involvement, or associated uric acid nephrolithiasis."4.84[Uricosuric agent]. ( Ohno, I, 2008)
"The association of elevated serum uric acid (hyperuricemia, gout) with the presence of classical coronary risk factors and coronary artery disease (CAD) or myocardial infarction (MI) has been analysed in many epidemiological studies."4.83[Is hyperuricemia a cardiovascular risk factor?]. ( Chizyński, K; Rózycka, M, 2006)
"Gout is a metabolic disorder in which there is either an increase in production or a decrease in excretion of uric acid leading to hyperuricemia."4.82Advanced imaging of gout. ( Gentili, A, 2003)
"Although allopurinol has been available for approximately 50 years, hyperuricemia and its sequelae are not only prevalent, but the incidence and costs associated with this disorder continue to increase."4.82Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase. ( Bomalaski, JS; Clark, MA, 2004)
"Treatment of asymptomatic hyperuricemia is not necessary in most patients, unless perhaps they have very high levels of uric acid or are otherwise at risk of complications, such as those with a personal or strong family history of gout, urolithiasis, or uric acid nephropathy."4.81Asymptomatic hyperuricemia: to treat or not to treat. ( Dincer, AP; Dincer, HE; Levinson, DJ, 2002)
"Gout is a common disease arising due to abnormal purin metabolism and excessive accumulation of uric acid in the blood (hyperuricemia) and manifesting with attacks of acute gouty arthritis."4.81[Gout: current views. Stage oriented treatment]. ( Fedorova, NE; Grigor'eva, VD, 2002)
"Gout is a disease resulting from the deposition of urate crystals caused by the overproduction or underexcretion of uric acid."4.80Diagnosis and management of gout. ( Bross, MH; Pittman, JR, 1999)
" Calcium pyrophosphate deposition disease ("pseudogout") usually affects larger joints and often follows trauma, surgery, or ischemic heart disease."4.79Gout or 'pseudogout': how to differentiate crystal-induced arthropathies. ( Joseph, J; McGrath, H, 1995)
"A critical appraisal of the evidence commonly cited to support a link between high urate excretion and calcium oxalate (CaOx) urinary calculi is presented."4.79Urate and calcium oxalate stones: from repute to rhetoric to reality. ( Grover, PK; Ryall, RL, 1994)
"The proper diagnosis of gout and pseudogout (ie, calcium pyrophosphate dihydrate crystal deposition disease) leads to correct treatment."4.79Gout and 'pseudogout'. When are arthritic symptoms caused by crystal deposition? ( Beutler, A; Schumacher, HR, 1994)
"The molecular and biochemical aspects of purine nucleotide biosynthesis through de novo and salvage pathways, the production of uric acid, and their regulation mechanisms are reviewed for further understanding of hyperuricemia and gout."4.79[Metabolism of purine nucleotides and the production of uric acid]. ( Itakura, M; Yamaoka, T, 1996)
" PRS superactivity is an X-chromosome linked disorder, characterized by gout and uric acid overproduction resulting from accelerated synthesis of PRPP and purine nucleotides."4.79[PRPP synthetase superactivity]. ( Fujimori, S, 1996)
"Purine nucleotide degradation during ethanol catabolism, inhibition of renal excretion of urate by lactic acid, and high purine content of certain kinds of beverage are responsible for the elevation of serum uric acid level following alcohol drinking."4.79[Alcohol ingestion and hyperuricemia]. ( Yamanaka, H, 1996)
"A number of pharmacological agents can induce hyperuricaemia, and sometimes gout, usually by interfering with the renal tubular excretion of urate but also in some instances by increasing the formation of uric acid."4.78Drug-induced gout. ( Scott, JT, 1991)
"Gout is a clinical syndrome encompassing a group of metabolic diseases that are all characterized by abnormal uric acid metabolism."4.77Hyperuricemia and gout. ( German, DC; Holmes, EW, 1986)
"The therapy of gout is discussed taking into consideration the concomitant diseases occurring significantly frequently in patients with gout: Hypertension, uric acid-nephrolithiasis, hyperlipoproteinaemia, obesity, premature arteriosclerosis as well as diabetes mellitus."4.75[Therapy of gout]. ( Heidelmann, G; Thiele, P, 1977)
"Benzbromarone1 is a benzofuran derivative which lowers serum urate and increases urinary urate excretion in normal, hyperuricaemic and gouty subjects."4.75Benzbromarone: a review of its pharmacological properties and therapeutic use in gout and hyperuricaemia. ( Avery, GS; Brogden, RN; Heel, RC; Speight, TM, 1977)
"Patients (n = 223) with gout taking allopurinol ≥300 mg daily attended a standardized gout assessment visit."4.31Predictors of Patient and Physician Assessments of Gout Control. ( Baumgartner, S; Choi, HK; Dalbeth, N; Frampton, C; Fung, M, 2023)
"Increased uric acid may have a protective effect in motor neuron diseases (MNDs)."4.31Prevalence of motor neuron diseases in gout patients: a nationwide population-based cohort study. ( Choi, H; Jun, JB; Kang, DR; Kim, JH; Kim, SH; Kwon, HS; Park, S; Park, Y, 2023)
"This study aimed to describe the incidence and prevalence of gout, describe the use of allopurinol among prevalent gout cases, and determine persistence with allopurinol and degree of compliance with treat-to-target recommendations before and after the publication of Swedish national guidelines in 2016."4.31Gout in Dalarna, Sweden - a population-based study of gout occurrence and compliance to treatment guidelines. ( Dehlin, M; Jacobsson, L; Sigurdardottir, V; Svärd, A, 2023)
"The occurrence of gout attacks at the start of uric acid lowering treatment worsens compliance."4.31A retrospective observational study of the appropriate starting dose of febuxostat in patients with gout. ( Ghang, B; Jeong, W; Kim, J; Lee, J, 2023)
"Our findings linked normouricemic erosive gout to attenuated lubricin, with impaired control of cathepsin G activity, compounded by deleterious NLRP3 variants."4.31Amplification of Inflammation by Lubricin Deficiency Implicated in Incident, Erosive Gout Independent of Hyperuricemia. ( Cadzow, M; Campeau, A; Chhana, A; Dalbeth, N; Dambruoso, TJ; Elsaid, K; Elsayed, S; Ghassemian, M; Gonzalez, DJ; Höglund, J; Jay, GD; Karlsson, NG; Karsh, J; Liu-Bryan, R; Maltez, N; Merriman, TR; Miner, M; Phipps-Green, A; Qadri, M; Rossitto, LA; Schmidt, TA; Terkeltaub, R, 2023)
" Reducing uric acid and inhibiting inflammation are the focused areas of drug research and development on gout."4.31Rutin ameliorates gout via reducing XOD activity, inhibiting ROS production and NLRP3 inflammasome activation in quail. ( Huang, J; Li, Y; Lin, Z; Wang, Y; Wu, H; Zhang, B, 2023)
"Serial DECT scans from 32 people with gout were obtained over 2 years of allopurinol therapy, dose-escalated to serum urate of <0."4.31Changes in Tophus Composition During Urate-Lowering Therapy: A Dual-Energy Computed Tomography Study. ( Chen, L; Dalbeth, N; Doyle, AJ; Drake, J; Gamble, GD; Horne, A; Stamp, LK; Uhlig, T, 2023)
"Poor adherence to allopurinol among people with gout contributes to suboptimal gout management."4.31Optimizing adherence to allopurinol for gout: patients' perspectives. ( Aslani, P; Chan, JS; Coleshill, MJ; Day, RO; Michael, TJF; Spragg, JCJ; Stocker, SL, 2023)
"Nonalcoholic fatty liver disease (NAFLD) is a common chronic disease that is related to high serum uric acid; however, the association between the frequency of gout flares and NAFLD risk remains unclear."4.31The risk of nonalcoholic fatty liver disease in gout patients with frequent flares: a retrospective cohort study. ( Chen, Y; Chi, J; Dong, B; Liu, C; Si, K; Wang, Y; Xu, L, 2023)
"This study aimed to explore the clinical characteristics of perioperative acute gout attacks in patients with varying uric acid levels undergoing orthopedic surgery, identify the risk factors for gout recurrence within the first postoperative year, and provide a disease prevention and diagnostic reference."4.31Acute gout attacks during the perioperative period and risk factors of recurrence after orthopedic surgery among untreated gout patients. ( Sun, X; Wang, H; Wang, W; Wu, Q; Yan, C; Zeng, H; Zhang, Z, 2023)
"In patients with gout receiving uric acid-lowering therapy, musculoskeletal ultrasound has the potential to observe changes in gout lesions."4.31Musculoskeletal Ultrasound in Monitoring the Efficacy of Gout: A Prospective Study Based on Tophus and Double Contour Sign ( Fan, Y; Gu, P; He, Y; Mou, X; Qing, Y; Tang, X; Yan, X; Yang, Q; Yuan, H; Yue, W, 2023)
" This research aimed to study the relation of ischemic cerebrovascular disease with benzbromarone use among persons with gout-related disorders."4.31The risk of ischemic cerebrovascular disease associated with benzbromarone use in gout people: A retrospective cohort study in Taiwan. ( Hwang, BF; Kuo, YH; Lai, SW; Liao, KF; Liu, CS, 2023)
"Correlation influence factor analysis of gout patients' serum uric acid (SUA) levels, their examination fees, and various complications were explored."4.31Association between serum uric acid levels of patients with gout and their complications and examination fees: A cross-sectional analysis. ( Dang, W; Liu, J; Wang, J; Xu, D; You, L; Zhao, L, 2023)
"Treatment of gout involves two basic approaches: reducing the serum uric acid mainly by xanthine oxidase inhibitors (XOIs) and alleviating the intensity of the accompanying acute arthritic inflammation using non-steroidal anti-inflammatory drugs (NSAIDs)."4.31Towards the Development of Dual Hypouricemic and Anti-inflammatory Candidates: Design, Synthesis, Stability Studies and Biological Evaluation of Some Mutual Ester Prodrugs of Febuxostat-NSAIDs. ( Abdel Moneim, AE; Daabees, HG; Elagawany, M; Rashad, AY; Rostom, SAF; Shahin, M, 2023)
"Spontaneous serum uric acid (SUA) decrease has been found in many patients during acute gout attacks, but its mechanism remains unclear."4.31Intestinal uric acid excretion contributes to serum uric acid decrease during acute gout attack. ( Cao, L; Du, X; Lin, C; Wan, W; Xu, R; Yang, X; Zhao, T; Zhou, M; Zhu, X; Zou, H, 2023)
" A Mendelian randomization analysis of the association between caffeine-containing drinks and gout risk was conducted."4.31Exploring the mechanism underlying hyperuricemia using comprehensive research on multi-omics. ( Dai, Q; Fang, J; Li, B; Liu, H; Xie, R; Xu, Y, 2023)
" The volume of MSU crystals is associated with the improved SvdH erosion score based on CT images, regardless of serum uric acid level, demonstrating the potential of combining DECT and serum uric acid measurements in helping optimize the management of patients with gout."4.31Detailed analysis of the association between urate deposition and bone erosion in gout: a dual-energy computed tomography study. ( Deng, WM; Hung, YK; Jiang, GH; Wang, JY; Wang, W; Zhan, WF; Zheng, WY, 2023)
"Uric acid, the end product of purine degradation, causes hyperuricemia and gout, afflicting hundreds of millions of people."4.31Anaerobic purinolytic enzymes enable dietary purine clearance by engineered gut bacteria. ( Gao, L; Hu, Y; Ju, Y; Li, L; Li, P; Li, Z; Liu, D; Liu, S; Luo, Y; Tong, Y; Wang, J; Wang, Y; Wei, Y; Yu, H; Zhang, Y, 2023)
"Gout is a form of inflammatory arthritis that results from elevated serum uric acid levels and the deposition of urate crystals in multiple joints."4.31Development of a novel anti-inflammatory recombinant uricase with extended half-life for gout therapy. ( Fu, N; Li, Q; Quan, J; Zhang, Z, 2023)
"SIM0295, a novel inhibitor of human uric acid transporter 1 (hURAT1), is used to treat patients with gout and hyperuricemia."4.31Model Informed Development of SIM0295 in Patients with Gout and Hyperuricemia and Healthy Volunteers Using a Population Pharmacokinetics/ Pharmacodynamics Approach. ( Chen, Y; Huang, Q; Jiao, Z; Kim, JS; Shu, P; Wang, C; Xu, S; Yang, Y; Zhang, X, 2023)
"Pathophysiologic processes promoted by uric acid, including inflammation and oxidative stress, play a key role in the pathogenesis of several cardiovascular diseases."4.31[ANMCO statement: Uric acid and cardiovascular disease: evidence and therapeutic approach]. ( Aquilani, S; Castello, L; Colivicchi, F; Di Fusco, SA; Flori, M; Gabrielli, D; Gulizia, MM; Marino, G; Nardi, F; Oliva, F; Riccio, C, 2023)
" Uric acid (UA), a major risk factor for gout, has also been suggested to be a risk factor for CKD, but the efficacy of existing urate-lowering therapies for CKD is controversial."4.31GLUT9 as a potential drug target for chronic kidney disease: Drug target validation by a Mendelian randomization study. ( Fukui, K; Kamatani, N; Kamitsuji, S; Matsuo, A; Matsushita, M; Nishiu, J; Sasase, T; Ueda, M, 2023)
"Monosodium uric acid (MSU) crystal, the etiological agent of gout, has been shown to trigger innate immune responses via multiple pathways."4.31Clec12a inhibits MSU-induced immune activation through lipid raft expulsion. ( Li, S; Shi, Y; Song, D; Wang, W; Xia, T; Xu, Y; Yue, T, 2023)
"We investigated the appropriate duration of colchicine prophylaxis to maximize the persistence of xanthine oxidase inhibitors (XOIs) as first-line urate-lowering therapy (ULT) in patients with gout."4.31Analysis of appropriate duration of colchicine prophylaxis to maximize the persistence of xanthine oxidase inhibitors as the first-line urate-lowering therapy in patients with gout using the Korean Health Insurance Review and Assessment Service database. ( Kim, AR; Lee, SG; So, MW, 2023)
" It suppressed liver xanthine oxidase activity to decrease uric acid synthesis and modulated renal urate transporters to stimulate uric acid excretion, alleviating kidney damage caused by hyperuricemia."4.31Paeonia × suffruticosa Andrews leaf extract and its main component apigenin 7-O-glucoside ameliorate hyperuricemia by inhibiting xanthine oxidase activity and regulating renal urate transporters. ( An, J; Li, C; Li, Y; Lin, F; Ma, S; Wang, S; Xie, Y; Xu, L; Zhang, Y; Zhao, Y, 2023)
"Approximately 15% of US adults have circulating levels of uric acid above its solubility limit, which is causally linked to the disease gout."4.31A widely distributed gene cluster compensates for uricase loss in hominids. ( Augustijn, HE; Cabrera, AV; Chen, H; DeFeo, ME; Dodd, D; Ganesan, C; Gombar, S; Hou, BH; Huang, S; Jarman, JB; Liu, Y; Low, YS; Medema, MH; Meng, X; Pao, AC; Sekiba, K; van Wezel, G; Weakley, AM; Zhou, Z, 2023)
"Higher serum uric acid (SUA) can cause gout, which is principally characterized by arthritis due to monosodium urate crystal deposition in the lower extremities."4.31Association between serum uric acid levels and peripheral artery disease in Chinese adults with hypertension. ( Bao, H; Cheng, X; Han, F; Hu, F; Huang, X; Wang, T; Yu, C; Zhou, W; Zhu, L, 2023)
"This study aimed to examine the association of serum uric acid levels with incident cardiovascular disease and mortality in Korean adults without gout."4.31Uric Acid and Risk of Cardiovascular Disease and Mortality: A Longitudinal Cohort Study. ( Chang, TI; Kim, JY; Lim, H; Pak, H; Seo, C, 2023)
"To determine the risk of adverse events associated with colchicine or non-steroidal anti-inflammatory drug (NSAID) prophylaxis when initiating allopurinol for gout."4.31Safety of colchicine and NSAID prophylaxis when initiating urate-lowering therapy for gout: propensity score-matched cohort studies in the UK Clinical Practice Research Datalink. ( Bajpai, R; Clarson, LE; Forrester, H; Mallen, CD; Muller, S; Padmanabhan, N; Partington, RJ; Roddy, E; Whittle, R, 2023)
" Thus, we aimed to investigate diurnal variations in serum levels of UA and plasma levels of xanthine, hypoxanthine, and xanthine oxidoreductase (XOR) activity, which were measured at 18:00, 6:00, and 12:00 in male patients with coronary artery disease."4.31Diurnal Variations in Serum Uric Acid, Xanthine, and Xanthine Oxidoreductase Activity in Male Patients with Coronary Artery Disease. ( Hiki, M; Ishiwata, S; Kasai, T; Kato, T; Kuwabara, M; Matsumoto, H; Murase, T; Murata, A; Naito, R; Nakamura, T; Sato, A; Shimizu, M; Shitara, J; Suda, S; Yatsu, S, 2023)
"Hyperuricemia is a clinical disease characterized by a continuous increase in uric acid (UA) due to purine metabolism disorder."4.31Peptide NCTX15 derived from spider toxin gland effectively relieves hyperuricemia in mice. ( Bian, W; Fu, Z; Li, C; Liu, N; Liu, Y; Peng, Y; Ru, Z; Wang, Y; Wu, Y; Yang, X; Zhang, Y, 2023)
" Two definitions of hyperuricemia were used: capillary level equivalent to plasma uric acid level>360μmol/l (6mg/dl) and>420μmol/l (7mg/dl) and/or urate-lowering drug treatment for both thresholds."4.12Epidemiology of gout and hyperuricemia in New Caledonia. ( Bardin, T; Clerson, P; Magnat, E; Richette, P; Rouchon, B, 2022)
" The averaged serum uric acid levels in patients with gout reduced after WMT (p = 0."4.12Effects of Washed Microbiota Transplantation on Serum Uric Acid Levels, Symptoms, and Intestinal Barrier Function in Patients with Acute and Recurrent Gout: A Pilot Study. ( Cai, JY; Deng, ZH; He, XX; Kong, LP; Wu, LH; Xia, HH; Xie, WR; Yang, XY; Zhang, R; Zheng, YM, 2022)
"Lesinurad is a uricosuric agent for the treatment of hyperuricemia associated with gout, which was found lacking in efficacy and safety."4.12Discovery of Novel Bicyclic Imidazolopyridine-Containing Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Improved Efficacy and Favorable Druggability. ( Ji, J; Liang, R; Liao, H; Liu, X; Pang, J; Shi, X; Tao, Y; Wu, T; Zhan, P; Zhang, J; Zhang, Z; Zhao, F; Zhao, T, 2022)
" Patients were aged ≥19 years; had CKD G3-G4; and used drugs including colchicine, allopurinol and febuxostat for hyperuricaemia or chronic gout during the period from April 2000 to October 2020."4.12Colchicine use and the risk of CKD progression: a multicentre nested case-control study. ( Chang, TI; Han, SH; Jhee, JH; Joo, YS; Kang, SW; Kim, HW; Kim, JY; Park, JT; Roh, YH; Yoo, TH; Yun, HR, 2022)
"Sixty-nine men with gout attending rheumatology clinics, all prescribed allopurinol for ≥ 6 months, completed the Intentional Non-Adherence Scale (INAS)."4.12Why Do Patients With Gout Not Take Allopurinol? ( Chalder, T; Dalbeth, N; Emad, Y; Petrie, KJ; Weinman, J, 2022)
"Six male patients with gout were treated with combined oral medication (febuxostat, 120 mg/d, and benzbromarone, 50 or 100 mg/d), aiming at a more rapid success of uric acid lowering treatment (ULT) compared to guideline suggestions."4.12Treating gout - can hypouricemia produced by moderate doses of combined oral treatment give early treatment success? Preliminary observations. ( Fairbanks, L; Gibson, T; Löffler, W, 2022)
"In gout, crystallization of uric acid in the form of monosodium urate (MSU) leads to a painful inflammatory response."4.12Natural antibodies and CRP drive anaphylatoxin production by urate crystals. ( Alberts, A; Brand, K; Hoffmeister, L; Klingberg, A; Neumann, K; Pich, A; Wessig, AK; Witte, T, 2022)
" Potential factors associated with reduced renal function including age, ethnicity, educational level, history of diabetes, hypertension, gout, hydronephrosis, serum uric acid level, and type of renal stone were evaluated using univariable and multivariable analyses."4.12Cardiovascular risk factors, ethnicity and infection stone are independent factors associated with reduced renal function in renal stone formers. ( Choy, SH; J R, S; Kamaruzaman, S; Lim, J; Malek, R; Md Yusoff, NA; Nagappan, P; Nyanatay, SA; Ong, TA; Sothilingam, S; Sundram, M; Toh, CC; Yeoh, WS, 2022)
"In the treat-to-target, tight control NOR-Gout study patients started ULT with escalating doses of allopurinol."4.12One- and 2-year flare rates after treat-to-target and tight-control therapy of gout: results from the NOR-Gout study. ( Haavardsholm, EA; Hammer, HB; Karoliussen, LF; Kvien, TK; Perez-Ruiz, F; Sexton, J; Uhlig, T, 2022)
"Characterized by an excessively increased uric acid (UA) level in serum, hyperuricemia induces gout and also poses a great threat to renal and cardiovascular systems."4.12Noninvasive and Individual-Centered Monitoring of Uric Acid for Precaution of Hyperuricemia via Optical Supramolecular Sensing. ( Chai, S; Chai, X; Geng, WC; Guo, DS; Li, JJ; Wang, L; Wang, Y; Yu, H; Yue, YX; Zhang, Y, 2022)
" These physiological characteristics have promoted the study of poly-gallic acid (PGAL), a poly-oxidized form of gallic acid reported to be effective in in vitro models of inflammation."4.12Anti-inflammatory and Antioxidant Effect of Poly-gallic Acid (PGAL) in an In Vitro Model of Synovitis Induced by Monosodium Urate Crystals. ( Fernández-Torres, J; Gimeno, M; Luján-Juárez, IA; Martínez-Flores, K; Martínez-López, V; Montaño-Armendariz, N; Sánchez-Sánchez, R; Zamudio-Cuevas, Y, 2022)
"Gout is the most common form of inflammatory arthritis and is caused by deposition of monosodium urate crystals resulting from a high burden of uric acid (UA)."4.12Urate-lowering therapy for patients with gout on hemodialysis. ( Alkilany, R; Antonelli, M; Einstadter, D, 2022)
" the xanthine oxidase inhibitors allopurinol and febuxostat), traditional Chinese medicine has fewer side effects in the treatment of gout and can safely control serum uric acid and the level of inflammation."4.12Phytochemicals in traditional Chinese medicine can treat gout by regulating intestinal flora through inactivating NLRP3 and inhibiting XOD activity. ( Liu, ZB; Liu, ZQ; Sun, X; Wu, CJ; Zhang, LL; Zhang, T, 2022)
" In this study, the xanthine oxidase (XO) inhibition and uric acid-lowering effect of corni fructus extract (CFE) were evaluated in mice with potassium oxonate-induced hyperuricemia."4.12Protective effects of corni fructus extract in mice with potassium oxonate-induced hyperuricemia. ( Chen, C; Chen, FA; Chen, HC; Chiu, PY; Li, YL; Wang, CC, 2022)
"The results obtained show that uric acid crystal detection using less invasive imaging methods in an animal model with birds and reptiles may expand gout diagnostics not only in veterinary medicine but also in human medicine and possibly replace arthrocentesis if a DF signal is detectable."4.12[X-Ray Dark-field radiography: Does this carry potential for diagnosing gout in exotic pets?] ( Andrejewski, J; Baumgartner, C; Braig, E; Herzen, J; Kimm, MA; Korbel, R; Pfeiffer, D; Roiser, N; Scholz, J, 2022)
"Sera of gout patients meeting the 2015 ACR/EULAR gout classification criteria (n = 20) and with hyperuricemia were studied at time zero and weeks 12 and 24 of febuxostat or allopurinol dose titration ULT."4.12Xanthine oxidase inhibitor urate-lowering therapy titration to target decreases serum free fatty acids in gout and suppresses lipolysis by adipocytes. ( Bittleman, D; Coras, R; Dadpey, B; Guma, M; Hamilton, B; Lauro, K; Liu-Bryan, R; Mikuls, TR; Quehenberger, O; Reilly, SM; Terkeltaub, R; Thorisdottir, H, 2022)
"Abnormal uric acid level result in the development of hyperuricemia and hallmark of various diseases, including renal injury, gout, cardiovascular disorders, and non-alcoholic fatty liver."4.12Anti-inflammatory potential of stevia residue extract against uric acid-associated renal injury in mice. ( Alharthi, F; Althobaiti, F; Chen, X; Mehmood, A; Murtaza, MA; Nadeem, M; Ranjha, MMAN; Shah, AA; Soliman, MM; Usman, M; Wang, C; Zhao, L, 2022)
" Ongoing research is examining the association of obesity, dietary patterns, and blood pressure (BP) with serum uric acid (sUA)."4.12Correlation of obesity, dietary patterns, and blood pressure with uric acid: data from the NHANES 2017-2018. ( Fan, GJ; Lin, YP; Lu, QY; Yao, J; Zhang, Y; Zhao, J, 2022)
"Pegloticase + methotrexate co-therapy was well-tolerated over 12 months, with sustained SU lowering, progressive gout flare reduction, and no new safety concerns."4.12A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an ( Bennett, R; Botson, JK; Chamberlain, J; Kenney, HM; LaMoreaux, B; Obermeyer, K; Peloso, PM; Peterson, J; Ramanathan, S; Song, Y; Tesser, JRP; Weinblatt, ME; Xin, Y; Zhao, L, 2022)
"Patients with hyperuricemia or gout or patients with high and low levels of serum uric acid may face poor outcomes of hip fractures."4.12The paradoxical relation between serum uric acid and outcomes of hip fracture in older patients after surgery: A 1-year follow-up study. ( Chu, Q; Fu, M; Liu, M; Sun, G; Wang, J; Yang, C; Zhang, Z, 2022)
" The language was used to formalize one- and two-drug titration of chronic and acute cases, and to perform retrospective analysis of the drug titration processes on 253 patients diagnosed of diabetes mellitus type 2 and treated with metformin, 321 patients treated of chonic heart failure with furosemide, 155 patients with hyperuricemia treated with allopurinol as initial drug and febuxostat as alternative drug, and 187 hyperuricemia patients with primary drug allopurinol and supplementary drug probenecid, in order to identify different types of drug titration deviations from standard DT methods."4.12Modelling and assessing one- and two-drug dose titrations. ( Alonso, JR; Kamišalić, A; Pečnik, Š; Riaño, D, 2022)
"Multiple observational studies have reported the close associations of obstructive sleep apnea (OSA) with serum uric acid (SUA) levels and gout."4.12Assessing the causal associations of obstructive sleep apnea with serum uric acid levels and gout: a bidirectional two-sample Mendelian randomization study. ( Cen, H; Ding, C; He, W; Huang, L; Jin, T; Ni, J; Xie, Y; Zeng, Z; Zhang, L, 2022)
" The frequency of gout attack and blood uric acid of patients 3 months after operation was lower than those before operation, and the differences were statistically significant."4.12Surgical Treatment of Hand and Foot Gout Stone and Influence Factors on Prognosis. ( Du, X; Jin, S; Qiu, X; Zhao, B; Zhao, W, 2022)
"Urate Transporter 1 (URAT1) plays a crucial role in uric acid transport, making it an attractive target for the treatment of gout and hyperuricemia."4.12Design, synthesis and activity evaluation of novel lesinurad analogues containing thienopyrimidinone or pyridine substructure as human urate transporter 1 inhibitors. ( Dong, Y; Gao, S; Liang, R; Liao, H; Liu, X; Pang, J; Qi, D; Shi, X; Wu, T; Zhan, P; Zhang, J; Zhang, X; Zhang, Z; Zhao, T, 2022)
"Gout is characterized by the deposition of monosodium urate crystals in patients with chronically elevated blood levels of uric acid."4.12Orthopaedic Management of Gout. ( Cohen-Rosenblum, AR; Guevara, ME; Hynes, KK; Somogyi, JR, 2022)
"Along with uric acid, which is the primary driving factor of gout, downstream inflammatory mediators have been shown to be involved in the pathogenesis of gouty arthritis flares."4.12Plasma adsorption in refractory chronic gouty arthritis flare: A case report. ( Cui, TJ; Lei, Y; Tang, C; Wang, XH; Zhang, XM; Zheng, ZH, 2022)
"Epidemiological evidence of the associations between metal exposure and gout-related outcomes (including serum uric acid [SUA], hyperuricemia and gout) is scarce."4.12Associations of metal exposure with hyperuricemia and gout in general adults. ( Hui, R; Shi, S; Wang, J; Xing, Y; Xu, J; Zhang, Y; Zhu, L; Zhu, X, 2022)
" The relationship between the uric acid metabolism target and the NLRP3 inflammasome may be the critical immune response between hyperuricemia and gouty arthritis."4.12Overnutrition-induced gout: An immune response to NLRP3 inflammasome dysregulation by XOD activity increased in quail. ( Huang, J; Li, Y; Lin, Z; Ren, Z; Wang, Y; Wu, H; Zhang, B, 2022)
"Pegloticase is an enzyme used to reduce serum uric acid levels in patients with chronic, treatment-refractory gout."4.02High MW polyethylene glycol prolongs circulation of pegloticase in mice with anti-PEG antibodies. ( Frank, JE; Lai, SK; LaMoreaux, B; Li, Z; Livingston, EW; McSweeney, MD; Nyborg, AC; Talkington, AM; Yuan, H; Zhang, T, 2021)
"Self-reported gout or hyperuricemia and uric acid level."4.02Should we be more aware of gender aspects in hyperuricemia? Analysis of the population-based German health interview and examination survey for adults (DEGS1). ( Engel, B; Freitag, MH; Hoffmann, F; Jacobs, H, 2021)
"Our previous research showed that uric acid lowering therapy (ULT) for gout and hyperuricemia is being prescribed for pediatric patients even though these drugs have not been approved for use in children."4.02Urate-lowering therapy for gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database. ( Honda, M; Horiuchi, H; Iijima, T; Ito, S; Murano, H; Nakajima, A; Torii, T; Yamanaka, H, 2021)
" Current data suggest that the mechanism of action of metformin contributes to the development of an anti-inflammatory effect, as well as a decrease in the level of uric acid, and its use can be potentially useful in patients with hyperuricemia and gout."4.02[Advantages of the use of metformin in patients with impaired uric acid metabolism]. ( Eliseev, MS; Nasonov, EL; Panevin, TS; Zhelyabina, OV, 2021)
"To investigate the efficacy and tolerability of febuxostat in gout patients on dialysis."4.02Efficacy and tolerability of febuxostat in gout patients on dialysis. ( Choi, SW; Choi, SY; Lee, S; Lim, DH; Oh, JS; So, MW, 2021)
"The objectives of our study were to compare the efficacy of febuxostat with allopurinol in Thai subjects with gout, as well as to determine the predictive factors of responsiveness to urate-lowering agents and to evaluate the safety of febuxostat in a real-world setting."4.02Efficacy of febuxostat versus allopurinol and the predictors of achieving target serum urate in a cohort of Thai people with gout. ( Jatuworapruk, K; Lertnawapan, R, 2021)
"This is a single-center, prospective cohort study conducted in one adult Arthritis Clinic at the University of the Philippines-Philippine General Hospital which included 138 patients with gout (1977 ACR criteria), SUA ≥ 6 mg/dl prior to ULT, initiated on ULT (allopurinol or febuxostat), with six months minimum follow-up and with SUA determination post-treatment."4.02Achievement of the target serum urate level among patients with gout treated with allopurinol or febuxostat in an arthritis clinic in the Philippines. ( Penserga, EG; Quilisadio, JEC; Salido, EO, 2021)
"The coexistence of calcium pyrophosphate dihydrate (CPPD) and monosodium urate monohydrate crystals in gouty tophi has rarely been reported."4.02Calcium Pyrophosphate Dihydrate Crystal Deposition in Gouty Tophi. ( Bardin, T; Bazin, D; Cohen-Solal, M; Ea, HK; Frochot, V; Gauffenic, A; Laredo, JD; Le, NH; Marty, C; Nguyen, QD; Olivier, O; Ostertag, A; Pham, NG; Richette, P, 2021)
"This study assessed factors associated with achieving target serum uric acid (sUA) level and occurrence of gouty arthritis in Japanese clinical practice."4.02Factors associated with achieving target serum uric acid level and occurrence of gouty arthritis: A retrospective observational study of Japanese health insurance claims data. ( Horiuchi, H; Koto, R; Nakajima, A; Yamanaka, H, 2021)
" Variables associated with the diagnosis of gout were as follows: serum uric acid > 350 μmol/L (OR 5."4.02External validation of Gout-calculator performance on a cohort of acute arthritis (SYNOLACTATE) sparing distal joints such as hallux and midfoot. A cross-sectional study of 170 patients. ( Albert, JD; Bendavid, C; Berthoud, O; Cadiou, S; Coiffier, G; Gougeon-Jolivet, A; Guggenbuhl, P; Robin, F, 2021)
" We used a case study of febuxostat versus allopurinol for the treatment of hyperuricemia in patients with gout."4.02Combining Model-Based Clinical Trial Simulation, Pharmacoeconomics, and Value of Information to Optimize Trial Design. ( Hill-McManus, D; Hughes, DA, 2021)
"Gout is present in one third of subjects with CKD but is usually an exclusion criterion in clinical trials investigating the role of uric acid in kidney disease."4.02Does gouty nephropathy exist, and is it more common than we think? ( Johnson, RJ; Piani, F, 2021)
"In this nonrandomized, open-label, single-arm trial, we administered topiroxostat 40-160 mg/day to HFpEF patients with hyperuricemia or gout to achieve a target uric acid level of 6."4.02Effect of Topiroxostat on Brain Natriuretic Peptide Level in Patients with Heart Failure with Preserved Ejection Fraction: A Pilot Study. ( Asai, K; Koen, M; Kubota, Y; Shimizu, W; Wakita, M, 2021)
"A high serum uric acid (SUA) concentration is associated with hyperuricemia (HUA) and gout."4.02Expression, localization and metabolic function of "resurrected" human urate oxidase in human hepatocytes. ( Chen, J; Duan, Y; Jiang, N, 2021)
"Gout is a type of inflammatory arthritis caused by the deposition of monosodium uric acid (MSU) crystals in tissues."4.02Loganin Alleviates Gout Inflammation by Suppressing NLRP3 Inflammasome Activation and Mitochondrial Damage. ( Cho, YY; Choi, N; Jang, JH; Kang, HC; Lee, HS; Lee, JY; Yang, G, 2021)
"To investigate the incidence and potential risk factors for development of fenofibrate-associated nephrotoxicity in gout patients."4.02Effects of fenofibrate therapy on renal function in primary gout patients. ( Chen, Y; Cheng, X; Cui, L; Han, L; He, Y; Ji, A; Ji, X; Li, C; Li, H; Li, X; Liu, Z; Lu, J; Ma, L; Merriman, TR; Ren, W; Sun, W; Wang, C; Wang, X; Yuan, X; Zhang, H, 2021)
"Uric acid has long been considered responsible for a single specific disease, namely gout."4.02The URRAH study. ( Carubbi, F; Del Pinto, R; Ferri, C; Pontremoli, R; Russo, E; Viazzi, F, 2021)
"Gout, caused by chronic elevation of serum uric acid levels, is the commonest form of inflammatory arthritis."4.02Substantial anti-gout effect conferred by common and rare dysfunctional variants of URAT1/SLC22A12. ( Higashino, T; Ichida, K; Inoue, I; Kawamura, Y; Matsuo, H; Morimoto, K; Nakaoka, H; Nakayama, A; Ooyama, H; Shigesawa, R; Shimizu, S; Shinomiya, N; Suzuki, H; Takada, T; Takeuchi, K; Toyoda, Y; Uchida, N, 2021)
"Gout is an autoinflammatory disease driven by interleukin-1 (IL-1) induction in response to uric acid crystals."4.02Cold-inducible RNA-binding protein (CIRP) potentiates uric acid-induced IL-1β production. ( Asano, T; Fujita, Y; Kawakami, A; Matsumoto, H; Matsuoka, N; Migita, K; Sato, S; Suzuki, E; Temmoku, J; Watanabe, H; Yago, T; Yashiro-Furuya, M, 2021)
"The aim of this study was to identify the effects of melatonin on acute gouty inflammation and to investigate the underlying mechanisms."4.02Melatonin Alleviates Acute Gouty Inflammation In Vivo and In Vitro. ( Cao, L; Xiao, WZ; Zhao, L; Zhu, XX; Zou, HJ, 2021)
"Abnormal blood uric acid (UA) levels can lead to its crystallization in the joints, consequently resulting in gout."4.02Highly permselective uric acid detection using kidney cell membrane-functionalized enzymatic biosensors. ( Jung, HG; Kim, I; Kim, YI; Lee, G; Lee, SW; Yoon, DS, 2021)
"In patients with gout, treating to target serum uric acid levels (sUA) of ≤6."4.02Serum uric acid control for prevention of gout flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance claims and medical check-up data in Japan. ( Horiuchi, H; Koto, R; Nakajima, A; Yamanaka, H, 2021)
"To analyse the antinociceptive interaction between quercetin (QUER) and diclofenac (DIC) in experimental arthritic gout-pain."4.02Quercetin decreases the antinociceptive effect of diclofenac in an arthritic gout-pain model in rats. ( Ángeles-López, GE; Aviles-Herrera, J; Bustamante-Marquina, A; Déciga-Campos, M; González-Trujano, ME; Navarrete-Vázquez, G; Ventura-Martínez, R, 2021)
" In this study, the differences between gout with cerebral infarction (gout+CI) and gout with coronary heart disease (gout+CHD) and related factors that affect serum uric acid (sUA) levels in gout+CI were investigated by a cross-sectional study."4.02Factors Influencing the Serum Uric Acid in Gout with Cerebral Infarction. ( Duan, L; Li, Y; Tian, Y; Yang, H, 2021)
"To assess factors associated with the ability to achieve and maintain target serum urate (SU) with allopurinol in patients with gout."3.96Factors Influencing the Effectiveness of Allopurinol in Achieving and Sustaining Target Serum Urate in a US Veterans Affairs Gout Cohort. ( Saag, KG; Singh, JA; Yang, S, 2020)
" We demonstrate continuous detection of temperature, respiration rate and low concentrations of uric acid and tyrosine, analytes associated with diseases such as gout and metabolic disorders."3.96A laser-engraved wearable sensor for sensitive detection of uric acid and tyrosine in sweat. ( Bo, X; Gao, W; Hsiai, TK; Kogan, A; Li, Z; Min, J; Pak, OS; Song, Y; Tu, J; Wang, M; Yang, Y; Zhang, H; Zhu, L, 2020)
"Eucalyptol alleviates MSU-induced pain and inflammation via mechanisms possibly involving anti-oxidative effect."3.96Eucalyptol alleviates inflammation and pain responses in a mouse model of gout arthritis. ( Li, X; Li, Y; Liu, B; Tai, Y; Wang, C; Wang, P; Yin, C; Zheng, X, 2020)
"Elevated blood uric acid (UA) levels have been positively associated with the severity of periodontitis."3.96Hyperuricemia as a potential plausible risk factor for periodontitis. ( Chen, ZY; Gao, J; Liang, ZJ; Ye, LW; Yu, T; Zhao, L, 2020)
" Hyperuricemia is the hallmark of developing gout and mostly caused by uric acid underexcretion."3.96The prevalence of the gout-associated polymorphism rs2231142 G>T in ABCG2 in a pregnant female Filipino cohort. ( Prom-Wormley, E; Roman, Y; Tiirikainen, M, 2020)
" Our study was to discover different lipid levels of gout and asymptomatic hyperuricemia and the predictors of sUA (serum uric acid) levels."3.96The comparison of dyslipidemia and serum uric acid in patients with gout and asymptomatic hyperuricemia: a cross-sectional study. ( Gu, J; Huang, Y; Jiang, Y; Li, X; Liang, J; Ou, J; Song, W; Wei, Q, 2020)
"Staged operation for the treatment of giant gout stone on the first metatarsophalangeal joint of foot could correct joint deformity, restore shape of the first metatarsophalangeal joint, relieve pain of the affected foot, and beneficial for control content of serum uric acid, and has less complications."3.96[Clinical study of staging operation for large gouty stone on the first metatarsophalangeal joint]. ( Li, P; Wang, Y; Xu, SQ; Zhang, WJ; Zhang, Y, 2020)
"The 24-hour uric acid excretion measurement is important in assessing disease status and helping to select the appropriate uric acid-lowering agent for patients with gout, however, it is inconvenient."3.96The Utility of the Random Urine Uric Acid-to-Creatinine Ratio for Patients with Gout Who Need Uricosuric Agents: Retrospective Cross-Sectional Study. ( Choi, ST; Kim, CH; Kim, SJ; Moon, SJ; Song, JS, 2020)
" Included were all their patients receiving urate-lowering therapy (ULT), with a diagnostic code for gout or who had a serum uric acid (SUA) measurement."3.96Gout management in Swiss primary care - a retrospective observational study. ( di Gangi, S; Meier, R; Rosemann, T; Valeri, F; Zechmann, S, 2020)
"We conducted a cross-sectional Internet survey of people who visited the Gout and Uric Acid Education Society's website to assess patient/respondent perception of gout management goals."3.96Patient Perceptions of Gout Management Goals: A Cross-sectional Internet Survey. ( Edwards, NL; Singh, JA, 2020)
"Lifelong urate-lowering therapy (ULT) with xanthine oxidase inhibitors (XOIs), such as allopurinol and febuxostat, is the cornerstone of gout treatment."3.96Comparison of persistence rates between allopurinol and febuxostat as first-line urate-lowering therapy in patients with gout: an 8-year retrospective cohort study. ( Ahn, E; Kim, A; Kim, GT; Kim, Y; Lee, SG; So, MW, 2020)
"Excessive production of uric acid (UA) in blood may lead to gout, hyperuricaemia and kidney disorder; thus, a fast, simple and reliable biosensor is needed to routinely determine the UA concentration in blood without pretreatment."3.96Mobile healthcare system based on the combination of a lateral flow pad and smartphone for rapid detection of uric acid in whole blood. ( Chen, YT; Hsu, YP; Huang, CY; Li, NS; Pang, HH; Shiue, YL; Wei, KC; Yang, HW, 2020)
" The objective of the study is to investigate whether there is an association between concurrent serum levels of several PFAAs and gout, serum uric acid (SUA) or hyperuricemia in the U."3.96Perfluoroalkyl acids, hyperuricemia and gout in adults: Analyses of NHANES 2009-2014. ( Abadin, HG; Attanasio, R; Balluz, L; Buser, MC; Gehle, K; Murray, HE; Scinicariello, F, 2020)
"Topiroxostat, a selective xanthine oxidoreductase inhibitor, is used for the management of hyperuricemic patients with or without gout in Japan."3.96Long-Term Safety and Effectiveness of the Xanthine Oxidoreductase Inhibitor, Topiroxostat in Japanese Hyperuricemic Patients with or Without Gout: A 54-week Open-label, Multicenter, Post-marketing Observational Study. ( Hashimoto, T; Ichikawa, K; Ishikawa, T; Kanno, Y; Maeda, T; Nakagawa, T; Sato, Y, 2020)
"To investigate the effects of serum uric acid (SUA) level and its fluctuation on renal dysfunction in gout patients."3.96Uric acid fluctuation had no effect on renal function among gout patients. ( Fu, Y; Mo, M; Shao, B; Shen, J; Shen, Y; Si, S; Wang, S; Wu, H; Xin, X; Yu, Y; Zhu, J, 2020)
"Macrophage activation by monosodium urate (MSU) and calcium pyrophosphate (CPP) crystals mediates an interleukin (IL)-1β-dependent inflammation during gout and pseudo-gout flare, respectively."3.96Gout and pseudo-gout-related crystals promote GLUT1-mediated glycolysis that governs NLRP3 and interleukin-1β activation on macrophages. ( Adimy, Y; Alzaid, F; Bardin, T; Campillo-Gimenez, L; Castelli, F; Cohen-Solal, M; Combes, C; Delvaux, A; Ea, HK; Fenaille, F; Lioté, F; Orliaguet, L; Prignon, A; Renaudin, F; Richette, P; Riveline, JP; Venteclef, N, 2020)
"To assess the impact of allopurinol on diabetes in a retrospective cohort of Veterans' Affairs patients with gout."3.96Allopurinol use and type 2 diabetes incidence among patients with gout: A VA retrospective cohort study. ( Crittenden, DB; Greenberg, J; Pike, VC; Pillinger, MH; Qian, Y; Slobodnick, A; Toprover, M; Zhong, H, 2020)
" Serum uric acid (UA) is a terminal metabolite of purine compound, while hyperuricemia (HU) and UA crystals are recognized causes of gout."3.96Association between hyperuricemia, gout, urate lowering therapy, and osteoarthritis: A protocol for a systematic review and meta-analysis. ( Chen, Y; Li, H; Li, X; Wang, Y; Yang, Z; Zhu, J, 2020)
" Herein we aimed to investigate whether procyanidin B2 (PCB2), a natural dietary compound, can suppress MSU crystals-stimulated gouty inflammation."3.96Management of Gout-associated MSU crystals-induced NLRP3 inflammasome activation by procyanidin B2: targeting IL-1β and Cathepsin B in macrophages. ( Jiang, M; Jiao, JY; Li, Y; Lian, LH; Lin, YC; Liu, J; Nan, JX; Piao, MH; Qiao, CY; Shang, Y; Sun, RH; Wu, YL; Ye, H; Zhan, ZY; Zhang, ZH, 2020)
" Outcomes were measured for prevalence, patient characteristics, treatment with uric acid lowering drugs for gout and asymptomatic hyperuricemia, and prevalence and incidence of gouty arthritis."3.96Prevalence of gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database. ( Honda, M; Horiuchi, H; Iijima, T; Ito, S; Murano, H; Nakajima, A; Torii, T; Yamanaka, H, 2020)
"Compared to hyperuricaemia model or acute gout model, the compound gout model showed little advantages of elevating serum uric acid, causing foot swelling and gout inflammation, while it caused more severe serum inflammation and gut microbiota dysbiosis."3.96Combined effects of MSU crystals injection and high fat-diet feeding on the establishment of a gout model in C57BL/6 mice. ( He, Z; Lin, X; Shao, T; Wang, M; Wen, C; Wen, X, 2020)
"12 a week-long combined therapy of the allopurinol-reducing drug with the anti-inflammatory dose movalis prevents the exacerbation of the articular syndrome and improves the quality of life of patients with gout."3.96[Evaluation of a 12-week allopurinol-lowering therapy in combination with the non-steroidal anti-inflammatory drug meloxicam in patients with gout]. ( Gromova, MA; Kislyak, OA; Malysheva, NV; Tsurko, VV, 2020)
" The best studied of these diseases is gout, in which crystallization of uric acid in the form of monosodium urate (MSU) mainly in synovial fluid of the joints leads to sterile inflammation."3.96Binding of Macrophage Receptor MARCO, LDL, and LDLR to Disease-Associated Crystalline Structures. ( Alberts, A; Brand, K; Hoffmeister, L; Klingberg, A; Neumann, K; Pich, A; Wessig, AK, 2020)
" Serum uric acid levels and estimated glomerular filtration rate (eGFR) of patients with gouty arthritis were collected at baseline and 1 year after febuxostat administration."3.96Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4-5 chronic kidney disease not yet on dialysis. ( Kim, JM; Kim, SH; Lee, SY; Son, CN, 2020)
"DECT scans of bilateral hands/wrists, feet/ankles, and knees were obtained on 153 patients with gout on allopurinol ≥300 mg daily for ≥3 months."3.96Radiologic evidence of symmetric and polyarticular monosodium urate crystal deposition in gout - A cluster pattern analysis of dual-energy CT. ( Baumgartner, S; Choi, HK; Dalbeth, N; Fung, M; Nicolaou, S; Simeone, FJ; Wei, J; Yokose, C; Zhang, Y, 2020)
"Elevated uric acid (UA) is a key risk factor for many disorders, including metabolic syndrome, gout and kidney stones."3.91A conserved role of the insulin-like signaling pathway in diet-dependent uric acid pathologies in Drosophila melanogaster. ( Beck, JN; Bose, N; Brackman, DJ; Chen, L; Chi, T; Giacomini, K; Hilsabeck, TA; Ho, S; Kahn, A; Kapahi, P; Killilea, DW; Lang, S; Sharma, A; Stoller, ML; Watson, MA; Wilson, KA, 2019)
"Altered corneal endothelial function was found in patients with gout when compared to healthy subjects and the alteration increased as gout duration and uric acid value increased."3.91Corneal Endothelial Morphology and Thickness Changes in Patients with Gout ( Atılgan, KG; Çağlayan, M; Göker, YŞ; Koç, M; Kösekahya, P; Tekin, K; Üçgül Atılgan, C, 2019)
"EATP lowered the serum uric acid level and increased the urine uric acid level through excretion, which is useful in the treatment of gout."3.91Therapeutic potential of ethyl acetate fraction of Tephrosia purpurea Linn. leaves in a rat model of gout. ( Nipate, SS; Yelmar, PS, 2019)
"Gout is caused by deposition of monosodium urate crystals in joints when plasma uric acid levels are chronically elevated beyond the saturation threshold, mostly due to renal underexcretion of uric acid."3.91Hyperuricemia and gout caused by missense mutation in d-lactate dehydrogenase. ( Birk, OS; Drabkin, M; Gurevich, E; Halperin, D; Kadir, R; Landau, D; Perez, Y; Wormser, O; Yogev, Y; Zalk, R; Zarivach, R; Zeller, L, 2019)
"Reduced renal clearance of uric acid is a major contributor to hyperuricemia."3.91Population-specific factors associated with fractional excretion of uric acid. ( Dalbeth, N; Merriman, TR; Narang, RK; Phipps-Green, A; Stamp, LK; Vincent, Z, 2019)
"To evaluate the corneal and tear film characteristics in patients with gout and compare these data with those of healthy subjects and to investigate the correlation of corneal densitometry with uric acid value and duration of disease."3.91Could corneal densitometry be used as a diagnostic and screening tool for ocular involvement in patients with gout? ( Atilgan, CU; Atilgan, KG; Ayli, D; Caglayan, M; Koc, M; Kosekahya, P; Tekin, K; Yilmazbas, P, 2019)
"Lesinurad (LESU) is a selective urate reabsorption inhibitor approved at 200 mg daily for use with a xanthine oxidase inhibitor (XOI) to treat hyperuricaemia in gout patients failing to achieve target serum urate on XOI."3.91Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout. ( Baumgartner, S; Goldfarb, DS; Jalal, D; Pillinger, M; Saag, KG; Schechter, BM; Terkeltaub, R; Valiyil, R; White, WB, 2019)
"Gout is experienced by approximately one in four adults treated with dialysis and two-thirds are prescribed allopurinol."3.91Serum urate levels and therapy in adults treated with long-term dialysis: a retrospective cross-sectional study. ( Chapman, PT; Frampton, C; Palmer, SC; Stamp, LK; Yeo, E, 2019)
"Circulating uric acid (UA) is an important biomarker, not only in the detection and management of gout, but also in assessing the risk of related comorbidity."3.91Antioxidant properties of citric acid interfere with the uricase-based measurement of circulating uric acid. ( Dover, SK; Duryee, MJ; Hollins, A; Hunter, CD; Mikuls, TR; Pirruccello, S; Real, KD; Ryan, EM; Sayles, H; Thiele, GM, 2019)
" Then serum urate (Sua), renal function, uric acid metabolism, and the prevalence of metabolic syndrome (Mets) were compared among these groups by the Tukey-Kramer test or Fisher's exact test."3.91Characteristics of gout patients according to the laterality of nephrolithiasis: A cross-sectional study using helical computed tomography. ( Hori, H; Shimizu, K; Shimizu, T; Umeyama, M, 2019)
" In the present study, we aimed to explore the relationship between TAK1 and gout as well as the effects of resveratrol on TAK1 activity and MSU crystal-induced inflammation."3.91Resveratrol attenuates the MSU crystal-induced inflammatory response through the inhibition of TAK1 activity. ( He, Y; Li, H; Ou, G; Ren, L; Yang, X; Zeng, M, 2019)
"Serum uric acid (SUA), hyperuricemia (HUA) and gout are complex traits with relatively high heritability."3.91Common variants in the ( Cheng, X; Li, C; Li, X; Li, Z; Shi, Y; Wang, C; Zhou, Z, 2019)
"To further explore the possibility of xanthine and hypoxanthine to be gout biomarkers as substitutes for uric acid."3.91Study on the diagnosis of gout with xanthine and hypoxanthine. ( Deng, B; Deng, M; Fei, X; Huang, Z; Wang, Y; Ye, L, 2019)
" The RSGE treatment dose-dependently reduced PO- and MSU-induced paw edema, serum TNF-α, IL-1β, IL-6, IL-12, uric acid, and BUN, while significantly elevated serum IL-10, urinary uric acid and creatinine levels as compared with the respective values in the hyperuricemic and gouty mice group (vehicle group)."3.91Protective effects of Rhizoma smilacis glabrae extracts on potassium oxonate- and monosodium urate-induced hyperuricemia and gout in mice. ( Chang, Y; Liang, C; Liang, G; Nie, Y; Xiao, D; Zeng, S; Zhan, S; Zheng, Q; Zheng, X, 2019)
" Of the 62% of q2w responders exhibiting persistent decreases in MAP, there were no significant differences in baseline age, sex, race, weight, body mass index, history of hypertension, hyperlipidemia, history of coronary artery disease, gout duration, MAP, serum urate, estimated glomerular filtration rate or urinary uric acid/creatinine ratio compared with those who did not lower MAP."3.91Pegloticase Treatment Significantly Decreases Blood Pressure in Patients With Chronic Gout. ( Choi, HK; Johnson, RJ; Lipsky, PE; Yeo, AE, 2019)
"Gout patients with chronic kidney disease (CKD) accumulate the active allopurinol metabolite oxypurinol, suggesting that allopurinol may promote greater serum urate (sU) lowering in CKD patients."3.91Low-Dose Allopurinol Promotes Greater Serum Urate Lowering in Gout Patients with Chronic Kidney Disease Compared with Normal Kidney Function. ( Crittenden, DB; Fisher, MC; Keenan, RT; Krasnokutsky, S; Modjinou, DV; Oh, C; Pillinger, MH; Toprover, M, 2019)
"The treat-to-target approach for serum uric acid is the recommended model in gout management according to the 2012 American College of Rheumatology (ACR) guidelines."3.91Pharmacist-managed titration of urate-lowering therapy to streamline gout management. ( Bays, AM; Crawford, C; Huang, IJ; Liew, JW; Morcos, MB; Zuo, S, 2019)
" We investigated whether epigallocatechin-3-gallate (EGCG) suppresses the activation of the NLRP3 inflammasome, thereby effectively preventing gouty inflammation."3.91Epigallocatechin-3-Gallate Prevents Acute Gout by Suppressing NLRP3 Inflammasome Activation and Mitochondrial DNA Synthesis. ( Cho, YY; Kang, HC; Lee, HE; Lee, HS; Lee, JY; Park, YB; Yang, G, 2019)
"Gout is a common metabolic disease in humans, and it is due to persistently elevated levels of uric acid in the blood."3.91Decreased Expression of CD14 in MSU-Mediated Inflammation May Be Associated with Spontaneous Remission of Acute Gout. ( Chen, J; Duan, L; Fu, Q; Li, Y; Luo, J; Shang, K; Wang, Y; Wei, Y, 2019)
"To investigate the effects on hypercholesterolemia and hypertriglyceridemia in gouty patients receiving uric acid-lowering therapy (UALT)."3.91Efficacy of uric acid-lowering therapy on hypercholesterolemia and hypertriglyceridemia in gouty patients. ( Deng, JX; Jie, LG; Qu, Y; Wu, J; Yu, QH; Zhang, YP, 2019)
"A study to evaluate the prevalence of uric acid (UA) nephrolithiasis with dual-energy CT (DECT) and explore the risk factors for kidney stones in primary gout patients."3.91Evaluation of the chemical composition of nephrolithiasis using dual-energy CT in Southern Chinese gout patients. ( Bashir, S; Cheng, ZY; Jiao, GL; Li, ZX; Zhou, SM; Zhou, Y, 2019)
"Adequate uric acid control before surgery could prevent the postsurgical gout flare."3.91Clinical characteristics and risk factors for gout flare during the postsurgical period. ( Jeon, CH; Jeong, H, 2019)
"In patients with gout, maintaining too low serum uric acid (SUA) level with urate-lowering therapy is a concern because uric acid is thought to be neuroprotective."3.88Uric acid and incident dementia over 12 years of follow-up: a population-based cohort study. ( Bardin, T; Debette, S; Latourte, A; Perez-Ruiz, F; Richette, P; Soumaré, A, 2018)
" The PKPD model was used to simulate mono and dual-ULT in gout patients with either under-excretion (lowered clearance) or overproduction of uric acid, with suboptimal adherence modelled as either a single drug holiday of increasing duration or doses taken at random."3.88Impact of non-adherence on the safety and efficacy of uric acid-lowering therapies in the treatment of gout. ( Hill-McManus, D; Hughes, D; Lane, S; Marshall, S; Soto, E, 2018)
"Forty-seven clinically diagnosed gout patients and 50 subjects (serum uric acid < 7 mg/dL) as controls were included."3.88Ultrasonographic detection of double contour sign and hyperechoic aggregates for diagnosis of gout: two sites examination is as good as six sites examination. ( Bhadu, D; Das, SK; Dhakad, U; Sharma, M; Wakhlu, A, 2018)
"Uric acid is best known for its role in gout-the most prevalent inflammatory arthritis in humans-that is also described as an unusual complication of anorexia nervosa (AN)."3.88Anorexia nervosa and uric acid beyond gout: An idea worth researching. ( Maas, J; Simeunovic Ostojic, M, 2018)
"The aetiology of gout is closely linked to the deposition of monosodium uric acid (MSU) crystals and the consequent activation of the NOD-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome."3.88Suppression of NLRP3 inflammasome by oral treatment with sulforaphane alleviates acute gouty inflammation. ( Cho, YY; Kang, HC; Lee, HE; Lee, HS; Lee, JY; Yang, G; Yeon, SH, 2018)
"This narrative review aims to highlight recent findings on the relation between uric acid level and cognitive decline or dementia."3.88Uric acid and cognitive decline: a double-edge sword? ( Bardin, T; Latourte, A; Richette, P, 2018)
"Uric acid has been known since long ago for its implication in gout and in certain kinds of nephrolithiasis."3.88[Acid uric : key player in a recently recognized devastating nephropathy and in the development of chronic kidney disease.] ( Humbert, A; Stucker, F, 2018)
"Numerous epidemiological studies have shown that male patients with uric acid nephrolithiasis outnumber female patients."3.88Mediators of the Effects of Gender on Uric Acid Nephrolithiasis: A Novel Application of Structural Equation Modeling. ( Chang, YY; Chen, HW; Chen, YC; Chou, YH; Li, CC; Wu, WJ; Yang, FM, 2018)
" For each journal, articles relevant to gout and hyperuricaemia were identified by the search terms 'gout' and/or 'urate' and/or 'uric acid' using MEDLINE."3.88The nomenclature of the basic disease elements of gout: A content analysis of contemporary medical journals. ( Bursill, D; Dalbeth, N; Taylor, WJ; Terkeltaub, R, 2018)
"The uric acid (UA) level in patients with gout is a key factor in disease management and is typically measured in the laboratory using plasma samples obtained after venous puncture."3.88Accuracy of the HumaSens ( Abrahamsson, A; Bardin, T; Clerson, P; Fabre, S; Gautier, JF; Hughes, G; Launay, JM; Miner, JN; Platt, A; Richette, P; Riveline, JP; Vidal-Trecan, T, 2018)
"Three SNPs, URAT1 rs11231825, GLUT9 rs16890979 and ABCG2 rs2231142, previously associated in our population with hyperuricemia and gout, were analyzed in 27 patients with HPRT deficiency treated with allopurinol for at least 5 years."3.88GLUT9 influences uric acid concentration in patients with Lesch-Nyhan disease. ( Puig, JG; Torres, RJ, 2018)
"A retrospective data analysis was performed within the UK Clinical Practice Research Datalink (1987-2014) among incident gout patients, aged ⩾40 years and starting allopurinol (n = 48 280)."3.88Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD). ( Arts, ICW; Boonen, A; Burden, AM; de Vries, F; Scheepers, LEJM; Souverein, P; Spaetgens, B, 2018)
"There is evidence that uric acid may have antioxidant and neuroprotective effects and might therefore alter the risk for neurodegenerative diseases such as dementia."3.88Hyperuricemia and dementia - a case-control study. ( Broich, K; Engel, B; Gomm, W; Haenisch, B; Maier, W; Weckbecker, K, 2018)
"To retrospectively analyze the efficacy and safety of febuxostat on gout patients with low serum uric acid level."3.88Febuxostat in the treatment of gout patients with low serum uric acid level: 1-year finding of efficacy and safety study. ( Chen, X; Gu, B; Li, C; Qian, K; Ren, Q; Shen, M; Su, D; Wang, X; Xu, W; Yang, L; Yuan, H; Zhang, J, 2018)
" SUA was downregulated during acute gouty arthritis, which might be associated with increased urinary excretion of uric acid."3.88Renal excretion is a cause of decreased serum uric acid during acute gout. ( Cao, L; Guo, M; Lv, X; Wan, W; Xue, Y; Zhao, T; Zheng, S; Zhu, X; Zou, H, 2018)
"Dual urate-lowering therapy (ULT) with lesinurad in combination with either allopurinol or febuxostat is an option for patients with gout unsuccessfully treated on either monotherapy."3.88Impact of Non-Adherence and Flare Resolution on the Cost-Effectiveness of Treatments for Gout: Application of a Linked Pharmacometric/Pharmacoeconomic Model. ( Hill-McManus, D; Hughes, D; Lane, S; Marshall, S; Soto, E, 2018)
" He was diagnosed as primary myelofibrosis and treated with interferon-α, together with urate acid-lowing therapy (febuxostat 60 mg once daily)."3.88[A case of gout secondary to primary myelofibrosis]. ( Hao, YJ; Ji, LL; Zhang, ZL, 2018)
"An association between ABCC4 and gout and fractional excretion of uric acid is consistent with the established role of MRP4 as a unidirectional renal uric acid efflux pump."3.85Population-Specific Resequencing Associates the ATP-Binding Cassette Subfamily C Member 4 Gene With Gout in New Zealand Māori and Pacific Men. ( Boocock, J; Cadzow, M; Choi, HK; Dalbeth, N; Dobbyn, A; Hindmarsh, JH; Mandal, AK; Merriman, TR; Mount, DB; Phipps-Green, AJ; Stahl, EA; Stamp, LK; Tanner, C; Topless, RK, 2017)
"Procyanidins significantly attenuated gout pain and suppressed ankle swelling."3.85Grape seed-derived procyanidins alleviate gout pain via NLRP3 inflammasome suppression. ( Fan, YX; Gui, X; Han, Y; Hu, L; Jiang, CY; Liu, BQ; Liu, HJ; Liu, WT; Pan, XX; Tang, YL, 2017)
"Gout is caused by elevated serum urate levels, which can be treated using inhibitors of the uric acid transporter, URAT1."3.85Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout. ( Gunic, E; Liu, S; Miner, JN; Tan, PK, 2017)
"Studies have suggested a relationship between higher baseline serum uric acid (sUA) levels and an elevated risk of subsequent ischemic cardiovascular outcomes among acute coronary syndrome (ACS) patients; this relationship may be modified by a clinical history of gout and has not been studied in large patient cohorts."3.85An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome. ( Akerblom, A; Clare, RM; Held, C; Hess, CN; James, S; Keenan, RT; Klein, AB; Mahaffey, KW; Pagidipati, NJ; Roe, MT; Tricoci, P; Wallentin, L; Wojdyla, D, 2017)
"Febuxostat has currently played pivotal role in the treatment of hyperuricemia, but there is little comprehensive information for the determinants of individual difference in efficacy of febuxostat."3.85Previous Dosage of Allopurinol Is a Strong Determinant of Febuxostat Efficacy. ( Hira, D; Ikeda, Y; Katsube, Y; Koide, H; Minegaki, T; Morita, SY; Nishiguchi, K; Terada, T; Tsujimoto, M; Uzu, T, 2017)
"Gout is one of the most painful types of arthritis that arises when the body mounts an acute inflammatory reaction against a crystallized form of uric acid known as monosodium urate crystals (MSUs)."3.85S100A9 potentiates the activation of neutrophils by the etiological agent of gout, monosodium urate crystals. ( Fernandes, M; Lachhab, A; Marceau, F; Naccache, PH; Paré, G; Pelletier, M; Rousseau, LS; Tessier, P, 2017)
"Patient and provider factors, including allopurinol medication adherence, affect gout treatment outcomes."3.85Allopurinol Medication Adherence as a Mediator of Optimal Outcomes in Gout Management. ( Bendlin, KA; Coburn, BW; Meza, J; Mikuls, TR; Russell, CL; Sayles, H, 2017)
"There is poor adherence to recommended practice for dosing of colchicine in acute gout."3.85A survey of the assessment and management of gout in general practitioners and medical officers within the Illawarra Network, Australia. ( Riordan, J; Terrill, M, 2017)
"Adult gout patients were examined by serial ultrasonography after initiation of ULT with target serum uric acid (SUA) < 6 mg/dL."3.85Temporal evolution of urate crystal deposition over articular cartilage after successful urate-lowering therapy in patients with gout: An ultrasonographic perspective. ( Basu, K; Das, S; Ghosh, A; Ghosh, P; Goswami, RP; Lahiri, D, 2017)
"This study aimed to assess the sensitivity and specificity of ultrasonographic features of gout in intercritical and chronic stages and compared ultrasonographic features of gout between patients with persistent high serum uric acid (SUA) and patients with low SUA."3.85Sensitivity and specificity of ultrasonographic features of gout in intercritical and chronic phase. ( Basu, K; Das, S; Ghosh, A; Ghosh, P; Lahiri, D; Sinhamahapatra, P, 2017)
"ACP recommends that clinicians choose corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), or colchicine to treat patients with acute gout."3.85Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians. ( Barry, MJ; Boyd, C; Chow, RD; Denberg, TD; Forciea, MA; Harris, RP; Humphrey, LL; Kansagara, D; Qaseem, A; Vijan, S; Wilt, TJ, 2017)
"Arthritic gout is caused by joint inflammation triggered by the damaging effects of monosodium uric acid (MSU) crystal accumulation in the synovial space."3.85Macrophage-derived IL-1β enhances monosodium urate crystal-triggered NET formation. ( Rada, B; Sil, P; Surell, C; Wicklum, H, 2017)
"We aimed to investigate the effects of febuxostat on IR and the expression of high-sensitivity C-reactive protein (hs-CRP) in patients with primary gout."3.85Effects of febuxostat on insulin resistance and expression of high-sensitivity C-reactive protein in patients with primary gout. ( Li, Y; Lu, Y; Meng, J; Yuan, X, 2017)
"To evaluate and compare the safety and efficacy of three urate lowering agents: febuxostat, allopurinol, and benzbromarone, when used to treat Chinese gout patients."3.85A study comparing the safety and efficacy of febuxostat, allopurinol, and benzbromarone in Chinese gout patients: a retrospective cohort study
. ( Chen, X; Su, J; Tian, J; Zhou, Q; Zhou, T; Zhu, J, 2017)
"This study showed that DNI was an effective independent marker to differentiate between an acute gout attack and cellulitis at the crucial early phase irrespective of MSU crystal confirmation or serum uric acid concentration."3.85Delta neutrophil index contributes to the differential diagnosis between acute gout attack and cellulitis within 24 hours after hospitalization. ( Ha, YJ; Lee, SK; Lee, SW; Park, YB; Pyo, JY; Song, JJ, 2017)
"The aim of this study was to evaluate relationships between serum uric acid (SUA) and newly emergent acute myocardial infarction (AMI), congestive heart failure (CHF), coronary artery disease (CAD), composite cardiovascular (CV) events (AMI, CHF, CAD), hypertension, hyperlipidemia, and renal disease in gout patients."3.85Evaluation of the Relationship Between Serum Uric Acid Levels and Cardiovascular Events in Patients With Gout: A Retrospective Analysis Using Electronic Medical Record Data. ( Bienen, EJ; Essex, MN; Hopps, M; Makinson, GT; Mardekian, J; Udall, M, 2017)
" Colchicine, at low concentration (10 nM) achieved in gout flare prophylaxis dosing, promoted phosphorylation of AMPKα and macrophage M2 polarisation, and reduced activation of caspase-1 and release of IL-1β and CXCL1 by MSU crystals in BMDMs in vitro."3.83AMP-activated protein kinase suppresses urate crystal-induced inflammation and transduces colchicine effects in macrophages. ( Liu-Bryan, R; Terkeltaub, R; Viollet, B; Wang, Y, 2016)
"The purpose of this study is to investigate the effect of urate-lowering therapies (ULTs) on renal uric acid excretion in gout patients."3.83Influence of urate-lowering therapies on renal handling of uric acid. ( Chen, H; Ji, Z; Jiang, L; Ma, L; Wei, L; Yu, Q; Zhang, Z, 2016)
" Hyperuricemia was defined as a serum uric acid level >7 mg/dl for men and >6 mg/dl for women or allopurinol use."3.83Hyperuricemia is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes. ( Bergamini, C; Bonora, E; Mantovani, A; Pernigo, M; Pichiri, I; Rigolon, R; Targher, G; Zoppini, G, 2016)
"A population analysis was conducted in nonmem using oxypurinol and urate plasma concentrations from 133 gout patients."3.83Predicting allopurinol response in patients with gout. ( Barclay, ML; Dalbeth, N; Duffull, SB; Merriman, TR; Stamp, LK; Wright, DF, 2016)
" Model flow based on guideline and real-world treatment paradigms incorporated gout flare, serum uric acid (sUA) testing, treatment titration, discontinuation, and adverse events, chronic kidney disease (CKD) incidence and progression, and type 2 diabetes mellitus (T2DM) incidence."3.83Febuxostat in the management of gout: a cost-effectiveness analysis. ( Gahn, JC; Mitri, G; Shiozawa, A; Smolen, LJ, 2016)
"Psoriasis has been reported to be associated with raised serum uric acid levels and gout, and uric acid has been demonstrated to mediate inflammatory pathways via secretion of pro-inflammatory chemokines."3.83Psoriasis and uric acid: a population-based cross-sectional study. ( Lai, YC; Yew, YW, 2016)
"Anti-hyperuricemic effect was investigated using xanthine oxidase assay and uricosuric studies with rats in which hyperuricemia was induced by potassium oxonate and uric acid."3.83Effects of Pimenta pseudocaryophyllus extracts on gout: Anti-inflammatory activity and anti-hyperuricemic effect through xantine oxidase and uricosuric action. ( Antunes Saúde-Guimarães, D; Barros, CH; de Paula Michel Araújo, MC; Ferrari, FC; Lemos Lima, Rde C; Schimith Ferraz Filha, Z, 2016)
" The simple definition had similar performance to a SUGAR data-driven case definition with 5 weighted items: self-report, self-report of doctor diagnosis, colchicine use, urate-lowering therapy use, and hyperuricemia (sensitivity 87%, specificity 70%)."3.83Survey Definitions of Gout for Epidemiologic Studies: Comparison With Crystal Identification as the Gold Standard. ( Brown, M; Cavagna, L; Chen, JH; Chou, YY; Cimmino, MA; da Rocha Castelar-Pinheiro, G; Dalbeth, N; Ea, HK; Eliseev, M; Fransen, J; Gerritsen, M; Jansen, TL; Janssen, M; Lin, C; Louthrenoo, W; McCarthy, G; Neogi, T; Perez-Ruiz, F; Schumacher, HR; Scire, CA; Sivera, F; Stamp, LK; Tausche, AK; Taylor, WJ; Uhlig, T; Vazquez-Mellado, J, 2016)
"To compare total and disease-specific health care expenditures by line of therapy in allopurinol and febuxostat initiators after diagnosis with gout and moderate-to-severe CKD."3.83Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease. ( Mitri, G; Schulman, KL; Tidwell, BA; Turpin, RS; Wittbrodt, ET, 2016)
"Gout is a chronic disease characterized by the deposition of urate crystals in the joints and throughout the body, caused by an excess burden of serum uric acid (sUA)."3.83The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed Care Pharmacy and Medical Costs Perspective. ( Gahn, JC; Mitri, G; Shiozawa, A; Smolen, LJ, 2016)
" Whether gout, the most common rheumatologic inflammatory arthritis, or its cause, elevated serum uric acid (SUA), is associated with VTE incidence is unknown."3.83Serum uric acid, gout, and venous thromboembolism: The atherosclerosis risk in communities study. ( Folsom, AR; Kubota, Y; McAdams-DeMarco, M, 2016)
"Benzbromarone provides useful urate-lowering efficacy and does not appear unsafe in patients with gout."3.83The safety and efficacy of benzbromarone in gout in Aotearoa New Zealand. ( Cathro, A; Corkill, M; Dalbeth, N; Frampton, C; Gardner, D; Grainger, R; Haslett, J; Kain, T; Kumar, R; Kumar, S; Metcalfe, S; Porter, D; Stamp, LK; Stebbings, S; Taylor, G; White, D; Wyeth, J, 2016)
"BACKGROUND Gout is characterized by deposition of uric acid crystals (monosodium urate) in tissues and fluids."3.83Tophaceous Gout in an Anorectic Patient Visualized by Dual Energy Computed Tomography (DECT). ( Christensen, HD; Hansen, IM; Morillon, MB; Sheta, HM, 2016)
"The aim of this study is to evaluate the diagnostic yield of dual-energy computed tomography (DECT) in detection of uric acid accumulation in joints or periarticular structures in patients suspected of having gout, in their intercritical period."3.83Dual-energy computed tomography as a diagnostic tool for gout during intercritical periods. ( Bogot, N; Breuer, GS; Nesher, G, 2016)
"Smoking has been found to be negatively correlated with serum uric acid levels by virtue of reduced production and increased consumption of endogenous antioxidant uric acid among smokers and has been reported to decrease incidence of gout."3.83Risk of acute gout among active smokers: data from nationwide inpatient sample. ( Donato, A; Karmacharya, P; Poudel, DR, 2016)
"Gout is caused by the overproduction of uric acid and the inefficient metabolism of dietary purines in humans."3.83Decrystallization of Crystals Using Gold "Nano-Bullets" and the Metal-Assisted and Microwave-Accelerated Decrystallization Technique. ( Aslan, K; Bonyi, E; Boone-Kukoyi, Z; Kioko, B; Lansiquot, C; Ozturk, B; Shortt, R; Thompson, N; Toker, S, 2016)
"Gouty arthritis is caused by the deposition of uric acid crystals, which induce the activation of NOD-like receptor family, pyrin domain containing 3(NLRP3) inflammasome."3.83Targeting ASC in NLRP3 inflammasome by caffeic acid phenethyl ester: a novel strategy to treat acute gout. ( Choi, JY; Jeong, S; Jung, Y; Kim, ND; Lee, HE; Lee, JY; Park, HH; Yang, G, 2016)
"We report three Caucasian patients affected by gout and type 2 diabetes, who were treated with the recombinant nonglycosylated human interleukin-1 receptor antagonist anakinra (100 mg/day subcutaneously) after an unsatisfactory or incomplete response to urate-lowering therapy, colchicine, nonsteroidal anti-inflammatory drugs, and prednisone."3.81Anakinra treatment in patients with gout and type 2 diabetes. ( Bardelli, M; Cantarini, L; Galeazzi, M; Rigante, D; Vitale, A, 2015)
" The variables of the diagnostic rule (male sex, previous arthritis attack, onset <1 day, joint redness, involvement of the first MTP joint, hypertension or one or more cardiovascular disease, and serum uric acid >5."3.81The validation of a diagnostic rule for gout without joint fluid analysis: a prospective study. ( Fransen, J; Janssen, M; Janssens, HJ; Kienhorst, LB, 2015)
" In addition, we, for the first time, wanted to determine which concentrations of monosodium urate (MSU) in gout and calcium pyrophosphate (CP) in pseudogout are needed to detect or distinguish these soft tissue depositions with DECT."3.81Detection and characterization of crystal suspensions using single-source dual-energy computed tomography: a phantom model of crystal arthropathies. ( Ackermann, B; Blobel, J; Diekhoff, T; Hamm, B; Hermann, KG; Juran, R; Kiefer, T; Mews, J; Pilhofer, I; Stroux, A; Tsuyuki, M, 2015)
"There is very limited information on the association between arsenic and serum uric acid levels or gout."3.81Arsenic exposure, hyperuricemia, and gout in US adults. ( Fadrowski, JJ; Guallar, E; Kuo, CC; Lin, YS; Navas-Acien, A; Weaver, V, 2015)
"To identify modifiable patient and provider factors associated with allopurinol adherence and the achievement of a serum urate acid (SUA) goal in gout."3.81Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system. ( Cheetham, TC; Coburn, BW; Curtis, JR; Mikuls, TR; Rashid, N; Saag, KG; Wu, YL, 2015)
"To quantify the risk of non-fatal acute myocardial infarction (AMI) among users of allopurinol."3.81Allopurinol use and risk of non-fatal acute myocardial infarction. ( Álvarez, A; Bryant, V; de Abajo, FJ; García-Poza, P; García-Rodríguez, LA; Gil, MJ; Rodríguez, A, 2015)
"To evaluate the cost-effectiveness of allopurinol versus febuxostat in adult patients with gout over a 5-year time period from a U."3.81Cost-effectiveness analysis of allopurinol versus febuxostat in chronic gout patients: a U.S. payer perspective. ( Bottorff, MB; Gandhi, PK; Gentry, WM; Ma, Q, 2015)
"Allopurinol is used as long-term therapy to reduce the occurrence of gout flares."3.81Allopurinol adherence among patients with gout: an Italian general practice database study. ( Antonioli, L; Blandizzi, C; Capogrosso-Sansone, A; Convertino, I; Cricelli, C; Cricelli, I; Fornai, M; Lapi, F; Mantarro, S; Montagnani, S; Pecchioli, S; Tuccori, M, 2015)
"Inefficient renal excretion of uric acid is the main pathophysiological mechanism for hyperuricemia in gout patients."3.81Renal clearance of uric acid is linked to insulin resistance and lower excretion of sodium in gout patients. ( Aniel-Quiroga, MA; Chinchilla, SP; Erauskin, GG; Herrero-Beites, AM; Merriman, T; Perez-Ruiz, F, 2015)
"The objective of the present work was to develop polymeric nanoparticles of uricase and aceclofenac (NSAID) and to incorporate them into gel, for delivering drugs to synovial joints, for effective treatment of Gout."3.81Urate crystal degradation for treatment of gout: a nanoparticulate combination therapy approach. ( Dwivedi, H; Kymonil, KM; Saraf, SA; Tiwari, S, 2015)
"Predicted by the core ingredient-target-pathway network, we collected 30 core ingredients in MSW and 25 inflammatory cytokines and uric acid synthetase or transporters, which are effective for gouty treatment through some related pathways."3.81A network pharmacology approach to determine active ingredients and rationality of herb combinations of Modified-Simiaowan for treatment of gout. ( Guochun, L; Shi, L; Xu, L; Yang, Y; Yin, L; Zhao, F, 2015)
"This study investigated the epidemiological evidence for a protective role of high serum concentration of uric acid, for which we used gout as a proxy, in the aetiology of MS, PD or MND."3.81Clinical associations between gout and multiple sclerosis, Parkinson's disease and motor neuron disease: record-linkage studies. ( Goldacre, MJ; Pakpoor, J; Ramagopalan, SV; Seminog, OO, 2015)
" Study patients had at least one medical claim with a diagnosis of gout, at least one filled prescription for febuxostat or allopurinol and at least one sUA measurement post-index prescription."3.81Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort. ( Akhras, KS; Shiozawa, A; Singh, JA, 2015)
"Gout is a common inflammation disease resulting from an increase in serum uric acid."3.81Common Variants in LRP2 and COMT Genes Affect the Susceptibility of Gout in a Chinese Population. ( Dong, Z; He, H; Ji, H; Jin, L; Ma, Y; Pang, Y; Qian, Q; Wang, J; Wang, X; Xu, X; Yang, C; Yang, Y; Zhao, D; Zhou, J; Zou, H, 2015)
"Among the gouty patients, 36% refrain from the use of allopurinol, only 23% out of them require that its dose be adjusted to achieve the target level of UA."3.81[Time course of changes in the clinical manifestations of gout in men: data of a 7-year retrospective follow-up]. ( Barskova, VG; Denisov, IS; Eliseev, MS, 2015)
"Gout is managed poorly in Australian primary care, with low levels of allopurinol prescribing and serum urate testing."3.81An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population. ( Dalbeth, N; Robinson, PC; Taylor, WJ, 2015)
"Gout is an acute inflammatory disease characterised by the presence of uric acid crystals in the joint."3.81Oral treatment with Bifidobacterium longum 51A reduced inflammation in a murine experimental model of gout. ( Amaral, FA; Galvão, I; Martins, FS; Nicoli, JR; Teixeira, MM; Vieira, AT, 2015)
"These data suggest that BMI influences serum urate and gout risk in response to chronic SSB intake, and renal tubular uric acid handling in response to an acute fructose load."3.81Body mass index modulates the relationship of sugar-sweetened beverage intake with serum urate concentrations and gout. ( Dalbeth, N; Gamble, GD; Horne, A; House, ME; Merriman, TR; Phipps-Green, A; Stamp, LK, 2015)
"The main purpose of the present supplement, which is based on a symposium held in Bologna, 6-8 November 2014, is twofold: first of all, to reinforce the role of uric acid in the pathogenesis of gout and gout-related non-rheumatic diseases including renal involvement; second, to provide an updated review of the evidence supporting the relevant role of elevated uric acid as a risk factor for cardiovascular diseases."3.81The role of uric acid in the development of cardiovascular disease. ( Borghi, C, 2015)
"Using a Danish Register cohort of 86,039 adult new allopurinol users and propensity score matched controls, we found that gout requiring allopurinol prescription was associated with an increased fracture risk."3.81Is allopurinol use associated with an excess risk of osteoporotic fracture? A National Prescription Registry study. ( Abrahamsen, B; Bone, KW; Cooper, C; Dennison, EM; Harvey, NC; Rubin, KH; Schwarz, P, 2015)
"In a retrospective claims data study of enrollees in health plans affiliated with Optum, we evaluated patients from February 1, 2009, to May 31, 2012, with a gout diagnosis, a pharmacy claim for allopurinol or febuxostat, and at least 1 serum uric acid (SUA) result available during the follow-up period."3.81A Real-World Study of Switching From Allopurinol to Febuxostat in a Health Plan Database. ( Altan, A; Bancroft, T; Shiozawa, A; Singh, JA, 2015)
"Our objective was to evaluate data on the cost-effectiveness of febuxostat compared with standard clinical practice with allopurinol in patients with gout that was presented to the Scottish Medicines Consortium (SMC) in 2010."3.80Cost-effectiveness of febuxostat in chronic gout. ( Beard, SM; Nuki, G; Pearson, IV; von Scheele, BG, 2014)
"American College of Rheumatology and European League Against Rheumatism guidelines recommend colchicine to prevent gout flares in patients initiating and increasing uric acid–lowering therapy until serum uric acid is maintained at ≤6 mg/dl."3.80Evaluating appropriate use of prophylactic colchicine for gout flare prevention. ( George, M; Hussain, F; Pullman-Mooar, S; Schumacher, HR, 2014)
"Serum uric acid levels were not significantly different in the asymptomatic hyperuricaemia, gouty arthritis without tophi and gouty tophi groups."3.80The effects of gout on left atrial volume remodelling: a prospective echocardiographic study. ( Chang, PJ; Chang, ST; Chen, MC; Chung, CM; Hsiao, JF; Lin, CL; Lin, JC; Pan, KL, 2014)
" The pharmacist contacted each patient by phone, provided educational and dietary materials, and used a protocol that employs standard gout medications to achieve and maintain a serum uric acid (sUA) level of 6 mg/dL or less."3.80Effectiveness of a pharmacist-based gout care management programme in a large integrated health plan: results from a pilot study. ( Avins, AL; Goldfien, RD; Hwe, A; Jacobson, A; Ng, MS; Pressman, A; Yip, G, 2014)
" riparia in reducing serum uric acid levels in a potassium oxonate-induced hyperuricemia mouse model."3.80Smilax riparia reduces hyperuricemia in mice as a potential treatment of gout. ( Anderson, S; Wu, XH; Yu, CH; Zhang, CF; Zhang, YW, 2014)
"The mean serum uric acid level of patients with gout in the practice had risen in comparison with a similar audit carried out in March 2009."3.80Management of gout in a South Auckland general practice. ( Arroll, B; Reaves, E, 2014)
"Febuxostat is recommended as 1 of 2 first-line urate-lowering therapies (ULT) for treating gout in the 2012 American College of Rheumatology Guidelines."3.80Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat. ( Akhras, KS; Hatoum, H; Khanna, D; Khanna, P; Lin, SJ; Shiozawa, A, 2014)
"The object of this study was to evaluate the effect of uric acid lowering therapy in reducing the new development of comorbidities and the frequency of acute attacks in gout patients."3.80Prevention of comorbidity and acute attack of gout by uric acid lowering therapy. ( Joo, H; Joo, K; Jung, KH; Kwon, SR; Lim, MJ; Park, W, 2014)
"Hyperhomocysteinemia is one of the important factors of the cardiovascular disease, and gout is well known to be associated with cardiovascular disease."3.80Elevated serum homocysteine levels were not correlated with serum uric acid levels, but with decreased renal function in gouty patients. ( Choi, ST; Kim, JS; Song, JS, 2014)
"Gout with uric acid underexcretion is associated with transporter gene SNP related mainly to tubular reabsorption, whereas uric acid normoexcretion is associated only with tubular secretion SNP."3.80Tubular urate transporter gene polymorphisms differentiate patients with gout who have normal and decreased urinary uric acid excretion. ( Bailén, R; Banegas, JR; de Miguel, E; Puig, JG; Torres, RJ, 2014)
"Among a renal transplant population with at least 1 year of follow-up, we included 27 patients with sustained hyperuricemia and 11 with normal serum uric acid (SUA) levels."3.80A pilot study on dual-energy computed tomography for detection of urate deposits in renal transplant patients with asymptomatic hyperuricemia. ( Alberú, J; Betanzos, JL; Criales-Vera, S; Hernández-Molina, G; Kimura-Hayama, E; Nicolaou, S; Rivera, Y; Rull-Gabayet, M, 2014)
" Increased serum uric acid level during this month had been reported in past studies of nongout patients."3.80The impact of Ramadan fast on patients with gout. ( Artul, S; Badarny, S; Habib, G; Hakim, G; Khazin, F; Khreish, M; Shehadeh, V, 2014)
"While the prevalence of gout was calculated by counting patients with this diagnosis hyperuricemia was inferred in patients taking allopurinol at hospital admission or discharge, on the assumption that this drug was only prescribed owing to the finding of high serum levels of uric acid."3.80Gout, allopurinol intake and clinical outcomes in the hospitalized multimorbid elderly. ( Conca, A; Corrao, S; Djade, CD; Franchi, C; Mannucci, PM; Marcucci, M; Marengoni, A; Nobili, A; Pasina, L; Salerno, F; Tettamanti, M, 2014)
"Probenecid is recommended as urate-lowering therapy (ULT) in patients with gout where xanthine oxidase inhibitors are ineffective, not tolerated, or contraindicated."3.79Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population. ( Dalbeth, N; Gow, PJ; Pui, K, 2013)
" Hyperuricemia was defined as serum uric acid >6."3.79Dose-response association of uncontrolled blood pressure and cardiovascular disease risk factors with hyperuricemia and gout. ( Gelber, AC; Juraschek, SP; Kovell, LC; Miller, ER, 2013)
" Further evidences were collected about the role of diet in the non-pharmacological treatment of gout and the efficacy of oral corticosteroids and low-dose colchicine in the management of acute attacks."3.79Italian Society of Rheumatology recommendations for the management of gout. ( Bianchi, G; Borghi, C; Bortoluzzi, A; Cimmino, MA; D'Avola, GM; Desideri, G; Di Giacinto, G; Favero, M; Govoni, M; Grassi, W; Lombardi, A; Manara, M; Marangella, M; Matucci Cerinic, M; Medea, G; Minisola, G; Prevete, I; Punzi, L; Ramonda, R; Scirè, CA; Spadaro, A, 2013)
"A loss-of-function mutation (Q141K, rs2231142) in the ATP-binding cassette, subfamily G, member 2 gene (ABCG2) has been shown to be associated with serum uric acid levels and gout in Asians, Europeans, and European and African Americans; however, less is known about these associations in other populations."3.79Association of functional polymorphism rs2231142 (Q141K) in the ABCG2 gene with serum uric acid and gout in 4 US populations: the PAGE Study. ( Best, LG; Brown-Gentry, KD; Cole, SA; Crawford, DC; Deelman, E; Fornage, M; Franceschini, N; Gaffo, AL; Glenn, KR; Heiss, G; Jenny, NS; Jorgensen, NW; Kao, WH; Kottgen, A; Li, Q; Liu, K; Matise, TC; North, KE; Spencer, KL; Umans, JG; Voruganti, VS; Zhang, L, 2013)
"Gout and serum uric acid are associated with mortality but their simultaneous contributions have not been fully evaluated in the general population."3.79Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality. ( Abdalla, AA; Casserly, LF; Cronin, CJ; Hanley, A; Hannigan, A; Hegarty, A; Kiernan, TJ; Murthy, BV; Nguyen, HT; Stack, AG, 2013)
"Gout is an abnormality in the body resulting in the accumulation of uric acid mainly in joints."3.79Enzyme-entrapped mesoporous silica for treatment of uric acid disorders. ( Chandra, MS; Krishnan, UM; Muthukoori, S; Narayanan, N; Sethuraman, S, 2013)
"Gout is a common disease caused by hyperuricemia, which shows elevated serum uric acid (SUA) levels."3.79Common missense variant of monocarboxylate transporter 9 (MCT9/SLC16A9) gene is associated with renal overload gout, but not with all gout susceptibility. ( Chiba, T; Hamajima, N; Hishida, A; Ichida, K; Inoue, K; Kato, Y; Kawai, S; Matsuo, H; Nakamura, T; Nakashima, H; Nakayama, A; Ogata, H; Sakiyama, M; Sakurai, Y; Shimizu, S; Shimizu, T; Shinomiya, N; Takada, T; Takada, Y; Ushiyama, C; Wakai, K, 2013)
" Caspase-1, IL-1β, IL-18, and uric acid were measured in synovial fluid from 112 patients with gout and other arthritides, such as rheumatoid arthritis, osteoarthritis, and spondyloarthropathy."3.79Caspase-1 level in synovial fluid is high in patients with spondyloarthropathy but not in patients with gout. ( Bang, SY; Choi, CB; Jun, JB; Kim, JH; Kim, TH; Son, CN, 2013)
"Acute gout is associated with a decrease in serum uric acid (SUA) that is considered to be in response to acute inflammation but it may be a feature of gout itself."3.79The effect of the systemic inflammatory response, as provoked by elective orthopaedic surgery, on serum uric acid in patients without gout: a prospective study. ( Ashby, HL; Chugh, S; Deshpande, S; Ford, C; Gama, R; Razavi, C; Thomas, OL; Waldron, JL, 2013)
"The associations and gene-diet interactions involving VEGFR-2 gene polymorphisms and FD on uric acid provide new information on gout and hyperuricaemia risks in Malays."3.78Association and interaction effect between VEGF receptor-2 (VEGFR-2) gene polymorphisms and dietary pattern on blood uric acid in Malays and Indians. ( Hon, WM; Masaki, M; Roseline, YW; Shidoji, Y, 2012)
"Previous reports suggested that gout incidence increased with serum uric acid (sUA) level."3.78Gender-specific risk factors for incident gout: a prospective cohort study. ( Chen, JH; Chuang, SY; Pan, WH; Wu, YY; Yeh, WT, 2012)
"These were post hoc analyses of datasets from the Aspirin Myocardial Infarction Study, a 1:1 randomized, double-blind clinical trial, conducted from 1975 to 1979, that examined mortality rates following daily aspirin administration over three years in individuals with documented MI."3.78Hyperuricemia and untreated gout are poor prognostic markers among those with a recent acute myocardial infarction. ( Dabbous, O; Hariri, A; Krishnan, E; Lingala, B; Pandya, BJ, 2012)
"Several genome-wide association studies (GWASs) have reported associations between single nucleotide polymorphisms (SNPs) and uric acid concentrations or gout in a number of different ethnic populations."3.78Association between gout and polymorphisms in GCKR in male Han Chinese. ( Chu, N; Han, L; Li, C; Liu, S; Ma, X; Meng, D; Miao, Z; Wang, B; Wang, J; Zhang, K, 2012)
"Although hyperuricemia is suggested to increase allantoin production in both pro- and antioxidant manners, it remains undetermined whether it increases the serum concentration of allantoin."3.78Relationship between serum allantoin and urate in healthy subjects and effects of benzbromarone in gout patients. ( Koga, M; Koyama, H; Kurajoh, M; Moriwaki, Y; Shoji, T; Sumida, C; Tsutsumi, Z; Yamamoto, A; Yamamoto, T, 2012)
"Allopurinol is the most commonly used urate-lowering therapy in gout."3.78Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. ( Dalbeth, N; Dockerty, JL; Drake, J; Frampton, C; Jones, PB; Stamp, LK; Taylor, WJ, 2012)
"In this hypothesis-generating study, gout patients who took colchicine had a significantly lower prevalence of MI and exhibited trends toward reduced all-cause mortality and lower CRP level versus those who did not take colchicine."3.78Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. ( Crittenden, DB; Cronstein, BN; Greenberg, JD; Keenan, RT; Lehmann, RA; Pillinger, MH; Schneck, L; Sedlis, SP; Shah, B, 2012)
"These findings demonstrate that mangiferin has the potential to be developed as a new therapeutic agent for the treatment of hyperuricemia and gout."3.78Reducing effect of mangiferin on serum uric acid levels in mice. ( Gao, L; Li, L; Lin, H; Liu, X; Lu, W; Niu, Y, 2012)
"Blood lead levels in the range currently considered acceptable are associated with increased prevalence of gout and hyperuricemia."3.78Low-level lead exposure and the prevalence of gout: an observational study. ( Bhalla, V; Krishnan, E; Lingala, B, 2012)
"We report the unusual case of a 63-year-old man with gout and coexisting pseudogout (calcium pyrophosphate dihydrate crystal deposition disease) affecting the same joint."3.77Gout and coexisting pseudogout in the knee joint. ( Huh, M; Kim, SJ; Seo, YJ; Yoo, JH; Yoo, Y; Yun, KH, 2011)
"In contrast to large GWA studies based on thousands of individuals and large meta-analyses combining GWAS results, we analyzed a small case/control sample for uric acid nephrolithiasis."3.77Application of a new method for GWAS in a related case/control sample with known pedigree structure: identification of new loci for nephrolithiasis. ( Bonerba, B; Caruso, MR; Casu, G; Casula, S; Concas, MP; Deiana, I; Forabosco, P; Maestrale, GB; Mele, C; Persico, I; Pirastu, M; Pistidda, P; Sassu, A; Thornton, T; Tore, S; Usai, P, 2011)
" As gout is characterized by elevated serum concentrations of uric acid, we investigated ADRB3 as a potential candidate for gout."3.77Positive correlation between Beta-3-Adrenergic Receptor (ADRB3) gene and gout in a Chinese male population. ( Chu, N; Han, L; Jia, Z; Li, C; Liu, S; Ma, X; Meng, D; Wang, B; Wang, J; Zhang, K; Zhoub, S, 2011)
" We present a case of tophaceous gout with uric acid levels that did not respond to prescription of very high doses of allopurinol or uricosuric agents."3.77Febuxostat efficacy in allopurinol-resistant tophaceous gout. ( Reid, G; Uh, M, 2011)
" This study investigated trends in uric acid levels, hyperuricemia and gout among adults in Taiwan from 1993-1996 to 2005-2008, using data collection from, Nutrition and health surveys in Taiwan (NAHSIT) conducted in 1993-1996 and 2005-2008."3.77Trends in hyperuricemia and gout prevalence: Nutrition and Health Survey in Taiwan from 1993-1996 to 2005-2008. ( Chuang, SY; Hsieh, YT; Lee, SC; Pan, WH, 2011)
" Subjects were further categorized into 3 diagnostic groups: gout, asymptomatic hyperuricemia (no gout, serum uric acid [UA] ≥6."3.77Reproducibility of musculoskeletal ultrasound for determining monosodium urate deposition: concordance between readers. ( Gyftopoulos, S; Howard, RG; Pillinger, MH; Samuels, J; Swearingen, CJ; Thiele, RG, 2011)
"Allopurinol, a purine base analog inhibitor of xanthine oxidase (XO) activity, remains the standard for pharmacologic urate-lowering management of gout."3.77Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. ( Chohan, S, 2011)
"The treatment of gout requires a lowering of serum urate (SU) levels, and allopurinol is the drug that is most commonly used for this purpose."3.77Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level. ( Barclay, ML; Chapman, PT; Drake, J; Frampton, C; O'Donnell, JL; Stamp, LK; Zhang, M, 2011)
"To study the prevalence of chronic kidney disease (CKD) and its impact on allopurinol dosing and uric acid control among patients with gout."3.77Chronic kidney disease in gout in a managed care setting. ( Dabbous, O; Fuldeore, MJ; Krishnan, E; Pandya, BJ; Riedel, AA; Zarotsky, V, 2011)
"Urate-lowering therapy (ULT), adjusted to achieve and maintain a serum uric acid (SUA) of <6 mg/dl, remains the standard of care for the chronic management of gout."3.77Improving the use of allopurinol in chronic gout: monitoring oxypurinol levels to guide therapy. ( Gilliland, WR; Keith, MP, 2011)
"To identify factors associated with acute gout attacks in normouricaemic gout patients receiving allopurinol."3.77Factors associated with acute gout attacks in normouricaemic gout patients receiving allopurinol: a retrospective study. ( Kim, YG; Lee, CK; Lee, SG; So, MW; Yoo, B, 2011)
"To estimate the accuracy, sensitivity, specificity, and interobserver agreement of dual-energy computed tomography (CT) in detection of uric acid crystals in joints or periarticular structures in patients with arthralgia and patients suspected of having gout, with joint aspiration results as reference standard."3.77Identification of intraarticular and periarticular uric acid crystals with dual-energy CT: initial evaluation. ( Black, DF; Bongartz, T; Fletcher, JG; Glazebrook, KN; Guimarães, LS; Leng, S; Manek, NJ; McCollough, CH; Murthy, NS, 2011)
"Recent genome-wide association studies showed that serum uric acid (SUA) levels relate to ABCG2/BCRP gene, which locates in a gout-susceptibility locus revealed by a genome-wide linkage study."3.77ABCG2/BCRP dysfunction as a major cause of gout. ( Hosoya, T; Ichida, K; Matsuo, H; Nakamura, T; Nakayama, A; Shinomiya, N; Suzuki, H; Takada, T, 2011)
"High serum uric acid levels are associated with gout, atherosclerosis and cardiovascular disease."3.76Sex and age interaction with genetic association of atherogenic uric acid concentrations. ( Adams, TD; Brandstätter, A; Coassin, S; Hunt, SC; Kedenko, L; Kiechl, S; Kramer, F; Kronenberg, F; Lamina, C; Paulweber, B; Summerer, M; Willeit, J, 2010)
"These prospective data with long-term followup provide evidence that higher levels of serum uric acid increase the risk of gout in a graded manner among women, but the rate of increase is lower than that among men."3.76Epidemiology of gout in women: Fifty-two-year followup of a prospective cohort. ( Bhole, V; Choi, H; de Vera, M; Krishnan, E; Rahman, MM, 2010)
"Recent genome-wide association and functional studies have shown that the ABCG2 gene encodes for a urate transporter, and a common causal ABCG2 variant, rs2231142, leads to elevated uric acid levels and prevalent gout among Whites and Blacks."3.76The rs2231142 variant of the ABCG2 gene is associated with uric acid levels and gout among Japanese people. ( Folsom, AR; Iso, H; Kitamura, A; Köttgen, A; Tanigawa, T; Yamagishi, K, 2010)
" We apply all the methods to GWAS of serum uric acid levels and gout with 550,000 single nucleotide polymorphisms in the Framingham Heart Study."3.76Analyze multivariate phenotypes in genetic association studies by combining univariate association tests. ( Fox, CS; Guo, CY; Wu, H; Yang, Q, 2010)
"To enable clinicians to initiate appropriate steps for long-term management of gout, including controlling acute exacerbations and pain and sustaining target serum uric acid (SUA) levels to control hyperuricemia as the underlying metabolic disorder."3.76The current state of care in gout: Addressing the need for better understanding of an ancient disease. ( Graser, E; Pope, RS; Zychowicz, ME, 2010)
"Fructose-rich beverages such as sugar-sweetened soda and orange juice can increase serum uric acid levels and, thus, the risk of gout, but prospective data on the relationship are limited."3.76Fructose-rich beverages and risk of gout in women. ( Choi, HK; Curhan, G; Willett, W, 2010)
"Published evidence in the literature, regulatory status, and relative costs of colchicine and nonsteroidal anti-inflammatory drugs (NSAIDs) for prophylaxis of gouty flares during early urate-lowering therapy are reviewed."3.76Nonsteroidal anti-inflammatory drugs and colchicine to prevent gout flare during early urate-lowering therapy: perspectives on alternative therapies and costs. ( Peterson, DM, 2010)
"To assess the value of dual energy computed tomography (DECT) for the detection of uric acid (UA) deposition in patients with gout."3.76[Application of dual-energy computed tomography for detecting uric acid deposition in patients with gout]. ( Chen, Y; Jin, ZY; Liu, W; Sun, H; Wang, X; Xu, K; Xue, HD; Zeng, XJ; Zhang, YQ, 2010)
"In a cohort of veterans with a diagnosis of gout prescribed allopurinol, colchicine or probenecid, quality of care was assessed by examining adherence to the following evidence-based recommendations: (1) whether patients starting a new allopurinol prescription (a) received continuous allopurinol, (b) received colchicine prophylaxis, (c) achieved the target uric acid level of 3.75Opportunities for improving medication use and monitoring in gout. ( Asch, SM; Hodges, JS; Singh, JA, 2009)
"In this article we describe a gouty caucasian male patient who had high levels of serum uric acid since 1970s."3.75Persistent normalization of serum levels of uric acid in a gouty patient after administration of cyproterone acetate. ( D'Angelo, S; Olivieri, I; Palazzi, C; Pennese, E, 2009)
"To determine longterm urate-lowering efficacy and clinical benefits and safety of therapy with febuxostat or allopurinol in subjects with gout."3.75Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. ( Becker, MA; Lademacher, C; Lloyd, E; MacDonald, PA; Schumacher, HR, 2009)
"We identified persons using two integrated delivery systems aged 18 years or older with a diagnosis of gout who initiated use of allopurinol, probenecid or sulfinpyrazone from 1 January 2000 to 30 June 2006."3.75Adherence with urate-lowering therapies for the treatment of gout. ( Andrade, SE; Briesacher, BA; Fouayzi, H; Harrold, LR; Ockene, IS; Raebel, MA; Yood, RA, 2009)
" Rosiglitazone was also administered to demonstrate whether improved insulin sensitivity would prevent high-purine diet induced renal injury and gouty-like lesions."3.75Insulin resistance acts as an independent risk factor exacerbating high-purine diet induced renal injury and knee joint gouty lesions. ( Gu, J; Li, C; Li, Y; Meng, D; Miao, Z; Wang, B; Wang, CY; Wang, J; Wang, L; Xing, X; Yan, S; Yuan, Y; Zhang, S, 2009)
"We examined the association between serum uric acid (SUA) level and the frequency, risk, and cost of gout flares among the elderly."3.75Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter? ( Cahill, KE; Krishnan, E; Mody, RR; Patel, PA; Tang, J; Wu, EQ; Yu, AP, 2009)
" At moderate or high doses, an effect on any one marker may be absent or even the opposite of that observed at very high or excessive doses; examples include fasting plasma triglyceride, insulin sensitivity, and the putative marker uric acid."3.75Fructose ingestion: dose-dependent responses in health research. ( Livesey, G, 2009)
"To determine the association between allopurinol compliance and serum urate (sUA) level; and examine the association between sUA and gout-related healthcare costs in a large managed care population."3.75Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis. ( Fuldeore, MJ; Halpern, R; Mikuls, TR; Mody, RR; Patel, PA, 2009)
"The aim of this prospective study was to evaluate results of metformin (MF) therapy during 1 year of uric acid (UA) metabolism and the clinical course of gout with insulin resistance (IR)."3.75[Effect of metformin on the clinical course of gout and insulin resistance]. ( Aleksandrova, EN; Barskova, VG; Eliseev, MS; Kudaeva, FM; Nasonov, EL; Nasonova, VA; Volkov, AV, 2009)
"Gout is well known to be produced by increased uric acid level in blood."3.75Calcium oxalate stone and gout. ( Marickar, YM, 2009)
"The name of Sir Alfred Baring Garrod is linked with the first detection of uric acid in blood and its accumulation in sufferers from gout as well as the formulation of the term rheumatoid arthritis."3.75[The High Priest of gout - Sir Alfred Baring Garrod (1819-1907)]. ( Keitel, W, 2009)
"Understanding how uric acid crystals provoke inflammation is crucial to improving our management of acute gout."3.74Gout in the spotlight. ( So, A, 2008)
" Conditions known to increase uric acid production (psoriasis, chronic bronchitis) and to decrease uric acid excretion (hypothyroidism, metabolic syndrome, and nephroangiosclerosis) may operate in a single patient, illustrating the dramatic clinical course of untreated gout."3.74An unusual patient with hypothyroidism, tophaceous gout, and marked joint destruction. ( Fraile, JM; Montoya, F; Puig, JG; Torres, RJ, 2008)
"We identified three genetic loci associated with uric acid concentration and gout."3.74Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. ( Astor, BC; Benjamin, EJ; Boerwinkle, E; Coresh, J; Dehghan, A; Fox, CS; Hofman, A; Hwang, SJ; Kao, WL; Köttgen, A; Levy, D; Rivadeneira, F; van Duijn, CM; Witteman, JC; Yang, Q, 2008)
"Our population-based data provide evidence for a protective effect of gout on the risk of PD and support the purported protective role of uric acid."3.74Gout and the risk of Parkinson's disease: a cohort study. ( Choi, H; De Vera, M; Gao, X; Kopec, J; Rahman, MM; Rankin, J, 2008)
"In 18 patients with monosodium urate (MSU) crystal proven gout, and after the initiation of successful serum uric acid (SUA)-lowering treatment, an arthrocentesis of the asymptomatic signal joint (11 knees, 7 first metatarsophalangeal joints) was performed every 3 months to obtain a synovial fluid (SF) sample."3.74Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. ( Pascual, E; Sivera, F, 2007)
"Using the Minneapolis Veterans Affairs electronic medical record system, we identified a cohort of veterans receiving medication to treat gout between January 1, 1999 and December 31, 2003, and evaluated 3 recently published evidence-based QIs for gout management: QI 1 = allopurinol dose <300 mg in gout patients with renal insufficiency, QI 2 = uric acid check within 6 months of starting a new allopurinol prescription, and QI 3 = complete blood count and creatine kinase check every 6 months for gout patients receiving prolonged colchicine therapy."3.74Quality of care for gout in the US needs improvement. ( Asch, SM; Hodges, JS; Singh, JA; Toscano, JP, 2007)
"2 mg/kg (monthly vs daily) in patients with tophaceous gout not treatable by allopurinol."3.74Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study. ( Bardin, T; Brière, C; Hoenen-Clavert, V; Loeuille, D; Richette, P, 2007)
"Serum uric acid concentrations are correlated with gout and clinical entities such as cardiovascular disease and diabetes."3.74SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. ( Coassin, S; Döring, A; Fischer, G; Gieger, C; Gohlke, H; Henke, K; Illig, T; Klopp, N; Kronenberg, F; Mehta, D; Meisinger, C; Meitinger, T; Paulweber, B; Pfeufer, A; Prokisch, H; Rosskopf, D; Völzke, H; Wichmann, HE, 2008)
"For older adults with gout to (1) assess health care utilization and costs from a third-party payer perspective; (2) evaluate health care costs related to tophi; and (3) explore the relationship between elevated serum uric acid (UA) level, an indicator of disease control, and health care utilization."3.74Disease-related and all-cause health care costs of elderly patients with gout. ( Cahill, KE; Krishnan, E; Mody, RR; Patel, PA; Tang, J; Wu, EQ; Yu, AP, 2008)
"To evaluate haemoglobin A1c (HbA1c), fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels in a nationally representative sample of men and women."3.74Haemoglobin A1c, fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels--the Third National Health and Nutrition Examination Survey. ( Choi, HK; Ford, ES, 2008)
"Greater intakes of total vitamin C were significantly associated with lower serum uric acid concentrations, after adjustment for smoking, BMI, ethnicity, blood pressure, presence of gout, use of aspirin, and intake of energy, alcohol, dairy protein, fructose, meat, seafood and coffee."3.74Vitamin C intake and serum uric acid concentration in men. ( Ascherio, A; Choi, HK; Curhan, G; Forman, JP; Gao, X, 2008)
"Cross-sectional studies indicate metabolic syndrome is a risk factor for elevated serum uric acid."3.74Impact of childhood metabolic syndrome components on the risk of elevated uric acid in adulthood: the Bogalusa Heart Study. ( Berenson, G; Chen, W; Menke, A; Muntner, P; Patel, DA; Srinivasan, S, 2008)
" We evaluated the hypouricemic effect of propolis from China on hyperuricemia induced by the uricase inhibitor, oxonic acid (500 mg/kg p."3.73[Xanthine oxidase inhibitory activity and hypouricemia effect of propolis in rats]. ( Nishioka, N; Tsuji, T; Yoshizumi, K, 2005)
"Identification of monosodium urate (MSU) and calcium pyrophosphate dehydrate (CPPD) crystals in synovial fluid samples is diagnostic of gout and CPPD crystal related arthropathy."3.73Analysis for crystals in synovial fluid: training of the analysts results in high consistency. ( Frasquet, J; González-Salinas, J; Hernández-Aguado, I; Lumbreras, B; Pascual, E; Rodríguez, E, 2005)
"We determined why calcium oxalate stones instead of uric acid stones form in some patients with gouty diathesis."3.73Physicochemical metabolic characteristics for calcium oxalate stone formation in patients with gouty diathesis. ( Moe, OW; Pak, CY; Peterson, RD; Poindexter, JR; Sakhaee, K, 2005)
" In this article, we focus on the three common crystals and diseases: hydroxyapatite crystal deposition disease, calcium pyrophosphate dihydrate (CPPD) deposition disease, and monosodium urate crystals (gout)."3.73Cervical spine and crystal-associated diseases: imaging findings. ( Carlier, R; Chevrot, A; Drapé, JL; Feydy, A; Lioté, F, 2006)
"5), hypercalciuria-calcium greater than 200 mg, hyperoxaluria-oxalate greater than 45 mg, hyperuricosuria-uric acid greater than 600 mg, hypocitraturia-citrate less than 600 mg and purine gluttony-sulfate greater than 20 mg."3.73Ethnic background has minimal impact on the etiology of nephrolithiasis. ( Ekeruo, WO; Enemchukwu, CU; Maloney, ME; Preminger, GM; Springhart, WP; Young, MD, 2005)
"Patients with system lupus erythematosus, rheumatic arthritis, chronic active hepatitis and gout were found to have considerable hyperuricemia and be decreased in aminoacides content, which are the predecessors of purine."3.73[Hyperuricemia and disorders in content of amino acids-purine precursors in patients with autoimmune diseases and gout]. ( Anan'eva, MN; Dubiaga, VV; Nikolenko, IuI; Nikolenko, VIu; Shchukin, IN; Siniachenko, OV, 2005)
"Development of the acute and chronic inflammatory responses known as gout and pseudogout are associated with the deposition of monosodium urate (MSU) or calcium pyrophosphate dihydrate (CPPD) crystals, respectively, in joints and periarticular tissues."3.73Gout-associated uric acid crystals activate the NALP3 inflammasome. ( Martinon, F; Mayor, A; Pétrilli, V; Tardivel, A; Tschopp, J, 2006)
"The objectives of this study were to evaluate attainment of this target SUA among gout patients on allopurinol in a naturalistic setting and to assess its impact on gout flare risk."3.73Serum urate levels and gout flares: analysis from managed care data. ( Bakst, AW; Brewer, KK; Patel, PA; Sarawate, CA; Schumacher, HR; Yang, W, 2006)
" A diagnosis of gouty tophi was offered which was confirmed by histopathology and serum uric acid level."3.73FNAC of gouty tophi--a case report. ( Purohit, MB; Purohit, TM; Tandon, RK, 2006)
"Adherence to published allopurinol dosing guidelines led to suboptimal control of hyperuricemia in this population of patients with gout."3.73Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. ( Dalbeth, N; Gow, P; Kumar, S; Stamp, L, 2006)
"To assess the efficacy of fenofibrate treatment in combination with urate lowering agents in patients with gout."3.73Effect of fenofibrate in combination with urate lowering agents in patients with gout. ( Lee, CH; Lee, J; Lee, YH, 2006)
" Further antihyperuricemic-guided purification of the fraction afforded three lignans, phyllanthin (1), hypophyllanthin (2) and phyltetralin (3), of which 1 significantly reversed the plasma uric acid level of hyperuricemic animals to its normal level in a dose-dependent manner, comparable to that of allopurinol, benzbromarone and probenecid which are used clinically for the treatment of hyperuricemia and gout."3.73Antihyperuricemic lignans from the leaves of Phyllanthus niruri. ( Chan, KL; Murugaiyah, V, 2006)
"The plasma levels of lipoproteins, cholesterol, triglycerides and uric acid, and the renal excretion of uric acid were studied in 68 patients with gout and in another control group of 50 healthy subjects."3.72The elevated prevalence of apolipoprotein E2 in patients with gout is associated with reduced renal excretion of urates. ( Cardona, F; Collantes, E; Escudero, A; García-Fuentes, E; Soriguer, FJ; Tinahones, FJ, 2003)
"To test the hypothesis that stone-forming patients with type II diabetes (DM-II) have a high prevalence of uric acid (UA) stones and present with some of the biochemical features of gouty diathesis (GD)."3.72Biochemical profile of stone-forming patients with diabetes mellitus. ( Ekeruo, W; Moe, O; Pak, CY; Peterson, RD; Pietrow, P; Poindexter, JR; Preminger, GM; Sakhaee, K, 2003)
" Three individuals had markedly high plasma uric acid levels posthibernation; of these, two individuals died from extensive visceral gout and one recovered with fluid therapy."3.72A comparison between pre- and posthibernation morphometry, hematology, and blood chemistry in viperid snakes. ( Dutton, CJ; Taylor, P, 2003)
" The cardinal clinical features in individuals with the uromodulin mutation included hyperuricemia, decreased fractional excretion of uric acid, and chronic interstitial renal disease leading to end-stage renal disease (ESRD) in the fifth through seventh decade."3.72Clinical characterization of a family with a mutation in the uromodulin (Tamm-Horsfall glycoprotein) gene. ( Bleyer, AJ; Deterding, E; Ganier, D; Gorry, MC; Hart, TC; McBride, D; Sandhu, J; Satko, SG; Shihabi, Z; Weller, N; Woodard, AS; Xu, L; Zhu, H, 2003)
"Overactivity of phosphoribosylpyrophosphate synthetase (PRS) is an X chromosome-linked disorder of purine metabolism that is characterized by gout with uric acid overproduction and, in some families, neurodevelopmental impairment."3.72Phosphoribosylpyrophosphate synthetase overactivity as a cause of uric acid overproduction in a young woman. ( Ahmed, M; Becker, MA; García-Pavía, P; García-Puig, J; Rivero, M; Torres, RJ, 2003)
" Pure and mixed uric acid stones were strongly associated with a gouty diathesis, and vice versa."3.72Predictive value of kidney stone composition in the detection of metabolic abnormalities. ( Adams-Huet, B; Pak, CY; Pearle, MS; Poindexter, JR, 2003)
"In 99% of the cases, the underlying cause of gout is an inborn disorder of uric acid excretion."3.72[Avoid purine-rich foods, drink a lot, reduce weight. The most important recipes against hyperuricemia]. ( Benecke, M, 2003)
"Among 127 consenting patients, 81 with rheumatoid arthritis taking nonsteroidal antiinflammatory drugs (13 diclofenac, 20 naproxen) or disease modifying antirheumatic drugs (25 sulfasalazine, 23 methotrexate), 17 patients with polymyalgia rheumatica taking prednisone, and 29 patients with gout taking daily prophylactic colchicine (n = 12) or the uric acid lowering drugs allopurinol (10) or benzbromaron (7), 104 used their medication from a regular medication bottle fitted with a special cap containing microelectronics capable of recording time and date of opening and closing, defined as a medication event."3.72The compliance-questionnaire-rheumatology compared with electronic medication event monitoring: a validation study. ( de Klerk, E; Landewé, R; van der Linden, S; van der Tempel, H; van der Heijde, D, 2003)
"Anthropometric parameters, blood lipid spectrum, levels of glucose, uric acid (UA), immunoreactive insulin, HOMA index were studied in 55 male patients with gout (mean age 50."3.72[Insulin resistance syndrome in patients with gout and its influence on formation of clinical characteristics of the disease]. ( Barskova, VG; Eliseev, MS; Iakunina, IA; Il'inykh, EV; Nasonov, EL; Zilov, AV, 2004)
"The role of nitric oxide (NO) in the antinociceptive effect of indomethacin was assessed in the pain-induced functional impairment model in the rat (PIFIR model), a model of inflammatory and chronic pain similar to that observed in clinical gout."3.72Peripheral involvement of the nitric oxide-cGMP pathway in the indomethacin-induced antinociception in rat. ( Déciga-Campos, M; Díaz-Reval, MI; González-Trujano, ME; López-Muñoz, FJ; Ventura-Martínez, R, 2004)
"To determine whether the biochemical presentation and urinary physicochemical environment of patients with hyperuricosuria presenting with calcium stones (hyperuricosuric calcium urolithiasis [HUCU]) differs from those of patients with gouty diathesis (GD) or idiopathic uric acid urolithiasis."3.71Biochemical distinction between hyperuricosuric calcium urolithiasis and gouty diathesis. ( Koska, J; Pak, CY; Peterson, RD; Poindexter, JR; Sakhaee, K, 2002)
"To compare renal handling of uric acid in patients with primary gout with that of a control group."3.71Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. ( Calabozo, M; Erauskin, GG; Herrero-Beites, AM; Perez-Ruiz, F; Ruibal, A, 2002)
" Treatment with allopurinol results in a significant reduction in serum creatinine in patients with gout and in those with hyperuricemia and renal impairment."3.71Hyperuricemia, gout, and renal function after liver transplantation. ( Alexander, GJ; Gibbs, P; Gimson, AE; Neal, DA; Tom, BD, 2001)
", anorexia nervosa and alcoholism, and the mechanisms by which increased uric acid level may be explained."3.70Tophaceous gout of the navicular bone as a cause of medial inflammatory tumor of the foot. ( Baldet, P; Blotman, F; Bonnel, F; Canovas, F; Leroux, JL; Medioni, D; Olive, P; Thomas, E, 1998)
"We measured serum concentrations of 1,25(OH)2-vitamin D3, 25(OH)-vitamin D3, parathyroid hormone (PTH), and uric acid in 114 male patients with primary gout and 51 normal male control subjects."3.70Decreased serum concentrations of 1,25(OH)2-vitamin D3 in patients with gout. ( Higashino, K; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamakita, J; Yamamoto, T, 1998)
"We measured the serum concentrations of 1,25(OH)2-vitamin D3, 25(OH)-vitamin D3, parathyroid hormone (PTH) in 82 male patients with primary gout whose serum uric acid was significantly higher than that of 41 normal control male subjects (8."3.70Decreased serum concentrations of 1,25(OH)2-vitamin D3 in patients with gout. ( Higashino, K; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamakita, J; Yamamoto, T, 1998)
"We studied 34 apparently healthy children and 2 propositi from kindreds with familial juvenile hyperuricaemic nephropathy (FJHN) - a disorder characterised by early onset, hyperuricaemia, gout, familial renal disease and a similarly low urate clearance relative to glomerular filtration rate (GFR) [fractional excretion of uric acid (FEur) 5."3.70Presymptomatic detection of familial juvenile hyperuricaemic nephropathy in children. ( Cameron, JS; Dalton, N; Haycock, GB; McBride, MB; Moro, F; Ogg, CS; Raman, GV; Rees, L; Rigden, S; Simmonds, HA; Van't Hoff, W, 1998)
" Alcohol consumption and central obesity were independent predictors of gout among hyperuricemic subjects irrespective of uric acid level."3.70Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kinmen. ( Chou, P; Lin, HY; Lin, KC, 2000)
"Accurate determination of serum and urinary uric acid concentrations is essential for the diagnosis and classification of gout according to uric acid metabolism derangement."3.70Effect of urine storage on urinary uric acid concentrations. ( Hada, T; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamakita, J; Yamamoto, T, 2000)
"To investigate the incidence of gout and the interaction between uric acid level and other risk factors in the development of gout."3.70The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. ( Chou, P; Lin, HY; Lin, KC, 2000)
" We examined the development of gout and an increased uric acid level in relation to lead, adjusting for other known risk factors."3.70Effect of low level lead exposure on hyperuricemia and gout among middle aged and elderly men: the normative aging study. ( Hu, H; Kim, R; Liang, MH; Shadick, NA; Sparrow, D; Weiss, S, 2000)
"Uric acid crystal was found in four patients pleural effusion and stones in two patients' spittle which were consist of monosodium urate (MSU)."3.70[Pleural effusion of gout]. ( Han, Y; Liu, L; Zhang, K, 2000)
" In this study, we show that the inflammatory microcrystals monosodium urate monohydrate (MSU) and calcium pyrophosphate dihydrate (CPPD), the major mediators of gout and pseudogout, differentially regulate the production of these two chemokines by human neutrophils."3.69Inflammatory microcrystals differentially regulate the secretion of macrophage inflammatory protein 1 and interleukin 8 by human neutrophils: a possible mechanism of neutrophil recruitment to sites of inflammation in synovitis. ( Hachicha, M; McColl, SR; Naccache, PH, 1995)
"We compared gouty diathesis with uric acid versus calcium stones."3.69Clinical and biochemical presentation of gouty diathesis: comparison of uric acid versus pure calcium stone formation. ( Adams-Huet, B; Khatchadourian, J; Pak, CY; Preminger, GM; Whitson, PA, 1995)
" Accordingly, the glycosuria- and/or hyperglycemia-induced decrease in the biological half-life of oxypurinol must be considered in the administration of allopurinol to gouty patients with uncontrolled diabetes mellitus."3.69Effect of glucose infusion on the renal transport of purine bases and oxypurinol. ( Higashino, K; Moriwaki, Y; Suda, M; Takahashi, S; Yamamoto, T, 1995)
"Ten women with crystal-proved primary gout and normal serum creatinine levels (below 116 mmol/L) were studied while they were on a purine-restricted diet and taking no medications known to influence uric acid metabolism."3.69Purine metabolism in women with primary gout. ( de Miguel, E; Gil, AA; Mateos, FA; Miranda, ME; Pérez de Ayala, C; Puig, JG; Torres, RJ, 1994)
"Uricaemia-lowering treatment is indicated when hyperuricaemia is pronounced (90 mg/L or more) or when it is expressed by uric acid stones and/or gout."3.69[Hyperuricemia and gout: therapeutic indications]. ( Pawlotsky, Y, 1994)
" The 1977 ARA criteria for gout in a survey setting were used and serum uric acid was determined by a uricase method."3.69Gout is on the increase in New Zealand. ( Castle, B; Klemp, P; Robertson, MC; Stansfield, SA, 1997)
"Primary gout is characterized by increased plasma and decreased urinary concentrations of hypoxanthine, xanthine and uric acid."3.69Purine metabolism in patients with gout: the role of lead. ( Herrero, E; Mateos, FA; Miranda-Carús, E; Puig, JG; Ramos, T; Sanz, AG, 1997)
"We describe a patient with no history of gout and persistently normal serum uric acid concentrations in whom septic acute prepatellar bursitis was diagnosed initially, but empiric antibiotic therapy failed."3.69Prepatellar bursitis: a unique presentation of tophaceous gout in an normouricemic patient. ( Dawn, B; Walker, SE; Williams, JK, 1997)
"To determine whether the plasma level of uridine can be used to identify patients with gout, the plasma concentration of uridine was determined in patients with gout and normal subjects."3.69Is the plasma uridine level a marker of the overproduction of uric acid? ( Higashino, K; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamakita, J; Yamamoto, T, 1997)
"Uric acid in blood has been widely accepted as a reliable indicator of hyperuricemia and gout, and its assay method has been established."3.69[Determination of uric acid in scalp hair for non-invasive estimation of uricemic control in hyperuricemia]. ( Isaka, Y; Kobayashi, K; Morioka, Y; Tozawa, T, 1997)
"Increased serum urate concentrations in hereditary nephropathy associated with hyperuricemia and gout are due to severe impairment of uric acid excretion."3.68Hereditary nephropathy associated with hyperuricemia and gout. ( Calvin, TS; Gil, AA; Jiménez, ML; Mateos, FA; Miranda, ME; Picazo, ML; Puig, JG, 1993)
"Hyperuricemia and gout have been associated with cyclosporine A (CyA) therapy in transplant recipients."3.68Tophaceous gout in patients with renal transplants treated with cyclosporine A. ( Baethge, BA; Landreneau, MD; McDonald, JC; Work, J, 1993)
"The relation between creatinine and uric acid metabolism was analysed in 77 male patients with primary gout and 62 healthy male subjects."3.68Relation between creatinine and uric acid excretion. ( Nishida, Y, 1992)
"To determine the frequency and characteristics of hyperuricemia and gouty arthritis among cyclosporine-treated heart transplant recipients."3.68Hyperuricemia and gout among heart transplant recipients receiving cyclosporine. ( Burack, DA; Griffith, BP; Kahl, LE; Thompson, ME, 1992)
"Synovial fluid (SF) samples, all containing monosodium urate crystals, obtained from 18 asymptomatic knees of 12 patients with gout, were serially analyzed before and one month after treatment with 1 mg/day of oral colchicine."3.68Treatment with colchicine decreases white cell counts in synovial fluid of asymptomatic knees that contain monosodium urate crystals. ( Castellano, JA; Pascual, E, 1992)
"Hypotheses concerning the development of uric acid and gouty nephropathy suggest that the initiating disease mechanism involves an interaction between uric acid or monosodium urate monohydrate (MSUM) crystals and renal tubular epithelial cells."3.68Ultrastructural studies of the reaction of urate crystals with a cultured renal tubular cell line. ( Axelsen, RA; Cross, M; Emmerson, BT; Osborne, JM, 1991)
"Effects of alminoprofen (AP), a non-steroidal anti-inflammatory agent, were investigated using several experimental gouty models."3.68[Effects of alminoprofen on sodium urate crystal-induced inflammation]. ( Hujiyoshi, T; Maeda, E; Uematsu, T, 1991)
" The three main types of crystal arthritis are monosodium urate (gout), calcium pyrophosphate dihydrate, and calcium phosphate (usually hydroxyapatite)."3.68Crystal arthritis: a clinician's view. ( Hall, S, 1991)
"The effect of serum and synovial fluid obtained from six healthy subjects and from 12 patients with gout, six with rheumatoid arthritis and 18 with calcium pyrophosphate dihydrate arthropathy (CPPD) on the rate of in vitro urate crystal formation was measured."3.68Evidence for a promoter of urate crystal formation in gouty synovial fluid. ( Dieppe, PA; McGill, NW, 1991)
"We reviewed the clinical features and uric acid metabolism in 37 female patients with gout."3.68Female gout. Clinical spectrum and uric acid metabolism. ( Capitán, CF; de Miguel, E; Gijón, JB; Jiménez, ML; Mateos, FA; Michán, AD; Pérez de Ayala, C; Puig, JG, 1991)
"The overactivity of PRPP synthetase is transmitted as a sex-linked abnormality, being characterized by uric acid overproduction and, in some patients, by muscular hypotonia, neurosensitive deafness and/or ataxia."3.68[Metabolism of purine nucleotides in the central nervous system in patients with phosphoribosylpyrophosphate synthetase hyperactivity and neurosensory deafness]. ( García Neito, V; García Puig, J; López Jiménez, M; Mateos Antón, F; Ramos Hernández, T; Sebastián Melián, J, 1990)
"Superactivity of phosphoribosylpyrophosphate (PRPP) synthetase is one of several hereditary enzyme abnormalities associated with gout and excessive uric acid excretion."3.67Diagnostic evaluation of phosphoribosylpyrophosphate synthetase activities in hemolysates. ( Becker, MA; Hecker, S; Losman, MJ; Woo, S, 1984)
"Ten patients with gout, hypertension, and mild to moderate renal insufficiency were studied for possible lead nephropathy by measuring stimulated urinary lead excretion."3.67Occult lead intoxication in patients with gout and kidney disease. ( Cecere, FA; Saylor, RP; Wright, LF, 1984)
"Sixteen hyperuricemic gouty patients were treated with diflunisal, a novel salicylate, 500 mg BID."3.67Hypouricemic action of diflunisal in gouty patients: in vitro and in vivo studies. ( Ambanelli, U; Ferraccioli, G; Spisni, A, 1984)
"The behavior of plasma and urine oxypurines (hypoxanthine and xanthine) and of uric acid has been studied in normal subjects and in gout patients."3.67[Analysis of uric acid and oxypurines in normal subjects and in gout patients]. ( Di Stefano, A; Leoncini, R; Marinello, E; Pizzichini, M; Porcelli, B; Taddeo, A, 1989)
"The clearance of uric acid, hypoxanthine and xanthine has been examined in gout patients and in normal subjects compared to creatinine, after a purine-free diet."3.67[Clearance of oxypurines in normal subjects and in gout patients subjected to a purine-free diet. Effects of allopurinol]. ( Di Stefano, A; Leoncini, R; Marinello, E; Pizzichini, M; Porcelli, B; Taddeo, A, 1989)
"To evaluate the frequency and the pathogenesis of hyperuricemia and gout during cyclosporine therapy, we studied renal-transplant recipients who were treated with either cyclosporine and prednisone (n = 129) or azathioprine and prednisone (n = 168)."3.67Cyclosporine-induced hyperuricemia and gout. ( Fox, IH; Lin, HY; McQuillan, MA; Palella, TD; Rocher, LL; Schmaltz, S, 1989)
"The relationship between uric acid metabolism and lipid levels was analyzed in 148 male subjects with primary gout."3.67Relationship between hypertriglyceridemia and uric acid production in primary gout. ( Jiao, S; Kubo, M; Matsubara, K; Matsuzawa, Y; Takama, T; Tarui, S, 1989)
"Two members of a Spanish family were studied: an eight-year-old boy (Patient 1) with tophaceous gout, purine nucleotide and uric acid overproduction, and sensorineural deafness, and his 27-year-old mother (Patient 2), who had gout."3.67Inherited superactivity of phosphoribosylpyrophosphate synthetase: association of uric acid overproduction and sensorineural deafness. ( Becker, MA; Jimenez, ML; Kim, M; Mateos, FA; Puig, JG; Simmonds, HA, 1988)
"A patient with coexistent Klinefelter's syndrome, systemic lupus erythematosus (SLE) and chronic tophaceous gouty arthritis developed allopurinol hypersensitivity."3.67Allopurinol hypersensitivity in a patient with coexistent systemic lupus erythematosus and tophaceous gout. ( Fam, AG; McDonald, J; Paton, T; Senn, J, 1988)
"The renal excretion of uric acid is usually diminished in primary gout with respect to increased serum urate levels."3.67Renal excretion of hypoxanthine and xanthine in primary gout. ( Jiménez, ML; Mateos, FA; Puig, JG; Ramos, TH, 1988)
"20 patients with elevated serum uric acid levels and osteoarthritis of the hip or knee were given diflunisal 500 mg b."3.67[The uric acid-lowering effect of diflunisal]. ( Fasching, U, 1987)
"Similarity of the morphological picture of gouty nephropathy and primary glomerulonephritides in which purine antagonists turned out to be effective, a positive effect of azathioprine (Az) and 6-mercaptopurine (MP) on purine metabolism, and changes in immunity indices revealed in gout (hyperproduction of immunoglobulins and circulating immune complexes) necessitates the use of antimetabolites in combined therapy of gout patients with proteinuric and latent types of nephropathy."3.67[Substantiation and effectiveness of the use of purine antagonists in gouty nephropathy]. ( Diadyk, AI; Nikolenko, IuI; Shpilevaia, NI; Siniachenko, OV; Vasilenko, IV, 1987)
"It's reported that oral administration of fructose in normal and gouty patients causes a rise in serum uric acid (see "References": Stirpe et al."3.67[Evaluation of hyperuricemia caused by fructose in a status of altered uric acid metabolism]. ( Della Corte, E; Menghini, S, 1987)
"Uric acid concentration in the serum was investigated 3 times a day using the uricase method in 15 gout inpatients on a hypopurine diet with age- and sex-adjusted caloric content."3.67[Circadian rhythm of uric acid levels of the serum in gout]. ( Atanasov, NA; Karastanev, II; Kereziev, IK; Kuzmanova, SI; Solakov, PTs, 1987)
" Dispensary examinations of the patients resulted in a decrease in the level of uric acid and in the number of exacerbations of gouty arthritis, the reduction of the sizes of tophi or their disappearance."3.67[Rehabilitation of patients with gout during outpatient follow-up]. ( Akimova, TF; Ivanova, MM; Novoselova, TM; Tsurko, VV, 1987)
" Three of the four females showed impaired renal function and elevated serum uric acid levels, two of them suffered from recurrent gouty attacks."3.67[Secondary gout and pseudo-Bartter syndrome in females with laxative abuse]. ( Adam, O; Goebel, FD, 1987)
"The plasma concentrations of oxipurinol, the chief metabolite of allopurinol, were studied in 66 patients with gout in whom the dose of allopurinol varied between 100 and 400 mg per day."3.67Plasma oxipurinol concentrations during allopurinol therapy. ( Cross, M; Emmerson, BT; Gordon, RB; Thomson, DB, 1987)
"Gout is a disease linked to altered uric acid metabolism with increased uric acid concentration in the blood, the deposition of sodium urate crystals in certain tissues and abscesses."3.67[Arthropathies and nutrition: gout]. ( Milano, L, 1986)
"In a study designed to evaluate the radionuclide images in patients with gout, six (23%) of the 26 patients had clear evidence of Paget's disease of bone by technetium Tc 99m medronate imaging."3.67Paget's disease of bone in patients with gout. ( Hansell, JR; Lluberas-Acosta, G; Schumacher, HR, 1986)
"A family is described in which four members in three generations showed evidence of crystal deposition disease: two developed calcium pyrophosphate dihydrate (CPPD) crystal deposition, one calcific periarthritis, and one mixed crystal deposition disease (gout + chondrocalcinosis)."3.67Multiple microcrystal deposition within a family. ( Dieppe, PA; Doherty, M, 1985)
" Examples of calculating the risk for gout attack and of EPH gestosis, depending on serum uric acid level, is presented."3.67[Criteria for the selection and evaluation of diagnostic tests]. ( Keller, H, 1985)
" The association of arthritic disease and joint degeneration with the deposition of sodium urate crystals in gout and calcium pyrophosphate crystals in pseudogout (chondrocalcinosis) is clinically well established."3.67Apatite-type crystal deposition in arthritic cartilage. ( Ali, SY, 1985)
"1) is associated with gout and uric acid overproduction in affected hemizygous males."3.66Gout with superactive phosphoribosylpyrophosphate synthetase due to increased enzyme catalytic rate. ( Becker, MA; Itkin, P; Losman, MJ; Simkin, PA, 1982)
"Forty-seven patients with gout, 28 of whom had not previously been treated with allopurinol, and 25 normal subjects, were examined for 24-h urinary excretion of the most important adrenal steroid derivatives."3.66Hormonal aspects of human gout--excretion of adrenal hormone derivatives in gouty patients. ( Aleo, MF; Bianchi, E; Ferrari, S; Gregolini, L; Marcolongo, R; Marinello, E, 1983)
" The relationship between calcium oxalate (COX) crystals - implicated in the vasculitis of primary oxalosis - and immunologically mediated endothelial injury was also explored."3.66Mechanisms of vascular damage in gout and oxalosis: crystal induced, granulocyte mediated, endothelial injury. ( Boogaerts, MA; Hammerschmidt, DE; Jacob, HS; Roelant, C; Verwilghen, RL, 1983)
"In an open trial 15 patients with acute gout attacks were treated with Tolmetin."3.66[Treatment of acute gout attacks with tolmetin (author's transl)]. ( Gaismayer, K; Petera, P; Tausch, G, 1982)
"The incorporation of 15N-glycine into urinary uric acid was studied in three gouty patients, repeating a study carried out 13 to 27 years ago."3.66Long-term follow-up of incorporation of 15N from glycine into uric acid in gout. ( Roboz, J; Yu, TF, 1981)
"The results over 10 years in 200 patients (103 with gout and 97 with hyperuricaemia) treated with benzbromarone 75 - 120 mg/d are reported."3.66Ten years' experience with benzbromarone in the management of gout and hyperuricaemia. ( Giudicelli, CP; Masbernard, A, 1981)
"Forty-nine patients with gout, many with hypertension and/or renal calculi, were given hydrochlorothiazide, furosemide, or ticrynafen."3.66Effects of diuretics on urate and calcium excretion. ( Berger, L; Kaung, C; Sarkozi, L; Yü, T, 1981)
" Drugs used for hyperuricemia and gout such as colchicine, allopurinol, probenecid, and sulphinpyrazone have not been implicated in affecting exercise performance."3.66Effects of exercise performance on drugs used in musculoskeletal disorders. ( Day, RO, 1981)
"Ten generations of selection for uricemia and articular gout have led to the development of the HUA line which is characterized by a threefold increase in plasma level of uric acid when compared to the control LUA line, even when fed diets containing normal levels of protein."3.66Hereditary uricemia and articular gout in chickens. ( Austic, RE; Cole, RK, 1980)
"Inherited enzyme deficiencies are found in a small proportion of patients with gout who produce an excess of uric acid."3.66Primary overproduction of urate caused by a partial deficiency of hypoxanthine-guanine phosphoribosyl transferase. ( Cassidy, M; Gregory, MC; Harley, EH, 1980)
"We describe three patients in whom severe, life-threatening hyperkalemia and renal insufficiency developed after treatment of acute gouty arthritis with indomethacin."3.66Indomethacin-induced hyperkalemia in three patients with gouty arthritis. ( Beckstrom, D; Findling, JW; Itskovitz, H; Kozin, F; Rawsthorne, L, 1980)
" In 17 subjects with gout, blood uric acid levels were reduced by approximately 50%."3.66Tienilic acid: a single treatment for hyperuricaemia and hypertension? ( Gibson, T; Potter, CF; Rodgers, VA; Simmonds, HA, 1980)
"A patient with intractable tophaceous gout and advanced renal failure responded favorably to treatment by long-term hemodialysis and administration of allopurinol."3.66Chronic gouty nephropathy treated by long-term hemodialysis and allopurinol. ( Johnson, WJ; O'Duffy, JD, 1979)
"In most patients with primary gout hyperuricaemia results from a renal defect in tubular uric acid secretion."3.66Uricosuric therapy and urate solubility in blood and urine. ( Gröbner, W; Zöllner, N, 1979)
"After a short survey of the purine metabolism, excretion of uric acid, theories of gout and urate nephropathy methodical references are given for the estimation of excretion of uric acid, a normal region on test persons was established and compared with other authors."3.66[Diagnostic value of renal urate excretion]. ( Häntzschel, U; Költzsch, V, 1978)
" Synthesis of 14C-labelled N-formyl glycinamide ribonucleotide by lymphocytes was measured in healthy control subjects and patients with primary gout or hyperuricaemia secondary to renal failure, with or without allopurinol therapy."3.66Purine biosynthesis de novo by lymphocytes in gout. ( Brami, M; Chanard, J; Funck-Brentano, JL; Kamoun, P, 1978)
"Intrasynovial deposits of monourate crystals in the presence of serum hyperuricaemia, and calcium pyrophosphate dihydrate (CPPD) crystals, are responsible for gout and pseudogout respectively."3.66Crystal induced arthritis: gout and pseudogout. ( Webb, J, 1978)
" The color compensator allows differentiation between the monosodium urate crystals of gout and the crystals of pseudogout, or calcium pyrophosphate deposition disease."3.65An office technique for identifying crystal in synovial fluid. ( Wild, JH; Zvaifler, NJ, 1975)
"We have reported previously two siblings with gout and uric acid lithiasis associated with excessive purine production."3.65Mutant feedback-resistant phosphoribosylpyrophosphate synthetase associated with purine overproduction and gout. Phosphoribosylpyrophosphate and purine metabolism in cultured fibroblasts. ( De Vries, A; Sperling, O; Zoref, E, 1975)
"In the majority of patients with gout and excessive uric acid production, underlying enzyme abnormalities have not been identified."3.65Patterns of phosphoribosylpyrophosphate and ribose-5-phosphate concentration and generation in fibroblasts from patients with gout and purine overproduction. ( Becker, MA, 1976)
"A mutant feedback-resistant, physiologically superactive, phosphoribosylpyrophosphate (PP-ribose-P) synthetase was found in a family with purine overproduction, gout and uric acid lithiasis."3.65Superactivity of phosphoribosylpyrophosphate synthetase, due to feedback resistance, causing purine overproduction and gout. ( Boer, P; Brosh, S; de Vries, A; Sperling, O; Zoref, E, 1977)
"Chronic lead nephtropathy, secondary gout (lead-gout) and porphyrinuria may develop after long lasting professional exposure to lead."3.65[Chronic lead poisoning: Lead gout with giant tophi on the skin, nephrophathy and porphyrinopathy]. ( Künzig, M; Orfanos, CE, 1975)
" 91% have serum uric acid levels above the normal range and 61% present "hyperuricemia," according to "gouty risk" criteria."3.65[Occurrence of hyperuricemia in atrioventricular block. (Results of a study of 158 patients with isotopic pacemaker implantations)]. ( Gavelle, P; Laurens, P; Maurice, P, 1976)
"Plasma uric acid levels in 35 obese gouty and non-gouty subjects showed a highly significant mean fall of 0."3.65The effect of weight loss on plasma and urinary uric acid and lipid levels. ( Scott, JT; Sturge, RA, 1977)
"A case of recurrent, superficial phlebitis in the lower extremities, with raised blood uric acid levels, responsive to colchicine and to urate pool depletion, but unassociated with articular complaint is reported."3.65Recurrent gouty phlebitis without articular gout. ( Pasero, G, 1977)
"Dark red nodules that drained an opaque amber liquid developed on the extensor surfaces of both legs in a 69-year-old woman receiving furosemide and spironolactone for congestive heart failure."3.65Panniculitis of the legs with urate crystal deposition. ( Niemi, KM, 1977)
"The diagnosis of gout and pseudogout has traditionally been established by the identification, in synovial fluid, of monosodium urate and calcium pyrophosphate dihydrate crystals with compensated polarizing light microscopy."3.65Crystal deposition disease. Diagnosis by electron microscopy. ( Gorevic, P; Hoffstein, S; Honig, S; Weissmann, G, 1977)
"The prevalence of gout and the frequency distribution of serum uric acid (SUA) concentrations have been studied in four South African populations."3.65Rheumatic disorders in the South African Negro. Part IV. Gout and hyperuricaemia. ( Beighton, P; Solomon, L; Soskolne, CL; Sweet, MB, 1977)
" Such a synthesis was measured in 20 healthy controls, 24 patients with primary gout (11 on allopurinol therapy) and 26 patients with chronic renal failure and secondary hyperuricemia (8 on allopurinol therapy)."3.65[De novo purine biosynthesis. In vitro measurement in hyperuricemia (author's transl)]. ( Brami, M; Brunois, JP; Chanard, J; Funck-Brentano, JL; Kamoun, P; Pleau, JM, 1977)
" The drug is particularly useful in patients with chronic gouty arthritis and tophi, either refractory or allergic to probenecid, sulfinpyrazone, or allopurinol."3.65Pharmacokinetic and clinical studies of a new uricosuric agent - benzbromarone. ( Yu, TF, 1976)
"Three patients with gout and seven with hyperuricaemia, previously untreated, took a single dose of 100 mg allopurinol and 20 mg benzbromaron (as a combined preparation) each morning."3.65[Treatment of hyperuricaemia with a combination of allopurinol and benzbromaron (author's transl)]. ( Berg, G; Matzkies, F, 1976)
"Chickens genetically selected for high incidence of articular gout and hyperuricemia were used to determine the site of defective uric acid (UA) transport in gout."3.65Localization of renal tubular uric acid transport defect in gouty chickens. ( Quebbemann, AJ; Zmuda, MJ, 1975)
" Calcium pyrophosphate crystals induced modest erythrocyte hemolysis, also, and time-course experiments showed a markedly different reaction curve from those produced by silica and urate."3.65Differential membranolytic effects of microcrystalline sodium urate and calcium pyrophosphate dihydrate. ( McCarty, DJ; Wallingford, WR, 1971)
"THE CONCEPT OF AN ABNORMALITY OF GLUTAMINE METABOLISM IN PRIMARY GOUT WAS FIRST PROPOSED ON THE BASIS OF ISOTOPE DATA: when [(15)N]glycine was administered to gouty subjects, there was disproportionately great enrichment of N-(3 + 9) of uric acid, which derive from the amide-N of glutamine."3.65The kinetics of intramolecular distribution of 15N in uric acid after administration of (15N) glycine. A reappraisal of the significance of preferential labeling of N-(3+9) of uric acid in primary gout. ( Sperling, O; Starmer, CF; Wyngaarden, JB, 1973)
"Certain gouty subjects with excessive de novo purine synthesis are deficient in hypoxanthineguanine phosphoribosyltransferase (HG-PRTase [EC 2."3.65Mechanism of excessive purine biosynthesis in hypoxanthine-guanine phosphoribosyltransferase deficiency. ( Sorensen, LB, 1970)
"Activity of hypoxanthine-guanine and adenine phosphoribosyl transferase enzymes has been assayed in erythrocytes from 10 normal adults, 37 subjects with gout, and 21 mentally retarded children with high and normal urinary uric acid:creatinine ratios."3.65Phosphoribosyl transferase activity in normal subjects, gout patients, and children with mental retardation. ( Davison, AN; Eyre, C; Scott, JT, 1971)
" Serum uric acid levels may rise slightly, but no clinical gout was seen in this study."3.64TREATMENT OF CONGESTIVE HEART FAILURE WITH TRIAMTERENE. ( FRIEDMAN, R; SCHUCHER, R; WENER, J, 1965)
"The characteristic phenomena of acute gouty arthritis are acute arthritis in a middle-aged male, associated with serum uric acid above 6 mg."3.63Diagnosis and treatment of gouty arthritis. ( TALBOTT, JH, 1953)
"Gout is triggered by high urate levels and causes inflammation, pain, and an impaired quality of life."3.30Immersion in Water Between 20-30 ( Chou, KR; Karwur, FF; Kurniasari, MD; Miao, NF; Rayanti, RE; Shen, CJ; Shih, YW; Tsai, HT; Yuliana, S, 2023)
" The incidence of adverse events was 50."3.30Serum Urate-Lowering Efficacy and Safety of Tigulixostat in Gout Patients With Hyperuricemia: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Trial. ( Lee, J; Min, J; Saag, KG; Shin, S; Terkeltaub, R, 2023)
" Most guidelines recommend using a lifelong continuation treat-to-target (T2T) strategy, in which ULT is dosed or combined until a serum urate target has been reached and maintained."3.30Urate-lowering therapy following a treat-to-target continuation strategy compared to a treat-to-avoid-symptoms discontinuation strategy in gout patients in remission (GO TEST Finale): study protocol of a multicentre pragmatic randomized superiority trial. ( den Broeder, AA; den Broeder, N; Flendrie, M; Peeters, IR; Taylor, WJ; van Herwaarden, N, 2023)
" The MGH Acupuncture Sensation Scale and adverse events related to acupuncture will be measured after each treatment."3.30Evaluating the effectiveness and safety of acupuncture on serum uric acid in asymptomatic hyperuricemia population: a randomized controlled clinical trial study protocol. ( Chen, Z; Fang, MY; Huang, Y; Li, CN; Lin, FP; Liu, WH; Ma, Y; Tu, SH; Wang, B; Wang, Y; Xie, WX; Yu, LL; Zhang, RY; Zheng, CH, 2023)
"Uricosuric agents are the typical approach to the control of hyperuricemia; however, their use has been eclipsed by adverse reactions, and a safer uricosuric drug is badly needed."3.11Safety, Efficacy, and Pharmacokinetics of HP501 in Healthy Volunteers and Hyperuricemic Patients: A Phase I/IIa Study. ( Chen, Y; Di, X; Fan, L; Jin, Y; Li, X; Liu, R; Wang, Y; Wang, Z; Zheng, L; Zhou, Y, 2022)
"To determine the long-term use of and adherence to urate-lowering therapy (ULT), serum urate (SU) control, and self-reported flares in participants from a randomized controlled trial of allopurinol dose escalation, in order to achieve target SU concentration (< 0."3.11Long-Term Follow-up of a Randomized Controlled Trial of Allopurinol Dose Escalation to Achieve Target Serum Urate in People With Gout. ( Coleman, GB; Dalbeth, N; Drake, J; Frampton, C; Haslett, J; Horne, AM; Stamp, LK; Su, I, 2022)
"Overweight and obesity are typical risk factors for the increased prevalence and incidence of gout."3.11The effects of aerobic exercise on body composition in overweight and obese patients with gout: a randomized, open-labeled, controlled trial. ( Geng, H; Jia, E; Liu, R; Ma, W; Wo, X; Yao, X; Zeng, Y; Zhan, Z; Zhang, J; Zhu, H, 2022)
"The prevalence of renal calculi in patients with gout is high."3.01Effect of alkalized urine on renal calculi in patients with gout: a protocol for a placebo-controlled, double-blinded randomized controlled trial. ( Geng, H; Jia, E; Lin, F; Liu, S; Wang, Y; Zhang, J; Zhong, L; Zhu, H, 2021)
"Gout is a painful chronic disease which disrupts work and family life and can lead to chronic joint damage."3.01Design and implementation of a Pacific intervention to increase uptake of urate-lowering therapy for gout: a study protocol. ( Dalbeth, N; Goodyear-Smith, F; Grey, C; Heather, M; Lutui, H; Ofanoa, M; Ofanoa, SM; Tu'akoi, S; van der Werf, B, 2021)
"Gout is an autoinflammatory disease caused by the deposition of urate crystals."3.01Recent advances in gout drugs. ( Chen, R; Chi, X; Jiang, Z; Liu, Z; Shi, C; Xiu, S; Yi, C; Zhang, L; Zhou, Z, 2023)
"Hyperuricemia and gout are a group of disorders of purine metabolism."3.01The biomarkers discovery of hyperuricemia and gout: proteomics and metabolomics. ( Wu, X; You, C, 2023)
"If untreated, acute gout may eventually develop into chronic tophaceous gout characterized by tophi, chronic gouty synovitis, and structural joint damage, leading the crushing burden of treatment."3.01A review on gout: Looking back and looking ahead. ( Liu, W; Mo, Y; Tao, H; Wang, H, 2023)
"Gout is one of the most common noncommunicable diseases in Hong Kong."3.01The Hong Kong Society of Rheumatology consensus recommendations for the management of gout. ( Chan, JP; Cheung, TT; Ho, CT; So, H; Tsang, HH; Wong, PC; Yip, RM; Yu, CK, 2023)
"Gout is an autoimmune disease characterized by acute or chronic inflammation and damage to bone joints induced due to the precipitation of monosodium urate (MSU) crystals."3.01Immune and inflammatory mechanisms and therapeutic targets of gout: An update. ( Li, H; Liu, W; Peng, J; Wu, R; Wu, Y; Ye, Z; Zong, Z, 2023)
"Undertreated, gout can progress to palpable tophi and joint damage."3.01Emerging Urate-Lowering Drugs and Pharmacologic Treatment Strategies for Gout: A Narrative Review. ( Terkeltaub, R, 2023)
"Gout is a multifactorial metabolic and inflammatory disease that occurs when increased uric acid (UA) induce HU resulting in monosodium urate (MSU) crystal deposition in joints."3.01Uric acid en route to gout. ( Zhang, WZ, 2023)
"Gout is characterized by hyperuricemia and the deposition of monosodium urate (MSU) crystals around joints."3.01Agents for the Treatment of Gout: Current Advances and Future Perspectives. ( Fan, Y; Liu, Y; Meng, Y; Qin, M; Wu, D; Zeng, X, 2023)
"KEY POINTS: • Gout flare recurrences were common within the first 3 months after starting urate-lowering therapy in gout patients."2.90Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare. ( Janssen, CA; Oude Voshaar, MAH; Ten Klooster, PM; van de Laar, MAFJ; Vonkeman, HE, 2019)
"Nurse-led gout care is efficacious and cost-effective compared with usual care."2.87Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. ( Abhishek, A; Ashton, D; Barclay, C; Doherty, M; Doherty, S; Duley, L; Hatton, R; Jenkins, W; Rees, F; Richardson, H; Sarmanova, A; Stevenson, M; Zhang, W, 2018)
"Allopurinol dosing has frequently been limited based on creatinine clearance (CrCL), resulting in failure to achieve target serum urate (SU)."2.87How much allopurinol does it take to get to target urate? Comparison of actual dose with creatinine clearance-based dose. ( Barclay, ML; Chapman, PT; Dalbeth, N; Drake, J; Frampton, C; Horne, A; Stamp, LK; Tan, P, 2018)
"Gout is increasing despite effective therapies to lower serum urate concentrations to 0."2.84Effectiveness of an electronic patient-centred self-management tool for gout sufferers: a cluster randomised controlled trial protocol. ( Aung, E; Baysari, MT; Braithwaite, J; Buchbinder, R; Clay-Williams, R; Coiera, E; Day, RO; Frensham, LJ; Hunter, DJ; Laba, T; Lau, AYS; Li, L; McLachlan, A; McNeil, HP; Nguyen, AD; Pile, KD; Portek, I; Reath, J; Runciman, WB; Westbrook, JI; WIlliams, KM; Zwar, N, 2017)
"Gout is an auto-inflammatory disease driven by urate deposits with a second co-stimulatory factor evoking an (peri)arthritic fulminant inflammation often with a debute at night; inflammatory signals are enhanced via a NLRP3 pathway."2.82A historical journey of searching for uricosuric drugs. ( Jansen, TL; Matthijs, J; Tanja, G, 2022)
"Gout is a common hyperuricaemic metabolic condition that leads to painful inflammatory arthritis and a high comorbidity burden, especially cardiometabolic-renal (CMR) conditions, including hypertension, myocardial infarction, stroke, obesity, hyperlipidaemia, type 2 diabetes mellitus and chronic kidney disease."2.82Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care. ( Choi, HK; McCormick, N; Yokose, C, 2022)
"Allopurinol is an agent of first choice for urate lowering therapy."2.82What's new on the front-line of gout pharmacotherapy? ( Blake, KEG; Saag, JL; Saag, KG, 2022)
"Gout is a systemic disease from which some patients develop numerous painful tophi that adversely affect quality of life and functionality."2.82Expert Opinion on Pegloticase with Concomitant Immunomodulatory Therapy in the Treatment of Uncontrolled Gout to Improve Efficacy, Safety, and Durability of Response. ( Abdellatif, A; Albert, J; Amin, M; Baraf, HSB; Botson, JK; Edwards, NL; Freyne, B; Keenan, RT; Masri, KR; Peterson, J; Soloman, N; Strand, V; Yung, C, 2022)
"Gout is a common inflammatory arthritis caused by the deposition of sodium urate crystals in the joints."2.82The Role of the Intestine in the Development of Hyperuricemia. ( Chen, J; Liu, N; Yin, H, 2022)
"Gout is the most common inflammatory arthritis in the United States."2.82Management and Cure of Gouty Arthritis. ( Keller, SF; Mandell, BF, 2022)
"Gout is a common and potentially debilitating disease characterized by a painful inflammatory arthritis ("gout flare"), caused by the deposition of monosodium urate crystals in joints and surrounding tissues."2.82Emerging strategies for treating gout. ( Gaffo, AL; Huddleston, EM, 2022)
"In addition to traditional treatments for gout, novel therapies have been introduced in recent years."2.82Current state and prospects of gout treatment in Korea. ( Choi, ST; Park, EH; Song, JS, 2022)
"Gout is a common type of inflammatory arthritis characterized by the presence of monosodium urate crystals (MSU) in the joints."2.82Recent Insights Into the Role of Macrophages in Acute Gout. ( Liu, L; Liu, M; Shan, L; Xue, Y; Yu, Y; Zhao, L; Zhu, L, 2022)
"Gout is a chronic metabolic disease that seriously affects human health."2.82Susceptibility genes of hyperuricemia and gout. ( Nian, YL; You, CG, 2022)
"Gouty arthritis is a common inflammatory disease."2.82Role of microRNA alternation in the pathogenesis of gouty arthritis. ( Chen, B; Hong, S; Hu, Y; Li, L; Luo, Z; Wang, J; Wang, S; Wu, J; Xu, T; Yang, C; Yang, F; Yang, J; Yao, Y, 2022)
"Gout is a metabolic disorder, and one of the most common inflammatory arthritic conditions, caused by elevated serum urate (SU)."2.82Moving the Needle in Gout Management: The Role of Culture, Diet, Genetics, and Personalized Patient Care Practices. ( Roman, YM, 2022)
" All of the above RCTs showed that probiotics did not increase the incidence of adverse events."2.82Safety and efficacy of probiotic supplementation in 8 types of inflammatory arthritis: A systematic review and meta-analysis of 34 randomized controlled trials. ( Chen, H; Deng, Y; He, Q; Li, J; Liu, H; Xiang, W; Yang, K; Zeng, L; Zhu, X, 2022)
" Although dosing was otherwise well tolerated, two subjects experienced serious adverse events of acute kidney injury."2.82Acute kidney injury observed during phase 1 clinical trials of a novel xanthine oxidase/URAT1 dual inhibitor PF-06743649. ( Dua, P; Gurrell, R; Kirby, S; Loudon, PT; Sudworth, M, 2016)
" ABT-639 demonstrated acceptable safety and pharmacokinetic profiles in human."2.80Population pharmacokinetics and exposure-uric acid analyses after single and multiple doses of ABT-639, a calcium channel blocker, in healthy volunteers. ( An, G; Awni, W; Duan, WR; Dutta, S; Liu, W; Nothaft, W, 2015)
"A modest dosage of vitamin C (500 mg/day) for 8 weeks had no clinically significant urate-lowering effects in patients with gout, despite the fact that plasma ascorbate levels increased."2.78Clinically insignificant effect of supplemental vitamin C on serum urate in patients with gout: a pilot randomized controlled trial. ( Chapman, PT; Drake, JM; Frampton, C; O'Donnell, JL; Stamp, LK; Zhang, M, 2013)
"Hyperuricemia is associated with the presence and severity of obstructive sleep apnea (OSA)."2.78Serum urate levels are unchanged with continuous positive airway pressure therapy for obstructive sleep apnea: a randomized controlled trial. ( Prudon, B; Roddy, E; Stradling, JR; West, SD, 2013)
" Gout flares and IRs were the most frequently reported adverse events; these were least common in patients with a sustained urate-lowering response to treatment and those receiving biweekly treatment."2.78Long-term safety of pegloticase in chronic gout refractory to conventional treatment. ( Baraf, HS; Becker, MA; Dillon, A; Khanna, D; Ottery, FD; Sundy, JS; Vázquez-Mellado, J; Yood, RA, 2013)
"Hyperuricemia is the greatest risk factor for gout and is caused by an overproduction and/or inefficient renal clearance of urate."2.77Fractional clearance of urate: validation of measurement in spot-urine samples in healthy subjects and gouty patients. ( Day, RO; Graham, GG; Indraratna, PL; Jones, G; Kannangara, DR; Portek, I; Ramasamy, SN; Stocker, SL; Williams, KM, 2012)
"Despite an increasing incidence of gout in older age patients with multiple metabolic and cardiovascular comorbidities, there are limited data addressing whether currently available urate-lowering therapy is comparably effective and safe in older (≥65 years of age) versus younger (<65 years of age) patients."2.76Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects. ( Becker, MA; Gunawardhana, L; Hunt, B; MacDonald, PA, 2011)
"Forty-one patients were randomized to undergo 12-14 weeks of treatment with pegloticase at 1 of 4 dosage levels: 4 mg every 2 weeks, 8 mg every 2 weeks, 8 mg every 4 weeks, or 12 mg every 4 weeks."2.73Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. ( Baraf, HS; Barkhuizen, A; Becker, MA; Horowitz, Z; Huang, W; Maroli, AN; Moreland, LW; Sundy, JS; Waltrip, RW, 2008)
"Treatment with benzbromarone monotherapy (range: 100-200 mg/day; mean 138 mg/day) resulted in 92% of patients reaching target levels sUr 2.73Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. ( Brouwers, JR; Houtman, PM; Jansen, TL; Reinders, MK; van Roon, EN, 2007)
" Maximum pUox was linearly related to the IV dose of PEG-uricase, the area under the curve (AUC) value increased linearly (up to a dose of 8 mg), and the pUox half-life was 6."2.73Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. ( Ganson, NJ; Hershfield, MS; Huang, W; Kelly, SJ; Rehrig, CD; Scarlett, EL; Sundy, JS, 2007)
"Recently, nephrolithiasis has been reported to be involved with renal manifestation of metabolic syndrome."2.73Relationship between insulin resistance and low urinary pH in patients with gout, and effects of PPARalpha agonists on urine pH. ( Inokuchi, T; Ka, T; Kobayashi, T; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamamoto, T, 2007)
" The dosing regimens to maintain uric acid levels below the therapeutic target of 6 mg/dL were then predicted by the model."2.73Population pharmacokinetic and pharmacodynamic analysis of pegloticase in subjects with hyperuricemia and treatment-failure gout. ( Alton, M; Huang, W; Marco, MD; Maroli, AN; Waltrip, RW; Wright, D; Yue, CS, 2008)
"Gout is a common form of inflammatory arthritis where urate crystals deposit in joints and surrounding tissues."2.72The Role of Advanced Imaging in Gout Management. ( Cao, H; Li, S; Liang, J; Lin, J; Wan, L; Xu, G, 2021)
"Gout is a common chronic disease with a high recurrence rate."2.72The clinical efficacy of urate-lowering therapy in acute gout: a meta-analysis of randomized controlled trials. ( Li, Q; Tang, Y; Wang, D; Wang, M; Zhang, X, 2021)
"Gout is the most common form of inflammatory arthritis, and its incidence is highest in middle-aged and older patients."2.72Gout Flare Burden, Diagnosis, and Management: Navigating Care in Older Patients with Comorbidity. ( Kumar, M; Manley, N; Mikuls, TR, 2021)
"Treatment with febuxostat resulted in a significant reduction of sUA levels at all dosages."2.71Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. ( Becker, MA; Eustace, D; Joseph-Ridge, N; MacDonald, PA; Palo, WA; Schumacher, HR; Vernillet, L; Wortmann, RL, 2005)
"Losartan has been shown to increase urinary uric acid excretion and hence to lower serum uric acid levels."2.70Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. ( Brunner, HR; Burnier, M; Chiolero, A; Fallab-Stubi, CL; Gerster, JC; Maillard, M; Würzner, G, 2001)
"Gout is a chronic inflammatory disease caused by precipitation of urate crystals in the joints, kidneys, and urinary tract."2.66Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia. ( Kuriyama, S, 2020)
"Hyperuricemia is a strong precursor of gout, which deteriorates patients' health and quality of life."2.66Evaluation of urate-lowering therapy in hyperuricemia patients: a systematic review and Bayesian network meta-analysis of randomized controlled trials. ( Chang, SS; Lin, CH; Lin, SY; Lin, YJ; Wang, ST, 2020)
"Gout is a chronic disease due to the deposition of monosodium urate microcrystals in joints and tissues."2.66[Gout]. ( Bernard, A; Oehler, E; Pascart, T; Scuiller, A, 2020)
"Gout is the most common type of arthritis and is evoked by arousal of the inflammasome in the presence of urate crystals superponed on a dysmetabolism with urate accumulation."2.66Lessons and pitfalls from the 2020 Gout Clinical Practice Guideline presented in Atlanta at the ACR 2019. ( Jansen, TL; Janssen, M, 2020)
" Allopurinol, a urate synthesis inhibitor, is generally administered at a reduced dosage to patients with renal impairment."2.66Recent approaches to gout drug discovery: an update. ( Anzai, N; Hisatome, I; Kudo, H; Otani, N; Ouchi, M; Tsuruoka, S, 2020)
"Gout is a disease with acute and/or chronic inflammation and tissue damage induced by the precipitation of monosodium urate crystal (MSU) crystals in bone joints, kidneys, and subcutaneous sites."2.66Gout: a disease involved with complicated immunoinflammatory responses: a narrative review. ( Guo, C; Tian, Y; Wang, Q; Wu, M, 2020)
"Febuxostat had the best efficacy and safety results among the tested agents, and topiroxostat and allopurinol appeared to have fewer adverse events."2.66Efficacy and safety of urate-lowering treatments in patients with hyperuricemia: A comprehensive network meta-analysis of randomized controlled trials. ( Lin, CJ; Lin, JY; Shi, Y; Sun, SS; Zhang, DH, 2020)
"Gout is the most common inflammatory arthritis and occurs when hyperuricaemia, sustained elevation of serum urate levels resulting in supersaturation of body tissues with urate, leads to the formation and deposition of monosodium urate crystals in and around the joints."2.66Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. ( Dehlin, M; Jacobsson, L; Roddy, E, 2020)
"Gout is now the commonest type of inflammatory arthritis despite availability of safe, effective and potentially 'curative' urate-lowering drugs."2.66Changing paradigms in the management of gout. ( Nuki, G; Riches, P, 2020)
"Gout is a disease in which the metabolic condition hyperuricemia leads to the formation of monosodium urate crystals, which provoke acute and chronic inflammatory responses through activation of the innate immune system."2.66Therapeutic approaches in the treatment of gout. ( Mandell, BF; Pillinger, MH, 2020)
"Gout is caused by monosodium urate crystal deposition in joints and tissues."2.66Gout: Rapid Evidence Review. ( Clebak, KT; Croad, JR; Morrison, A, 2020)
"Hyperuricemia is the key risk factor for gout and is considered a prerequisite for monosodium urate (MSU) crystal formation."2.66Pathophysiology of Gout. ( Dalbeth, N; Narang, RK, 2020)
" On the 5th and 6th day after beginning the treatment the dosage of 25 mg of Benzbromarone renders a morning value of 5,3 +/- 1,0 and an evening value of 5,0 +/- 0,9 mg/100 ml."2.64[Treatment of hyperuricemia using daily doses of 50 and 25mg of benzbromarone]. ( Berg, G; Matzkies, F; Minzlaff, R, 1977)
"Gout is a chronic disease caused by monosodium urate (MSU) crystal deposition."2.61Gout. ( Choi, HK; Dalbeth, N; Joosten, LAB; Khanna, PP; Matsuo, H; Perez-Ruiz, F; Stamp, LK, 2019)
"Gout is one of the most prevalent inflammatory rheumatic disease."2.61Dietary Interventions for Gout and Effect on Cardiovascular Risk Factors: A Systematic Review. ( de Vries, R; Gerritsen, M; Heslinga, M; Nurmohamed, M; van Schaardenburg, D; Vedder, D; Walrabenstein, W, 2019)
" The main management issues are related to patient adherence, because gout patients have the lowest rate of medication possession ratio at 1 year, but they also include clinical inertia by physicians, meaning XOI dosage is not titrated according to regular serum uric acid level measurements for targeting serum uric acid levels for uncomplicated (6."2.61Gout: state of the art after a decade of developments. ( Lioté, F; Pascart, T, 2019)
"Despite many effective treatments for gout, its management remains a challenge internationally."2.61The Challenges of Approaching and Managing Gout. ( Fields, TR, 2019)
"Gout is associated with the risk of cardiovascular morbidity and mortality, but the biological relationship between the two remains uncertain."2.61Gout and cardiovascular disease: crystallized confusion. ( Abeles, AM; Pillinger, MH, 2019)
"This has been ascribed, in part, to haemodynamic changes, body weight reduction and several possible effects on myocardial, endothelial and tubulo-glomerular functions, as well as to reduced glucotoxicity."2.61Uric acid and the cardio-renal effects of SGLT2 inhibitors. ( Bailey, CJ, 2019)
"Older drugs for ULT like allopurinol are well studied and extensively described from typical adverse effects (mild skin rash) to unusual fatal reactions, while febuxostat seems to be overall well tolerated."2.61Safety and tolerability of available urate-lowering drugs: a critical review. ( Cicero, AF; Fogacci, F; Strilchuk, L, 2019)
"Gout is the most common type of inflammatory arthritis in adults with rising incidence and prevalence."2.58Gout Keratitis: A Case of Peripheral Ulcerative Keratitis Secondary to Gout With a Review of the Literature. ( Denisova, K; Lazzaro, DR; Mechel, E; Rizzuti, AE; Yazdanyar, A, 2018)
"Crystal arthritis is the most common type of inflammatory arthritis, and fractures contribute to significant morbidity and mortality, therefore, the relationship between the two is of clinical importance."2.58Crystalline arthropathy and bone health. ( Chang, I; Gazeley, D, 2018)
"Relapse of gout is common although delayed after discontinuation of ULT."2.58Effects of Discontinuation of Urate-Lowering Therapy: A Systematic Review. ( Beslon, V; Fournier, JP; Giraudeau, B; Maisonneuve, H; Maruani, A; Moreau, P, 2018)
"Evidence suggests that not treating gout to target in the long term is overall associated with worsening outcomes, such as flares, tophi and structural damage, which is associated to loss of quality of life and mortality."2.58Treat to target in gout. ( Dickson, AJ; Moreno-Lledó, A; Perez-Ruiz, F; Urionagüena, I, 2018)
"Gout is an inflammatory disease manifested by the deposition of monosodium urate (MSU) crystals in joints, cartilage, synovial bursa, tendons or soft tissues."2.58Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan. ( Chen, DY; Chen, JH; Chen, SM; Chen, SY; Cheng, TT; Hsieh, SC; Hsieh, TY; Hsu, PF; Kuo, CF; Kuo, MC; Lam, HC; Lee, IT; Liang, TH; Lin, HY; Lin, SC; Tsai, WC; Tsai, WP; Tsay, GJ; Wei, JC; Yang, CH; Yu, KH, 2018)
"Despite being regarded as an easily-treatable disease, gout diagnosis and management can be challenging."2.58Change gout: how to deal with this "silently-developing killer" in everyday clinical practice. ( Borghi, C; Genderini, A; Grassi, W; Punzi, L; Rossi, C; Scirè, CA, 2018)
"Gout is the most common inflammatory arthritis and is increasing in relevance due to its rising prevalence and incidence."2.58Current status of ultrasound and dual-energy computed tomography in the evaluation of gout. ( Garner, HW; Wessell, DE, 2018)
"To review the extent of treatment success or failure with the xanthine oxidoreductase inhibitors allopurinol and febuxostat and indicate how the dosage of urate-lowering therapy (ULT) may be modified to increase the response in the majority of patients with gout."2.58Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout. ( Day, RO; Graham, GG; Kannangara, DRW; Stocker, SL, 2018)
"Examining therapies aimed at treating gout flares [anti-inflammatory action], bucillamine has some potential, but more data and Phase III studies are needed, to better understand its efficacy and safety."2.58Expert opinion on emerging urate-lowering therapies. ( Merriman, TR; Singh, JA; Stamp, LK, 2018)
" The use of allopurinol has been researched extensively and newer strategies for safer effective dosing are now recommended."2.58Gout - An update of aetiology, genetics, co-morbidities and management. ( Robinson, PC, 2018)
"The treatment of gout is based on several principles."2.58Crystal arthritides - gout and calcium pyrophosphate arthritis : Part 3: Treatment. ( Bertsch, T; Bollheimer, LC; Härle, P; Schlee, S; Sieber, CC, 2018)
" Genetic data may inform assessment of disease prognosis in individuals with hyperuricaemia or established gout, personalised lifestyle advice, selection and dosing of urate-lowering therapy, and prevention of serious medication adverse effects."2.55The genetics of gout: towards personalised medicine? ( Dalbeth, N; Merriman, TR; Stamp, LK, 2017)
"Gout is an inflammatory arthritis characterized by red, tender, hot and tumid joints."2.55The Immunological Basis in the Pathogenesis of Gout. ( Chen, J; Li, X; Qiao, Y; Wang, J; Wu, M; Yang, J, 2017)
"Gout is a common disease responsible for recurrent flares triggered by the deposition of monosodium urate crystals secondary to longstanding hyperuricaemia."2.55Current and future therapies for gout. ( Pascart, T; Richette, P, 2017)
"Gout is both an inflammatory and a metabolic disease."2.55Gout and Metabolic Syndrome: a Tangled Web. ( Krasnokutsky, S; Pillinger, MH; Thottam, GE, 2017)
" Two studies indicated dose-response relationship for sUA, achieving sUA target and gout attacks."2.55Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies. ( Astrup, A; Bartels, EM; Bliddal, H; Carmona, L; Christensen, R; Gudbergsen, H; Henriksen, M; Knop, FK; Kristensen, LE; Nielsen, SM; Perez-Ruiz, F; Singh, JA; Taylor, WJ; Wæhrens, EE, 2017)
"Hyperuricemia has long been known to cause gout, and has recently been correlated with cardiovascular disease, hypertension, and renal disease."2.55The role of urate-lowering treatment on cardiovascular and renal disease: evidence from CARES, FAST, ALL-HEART, and FEATHER studies. ( Pontremoli, R, 2017)
"Gout is a clinical disorder that is characterized by the deposition of monosodium urate crystals (MSU) in joints and tendons, usually in the presence of prolonged hyperuricaemia."2.55Review of the ophthalmic manifestations of gout and uric acid crystal deposition. ( Ao, J; Casson, RJ; Goldblatt, F, 2017)
"Although gout is one of the most common forms of inflammatory arthritis, it has been relatively neglected until recently."2.55Major unanswered questions in the clinical gout field. ( Stamp, LK, 2017)
" Expert opinion: The initial dosage of allopurinol should be low, particularly in patients with renal impairment."2.55Allopurinol: insights from studies of dose-response relationships. ( Carland, JE; Day, RO; Graham, GG; Kannangara, DR; Stocker, SL; Williams, KM, 2017)
" Studies are needed in gout patients with chronic kidney disease and/or cardiovascular disease, so that escalation of dosing /combination of anti-inflammatory drugs needed to suppress gouty inflammation as well as escalation of dosing/combination of urate lowering drugs needed to achieve target serum urate level will lead to better understanding of gout treatment safety issues."2.55The safety of treatment options available for gout. ( Schlesinger, N, 2017)
"Gout affects the structure and function of the 1(st) MTP."2.53The first metatarsophalangeal joint in gout: a systematic review and meta-analysis. ( Dalbeth, N; Rome, K; Stewart, S; Vandal, AC, 2016)
"Flares of gout are often caused by large meals and high alcohol consumption."2.53[Nutritional therapy of gout]. ( Kiss, C; Nickolai, B, 2016)
"Gout is a true crystal deposition arthropathy caused by the precipitation of monosodium urate into joints and periarticular soft tissues."2.53Dual-Energy Computed Tomography of the Knee, Ankle, and Foot: Noninvasive Diagnosis of Gout and Quantification of Monosodium Urate in Tendons and Ligaments. ( Fishman, EK; Fritz, J; Fuld, MK; Henes, JC; Horger, MS, 2016)
"Gout is a common inflammatory arthritis among middle-aged men and postmenopausal women and can be a debilitating disease."2.53Beyond Joints: a Review of Ocular Abnormalities in Gout and Hyperuricemia. ( Schlesinger, N; Sharon, Y, 2016)
"The salient points include the need to treat gout to a serum urate target, the ability to start allopurinol during acute attacks, the need to treat with prophylactic anti-inflammatory drugs for adequate time periods, and the availability of a new urate-lowering drug on the Pharmaceutical Benefits Scheme (PBS)."2.53The management of gout: Much has changed. ( Robinson, PC; Stamp, LK, 2016)
"The prevalence of gout is rising and is likely attributed to several factors including increased incidence of comorbidities, lifestyle factors, and increased use of causative medications."2.53Gouty Arthritis: A Review of Acute Management and Prevention. ( Saseen, JJ; Wilson, L, 2016)
" Drug efficacy and safety, as outcomes, were measured by whether the target level of serum urate acid was achieved and whether any adverse events occurred, respectively."2.53Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis. ( Gao, Y; Guo, Y; Li, D; Li, M; Li, S; Li, W; Sun, L; Wang, Y; Wei, F; Xu, W; Yang, H; Yang, X, 2016)
"Gout is the most common inflammatory arthritis in men over 40 years of age."2.53Using serum urate as a validated surrogate end point for flares in patients with gout: protocol for a systematic review and meta-regression analysis. ( Christensen, R; Dalbeth, N; Fransen, J; Lassere, M; Morillon, MB; Singh, JA; Stamp, L; Taylor, W, 2016)
"This systematic review aims to summarise published evidence that assessed the management of gout in regard to the following: prescription of urate lowering therapy (ULT), monitoring of serum urate levels (sUA) and allopurinol dosing in patients with renal impairment, lifestyle advice and acute management of gout."2.52Management of gout in general practice--a systematic review. ( Jeyaruban, A; Larkins, S; Soden, M, 2015)
"Allopurinol is a safe option, slightly better than other ULDs."2.52Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis. ( Carmona, L; Castrejon, I; Loza, E; Pérez-Ruiz, F; Rosario, MP; Toledano, E, 2015)
" Studies have identified the safe and effective dosing strategies for 'old' drugs such as allopurinol and colchicine."2.52Advances in pharmacotherapy for the treatment of gout. ( Dalbeth, N; Robinson, PC, 2015)
"Uric acid has a stimulating effect on the cerebral cortex, and this could have allowed humans, compared with other animals, to develop higher brain mass volume, better intellectual performances, and maybe evolutionary supremacy."2.52Uric acid: friend or foe? Uric acid and cognitive function "Gout kills more wise men than simple". ( De Giorgi, A; Fabbian, F; Manfredini, R; Misurati, E; Pala, M; Parisi, C; Tiseo, R, 2015)
"Gout is one of the most common forms of arthritis and the prevalence is increasing."2.52Pharmacogenetic considerations in the treatment of gout. ( Roberts, RL; Stamp, LK, 2015)
"The pharmacological treatment of pain in CIA is strictly associated with the treatment of acute phases and flares of the disease, during which crystals trigger the inflammatory response."2.52Molecular mechanisms of pain in crystal-induced arthritis. ( Frallonardo, P; Galozzi, P; Lorenzin, M; Oliviero, F; Ortolan, A; Punzi, L; Ramonda, R; Scanu, A, 2015)
"Acute gout is an auto-inflammatory disease characterized by self-limiting inflammation in response to the deposition of monosodium urate (MSU) crystals in the joints or tissues."2.50Mechanisms of spontaneous resolution of acute gouty inflammation. ( Harper, JL; Steiger, S, 2014)
"Gout is a common crystal-induced arthritis, in which monosodium urate (MSU) crystals precipitate within joints and soft tissues and elicit an inflammatory response."2.50The crystallization of monosodium urate. ( Crittenden, DB; Martillo, MA; Nazzal, L, 2014)
"Gout is defined as an arthritic condition resulting from the deposition of monosodium urate (MSU) crystals in and/or around joints, following long-standing hyperuricemia."2.50Definition of hyperuricemia and gouty conditions. ( Bardin, T; Richette, P, 2014)
"Gout is the most common inflammatory arthritis worldwide."2.50Optimizing current treatment of gout. ( Doherty, M; Hui, M; Rees, F, 2014)
"Gout has been academically considered to be a step-up disease consisting of different stages: acute gout, intercritical gout, and chronic gout."2.50Clinical manifestations and diagnosis of gout. ( Castillo, E; Chinchilla, SP; Herrero-Beites, AM; Perez-Ruiz, F, 2014)
"Gout is a common inflammatory arthritis precipitated by an inflammatory reaction to urate crystals in the joint."2.50Gout: joints and beyond, epidemiology, clinical features, treatment and co-morbidities. ( Horsburgh, S; Robinson, PC, 2014)
"Gout is one of the most common forms of arthritis."2.50Impaired response or insufficient dosage? Examining the potential causes of "inadequate response" to allopurinol in the treatment of gout. ( Barclay, ML; Dalbeth, N; Merriman, TR; Roberts, RL; Singh, JA; Stamp, LK; Wright, DF, 2014)
"Gout is increasingly seen in the elderly population, in large part due to physiological decline in renal function with age, and as a result of therapy for comorbidities, in particular the use of diuretic therapies for hypertension and congestive heart failure."2.50Urate-lowering therapy: current options and future prospects for elderly patients with gout. ( Chapman, PT; Stamp, LK, 2014)
"Gout is characterized by painful joint inflammation, most commonly in the first metatarsophalangeal joint, resulting from precipitation of monosodium urate crystals in a joint space."2.50Diagnosis, treatment, and prevention of gout. ( Hainer, BL; Matheson, E; Wilkes, RT, 2014)
"If tophaceous gout is suspected, alcohol fixation of the biopsy specimen is preferable, as it enables visualization of characteristic needle-shaped urate crystals."2.49Gouty tophi on the ear: a review. ( Chabra, I; Singh, R, 2013)
"Uric acid is a waste product of purine catabolism."2.49Uric acid as a danger signal in gout and its comorbidities. ( Kataoka, H; Lai, JJ; Rock, KL, 2013)
"Gout is a painful inflammatory arthritis associated with hyperuricemia, with a prevalence of almost 10 million in the USA."2.49The kidney in hyperuricemia and gout. ( Mount, DB, 2013)
"Gout is a prototype crystal-induced inflammatory disorder, characterized by neutrophil infiltration into inflamed joints."2.49Neutrophils, IL-1β, and gout: is there a link? ( Kambas, K; Mitroulis, I; Ritis, K, 2013)
"Gout is a growing health problem worldwide especially in affluent countries, such as Australia."2.48Systematic review of the prevalence of gout and hyperuricaemia in Australia. ( Merriman, TR; Robinson, PC; Taylor, WJ, 2012)
"Acute inflammation is the hallmark of the acute tissue reaction to crystals in both gout and pseudogout."2.48The mechanisms of inflammation in gout and pseudogout (CPP-induced arthritis). ( Busso, N; Ea, HK, 2012)
"Gout is a metabolic disease characterized by hyperuricemia and the deposition of monosodium urate (MSU) crystals in the joints and soft tissues, consisting of a self-limited acute phase characterized by recurrent attacks of synovitis and a chronic phase in which inflammatory and structural changes of the joints and periarticular tissues may lead to persistent symptoms."2.48Clinical features of gout. ( De Angelis, R; Grassi, W, 2012)
"Febuxostat is a novel non-purine, selective inhibitor of xanthine oxidase, metabolized and excreted by the liver, so no dose adjustment appears to be necessary in patients with mild-to-moderate renal impairment."2.48[Gout: an overview of available urate lowering therapies]. ( Richette, P, 2012)
"Gout is the most common inflammatory arthritis and one in which pathogenesis and risk factors are best understood."2.48Gout: why is this curable disease so seldom cured? ( Bardin, T; Doherty, M; Jansen, TL; Nuki, G; Pascual, E; Perez-Ruiz, F; Punzi, L; So, AK, 2012)
"Gout is probably one of the oldest diseases affecting men."2.48Gout as autoinflammatory disease: new mechanisms for more appropriated treatment targets. ( Oliviero, F; Punzi, L; Ramonda, R; Scanu, A, 2012)
"Gout is a chronic, progressive inflammatory disease with intermittent arthritic flares, which should not be regarded as a minor inconvenience or nuisance."2.48The unwelcome visitor. ( Goh, LH; How, CH; Teng, GG; Tong, CY, 2012)
"Gout is a common and very painful inflammatory arthritis caused by hyperuricaemia."2.48The genetics of hyperuricaemia and gout. ( Choi, HK; Mount, DB; Reginato, AM; Yang, I, 2012)
"The new epidemic of gout is likely secondary in significant part to the rise in fructose consumption, as well as to the increase in obesity, the endurance of other dietary and non-dietary gout risk factors such as consumption of meat and alcohol, the continued use of culprit medications and potentially to the under-recognition of the benefits of certain foods and drinks (such as dairy products and coffee)."2.48A perspective on diet and gout. ( Kedar, E; Simkin, PA, 2012)
"Gout is a metabolic disorder of purine metabolism with primary manifestations of acute and chronic arthritis and tophus formation."2.48The rheumatology of gout. ( Sundy, JS, 2012)
"One of the limitations for successful treatment of gout is to consider it as an intermittent disease rather than a chronic inflammatory disease which, if improperly treated, leads to chronic clinical manifestations."2.48Evaluation and treatment of gout as a chronic disease. ( Herrero-Beites, AM; Perez-Ruiz, F, 2012)
"Gout and hyperuricemia have likewise been associated with the development of cardiovascular disease and metabolic syndrome."2.48The interplay between diet, urate transporters and the risk for gout and hyperuricemia: current and future directions. ( De Jesus, E; Rachabattula, S; Torralba, KD, 2012)
"Gout is not common in childhood compared with adulthood, and careful consideration of inborn errors of metabolism should be considered in these cases."2.47Gout and hyperuricemia in young people. ( Yamanaka, H, 2011)
"Uric acid has been identified as an endogenous adjuvant that drives immune responses in the absence of microbial stimulation."2.47The role of uric acid as an endogenous danger signal in immunity and inflammation. ( Ghaemi-Oskouie, F; Shi, Y, 2011)
" Allopurinol is the most commonly used ULT, but there is no consensus on dosing in renal impairment."2.47The challenges of gout management in the elderly. ( Jordan, S; Stamp, LK, 2011)
"Gout is frequently associated with the metabolic syndrome."2.47Diagnosis and treatment of gout in primary care. ( Conaghan, PG; Rakieh, C, 2011)
"Although classic gout is still most commonly seen, the disease can manifest as with a wide array of presentations."2.46Unusual clinical presentations of gout. ( Keenan, RT; Ning, TC, 2010)
"Hyperuricemia is considered to be a risk factor of not only gout but also renal and cardiovascular diseases, thus, it is important to use CCBs without adverse effect on uric acid metabolisms."2.46[Calcium antagonists: current and future applications based on new evidence. The mechanisms on lowering serum uric acid level by calcium channel blockers]. ( Hamada, T; Hisatome, I; Igawa, O; Mizuta, E; Shigemasa, C, 2010)
"Gout and hyperuricemia have long been suspected to be risk factors for cardiovascular disease."2.46Gout, hyperuricemia, and the risk of cardiovascular disease: cause and effect? ( Keenan, RT; Shah, A, 2010)
"An acute attack of gout is a paradigm of acute sterile inflammation, as opposed to pyogenic inflammation."2.46Mechanisms of inflammation in gout. ( Busso, N; So, A, 2010)
"Over time, untreated or insufficiently treated gout may progress, with more frequent flares and formation of urate crystal deposits (tophi) and associated chronic, deforming arthritis (gouty arthropathy)."2.46What do I need to know about gout? ( Becker, MA; Ruoff, GE, 2010)
"Accumulating evidence suggests that hemiparesis exerts a protective effect against gout via the down-regulation of mechanical and neural modulators of inflammation in neurologically impaired extremities."2.46Polyarticular gout attacks following cerebrovascular accidents: is hemiparesis in fact protective? 2 cases and a review of the literature. ( Furer, V; Hsiao, SJ; Samuels, J; Vaynrub, M, 2010)
"Gout is the most common cause of inflammatory arthritis among men and postmenopausal women."2.46Gout: epitome of painful arthritis. ( VanItallie, TB, 2010)
"Gout is an acute inflammatory arthritis with the potency to fully destroy the integrity of the joint leading to severe disability."2.46Gout: a clinical syndrome illustrated and discussed. ( Bhansing, KJ; Janssen, M; Radstake, TR; van Bon, L, 2010)
"Gout is a true crystal deposition disease caused by formation of monosodium urate crystals in joints and other tissues."2.45New insights into the epidemiology of gout. ( Doherty, M, 2009)
"When treating gout one needs to treat acute attacks, and lower excess stores of uric acid to achieve dissolution of monosodium urate crystals through a long-term reduction of SU concentrations far beyond the threshold for saturation of urate and provide prophylaxis to prevent acute flares."2.45Gout--what are the treatment options? ( Dalbeth, N; Perez-Ruiz, F; Schlesinger, N, 2009)
"Gout is a disease caused by the deposition of monosodium urate monohydrate crystals."2.44Recent advances in crystal-induced acute inflammation. ( Akahoshi, T; Kitasato, H; Murakami, Y, 2007)
"Treatment of gout is usually considered after the first attack of arthritis, typically podagra."2.44Updates in the management of gout. ( Gilliland, WR; Keith, MP, 2007)
"Gout is the most common inflammatory arthropathy for men."2.44[Crystal-induced arthritis--old but important]. ( Aringer, M; Grässler, J; Winzer, M, 2007)
"There has been renewed interest in the treatment of gout with recent reported intervention studies of new agents such as etoricoxib, febuxostat and pegylated-uricase."2.44Assessment of outcome in clinical trials of gout--a review of current measures. ( Dalbeth, N; Grainger, R; Schumacher, HR; Singh, JA; Taylor, WJ, 2007)
"Novel therapies for gout have recently been developed which has prompted considerable efforts in defining the relevant outcomes for measurement in intervention trials of gout."2.44Establishing outcome domains for evaluating treatment of acute and chronic gout. ( Grainger, R; Taylor, WJ, 2008)
"Gout has been a recognized disease since the fifth century B."2.44[Historical review of gout and hyperuricemia investigations]. ( Nakamura, T, 2008)
"Uric acid is a weak acid that exists largely as MSU, the ionized form, in urate pool at physiologic pH."2.44[Physiology and dynamics of uric acid in hyperuricemia]. ( Nakamura, T; Takagi, K; Ueda, T, 2008)
"Urolithiasis is a clinically important complication of gout."2.44[Urolithiasis and nephropathy complicated with gout]. ( Shimizu, T, 2008)
"Gout is a crystal deposition disease."2.44[Establishment of therapeutic goal and plan of gout and asymptomatic hyperuricemia]. ( Fujimori, S, 2008)
"Thus, the treatment of hypertension and hyperlipidemia associated with hyperuricemia is also important."2.44[Other antihyperuricemic agents]. ( Hisatome, I; Igawa, O; Ogino, K, 2008)
"Gout is one of the best understood among the rheumatological disorders and one of the most satisfying to treat."2.43Diagnosis and management of gout: a rational approach. ( Suresh, E, 2005)
"Gout and calcium pyrophosphate deposition disease are two common causes of inflammatory joint disease."2.43An update on the treatment options for gout and calcium pyrophosphate deposition. ( Choy, G, 2005)
"Gout is one of the most readily manageable of the rheumatic diseases."2.43Understanding treatments for gout. ( Cannella, AC; Mikuls, TR, 2005)
"Future directions in the treatment of gout, in part guided by a better understanding of pathophysiology, are discussed."2.43Overview of hyperuricaemia and gout. ( Agudelo, C; Liu-Bryan, R; Masseoud, D; Rott, K, 2005)
"Gout is the most common inflammatory arthritis in men, affecting approximately 1-2% of adult men in Western countries."2.43Recent developments in diet and gout. ( Kavanaugh, A; Lee, SJ; Terkeltaub, RA, 2006)
"Hyperuricemia and gout are common conditions that have long been known to have a heritable component."2.43Genetic factors associated with gout and hyperuricemia. ( Bleyer, AJ; Hart, TC, 2006)
"Throughout history, gout has been associated with rich foods and excessive alcohol consumption."2.43A concise history of gout and hyperuricemia and their treatment. ( Nuki, G; Simkin, PA, 2006)
"Gouty arthritis is a characteristically intense acute inflammatory reaction that erupts in response to articular deposits of monosodium urate (MSU) crystals."2.43The inflammatory process of gout and its treatment. ( Cronstein, BN; Terkeltaub, R, 2006)
"Gout is a chronic metabolic disease caused by a disorder of the purine metabolism leading to hyperuricaemia."2.43Pathogenesis, clinical findings and management of acute and chronic gout. ( Cantatore, FP; Corrado, A; D'Onofrio, F; Melillo, N; Santoro, N, 2006)
"In most cases, gout is an easy disease to treat, but we do not have enough information about how to handle those few patients with "difficult" disease, and what we refer colloquially to as difficult gout has not been properly defined yet."2.42Gout. ( Pascual, E; Pedraz, T, 2004)
"Uric acid has profound beneficial effects since it scavenges potential harmful radicals in our body."2.42[Physiology and biochemistry of uric acid]. ( Hediger, MA, 2004)
"Gout is an inflammatory response to deposition of monosodium urate crystals in and around joints."2.41Clinical manifestations of gout and their management. ( Ryan, PF; van Doornum, S, 2000)
"Gout is a common form of arthritis, in which many of the risk factors, pathogenetic mechanisms, and clinical features have been recognized for years."2.41Gout: diagnosis, pathogenesis, and clinical manifestations. ( Agudelo, CA; Wise, CM, 2001)
"Gout is a condition characterized by the deposition of monosodium urate crystals in the joints or soft tissue."2.40Gout and hyperuricemia. ( Alloway, JA; Harris, MD; Siegel, LB, 1999)
"Hyperuricemia and gout are known to occur in patients receiving diuretic therapy."2.40Finger pad tophi. ( Chopra, KF; Grossman, ME; Schneiderman, P, 1999)
"Carpal tunnel syndrome is well known in gout (28 reported cases), and is secondary to gouty tenosynovitis."2.39[Double tunnel syndrome of the upper limb in tophaceous gout. Apropos of a case]. ( Jacoulet, P, 1994)
"Gout is a disease caused by deposits of sodium urate crystals in tissues."2.39[What remains of gout in 1993?]. ( Bourgeois, P; Rozenberg, S, 1994)
"Corticosteroids favour osteopenia which can be detected by measurement of bone density."2.39[Osteo-articular complications of heart transplantation]. ( Bourgeois, P; Rozenberg, S, 1995)
"Uric acid is a useful diagnostic tool as screening for most of purine metabolic disorders."2.39The importance of uric acid examination. ( Krijt, J; Schneiderka, P; Sebesta, I, 1994)
"Uric acid is one of the composition of urinary stones itself, but it has an activity of calcium oxalate stone formation."2.39[Hyperuricosuria and urolithiasis]. ( Koide, T, 1996)
"Tumor lysis syndrome is a critical illness characterized by massive tumor cell death leading to severe hyperuricemia, hyperphosphatemia, hypocalcemia, and acute renal failure after starting chemotherapy to cancers, especially lymphoproliferative malignancies."2.39[Hyperuricemia and the kidney]. ( Hikita, M; Hosoya, T; Ichida, K, 1996)
" Because of potential toxicity, colchicine should not be used to treat acute gout, but should be used in low dosage (0."2.38Prevention and management of gout. ( Hochberg, MC; Star, VL, 1993)
"Selective medical therapy of nephrolithiasis is highly effective in preventing new stone formation."2.38Renal calculi: pathogenesis, diagnosis, and medical therapy. ( Preminger, GM, 1992)
"Although typical gout is easily recognized and treated, several recent papers have addressed atypical presentations of gout, as well as other causes of podagra that might have been attributed previously to gout."2.38Gout and hyperuricemia. ( Agudelo, CA; Wise, CM, 1991)
"Gout is largely solved, both from diagnostic and therapeutic standpoints."2.37Crystal identification in human synovial fluids. Methods and interpretation. ( McCarty, DJ, 1988)
"Gout is a clinical syndrome with a limited range of manifestations arising as a result of the deposition of crystals of monosodium urate, the final product of purine metabolism in humans."2.37Clinical aspects of monosodium urate monohydrate crystal deposition disease (gout). ( Becker, MA, 1988)
"Acute gout is best treated with colchicine or indomethacin."2.36Hyperuricemia and gout. ( Sloan, RW, 1982)
" The ideal uricase inhibitor for induction of hyperuricemia would be one which is irreversible, noncompetitive, and relatively nontoxic, so that its activity would be independent of high levels of uric acid, and effective inhibition could be attained at low dosage levels."2.36Use of the uricase-inhibited rat as an animal model in toxicology. ( Nera, EA; Stavric, B, 1978)
"Gout is a painful and potentially crippling disorder."2.35The radiology of gout. Review article. ( Middlemiss, H; Watt, I, 1975)
"NAFLD was assessed using the Fibrosis-4 (Fib-4) index."1.91Improvement in hepatic fibrosis estimated by Fibrosis-4 index in pegloticase treated chronic refractory gout patients. ( Lipsky, PE; Rustgi, VK; Schlesinger, N; Yeo, AE, 2023)
"Gout is a common chronic inflammatory disorder due to monosodium urate deposition, which results in severe inflammatory arthritis."1.91The disproportionately large contribution of the Māori and Pacific Islander community to the healthcare burden of gout in Western Sydney. ( Cai, K; Han, J; Lam, C; Manolios, N; Mitchell, J; Ng, BCK; Spencer, D; Wong, PKK, 2023)
" Moreover, the PRS also revealed a dose-response trend between AH rates and quartile scores."1.91Genetic contributions to female gout and hyperuricaemia using genome-wide association study and polygenic risk score analyses. ( Chang, JG; Chang, SJ; Chang, YS; Chen, YC; Chung, CC; Huang, CM; Lin, CY; Liu, TY; Tsai, FJ, 2023)
"Gout is a common crystal induced disease of high personal and social burden, characterised by severe arthritis and comorbidity if untreated."1.91Genetic polymorphisms and decreased protein expression of ABCG2 urate transporters are associated with susceptibility to gout, disease severity and renal-overload hyperuricemia. ( Juhász, P; Kulin, A; Mózner, O; Nagy, K; Pálinkás, M; Poór, G; Rásonyi, R; Sarkadi, B; Szabó, E; Várady, G; Vörös, D; Zámbó, B, 2023)
"Chronic gout has an important impact on the daily life of patients and their families."1.91Living with gout. Experiences, impact and challenges of the disease. Qualitative study through focus groups. ( Díaz-Torné, C; Pou, MA; Pujol-Ribera, E; Rodríguez-Díez, B, 2023)
"Gout is a chronic disease caused by monosodium urate crystal deposition, typically affecting the big toe, midfoot, and ankle."1.91Gouty sacroiliitis: A case report of an often-overlooked cause of inflammatory back pain. ( Chen, SH; Guo, QH; Li, T; Lu, JG; Zheng, BL, 2023)
"Tophaceous gout is a common arthritis caused by the deposition of urate crystals and is related to limited joint function."1.91Interplay between fat, muscle, bone mass, and oteophytes and risk for tophaceous gout. ( Chen, YC; Hsu, CC; Hsu, CM; Huang, CC; Wu, RW, 2023)
"Gout is the most common inflammatory arthritis with an increasing prevalence and incidence across the globe."1.91Global status and trends in gout research from 2012 to 2021: a bibliometric and visual analysis. ( Han, Y; Li, W; Lin, Z; Wang, Y; Wu, H; Zhang, B, 2023)
"Gout is a chronic disease caused by monosodium urate crystal deposition."1.91Single-Cell Analysis in Blood Reveals Distinct Immune Cell Profiles in Gouty Arthritis. ( Chen, W; Chen, X; Gao, K; Huang, H; Huang, R; Mei, L; Wang, M; Wu, X; Yang, Z; Zhang, X, 2023)
"As pioglitazone is an insulin sens MSDC-itizer used for diabetes, its MPC inhibitory effect in diabetic individuals was investigated."1.91Inactivation of mitochondrial pyruvate carrier promotes NLRP3 inflammasome activation and gout development via metabolic reprogramming. ( Chen, CC; Chen, LC; Chen, YJ; Chien, WC; Chung, CH; Huang, CN; Huang, KY; Liao, NS; Lin, HA; Lin, HC; Lin, YY; Ojcius, DM; Shih, CT; Tsai, KJ; Wang, JY, 2023)
"Dimethyl fumarate (DMF) has shown anti-inflammatory and antioxidant activities."1.91Dimethyl fumarate attenuates MSU-induced gouty arthritis by inhibiting NLRP3 inflammasome activation and oxidative stress. ( Cao, Y; Hu, Y; Jin, XF; Liu, Y; Zou, JM, 2023)
"MSU-associated inflammation is majorly triggered by NOD-like receptor protein 3 (NLRP3) inflammasome that promotes interleukin (IL)-1β secretion."1.91Diallyl trisulfide inhibits monosodium urate-induced NLRP3 inflammasome activation via NOX3/4-dependent mitochondrial oxidative stress in RAW 264.7 and bone marrow-derived macrophages. ( Bang, E; Choi, YH; Hong, SH; Hwangbo, H; Ji, SY; Kim, DH; Kim, GY; Kim, MY; Lee, H; Park, C, 2023)
"Gout is considered uncommon among Black Africans."1.91Pattern of gout and its association with chronic kidney disease in Maiduguri, northeastern Nigeria. ( Adamu, AA; Sulaiman, MM; Yerima, A, 2023)
"Gout is associated with a higher risk of fracture; however, findings on the associations of hyperuricemia and urate-lowering therapy (ULT) with the risk of fracture have been inconsistent."1.91Lowering Serum Urate With Urate-Lowering Therapy to Target and Incident Fracture Among People With Gout. ( Choi, HK; Dalbeth, N; Lane, NE; Lei, G; Lyu, H; Wei, J; Wu, J; Zeng, C; Zhang, Y, 2023)
"Gout is the most common inflammatory rheumatic disease and elevated levels of serum urate (SU) are the main cause for its development."1.91Relationship between rs4349859 and rs116488202 polymorphisms close to MHC-I region and serum urate levels in patients with gout. ( Fernández-Torres, J; Martínez-Flores, K; Martínez-Nava, GA; Ruíz-Dávila, X; Sánchez-Sánchez, R; Zamudio-Cuevas, Y, 2023)
" We emulated a hypothetical trial comparing the rate of major adverse cardiovascular events (nonfatal myocardial infarction, nonfatal stroke, and cardiovascular death) among seven different strategies over 24 months."1.91Comparative Safety of Gout Treatment Strategies on Cardiovascular Outcomes Using Observational Data: Clone-censor-weight Target Trial Emulation Approach. ( Desai, RJ; Glynn, RJ; Kim, SC; Liu, J; Solomon, DH; Yoshida, K, 2023)
"BACKGROUND Spinal gout is not so uncommon."1.91Unusual Cause of Cord Compression in a Patient with Chronic Lymphocytic Leukemia. ( Gebreselassie, KZ; Kligora, C; Ranic, LM; Valancius, D, 2023)
"Uric acid is an emerging biomarker for cardiovascular morbidity and mortality, but its association with all-cause mortality and ECG findings remains unestablished, specifically among older adults."1.91Sex specific serum uric acid levels are associated with ischemic changes on ECG and with 20-year all-cause mortality among older adults. ( Chetrit, A; Dankner, R; Goldman, A; Moshkovits, Y, 2023)
"In 2017 to 2018, gout affected 12."1.91Trends in Prevalence of Gout Among US Asian Adults, 2011-2018. ( Choi, HK; Hsu, J; Joshi, AD; Lin, K; Lu, N; McCormick, N; Merriman, T; Raffield, LM; Saag, K; Tanikella, S; Warner, E; Yokose, C; Zhang, Y, 2023)
"In Japan, hyperuricemia is on the rise."1.91Effect of Dietary Counseling on Patients with Asymptomatic Hyperuricemia. ( Akiyama, M; Arai, H; Asai, T; Kawakami, Y; Koike, R; Kondo, R; Onishi, M, 2023)
"Gout is an inflammatory arthritis initiated by the deposition of monosodium urate crystals (MSU) around the joints and surrounding tissues."1.91A wild rice-derived peptide R14 ameliorates monosodium urate crystals-induced IL-1β secretion through inhibition of NF-κB signaling and NLRP3 inflammasome activation. ( Chanjitwiriya, K; Charoenwutthikun, S; Kunthalert, D; Roytrakul, S, 2023)
"Gout is caused by monosodium urate (MSU) crystal deposition within joints."1.91Monosodium urate crystals alter the circadian clock in macrophages leading to loss of NLRP3 inflammasome repression: Implications for timing of the gout flare. ( Alhilali, M; Dalbeth, N; Jain, L; Popov, D; Poulsen, RC, 2023)
"Uric acid has antioxidant and neuroprotective properties."1.91[The influence of uric acid on the course of amyotrophic lateral sclerosis]. ( Areprintseva, DK; Kutlubaev, MA; Pervushina, EV, 2023)
"Gout is a common metabolic rheumatic disease, and there have been no reports on the serum levels of interleukin (IL)-41 in gout patients."1.91Potential clinical value of serum interleukin-41 levels in patients with acute gout. ( Li, M; Li, Y; Meng, S; Shi, S; Wu, X; Zhao, H; Zhou, Y, 2023)
"Gout is a common metabolic disorder characterized by deposits of monosodium urate monohydrate crystals (tophi) in soft tissue, triggering intense and acute arthritis with intolerable pain as well as articular and periarticular inflammation."1.91Identification of tophi in ultrasound imaging based on transfer learning and clinical practice. ( Chang, CC; Chang, CK; Lee, HY; Lin, KH; Lin, TM; Peng, SJ; Wu, BF, 2023)
" Logistic regression was used to estimate the association between hyperuricemia and nephrolithiasis, and a restricted cubic spline (RCS) model was used to explore the dose-response relationship between SUA and the risk of nephrolithiasis."1.91Asymptomatic hyperuricemia associated with increased risk of nephrolithiasis: a cross-sectional study. ( Cheng, N; Deng, H; Hou, Z; Li, Y; Meng, Q; Song, C; Sun, Y; Wang, Q; Yin, J; Zhang, J; Zhang, X, 2023)
"Gout is a metabolic disease resulting from the accumulation of monosodium urate (MSU) in joints, leading to crystal-induced arthritis."1.91[Recommendations for the diagnosis and treatment of gout in China]. ( Lin, H; Xu, D; Zhao, Y; Zhu, XX; Zou, HJ, 2023)
"The Gout Impact Scale (GIS), part of the Gout Assessment Questionnaire 2."1.91Reliability and Validity of the Korean Version of the Gout Impact Scale. ( Kim, JY; Kim, MJ; Lee, JJ; Moon, KW; Shin, K, 2023)
"Gout is the most common inflammatory arthritis and closely related to metabolic syndrome, leading to excruciating pain and the decline in quality of patients' life."1.91Metabolomic analysis for asymptomatic hyperuricemia and gout based on a combination of dried blood spot sampling and mass spectrometry technology. ( Liu, S; Liu, Y; Liu, Z; Wu, X, 2023)
"Gout is the most common inflammatory arthritis and is almost exclusively managed in primary care, however the course and severity of the condition is variable and poorly characterised."1.91Cohort study investigating gout flares and management in UK general practice. ( Finnikin, S; Mallen, CD; Roddy, E, 2023)
"Gout is associated with lifestyle, body mass index (BMI) and comorbidities, including dyslipidaemia."1.91Lifestyle factors predict gout outcomes: Results from the NOR-Gout longitudinal 2-year treat-to-target study. ( Haavardsholm, EA; Hammer, HB; Karoliussen, LF; Kvien, TK; Sexton, J; Uhlig, T, 2023)
"And gout and hyperuricemia are also possible connection with cardiovascular disease and metabolic syndrome."1.72Triterpenoid acids from medicinal mushroom Inonotus obliquus (Chaga) alleviate hyperuricemia and inflammation in hyperuricemic mice: Possible inhibitory effects on xanthine oxidase activity. ( Dai, LJ; He, FX; Luo, LS; Wang, Y; Zhang, JL; Zhou, Q, 2022)
"The gouty ulcers were not completely healed by Day 14 compared with those in the PBS controls."1.72Gout-associated uric acid crystals induce tophi ulcerations and impair wound healing in a novel gouty ulcer model. ( Bao, W; Cheng, X; Jia, C; Su, Y; Wang, P; Xue, Y; Yin, B, 2022)
"Gout is the most common inflammatory arthritis, but was not considered in most COVID-19 and rheumatic diseases reports."1.72Gout during the SARS-CoV-2 pandemic: increased flares, urate levels and functional improvement. ( Burgos-Vargas, R; García-Maturano, JS; Gómez-Ruiz, C; Mosqueda-Gutiérrez, M; Peláez-Ballestas, I; Tafoya-Amado, A; Torres-Ordaz, DE; Vázquez-Mellado, A; Vázquez-Mellado, J, 2022)
"Melatonin (MLT) is a powerful endogenous anti-inflammatory agent and effective in reducing cellular damage."1.72Influence of Pinealectomy and Long-term Melatonin Administration on Inflammation and Oxidative Stress in Experimental Gouty Arthritis. ( Altinoz, E; Ballur, AFH; Bicer, Y; Demir, M; Elbe, H; Karayakali, M; Onal, MO; Yigitturk, G, 2022)
"The prevalence of nephrolithiasis, microhematuria, and proteinuria were 16."1.72Association of acidic urine pH with impaired renal function in primary gout patients: a Chinese population-based cross-sectional study. ( Chen, Y; Cui, L; Dalbeth, N; Feng, Z; He, Y; Ji, A; Ji, X; Li, C; Li, H; Li, X; Liu, Z; Lu, J; Merriman, TR; Mount, DB; Terkeltaub, R; Wang, X; Xu, Y; Xue, X, 2022)
"Pharmacological treatment of gout consists of treating acute flares with anti-inflammatory drugs and, if indicated, of urate lowering therapies (ULT)."1.72[Gout: an overview of diagnostics and treatment]. ( Flendrie, M; Jansen, TLTA; Janssen, M; Moses, A; Oude Voshaar, AMH; Peeters, IR; van Herwaarden, N, 2022)
"Our findings reinforce the need to treat gout early, before destruction of bone scaffold by extensive tophi, as MSU crystal dissolution by ULT may further weaken these areas and induce their collapse."1.72The shrinking toe sign in gout. ( Bardin, T; Bousson, V; Dalbeth, N; Do, MD; Ea, HK; Hieu, NL; Nguyen, QD; Resche-Rigon, M; Richette, P; Tran, KM, 2022)
"Recent studies showed that treatment of hyperuricemia did not affect the progression in chronic kidney disease (CKD) patients."1.72[Management of hyperuricemia in chronic kidney disease]. ( Auberson, M; Bonny, O; Livio, F; Schwotzer, N; So, A, 2022)
"Hyperuricemia was defined as a serum uric acid level of ≥7."1.72Association between serum uric acid and α-klotho protein levels in the middle-aged population. ( Choi, JY; Kim, D; Lee, HJ; Lee, J; Min, JY; Min, KB, 2022)
"Gout is usually found in patients with atrial fibrillation (AF)."1.72Kv1.5 channel mediates monosodium urate-induced activation of NLRP3 inflammasome in macrophages and arrhythmogenic effects of urate on cardiomyocytes. ( Higaki, K; Hisatome, I; Kurata, Y; Kuwabara, M; Lanaspa, MA; Li, P; Ninomiya, H; Shirayoshi, Y; Taufiq, F; Tsuneto, M, 2022)
"Nonalcoholic fatty liver disease (NAFLD) and chronic kidney disease (CKD) share common pathogenic mechanisms and risk factors."1.72The Negative Association Between NAFLD Severity and CKD in a Non-Diabetic Gouty Population. ( Chen, Y; Chi, J; Huang, Y; Lv, W; Wang, Y; Zhou, Y, 2022)
"Gout is a disease that manifests itself after decades of following a high-purine diet, with excessive alcohol consumption assumed to be one of the main contributors to the development of the disease."1.72The Relationship between Alcohol Consumption and Gout: A Mendelian Randomization Study. ( Chen, H; Chen, J; Fahira, A; Li, Z; Shi, Y; Syed, AAS; Yang, Q, 2022)
"Gout is the most common inflammatory arthritis in men with a rising incidence worldwide."1.72[Gout]. ( Tausche, AK, 2022)
"In the reverse direction analysis, genetic predisposition to both urate and gout were not associated with PA being investigated."1.72Genetically predicted physical activity is associated with lower serum urate concentrations. ( Chen, D; Guan, Y; Li, Y; Meng, L; Qian, Q; Wang, T; Wei, J, 2022)
"Gout is caused by deposition of monosodium urate (MSU) crystals."1.72Investigation on monosodium urate deposition in the first metatarsophalangeal joint and ankle of primary gout patients using dual-energy computed tomography. ( Nam, VT; Quoc, TAH; Tam, V, 2022)
"Gout is a common arthritis caused by deposition of monosodium urate crystals."1.72Natural Adrenocorticotropic Hormone (ACTH) Relieves Acute Inflammation in Gout Patients by Changing the Function of Macrophages. ( Cao, L; Liu, J; Wan, W; Xu, R; Xuan, D; Xue, Y; Yu, Y; Zhao, L; Zhao, T; Zou, H, 2022)
"Gout is the most common form of inflammatory arthritis in men."1.72Persistence with urate-lowering therapy in Australia: A longitudinal analysis of allopurinol prescriptions. ( Aung, E; Caillet, V; Coleshill, MJ; Cronin, P; Day, RO; Kannangara, DRW; Kouhkamari, M; Rodgers, A; Stocker, SL; Tam, K, 2022)
"Gout is a chronic disease caused by monosodium urate (MSU) crystal deposition in the joints and surrounding tissues."1.72Taxifolin blocks monosodium urate crystal-induced gouty inflammation by regulating phagocytosis and autophagy. ( Jiang, YJ; Lian, LH; Nan, JX; Piao, MH; Wang, H; Wu, YL, 2022)
"Gout is a common inflammatory arthritis caused by precipitation of monosodium urate (MSU) crystals in individuals with hyperuricemia."1.72TET2-mutant clonal hematopoiesis and risk of gout. ( Agrawal, M; Bick, AG; Cunin, P; Ebert, BL; Gibson, CJ; Griffin, GK; Jaiswal, S; Kim, PG; Lin, AE; McConkey, M; Miller, PG; Natarajan, P; Neuberg, D; Nigrovic, PA; Niroula, A; Rao, DA; Schaefer, IM; Sekar, A; Shkolnik, V; Stone, RM; Uddin, MM; Weeks, LD; Wong, WJ, 2022)
"Hyperuricemia was associated with greater NLRP3 and gasdermin-D expression on human atheroma plaques in patients with peripheral artery disease."1.72Birefringent crystals deposition and inflammasome expression in human atheroma plaques by levels of uricemia. ( Andrés, M; Argente-Del-Castillo, E; Mendieta, L; Miñano, A; Pascual, E; Trigueros, M, 2022)
"Gout is the most common cause of inflammatory arthritis in adults."1.72Monosodium urate deposition in the lumbosacral spine of patients with gout compared with non-gout controls: A dual-energy CT study. ( Becce, F; Fields, T; Mechlin, M; Oh, C; Pillinger, MH; Toprover, M, 2022)
"Gout is of unknown reason associated with cardiovascular disease."1.72Urate crystal deposition is associated with inflammatory markers and carotid artery pathology in patients with intercritical gout: results from the NOR-Gout study. ( Haavardsholm, EA; Hammer, HB; Jensen, G; Karoliussen, LF; Kvien, TK; Rollefstad, S; Semb, AG; Terslev, L; Uhlig, T, 2022)
"Gout is a self-limiting inflammatory arthritis mediated by the precipitation of monosodium urate (MSU) crystals that further activate the NLRP3 inflammasome and initiate a cascade of inflammatory events."1.72Monosodium urate crystals with controlled shape and aspect ratio for elucidating the pathological progress of acute gout. ( Chen, C; Fu, D; Ge, D; Guo, Y; Li, M; Liang, Z; Liu, Y; Sun, B; Wang, J; Yang, X; Zhang, L, 2022)
"Gout is an inflammatory joint disease caused by urate crystal deposition, which is associated with hyperuricemia."1.72Study on the interaction mechanism between luteoloside and xanthine oxidase by multi-spectroscopic and molecular docking methods. ( Cao, X; Chen, J; Cheng, Y; Liu, J; Pan, X; Wang, Y, 2022)
"Gout is a highly hereditary disease, but not all those carrying well-known risk variants have developing gout attack even in hyperuricemia status."1.72Polygenic risk score trend and new variants on chromosome 1 are associated with male gout in genome-wide association study. ( Chang, JG; Chang, SJ; Chang, YS; Chen, YC; Chung, CC; Huang, CM; Lin, CY; Liu, TY; Tsai, FJ, 2022)
"Gout is one of the most common inflammatory arthritis, where identification of MSU crystals in synovial fluid is a widely used diagnostic measure."1.72The Role of Ultrasound in Evaluating the Effect of Urate-lowering Drugs in Gout Patients. ( El Attar, EA; El-Mallah, R; Ibrahim, RA, 2022)
"Gout is a painful form of inflammatory arthritis characterized by the deposition of monosodium urate (MSU) crystals in the joints."1.72The Therapeutic Effect of Phosphopeptide P140 Attenuates Inflammation Induced by Uric Acid Crystals in Gout Arthritis Mouse Model. ( Aganetti, M; Amaral, FA; Braga, AD; de Faria, AMC; de Oliveira, VLS; Galvão, I; Georgel, P; Martins, VD; Mastrippolito, D; Mendes, V; Muller, S; Rocha, V; Talamini, L; Verdot, C; Vieira, AT, 2022)
"Gout is caused by elevated serum urate leading to the deposition of monosodium urate (MSU) crystals that can trigger episodes of acute inflammation."1.72Uricase-Deficient Larval Zebrafish with Elevated Urate Levels Demonstrate Suppressed Acute Inflammatory Response to Monosodium Urate Crystals and Prolonged Crystal Persistence. ( Astin, JW; Dalbeth, N; Hall, CJ; Linnerz, T; Rolland, L; Sung, YJ, 2022)
"Gout is a common inflammatory disease."1.72Lipoxin A4 attenuates MSU-crystal-induced NLRP3 inflammasome activation through suppressing Nrf2 thereby increasing TXNRD2. ( Chen, Y; Guo, X; Xia, H; Xu, L; You, CG; Zhao, M; Zhong, X; Zhou, Y, 2022)
"Hyperuricemia and gout have become gradually more common."1.72Associations between serum urate and telomere length and inflammation markers: Evidence from UK Biobank cohort. ( Cui, J; Lv, Z; Zhang, J, 2022)
"Meanwhile, untreated hyperuricemia was also suggested to lead to hypertension."1.72Increased Systolic Blood Pressure Mediates the Relationship Between Urate and Gout Risk in Indonesia: A Novel Application of a Partial Least Squares-Structural Equation Model. ( Dyah Kurniasari, M; Huruta, AD; Karwur, FF; Lin, YH; Rayanti, RE; Tsai, HT; Weng, SF, 2022)
"Gout is the most common form of inflammatory arthritis, caused by the deposition of monosodium urate (MSU) crystals in peripheral joints and tissue."1.62X-ray dark-field radiography for in situ gout diagnosis by means of an ex vivo animal study. ( Andrejewski, J; Birnbacher, L; Braig, EM; Busse, M; Herzen, J; Kimm, MA; Korbel, R; Petrich, C; Pfeiffer, D; Roiser, N; Sauter, A; Scholz, J, 2021)
"BACKGROUND Gout is a chronic disease characterized by deposition of monosodium urate crystals, typically manifesting as arthritis."1.62Gout Storm. ( Cardoso Nóbrega, V; Curcelli, EC; Junior, LAJ; Luiz da Silva, D; Martins, D; Matchil, NL; Okoshi, MP; Pacca, RL; Padovani de Toledo Moraes, M; Padovese, V; Pereira, FWL; Queiroz, DS; Silva, AM; Tonon, CR, 2021)
"Pretreatment with baricitinib, which blocks IL-6 receptor signaling, prevented MSU-induced cleaved caspase-1 or IL-1β induction in IL-6-primed neutrophils."1.62Uric acid-mediated inflammasome activation in IL-6 primed innate immune cells is regulated by baricitinib. ( Asano, T; Fujita, Y; Furuya, MY; Kawakami, A; Kozuru, H; Matsumoto, H; Matsuoka, N; Migita, K; Sato, S; Temmoku, J; Urano, T; Watanabe, H; Yatsuhashi, H, 2021)
" The lower risk of incident HTN after xanthine oxidase inhibitors exhibited a significant dose-response trend."1.62Urate-lowering therapy exerts protective effects against hypertension development in patients with gout. ( Hsu, CC; Hwu, CM; Li, HL; Lin, KH; Wei, JC; Yang, CC; Yen, FS, 2021)
"Gout is the most common inflammatory arthritis affecting 1."1.62Treat-to-Target urate-lowering therapy in primary gout patients: A real-world retrospective study at a dedicated gout clinic in China. ( Bai, XS; Cui, LL; He, YW; Li, CG; Li, XD; Qu, XJ; Sun, MS; Wang, C; Wang, M; Zhao, XD, 2021)
"Gout is the most common form of inflammatory arthritis in men, yet both patients and the public often do not recognise gout as a form of arthritis."1.62Rebranding Gout: Could a Name Change for Gout Improve Adherence to Urate-Lowering Therapy? ( Aung, E; Carland, JE; Coleshill, MJ; Day, RO; Faasse, K; Stocker, S, 2021)
"Gout is a complex inflammatory arthritis affecting ~20% of people with an elevated serum urate level (hyperuricemia)."1.62Trans-ancestral dissection of urate- and gout-associated major loci SLC2A9 and ABCG2 reveals primate-specific regulatory effects. ( Bixley, M; Cadzow, M; Choi, HK; Dalbeth, N; Guo, H; He, M; Hu, H; Li, C; Li, Z; Major, TJ; Markie, D; Merriman, TR; Phipps-Green, A; Shi, Y; Stamp, LK; Takei, R; Wei, WH, 2021)
"Gout was commonly observed in middle-aged men."1.62A Study of Metabolic Parameters in Patients with Gout: A Single Center Study from Nepal. ( Baral, R; Bhochhibhoya, M; Joshi, R; Lama, LD; Nakarmi, S; Vaidya, B, 2021)
"Thus, hyperuricemia is associated with impaired endothelial function."1.62Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease - Japanese Guideline on the Management of Asymptomatic Hyperuricemia. ( Bahrudin, U; Hisatome, I; Kuwabara, M; Li, P; Maharani, N; Mahati, E; Miake, J; Ninomiya, H; Taufiq, F; Utami, SB, 2021)
"Gout is the most common inflammatory arthritis in adults."1.62Non-alcoholic fatty kidney disease (NAFKD): A novel disease that explains the etiology of hyperuricemia and gout in metabolic syndrome. ( Abrahim, M, 2021)
"Gout is a common metabolic disease with growing burden, caused by monosodium urate (MSU) microcrystal deposition."1.62Highly specific and label-free histological identification of microcrystals in fresh human gout tissues with stimulated Raman scattering. ( Ao, J; Chen, J; Hua, Y; Ji, M; Xu, H; Xue, Y; Yang, Y; Zhang, B; Zhu, X, 2021)
"Studies show that hyperuricemia is an element of the pathophysiology of many conditions."1.62How Are We Managing Patients with Hyperuricemia and Gout: A Cross Sectional Study Assessing Knowledge and Attitudes of Primary Care Physicians? ( Bozic, J; Rada, M; Rumboldt, M; Rumboldt, Z; Rusic, D; Tomicic, M; Zuzic Furlan, S, 2021)
"Gout is the most common inflammatory arthritis in men with a rising incidence worldwide."1.62[Gout]. ( Tausche, AK, 2021)
"In the reverse direction analysis, genetic predisposition to both urate and gout were not associated with T2D or any of 4 glycemic traits being investigated."1.62Genetic Predisposition to Type 2 Diabetes and Insulin Levels Is Positively Associated With Serum Urate Levels. ( Fan, J; Li, Y; Sun, L; Tse, LA; Yang, J; Zhu, J, 2021)
"Gout is often not adequately treated, and we aimed to apply urate lowering treatment (ULT) combined with individual information to achieve target serum urate (sUA) in clinical practice, and to identify predictors of achievement of this sUA target."1.6212-month results from the real-life observational treat-to-target and tight-control therapy NOR-Gout study: achievements of the urate target levels and predictors of obtaining this target. ( Borgen, T; Haavardsholm, EA; Hammer, HB; Karoliussen, LF; Kvien, TK; Sexton, J; Uhlig, T, 2021)
"Patients with gout have an increased risk of urolithiasis and usually need urate-lowering therapy (ULT) for the prevention of disease progression."1.62Association of urate-lowering drugs with the risk of future urolithiasis in patients with gout: A population-based nested case-control study. ( Cheng-Chung Wei, J; Liu, CY; Wang, YH; Wu, SW; Yeh, CJ, 2021)
"Gout is a multifaceted inflammatory disease involving vascular impairments induced by hyperuricemia."1.62Gout-induced endothelial impairment: The role of SREBP2 transactivation of YAP. ( He, M; Li, X; Shi, W; Shyy, JY; Wang, L; Zhang, Y; Zhao, Y; Zhao, Z, 2021)
"Hyperuricemia is closely associated with insulin resistance syndrome (and its many cardiometabolic sequelae); however, whether they are causally related has long been debated."1.62Assessing the Causal Relationships Between Insulin Resistance and Hyperuricemia and Gout Using Bidirectional Mendelian Randomization. ( Choi, HK; Leong, A; McCormick, N; Merriman, TR; Mount, DB; O'Connor, MJ; Yokose, C, 2021)
"Gout is an inflammatory disease triggered by deposition of monosodium urate (MSU) crystals in the joints, resulting in high neutrophil influx and pain."1.62CD300a contributes to the resolution of articular inflammation triggered by MSU crystals by controlling neutrophil apoptosis. ( Galvão, I; Levi-Schaffer, F; Queiroz-Junior, CM; Teixeira, MM; Valiate, BVS, 2021)
"Gout is a metabolically-related joint disease, characterized by recurrent episodic arthritis."1.62Non-pharmacological treatment of gout. ( Líška, D, 2021)
"• Enthesopathy is most frequently involved in the patellar insertion of the quadriceps tendon in gout."1.62Entheseal involvement of the lower extremities in gout: an ultrasonographic descriptive observational study. ( Cao, H; Liang, J; Lin, J; Xu, G; Yang, Y; Ye, Z; Zhu, G, 2021)
"Patients with hyperuricemia are among the high-risk group of postoperative gout attacks."1.62Factors Influencing Early Serum Uric Acid Fluctuation After Bariatric Surgery in Patients with Hyperuricemia. ( Fu, L; Liu, Y; Wen, J; Xu, C; Yan, T; Yang, H; You, Y; Yu, J; Zhan, D; Zhang, T, 2021)
"Comparative analysis with obesity, type 2 diabetes, ankylosing spondylitis and rheumatoid arthritis indicated that gout metagenomes were more similar to those of autoimmune than metabolic diseases."1.62Metagenomic analysis revealed the potential role of gut microbiome in gout. ( Bai, X; Chen, X; Chu, Y; Ding, F; Fang, X; Gao, Q; He, X; Huang, Q; Huang, R; Huang, Y; Jiang, Y; Li, J; Liang, L; Sun, S; Wang, M; Wang, P; Wang, Z; Wei, X; Wu, J; Wu, X; Xie, X; Yang, J; Yue, Z; Zhang, Y; Zhao, Y; Zhou, C, 2021)
"Gout is a recurrent and chronic form of arthritis caused by the deposition of monosodium urate (MSU) crystals in the joints."1.62Lower Temperatures Exacerbate NLRP3 Inflammasome Activation by Promoting Monosodium Urate Crystallization, Causing Gout. ( Ahn, H; Lee, G; Lee, GS, 2021)
"Gout has significant impact on the quality of life with over-utilisation of health resources."1.56Burden and management of gout in a multi-ethnic Asian cohort. ( Cheung, PP; Chua, CKT; Lim, AYN; Santosa, A; Teng, GG, 2020)
"Gout and hyperuricemia are common public health problem."1.56The prevalence of gout and hyperuricemia in middle-aged and elderly people in Tibet Autonomous Region, China: A preliminary study. ( Baima, Y; Gong, H; Lin, C; Lin, J; Liu, Q; Wang, Y; Zhang, Q, 2020)
"Currently, the treatment of gout mainly includes two basic methods: reducing uric acid and alleviating inflammation."1.56Development of novel NLRP3-XOD dual inhibitors for the treatment of gout. ( Ha, EH; Hu, Q; Li, H; Li, Z; Pang, J; Tian, S; Wang, W; Zhou, M, 2020)
"Gout is a common arthritis caused by monosodium urate crystals."1.56Contribution of Rare Variants of the ( Anzai, N; Hasegawa, T; Jutabha, P; Kawai, Y; Kojima, K; Matsuo, M; Misawa, K; Mishima, E; Nagasaki, M; Ouchi, M, 2020)
"Final diagnosis was FHL tendonitis secondary to gout proven by synovial fluid analysis."1.56Gout in the Flexor Hallucis Longus Tendon Mimicking Cellulitis: A Case Report. ( Ishimaru, N; Kanzawa, Y; Kinami, S; Ohnishi, J; Seto, H, 2020)
"Gout is increasing in prevalence despite effective pharmacotherapies."1.56Better outcomes for patients with gout. ( Aung, E; Coleshill, M; Day, R; Graham, G; Nguyen, A; Stocker, S, 2020)
"Gout is characterised by severe interleukin (IL)-1-mediated joint inflammation induced by monosodium urate crystals."1.56Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout. ( Arts, P; Cavalli, G; Cleophas, MC; Crișan, TO; Dagna, L; Dalbeth, N; Dinarello, CA; Eisenmesser, EZ; Gilissen, C; Hindmarsh, JH; Hoischen, A; Jansen, TLTA; Janssen, M; Joosten, LA; Kim, S; Klück, V; Lelieveld, S; Merriman, TR; Netea, MG; Riches, P; Shaukat, A; Stamp, LK; Steehouwer, M; Tausche, AK; Van de Veerdonk, FL; van de Vorst, M; van Deuren, RC, 2020)
"Gout is the most common inflammatory arthritis and the worldwide incidence is increasing."1.56Identification of the urine and serum metabolomics signature of gout. ( Cao, S; Chen, Z; Gu, J; Huang, Y; Jiang, Y; Lv, Q; Ou, J; Qi, J; Qiu, M; Tu, L; Wei, Q; Wu, J; Xiao, M; Zhang, X, 2020)
"Gout is a painful form of inflammatory arthritis associated with several comorbidities, particularly cardiovascular disease."1.56Effect of tart cherry juice on risk of gout attacks: protocol for a randomised controlled trial. ( Barker, ME; Lamb, KL; Lynn, A; Russell, J, 2020)
"Gout is the typical feature of GAstrV infection in goslings."1.56Goose astrovirus infection affects uric acid production and excretion in goslings. ( Bao, E; Lv, Y; Wu, W; Xu, R, 2020)
"Hyperuricemia is a central risk factor for gout and increases the risk for other chronic diseases, including cardiometabolic disease, kidney disease, and hypertension."1.56High-Protein Diet Induces Hyperuricemia in a New Animal Model for Studying Human Gout. ( Dai, S; Guo, Y; Hong, F; Li, L; Liu, G; Pan, S; Qiao, X; Wang, J; Xie, X; Xu, P; Xue, T; Zhai, Y; Zheng, A, 2020)
" Further investigations are required to confirm the present results following multiple dosing with febuxostat."1.56A pharmacokinetic-pharmacodynamic study of a single dose of febuxostat in healthy subjects. ( Carland, JE; Day, RO; Graham, GG; Kamel, B; Liu, Z; Pile, KD; Stocker, SL; Williams, KM, 2020)
"Hyperuricemia and gout are common in patients with heart failure (HF) and are associated with poor outcomes."1.56Comparison of Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction With Versus Without Hyperuricemia or Gout. ( Andersson, K; Bjursell, M; Carnicelli, AP; Chiswell, K; Clare, R; Hedman, K; Lytle, B; Mentz, RJ; Pagidipati, N; Perl, S; Roe, MT; Vemulapalli, S, 2020)
"Gout is an inflammatory disease caused by monosodium urate (MSU) crystals."1.56In Vivo Transmigrated Human Neutrophils Are Highly Primed for Intracellular Radical Production Induced by Monosodium Urate Crystals. ( Björkman, L; Buck, A; Bylund, J; Christenson, K; Dahlstrand Rudin, A; Davidsson, L; Sanchez Klose, FP, 2020)
"Allopurinol treatment significantly reduced MAGE (4."1.56Blood glucose fluctuations detected by continuous glucose monitoring system in gout patients with normal glucose tolerance and the effect of urate-lowering therapy. ( Chen, Y; Dong, B; Lv, W; Mu, Z; Wang, F; Wang, J; Wang, W; Wang, Y; Wang, Z; Zhao, Y, 2020)
"Gout is a crystal associated arthritis caused by monosodium urate (MSU) accumulating in joint, and it belongs to metabolic rheumatic disease."1.56[Recommendations of diagnosis and treatment of gout in China]. ( Gu, JR; Xu, D; Zeng, XF; Zeng, XJ; Zhao, Y; Zhou, JG; Zhu, XX; Zou, HJ, 2020)
" The effect of uricosuric agents on the decrease in hospitalized stroke risk indicated a dose-response relationship."1.56Urate-lowering therapy may mitigate the risks of hospitalized stroke and mortality in patients with gout. ( Hsu, CC; Hwu, CM; Li, HL; Wei, JC; Yen, FS, 2020)
"Gout is an inflammatory arthritis caused by the phagocytosis of monosodium urate (MSU) crystal deposition in joints."1.56EPS8 regulates an NLRP3 inflammasome-independent caspase-1 activation pathway in monosodium urate crystal-treated RAW264.7 macrophages. ( Chuang, JP; Kao, CY; Lee, JC; Leu, TH; Ling, P; Maa, MC, 2020)
"Gout is a heterogeneous inflammatory disease with numerous clinical manifestations."1.56Development of a multivariable improvement measure for gout. ( Edwards, NL; Lipsky, PE; Schlesinger, N; Yeo, AE, 2020)
"Gout is a multisystem disease that may present in different ways."1.56A leg ulcer with hard, yellow projections. ( Azevedo, F; Baudrier, T; Cerejeira, A; Gomes, N; Lopes, JM; Moura, CS, 2020)
"Gout is the most prevalent inflammatory arthritis in adults."1.56Association between Gout, Urate-Lowering Therapy, and Risk of Developing Type 2 Diabetes Mellitus: A Nationwide Population-Based Retrospective Cohort Study. ( Chung, YL; Fang, YJ; Lim, YP; Lin, CL, 2020)
"Gout is a serious medical, social and economic problem of today."1.56[INDICATORS OF GOUT INTERLAYKINS AND THERMOGRAPHY OF JOINTS ON THE BACKGROUND OF ENTEROSORBTION THERAPY]. ( Andreychyn, S; Hanberher, I; Korylchuk, N; Mudra, U, 2020)
"Nevertheless, gout is a "curable disease" by ULT, a treatment which in adequate doses may also have positive effect on several associated co-morbidities."1.56[Consequences of Gout and Hyperuricemia]. ( Bengtsson Boström, K; Dehlin, M; Forsblad d'Elia, H; Jacobsson, L; Kapetanovic, M; Sigurdardottir, V; Svärd, A; Wändell, P, 2020)
"Gout has a prevalence of 1."1.56[Gout - a common and well known disease]. ( Bengtsson Boström, K; Dehlin, M; Forsblad d'Elia, H; Jacobsson, L; Kapetanovic, M; Sigurdardottir, V; Svärd, A; Wändell, P, 2020)
"Gout was defined by the diagnosis codes in CDARS."1.56Epidemiology of gout in Hong Kong: a population-based study from 2006 to 2016. ( Cheung, BMY; Cheung, TT; Chung, MH; Lau, CS; Tsoi, MF, 2020)
"Patients with gout are at a higher risk of cardiovascular disease, which is associated with hyperlipidemia."1.56Effects of Urate-Lowering Therapy on Risk of Hyperlipidemia in Gout by a Population-Based Cohort Study and on ( Chung, YL; Fang, YJ; Li, JR; Lim, YP; Lin, CL; Su, CY; Tien, N; Wu, TY, 2020)
"Acute gout is an inflammatory response induced by monosodium urate (MSU) crystals."1.56HSP60 Regulates Monosodium Urate Crystal-Induced Inflammation by Activating the TLR4-NF- ( Gao, W; Huang, Q; Liu, J; Long, F; Mu, H; Qin, T; Ren, L; Tang, H; Zeng, M, 2020)
"Gout is a crystal-related arthropathy resulting from the deposition of monosodium urate."1.56Progress in Treatment of Gout Using Chinese and Western Medicine. ( Wang, X; Wang, YG, 2020)
"Although gout is the most common inflammatory arthritis, it is still frequently misdiagnosed."1.562018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. ( Bardin, T; Barskova, V; Becce, F; Castaneda, J; Coyfish, M; Doherty, M; Guillo, S; Jansen, T; Janssens, H; Lioté, F; Mallen, CD; Nuki, G; Pascual, E; Perez-Ruiz, F; Pimentao, J; Punzi, L; Pywell, A; Richette, P; So, AK; Tausche, AK; Tubach, F; Uhlig, T; Zavada, J; Zhang, W, 2020)
"Gout is common crystal arthritis that is often managed sub-optimally."1.56Management of patients with gout and achievement of target serum urate levels at a tertiary rheumatology service in Australia. ( Bavanendrakumar, M; Robinson, PC, 2020)
"For instance, hypertension is found in 36-41% gout patients, and combined with metabolic syndrome it may reach 80%."1.51Role of immune system in development and progress of combined arterial hypertension and gout. ( Bychkov, ОА; Bychkova, NG; Bychkova, SA; Kondratiuk, VE; Morozova, ZV; Tarasiuk, AP, 2019)
"Curcumin treatment markedly inhibited the degradation of IκBα, the activation of NF-κB signaling pathway, and the expression levels of the NF-κB downstream inflammatory genes such as IL-1β, IL-6, TNF-α, COX-2, and PGE2 in the MSU-stimulated THP-1-derived macrophages."1.51Curcumin attenuates MSU crystal-induced inflammation by inhibiting the degradation of IκBα and blocking mitochondrial damage. ( Chen, B; Li, H; Ou, G; Ren, L; Yang, X; Zeng, M, 2019)
"The prevalence of gout has increased in recent decades."1.51Dual-Energy Computed Tomography Detection of Cardiovascular Monosodium Urate Deposits in Patients With Gout. ( Bellmann-Weiler, R; Feuchtner, G; Gruber, J; Halpern, EJ; Jaschke, W; Klauser, AS; Stofferin, H; Strobl, S; Weiss, G, 2019)
"Gout is a prevalent and incapacitating disease triggered by the deposition of monosodium urate (MSU) crystals in joints, which are also massively infiltrated by neutrophils."1.51Cytokine Production and NET Formation by Monosodium Urate-Activated Human Neutrophils Involves Early and Late Events, and Requires Upstream TAK1 and Syk. ( de Carvalho Oliveira, V; Dubois, CM; Isabel, M; Mayer, TZ; McDonald, PP; Sylvain-Prévost, S; Tatsiy, O, 2019)
"Gout is independently associated with increased risk of type 2 diabetes mellitus (T2DM)."1.51Associations between urate-lowering therapy and the risk of type 2 diabetes mellitus. ( Chang, HW; Lan, YC; Lin, MH; Lin, YW; Wang, RY, 2019)
"Hyperuricemia was defined as having a serum urate level of >7."1.51Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016. ( Chen-Xu, M; Choi, HK; Pillinger, MH; Rai, SK; Yokose, C, 2019)
"Gout was present in 6768 (4."1.51Interactions between serum urate-associated genetic variants and sex on gout risk: analysis of the UK Biobank. ( Cadzow, M; Dalbeth, N; Gamble, G; Merriman, TR; Narang, RK; Stamp, LK; Topless, R, 2019)
"Gout is a common inflammatory arthritis associated with adverse clinical outcomes."1.51Prevalence and treatment of gout among patients with chronic kidney disease in the Irish health system: A national study. ( Adeeb, F; Browne, LD; Fraser, AD; Kumar A U, A; Mohammed, E; Stack, AG, 2019)
"Gout is a disease driven solely by IL-1β secretion in response to monosodium urate (MSU) crystals which form during periods of hyperuricemia and thus presents an opportunity to study factors contributing to IL-1β secretion."1.51Secretion of IL-1β From Monocytes in Gout Is Redox Independent. ( Alberts, BM; Basnayake, K; Bruce, C; Davies, KA; Ghezzi, P; Mullen, LM, 2019)
"Gout is the most common inflammatory arthritis worldwide, and patients experience a heavy burden of cardiovascular and metabolic diseases."1.51mTOR inhibition by metformin impacts monosodium urate crystal-induced inflammation and cell death in gout: a prelude to a new add-on therapy? ( Broen, JCA; Jansen, M; Merriman, T; Ottria, A; Phipps-Green, A; Radstake, TRDJ; Schuiveling, M; van der Linden, M; van Lochem, E; Vazirpanah, N; Wichers, CGK; Zimmermann, M, 2019)
"Hyperuricemia was identified in 30."1.51Hyperuricemia and acute gout after laparoscopic sleeve gastrectomy. ( Katsogridaki, G; Magouliotis, D; Perivoliotis, K; Sioka, E; Tasiopoulou, V; Tzovaras, G; Zachari, E; Zacharoulis, D, 2019)
"Gout is one of the most common metabolic disorders in human."1.51Alpha2B-Adrenergic Receptor Regulates Neutrophil Recruitment in MSU-Induced Peritoneal Inflammation. ( Chen, J; Duan, L; Rao, X; Razavi, M; Tao, Y; Wei, Y; Zhong, J, 2019)
"Spinal gout is rarely encountered in clinical practice, is easily misdiagnosed, and often remains undiagnosed."1.51Diagnostic challenges of spinal gout: A case series. ( An, Q; Gu, R; Jiang, R; Ma, S; Zhao, J, 2019)
"Acute gout is an inflammatory response to MSU crystals."1.51Sirt1 ameliorates monosodium urate crystal-induced inflammation by altering macrophage polarization via the PI3K/Akt/STAT6 pathway. ( Liu, L; Xue, Y; Yu, Y; Zhao, T; Zhu, X; Zou, H, 2019)
"Gout was associated with higher risk of venous thromboembolism compared with controls (absolute rate 37."1.51Venous thromboembolism in patients with gout and the impact of hospital admission, disease duration and urate-lowering therapy. ( Clarson, L; Mallen, C; Muller, S; Roddy, E; Sultan, AA; Whittle, R, 2019)
"People with gout are at an increased risk of readmission for heart failure and have longer hospital stays."1.51Associations of Gout and Baseline Serum Urate Level With Cardiovascular Outcomes: Analysis of the Coronary Disease Cohort Study. ( Doughty, RN; Drake, J; Frampton, C; Richards, AM; Stamp, LK; Troughton, RW, 2019)
"Thus, AE may be a potential treatment for hyperuricemia and gout."1.51Anti-hyperuricemic effect of Alpinia oxyphylla seed extract by enhancing uric acid excretion in the kidney. ( Kim, DS; Kim, JS; Lee, S; Lee, YS; Son, E; Sung, YY; Yuk, HJ, 2019)
"Gout is sterile joint inflammation triggered by the damaging effects of monosodium urate (MSU) crystals accumulation."1.51Downregulation of Transcription Factor T-Bet as a Protective Strategy in Monosodium Urate-Induced Gouty Inflammation. ( He, YL; Mi, QS; Yang, QB; Zhang, QB; Zhou, JG, 2019)
"Among treated gout patients, 76% were receiving allopurinol at a mean dose lower than 200mg/d, most without any further change of dose regimen over one year."1.48Persistent clinical inertia in gout in 2014: An observational French longitudinal patient database study. ( Flipo, RM; Hincapie, N; Lioté, F; Maravic, M; Pilet, S, 2018)
"2% were aware of first-line pharmacological management options; 28% answered the correct dosing regimen for colchicine."1.48A survey on the beliefs and knowledge of gout management in new medical graduates - New South Wales, Australia. ( Riordan, J; Terrill, M, 2018)
"Gout is a multifactorial disease characterized by acute inflammatory arthritis, and it is caused as a consequence of hyperuricemia."1.48A common variant of MAF/c-MAF, transcriptional factor gene in the kidney, is associated with gout susceptibility. ( Higashino, T; Hishida, A; Imaki, J; Kawaguchi, M; Komatsu, M; Matsuo, H; Nakashima, H; Nakatochi, M; Nakayama, A; Okada, Y; Ooyama, H; Sakiyama, M; Shimizu, S; Shinomiya, N; Tadokoro, S, 2018)
"His uric acid was 11 mg/dL despite maximal dosing of febuxostat."1.48Effective uric acid reduction with probenecid and febuxostat in a patient with chronic kidney disease. ( Case, R; Jester, G; Wentworth, B, 2018)
"This is a cross-sectional study of untreated gout subjects (n = 34) and non-gout healthy controls (n = 64)."1.48Impaired arterial responsiveness in untreated gout patients compared with healthy non-gout controls: association with serum urate and C-reactive protein. ( Bang, D; Dektiarev, I; Guo, Y; Igel, TF; Katz, SD; Krasnokutsky, S; Pike, VC; Pillinger, MH; Romero, AG; Shah, B; Zhong, J, 2018)
"Gout is the most common inflammatory arthritis affecting men."1.48Blocking fatty acid-fueled mROS production within macrophages alleviates acute gouty inflammation. ( Ashimbayeva, E; Astin, JW; Britto, D; Crosier, KE; Crosier, PS; Dalbeth, N; Hall, CJ; Harper, JL; Lawrence, LM; Lieschke, GJ; Pool, B; Sanderson, LE; van der Kroef, M, 2018)
"Gout is a disabling and common arthritis with increasing prevalence."1.48[Gout - a treatable condition]. ( Gudbjornsson, B; Johannsdottir, GA; Jonsson, H; Palsson, O, 2018)
"Gout is an inflammatory arthritis characterized by abrupt self-limiting attacks of inflammation caused by precipitation of monosodium urate crystals (MSU) in the joint."1.484-(2-(4-chlorophenyl)-1-((4-chlorophenyl)amino)ethyl)benzene-1, 3-diol is a potential agent for gout therapy as a dual inhibitor of XOD and NLRP3. ( Hu, Q; Li, S; Liu, W; Song, L; Zhou, M, 2018)
"Ethnicity and hypertension are predictive of gout risk, and the associations cannot be fully explained by serum urate."1.48Untangling the complex relationships between incident gout risk, serum urate, and its comorbidities. ( Gaffo, AL; Los Campos, G; Merriman, TR; Reeves, M; Reynolds, RJ; Singh, JA; Sun, M; Vazquez, AI, 2018)
"Gout is a common inflammatory arthritis caused by the deposition of urate crystals within joints."1.48Pharmacophore modeling, molecular docking and molecular dynamics studies on natural products database to discover novel skeleton as non-purine xanthine oxidase inhibitors. ( Li, Y; Liu, X; Peng, J; Zhang, L; Zhou, Y; Zuo, Z, 2018)
"Gout is associated with higher cardiovascular risk that increases with disease severity."1.48The lack of association between the burden of monosodium urate crystals assessed with dual-energy computed tomography or ultrasonography with cardiovascular risk in the commonly high-risk gout patient. ( Budzik, JF; Capon, B; Ducoulombier, V; Godart, C; Grandjean, A; Houvenagel, E; Legrand, J; Luraschi, H; Motte, M; Namane, N; Norberciak, L; Pascart, T; Vandecandelaere, M, 2018)
"Gout is one of the most common inflammatory arthropathies, and the pathogenesis is well understood."1.48Chronic gout: Barriers to effective management. ( Arnold, MH; Rogenmoser, S, 2018)
"To examine whether gout is an independent risk factor for total joint replacement (TJR) and whether urate-lowering treatment (ULT) reduces this risk."1.48Urate-lowering treatment and risk of total joint replacement in patients with gout. ( Chen, JS; Chou, IJ; Doherty, M; Hsieh, AH; Kuo, CF; Luo, SF; See, LC; Yu, KH; Zhang, W, 2018)
"Gout is an inflammatory disease affecting multiple joints."1.48Plasma D-dimer is a Promising Indicator for the Treatment of Acute Gouty Attack. ( Chu, C; Lin, C; Song, P; Wu, Y; Xu, Q; Yang, Y, 2018)
"Hyperuricemia is the main risk factor for gout."1.48The benchmark dose estimation of reference levels of serum urate for gout. ( Chen, X; Cui, W; Ding, X; Duan, N; Jin, T; Wang, Z, 2018)
"Gout is one of the most common inflammatory arthritis in Malaysia."1.48Association of solute carrier family 2, member 9 (SLC2A9) genetic variant rs3733591 with gout in a Malay sample set. ( Amanda Jane, PG; Mahfudzah, A; Nazihah, MY; Tan, HL; Tony Richard, M; Wan Rohani, WT; Wan Syamimee, WG, 2018)
"Gout was associated with an increased risk of incident CKD (adjusted HR 1."1.48Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study. ( Belcher, J; Clarson, L; Mallen, CD; Muller, S; Roddy, E; Roughley, M; Sultan, AA; Whittle, R, 2018)
"Gout is a chronic disease associated with deposition of monosodium urate crystals and accompanied by diabetes, hypertension, and dyslipidemia."1.48Effect of fenofibrate on uric acid level in patients with gout. ( Choi, Y; Jung, JY; Kim, HA; Suh, CH; Yoon, D, 2018)
"Gout is a chronic disease, characterised by deposition of monosodium urate crystals in joints and tissues."1.48[A woman with a white skin lesion of her toe]. ( Hondebrink, LLC; Opstelten, W, 2018)
"Sensitivity and specificity were calculated by using the presence of monosodium urate (MSU) crystals in the synovial fluid or tissue aspirate as gold standard for gout diagnosis."1.46Performance of the 2015 American College of Rheumatology/European League Against Rheumatism gout classification criteria in Thai patients. ( Jatuworapruk, K; Lhakum, P; Louthrenoo, W; Pattamapaspong, N, 2017)
"2%) 19 patients received the recommended starting dosage of 100mg/day."1.46GOSPEL 3: Management of gout by primary-care physicians and office-based rheumatologists in France in the early 21st century - comparison with 2006 EULAR Recommendations. ( Delva, C; Ea, HK; Goossens, J; Guggenbuhl, P; Lambert, C; Lancrenon, S; Lanz, S; Lioté, F; Sahbane, S; Saraux, A, 2017)
"Tophaceous gout is painful and impairs quality of life."1.46Comparison of dual-energy CT, ultrasound and surface measurement for assessing tophus dissolution during rapid urate debulking. ( Crittenden, DB; Gyftopoulos, S; Karis, E; Keenan, RT; Krasnokutsky, S; Lee, K; Modjinou, DV; Pike, VC; Pillinger, MH; Samuels, J, 2017)
"Gout is a chronic disease resulting from elevated serum urate (SU)."1.46Replication of Gout/Urate Concentrations GWAS Susceptibility Loci Associated with Gout in a Han Chinese Population. ( Chen, J; Cheng, X; Cui, L; Han, L; Hou, X; Ji, J; Jia, Z; Li, C; Li, X; Li, Z; Liu, T; Liu, Z; Lu, D; Lu, J; Ma, L; Mi, QS; Ren, W; Shi, Y; Wang, C; Wang, X; Xin, Y; Yu, Q; Yuan, X; Zhang, K; Zhou, Z, 2017)
"Management of gout is frequently suboptimal."1.46Management of Gout in a Hospital Setting: A Lost Opportunity. ( Chapman, PT; Frampton, C; O'Donnell, JL; Raja, R; Stamp, LK; Wright, S, 2017)
"Gout is the most common form of inflammatory arthritis in the United States."1.46My Treatment Approach to Gout. ( Aslam, F; Michet, C, 2017)
"Uric acid (UA) is an end product of purine metabolism by the enzyme xanthine oxidase (XOD)."1.46Evaluating the urate-lowering effects of different microbial fermented extracts in hyperuricemic models accompanied with a safety study. ( Chen, HM; Chen, MH; Chen, RJ; Chen, SJ; Chen, YL; Hsiao, CM; Wang, YJ; Wu, MD; Yech, YJ; Yuan, GF, 2017)
"Patients, who were treated for gout attack in two tertiary medical centers between January 2000 and April 2014, were divided into young (≤ 50 years), middle-aged, and elderly (> 65 years) groups."1.46Elderly Patients Exhibit Stronger Inflammatory Responses during Gout Attacks. ( Lee, EB; Lee, EY; Lee, GH; Lee, JH; Lee, WW; Park, JK; Shin, K; Song, YW; Yang, JA, 2017)
"Though efficacious and affordable treatments for gout are widely available, gout is still not well controlled in many countries of the world including China."1.46Adherence to gout management recommendations of Chinese patients. ( Fang, W; Sha, Y; Sheng, F; Zeng, X; Zhang, B, 2017)
"Gout is a disease characterized by the deposition of monosodium urate (MSU) crystals in the joints."1.46Dietary fiber and the short-chain fatty acid acetate promote resolution of neutrophilic inflammation in a model of gout in mice. ( Amaral, FA; Galvão, I; Garcia, CC; Macia, LM; Mackay, CR; Martins, FS; Sernaglia, ÉM; Sousa, LP; Tavares, LP; Teixeira, MM; Vieira, AT; Vinolo, MA, 2017)
"Gout was not associated with a risk of non-vertebral fracture."1.46Gout and the Risk of Non-vertebral Fracture. ( Curhan, GC; Kim, SC; Liu, J; Paik, JM; Solomon, DH, 2017)
"Gout is a chronic disease with a high burden of pain and inflammation."1.46Treat-to-target (T2T) recommendations for gout. ( Bardin, T; Braun, J; Cohen Solal, A; da Rocha Castelar-Pinheiro, G; Dalbeth, N; Doherty, M; Engel, B; Flader, C; Kay, J; Kiltz, U; Matsuoka, M; Perez-Ruiz, F; Saag, K; Smolen, J; So, A; Vazquez Mellado, J; Weisman, M; Westhoff, TH; Yamanaka, H, 2017)
"Gout is a self-limited inflammatory disease caused by deposition of monosodium urate (MSU) crystals in the joints."1.46Annexin A1 promotes timely resolution of inflammation in murine gout. ( Amaral, FA; Barroso, LC; Carneiro, FS; Costa, VV; Ferreira, TP; Galvão, I; Queiroz-Junior, CM; Silva, PM; Sousa, LP; Tavares, LP; Teixeira, MM; Vago, JP, 2017)
"Uric acid (UA) has been proven to directly cause mesangial cell (MC) proliferation with elusive mechanisms."1.46COX-2/mPGES-1/PGE2 cascade activation mediates uric acid-induced mesangial cell proliferation. ( Chen, Q; Ding, G; Gong, W; He, JC; Huang, S; Jia, Z; Li, S; Ruan, Y; Sun, Z; Xia, W; Yu, J; Zhang, A; Zhang, Y, 2017)
"Gout is a painful disorder which does not have an efficient delivery system for its treatment."1.46Oral delivery of allopurinol niosomes in treatment of gout in animal model. ( Kaithwas, G; Kanoujia, J; Parashar, P; Saraf, SA; Singh, N; Tripathi, CB, 2017)
"Gout is a common arthritis resulting from increased serum urate, and many loci have been identified that are associated with serum urate and gout."1.46Effects of multiple genetic loci on the pathogenesis from serum urate to gout. ( Dong, Z; He, H; Ji, H; Jiang, S; Jin, L; Li, Y; Ma, Y; Pang, Y; Wang, J; Wang, X; Wang, Y; Xu, X; Yang, C; Yang, Y; Zhao, D; Zhou, J; Zou, H, 2017)
"-Some of the reasons identified for poor adherence to anti-gout medications include the risk of flare of acute gout with the initiation of urate-lowering therapy (ULT), poor response to ULT and persistence of attacks of acute gout, suboptimal dosing of allopurinol therapy and intolerance of allopurinol."1.43Adherence and persistence to urate-lowering therapies in the Irish setting. ( Bennett, K; McGowan, B; Silke, C; Whelan, B, 2016)
"Gout is a chronic, extremely painful disease that is potentially curable when treated effectively."1.43Management of gout in the real world: current practice versus guideline recommendations. ( Baumgartner, S; Doghramji, PP; Fermer, S; Morlock, R; Wood, R, 2016)
" It remains to be seen whether allopurinol has a dose-response relationship with cardiovascular events at higher doses."1.43Impact of Urate Level on Cardiovascular Risk in Allopurinol Treated Patients. A Nested Case-Control Study. ( Hallas, J; Lindegaard, HM; Pottegård, A; Søltoft Larsen, K, 2016)
"Hyperuricaemia and gout are well-recognized complications of diuretic use."1.43Clinical and genetic features of diuretic-associated gout: a case-control study. ( Dalbeth, N; Franklin, C; Horne, A; Merriman, TR; Mitnala, S; Phipps-Green, A; Stamp, LK, 2016)
"Gout is associated with dyslipidaemia."1.43Replication of association of the apolipoprotein A1-C3-A4 gene cluster with the risk of gout. ( Dalbeth, N; Harrison, AA; Hill, C; Jansen, TL; Janssen, M; Jones, GT; Joosten, LA; Lester, S; Lioté, F; McCormick, SP; Merriman, TR; Phipps-Green, AJ; Radstake, TR; Rasheed, H; Riches, PL; Rischmueller, M; Smith, MD; So, A; Stamp, LK; Tausche, AK; Topless, R; van Rij, A, 2016)
"Gout is characterized by the monosodium urate monohydrate (MSU)-induced arthritis."1.43ALPK1 phosphorylates myosin IIA modulating TNF-α trafficking in gout flares. ( Chang, JG; Chen, CL; Chiang, SL; Huang, CM; Ko, AM; Ko, YC; Kuo, TM; Lee, CP; Liu, YF; Lu, CY; Ma, C; Tsai, EM, 2016)
"Gout is the most common inflammatory arthropathy of metabolic origin and it is characterized by intense inflammation, the underlying mechanisms of which are unknown."1.43Monosodium urate crystals induce oxidative stress in human synoviocytes. ( Camacho-Galindo, J; Cerna-Cortés, JF; Fernández-Torres, J; Gutierrez, M; Hernández-Díaz, C; Loissell-Baltazar, YA; López-Macay, A; López-Reyes, A; López-Villegas, EO; Martínez-Flores, K; Medina-Luna, D; Oliviero, F; Pineda, C; Santamaría-Olmedo, MG; Scanu, A; Zamudio-Cuevas, Y, 2016)
"Gout is a form of crystal arthropathy where monosodium urate (MSU) crystals deposit and elicit inflammation in a joint."1.43Wide-field imaging of birefringent synovial fluid crystals using lens-free polarized microscopy for gout diagnosis. ( Fitzgerald, J; Furst, D; Lee, SY; Ozcan, A; Zhang, Y, 2016)
"Gout was diagnosed according to the American College of Rheumatology criteria."1.43Usefulness of plain radiography for assessing hypouricemic treatment response in patients with tophaceous gout. ( Cheon, YH; Kim, HO; Kim, JE; Kim, JM; Kim, SH; Lee, SI; Lee, WS; Suh, YS; Yoo, WH, 2016)
"Gout is a systemic disorder characterized by hyperuricemia and recurrent arthritis, most involvement of ankles, midfoot joint and first metatarsophalangeal joint, with monosodium urate crystals deposition in synovial fluid and other tissues."1.43Miliarial gout: a rare presentation of extensive cutaneous tophi. ( Chiang, CP; Hung, TL; Wang, WM, 2016)
"Colchicine was more commonly used for attack prophylaxis than allopurinol."1.43The management of gout in different clinical specialties in Turkey: a patient-based survey. ( Balcı, MA; Balkarlı, A; Çobankara, V; Gök, K; Kaya, A; Kimyon, G; Kısacık, B; Küçük, A; Mercan, R; Onat, AM; Öztürk, MA; Pamuk, Ö; Şahin, Ş; Sayarlıoğlu, M; Şenel, S; Tezcan, ME; Tufan, A; Üreten, K; Yıldırım Çetin, G, 2016)
"Hyperuricemia is a common symptom in adult population."1.43Familial juvenile hyperuricemic nephropathy as rare cause of dialysis-dependent chronic kidney disease-a series of cases in two families. ( Adamczyk, P; Beck, B; Dyga, K; Kaminska-Pajak, KA; Szczepańska, M; Tkaczyk, M; Zaniew, M, 2016)
"Gout is the most common inflammatory arthritis in adults in the Western world."1.43Gout: will the "King of Diseases" be the first rheumatic disease to be cured? ( Singh, JA, 2016)
"Acute gout is a self-limiting inflammatory response to monosodium urate (MSU) crystals."1.43Interleukin 37 limits monosodium urate crystal-induced innate immune responses in human and murine models of gout. ( Liang, M; Liu, L; Wang, J; Xuan, D; Xue, Y; Yang, X; Zhang, J; Zhu, X; Zhu, Y; Zou, H, 2016)
"Differentiating gout, calcium pyrophosphate deposition disease (CPPD), and non-crystal-related inflammatory arthropathies (non-CRA) is essential but often clinically impossible."1.42Distinguishing gouty arthritis from calcium pyrophosphate disease and other arthritides. ( Bergner, R; Löffler, C; Löffler, U; Peters, L; Sattler, H; Uppenkamp, M, 2015)
"Twelve patients indicated that treatment of gout only encompasses treatment of the acute attack."1.42Health literacy in patients dealing with gout: a qualitative study. ( Boonen, A; de Vries, H; Hinsenveld, E; van Onna, M, 2015)
"Hyperuricemia is very common in industrialized countries and known to promote vascular smooth muscle cell proliferation."1.42Smaller caliber renal arteries are a novel feature of uromodulin-associated kidney disease. ( Adamczak, M; Blondin, D; Dekomien, G; Epplen, JT; Helmchen, U; Januszewicz, A; Januszewicz, M; Litwin, M; Matuszkiewicz-Rowińska, J; Michałowska, I; Prejbisz, A; Rump, LC; Sajnaga, D; Sellin, L; Szwench-Pietrasz, E; Więcek, A; Woznowski, M, 2015)
"Gout is a metabolic disorder that results in hyperuricemia and the deposition of positively birefringent monosodium urate crystals in various parts of the body."1.42Clinicopathologic characterization of visceral gout of various internal organs--a study of 2 cases from a venom and toxin research center. ( Fayyaz, AF; Kamyabi-Moghaddam, Z; Mokarizadeh, A; Nasoori, A; Pedram, B; Pirasteh, H; Shooshtari, MB, 2015)
"Gout was induced by the injection of MSU crystals into the knee joints of mice."1.42A Role for Gut Microbiota and the Metabolite-Sensing Receptor GPR43 in a Murine Model of Gout. ( Amaral, FA; Canesso, MC; De Leon, E; Galvão, I; Garcia, CC; Harper, JL; Macia, L; Mackay, CR; Martins, FS; Maslowski, KM; Nicoli, JR; Shim, D; Teixeira, MM; Vieira, AT, 2015)
"Gout is a disorder of purine metabolism that primarily occurs in adult males."1.42Treatment and prevention of gout. ( Ferrara, LR; Saccomano, SJ, 2015)
"Gout is a common clinical problem encountered by both general and specialist clinicians."1.42Update on the diagnosis and management of gout. ( Graf, SW; Ting, K; Whittle, SL, 2015)
"Gout is an inflammatory arthritis characterised by hyperuricemia, which, if poorly controlled, can lead to the development of tophi."1.42Ulcerated tophaceous gout. ( Filanovsky, MG; McNamara, MC; Sukhdeo, K, 2015)
"Gout is a consequence of an innate immune reaction to monosodium urate crystals deposited in joints."1.42Positive association of tomato consumption with serum urate: support for tomato consumption as an anecdotal trigger of gout flares. ( Cadzow, M; Dalbeth, N; Flynn, TJ; Hindmarsh, JH; Jones, PB; Merriman, TR; Stamp, LK; Todd, AS; Topless, R; Walker, RJ, 2015)
"Gout is a potentially destructive inflammatory disorder occurring in the setting of hyperuricaemia and urate crystal deposition in tissue."1.42[Dual-energy computer tomography can be used for gout diagnostics]. ( Jørgensen, SH; Knudsen, ET; Rasmussen, C, 2015)
"Although gout is potentially curable with long-term urate lowering therapy, confusion about the details of urate measurement has contributed to suboptimal care."1.42Urate testing in gout: why, when and how. ( Arroll, B; Boswell, DR; Dalbeth, N; Gow, PJ; Lindsay, K; Stamp, LK; Te Karu, L; Winnard, D, 2015)
"Gout is a common metabolic disorder characterized by hyperuricemia and chronic inflammation."1.42Gout, not hyperuricemia alone, impairs left ventricular diastolic function. ( Chang, PJ; Chang, ST; Chen, MC; Chung, CM; Lin, CL; Lin, JC; Pan, KL, 2015)
"Gout is a metabolic disease, which is characterized by acute or chronic arthritis, and deposition of monosodium urate crystals in joint, bones, soft tissues, and kidneys."1.42Chronic tophaceous gout with unusual large tophi: case report. ( Abourazzak, FZ; Aradoini, N; Berrada, K; Harzy, T; Talbi, S, 2015)
" However, inadequate dosing and patient nonadherence or intolerance to therapy often lead to treatment failure."1.40CaseBook challenges: Managing gout, hyperuricemia and comorbidities -- dialogue with the experts. ( Bakris, GL; Doghramji, PP; Keenan, RT; Silber, SH, 2014)
"Gout is a common disease resulting from hyperuricemia which causes acute arthritis."1.40Common variant of leucine-rich repeat-containing 16A (LRRC16A) gene is associated with gout susceptibility. ( Chiba, T; Hamajima, N; Ichida, K; Inoue, H; Kanai, Y; Makino, T; Matsuo, H; Morita, E; Naito, M; Nakamura, T; Nakayama, A; Sakiyama, M; Sakurai, Y; Sato, J; Satoh, T; Shimizu, S; Shimizu, T; Shimono, K; Shinomiya, N; Suzuki, H; Takada, T; Takada, Y; Tatsukawa, S; Wakai, K, 2014)
"Hip fractures were not significantly associated with UA."1.40Association of serum uric acid and incident nonspine fractures in elderly men: the Osteoporotic Fractures in Men (MrOS) study. ( Cawthon, PM; Lane, NE; Lay, YA; Lui, LY; Orwoll, E; Parimi, N; Wise, BL; Yao, W, 2014)
"Gout is an important but certainly not an exclusive cause of arthritis of the first metatarsophalangeal joint."1.40Arthritis of the first metatarsophalangeal joint is not always gout: a prospective cohort study in primary care patients. ( Fransen, J; Janssen, M; Janssens, HJ; Kienhorst, LB; van de Lisdonk, EH, 2014)
"Gout was diagnosed at the last visit in 34 subjects; four in the normouricemia group and 30 in the hyperuricemia group (0."1.40The degree of asymptomatic hyperuricemia and the risk of gout. A retrospective analysis of a large cohort. ( Cohen, E; Duskin-Bitan, H; Garty, M; Goldberg, E; Krause, I; Levi, A; Shochat, T, 2014)
"Gout is characterized by an acute inflammatory reaction and the accumulation of neutrophils in response to monosodium urate (MSU) crystals."1.40Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines. ( Bilyy, R; Frey, B; Harrer, T; Herrmann, M; Hoffmann, M; Holmdahl, R; Janko, C; Jeremic, I; Kienhöfer, D; Krenn, V; Lell, M; Manger, B; Munoz, LE; Naschberger, E; Rech, J; Schauer, C; Schett, G; Zhao, Y, 2014)
"Gout/hyperuricemia is a common multifactorial disease having typical environmental risks."1.40Common dysfunctional variants of ABCG2 have stronger impact on hyperuricemia progression than typical environmental risk factors. ( Abe, J; Akashi, A; Chiba, T; Hosoya, T; Ichida, K; Kawai, S; Kawamura, Y; Matsuo, H; Nakamura, T; Nakaoka, H; Nakashima, H; Nakayama, A; Oikawa, Y; Okada, R; Sakiyama, M; Sakurai, Y; Shichijo, Y; Shimizu, S; Shinomiya, N; Suzuki, H; Takada, T; Takada, Y; Tamura, T; Wakai, K, 2014)
"Age of onset of gout has recently decreased; however, patients with early-onset gout remain uncommon, and relevant information is scant."1.40Clinical characteristics of and relationship between metabolic components and renal function among patients with early-onset juvenile tophaceous gout. ( Chen, HY; Chung, WS; Lee, MC; Lu, CC; Wu, SK; Yeh, CJ, 2014)
"Gout is a metabolic disorder associated with hyperuricemia resulting in the deposition of monosodium urate (MSU) crystals in joints and tissues."1.40Study on the anti-gout activity of chlorogenic acid: improvement on hyperuricemia and gouty inflammation. ( Cao, L; Ding, G; Guo, CR; Huang, WZ; Meng, ZQ; Tang, ZH; Wang, KD; Wang, ZZ; Xiao, W; Yan, YX; Yang, ZL, 2014)
"Gout affects 2."1.40Patients with gout can be cured in primary care. ( Doherty, M; Rees, F, 2014)
"Hyperuricemia is known to be a risk factor for incident type 2 diabetes mellitus, but the absolute magnitude of the association is not known."1.39Relative and attributable diabetes risk associated with hyperuricemia in US veterans with gout. ( Akhras, KS; Krishnan, E; Liu, J; Marynchenko, M; Sharma, H; Shi, L; Tawk, R; Wu, EQ, 2013)
" Inappropriate dosing of medications in the setting of renal disease and lack of prophylaxis when initiating urate-lowering therapy (ULT) accounted for much of the lack of compliance with treatment recommendations."1.39Primary care providers' knowledge, beliefs and treatment practices for gout: results of a physician questionnaire. ( Firneno, C; Harrold, LR; Mazor, KM; Negron, A; Ogarek, J; Yood, RA, 2013)
"Gout is an ancient autoinflammatory disease that affects millions of people worldwide."1.39Transient receptor potential melastatin 2: a novel target for treatment of gout. ( Qiao, L; Zhai, Y; Zhong, Z, 2013)
"Infectious spondylodiscitis was first supposed due to the imaging of the spine although no pathogenic agent could be proved."1.39[<> spondylodiscitis]. ( Dünkel, J; Jonczy, M; Oestmann, A, 2013)
"Most research in gout has concentrated on the proinflammatory mechanisms to explain the inflammation that is generated when leucocytes are in contact with monosodium urate crystals."1.39How to regulate neutrophils in gout. ( So, A, 2013)
"Gout is estimated to affect 1."1.39Improvement in the management of gout is vital and overdue: an audit from a UK primary care medical practice. ( Cottrell, E; Crabtree, V; Edwards, JJ; Roddy, E, 2013)
"Chronic tophaceous gout is treated with dietary control and medication."1.39Gout with auricular tophi following anti-tuberculosis treatment: a case report. ( Chang, HJ; Hsu, YC; Huang, SH; Wang, PC, 2013)
" On 48% of occasions, the time of allopurinol dosing was recorded, while just 79 (19%) blood samples were collected 6-9 hours postdosing, the time window used to establish the therapeutic range for oxypurinol."1.39An audit of a therapeutic drug monitoring service for allopurinol therapy. ( Day, RO; Graham, GG; Jones, G; Kannangara, DR; Ramasamy, SN; Ray, JE; Williams, KM, 2013)
"Gout has been recognized for centuries but is also a modern day scourge."1.38Dual energy computed tomography for quantification of tissue urate deposits in tophaceous gout: help from modern physics in the management of an ancient disease. ( Bacani, AK; Bond, JR; Glazebrook, KN; Manek, NJ; McCollough, CH; Michet, CJ; Milks, J, 2012)
"Mean uric acid serum level was 281."1.38[Hyperuricemia in sickle cell disease in France]. ( Arlet, JB; Chatellier, G; Courbebaisse, M; de Montalembert, M; Pouchot, J; Prié, D; Ribeil, JA, 2012)
"Gout was induced by injecting MSU crystals into the joints of mice."1.38NLRP3 inflammasome-mediated neutrophil recruitment and hypernociception depend on leukotriene B(4) in a murine model of gout. ( Amaral, FA; Coelho, FM; Costa, VV; Cunha, FQ; Cunha, LD; Cunha, TM; Fagundes, CT; Peres, RS; Quesniaux, V; Ryffel, B; Sachs, D; Silveira, TN; Soriani, FM; Souza, DG; Tavares, LD; Teixeira, MM; Zamboni, DS, 2012)
"Incident gout was defined as self-reported onset of gout after baseline."1.38Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension: the Atherosclerosis Risk in Communities cohort study. ( Alonso, A; Baer, AN; Coresh, J; Gelber, AC; Maynard, JW; McAdams DeMarco, MA; Young, JH, 2012)
"The prevalence of gout has been increasing."1.38Evaluation of health care costs and utilization patterns for patients with gout. ( McBayne, T; Park, H; Prasla, K; Rascati, KL, 2012)
"Gout is a painful inflammatory arthropathy caused by crystallization of monosodium urate within the joints."1.38False-negative dual-energy computed tomography in a patient with acute gout. ( Glazebrook, KN; Ida, CM; Kakar, S; Laurini, JA; Leng, S; Moder, KG, 2012)
"Gout care is suboptimal because of lack of translation of knowledge into real-world practice, despite evidence-based guidelines."1.38Achieving treat to target in gout: a clinical practice improvement project. ( Lateef, A; Lau, TC; Lim, AY; Shen, L; Tan, CH; Teng, GG, 2012)
"Gout is a chronic, potentially debilitating condition characterized by an inflammatory process in the joints or periarticular tissues that results from the deposition of monosodium urate crystals."1.38Casebook consults: improving outcomes in gout (multimedia activity). ( Doghramji, PP; Mandell, BF; Pope, RS, 2012)
"ULT prescription and dosing are key modifiable factors associated with achieving SU target."1.38Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout. ( Dalbeth, N; Horne, A; House, ME; McQueen, FM; Petrie, KJ; Taylor, WJ, 2012)
"The concept of 'treatment-failure gout' describes a unique population that has been either unable to tolerate allopurinol or who have not experienced normalization of serum urate levels on allopurinol."1.38Pegloticase and the patient with treatment-failure gout. ( Dave, AJ; Kelly, VM; Krishnan, E, 2012)
"Women who develop gout are more likely to be over the age of 50, have other comorbidities and be on diuretics."1.38Gout in women: differences in risk factors in young and older women. ( Gupta, R; Kumar, S; Suppiah, R, 2012)
"Gout is an ancient disease."1.38Management of gout: a 57-year-old man with a history of podagra, hyperuricemia, and mild renal insufficiency. ( Shmerling, RH, 2012)
"Insulin sensitivity was estimated using the homeostatic model assessment index (HOMA-B) for beta cell function and HOMA-IR for peripheral tissue IR."1.38Insulin resistance and metabolic syndrome in primary gout: relation to punched-out erosions. ( El-Fishawy, HS; Gheita, TA; Hussein, H; Nasrallah, MM, 2012)
"Gouty panniculitis is an unusual clinical manifestation of gout, characterized by the deposition of monosodium urate crystals in the lobular hypodermis."1.37Panniculitis: another clinical expression of gout. ( Espinoza, LR; Iglesias-Gamarra, A; Mejia, J; Ochoa, CD; Restrepo, JF; Rondon, F; Valderrama, V; Villaroya, N, 2011)
"Gout has not been described previously as a complication in cystic fibrosis (CF)."1.37Gout and hyperuricaemia in adults with cystic fibrosis. ( Brennan, A; Bright-Thomas, R; Helm, J; Horsley, A; Jones, A; Webb, K, 2011)
"Gout is increasing in prevalence throughout the world, particularly in developed countries."1.37Hyperuricaemia and gout. ( Shipley, M, 2011)
"Gout is an inflammatory-rheumatic disease characterized by an elevated serum urate concentration and recurrent flares, including painful, hot, red, and swollen joints and surrounding tissue."1.37Giant gouty tophi of the hand and wrist. ( Mittag, F; Wuenschel, M, 2011)
"The blood Cr level just reached the chronic renal failure level on the 26th day of the administration (about the 4th week), and obviously exceeded the renal failure level on the 41st day (about the 6th week)."1.37[Exploration on the establishment of animal models for gouty nephropathy complicated with chronic renal failure]. ( Meng, DM; Ren, W; Xing, RL, 2011)
"Asymptomatic hyperuricemia affects one in five adults in the general population and is associated with elevated cardiovascular risk."1.37[Contribution of the CoLaus study to decipher the determinants of serum uric acid]. ( Bochud, M; Vollenweider, P; Waeber, G, 2011)
"Gout is a prevalent inflammatory arthritis affecting 1-2% of adults characterized by activation of innate immune cells by monosodium urate (MSU) crystals resulting in the secretion of interleukin-1β (IL-1β)."1.37Neutrophil extracellular trap formation is associated with IL-1β and autophagy-related signaling in gout. ( Apostolidou, E; Boumpas, DT; Chrysanthopoulou, A; Drosos, GI; Kambas, K; Kourtzelis, I; Mitroulis, I; Ritis, K; Skendros, P, 2011)
"Gout is a common rheumatologic condition of recurrent polyarticular involvement."1.37Unknown: Multiple painful nodules - what is the diagnosis? Chronic tophaceous gout. ( Avhad, G; Dandale, A; Dhurat, R; Ghate, S, 2011)
"Published guidelines for the treatment of gout aim to improve the evidenced-based management of this disorder."1.36Adherence to treatment guidelines in two primary care populations with gout. ( Bottenberg, MM; Hegge, KA; Koenigsfeld, CF; Wall, GC, 2010)
"Asymptomatic hyperuricemia is not associated with suppressed neutrophil function."1.36Differences in MSU-induced superoxide responses by neutrophils from gout subjects compared to healthy controls and a role for environmental inflammatory cytokines and hyperuricemia in neutrophil function and survival. ( Grainger, R; Harper, JL; Harrison, A; Martin, WJ, 2010)
"Gout is commonly associated with obesity, arterial hypertension, diabetes, and dyslipidemia."1.36Metabolic syndrome characteristics in gout patients. ( de Miguel, ME; Fraile, JM; Lundelin, KJ; Martínez, P; Puig, JG; Torres, RJ; Vázquez, JJ, 2010)
" In addition, there was a dose-response relationship between SU and NAFLD in subjects with and without gout."1.36Gout and risk of non-alcoholic fatty liver disease. ( Chang, HC; Chen, HW; Chiu, CT; Hwang, JS; Ko, YS; Kuo, CF; Luo, SF; See, LC; Tseng, WY; Yu, KH, 2010)
"Uric acid was successfully extracted through the subjects' skin into the collection solution."1.36Non-invasive and transdermal measurement of blood uric acid level in human by electroporation and reverse iontophoresis. ( Chien, MY; Ching, CT; Huang, HH; Huang, HW; Huang, SY; Huang, W; Kuo, JF; Lai, LH; Lee, CK; Liu, CM; Liu, WH; Pan, HT; Shieh, HL; Sun, TP; Tsai, CL; Tseng, HH, 2010)
"Moreover, hyperuricemia is likely a risk factor for the development of diabetes mellitus."1.35Dietary and lifestyle changes associated with high prevalence of hyperuricemia and gout in the Shandong coastal cities of Eastern China. ( Chen, X; Chen, Y; Hu, J; Li, C; Miao, Z; Song, W; Sun, R; Wang, CY; Wang, F; Wang, Y; Wang, Z; Xu, F; Yan, S; Zhao, S, 2008)
"Gout is characterized by the deposition of monosodium urate crystals on the surface of the articular cartilage, within periarticular tissues, and within bone and skin."1.35Ultrasonography for diagnosing atypical gout. Two case reports. ( André, V; Berthelot, JM; Guillot, P; Le Goff, B; Maugars, Y, 2008)
"We documented 1215 new cases of type 2 diabetes."1.35Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. ( Choi, HK; De Vera, MA; Krishnan, E, 2008)
"Hyperuricemia is significantly predicted by anthropometric measure of SFT which is a simple clinical screening method along with creatinine levels."1.35Hyperuricemia and its related factors in an urban population, Izmir, Turkey. ( Akar, S; Akkoc, N; Birlik, M; Gurler, O; Onen, F; Pakoz, B; Sari, I; Sisman, AR, 2009)
"Gout is the most common autoinflammatory arthritis characterized by elevated serum urate and recurrent attacks of intra-articular crystal deposition of monosodium urate (MSU)."1.35NALP3 inflammasome functional polymorphisms and gout susceptibility. ( Li, CG; Meng, DM; Mi, QS; Miao, ZM; Wang, YG; Yan, SL; Zhao, SH; Zhou, L, 2009)
"Gout is an acute form of arthritis caused by the deposition of urate crystals, in which phagocytic cells and cytokines play a major pathogenic role."1.35Melanocortin peptides inhibit urate crystal-induced activation of phagocytic cells. ( Capsoni, F; Catania, A; Ongari, AM; Reali, E, 2009)
"In the treatment of acute gout, 68."1.35A survey on the management of gout in Malaysia. ( Goh, EM; Gun, SC; Yeap, SS, 2009)
"The presence of crystals cannot exclude septic arthritis with certainty."1.34Does the presence of crystal arthritis rule out septic arthritis? ( Edlow, JA; McCauley, J; Nathanson, LA; Shah, K; Spear, J, 2007)
"Chronic gout and rheumatoid arthritis are common medical manifestations with debilitating effects on patients."1.34Tophaceous gout in a patient with rheumatoid arthritis. ( Baker, DL; Gilstrap, CA; Stroup, JS, 2007)
"Gout is the most common crystal-induced arthritis."1.33Intra-abdominal gout mimicking pelvic abscess. ( Chen, CH; Chen, CK; Pan, HB; Yang, CF; Yeh, LR, 2005)
"Gout is a metabolic disorder that results in hyperuricemia and the deposition of positively birefringent monosodium urate crystals in various parts of the body."1.33Gout induced by intoxication of sodium bicarbonate in Korean native broilers. ( Ejaz, S; Kim, BS; Lim, CW, 2005)
"As gout is very often primarily caused by a renal secretion disturbance of uric acid special diagnostics should be done."1.33[Hyperuricemia and gout: diagnosis and therapy]. ( Grässler, J; Richter, K; Roch, B; Schröder, HE; Tausche, AK; Unger, S; Wunderlich, C, 2006)
"Hyperuricemia and gout have shown an increase worldwide."1.33The prevalence of hyperuricemia in a population of the coastal city of Qingdao, China. ( Dong, Y; Gao, W; Nan, H; Qian, R; Qiao, Q; Tang, B; Tuomilehto, J, 2006)
"Hyperuricemia and gout are common complications in adult renal transplant recipients."1.33Hyperuricemia and gout following pediatric renal transplantation. ( Kemper, MJ; Neuhaus, TJ; Spartà, G, 2006)
"When treating acute gout in otherwise healthy patients, most physicians (77%) prefer oral colchicine, and in patients with renal impairment, about half of them (48%) choose corticosteroids or corticotropin as their first treatment."1.33The management of gout at an academic healthcare center in Beijing: a physician survey. ( Chen, LX; Fang, W; Li, M; Schumacher, HR; Zeng, X; Zhang, F, 2006)
"Furthermore, congestive heart failure is associated with impaired creatinine clearance and increased urea and urate, and osteoporosis and hip fractures are characterized by low albumin and cholesterol."1.32Association of biochemical values with morbidity in the elderly: a population-based Swedish study of persons aged 82 or more years. ( Berg, S; Evrin, PE; Johansson, B; McClearn, G; Nilsson, SE; Takkinen, S; Tryding, N, 2003)
"Hyperuricemia is the hallmark of severe gout with tophi formation."1.32[Rasburicase (Fasturtec)]. ( Frey, FJ; Gugger, M; Vogt, B, 2004)
"Thirteen patients with ESRD on intermittent haemodialysis treatment, six patients with chronic renal failure not yet on dialysis, and 15 age- and sex-matched healthy controls were examined."1.31Reduced secretion of proinflammatory cytokines of monosodium urate crystal-stimulated monocytes in chronic renal failure: an explanation for infrequent gout episodes in chronic renal failure patients? ( Galle, PR; Himmelsbach, F; Märker-Hermann, E; Schreiner, O; Wandel, E, 2000)
" Allopurinol dosing guidelines and a therapeutic range for plasma oxypurinol levels have been published."1.31The optimal use of allopurinol: an audit of allopurinol use in South Auckland. ( Gow, P; Raill, B; Sharples, K; Stamp, L, 2000)
"In idiopathic uric acid nephrolithiasis, urinary pH and fractional excretion of urate are significantly lower than in control subjects, suggestive of defects in urinary acidification and urate excretion."1.31Biochemical profile of idiopathic uric acid nephrolithiasis. ( Frawley, WH; Pak, CY; Peterson, RD; Poindexter, JR; Sakhaee, K, 2001)
"We conclude that CPPD in pseudogout and monosodium urate in gout may not polarize in the routine H&E-stained sections."1.31Evaluation of crystals in formalin-fixed, paraffin-embedded tissue sections for the differential diagnosis of pseudogout, gout, and tumoral calcinosis. ( Basir, Z; Chivukula, M; Shidham, G; Shidham, V, 2001)
"Episodes of gout are common in the setting of renal transplantation."1.31Tacrolimus for the treatment of gout in renal transplantation: two case reports and review of the literature. ( Dittmer, I; Faire, B; Pilmore, HL, 2001)
"Gout is an acute rheumatic disorder that occurs in connection with the deposition of monosodium urate (MSU) crystals in the joints."1.30Altered arachidonic acid metabolism in urate crystal induced inflammation. ( Duffin, KL; Gregory, SA; Isakson, PC; Margalit, A; Shaffer, AF, 1997)
"Cases of gout were identified from self-reporting of a doctor's diagnosis based on clinical criteria."1.30High prevalence of gout and related risk factors in Taiwan's Aborigines. ( Chang, FT; Chang, SJ; Chen, CJ; Cinkotai, FF; Ko, YC; Wang, TN, 1997)
"Gout is common disease with a worldwide distribution."1.30[Epidemiology, incidence and sex specific differences in primary gout]. ( Peichl, P, 1997)
"The uric acid level was 7."1.30The epidemiology of hyperuricaemia and gout in Taiwan aborigines. ( Chou, CT; Lai, JS, 1998)
"Gout was diagnosed in 106 of the 3517 patients seen from October 1989 through October 1993."1.29Gout in patients attending the rheumatology unit of Lomé Hospital. ( Mijiyawa, M, 1995)
" Urate-oxidase was given parenterally in a dosage of 1000 units per day, seven days a month."1.29Urate-oxidase for the treatment of tophaceous gout in heart transplant recipients. A report of three cases. ( Borget, C; Bourgeois, P; Dorent, R; Koeger, AC; Roche, B; Rozenberg, S; Wrona, N, 1995)
"Gout is increasingly recognized in African populations, especially in urban centres."1.29Gout and hyperuricaemia. ( Darmawan, J; Lutalo, SK, 1995)
"A 20-day-old male infant presented with acute renal failure."1.29Lesch-Nyhan syndrome presenting with renal insufficiency in infancy and transient neonatal hypothyroidism. ( Hallett, RJ; Hull, RG; Jenkins, EA, 1994)
"Nine patients (43%) had a recurrence of tophi after an average period of 39."1.29Withdrawal of longterm antihyperuricemic therapy in tophaceous gout. ( Breedveld, FC; van Lieshout-Zuidema, MF, 1993)
"We reviewed 5477 patients with urinary calculi who presented during the years from 1975 to 1993."1.29[An epidemiologic study on pathogenesis of uric acid urolithiasis]. ( Hikita, M; Hosoya, T; Ichida, K; Okabe, H; Saji, M; Sakai, O; Tabe, A, 1995)
"In addition, a single patient with von Gierke's disease showed a marked increase in the plasma activity of this enzyme, relative to that apparent in normal subjects."1.29Determination of human plasma xanthine oxidase activity by high-performance liquid chromatography. ( Higashino, K; Hiroishi, K; Moriwaki, Y; Nasako, Y; Takahashi, S; Tsutsumi, Z; Yamakita, J; Yamamoto, T, 1996)
"Gout is a common disease in the primary health care setting."1.28Gout. ( Feng, PH; Leong, KH, 1992)
"Subcutaneous fat necrosis is a well described, rare sequela of acute pancreatitis."1.28Subcutaneous pancreatic fat necrosis associated with acute arthritis. ( Naides, SJ; Niemann, TH; Saag, KG; Warner, CA, 1992)
"Dupuytren's disease is a relatively rare occurrence in a patient of the black race."1.28Dupuytren's contracture and gouty tophi in a black patient. ( Antoine, GA; LeFlore, I, 1991)
"The proteinuria was detected at age 10 and 6 years, respectively."1.28Underexcretory-type hyperuricemia, disproportionate to the reduced glomerular filtration rate, in two boys with mild proteinuria. ( Jojima, K; Kawakami, H; Matsuzaki, H; Murakami, T; Nakatsuka, K; Nohno, H, 1990)
"Pretreatment with colchicine, but not aspirin, indomethacin, allopurinol, or islet activating protein, abrogated the enhanced phospholipase A2 activities."1.28Monosodium urate crystals stimulate phospholipase A2 enzyme activities and the synthesis of a phospholipase A2-activating protein. ( Baker, DG; Bomalaski, JS; Brophy, LM; Clark, MA, 1990)
"In the patients with recurrent calcium nephrolithiasis and hypercalcinosis one should look for active impairment of uric acid metabolism which should be kept in mind when an antirecurrence treatment is planned."1.28[The effect of oral calcium loading on the serum concentrations and urinary excretion of uric acid in patients with recurrent calcium nephrolithiasis and hypercalciuria]. ( Ivanov, I; Tsachev, K, 1990)
"Gout was diagnosed through clinical history, physical examination and identification of monosodium urate crystals in the joint aspirate."1.28Polyarticular symmetric tophaceous joint inflammation as the initial presentation of gout. ( Verdile, VP; Vukmir, RB; Weiss, L, 1990)
"Gout is primarily a disease of middle-aged males and is unusual in females and adolescent males."1.28Precocious familial gout with reduced fractional urate clearance and normal purine enzymes. ( Calabrese, G; Cameron, JS; Davies, PM; Simmonds, HA, 1990)
"The coexistence of systemic lupus erythematosus and tophaceous gout is very rare."1.28A case of multiple urate deposition, without gouty attacks, in a patient with systemic lupus erythematosus. ( Kurita, Y; Numata, K; Ogawa, H; Tsuboi, R, 1989)
"Clinical gout was identified in 24% of patients with ADPKD; none of the patients with chronic renal failure of other etiologies had gout."1.28Hyperuricemia, gout, and autosomal dominant polycystic kidney disease. ( Lluberes, R; Martínez-Maldonado, M; Mejías, E; Navas, J, 1989)
"Obesity is common amongst the Maoris and accentuates their natural tendency to hyperuricaemia."1.27Hyperuricaemia, gout and kidney function in New Zealand Maori men. ( Bremner, K; Gibson, T; Hatfield, P; Robinson, G; Waterworth, R, 1984)
"Chronic tophaceous gout has become less common since the introduction of allopurinol and probenecid."1.27Mitral stenosis associated with valvular tophi. ( Callahan, JA; Edwards, WD; Ginsburg, WW; Scalapino, JN; Steckelberg, JM; Wooten, RS, 1984)
"31P-MRS could be used to diagnose fructose intolerance and to monitor the patients' compliance with a fructose-restricted diet."1.27Study of hereditary fructose intolerance by use of 31P magnetic resonance spectroscopy. ( Collins, JE; Herschkowitz, N; Leonard, JV; Oberhaensli, RD; Radda, GK; Rajagopalan, B; Schwarz, H; Taylor, DJ, 1987)
"Coexistent gout and systemic lupus erythematosus (SLE) have received increasing attention."1.27Gout and hyperuricaemia in systemic lupus erythematosus. ( Frocht, A; Leek, JC; Robbins, DL, 1987)
"Accordingly, one must treat the patient's gout as well as his various stages of the associated medical conditions, and each patient must be individualized."1.27Impact of associated medical conditions on clinical features of gout. ( Smith, H; Yu, TF, 1986)
"Obesity has to be considered a connecting link between both of them, and it is accelerating their genesis."1.26[Hallux rigidus arthrosis and gout]. ( Mertz, DP, 1982)
"It is shown that in osteoarthrosis the clinical characteristics vary from one joint group to another."1.26Heberden Oration 1981: epidemiology and the arthritides. ( Acheson, RM, 1982)
"Chondrocalcinosis was detected in knee radiographs of 8 of 138 gouty patients compared with none of 142 age matched nongouty normouricaemic controls (p less than 0."1.26Frequency of chondrocalcinosis of the knees in asymptomatic hyperuricaemia and rheumatoid arthritis: a controlled study. ( Hollingworth, P; Scott, JT; Williams, PL, 1982)
"Gout is principally a disease of middle-aged men."1.26Uric acid crystal-induced nephropathy: evidence for a specific renal lesion in a gouty family. ( Cameron, JS; Dillon, MJ; Farebrother, DA; Pincott, JR; Simmons, HA; Warren, DJ, 1981)
"Coronary heart disease is the leading cause of death in the gouty and nongouty population."1.26Changing trends of mortality in gout. ( Talbott, JH; Yü, T, 1980)
" A twice-daily regimen was considerably more effective than a single morning dosage in reduction of plasma urate, though both regimens were equally effective in antihypertensive potency."1.26Controlled inpatient study of tienilic acid in treatment of gout and hypertension. ( Reardon, JA; Scott, JT, 1980)
"Uric acid clearance was decreased to 3."1.26A case of gouty arthritis associated with Down's syndrome. ( Aikawa, T; Akaoka, I; Horiuchi, Y; Maruki, M; Mitamura, T; Nishida, Y; Nishizawa, T; Yokohari, R, 1976)
"The histological alterations in pseudogout were uniform, 2-4 rows of slightly pleomorphic synovial cells lined the inner surface of the joint capsule, sclerosing alterations were less frequent."1.26[Needle biopsy in gout and pseudogout (author's transl)]. ( Huth, F; Klein, W; Lenz, W, 1976)
"The management of gout has four phases: control of inflammation, diagnostic evaluation, education of the patient, and treatment for the hyperuricemia."1.26Management of gout. ( Simkin, PA, 1979)
"Eight of 36 untreated gouty men excreted acid at a rate more than three standard deviations above normal."1.26Uric acid excretion: quantitative assessment from spot, midmorning serum and urine samples. ( Hoover, PL; Paxson, CS; Simkin, PA; Wilson, WF, 1979)
"Hypertension was found in 18% of 65 patients with untreated gout, a lower prevalence than that previously reported."1.26Hypertension, renal function and gout. ( Gibson, T; Highton, J; Potter, CF; Simmonds, HA, 1979)
"Uric acid clearance was increased by benzbromarone from 3."1.26[The effect of benzbromaron in gout patients with limited kidney function]. ( Bresnik, W; Kuzmits, R; Müller, MM, 1979)
"Ticrynafen is an orally administered diuretic that is similar to the thiazides in its therapeutic actions, but unlike the thiazides, it increases urate excretion and lowers serum uric acid levels."1.26Evaluation of a new uricosuric diuretic--ticrynafen. ( Kosman, ME, 1979)
"A pheochromocytoma was found to be the cause of malignant hypertension, which had been present for many years."1.26[Juvenile gout with decreased activity of hypoxanthine-guanine-phosphoribosyl transferase and pheochromocytoma: partial persistence of tophi despite uric-acid reducing treatment for 12 years (author's transl)]. ( Goebel, FD; Gröbner, W; Ohlschlägel, G; Zöllner, N, 1978)
"The incidence of gout has increased in recent years."1.26[Gout - a surgical problem]. ( Flügel, M; Geldmacher, J, 1978)
"At the high dosage of 600 mg daily, the uric-acid reducing effect of allopurinol depends on the initial level of uric-acid concentration in the same manner as at the usual dosage of 300 mg daily, but is more marked at the entire hyperuricaemic concentration range of 65--71 mumol/l (11--12 mg/l)."1.26[Uric-acid reduction with high allopurinol dosages (author's transl)]. ( Loewer, H; Mertz, DP, 1979)
"Both renal calculi and tophi are frequent in female gout associated with blood dyscrasias."1.26Some unusual features of gouty arthritis in females. ( Yü, TF, 1977)
"Nearly 25% of all examined renal calculi contain uric acid, sodium acid urate or ammonium acid urate as constituents."1.26[Urate nephrolithiasis. Cause of consequence?]. ( Mertz, DP, 1976)
" The control of the hyperuricemia and gout has been satisfactorily accomplished in the Filipino patients with the long-term use of allopurinol, sometimes complemented with colchicine taken daily."1.25The Filipino and gout. ( Bayani-Sioson, PS; Torralba, TP, 1975)
"A nearly 72-old black male with sickle cell anemia suffered from heart failure, hypertension, chronic impaired kidney function with hyperuricemia and gout."1.25Long survival in sickle cell anemia. ( Huisman, TH; Sar, AV, 1975)
"The occurence of gout is questionable in this connection, relevant seems to be only the coincidence of psoriasis and gout."1.25[The simultaneous occurrence of psoriasis, sarcoidosis and gout. Report of 3 cases]. ( Eckes, L, 1975)
"Allopurinol has been universally successful in lowering the serum uric acid concentration and uric acid excretion to normal levels, while not significantly affecting the clearance of urate or other aspects of renal function."1.24The treatment of gout and disorders of uric acid metabolism with allopurinol. ( Houpt, JB; Ogryzlo, MA; Urowitz, MB; Weber, HM, 1966)

Research

Studies (4,404)

TimeframeStudies, this research(%)All Research%
pre-19901904 (43.23)18.7374
1990's285 (6.47)18.2507
2000's435 (9.88)29.6817
2010's1084 (24.61)24.3611
2020's696 (15.80)2.80

Authors

AuthorsStudies
Ichida, K24
Hosoyamada, M3
Kimura, H1
Takeda, M1
Utsunomiya, Y1
Hosoya, T32
Endou, H5
Talkington, AM1
McSweeney, MD1
Zhang, T3
Li, Z16
Nyborg, AC1
LaMoreaux, B8
Livingston, EW1
Frank, JE1
Yuan, H4
Lai, SK1
Adams, CD1
Boutwell, BB1
Wang, M11
Zhang, Y38
Zhang, M10
Li, H18
Wen, C4
Zhao, T12
Xie, Z3
Sun, J4
Riches, PL5
Downie, L1
Thomson, C1
Luo, LS1
Wang, Y53
Dai, LJ1
He, FX1
Zhang, JL1
Zhou, Q4
Scholz, J3
Roiser, N3
Braig, EM2
Petrich, C2
Birnbacher, L1
Andrejewski, J3
Kimm, MA3
Sauter, A2
Busse, M2
Korbel, R3
Herzen, J3
Pfeiffer, D3
Jansen, TL29
Tanja, G1
Matthijs, J1
Méndez-Salazar, EO2
Martínez-Nava, GA4
Ran, Z6
Xue, X8
Han, L8
Terkeltaub, R35
Merriman, TR67
He, Y15
Wang, C17
Li, X31
Liu, Z19
Cui, L8
Ji, A11
Hu, S8
Lu, J12
Li, C29
Bardin, T33
Magnat, E1
Clerson, P3
Richette, P34
Rouchon, B1
Kojima, S2
Uchiyama, K2
Yokota, N2
Tokutake, E2
Wakasa, Y2
Hiramitsu, S2
Waki, M2
Jinnouchi, H2
Kakuda, H2
Hayashi, T2
Kawai, N2
Sugawara, M3
Mori, H2
Tsujita, K2
Matsui, K2
Hisatome, I15
Ohya, Y2
Kimura, K2
Saito, Y4
Ogawa, H4
Borghi, C14
Fiorini, G1
Zhou, GQ1
Chen, G3
Yang, J6
Qin, WY1
Ping, J1
Wen, S1
Arakawa, H1
Tamai, I2
Teng, MS1
Wu, S2
Hsu, LA1
Chou, HH1
Ko, YL1
Engel, B4
Hoffmann, F1
Freitag, MH1
Jacobs, H1
Huang, Q4
Wang, P8
Liao, X1
Lan, Z1
Chen, L8
Feng, J2
Wang, F4
Liu, P2
Yue, X1
Du, L1
Zhao, Y10
Yang, P1
Luo, J2
Zhu, Z3
Hu, X2
Cao, L11
Lu, P1
Sah, R1
Lavine, K1
Kim, B2
Hu, H4
Bao, W1
Xue, Y13
Cheng, X9
Yin, B1
Su, Y1
Jia, C1
Halperin Kuhns, VL3
Woodward, OM8
Jia, E8
Zhu, H6
Geng, H7
Zhong, L4
Liu, S11
Lin, F3
Zhang, J20
Gaffo, AL9
Saag, K7
Doyle, AJ12
Melnick, J1
Horne, A28
Foster, J1
Mudano, A2
Biggers-Clark, S1
Redden, D1
Dalbeth, N183
Liu, W9
Wu, YH1
Xue, B1
Jin, Y3
Zhang, SM1
Li, PH1
Xie, Q2
Wang, AH1
Gao, JY1
Cai, Y2
Zhang, B12
Liu, XY1
Duan, R1
Chabernaud Negrier, A1
Taihi, L1
Vicaut, E1
Lioté, F24
Ea, HK17
Bousson, V3
Leask, MP1
Yu, CW1
Wu, SC1
Li, TH1
Wei, JC6
Sandoval-Plata, G5
Nakafero, G4
Chakravorty, M2
Morgan, K5
Abhishek, A16
Singh, JA41
Joseph, A1
Baker, J1
Richman, JS1
Shaneyfelt, T1
Saag, KG20
Eisen, S1
Stamp, LK81
Farquhar, H1
Lee, YH11
Song, GG8
Helm, M1
Ng, B1
Mogavero, A1
Jatuworapruk, K11
Grainger, R16
Taylor, WJ41
García-Maturano, JS1
Torres-Ordaz, DE1
Mosqueda-Gutiérrez, M1
Gómez-Ruiz, C2
Vázquez-Mellado, A1
Tafoya-Amado, A1
Peláez-Ballestas, I4
Burgos-Vargas, R8
Vázquez-Mellado, J18
Kimura, Y1
Tsukui, D1
Kono, H6
Morillon, MB6
Christensen, R7
Neogi, T23
Kennedy, MA2
Pedersen, BM2
McCarthy, GM2
Shea, B2
Diaz-Torne, C10
Tedeschi, SK2
Gaffo, A6
Nielsen, SM3
Noerup, A1
Simon, LS3
Lassere, M4
Tugwell, P2
Gout Working Group, FTO1
Martins, D1
Tonon, CR1
Pacca, RL1
Matchil, NL1
Junior, LAJ1
Queiroz, DS1
Pereira, FWL1
Silva, AM1
Padovese, V1
Padovani de Toledo Moraes, M1
Luiz da Silva, D1
Cardoso Nóbrega, V1
Curcelli, EC1
Okoshi, MP1
Xie, WR1
Yang, XY1
Deng, ZH1
Zheng, YM1
Zhang, R1
Wu, LH1
Cai, JY1
Kong, LP1
Xia, HH1
He, XX1
Tin, A6
Schlosser, P1
Matias-Garcia, PR1
Thio, CHL2
Joehanes, R1
Liu, H5
Yu, Z2
Weihs, A1
Hoppmann, A2
Grundner-Culemann, F1
Min, JL1
Kuhns, VLH1
Adeyemo, AA2
Agyemang, C1
Ärnlöv, J2
Aziz, NA1
Baccarelli, A1
Bochud, M6
Brenner, H1
Bressler, J1
Breteler, MMB1
Carmeli, C1
Chaker, L1
Coresh, J12
Corre, T2
Correa, A1
Cox, SR1
Delgado, GE1
Eckardt, KU3
Ekici, AB2
Endlich, K2
Floyd, JS1
Fraszczyk, E1
Gao, X6
Gelber, AC8
Ghanbari, M1
Ghasemi, S2
Gieger, C6
Greenland, P1
Grove, ML2
Harris, SE2
Hemani, G1
Henneman, P1
Herder, C1
Horvath, S1
Hou, L1
Hurme, MA1
Hwang, SJ5
Kardia, SLR1
Kasela, S1
Kleber, ME3
Koenig, W2
Kooner, JS3
Kronenberg, F5
Kühnel, B2
Ladd-Acosta, C1
Lehtimäki, T3
Lind, L1
Liu, D3
Lloyd-Jones, DM1
Lorkowski, S1
Lu, AT1
Marioni, RE1
März, W3
McCartney, DL1
Meeks, KAC1
Milani, L1
Mishra, PP2
Nauck, M5
Nowak, C1
Peters, A2
Prokisch, H3
Psaty, BM4
Raitakari, OT2
Ratliff, SM1
Reiner, AP1
Schöttker, B1
Schwartz, J1
Sedaghat, S2
Smith, JA1
Sotoodehnia, N1
Stocker, HR1
Stringhini, S1
Sundström, J1
Swenson, BR1
van Meurs, JBJ1
van Vliet-Ostaptchouk, JV1
Venema, A1
Völker, U3
Winkelmann, J1
Wolffenbuttel, BHR1
Zhao, W2
Zheng, Y3
Loh, M1
Snieder, H4
Waldenberger, M4
Levy, D2
Akilesh, S1
Susztak, K2
Teumer, A5
Köttgen, A15
Chen, D2
Xu, H5
Sun, L3
Li, Y36
Wang, T8
Patel, V1
Dass, N1
Peng, Z1
Ding, YM1
Pei, L2
Yao, HH1
Zhang, XW1
Tang, SM1
Liu, X15
Li, B4
Zhang, X15
Mo, S1
Liang, D1
Zhu, J7
Choi, HK39
McCormick, N5
Yokose, C8
Honda, M2
Horiuchi, H5
Torii, T2
Nakajima, A5
Iijima, T2
Murano, H2
Yamanaka, H26
Ito, S2
Billington, K2
Gamble, GD19
Tan, P12
Latto, K1
Parshu Ram, T1
Narang, R2
Murdoch, R1
Bursill, D4
Mihov, B3
Blake, KEG1
Saag, JL1
Ofanoa, M2
Ofanoa, SM1
Heather, M2
Tu'akoi, S2
Lutui, H2
Grey, C2
van der Werf, B1
Goodyear-Smith, F2
Chen, T1
Ma, DL1
Gutierrez, M7
Sandoval, H1
Bertolazzi, C1
Soto-Fajardo, C1
Tellez-Gastelum, RM1
Reginato, AM4
Clavijo-Cornejo, D1
Yip, K2
Berman, J1
Anderson, IJ1
Davis, AM1
Jan, RH1
Seifert, KD1
Zohrabian, VM1
Ikuta, I1
Latourte, A8
Dumurgier, J1
Paquet, C1
Rasmussen, C2
Larsen, MB1
Linauskas, A1
Mikuls, TR18
Soto, Q1
Petro, A1
Helget, L1
Roul, P1
Sayles, H4
Cope, B1
O'Dell, JR2
England, BR1
ElSayed, S4
Jay, GD4
Cabezas, R1
Qadri, M4
Schmidt, TA4
Elsaid, KA1
Zhao, L14
Yang, X14
Xu, R5
Liu, J15
Lin, C8
Yu, Y7
Xuan, D3
Zhu, X14
Liu, L12
Hua, Y5
Deng, C1
Wan, W6
Zou, H15
Alhilali, M2
Riordan, P1
Chhana, A13
McGlashan, S2
Doyle, A4
Andres, M18
Khanna, P4
Pascart, T15
Budzik, JF9
Ballur, AFH1
Altinoz, E1
Yigitturk, G1
Onal, MO1
Elbe, H1
Bicer, Y1
Karayakali, M1
Demir, M1
Xue, L1
Chen, Y25
Quan, F1
Xiao, Y6
Han, M2
Jiang, Q1
Lu, L1
Mount, DB9
Feng, Z1
Xu, Y8
Ji, X7
Wang, X20
Baffour, FI1
Ferrero, A1
Aird, GA1
Powell, GM1
Adkins, MC1
Bekele, DI1
Johnson, MP1
Fletcher, JG2
Glazebrook, KN5
Tao, Y3
Liao, H2
Zhao, F2
Liang, R2
Shi, X4
Zhang, Z11
Ji, J2
Wu, T3
Pang, J4
Zhan, P3
van de Laar, CJ1
Janssen, CA3
Janssen, M24
Oude Voshaar, MAH3
Al, MJ1
van de Laar, MAFJ3
Barranco-Trabi, J1
Mank, V1
Minns, R1
Ryan, C1
Roberts, J3
Yao, X3
Xie, J4
Jiang, Y12
Qiu, X4
Xiao, M6
Tang, D2
Wei, J9
Li, S8
Xu, G3
Liang, J4
Wan, L1
Cao, H4
Lin, J4
Stewart, S7
Phipps-Green, A21
Wang, Z11
Liu, R3
Di, X1
Zhou, Y7
Fan, L1
Zheng, L1
Drosos, GC1
Vedder, D2
Houben, E1
Boekel, L1
Atzeni, F1
Badreh, S1
Boumpas, DT2
Brodin, N1
Bruce, IN1
González-Gay, MÁ4
Jacobsen, S1
Kerekes, G1
Marchiori, F1
Mukhtyar, C1
Ramos-Casals, M1
Sattar, N1
Schreiber, K1
Sciascia, S1
Svenungsson, E1
Szekanecz, Z1
Tausche, AK24
Tyndall, A1
van Halm, V1
Voskuyl, A1
Macfarlane, GJ1
Ward, MM1
Nurmohamed, MT2
Tektonidou, MG1
Peeters, IR2
Oude Voshaar, AMH1
Moses, A1
Jansen, TLTA4
Flendrie, M3
van Herwaarden, N2
Kim, HW1
Joo, YS1
Yun, HR1
Kim, JY3
Jhee, JH1
Roh, YH1
Park, JT1
Chang, TI2
Yoo, TH1
Kang, SW1
Han, SH1
McPherson, M1
Aslam, F3
Botson, JK8
Baraf, HSB2
Keenan, RT15
Albert, J1
Masri, KR2
Peterson, J6
Yung, C1
Freyne, B2
Amin, M1
Abdellatif, A2
Soloman, N1
Edwards, NL21
Strand, V3
Emad, Y1
Weinman, J1
Chalder, T1
Petrie, KJ3
Pérez Ruiz, F2
Pérez Herrero, N1
Gantes Pedraza, MÁ1
Nguyen, QD3
Hieu, NL1
Tran, KM2
Do, MD2
Resche-Rigon, M2
Te Kampe, R4
Boonen, A10
Jansen, T2
de Vries, H3
van Durme, C6
Xu, N1
Han, X3
Huang, X3
Zhu, W1
Shen, M2
Zhang, W16
Jialin, C1
Wei, M2
Qiu, Z1
Zeng, X6
Schwotzer, N1
Auberson, M1
Livio, F1
So, A15
Bonny, O1
Luo, L2
Gan, R1
Zeng, L4
Yeo, AE6
Lipsky, PE7
Löffler, W4
Fairbanks, L3
Gibson, T17
Siddiq, MAB1
Rasker, JJ3
Sun, M9
Sun, W10
Zhao, X1
Qu, H1
Zheng, G1
Ma, L8
Wang, J32
Shi, Y13
Fang, X2
Chen, H10
Cong, R1
Song, Z2
Chen, S6
Liu, G2
Liu, Y20
Pang, X1
Dong, F1
Xing, W1
Xu, X5
Yin, H1
Liu, N4
Chen, J14
Russell, MD2
Nagra, D1
Clarke, BD1
Balachandran, S1
Buazon, A1
Boalch, A1
Bechman, K1
Adas, MA1
Alveyn, EG1
Rutherford, AI2
Galloway, JB2
Becce, F10
Kumar, A1
Wessig, AK2
Hoffmeister, L2
Klingberg, A2
Alberts, A2
Pich, A2
Brand, K2
Witte, T1
Neumann, K2
Christiansen, SN5
Østergaard, M5
Slot, O11
Fana, V2
Terslev, L7
Türker, PF1
Hoca, M1
Özduran, G1
Akçil Ok, M1
Demir Çelebi, M1
Filippou, G3
Pacini, G2
Sirotti, S2
Zadory, M1
Carboni, D1
Damiani, A1
Fiorentini, E1
Cipolletta, E5
Filippucci, E6
Froehlich, JM1
Sarzi Puttini, P1
Schlesinger, N29
Padnick-Silver, L2
Rustgi, VK1
Lee, HJ1
Choi, JY2
Lee, J7
Kim, D1
Min, JY1
Min, KB1
Phrintrakul, N1
Wongthanee, A1
Kasitanon, N2
Louthrenoo, W8
Li, P6
Kurata, Y1
Taufiq, F2
Kuwabara, M8
Ninomiya, H5
Higaki, K1
Tsuneto, M1
Shirayoshi, Y1
Lanaspa, MA3
Huang, Y11
Chi, J2
Lv, W3
Hilsabeck, TAU1
Liu-Bryan, R10
Guo, T1
Wilson, KA2
Bose, N2
Raftery, D1
Beck, JN2
Lang, S2
Jin, K1
Nelson, CS1
Oron, T1
Stoller, M1
Promislow, D1
Brem, RB1
Kapahi, P2
Brunetti, L2
Androulakis, IP1
Elling, JM1
van Eijk-Hustings, Y2
Keller, SF1
Mandell, BF11
Sinnappah, KA1
Stocker, SL13
Chan, JS2
Hughes, DA3
Wright, DFB5
Ramos, GK1
Goldfarb, DS4
Choy, SH1
Nyanatay, SA1
Sothilingam, S1
Malek, R1
J R, S1
Toh, CC1
Sundram, M1
Md Yusoff, NA1
Nagappan, P1
Kamaruzaman, S1
Yeoh, WS1
Ong, TA1
Lim, J1
Lee, Y1
Kim, N1
Werlinger, P1
Suh, DA1
Lee, H4
Cho, JH1
Cheng, J2
Uhlig, T18
Karoliussen, LF8
Sexton, J7
Kvien, TK8
Haavardsholm, EA8
Perez-Ruiz, F55
Hammer, HB8
Schuh, A1
Goyal, T1
Schmidtmann, M1
Koehl, P1
Syed, AAS1
Fahira, A1
Yang, Q11
Tse, JJ1
Kondro, DA1
Kuczynski, MT1
Pauchard, Y1
Veljkovic, A1
Holdsworth, DW1
Frasson, V1
Manske, SL1
MacMullan, P1
Salat, P1
Yu, H6
Chai, S1
Chai, X1
Wang, L6
Geng, WC1
Li, JJ1
Yue, YX1
Guo, DS1
Wu, ZD1
Yang, XK1
He, YS1
Ni, J2
Yin, KJ1
Huang, JX1
Feng, YT1
Pan, HF1
Pou, MA3
Orfila, F1
Pagonabarraga, J1
Ferrer-Moret, S1
Corominas, H2
Zamudio-Cuevas, Y5
Martínez-López, V1
Luján-Juárez, IA1
Montaño-Armendariz, N1
Martínez-Flores, K5
Fernández-Torres, J5
Gimeno, M1
Sánchez-Sánchez, R2
Natsuko, PD1
Laura, SC1
Denise, CC1
Lucio, VR1
Carlos, AS1
Fausto, SM1
Ambar, LM1
Copur, S1
Demiray, A1
Kanbay, M1
Becker, MA35
White, WB4
Whelton, A3
Borer, JS1
Gorelick, PB1
Hunt, B8
Castillo, M2
Gunawardhana, L7
Chen, HW3
Chen, YC5
Lee, JT1
Yang, FM2
Kao, CY2
Chou, YH3
Chu, TY1
Juan, YS1
Wu, WJ3
Alkilany, R2
Einstadter, D2
Antonelli, M2
Yuan, X7
Chen, R3
Lin, X2
Juraschek, SP7
Gaziano, JM2
Glynn, RJ5
Gomelskaya, N1
Bubes, VY1
Buring, JE1
Shmerling, RH3
Sesso, HD1
Weisshaar, S1
Litschauer, B1
Reichardt, B1
Gruber, F1
Leitner, S1
Sibinovic, S1
Kossmeier, M1
Wolzt, M1
Huddleston, EM1
Ye, W1
Zhu, Y6
Chen, F3
Wang, Q4
Lv, X2
Du, Z1
Silva, CR4
Saraiva, AL1
Rossato, MF3
Trevisan, G3
Oliveira, SM4
Guan, Y2
Meng, L1
Qian, Q2
Cândido, FG1
Alves, RDM1
Freitas, DMO1
Bittencourt, JM1
Rocha, DMUP1
Alfenas, RCG1
Sahin, A1
Kilic, K1
Sakat, MS1
Melikoglu, MA1
Sarihan, K1
Tam, V1
Nam, VT1
Quoc, TAH1
Liu, ZQ1
Sun, X6
Liu, ZB1
Zhang, LL1
Wu, CJ1
Ren, L5
Li, Q6
Zhan, X1
Yang, R1
Fang, Z1
Liu, T5
Wei, Z1
Zhao, J3
Lin, L1
Mou, W1
Dai, W1
Bai, Z2
Cao, J1
Wong, PKK1
Ng, BCK1
Mitchell, J1
Han, J1
Lam, C1
Spencer, D1
Cai, K1
Manolios, N1
Coleshill, MJ5
Day, RO16
Tam, K1
Kouhkamari, M1
Caillet, V1
Aung, E6
Kannangara, DRW2
Cronin, P1
Rodgers, A1
Li, R1
Ren, W4
Ning, C1
Piao, MH2
Wang, H8
Jiang, YJ1
Wu, YL5
Nan, JX2
Lian, LH2
Agrawal, M1
Niroula, A1
Cunin, P1
McConkey, M1
Shkolnik, V1
Kim, PG1
Wong, WJ1
Weeks, LD1
Lin, AE1
Miller, PG1
Gibson, CJ1
Sekar, A1
Schaefer, IM1
Neuberg, D1
Stone, RM1
Bick, AG1
Uddin, MM1
Griffin, GK1
Jaiswal, S1
Natarajan, P1
Nigrovic, PA1
Rao, DA1
Ebert, BL1
Mendieta, L1
Argente-Del-Castillo, E1
Trigueros, M1
Miñano, A1
Pascual, E33
Van Demark, RE1
Brown, J1
Hayes, M2
Smith, VJS1
Yan, J1
Wu, J9
He, X2
Kampe, RT1
Hotea, I1
Orji, OC1
López-Domínguez, MB1
Guetta-Baranes, T1
Valdes, AM4
Doherty, M32
Hull, SD1
Andersen, MW1
Bengtsson, J1
Skovgaard, N1
Backe, MB1
Pedersen, ML1
Lin, CY2
Chang, YS2
Liu, TY2
Huang, CM5
Chung, CC2
Tsai, FJ2
Chang, JG4
Chang, SJ6
Fukuuchi, T3
Itahashi, I1
Takayanagi, F2
Yamaoka, N2
Kaneko, K3
Avery, AJ2
Mamas, M1
Tata, LJ2
Zhang, H17
Coleman, GB1
Frampton, C25
Haslett, J3
Drake, J17
Su, I2
Horne, AM2
Wang, CC1
Li, YL1
Chiu, PY1
Chen, C3
Chen, HC2
Chen, FA1
Leung, N1
Pillinger, MH21
Toprover, M5
Baumgartner, C1
Braig, E1
Yan, F2
Qi, H1
Yu, Q4
Mechlin, M1
Fields, T1
Oh, C2
Park, EH1
Choi, ST5
Song, JS4
Akari, S1
Nakamura, T25
Furusawa, K1
Miyazaki, Y1
Kario, K1
Topless, R11
Noorbaloochi, S1
Zhao, SS2
Rajasundaram, S1
Karhunen, V1
Alam, U1
Gill, D1
Stauder, SK1
Peloso, PM3
Luo, Q1
Zhao, Q3
Tian, L1
Liu, WJ1
Rollefstad, S1
Semb, AG1
Jensen, G1
Zhu, L6
Liu, M3
Shan, L2
Galozzi, P4
Oliviero, F9
Scanu, A10
Lorenzin, M4
Ortolan, A4
Favero, M3
Doria, A3
Ramonda, R8
Guma, M1
Dadpey, B1
Coras, R1
Hamilton, B1
Quehenberger, O1
Thorisdottir, H1
Bittleman, D1
Lauro, K1
Reilly, SM1
Vio, S1
Gallo, M1
Liang, Z1
Li, M13
Fu, D1
Zhang, L9
Guo, Y8
Ge, D1
Sun, B3
Cao, W1
Liang, F1
Fang, Y1
Cheng, Y2
Pan, S2
Pan, X1
Cao, X1
Mei, Y1
Dong, B4
Geng, Z1
Xu, L8
Di Battista, J2
Grassi, W9
Uchino, T1
Motoki, N1
Uchida, K1
Asakura, H1
Uno-Eder, K1
Nomura, T1
Tsukamoto, K1
Nian, YL1
You, CG2
Mehmood, A1
Althobaiti, F1
Usman, M1
Chen, X13
Alharthi, F1
Soliman, MM1
Shah, AA1
Murtaza, MA1
Nadeem, M1
Ranjha, MMAN1
Ughi, N1
Ariani, A2
Raffeiner, B1
Frallonardo, P2
Hoxha, A1
Parisi, S1
Bortoluzzi, A2
Ceccarelli, F1
Lucchetti, R1
Furini, F1
Del Ross, T1
Zanetti, A1
Carrara, G2
Scirè, CA7
Yao, J1
Lin, YP2
Lu, QY1
Fan, GJ1
Pálinkás, M1
Szabó, E1
Kulin, A1
Mózner, O1
Rásonyi, R1
Juhász, P1
Nagy, K1
Várady, G1
Vörös, D1
Zámbó, B1
Sarkadi, B2
Poór, G3
Deng, JH1
Zhong, GW1
Zhang, JX1
Ou, YN1
Zhao, B3
Fu, Y5
Sheng, ZH1
Gao, PY1
Tan, L1
Yu, JT1
Yang, Y16
Xian, W1
Wu, D2
Huo, Z1
Hong, S4
Xiao, H1
Tesser, JRP3
Bennett, R2
Kenney, HM2
Obermeyer, K4
Song, Y3
Xin, Y5
Chamberlain, J3
Ramanathan, S1
Weinblatt, ME4
Chu, Q2
Yang, C12
Fu, M1
Sun, G1
Luo, Z1
Yang, F3
Chen, B4
Li, L13
Yao, Y3
Hu, Y5
Wang, S8
Xu, T2
Li, YJ1
Chen, LR1
Yang, ZL2
Jiang, FF1
Qian, K2
Yang, M6
Yin, SJ1
He, GH1
Hammam, N1
Li, J7
Kay, J2
Izadi, Z1
Yazdany, J1
Schmajuk, G1
Lauffenburger, JC1
Lu, Z1
Mahesri, M1
Kim, E1
Tong, A1
Kim, SC6
Rodríguez-Díez, B1
Pujol-Ribera, E1
Wo, X1
Zeng, Y1
Ma, W4
Zhan, Z1
Yuan, M1
Roman, YM1
Parikh, N1
Ong, S1
La, D1
LoCicero, K1
Verma, S1
Sainati, S1
Grewal, S1
Majjhoo, A1
Riaño, D1
Pečnik, Š1
Alonso, JR1
Kamišalić, A1
Zhu, Q1
Miao, Y1
Bai, W1
Yu, S1
Guo, D1
Sun, D2
Zeng, F1
Wang, W11
Chen, Z4
Shi, J2
He, R1
Ji, M2
Mikhailidis, DP2
Kouvari, M1
Pangiotakos, DB1
Zeng, Z1
Jin, T3
Huang, L1
Xie, Y4
He, W2
Ding, C1
Cen, H1
Jiang, X3
Deng, Y3
Sun, F1
Lin, P1
Ma, Y7
Cao, Y3
Guo, QH1
Lu, JG1
Zheng, BL1
Li, T2
Chen, SH1
Żyluk, A1
Fliciński, F1
Helget, LN1
Sabolová, M1
Kulma, M1
Petříčková, D1
Kletečková, K1
Kouřimská, L1
Du, X2
Jin, S1
Kurniasari, MD1
Karwur, FF2
Rayanti, RE2
Shih, YW1
Yuliana, S1
Miao, NF1
Chou, KR1
Shen, CJ1
Tsai, HT2
Mackenzie, IS3
Hawkey, CJ2
Ford, I2
Greenlaw, N1
Pigazzani, F1
Rogers, A1
Struthers, AD2
Begg, AG1
Wei, L4
Taggar, JS1
Walker, A1
Duce, SL1
Barr, RJ1
Dumbleton, JS1
Rooke, ED1
Townend, JN1
Ritchie, LD1
MacDonald, TM3
He, Q1
Yang, K1
Xiang, W2
Dong, Y2
Gao, S3
Qi, D1
Fazlollahi, A1
Zahmatyar, M1
Alizadeh, H1
Noori, M1
Jafari, N1
Nejadghaderi, SA1
Sullman, MJM1
Gharagozli, K1
Kolahi, AA1
Safiri, S1
Mass, BB1
Talevi, V1
Hou, R1
North, KE2
Voruganti, VS2
Tsai, YS2
Ko, MY1
Fung, M5
Baumgartner, S13
El-Mallah, R1
Ibrahim, RA1
El Attar, EA1
Kwon, HS1
Park, Y2
Kim, JH5
Kim, SH5
Jun, JB3
Park, S2
Kang, DR1
Choi, H6
Miguel-Pérez, M1
Coronel, L1
Bong, D1
Möller, I2
Eliseev, MS7
Panevin, TS1
Zhelyabina, OV1
Nasonov, EL6
Sigurdardottir, V5
Svärd, A5
Jacobsson, L9
Dehlin, M9
Si, K2
Wei, C1
Hsu, CM1
Hsu, CC3
Wu, RW1
Huang, CC1
Sawada, S1
Kajiyama, K1
Shida, H1
Kimura, R1
Nakazato, Y1
Iguchi, T1
Oniyama, Y1
Ishiguro, C1
Uyama, Y1
Kim, J1
Ghang, B1
Jeong, W1
Shi, C1
Zhou, Z7
Chi, X1
Xiu, S1
Yi, C1
Jiang, Z1
Yilmaz, F1
Acikalin, MF1
Kasifoglu, T1
Cohen-Rosenblum, AR1
Somogyi, JR1
Hynes, KK1
Guevara, ME1
Roddy, E21
Ellis, B1
Norton, S1
Douiri, A1
Gulliford, MC1
Cope, AP1
Satpanich, P4
Robinson, PC14
Hishe, HZ3
Yang, N3
Cao, B3
Miyazaki, S3
Hamada, T4
Isoyama, T3
Okada, S4
Tomita, K4
Endo, Y3
Sugihara, S3
Ogino, K5
Yamamoto, K7
Takenaka, A3
Ul-Haq, A3
Lee, KA3
Seo, H3
Kim, S4
Jo, S3
Ko, KM3
Moon, SJ4
Kim, YS3
Choi, JR4
Song, HY3
Kim, HS4
Zhao, LJ3
Gao, HY3
Gao, C3
Li, XF3
Elsaid, K3
Rossitto, LA3
Karsh, J3
Miner, M3
Cadzow, M16
Dambruoso, TJ3
Höglund, J3
Ghassemian, M3
Campeau, A3
Maltez, N3
Karlsson, NG3
Gonzalez, DJ3
Zhou, M7
Liu, C7
Qian, J3
Hao, K3
Jiang, C3
Hu, Q6
Xu, Q4
Lin, CS3
Galvão, I10
Mastrippolito, D2
Talamini, L2
Aganetti, M2
Rocha, V2
Verdot, C2
Mendes, V2
de Oliveira, VLS2
Braga, AD2
Martins, VD2
de Faria, AMC2
Amaral, FA10
Georgel, P3
Vieira, AT5
Muller, S7
Lei, Y2
Cui, TJ2
Wang, XH2
Zhang, XM2
Tang, C3
Zheng, ZH2
Tu, Y2
Du, J4
Yu, D2
He, P2
Xu, J3
Hui, R1
Xing, Y1
Shi, S2
Jarraya, M1
Roemer, F1
Kwoh, CK1
Guermazi, A1
Linnerz, T1
Sung, YJ1
Rolland, L1
Astin, JW2
Hall, CJ2
Saffarzadeh, M1
Haydar, SMA1
Shojania, K3
Ouellette, H3
Nicolaou, S8
Murray, N1
Wu, H10
Ren, Z1
Huang, J3
Lin, Z3
Zhong, X1
Xia, H1
Zhao, M2
Guo, X2
Schauer, C3
Schoen, J1
Lu, C1
Herrmann, M5
Lv, Z1
Cui, J1
Wang, JX1
Fonseca, AC1
Spragg, JCJ1
Michael, TJF1
Aslani, P1
Tan, H1
Zhang, S3
Yang, DH1
da Silva-Júnior, EF1
Xu, S3
Wu, X9
You, C1
Mirzaesmaeili, A1
Zangiabadi, S1
Raspanti, J1
Akram, A1
Inman, RD1
Abdul-Sater, AA1
Ohashi, Y1
Toyoda, M1
Saito, N1
Koizumi, M1
Kanai, G1
Komaba, H1
Kimura, M2
Wada, T1
Takahashi, H2
Takahashi, Y1
Ishida, N1
Kakuta, T1
Fukagawa, M1
Min, J3
Shin, S2
Prest, M1
Li, W3
Han, Y5
Yan, C1
Wu, Q1
Zeng, H1
Wan, A1
Luo, C1
Tao, J1
Zhong, H3
Huang, Z2
Zou, B1
Zou, G1
Xie, N1
Liang, Y2
Chen, W3
Mei, L1
Yang, Z3
Gao, K1
Huang, H2
Huang, R2
Chen, LC1
Chen, YJ1
Lin, HA1
Chien, WC1
Tsai, KJ1
Chung, CH1
Wang, JY2
Chen, CC2
Liao, NS1
Shih, CT1
Lin, YY1
Huang, CN2
Ojcius, DM1
Huang, KY1
Lin, HC2
Fan, Y4
Mou, X1
Qing, Y1
Yan, X2
Tang, X3
Yue, W1
Gu, P1
Wen, YF1
Culhane-Pera, KA1
Pergament, SL1
Moua, Y1
Vue, B1
Yang, T1
Lo, M1
Knights, D1
Straka, RJ1
Xiao, C1
Cui, H1
Yan, P1
Tang, M2
Zou, Y2
Alfredsson, L1
Klareskog, L1
Jin, XF1
Zou, JM1
Lai, SW4
Liao, KF4
Kuo, YH3
Hwang, BF1
Liu, CS1
Kohagura, K1
Kou, J1
Dang, W2
Xu, D5
You, L1
Zhu, F1
Kim, MY1
Bang, E1
Hwangbo, H1
Ji, SY1
Kim, DH1
Park, C1
Hong, SH1
Kim, GY1
Choi, YH1
Butt, JH1
Docherty, KF1
Claggett, BL1
Desai, AS1
Petersson, M1
Langkilde, AM1
de Boer, RA1
Hernandez, AF1
Inzucchi, SE1
Kosiborod, MN1
Køber, L1
Lam, CSP1
Martinez, FA1
Ponikowski, P1
Sabatine, MS1
Shah, SJ1
Vaduganathan, M1
Jhund, PS1
Solomon, SD1
McMurray, JJV2
Lekpa, FK1
Bebey, FS1
Bouallo, I1
Njonnou, SRS1
Luma, HN1
Singwe-Ngandeu, M1
Choukem, SP1
Klück, V3
Cabău, G1
Mies, L1
Bukkems, F1
van Emst, L1
Bakker, R1
van Caam, A1
Crişan, TO8
Joosten, LAB6
Teramura, S1
Yamagishi, K2
Umesawa, M1
Hayama-Terada, M1
Muraki, I1
Maruyama, K1
Tanaka, M1
Kishida, R1
Kihara, T1
Takada, M1
Ohira, T1
Imano, H1
Shimizu, Y1
Sankai, T1
Okada, T1
Kitamura, A2
Kiyama, M1
Iso, H2
Yerima, A1
Sulaiman, MM1
Adamu, AA1
Kawada, T1
Lane, NE2
Lyu, H1
Zeng, C2
Lei, G1
Provan, SA1
Ruíz-Dávila, X1
Yoshida, K1
Desai, RJ2
Solomon, DH5
Gebreselassie, KZ1
Valancius, D1
Ranic, LM1
Kligora, C1
Nørup, A1
Ellingsen, TJ1
Wu, M6
Lu, T1
Lu, H1
Gong, S1
Zheng, Z1
Hu, J2
Moshkovits, Y1
Goldman, A1
Chetrit, A1
Dankner, R1
Ofanoa, S1
Jansen, RM1
Tao, H1
Mo, Y1
Yip, RM1
Cheung, TT2
So, H1
Chan, JP1
Ho, CT2
Tsang, HH1
Yu, CK1
Wong, PC1
Rashad, AY1
Daabees, HG1
Elagawany, M1
Shahin, M1
Abdel Moneim, AE1
Rostom, SAF1
Joshi, AD2
Yu, B1
Eliassen, AH1
Curhan, GC2
Raffield, LM3
Bao, D1
Lv, N1
Duan, X1
Zhao, MH1
Hou, T1
Dai, H2
Hou, Y1
Lin, H3
Zhao, Z2
Gu, Y1
Zheng, J1
Bi, Y1
Ning, G1
Xu, M1
Wang, G3
Zhuo, N2
Yan, D1
den Broeder, AA1
den Broeder, N1
Oberhofer, E1
Lu, N4
Tanikella, S1
Lin, K1
Warner, E1
Merriman, T7
Hsu, J1
Xie, R1
Dai, Q1
Fang, J2
Cherny, K1
Marder, BA1
Scandling, JD1
Zheng, WY1
Zhan, WF1
Deng, WM1
Hung, YK1
Jiang, GH1
Tong, Y1
Wei, Y4
Ju, Y1
Gao, L3
Luo, Y2
Koike, R1
Kawakami, Y1
Kondo, R1
Onishi, M1
Akiyama, M3
Asai, T1
Arai, H1
Fu, N1
Quan, J1
Shu, P1
Kim, JS3
Jiao, Z1
Charoenwutthikun, S1
Chanjitwiriya, K1
Roytrakul, S1
Kunthalert, D1
Du, K1
Mo, C1
Dong, W1
Wei, N1
Zhong, W2
You, Y2
Di Fusco, SA1
Castello, L1
Marino, G1
Flori, M1
Aquilani, S1
Riccio, C1
Nardi, F1
Gulizia, MM1
Gabrielli, D1
Oliva, F1
Colivicchi, F1
Kang, SH1
Kim, BY1
Son, EJ1
Kim, GO1
Do, JY1
Popov, D1
Jain, L1
Poulsen, RC1
Kwok, TSH2
Kuriya, B1
Hawker, G1
Choy, G2
Widdifield, J1
Holbrook, HS1
Calandruccio, JH1
Meng, Y3
Qi, Z1
Niu, Y2
Yuan, Z2
He, G1
Yu, M1
Moon, KW4
Kim, MJ5
Shin, K4
Ueda, M1
Fukui, K1
Kamatani, N22
Kamitsuji, S1
Matsuo, A1
Sasase, T1
Nishiu, J1
Matsushita, M1
Peng, J2
Wu, Y4
Ye, Z4
Zong, Z1
Wu, R2
Kutlubaev, MA1
Areprintseva, DK1
Pervushina, EV1
Song, D2
Yue, T1
Xia, T1
Nehme, R1
Nahas, PC1
de Oliveira, EP1
Kilimci, U1
Uygun, DA1
Bajad, S1
Tanna, D1
Durga Rao Yadavalli, JN1
Gupta, R2
Sheu, KL1
Chen, SC1
Zhang, Q6
Li, N1
Guo, R1
Doğan, İ1
Kor, A1
Güven, SC1
Fırat Oğuz, E1
Başer, S1
Atalar, E1
Maraş, Y1
Erel, Ö1
Erten, Ş1
So, MW4
Kim, AR1
Lee, SG4
Meng, S1
Zhao, H2
Di, H1
Yin, Y3
Niessink, T1
Giesen, T1
Efdé, M1
Comarniceanu, A1
Otto, C1
Hua, Q1
Lin, Y1
Zheng, K1
Xia, A1
Lv, L1
Jiang, H1
Zhou, X1
Zeng, M4
Ma, S2
An, J1
Grelska, A1
Sharan, D1
Light, SH1
Wang, YY2
Wang, N2
Zhang, TJ1
Jiang, YG1
He, N2
Zhao, GM1
Wexler, DJ1
Aviña-Zubieta, JA1
De Vera, MA3
Tong, J1
Liao, Z1
Jiang, M4
Kannuthurai, V1
Lin, TM1
Lee, HY1
Chang, CK1
Lin, KH2
Chang, CC1
Wu, BF1
Peng, SJ1
Jarman, JB1
Low, YS1
Augustijn, HE1
Huang, S4
DeFeo, ME1
Sekiba, K1
Hou, BH1
Meng, X3
Weakley, AM1
Cabrera, AV1
van Wezel, G1
Medema, MH1
Ganesan, C1
Pao, AC1
Gombar, S1
Dodd, D1
Jia, Z5
Dong, JF1
Yan, WJ1
Feng, XX1
Li, LS1
Cheng, W1
Sun, CS1
Li, CR1
Deng, H1
Cheng, N1
Song, C1
Sun, Y3
Hou, Z2
Yin, J1
Meng, Q1
Qin, H1
Husain, H1
Shah, V2
Bankole, A1
Martinez-Laguna, D1
Estebanez, JL1
Aivar, M1
Gayarre, R1
Conesa, A1
Hoyo, J1
Carbonell, C1
Reyes, C1
Zhu, XX3
Zou, HJ3
Stamp, L9
Chapman, PT16
Lee, JJ1
Han, F1
Yu, C1
Hu, F1
Zhou, W2
Bao, H1
Peng, X1
Xie, B1
Lai, Y1
Sosnik, A1
Boucetta, H1
Castilla-Ojo, N1
Turkson-Ocran, RA1
Conlin, PR1
Appel, LJ5
Miller, ER6
Wani, SK1
Bhat, MDA1
Malik, R1
Seo, C1
Pak, H1
Lim, H1
Gu, H1
Qin, L1
Zhao, D7
Xue, W1
Ai, Z1
Xu, B1
Peng, A1
Calabuig, I3
Marty-Ané, A2
Norberciak, L7
Legrand, J6
Martínez-Sanchis, A1
Bajpai, R1
Forrester, H1
Partington, RJ1
Mallen, CD6
Clarson, LE1
Padmanabhan, N1
Whittle, R3
Zhang, WZ1
Andres Cerezo, L1
Navrátilová, A1
Hulejová, H1
Pavlíková, M3
Závada, J4
Pavelka, K6
Šenolt, L1
Stiburkova, B6
Yamaguchi, A1
Mukai, Y1
Sakuma, T1
Suganuma, Y1
Furugen, A1
Narumi, K1
Kobayashi, M1
Aoki, Y1
Mizuta, E3
Ouchi, M4
Kurajoh, M2
Maruhashi, T1
Tanaka, A2
Morikawa, N1
Nishimiya, K1
Akashi, N1
Tanaka, Y2
Otani, N3
Morita, M1
Miyata, H1
Takada, T14
Tsutani, H2
Abe, K1
Shimizu, M2
Naito, R1
Sato, A1
Ishiwata, S1
Yatsu, S1
Shitara, J1
Matsumoto, H3
Murata, A1
Kato, T1
Suda, S1
Hiki, M1
Murase, T1
Kasai, T1
Yu, LL1
Li, CN1
Fang, MY1
Wang, B4
Lin, FP1
Liu, WH2
Tu, SH1
Xie, WX1
Zhang, RY1
Zheng, CH1
Qin, M1
Nabrdalik, K1
Lip, GYH1
Laurent, V1
Jauffret, C1
Pacaud, A1
Ducoulombier, V7
Verdun, S1
Hao, P1
Ward, R1
Tang, T1
Luo, G1
Xiang, C1
An, S1
Xu, TR1
Bian, W1
Peng, Y2
Ru, Z1
Fu, Z1
Do, H1
Choi, HJ2
Choi, B1
Son, CN4
Choi, SR1
Kim, HO2
Song, R1
Lee, SW5
Ahn, JK1
Lee, CH5
Son, KM1
Finnikin, S1
Kvasnička, A1
Friedecký, D1
Brumarová, R1
Pavelcová, K3
Mašínová, J1
Hasíková, L1
Ješina, P1
Li, D2
Yuan, S1
Ouyang, J1
Lin, D1
Quan, H2
Fu, X1
Mao, W1
Bychkov, ОА1
Kondratiuk, VE1
Bychkova, NG1
Morozova, ZV1
Bychkova, SA1
Tarasiuk, AP1
Berrocal, V1
An, L1
Khanna, D9
Hilsabeck, TA1
Sharma, A1
Brackman, DJ1
Watson, MA1
Killilea, DW1
Ho, S1
Kahn, A1
Giacomini, K1
Stoller, ML2
Chi, T1
Yang, S4
Teramoto, K1
Takeda, T1
Matsumura, Y1
Ohtahara, A2
Kondoh, H1
Barclay, M4
Kwong, JS1
Chung, SC1
Shah, A2
An, Z1
Hemingway, H1
Tian, H1
Ou, G2
Yeo, C1
Kaushal, S1
Lim, B1
Syn, N1
Oo, AM1
Rao, J1
Koura, A1
Yeo, D1
Fini, MA1
Stenmark, KR1
Ankli, B2
Berger, CT2
Haeni, N1
Kyburz, D2
Hügle, T2
So, AK3
Daikeler, T2
Chapman, P3
Hudson, B1
Hamilton, G1
Judd, A1
Liang, N1
Sun, R3
Zhuo, Y1
Cai, X1
Kösekahya, P2
Üçgül Atılgan, C1
Atılgan, KG2
Koç, M2
Tekin, K2
Çağlayan, M2
Göker, YŞ1
Gamala, M4
Jacobs, JWG4
Linn-Rasker, SF1
Nix, M2
Heggelman, BGF2
Pasker-de Jong, PCM2
van Laar, JM3
Klaasen, R3
Klauser, AS3
Halpern, EJ2
Strobl, S1
Gruber, J3
Feuchtner, G1
Bellmann-Weiler, R1
Weiss, G1
Stofferin, H1
Jaschke, W1
Singh, AK1
Haque, M1
O'Sullivan, K1
Chourasia, M1
Ouseph, MM1
Ahmed, S3
Zhou, S1
Zhong, Y1
Yang, H5
Nipate, SS1
Yelmar, PS1
Ha, YJ2
Chung, SW1
Lee, JH3
Kang, EH2
Lee, YJ2
Song, YW3
Chung, TT1
Yu, KH6
Kuo, CF5
Luo, SF5
Chiou, MJ1
Lan, WC1
Chen, JS2
Tseng, WY3
Hsieh, AH2
Wang, LC1
Khanna, PP5
Matsuo, H17
Collison, J1
Marten, J1
Wuttke, M1
Kirsten, H1
Sieber, KB1
Qiu, C1
Gorski, M1
Giri, A1
Sveinbjornsson, G1
Chu, AY1
O'Connor, LJ1
Prins, B1
Nutile, T2
Noce, D1
Cocca, M1
van der Most, PJ1
Horn, K1
Fuchsberger, C1
Afaq, S1
Amin, N1
Bakker, SJL1
Bansal, N1
Baptista, D1
Bergmann, S2
Biggs, ML1
Biino, G1
Boerwinkle, E5
Bottinger, EP1
Boutin, TS1
Brumat, M1
Burkhardt, R1
Campana, E1
Campbell, A1
Campbell, H8
Carroll, RJ1
Catamo, E1
Chambers, JC2
Ciullo, M3
Concas, MP2
Cusi, D1
Felicita, SC1
de Borst, MH1
De Grandi, A1
de Mutsert, R1
de Vries, APJ1
Delgado, G1
Demirkan, A2
Devuyst, O4
Dittrich, K1
Ehret, G1
Evans, MK2
Gansevoort, RT1
Gasparini, P3
Giedraitis, V1
Girotto, G1
Gögele, M1
Gordon, SD1
Gudbjartsson, DF3
Gudnason, V4
Haller, T3
Hamet, P1
Harris, TB3
Hayward, C4
Hicks, AA3
Hofer, E1
Holm, H3
Huang, W6
Hutri-Kähönen, N1
Ikram, MA1
Lewis, RM2
Ingelsson, E1
Jakobsdottir, J1
Jonsdottir, I2
Jonsson, H3
Joshi, PK1
Josyula, NS1
Jung, B1
Kähönen, M2
Kamatani, Y3
Kanai, M2
Kerr, SM1
Kiess, W1
Körner, A1
Kovacs, P1
Krämer, BK1
Kubo, M6
La Bianca, M1
Lange, LA1
Lehne, B1
Loeffler, M1
Loos, RJF1
Lyytikäinen, LP1
Magi, R2
Mahajan, A1
Martin, NG2
Mascalzoni, D1
Matsuda, K2
Meisinger, C2
Meitinger, T3
Metspalu, A3
Milaneschi, Y1
O'Donnell, CJ2
Wilson, OD1
Mohlke, KL1
Mononen, N1
Montgomery, GW3
Mook-Kanamori, DO1
Müller-Nurasyid, M1
Nadkarni, GN1
Nalls, MA3
Nikus, K1
Ning, B1
Nolte, IM3
Noordam, R1
O'Connell, JR1
Olafsson, I2
Padmanabhan, S1
Penninx, BWJH1
Perls, T1
Pirastu, M4
Pirastu, N3
Pistis, G3
Polasek, O4
Ponte, B1
Porteous, DJ1
Poulain, T1
Preuss, MH1
Rabelink, TJ1
Rettig, R1
Rheinberger, M1
Rice, KM1
Rizzi, F1
Robino, A1
Rudan, I6
Krajcoviechova, A1
Cifkova, R1
Rueedi, R1
Ruggiero, D3
Ryan, KA1
Saba, Y1
Salvi, E1
Schmidt, H2
Schmidt, R2
Shaffer, CM1
Smith, AV4
Smith, BH1
Spracklen, CN1
Strauch, K3
Stumvoll, M2
Sulem, P3
Tajuddin, SM1
Teren, A1
Thiery, J1
Thorsteinsdottir, U3
Toniolo, D3
Tönjes, A2
Tremblay, J1
Uitterlinden, AG4
Vaccargiu, S1
van der Harst, P2
van Duijn, CM5
Verweij, N1
Vollenweider, P5
Waeber, G5
Whitfield, JB3
Wild, SH4
Wilson, JF5
Zonderman, AB2
Wilson, JG1
Pendergrass, SA1
Ho, K1
Parsa, A2
Pramstaller, PP3
Böger, CA1
Butterworth, AS1
Okada, Y6
Edwards, TL1
Stefansson, K3
Scholz, M1
Heid, IM1
Hung, AM1
Pattaro, C1
Vitart, V5
Drabkin, M1
Yogev, Y1
Zeller, L1
Zarivach, R1
Zalk, R1
Halperin, D1
Wormser, O1
Gurevich, E1
Landau, D1
Kadir, R1
Perez, Y1
Birk, OS1
Teh, CL1
Cheong, YK1
Wan, SA1
Ling, GR1
Fautrel, B1
Belhassen, M1
Hudry, C1
Woronoff-Lemsi, MC1
Levy-Bachelot, L1
Van Ganse, E1
Tubach, F3
Stack, AG4
Karra Gurunath, R1
García de Yébenes, MJ1
Carmona, L8
Narang, RK5
Vincent, Z1
Palazzuoli, A1
Landolfo, M2
Cosentino, E1
Sano, T3
Sasaki, T6
Fushimi, M4
Ohashi, T8
Kuriyama, S1
Chua, CKT1
Cheung, PP1
Santosa, A2
Lim, AYN2
Teng, GG4
Wilkinson, SL1
Divers, SJ1
Bo, X1
Pak, OS1
Tu, J1
Kogan, A1
Hsiai, TK1
Gao, W4
Yang, BY1
Yu, HX1
Song, XX1
Higashino, T5
Morimoto, K3
Nakaoka, H5
Toyoda, Y3
Kawamura, Y8
Shimizu, S12
Hosomichi, K2
Nakayama, A13
Ooyama, K2
Ooyama, H6
Shimizu, T13
Ueno, M1
Ito, T2
Tamura, T3
Naito, M8
Nakashima, H9
Kawaguchi, M4
Takao, M3
Kawai, Y3
Osada, N1
Suzuki, H8
Shinomiya, N13
Inoue, I4
Tallon, A1
Jadhav, PP1
Walrabenstein, W1
Heslinga, M1
de Vries, R1
Nurmohamed, M1
van Schaardenburg, D1
Gerritsen, M5
Parashar, P2
Mazhar, I1
Kanoujia, J2
Yadav, A1
Kumar, P2
Saraf, SA3
Saha, S1
Shi, D2
Chen, JY1
Wu, HX2
Zhou, QJ2
Chen, HY2
Lu, YF1
Yu, RS2
Guo, G1
Dong, C1
Yin, R3
Zhao, R2
Guo, J2
Lu, G1
Okui, D1
Sumpter, NA3
Reynolds, RJ6
Yin, C2
Liu, B7
Zheng, X3
Tai, Y2
Duffull, SB2
Gong, H1
Liu, Q2
Baima, Y1
Ha, EH1
Tian, S1
Min, HK2
Kim, HR1
Leonardo, N1
Lester, S2
Whittle, S1
Rischmueller, M2
Brucato, A1
Cianci, F1
Carnovale, C1
Lin, YJ1
Lin, SY1
Lin, CH2
Wang, ST1
Chang, SS1
Furuno, K1
Kanda, S1
Boocock, J2
Leask, M1
Mandal, AK3
Gosling, AL1
Major, TJ8
Horsfield, JA1
Fadason, T1
O'Sullivan, J1
Stahl, EA3
Zaidi, F1
Gamble, GG1
Riches, P4
Kurreeman, F1
Torres, RJ13
Miner, JN12
Dong, Z4
Zhou, J6
Jiang, S3
He, H4
Ji, H5
Jin, L4
Misawa, K1
Hasegawa, T1
Mishima, E1
Jutabha, P2
Kojima, K1
Matsuo, M1
Anzai, N7
Nagasaki, M1
Chen, ZY1
Ye, LW1
Liang, ZJ1
Yu, T6
Gao, J1
Gamble, G5
Phipps-Green, AJ9
Tatsiy, O1
Mayer, TZ1
de Carvalho Oliveira, V1
Sylvain-Prévost, S1
Isabel, M1
Dubois, CM1
McDonald, PP1
Xie, L1
Feuchtner, GM1
Ghoshhajra, B1
Lianes, O1
Nystad, TW1
Røen, SA1
Fevang, BS1
Choi, SY1
Choi, SW1
Lee, S3
Oh, JS3
Lim, DH1
Felten, R1
Duret, PM1
Gottenberg, JE1
Spielmann, L1
Messer, L1
Lu, B1
Lu, Q1
Huang, B1
Zheng, F1
Ohnishi, J1
Ishimaru, N1
Seto, H1
Kanzawa, Y1
Kinami, S1
Lu, X2
Chi, H1
Liao, E1
Teng, D1
Teng, X1
Ba, J1
He, L1
Lai, X1
Qin, G1
Qin, Y1
Shi, B1
Sun, H3
Tong, N1
Zhang, JA1
Yan, L1
Yang, L2
Zhu, M1
Shan, Z1
Teng, W1
Day, R3
Nguyen, A1
Graham, G1
Coleshill, M1
Stocker, S2
Mariotte, A1
De Cauwer, A1
Po, C1
Abou-Faycal, C1
Pichot, A1
Paul, N1
Aouadi, I1
Carapito, R1
Frisch, B1
Macquin, C1
Chatelus, E1
Sibilia, J1
Armspach, JP1
Bahram, S1
Roman, Y1
Tiirikainen, M1
Prom-Wormley, E1
de Carvalho, RVH1
Vago, JP2
Silva, ALN1
Carvalho, TG1
Antunes, MM1
Ribeiro, FM1
Menezes, GB1
Zamboni, DS2
Sousa, LP4
Teixeira, MM10
van Deuren, RC1
Cavalli, G1
Shaukat, A1
Arts, P1
Cleophas, MC5
Hindmarsh, JH4
Steehouwer, M1
Lelieveld, S1
van de Vorst, M1
Gilissen, C1
Dagna, L1
Van de Veerdonk, FL2
Eisenmesser, EZ1
Hoischen, A1
Netea, MG5
Dinarello, CA3
Joosten, LA6
Nguyen, AD3
Robinson, P1
Song, W2
Ou, J2
Wei, Q2
Gu, J6
Lv, Q3
Tu, L1
Qi, J1
Qiu, M1
Cao, S2
Loh, K1
Sharma, C1
Keen, HI2
Bavanendrakumar, M2
Temmoku, J2
Fujita, Y2
Matsuoka, N2
Urano, T1
Furuya, MY1
Asano, T2
Sato, S3
Watanabe, H2
Kozuru, H1
Yatsuhashi, H1
Kawakami, A4
Migita, K3
Wrigley, R1
Topless, RK4
Harré Hindmarsh, J1
Lawrence, A1
Scott, S1
Saparelli, F1
Greville, G1
Miller, A1
Taylor, A1
Gow, P7
Lamb, KL1
Lynn, A1
Russell, J1
Barker, ME1
Pietsch, DEW1
Kubler, P1
Li, A1
Zheng, S4
Scuiller, A1
Bernard, A1
Oehler, E1
Onuora, S1
Xu, SQ1
Zhang, WJ1
Wu, W1
Lv, Y3
Bao, E1
Kim, SJ2
Kim, CH1
Hong, F1
Zheng, A1
Xu, P2
Xue, T1
Dai, S1
Xie, X3
Qiao, X1
Zhai, Y2
Gustschin, A1
Bodden, J1
Meurer, F1
Pfeiffer, F1
Punzi, L18
Medea, G2
Kudo, H1
Tsuruoka, S1
Meier, R1
di Gangi, S1
Valeri, F1
Rosemann, T1
Zechmann, S1
Jorge, A1
D'Silva, K1
Serling-Boyd, N1
Matza, M1
Nasrallah, M1
Keller, S1
Oza, A1
Bolster, MB1
Collier, D1
Huang, YY1
Gu, SW1
Jiang, ZY1
Yen, FS2
Li, HL2
Yang, CC1
Hwu, CM2
Tian, Y3
Guo, C1
Kamel, B3
Graham, GG7
Williams, KM7
Carland, JE3
Pile, KD2
Carnicelli, AP1
Clare, R1
Chiswell, K1
Lytle, B1
Bjursell, M1
Perl, S1
Andersson, K1
Hedman, K1
Pagidipati, N1
Vemulapalli, S1
Roe, MT2
Mentz, RJ1
Keen, H3
Bruyn, GAW1
D'Agostino, MA1
Sun, SS1
Zhang, DH1
Lin, CJ1
Lin, JY1
Hu, AM1
Brown, JN1
Bupparenoo, P1
Pakchotanon, R1
Narongroeknawin, P1
Asavatanabodee, P1
Chaiamnuay, S1
Bai, XS1
Zhao, XD1
Cui, LL1
He, YW1
Li, XD1
Qu, XJ1
Sun, MS1
Li, CG2
Moulay Berkchi, J1
Rkain, H1
Benbrahim, L1
Aktaou, S1
Lazrak, N1
Faiz, S1
Ahid, S1
Abouqal, R1
Labzizi, S1
Ouzeddoun, N1
Oukerraj, L1
Hmamouchi, I1
Hajjaj-Hassouni, N1
Allali, F1
Kim, A1
Kim, Y2
Kim, GT1
Ahn, E1
Davidsson, L1
Dahlstrand Rudin, A1
Sanchez Klose, FP1
Buck, A1
Björkman, L1
Christenson, K1
Bylund, J1
Li, NS1
Chen, YT1
Hsu, YP1
Pang, HH1
Huang, CY1
Shiue, YL1
Wei, KC1
Yang, HW1
Phang, KF1
Low, BPL1
Tan, PSH1
Khong, ZW1
Tay, SH1
Mu, Z1
Zeng, XJ3
Gu, JR1
Zhou, JG2
Zeng, XF1
Hoque, KM1
Dixon, EE1
Allan, J2
Cho, SK1
Myung, W1
Chang, Y2
Ryu, S1
Kim, HN1
Kim, HL1
Kuo, PH1
Winkler, CA1
Won, HH1
Chock, YP1
Ross, JS1
Suter, LG1
Rhee, TG1
Bansal, P1
Virata, AR1
Yin, S2
Xie, C3
Shu, L2
Ponticelli, C1
Moroni, G1
Sullivan, JI1
Tang, Y1
Wang, D1
Nuki, G14
Arenas, MD1
Soriano, R2
Scinicariello, F1
Buser, MC1
Balluz, L1
Gehle, K1
Murray, HE1
Abadin, HG1
Attanasio, R1
Chuang, JP1
Lee, JC2
Ling, P1
Maa, MC2
Leu, TH1
Novikova, AM1
Lertnawapan, R2
Ishikawa, T3
Maeda, T1
Hashimoto, T1
Nakagawa, T3
Ichikawa, K1
Sato, Y1
Kanno, Y1
Gomes, N1
Cerejeira, A1
Moura, CS1
Lopes, JM1
Baudrier, T1
Azevedo, F1
Tseng, CC1
Wong, MC1
Liao, WT1
Chen, CJ4
Lee, SC3
Yen, JH1
Fan, M1
Faasse, K1
Shen, J2
Si, S1
Mo, M1
Xin, X1
Shao, B1
Shen, Y1
Sung, KT1
Lo, CI1
Lai, YH1
Tsai, JP1
Yun, CH1
Hsiao, CC1
Kuo, JY1
Hou, CJ1
Hung, TC1
Su, CH1
Hung, CL1
Yeh, HI1
Sivera, F15
Renaudin, F1
Orliaguet, L1
Castelli, F1
Fenaille, F1
Prignon, A1
Alzaid, F1
Combes, C1
Delvaux, A1
Adimy, Y1
Cohen-Solal, M2
Riveline, JP2
Venteclef, N1
Campillo-Gimenez, L1
Quilisadio, JEC1
Salido, EO1
Penserga, EG1
Rosas, G1
Rahn, EJ2
Agabiti-Rosei, E1
Johnson, RJ13
Kielstein, JT1
Lurbe, E1
Mancia, G2
Redon, J1
Tsioufis, KP1
Watson, L3
Belcher, J2
Nicholls, E1
Mallen, C3
Fang, YJ2
Chung, YL2
Lin, CL6
Lim, YP2
Takei, R2
Markie, D1
Bixley, M1
Guo, H2
He, M2
Wei, WH1
Singh, JV1
Bedi, PMS1
Singh, H1
Sharma, S1
Vaidya, B1
Baral, R1
Lama, LD1
Joshi, R1
Bhochhibhoya, M1
Nakarmi, S1
Guan, J1
Huang, XQ1
Dong, JL1
Lu, HM1
Lin, YW2
Yi, ZB1
Wu, LM1
Huang, YM1
Lan, T1
Mudra, U1
Andreychyn, S1
Hanberher, I1
Korylchuk, N1
Baidurin, S1
Bekenova, F1
Nakysh, A1
Akhmetzhanova, S1
Abai, G1
Kapetanovic, M4
Bengtsson Boström, K3
Wändell, P3
Forsblad d'Elia, H2
Bergsten, U2
Slobodnick, A1
Greenberg, J1
Crittenden, DB5
Pike, VC3
Qian, Y2
Zou, Z2
Tsoi, MF1
Chung, MH1
Cheung, BMY1
Lau, CS1
Sakaguchi, S1
Le, NH2
Letavernier, E1
Correas, JM1
Gauffenic, A1
Pham, NG1
Olivier, O1
Frochot, V1
Bazin, D1
Marty, C1
Ostertag, A1
Laredo, JD1
Bodofsky, S1
Thomas, TJ1
Müller, FC2
Møller, JM1
Børgesen, HF1
Gosvig, KK1
Checa, A4
Pyne, L1
Walsh, M2
Miller, HN1
Charleston, J2
Wu, B2
Gleason, K1
White, K2
Dennison Himmelfarb, CR1
Ford, DE1
Plante, TB1
Ton, J1
Kolber, MR1
Pooni, RS1
Corbett, R1
Koto, R2
Chui, CSK1
Choi, AKY1
Lam, MMY1
Kwan, TH1
Li, OC1
Leng, Y1
Chow, DLY1
Liu, F2
Hu, Z1
Guo, K1
Min, JZ1
Petreski, T1
Ekart, R1
Hojs, R1
Bevc, S1
Ebstein, E1
Forien, M1
Norkuviene, E2
Mouterde, G1
Daien, C1
Brière, C2
Petraitis, M2
Ora, J1
Dieudé, P2
Ottaviani, S2
Taylor, W4
Qiao, CY1
Shang, Y2
Zhan, ZY1
Ye, H1
Lin, YC1
Jiao, JY1
Sun, RH1
Zhang, ZH1
Homolya, L1
Hegedűs, T1
Takakubo, Y1
Imamura, Y1
Tezuka, H1
Naganuma, Y1
Ito, J1
Oki, H1
Sasaki, A1
Sasaki, K1
Konta, T1
Takagi, M1
Murayama, M1
Nishida, M1
Kudo, Y1
Deguchi, T1
Marukawa, K1
Fujieda, Y1
Abe, N1
Kato, M1
Shibuya, H1
Matsuno, Y1
Atsumi, T1
Lukkunaprasit, T1
Rattanasiri, S1
Turongkaravee, S1
Suvannang, N1
Ingsathit, A1
Attia, J2
Thakkinstian, A1
Yu, X1
Zeng, P1
Robin, F1
Berthoud, O1
Albert, JD2
Cadiou, S1
Gougeon-Jolivet, A1
Bendavid, C1
Guggenbuhl, P2
Coiffier, G2
Clebak, KT1
Morrison, A1
Croad, JR1
Shao, T1
Wen, X1
He, Z1
Meyer, MM1
Marks, LA1
Hallas, J3
Webster, J1
Ralston, SH3
Walters, M1
Robertson, M1
De Caterina, R1
Findlay, E1
Meng, B1
Shou, Q1
Shao, X1
Zhou, H2
Mi, W1
Wu, TY1
Su, CY1
Li, JR1
Tien, N1
Chen, SK1
Hill-McManus, D4
Miake, J1
Mahati, E1
Maharani, N1
Utami, SB1
Bahrudin, U1
Gromova, MA1
Tsurko, VV4
Kislyak, OA1
Malysheva, NV1
Kang, L2
Hu, P2
Abrahim, M1
Node, K1
Kobayashi, Y2
Köttgen, M3
Piani, F1
Premachandra, KH1
Roberts, DM1
Cui, X1
Houvenagel, E5
Desideri, G5
Rajzer, M1
Giannattasio, C1
Wakita, M1
Asai, K1
Kubota, Y2
Koen, M1
Shimizu, W1
Mu, H1
Qin, T1
Long, F1
Tang, H1
Morgan, SL1
Duan, Y1
Jiang, N1
Xu, VYY1
Lake, SL1
Ahn, SJ1
Zhang, D2
Levine, BD1
Pool, B15
Ranganath, VK1
Benhaim, P1
Nelson, SD1
Hsieh, SS1
FitzGerald, JD2
Ao, J2
Vernerová, A1
Kujovská Krčmová, L1
Melichar, B1
Švec, F1
Døssing, A1
Bliddal, H2
Boesen, M1
Rai, SK3
Carson, KA1
Zuzic Furlan, S1
Rusic, D1
Bozic, J1
Rumboldt, M1
Rumboldt, Z2
Rada, M1
Tomicic, M1
Ventura-Ríos, L3
Rodríguez-Henríquez, P2
Pineda, C8
Franco-Cendejas, R1
Lozada-Pérez, CA1
Albert, JA1
Irvin, MR1
Bridges, SL4
Kim, H3
Arnett, DK1
Lupi, AS1
Vazquez, AI3
Suissa, S1
Suissa, K1
Hudson, M1
Topless, RKG1
Florez, JC1
Hirschhorn, JN1
Wilcox, PL1
Cole, JB1
Choi, N1
Yang, G4
Jang, JH1
Kang, HC3
Cho, YY3
Lee, HS4
Lee, JY4
Estiverne, C1
Oh, YJ1
Jeong, JH1
Choi, SJ4
Ahn, SM1
Kim, YG4
Lee, CK4
Yoo, B3
Del Pinto, R2
Viazzi, F2
Pontremoli, R4
Ferri, C3
Carubbi, F1
Russo, E1
Fan, J1
Tse, LA1
Lefebvre, A1
Calhoun, DA1
Oparil, S1
Dudenbostel, T1
Feig, DI1
Redden, DT3
Muntner, P2
Foster, PJ2
Biggers-Clark, SR1
Sattui, SE1
Saddekni, MB1
Borgen, T1
Jin, Z2
Mackie, SL1
Mao, Y2
Wan, Z1
Song, L2
Hu, L2
Lei, X2
Xie, XQ1
Geng, Y1
Guan, Q1
Ren, Y1
Guo, L1
Lu, ZM1
Shi, JS1
Xu, ZH1
Uchida, N1
Shigesawa, R1
Takeuchi, K1
Mank, VMF1
Goldstein, E1
Babb, S1
Meghpara, S1
Breighner, C1
Salavastru, C1
Copaci, FI1
Vrinceanu, D1
Sendrea, AM1
Tiplica, GS1
Ortiz, MA1
Garcia-Guillen, A1
Jeria-Navarro, S1
Sainz, L1
Fernandez-Sanchez, S1
Vidal, S1
Mikhailichenko, N1
Wang, YH2
Lai, TJ1
Nieradko-Iwanicka, B1
Borelli, CM1
Doherty, BT1
Yago, T1
Yashiro-Furuya, M1
Suzuki, E1
Wu, SW1
Liu, CY1
Yeh, CJ3
Cheng-Chung Wei, J1
Takahashi, T1
Taniguchi, T1
Lee, LE1
Kim, JE2
Lee, SJ2
Yoon, S2
Kang, H1
Song, JJ3
Shi, W1
Shyy, JY1
O'Connor, MJ1
Leong, A1
Valiate, BVS1
Queiroz-Junior, CM3
Levi-Schaffer, F1
Calvo-Aranda, E1
Sanchez-Aranda, FM1
Casimiro-Soriguer, CS1
Dopazo, J1
Çubuk, C1
Francisco-Balderas, A1
Lozada-Pérez, C1
Sánchez-González, A1
Silveira, LH2
Burguete-García, AI1
Orbe-Orihuela, C1
Lagunas-Martínez, A1
Vazquez-Gomez, A1
López-Reyes, A3
Palacios-González, B1
Xiao, WZ1
Bindoli, S1
Luisetto, R3
Sfriso, P3
Líška, D1
Diez-Lopez, C1
Perez-Contreras, J1
Yue, H1
Ou, Y1
Liang, S1
Deng, W1
Zhang, C3
Hua, L1
Hu, W1
Sun, P1
Kumar, M1
Manley, N1
Kim, I1
Kim, YI1
Jung, HG1
Lee, G3
Yoon, DS1
Shang, J1
Li, XH1
Lu, SQ1
Li, LL1
Zhu, C1
Zhu, G1
Nguyen, HT2
Vu, TY1
Dakal, TC1
Dhabhai, B1
Nguyen, XHQ1
Tatipamula, VB1
Carpentier, P1
Luraschi, H4
Verclytte, S1
Ventura-Martínez, R2
Déciga-Campos, M2
Bustamante-Marquina, A1
Ángeles-López, GE1
Aviles-Herrera, J1
González-Trujano, ME2
Navarrete-Vázquez, G1
Di Carlo, M2
Di Matteo, A1
Salaffi, F3
Eskild, T1
Agnoletti, D1
Cicero, AFG1
Khanna, I1
Pietro, R1
Ali, Y1
Song, H1
Man, S1
Hanvivadhanakul, P2
Towiwat, P4
Shi, L4
Xu, C1
Wen, J1
Zhan, D1
Yu, J2
Fu, L1
Yan, T1
Badii, M1
Gaal, OI1
Davar, R1
Habibi, E1
Keating, ST1
Novakovic, B2
Helsen, MM1
Macartney-Coxson, D1
Stunnenberg, HG2
Noori, S1
Mirzababaei, A1
Amini, MR1
Clark, CCT1
Mirzaei, K1
Duan, L3
Dyah Kurniasari, M1
Huruta, AD1
Lin, YH1
Weng, SF1
Chu, Y1
Sun, S1
Gao, Q1
Liang, L1
Zhou, C1
Ding, F1
Bai, X1
Wei, X1
Yue, Z1
Zhong, CS1
Zeng, B1
Qiu, JH1
Xu, LH1
Zhong, MY1
Huang, YT1
Liu, SY1
Zha, QB1
Hu, B1
Ou-Yang, DY1
He, XH1
Pongsittisak, W1
Manavathongchai, S1
Handa, R1
Malaviya, AN3
Ahn, H1
Lee, GS1
Barclay, ML7
Cochrane, E1
Harper, R1
Lhakum, P1
Pattamapaspong, N1
Tanner, C1
Dobbyn, A1
Liu, HJ1
Pan, XX1
Liu, BQ1
Gui, X1
Jiang, CY1
Fan, YX1
Tang, YL1
Liu, WT1
Tan, PK3
Gunic, E1
Goossens, J1
Lancrenon, S1
Lanz, S1
Lambert, C1
Saraux, A1
Delva, C1
Sahbane, S1
Boumans, D1
Hettema, ME1
Vonkeman, HE4
Maatman, RG1
van de Laar, MA5
Deeks, ED1
Janssens, HJEM4
Fransen, J12
Schumacher, HR53
Just, J1
Bleckwenn, M1
Weckbecker, K2
Pagidipati, NJ1
Hess, CN1
Clare, RM1
Akerblom, A1
Tricoci, P1
Wojdyla, D1
James, S1
Held, C1
Mahaffey, KW1
Klein, AB2
Wallentin, L1
Vargas-Santos, AB2
Koide, H1
Hira, D1
Tsujimoto, M1
Katsube, Y1
Minegaki, T1
Uzu, T1
Ikeda, Y2
Morita, SY1
Nishiguchi, K1
Terada, T1
Maravic, M1
Hincapie, N1
Pilet, S1
Flipo, RM2
Gao, Z1
Lü, K1
Cleophas, MCP1
Erler, K1
Lu, CC2
Wu, SK2
Chung, WS2
Lin, LH1
Hung, TW1
La-Crette, J1
Jenkins, W4
Fernandes, G1
Bangalore, S1
Morlock, R4
Terrill, M2
Riordan, J2
Fisher, MC3
Rousseau, LS1
Paré, G3
Lachhab, A1
Naccache, PH9
Marceau, F1
Tessier, P2
Pelletier, M1
Fernandes, M2
Fu, T2
Gu, Z2
Shields, GE1
Timofeeva, M2
Tzoulaki, I2
Tsilidis, KK1
Ioannidis, JP1
Theodoratou, E5
Jones, G4
Kopicko, J2
Bhakta, N2
Adler, S2
Storgard, C4
Apanaviciene, I1
Virviciute, D1
Baranauskaite, A1
Modjinou, DV2
Krasnokutsky, S5
Gyftopoulos, S2
Karis, E1
Lee, K1
Samuels, J3
Qiao, Y1
Hou, X1
Lu, D1
Zhang, K4
Mi, QS3
Habib, G2
Rashid, I1
Otter, S1
Kumar, S5
Rome, K4
Soskind, R1
Abazia, DT1
Bridgeman, MB1
Rasheed, H3
Rech, HJ1
Cavallaro, A4
Wijkström, J1
Söderberg, M1
Wernerson, A1
Dong, A1
Bai, Y1
Zuo, C1
Grandjean, A3
Motte, M3
Vandecandelaere, M3
Godart, C3
Namane, N3
Pyo, JY2
Kim, DS2
Jung, SM1
Park, YB5
Soumaré, A2
Debette, S2
Wright, S1
O'Donnell, JL5
Raja, R1
Michet, C1
Hirschmann, A1
Manigold, T1
Coburn, BW5
Bendlin, KA2
Meza, J1
Russell, CL1
Kim, JW1
Kwak, SG1
Park, SH4
Thottam, GE1
Bartels, EM1
Henriksen, M1
Wæhrens, EE1
Gudbergsen, H1
Astrup, A1
Knop, FK1
Kristensen, LE1
Soto, E3
Marshall, S3
Lane, S2
Hughes, D2
Dai, J1
Duan, S1
Chen, RJ1
Chen, MH2
Chen, YL1
Hsiao, CM1
Chen, HM1
Chen, SJ1
Wu, MD1
Yech, YJ1
Yuan, GF1
Wang, YJ1
Zoccali, C1
Bollen, SM1
Rutten, MJCM1
Palmer, WE1
MacDonald, PA15
Thienel, U1
Cutolo, M2
Cimmino, MA7
Frensham, LJ1
Baysari, MT2
Lau, AYS1
Zwar, N1
Reath, J1
Laba, T1
McLachlan, A1
Runciman, WB1
Buchbinder, R5
Clay-Williams, R1
Coiera, E1
Braithwaite, J1
McNeil, HP1
Hunter, DJ1
Portek, I2
Westbrook, JI1
Yazdanyar, A1
Rizzuti, AE1
Mechel, E1
Denisova, K1
Lazzaro, DR1
Sakiyama, M9
Tadokoro, S1
Komatsu, M1
Hishida, A5
Nakatochi, M3
Imaki, J1
Tamaki, S1
Ide, Y1
Inoue, K3
Sugimoto, M1
Hidaka, Y3
Taniguchi, A8
Fujimori, S14
Yamamoto, T33
Yang, JA1
Lee, GH1
Lee, WW1
Lee, EY2
Lee, EB2
Park, JK1
Panova, E1
Sheng, F1
Fang, W2
Sha, Y1
Cleveland, J1
Hasan, MM1
Mahmood, ZA1
Chang, I1
Gazeley, D1
Beslon, V1
Moreau, P1
Maruani, A1
Maisonneuve, H1
Giraudeau, B1
Fournier, JP1
Bhadu, D1
Das, SK1
Wakhlu, A1
Dhakad, U1
Sharma, M1
Xing, ZH1
Ma, YC1
Li, XP1
Zhang, MD1
Fujita, K2
Moreno-Lledó, A1
Urionagüena, I2
Dickson, AJ1
Jhang, JJ2
Lin, JH1
Yen, GC2
Simeunovic Ostojic, M1
Maas, J1
Marcotti, A1
Miralles, A1
Dominguez, E1
Gomis, A1
Belmonte, C1
de la Peña, E1
Yeon, SH1
Lee, HE3
Brenner, JE1
Foster, WJ1
Chen, DY2
Chen, JH5
Chen, SY2
Chen, SM2
Cheng, TT1
Hsieh, SC1
Hsieh, TY1
Hsu, PF1
Kuo, MC1
Lam, HC1
Lee, IT1
Liang, TH1
Lin, HY7
Lin, SC1
Tsai, WP1
Tsay, GJ1
Yang, CH1
Tsai, WC1
Chatfield, SM2
Grebe, K1
Whitehead, LW1
Rogers, KL1
Nebl, T1
Murphy, JM2
Wicks, IP2
Linn-Rasker, SP1
Case, R1
Wentworth, B1
Jester, G1
Tang, SCW1
Fanning, N1
Spiliopoulou, A1
Wei, WQ1
Gifford, A1
Shen, X1
Varley, T1
McKeigue, P1
Wright, AF7
Joshi, P1
Denny, JC1
Yuan, Y3
Xiang, X1
Yuan, TL1
Qiu, L1
Luo, YB1
Packham, J1
Obrenovic, K1
Rivett, A1
Ledingham, JM1
Donovan, P1
Romero, AG1
Bang, D1
Shah, B2
Igel, TF1
Dektiarev, I1
Zhong, J2
Katz, SD1
Ran, B1
Estevez-Garcia, IO1
Gallegos-Nava, S1
Vera-Pérez, E1
Vancini, G1
Hernández-Díaz, C4
Sánchez-Muñoz, F1
Ballinas-Verdugo, MA1
Castillo-Martínez, D1
Amezcua-Guerra, LM1
Heppner, HJ1
Humbert, A1
Stucker, F1
Miao, M1
Davis, WA1
Latkovic, E1
Drinkwater, JJ1
Nossent, J1
Davis, TME2
Franklin, JM1
Spoendlin-Allen, J1
Danaei, G1
Lee, CA2
Shen, Z7
Wilson, DM2
Ostertag, TM1
Girardet, JL3
Hall, J3
Gillen, M3
Larsson, SC2
Carlström, M1
Waldman, B1
Ansquer, JC1
Sullivan, DR1
Jenkins, AJ1
McGill, N2
Buizen, L1
Best, JD1
Feher, MD4
Foucher, C1
Kesaniemi, YA1
Flack, J1
d'Emden, MC1
Scott, RS1
Hedley, J1
Gebski, V1
Keech, AC1
Pang, Y3
Kuehn, BM1
Alvarez-Hernández, E2
García-Méndez, S1
Pascual-Ramos, V1
Rull-Gabayet, M2
Rossi, C1
Genderini, A1
Ding, X2
Atilgan, CU1
Ayli, D1
Yilmazbas, P1
Ranieri, L2
Contero, C1
Peral, ML1
Zapater, P1
Sanderson, LE1
Lawrence, LM1
van der Kroef, M1
Ashimbayeva, E1
Britto, D1
Harper, JL9
Lieschke, GJ1
Crosier, KE1
Crosier, PS1
Timilsina, S1
Brittan, K1
Brophy, M1
Davis-Karim, A1
Henrie, AM1
Newcomb, J1
Palevsky, PM1
Pittman, D1
Taylor, TH1
Johannsdottir, GA1
Palsson, O1
Gudbjornsson, B1
Zhang, G1
Cui, Y2
Chin, CY1
Ho, LJ1
Lai, JH2
Disveld, IJM2
Rongen, GA2
Kienhorst, LBE2
Zoakman, S2
Li, CC1
Chang, YY1
McHugh, J1
Fabre, S1
Launay, JM1
Gautier, JF1
Vidal-Trecan, T1
Platt, A1
Abrahamsson, A1
Hughes, G1
Reeves, M1
Los Campos, G1
Garner, HW1
Wessell, DE1
Yeh, LT3
Kerr, B2
Manhard, K3
Quart, B3
Kankam, M1
Lee, C2
Walker, S1
Clauson, V1
Wilson, D2
Nguyen, M1
Lin, CT1
Harrold, LR6
McCarthy, G10
Kumar, N1
da Rocha Castelar-Pinheiro, G4
Biernat-Kaluza, E1
Rosenthal, A1
Hershfield, MS7
Czegley, C1
Zuo, Z1
Capon, B2
Drivelegka, P1
Jacobsson, LTH2
Shiramoto, M1
Yamamoto, A4
Ito, Y2
Puig, JG22
Scheepers, LEJM2
Burden, AM1
Arts, ICW1
Spaetgens, B3
Souverein, P1
de Vries, F1
Ma, A1
Giannopoulos, G1
Angelidis, C1
Deftereos, S1
Xie, W1
Zhou, R1
Hu, C1
Lu, S1
Chai, Y1
Rogenmoser, S1
Arnold, MH1
Hutton, J1
Fatima, T3
Kupfer, S1
Winklhofer, S1
Becker, AS1
Distler, O1
Chung, CB2
Alkadhi, H2
Finkenstaedt, T1
Black-Maier, E1
Daubert, JP1
Chou, IJ1
See, LC2
Yagnik, D1
Hills, F1
Kisfalvi, K1
Burgess, S1
Michaëlsson, K1
Reuss-Borst, M1
McKinney, C1
Iverson, C2
Schechter, BM1
Valiyil, R1
Jalal, D1
Pillinger, M1
Doghramji, PP4
Chu, C1
Song, P1
Duan, N1
Cui, W1
Kapetanovic, MC1
Nilsson, P1
Turesson, C1
Englund, M1
Gomm, W1
Broich, K1
Maier, W1
Haenisch, B1
Fernandes, MJ2
Jing, J1
Sitter, T1
Schaeffner, E1
Schultheiss, UT1
Xu, W2
Gu, B1
Ren, Q1
Su, D1
Callon, KE5
Tay, ML1
Musson, D1
Naot, D6
Cornish, J11
Ogawa, Y2
Sakamoto, R3
Calvo Aranda, E1
Gonzalez Martin, J1
Abdelkader Abu-Sneimeh, A1
Carrion, O1
Sainz, F1
Garcia de la Peña, P1
Zhang, P1
Ashcroft, JA1
MacFadyen, JG1
Libby, P1
Thuren, T1
Everett, BM1
Ridker, PM3
Ebrahimpour-Koujan, S1
Saneei, P1
Larijani, B1
Esmaillzadeh, A1
Yu, XN1
Wu, HY1
Deng, YP1
Zhuang, GT1
Tan, BH1
Huang, YZ2
Tang, SY1
Tu, X1
Jordan, JB1
Zhong, S2
Tognetti, L1
Cinotti, E1
Fiorani, D1
Rubegni, P1
Perrot, JL1
Bhattacharyya, S1
Macklin, EA1
Schwarzschild, MA2
Perez-Gomez, MV1
Bartsch, LA1
Ortiz, A1
Montenegro, MF1
Lundberg, JO1
Weitzberg, E1
Richardson, H1
Sarmanova, A1
Ashton, D1
Barclay, C1
Doherty, S1
Duley, L1
Hatton, R1
Rees, F4
Stevenson, M1
Guo, M1
Saigal, R1
Goyal, LK1
Jain, DK1
Wan Rohani, WT1
Mahfudzah, A1
Nazihah, MY1
Tan, HL1
Wan Syamimee, WG1
Amanda Jane, PG1
Tony Richard, M1
Tecer, D1
Yardımcı, GK1
Sari, A1
Babaoglu, H1
Alammari, YM1
Gheta, D1
Flood, RM1
Boran, G1
Kane, DJ1
Mullan, RH1
Bouaziz, W1
Rekik, MA1
Guidara, AR1
Keskes, H1
Roughley, M1
Sultan, AA2
Clarson, L2
Chavarriaga, J1
Ocampo, M1
Fakih, N1
Silva Herrera, J1
Lee, CP5
Huang, YN1
Nithiyanantham, S1
Ko, YC8
Latif, ZP1
Jung, JY1
Choi, Y1
Suh, CH3
Yoon, D1
Kim, HA2
Yeo, E1
Palmer, SC1
Zhou, D2
Renner, M1
Ryan, EM1
Duryee, MJ1
Hollins, A1
Dover, SK1
Pirruccello, S1
Real, KD1
Hunter, CD1
Thiele, GM1
Fields, TR3
Tiku, A1
Badve, SV1
Johnson, DW1
Hori, H1
Umeyama, M1
Shimizu, K1
Hondebrink, LLC1
Opstelten, W2
Cheetham, TC4
Levy, GD3
Rashid, N4
Kerimian, A2
Low, KJ2
Curtis, JR3
Ji, LL1
Hao, YJ1
Zhang, ZL1
Tai, V1
Bessen, SY1
Bessen, MY1
Yung, CM1
Abeles, AM3
Chang, HW1
Lin, MH1
Lan, YC1
Wang, RY1
Chen-Xu, M1
Duong, NT1
Ngoc, NT1
Thang, NTM1
Phuong, BTH1
Nga, NT1
Tinh, ND1
Quynh, DH1
Ton, ND1
Hai, NV1
Katayama, A1
Yokokawa, H1
Fukuda, H1
Ono, Y1
Isonuma, H1
Hisaoka, T1
Naito, T1
Kiyani, MM1
Sohail, MF1
Shahnaz, G1
Rehman, H1
Akhtar, MF1
Nawaz, I1
Mahmood, T1
Manzoor, M1
Bokhari, SAI1
Wang, YG2
Mohammed, E1
Browne, LD1
Kumar A U, A1
Adeeb, F1
Fraser, AD1
Lee, JS2
Kwon, OC1
Anderson, NG1
Rajeswari, M1
Polson, M1
Guyen, O1
Viry, A1
Choi, C1
Kirkbride, TE1
Raja, AY1
IIliev, G1
Ivanova, PP1
Nedev, P1
Popov, H1
Alberts, BM1
Bruce, C1
Basnayake, K1
Ghezzi, P1
Davies, KA1
Mullen, LM1
Bailey, CJ1
Deng, M1
Deng, B1
Ye, L1
Fei, X1
Vazirpanah, N1
Ottria, A1
van der Linden, M1
Wichers, CGK1
Schuiveling, M1
van Lochem, E1
Zimmermann, M1
Jansen, M1
Radstake, TRDJ1
Broen, JCA1
Katsogridaki, G1
Tzovaras, G1
Sioka, E1
Perivoliotis, K1
Zachari, E1
Magouliotis, D1
Tasiopoulou, V1
Zacharoulis, D1
Gupta, MK1
Vanquaethem, H1
Biale, L1
Thierry, C1
Lee, SH3
Park, G1
Oh, SM1
Oh, DS1
Narkiewicz, K1
Chen, SL1
Chen, JR1
Yang, SW1
Ehlers, PF1
Mihara, K1
Shi, T1
Min, M1
Sun, C2
Cheng, C1
Liang, M2
Rizeq, FK1
Strilchuk, L1
Fogacci, F1
Cicero, AF1
Landgren, AJ1
Razavi, M1
Rao, X1
Lee, SY3
Kim, JM2
Huangfu, N1
Xu, Z1
Zhang, F2
Zheng, W1
Schulz, M1
McLachlan, AJ2
Ichihara, S2
Ikezaki, H1
Furusyo, N1
Hirata, M3
Okada, R3
Kawai, S3
Nishida, Y6
Shimanoe, C1
Ibusuki, R2
Takezaki, T2
Nakajima, M2
Ozaki, E1
Matsui, D1
Nishiyama, T2
Suzuki, S1
Takashima, N1
Kita, Y1
Endoh, K1
Kuriki, K1
Uemura, H2
Arisawa, K2
Oze, I1
Matsuo, K1
Nakamura, Y3
Mikami, H1
Kato, N1
Murakami, Y2
Matsubara, T1
Yokota, M2
Wakai, K5
Mančíková, A1
Krylov, V1
Bohatá, J1
Liang, G1
Nie, Y1
Zeng, S1
Liang, C1
Xiao, D1
Zhan, S1
Zheng, Q1
Jiang, R1
An, Q1
Gu, R1
Yu, SH1
Kim, MK1
Akther, M1
Han, JH1
Kim, TY1
Jiang, J1
Kang, TB1
Lee, KH1
Ten Klooster, PM2
Alvarado-de la Barrera, C1
López-López, CO1
Lee, HA1
Yu, KS1
Park, SI1
Onohara, M1
Ahn, Y1
Deprouw, C1
Guignot, M1
Bougeois-Sarran, C2
Coblentz-Baumann, L1
Sing, K1
Berg, K1
Virdis, A1
Aati, O11
El-Tantawy, WH1
Zavisanos, A1
Hasenstein, T1
Meyr, AJ1
Huang, IJ1
Liew, JW1
Morcos, MB1
Zuo, S1
Crawford, C1
Bays, AM1
Trost, JR1
Konstantinov, KN1
Doughty, RN1
Troughton, RW1
Richards, AM1
Barskova, V3
Castaneda, J1
Coyfish, M2
Guillo, S2
Janssens, H2
Pimentao, J3
Pywell, A1
Lee, YS1
Sung, YY1
Yuk, HJ1
Son, E1
Cho, H1
Rashidi, M1
Simpson, DS1
Hempel, A1
Frank, D1
Petrie, E1
Vince, A1
Feltham, R1
Murphy, J1
Salvesen, GS1
Vince, JE1
Cheng, KW1
Yan, M1
Ma, X4
Yang, QB1
He, YL1
Zhang, QB1
Nagase, M2
Shirahama, Y1
Shimoshikiryo, I1
Katsuura-Kamano, S1
Hara, M1
Iwasawa, S1
Ohnaka, K1
Saitoh, T1
Takahashi, A2
Tanaka, K1
Braun, J2
Kiltz, U2
Choi, A1
Gao, R1
Munro, J2
Ferrari, AJL1
Corrêa Fernandes, AR1
De Almeida Agustinelli, R1
Seike, H1
De Ávila Fernandes, E1
Fu, Q1
Shang, K1
Zhang, YP1
Qu, Y1
Jie, LG1
Deng, JX1
Yu, QH1
Li, ZX1
Jiao, GL1
Zhou, SM1
Cheng, ZY1
Bashir, S1
Zeitoun, D1
Sverzut, JM1
Jeong, H1
Jeon, CH1
Ellmann, H1
Bayat, S3
Araujo, E2
Manger, B6
Kleyer, A1
Lell, M4
Schenker, H1
Simon, D1
Tascilar, K1
Schett, G6
Rech, J4
Jakše, B2
Pajek, M1
Pajek, J1
Qi, X1
Jin, H1
Simeone, FJ1
Liu, CW1
Chang, WC3
Lee, CC1
Shau, WY1
Hsu, FS1
Wang, ML1
Chen, TC1
Lo, C1
Hwang, JJ1
Inaba, S1
Sautin, Y1
Garcia, GE1
Schernhammer, E1
Qiu, J1
Wermuth, L1
Lassen, CF1
Friis, S1
Ritz, B1
Pui, K1
Gow, PJ3
Kovell, LC2
Mitha, E1
Fouche, L1
Weinstein, SP3
Yancopoulos, GD2
King-Davis, S2
Evans, RR3
Bray, GA1
Di Geso, L2
Rovisco, J1
dos Santos, RM1
Hoffmeister, C3
Ferreira, J3
Assreuy, J1
Manara, M2
Prevete, I1
Bianchi, G1
D'Avola, GM1
Di Giacinto, G1
Govoni, M3
Lombardi, A2
Marangella, M1
Matucci Cerinic, M1
Spadaro, A1
Minisola, G2
Spencer, KL1
Jorgensen, NW1
Fornage, M2
Best, LG1
Brown-Gentry, KD1
Cole, SA1
Crawford, DC1
Deelman, E1
Franceschini, N1
Glenn, KR1
Heiss, G1
Jenny, NS1
Liu, K3
Matise, TC1
Umans, JG1
Kao, WH4
Hanley, A1
Casserly, LF1
Cronin, CJ1
Abdalla, AA1
Kiernan, TJ1
Murthy, BV1
Hegarty, A1
Hannigan, A1
Ko, AM5
Tu, HP4
Liu, TT1
Yuo, CY1
Chiang, SL4
Liu, YF2
Chang, CM1
Tsai, SF1
Krishnan, E14
Akhras, KS4
Sharma, H2
Marynchenko, M2
Wu, EQ3
Tawk, R1
Mazor, KM1
Negron, A1
Ogarek, J1
Firneno, C1
Yood, RA9
Fornaciari, G1
Giuffra, V1
Li, XX1
Liu, JP1
Yip, S1
Murphy, R1
Wu, E1
Tawk, RH1
Drake, JM2
Naredo, E1
Uson, J1
Jiménez-Palop, M1
Martínez, A3
Vicente, E1
Brito, E1
Rodríguez, A2
Cornejo, FJ1
Castañeda, S1
Martínez, MJ1
Sanz, J1
Batlle-Gualda, E2
Garrido, J1
Beard, SM1
von Scheele, BG1
Pearson, IV1
Urano, W3
Inoue, E1
Sekita, C1
Ichikawa, N1
Koseki, Y1
Kemter, E1
Prueckl, P1
Sklenak, S1
Rathkolb, B1
Habermann, FA1
Hans, W1
Gailus-Durner, V1
Fuchs, H1
Hrabě de Angelis, M1
Wolf, E1
Aigner, B1
Wanke, R1
Muthukoori, S1
Narayanan, N1
Chandra, MS1
Sethuraman, S1
Krishnan, UM1
McQueen, FM20
Sundy, J1
Baraf, HS8
Gagné, V1
Marois, L2
Levesque, JM1
Galarneau, H1
Lahoud, MH1
Caminschi, I1
Miyaji, T2
Kawasaki, T1
Togawa, N1
Omote, H2
Moriyama, Y4
Yeter, KC1
Ortiz, EC1
Arkfeld, DG1
Ogata, H2
Takada, Y4
Chiba, T6
Ushiyama, C1
Hamajima, N4
Sakurai, Y5
Kato, Y2
Zhong, Z1
Qiao, L1
Bang, SY1
Choi, CB1
Kim, TH1
Dünkel, J1
Oestmann, A1
Jonczy, M1
Christoph, M1
Forkmann, M1
Richter, U1
Kopprasch, S2
Bielitz, C1
Aringer, M6
Wunderlich, C3
Batt, C1
Black, MA1
Merriman, ME2
Harrison, A2
Highton, J3
Jones, P1
Voshaar, MA1
Bode, C1
Prudon, B1
Stradling, JR1
West, SD1
Mulay, SR1
Evan, A1
Anders, HJ1
Nasi, S1
Silva, MA1
Guerra, GP2
Dray, M2
Pitto, R1
Bentley, J1
Chabra, I1
Singh, R1
Herrero-Beites, AM12
Cottrell, E1
Crabtree, V1
Edwards, JJ1
Chen, P3
White, M1
Barratt-Boyes, C1
Orr-Walker, B1
Chang, HJ1
Wang, PC1
Hsu, YC3
Huang, SH1
Kannangara, DR4
Ramasamy, SN2
Ray, JE1
Bakris, GL1
Silber, SH1
Nagoba, BS1
Punpale, A1
Poddar, A1
Suryawanshi, NM1
Swami, GA1
Selkar, SP1
Hollis-Moffatt, JE1
Franklin, C5
Jones, PB3
White, DH1
Rajan, A1
Kalluru, R3
Gutierrez-Urena, SR2
Treadwell, EL2
Rehrig, CD2
Ottery, FD3
Sundy, JS15
Morita, E2
Inoue, H2
Tatsukawa, S2
Sato, J1
Shimono, K1
Makino, T1
Satoh, T2
Kanai, Y4
Gruaz, L3
Burger, D3
Faruque, LI1
Ehteshami-Afshar, A1
Wiebe, N1
Tjosvold, L1
Homik, J1
Tonelli, M1
Doucet, BP1
Jegatheesan, D1
Burke, J1
Maynard, JW4
McAdams-DeMarco, MA4
Law, A2
Kao, L1
Baer, AN5
Mallinson, PI2
Reagan, AC1
Coupal, T1
Munk, PL3
Steiger, S3
Parimi, N1
Lui, LY1
Wise, BL1
Yao, W1
Lay, YA1
Cawthon, PM1
Orwoll, E1
Martillo, MA1
Nazzal, L1
House, ME9
George, M1
Pullman-Mooar, S1
Hussain, F1
Stumpf, J1
Toniolo, M1
Haller, C1
Pan, KL3
Lin, JC3
Chen, MC3
Chang, PJ2
Hsiao, JF1
Chang, ST3
Chung, CM3
Goldfien, RD1
Ng, MS1
Yip, G1
Hwe, A1
Jacobson, A2
Pressman, A2
Avins, AL1
Akkus, O2
Bach, MH1
Simkin, PA24
Ohno, I2
Nomura, S1
Uchida, S2
Hara, S2
Chinchilla, SP4
Zhou, L2
Pettigrew, JC1
Cheng, D1
Yi, D1
Wu, XH1
Yu, CH1
Zhang, CF1
Anderson, S1
Zhang, YW1
Du, H2
Jiang, L2
Zuo, X1
Zhu, P1
Huang, A1
Bao, C1
Kienhorst, LB3
Janssens, HJ4
van de Lisdonk, EH1
Holzinger, D1
Nippe, N1
Vogl, T2
Marketon, K1
Mysore, V1
Weinhage, T1
Baeten, D1
Ives, A1
Busso, N5
Foell, D1
Bas, S1
Gabay, C1
Roth, J1
Purvis, L2
Stewart, A2
Merriman, M2
Fleischmann, R1
Suster, M1
Polvent, E1
Hingorani, V1
Lamers-Karnebeek, FB1
Van Riel, PL2
Duskin-Bitan, H1
Cohen, E1
Goldberg, E1
Shochat, T1
Levi, A1
Garty, M1
Krause, I1
Roseline, YW1
Shidoji, Y1
Hon, WM1
Masaki, M1
Hui, M1
Huppertz, A1
Hermann, KG2
Diekhoff, T2
Wagner, M2
Hamm, B2
Schmidt, WA1
Saar, J1
Kirch, W1
Reaves, E1
Arroll, B4
Olazagasti, J1
Wang, AS1
Isseroff, R1
Bongartz, T3
Kavros, SJ1
Murthy, NS2
Merry, SP1
Franz, WB1
Michet, CJ2
Veetil, BM1
Davis, JM1
Mason, TG1
Warrington, KJ1
Ytterberg, SR1
Matteson, EL1
Crowson, CS1
Leng, S3
McCollough, CH3
Hatoum, H1
Lin, SJ1
Shiozawa, A8
Marcotte, G1
Rai, S1
Galo, JS1
Bhole, V2
Castillo, E1
Coleman, B1
Bennett, M2
Wolfenden, TP1
Jackson, J1
Vitale, A1
Cantarini, L1
Rigante, D1
Bardelli, M1
Galeazzi, M1
Robier, C2
Stettin, M1
Quehenberger, F2
Neubauer, M3
Ray, K1
Berendsen, D3
Janssen, MC1
Janko, C2
Munoz, LE2
Kienhöfer, D2
Frey, B1
Naschberger, E1
Holmdahl, R1
Krenn, V1
Harrer, T1
Jeremic, I1
Bilyy, R1
Hoffmann, M1
Ling, X1
Bochu, W1
Carter, JD1
Patelli, M1
Anderson, SR1
Prakash, N1
Rodriquez, EJ1
Bateman, H1
Sterrett, A1
Valeriano, J1
Ricca, LR1
Akram, M1
Usmanghani, K1
Ahmed, I1
Azhar, I1
Hamid, A1
Cavagna, L4
Liu, LM1
Cheng, SF1
Shieh, PC1
Chen, JJ1
Kuo, SC2
Kuo, DH1
Huang, LJ1
Way, TD1
Joo, K1
Kwon, SR1
Lim, MJ1
Jung, KH1
Joo, H1
Park, W1
Castaldo, G1
Mussap, M1
Testa, A1
Horsburgh, S1
Turner, R2
Khalilova, IS1
Forbes, LV1
Kettle, AJ1
Oikawa, Y1
Abe, J2
Shichijo, Y1
Akashi, A1
Füessl, HS5
Ogdie, A4
Weatherall, M1
Oderda, GM1
Hess, K1
Brixner, DI1
Feehan, M1
Akhras, K1
Roberts, RL3
Wright, DF2
Xu, JX1
Bailén, R2
González Senac, NM1
López, MM1
Llena, ML1
Migoya, M1
Rodríguez, MT1
de Miguel, E9
Mireku, KA1
Burgy, JR1
Davis, LS1
Kivitz, A1
Cai, J1
Xia, L1
Ding, Q1
Lee, MC1
Cheng, YT1
Ho, CY1
Siegert, RJ1
Banegas, JR1
Kimura-Hayama, E1
Criales-Vera, S1
Betanzos, JL1
Rivera, Y1
Alberú, J1
Hernández-Molina, G1
Yoon, BY1
Joo, HY1
Shin, KC1
Baek, HJ1
Sorensen, LB17
Falzon, L3
van der Heijde, DM3
Kydd, AS4
Seth, R3
Edwards, CJ4
Bombardier, C4
Altaf, S2
Jones, GT2
van Rij, AM1
White, D4
Jeyaruban, A1
Larkins, S1
Soden, M1
Agilli, M1
Aydin, FN1
Cayci, T1
Kurt, YG1
Hsu, JT1
Nagamori, S1
Taketani, Y1
Suma, S2
Oda, T1
Kumagai, H1
Orlowsky, EW1
Stabler, TV1
Montell, E1
Vergés, J1
Kraus, VB1
Wangkaew, S1
Hongsongkiat, S1
Tanasombat, C1
Sukittawut, W1
Badarny, S1
Khreish, M1
Khazin, F1
Shehadeh, V1
Hakim, G1
Artul, S1
Inani, K1
Mernissi, F1
Sriranganathan, MK1
Vinik, O1
Kiefer, T1
Stroux, A1
Pilhofer, I1
Juran, R1
Mews, J1
Blobel, J1
Tsuyuki, M1
Ackermann, B1
Funck, V1
Tonello, R1
Pesquero, JB1
Bader, M1
Oliveira, MS1
McDougall, JJ1
Brown, M4
Eliseev, M3
Scire, C1
Chou, YY3
Cimmino, M1
Viollet, B1
Ji, Z1
Němec, P1
Meng, ZQ1
Tang, ZH1
Yan, YX1
Guo, CR1
Ding, G2
Huang, WZ1
Wang, ZZ1
Wang, KD1
Xiao, W1
Löffler, C1
Sattler, H1
Peters, L1
Löffler, U1
Uppenkamp, M1
Bergner, R1
McGowan, B1
Bennett, K1
Silke, C1
Whelan, B2
Franchi, C1
Salerno, F1
Conca, A1
Djade, CD1
Tettamanti, M1
Pasina, L1
Corrao, S1
Marengoni, A1
Marcucci, M1
Mannucci, PM1
Nobili, A1
Mead, T1
Arabindoo, K1
Smith, B1
Lund-Iversen, M1
Holland, R1
McGill, NW6
Kuo, CC1
Weaver, V1
Fadrowski, JJ1
Lin, YS1
Guallar, E1
Navas-Acien, A1
van Onna, M1
Hinsenveld, E1
Castrejon, I1
Toledano, E1
Rosario, MP1
Loza, E1
Gill, G1
Aubrun, A1
Palazzo, E1
Meyer, O1
de Abajo, FJ1
Gil, MJ1
García-Poza, P1
Álvarez, A1
Bryant, V1
García-Rodríguez, LA1
An, G1
Duan, WR1
Nothaft, W1
Awni, W1
Dutta, S1
Hainer, BL1
Matheson, E1
Wilkes, RT1
Davies, MJ1
Trujillo, A1
Vijapurkar, U1
Damaraju, CV1
Meininger, G1
Pisetsky, DS1
Das, A1
Savant, SS1
Mandal, RK1
Hassan, S1
Kodithuwakku, ND1
Feng, YD1
Zhang, YY1
Pan, M1
Fang, WR1
Li, YM1
Gandhi, PK1
Gentry, WM1
Ma, Q1
Bottorff, MB1
Vela, P4
Durcan, L1
Lawrence Edwards, N1
Shaw, OM1
Danjoh, I1
Terashige, S1
Yin, G1
Tokumasu, A1
Onoue, H1
Iwaya, K1
Oosting, M1
Lemmers, H1
Toenhake-Dijkstra, H1
Moilanen, LJ1
Hämäläinen, M1
Lehtimäki, L1
Nieminen, RM1
Moilanen, E1
Prejbisz, A1
Sellin, L1
Szwench-Pietrasz, E1
Woznowski, M1
Michałowska, I1
Blondin, D1
Sajnaga, D1
Epplen, JT1
Litwin, M1
Dekomien, G1
Januszewicz, M1
Helmchen, U1
Matuszkiewicz-Rowińska, J1
Adamczak, M1
Więcek, A1
Januszewicz, A1
Rump, LC1
Mantarro, S1
Capogrosso-Sansone, A1
Tuccori, M1
Blandizzi, C1
Montagnani, S1
Convertino, I1
Antonioli, L1
Fornai, M1
Cricelli, I1
Pecchioli, S1
Cricelli, C1
Lapi, F1
Greenberg, KI1
Grams, ME1
Flipo, RN1
Patrikos, DK1
De Giorgi, A1
Fabbian, F1
Pala, M1
Tiseo, R1
Parisi, C1
Misurati, E1
Manfredini, R1
Aniel-Quiroga, MA2
Erauskin, GG2
Tiwari, S1
Dwivedi, H1
Kymonil, KM1
Hill, EM1
Sky, K1
Sit, M1
Collamer, A1
Higgs, J1
Huffman, JE1
Albrecht, E3
Mangino, M3
Kapur, K1
Johnson, T2
Kutalik, Z2
Lopez, LM2
Salo, P3
Goel, A2
Tanaka, T3
Dehghan, A4
Malerba, G2
Portas, L2
Boteva, L1
Navarro, P2
Johansson, A3
Esko, T2
Peden, JF2
Murgia, F2
Tenesa, A4
Mihailov, E1
Grotevendt, A2
Gislason, GK2
D'Adamo, P2
Ulivi, S2
Campbell, S4
Kolcic, I3
Fisher, K1
Viigimaa, M2
Metter, JE2
Masciullo, C1
Trabetti, E2
Bombieri, C1
Sorice, R2
Döring, A3
Reischl, E1
Hofman, A4
Wichmann, HE4
Davies, G2
Gow, AJ2
Smit, JH2
Kirin, M2
Nagaraja, R3
Schurmann, C2
Budde, K2
Farrington, SM3
Jula, A2
Salomaa, V3
Sala, C2
Hengstenberg, C4
Burnier, M3
Klopp, N3
Kloiber, S2
Schipf, S2
Ripatti, S2
Cabras, S1
Soranzo, N2
Homuth, G2
Munroe, PB2
Hastie, N2
Cabrera, C1
Haley, C1
Franco, OH1
Penninx, BW2
Ferrucci, L2
Gambaro, G2
Deary, IJ2
Dunlop, MG3
Gyllensten, U3
Spector, TD3
Watkins, H3
Perola, M3
Caulfield, M3
Völzke, H4
Guochun, L1
Yin, L1
Reid, G4
Kennedy, NJ1
Healy, PJ1
Harrison, AA4
Pakpoor, J1
Seminog, OO1
Ramagopalan, SV1
Goldacre, MJ1
Nasoori, A1
Pedram, B1
Kamyabi-Moghaddam, Z1
Mokarizadeh, A1
Pirasteh, H1
Fayyaz, AF1
Shooshtari, MB1
Gupta, S2
Yui, JC1
Fitzhugh, CD1
Clark, C1
Siddiqui, S1
Conrey, AK1
Kato, GJ1
Minniti, CP1
Galassi, FM1
Macia, L1
Martins, FS3
Canesso, MC1
Garcia, CC2
Maslowski, KM1
De Leon, E1
Shim, D1
Nicoli, JR2
Mackay, CR2
Zhou, TY1
Lu, W2
Eijgelaar, RS1
Radstake, TR3
Bruderer, SG1
Bodmer, M1
Jick, SS1
Meier, CR1
Zykova, SN1
Storhaug, HM1
Toft, I1
Chadban, SJ1
Jenssen, TG1
White, SL1
Zhang, N1
Li, G3
Zheng, C1
Koblick, R1
Maueröder, C1
Hahn, J3
Hoffmann, MH1
Ming, J1
Lu, Y2
Ji, Q1
Yu, YK1
Yu, F1
Ye, C1
Shen, GF1
Lei, XM1
Zhang, ST1
Hu, SX1
Shahid, H1
Stasinopoulou, K1
Li, ZG1
Montagna, P1
Brizzolara, R1
Ferrone, C1
Paolino, S1
Barskova, VG6
Denisov, IS1
Saccomano, SJ1
Ferrara, LR1
Ting, K2
Graf, SW2
Whittle, SL2
Mantovani, A1
Rigolon, R1
Pichiri, I1
Pernigo, M1
Bergamini, C1
Zoppini, G1
Bonora, E1
Targher, G1
Vanheule, V1
Janssens, R1
Boff, D1
Kitic, N1
Berghmans, N1
Ronsse, I1
Kungl, AJ1
Van Damme, J1
Proost, P1
Mortier, A1
Fitz-Patrick, D1
Cravets, M1
Filanovsky, MG1
Sukhdeo, K1
McNamara, MC1
Flynn, TJ2
Todd, AS1
Walker, RJ1
Baek, S1
Lee, DG1
Kim, EK1
Cho, ML1
Kwok, SK1
Ju, JH1
Jørgensen, SH1
Knudsen, ET1
Atxotegi, J1
Agarwaal, A1
Green, L1
Thiagarajan, P1
Naden, RP1
Vaquez-Mellado, J1
Yarows, SA1
Winnard, D1
Boswell, DR1
Te Karu, L2
Lindsay, K2
Addadi, L3
Volterrani, M1
Iellamo, F1
Sposato, B1
Romeo, F1
de Lautour, H1
Adebajo, A1
Alten, R1
da Rocha Castelar Pinheiro, G1
Helliwell, P1
Kerr, G1
Kavanaugh, A2
Ralph Schumacher, H1
van de Laar, M1
Srinivasasainagendra, V1
Klimentidis, YC1
Allison, DB1
Lan, B1
Jiri, M1
Feng, T2
Bastos, LF1
Oliveira, TH1
Dias, AC2
Oliveira, VL1
Tavares, LD3
Costa, VV4
Soriani, FM2
Szymkowski, DE1
Ryffel, B2
Souza, DG3
Daoussis, D1
Karamessini, M1
Chroni, E1
Kraniotis, P1
Kim, SK4
Choe, JY4
Park, KY3
Feng, X1
Sapsford, M2
Petsch, C2
Dennison, EM1
Rubin, KH1
Schwarz, P1
Harvey, NC1
Bone, KW1
Cooper, C1
Abrahamsen, B1
Müller-Ladner, U2
Larsen, KS1
Pottegård, A2
Lindegaard, H1
Smolen, LJ2
Gahn, JC2
Mitri, G3
Altan, A1
Bancroft, T1
Fermer, S2
Wood, R2
Lai, YC1
Yew, YW1
Lessing, JN1
Mathias, PC1
Pierce, RG1
Gao, H1
Burke, BT1
Grams, M1
Deng, J1
Lin, W1
Yin, Z1
Yao, C1
Araujo, EG2
Englbrecht, M1
Hueber, AJ1
Metzger, SC1
Koehm, M1
Wichmann, JL1
Buettner, S1
Scholtz, JE1
Beeres, M1
Kerl, JM1
Albrecht, MH1
Hammerstingl, R1
Vogl, TJ1
Bauer, RW1
Søltoft Larsen, K1
Lindegaard, HM1
Gill, TK1
Tucker, GR1
Hill, CL1
Hsu, PN1
Ferrari, FC1
Lemos Lima, Rde C1
Schimith Ferraz Filha, Z1
Barros, CH1
de Paula Michel Araújo, MC1
Antunes Saúde-Guimarães, D1
Hentzen, KS1
Hrdy, MM1
Wallace, MC1
Qu, J1
Zhan, Y1
Viroli, C1
Montecucco, C1
Matucci-Cerinic, M1
Guo, Z1
Ang, KY1
Hou, Q1
Su, X1
Qiao, J1
Koh, E1
Danliang, H1
Lee, YK1
Vandal, AC3
Rodrigues, IP1
Reis, AC1
Ribeiro Oliveira, RD1
Louzada-Junior, P1
Leng, L1
Bucala, R1
Bozza, MT1
Venkat-Raman, G1
Gast, C1
Marinaki, A2
Aradoini, N1
Talbi, S1
Berrada, K1
Abourazzak, FZ1
Harzy, T1
Kurano, T1
Thakur, UJ1
Thawait, GK1
Fuld, MK2
McAdams-DeMarco, M2
Fishman, EK2
Carrino, JA1
Pustjens, T1
van der Linden, S2
Kim, HJ1
Ahn, HS1
Park, EJ1
Yim, SY1
Ren, YC1
Jin, TB1
Sun, XD1
Geng, TT1
Zhang, MX1
Kang, LL1
Sylvester, JE1
Leggit, JC1
Shah, N1
Fernandes, A1
Faria, MT1
Oliveira, A1
Vieira, T1
Pereira, J1
Ruan, S1
Carr, A1
Bäurle, A1
Sun, N1
Wu, L1
Di, Y1
Mitnala, S1
Hopfer, H1
Mayr, M2
Nickolai, B1
Kiss, C1
Goldblatt, F1
Casson, RJ1
Tamura, K1
Kiguchi, T1
Okamoto, M1
Kaneko, M2
Maemondo, M1
Gemba, K1
Fujimaki, K1
Kirito, K1
Goto, T1
Fujisaki, T1
Takeda, K1
Ueda, T10
Wittbrodt, ET1
Turpin, RS1
Tidwell, BA1
Schulman, KL1
Ramachandran, S1
Fritz, J1
Henes, JC1
Horger, MS1
Hashimoto, H2
Smith, MD1
Hill, C1
van Rij, A1
McCormick, SP1
Dua, P1
Gurrell, R1
Kirby, S1
Sudworth, M1
Loudon, PT1
Hyndman, D2
Ahmad, Z1
Gupta, AK1
Sharma, R1
Bhalla, AS1
Kumar, U1
Sreenivas, V1
Sharon, Y1
Ma, C1
Lu, CY1
Kuo, TM2
Chen, CL2
Tsai, EM1
Loissell-Baltazar, YA1
Medina-Luna, D1
López-Macay, A1
Camacho-Galindo, J1
Santamaría-Olmedo, MG1
López-Villegas, EO1
Cerna-Cortés, JF1
Mome, R1
Bakinde, N1
Filiopoulos, V1
Hadjiyannakos, D1
Vlassopoulos, D1
Sircar, D1
Wallace, AB1
Johnson, W1
Sánchez-Bringas, G1
Reginato, A2
Alva, M1
Audisio, M1
Bertoli, A1
Cazenave, T1
Mora, C1
Py, G1
Sedano, O1
Solano, C1
Richardson, JC1
Liddle, J1
Hider, S1
Prinjha, S1
Ziebland, S1
Quilis, N1
Gil, S1
Petru, L1
Sebesta, I5
Wilson, L1
Saseen, JJ1
Stiefelhagen, P2
Folsom, AR2
Schils, R1
Krzesinski, JM1
Goldfien, R1
Ng, M1
Avins, A1
Farrar, JE1
Gaucher, EA1
Furst, D1
Fitzgerald, J2
Ozcan, A1
Jimenez-Liñan, LM1
Edwards, L2
Gardner, D1
Stebbings, S1
Taylor, G1
Kumar, R1
Kain, T1
Porter, D1
Corkill, M1
Cathro, A1
Metcalfe, S1
Wyeth, J1
Robbins, RC1
Edison, JD1
Hedrich, C1
Christensen, HD1
Sheta, HM1
Hansen, IM1
Feltelius, N1
Chang, JM1
Das Gupta, E1
Sakthiswary, R1
Lee, SL1
Wong, SF1
Hussein, H2
Gun, SC2
Castañeda-Sanabria, J1
Pywell, T1
Breuer, GS1
Bogot, N1
Nesher, G1
Jalal, DI1
Humphrey, C1
Hulme, R1
Das, S2
Goswami, RP1
Ghosh, A2
Ghosh, P2
Lahiri, D2
Basu, K2
Macia, LM1
Sernaglia, ÉM1
Vinolo, MA1
Tavares, LP2
Ben Salem, C1
Slim, R1
Fathallah, N1
Hmouda, H1
Bianucci, R1
Perciaccante, A1
Appenzeller, O1
Suh, YS1
Cheon, YH1
Lee, WS1
Yoo, WH1
Lee, SI1
Sinhamahapatra, P1
Paik, JM1
Chia, FL1
Lee, SS2
Oh, DH1
Park, DJ1
Chae, SC1
Yun, KJ1
Chung, WT1
Ruoff, G1
Castelar, G1
Singh, J2
Wei, F1
Gao, Y1
Kumar, B1
Lenert, P1
Allen, B1
Miranda, R1
Poudel, DR1
Karmacharya, P1
Donato, A1
Smolen, J1
Cohen Solal, A1
Flader, C1
Matsuoka, M1
Vazquez Mellado, J1
Weisman, M1
Westhoff, TH1
Buysman, EK1
Korrer, S1
Hung, TL1
Wang, WM1
Chiang, CP1
Nanavati, P1
Hagerty, DT1
Öztürk, MA1
Mercan, R1
Gök, K1
Onat, AM1
Kısacık, B1
Kimyon, G1
Balkarlı, A1
Kaya, A1
Çobankara, V1
Balcı, MA1
Pamuk, Ö1
Yıldırım Çetin, G1
Sayarlıoğlu, M1
Şenel, S1
Tezcan, ME1
Küçük, A1
Üreten, K1
Şahin, Ş1
Tufan, A1
Jung, JH1
Ji, JD1
Seo, YH1
Kissin, EY1
Cagnotto, G1
Lima Gomes Ochtrop, M1
Lazovskis, J1
Thompson, N1
Boone-Kukoyi, Z1
Shortt, R1
Lansiquot, C1
Kioko, B1
Bonyi, E1
Toker, S1
Ozturk, B1
Aslan, K1
Kaminska-Pajak, KA1
Dyga, K1
Adamczyk, P1
Szczepańska, M1
Zaniew, M1
Beck, B1
Tkaczyk, M1
Carroll, MB1
Smith, DM1
Shaak, TL1
Qaseem, A2
McLean, RM1
Starkey, M1
Forciea, MA2
Denberg, TD2
Barry, MJ2
Boyd, C2
Chow, RD2
Fitterman, N1
Humphrey, LL2
Kansagara, D2
Manaker, S1
Vijan, S2
Wilt, TJ2
Newberry, SJ1
Motala, A1
Booth, M1
Maglione, MA1
Han, D1
Tariq, A1
O'Hanlon, CE1
Shanman, R1
Dudley, W1
Shekelle, PG1
Harris, RP1
Knight, J2
Sil, P2
Wicklum, H1
Surell, C1
Rada, B2
Coupal, TM1
McLaughlin, PD1
Ouellette, HA1
Meng, J1
Hughes, JC1
Wallace, JL1
Bryant, CL1
Salvig, BE1
Fourakre, TN1
Stone, WJ1
El-Zawawy, H1
Hayes, CP1
Reaves, BJ1
Breen, P1
Quinn, S1
Sokolove, J1
Beltrán, LM1
Mejía-Chew, C1
Tevar, D1
Webers, C1
Tran-Duy, A1
Schoonbrood, T1
Jutkowitz, E1
Dubreuil, M1
Kuntz, KM1
Thiele, RG5
Kim, ND1
Jeong, S1
Jung, Y1
Park, HH1
Su, J1
Zhou, T1
Tian, J1
Vincent, ZL1
House, M2
Kulasegaran, T1
Barroso, LC1
Carneiro, FS1
Ferreira, TP1
Silva, PM1
Lusco, MA1
Fogo, AB2
Najafian, B1
Alpers, CE1
Min-Shan Ko, A1
Wang, SJ4
Sun, Z1
Ruan, Y1
Chen, Q1
Gong, W1
Xia, W1
He, JC1
Zhang, A1
Wallace, M1
Singh, N1
Tripathi, CB1
Kaithwas, G1
Maglio, C1
Peltonen, M1
Neovius, M1
Jacobson, P1
Rudin, A1
Carlsson, LM1
Westerfield, KL1
Mounsey, A1
Nashelsky, J1
Lee, SK4
Szabo, SM1
Bolzani, A1
Cheung, A1
Daimon, M1
Wang, CH1
Ho, Y1
Uang, YS1
Chiang, SJ1
Wang, LH1
Corbett, EJM1
Pentony, P1
Schlee, S3
Bollheimer, LC3
Bertsch, T3
Sieber, CC3
Härle, P3
Li, XA1
Li, LJ1
Deng, YH1
Lei, GH1
Essex, MN1
Hopps, M1
Bienen, EJ1
Udall, M1
Mardekian, J1
Makinson, GT1
Goldberg, EL1
Asher, JL1
Molony, RD1
Shaw, AC1
Zeiss, CJ1
Morozova-Roche, LA1
Herzog, RI1
Iwasaki, A1
Dixit, VD1
Pennick, KE1
Holicky, RA1
Wilkerson, MJ1
Jing, X1
Smith, T2
Nicolson, B1
Clark, B2
Callon, K2
Haskard, DO4
Reid, IR2
Popa-Nita, O3
Fontenot, A1
Harris, P1
Macasa, A1
Menon, Y1
Quinet, R1
Angeles, RM1
Gong, Y1
Iwasaki, Y1
Kano, O1
Ikeda, K1
Schlesinger, I1
Montoya, F1
Fraile, JM3
Le, MT1
Shafiu, M1
Mu, W2
Owens, D1
Reinders, MK3
Haagsma, C1
van Roon, EN3
Delsing, J2
Brouwers, JR3
Miao, Z3
Zhao, S1
Xu, F1
Yan, S2
Wang, CY2
Sautin, YY1
Oliver, WJ1
Roncal, C1
Gabriela Sanchez-Lozada, L1
Rodriguez-Iturbe, B1
Benner, SA1
Le Goff, B1
Berthelot, JM1
André, V1
Guillot, P1
Maugars, Y1
Song, EF1
Xiang, Q1
Ren, KM1
Hu, JC1
Wu, F1
Gong, MF1
Bi, HM1
Hodges, JS2
Asch, SM2
Gregory, K1
Sheehan, T1
Chen, LX5
Hair, PI1
McCormack, PL1
Keating, GM1
Barkhuizen, A1
Moreland, LW2
Waltrip, RW6
Maroli, AN4
Horowitz, Z2
Abrams, B3
Dore, RK1
Weaver, AL1
Cheh, MA1
Kennison, RH1
Graessler, J3
Kao, WL1
Rivadeneira, F3
Astor, BC1
Benjamin, EJ1
Witteman, JC3
Fox, CS5
Riddell, CM1
Elliott, M1
Cairns, AP1
ROBINSON, WD3
CONN, JW1
Matsumoto, AK1
De Vera, M2
Rahman, MM2
Rankin, J1
Kopec, J1
Wortmann, RL9
Streit, J3
Lademacher, C4
Joseph-Ridge, N4
Thissen, CA1
Frank, J1
Lucker, GP1
Palazzi, C1
D'Angelo, S1
Pennese, E1
Olivieri, I1
Sari, I1
Akar, S1
Pakoz, B1
Sisman, AR1
Gurler, O1
Birlik, M1
Onen, F1
Akkoc, N1
Al-Arfaj, AM1
Eftekhari, A1
Miao, ZM1
Zhao, SH1
Yan, SL1
Meng, DM2
Martin, WJ3
Walton, M1
Harper, J1
Malik, A1
Dinnella, JE1
Clayburne, GM1
Lloyd, E3
Shulten, P1
Thomas, J4
Miller, M1
Smith, M2
Ahern, M1
Kanevets, U1
Sharma, K1
Dresser, K1
Titov, VN1
Dmitriev, VA1
Oshchepkova, EV1
Curhan, G4
Traynor, K1
Guan, M2
Kong, N1
Andrade, SE3
Briesacher, BA1
Raebel, MA3
Fouayzi, H2
Ockene, IS2
Xing, X1
Meng, D3
Chohan, S4
Marasini, B1
Massarotti, M1
Haggins, DG1
York, RH1
Yeni, YN1
Norquist, JM1
Watson, DJ1
Patel, PA4
Mody, RR3
Yu, AP2
Cahill, KE2
Tang, J3
Livesey, G1
Courtney, P1
Weaver, J1
Somani, N1
Bauer, TW1
Piliang, M1
Slobodin, G1
Lurie, M1
Rosner, I1
Odeh, M1
Rozenbaum, M1
Halpern, R1
Fuldeore, MJ2
Kolz, M1
Sanna, S2
Wallace, C1
Farrall, M1
Nyholt, DR1
Aulchenko, Y1
Beckmann, JS1
Connell, J1
Dominiczak, A1
Lamina, C2
McCarthy, MI1
Mooser, V1
Munroe, P1
Peden, J1
Samani, NJ2
Schlessinger, D1
Uda, M1
Waterworth, D1
Wang-Sattler, R1
Adamski, J1
Pramstaller, P1
Doering, A1
Peltonen, L1
Illig, T3
Guggino, WB1
Hughes, T1
Penna, KJ1
Zelman, D1
Scavulli, J1
Wall, GC1
Koenigsfeld, CF1
Hegge, KA1
Bottenberg, MM1
Berger, JS1
Weinik, MM1
Nygaard, HB1
Shenoi, S1
Shukla, S1
Hayman, S1
Marcason, W1
Kudaeva, FM2
Aleksandrova, EN1
Volkov, AV2
Nasonova, VA2
Gracey, E1
MacGibbon, A1
Palmano, K2
Marickar, YM1
McMahan, Z1
Patel, PC1
Markham, DW1
Drazner, MH1
Mammen, PP1
Capsoni, F1
Ongari, AM1
Reali, E1
Catania, A1
Evans, R2
MacDonald, P2
McQueen, F1
Winzer, M2
Ka, T5
Inokuchi, T3
Tamada, D1
Suda, M2
Tsutsumi, Z20
Okuda, C1
Takahashi, S20
Moriwaki, Y22
Artmann, A1
Ratzenböck, M1
Noszian, I1
Trieb, K1
Stark, K2
Reinhard, W2
Grassl, M1
Erdmann, J2
Schunkert, H2
Lea, RA1
Chiang, HC1
Wang, TN3
Huang, MC1
Ou, TT1
Lin, GT1
Wiesner, T1
Fried, I1
Keitel, W3
Khitrik, NM1
Didkovskiĭ, NA1
Malashenkova, IK1
Egorov, IV2
Selvi, E1
Friedman, JH1
Sachs, L1
Batra, KL1
Zimmermann, B1
McClory, J1
Said, N1
Kobayashi, S1
Okamoto, H1
Momohara, S1
Tomatsu, T1
Bacani, AK1
Bond, JR1
Milks, J1
Manek, NJ2
Ning, TC1
Igawa, O4
Shigemasa, C2
Brandstätter, A1
Kiechl, S1
Hunt, SC1
Coassin, S2
Paulweber, B2
Kramer, F1
Summerer, M1
Willeit, J1
Kedenko, L1
Adams, TD1
Briesacher, B1
Ernst, ME1
Fravel, MA1
Pozzuoli, A1
Frezzato, F1
Agostini, C1
Schorn, C1
Strysio, M1
Kortan, N1
Roebuck, J1
Law, YY1
Lue, KH1
Lu, KH1
Hu, QH1
Jiao, RQ1
Lv, YZ1
Kong, LD1
Espinoza, LR2
Wells, AF1
Yeap, SS1
Goh, EM1
Tanigawa, T1
Martinon, F2
Nowatzky, J1
Howard, R1
Alonso, A2
Sovell, KA1
Mascitelli, L1
Pezzetta, F1
Goldstein, MR1
Ostović, KT1
Kaić, G1
Ostović, I1
Skoro, M1
Novak, NP1
Morović-Vergles, J1
Perry, ME2
Madhok, R1
Simon, HB2
Regule, D1
Wong, S1
Mason, B1
Sarma, P1
Das, D1
Deka, P1
Deka, AC1
Ng, G1
Chau, EM1
Hernandez-Baldizon, S1
Carotti, M1
Ciapetti, A1
Akkara Veetil, BM1
Pile, JC1
Thorens, B1
Ruoff, GE1
de Miguel, ME1
Martínez, P2
Lundelin, KJ1
Vázquez, JJ3
Hernández Cuevas, C1
Hernández Roque, L1
Terán, L1
Espinoza, J1
Esquivel-Valerio, JA1
Goycochea-Robles, MV1
Aceves, FJ1
Bernard, AG1
Ventura, L1
Shumsky, C1
Hernández Garduño, A1
Chiu, CT1
Ko, YS1
Hwang, JS1
Chang, HC1
Iharada, M1
Fujimoto, T1
Hiasa, M1
Guo, CY1
Roberts, LJ1
Ganson, NJ3
Kelly, SJ4
Santisteban, I1
Scarlett, E2
Jaggers, D1
Indridason, OS1
Thorleifsson, G1
Edvardsson, V1
de Vegt, F1
d'Ancona, FC1
den Heijer, M1
Wetzels, JF1
Franzson, L1
Rafnar, T2
Kristjansson, K1
Bjornsdottir, US1
Eyjolfsson, GI2
Kiemeney, LA2
Kong, A2
Palsson, R1
Hsiao, SJ1
Vaynrub, M1
Furer, V1
Hettiarachchi, D1
Ben, C1
Shelling, G1
Tabara, Y1
Kohara, K1
Kawamoto, R1
Hiura, Y1
Nishimura, K1
Morisaki, T1
Kokubo, Y1
Okamura, T1
Tomoike, H1
Iwai, N1
Miki, T1
Burns, CM1
Ochoa, CD1
Valderrama, V1
Mejia, J1
Rondon, F1
Villaroya, N1
Restrepo, JF1
Iglesias-Gamarra, A1
Lebedeva, MV2
Stakhova, TIu1
Zaĭtseva, LI1
Selivanova, OIu1
Severova, MM1
Yoo, Y1
Seo, YJ1
Huh, M1
Yoo, JH1
Yun, KH1
Kitamura, K1
Kaneko, S1
Yan, K1
Yamada, H1
Shimada, H1
Kimura, T1
Katada, T1
Fukutomi, T1
Seki, G1
Fujita, T3
Yamada, A1
Wempe, MF1
Sakurai, H1
VanItallie, TB1
Panzner, I2
Aust, D1
Bhansing, KJ1
van Bon, L1
Handler, J1
Glazer, NL1
Chasman, DI2
Aspelund, T1
Eiriksdottir, G1
Launer, L1
Nalls, M1
Hernandez, D1
Arking, DE1
Linda Kao, WH1
Chonchol, M1
Haritunians, T1
Lumley, T1
Shlipak, M1
Larson, MG1
Upadhyay, A1
Stricker, B1
Parker, AN1
Siscovick, DS2
Cipriani, S1
Rainer, F1
Piret, SE1
Danoy, P1
Dahan, K2
Reed, AA1
Pryce, K1
Wong, W1
Müller, T1
Kotanko, P1
Lhotta, K2
Brown, MA2
Thakker, RV1
FIESSINGER, N1
Quillen, DM1
Zychowicz, ME1
Pope, RS2
Graser, E1
Jordan, S2
Willett, W1
Cayley, WE1
Meyer zu Schwabedissen, HE1
Kroemer, HK1
Pu, J1
Bu, Y1
Liao, F1
Harris, DJ1
Kuritzky, L1
Panchal, R1
Peterson, DM1
Flemmig, J1
Kuchta, K1
Arnhold, J1
Rauwald, HW1
Maranian, P1
Yu, JW1
Yang, TG1
Diao, WX1
Cai, XQ1
Hu, DL1
Chen, CQ1
Chen, ZX1
Widerøe, TE1
Wijnands, JM1
Arts, IC1
Dagnelie, PC1
Stehouwer, CD1
Ching, CT1
Sun, TP1
Tsai, CL1
Huang, HH1
Kuo, JF1
Lai, LH1
Chien, MY1
Tseng, HH1
Pan, HT1
Huang, SY1
Shieh, HL1
Liu, CM1
Huang, HW1
Xue, HD1
Zhang, YQ1
Xu, K1
Jin, ZY1
Ghaemi-Oskouie, F1
Cohen, MG1
Akl, KF1
James, J1
Tore, S2
Casula, S1
Casu, G1
Pistidda, P1
Persico, I2
Sassu, A1
Maestrale, GB1
Mele, C1
Caruso, MR1
Bonerba, B1
Usai, P1
Deiana, I1
Thornton, T1
Forabosco, P1
Zhoub, S1
Chu, N2
Charles, BA1
Shriner, D2
Doumatey, A1
Herbert, A1
Gerry, NP1
Christman, MF1
Adeyemo, A1
Rotimi, CN2
Kessenich, CR1
Jackson, RL3
Keller, DL1
Wertheimer, AI1
Davis, MW1
Lauterio, TJ1
Dubost, JJ1
Mathieu, S1
Soubrier, M1
Allaeys, I1
Rusu, D1
Picard, S1
Pouliot, M1
Borgeat, P1
Poubelle, PE1
GUTMAN, AB35
YÜ, TF39
Tirado-González, M1
González-Serva, A1
Shaw, O1
Messerli, FH1
Makani, H1
Halpern, D1
Zhang, LY1
Wittköpper, K1
Emons, J1
El-Armouche, A1
Shen, L2
Ji, HF1
Uh, M1
Watson, M1
Wong, H1
Chun, W1
Naoyuki, K4
Tatsuo, H4
Hada, T11
Kohri, K5
Matsuzawa, Y6
Shin, F3
Toshikazu, H3
Kenjiro, K3
Toshitaka, N3
Takanori, U3
Tetsuya, Y3
Hisashi, Y3
Yuji, M3
Chuang, SY2
Hsieh, YT1
Pan, WH3
Howard, RG1
Swearingen, CJ1
Horsley, A1
Helm, J1
Brennan, A1
Bright-Thomas, R1
Webb, K1
Jones, A1
Boers, M1
Maksymowych, WP1
Yeh, WT2
Wu, YY1
Liu, CT1
Semmo, M1
Akylbekova, EL1
Wyatt, SB1
Palmer, C1
Reilly, M1
Shlipak, MG1
Siscovick, D1
Flessner, MF1
Cupples, LA1
Riedel, AA1
Zarotsky, V1
Pandya, BJ2
Dabbous, O2
Chiou, SJ1
Kriegsmann, J1
Lange, U1
Hamburger, SA1
Messina, M1
Messina, VL1
Chan, P1
Keith, MP2
Gilliland, WR2
Bollée, G1
Flamant, M1
Morinière, V1
Pawtowski, A1
Heidet, L1
Lacombe, D1
Pirson, Y1
Antignac, C2
Knebelmann, B1
Tardella, M1
Arlet, JB1
Ribeil, JA1
Chatellier, G1
Pouchot, J1
de Montalembert, M1
Prié, D1
Courbebaisse, M1
Alvarez-Lario, B1
Macarrón-Vicente, J1
Guimarães, LS1
Black, DF1
Yébenes, MJ1
Ureña, I1
Adenwalla, HN1
O'Connor, CR1
Shipley, M1
Sachs, D1
Coelho, FM1
Fagundes, CT1
Silveira, TN1
Cunha, LD1
Quesniaux, V1
Peres, RS1
Cunha, TM1
Cunha, FQ1
Policarpio-Nicolas, ML1
Valente, PT1
Leiszler, M1
Poddar, S1
Fletcher, A1
Walters, GB1
Helgadottir, HT1
Helgason, A1
Gudjonsson, SA1
Zanon, C1
Besenbacher, S1
Bjornsdottir, G1
Magnusson, OT1
Magnusson, G1
Hjartarson, E1
Saemundsdottir, J1
Gylfason, A1
Jonasdottir, A1
Karason, A1
Stefansson, H1
Andreassen, OA1
Pedersen, JH1
Pack, AI1
de Visser, MC1
Geirsson, AJ1
Masson, G1
Rho, YH1
Herbert, JD1
Coulson, JO1
Coulson, TD1
McAdams DeMarco, MA1
Young, JH1
Mittag, F1
Wuenschel, M1
Chefo, S2
Chales, G1
Xing, RL1
Uratsuji, H1
Tada, Y1
Kawashima, T1
Kamata, M1
Hau, CS1
Asano, Y1
Sugaya, M1
Kadono, T1
Asahina, A1
Tamaki, K1
Yashio, K1
Katayama, Y1
Takashima, T1
Ishiguro, N1
Doi, H1
Suzuki, M1
Wada, Y3
Watanabe, Y1
Gao, A1
Mitroulis, I2
Kambas, K2
Chrysanthopoulou, A1
Skendros, P1
Apostolidou, E1
Kourtzelis, I1
Drosos, GI1
Ritis, K2
Suresh, E2
Das, P1
Jin, M1
Yang, I2
Luo, JJ1
Yang, XF1
Frediani, B1
Delle Sedie, A1
Bombardieri, S1
Iagnocco, A1
Valesini, G1
Avhad, G1
Dandale, A1
Ghate, S1
Dhurat, R1
Lingala, B2
Hariri, A1
Rakieh, C1
Conaghan, PG1
Marson, P1
Pasero, G4
De Angelis, R2
Leoncini, G1
Lipkowitz, MS1
Park, H1
Rascati, KL1
Prasla, K1
McBayne, T1
Burns, LC1
Koenig, N1
Abufayyah, M1
Law, G1
Hu, M1
Tomlinson, B1
Kakar, S1
Ida, CM1
Laurini, JA1
Moder, KG1
Koyama, H1
Shoji, T1
Sumida, C1
Koga, M1
Dockerty, JL1
Shin, J1
Kong, M1
Li, WM1
Huang, SP1
Tsai, CC1
Chang, AW1
Lin, YL1
Clower, J1
Jennings, W1
Koga, T1
Satomura, K1
Izumi, M1
Torigoshi, T1
Maeda, Y1
Izumi, Y1
Jiuchi, Y1
Miyashita, T1
Yamasaki, S1
Aiba, Y1
Komori, A1
Nakamura, M1
Motokawa, S1
Ishibashi, H1
Kushnarenko, NN1
Govorin, AV1
Shcherbakova, OA1
Sotnikova, SG1
Ivanitskaia, OV1
Kotz, J1
Hofmann, F1
Forsythe, A1
Lehmann, RA1
Schneck, L1
Greenberg, JD1
Cronstein, BN3
Sedlis, SP1
Zgaga, L2
Kyle, J1
Agakov, F1
Walker, M1
McNeill, G1
Kunitskaia, NA1
Ar'ev, AL1
He, J1
Peng, DQ1
Kao, LW1
Mylona, EE1
Mouktaroudi, M1
Makri, S1
Pistiki, A1
Georgitsi, M1
Savva, A1
van der Meer, JW1
Giamarellos-Bourboulis, EJ1
Lim, AY1
Tan, CH1
Lateef, A1
Lau, TC1
George, RL1
Indraratna, PL1
Bhalla, V1
Hou, CW1
Lee, YC1
Hung, HF1
Fu, HW1
Jeng, KC1
Yu, P1
Di, D1
Xue, R1
Cao, G1
Pan, Z1
Gong, C1
Tong, CY1
How, CH1
Goh, LH1
Rock, KL2
Kataoka, H1
Lai, JJ1
Conway, R1
Coughlan, RJ1
Carey, JJ1
Krüger, K1
Ordóñez, S1
Reeves, Q1
Katsiki, N1
Karagiannis, A1
Athyros, VG1
Yee, J1
Bleyer, AJ3
Kmoch, S2
Bobulescu, IA1
Moe, OW2
Kedar, E1
Mehta, TH1
Murea, M1
Dave, AJ1
Kelly, VM1
Yakut, S1
Cetin, Z1
Arman, M1
Akbas, H1
Manguoglu, AE1
Luleci, G1
Zochling, J1
Dillon, A1
Suppiah, R1
Grassi, D1
Ferri, L1
Di Giosia, P1
Cheli, P1
Properzi, G1
Rivard, C1
Pluta, RM1
Burke, AE1
Livingston, EH1
McLaughlin, RJ1
Yilmaz, S1
Celik, G1
Gündogdu, A1
Choi, CM1
Lew, BL1
Sim, WY1
Garay, R1
Torralba, KD1
De Jesus, E1
Rachabattula, S1
Gheita, TA1
El-Fishawy, HS1
Nasrallah, MM1
Waldron, JL1
Ashby, HL1
Razavi, C1
Thomas, OL1
Chugh, S1
Deshpande, S1
Ford, C1
Gama, R1
Krumsiek, J1
Hundertmark, C1
O'Seaghdha, CM1
Johnson, AD1
Struchalin, M1
Middelberg, RP1
Brown, MJ1
Zemunik, T1
Huffman, J1
Yengo, L1
Zhao, JH1
Feitosa, MF1
Bakker, SJ1
Steri, M1
Lagou, V1
Rose, LM1
Müller, C1
Oldmeadow, C1
Putku, M1
Czamara, D1
Kraft, P1
Frogheri, L1
Thun, GA1
Launer, LJ1
McArdle, P1
Shuldiner, AR1
Schallert, M1
Jacobs, DR1
Rotter, JI1
Balkau, B1
Froguel, P1
Salumets, A1
Khaw, KT1
Langenberg, C1
Wareham, NJ1
Isaacs, A1
Kraja, A1
Wild, PS1
Scott, RJ1
Holliday, EG1
Org, E1
Bandinelli, S1
Lupo, A1
Lattka, E1
Theis, F1
Bruinenberg, M1
Stolk, RP1
Winkelmann, BR1
Boehm, BO1
Lucae, S1
Mudgal, P1
Plenge, RM1
Mateo Leach, I1
van Gilst, WH1
Ongen, H1
Imboden, M1
von Eckardstein, A1
Cucca, F1
Piras, MG1
Ernst, F1
Prokopenko, I1
Shin, SY1
Viikari, J1
Nelson, CP1
Meschia, JF1
Sharma, P2
Singleton, AB1
Zeller, T1
Laan, M1
Hillege, HL1
Probst-Hensch, NM1
Bouatia-Naji, N1
Loos, RJ1
Borecki, IB1
Wolffenbuttel, BH1
Navis, G1
Raitakari, O1
Meltzer, M1
Martínez-Indart, L1
Pijoan, JI3
Hsu, SN1
Chiu, SK1
Ye, P1
Cheng, Q1
Mei, M1
Luo, T1
Russell, E1
Schiltz, C2
Prudhommeaux, F2
Meunier, A1
Champy, R2
Callebert, J1
Abdelrahman, M1
Rafi, A1
Ghacha, R1
Youmbissi, JT1
Qayyum, T1
Karkar, A1
Spieker, LE1
Ruschitzka, FT1
Lüscher, TF1
Noll, G1
Isomäki, H4
Dincer, HE1
Dincer, AP1
Levinson, DJ5
Akkasilpa, S2
Deesomchok, U2
Calabozo, M5
Ruibal, A2
Fukuchi, M1
Shekarriz, B1
Ziegler, E1
Ohta, H2
Pak, CY6
Poindexter, JR5
Peterson, RD4
Koska, J1
Sakhaee, K4
Lin, JL2
Tan, DT1
Ho, HH3
Yu, CC2
Sorensen, CM1
Chandhoke, PS1
Park, YS2
Yoon, SJ1
Wakefield, RJ1
Emery, P1
Pease, C1
Hepburn, AL3
Hogarth, MB1
Ball, SG1
Kaye, SA2
Cardona, F1
Tinahones, FJ1
Collantes, E1
Escudero, A1
García-Fuentes, E1
Soriguer, FJ1
Nakajima, H1
Iwatani, M4
Yamanouchi, T7
Matsumoto, Y1
Mineo, I2
Nakagawa, C1
Tarui, S4
Yoshio, N1
Moe, O1
Preminger, GM4
Pietrow, P1
Ekeruo, W1
Moyer, RA1
John, DS1
Dutton, CJ1
Taylor, P1
Woodard, AS1
Shihabi, Z1
Sandhu, J1
Satko, SG1
Weller, N1
Deterding, E1
McBride, D1
Gorry, MC1
Ganier, D1
Hart, TC2
Huang, CT1
Chen, ML1
Huang, LL1
Mao, IF1
Nitti, F1
Fumagalli, M1
Incorvaia, C1
García-Pavía, P1
Rivero, M1
Ahmed, M1
García-Puig, J2
Adams-Huet, B2
Pearle, MS1
Lien, LC1
SEIFERT, P1
WEISS, TE3
MULLER, AF4
BAUER, W2
BENEDICT, JD6
BIEN, EJ5
STETTEN, D8
TALBOTT, JH16
BISHOP, C9
BEECHER, L1
BOLLIGER, A2
GROSS, R2
BALLABIO, CB3
AMIRA, A1
DIOGUARDI, N1
WASSERMAN, LR1
LASTER, L6
HOFFMAN, WS2
SIROTA, JH2
MARSON, FG4
MASON, RM2
BONELLI, M1
BUCHBORN, E1
WENK, M1
BEYER, A1
RANDOLPH, V1
BUZARD, JA1
ZUMOFF, B1
ZUCKER, M1
CANOA, E2
CIFUENTES DELATTE, L2
HAUGE, M1
HARVALD, B1
PATON, BC1
CHENKIN, T1
BURNS, JJ1
BRODIE, BB1
CIRLA, E1
MOORE, CB1
POMMATAU, E1
WYNGAARDEN, JB16
Jeune, M1
Charrat, A1
Bertrand, J1
VIOLA, PL1
COODLEY, E1
BLAIR, AE1
HILLEY, L1
BACRI, J1
SEEGMILLER, JE42
LIDDLE, LV1
LACAPERE, J1
OREN, BG1
RICH, M1
BELLE, MS1
GOLDTHWAIT, JC1
BUTLER, CF1
STILLMAN, JS1
BARBIERI, P2
FUOCO, L1
RUSCONI, A1
SALA, G1
BLACK, H1
YALOW, RS1
BERSON, SA1
BLATT, IM1
MIKKELSEN, WM12
DENNING, RM1
GOLDSMITH, LI1
BLAHOS, J2
LAVICKA, J3
ATSMON, A1
DE VRIES, A14
LAZEBNIK, J2
SALINGER, H1
ARONOFF, A1
BARKUM, H1
BARCELO, P9
PUIG MUSET, P1
SANS SOLA, L2
BECKER, JH1
BECKETT, AG1
LEWIS, JG1
FREEMAN, RB1
DUNCAN, GG4
GRAYZEL, AI2
LIDDLE, L1
MUGLER, A9
MCCARTY, DJ22
HOLLANDER, JL2
VILLA, L1
LOVE, E1
KERSLEY, GD8
GIBBS, AR1
VACHTENHEIM, J3
SVOJITKA, J1
YU, FT1
ADLER, M1
JAVITT, NB1
SISON, AB1
REYES, MG1
GUTIERREZ, MT1
SNODELL, FE1
THOMPSON, GR4
DUFF, IF4
GALINDEZ, H1
VIOLLE, PL1
HOWELL, RR8
EANES, ED1
ITSKOVITZ, HD1
SELLERS, AM1
HOLLANDER, E7
ATTALI, P1
PRUNIER, P1
SUTTENFIELD, FD1
REUBI, F1
VORBURGER, C1
WALLACE, SL7
BERNSTEIN, D2
YU, TS1
BERGER, L6
ZVAIFLER, NJ2
PEKIN, TJ1
ZELMAN, S1
COMMANDRE, F1
LAPEYRE, L1
BERNET, C1
BARALIS, G1
PRUVOST, JY1
DELBARRE, F25
PERLES, L1
MARTINE AU, J1
LEPROVOST, J1
RICCIONI, N1
DUNCAN, H2
WAKIM, KG1
WARD, LE4
NUGENT, CA4
MACDIARMID, WD2
TYLER, FH3
SERRE, H4
SIMON, L3
CLAUSTRE, J3
JOCSON, CT1
PERET RIERA, J1
MURIACH, V1
BALAGUER VINTRO, I1
MARTEL, W2
RAKIC, MT3
HAYES, JT1
AYVAZIAN, JH1
AYVAZIAN, IF1
MUSTARD, JF1
MURPHY, EA1
OGRYZLO, MA5
SMYTHE, HA1
BORRACHERO, J2
MADRID, J1
ROSE, BS5
PRIOR, IA8
YUE, TF2
FRANCOMANERA, R1
AUSCHER, C19
VERDU, R1
YEARWOOD, HM1
BAKER, OA1
WILLIAMSON, CI1
BEETHAM, WP1
LABOUCHE, F1
DULUC, J1
BARREAU, J1
THOMAS, E3
SCOTT, JT54
DIXON, AS1
BYWATERS, EG2
DAVIDSON, F2
FOX, SL1
AGNOLETTO, A1
CARNELUTTI, M1
CONTI, M1
FOA, V1
ROSENTHAL, IM1
GABALLAH, S1
RAFELSON, ME1
ITO, H1
OKAZAKI, M1
AKAOKA, I10
KOYAMA, S1
BRILL, JM2
KELLGREN, JH1
DENMAN, AM1
SZUR, L1
ANSELL, BM1
MCKECHNIE, JK1
FELDMAN, EB4
RICHET, G4
ALBAHARY, C1
ARDAILLOU, R2
SULTAN, C1
MOREL-MAROGER, A1
SIMPSON, FO1
WAAL, HJ1
LESCH, M2
NYHAN, WL5
CANER, JE1
DECKER, JL4
GASPARDY, G1
SCHULHOF, O1
VIDA, M1
RYCKEWAERT, A16
KAHN, MF3
FRENEAUX, B1
DE SEZE, S9
ICHISEKI, H1
ARAI, K1
REUTTER, F2
SCHAUB, F1
GRAVANO, L1
MEYER, JS1
KYPROS, GP1
GILROY, J1
AMAKO, T1
YAMAMOTO, M2
ODA, H2
FUJIKI, A1
HOLLOWAY, VP5
FISHBACK, DB1
CASTOR, LH1
HANSEN, OE3
TVETER, KJ1
LIUM, O1
PAKULA, A1
BARTON, EM1
DEDMON, RE1
SUNDSTROM, WR1
SANSSOLA, YL1
PADOVA, J1
PATCHEFSKY, A1
ONESTI, G1
FALUDI, G1
BENDERSKY, G1
ISHMAEL, WK1
OWENS, JN1
PAYNE, RW1
HONICK, MD1
BERKOWITZ, D1
ANICHINI, M1
GARGANO, N1
BARTORELLI, C1
VIX, VA1
TREADWELL, B1
LAURENT, TC1
REAH, TG1
FUJIKI, T1
ROBECCHI, A1
KUZELL, WC2
GLOVER, RP2
GIBBS, JO1
BLAU, RA1
HALL, AP5
BOURSIER, B1
MIGNON, F1
VALKENBURG, HA3
DAVIDSON, RT2
ENGELS, JP1
NEEL, JV2
KOELBEL, F1
GREGOROVA, I1
SONKA, J1
WENER, J1
SCHUCHER, R1
FRIEDMAN, R1
HELLER, H1
ALVSAKER, JO10
DUARTE, CG1
BLAND, JH1
KELLERMEYER, RW3
BRECKENRIDGE, RT1
SANCHEZMDEL, C1
MONTERO, M1
BERMEJILLO, F1
PAKPOY, RK1
KLINENBERG, JR23
GOLDFINGER, SE4
MALAWISTA, SE5
KAPLAN, D3
HALBERSTAM, D2
GONICK, HC3
RUBINI, ME1
GLEASON, IO1
SOMMERS, SC1
FREUDWEILER, M1
BUCHANAN, WW2
DUNCAN, TG3
SCHLESS, GL2
CRISTOFORI, FC2
RINGOIR, S1
RIVERA, JV1
MARTINEZ MALDONADO, M1
RAMIREZDEARELLANO, GA1
EHRLICH, L1
GATTER, RA1
HOGAN, JM1
KOLLER, F1
CURREY, HL1
SWETTENHAM, KV1
RIBI, A1
VELAYOS, EE1
SMYTH, CJ4
DODGE, HJ4
VALKENBURG, H1
GAST, LF3
BRECKENRIDGE, A1
METCALFE-GIBSON, A1
MCCORMICK, EW1
BLOCH, R1
VOGT, R1
RAND, R2
PASCALE, LR1
DUBIN, A1
BRONSKY, D1
ALLEN, GE1
ROGERS, FB1
LANSBURY, J1
BUZARD, J1
PERNET, JL1
PERNET, A1
FRIEDRICH, S1
LANE, M1
KEMPER, JW1
LAUDAT, MH1
LAGRUE, G7
MILLIEZ, P1
MASONI, A1
TOMASI, AM1
ANTONIOLI, G1
MORRIS, JB1
POPERT, AJ1
HEWITT, JV1
Benecke, M1
Enomoto, A2
Niwa, T1
Gentili, A1
Darmawan, J3
Nuralim, H1
de Klerk, E1
van der Heijde, D1
Landewé, R1
van der Tempel, H1
van der Linden, S1
Terkeltaub, RA9
Lunam, CA1
Gentle, MJ2
Nilsson, SE1
Takkinen, S1
Tryding, N1
Evrin, PE1
Berg, S1
McClearn, G1
Johansson, B1
Oaks, JL1
Gilbert, M1
Virani, MZ1
Watson, RT1
Meteyer, CU1
Rideout, BA2
Shivaprasad, HL1
Chaudhry, MJ1
Arshad, M1
Mahmood, S1
Ali, A1
Khan, AA1
Meyers, OL3
Cassim, B1
Mody, GM2
BRAMIGK, F1
GARNER, W1
BENE, E2
MANDEL, L1
NORCROSS, BM1
LOCKIE, LM1
ROCHE, M2
IZAR, G1
Casimire-Etzioni, AL1
Wellehan, JF1
Embury, JE1
Terrell, SP1
Raskin, RE1
Zeng, QY1
Pedraz, T1
Bomalaski, JS4
Clark, MA2
Iakunina, IA3
Zilov, AV2
Il'inykh, EV2
Snaith, M2
Leclercq, P1
Malaise, MG1
López Jiménez, M5
García Puig, J6
Zakharova, MM1
Karateev, AE1
Fedorova, AA1
Bieber, JD1
Tramontini, N1
Huber, C1
Kilgore, KS1
FORSHAM, PH2
FRIEDMAN, M1
BYERS, SO1
ORSTROM, A1
ORSTROM, M1
SOLOWAY, S1
Proffitt, F1
Bagla, P1
Aslam, N1
Lo, S1
McNab, I1
Hediger, MA2
Vock, P1
Bonel, H1
Villiger, PM1
Vogt, B1
Gugger, M1
Frey, FJ1
Díaz-Reval, MI1
López-Muñoz, FJ1
Osiri, M1
Avihingsanon, Y1
Kodali, VR1
Dunn, NA1
Ye, J1
Yoshizumi, K1
Nishioka, N2
Tsuji, T1
Palo, WA3
Eustace, D2
Vernillet, L1
Lumbreras, B1
Frasquet, J1
González-Salinas, J1
Rodríguez, E2
Hernández-Aguado, I1
Chen, CH1
Chen, CK2
Yeh, LR1
Pan, HB2
Yang, CF2
Kostrzewa-Zabłocka, E1
Pritzker, K1
Firestein, GS1
Kolyvanos Naumann, U1
Suter, PM1
Käser, L1
Vetter, W1
Feydy, A1
Carlier, R1
Chevrot, A1
Drapé, JL1
Ejaz, S1
Kim, BS1
Lim, CW1
Fam, AG6
Melloni, P1
Valls, R1
Yuguero, M1
Larrosa, M1
Hung, JY1
Wu, SS1
Maloney, ME1
Springhart, WP1
Ekeruo, WO1
Young, MD1
Enemchukwu, CU1
Yang, YH1
Quiceno, GA1
Cush, JJ1
Ng, J1
Wong, ML1
Yamanaka, M1
Nikolenko, IuI4
Siniachenko, OV7
Anan'eva, MN1
Nikolenko, VIu1
Dubiaga, VV1
Shchukin, IN1
Garcia-Porrua, C1
Canedo, C1
Argueso, R1
Cannella, AC1
Huang, GS1
Chang, DM1
Kao, HW1
Chen, CY1
Huang, K1
Masseoud, D1
Rott, K1
Agudelo, C1
Espejo-Baena, A1
Coretti, SM1
Fernandez, JM1
Garcia-Herrera, JM1
Del Pino, JR1
Pétrilli, V1
Mayor, A1
Tardivel, A1
Tschopp, J2
van den Berge, M1
Vrugt, B1
Holt, C1
Smit, CJ1
Hoogenberg, K1
Bernad, B1
Narvaez, J1
Diez-Garcia, M1
Valverde, J1
Coassin, M1
Piovanetti, O1
Stark, WJ1
Green, WR1
Tsapina, TN1
Rozin, AP1
Braun-Moscovici, Y1
Balbir-Gurman, A1
Unger, S2
Richter, K1
Grässler, J2
Roch, B1
Schröder, HE10
Sarawate, CA1
Yang, W1
Brewer, KK1
Bakst, AW1
Purohit, MB1
Purohit, TM1
Tandon, RK1
Davis, J1
Fuller, J1
Chan, KA1
Roblin, D1
Von Worley, A1
Platt, R1
Bornstein, SR1
Soriano, F1
Campana, V1
Moya, M1
Gavotto, A1
Simes, J1
Soriano, M1
Spitale, L1
Palma, J1
Conaghan, P1
Gerster, J1
Jacobs, J1
Leeb, B1
Netter, P2
Pignone, A1
Zimmermann-Gòrska, I3
Kwon, CY1
Zandi-Nejad, K1
Nan, H1
Qiao, Q1
Tang, B1
Qian, R1
Tuomilehto, J1
Ordi, J1
Alonso, PL1
de Zulueta, J1
Esteban, J1
Velasco, M1
Mas, E1
Campo, E1
Fernández, PL1
Hearn, A1
Fitzgerald, K1
Golenbock, D1
Reed, G1
Akira, S1
Shima, Y1
Teruya, K1
Rao, S1
Gupta, K1
Arora, R1
Arulselvi, S1
Spartà, G1
Kemper, MJ1
Neuhaus, TJ1
Murugaiyah, V1
Chan, KL1
Pohar, S1
Murphy, G1
Gersch, MS1
Rose, DM1
Sydlaske, AD1
Agha-Babakhani, A1
Johnson, K1
Moore, DF1
Sun, JD1
Chizyński, K1
Rózycka, M1
Caldas, CA1
Fuller, R1
Scott, P1
Ma, H1
Viriyakosol, S1
Croft, JD1
Corrado, A1
D'Onofrio, F1
Santoro, N1
Melillo, N1
Cantatore, FP1
Shah, K1
Spear, J1
Nathanson, LA1
McCauley, J1
Edlow, JA1
Akahoshi, T1
Kitasato, H1
Houtman, PM1
Scarlett, EL1
Wise, CM4
Jacobs, JW4
Bijlsma, JW4
Cammalleri, L1
Malaguarnera, M1
Martínez-Villén, G1
Canales, V1
Hernández-Rossi, A1
Herrera, A1
Toscano, JP1
Liebman, SE1
Taylor, JG1
Bushinsky, DA1
Rollet-Labelle, E1
Thibault, N1
Gilbert, C2
Bourgoin, SG2
Spackey, J1
Demos, TC1
Lomasney, LM1
Kobayashi, T1
Dahiya, A1
Leach, J1
Levy, H1
De Leonardis, F1
Colina, M1
Bruschi, M1
Trotta, F1
Martin, I1
Canteli, B1
Alvarado-Romano, V1
Jiménez-Vaca, AL1
Pozo-Molina, G1
Cuevas-Covarrubias, SA1
Johnson, TR1
Weckbach, S1
Kellner, H1
Reiser, MF1
Becker, CR1
Alderman, MH1
Kutzing, MK1
Firestein, BL1
Grusch, B1
Rintelen, B1
Leeb, BF1
Hoenen-Clavert, V1
Loeuille, D1
Pope, RM1
Bellini, LP1
Rosenthal, P1
Jerome, JT1
Sankaran, B1
Thirumagal, K1
Annemans, L1
Spaepen, E1
Gaskin, M1
Bonnemaire, M1
Malier, V1
Gilbert, T1
COTTERMAN, CW1
FREYBERG, RH1
WOLFSON, WQ1
HUNT, HD1
Park, JY1
Baker, DL1
Stroup, JS1
Gilstrap, CA1
Sturrock, RD1
Phelps, P6
Griep, EN1
Hoekstra, M1
Marie, I1
Parrad, M1
Lahaxe, L1
Levesque, H1
Houdent, C1
Earl, SC1
Hull, R1
Kasifoglue, T1
Cansu, D1
Korkmaz, C1
Mehta, D1
Gohlke, H1
Fischer, G1
Henke, K1
Pfeufer, A1
Rosskopf, D1
Gray, NK1
Floyd, J1
Palmer, CN1
Knott, SA1
Shu, X1
Janicijevic, B1
Smolej-Narancic, N1
Gorgoni, B1
Morgan, J1
Biloglav, Z1
Barac-Lauc, L1
Pericic, M1
Klaric, IM1
Skaric-Juric, T1
Richardson, WA1
Hohenstein, P1
Kimber, CH1
Donnelly, LA1
Fairbanks, LD2
McKeigue, PM1
Morris, AD1
Rudan, P1
Hastie, ND1
Proctor, PH1
Ford, ES1
Neureuther, K1
Wiedmann, S1
Sedlacek, K1
Baessler, A1
Fischer, M2
Weber, S1
Kaess, B1
Hollowell, M1
Thompson, LD1
Pantanowitz, L1
Takagi, K2
Iizasa, T1
Yue, CS1
Alton, M1
Wright, D1
Marco, MD1
Panomvana, D1
Sripradit, S1
Angthararak, S1
Forman, JP1
Ascherio, A1
Srinivasan, S1
Menke, A1
Patel, DA1
Berenson, G1
Tanabe, Y2
Schulze, H1
Meier, MS1
Barry, PE1
Dawber, TR1
McNamara, PM1
Maclachlan, MJ1
Rodnan, GP6
Blechman, WJ1
Rosenberg, DG1
Hilf, P1
Ask-Upmark, E1
Melmon, KL1
Webster, ME2
Healey, LA8
Skeith, MD1
Bayani-Sioson, PS2
Emmerson, BT36
Wilson, JD1
Simmonds, HA30
North, JD2
Zöllner, N26
Schattenkirchner, M5
Jakovcic, S1
Benedek, TG2
Jeremy, R3
Cottet, J2
Vittu, C1
Bourde, CH1
Saker, BM1
Tofler, OB1
Burvill, MJ1
Reilly, KA1
Benke, PJ2
Lampe, WT1
Krawczyński, J1
Zulawnik, W1
Drewnowska, I1
Orndahl, G3
Chase, PH1
Ellman, A1
Martin, JH1
Gordon, M1
Wallace, R1
Nissen, NI1
Paikin, H1
Marie, J1
Royer, P2
Rappaport, R1
Dimopoulos, C1
Chinaris, L1
Polić, V1
Sigaher, V1
Verger, D1
Leroux-Robert, C2
Ganter, P1
Inagaki, K3
Bufalari, A1
Meloni, G1
Aignan, M1
Fournout, J1
Fabre, P1
Lagarde, G1
Duff, GW3
Atkins, E2
Higson, FK1
Jones, OT1
Fox, IH18
McMillan, RM2
Vater, CA2
Hasselbacher, P4
Harris, ED2
Rae, SA1
Davidson, EM1
Smith, MJ2
Sanwald, R1
Ullman, B2
Yip, LC1
Balis, ME3
Ward, PC1
Weinberger, A9
Pinkhas, J4
Hankiewicz, J1
Losman, MJ2
Itkin, P1
Wisner, DE1
Gutensohn, W1
Akizuki, M1
Yoshida, S1
Gregolini, L1
Ferrari, S1
Marcolongo, R15
Aleo, MF2
Marinello, E9
Bianchi, E1
Ciompi, ML1
Bazzichi, LM1
Bertolucci, D1
Mazzoni, MR1
Mencacci, S1
Macchia, D1
Mariani, G3
Tirri, G2
La Montagna, G1
Tirri, R1
Dieppe, PA6
Whicher, JT1
Walters, G1
Nakonechny, DS1
Sailer, D4
Paul, H1
Papadimitriou, GM1
Hardwell, TR1
Braven, J1
Shaw, S2
Whittaker, M1
Watt, I2
Wall, B1
Agudelo, CA13
Tesser, JR1
Mountz, J1
Holt, D1
Turner, RA3
de Médicis, R3
Lussier, A3
Kahan, A1
Tétreault, L1
Carcassi, A10
Galli, M1
Boschi, S3
Di Cairano, G1
Hecker, S1
Woo, S1
Jacobs, RP1
Porter, GA1
Johnson, FN1
Amdisen, A1
Reynolds, MD1
Valasco Domínguez, E1
García Velasco, F1
Arranz Velasco, JL1
Sanz Cantalapiedra, R1
Barrio Arredondo, MT1
del Pozo Pérez, MA1
Gröbner, W17
Foley, RJ1
Weinman, EJ3
Kagami, T3
Ginsberg, MH2
Nys, Y1
Rzasa, J1
McFarland, DC1
Coon, CN1
Reynolds, PP1
Knapp, MJ1
Holmes, EW5
Wilson, JM1
Kelley, WN25
Wright, LF1
Saylor, RP1
Cecere, FA1
Loré, F1
Manasse, G1
Macrí, P4
Pisani, M1
Altman, RD1
Newman, JH1
Diadyk, AI6
Vasilenko, IV4
Yarom, A1
Rennebohm, RM1
Strife, F1
Levinson, JE1
Sharpe, CR1
Kennedy, TD1
Higgens, CS2
Woodrow, DF1
Williamson, PJ1
Ene, MD1
Roberts, CJ1
Waterworth, R2
Hatfield, P2
Robinson, G2
Bremner, K2
Palella, TD4
Barats, IS2
Antommattei, O1
Reginato, AJ1
Clayburne, G2
Levy, A1
Salamon, F1
Mertz, DP44
Eichhorn, R1
Ferraccioli, G1
Spisni, A1
Ambanelli, U1
Dumas, JR1
Kolba, KS1
Harlay, A2
Chayen, J2
Maidment, CG1
Greaves, MF1
Black, AJ1
Stĕpán, J4
Cáp, F2
Fiddis, RW1
Vlachos, N1
Calvert, PD1
Sváb, V2
Kolár, J1
Susta, A1
Turpin, G1
Kuntz, D9
Boogaerts, MA1
Hammerschmidt, DE1
Roelant, C1
Verwilghen, RL1
Jacob, HS1
Earll, JM1
Saavedra, M1
Yu, CF2
Garman, RH1
Nuzzi, MJ1
Geraci, JN1
Bueno Jiménez, C3
Gil Micharet, MS3
Grau Linares, V3
Pérez Miranda, M3
Sugai, M1
Gertner, E1
Lewis, A1
Cats, A2
van Romunde, LK1
Pauri, A1
Thomas, AL1
Majoos, FL1
Pompucci, G4
D'Amato, MS2
Tiitinen, S1
Nissilä, M1
Ruutsalo, HM1
Armstrong, RD1
Rodgers, AV4
Panetti, M1
Pisko, E1
Morawska, Z1
Makulska, I1
Morawska, A1
Spaccarelli, A1
Giacomello, A4
Sorgi, ML3
Zoppini, A4
Roboz, J2
Darlington, LG6
Hollingworth, P3
Burry, HC2
Mondillo, S1
Huston, GJ1
Webster, DR1
Mateos, F3
Muñoz, A1
Gaspar, G1
Ramos, T3
Gijón Baños, J1
Toseland, P2
Faller, J2
Bayliss, R1
Clarke, C1
Whitehead, TP1
Whitfield, AG1
Scalapino, JN1
Edwards, WD1
Steckelberg, JM1
Wooten, RS1
Callahan, JA1
Ginsburg, WW1
Rotés Querol, J1
Naidoo, PD1
MacDermot, KD1
Allsop, J1
Watts, RW9
Russell, IJ2
Mansen, C1
Kolb, LM1
Kolb, WP1
Hirai, A2
Kumagai, A3
Chodorowski, Z3
Batuman, V1
Maesaka, JK1
Haddad, B1
Tepper, E1
Landy, E1
Wedeen, RP1
Vigo, P1
Ortolani, S1
Soldati, L1
Girardello, R1
Fleischmann, L1
Polli, EE1
Leaney, BJ1
Calvert, JM1
Schindel, B1
Liberman, UA3
Sperling, O13
Leumann, EP1
Wegmann, W1
Abramson, SB1
Weissmann, G4
Kaplan, AP1
Ghebrehiwet, B1
Matzkies, F13
Gerster, JC3
Papaioannou, C1
McDuffie, FC1
MacIntyre, S1
Kushner, I2
Jaworski, RC1
Gibson, M1
Horváth, G1
Niepel, G1
Boss, GR2
Ragsdale, RA1
Zettner, A1
Beck, LH2
Khachadurian, AK1
Feng, RJ1
Wormsted, MA1
Cohen, MB1
Martin, DW1
Fellström, B1
Prior, L1
Reinhardt, K1
Kawenoki-Minc, E14
Brzozowska-Jurkowska, AM3
Arkhipov, VE1
Borisov, IA1
Sura, VV1
Kawaguchi, Y1
Shirasawa, K1
Yotsumoto, S1
Nagahara, S1
Zalokar, J3
Lellouch, J3
Claude, JR3
Potter, C2
Rogers, V2
Vitali, C2
Clerico, A2
Riente, L2
Molea, N1
Pilo, A2
Bianchi, R2
Bluestone, R16
Klinenberg, J3
Lee, IK1
Ferber, H1
Bader, U1
Mamasaliev, NS1
Tursunov, SIu1
Nabieva, AF1
Pritchard, MH1
Berni, G1
Lagi, A1
Francois, C1
Pikhlak, EG1
Piliaev, VG3
Sloan, RW1
Rapado, A7
Dorn, M1
King, DF1
King, LA1
Gerber, NJ1
Schorn, D1
Rouault, T1
Caldwell, DS1
Martin, SM1
Gastwirth, CM1
Petera, P1
Gaismayer, K1
Tausch, G2
Dewes, W1
Bach, D1
Zilliken, F1
Schneeberger, W1
Kraines, JL1
Ellman, MH1
Lundquist, CD1
Aronson, IK1
Henderson, TW1
Skosey, JL1
Solomon, LM1
Dennstedt, FE1
Weilbaecher, DG1
Kolb, S1
König, HJ2
Sensi, S1
Gisser, SD1
Kletter, I1
Slack, J2
Colton, RS3
Acheson, RM3
Williams, PL1
Gordon, RB6
Counsilman, AC1
Cross, SM1
Akizuki, S1
Schoenberg, O1
David, M1
Feuerman, EI1
Schoenberg, A1
Myrhed, M1
Stark, TW1
Hirokawa, RH1
Naveau, B1
Thiele, P12
Heidelmann, G14
Häntzschel, H3
Reinelt, D2
Otto, W4
Heuckenkamp, PU3
Mikulíková, D2
Trnavský, K3
Mituszova, M3
Horwitz, LR1
Liebman, JA1
Cavolo, DJ1
Kalmár, L1
Ablonczy, E1
Müzes, G1
Neumark, T1
Répay, I1
Gergely, P1
Zechner, O1
Pflüger, H1
Scheiber, V1
Templeton, JS1
Vukotić, D3
Berndt, H1
Vitić, J1
Nikolić, V1
Pilipović, N1
Jechová, D1
Smeralová, V1
Fiechtner, JJ2
Masbernard, A2
Giudicelli, CP1
Baiatova, KV1
Sankalé, M1
Muñez-Sanz, A1
Sarkozi, L1
Kaung, C3
Dunky, A1
Nitsche, V1
Eberl, R4
Grabner, W2
Worlicek, H1
Fay, R1
Bollet, AJ1
Beenken, O1
Kopperschläger, G1
Pietruschka, WD1
Weinhold, D1
Fraser, KJ1
Duffy, WB1
Senekjian, HO1
Knight, TF1
Akimova, TF2
Novoselova, TM2
Aliab'eva, AP1
Warren, DJ3
Naik, RB1
Müller, M1
Kuzmits, R2
Frassine, I1
Lorant, P1
Tak, HK2
Wilcox, WR4
Cooper, SM2
Farebrother, DA2
Pincott, JR1
Simmons, HA1
Dillon, MJ1
Cameron, JS13
Hägeli, S1
Burke, C1
Scholer, A1
Linnane, JW1
Burry, AF1
Counts, GB1
Treadway, WJ1
Holt, DA1
Pegram, RA1
Wyatt, RD1
Klarica, J3
Guzmán, L1
Weryńska-Przybylska, J5
Eyman, E9
Frackiewicz, A1
Mikołajew, M1
Pilichowska, I1
Stachurska, J1
Szymańska, M1
Glaser, B1
Abeles, M2
Fessel, WJ6
Jessee, EF1
Toone, E2
Owen, DS3
Irby, R3
Lamphier, TA1
Fenner, H1
Miskew, DB1
Goldflies, ML1
Verheggen, T1
Mikkers, F1
Everaerts, F1
Oerlemans, F1
De Bruyn, C1
Oehler, G1
Lasch, HG1
Jelke, K1
Krause, G1
Jüttner, A1
Angar, T1
Grosse-Kielisch, C1
Bach, GL1
Cole, RK4
Austic, RE4
Cassidy, M1
Gregory, MC1
Harley, EH1
Astapenko, MG2
Mikanagi, K9
Kawai, K1
Itakura, M3
Koide, Y1
Kugai, N1
Kimura, S1
Yamashita, K1
Ogata, E2
Murray, JB1
Findling, JW1
Beckstrom, D1
Rawsthorne, L1
Kozin, F1
Itskovitz, H1
Young, D1
Nishioka, K8
Gleadle, RI1
Chiaroni, G1
Potter, CF3
Jarvik, ME1
Trubnikov, VF1
Egorov, VP1
Reardon, JA1
Rodgers, VA1
Sorensen, LF1
Reif, MC1
Constantiner, A1
Levitt, MF1
Sforza, GR1
Della Fazia, L1
Masciangelo, F1
Morozzi, G3
Lo Cosmo, C1
Famaey, JP2
Jackson, L2
Taylor, R1
Faaiuso, S1
Ainuu, SP1
Whitehouse, S2
Zimmet, P1
Heinrich, JJ2
Ben Hmida, M2
Hachicha, J1
Bahloul, Z1
Kaddour, N1
Kharrat, M1
Jarraya, F1
Jarraya, A1
Hachicha, M1
McColl, SR1
Jacoulet, P1
Jovaní, V1
Eastmond, CJ1
Garton, M1
Robins, S1
Riddoch, S1
Khatchadourian, J1
Whitson, PA1
Mijiyawa, M1
Akaoka, Y1
Rozenberg, S3
Roche, B1
Dorent, R1
Koeger, AC1
Borget, C1
Wrona, N1
Bourgeois, P3
McBride, MB7
Hatfield, PJ3
Graham, R2
McCaskey, J2
Jackson, M2
Quaratino, CP2
Rucci, C1
Ciaglia, P1
Porcelli, B3
Vannoni, D1
Leoncini, R3
Pizzichini, M3
Pagani, R1
Hakoda, M2
Terai, C2
Kawaguchi, R1
Kashiwazaki, S3
Mateos, FA13
Miranda, ME3
Pérez de Ayala, C3
Gil, A2
Krijt, J2
Maly, J1
Higashino, K12
Nasako, Y3
Hiroishi, K3
Gresser, U4
Gathof, BS1
Gross, M2
Yamakita, J9
Star, VL1
Hochberg, MC1
Bagatin, J1
Simunić, M1
Sardelić, S1
Pritzker, KP2
Bassett, JE1
Lee, QP1
O'Reilly, S1
Joseph, J1
McGrath, H1
Lutalo, SK2
Jajić, I2
Youssef, P1
Brama, T1
York, H1
Pickard, P1
Stewart, P1
Grover, PK2
Ryall, RL2
Peterseim, U1
von Gizycki-Nienhaus, B1
Meurer, M1
Reiter, L1
Edmonds, J1
Snaith, ML5
Chou, P3
Soong, LN1
Gil, AA3
Ghio, AJ1
Kennedy, TP1
Rao, G1
Cooke, CL1
Miller, MJ1
Hoidal, JR2
Komoriya, K1
Osada, Y1
Hasegawa, M1
Kondo, S1
Couch, RC1
Griffin, TB1
Matsubara, C1
Yokoi, Y1
Nakamichi, N1
Takamura, K1
Mukhin, NA1
Balkarov, IM7
Maksimov, NA3
Jenkins, EA1
Hallett, RJ1
Hull, RG1
Pawlotsky, Y1
Gonzalez, EB2
Miller, SB1
Yasuhara, K1
Tomita, Y1
Takayama, A1
Fujikawa, H1
Otake, Y1
Takahashi, K1
Ortiz-Bravo, E2
Sieck, MS1
van Lieshout-Zuidema, MF1
Breedveld, FC1
Kanbe, K1
Kobuna, Y1
Beutler, A3
Jacobs, F1
Hurault de Ligny, B1
Le Goff, C1
Ryckelynck, JP1
Michelsen, A1
Picazo, ML1
Jiménez, ML7
Calvin, TS1
Müller, FO1
Schall, R1
Groenewoud, G1
Hundt, HK1
van der Merwe, JC1
van Dyk, M1
Moro, F4
Jinnai, K1
Kono, N2
Yamamoto, Y1
Kanda, F1
Ohno, S1
Tsutsumi, M1
Yamada, Y2
Kawachi, M2
Donegan, CF1
Berman, P1
Baethge, BA1
Work, J1
Landreneau, MD1
McDonald, JC1
Veerapen, K1
van Linthoudt, D1
Neilson, EG1
Boyd, RE1
Domoto, K1
Okabe, H1
Tabe, A1
Saji, M1
Hikita, M2
Sakai, O2
van Vugt, RM1
Wang, HC1
Tsai, MD1
Jamar, F1
Schofield, JB1
Peters, AM1
Binns, RM1
Herbelin, A1
Georgadze, ZO1
Balabolkin, MI1
Mamaeva, GG1
Liudina, LI1
Mishchenko, BP1
Arbuzova, MI1
Holland, NW1
Jost, D1
Duprez, TP1
Malghem, J1
Vande Berg, BC1
Noel, HM1
Munting, EA1
Maldague, BE1
Lukicheva, TI1
Aleksandrovskaia, TN1
Oleĭnikova, EB1
Kozlova, VG1
Shovskaia, TN1
Zonana-Nacach, A1
Alarcón, GS1
Daniel, WW1
Corr, SA1
Seaton, K1
Popp, JD1
Bidgood, WD1
Reber, P1
Crevoisier, X1
Noesberger, B1
Kosaka, H1
Ohtahara, K1
Tsuboi, M1
Manabe, I1
Sawaguchi, M1
Fujimoto, Y1
Yoshida, A1
Takeda, A1
Schneiderka, P1
Asplin, JR1
al Ali, N1
Iglesias, A1
Londono, JC1
Saaibi, DL1
Peña, M1
Lizarazo, H1
Yamaoka, T1
Tatibana, M1
Koide, T1
Wrenger, E1
Bahlmann, J1
Floege, J2
Klemp, P1
Stansfield, SA1
Castle, B1
Robertson, MC1
Eulderink, F1
Postma, T1
Miranda-Carús, E1
Sanz, AG1
Herrero, E1
Hoffman, GS1
al-Ali, N1
al-Sughayer, A1
Umamaheswaran, I1
al-Gaurer, S1
Hussain, AA1
Kundu, AK1
Dawn, B1
Williams, JK1
Walker, SE1
Margalit, A2
Duffin, KL1
Shaffer, AF1
Gregory, SA1
Isakson, PC2
Chang, FT2
Cinkotai, FF1
Gurwitz, JH1
Kalish, SC1
Bohn, RL1
Monane, M1
Mogun, H1
Avorn, J1
Nickeleit, V1
Mihatsch, MJ1
Getting, SJ1
Flower, RJ1
Parente, L1
Woliztky, BA1
Martins, MA1
Perretti, M1
Chaoui, A1
Garcia, J1
Kurt, AM1
Toda, K1
Goriki, K1
Ochiai, M1
Tokunou, H1
Uehara, S1
Okusaki, K1
Kobayashi, K2
Morioka, Y2
Isaka, Y2
Tozawa, T2
Curto, R1
Voit, EO1
Cascante, M1
Peichl, P1
Pöllmann, G1
Kullich, W3
Klein, G5
Logan, JA1
Morrison, E1
McGill, PE1
Olive, P1
Canovas, F1
Medioni, D1
Leroux, JL1
Baldet, P1
Bonnel, F1
Blotman, F1
Walter-Sack, I4
de Vries, JX1
Chou, CT1
Lai, JS1
Ushijima, K1
Sancho, T1
Buño, A1
Togashi, R1
Dan, T1
Grahame, R9
Marsh, FP1
Page, T1
Coleman, M1
Darby, AJ1
Harness, NF1
Pritchard, MS1
Stavrou, C1
Pierides, A1
Zouvani, I1
Kyriacou, K1
Neophytou, P1
Christodoulou, K1
Deltas, CC1
von Essen, R2
Hölttä, AM2
Pikkarainen, R1
Lloyd, A1
Burchett, I1
Alonso-Ruiz, A2
Duruelo, J1
Khattak, FH1
Morris, IM1
Harris, K1
Owen-Smith, B1
Quiney, J1
Read, J1
Sgonc, R1
Fend, F1
König, P1
Rigden, S1
Haycock, GB1
Dalton, N1
Van't Hoff, W1
Rees, L1
Raman, GV1
Ogg, CS4
Beutler, AM1
Decaux, G1
Soupart, A1
Musch, W1
Hannotier, P1
Prospert, F1
Emmerson, B1
Herrero-Beites, A1
García-Erauskin, G2
Ruiz-Lucea, E1
Marcil, J1
Harbour, D1
Houle, MG1
Bourgoin, S1
Vague, J1
Cuan, A1
Magaña, M1
Cazarín, J1
Pacheco-Tena, C1
Kivlighn, SD1
Suga, S1
Chazerain, P2
Ziza, JM2
Harris, MD1
Siegel, LB1
Alloway, JA1
Barynov, EF1
Syniachenko, OV1
Hryn', VK1
Bondarenko, NM1
Barynova, ME1
Pittman, JR1
Bross, MH1
Dieppe, P5
Swan, A2
Nakanishi, N1
Suzuki, K1
Kawashimo, H1
Nakamura, K1
Tatara, K1
Aboulafia, AJ1
Prickett, B1
Giltman, L1
Hayashi, H1
Nagasaka, S1
Ishikawa, S1
Rokkaku, K1
Saito, T2
Kusaka, I1
Higashiyama, M1
Kubota, K1
Murakami, T2
Sanders, KA1
Huecksteadt, T1
Sturrock, AB1
Bruin-Weller, MS1
Van Vloten, WA1
Van Velde, JI1
Perkins, P1
Jones, AC1
Wyndham, M1
Baker, DG3
Chopra, KF1
Schneiderman, P1
Grossman, ME1
Rosas, J1
Zoref-Shani, E1
Feinstein, S1
Frishberg, Y1
Bromberg, Y1
Hauser, SD1
Wasada, T1
Iwamoto, Y1
Moritani, M1
Takeuchi, F2
Clive, DM1
Majewski, J1
Ott, J1
Shidham, V2
Shidham, G2
Lin, KC2
Ellis, S1
Isenberg, D1
Song, J1
Lee, WK1
Schreiner, O1
Wandel, E1
Himmelsbach, F1
Galle, PR1
Märker-Hermann, E1
Johnson, JR1
Dessein, PH1
Shipton, EA1
Stanwix, AE1
Joffe, BI1
Ramokgadi, J1
van Doornum, S1
Ryan, PF1
Yuan, SC1
Wang, CJ1
Kuo, HW1
Hsieh, YS1
Mader, R1
Shadick, NA1
Kim, R1
Weiss, S1
Liang, MH2
Sparrow, D1
Yeh, L1
Lai, PH1
Liang, HL1
Resnick, D1
Jinnah, HA1
De Gregorio, L1
Harris, JC1
O'Neill, JP1
Tatsuno, I1
Sharples, K1
Raill, B1
Dudler, J1
Weinzweig, J1
Fletcher, JW1
Linburg, RM1
Landis, RC1
Al-Arfaj, AS1
Yamakita , J1
Ishibuchi, S1
Morimoto, H1
Oe, T1
Ikebe, T1
Fukunari, A1
Kamezawa, M1
Yamada, I1
Naka, Y1
Li-Yu, J1
Sieck, M1
Rull, M1
Eisner, E1
Delnomdedieu, M1
Oliverio, MI1
Williams, LD1
Saifer, MGP1
Sherman, MR1
Coffman, TM1
Johnson, GA1
Schumacher , HR1
Sancho Bueso, T1
Bol, P1
Lin-Tan, DT1
Monev, SD1
Chang, HY1
Tsai, KS1
Frawley, WH1
Habermann, W1
Kiesler, K1
Eherer, A1
Beham, A1
Friedrich, G1
Chivukula, M1
Basir, Z1
Badilla, A1
Rojas, C1
Shcherbak, AV1
Kozlovskaia, LV1
Podorol'skaia, LV1
Gindis, AA1
Stein, M1
Shen, ML1
Desaulniers, P1
Würzner, G1
Chiolero, A1
Maillard, M1
Fallab-Stubi, CL1
Brunner, HR1
Sturm, E1
Scolari, F1
Viola, BF1
Prati, E1
Ghiggeri, GM1
Caridi, G1
Amoroso, A1
Casari, G1
Maiorca, R1
Neal, DA1
Tom, BD1
Gimson, AE1
Gibbs, P1
Alexander, GJ1
Pilmore, HL1
Faire, B1
Dittmer, I1
Aupperle, K1
Liberopoulos, E1
Christides, D1
Elisaf, M1
Fedorova, NE1
Grigor'eva, VD1
Boye, T1
Guennoc, B1
Carsuzaa, F1
Weselman, KO1
Tsai, LY1
Gálvez, J1
Sáiz, E1
Linares, LF1
Climent, A1
Marras, C1
Pina, MF1
Castellón, P1
Amer, H1
Zaloga, B1
Hughes, JL1
Hoda, RS1
Neto, M1
Pilloff, B1
Simon, J1
Musil, J1
Hannan, SF1
Potter, CS1
Crute, CM1
Pinto, B2
Rocha, E2
Brien, G1
Bick, C1
Gremske, D1
Winocour, PD2
Turner, MR1
Taylor, TG2
Munday, KA2
Hers, HG1
Van Den Berghe, G2
Bogner, G1
Tilscher, H1
Nishizawa, T5
Maruki, M1
Aikawa, T1
Mitamura, T1
Yokohari, R1
Horiuchi, Y1
Henninces, D1
Anisimov, VE1
Raivio, KO1
Becker, 7A1
Meyer, LJ4
Greene, ML6
Wild, JH1
Hohneck, A1
Griebsch, A7
Korfmacher, I2
Zoref, E3
Lenz, W1
Klein, W1
Huth, F1
Loizzi, P2
Terlizzi, N1
Micheli, V2
Boer, P1
Brosh, S1
Kippen, I7
Pollet, J1
Galliot, M1
Khalaf, AA1
Riario-Sforza, G4
Sales, LM1
Pallalardo, A1
Gancitano, A1
Krupar, V2
Rieselbach, RE4
Berg, G7
Minzlaff, R1
Hauss, J1
Schönleben, K1
Hrubesch, M1
Schmidt, E1
Müller, KM1
Sany, J1
Rosenberg, F1
Bataille, R1
Heel, RC1
Brogden, RN1
Speight, TM1
Avery, GS1
Schräpler, P2
Schulz, E2
Kleinschmidt, A1
Schettler, G1
Stavric, B1
Nera, EA1
Mangini, RJ2
Peitzman, SJ1
Fernandez, PC1
Bodison, W1
Ellis, I1
Dorhout Mees, DJ1
Dzhen-gu, K1
Serry, MM1
Gall, EP1
Westberg, NG1
Rosén, E1
Waldenström, J1
Korom, I1
Szabó, L1
László, A1
Dallmann, L1
Ormos, J1
Kilbourn, K1
Horner, I1
Böhmer, R2
Molina, J1
Hoover, PL1
Paxson, CS1
Wilson, WF1
Payne, RB1
Johnson, WJ1
O'Duffy, JD2
Krey, PR1
Bailen, DA1
Wolfram, G9
Fusani, L1
King, RS1
Wichman, BA1
Morton, NE1
Canoso, JJ2
Warnock, DG1
Zacharias, F1
Sergent, JS1
Dansereau, JY1
Ménard, HA1
Dorph, DJ1
Smith, H2
Bresnik, W3
Müller, MM4
Kosman, ME1
Murphy, JE1
Barsom, S1
Green, EJ1
Dilworth, JH1
Levitin, PM1
Urman, JD1
Ballou, SP1
Khan, MA1
Harris, JW1
Lowenthal, MN1
Dymond, ID1
Flouvier, B1
Devulder, B1
Heyden, S4
Romanoff, NR1
Rubinow, A1
Spark, EC1
Kozhevnikov, EM1
Voĭtov, LI1
Efimova, MN1
Samokhina, RF1
Zahn, CE1
Nyburg, SC1
Luk, SC1
Houpt, JB3
Häntzschel, U1
Költzsch, V1
Fries, JF1
Zimmet, PZ1
Thoma, K1
Perricone, E1
Brandt, KD2
Kamoun, P2
Chanard, J2
Brami, M2
Funck-Brentano, JL2
Goebel, FD3
Ohlschlägel, G1
Lang, F1
Greger, R1
Silbernagel, H1
Günther, R8
Deetjen, P2
Remmele, W1
Meyer, R1
Gnauck, H1
Bettendorf, U1
Kanzler, G1
Hevia, P2
Shaffer, RH1
Peterson, DW1
Clifford, AJ2
Sůnová, J1
Flügel, M1
Geldmacher, J1
Sundaram, PV1
Igloi, MP1
Wassermann, R1
Hinsch, W1
Wongsurawat, V1
Wongsurawat, N1
Badley, EM1
Meyrick, JS1
Wood, PH1
Masuda, T1
Abgarowicz, T1
Brzozowska-Jurkowska, M1
Webb, J1
Lindsley, HB1
Kästner, P1
Schäfer, W1
Brauer, GW1
Weiss, JJ1
Goldman, RT1
Rigg, GA1
Campbell, BC1
Moore, MR2
Goldberg, A1
Hernandez, LA1
Dick, WC1
Gioffrè, W1
Brandi, L1
Pallassini, A1
Faure, G1
Pusevski, A1
Berg, H2
Steele, TH5
Loewer, H2
Morin, C1
Bernier, J1
Johnson, LA1
Mähr, G1
Krízek, V6
Nebout, T1
Kazandjian, M1
Haslock, I1
Wright, V1
Chamney, B1
Middlemiss, H1
Orfanos, CE1
Künzig, M1
Bröll, H1
Sochor, H1
Babucke, G4
Sagebiel, L1
Laurens, P1
Gavelle, P1
Maurice, P1
McCarthy, DJ1
Coomes, EN1
Haeckel, R1
de Gèry, A13
Pasquier, C3
Novak, A1
Knesl, E1
Kaiser, E1
Campion, DS2
Olsen, RW1
Caughey, D1
Stuhlsatz, HW1
Enzensberger, W1
Greiling, H3
Jacobs, D2
Frank, O5
Sturge, RA1
Marcellan, FJ1
Robinson, H1
Masi, AT1
Castrillo, JM1
Niemi, KM1
Appelboom, T1
Honig, S1
Gorevic, P1
Hoffstein, S1
Rosenthal, M1
Beighton, P2
Solomon, L3
Soskolne, CL2
Sweet, MB1
Brzozowska, AM1
Pleau, JM1
Brunois, JP1
Tofuku, Y4
Kuroda, M2
Takeda, R1
Barr, GD1
Waisman, J6
Erzsébet, H1
István, H1
Wolff, G1
Tobiasch, V1
Eder, M1
Singer, P1
Tuner, MR1
Neuwirth, R1
Reynolds, AF1
Wyler, AR1
Norris, HT1
Gascon, J1
Jaross, W1
Szmigiel, Z1
Pawlicka, G1
Sowa, M1
Glynn, JJ1
Clayton, ML1
Shenoy, TS1
de Graciansky, P1
Larrégue, M1
Martinet, C1
Lemaire, V1
Klemens, UH1
von Löwis of Menar, P1
Bartolozzi, G1
Bernini, G1
Marianelli, L1
Nassi, P1
Thompson, L2
Hiisi-Brummer, L1
Yolken, RH1
Miller, DR1
Morley, CJ1
Houston, IB1
Morris-Jones, P1
Synková, J1
Brátová, M1
Groh, J1
Dítĕ, P1
Warembourg, H1
Stalnikiewicz, G1
Ravera, R1
Potaux, L1
Aparicio, M1
Maurel, C1
Ruedas, ME1
Martin-Dupont, Cl1
Brewis, I1
Ellis, RM1
Row, PG1
Gottlieb, N1
Grendelmeier, P1
Marshall, LL1
Uccella, R1
Torralba, TP1
Brewis, ID1
Loebl, WY3
Al-Hujaj, M3
Schonthal, H3
Sar, AV1
Huisman, TH1
Ibrahim, SA1
Blécourt, JJ1
Ferretti, PG1
Marchini, L1
Africa, A1
Passeri, M1
Meyer, WJ1
Gill, JR1
Bartter, FC1
Sosovec, V1
Nicholson, G1
Yonezawa, H2
Naito, H1
Robin, JA2
Tolchin, SF2
Elion, GB4
Keller, H3
Lequesne, M1
Bensasson, M1
Dwosh, IL1
Marchant, PJ1
Lacroix, S1
Omura, S1
Wyhofsky, V1
Mwasi, LM1
Stanhope, JM1
Mielants, H3
Veys, EM3
DeBussere, A1
van der Jeught, J1
Sinclair, DS1
Schirmeister, J1
Ooi, Y1
Hara, I1
Iwao, T1
Zmuda, MJ1
Quebbemann, AJ1
Eckes, L1
Barlattani, M1
Messina, B2
Gallen, S1
Erill, S1
Laporte, J1
Mandel, NS2
Mandel, GS2
Siegenthaler-Zuber, G1
De Biasio, R1
Alth, G1
Ogris, E1
Müller, G1
Judák, A2
Gyódi, E1
Stenszky, V1
Leong, KH1
Feng, PH1
Delaney, V1
Sumrani, N1
Daskalakis, P1
Hong, JH1
Sommer, BG1
Rühle, H1
Roselló Pardo, R1
Rodríguez Ruiz, T1
Graff, SN1
Seiler, JG1
Jupiter, JB1
Low, LL1
Cervantes, AG1
Melcher, WL1
Culora, G1
Gallagher, PJ1
Muirden, KD1
Wigley, RD1
Ford, TC1
Peters, TD1
Ball, GV3
Burack, DA1
Griffith, BP1
Thompson, ME1
Kahl, LE1
Kawagoe, Y1
Kaneko, N1
Kimata, S1
Hosoda, S1
Wernick, R1
Winkler, C1
Adam, RF1
Loynes, RD1
Kam, M1
Perl-Treves, D2
Caspi, D1
Castellano, JA1
Niemann, TH1
Warner, CA1
Naides, SJ1
Roessler, BJ1
Golovoy, N1
Heidler, S1
Paulsen, TP1
Cross, M3
Osborne, JM1
Axelsen, RA1
Maeda, E1
Hujiyoshi, T1
Uematsu, T1
Raman, V1
Chantler, C3
Duley, JA2
Miranda Carús, ME1
Luz Picazo, M1
Ortíz Vázquez, J1
Sorghi, ML1
Savini, F1
Sönmez, G1
Mert, N1
Hall, S1
Bagriĭ, EA1
Davies, PM2
Dyer, CA1
Martin, J1
Curtiss, LK1
LeFlore, I1
Antoine, GA1
Marshall, VR1
di Giovine, FS1
Thornton, E1
Michán, AD1
Capitán, CF1
Gijón, JB1
Stankovíc, A1
Front, P1
Barbara, A1
Mitrovíc, DR1
Wolfe, F1
Sterling, LP1
Matsushima, M1
Noto, M1
Kawakami, H1
Nakatsuka, K1
Jojima, K1
Nohno, H1
Matsuzaki, H1
Keller, C2
Lathan, HH1
Fabian, K1
Kämpfe, U1
Dixon, RM2
Kemp, GJ2
Angus, PW2
McAlindon, TE2
Rajagopalan, B3
Radda, GK3
Mateos Antón, F2
Ramos Hernández, T1
Sebastián Melián, J1
García Neito, V1
Hess, B1
Binswanger, U1
Roubenoff, R1
Schwandt, P3
Brophy, LM1
Imanishi, M1
Ikegami, M1
Ishii, T1
Nishioka, T1
Uemura, T1
Kunikata, S1
Kanda, H1
Matsuura, T1
Akiyama, T1
Kurita, T1
Foreman, JW1
Yudkoff, M1
Loenen, HM1
Eshuis, H1
Löwik, MR1
Schouten, EG1
Hulshof, KF1
Odink, J1
Kok, FJ1
Kamilli, I1
Ivanov, I1
Tsachev, K1
Gathof, B1
Vukmir, RB1
Weiss, L1
Verdile, VP1
Safir, A1
Dunn, SN1
Martin, RG1
Tate, GW1
Mincey, GJ1
Deray, G1
Assogba, U1
Le Hoang, P1
Brillet, G1
Baumelou, B1
Jacobs, C1
Borghi, L1
Ferretti, PP1
Elia, GF1
Amato, F1
Melloni, E1
Trapassi, MR1
Novarini, A1
Horowitz, MD1
Abbey, L1
Sirota, DK1
Spiera, H1
Hall, IH1
Scoville, JP1
Reynolds, DJ1
Simlot, R1
Duncan, P1
Landau, A1
Reese, DJ1
Blumenthal, DR1
Chin, NW1
Calabrese, G1
Ballhaus, S1
Mees, K1
Guerne, PA1
Zuraw, B1
Lotz, M1
Axelsen, R1
Riccieri, V1
Salerno, C1
Anna, T1
Gabriella, M1
Roberto, M2
González, AA1
Casas, E2
Capitán, MC2
Bull, PW2
Rocher, LL2
McQuillan, MA2
Di Stefano, A2
Taddeo, A3
Stiefel, M1
Verberckmoes, R1
Ritz, E1
Schmaltz, S1
Richter, WO1
Konrád, K1
Costantini, AV1
Ferreira, A1
Silva Júnior, BA1
Braga, FM1
Gargiulo, NM1
Stávale, JN1
Kurita, Y1
Tsuboi, R2
Numata, K1
Matsubara, K1
Jiao, S1
Takama, T1
Ulreich, A2
González Sanz, A1
Calabria, AA3
Lalumera, M2
Gerli, R1
Alessandrini, C2
Cavallo, G3
Halverson, PB1
Kim, M1
Zhovnirenko, LP1
Gostishcheva, IA1
Tiller, DJ1
Hall, BM1
Horvarth, JS1
Duggin, GG1
Thompson, JF1
Sheil, AG1
D'Ubaldo, F1
Petrini, G1
Campagna, S1
Oberhaensli, RD1
Taylor, DJ1
Collins, JE1
Leonard, JV1
Schwarz, H1
Herschkowitz, N1
Palmer, DG2
Hessian, PA1
Mejías, E1
Navas, J1
Lluberes, R1
Martínez-Maldonado, M3
Varshavskiĭ, VA1
Pal'tsev, MA1
Poliantseva, LR1
Cheung, HS1
Parrini, E1
Bacarelli, MR1
Mazzullo, G1
Rosen, MS1
Cherian, PV2
Pascual Gómez, E1
Campion, G1
Singer, JZ1
Campbell, SM1
Gores, PF1
Fryd, DS1
Sutherland, DE1
Najarian, JS1
Simmons, RL1
Price, CP1
James, DR1
German, DC2
Welby, TJ1
Ostbye, T1
Salmond, CE1
Stokes, YM1
Khan, MS1
Akhtar, P1
Majeed, A1
Derus, CL1
Bowman, B1
Bengoa, JM1
Sitrin, MD1
Akaoka, L1
McDonald, J1
Paton, T1
Senn, J1
Ramos, TH1
Aoyagi, Y1
Kamimura, T1
Ichida, F1
González Buitrago, JM1
Arroyo, A1
Vega, L1
García Fernández, N1
De la Rua, A1
Navajo, JA1
Martínez-Cordero, E2
Bessudo-Babani, A1
Treviño Pérez, SC1
Guillermo-Grajales, E1
Benabe, JE1
Jósfay, J1
Ludányi, E1
West, C2
Carpenter, BJ1
Hakala, TR1
Misz, I1
Vizi, F1
Ikeda, H3
Miyahara, T3
Fraser, RC1
Davis, RH1
Walker, FS1
Coderre, TJ1
Wall, PD1
Hara, N1
Kiyokawa, H1
Himeno, S1
Miyazaki, T1
Popova, IuP2
Ogura, Y1
Mimura, N2
Serniak, PS1
Kobets, VG1
Collado, A1
Kanterewicz, E1
Sanmartí, R1
Alba, R1
Brancós, MA1
Rotés-Querol, J1
Fasching, U1
Broulik, PD1
Stĕpán, JJ1
Pacovský, V1
Colling, M1
Matulis, AA1
Bareĭkene, IP1
Venalis, AI1
Shpilevaia, NI1
Krapac, L1
Gross, BD1
Williams, RB1
DiCosimo, CJ1
Williams, SV1
Bośmanský, K3
Ondrasík, M2
Faragher, RI1
Caelli, DJ1
Menghini, S1
Della Corte, E2
Golovanova, OE1
Reznikov, IuP1
Pankrat'ev, LM1
Pennes, DR1
Dong, SQ1
Soliev, TS1
Thiehle, P1
Solakov, PTs1
Atanasov, NA1
Karastanev, II1
Kereziev, IK1
Kuzmanova, SI1
Ivanova, MM1
Hazelton, RA1
Whyte, IM1
Dykman, D1
Simon, EE1
Frocht, A1
Leek, JC1
Robbins, DL1
Garyfallos, A1
Magoula, I1
Tsapas, G1
Mohanaruban, K1
Joglekar, M1
Swift, CG1
Tomlinson, K1
Ortman, BL1
Pack, LL1
Adam, O1
Bergman, HD1
Filippova, VG1
Popova, LA1
Chekova, VV1
L'vova, GN1
Vasil'eva, IM1
Thomson, DB1
Lianga, J1
Waslen, GD1
Penney, CJ1
Alessandri, C1
Violi, F1
Bonavita, MS1
Barreira-Mercado, E1
Katona, G1
Milano, L1
Kummer, H1
Fleckenstein, JL1
Herrero, EH1
Arnalich, FF1
Fioravanti, A1
Renieri, A1
Vacha, J2
Kohoutova, B2
Bergström, G1
Bjelle, A1
Sundh, V1
Svanborg, A1
Hoyt, RE1
Gordon, TP2
Roberts-Thomson, PJ2
Porst, H1
Liebscher, K1
Gocheva, V1
Atanasova, P1
Strader, KW1
Lally, EV1
Ho, G1
Kaplan, SR1
Lluberas-Acosta, G1
Hansell, JR1
Taneda, A1
Conthe Gutiérrez, P1
Monteagudo, FS2
Lluberas, G1
Dong, DC1
Li, ZC1
Fu, XL1
Woods, HF1
Bax, ND1
Jackson, PR1
ter Borg, EJ1
Pechán, I1
Bosák, V1
Gerová, Z1
Tvarozková, Z1
Campion, EW1
DeLabry, LO1
van Soesbergen, RM1
Matricali, B1
Mahapatro, RC1
Sylvia, LC1
Becker, SM1
Bodem, H1
Moxley, G1
Ruddy, S1
Zoppi, A1
Fogari, R1
Corradi, L1
Finardi, G1
Rundles, RW3
Frantsova, Zh1
Ridolfo, AS1
Lightfoot, RW2
Varga, J1
Giampaolo, C1
Goldenberg, DL1
Tsujimoto, F1
Tada, S1
Schlapbach, P1
Lo, B1
Hankin, FM1
Mayhew, DE1
Coapman, RA1
Snedden, M1
Schneider, LH1
Moore, JR1
Weiland, AJ1
Littman, BH1
O'Connor, JP1
Macfarlane, DG1
Mank, H1
Mende, T1
Ahern, MJ1
Reid, C1
John, D1
DeBruyne, S1
Dwosh, I1
Marliss, EB1
Gawoski, JM1
Balogh, K1
Landis, WJ1
Wordsworth, BP1
Mowat, AG1
Matsushige, H1
Gotcheva, V1
Atanassova, P1
Todorova, L1
Astrug, A1
Dimitrov, T1
Heidland, A1
Hörl, WH1
Schaefer, RM1
Teschner, M1
Weipert, J1
Heidbreder, E1
Buzzone, G1
Sambataro, A1
Camarda, G1
Castiglione, F1
Schillaci, W1
Balsamo, S1
Verde, F1
Borade, VB1
Kakrani, AL1
Ahaley, SK1
Ruiz, M1
Furió Bacete, V1
Juárez Centeno, D1
Khalifa, P1
Sereni, D1
Boissonnas, A1
Cremer, GA1
Laroche, C2
Ali, SY1
Loginova, TK1
Ershov, IuA1
Stirpe, F1
Bonetti, E1
Abbondanza, A1
Abbati, A1
De Stefano, F1
Mazurkiewicz, M1
Seniów, A1
Wachnik, Z1
Sletten, K1
Aakesson, I1
Casey, AE1
Gilbert, F1
Ratliff, CR1
Downey, EL1
Elbrechter, J1
Nicholls, A1
Dobiás, J1
Yamamura, Y2
Katsunuma, N1
Kawano, H2
Becher, H1
Mecke, D1
Kleinen, R1
Jensen, J1
Blankenhorn, DH1
Kornerup, V1
Harvey, HP1
Finn, R1
Tweedie, MC1
Jones, PO1
Hall, SM1
Dinsdale, OF1
Bourdillon, RE1
Perheentupa, J1
Raivio, K1
Harvey, WC1
Scull, E1
Leroy, EC1
Kagen, LJ1
Sandson, J1
Gieseking, R1
Barth, WF1
Carmena, R1
Fruhmann, G1
Fritz, H2
Bergstermann, H1
Lozano-Tonkin, C1
Kallie, RN3
D'Aeth, R1
Dowdle, EB1
Joubert, SM3
Casey, JH1
Hoffman, MM1
Solomon, S1
Kölle, G1
Maldyk, E3
Polowiec, Z2
Wagner, T2
Sparagana, M1
Phillips, G1
Holzmann, H3
Hoede, N1
Morsches, B2
Pasero, GP1
Ciompi, MI1
Ostendorp, U1
Cayla, J2
Rondier, J3
Perreau, C1
Zsernaviczky, J1
von Torklus, D1
Wilke, H1
Frahm, H1
Bach, JF1
Bach, MA1
Dardenne, M1
Berlyne, GM1
Shaw, AB1
Nilwarangkur, S1
Nivet, M1
Marcovici, J1
Compagnon, P1
Laruelle, P1
Rosenbloom, FM4
Henderson, JF3
Braun, S1
Saint-Georges-Chaumet, F1
Amor, B5
Foglierini, J2
Larrieu, F1
Frugier, JC1
Brouilhet, H5
Olivier, JL2
Rose, A1
Solnica, J3
Mitrovic, D2
Massé, C1
Jurmand, SH1
Caroit, M2
Durieu, J1
Guérin, C1
Dreyfus, P2
Six, B2
Forette, B2
Kahn, CB1
Wallingford, WR1
Meyskens, FL1
Williams, HE1
Schilling, F2
Freeman, D1
Eilam, G1
Hunt, RD1
Garcia, FG1
Walsh, RJ1
Cottin, S1
Prost, A4
Rita, GA1
Newcombe, DS2
Wood, AW1
Naff, GB2
Byers, PH2
MacCarty, DJ1
Silcox, DC2
Starmer, CF2
de Weerdt, A2
Catto, M1
Kostel, PJ1
Johnson, MG1
Rosenweig, S1
Switzer, RL1
Gershon, SL1
McLaughlin, RE1
Davis, JS1
Webb, FW1
Roux, H3
Shirahama, T1
Cohen, AS1
Pentikäinen, P1
Frank, W1
Petroni, D1
Leńko, J1
Ferguson, RH2
Worthington, JW2
Fallet, GH1
Lechi, A1
Covi, G1
Pedrolli, E1
D'Andrea, F1
Lechi, C1
Mengoli, C1
Sguizzato, G1
Cadenhead, A2
Dean, BM2
Riley, MJ1
Fuss, M1
Van Landuyt, P1
Weiser, M1
Fontinoy, N1
Hasslacher, C1
Wahl, P1
Vollmar, J1
Pérez Cano, R1
Yánez Polo, MA1
Melero Bellido, M1
Casimiro Soringuer, F1
Causse Prado, M1
Muñóz González, J1
Allwright, GT1
Diamond, HS3
Carter, AC3
Tondreau, NE1
Hirose, K1
Debolini, A1
Fontenaille, C3
Guiheneuc, P3
Heron, B3
Lucas, J2
Campion, D2
Whitehouse, M2
Emmrich, R1
Gluck, FB1
Wellmann, KF1
Volk, BW1
Doerr, W1
Lasaroff, N1
Réthyly, E1
Pálfy, A1
Tanaka, H1
Sato, T1
Mundy, GR1
Fleckenstein, L1
Mazzullo, JM1
Sundaresan, PR1
Weintraub, M1
Lasagna, L1
Johnson, ES2
Hollander, IJ1
Kościańska, J1
Blacket, RB1
Leelarthaepin, B1
Palmer, AJ1
Woodhill, JM1
Whitehouse, MW4
Schlosstein, L2
Richmond, DE1
Moskowitz, RW1
Garcia, F1
Carrozzo, M1
Pipitone, V1
Tidl, G1
Rastegar, A2
Thier, SO3
Swales, JD1
Kopstein, J1
Wrong, OM1
Asch, L2
Villiaumey, J1
Larget-Piet, B1
Rotterdam, M1
Cristol, R1
Loeper, J1
Buchanan, KD2
Boine, L1
Stamler, J1
Swiderska-Kulikowa, B1
Jelińska, S1
Caraway, WT1
Holmes, E1
Escher, M1
Boyle, JA4
Semple, PF1
Laszlo, J1
Kilani, C1
Saporta, L2
Suzuki, Y1
de Haas, WH1
Ramsdell, CM2
Postlethwaite, AE3
Kröpelin, T1
Brogard, JM2
Coumaros, D1
Franckhauser, J1
Stahl, A2
Stahl, J1
Sopata, I2
Hofmeister, F1
Brandt, H1
Deák, J1
Lukes, J1
Kazandjan, M1
Urbánek, T2
Hüttl, S2
Hüttlová, O2
Srámek, F2
Stein, G1
Schneider, V3
Mikus, F1
Vojtisek, O1
Kanková, D1
Jorda, V1
Vykydal, M2
Pegrimová, E2
Bouvenot, G1
Mosora, M1
Boloşiu, H1
Scott, WA1
Robinson, RG1
Corrigan, AB1
Hayashi, TT1
Gillo, D1
Turner, JH1
Zieliński, Z1
Vovan, L2
Dutertre, P2
Serratrice, G2
Recordier, AM2
Royer, R4
Boulange, M1
Maling, HM1
Zweig, MH1
Williams, MA1
Anderson, W1
Hagen, K1
Mahrenholz, U1
Green, H1
Ishii, K1
Klabusay, L1
Raska, P1
Duda, V1
Bachmann, K1
Bergner, D1
Bornhofen, E1
Stürzenhofecker, P1
Kunev, K1
Katranushkov, I1
Denninger, K1
Ravera, M5
Spaziante, B1
Chini, V1
Frankhauser, J1
Ward, PA1
Hood, B4
Olander, R4
Bluhm, GB2
Riddle, JM2
Alarcón-Segovia, DA1
Cetina, JA1
Díaz-Jouanen, E1
Simon, KH1
Terhorst, B1
Bastian, HP1
Siegelaub, AB1
de Grey, A1
Danchot, J1
Kayembe, D1
Sigg-Farner, C1
Deplaen, JL1
Sweet, B1
Percy, JS1
Starmer, F1
Katz, JL1
Weiner, H1
Gutman, A1
Schlosstein, LH1
Paulus, HE2
Litvak, J1
Briney, W1
Geerdink, RA1
de Vries, WH1
Willemse, J1
Oei, TL1
de Bruyn, CH1
Fleischmann, V1
Adadevoh, BK1
Martin, E1
Ody, B1
Bennett, RM1
Chait, A1
Lewis, B2
Tcherdakoff, P3
Backmann, L4
Olin, JS1
Devenyi, P1
Weldon, KL1
Rubens-Duval, A1
Malhotra, KK1
Kathpalia, SC1
Goulatia, RK1
Butturini, U2
Herzberg, L1
Mincu, I1
Navas, P1
Grasset, D1
Helm, E1
Koçak, N1
Tunali, A1
Ozdoğan, E1
Tuna, S1
Mituszova, L1
Erdély, E1
Bényai, B1
Basu, TK1
Stein, RM1
Peavy, PW1
Franco, DJ1
Gibson, TJ1
Franck, WA2
Bress, NM2
Singer, FR1
Krane, SM2
Coe, F1
Jacobelli, S1
Reiss, E1
Genant, H1
Ellman, M1
Hadler, NM1
Robinson, DR1
Muszkowska-Penson, J1
Stolarczyk, J1
Chang, GN1
Fam, A1
Little, AH1
Malkin, A1
Machtey, I1
Meer, A1
Goldberg, LS1
Rosenfeld, JB1
Mercier, N1
Bartel, AG1
Blétry, O1
Cartier, P4
Hamet, M3
Clauvel, JP1
Koperska, M1
Jezewska, MM1
Wessler, S1
Avioli, LV1
Fluur, E1
Haverling, M1
Molin, C1
Christian, CL1
Butler, VP1
Hamerman, D1
Larson, CB1
Pearson, CM1
Symthe, HA1
Taranta, A1
Tomasi, TB1
Weinberger, HJ1
Miyahara, M1
Fujise, Y1
Hoshikawa, K1
Nakagawa, K1
Bäumer, A4
Susić, D1
Reese, GM1
Vogler, WR2
Drane, JW1
Rouques, C1
Paolaggi, F4
Mertz, P1
Strohmeyer, G2
Douglas, G1
Thompson, M1
Larmon, WA1
Pollard, AC1
Shelp, WD1
Kaplan, G1
Balasubramaniam, P1
Silva, JF1
Harvengt, C1
Lavenne, F1
Galmiche, P1
Mizon, JP1
Plaquet, R1
Gentit, F1
Quiret, JC1
Gottesbüren, H1
Brown, CH1
Stashick, E1
Carbone, PP1
Radi, I1
Frayha, RA1
French, JG1
Kjelsberg, MO1
Schull, WJ1
Glynn, LE1
Delbarre, MF1
Henrard, JC1
Puel, M2
Aldo, C1
Sunder, JH1
Kantor, TG1
Krenitsky, TA1
Dancis, J1
Silvers, DN1
Mogrovejo Velarde, A1
Figueiredo, G1
Salvatella Viñals, J1
Barnes, CG1
Falls, WF1
Kramer, HJ1
Lu, E1
Herrick, N1
Vinstein, AL1
Cockerill, EM1
Masszi, J1
Horváth, A1
Mecher, T1
Kulcsár, G1
O'Sullivan, JB1
Beardmore, TD2
Cashman, JS1
Tobias, PV1
Shaw, AH1
Cafiero, M1
Buono, G1
Sensale, P1
Diamond, H1
Wiedemann, E1
Rose, HG1
Schwartz, E1
Honda, H1
Gindin, RA1
Henninges, D4
Schwoerer, P1
Rückert, KH1
Chowanetz, W1
Leo, W1
Dabrowski, W1
Maeder, HU1
Gietka, J1
Sulek, K1
Marion, RB1
Alperin, JE1
Maloney, WH1
Cassagrande, PA1
Towson, J1
Guilbaud, J1
Droniou, J1
Treadwell, BL1
Chalmers, RA2
Bitensky, L1
Balasse-Ketelbant, P1
Horacio Day, J1
Addae, SK1
Konotey-Ahulu, FI1
Hoshino, T1
Tsutsui, K1
Minegishi, T1
Murata, H1
Shibata, K1
Nikolov, GS1
Tellkamp, F3
Feuerstein, C1
Alexopoulos, J1
Schmidt, K1
Engelhardt, K1
Jonas, S1
Snedden, W2
Parker, RB1
Hajzok, O1
Hajzoková, M1
Thorpe, JJ1
Daley, JM1
Varricchio, M1
Russo, R1
Gentile, S1
Ugo, C2
Louyot, P2
Pourel, J1
Gaucher, A2
Montet, Y1
Cammeo, F1
Traina, GC1
Olmi, R1
De Vecchis, L1
Soria, C1
Guerin, B1
Coscelli, C1
Palmari, V1
Vargazon, B1
Pecenko, M1
Alepa, FP1
Frazier, PD1
Smith, EE1
Kurlander, GJ1
Powell, RC1
Bowie, EA1
Jakubowska, D1
Ziólkiewicz, Z1
Kleinman, HZ1
Ewbank, RL1
Benedetti, A3
Bucciante, G1
Cattano, G1
Nardini, A3
Neubaur, J1
Willms, B1
Söling, HD1
Creutzfeldt, W1
Woodbury, JF1
Mehta, DM1
Morse, WI1
Preger, L1
Sanders, GW1
Gold, RH1
Steinbach, HL1
Pitman, P1
Falk, S1
Bronstein, LH1
Berger, AR1
Hutchison, JC1
Wilkinson, WH1
McMahon, FG1
Helbig, W1
Findeisen, B1
Mirosch, W1
Douglas, JB1
Emmrich, P1
Gerbaux, JO1
Rodhain, J1
Morgenroth, K1
Backmann, R1
Mello, A1
Mello, NR1
Josef, H1
Cossermelli, W1
Debes, AC1
Kopersztych, S1
Brunelli, E1
Klotz, H1
Prohaska, E1
Salmhofer, H1
Schmid, L1
Hiroata, R1
Nomura, Y1
Aibara, K1
Miyaki, K1
Dry, J3
Seebach, LM1
Jackman, AE1
Barnhart, MI1
Caraceni, C1
Marugo, M3
Scopinaro, N2
Minuto, F2
Busonera, G2
Rail, GA1
Bergstresser, P1
Weed, CL1
Isomäki, HA1
Takkunen, H1
Kastner, C1
Canlorbe, P1
Busuttil, R1
Knapp, E5
Hohenegger, M1
Khachadurian, A1
Gospodinoff, L1
Salvini, S1
Bourde, C4
Boyce, WH1
Bayeli, PF1
Montagnani, M1
Labrune, B1
Bonnenfant, F1
Ribierre, M1
Mallet, R1
Virtanen, KS1
Halonen, PI1
Ripault, J1
Benoist, M1
Nguyen-Huy, D1
Bloch-Michel, H1
Carnovale, M2
Baccarini, V2
Martina, GD1
Schwarczmann, P2
Lejeune, E3
Tolot, F1
Meunier, P4
van Bogaert, P1
Santamaria, A2
Schatanoff, J1
Bosco, JS1
Greenleaf, JE1
Kaye, RL1
Averkin, EG1
Kogut, MD1
Donnell, GN1
Sweetman, L3
Glueck, CJ1
Fujimoto, WY1
Mérillon, H1
Camus, JP1
Laveant-Hébrard, C1
Frank, M4
Tkach, S1
Cagli, V1
Ruotolo, V1
Bossini, A1
Bologna, E1
Boettcher, WG1
Bonfiglio, M1
Hamilton, HH1
Sheets, RF1
Smith, K1
Thomson, AE1
Denko, CW1
Robert D'Eshougues, J1
Sfikakis, P2
Taddeucci, E1
Terreni, F1
De Moro, ER1
De Dahinten, NM1
Katz, WA2
Schubert, M1
Carrel, JL1
Carrel, JM1
Davidson, DM1
Coutts, A1
Calabro, JJ1
Kitamura, M1
Nakayama, T1
Narasaki, K1
Okazaki, T1
Yoshimura, T2
Ueda, Y1
Kagawa, K1
Ravault, PP2
Vignon, G5
Bouvier, M3
Queneau, P1
Coste, F1
Healy, LA1
Jolley, RL1
Scott, CD1
Weilerstein, R1
Del Regno, F1
Capobianco, G1
Lloyd-Mostyn, RH1
Lord, PS1
Glover, R1
Gilliland, IC1
Chow, DC1
Kawahara, FS1
Saunders, T1
Fink, JK1
Biagi, RW1
Bapat, BN1
Barreca, T2
Ophir, R1
Adam, A1
Prasse, D1
Klöpfer-Zaar, M2
Houli, J1
Sabah, D1
Krapp, R1
Gärtner, A1
Schneider, HJ1
Tscharnke, J1
Rolle, E1
Chapuy, P1
Megard, M1
Chatin, B1
Sulzberger, I1
Klöpfer, M1
Zimmerman, WJ1
Heinz, K1
Schabel, F1
Zaar, I1
Thieme, G1
Scheier, CA1
Ménard, J2
Tachon, G1
Eyre, C1
Davison, AN1
Gorden, P1
Robertson, GL1
Van Goor, W1
Kooiker, CJ1
Mees, EJ1
Gresham, GE1
Keller, MD1
Parker, RA1
Van Peenen, HJ1
Knowles, BR1
Mervart, I1
Platzbecker, H1
Lange, A1
Böhme, A2
Wiegleb, C1
Dörner, K1
Manzke, H1
Tremel, R1
Pohl, W1
Rastogi, SP1
Volans, G1
Elliott, RW1
Eccleston, DW1
Ashcroft, R1
Webster, D1
Kerr, DN1
Kato, H1
Russell, WJ1
Uda, Y1
Hamilton, HB1
Kawamoto, S1
Johnson, KG1
Herbst, M2
Gebhardt, R1
Lührs, M1
Fritze, E1
Kallweit, C1
Müller, HO1
Südhof, H1
Clausen, JE1
Klimov, AN1
Sil'vestrov, VP1
Sigareva, VM1
Ban'kovskaia, EB1
Nyfos, L1
Rapado Errazti, A2
Mardomingo Varela, P1
Rubio Caballero, M1
Giovannelli, G1
Gragnoli, G1
Pupillo, A1
Sternon, J1
Kocheleff, P1
Couturier, E1
Balasse, E1
Vanden Abeele, P1
Terjung, E1
Stĕpánek, P2
Sadílek, L1
Müller, GW2
Gutschmidt, HJ1
Lenoch, F2
Sobĕslavský, C1
Carpenter, DG1
Carter, CH1
Hoefnagel, D1
Kissel, P3
Lamarche, M2
Miller, J2
Barlow, KA2
Haslam, RM1
Pardo, V1
Perez-Stable, E1
Fisher, ER1
Himes, DS1
Schindera, F2
Plante, GE1
Durivage, J1
Lemieux, G1
Michotte, JL1
Burtonboy, G1
Shreeve, WW1
Munsat, TL1
Carell, RE1
Menkes, J1
Ostberg, Y1
Hitchings, GH1
Becker, MH1
Wallin, JK1
Grígel, M1
Kacina, F1
Kokles, M1
Cagán, S1
Schilling, A1
Slansky, HH1
Kubara, T1
Catlett, GF1
Kidera, GJ1
Riccitelli, ML1
Boyett, JD1
Furtado, VD1
Schmidt, FH1
Arnot, R1
Glass, HI3
Kaufman, JM1
Myers, AR1
Epstein, FH1
Toone, EC1
Highton, TC1
Malamos, B1
Tsekos, G1
Tasiopoulos, T1
Siller, K2
Hunder, GG1
Bickel, WH1
Steele, AD1
Gold, MS1
Williams, JC1
Spivack, M1
Grann, V1
Howorth, PJ1
Zilva, JF1
Bernheim, C1
Bibus, B1
Misgeld, V1
Kotzaurek, R1
Hueber, EF1
Kemilä, S1
Pecherstorfer, M2
Callies, R1
Jordan, H1
Griendl, W1
Kalb, R1
Koch, G1
Schlosser, GA1
Doumerg, C1
Zaunbauer, W1
Sobti, P1
Bhasin, RC1
Morioka, S2
Bianco, G2
Gilles, DC1
Arnot, RN2
Ben Hameid, SS1
Krömer, H1
Sjöberg, KH3
Killen, BU1
Moesmann, G1
Strejcek, J1
Kucerová, L1
Moore, RY1
Pokorný, M1
Resl, V1
Zucchelli, P1
Sasdelli, M1
Fusaroli, M1
Salvatierra, D1
De la Higuera, J1
Pérez Gálvez, M1
Solnica, F1
Vindel, J1
Lira, MA1
Fraga Filho, C1
de Aguiar, JA1
Kovach, RD1
Rabussier, H1
Desgrez, P1
Fossati, P1
Lefebvre, J1
Decoulx, M1
Peltier, JM1
Linquette, M1
Chirone, E1
Kikutani, T1
Muranaka, M1
Scherbel, AL1
Di Paolo, N1
Lunghetti, R1
Bravi, A1
Steel, K1
Boggiano, C1
Shorthouse, PH1
Chattapadhyay, K1
Friedland, M1
Ehrlich, GE1
Streiker, FB1
Godfrey, RG1
Rankin, TJ1
James, JA1
Teberg, AJ1
Nelson, LG1
Komatsu, T1
McKiddie, M1
Jasani MK GRAY, HW1
Jackson, IM1
Champion, D1
Antila, V1
Elsilä, M1
Teisberg, P1
Dihlmann, W1
Fernholz, HJ1
Pagliara, AS1
Goodman, AD1
Altus, RE1
Chaloupková, E1
Anumonye, A1
Dobson, JW1
Oppenheim, S1
Sutherland, JS1
Flückiger, P1
Runcie, J1
Thomson, TJ1
Sass, JK1
Itabashi, HH1
Dexter, RA1
Ruitton, P1
Volle, L1
Bertrand, JN1
Reeves, B1
Trevaks, G1
Lovell, RR1
Iglesias, EJ1
Kotler, A1
Blumberg, BS1
Wyncaarden, JB1
Sokoloff, L1
Lieber, CS1
Drenick, EJ1
Allen, DJ1
Milosovich, G1
Mattocks, AM1
Sarre, H1
Lapidus, PW1
Guidotti, FP1
Benoit, P1
Ginsbourger, R1
Ryan, JA1
Goy, P1
Spanio, L1
De Battisti, C1
Garrod, PR1
McSwiney, RR1
Bold, AM1
Newton, DR1
Rosenthale, ME1
Kassarich, J1
Schneider, F1
Urowitz, MB2
Weber, HM2
Krakoff, IH1
Turrian, H1
Maier, C1
Burch, TA1
O'Brien, WM1
Need, R1
Kurland, LT1
Maher, FT1
Humphreys, DM1
Eisen, V1
Milne, MD1
Bremner, JM1
Lawrence, JS1
Goldfarb, E1
Podevin, R1
Amiel, C1
Strottman, MP1
Brooks, GW1
Mueller, E1
Whitehouse, FW1
Cleary, WJ1
Bartels, EC1
Levin, NW1
Abrahams, OL1
Rajan, KT1
Moore, JD1
Breitenbach, RP1
Boland, EW1
Binder, E1
Munck, A1
Chériè Lignière, G1
Menozzi, M1
Necchi Della Silva, A1
Heise, GW1
Bukhtoiarova, FG1
Malova, MN1
Linkin, SM1
Boĭchenko, LM1

Clinical Trials (80)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multicenter, Randomized, Comparative Trial on the Effect of Febuxostat in Preventing Cerebral and Cardiorenovascular Events in Patients With Hyperuricemia[NCT01984749]1,000 participants (Anticipated)Interventional2013-11-30Active, not recruiting
STorytelling to Improve DiseasE Outcomes in GoUT: The STRIDE-GO Study[NCT02741700]306 participants (Actual)Interventional2017-05-31Completed
A Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving KRYSTEXXA® (Pegloticase) (MIRROR Open-Label [OL])[NCT03635957]Phase 414 participants (Actual)Interventional2018-09-26Completed
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities[NCT01101035]Phase 36,198 participants (Actual)Interventional2010-04-23Completed
Physicians' Health Study II: Trial of Vitamins in the Chemoprevention of Cancer, CVD, and Eye Disease[NCT00270647]14,641 participants (Actual)Interventional1997-07-31Completed
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor[NCT01508702]Phase 3214 participants (Actual)Interventional2012-01-31Completed
Long-term Allopurinol Safety Study Evaluating Outcomes in Gout Patients (LASSO)[NCT01391325]Phase 41,735 participants (Actual)Interventional2011-07-31Completed
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Allopurinol Compared to Allopurinol Alone in Subjects With Gout Who Have Had an Inadequate Hypouricemic Response to[NCT01510158]Phase 3607 participants (Actual)Interventional2012-01-31Completed
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Febuxostat Compared to Febuxostat Alone at Lowering Serum Uric Acid and Resolving Tophi in Subjects With Tophaceou[NCT01510769]Phase 3330 participants (Actual)Interventional2012-01-31Completed
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Allopurinol Compared to Allopurinol Alone in Subjects With Gout Who Have Had an Inadequate Hypouricemic Response t[NCT01493531]Phase 3610 participants (Actual)Interventional2011-12-31Completed
Diagnostic Value of DECT Scan Compared to Diagnostic Needle Aspiration[NCT03038386]100 participants (Anticipated)Interventional2016-04-30Recruiting
Exploratory Study of FYU-981 for Hyperuricemia With or Without Gout (Phase II (IIa) Study)[NCT02344862]Phase 280 participants (Actual)Interventional2014-01-31Completed
Confirmatory Study of FYU-981 for Hyperuricemia With or Without Gout (Phase II (IIb) Study)[NCT02416167]Phase 2200 participants (Anticipated)Interventional2015-05-31Completed
Official Title: Safety and Efficacy Evaluation Study of FYU-981 Long-term Administration for Hyperuricemia With or Without Gout (Phase III Study)[NCT03006445]Phase 3330 participants (Actual)Interventional2016-12-31Completed
Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 for Hyperuricemia With or Without Gout to Evaluate the Safety and Noninferiority of FYU-981 (Phase III Study)[NCT03100318]Phase 3201 participants (Actual)Interventional2017-04-01Completed
The Effect of Tart Cherry Juice on Risk of Gout Attacks: a Randomised Controlled Trial[NCT03621215]120 participants (Anticipated)Interventional2019-07-15Active, not recruiting
A Three Arms, Randomized, Double-blind Controlled Trial of the Efficacy of Amway Uric Acid Lowering Product on Hyperuricemia[NCT06084585]180 participants (Anticipated)Interventional2023-10-23Recruiting
Dietary Approaches to Stop Hypertension (DASH) Diet Effects on Serum Uric Acid (SUA) in Adults With Hyperuricemia and Gout[NCT03569020]43 participants (Actual)Interventional2018-08-07Completed
University of Alabama at Birmingham CORT Project 2: The Effects of Urate Lowing Therapy (ULT) in Inflammation, Endothelial Function, and Blood Pressure[NCT02038179]Phase 2/Phase 399 participants (Actual)Interventional2014-07-31Completed
Pragmatic, Randomized, Multicenter, Double-blind, Controlled, Clinical Trial of Prednisolone Versus Colchicine for Acute Gout in Primary Care[NCT05698680]Phase 4314 participants (Anticipated)Interventional2023-01-18Recruiting
Prospective Study of the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders[NCT06092346]999 participants (Anticipated)Observational2024-01-03Recruiting
Serum Uric Acid Levels and Initial Presentation of Cardiovascular Diseases: a CALIBER Study[NCT03425305]180,000 participants (Actual)Observational1998-01-31Active, not recruiting
African American Study of Kidney Disease and Hypertension ABPM Pilot Study[NCT00582777]Phase 2/Phase 3180 participants (Anticipated)Interventional2007-11-30Completed
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo in Joint Damage in Hyperuricemic Subjects With Early Gout[NCT01078389]Phase 2314 participants (Actual)Interventional2010-03-31Completed
Effects of Allopurinol on Inflammatory Markers and Morphostructural Changes Evidenced by Musculoskeletal Ultrasound in Individuals With Asymptomatic Hyperuricemia. A Proof of Concept[NCT04012294]Phase 3200 participants (Anticipated)Interventional2019-08-30Recruiting
FEnofibRate as a Metabolic INtervention for Coronavirus Disease 2019[NCT04517396]Phase 2701 participants (Actual)Interventional2020-08-18Completed
CSP #594 - Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat[NCT02579096]Phase 4950 participants (Actual)Interventional2017-03-06Completed
A Phase 2a, Randomized, Open-Label, Single-Site Study to Evaluate the Pharmacodynamic Effects and Safety of RDEA3170 Administered in Combination With Febuxostat Compared to RDEA3170 Administered Alone and Febuxostat Administered Alone, Respectively in Jap[NCT02317861]Phase 1/Phase 2110 participants (Actual)Interventional2014-12-31Completed
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout[NCT02139046]Phase 31,790 participants (Actual)Interventional2014-04-30Completed
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP[NCT01327846]Phase 310,066 participants (Actual)Interventional2011-04-11Completed
Arthritis Research UK Gout Treatment Trial. Phase 2: Two Year Randomised Controlled Trial of a Nurse Led Package of Care[NCT01477346]517 participants (Actual)Interventional2013-03-31Completed
Effect of a Cold Water Immersion (CWI) on Pain in People With Gouty Arthritis: A Community Based Randomized Controlled Trial[NCT04587544]76 participants (Actual)Interventional2019-07-01Completed
A Novel Centralized 'Virtual' Gout Clinic for Chronic Gout Management (NIAMS :CoRT)[NCT02790463]1,463 participants (Actual)Interventional2013-01-31Completed
Novel Complex Radiodiagnostics of Peripherial Arthropathies[NCT05657847]500 participants (Anticipated)Observational2022-03-07Recruiting
A Phase I, Placebo-controlled, Randomized, Double Blind, Single or Multiple Dose Study of URC102 in Healthy Male Volunteers of Korean and Caucasian to Assess Safety, Pharmacokinetics and Pharmacodynamics[NCT01953497]Phase 181 participants (Actual)Interventional2013-05-23Completed
A Phase I, Placebo-controlled, Randomized, Double Blind, Dose-escalation Study to Assess the Safety and Pharmacokinetic and Pharmacodynamic Characteristics of Repeated-dose URC102 in Healthy Korean Adult Males[NCT02524678]Phase 121 participants (Actual)Interventional2015-08-05Completed
Randomized, Multicenter, Double-blind, Placebo-controlled Efficacy and Safety Study of 8 mg PEG-uricase in Two Dose Regimens in Hyperuricemic Subjects With Symptomatic Gout[NCT00325195]Phase 3225 participants (Actual)Interventional2006-05-31Completed
Multicenter, Open Label Extension Study of 8 mg PEG-uricase in Subjects Who Completed Protocols C0405 or C0406 for Symptomatic Gout[NCT01356498]Phase 3151 participants (Actual)Interventional2006-12-31Completed
A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Rilonacept for the Prophylaxis of Gout Flares During the Initiation of Allopurinol Therapy[NCT00958438]Phase 3248 participants (Actual)Interventional2009-07-31Completed
Assessing Patients With Suspected Stress or Insufficiency Fracture of the Lower Extremity With Photon-Counting-Computed-Tomography[NCT06024798]50 participants (Anticipated)Observational [Patient Registry]2023-09-30Not yet recruiting
Comparison of the Ease of Swallowability of B/F/TAF Placebo Compared to DTG/ABC/3TC Placebo[NCT04600687]50 participants (Actual)Interventional2018-11-06Completed
Assessing the Role of the NLRP3 Inflammasome in Driving Inflammation in Affected Joints of Patients With Intercritical Gout[NCT04125459]8 participants (Anticipated)Observational2020-01-22Active, not recruiting
Value of Uric Acid as Early Predictor of Lupus Nephritis in Assiut University Hospital[NCT05402735]100 participants (Anticipated)Observational2022-06-15Recruiting
A Multi-Center, Randomized, Double-Blind, Placebo Controlled Trial of the Safety of Rilonacept for the Prophylaxis of Gout Flares in Patients on Urate- Lowering Therapy[NCT00856206]Phase 31,315 participants (Actual)Interventional2009-03-31Completed
Allopurinol in the Treatment of Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Treated by Either PCI or CABG: Pilot Study[NCT03700645]Phase 4100 participants (Anticipated)Interventional2018-12-01Not yet recruiting
A Phase 3, Randomized, Multicenter, Allopurinol-Controlled Study Assessing the Safety and Efficacy of Oral Febuxostat in Subjects With Gout[NCT02082769]Phase 3504 participants (Actual)Interventional2011-07-31Completed
A Structured Nurse Led Patient Management Programme to Improve Outcomes in Gout: A Randomized Controlled Trial[NCT03345186]56 participants (Anticipated)Interventional2019-04-01Active, not recruiting
Effects of Bariatric Surgery in Swedish Obese Subjects[NCT01479452]4,047 participants (Actual)Interventional1987-01-31Completed
Keto-diet for Intubated Critical Care COVID-19 (KICC-COVID19)[NCT04358835]0 participants (Actual)Interventional2020-09-01Withdrawn (stopped due to Study did not begin enrollment, multiple competing studies at same institution)
A Phase II Study of Multiple Doses of Intravenous Puricase in Subjects With Hyperuricemia and Refractory Gout[NCT00080210]Phase 240 participants Interventional2004-03-31Completed
A Phase 3, Randomized, Multicenter, Allopurinol and Placebo-Controlled Study Assessing the Safety and Efficacy of Oral Febuxostat in Subjects With Gout.[NCT00174915]Phase 31,072 participants (Actual)Interventional2003-02-28Completed
Novel Methods for Ascertainment of Gout Flares -A Pilot Study[NCT02855437]44 participants (Actual)Interventional2016-09-30Completed
Phase II, Open-Label Study, to Assess the Long-Term Safety of Oral TMX-67 in Subjects With Gout[NCT00174941]Phase 2116 participants (Actual)Interventional2001-03-31Completed
A Phase 3, Open-Label, Randomized, Allopurinol-Controlled Study to Assess the Long-Term Safety of Oral Febuxostat in Subjects With Gout[NCT00175019]Phase 31,086 participants (Actual)Interventional2003-07-31Completed
Postprandial Modulation of HDL Metabolism[NCT01803594]18 participants (Actual)Interventional2012-08-31Completed
Effects of Dairy Fat on Postprandial Inflammation- Phase 1[NCT01811329]38 participants (Actual)Interventional2013-08-01Active, not recruiting
A Phase 3, Randomized, Multicenter, Double-Blind, Allopurinol-Controlled Study Assessing the Efficacy and Safety of Oral Febuxostat in Subjects With Gout.[NCT00430248]Phase 32,269 participants (Actual)Interventional2007-02-28Completed
Allopurinol Versus Febuxostat: A New Approach for Management of Hepatic Steatosis in Metabolic-Associated Fatty Liver Disease[NCT05474560]Phase 490 participants (Actual)Interventional2022-01-01Completed
A Phase II Multidose Study of Intravenous PEG-uricase in Patients With Refractory Gout[NCT00111657]Phase 230 participants (Actual)Interventional2004-12-31Completed
A Phase 3, Randomized, Multicenter Study Comparing the Safety and Efficacy of Oral Febuxostat Versus Allopurinol in Subjects With Gout[NCT00102440]Phase 3760 participants (Actual)Interventional2002-07-31Completed
Phase II, Dose-Response, Safety and Efficacy Study of Oral TMX-67 in Subjects With Gout.[NCT00174967]Phase 2153 participants (Actual)Interventional2001-01-31Completed
Study Protocol for a Prospective Observational Study Investigating the Role of Luminal Pressure on Arteriovenous Fistula Maturation[NCT04017806]60 participants (Anticipated)Observational2018-09-19Recruiting
Observational Study of the Use of KRYSTEXXA® (Pegloticase) in Adult Hyperuricemic Patients With Gout Refractory to Conventional Therapy[NCT01466166]188 participants (Actual)Observational2011-11-15Completed
ACTH vs Betamethasone for the Treatment of Acute Gout in Hospitalized Patients: A Randomized, Open Label, Comparative Study[NCT04306653]60 participants (Anticipated)Interventional2018-01-05Recruiting
A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Rilonacept for the Prophylaxis of Gout Flares During the Initiation of Allopurinol Therapy[NCT00829829]Phase 3241 participants (Actual)Interventional2009-02-28Completed
Effectiveness of Colchicine Among Patients With COVID-19 Infection[NCT04867226]Phase 2100 participants (Actual)Interventional2021-05-08Completed
Alternative Haemodiafiltration in Summer Season for Chronic Kidney Disease Patients[NCT05861219]100 participants (Anticipated)Interventional2023-06-21Not yet recruiting
Using of the Skin as a Third Spare Kidney for Patients With Chronic Renal Failure[NCT03810989]86 participants (Anticipated)Interventional2019-06-01Not yet recruiting
Apple Cider Vinegar for the Prevention of Urinary Lithiasis (APUL)[NCT04073719]50 participants (Anticipated)Interventional2019-09-01Not yet recruiting
Observational Study to Determine the Effect of Wearing of White Coat on Patient Satisfaction in Indian Out Patient Department (OPD) Setting[NCT02669355]123 participants (Actual)Observational2015-10-31Completed
A Study to Assess a Direct Physical Measurement Method for Evaluation of Tophus Nodules in Subjects With Gout.[NCT00175006]13 participants (Actual)Observational2002-11-30Completed
Effect of Low Dose of Colchicine on Platelet Reactivty in Patients With Chronic Coronary Disease[NCT05956145]Phase 380 participants (Anticipated)Interventional2021-06-17Recruiting
Genetics of Diabetes Audit and Research in Tayside Scotland (DOLORisk Dundee)[NCT02783469]1,915 participants (Actual)Observational2004-10-31Completed
Febuxostat (Zurig) Efficacy & Safety Trial in Comparison With Allopurinol in Hyperuricemic Subjects With or Without Gout[NCT02600780]Phase 450 participants (Actual)Interventional2013-11-30Completed
The Bogalusa Heart Study[NCT00005129]11,737 participants (Actual)Observational1972-06-30Active, not recruiting
Losartan and Uric Acid Metabolism in Children With Proteinuric Nephropathies: a Cross-over Randomized Clinical Trail[NCT05402397]Phase 440 participants (Anticipated)Interventional2022-07-01Recruiting
Nitrite Supplementation to Mitigate Fatigability and Increase Function in Long COVID Patients[NCT05618574]Phase 340 participants (Anticipated)Interventional2023-12-01Recruiting
[NCT00000482]Phase 30 participants Interventional1965-04-30Completed
Do Different Methods of Educating Patients Regarding Fluid Intake Reduce Kidney Stone Risks?[NCT01928108]10 participants (Actual)Observational2013-07-31Completed
Does Potassium Citrate Supplementation Reduce Stone Recurrence in Calcium Phosphate Stone Formers With Risk Factors?[NCT01980004]Phase 20 participants (Actual)Interventional2013-11-30Withdrawn (stopped due to closure due to failure to recruit any patients that met study criteria)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Gout Flares

Participant-reported total number of gout flares in the last 1 month (NCT02741700)
Timeframe: 12 months

InterventionSelf-reported gout flares in 1 month (Mean)
Gout Storytelling Video0.74
Video About Management of Another Chronic Condition0.99

Patient Satisfaction

Patient satisfaction with medication on the patient questionnaire (SATMED composite score), range 0-100. The SATMED-Q contains 17 items, each scored on a 5-point Likert scale. The total composite score ranges between 0 and 68. The score was converted to a percentage as recommended (=(raw score*100)/68); higher score = more satisfaction with medication. (NCT02741700)
Timeframe: 12 months

Interventionunits on a scale (Mean)
Gout Storytelling Video62.16
Video About Management of Another Chronic Condition67.43

Target Serum Urate

Serum urate with absolute value in mg/dl, as indirect measures of better ULT adherence and important gout outcomes (NCT02741700)
Timeframe: 12 months

Interventionmg/dL (Mean)
Gout Storytelling Video5.94
Video About Management of Another Chronic Condition5.72

Medication Adherence

ULT adherence, directly measured by using MEMS (Medication Event Monitoring System) Caps at 3, 6, and 9 months (assess intervention's effect) and 12 months (assess the durability of effect) (NCT02741700)
Timeframe: 3, 6, 9, and 12 months

,
Interventionpercentage of days ULT was taken (Mean)
MEMSCap™ ULT MPR at 3-monthsMEMSCap™ ULT MPR at 6-monthsMEMSCap™ ULT MPR at 9-monthsMEMSCap™ ULT MPR at 12-months
Gout Storytelling Video72.6168.5265.8560.54
Video About Management of Another Chronic Condition70.1269.3367.3263.82

Percentage of Serum Uric Acid (sUA < 5 mg/dL) Overall Responders

Serum uric acid (sUA < 5 mg/dL) overall responders are defined as participants achieving and maintaining sUA < 5 mg/dL for at least 80% of the time during Month 3 and Month 6 (Weeks 10, 12, 14, 20, 22, and 24) combined. Participants with more than one sUA result in Month 3 and Month 6 are considered responders if a participant's weighted proportion of hours that sUA is < 6 mg/dL is greater than or equal to 80%. Participants with the proportion of hours less than 80% are counted as non-responders. Participants with only one value in Month 3 and Month 6 are considered overall responders if they are considered responders in both Month 3 and Month 6. (NCT03635957)
Timeframe: Month 3 and Month 6 combined (Weeks 10, 12, 14, 20, 22, and 24)

Interventionpercentage of participants (Number)
Pegloticase With Methotrexate (MTX)78.6

Percentage of Serum Uric Acid (sUA < 5 mg/dL) Responders During Month 3

Serum uric acid (sUA < 5 mg/dL) responders are defined as participants achieving and maintaining sUA < 5 mg/dL for at least 80% of the time during Month 3. Month 3 includes pre-infusion and post-infusion sUA assessments at Week 10, pre-infusion and post-infusion sUA assessments at Week 12, pre-infusion assessments at Week 14, and unscheduled assessments between Week 10 and Week 14 pre-infusion. (NCT03635957)
Timeframe: Month 3 (Weeks 10, 12, and 14)

Interventionpercentage of participants (Number)
Pegloticase With Methotrexate (MTX)78.6

Percentage of Serum Uric Acid (sUA < 5 mg/dL) Responders During Month 6

Serum uric acid (sUA < 5 mg/dL) responders are defined as participants achieving and maintaining sUA < 5 mg/dL for at least 80% of the time during Month 6. Month 6 includes pre-infusion and post-infusion sUA assessments at Week 20, pre-infusion and post-infusion sUA assessments at Week 22, pre-infusion assessments at Week 24, and unscheduled sUA assessments between Week 20 and Week 24. (NCT03635957)
Timeframe: Month 6 (Weeks 20, 22, and 24)

Interventionpercentage of participants (Number)
Pegloticase With Methotrexate (MTX)78.6

Percentage of Serum Uric Acid (sUA < 6 mg/dL) Overall Responders

Serum uric acid (sUA < 6 mg/dL) overall responders are defined as participants achieving and maintaining sUA < 6 mg/dL for at least 80% of the time during Month 3 and Month 6 (Weeks 10, 12, 14, 20, 22, and 24) combined. Participants with more than one sUA result in Month 3 and Month 6 are considered responders if a participant's weighted proportion of hours that sUA is < 6 mg/dL is greater than or equal to 80%. Participants with the proportion of hours less than 80% are counted as non-responders. Participants with only one value in Month 3 and Month 6 are considered overall responders if they are considered responders in both Month 3 and Month 6. (NCT03635957)
Timeframe: Month 3 and Month 6 combined (Weeks 10, 12, 14, 20, 22, and 24)

Interventionpercentage of participants (Number)
Pegloticase With Methotrexate (MTX)78.6

Percentage of Serum Uric Acid (sUA < 6 mg/dL) Responders During Month 3

Serum uric acid (sUA < 6 mg/dL) responders are defined as participants achieving and maintaining sUA < 6 mg/dL for at least 80% of the time during Month 3 (Weeks 10, 12, and 14). Month 3 includes pre-infusion and post-infusion sUA assessments at Week 10, pre-infusion and post-infusion sUA assessments at Week 12, pre-infusion assessments at Week 14, and unscheduled assessments between Week 10 and Week 14 pre-infusion. (NCT03635957)
Timeframe: Month 3 (Weeks 10, 12, and 14)

Interventionpercentage of participants (Number)
Pegloticase With Methotrexate (MTX)78.6

Percentage of Serum Uric Acid (sUA < 6 mg/dL) Responders During Month 6

Serum uric acid (sUA < 6 mg/dL) responders are defined as participants achieving and maintaining sUA < 6 mg/dL for at least 80% of the time during Month 6 (Weeks 20, 22, and 24). Month 6 includes pre-infusion and post-infusion sUA assessments at Week 20, pre-infusion and post-infusion sUA assessments at Week 22, pre-infusion assessments at Week 24, and unscheduled sUA assessments between Week 20 and Week 24. (NCT03635957)
Timeframe: Month 6 (Weeks 20, 22, and 24)

Interventionpercentage of participants (Number)
Pegloticase With Methotrexate (MTX)78.6

Mean Change in sUA From Pegloticase Baseline to Weeks 14, 24, 36, 52

The mean change from baseline is based on observed values in participants remaining on treatment at given time point. For sUA values less than the lower limit of detection (up to 1.5 mg/dL), 0 is used in the analysis. (NCT03635957)
Timeframe: Baseline (defined as the last measurement taken prior to the first infusion of pegloticase in the pegloticase + IMM period), Pre- and Post-Infusion at Weeks 14, 24, 36 and Week 52

Interventionmg/dL (Mean)
Change at Week 14 - pre-infusionChange at Week 14 - post-infusionChange at Week 24 - pre-infusionChange at Week 24 - post-infusionChange at Week 36 - pre-infusionChange at Week 36 - post-infusionChange at Week 52
Pegloticase With Methotrexate (MTX)-9.27-9.31-9.27-9.48-8.13-9.41-8.15

Percentage of Participants With Antiplatelet Trialists' Collaborative (APTC) Event

APTC events were defined as a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke; these events were adjudicated by an independent cardiovascular endpoints committee. (NCT01101035)
Timeframe: Up to last dose of study drug (approximately 83 months)

Interventionpercentage of participants (Number)
Febuxostat9.6
Allopurinol8.8

Percentage of Participants With Cardiovascular (CV) Death

Events were adjudicated by an independent cardiovascular endpoints committee as CV death. (NCT01101035)
Timeframe: Up to last dose of study drug (approximately 83 months)

Interventionpercentage of participants (Number)
Febuxostat4.3
Allopurinol3.2

Percentage of Participants With Non-fatal Myocardial Infarction (MI)

Events were adjudicated by an independent cardiovascular endpoints committee as non-fatal MI. (NCT01101035)
Timeframe: Up to last dose of study drug (approximately 83 months)

Interventionpercentage of participants (Number)
Febuxostat3.6
Allopurinol3.8

Percentage of Participants With Non-fatal Stroke

Events were adjudicated by an independent cardiovascular endpoints committee as non-fatal stroke. (NCT01101035)
Timeframe: Up to last dose of study drug (approximately 83 months)

Interventionpercentage of participants (Number)
Febuxostat2.3
Allopurinol2.3

Percentage of Participants With Primary MACE Composite (Final Analysis)

Major adverse cardiovascular events (MACE) were defined as a composite of cardiovascular (CV) death, non-fatal myocardial infarction (MI), nonfatal stroke and unstable angina with urgent coronary revascularization; these events were adjudicated by an independent cardiovascular endpoints committee. (NCT01101035)
Timeframe: Up to last dose of study drug (approximately 83 months)

Interventionpercentage of participants (Number)
Febuxostat10.8
Allopurinol10.4

Percentage of Participants With Primary Major Adverse Cardiovascular Events (MACE) Composite (75% Interim Analysis)

Major adverse cardiovascular events (MACE) were defined as a composite of cardiovascular (CV) death, non-fatal myocardial infarction (MI), nonfatal stroke and unstable angina with urgent coronary revascularization; these events were adjudicated by an independent cardiovascular endpoints committee. (NCT01101035)
Timeframe: Up to last dose of study drug (approximately 83 months)

Interventionpercentage of participants (Number)
Febuxostat8.0
Allopurinol8.0

Percentage of Participants With Unstable Angina With Urgent Coronary Revascularization

Events were adjudicated by an independent cardiovascular endpoints committee as unstable angina with urgent coronary revascularization. (NCT01101035)
Timeframe: Up to last dose of study drug (approximately 83 months)

Interventionpercentage of participants (Number)
Febuxostat1.6
Allopurinol1.8

Number of Subjects With an sUA Level That is < 6.0 mg/dL

(NCT01508702)
Timeframe: 6 months

InterventionNumber of Subjects (Number)
Lesinurad 400 mg32
Placebo2

Incidence of Gout Flares

Proportion of subjects who experienced at least one gout flare requiring treatment during the study. (NCT01391325)
Timeframe: Every month for 6 months.

Interventionpercentage of subjects (Number)
Allopurinol33.4

Proportion of Subjects With Serum Urate (sUA) Less Than 6.0 mg/dL

Proportion of subjects with serum urate (sUA) less than 6.0 mg/dL at Month 6 using Last Observation Carried Forward (LOCF) for subjects with missing values at Month 6. (NCT01391325)
Timeframe: Month 6

Interventionpercentage of subjects (Number)
Allopurinol43.4

Safety of Allopurinol

Proportion of subjects who experienced at least one Treatment Emergent Adverse Event (TEAE) during the study. (NCT01391325)
Timeframe: Every month for 6 months.

Interventionpercentage of subjects (Number)
Allopurinol55.1

Mean Change From Baseline to Month 6 in SF-36 PCS+MCS

The SF-36 is a short-form health survey with 36 questions that yields an 8-scale profile of functional health and well-being scores as well as psychometrically-based physical (PCS) and mental health (MCS) summary. Each scale is directly transformed into a 0-100 scale. The lower the score the more disability. The higher the score the less disability. The component scores (PCS and MCS) are norm-based to a standard population with a mean of 50 and a standard deviation of 10. (NCT01391325)
Timeframe: Month 6

Interventionunits on a scale (Mean)
SF-36 Physical Component SummarySF-36 Mental Health Component Summary
Allopurinol3.880.71

Gout Flares

Mean rate of gout flares requiring treatment for the 6-month period from the end of Month 6 to the end of Month 12 (NCT01510158)
Timeframe: 12 Months

InterventionGout Flares (Mean)
Lesinurad 200 mg + Allopurinol.60
Lesinurad 400 mg + Allopurinol.50
Placebo + Allopurinol.60

Proportion of Subjects With an sUA Level That is < 6.0 mg/dL

(NCT01510158)
Timeframe: 6 Months, analysis after all subjects complete 12 months

InterventionProportion of Subjects (Number)
Lesinurad 200 mg + Allopurinol0.542
Lesinurad 400 mg + Allopurinol0.592
Placebo + Allopurinol0.279

Tophus

Proportion of subjects with ≥ 1 target tophus at Baseline who experience complete resolution of at least 1 target tophus by Month 12 (NCT01510158)
Timeframe: 12 Months

InterventionProportion of Subjects (Number)
Lesinurad 200 mg + Allopurinol0
Lesinurad 400 mg + Allopurinol0.211
Placebo + Allopurinol0.294

Complete or Partial Response of at Least One Tophus

Proportion of subjects with a best tophus response on at least 1 target tophus of complete (disappearance of at least 1 target tophus) or partial (≥ 50% decrease in the area of at least 1 target tophus) resolution by Month 12 (NCT01510769)
Timeframe: 12 Months

InterventionProportion of Subjects (Number)
Lesinurad 200 mg + Febuxostat 80 mg0.566
Lesinurad 400 mg + Febuxostat 80 mg0.587
Placebo + Febuxostat 80 mg0.505

Complete Resolution of at Least One Target Tophus

Proportion of subjects who experience complete resolution of at least 1 target tophus by Month 12 (NCT01510769)
Timeframe: 12 Months

InterventionProportion of Subjects (Number)
Lesinurad 200 mg + Febuxostat 80 mg0.255
Lesinurad 400 mg + Febuxostat 80 mg0.303
Placebo + Febuxostat 80 mg0.211

Quality of Life

Proportion of subjects with an improvement from Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) of at least 0.25 at Month 12. The HAQ-DI assesses a patient's level of functional ability with items scores ranging from 0-3 with 0 being the least disability. (NCT01510769)
Timeframe: 12 Months

InterventionProportion of Subjects (Number)
Lesinurad 200 mg + Febuxostat 80 mg0.442
Lesinurad 400 mg + Febuxostat 80 mg0.333
Placebo + Febuxostat 80 mg0.525

Subjects With a Serum Urate (sUA) Level That is < 5.0 mg/dL by Month 6

Proportion of subjects with an sUA level that is < 5.0 mg/dL by Month 6 (NCT01510769)
Timeframe: 6 months, analysis after all subjects complete 12 months

InterventionProportion of Subjects (Number)
Lesinurad 200 mg + Febuxostat 80 mg0.566
Lesinurad 400 mg + Febuxostat 80 mg0.761
Placebo + Febuxostat 80 mg0.468

Gout Flares

Mean rate of gout flares requiring treatment for the 6-month period from the end of Month 6 to the end of Month 12. (NCT01493531)
Timeframe: 12 Months

InterventionGout Flares (Mean)
Lesinurad 200 mg + Allopurinol0.7
Lesinurad 400 mg + Allopurinol0.8
Placebo + Allopurinol0.9

Subjects With ≥ 1 Target Tophus at Baseline Who Experience Complete Resolution of at Least 1 Target Tophus by Month 12

Proportion of subjects with ≥ 1 target tophus at Baseline who experience complete resolution of at least 1 target tophus by Month 12 (NCT01493531)
Timeframe: 12 months

InterventionProportion of Subjects (Number)
Lesinurad 200 mg + Allopurinol0.314
Lesinurad 400 mg + Allopurinol0.276
Placebo + Allopurinol0.333

Subjects With a Serum Urate (sUA) < 6.0 mg/dL by Month 6.

Proportion of subjects with an sUA level that is < 6.0 mg/dL by Month 6. (NCT01493531)
Timeframe: 6 months

InterventionProportion of Subjects (Number)
Lesinurad 200 mg + Allopurinol0.554
Lesinurad 400 mg + Allopurinol0.665
Placebo + Allopurinol0.233

Uric Acid Level

Measured in serum (NCT03569020)
Timeframe: At 4-weeks

Interventionmg/dL (Mean)
Dietitian-Directed Diet7.67
Self-Directed Diet8.03

Uric Acid Level

Measured in serum (NCT03569020)
Timeframe: At 8-weeks

Interventionmg/dL (Mean)
Dietitian-Directed Diet7.75
Self-Directed Diet7.98

Uric Acid Level

Measured in serum (NCT03569020)
Timeframe: Baseline

Interventionmg/dL (Mean)
Dietitian-Directed Diet Then Self-Directed Diet8.23
Self-Directed Diet Then Dietitian-Directed Diet8.03

Body Mass Index (kg/m^2)

Derived from baseline height, and serial weight measurements (NCT03569020)
Timeframe: Baseline, 4-weeks, 8-weeks

,
Interventionkg/m^2 (Mean)
BaselinePeriod 1Period 2
Dietitian-Directed Diet Then Self-Directed Diet33.433.033.6
Self-Directed Diet Then Dietitian-Directed Diet33.533.633.5

Diastolic Blood Pressure (mm Hg)

(NCT03569020)
Timeframe: At baseline, 4-weeks, 8-weeks

,
Interventionmm Hg (Mean)
BaselinePeriod 1Period 2
Dietitian-Directed Diet Then Self-Directed Diet74.976.177.3
Self-Directed Diet Then Dietitian-Directed Diet72.675.074.0

Fasting Blood Glucose (mg/dL)

Measured in serum (NCT03569020)
Timeframe: Baseline, 4-weeks, 8-weeks

,
Interventionmg/dL (Mean)
BaselinePeriod 1Period 2
Dietitian-Directed Diet Then Self-Directed Diet93.096.597.1
Self-Directed Diet Then Dietitian-Directed Diet103.0103.297.6

Low Density Lipoprotein Cholesterol (mg/dL)

Measured in serum (NCT03569020)
Timeframe: Baseline, 4-weeks, 8-weeks

,
Interventionmg/dL (Mean)
BaselinePeriod 1Period 2
Dietitian-Directed Diet Then Self-Directed Diet109.0105.3107.5
Self-Directed Diet Then Dietitian-Directed Diet115.5113.4105.5

Systolic Blood Pressure (mm Hg)

(NCT03569020)
Timeframe: Baseline, 4-weeks, 8-weeks

,
Interventionmm Hg (Mean)
BaselinePeriod 1 (4-weeks)Period 2 (8-weeks)
Dietitian-Directed Diet Then Self-Directed Diet125.0126.4129.4
Self-Directed Diet Then Dietitian-Directed Diet123.5123.7124.8

Change in Flow-mediated Arterial Vasodilation

Compare endothelial function as indexed by flow-mediated arterial vasodilation (FMD) within each phase of treatment (allopurinol 300 mg/day PO or placebo). Percent (%) change in FMD is calculated by comparing FMD (%) at the end of each treatment phase to pre-treatment values. (NCT02038179)
Timeframe: 4 weeks (pre-treatment vs. post-treatment FMD Values (%))

Interventionpercent change (Mean)
Allopurinol Phase2.5
Placebo Phase-0.1

Change in Serum Levels of High Sensitivity C-reactive Protein

Serum level of high sensitivity C-reactive protein will be reported as a change during treatment phase (allopurinol 300 mg/day PO or placebo). Change in serum level of C-reactive protein is calculated by comparing serum values at the end of each treatment phase to pre-treatment levels. (NCT02038179)
Timeframe: 4 weeks (pre-treatment vs. post-treatment serum levels)

Interventionmg/L (Mean)
Allopurinol Phase0.6
Placebo Phase0.8

Change in Systolic Blood Pressure (SBP)

Compare systolic blood pressure (SBP) captured by wearing a 24 hour ambulatory blood pressure monitor during each phase of treatment (allopurinol 300 mg/day PO or placebo). Change in systolic blood pressure is calculated by comparing SBP at the end of each treatment phase to pre-treatment values. (NCT02038179)
Timeframe: 4 weeks (pre-treatment vs. post-treatment SBP)

Interventionmm Hg (Mean)
Allopurinol Phase-1.39
Placebo Phase-1.06

Mean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Erosion Score of the Single Affected Joint

The single affected joint was defined as the joint with the history of the first acute gout flare. Radiographs (X-rays) of this single joint in the hands or feet were evaluated using the modified Sharp/van der Heijde method. Each erosion was assessed using a 4-point scale where 0=no erosions (best) to 3=large erosion passing the mid-line (worst). Individual erosion scores were summed to a maximum erosion score of 5 for joints in the hands and 10 for joints in the feet. Higher scores indicated more joint damage. A negative change from Baseline indicated improvement. (NCT01078389)
Timeframe: Baseline and Month 24

,
Interventionscore on a scale (Mean)
BaselineChange from Baseline at Month 24
Febuxostat 40 mg or 80 mg0.160.01
Placebo0.110.01

Mean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Erosion Scores From Full Hands and Feet Radiographs

Radiographs (X-rays) of 40 joints in the hands and 12 joints in the feet were evaluated using the modified Sharp/van der Heijde method. Each erosion was assessed using a 4-point scale where 0=no erosions (best) to 3=large erosion passing the mid-line (worst) for a total erosion score range of 0 to 320. Higher scores indicated more joint damage. A negative change from Baseline indicated improvement. (NCT01078389)
Timeframe: Baseline and Month 24

,
Interventionscore on a scale (Mean)
BaselineChange from Baseline at Month 24 (n=78,74)
Febuxostat 40 mg or 80 mg0.360.17
Placebo0.170.11

Mean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Total Score of the Single Affected Joint

The single affected joint was defined as the joint with the history of the first acute gout flare. Radiographs (X-rays) of the single affected joint in the hands or feet were evaluated using the modified Sharp/van der Heijde method. Each erosion was assessed using a 4-point scale where 0=no erosions (best) to 3=large erosion passing the mid-line (worst) and Joint space narrowing (JSN) was assessed using a 5-point scale where 0=normal (best) to 4=absence of joint space, presumptive evidence of ankyloses, or complete luxation (worst). The Erosion Score and the JSN Score were summed for the Total Score. Higher scores indicated more joint damage. A negative change from Baseline indicated improvement. (NCT01078389)
Timeframe: Baseline and Month 24

,
Interventionscore on a scale (Mean)
BaselineChange from Baseline at Month 24(n=81,76)
Febuxostat 40 mg or 80 mg0.850.00
Placebo0.770.05

Mean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Total Scores From Full Hands and Feet Radiographs

Radiographs (X-rays) of 40 joints in the hands and 12 joints in the feet were evaluated using the modified Sharp/van der Heijde method. Each erosion was assessed using a 4-point scale where 0=no erosions (best) to 3=large erosion passing the mid-line (worst) for a total erosion score range of 0 to 320. Joint space narrowing (JSN) was assessed using a 5-point scale where 0=normal (best) to 4=absence of joint space, presumptive evidence of ankyloses, or complete luxation (worst) for a total JSN score range of 0 to 208. The Erosion Score and the JSN Score were combined for a total possible score of 0 to 528. Higher scores indicated more joint damage. A negative change from Baseline indicated improvement. (NCT01078389)
Timeframe: Baseline and Month 24

,
Interventionscore on a scale (Mean)
BaselineChange from Baseline at Month 24 (n=78,74)
Febuxostat 40 mg or 80 mg4.980.31
Placebo4.560.29

Mean Change From Baseline to Month 24 in the Rheumatoid Arthritis MRI Scoring System (RAMRIS) Score of the Single Affected Joint

The single affected joint was defined as the joint with the history of the first acute gout flare. Magnetic Resonance Imaging (MRI) was evaluated using the Rheumatoid Arthritis MRI Score (RAMRIS). Bone erosion in the proximal and distal location were each assessed in the affected joint using an 11-point scale where 0=no erosion (best) to 10=91-100% bone eroded (worst) for a bone erosion score range of 0 to 20. Bone marrow edema in the proximal and distal location were each assessed using a 4-point scale where 0=no edema (best) to 3=67-100% edema (worst) for a bone marrow edema (BME) score range of 0 to 6. Synovitis was assessed in the affected joint using a 4-point scale where 0=normal (best) to 3=severe (worst). Higher scores indicated more joint damage. A negative change from Baseline indicated improvement. (NCT01078389)
Timeframe: Baseline and Month 24

,
Interventionscore on a scale (Mean)
Synovitis:Baseline (BL)(n=82,76)Synovitis:Change from Baseline (n=75,67)Erosion (Distal+Proximal):Baseline (n=84,77)Erosion (Distal+Proximal):Change from BL(n=79,69)Edema (Distal+Proximal):Baseline (BL) (n=81,75)Edema (Distal+Proximal):Change from BL(n=77,66)
Febuxostat 40 mg or 80 mg1.29-0.431.63-0.010.73-0.36
Placebo1.09-0.071.480.040.51-0.10

All-Cause Death

Death from any cause during the observation period (NCT04517396)
Timeframe: Up to 30 days

InterventionParticipants (Count of Participants)
Fenofibrate + Usual Care19
Placebo + Usual Care22

Exploratory Hierarchical Composite Endpoint

The exploratory global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) The number of days out of the hospital during the 30 day-period following randomization. (NCT04517396)
Timeframe: Up to 30 days

Interventionscore on a scale (Median)
Fenofibrate + Usual Care5.03
Placebo + Usual Care5.03

Number of Days Alive and Out of the Hospital During the 30 Days Following Randomization

Number of days that participants were alive and out of the hospital during the 30 days following randomization (NCT04517396)
Timeframe: Up to 30 days

Interventiondays (Median)
Fenofibrate + Usual Care30
Placebo + Usual Care30

Number of Days Alive, Out of the Intensive Care Unit, Free of Mechanical Ventilation/Extracorporeal Membrane Oxygenation, or Maximal Available Respiratory Support in the 30 Days Following Randomization

Number of days participants were alive, out of the intensive care unit, free of mechanical ventilation/extracorporeal membrane oxygenation, or maximal available respiratory support during the 30 days that followed randomization (NCT04517396)
Timeframe: Up to 30 days

Interventiondays (Mean)
Fenofibrate + Usual Care28.8
Placebo + Usual Care28.3

Primary Hierarchical Composite Endpoint

The primary endpoint of the trial is a global rank score that ranks patient outcomes according to 5 factors. The global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, the modified Borg dyspnea scale (NCT04517396)
Timeframe: 30 days

InterventionRanked Severity Score (Median)
Fenofibrate + Usual Care5.32
Placebo + Usual Care5.33

Secondary Hierarchical Composite Endpoint

The secondary global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, a COVID-19 symptom scale rating fever, cough, dyspnea, muscle aches, sore throat, loss of smell or taste, headache, diarrhea, fatigue, nausea/vomiting, chest pain (each are rated from 0-10 then summed). (NCT04517396)
Timeframe: Up to 30 days

Interventionscore on a scale (Median)
Fenofibrate + Usual Care5.05
Placebo + Usual Care5.05

Seven-category Ordinal Scale

A seven-category ordinal scale consisting of the following categories: 1, not hospitalized with resumption of normal activities; 2, not hospitalized, but unable to resume normal activities; 3, hospitalized, not requiring supplemental oxygen; 4, hospitalized, requiring supplemental oxygen; 5, hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both; 6, hospitalized, requiring extracorporeal membrane oxygenation (ECMO), invasive mechanical ventilation, or both; and 7, death. (NCT04517396)
Timeframe: At 15 days

Interventionscore on a scale (Median)
Fenofibrate + Usual Care1
Placebo + Usual Care1

Percentage of Participants Experiencing ≥ 1 Gout Flare During Phase 3

"Participants were defined as flaring in Phase 3 if they:~-1) met 3 of 4 following participant-reported criteria:~a) warm joint(s)~b) swollen joint(s)~c) pain (>3) at rest on a scale of 0-10 (10 being the worst pain)~d) self-identified gout flare~OR~-2) reported use of medications to treat flare" (NCT02579096)
Timeframe: Phase III of the study (weeks 49-72 of study duration)

InterventionParticipants (Count of Participants)
Allopurinol / Sham Comparator (Febuxostat)135
Febuxostat / Sham Comparator (Allopurinol)165

Percentage of Participants With at Least One Gout Flare Requiring Treatment

"A participant was considered to have a gout flare if the following criteria were met:~Participant-reported acute particular pain typical of a gout attack that was deemed by participant and/or investigator to require treatment and was treated with colchicine, nonsteroidal anti-inflammatory drugs (NSAIDs) or steroids, Participant experienced at least 3 or more of: 1) Joint swelling, 2) Redness, 3) Tenderness, 4) Pain, Participant experienced at least one or more of: 1) Rapid onset of pain, 2) Decreased range of motion, 3) Joint warmth, 4) Other symptoms similar to a prior gout flare." (NCT02139046)
Timeframe: Baseline to Month 3

Interventionpercentage of participants (Number)
Placebo20.7
Febuxostat IR 40 mg21.0
Febuxostat XR 40 mg22.8
Febuxostat IR 80 mg27.2
Febuxostat XR 80 mg26.6

Percentage of Participants With Serum Urate <5.0 mg/dL at Month 3

(NCT02139046)
Timeframe: Month 3

Interventionpercentage of participants (Number)
Placebo0.3
Febuxostat IR 40 mg15.7
Febuxostat XR 40 mg25.9
Febuxostat IR 80 mg42.6
Febuxostat XR 80 mg50.1

Percentage of Participants With Serum Urate <6.0 mg/dL at Month 3

(NCT02139046)
Timeframe: Month 3

Interventionpercentage of participants (Number)
Placebo0.6
Febuxostat IR 40 mg40.3
Febuxostat XR 40 mg48.2
Febuxostat IR 80 mg57.7
Febuxostat XR 80 mg61.1

Core Phase All-cause Mortality

Number of participant deaths (NCT01327846)
Timeframe: From randomization, to end of treatment plus 30 days, up to approximately 6 years

InterventionParticipants (Number)
Group I239
Group II238
Group III228
Group IV375

Core Phase All-cause Mortality, Non-fatal MI, or Non-fatal Stroke

Occurrence of the composite endpoint consisting of all-cause mortality, non-fatal IM, or non-fatal stroke (NCT01327846)
Timeframe: From randomization, to end of treatment plus 30 days, up to approximately 6 years

InterventionParticipants (Number)
Group I403
Group II395
Group III394
Group IV661

Patients With Core Phase New Onset Type 2 Diabetes Among Patients With Pre-diabetes at Randomization

Time to CEC confirmed new onset of type 2 diabetes among those with pre-diabetes at randomization (i.e. excluding those that are normoglycemic at baseline) (NCT01327846)
Timeframe: From randomization up to approximately 6 years

InterventionParticipants (Number)
Group I169
Group II171
Group III161
Group IV246

Analysis of Core Phase First CEC Confirmed Major Adverse Cardiovascular Events (MACE) and Its Components

"Time to occurrence of CEC (Cardiovascular clinical events adjudication committee) confirmed MACE, which was a composite endpoint consisting of CEC confirmed CV death, CEC confirmed non-fatal MI,or CEC confirmed non-fatal stroke. Patients with the CEC adjudicated reason for death of Unknown were counted as CV (cardiovascular) death." (NCT01327846)
Timeframe: From randomization, to end of treatment plus 30 days, up to approximately 6 years

,,,
InterventionParticipants (Number)
MACECV deathMI (fatal and non-fatal)MI (non-fatal)Stroke (fatal and non-fatal)Stroke (non-fatal)
Group I3221511741715151
Group II3201441591586363
Group III3131371691685858
Group IV5352352922919291

Patients With Core Phase CEC Confirmed CV Death, Non-fatal MI, Non-fatal Stroke, or Hospitalization for Unstable Angina Requiring Unplanned Revascularization

"Occurrence of the composite cardiovascular endpoint consisting of cardiovascular death, non-fatal MI, non-fatal stroke or hospitalization for unstable angina requiring unplanned revascularization.~MACE includes CV death, non-fatal MI and non-fatal stroke. CEC = Clinical Endpoints Committee" (NCT01327846)
Timeframe: From randomization, to end of treatment pus 30 days, up to approximately 6 years

,,,
InterventionParticipants (Number)
MACE or unstable anginaUnstable angina
Group I34834
Group II35238
Group III34438
Group IV60185

Summary of Adverse Events (Core Phase)

Summary of Adverse Events (AEs) and Serious Adverse Events (SAEs) occurring during the double-blind Core phase of the study. AEs/SAEs are any signs or symptoms that occur during the study treatment. (NCT01327846)
Timeframe: From randomization, to end of treatment plus 30 days, up to approximately 6 years

,,,
InterventionParticipants (Number)
Patients with at least one AEAEs suspected to be related tostudy drugPatients with at least one SAEDiscontinued due to SAEsDiscontinued due to non-seriousAEsAEs leading to study treatmentinterruption
Group I198735583613540268
Group II197035081213034270
Group III187226774111726228
Group IV2915474120419847399

Summary of Adverse Events (Extension Phase)

Summary of Adverse Events (AEs) and Serious Adverse Events (SAEs) occurring during the Extension phase of the study. AEs/SAEs are any signs or symptoms that occur during the study treatment. (NCT01327846)
Timeframe: From start of Extension phase, to end of treatment plus 30 days, up to approximately 2 years

,,,
InterventionParticipants (Number)
Patients with at least one AEAEs suspected to be related tostudy drugPatients with at least one SAEDiscontinued due to SAEsDiscontinued due to non-seriousAEsAEs leading to study treatmentinterruption
Group I7884031067859
Group II8453432671672
Group III79343322711262
Group IV125065465988100

Adherence to Medication

Adherence to prescribed medication (NCT02790463)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Usual Care250
Intervention341

sUA < 6.0 mg/dl at 1 Year

Achievement of serum uric acid (sUA) < 6.0 mg/dl at 1 year (NCT02790463)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Usual Care117
Intervention204

Change in Number of Swollen Joints

Change from Baseline to Month 6 (or last observation carried forward)in number of swollen joints per subject. Values were inputed using last observation carried forward analysis for subjects who did not complete the studies. (NCT00325195)
Timeframe: Baseline and Final Visit (Month 6 or LOCF)

InterventionSwollen joints (Mean)
q2 Wks-5.5
q4 Wks-5.1
Placebo-2.6

Change in Number of Tender Joints

Change from Baseline to Month 6 (or last observation carried forward) in number of tender joints per participant (NCT00325195)
Timeframe: Baseline and Final Visit (Month 6 or LOCF)

InterventionTender joints (Mean)
q2 Wks-7.4
q4 Wks-6.1
Placebo-1.2

Plasma Uric Acid (PUA) Responder

PUA Responder was defined as a participant who achieved and maintained plasma uric acid concentrations < 6 mg/dL for at least 80% of the time during months 3 and 6 combined. Participants who withdrew from the study before month 6 were considered non-responders. (NCT00325195)
Timeframe: Months 3 and 6

InterventionParticipants (Number)
q2 Wks36
q4 Wks29
Placebo0

Reduction in Tophus Burden

percentage of tophaceous subjects who demonstrated a complete resolution (100 % decrease in measured area or complete disappearance)of at least one tophus in the absence of other tophus progression or new tophi, as assessed by a blinded Central Reader using standardized digital photographs and image analysis software. (NCT00325195)
Timeframe: Baseline and Final Visit (6 months or LOCF)

InterventionPercent subjects with resolved tophus (Number)
q2 Wks40
q4 Wks21
Placebo7

Change in Patient Reported Outcomes of Pain, Physical Function and Quality of Life

Health Assessment Questionnaire(HAQ: VAS pain scale where 0 (no pain)-100 (severe pain); HAQ disability index (HAQ-DI) on a scale from 0(no disability) to 3 (completely disabled), and a unit change of > or =0.22 is considerd a mimimal clinically important difference(MCID). SF-36 Physical Component Summary Score (SF36-PCS), a composite score where 0 is the worst score and 100 the best possible, and where a change of > or =2.5 units in the PCS is considered a MCID. (NCT00325195)
Timeframe: Baseline to Final Visit (Month 6 or LOCF)

,,
InterventionUnits on a scale (Mean)
HAQ-VAS PainHAQ-DISF-36 PCS
Placebo1.40.0-0.3
q2 Wks-11.4-0.224.4
q4 Wks-6.9-0.204.9

Percentage of Subjects With Gout Flare Per 3-month Period

Percent of participants reporting a gout flare during Months 1-3 and Months 4-6. Denominator during the respective period was based upon number of participants during that period. (NCT00325195)
Timeframe: Months 1-3 and Months 4-6

,,
InterventionPercent subjects reporting flares (Number)
Months 1-3Months 4-6
Placebo5467
q2 Wks7541
q4 Wks8156

Gout Flare Frequency

The the mean number of flares per subject (flare frequency)was assessed over 3-month periods for up to 2 years of treatment (NCT01356498)
Timeframe: Up to 2 years

,,,,,
InterventionFlares (Mean)
Months 1-3Months 4-6Months 7-9Months 10-12Months 16-18Months 22-24
Placebo in RCT, q2 in OLE2.31.31.20.60.20.4
Placebo in RCT, q4 in OLE1.50.80.40.40.40.7
q2 RCT, Non-responder0.61.00.60.90.70.3
q2 RCT, Responder0.40.40.00.10.10.1
q4 RCT Non-responder1.30.80.60.90.60.6
q4 RCT, Responder0.80.70.30.2.30.1

Gout Flare Incidence

Percentage of participants remaining in the study during the specified interval who experienced a gout flare during this interval. (NCT01356498)
Timeframe: Assessed in 3-month intervals up to 2 years

,,,,,
InterventionPercentage of participants (Number)
Months 1-3Months 4-6Months 7-9Months 10-12Months 16-18Months 22-24
Placebo in RCT, q2 in OLE65.245.043.828.618.227.3
Placebo in RCT, q4 in OLE68.838.522.228.620.033.3
q2 RCT, Non-responder45.535.027.847.133.325.0
q2 RCT, Responder25.723.53.09.46.53.4
q4 RCT Non-responder67.950.042.945.038.955.6
q4 RCT, Responder56.040.024.016.725.05.3

Patient Reported Outcome: SF-36 Physical Component Summary Score

"SF-36 is the Medical Outcomes Survey Short Form-36, a 36-item self-reported questionnaire which assesses health-related limitations in 8 dimensions. The Physical Component Summary Score (PCS) is a composite summary score derived from the dimensions related to physical functioning outcomes: Physical Function, Role Physical, General Health and Bodily Pain (each with a 0 to 100 scale where 0=worst, 100=best).~The Summary Score is constructed as a T-score with a mean of 50 and standard deviation of 10, where higher scores indicate a better health status." (NCT01356498)
Timeframe: RCT Week 25; OLE Week 25; OLE Week 53, OLE Week 77, OLE Week 101

,,,,,
Interventionunits on a scale (Mean)
Baseline value (pre-pegloticase)Final Visit value (LOCF)
Placebo in RCT, q2 in OLE27.5530.34
Placebo in RCT, q4 in OLE36.238.8
q2 RCT, Non-responder33.7137.68
q2 RCT, Responder34.9240.40
q4 RCT Responder34.1140.82
q4 RCT, Non-responder32.834.76

Tophus Response

Target tophi evaluated during the randomized, controlled study were followed for response at 3, 6, 12, 18 and 24 months in this open-label extention study. Results from each participant's final assessment on drug are reported (as last observation carried forward). Complete response=complete disappearance of at least one tophus with no new or worsening tophus. Partial Response=a 50% or more decrease in at least one tophus with no new or worsening tophus. (NCT01356498)
Timeframe: Up to 2 years

,,,,,
Interventionparticipants (Number)
Complete ResponsePartial Response
Placebo in RCT, q2 in OLE103
Placebo in RCT, q4 in OLE31
q2 RCT, Non-responder44
q2 RCT, Responder194
q4 RCT Non-responder72
q4 RCT, Responder130

Uric Acid (mg/dL)

Uric acid measured at 3 month-intervals (NCT01356498)
Timeframe: Week 13, Week 25, Week 53, Week 101

,,,,,
Interventionmg/dL (Mean)
OLE Week 13OLE Week 25OLE Week 53OLE Week 101
Placebo in RCT, q2 in OLE5.064.692.74.29
Placebo in RCT, q4 in OLE8.088.096.458.5
q2 RCT, Non-responder9.768.899.187.7
q2 RCT, Responder1.331.40.870.84
q4 RCT Non-responder9.669.949.599.42
q4 RCT, Responder1.911.951.551.47

Number of Gout Flare Days Per Participant From Day 1 to Day 113 (Week 16)

Gout flare was defined as acute articular pain typical of a gout attack that required treatment with an anti-inflammatory therapeutic: had at least 3 of the following 4 signs or symptoms: joint swelling, tenderness, redness, and pain, and with at least 1 of the following: rapid onset of pain, decreased range of motion, joint warmth or other symptoms similar to a prior gout flare. Number of gout flare days per participant was reported for this outcome measure. (NCT00958438)
Timeframe: Day 1 to Day 113 (Week 16)

InterventionGout flare days (Mean)
Placebo11.7
Rilonacept 80 mg4.30
Rilonacept 160 mg1.86

Number of Gout Flare Days With Participant's Pain Score of 5 or More (From Daily Diary) Per Participant From Day 1 to Day 113 (Week 16)

Participants were asked to complete a telephone diary by calling the IVRS daily beginning at the baseline visit (Day 1) through the follow-up visit (Day 141) and reported their general well-being, gout symptoms, and weekly study drug administrations. At the onset of pain from a gout flare, participants were to answer additional diary questions regarding their gout flare and had to continue daily flare assessments until they reported the flare had ended. If a flare occurred just prior to the follow-up visit (Day 141), participants were to continue completing the daily diary until the flare resolved. Gout flare pain was assessed on a scale from 0 to 10 (with 0=no pain and 10=severe pain) within the past 24 hours. (NCT00958438)
Timeframe: Day 1 to Day 113 (Week 16)

InterventionGout flare days (Mean)
Placebo4.28
Rilonacept 80 mg1.67
Rilonacept 160 mg0.88

Number of Gout Flares Per Participant Assessed From Day 1 to Day 113 (Week 16)

Gout flare was defined as acute articular pain typical of a gout attack that required treatment with an anti-inflammatory therapeutic: had at least 3 of the following 4 signs or symptoms: joint swelling, tenderness, redness, and pain and with at least 1 of the following: rapid onset of pain, decreased range of motion, joint warmth or other symptoms similar to a prior gout flare. Number of gout flares per participant was reported for this outcome measure. (NCT00958438)
Timeframe: Day 1 to Day 113 (Week 16)

InterventionGout flares (Mean)
Placebo1.23
Rilonacept 80 mg0.35
Rilonacept 160 mg0.34

Number of Modified Gout Flares Per Participant From Day 1 to Day 113 (Week 16)

Modified gout flare was defined using modified definition of a gout flare as participant-reported articular pain typical of a gout attack that was deemed to require treatment with anti-inflammatory therapy. Number of modified gout flares per participant were reported for this outcome measure. (NCT00958438)
Timeframe: Day 1 to Day 113 (Week 16)

InterventionGout flares (Mean)
Placebo1.51
Rilonacept 80 mg0.62
Rilonacept 160 mg0.48

Percentage of Participants With at Least One Flare From Day 1 to Day 113 (Week 16)

Gout flare was defined as acute articular pain typical of a gout attack that required treatment with an anti-inflammatory therapeutic: had at least 3 of the following 4 signs or symptoms: joint swelling, tenderness, redness, and pain; and with at least 1 of the following: rapid onset of pain, decreased range of motion, joint warmth or other symptoms similar to a prior gout flare. Percentage of participants with at least one gout flare was reported for this outcome measure. (NCT00958438)
Timeframe: Day 1 to Day 113 (Week 16)

Interventionpercentage of participants (Number)
Placebo56.1
Rilonacept 80 mg25.6
Rilonacept 160 mg20.5

Percentage of Participants With at Least Two Flares From Day 1 to Day 113 (Week 16)

Gout flare was defined as acute articular pain typical of a gout attack that required treatment with an anti-inflammatory therapeutic: had at least 3 of the following 4 signs or symptoms: joint swelling, tenderness, redness, and pain, and with at least 1 of the following: rapid onset of pain, decreased range of motion, joint warmth or other symptoms similar to a prior gout flare. Percentage of participants with at least two gout flares was reported for this outcome measure. (NCT00958438)
Timeframe: Day 1 to Day 113 (Week 16)

Interventionpercentage of participants (Number)
Placebo32.9
Rilonacept 80 mg8.5
Rilonacept 160 mg6.0

Number of Gout Flare Days Per Participant From Day 1 to Day 112 (Week 16)

A gout flare was defined as participant reported acute articular pain typical of a gout attack that required treatment with an anti-inflammatory therapeutic: had at least 3 of the following 4 signs or symptoms: joint swelling, tenderness, redness, and pain and with at least 1 of the following: rapid onset of pain, decreased range of motion, joint warmth or other symptoms similar to a prior gout flare. Number of gout flares per participant was reported for this outcome measure. Flare days were counted up to Week 16, regardless of whether or not the flares occurred during the treatment period. (NCT00856206)
Timeframe: Day 1 to Day 112 (Week 16)

InterventionGout flare Days (Mean)
Placebo7.66
Rilonacept 160 mg2.66

Number of Gout Flares Per Participant Assessed From Day 1 to Day 112 (Week 16)

A gout flare was defined as participant reported acute articular pain typical of a gout attack that required treatment with an anti-inflammatory therapeutic: had at least 3 of the following 4 signs or symptoms: joint swelling, tenderness, redness, and pain and with at least 1 of the following: rapid onset of pain, decreased range of motion, joint warmth or other symptoms similar to a prior gout flare. Number of gout flares per participant was reported for this outcome measure. For drop-outs, only flares occurred before Day 112 were counted, regardless whether the flares occurred during the treatment period or not. (NCT00856206)
Timeframe: Day 1 to Day 112 (Week 16)

InterventionGout flares (Mean)
Placebo1.73
Rilonacept 160 mg0.51

Percentage of Participants With at Least One Flare From Day 1 to Day 112 (Week 16)

A gout flare was defined as participant reported acute articular pain typical of a gout attack that required treatment with an anti-inflammatory therapeutic: had at least 3 of the following 4 signs or symptoms: joint swelling, tenderness, redness, and pain and with at least 1 of the following: rapid onset of pain, decreased range of motion, joint warmth or other symptoms similar to a prior gout flare. Percentage of participants with at least one gout flare was reported for this outcome measure. For drop-outs, only flares occurred before Day 112 were counted, regardless whether the flares occurred during the treatment period or not. (NCT00856206)
Timeframe: Day 1 to Day 112 (Week 16)

Interventionpercentage of participants (Number)
Placebo51.1
Rilonacept 160 mg25.7

Percentage of Participants With at Least Two Flares From Day 1 to Day 112 (Week 16)

A gout flare was defined as participant reported acute articular pain typical of a gout attack that required treatment with an anti-inflammatory therapeutic: had at least 3 of the following 4 signs or symptoms: joint swelling, tenderness, redness, and pain and with at least 1 of the following: rapid onset of pain, decreased range of motion, joint warmth or other symptoms similar to a prior gout flare. Percentage of participants with at least two gout flare was reported for this outcome measure. For drop-outs, only flares occurred before Day 112 were counted, regardless whether the flares occurred during the treatment period or not. (NCT00856206)
Timeframe: Day 1 to Day 112 (Week 16)

Interventionpercentage of participants (Number)
Placebo34.7
Rilonacept 160 mg11.7

Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)

Any untoward medical occurrence in a participant who received investigational medicinal product (IMP) was considered an AE without regard to possibility of causal relationship with this treatment. Treatment-emergent adverse events (TEAEs) were defined as AEs that developed or worsened or became serious during on-treatment period (time from the administration of first dose of study drug up to 35 days after the last dose of study drug). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs. (NCT00856206)
Timeframe: Baseline up to Week 20

,
Interventionpercentage of participants (Number)
With at least 1 TEAEWith TEAEs related to study drugWith serious TEAEsWith TEAEs resulting in drug withdrawalWith serious TEAEs resulting in drug withdrawalWith TEAEs leading to study discontinuationWith serious TEAE leading to study discontinuationTreatment emergent deaths
Placebo59.113.03.93.31.83.01.50.3
Rilonacept 160 mg66.627.53.15.01.14.71.00.2

Absolute Change in the Serum Urate Level at the Final Visit Relative to Baseline

(NCT02082769)
Timeframe: Baseline and Final Visit (up to 26 weeks)

Interventionumol/l (Mean)
Febuxostat 40 mg QD182.2
Febuxostat 80 mg QD216.0
Allopurinol 100mg QD170.4

Percentage of Subjects Whose Last Three Serum Urate Levels Are <6.0 Milligram Per Deciliter (mg/dL)

(NCT02082769)
Timeframe: Last 3 visits (any last 3 visits up to week 26)

Interventionpercentage of participants (Number)
Febuxostat 40 mg QD22.5
Febuxostat 80 mg QD33.5
Allopurinol 100mg QD17.0

Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Final Visit

(NCT02082769)
Timeframe: Final Visit (up to 26 weeks)

Interventionpercentage of participants (Number)
Febuxostat 40 mg QD45.0
Febuxostat 80 mg QD58.9
Allopurinol 100mg QD34.6

Change in the Total Number of Tophi at Final Visit in the Subset of Subjects With Palpable Tophi at the Screening Visit

Change in number of tophi/subject was calculated for the subset of subjects with palpable tophi at the Screening. If the tophi were not palpable at the Final Visit, total count was assumed to be 0. The timing of the final visit may have differed for each subject. (NCT00174915)
Timeframe: Final Visit (up to 28 weeks)

Interventionnumber of tophi (Median)
Febuxostat 80 mg QD0.0
Febuxostat 120 mg QD0.0
Febuxostat 240 mg QD0.0
Allopurinol QD0.0
Placebo QD0.0

Change in the Total Number of Tophi at Week 28 in the Subset of Subjects With Palpable Tophi at the Screening Visit.

Change from baseline at Week 28 in the total number of tophi per subject was calculated for the subset of subjects with palpable tophi at the Screening Visit. If the tophi were not palpable at the Week 28 visit, the total count was assumed to be 0. (NCT00174915)
Timeframe: Baseline and Week 28

Interventionnumber of tophi (Median)
Febuxostat 80 mg QD0.0
Febuxostat 120 mg QD0.0
Febuxostat 240 mg QD0.0
Allopurinol QD0.0
Placebo QD0.0

Percent Change From Baseline in Serum Urate Levels at Final Visit

The percent change in serum urate from baseline to the Final visit was summarized. The percent change in serum urate was calculated as [(Final visit - baseline levels)/baseline]*100. The final visit was the last visit at which a serum urate value was collected. The timing of the final visit may have differed for each subject. (NCT00174915)
Timeframe: Baseline and Final Visit (up to 28 weeks)

InterventionPercent change (Mean)
Febuxostat 80 mg QD-45.2
Febuxostat 120 mg QD-51.9
Febuxostat 240 mg QD-66.3
Allopurinol QD-33.7
Placebo QD-3.0

Percent Change From Baseline in Serum Urate Levels at Week 28.

Serum urate values were obtained at the Week 28 visit. The percent change in serum urate was calculated as [(Week 28 - baseline levels)/baseline]*100 and summarized. (NCT00174915)
Timeframe: Baseline and Week 28

InterventionPercent change (Mean)
Febuxostat 80 mg QD-47.6
Febuxostat 120 mg QD-54.9
Febuxostat 240 mg QD-67.8
Allopurinol QD-34.4
Placebo QD-3.6

Percent Change in Primary Tophus Size at Final Visit, as Determined by Physical Measurement in the Subset of Subjects With Palpable Tophi at the Screening Visit.

Percent change in primary tophus size was calculated as [(Final Visit - baseline sizes)/baseline]*100 for the subset of subjects with a primary palpable tophus at Screening. If tophus was not palpable at Final visit, the size was assumed to be 0. The timing of the final visit may have differed for each subject. (NCT00174915)
Timeframe: Baseline and Final Visit (up to 28 weeks)

Interventionpercent change from baseline (Median)
Febuxostat 80 mg QD-33.8
Febuxostat 120 mg QD-42.4
Febuxostat 240 mg QD-47.0
Allopurinol QD-22.6
Placebo QD-40.3

Percent Change in Primary Tophus Size at Week 28, as Determined by Physical Measurement in the Subset of Subjects With Palpable Tophi at the Screening Visit.

The percent change from baseline in primary tophus size as determined by physical measurement was calculated as [(Week 28 - baseline sizes)/baseline]*100 for the subset of subjects with a primary palpable tophus at the Screening Visit. If the primary tophus was no longer palpable at the Week 28 visit, the size was assumed to be zero. (NCT00174915)
Timeframe: Baseline and Week 28

Interventionpercent change from baseline (Median)
Febuxostat 80 mg QD-45.6
Febuxostat 120 mg QD-54.2
Febuxostat 240 mg QD-53.2
Allopurinol QD-31.5
Placebo QD-52.0

Percentage of Subjects Requiring Treatment for a Gout Flare Between Weeks 8 and 28 of the Double-Blind Treatment Period.

Percentage of subjects requiring treatment for a gout flare between Weeks 8 and 28 of the double-blind treatment period was summarized. A subject who reported more than 1 gout flare during this period was counted only once. (NCT00174915)
Timeframe: Weeks 8 through 28

Interventionpercentage of subjects (Number)
Febuxostat 80 mg QD55
Febuxostat 120 mg QD54
Febuxostat 240 mg QD57
Allopurinol QD46
Placebo QD52

Percentage of Subjects Whose Last Three Serum Urate Levels Are <6.0 Milligram Per Deciliter (mg/dL).

Each subject's serum urate at the last 3 visits determined the subject's response for the primary efficacy variable. A subject who prematurely discontinued without least 3 postbaseline serum urate levels was considered a nonresponder; if at least 3 serum urate were obtained postbaseline, those 3 visits were used. The last 3 visits used may have differed for each subject. (NCT00174915)
Timeframe: Last 3 visits (any last 3 visits up to week 28)

InterventionPercentage of subjects (Number)
Febuxostat 80 mg QD48
Febuxostat 120 mg QD65
Febuxostat 240 mg QD69
Allopurinol QD22
Placebo QD0

Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Final Visit

The percentage of subjects whose serum urate was <6.0 mg/dL at the final visit was summarized. The final visit was the last visit at which a serum urate value was collected and may have differed by subject. (NCT00174915)
Timeframe: Final Visit (up to 28 weeks).

InterventionPercentage of subjects (Number)
Febuxostat 80 mg QD72
Febuxostat 120 mg QD79
Febuxostat 240 mg QD92
Allopurinol QD39
Placebo QD1

Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Week 28

Serum urate values were obtained at the Week 28 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Week 28 visit was summarized. (NCT00174915)
Timeframe: Week 28

InterventionPercentage of subjects (Number)
Febuxostat 80 mg QD76
Febuxostat 120 mg QD87
Febuxostat 240 mg QD94
Allopurinol QD41
Placebo QD1

Feasibility of Using IVR vs. RheumPRO to Report Gout Flares

Feasibility ----Assessed by the percentage of participants completing answer IRV/RheumPRO queries. (NCT02855437)
Timeframe: 6 months

Interventionpercentage of weekly response (Mean)
Interactive Voice Response81
RheumPro Smartphone Application80

Preference IVR vs RheumPRO

Percentage of total study population preferring IVR vs. RheumPRO (NCT02855437)
Timeframe: 6 months

InterventionParticipants (Count of Participants)
Interactive Voice Response3
RheumPro Smartphone Application28

Percent Change in Serum Urate Levels From Baseline at Final Visit.

The percent change in serum urate from baseline to the final visit was summarized. The final visit was the last visit at which a serum urate value was collected. (NCT00174941)
Timeframe: Baseline and Last Visit on treatment (up to 66 months).

Interventionpercent change from baseline (Mean)
Febuxostat 40 mg QD-49.2
Febuxostat 80 mg QD-47.1
Febuxostat 120 mg QD-50.7
Total Febuxostat-48.1

Percent Change in Serum Urate Levels From Baseline at Month 12 Visit.

Serum urate values were obtained at the Month 12 visit. The percent change in serum urate from baseline to the Month 12 visit was summarized. (NCT00174941)
Timeframe: Baseline and Month 12

Interventionpercentage of subjects (Mean)
Febuxostat 40 mg QD-35.0
Febuxostat 80 mg QD-49.7
Febuxostat 120 mg QD-49.3
Total Febuxostat-48.3

Percent Change in Serum Urate Levels From Baseline at Month 18 Visit.

Serum urate values were obtained at the Month 18 visit. The percent change in serum urate from baseline to the Month 18 visit was summarized. (NCT00174941)
Timeframe: Baseline and Month 18

Interventionpercent change from baseline (Mean)
Febuxostat 40 mg QD-35.5
Febuxostat 80 mg QD-48.7
Febuxostat 120 mg QD-39.5
Total Febuxostat-45.4

Percent Change in Serum Urate Levels From Baseline at Month 24 Visit.

Serum urate values were obtained at the Month 24 visit. The percent change in serum urate from baseline to the Month 24 visit was summarized. (NCT00174941)
Timeframe: Baseline and Month 24

Interventionpercent change from baseline (Mean)
Febuxostat 40 mg QD-38.9
Febuxostat 80 mg QD-46.7
Febuxostat 120 mg QD-54.7
Total Febuxostat-47.3

Percent Change in Serum Urate Levels From Baseline at Month 36 Visit.

Serum urate values were obtained at the Month 36 visit. The percent change in serum urate from baseline to the Month 36 visit was summarized. (NCT00174941)
Timeframe: Baseline and Month 36

Interventionpercent change from baseline (Mean)
Febuxostat 40 mg QD-43.0
Febuxostat 80 mg QD-46.9
Febuxostat 120 mg QD-56.4
Total Febuxostat-48.4

Percent Change in Serum Urate Levels From Baseline at Month 48 Visit.

Serum urate values were obtained at the Month 48 visit. The percent change in serum urate from baseline to the Month 48 visit was summarized. (NCT00174941)
Timeframe: Baseline and Month 48

Interventionpercent change from baseline (Mean)
Febuxostat 40 mg QD-50.0
Febuxostat 80 mg QD-50.3
Febuxostat 120 mg QD-53.8
Total Febuxostat-51.1

Percent Change in Serum Urate Levels From Baseline at Month 6 Visit.

Serum urate values were obtained at the Month 6 visit. The percent change in serum urate from baseline to the Month 6 visit was summarized. (NCT00174941)
Timeframe: Baseline and Month 6

Interventionpercent change from baseline (Mean)
Febuxostat 40 mg QD-35.9
Febuxostat 80 mg QD-50.6
Febuxostat 120 mg QD-47.6
Total Febuxostat-48.3

Percent Change in Serum Urate Levels From Baseline at Month 60 Visit.

The secondary outcome was the mean percent change from baseline to Month 60 visit as assessed by serum urate levels collected at baseline and at the Month 60 visit by dose at observation. (NCT00174941)
Timeframe: Baseline and Month 60

Interventionpercent change from baseline (Mean)
Febuxostat 40 mg QD-45.5
Febuxostat 80 mg QD-51.1
Febuxostat 120 mg QD-59.0
Total Febuxostat-52.0

Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Final Visit.

The percentage of subjects whose serum urate was <6.0 mg/dL at the final visit was summarized. The final visit was the last visit at which a serum urate value was collected. (NCT00174941)
Timeframe: Last Visit on treatment (up to 66 months).

Interventionpercentage of subjects (Number)
Febuxostat 40 mg QD100
Febuxostat 80 mg QD82
Febuxostat 120 mg QD81
Total Febuxostat83

Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 12 Visit.

Serum urate values were obtained at the Month 12 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 12 visit was summarized. (NCT00174941)
Timeframe: Month 12

Interventionpercentage of subjects (Number)
Febuxostat 40 mg QD57
Febuxostat 80 mg QD85
Febuxostat 120 mg QD67
Total Febuxostat79

Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 18 Visit.

Serum urate values were obtained at the Month 18 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 18 visit was summarized. (NCT00174941)
Timeframe: Month 18

Interventionpercentage of subjects (Number)
Febuxostat 40 mg QD50
Febuxostat 80 mg QD82
Febuxostat 120 mg QD57
Total Febuxostat74

Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 24 Visit.

Serum urate values were obtained at the Month 24 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 24 visit was summarized. (NCT00174941)
Timeframe: Month 24

Interventionpercentage of subjects (Number)
Febuxostat 40 mg QD63
Febuxostat 80 mg QD76
Febuxostat 120 mg QD92
Total Febuxostat77

Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 36 Visit.

Serum urate values were obtained at the Month 36 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 36 visit was summarized. (NCT00174941)
Timeframe: Month 36

Interventionpercentage of subjects (Number)
Febuxostat 40 mg QD67
Febuxostat 80 mg QD84
Febuxostat 120 mg QD92
Total Febuxostat84

Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 48 Visit.

Serum urate values were obtained at the Month 48 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 48 visit was summarized. (NCT00174941)
Timeframe: Month 48

Interventionpercentage of subjects (Number)
Febuxostat 40 mg QD83
Febuxostat 80 mg QD92
Febuxostat 120 mg QD85
Total Febuxostat90

Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 6 Visit.

Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 6 visit was summarized. (NCT00174941)
Timeframe: Month 6

Interventionpercentage of subjects (Number)
Febuxostat 40 mg QD50
Febuxostat 80 mg QD93
Febuxostat 120 mg QD65
Total Febuxostat82

Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 60 Visit.

Serum urate values were obtained at the Month 60 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 60 visit was summarized. (NCT00174941)
Timeframe: Month 60

Interventionpercentage of subjects (Number)
Febuxostat 40 mg QD100
Febuxostat 80 mg QD93
Febuxostat 120 mg QD91
Total Febuxostat93

Percent Change From Baseline in Primary Tophus Size at Final Visit for Subjects With Palpable Tophi Measured at Baseline.

The area of the primary tophus was calculated based on the length and width of the tophus measured at baseline and final visit. The percent change from baseline in primary tophus size to the final visit was summarized. (NCT00175019)
Timeframe: Final Visit (up to 40 months).

Interventionpercent change from baseline (Median)
Febuxostat 80 mg QD-96
Febuxostat 120 mg QD-84
Allopurinol QD-67

Percent Change From Baseline in Primary Tophus Size at Month 12 for Subjects With Palpable Tophi Measured at Baseline.

The area of the primary tophus was calculated based on the length and width of the tophus measured at the Month 12 visit. The percent change from baseline in primary tophus size to the Month 12 visit was summarized. (NCT00175019)
Timeframe: Month 12

Interventionpercent change from baseline (Median)
Febuxostat 80 mg QD-82
Febuxostat 120 mg QD-79
Allopurinol QD-56

Percent Change From Baseline in Primary Tophus Size at Month 24 for Subjects With Palpable Tophi Measured at Baseline.

The area of the primary tophus was calculated based on the length and width of the tophus measured at baseline and Month 24 visit. The percent change from baseline in primary tophus size to the Month 24 visit was summarized. (NCT00175019)
Timeframe: Month 24

Interventionpercent change from baseline (Median)
Febuxostat 80 mg QD-100
Febuxostat 120 mg QD-96
Allopurinol QD-87

Percent Change From Baseline in Primary Tophus Size at Month 36 for Subjects With Palpable Tophi Measured at Baseline.

The area of the primary tophus was calculated based on the length and width of the tophus measured at baseline and Month 36 visit. The percent change from baseline in primary tophus size to the Month 36 visit was summarized. (NCT00175019)
Timeframe: Month 36

Interventionpercent change from baseline (Median)
Febuxostat 80 mg QD-83

Percent Change From Baseline in the Total Number of Tophi for Subjects With Palpable Tophi at Final Visit.

The number of tophi were counted at baseline and final visits. The percent change from baseline in the number of tophi to the final visit was summarized. (NCT00175019)
Timeframe: Final Visit (up to 40 months).

Interventionpercent change from baseline (Mean)
Febuxostat 80 mg QD-59.9
Febuxostat 120 mg QD-58.3
Allopurinol QD-48.7

Percent Change in Serum Urate Levels From Baseline to the Last Visit on Treatment.

The percent change in serum urate from baseline to the last visit on treatment was summarized. The last visit on treatment was the last visit at which a serum urate value was collected prior to any changes in drug and/or dose from the initial treatment assignment. (NCT00175019)
Timeframe: Last Visit on treatment (up to 40 months).

Interventionpercent change from baseline (Mean)
Febuxostat 80 mg QD-46.69
Febuxostat 120 mg QD-52.99
Allopurinol QD-32.17

Percentage of Subjects Requiring Treatment for Gout Flare After Month 12.

The percentage of subjects requiring treatment for gout flare after the first 12 months of final stable treatment was summarized. (NCT00175019)
Timeframe: After Month 12 to Final Visit

Interventionpercentage of subjects (Number)
Febuxostat 80 mg QD15.3
Febuxostat 120 mg QD19.8
Allopurinol QD23.2

Percentage of Subjects Requiring Treatment for Gout Flare up to Month 12.

The percentage of subjects requiring treatment for gout flare during the first twelve months of final stable treatment was summarized. (NCT00175019)
Timeframe: Month 12

Interventionpercentage of subjects (Number)
Febuxostat 80 mg QD29.4
Febuxostat 120 mg QD42.5
Allopurinol QD28.3

Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Last Visit on Treatment.

The percentage of subjects whose serum urate was <6.0 mg/dL at the last visit on treatment was summarized. The last visit on treatment was the last visit at which a serum urate value was collected prior to any changes in drug and/or dose from the initial treatment assignment. (NCT00175019)
Timeframe: Last Visit on treatment (up to 40 months).

Interventionpercentage of subjects (Number)
Febuxostat 80 mg QD70.8
Febuxostat 120 mg QD82.0
Allopurinol QD32.6

Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 1.

Serum urate values were obtained at the Month 1 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 1 visit was summarized. (NCT00175019)
Timeframe: Month 1

Interventionpercentage of subjects (Number)
Febuxostat 80 mg QD80.8
Febuxostat 120 mg QD87.0
Allopurinol QD46.0

Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 12.

Serum urate values were obtained at the Month 12 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 12 visit was summarized. (NCT00175019)
Timeframe: Month 12

Interventionpercentage of subjects (Number)
Febuxostat 80 mg QD88.9
Febuxostat 120 mg QD86.3
Allopurinol QD82.2

Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 24.

Serum urate values were obtained at the Month 24 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 24 visit was summarized. (NCT00175019)
Timeframe: Month 24

Interventionpercentage of subjects (Number)
Febuxostat 80 mg QD89.3
Febuxostat 120 mg QD87.2
Allopurinol QD78.6

Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 36.

Serum urate values were obtained at the Month 36 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 36 visit was summarized. (NCT00175019)
Timeframe: Month 36

Interventionpercentage of subjects (Number)
Febuxostat 80 mg QD90.8
Febuxostat 120 mg QD91.5
Allopurinol QD90.0

Mean Percent Change From Baseline in Serum Urate Levels at Final Visit.

The percent change in serum urate from baseline to the Final visit was summarized. The final visit was the last visit at which a serum urate value was collected. (NCT00430248)
Timeframe: Baseline and Last Visit on treatment (up to 6 months)

Interventionpercent change from baseline (Mean)
Febuxostat 40 mg QD-33.1
Febuxostat 80 mg QD-40.6
Allopurinol 200 mg or 300 mg QD-31.3

Mean Percent Change From Baseline in Serum Urate Levels at Month 2 Visit.

Serum urate values were obtained at the Month 2 visit. The percent change in serum urate from baseline to the Month 2 visit was summarized. (NCT00430248)
Timeframe: Baseline and Month 2

Interventionpercent change from baseline (Mean)
Febuxostat 40 mg QD-35.1
Febuxostat 80 mg QD-44.5
Allopurinol 200 mg or 300 mg QD-33.8

Mean Percent Change From Baseline in Serum Urate Levels at Month 4 Visit

Serum urate values were obtained at the Month 4 visit. The percent change in serum urate from baseline to the Month 4 visit was summarized. (NCT00430248)
Timeframe: Baseline and Month 4

Interventionpercent change from baseline (Mean)
Febuxostat 40 mg QD-34.9
Febuxostat 80 mg QD-45.5
Allopurinol 200 mg or 300 mg QD-34.5

Mean Percent Change From Baseline in Serum Urate Levels at Month 6 Visit.

Serum urate values were obtained at the Month 6 visit. The percent change in serum urate from baseline to the Month 6 visit was summarized. (NCT00430248)
Timeframe: Baseline and Month 6

Interventionpercent change from baseline (Mean)
Febuxostat 40 mg QD-35.6
Febuxostat 80 mg QD-45.1
Allopurinol 200 mg or 300 mg QD-34.4

Percentage of Renal Impairment Subjects Whose Final Visit Serum Urate Level is <6.0 mg/dl

The percentage of subjects with mild-to-moderate renal impairment whose serum urate was <6.0 mg/dL at the final visit was summarized. The final visit was the last visit at which a serum urate value was collected. (NCT00430248)
Timeframe: Last Visit on treatment (up to 6 months)

Interventionpercentage of subjects (Number)
Febuxostat 40 mg QD49.7
Febuxostat 80 mg QD71.6
Allopurinol 200 mg or 300 mg QD42.3

Percentage of Subjects Whose Serum Urate Level is <6.0 Milligrams Per Deciliter (mg/dL) at the Final Visit.

The percentage of subjects whose serum urate level was <6.0 mg/dL at the Final Visit was summarized. The Final Visit was the last visit at which a serum urate value was collected. (NCT00430248)
Timeframe: Last Visit on treatment (up to 6 months)

Interventionpercentage of subjects (Number)
Febuxostat 40 mg QD45.2
Febuxostat 80 mg QD67.1
Allopurinol 200 mg or 300 mg QD42.1

Percentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Final Visit

The percentage of subjects whose serum urate level was <4.0 mg/dL at the Final Visit was summarized. The Final Visit was the last visit at which a serum urate values was collected. (NCT00430248)
Timeframe: Last Visit on treatment (up to 6 months)

Interventionpercentage of subjects (Number)
Febuxostat 40 mg QD2.5
Febuxostat 80 mg QD17.5
Allopurinol 200 mg or 300 mg QD1.5

Percentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Month 2 Visit

Serum urate values were obtained at the Month 2 visit. The percentage of subjects whose serum urate was <4.0 mg/dL at the Month 2 visit was summarized. (NCT00430248)
Timeframe: Month 2

Interventionpercentage of subjects (Number)
Febuxostat 40 mg QD2.1
Febuxostat 80 mg QD17.5
Allopurinol 200 mg or 300 mg QD1.5

Percentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Month 4 Visit

Serum urate values were obtained at the Month 4 visit. The percentage of subjects whose serum urate was <4.0 mg/dL at the Month 4 visit was summarized. (NCT00430248)
Timeframe: Month 4

Interventionpercentage of subjects (Number)
Febuxostat 40 mg QD2.0
Febuxostat 80 mg QD18.6
Allopurinol 200 mg or 300 mg QD1.4

Percentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Month 6 Visit

Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was <4.0 mg/dL at the Month 6 visit was summarized. (NCT00430248)
Timeframe: Month 6

Interventionpercentage of subjects (Number)
Febuxostat 40 mg QD3.1
Febuxostat 80 mg QD20.3
Allopurinol 200 mg or 300 mg QD1.8

Percentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Final Visit.

The percentage of subjects whose serum urate level was <5.0 mg/dL at the Final Visit was summarized. The Final Visit was the last visit at which a serum urate values was collected. (NCT00430248)
Timeframe: Last Visit on treatment (up to 6 months)

Interventionpercentage of subjects (Number)
Febuxostat 40 mg QD16.5
Febuxostat 80 mg QD44.0
Allopurinol 200 mg or 300 mg QD13.2

Percentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Month 2 Visit.

Serum urate values were obtained at the Month 2 visit. The percentage of subjects whose serum urate was <5.0 mg/dL at the Month 2 visit was summarized. (NCT00430248)
Timeframe: Month 2

Interventionpercentage of subjects (Number)
Febuxostat 40 mg QD15.4
Febuxostat 80 mg QD45.9
Allopurinol 200 mg or 300 mg QD11.7

Percentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Month 4 Visit.

Serum urate values were obtained at the Month 4 visit. The percentage of subjects whose serum urate was <5.0 mg/dL at the Month 4 visit was summarized. (NCT00430248)
Timeframe: Month 4

Interventionpercentage of subjects (Number)
Febuxostat 40 mg QD15.0
Febuxostat 80 mg QD51.6
Allopurinol 200 mg or 300 mg QD13.5

Percentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Month 6 Visit.

Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was <5.0 mg/dL at the Month 6 visit was summarized. (NCT00430248)
Timeframe: Month 6

Interventionpercentage of subjects (Number)
Febuxostat 40 mg QD19.3
Febuxostat 80 mg QD49.7
Allopurinol 200 mg or 300 mg QD14.8

Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Month 2 Visit.

Serum urate values were obtained at the Month 2 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 2 visit was summarized. (NCT00430248)
Timeframe: Month 2

Interventionpercentage of subjects (Number)
Febuxostat 40 mg QD49.1
Febuxostat 80 mg QD74.1
Allopurinol 200 mg or 300 mg QD43.2

Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Month 4 Visit.

Serum urate values were obtained at the Month 4 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 4 visit was summarized. (NCT00430248)
Timeframe: Month 4

Interventionpercentage of subjects (Number)
Febuxostat 40 mg QD47.1
Febuxostat 80 mg QD75.2
Allopurinol 200 mg or 300 mg QD45.5

Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Month 6 Visit.

Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 6 visit was summarized. (NCT00430248)
Timeframe: Month 6

Interventionpercentage of participants (Number)
Febuxostat 40 mg QD48.9
Febuxostat 80 mg QD75.3
Allopurinol 200 mg or 300 mg QD46.6

Development of Antibodies to PEG-uricase

Number of patients who developed antibodies to PEG-uricase (NCT00111657)
Timeframe: baseline, then prior to infusions and 7 wks after last infusion

Interventionparticipants (Number)
Pegloticase15

Infusion 1: Maximum Concentration (Cmax) Value

The highest drug concentration in the blood after the first infusion of study drug. (NCT00111657)
Timeframe: 2 hours

InterventionmU/mL (Mean)
Single Arm - Pegloticase25.6

Infusion 1: Minimum Concentration (Cmin)

The lowest drug concentration in the blood after the first infusion of study drug. (NCT00111657)
Timeframe: 21 days after the infusion

InterventionmU/mL (Mean)
Single Arm - Pegloticase4.9

Reduction in Plasma Uric Acid to Less Than 6 mg/dL.

(NCT00111657)
Timeframe: Baseline to Day 105

InterventionParticipants (Number)
Single Arm17

Clinical Response: Number of Swollen and Tender Joints

Count of tenderness and swelling of 68 joints (NCT00111657)
Timeframe: Basline and day 134

Interventionjoints (Median)
Number of Tender joints at baselineNumber of Tender joints at day 134Number of Swollen jonts at baselineNumber of Swollen jonts at day 134
Pegloticase13296

Change From Baseline in Total Number of Tophi at Final Visit in Subjects With Palpable Tophi at Screening.

Change in number of tophi/subject calculated for the subset of subjects with palpable tophi at Screening. If the tophi were not palpable at the Final Visit, total count was assumed to be 0. The timing of the final visit may have differed for each subject. (NCT00102440)
Timeframe: Baseline and Final Visit (up to 52 weeks)

Interventionnumber of tophi (Median)
Febuxostat 80 mg QD0.0
Febuxostat 120 mg QD0.0
Allopurinol 300 mg QD0.0

Change From Baseline in Total Number of Tophi at Week 28 in Subjects With Palpable Tophi at Screening.

The change from baseline at Week 28 in the total number of tophi per subject was calculated for the subset of subjects with palpable tophi at the Screening Visit. If the tophi were no longer palpable at the Week 28 visit, the total count was assumed to be zero. (NCT00102440)
Timeframe: Baseline and Week 28

Interventionnumber of tophi (Median)
Febuxostat 80 mg QD0.0
Febuxostat 120 mg QD0.0
Allopurinol 300 mg QD0.0

Change From Baseline in Total Number of Tophi at Week 52 in Subjects With Palpable Tophi at Screening.

The change from baseline at Week 52 in the total number of tophi per subject was calculated for the subset of subjects with palpable tophi at the Screening Visit. If the tophi were no longer palpable at the Week 52 visit, the total count was assumed to be zero. (NCT00102440)
Timeframe: Baseline and Week 52

Interventionnumber of tophi (Median)
Febuxostat 80 mg QD0.0
Febuxostat 120 mg QD-1.0
Allopurinol 300 mg QD0.0

Percent Change From Baseline in Serum Urate Levels at Final Visit

The percent change in serum urate from baseline to the Final visit was calculated as [(Final Visit - baseline levels/baseline)]*100 and summarized. The Final visit was the last visit with a serum urate value. The timing of the final visit may have differed for each subject. (NCT00102440)
Timeframe: Baseline and Final Visit (up to 52 weeks)

Interventionpercent change from baseline (Mean)
Febuxostat 80 mg QD-44.7
Febuxostat 120 mg QD-51.5
Allopurinol 300 mg QD-33.0

Percent Change From Baseline in Serum Urate Levels at Week 28.

Serum urate values were obtained at the Week 28 visit. The percent change in serum urate was calculated as [(week 28 - baseline levels/baseline)]*100 and summarized. (NCT00102440)
Timeframe: Baseline and Week 28

Interventionpercent change from baseline (Mean)
Febuxostat 80 mg QD-46.3
Febuxostat 120 mg QD-53.5
Allopurinol 300 mg QD-34.8

Percent Change From Baseline in Serum Urate Levels at Week 52.

Serum urate values were obtained at the Week 52 visit. The percent change in serum urate was calculated as [(week 52 - baseline levels/baseline)]*100 and summarized. (NCT00102440)
Timeframe: Baseline and Week 52

Interventionpercent change from baseline (Mean)
Febuxostat 80 mg QD-47.7
Febuxostat 120 mg QD-53.0
Allopurinol 300 mg QD-34.8

Percent Change From Baseline in Tophus Size at Final Visit, as Determined by Physical Measurement, in Subjects With a Palpable Primary Tophus at Screening.

Percent change in primary tophus size was calculated as [(Final Visit - baseline sizes)/baseline]*100 for the subset of subjects with a primary palpable tophus at Screening. If tophus was not palpable at Final visit, the size was assumed to be 0. The timing of the final visit may have differed for each subject. (NCT00102440)
Timeframe: Baseline and Final Visit (up to 52 weeks)

Interventionpercent change from baseline (Median)
Febuxostat 80 mg QD-51.7
Febuxostat 120 mg QD-43.8
Allopurinol 300 mg QD-39.6

Percent Change From Baseline in Tophus Size at Week 28, as Determined by Physical Measurement, in Subjects With a Palpable Primary Tophus at Screening.

The percent change from baseline in primary tophus size as determined by physical measurement was calculated as [(Week 28 - baseline sizes)/baseline]*100 for the subset of subjects with a primary palpable tophus at the Screening Visit. If the primary tophus was no longer palpable at the Week 28 visit, the size was assumed to be zero. (NCT00102440)
Timeframe: Baseline and Week 28

Interventionpercent change from baseline (Median)
Febuxostat 80 mg QD-29.5
Febuxostat 120 mg QD-49.5
Allopurinol 300 mg QD-28.6

Percent Change From Baseline in Tophus Size at Week 52, as Determined by Physical Measurement, in Subjects With a Palpable Primary Tophus at Screening.

The percent change from baseline in primary tophus size as determined by physical measurement was calculated as [(Week 52 - baseline sizes)/baseline]*100 for the subset of subjects with a primary palpable tophus at the Screening Visit. If the primary tophus was no longer palpable at the Week 52 visit, the size was assumed to be zero. (NCT00102440)
Timeframe: Baseline and Week 52

Interventionpercent change from baseline (Median)
Febuxostat 80 mg QD-83.4
Febuxostat 120 mg QD-65.5
Allopurinol 300 mg QD-49.7

Percentage of Subjects Requiring Treatment for Gout Flares Between Weeks 8 and 52.

The percentage of subjects requiring treatment for a gout flare between Weeks 8 and 52 of the double-blind treatment period was summarized. A subject who reported more than 1 gout flare during this period was counted only once. (NCT00102440)
Timeframe: Weeks 8 through 52

Interventionpercentage of subjects (Number)
Febuxostat 80 mg QD64
Febuxostat 120 mg QD70
Allopurinol 300 mg QD64

Percentage of Subjects With Serum Urate <6.0 mg/dL at Final Visit

The percentage of subjects whose serum urate was <6.0 mg/dL at the final visit was summarized. The final visit was the last visit at which a serum urate value was collected. The timing of the final visit may have differed for each subject. (NCT00102440)
Timeframe: Final Visit (up to 52 weeks)

InterventionPercentage of subjects (Number)
Febuxostat 80 mg QD74
Febuxostat 120 mg QD80
Allopurinol 300 mg QD36

Percentage of Subjects With Serum Urate <6.0 mg/dL at Week 28 Visit

Serum urate values were obtained at the Week 28 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Week 28 visit was summarized. (NCT00102440)
Timeframe: Week 28

InterventionPercentage of subjects (Number)
Febuxostat 80 mg QD72
Febuxostat 120 mg QD82
Allopurinol 300 mg QD42

Percentage of Subjects With Serum Urate <6.0 mg/dL at Week 52 Visit

Serum urate values were obtained at the Week 52 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Week 52 visit was summarized. (NCT00102440)
Timeframe: Week 52

InterventionPercentage of subjects (Number)
Febuxostat 80 mg QD81
Febuxostat 120 mg QD82
Allopurinol 300 mg QD39

Percentage of Subjects With the Last 3 Serum Urate Levels <6.0 Milligrams Per Deciliter (mg/dL)

Each subject's serum urate at the last 3 visits determined the subject's response for the primary efficacy variable. A subject who prematurely discontinued without least 3 postbaseline serum urate levels was considered a nonresponder; if at least 3 serum urate were obtained postbaseline, those 3 visits were used. The last 3 visits used may have differed for each subject. (NCT00102440)
Timeframe: Last 3 Visits (up to 52 weeks)

InterventionPercentage of subjects (Number)
Febuxostat 80 mg QD53
Febuxostat 120 mg QD62
Allopurinol 300 mg QD21

Maximum Percent Change in Serum Urate Level From Baseline During the Entire Treatment Period.

Serum urate values were obtained at the Day 7, 14, 21,and 28 visits. The maximum percent change in serum urate levels obtained at any visit was summarized. (NCT00174967)
Timeframe: Baseline and Any visit (Day 7, 14, 21,or 28)

Interventionpercent change from baseline (Mean)
Febuxostat 40 mg QD42.5
Febuxostat 80 mg QD49.2
Febuxostat 120 mg QD62.8
Placebo QD10.0

Percent Change in 24-hour Urine Uric Acid Level From Baseline to Day 28.

24-hour urine uric acid levels were obtained at the Day 28 visit. The percent change in 24-hour urine uric acid level from baseline to the Day 28 visit was summarized. (NCT00174967)
Timeframe: Baseline and Day 28.

Interventionpercent change from baseline (Mean)
Febuxostat 40 mg QD-43.6
Febuxostat 80 mg QD-46.5
Febuxostat 120 mg QD-45.7
Placebo QD5.9

Percent Change in Serum Urate Levels From Baseline to the Day 14 Visit.

Serum urate values were obtained at the Day 14 visit. The percent change in serum urate from baseline to the Day 14 visit was summarized. (NCT00174967)
Timeframe: Baseline and Day 14.

Interventionpercent change from baseline (Mean)
Febuxostat 40 mg QD-37.1
Febuxostat 80 mg QD-41.8
Febuxostat 120 mg QD-56.9
Placebo QD1.62

Percent Change in Serum Urate Levels From Baseline to the Day 21 Visit

Serum urate values were obtained at the Day 21 visit. The percent change in serum urate from baseline to the Day 21 visit was summarized. (NCT00174967)
Timeframe: Baseline and Day 21.

Interventionpercent change from baseline (Mean)
Febuxostat 40 mg QD-37.3
Febuxostat 80 mg QD-43.9
Febuxostat 120 mg QD-59.4
Placebo QD-0.57

Percent Change in Serum Urate Levels From Baseline to the Day 28 Visit.

Serum urate values were obtained at the Day 28 visit. The percent change in serum urate from baseline to the Day 28 visit was summarized. (NCT00174967)
Timeframe: Baseline and Day 28.

Interventionpercent change from baseline (Mean)
Febuxostat 40 mg QD-36.6
Febuxostat 80 mg QD-44.3
Febuxostat 120 mg QD-59.1
Placebo QD-2.2

Percent Change in Serum Urate Levels From Baseline to the Day 7 Visit.

Serum urate values were obtained at the Day 7 visit. The percent change in serum urate from baseline to the Day 7 visit was summarized. (NCT00174967)
Timeframe: Baseline and Day 7.

Interventionpercent change from baseline (Mean)
Febuxostat 40 mg QD-35.0
Febuxostat 80 mg QD-39.2
Febuxostat 120 mg QD-53.44
Placebo QD0.71

Percentage of Subjects Whose Serum Urate Level Decreased to <6.0 mg/dL at the Day 14 Visit.

Serum urate values were obtained at the Day 14 visit. The percentage of subjects whose serum urate decreased to <6.0 mg/dL at the Day 14 visit was summarized. (NCT00174967)
Timeframe: Day 14.

Interventionpercentage of subjects (Number)
Febuxostat 40 mg QD56
Febuxostat 80 mg QD68
Febuxostat 120 mg QD94
Placebo QD0

Percentage of Subjects Whose Serum Urate Level Decreased to <6.0 mg/dL at the Day 21 Visit.

Serum urate values were obtained at the Day 21 visit. The percentage of subjects whose serum urate decreased to <6.0 mg/dL at the Day 21 visit was summarized. (NCT00174967)
Timeframe: Day 21.

Interventionpercentage of subjects (Number)
Febuxostat 40 mg QD59
Febuxostat 80 mg QD76
Febuxostat 120 mg QD97
Placebo QD0

Percentage of Subjects Whose Serum Urate Level Decreased to <6.0 mg/dL at the Day 7 Visit.

Serum urate values were obtained at the Day 7 visit. The percentage of subjects whose serum urate decreased to <6.0 mg/dL at the Day 7 visit was summarized. (NCT00174967)
Timeframe: Day 7.

Interventionpercentage of subjects (Number)
Febuxostat 40 mg QD50
Febuxostat 80 mg QD59
Febuxostat 120 mg QD91
Placebo QD3

Percentage of Subjects Whose Serum Urate Level Decreased to <6.0 Milligram Per Deciliter (mg/dL) at the Day 28 Visit.

Serum urate values were obtained at the Day 28 visit. The percentage of subjects whose serum urate decreased to <6.0 mg/dL at the Day 28 visit was summarized. (NCT00174967)
Timeframe: Day 28.

Interventionpercentage of subjects (Number)
Febuxostat 40 mg QD56
Febuxostat 80 mg QD76
Febuxostat 120 mg QD94
Placebo QD0

Number of Participants With Anaphylaxis

"Anaphylaxis was defined using the National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network (NIAID/FAAN) criteria: Acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal tissue, or both (e.g., generalized hives; pruritus or flushing; swollen lips, tongue, or uvula), and at least 1 of the following:~Respiratory compromise (e.g., dyspnea, wheeze-bronchospasm, stridor, reduced peak expiratory flow, hypoxemia).~Reduced blood pressure (i.e., systolic blood pressure < 90 mm Hg or greater than 30% decrease from that patient's baseline) or associated symptoms of end-organ failure (e.g., hypotonia [collapse], syncope, incontinence)." (NCT01466166)
Timeframe: 52 weeks

InterventionParticipants (Count of Participants)
Pegloticase5

Number of Participants With Immune Complex-related Events

Immune complex-related events were defined as any presumptive immune complex-related disorders that were confirmed by an appropriate investigation of the event and of complement markers (C3 and C4 levels). Clinical manifestations could have included skin rash, arthralgia, arthritis, proteinuria, serum sickness, and cryoglobulinemia. (NCT01466166)
Timeframe: From first dose of study drug to the end of the 12-week follow-up period (63 weeks).

InterventionParticipants (Count of Participants)
Pegloticase3

Number of Participants With Infusion Reactions

Infusion reactions were defined as adverse events (AEs) or clusters of events, not attributable to another cause that occurred during or within 2 hours after the infusion of pegloticase. Any other case that occurred outside of the 2-hour window was categorized per Investigator discretion. (NCT01466166)
Timeframe: 52 weeks

InterventionParticipants (Count of Participants)
Pegloticase42

Change From Baseline in Number of Gout Flares

The number of gout flares occurring in the 2 weeks prior to each visit. Baseline number of flares was calculated as the average number of flares that occurred in the 6-month baseline period divided by 12 weeks. (NCT01466166)
Timeframe: Baseline, week 24 and week 48

Interventionflares (Mean)
Week 24Week 48
Pegloticase-0.83-1.00

Number of Palpable Tophi Over Time

Gout tophi are nodular deposits of urate crystals and inflammatory cells in joints, soft tissues, bones, and in some organs. (NCT01466166)
Timeframe: Baseline and weeks 24 and 52

Interventiontophi (Mean)
BaselineWeek 24Week 52
Pegloticase13.585.703.68

Number of Swollen Joints Over Time

(NCT01466166)
Timeframe: Baseline and weeks 24 and 52

Interventionswollen joints (Mean)
BaselineWeek 24Week 52
Pegloticase8.604.051.46

Number of Tender Joints Over Time

(NCT01466166)
Timeframe: Baseline and weeks 24 and 52

Interventiontender joints (Mean)
BaselineWeek 24Week 52
Pegloticase9.332.380.79

Percentage of Participants With Normalization of Serum Uric Acid at Week 24 and Week 52

Normalization of serum uric acid was defined as serum uric acid value less than 6 mg/dL. (NCT01466166)
Timeframe: Week 24 and week 52

Interventionpercentage of participants (Number)
Week 24Week 52
Pegloticase27.712.2

Number of Gout Flare Days Per Participant From Day 1 to Day 112 (Week 16)

Gout flare was defined as acute articular pain typical of a gout attack that required treatment with an anti-inflammatory therapeutic: had at least 3 of the following 4 signs or symptoms: joint swelling, tenderness, redness, and pain, and with at least 1 of the following: rapid onset of pain, decreased range of motion, joint warmth or other symptoms similar to a prior gout flare. Number of gout flare days per participant was reported for this outcome measure. (NCT00829829)
Timeframe: Day 1 to Day 112 (Week 16)

InterventionGout flare Days (Mean)
Placebo5.52
Rilonacept 80 mg2.36
Rilonacept 160 mg0.98

Number of Gout Flare Days With Participant's Pain Score of 5 or More (From Daily Diary) Per Participant From Day 1 to Day 112 (Week 16)

Participants were asked to complete a telephone diary by calling the IVRS daily beginning at the baseline visit (Day 1) through the follow-up visit (Day 141) and reported their general well-being, gout symptoms, and weekly study drug administrations. At the onset of pain from a gout flare, participants were to answer additional diary questions regarding their gout flare and had to continue daily flare assessments until they reported the flare had ended. If a flare occurred just prior to the follow-up visit (Day 141), participants were to continue completing the daily diary until the flare resolved. Gout flare pain was assessed on a scale from 0 to 10 (with 0=no pain and 10=severe pain) within the past 24 hours. (NCT00829829)
Timeframe: Day 1 to Day 112 (Week 16)

InterventionGout flare days (Mean)
Placebo2.13
Rilonacept 80 mg0.85
Rilonacept 160 mg0.35

Number of Gout Flares Per Participant Assessed From Day 1 to Day 112 (Week 16)

A gout flare was defined as participant reported acute articular pain typical of a gout attack that required treatment with an anti-inflammatory therapeutic: had at least 3 of the following 4 signs or symptoms: joint swelling, tenderness, redness, and pain and with at least 1 of the following: rapid onset of pain, decreased range of motion, joint warmth or other symptoms similar to a prior gout flare. Number of gout flares per participant was reported for this outcome measure. For drop-outs, only flares occurred before Day 112 were counted, regardless whether the flares occurred during the treatment period or not. (NCT00829829)
Timeframe: Day 1 to Day 112 (Week 16)

InterventionNumber of Gout flares per participant (Mean)
Placebo1.06
Rilonacept 80 mg0.29
Rilonacept 160 mg0.21

Number of Modified Gout Flares Per Participant From Day 1 to Day 112 (Week 16)

Modified gout flare was defined using modified definition of a gout flare as participant-reported articular pain typical of a gout attack that was deemed to require treatment with anti-inflammatory therapy. Number of modified gout flares per participant were reported for this outcome measure. (NCT00829829)
Timeframe: Day 1 to Day 112 (Week 16)

Interventionmodified gout flares (Mean)
Placebo1.19
Rilonacept 80 mg0.40
Rilonacept 160 mg0.28

Percentage of Participants With at Least One Gout Flare From Day 1 to Day 112 (Week 16)

Gout flare was defined as acute articular pain typical of a gout attack that required treatment with an anti-inflammatory therapeutic: had at least 3 of the following 4 signs or symptoms: joint swelling, tenderness, redness, and pain; and with at least 1 of the following: rapid onset of pain, decreased range of motion, joint warmth or other symptoms similar to a prior gout flare. Percentage of participants with at least one gout flare was reported for this outcome measure. (NCT00829829)
Timeframe: Day 1 to Day 112 (Week 16)

Interventionpercentage of participants (Number)
Placebo46.8
Rilonacept 80 mg18.8
Rilonacept 160 mg16.3

Percentage of Participants With at Least Two Gout Flares From Day 1 to Day 112 (Week 16)

Gout flare was defined as acute articular pain typical of a gout attack that required treatment with an anti-inflammatory therapeutic: had at least 3 of the following 4 signs or symptoms: joint swelling, tenderness, redness, and pain, and with at least 1 of the following: rapid onset of pain, decreased range of motion, joint warmth or other symptoms similar to a prior gout flare. Percentage of participants with at least two gout flares was reported for this outcome measure. (NCT00829829)
Timeframe: Day 1 to Day 112 (Week 16)

Interventionpercentage of participants (Number)
Placebo31.6
Rilonacept 80 mg5.0
Rilonacept 160 mg3.8

Average Percent Difference in Area Between Raters

Each rater measured length and width (mm) of the tophus at 2 visits separated by no more than 10 days. Area of the tophus was summarized using the average percent difference, calculated as the absolute difference of Raters 1 and 2 divided by the average of Raters 1 and 2 for the same tophus, pooled across visits. (NCT00175006)
Timeframe: Visit 1 (Day 1 ) and Visit 2 (Day 6-11)

Interventionmm² (Mean)
Average Percent Difference
Tophi Participants32

Average Percent Difference in Area Between Visits

The rater measured length and width (mm) of the tophus at 2 visits separated by no more than 10 days. Area of the tophus was summarized using average percent difference, calculated as absolute difference of Visits 1 and 2 divided by the average of Visits 1 and 2 for the same tophus, pooled across raters. (NCT00175006)
Timeframe: Visit 1 (Day 1) and Visit 2 (Days 6-11)

Interventionmm² (Mean)
Average Percent Difference
Tophi Participants29

Reviews

755 reviews available for uric acid and Gout

ArticleYear
The major cardiovascular events of febuxostat versus allopurinol in treating gout or asymptomatic hyperuricemia: a systematic review and meta-analysis.
    Annals of palliative medicine, 2021, Volume: 10, Issue:10

    Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Tr

2021
A historical journey of searching for uricosuric drugs.
    Clinical rheumatology, 2022, Volume: 41, Issue:1

    Topics: Aged; Gout; Humans; Hyperuricemia; Pharmaceutical Preparations; Uric Acid; Uricosuric Agents

2022
Uric acid extrarenal excretion: the gut microbiome as an evident yet understated factor in gout development.
    Rheumatology international, 2022, Volume: 42, Issue:3

    Topics: Gastrointestinal Microbiome; Gout; Humans; Risk Factors; Uric Acid

2022
Urate transport in health and disease.
    Best practice & research. Clinical rheumatology, 2021, Volume: 35, Issue:4

    Topics: Gout; Humans; Hyperuricemia; Organic Cation Transport Proteins; Uric Acid

2021
The genetic basis of urate control and gout: Insights into molecular pathogenesis from follow-up study of genome-wide association study loci.
    Best practice & research. Clinical rheumatology, 2021, Volume: 35, Issue:4

    Topics: Aldehyde Dehydrogenase, Mitochondrial; Follow-Up Studies; Genetic Predisposition to Disease; Genome-

2021
Treatment advances in gout.
    Best practice & research. Clinical rheumatology, 2021, Volume: 35, Issue:4

    Topics: Gout; Gout Suppressants; Humans; Uric Acid

2021
Comparative efficacy and safety of dotinurad, febuxostat, and benzbromarone in hyperuricemic patients with or without gout: A network meta-analysis of randomized controlled trials.
    International journal of clinical pharmacology and therapeutics, 2022, Volume: 60, Issue:3

    Topics: Benzbromarone; Benzothiazoles; Febuxostat; Gout; Gout Suppressants; Humans; Network Meta-Analysis; R

2022
Uric Acid in Inflammation and the Pathogenesis of Atherosclerosis.
    International journal of molecular sciences, 2021, Nov-17, Volume: 22, Issue:22

    Topics: Animals; Atherosclerosis; Comorbidity; Diabetes Mellitus, Type 2; Gout; Humans; Hypertension; Hyperu

2021
Serum urate as a proposed surrogate outcome measure in gout trials: From the OMERACT working group.
    Seminars in arthritis and rheumatism, 2021, Volume: 51, Issue:6

    Topics: Biomarkers; Gout; Gout Suppressants; Humans; Outcome Assessment, Health Care; Treatment Outcome; Uri

2021
Comparative efficacy and safety of topiroxostat at different dosages in hyperuricemic patients with or without gout: A network meta-analysis of randomized controlled trials.
    International journal of clinical pharmacology and therapeutics, 2022, Volume: 60, Issue:4

    Topics: Gout; Gout Suppressants; Humans; Network Meta-Analysis; Nitriles; Pyridines; Randomized Controlled T

2022
Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care.
    Nature reviews. Rheumatology, 2022, Volume: 18, Issue:2

    Topics: Adult; Comorbidity; Diabetes Mellitus, Type 2; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric

2022
What's new on the front-line of gout pharmacotherapy?
    Expert opinion on pharmacotherapy, 2022, Volume: 23, Issue:4

    Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Quality of Life; Uric Acid

2022
Update of the current role of ultrasound in asymptomatic hyperuricemia. A systematic literature review.
    Joint bone spine, 2022, Volume: 89, Issue:3

    Topics: Arthritis, Gouty; Gout; Humans; Hyperuricemia; Ultrasonography; Uric Acid

2022
Hyperuricemia, Gout, and the Brain-an Update.
    Current rheumatology reports, 2021, 12-30, Volume: 23, Issue:12

    Topics: Brain; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid

2021
Dual-energy computed tomography in crystalline arthritis: knowns and unknowns.
    Current opinion in rheumatology, 2022, 03-01, Volume: 34, Issue:2

    Topics: Calcium Pyrophosphate; Gout; Humans; Tomography, X-Ray Computed; Ultrasonography; Uric Acid

2022
The effect of initiation of urate-lowering treatment during a gout flare on the current episode: a meta-analysis of randomized controlled trials.
    Advances in rheumatology (London, England), 2022, 01-29, Volume: 62, Issue:1

    Topics: Gout; Gout Suppressants; Humans; Randomized Controlled Trials as Topic; Treatment Outcome; Uric Acid

2022
The Role of Advanced Imaging in Gout Management.
    Frontiers in immunology, 2021, Volume: 12

    Topics: Biomarkers; Diagnostic Imaging; Disease Management; Disease Susceptibility; Gout; Humans; Hyperurice

2021
Expert Opinion on Pegloticase with Concomitant Immunomodulatory Therapy in the Treatment of Uncontrolled Gout to Improve Efficacy, Safety, and Durability of Response.
    Current rheumatology reports, 2022, Volume: 24, Issue:1

    Topics: Expert Testimony; Gout; Gout Suppressants; Humans; Immunologic Factors; Immunomodulation; Polyethyle

2022
Gout. What's up doc?
    Medicina clinica, 2022, 06-24, Volume: 158, Issue:12

    Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Kidney; Spain; Uric Acid

2022
Clinical features of gout in adult patients with type Ia glycogen storage disease: a single-centre retrospective study and a review of literature.
    Arthritis research & therapy, 2022, 02-26, Volume: 24, Issue:1

    Topics: Adolescent; Adult; Child; Female; Glycogen Storage Disease; Gout; Humans; Retrospective Studies; Sym

2022
The chemistry, processing, and preclinical anti-hyperuricemia potential of tea: a comprehensive review.
    Critical reviews in food science and nutrition, 2023, Volume: 63, Issue:24

    Topics: Gout; Humans; Hyperuricemia; Polyphenols; Tea; Uric Acid

2023
The Role of the Intestine in the Development of Hyperuricemia.
    Frontiers in immunology, 2022, Volume: 13

    Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Gout; Humans; Hyperuricemia; Intestines; Ne

2022
Enhancing the Response Rate to Recombinant Uricases in Patients with Gout.
    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2022, Volume: 36, Issue:2

    Topics: Allopurinol; Antibodies; Gout; Gout Suppressants; Humans; Urate Oxidase; Uric Acid

2022
Does seasonality of the microbiota contribute to the seasonality of acute gout flare?
    Clinical and experimental rheumatology, 2022, Volume: 40, Issue:9

    Topics: Arthritis, Gouty; Gout; Gout Suppressants; Humans; Hyperuricemia; Microbiota; Symptom Flare Up; Uric

2022
Management and Cure of Gouty Arthritis.
    Rheumatic diseases clinics of North America, 2022, Volume: 48, Issue:2

    Topics: Arthritis, Gouty; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid

2022
Clinical interventions to improve adherence to urate-lowering therapy in patients with gout: a systematic review.
    The International journal of pharmacy practice, 2022, Jun-25, Volume: 30, Issue:3

    Topics: Gout; Humans; Medication Adherence; Telephone; Text Messaging; Uric Acid

2022
Update on Uric Acid and the Kidney.
    Current rheumatology reports, 2022, Volume: 24, Issue:5

    Topics: Allopurinol; Female; Gout; Gout Suppressants; Humans; Kidney; Male; Parkinson Disease; Renal Insuffi

2022
Environmental factors and risk of gout.
    Environmental research, 2022, Volume: 212, Issue:Pt C

    Topics: Gout; Humans; Inflammation; Uric Acid

2022
Uric acid in metabolic syndrome: Does uric acid have a definitive role?
    European journal of internal medicine, 2022, Volume: 103

    Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Metabolic Syndrome; Uric Acid

2022
Emerging strategies for treating gout.
    Current opinion in pharmacology, 2022, Volume: 65

    Topics: Colchicine; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid

2022
Erosive Tophaceous Gouty Arthropathy of the Hand: A Case Report.
    South Dakota medicine : the journal of the South Dakota State Medical Association, 2022, Volume: 75, Issue:5

    Topics: Arthritis, Gouty; Gout; Humans; Hyperuricemia; Skin Abnormalities; Uric Acid

2022
Effect modification by contextual factors of urate-lowering therapy on serum urate in people with gout: A systematic review with meta-regression analysis.
    Seminars in arthritis and rheumatism, 2022, Volume: 56

    Topics: Gout; Gout Suppressants; Humans; Regression Analysis; Uric Acid

2022
Lowering and Raising Serum Urate Levels: Off-Label Effects of Commonly Used Medications.
    Mayo Clinic proceedings, 2022, Volume: 97, Issue:7

    Topics: Aspirin; Gout; Humans; Hyperuricemia; Off-Label Use; Uric Acid

2022
Current state and prospects of gout treatment in Korea.
    The Korean journal of internal medicine, 2022, Volume: 37, Issue:4

    Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Republic of Korea; Uric Acid

2022
Dual-Energy Computed Tomography Has Additional Prognostic Value Over Clinical Measures in Gout Including Tophi: A Systematic Literature Review.
    The Journal of rheumatology, 2022, Volume: 49, Issue:11

    Topics: Arthritis, Gouty; Gout; Humans; Prognosis; Prospective Studies; Reproducibility of Results; Tomograp

2022
Effects of allopurinol on renal function in patients with diabetes: a systematic review and meta-analysis.
    Renal failure, 2022, Volume: 44, Issue:1

    Topics: Allopurinol; Diabetes Mellitus; Gout; Gout Suppressants; Humans; Hyperuricemia; Kidney; Uric Acid

2022
Recent Insights Into the Role of Macrophages in Acute Gout.
    Frontiers in immunology, 2022, Volume: 13

    Topics: Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Gout; Macrophages; Mice; TRPV Cation Channels;

2022
When underlying biology threatens the randomization principle - initial gout flares of urate-lowering therapy.
    Nature reviews. Rheumatology, 2022, Volume: 18, Issue:9

    Topics: Biology; Gout; Gout Suppressants; Humans; Random Allocation; Randomized Controlled Trials as Topic;

2022
Excess Uric Acid Induces Gouty Nephropathy Through Crystal Formation: A Review of Recent Insights.
    Frontiers in endocrinology, 2022, Volume: 13

    Topics: Endothelial Cells; Gout; Humans; Hyperuricemia; Inflammation; Renal Insufficiency, Chronic; Uric Aci

2022
Susceptibility genes of hyperuricemia and gout.
    Hereditas, 2022, Aug-04, Volume: 159, Issue:1

    Topics: Gout; Humans; Hyperuricemia; Mutation; Risk Factors; Uric Acid

2022
Critical appraisal of serum urate targets in the management of gout.
    Nature reviews. Rheumatology, 2022, Volume: 18, Issue:10

    Topics: Gout; Gout Suppressants; Humans; Rheumatology; Uric Acid

2022
Role of microRNA alternation in the pathogenesis of gouty arthritis.
    Frontiers in endocrinology, 2022, Volume: 13

    Topics: Arthritis, Gouty; Gout; Humans; MicroRNAs; Uric Acid

2022
Comparative efficacy and safety of uricosuric agents in the treatment of gout or hyperuricemia: a systematic review and network meta-analysis.
    Clinical rheumatology, 2023, Volume: 42, Issue:1

    Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Network Meta-Analysis; Probenecid; Randomized Contro

2023
Gout and Diet: A Comprehensive Review of Mechanisms and Management.
    Nutrients, 2022, Aug-26, Volume: 14, Issue:17

    Topics: Arthritis, Gouty; Diet; Gout; Humans; Inflammation; Uric Acid

2022
Moving the Needle in Gout Management: The Role of Culture, Diet, Genetics, and Personalized Patient Care Practices.
    Nutrients, 2022, Aug-31, Volume: 14, Issue:17

    Topics: Aged; Diet; Gout; Gout Suppressants; Humans; Hyperuricemia; Patient Care; Reproducibility of Results

2022
Safety and efficacy of probiotic supplementation in 8 types of inflammatory arthritis: A systematic review and meta-analysis of 34 randomized controlled trials.
    Frontiers in immunology, 2022, Volume: 13

    Topics: Arthritis, Rheumatoid; Bone Diseases, Metabolic; Chronic Disease; Dietary Supplements; Gout; Humans;

2022
Association between gout and the development of Parkinson's disease: a systematic review and meta-analysis.
    BMC neurology, 2022, Oct-11, Volume: 22, Issue:1

    Topics: Antioxidants; Case-Control Studies; Female; Gout; Humans; Male; Parkinson Disease; Uric Acid

2022
Novel Insights into the Effects of Genetic Variants on Serum Urate Response to an Acute Fructose Challenge: A Pilot Study.
    Nutrients, 2022, Sep-28, Volume: 14, Issue:19

    Topics: Adult; Fructose; Gout; Humans; Hyperuricemia; Male; Middle Aged; Pilot Projects; Risk Factors; Uric

2022
Recent advances in gout drugs.
    European journal of medicinal chemistry, 2023, Jan-05, Volume: 245, Issue:Pt 1

    Topics: Gout; Gout Suppressants; Humans; Uric Acid

2023
Amyloid A amyloidosis on medullary sponge kidney in a 28-year-old male with gout: A case report and literature review.
    International journal of rheumatic diseases, 2023, Volume: 26, Issue:2

    Topics: Adult; Amyloidosis; Gout; Humans; Kidney; Kidney Diseases; Male; Medullary Sponge Kidney; Uric Acid

2023
Crystal arthropathies and osteoarthritis-where is the link?
    Skeletal radiology, 2023, Volume: 52, Issue:11

    Topics: Calcinosis; Crystal Arthropathies; Gout; Humans; Inflammation; Osteoarthritis; Uric Acid

2023
Novel perception of neutrophil extracellular traps in gouty inflammation.
    International immunopharmacology, 2023, Volume: 115

    Topics: Extracellular Traps; Gout; Humans; Inflammation; Neutrophils; Perception; Uric Acid

2023
Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2020-present).
    Expert opinion on therapeutic patents, 2022, Volume: 32, Issue:12

    Topics: Gout; Humans; Hyperuricemia; Organic Anion Transporters; Organic Cation Transport Proteins; Patents

2022
The biomarkers discovery of hyperuricemia and gout: proteomics and metabolomics.
    PeerJ, 2023, Volume: 11

    Topics: Biomarkers; Gout; Humans; Hyperuricemia; Proteomics; Uric Acid

2023
Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER.
    JAMA cardiology, 2023, 04-01, Volume: 8, Issue:4

    Topics: Aged; Colchicine; Gout; Heart Failure; Humans; Male; Stroke Volume; Uric Acid; Ventricular Function,

2023
Outcome reporting in randomized trials in gout: A systematic scoping review from the OMERACT gout working group assessing the uptake of the core outcome set.
    Seminars in arthritis and rheumatism, 2023, Volume: 60

    Topics: Gout; Humans; Outcome Assessment, Health Care; Randomized Controlled Trials as Topic; Systematic Rev

2023
Mechanisms of theaflavins against gout and strategies for improving the bioavailability.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2023, Volume: 114

    Topics: Animals; Biological Availability; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid

2023
Interventions designed to improve uptake of allopurinol for gout treatment in Aotearoa New Zealand: a scoping review.
    Journal of primary health care, 2023, Volume: 15, Issue:1

    Topics: Allopurinol; Gout; Gout Suppressants; Humans; New Zealand; Quality of Life; Uric Acid

2023
A review on gout: Looking back and looking ahead.
    International immunopharmacology, 2023, Volume: 117

    Topics: Arthritis, Gouty; Extracellular Traps; Glucose Transport Proteins, Facilitative; Gout; Humans; Infla

2023
The Hong Kong Society of Rheumatology consensus recommendations for the management of gout.
    Clinical rheumatology, 2023, Volume: 42, Issue:8

    Topics: Consensus; Gout; Gout Suppressants; Hong Kong; Humans; Hyperuricemia; Rheumatology; Uric Acid

2023
Efficacy of initiating urate-lowering therapy during an acute gout episode: a meta-analysis.
    Zeitschrift fur Rheumatologie, 2023, Volume: 82, Issue:9

    Topics: Arthritis, Gouty; Gout; Gout Suppressants; Humans; Pain; Uric Acid

2023
Management of Gout in the Hand and Wrist.
    The Orthopedic clinics of North America, 2023, Volume: 54, Issue:3

    Topics: Adult; Gout; Humans; Hyperuricemia; Upper Extremity; Uric Acid; Wrist

2023
Immune and inflammatory mechanisms and therapeutic targets of gout: An update.
    International immunopharmacology, 2023, Volume: 121

    Topics: Animals; Arthritis, Gouty; Cytokines; Gout; Inflammasomes; Inflammation; Macrophages; Uric Acid

2023
The Chinese patent medicine Tongfengding capsule for gout in adults: a systematic review of safety and effectiveness.
    Advances in rheumatology (London, England), 2023, 07-18, Volume: 63, Issue:1

    Topics: Adult; Capsules; Gout; Humans; Interleukin-8; Nonprescription Drugs; Randomized Controlled Trials as

2023
Analysis of Metabolites in Gout: A Systematic Review and Meta-Analysis.
    Nutrients, 2023, Jul-14, Volume: 15, Issue:14

    Topics: Creatinine; Gout; Humans; Hypoxanthine; Uric Acid; Xanthine

2023
Management of Patients with Gout and Kidney Disease: A Review of Available Therapies and Common Missteps.
    Kidney360, 2023, 09-01, Volume: 4, Issue:9

    Topics: Colchicine; Gout; Humans; Quality of Life; Renal Insufficiency, Chronic; Uric Acid

2023
Contributions of joint damage-related events to gout pathogenesis: new insights from laboratory research.
    Annals of the rheumatic diseases, 2023, Volume: 82, Issue:12

    Topics: Gout; Humans; Joints; Osteoarthritis; Uric Acid

2023
Mechanisms and rationale for uricase use in patients with gout.
    Nature reviews. Rheumatology, 2023, Volume: 19, Issue:10

    Topics: Allopurinol; Gout; Gout Suppressants; Humans; Hyperuricemia; Quality of Life; Urate Oxidase; Uric Ac

2023
Gout therapeutics and drug delivery.
    Journal of controlled release : official journal of the Controlled Release Society, 2023, Volume: 362

    Topics: Drug Delivery Systems; Gout; Humans; Hyperuricemia; Quality of Life; Uric Acid

2023
Emerging Urate-Lowering Drugs and Pharmacologic Treatment Strategies for Gout: A Narrative Review.
    Drugs, 2023, Volume: 83, Issue:16

    Topics: Diabetes Mellitus, Type 2; Gout; Gout Suppressants; Humans; Hyperuricemia; Symptom Flare Up; Uric Ac

2023
Uric acid en route to gout.
    Advances in clinical chemistry, 2023, Volume: 116

    Topics: Gout; Humans; Hyperuricemia; Symptom Flare Up; Uric Acid

2023
Exploring the Multifaceted Nexus of Uric Acid and Health: A Review of Recent Studies on Diverse Diseases.
    Biomolecules, 2023, 10-13, Volume: 13, Issue:10

    Topics: Diet; Gout; Humans; Hyperuricemia; Metabolic Syndrome; Uric Acid

2023
Agents for the Treatment of Gout: Current Advances and Future Perspectives.
    Journal of medicinal chemistry, 2023, 11-09, Volume: 66, Issue:21

    Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid; Xanthine Oxidase

2023
The dysregulation of immune cells induced by uric acid: mechanisms of inflammation associated with hyperuricemia and its complications.
    Frontiers in immunology, 2023, Volume: 14

    Topics: Arthritis, Gouty; Gout; Humans; Hyperuricemia; Inflammation; Uric Acid

2023
Diagnosis and treatment for hyperuricemia and gout: a systematic review of clinical practice guidelines and consensus statements.
    BMJ open, 2019, 08-24, Volume: 9, Issue:8

    Topics: Consensus; Gout; Gout Suppressants; Humans; Hyperuricemia; Practice Guidelines as Topic; Uric Acid

2019
Impact of bariatric surgery on serum uric acid levels and the incidence of gout-A meta-analysis.
    Obesity reviews : an official journal of the International Association for the Study of Obesity, 2019, Volume: 20, Issue:12

    Topics: Adolescent; Adult; Bariatric Surgery; Body Mass Index; Female; Gout; Humans; Male; MEDLINE; Middle A

2019
Gout.
    Nature reviews. Disease primers, 2019, 09-26, Volume: 5, Issue:1

    Topics: Adrenal Cortex Hormones; Gout; Gout Suppressants; Humans; Risk Factors; Uric Acid

2019
Gout.
    Rheumatic diseases clinics of North America, 2019, Volume: 45, Issue:4

    Topics: Gout; Gout Suppressants; Humans; Patient Care Management; Risk Reduction Behavior; Uric Acid

2019
Hyperuricemia: a novel old disorder-relationship and potential mechanisms in heart failure.
    Heart failure reviews, 2020, Volume: 25, Issue:1

    Topics: Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Disease Progression; Gout; Gout Su

2020
Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia.
    Clinical and experimental nephrology, 2020, Volume: 24, Issue:Suppl 1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Benzbromarone; Benzothiazoles; Drug Interactions; Febuxosta

2020
Clinical Management of Reptile Renal Disease.
    The veterinary clinics of North America. Exotic animal practice, 2020, Volume: 23, Issue:1

    Topics: Animals; Gout; Kidney; Kidney Diseases; Reptiles; Uric Acid

2020
A novel mutation in gene of PRPS1 in a young Chinese woman with X-linked gout: a case report and review of the literature.
    Clinical rheumatology, 2020, Volume: 39, Issue:3

    Topics: Asian People; Female; Genes, X-Linked; Gout; Humans; Hyperuricemia; Mutation, Missense; Purine-Pyrim

2020
How flare prevention outcomes are reported in gout studies: A systematic review and content analysis of randomized controlled trials.
    Seminars in arthritis and rheumatism, 2020, Volume: 50, Issue:2

    Topics: Female; Gout; Gout Suppressants; Humans; Male; Randomized Controlled Trials as Topic; Symptom Flare

2020
Dietary Interventions for Gout and Effect on Cardiovascular Risk Factors: A Systematic Review.
    Nutrients, 2019, Dec-04, Volume: 11, Issue:12

    Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Dietary Supplement

2019
Beyond urate lowering: Analgesic and anti-inflammatory properties of allopurinol.
    Seminars in arthritis and rheumatism, 2020, Volume: 50, Issue:3

    Topics: Allopurinol; Analgesics; Anti-Inflammatory Agents; Enzyme Inhibitors; Free Radical Scavengers; Gout;

2020
Comorbidities in gout and hyperuricemia: causality or epiphenomena?
    Current opinion in rheumatology, 2020, Volume: 32, Issue:2

    Topics: Cardiovascular Diseases; Comorbidity; Gout; Humans; Hyperuricemia; Prevalence; Renal Insufficiency,

2020
Management of hyperuricemia in asymptomatic patients: A critical appraisal.
    European journal of internal medicine, 2020, Volume: 74

    Topics: Allopurinol; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid

2020
Evaluation of urate-lowering therapy in hyperuricemia patients: a systematic review and Bayesian network meta-analysis of randomized controlled trials.
    Clinical rheumatology, 2020, Volume: 39, Issue:5

    Topics: Bayes Theorem; Gout; Gout Suppressants; Humans; Hyperuricemia; Network Meta-Analysis; Quality of Lif

2020
At the crossroads of gout and psoriatic arthritis: "psout".
    Clinical rheumatology, 2020, Volume: 39, Issue:5

    Topics: Arthritis, Psoriatic; Comorbidity; Gout; Humans; Hyperuricemia; Risk Factors; Uric Acid

2020
[Gout].
    La Revue de medecine interne, 2020, Volume: 41, Issue:6

    Topics: Chronic Disease; Diagnosis, Differential; Gout; Humans; Hyperuricemia; Prevalence; Risk Factors; Uri

2020
Lessons and pitfalls from the 2020 Gout Clinical Practice Guideline presented in Atlanta at the ACR 2019.
    Clinical rheumatology, 2020, Volume: 39, Issue:6

    Topics: Gout; Gout Suppressants; Guideline Adherence; Humans; Practice Guidelines as Topic; Rheumatology; So

2020
Recent approaches to gout drug discovery: an update.
    Expert opinion on drug discovery, 2020, Volume: 15, Issue:8

    Topics: Allopurinol; Arthritis, Gouty; Drug Discovery; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric

2020
Gout: a disease involved with complicated immunoinflammatory responses: a narrative review.
    Clinical rheumatology, 2020, Volume: 39, Issue:10

    Topics: Animals; Cytokines; Gout; Humans; Inflammasomes; Interleukin-1beta; Neutrophils; Uric Acid

2020
Efficacy and safety of urate-lowering treatments in patients with hyperuricemia: A comprehensive network meta-analysis of randomized controlled trials.
    Journal of clinical pharmacy and therapeutics, 2020, Volume: 45, Issue:4

    Topics: Allopurinol; Bayes Theorem; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Network Meta

2020
Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review.
    Clinical rheumatology, 2020, Volume: 39, Issue:11

    Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni

2020
Polygenic analysis of the effect of common and low-frequency genetic variants on serum uric acid levels in Korean individuals.
    Scientific reports, 2020, 06-08, Volume: 10, Issue:1

    Topics: Adult; Aldehyde Dehydrogenase, Mitochondrial; Asian People; Chromosomes, Human, Pair 12; Female; Gen

2020
Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors.
    Nature reviews. Rheumatology, 2020, Volume: 16, Issue:7

    Topics: Adult; Aged; Case-Control Studies; Comorbidity; Ethnicity; Female; Gout; Gout Suppressants; Humans;

2020
Renal disorders in rheumatologic diseases: the spectrum is changing (part 2. Arthridides).
    Journal of nephrology, 2021, Volume: 34, Issue:4

    Topics: Arthritis, Rheumatoid; Chronic Disease; Gout; Humans; Kidney Calculi; Uric Acid

2021
The clinical efficacy of urate-lowering therapy in acute gout: a meta-analysis of randomized controlled trials.
    Clinical rheumatology, 2021, Volume: 40, Issue:2

    Topics: Gout; Gout Suppressants; Humans; Randomized Controlled Trials as Topic; Treatment Outcome; Uric Acid

2021
Changing paradigms in the management of gout.
    The journal of the Royal College of Physicians of Edinburgh, 2020, Volume: 50, Issue:2

    Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Uric Acid

2020
The biology of urate.
    Seminars in arthritis and rheumatism, 2020, Volume: 50, Issue:3S

    Topics: Gout; Humans; Hyperuricemia; Kidney; Organic Anion Transporters; Uric Acid

2020
Therapeutic approaches in the treatment of gout.
    Seminars in arthritis and rheumatism, 2020, Volume: 50, Issue:3S

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Mal

2020
Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials.
    Clinical rheumatology, 2021, Volume: 40, Issue:2

    Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome; Uric Aci

2021
Gout: Where Is the Weak Link?
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2020, Volume: 26, Issue:5

    Topics: Gout; Gout Suppressants; Humans; Inflammation; Uric Acid

2020
Cardiovascular safety risks associated with gout treatments.
    Expert opinion on drug safety, 2020, Volume: 19, Issue:9

    Topics: Allopurinol; Animals; Cardiovascular Diseases; Colchicine; Gout; Gout Suppressants; Heart Disease Ri

2020
Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease.
    European journal of internal medicine, 2020, Volume: 80

    Topics: Diabetes Mellitus, Type 2; Gout; Humans; Hyperuricemia; Metabolic Syndrome; Uric Acid

2020
Xanthine oxidase inhibitors: patent landscape and clinical development (2015-2020).
    Expert opinion on therapeutic patents, 2020, Volume: 30, Issue:10

    Topics: Animals; Drug Development; Enzyme Inhibitors; Gout; Humans; Hyperuricemia; Patents as Topic; Reactiv

2020
Advances in our understanding of gout as an auto-inflammatory disease.
    Seminars in arthritis and rheumatism, 2020, Volume: 50, Issue:5

    Topics: Comorbidity; Gout; Humans; Hyperuricemia; Inflammation; Uric Acid

2020
Hyperuricemia, the heart, and the kidneys - to treat or not to treat?
    Renal failure, 2020, Volume: 42, Issue:1

    Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Kidney; Myocardium; Renal Insufficiency, Chron

2020
The ABCG2/BCRP transporter and its variants - from structure to pathology.
    FEBS letters, 2020, Volume: 594, Issue:23

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Drug Resistance, Neoplasm; Endopla

2020
The association between genetic polymorphisms in ABCG2 and SLC2A9 and urate: an updated systematic review and meta-analysis.
    BMC medical genetics, 2020, 10-21, Volume: 21, Issue:1

    Topics: Alleles; Asian People; ATP Binding Cassette Transporter, Subfamily G, Member 2; Female; Gene Express

2020
Gout: Rapid Evidence Review.
    American family physician, 2020, 11-01, Volume: 102, Issue:9

    Topics: Adrenal Cortex Hormones; Allopurinol; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Obesi

2020
Clinical implications of synovial fluid specimen handling for crystal associated arthritides: A systematic review.
    International journal of rheumatic diseases, 2021, Volume: 24, Issue:1

    Topics: Calcium Pyrophosphate; Crystal Arthropathies; Crystallization; Edetic Acid; Gout; Humans; Predictive

2021
Uric acid and cardiovascular disease: A clinical review.
    Journal of cardiology, 2021, Volume: 78, Issue:1

    Topics: Cardiovascular Diseases; Gout; Humans; Hypertension; Hyperuricemia; Risk Factors; Uric Acid

2021
Managing hyperuricemia and gout in chronic kidney disease: a clinical conundrum.
    Current opinion in nephrology and hypertension, 2021, 03-01, Volume: 30, Issue:2

    Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Uric Acid

2021
Non-invasive determination of uric acid in human saliva in the diagnosis of serious disorders.
    Clinical chemistry and laboratory medicine, 2021, 04-27, Volume: 59, Issue:5

    Topics: Biomarkers; Gout; Humans; Hyperuricemia; Saliva; Uric Acid

2021
The effect of immunomodulators on the efficacy and tolerability of pegloticase: a systematic review.
    Seminars in arthritis and rheumatism, 2021, Volume: 51, Issue:2

    Topics: Azathioprine; Gout; Gout Suppressants; Humans; Immunologic Factors; Polyethylene Glycols; Urate Oxid

2021
Effectiveness of Allopurinol in Reducing Mortality: Time-Related Biases in Observational Studies.
    Arthritis & rheumatology (Hoboken, N.J.), 2021, Volume: 73, Issue:9

    Topics: Allopurinol; Bias; Cause of Death; Gout; Gout Suppressants; Humans; Hyperuricemia; Mortality; Observ

2021
Molecular Pathophysiology of Uric Acid Homeostasis.
    Seminars in nephrology, 2020, Volume: 40, Issue:6

    Topics: Genome-Wide Association Study; Gout; Homeostasis; Humans; Organic Anion Transporters; Uric Acid

2020
Pathophysiology of Gout.
    Seminars in nephrology, 2020, Volume: 40, Issue:6

    Topics: Cytokines; Gout; Humans; Hyperuricemia; Uric Acid

2020
20 Years of Radiographic Imaging: Crystalline Deposits Causing Severe Arthropathy and Erosions.
    Military medicine, 2023, 01-04, Volume: 188, Issue:1-2

    Topics: Aged; Calcium Pyrophosphate; Chondrocalcinosis; Female; Gout; Humans; Joint Diseases; Middle Aged; O

2023
Tophaceous Gout - When the Skin Comes First.
    Acta dermatovenerologica Croatica : ADC, 2020, Volume: 28, Issue:7

    Topics: Gout; Humans; Quality of Life; Skin; Uric Acid

2020
The role of alcohol consumption in pathogenesis of gout.
    Critical reviews in food science and nutrition, 2022, Volume: 62, Issue:25

    Topics: Alcohol Drinking; Alcoholic Beverages; Beer; Ethanol; Gout; Humans; Hyperuricemia; Symptom Flare Up;

2022
Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout.
    Expert opinion on pharmacotherapy, 2021, Volume: 22, Issue:11

    Topics: Benzothiazoles; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid; Uricosuric Ag

2021
Regulation of crystal induced inflammation: current understandings and clinical implications.
    Expert review of clinical immunology, 2021, Volume: 17, Issue:7

    Topics: Gout; Humans; Inflammasomes; Inflammation; Interleukin-1beta; Macrophages; Uric Acid

2021
Gout Flare Burden, Diagnosis, and Management: Navigating Care in Older Patients with Comorbidity.
    Drugs & aging, 2021, Volume: 38, Issue:7

    Topics: Aged; Comorbidity; Gout; Gout Suppressants; Humans; Middle Aged; Symptom Flare Up; Uric Acid

2021
An update of genetics, co-morbidities and management of hyperuricaemia.
    Clinical and experimental pharmacology & physiology, 2021, Volume: 48, Issue:10

    Topics: Cardiovascular Diseases; Comorbidity; Genome-Wide Association Study; Gout; Humans; Hyperuricemia; Re

2021
Global patterns of treat-to-serum urate target care for gout: Systematic review and meta-analysis.
    Seminars in arthritis and rheumatism, 2021, Volume: 51, Issue:4

    Topics: Gout; Gout Suppressants; Humans; Research Design; Rheumatology; Uric Acid

2021
The Impact of Uric Acid and Hyperuricemia on Cardiovascular and Renal Systems.
    Cardiology clinics, 2021, Volume: 39, Issue:3

    Topics: Gout; Humans; Hyperuricemia; Kidney; Radiopharmaceuticals; Uric Acid

2021
What Has Dual Energy CT Taught Us About Gout?
    Current rheumatology reports, 2021, 07-14, Volume: 23, Issue:9

    Topics: Gout; Humans; Joints; Tomography, X-Ray Computed; Ultrasonography; Uric Acid

2021
Effect of orlistat on serum uric acid level in adults: A systematic review and meta-analysis of randomised controlled trials.
    International journal of clinical practice, 2021, Volume: 75, Issue:11

    Topics: Adult; Gout; Humans; Hyperuricemia; Orlistat; Randomized Controlled Trials as Topic; Uric Acid; Weig

2021
Lesinurad: A Review in Hyperuricaemia of Gout.
    Drugs & aging, 2017, Volume: 34, Issue:5

    Topics: Adult; Allopurinol; Drug Therapy, Combination; Enzyme Inhibitors; Febuxostat; Gout; Humans; Hyperuri

2017
Treatment Options for Gout.
    Deutsches Arzteblatt international, 2017, Mar-31, Volume: 114, Issue:13

    Topics: Adult; Germany; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid

2017
Value and Progress of Ultrasound in Diagnosis and Treatment of Hyperuricemia.
    Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae, 2017, Apr-20, Volume: 39, Issue:2

    Topics: Arthritis, Gouty; Carotid Artery Diseases; Gout; Humans; Hyperuricemia; Kidney; Non-alcoholic Fatty

2017
The genetics of gout: towards personalised medicine?
    BMC medicine, 2017, 05-31, Volume: 15, Issue:1

    Topics: Allopurinol; Genome-Wide Association Study; Gout; Gout Suppressants; Humans; Hyperuricemia; Life Sty

2017
Serum uric acid levels and multiple health outcomes: umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies.
    BMJ (Clinical research ed.), 2017, 06-07, Volume: 357

    Topics: Biomarkers; Gout; Humans; Mendelian Randomization Analysis; Nephrolithiasis; Observational Studies a

2017
The Immunological Basis in the Pathogenesis of Gout.
    Iranian journal of immunology : IJI, 2017, Volume: 14, Issue:2

    Topics: Adaptive Immunity; Animals; Disease Susceptibility; Gout; Humans; Immunity, Cellular; Immunity, Humo

2017
Updates on the treatment of gout, including a review of updated treatment guidelines and use of small molecule therapies for difficult-to-treat gout and gout flares.
    Expert opinion on pharmacotherapy, 2017, Volume: 18, Issue:11

    Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Gout; Gout Suppressant

2017
Change gout: the need for a new approach.
    Minerva medica, 2017, Volume: 108, Issue:4

    Topics: Biomarkers; Body Mass Index; Cardiovascular Diseases; Diet Therapy; Disease Progression; Evidence-Ba

2017
[Dual-energy computed tomography diagnostics for gout].
    Zeitschrift fur Rheumatologie, 2017, Volume: 76, Issue:7

    Topics: Crystallization; Follow-Up Studies; Gout; Humans; Joints; Prognosis; Tomography, X-Ray Computed; Uri

2017
Current and future therapies for gout.
    Expert opinion on pharmacotherapy, 2017, Volume: 18, Issue:12

    Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Practice Guidelines as Topic; Uric Acid

2017
Gout and Metabolic Syndrome: a Tangled Web.
    Current rheumatology reports, 2017, Aug-26, Volume: 19, Issue:10

    Topics: Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Fructose; Gout; Humans; Hyperlipide

2017
Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies.
    Annals of the rheumatic diseases, 2017, Volume: 76, Issue:11

    Topics: Bariatric Surgery; Diet Therapy; Diuretics; Exercise Therapy; Female; Gout; Humans; Hypoglycemic Age

2017
The challenge of Mendelian randomization approach.
    Current medical research and opinion, 2017, Volume: 33, Issue:sup3

    Topics: Cardiovascular Diseases; Disease Progression; Gout; Humans; Kidney Diseases; Randomized Controlled T

2017
The role of urate-lowering treatment on cardiovascular and renal disease: evidence from CARES, FAST, ALL-HEART, and FEATHER studies.
    Current medical research and opinion, 2017, Volume: 33, Issue:sup3

    Topics: Cardiovascular Diseases; Gout; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Kidney Diseas

2017
Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
    European review for medical and pharmacological sciences, 2017, Volume: 21, Issue:18

    Topics: Adult; Allopurinol; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Febuxostat; Female; Gout

2017
Gout Keratitis: A Case of Peripheral Ulcerative Keratitis Secondary to Gout With a Review of the Literature.
    Cornea, 2018, Volume: 37, Issue:3

    Topics: Adult; Corneal Stroma; Corneal Ulcer; Gout; Humans; Male; Uric Acid

2018
Guideline development for the management of gout: role of combination therapy with a focus on lesinurad.
    Drug design, development and therapy, 2017, Volume: 11

    Topics: Dose-Response Relationship, Drug; Drug Therapy, Combination; Gout; Gout Suppressants; Humans; Patien

2017
Crystalline arthropathy and bone health.
    Current opinion in rheumatology, 2018, Volume: 30, Issue:2

    Topics: Bone and Bones; Bone Density; Chondrocalcinosis; Crystal Arthropathies; Fractures, Bone; Gout; Human

2018
Effects of Discontinuation of Urate-Lowering Therapy: A Systematic Review.
    Journal of general internal medicine, 2018, Volume: 33, Issue:3

    Topics: Clinical Trials as Topic; Gout; Gout Suppressants; Humans; Observational Studies as Topic; Recurrenc

2018
[Research progress of puerarin and its derivatives on anti-inflammatory and anti-gout activities].
    Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, 2017, Volume: 42, Issue:19

    Topics: Anti-Inflammatory Agents; Gout; Gout Suppressants; Humans; Isoflavones; Uric Acid; Xanthine Oxidase

2017
New urate-lowing therapies.
    Current opinion in rheumatology, 2018, Volume: 30, Issue:2

    Topics: Acetamides; Drug Interactions; Enzyme Inhibitors; Gout; Gout Suppressants; Humans; Phenylacetates; P

2018
ABCG2 as a therapeutic target candidate for gout.
    Expert opinion on therapeutic targets, 2018, Volume: 22, Issue:2

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Drug Design; Gout; Gout Suppressan

2018
Cardiac and renal protective effects of urate-lowering therapy.
    Rheumatology (Oxford, England), 2018, 01-01, Volume: 57, Issue:suppl_1

    Topics: Cardiovascular Diseases; Gout; Gout Suppressants; Humans; Renal Insufficiency, Chronic; Uric Acid

2018
Treat to target in gout.
    Rheumatology (Oxford, England), 2018, 01-01, Volume: 57, Issue:suppl_1

    Topics: Disease Management; Gout; Gout Suppressants; Humans; Uric Acid

2018
Novel uricosurics.
    Rheumatology (Oxford, England), 2018, 01-01, Volume: 57, Issue:suppl_1

    Topics: Disease Management; Gout; Gout Suppressants; Humans; Uric Acid

2018
Beneficial Properties of Phytochemicals on NLRP3 Inflammasome-Mediated Gout and Complication.
    Journal of agricultural and food chemistry, 2018, Jan-31, Volume: 66, Issue:4

    Topics: Animals; Antioxidants; Crystallization; Diet; Flavonoids; Gout; Humans; Inflammasomes; Interleukin-1

2018
Retinal complications of gout: a case report and review of the literature.
    BMC ophthalmology, 2018, Jan-19, Volume: 18, Issue:1

    Topics: Anterior Eye Segment; Fluorescein Angiography; Fundus Oculi; Gout; Humans; Macula Lutea; Male; Middl

2018
Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan.
    International journal of rheumatic diseases, 2018, Volume: 21, Issue:4

    Topics: Biomarkers; Comorbidity; Consensus; Down-Regulation; Gout; Gout Suppressants; Humans; Hyperuricemia;

2018
Gout: A Disease of Kings.
    Contributions to nephrology, 2018, Volume: 192

    Topics: Glucose Transport Proteins, Facilitative; Gout; History, 19th Century; History, 20th Century; Histor

2018
An association of smoking with serum urate and gout: A health paradox.
    Seminars in arthritis and rheumatism, 2018, Volume: 47, Issue:6

    Topics: Gout; Humans; Hyperuricemia; Risk; Smoking; Uric Acid

2018
[Progress on diagnosis and treatment of tophus].
    Zhongguo gu shang = China journal of orthopaedics and traumatology, 2017, Sep-25, Volume: 30, Issue:9

    Topics: Arthritis, Gouty; Gout; Gout Suppressants; Humans; Uric Acid

2017
What Is the Evidence for Treat-to-Target Serum Urate in Gout?
    Current rheumatology reports, 2018, 03-08, Volume: 20, Issue:3

    Topics: Dose-Response Relationship, Drug; Drug Monitoring; Evidence-Based Medicine; Gout; Gout Suppressants;

2018
Gout: state of the art after a decade of developments.
    Rheumatology (Oxford, England), 2019, 01-01, Volume: 58, Issue:1

    Topics: Allopurinol; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid; Xant

2019
Change gout: how to deal with this "silently-developing killer" in everyday clinical practice.
    Current medical research and opinion, 2018, Volume: 34, Issue:8

    Topics: Gout; Humans; Male; Uric Acid; Uricosuric Agents

2018
Serum urate as surrogate endpoint for flares in people with gout: A systematic review and meta-regression analysis.
    Seminars in arthritis and rheumatism, 2018, Volume: 48, Issue:2

    Topics: Biomarkers; Clinical Trials as Topic; Gout; Gout Suppressants; Humans; Treatment Outcome; Uric Acid

2018
Rate of adherence to urate-lowering therapy among patients with gout: a systematic review and meta-analysis.
    BMJ open, 2018, 04-10, Volume: 8, Issue:4

    Topics: Adult; Aged; Cross-Sectional Studies; Female; Gout; Gout Suppressants; Humans; Longitudinal Studies;

2018
Investigational drugs for hyperuricemia, an update on recent developments.
    Expert opinion on investigational drugs, 2018, Volume: 27, Issue:5

    Topics: Animals; Drug Design; Drugs, Investigational; Gout; Gout Suppressants; Humans; Hyperuricemia; Medica

2018
Current status of ultrasound and dual-energy computed tomography in the evaluation of gout.
    Rheumatology international, 2018, Volume: 38, Issue:8

    Topics: Arthritis, Gouty; Gout; Humans; Tomography, X-Ray Computed; Ultrasonography; Uric Acid

2018
An update on the genetics of hyperuricaemia and gout.
    Nature reviews. Rheumatology, 2018, Volume: 14, Issue:6

    Topics: Animals; Disease Progression; Genetic Predisposition to Disease; Genetic Variation; Genome-Wide Asso

2018
Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout.
    Current rheumatology reports, 2018, 06-21, Volume: 20, Issue:8

    Topics: Gout; Gout Suppressants; Humans; Treatment Outcome; Uric Acid

2018
Gout and arrhythmias: In search for causation beyond association.
    Trends in cardiovascular medicine, 2019, Volume: 29, Issue:1

    Topics: Ablation Techniques; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Biomarkers; Gout; Gout Suppressan

2019
Combination urate-lowering therapy in the treatment of gout: What is the evidence?
    Seminars in arthritis and rheumatism, 2019, Volume: 48, Issue:4

    Topics: Drug Therapy, Combination; Gout; Gout Suppressants; Humans; Treatment Outcome; Uric Acid

2019
[Update on Gout and Calcium pyrophosphate deposition (CPPD)].
    Deutsche medizinische Wochenschrift (1946), 2018, Volume: 143, Issue:16

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Chondrocalcinosis; Colchicine; Diagnostic Imaging; Glucocor

2018
The Role of Inhibitory Receptors in Monosodium Urate Crystal-Induced Inflammation.
    Frontiers in immunology, 2018, Volume: 9

    Topics: Animals; Costimulatory and Inhibitory T-Cell Receptors; Disease Susceptibility; Gout; Humans; Immuno

2018
Expert opinion on emerging urate-lowering therapies.
    Expert opinion on emerging drugs, 2018, Volume: 23, Issue:3

    Topics: Anti-Inflammatory Agents; Drug Design; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid

2018
Consumption of sugar sweetened beverages and dietary fructose in relation to risk of gout and hyperuricemia: a systematic review and meta-analysis.
    Critical reviews in food science and nutrition, 2020, Volume: 60, Issue:1

    Topics: Fructose; Gout; Humans; Hyperuricemia; Sugar-Sweetened Beverages; Uric Acid

2020
Evaluation of the diet wide contribution to serum urate levels: meta-analysis of population based cohorts.
    BMJ (Clinical research ed.), 2018, Oct-10, Volume: 363

    Topics: Cohort Studies; Cross-Sectional Studies; Diet; Genetic Predisposition to Disease; Gout; Humans; Unit

2018
Gout - An update of aetiology, genetics, co-morbidities and management.
    Maturitas, 2018, Volume: 118

    Topics: Allopurinol; Chronic Disease; Comorbidity; Diet; Febuxostat; Gout; Gout Suppressants; Humans; Hyperu

2018
The Challenges of Approaching and Managing Gout.
    Rheumatic diseases clinics of North America, 2019, Volume: 45, Issue:1

    Topics: Acetamides; Allopurinol; Antibodies, Monoclonal, Humanized; Colchicine; Diet Therapy; Febuxostat; Go

2019
Genetic advances in gout: potential applications in clinical practice.
    Current opinion in rheumatology, 2019, Volume: 31, Issue:2

    Topics: Allopurinol; Disease Progression; Genome-Wide Association Study; Gout; Gout Suppressants; HLA-B Anti

2019
Patient perspectives in gout: a review.
    Current opinion in rheumatology, 2019, Volume: 31, Issue:2

    Topics: Biomarkers; Gout; Gout Suppressants; Humans; Medication Adherence; Quality Improvement; Uric Acid

2019
Recapture and improved outcome of pegloticase response with methotrexate-A report of two cases and review of the literature.
    Seminars in arthritis and rheumatism, 2019, Volume: 49, Issue:1

    Topics: Adult; Drug Therapy, Combination; Gout; Gout Suppressants; Humans; Immunosuppressive Agents; Male; M

2019
The role of febuxostat in gout.
    Current opinion in rheumatology, 2019, Volume: 31, Issue:2

    Topics: Biomarkers; Febuxostat; Gout; Gout Suppressants; Humans; Uric Acid

2019
Gout and cardiovascular disease: crystallized confusion.
    Current opinion in rheumatology, 2019, Volume: 31, Issue:2

    Topics: Biomarkers; Cardiovascular Diseases; Colchicine; Global Health; Gout; Gout Suppressants; Humans; Mor

2019
Rare Manifestation of Gout: Gouty Tophi in the Nose.
    Annals of plastic surgery, 2019, Volume: 82, Issue:6

    Topics: Allopurinol; Biopsy, Needle; Gout; Humans; Immunohistochemistry; Male; Middle Aged; Nasal Cavity; Na

2019
Uric acid and the cardio-renal effects of SGLT2 inhibitors.
    Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:6

    Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Gout; Heart; Humans; Hypoglycemic Agents; Kidney

2019
Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy.
    Drugs, 2019, Volume: 79, Issue:5

    Topics: Allopurinol; Anti-Inflammatory Agents; Cardiovascular Diseases; Febuxostat; Female; Gout; Gout Suppr

2019
Painless gouty tophus in the nasal bridge: A case report and literature review.
    Medicine, 2019, Volume: 98, Issue:11

    Topics: Aged; Arthritis, Gouty; Biopsy, Fine-Needle; C-Reactive Protein; Colchicine; Febuxostat; Gout; Gout

2019
A meta-analysis of the association between gout, serum uric acid level, and obstructive sleep apnea.
    Sleep & breathing = Schlaf & Atmung, 2019, Volume: 23, Issue:4

    Topics: Adult; Aged; Biomarkers; Body Mass Index; Brazil; Correlation of Data; Disease Susceptibility; Femal

2019
Safety and tolerability of available urate-lowering drugs: a critical review.
    Expert opinion on drug safety, 2019, Volume: 18, Issue:4

    Topics: Enzyme Inhibitors; Gout; Gout Suppressants; Humans; Uric Acid; Uricosuric Agents; Xanthine Oxidase

2019
The anatomical pathology of gout: a systematic literature review.
    BMC musculoskeletal disorders, 2019, Apr-01, Volume: 20, Issue:1

    Topics: Gout; Humans; Kidney; Musculoskeletal System; Skin; Uric Acid

2019
Hyperuricemia and Cardiovascular Disease.
    Current pharmaceutical design, 2019, Volume: 25, Issue:6

    Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Metabolic Syndrome; Uric Acid

2019
Comparative efficacy and safety of lesinurad 200 mg and 400 mg combined with a xanthine oxidase inhibitor in hyperuricemic patients with gout: A Bayesian network meta-analysis of randomized controlled trials
.
    International journal of clinical pharmacology and therapeutics, 2019, Volume: 57, Issue:7

    Topics: Bayes Theorem; Drug Therapy, Combination; Gout; Humans; Network Meta-Analysis; Randomized Controlled

2019
Genome-wide meta-analysis identifies multiple novel loci associated with serum uric acid levels in Japanese individuals.
    Communications biology, 2019, Volume: 2

    Topics: Alleles; Computational Biology; Genetic Predisposition to Disease; Genome-Wide Association Study; Ge

2019
The effects of fruit consumption in patients with hyperuricaemia or gout.
    Rheumatology (Oxford, England), 2019, 07-01, Volume: 58, Issue:7

    Topics: Ascorbic Acid; Dietary Fiber; Fructose; Fruit; Fruit and Vegetable Juices; Gout; Humans; Hyperuricem

2019
The diagnostic performance of dual energy CT for diagnosing gout: a systematic literature review and meta-analysis.
    Rheumatology (Oxford, England), 2019, 12-01, Volume: 58, Issue:12

    Topics: Gout; Humans; Joints; Sensitivity and Specificity; Tomography, X-Ray Computed; Uric Acid

2019
Natural products for the management of hyperuricaemia and gout: a review.
    Archives of physiology and biochemistry, 2021, Volume: 127, Issue:1

    Topics: Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Asteraceae; Biological Products; Double-Blind M

2021
Genome-wide association study revealed novel loci which aggravate asymptomatic hyperuricaemia into gout.
    Annals of the rheumatic diseases, 2019, Volume: 78, Issue:10

    Topics: Adult; Aldehyde Dehydrogenase, Mitochondrial; Asymptomatic Diseases; ATP Binding Cassette Transporte

2019
Uric acid level, gout and bone mineral density: A Mendelian randomization study.
    European journal of clinical investigation, 2019, Volume: 49, Issue:9

    Topics: Bone Density; Causality; Femur Neck; Gout; Humans; Hyperuricemia; Lumbar Vertebrae; Mendelian Random

2019
Uric Acid and Plant-Based Nutrition.
    Nutrients, 2019, Jul-26, Volume: 11, Issue:8

    Topics: Biomarkers; Diet, Healthy; Diet, Vegetarian; Gout; Humans; Hyperuricemia; Nutritive Value; Protectiv

2019
The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis.
    Nutrition, metabolism, and cardiovascular diseases : NMCD, 2019, Volume: 29, Issue:10

    Topics: Aged; Allopurinol; Asymptomatic Diseases; Biomarkers; Enzyme Inhibitors; Febuxostat; Female; Gout; G

2019
Energy and fructose from beverages sweetened with sugar or high-fructose corn syrup pose a health risk for some people.
    Advances in nutrition (Bethesda, Md.), 2013, Mar-01, Volume: 4, Issue:2

    Topics: Beverages; Diabetes Mellitus; Diet; Dietary Sucrose; Fatty Liver; Fructose; Glucose; Gout; Humans; L

2013
New classification criteria for gout: a framework for progress.
    Rheumatology (Oxford, England), 2013, Volume: 52, Issue:10

    Topics: Crystallization; Gout; Humans; Rheumatology; Sensitivity and Specificity; Uric Acid

2013
Serum uric acid and gout: from the past to molecular biology.
    Current medical research and opinion, 2013, Volume: 29 Suppl 3

    Topics: Gout; Humans; Risk Factors; Uric Acid

2013
Chinese herbal medicine for gout: a systematic review of randomized clinical trials.
    Clinical rheumatology, 2013, Volume: 32, Issue:7

    Topics: Drugs, Chinese Herbal; Gout; Humans; Inflammation; Medicine, Chinese Traditional; Pain Management; P

2013
Type 1 sodium-dependent phosphate transporter acts as a membrane potential-driven urate exporter.
    Current molecular pharmacology, 2013, Volume: 6, Issue:2

    Topics: Amino Acid Sequence; Animals; Gout; Humans; Membrane Potentials; Molecular Sequence Data; Polymorphi

2013
Treatment of hyperuricaemia and gout.
    Clinical medicine (London, England), 2013, Volume: 13, Issue:4

    Topics: Biological Products; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid

2013
Systematic review of the prevalence of gout and hyperuricaemia in Australia.
    Internal medicine journal, 2012, Volume: 42, Issue:9

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Australia; Blood Donors; Child; Europe; Female; Gout; Hu

2012
Gouty tophi on the ear: a review.
    Cutis, 2013, Volume: 92, Issue:4

    Topics: Biopsy; Diagnosis, Differential; Ear Diseases; Ear, External; Ethanol; Gout; Humans; Uric Acid

2013
Association of the lipoprotein receptor-related protein 2 gene with gout and non-additive interaction with alcohol consumption.
    Arthritis research & therapy, 2013, Nov-04, Volume: 15, Issue:6

    Topics: Adaptor Proteins, Signal Transducing; Alcohol Drinking; Carrier Proteins; Female; Genetic Predisposi

2013
A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout.
    Seminars in arthritis and rheumatism, 2013, Volume: 43, Issue:3

    Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Treatment Outcom

2013
The distribution of urate deposition within the extremities in gout: a review of 148 dual-energy CT cases.
    Skeletal radiology, 2014, Volume: 43, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Extremities; Female; Gout; Humans; Male; Mid

2014
Mechanisms of spontaneous resolution of acute gouty inflammation.
    Current rheumatology reports, 2014, Volume: 16, Issue:1

    Topics: Arthritis, Gouty; Cytokines; Gout; Humans; Inflammation; Joints; Macrophages; Neutrophils; Remission

2014
The crystallization of monosodium urate.
    Current rheumatology reports, 2014, Volume: 16, Issue:2

    Topics: Cartilage, Articular; Chemistry, Physical; Crystallization; Gout; Humans; Hyperuricemia; Immunity, H

2014
[New aspects of diagnosis and therapy of gout].
    Praxis, 2013, Dec-31, Volume: 103, Issue:1

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Diagnosis, Differential

2013
Definition of hyperuricemia and gouty conditions.
    Current opinion in rheumatology, 2014, Volume: 26, Issue:2

    Topics: Cardiovascular Diseases; Crystallization; Female; Gout; Humans; Hyperuricemia; Male; Risk Factors; U

2014
Uricosuric drugs: the once and future therapy for hyperuricemia?
    Current opinion in rheumatology, 2014, Volume: 26, Issue:2

    Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Drug Dis

2014
Canakinumab for gout: a specific, patient-profiled indication.
    Expert review of clinical immunology, 2014, Volume: 10, Issue:3

    Topics: Antibodies, Blocking; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Clinical Trials as

2014
Systematic review and meta-analysis of the clinical efficacy and adverse effects of Chinese herbal decoction for the treatment of gout.
    PloS one, 2014, Volume: 9, Issue:1

    Topics: Adult; Aged; Databases, Bibliographic; Drugs, Chinese Herbal; Gout; Gout Suppressants; Humans; Medic

2014
Gout.
    BMJ (Clinical research ed.), 2013, Oct-01, Volume: 347

    Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Colchicine; Comorbidi

2013
Optimizing current treatment of gout.
    Nature reviews. Rheumatology, 2014, Volume: 10, Issue:5

    Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Gout; Humans; Uric Aci

2014
Multiple firm nodules and tender, indurated plaques.
    JAMA dermatology, 2014, Volume: 150, Issue:5

    Topics: Adult; Allopurinol; Biopsy, Needle; Diagnosis, Differential; Follow-Up Studies; Gout; Humans; Immuno

2014
Medication adherence in gout: a systematic review.
    Arthritis care & research, 2014, Volume: 66, Issue:10

    Topics: Biomarkers; Gout; Gout Suppressants; Humans; Medication Adherence; Multivariate Analysis; Risk Facto

2014
Clinical manifestations and diagnosis of gout.
    Rheumatic diseases clinics of North America, 2014, Volume: 40, Issue:2

    Topics: Asymptomatic Diseases; Chronic Disease; Disease Progression; Gout; Humans; Hyperuricemia; Uric Acid

2014
Structural joint damage in gout.
    Rheumatic diseases clinics of North America, 2014, Volume: 40, Issue:2

    Topics: Bone Remodeling; Cartilage; Gout; Gout Suppressants; Humans; Hyperuricemia; Joints; Osteoblasts; Ost

2014
The genetic basis of gout.
    Rheumatic diseases clinics of North America, 2014, Volume: 40, Issue:2

    Topics: Gene-Environment Interaction; Genome-Wide Association Study; Glycolysis; Gout; Humans; Hyperuricemia

2014
Prophylaxis for acute gout flares after initiation of urate-lowering therapy.
    Rheumatology (Oxford, England), 2014, Volume: 53, Issue:11

    Topics: Acute Disease; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid

2014
A review of phytotherapy of gout: perspective of new pharmacological treatments.
    Die Pharmazie, 2014, Volume: 69, Issue:4

    Topics: Animals; Anti-Inflammatory Agents; Gout; Humans; Hyperuricemia; Phytotherapy; Plants, Medicinal; Uri

2014
The emerging role of biotechnological drugs in the treatment of gout.
    BioMed research international, 2014, Volume: 2014

    Topics: Biotechnology; Cytokines; Gout; Gout Suppressants; Humans; Polyethylene Glycols; Recombinant Protein

2014
Is it time to revise the normal range of serum uric acid levels?
    European review for medical and pharmacological sciences, 2014, Volume: 18, Issue:9

    Topics: Age Factors; Biomarkers; Female; Gout; Healthy Volunteers; Humans; Hyperuricemia; Male; Predictive V

2014
Gout: joints and beyond, epidemiology, clinical features, treatment and co-morbidities.
    Maturitas, 2014, Volume: 78, Issue:4

    Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Colchicine; Gout; Gout Suppressants; Humans; Hype

2014
Imaging modalities for the classification of gout: systematic literature review and meta-analysis.
    Annals of the rheumatic diseases, 2015, Volume: 74, Issue:10

    Topics: Gout; Humans; Magnetic Resonance Imaging; Tomography, X-Ray Computed; Ultrasonography; Uric Acid

2015
Impaired response or insufficient dosage? Examining the potential causes of "inadequate response" to allopurinol in the treatment of gout.
    Seminars in arthritis and rheumatism, 2014, Volume: 44, Issue:2

    Topics: Allopurinol; Biomarkers; Dose-Response Relationship, Drug; Gout; Gout Suppressants; Humans; Patient

2014
Diagnostic value of clinical, laboratory, and imaging findings in patients with a clinical suspicion of gout: a systematic literature review.
    The Journal of rheumatology. Supplement, 2014, Volume: 92

    Topics: Arthritis; Colchicine; Diagnostic Imaging; Gout; Gout Suppressants; Humans; Radiography; Sensitivity

2014
Urate-lowering therapy for the management of gout: a summary of 2 Cochrane reviews.
    The Journal of rheumatology. Supplement, 2014, Volume: 92

    Topics: Gout; Humans; Treatment Outcome; Uric Acid; Uricosuric Agents

2014
Treatment target and followup measures for patients with gout: a systematic literature review.
    The Journal of rheumatology. Supplement, 2014, Volume: 92

    Topics: Gout; Gout Suppressants; Humans; Treatment Outcome; Uric Acid

2014
Twenty-eight loci that influence serum urate levels: analysis of association with gout.
    Annals of the rheumatic diseases, 2016, Volume: 75, Issue:1

    Topics: AMP-Activated Protein Kinases; Basic-Leucine Zipper Transcription Factors; Carrier Proteins; Case-Co

2016
Management of gout in general practice--a systematic review.
    Clinical rheumatology, 2015, Volume: 34, Issue:1

    Topics: Disease Management; General Practice; Gout; Gout Suppressants; Humans; Life Style; Uric Acid

2015
Urate-lowering therapy: current options and future prospects for elderly patients with gout.
    Drugs & aging, 2014, Volume: 31, Issue:11

    Topics: Aged; Gout; Gout Suppressants; Humans; Uric Acid

2014
Allopurinol for chronic gout.
    The Cochrane database of systematic reviews, 2014, Oct-14, Issue:10

    Topics: Allopurinol; Benzbromarone; Chronic Disease; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans

2014
Interventions for tophi in gout.
    The Cochrane database of systematic reviews, 2014, Oct-20, Issue:10

    Topics: Gout; Humans; Polyethylene Glycols; Randomized Controlled Trials as Topic; Urate Oxidase; Uric Acid

2014
[Gout and cardiovascular risk].
    Vnitrni lekarstvi, 2014, Volume: 60, Issue:10

    Topics: Cardiovascular Diseases; Gout; Gout Suppressants; Humans; Hyperuricemia; Risk Factors; Uric Acid

2014
Uricosuric medications for chronic gout.
    The Cochrane database of systematic reviews, 2014, Nov-14, Issue:11

    Topics: Adult; Aged; Allopurinol; Benzbromarone; Chronic Disease; Controlled Clinical Trials as Topic; Femal

2014
Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2014, Volume: 20, Issue:8

    Topics: Aged; Chronic Disease; Clinical Trials, Phase III as Topic; Cluster Analysis; Dose-Response Relation

2014
Managing gout: there's more we can do.
    The Journal of family practice, 2014, Volume: 63, Issue:12

    Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Age Distribution; Aged; Allopurinol; Anti-Inflammator

2014
Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis.
    Rheumatology international, 2015, Volume: 35, Issue:7

    Topics: Allopurinol; Biomarkers; Down-Regulation; Gout; Gout Suppressants; Humans; Hyperuricemia; Odds Ratio

2015
A review of uric acid, crystal deposition disease, and gout.
    Advances in therapy, 2015, Volume: 32, Issue:1

    Topics: Early Diagnosis; Early Medical Intervention; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Ac

2015
Advances in pharmacotherapy for the treatment of gout.
    Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:4

    Topics: Adrenal Cortex Hormones; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclona

2015
Diagnosis, treatment, and prevention of gout.
    American family physician, 2014, Dec-15, Volume: 90, Issue:12

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Diagnosis, Differential; Diet Therapy; Disease Management;

2014
Gout nodulosis: report of a rare case and brief review.
    Dermatology online journal, 2015, Jan-15, Volume: 21, Issue:1

    Topics: Chronic Disease; Dermis; Foot Diseases; Gout; Humans; Male; Middle Aged; Subcutaneous Tissue; Uric A

2015
Imaging as an Outcome Measure in Gout Studies: Report from the OMERACT Gout Working Group.
    The Journal of rheumatology, 2015, Volume: 42, Issue:12

    Topics: Absorptiometry, Photon; Consensus Development Conferences as Topic; Diagnostic Imaging; Female; Gout

2015
Uric acid: friend or foe? Uric acid and cognitive function "Gout kills more wise men than simple".
    European review for medical and pharmacological sciences, 2015, Volume: 19, Issue:4

    Topics: Animals; Antioxidants; Cardiovascular Diseases; Cognition; Female; Gout; Humans; Hyperuricemia; Male

2015
The gouty tophus: a review.
    Current rheumatology reports, 2015, Volume: 17, Issue:3

    Topics: Disease Progression; Gout; Gout Suppressants; Humans; Quality of Life; Treatment Outcome; Uric Acid

2015
Modulation of genetic associations with serum urate levels by body-mass-index in humans.
    PloS one, 2015, Volume: 10, Issue:3

    Topics: Antigens, Nuclear; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Tra

2015
Pharmacogenetic considerations in the treatment of gout.
    Pharmacogenomics, 2015, Volume: 16, Issue:6

    Topics: Allopurinol; Gout; HLA-B Antigens; Humans; Pharmacogenetics; Treatment Outcome; Uric Acid

2015
[A model-based meta-analysis to compare urate-lowering response rate of febuxostat and allopurinol in gout patient].
    Yao xue xue bao = Acta pharmaceutica Sinica, 2014, Volume: 49, Issue:12

    Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Thiazoles; Uric Acid

2014
Sugar-sweetened beverages, urate, gout and genetic interaction.
    Pacific health dialog, 2014, Volume: 20, Issue:1

    Topics: Beverages; Dietary Sucrose; Gene-Environment Interaction; Gout; Humans; Native Hawaiian or Other Pac

2014
How neutrophil extracellular traps orchestrate the local immune response in gout.
    Journal of molecular medicine (Berlin, Germany), 2015, Volume: 93, Issue:7

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Extracellular Traps; Gout; Humans; Inflam

2015
[Serum uric acid reference values: clinical nonsense as a measure of quality].
    MMW Fortschritte der Medizin, 2015, Apr-02, Volume: 157, Issue:6

    Topics: Allopurinol; Gout; Humans; Male; Medication Adherence; Middle Aged; Quality Indicators, Health Care;

2015
Investigational drugs for hyperuricemia.
    Expert opinion on investigational drugs, 2015, Volume: 24, Issue:8

    Topics: Aged; Animals; Drug Design; Drugs, Investigational; Gout; Gout Suppressants; Humans; Hyperuricemia;

2015
The association of vitamin C, alcohol, coffee, tea, milk and yogurt with uric acid and gout.
    International journal of rheumatic diseases, 2015, Volume: 18, Issue:5

    Topics: Animals; Ascorbic Acid; Coffee; Culture; Diet; Ethanol; Feeding Behavior; Female; Global Health; Gou

2015
Rational pharmacotherapy (RPT) in goutology: Define the serum uric acid target & treat-to-target patient cohort and review on urate lowering therapy (ULT) applying synthetic drugs.
    Joint bone spine, 2015, Volume: 82, Issue:4

    Topics: Gout; Humans; Treatment Outcome; Uric Acid; Uricosuric Agents

2015
ABCG2: the molecular mechanisms of urate secretion and gout.
    American journal of physiology. Renal physiology, 2015, Sep-15, Volume: 309, Issue:6

    Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Gout; Hu

2015
[Gout and and calcium pyrophosphate crystal arthropathies: pathophysiology].
    La Revue du praticien, 2015, Volume: 65, Issue:5

    Topics: Acute Disease; Calcium Pyrophosphate; Chondrocalcinosis; Gout; Humans; Uric Acid

2015
Molecular mechanisms of pain in crystal-induced arthritis.
    Best practice & research. Clinical rheumatology, 2015, Volume: 29, Issue:1

    Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Calcium Pyrophosphate; Chondrocalc

2015
2015 Gout Classification Criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.
    Arthritis & rheumatology (Hoboken, N.J.), 2015, Volume: 67, Issue:10

    Topics: Arthralgia; Europe; Gout; Humans; Synovial Fluid; United States; Uric Acid

2015
Mechanisms of crystal formation in gout-a structural approach.
    Nature reviews. Rheumatology, 2015, Volume: 11, Issue:12

    Topics: Crystallization; Gout; Humans; Uric Acid

2015
Uric acid lowering therapy in cardiovascular diseases.
    International journal of cardiology, 2016, Jun-15, Volume: 213

    Topics: Cardiovascular Diseases; Enzyme Inhibitors; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatmen

2016
Association analysis of the beta-3 adrenergic receptor Trp64Arg (rs4994) polymorphism with urate and gout.
    Rheumatology international, 2016, Volume: 36, Issue:2

    Topics: Biomarkers; Case-Control Studies; Gene Frequency; Genetic Association Studies; Genetic Predispositio

2016
Why focus on uric acid?
    Current medical research and opinion, 2015, Volume: 31 Suppl 2

    Topics: Animals; Gout; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Metabolic Syndrome; Risk Fact

2015
The management of hyperuricemia with urate deposition.
    Current medical research and opinion, 2015, Volume: 31 Suppl 2

    Topics: Diet; Gout; Humans; Hyperuricemia; Obesity; Overweight; Uric Acid

2015
Factors influencing the crystallization of monosodium urate: a systematic literature review.
    BMC musculoskeletal disorders, 2015, Oct-14, Volume: 16

    Topics: Animals; Antibodies; Connective Tissue; Crystallization; Gout; Humans; Hydrogen-Ion Concentration; P

2015
The first metatarsophalangeal joint in gout: a systematic review and meta-analysis.
    BMC musculoskeletal disorders, 2016, Feb-11, Volume: 17

    Topics: Gout; Humans; Metatarsophalangeal Joint; Osteoarthritis; Uric Acid

2016
From juvenile hyperuricaemia to dysfunctional uromodulin: an ongoing metamorphosis.
    Pediatric nephrology (Berlin, Germany), 2016, Volume: 31, Issue:11

    Topics: Adolescent; Chromosomes, Human, Pair 16; DNA Mutational Analysis; Exons; Gout; Hepatocyte Nuclear Fa

2016
Effects of coffee consumption on serum uric acid: systematic review and meta-analysis.
    Seminars in arthritis and rheumatism, 2016, Volume: 45, Issue:5

    Topics: Coffee; Female; Gout; Humans; Hyperuricemia; Male; Sex Factors; Uric Acid

2016
[Studies on association between nonalcoholic fatty liver disease and hyperuricemia: current status and future prospects].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2016, Volume: 24, Issue:2

    Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Gout; Humans; Hyperuricemia; Non-alcoholic Fatty

2016
[Uric acid, kidney disease and nephrolithiasis].
    Therapeutische Umschau. Revue therapeutique, 2016, Volume: 73, Issue:3

    Topics: Acid-Base Equilibrium; Gout; Humans; Hyperuricemia; Insulin Resistance; Kidney; Nephrolithiasis; Ren

2016
[Nutritional therapy of gout].
    Therapeutische Umschau. Revue therapeutique, 2016, Volume: 73, Issue:3

    Topics: Alcohol Drinking; Combined Modality Therapy; Diet, Mediterranean; Feeding Behavior; Gout; Humans; Nu

2016
Urate lowering therapies in the treatment of gout: a systematic review and meta-analysis.
    European review for medical and pharmacological sciences, 2016, Volume: 20, Issue:5

    Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Treatment Outcome; Uric Acid

2016
Review of the ophthalmic manifestations of gout and uric acid crystal deposition.
    Clinical & experimental ophthalmology, 2017, Volume: 45, Issue:1

    Topics: Eye Diseases; Gout; Humans; Hyperuricemia; Uric Acid

2017
Dual-Energy Computed Tomography of the Knee, Ankle, and Foot: Noninvasive Diagnosis of Gout and Quantification of Monosodium Urate in Tendons and Ligaments.
    Seminars in musculoskeletal radiology, 2016, Volume: 20, Issue:1

    Topics: Ankle Joint; Foot; Gout; Humans; Knee Joint; Ligaments, Articular; Radiography, Dual-Energy Scanned

2016
Urate Handling in the Human Body.
    Current rheumatology reports, 2016, Volume: 18, Issue:6

    Topics: Gout; Humans; Hyperuricemia; Intestinal Mucosa; Kidney; Kidney Tubules; Organic Anion Transporters;

2016
Beyond Joints: a Review of Ocular Abnormalities in Gout and Hyperuricemia.
    Current rheumatology reports, 2016, Volume: 18, Issue:6

    Topics: Eye Diseases; Gout; Humans; Hyperuricemia; Risk Factors; Uric Acid; Uveitis

2016
The management of gout: Much has changed.
    Australian family physician, 2016, Volume: 45, Issue:5

    Topics: Gout; Gout Suppressants; Humans; Patient Education as Topic; Uric Acid

2016
Gouty Arthritis: A Review of Acute Management and Prevention.
    Pharmacotherapy, 2016, Volume: 36, Issue:8

    Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Gout

2016
[HYPERURICEMIA AND POTENTIAL RISK OF CARDIOVASCULAR AND RENAL DISEASES].
    Revue medicale de Liege, 2016, Volume: 71, Issue:5

    Topics: Aged; Cardiovascular Diseases; Gout; Gout Suppressants; Humans; Hyperuricemia; Kidney Diseases; Male

2016
Review: Gout: A Roadmap to Approaches for Improving Global Outcomes.
    Arthritis & rheumatology (Hoboken, N.J.), 2017, Volume: 69, Issue:1

    Topics: Comorbidity; Disease Management; Global Health; Gout; Gout Suppressants; Humans; Hyperuricemia; Magn

2017
[Inflammasome and gout].
    Zeitschrift fur Rheumatologie, 2016, Volume: 75, Issue:6

    Topics: Antibodies, Monoclonal; Arthritis, Rheumatoid; Cytokines; Evidence-Based Medicine; Gout; Gout Suppre

2016
2016 updated EULAR evidence-based recommendations for the management of gout.
    Annals of the rheumatic diseases, 2017, Volume: 76, Issue:1

    Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Delphi Technique; Directive Counse

2017
Hyperuricemia, the kidneys, and the spectrum of associated diseases: a narrative review.
    Current medical research and opinion, 2016, Volume: 32, Issue:11

    Topics: Gout; Humans; Hyperuricemia; Kidney; Kidney Diseases; Uric Acid

2016
Drug-induced hyperuricaemia and gout.
    Rheumatology (Oxford, England), 2017, 05-01, Volume: 56, Issue:5

    Topics: Androgens; Antitubercular Agents; Aspirin; Carbohydrates; Cytotoxins; Diuretics; Gout; Humans; Hyper

2017
Overview of Serum Uric Acid Treatment Targets in Gout: Why Less Than 6 mg/dL?
    Postgraduate medicine, 2016, Volume: 128, Issue:7

    Topics: Disease Management; Gout; Gout Suppressants; Humans; Hyperuricemia; Patient Compliance; Uric Acid

2016
Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis.
    Scientific reports, 2016, 09-08, Volume: 6

    Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Network Meta-Analysis; Odds Ratio; Probability; Rand

2016
Gout and African Americans: Reducing disparities.
    Cleveland Clinic journal of medicine, 2016, Volume: 83, Issue:9

    Topics: Black or African American; Gout; Gout Suppressants; Healthcare Disparities; Humans; Medication Thera

2016
Using serum urate as a validated surrogate end point for flares in patients with gout: protocol for a systematic review and meta-regression analysis.
    BMJ open, 2016, 09-20, Volume: 6, Issue:9

    Topics: Biomarkers; Gout; Humans; Reproducibility of Results; Research Design; Systematic Reviews as Topic;

2016
Xanthine oxidoreductase and its inhibitors: relevance for gout.
    Clinical science (London, England : 1979), 2016, 12-01, Volume: 130, Issue:23

    Topics: Allopurinol; Animals; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Humans; Hypoxanthine;

2016
Diagnosis of Gout: A Systematic Review in Support of an American College of Physicians Clinical Practice Guideline.
    Annals of internal medicine, 2017, Jan-03, Volume: 166, Issue:1

    Topics: Algorithms; Gout; Humans; Practice Guidelines as Topic; Reference Standards; Sensitivity and Specifi

2017
Dual-Energy CT for the Musculoskeletal System.
    Radiology, 2016, Volume: 281, Issue:3

    Topics: Adult; Aged; Arthrography; Artifacts; Bone Density; Bone Marrow Diseases; Collagen; Edema; Female; G

2016
Update on Crystal-Induced Arthritides.
    Clinics in geriatric medicine, 2017, Volume: 33, Issue:1

    Topics: Aged; Global Health; Gout; Humans; Morbidity; Prevalence; Uric Acid

2017
Major unanswered questions in the clinical gout field.
    Current opinion in rheumatology, 2017, Volume: 29, Issue:2

    Topics: Allopurinol; Benzbromarone; Colchicine; Disease Progression; Febuxostat; Gout; Gout Suppressants; Hu

2017
Allopurinol: insights from studies of dose-response relationships.
    Expert opinion on drug metabolism & toxicology, 2017, Volume: 13, Issue:4

    Topics: Allopurinol; Dose-Response Relationship, Drug; Female; Gout; Gout Suppressants; Humans; Hyperuricemi

2017
Imaging of gout: New tools and biomarkers?
    Best practice & research. Clinical rheumatology, 2016, Volume: 30, Issue:4

    Topics: Biomarkers; Gout; Humans; Uric Acid

2016
Factors modulating the inflammatory response in acute gouty arthritis.
    Current opinion in rheumatology, 2017, Volume: 29, Issue:2

    Topics: Arthritis, Gouty; Autophagy; Gastrointestinal Microbiome; Gout; Humans; Hyperuricemia; Inflammasomes

2017
Limitations of the Current Standards of Care for Treating Gout and Crystal Deposition in the Primary Care Setting: A Review.
    Clinical therapeutics, 2017, Volume: 39, Issue:2

    Topics: Chronic Disease; Comorbidity; Gout; Gout Suppressants; Humans; Hyperuricemia; Patient Compliance; Pr

2017
The safety of treatment options available for gout.
    Expert opinion on drug safety, 2017, Volume: 16, Issue:4

    Topics: Acute Disease; Aged; Anti-Inflammatory Agents; Chronic Disease; Comorbidity; Gout; Gout Suppressants

2017
Serum Uric Acid and the Risk of Incident and Recurrent Gout: A Systematic Review.
    The Journal of rheumatology, 2017, Volume: 44, Issue:3

    Topics: Gout; Humans; Incidence; Recurrence; Risk; Uric Acid

2017
Crystal arthritides - gout and calcium pyrophosphate arthritis : Part 2: clinical features, diagnosis and differential diagnostics.
    Zeitschrift fur Gerontologie und Geriatrie, 2018, Volume: 51, Issue:5

    Topics: Aged; Arthritis; Calcium; Calcium Pyrophosphate; Chondrocalcinosis; Diagnosis, Differential; Gout; H

2018
Crystal arthritides - gout and calcium pyrophosphate arthritis : Part 1: Epidemiology and pathophysiology.
    Zeitschrift fur Gerontologie und Geriatrie, 2018, Volume: 51, Issue:4

    Topics: Aged; Aged, 80 and over; Calcium; Calcium Phosphates; Calcium Pyrophosphate; Chondrocalcinosis; Crys

2018
Is tea consumption associated with the serum uric acid level, hyperuricemia or the risk of gout? A systematic review and meta-analysis.
    BMC musculoskeletal disorders, 2017, 02-28, Volume: 18, Issue:1

    Topics: Gout; Humans; Hyperuricemia; Observational Studies as Topic; Tea; Uric Acid

2017
Crystal arthritides - gout and calcium pyrophosphate arthritis : Part 3: Treatment.
    Zeitschrift fur Gerontologie und Geriatrie, 2018, Volume: 51, Issue:6

    Topics: Aged; Arthritis; Calcium; Calcium Pyrophosphate; Gout; Gout Suppressants; Humans; Uric Acid

2018
SLC2A9--a fructose transporter identified as a novel uric acid transporter.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2008, Volume: 23, Issue:9

    Topics: Animals; Female; Fructose; Glucose Transport Proteins, Facilitative; Gout; Homeostasis; Humans; Hype

2008
Lessons from comparative physiology: could uric acid represent a physiologic alarm signal gone awry in western society?
    Journal of comparative physiology. B, Biochemical, systemic, and environmental physiology, 2009, Volume: 179, Issue:1

    Topics: Animals; Antioxidants; Ascorbic Acid; Blood Pressure; Evolution, Molecular; Fasting; Fructose; Gout;

2009
Febuxostat.
    Drugs, 2008, Volume: 68, Issue:13

    Topics: Administration, Oral; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Molecular Structur

2008
The pathogenesis of gout.
    Cleveland Clinic journal of medicine, 2008, Volume: 75 Suppl 5

    Topics: Gout; Humans; Prognosis; Risk Factors; Synovial Membrane; Uric Acid

2008
Clinical manifestations of hyperuricemia and gout.
    Cleveland Clinic journal of medicine, 2008, Volume: 75 Suppl 5

    Topics: Diagnosis, Differential; Gout; Humans; Hyperuricemia; Uric Acid

2008
The gout diagnosis.
    Cleveland Clinic journal of medicine, 2008, Volume: 75 Suppl 5

    Topics: Biomarkers; Diagnosis, Differential; Gout; Humans; Physical Examination; Uric Acid

2008
Gout: an evidence-based review.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2008, Volume: 14, Issue:5 Suppl

    Topics: Anti-Inflammatory Agents; Evidence-Based Medicine; Gout; Gout Suppressants; Humans; Uric Acid

2008
Crystal ball gazing: new therapeutic targets for hyperuricaemia and gout.
    Rheumatology (Oxford, England), 2009, Volume: 48, Issue:3

    Topics: Bone Resorption; Crystallization; Glucose Transport Proteins, Facilitative; Gout; Gout Suppressants;

2009
Quality of life and quality of care for patients with gout.
    Current rheumatology reports, 2009, Volume: 11, Issue:2

    Topics: Allopurinol; Delivery of Health Care; Disability Evaluation; Female; Gout; Gout Suppressants; Health

2009
Reassessing serum urate targets in the management of refractory gout: can you go too low?
    Current opinion in rheumatology, 2009, Volume: 21, Issue:2

    Topics: Crystallization; Gout; Gout Suppressants; Humans; Oxidative Stress; Uric Acid

2009
Update on emerging urate-lowering therapies.
    Current opinion in rheumatology, 2009, Volume: 21, Issue:2

    Topics: Allopurinol; Drug Discovery; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Humans; Polyeth

2009
Joint aspiration and injection and synovial fluid analysis.
    Best practice & research. Clinical rheumatology, 2009, Volume: 23, Issue:2

    Topics: Adrenal Cortex Hormones; Calcium Pyrophosphate; Crystallization; Gout; Humans; Injections, Intra-Art

2009
New insights into the epidemiology of gout.
    Rheumatology (Oxford, England), 2009, Volume: 48 Suppl 2

    Topics: Acute Disease; Diagnosis, Differential; Gout; Humans; Risk Factors; Uric Acid

2009
Gout--what are the treatment options?
    Expert opinion on pharmacotherapy, 2009, Volume: 10, Issue:8

    Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anti-Inflammatory Agents, Non-Steroidal; Colch

2009
Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations.
    PLoS genetics, 2009, Volume: 5, Issue:6

    Topics: Female; Genetic Variation; Genome-Wide Association Study; Gout; Humans; Male; Uric Acid

2009
Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link?
    Arthritis research & therapy, 2009, Volume: 11, Issue:4

    Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Uric Acid

2009
Recent insights into the pathogenesis of hyperuricaemia and gout.
    Human molecular genetics, 2009, Oct-15, Volume: 18, Issue:R2

    Topics: Animals; Genetic Predisposition to Disease; Genome-Wide Association Study; Gout; Humans; Hyperuricem

2009
Crystal-induced neutrophil activation.
    Immunology and cell biology, 2010, Volume: 88, Issue:1

    Topics: Animals; Crystallization; Gout; Humans; Neutrophil Activation; Signal Transduction; Uric Acid

2010
Medical implications of hyperuricemia.
    Medicine and health, Rhode Island, 2009, Volume: 92, Issue:11

    Topics: Animals; Cardiovascular Diseases; Gout; Humans; Hypertension; Hyperuricemia; Kidney Diseases; Metabo

2009
Gout in women.
    Medicine and health, Rhode Island, 2009, Volume: 92, Issue:11

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Diagnostic Errors; Female; Gout; Gout Suppressants; Humans;

2009
Unusual clinical presentations of gout.
    Current opinion in rheumatology, 2010, Volume: 22, Issue:2

    Topics: Aged; Diagnosis, Differential; Gout; Humans; Uric Acid

2010
[Calcium antagonists: current and future applications based on new evidence. The mechanisms on lowering serum uric acid level by calcium channel blockers].
    Clinical calcium, 2010, Volume: 20, Issue:1

    Topics: Anaerobiosis; Calcium Channel Blockers; Cardiovascular Diseases; Depression, Chemical; Gout; Humans;

2010
Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
    Clinical therapeutics, 2009, Volume: 31, Issue:11

    Topics: Allopurinol; Biotransformation; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibito

2009
Inflammation, oxidative stress and lipids: the risk triad for atherosclerosis in gout.
    Rheumatology (Oxford, England), 2010, Volume: 49, Issue:7

    Topics: Atherosclerosis; Gout; Humans; Hyperuricemia; Inflammasomes; Lipid Metabolism; Lipids; Oxidative Str

2010
Diagnosing and treating gout: a review to aid primary care physicians.
    Postgraduate medicine, 2010, Volume: 122, Issue:2

    Topics: Adrenal Cortex Hormones; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Gout; Gou

2010
Gout, hyperuricemia, and the risk of cardiovascular disease: cause and effect?
    Current rheumatology reports, 2010, Volume: 12, Issue:2

    Topics: Animals; Antioxidants; Cardiovascular Diseases; Cells, Cultured; Clinical Trials as Topic; Comorbidi

2010
Update on biology: uric acid and the activation of immune and inflammatory cells.
    Current rheumatology reports, 2010, Volume: 12, Issue:2

    Topics: Acute Disease; Crystallization; Gout; Humans; Immune System; Immunity, Innate; Inflammation; Inflamm

2010
The role of uric acid and other crystals in osteoarthritis.
    Current rheumatology reports, 2010, Volume: 12, Issue:2

    Topics: Calcium Pyrophosphate; Crystallization; Gout; Humans; Joints; Osteoarthritis; Uric Acid

2010
Gout, hyperuricemia, and Parkinson's disease: a protective effect?
    Current rheumatology reports, 2010, Volume: 12, Issue:2

    Topics: Aged; Biomarkers; Clinical Trials as Topic; Comorbidity; Female; Gout; Humans; Hyperuricemia; Male;

2010
Mechanisms of inflammation in gout.
    Arthritis research & therapy, 2010, Volume: 12, Issue:2

    Topics: Acute Disease; Animals; Carrier Proteins; Chemotaxis, Leukocyte; Crystallization; Disease Models, An

2010
An update on inflammatory arthropathies including pharmacologic management and preoperative considerations.
    Clinics in podiatric medicine and surgery, 2010, Volume: 27, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Diagnosis, Differential; Foot Diseases; Foot Joi

2010
Recent developments in immune activation by uric acid crystals.
    Archivum immunologiae et therapiae experimentalis, 2010, Volume: 58, Issue:4

    Topics: Animals; Crystallization; Gout; Humans; Immunity, Innate; Uric Acid

2010
Uric acid transport and disease.
    The Journal of clinical investigation, 2010, Volume: 120, Issue:6

    Topics: Animals; Biological Transport; Glucose Transport Proteins, Facilitative; Gout; Humans; Hypertension;

2010
What do I need to know about gout?
    The Journal of family practice, 2010, Volume: 59, Issue:6 Suppl

    Topics: Clinical Competence; Female; Gout; Gout Suppressants; Humans; Male; Morbidity; Physicians, Family; R

2010
Management of gout: beyond allopurinol.
    Internal medicine journal, 2010, Volume: 40, Issue:8

    Topics: Allopurinol; Animals; Biomarkers; Disease Management; Gout; Humans; Uric Acid

2010
Polyarticular gout attacks following cerebrovascular accidents: is hemiparesis in fact protective? 2 cases and a review of the literature.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2010, Volume: 16, Issue:6

    Topics: Central Nervous System; Gout; Humans; Male; Middle Aged; Paresis; Rheumatic Diseases; Stroke; Thromb

2010
Gout therapeutics: new drugs for an old disease.
    Lancet (London, England), 2011, Jan-08, Volume: 377, Issue:9760

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Clinical Trials as Topic; Drug Administra

2011
Gout: epitome of painful arthritis.
    Metabolism: clinical and experimental, 2010, Volume: 59 Suppl 1

    Topics: Arthritis; Female; Gout; Humans; Hyperuricemia; Immunity, Innate; Male; Pain; Uric Acid

2010
Gout: a clinical syndrome illustrated and discussed.
    The Netherlands journal of medicine, 2010, Volume: 68, Issue:9

    Topics: Aged; Aged, 80 and over; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseas

2010
Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors.
    Circulation. Cardiovascular genetics, 2010, Volume: 3, Issue:6

    Topics: Cardiovascular Diseases; Coronary Disease; Female; Genetic Loci; Genome-Wide Association Study; Gout

2010
Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis.
    Biomarkers in medicine, 2010, Volume: 4, Issue:5

    Topics: Biomarkers; Gout; Humans; Oxidative Stress; Parkinson Disease; Prognosis; Risk Factors; Urate Oxidas

2010
Crystal arthropathies: recognizing and treating "the gouch".
    Primary care, 2010, Volume: 37, Issue:4

    Topics: Allopurinol; Antimetabolites; Chronic Disease; Colchicine; Febuxostat; Gout; Gout Suppressants; Huma

2010
Serum urate as a soluble biomarker in chronic gout-evidence that serum urate fulfills the OMERACT validation criteria for soluble biomarkers.
    Seminars in arthritis and rheumatism, 2011, Volume: 40, Issue:6

    Topics: Biomarkers; Chronic Disease; Endpoint Determination; Female; Gout; Humans; Male; Predictive Value of

2011
In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2).
    Handbook of experimental pharmacology, 2011, Issue:201

    Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding

2011
[Molecular mechanism of renal urate transport: urate transporters as novel targets for drug development].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2010, Volume: 136, Issue:6

    Topics: Animals; Biological Transport; Drug Design; Gout; Humans; Hyperuricemia; Kidney; Kidney Glomerulus;

2010
Gout and hyperuricemia in young people.
    Current opinion in rheumatology, 2011, Volume: 23, Issue:2

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Gout; Humans; Hyperuricemia; Middle Aged; U

2011
The role of uric acid as an endogenous danger signal in immunity and inflammation.
    Current rheumatology reports, 2011, Volume: 13, Issue:2

    Topics: Adjuvants, Immunologic; Animals; Autoimmunity; Carrier Proteins; Crystallization; Disease Models, An

2011
Synovial fluid analysis for crystals.
    Current opinion in rheumatology, 2011, Volume: 23, Issue:2

    Topics: Calcium Pyrophosphate; Chondrocalcinosis; Gout; Humans; Synovial Fluid; Uric Acid

2011
Clinical practice. Gout.
    The New England journal of medicine, 2011, Feb-03, Volume: 364, Issue:5

    Topics: Allopurinol; Anti-Inflammatory Agents; Colchicine; Gout; Gout Suppressants; Humans; Hyperuricemia; M

2011
Pegloticase (krystexxa) for treatment of refractory gout.
    The Medical letter on drugs and therapeutics, 2011, Feb-07, Volume: 53, Issue:1357

    Topics: Animals; Clinical Trials as Topic; Enzymes, Immobilized; Gout; Humans; Polyethylene Glycols; Treatme

2011
A new perspective on the pharmacoeconomics of colchicine.
    Current medical research and opinion, 2011, Volume: 27, Issue:5

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Chronic Disease; Colchicine; Costs and Cos

2011
[Treatment of gout].
    La Revue de medecine interne, 2011, Volume: 32, Issue:12

    Topics: Adrenal Cortex Hormones; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Febuxosta

2011
Uric acid metabolism in normal man and in primary gout.
    The New England journal of medicine, 1965, Aug-05, Volume: 273, Issue:6

    Topics: Arthritis, Gouty; Gout; Humans; Hyperuricemia; Inosine Monophosphate; Male; Quaternary Ammonium Comp

1965
[Febuxostat].
    Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:23

    Topics: Allopurinol; Enzyme Activation; Febuxostat; Gout; Gout Suppressants; Humans; Randomized Controlled T

2011
A new standard of care? Studies on febuxostat in the management of hyperuricemia with and without gout.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2011, Volume: 17, Issue:4 Suppl 2

    Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Primary Health Care; Thiazoles; Treatmen

2011
Genome-wide association study for serum urate concentrations and gout among African Americans identifies genomic risk loci and a novel URAT1 loss-of-function allele.
    Human molecular genetics, 2011, Oct-15, Volume: 20, Issue:20

    Topics: Adult; Aged; Animals; Black or African American; CHO Cells; Cricetinae; Female; Genetic Loci; Geneti

2011
The challenges of gout management in the elderly.
    Drugs & aging, 2011, Aug-01, Volume: 28, Issue:8

    Topics: Aged; Aging; Gout; Humans; Uric Acid

2011
[Gout - regardless of therapeutic options a "forgotten" disease].
    Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:33

    Topics: Allopurinol; Arthritis, Gouty; Benzbromarone; Combined Modality Therapy; Cytokines; Europe; Febuxost

2011
Soyfoods, hyperuricemia and gout: a review of the epidemiologic and clinical data.
    Asia Pacific journal of clinical nutrition, 2011, Volume: 20, Issue:3

    Topics: Asia; Attitude of Health Personnel; Diet; Gout; Humans; Hyperuricemia; Prevalence; Risk Factors; Soy

2011
Is there anything good in uric acid?
    QJM : monthly journal of the Association of Physicians, 2011, Volume: 104, Issue:12

    Topics: Age Factors; Brain Diseases; Cardiovascular Diseases; Female; Gout; Humans; Hypertension; Hyperurice

2011
Clinical inquiry. Are serum uric acid levels always elevated in acute gout?
    The Journal of family practice, 2011, Volume: 60, Issue:10

    Topics: Acute Disease; Allopurinol; Arthritis, Gouty; Biomarkers; Gout; Gout Suppressants; Humans; Hyperuric

2011
The epidemiology of uric acid and fructose.
    Seminars in nephrology, 2011, Volume: 31, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Beverages; Diabetes Mellitus; Female; Fructose; Gout; Humans; Hyperu

2011
Hyperuricemia, gout and the kidney.
    Current opinion in rheumatology, 2012, Volume: 24, Issue:2

    Topics: Gout; Humans; Hyperuricemia; Kidney Failure, Chronic; Uric Acid

2012
Recent advances in management of gout.
    QJM : monthly journal of the Association of Physicians, 2012, Volume: 105, Issue:5

    Topics: Adrenal Cortex Hormones; Alcohol Drinking; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Ant

2012
Uric acid, hyperuricemia and vascular diseases.
    Frontiers in bioscience (Landmark edition), 2012, 01-01, Volume: 17, Issue:2

    Topics: Coronary Disease; Gout; Humans; Hypertension; Hyperuricemia; Inflammasomes; Inflammation; Metabolic

2012
Diagnosis and treatment of gout in primary care.
    The Practitioner, 2011, Volume: 255, Issue:1746

    Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Gout; Gout Suppressants; Humans; Primary Healt

2011
Some historical remarks on microcrystalline arthritis (gout and chondrocalcinosis).
    Reumatismo, 2012, Jan-19, Volume: 63, Issue:4

    Topics: Arthritis, Gouty; Biomarkers; Chondrocalcinosis; Crystallization; Gout; History, 19th Century; Histo

2012
Metabolism of crystals within the joint.
    Reumatismo, 2012, Jan-19, Volume: 63, Issue:4

    Topics: Arthritis, Gouty; Biomarkers; Calcium Phosphates; Calcium Pyrophosphate; Chondrocalcinosis; Chondroc

2012
The mechanisms of inflammation in gout and pseudogout (CPP-induced arthritis).
    Reumatismo, 2012, Jan-19, Volume: 63, Issue:4

    Topics: Apoptosis; Arthritis, Gouty; Biomarkers; Calcium Phosphates; Carrier Proteins; Chondrocalcinosis; En

2012
Clinical features of gout.
    Reumatismo, 2012, Jan-19, Volume: 63, Issue:4

    Topics: Acute Disease; Arthritis, Gouty; Biomarkers; Chronic Disease; Crystallization; Diagnosis, Differenti

2012
Cardiovascular and renal effects of hyperuricaemia and gout.
    Reumatismo, 2012, Jan-19, Volume: 63, Issue:4

    Topics: Biomarkers; Cardiovascular Diseases; Diabetes Complications; Disease Progression; Evidence-Based Med

2012
[Urate exporter gene ABCG 2/BCRP and gout risk].
    Seikagaku. The Journal of Japanese Biochemical Society, 2011, Volume: 83, Issue:12

    Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Gout; Hy

2011
Regulation of uric acid excretion by the kidney.
    Current rheumatology reports, 2012, Volume: 14, Issue:2

    Topics: Gout; Humans; Hyperuricemia; Kidney; Organic Anion Transporters; Organic Cation Transport Proteins;

2012
Gout measures: Gout Assessment Questionnaire (GAQ, GAQ2.0), and physical measurement of tophi.
    Arthritis care & research, 2011, Volume: 63 Suppl 11

    Topics: Gout; Humans; Physical Examination; Reproducibility of Results; Severity of Illness Index; Surveys a

2011
Pathway analysis of genome-wide association studies on uric acid concentrations.
    Human immunology, 2012, Volume: 73, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Genome-Wide Association Study; Gout; Humans; Male; Metab

2012
[Renal affection in gout].
    Terapevticheskii arkhiv, 2012, Volume: 84, Issue:1

    Topics: Creatinine; Gout; Humans; Hyperuricemia; Insulin Resistance; Kidney Diseases; Kidney Glomerulus; Pro

2012
[Gout: an overview of available urate lowering therapies].
    Annales pharmaceutiques francaises, 2012, Volume: 70, Issue:3

    Topics: Allopurinol; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Guidelines as Topic; Humans; Or

2012
Pegloticase for treating refractory chronic gout.
    Drugs of today (Barcelona, Spain : 1998), 2012, Volume: 48, Issue:7

    Topics: Animals; Biomarkers; Chronic Disease; Drug Interactions; Evidence-Based Medicine; Gout; Gout Suppres

2012
Gout: why is this curable disease so seldom cured?
    Annals of the rheumatic diseases, 2012, Volume: 71, Issue:11

    Topics: Attitude to Health; Chronic Disease; Disease Management; Drug Utilization; Gout; Humans; Life Style;

2012
Gout as autoinflammatory disease: new mechanisms for more appropriated treatment targets.
    Autoimmunity reviews, 2012, Volume: 12, Issue:1

    Topics: Animals; Gout; Hereditary Autoinflammatory Diseases; Humans; Hyperuricemia; Uric Acid

2012
The unwelcome visitor.
    Singapore medical journal, 2012, Volume: 53, Issue:8

    Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Colchicine

2012
Uric acid as a danger signal in gout and its comorbidities.
    Nature reviews. Rheumatology, 2013, Volume: 9, Issue:1

    Topics: Biomarkers; Cardiovascular Diseases; Comorbidity; Crystallization; Diabetes Mellitus; Gout; Humans;

2013
The genetics of hyperuricaemia and gout.
    Nature reviews. Rheumatology, 2012, Volume: 8, Issue:10

    Topics: Allopurinol; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transport

2012
Hyperuricaemia: more than just a cause of gout?
    Journal of cardiovascular medicine (Hagerstown, Md.), 2013, Volume: 14, Issue:6

    Topics: Animals; Biomarkers; Cardiovascular Diseases; Female; Gout; Humans; Hyperuricemia; Inflammation; Kid

2013
Renal transport of uric acid: evolving concepts and uncertainties.
    Advances in chronic kidney disease, 2012, Volume: 19, Issue:6

    Topics: Biological Transport; Glucose Transport Proteins, Facilitative; Gout; Humans; Hyperuricemia; Kidney;

2012
A perspective on diet and gout.
    Advances in chronic kidney disease, 2012, Volume: 19, Issue:6

    Topics: Diet; Fructose; Gout; Humans; Hyperuricemia; Purines; Risk Factors; Uric Acid

2012
Genetic disorders resulting in hyper- or hypouricemia.
    Advances in chronic kidney disease, 2012, Volume: 19, Issue:6

    Topics: Gout; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Renal Tubular Transport, Inborn Errors; U

2012
The rheumatology of gout.
    Advances in chronic kidney disease, 2012, Volume: 19, Issue:6

    Topics: Gout; Gout Suppressants; Humans; Kidney Failure, Chronic; Uric Acid

2012
Uric acid stones and hyperuricosuria.
    Advances in chronic kidney disease, 2012, Volume: 19, Issue:6

    Topics: Enzyme Inhibitors; Gout; Humans; Hydrogen-Ion Concentration; Risk Factors; Uric Acid; Urolithiasis;

2012
Advanced kidney failure and hyperuricemia.
    Advances in chronic kidney disease, 2012, Volume: 19, Issue:6

    Topics: Gout; Humans; Hyperuricemia; Kidney Failure, Chronic; Renal Dialysis; Uric Acid

2012
Evaluation and treatment of gout as a chronic disease.
    Advances in therapy, 2012, Volume: 29, Issue:11

    Topics: Arthritis, Gouty; Chronic Disease; Disease Progression; Evaluation Studies as Topic; Febuxostat; Fem

2012
Safety of urate-lowering therapies: managing the risks to gain the benefits.
    Rheumatic diseases clinics of North America, 2012, Volume: 38, Issue:4

    Topics: Allopurinol; Comorbidity; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Risk Factors;

2012
The accuracy of methods for urate crystal detection in synovial fluid and the effect of sample handling: a systematic review.
    Clinical rheumatology, 2013, Volume: 32, Issue:2

    Topics: Chemistry, Clinical; Crystallization; Gout; Humans; Reproducibility of Results; Specimen Handling; S

2013
Update on gout 2012.
    Joint bone spine, 2012, Volume: 79, Issue:6

    Topics: Disease Management; Gout; Gout Suppressants; Humans; Hyperuricemia; Tomography, X-Ray Computed; Ultr

2012
Chronic hyperuricemia, uric acid deposit and cardiovascular risk.
    Current pharmaceutical design, 2013, Volume: 19, Issue:13

    Topics: Cardiovascular Diseases; Chronic Disease; Gout; Humans; Hyperuricemia; Risk Factors; Uric Acid

2013
Novel drug discovery strategies for gout.
    Expert opinion on drug discovery, 2013, Volume: 8, Issue:2

    Topics: Drug Discovery; Gout; Gout Suppressants; Humans; Polyethylene Glycols; Uric Acid; Uricosuric Agents;

2013
The interplay between diet, urate transporters and the risk for gout and hyperuricemia: current and future directions.
    International journal of rheumatic diseases, 2012, Volume: 15, Issue:6

    Topics: Animals; Diet; Gout; Humans; Hyperuricemia; Organic Anion Transporters; Risk Factors; Uric Acid

2012
Genome-wide association analyses identify 18 new loci associated with serum urate concentrations.
    Nature genetics, 2013, Volume: 45, Issue:2

    Topics: Analysis of Variance; Gene Frequency; Genetic Loci; Genome-Wide Association Study; Glucose; Gout; Hu

2013
Dual-energy computed tomography for gout diagnosis and management.
    Current rheumatology reports, 2013, Volume: 15, Issue:1

    Topics: Arthritis, Gouty; Drug Monitoring; Gout; Gout Suppressants; Humans; Tomography, X-Ray Computed; Uric

2013
The kidney in hyperuricemia and gout.
    Current opinion in nephrology and hypertension, 2013, Volume: 22, Issue:2

    Topics: Animals; Gout; Homeostasis; Humans; Hyperuricemia; Kidney; Kidney Diseases; Prognosis; Uric Acid

2013
Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis.
    Clinical therapeutics, 2013, Volume: 35, Issue:2

    Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Randomized Controlled Trial

2013
Neutrophils, IL-1β, and gout: is there a link?
    Seminars in immunopathology, 2013, Volume: 35, Issue:4

    Topics: Animals; Apoptosis; Gout; Humans; Interleukin-1beta; Intracellular Space; Neutrophil Activation; Neu

2013
The management of hyperuricemia and gout in patients with heart failure.
    European journal of heart failure, 2002, Volume: 4, Issue:4

    Topics: Cardiovascular Agents; Comorbidity; Gout; Gout Suppressants; Heart Failure; Humans; Risk Factors; Ur

2002
Asymptomatic hyperuricemia: to treat or not to treat.
    Cleveland Clinic journal of medicine, 2002, Volume: 69, Issue:8

    Topics: Age Factors; Allopurinol; Cardiovascular Diseases; Clinical Trials as Topic; Gout; Gout Suppressants

2002
Uric acid nephrolithiasis: current concepts and controversies.
    The Journal of urology, 2002, Volume: 168, Issue:4 Pt 1

    Topics: Cross-Sectional Studies; Gout; Humans; Hydrogen-Ion Concentration; Incidence; Kidney Calculi; Potass

2002
Hyperuricosuric calcium nephrolithiasis.
    Endocrinology and metabolism clinics of North America, 2002, Volume: 31, Issue:4

    Topics: Allopurinol; Calcium Oxalate; Citrates; Female; Gout; Gout Suppressants; Humans; Kidney Calculi; Lit

2002
[Mode of existence and dynamics of uric acid in blood].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 1

    Topics: Animals; Gout; Humans; Hyperuricemia; Uric Acid

2003
[Influence of sex and age on serum uric acid level].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 1

    Topics: Age Factors; Estrogens; Female; Gout; Humans; Hyperuricemia; Male; Sex Factors; Uric Acid

2003
[Effect of foods on serum uric acid level].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 1

    Topics: Diet; Dietary Carbohydrates; Dietary Fats; Dietary Proteins; Drinking; Food; Food Analysis; Gout; Hu

2003
[Effect of ethanol on uric acid level].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 1

    Topics: Acetaldehyde; Animals; Erythrocytes; Ethanol; Gout; Humans; Hyperuricemia; Purines; Pyrazinamide; Ur

2003
[Definition and determination of serum uric acid level].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 1

    Topics: Biomarkers; Blood Chemical Analysis; Gout; Humans; Hyperuricemia; Practice Guidelines as Topic; Refe

2003
[Exercise therapy for hyperuricemia].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 1

    Topics: Anaerobic Threshold; Exercise; Exercise Therapy; Gout; Humans; Hyperuricemia; Purine Nucleotides; Ur

2003
[Diet therapy for management of hyperuricemia and gout].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 1

    Topics: Adult; Alcoholic Beverages; Diet, Reducing; Gout; Humans; Hyperuricemia; Male; Obesity; Purines; Tem

2003
[Tophaceous gout].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 1

    Topics: Bone and Bones; Diagnosis, Differential; Gout; Humans; Joints; Macrophages; Magnetic Resonance Imagi

2003
[Gouty kidney].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 1

    Topics: Animals; Diet; Gout; Humans; Hyperuricemia; Kidney Diseases; Sodium Bicarbonate; Tartrates; Uric Aci

2003
[Sleep apnea syndrome].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 1

    Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Life Style; Sleep Apnea Syndromes; Uric Acid

2003
[Idiopathic retroperitoneal fibrosis and hyperuricemia].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 1

    Topics: Gout; Humans; Hyperuricemia; Male; Middle Aged; Prednisolone; Receptors, Interleukin-2; Retroperiton

2003
[Blood antioxidant capacity in gout].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 1

    Topics: Allopurinol; Animals; Antioxidants; Arteriosclerosis; Enzyme Inhibitors; Free Radical Scavengers; Go

2003
[Interleukin 6 deduces serum urate concentration].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 1

    Topics: Clinical Trials as Topic; Gout; Humans; Inflammation Mediators; Interleukin-6; Recombinant Proteins;

2003
[DISEASES OF THE METABOLISM OF PURINES AND PYRIMIDINES].
    Revista clinica espanola, 1963, Aug-31, Volume: 90

    Topics: Gout; Humans; Metabolic Diseases; Orotic Acid; Purines; Pyrimidines; Uric Acid; Urine; Xanthines

1963
ACUTE GOUT--UNSOLVED.
    The Medical journal of Australia, 1963, Dec-28, Volume: 2

    Topics: Arthritis; Colchicine; Gout; Humans; Uric Acid; Uricosuric Agents

1963
[HYPERURICEMIA AND ATHEROSCLEROSIS].
    Ugeskrift for laeger, 1964, Jun-25, Volume: 126

    Topics: Arteriosclerosis; Atherosclerosis; Blood; Cerebrovascular Disorders; Coronary Disease; Gout; Humans;

1964
[THE GOUTY KIDNEY--PATHOGENESIS OF HYPERURICEMIA AND PATHOGENIC ROLE OF THE KIDNEY].
    Reumatologia, 1963, Volume: 1

    Topics: Blood; Gout; Humans; Hyperuricemia; Kidney; Kidney Diseases; Uric Acid

1963
RECENT ADVANCES IN STUDY OF URIC ACID METABOLISM AND GOUT.
    Postgraduate medicine, 1965, Volume: 37

    Topics: Gout; Humans; Metabolism; Uric Acid

1965
Advanced imaging of gout.
    Seminars in musculoskeletal radiology, 2003, Volume: 7, Issue:3

    Topics: Gout; Humans; Magnetic Resonance Imaging; Tomography, X-Ray Computed; Uric Acid

2003
Hyperuricaemia and gout: clinical guideline 2003.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2003, Volume: 93, Issue:12 Pt 2

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Child; Colchicine; Female; Gout; Gout Suppress

2003
Gout.
    Current opinion in rheumatology, 2004, Volume: 16, Issue:3

    Topics: Crystallization; Feeding Behavior; Gout; Gout Suppressants; Humans; Joints; Uric Acid

2004
Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase.
    Current rheumatology reports, 2004, Volume: 6, Issue:3

    Topics: Allopurinol; Amlodipine; Clinical Trials as Topic; Enzyme Inhibitors; Febuxostat; Gout; Humans; Hype

2004
[Gout].
    Revue medicale de Liege, 2004, Volume: 59, Issue:5

    Topics: Arthritis, Infectious; Comorbidity; Diagnosis, Differential; Gout; Gout Suppressants; Humans; Progno

2004
[Uratic gout].
    Medicina clinica, 2004, Jun-26, Volume: 123, Issue:4

    Topics: Arthritis, Gouty; Diet; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid

2004
Gout: on the brink of novel therapeutic options for an ancient disease.
    Arthritis and rheumatism, 2004, Volume: 50, Issue:8

    Topics: Acute Disease; Benzothiadiazines; Diuretics; Female; Gout; Humans; Hypertension; Hyperuricemia; Kidn

2004
Gouty flexor tenosynovitis mimicking infection: a case report emphasising the value of ultrasound in diagnosis.
    Acta orthopaedica Belgica, 2004, Volume: 70, Issue:4

    Topics: Adult; Colchicine; Female; Fingers; Follow-Up Studies; Gout; Humans; Pain Measurement; Risk Assessme

2004
[Physiology and biochemistry of uric acid].
    Therapeutische Umschau. Revue therapeutique, 2004, Volume: 61, Issue:9

    Topics: Animals; Birds; Carrier Proteins; Glomerular Filtration Rate; Gout; Humans; Kidney Calculi; Organic

2004
[Uric acid and diabetes mellitus].
    Przeglad lekarski, 2004, Volume: 61, Issue:9

    Topics: Diabetes Mellitus; Diabetic Nephropathies; Gout; Humans; Uric Acid

2004
Recent advances in the management of gout and hyperuricemia.
    Current opinion in rheumatology, 2005, Volume: 17, Issue:3

    Topics: Gout; Humans; Hyperuricemia; Treatment Outcome; Uric Acid; Uricosuric Agents

2005
[Hyperuricemia/gout. Main symptoms of arthropathy. Severe acute joint pain, redness, inflammation].
    Praxis, 2005, Apr-06, Volume: 94, Issue:14

    Topics: Allopurinol; Anesthetics, Local; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Diagnosis, Dif

2005
Gout: excess calories, purines, and alcohol intake and beyond. Response to a urate-lowering diet.
    The Journal of rheumatology, 2005, Volume: 32, Issue:5

    Topics: Alcohol Drinking; Dietary Proteins; Energy Intake; Gout; Humans; Purines; Uric Acid

2005
Iatrogenic rheumatic syndromes in the elderly.
    Clinics in geriatric medicine, 2005, Volume: 21, Issue:3

    Topics: Aged; Arthralgia; Colchicine; Connective Tissue Diseases; Gout; Gout Suppressants; Humans; Hydroxyme

2005
Renal urate handling: clinical relevance of recent advances.
    Current rheumatology reports, 2005, Volume: 7, Issue:3

    Topics: Animals; Biological Transport; Carrier Proteins; Gout; Humans; Hyperuricemia; Kidney Tubules; Mutati

2005
Diagnosis and management of gout: a rational approach.
    Postgraduate medical journal, 2005, Volume: 81, Issue:959

    Topics: Acute Disease; Chronic Disease; Crystallization; Diagnosis, Differential; Gout; Humans; Hyperuricemi

2005
Pathogenesis of gout.
    Annals of internal medicine, 2005, Oct-04, Volume: 143, Issue:7

    Topics: Cardiovascular Diseases; Crystallization; Diet; Gout; Humans; Hyperuricemia; Inflammation; Insulin R

2005
An update on the treatment options for gout and calcium pyrophosphate deposition.
    Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:14

    Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Allopurinol; Animals; Anti-Inflammatory Agents

2005
Understanding treatments for gout.
    The American journal of managed care, 2005, Volume: 11, Issue:15 Suppl

    Topics: Acute Disease; Adrenal Cortex Hormones; Behavior Therapy; Chronic Disease; Colchicine; Female; Gout;

2005
Diagnosis of gout: clinical, laboratory, and radiologic findings.
    The American journal of managed care, 2005, Volume: 11, Issue:15 Suppl

    Topics: Acute Disease; Adult; Age Factors; Aged; Arthrography; Chondrocalcinosis; Diagnosis, Differential; F

2005
Overview of hyperuricaemia and gout.
    Current pharmaceutical design, 2005, Volume: 11, Issue:32

    Topics: Antioxidants; Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Prevalence; Uric Acid

2005
Current trends in crystal identification.
    Current opinion in rheumatology, 2006, Volume: 18, Issue:2

    Topics: Calcinosis; Calcium Phosphates; Diagnostic Errors; False Positive Reactions; Gout; Humans; Joints; O

2006
Recent developments in diet and gout.
    Current opinion in rheumatology, 2006, Volume: 18, Issue:2

    Topics: Beer; Feeding Behavior; Female; Food, Formulated; Gout; Humans; Insulin Resistance; Male; Metabolic

2006
New insights into gout epidemiology.
    Current opinion in rheumatology, 2006, Volume: 18, Issue:2

    Topics: Cardiovascular Diseases; Comorbidity; Feeding Behavior; Female; Gout; Humans; Male; Prevalence; Risk

2006
[Hyperuricemic nephropathy: Pathogenesis, pathophysiology, and therapy].
    Nihon rinsho. Japanese journal of clinical medicine, 2006, Volume: 64 Suppl 2

    Topics: DNA-Binding Proteins; Gout; Hepatocyte Nuclear Factor 1-beta; Humans; Hyperuricemia; Kidney Diseases

2006
Genetic factors associated with gout and hyperuricemia.
    Advances in chronic kidney disease, 2006, Volume: 13, Issue:2

    Topics: Blood Group Antigens; Genetic Markers; Genetic Predisposition to Disease; Gout; Humans; Hyperuricemi

2006
EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).
    Annals of the rheumatic diseases, 2006, Volume: 65, Issue:10

    Topics: Advisory Committees; Biomedical Research; Comorbidity; Delphi Technique; Evidence-Based Medicine; Go

2006
Gout: update on some pathogenic and clinical aspects.
    Rheumatic diseases clinics of North America, 2006, Volume: 32, Issue:2

    Topics: Crystallization; Gout; Humans; Inflammation; Joints; Magnetic Resonance Imaging; Uric Acid

2006
Renal urate transport.
    Rheumatic diseases clinics of North America, 2006, Volume: 32, Issue:2

    Topics: Animals; Biological Transport, Active; Carrier Proteins; Gout; Humans; Kidney Tubules, Proximal; Org

2006
A concise history of gout and hyperuricemia and their treatment.
    Arthritis research & therapy, 2006, Volume: 8 Suppl 1

    Topics: Arthritis, Gouty; Gout; History, 19th Century; History, Ancient; Humans; Hyperuricemia; Politics; Un

2006
The inflammatory process of gout and its treatment.
    Arthritis research & therapy, 2006, Volume: 8 Suppl 1

    Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Clinical Trials

2006
Uric acid and the immune response.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2006, Volume: 21, Issue:11

    Topics: Gout; Humans; Immunity, Active; Immunity, Innate; Uric Acid

2006
[Is hyperuricemia a cardiovascular risk factor?].
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 2006, Volume: 59, Issue:5-6

    Topics: Cardiovascular Diseases; Comorbidity; Female; Gout; Humans; Hyperuricemia; Obesity; Risk Factors; Se

2006
Gout in 2006: the perfect storm.
    Bulletin of the NYU hospital for joint diseases, 2006, Volume: 64, Issue:1-2

    Topics: Global Health; Gout; Gout Suppressants; Humans; Morbidity; Prognosis; Uric Acid

2006
Pathogenesis, clinical findings and management of acute and chronic gout.
    Minerva medica, 2006, Volume: 97, Issue:6

    Topics: Acute Disease; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Co

2006
Therapeutic advances in gout.
    Current opinion in rheumatology, 2007, Volume: 19, Issue:2

    Topics: Allopurinol; Feeding Behavior; Gout; Humans; Metabolic Syndrome; Risk Reduction Behavior; Uric Acid;

2007
Recent advances in crystal-induced acute inflammation.
    Current opinion in rheumatology, 2007, Volume: 19, Issue:2

    Topics: Acute Disease; Carrier Proteins; Gout; Humans; Immunity, Innate; Inflammation; Interleukin-1beta; Me

2007
Updates in the management of gout.
    The American journal of medicine, 2007, Volume: 120, Issue:3

    Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Aged; Allopurinol; Anti-Inflammatory Agents, Non-Ster

2007
Crystal-associated arthritis in the elderly.
    Rheumatic diseases clinics of North America, 2007, Volume: 33, Issue:1

    Topics: Aged; Allopurinol; Arthritis; Arthritis, Gouty; Calcium Pyrophosphate; Chondrocalcinosis; Comorbidit

2007
Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout.
    International journal of medical sciences, 2007, Mar-02, Volume: 4, Issue:2

    Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Tumor Lysis Syndrome; Urate Oxidase; Uric Acid

2007
Recent developments in crystal-induced inflammation pathogenesis and management.
    Current rheumatology reports, 2007, Volume: 9, Issue:3

    Topics: Chondrocalcinosis; Evidence-Based Medicine; Gout; Humans; Inflammation; Uric Acid

2007
Uric acid nephrolithiasis.
    Current rheumatology reports, 2007, Volume: 9, Issue:3

    Topics: Diabetes Complications; Gout; Humans; Nephrolithiasis; Uric Acid; Urine

2007
Uricase and other novel agents for the management of patients with treatment-failure gout.
    Current rheumatology reports, 2007, Volume: 9, Issue:3

    Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Randomized Controlled Trials as Topic; Rec

2007
[Crystal-induced arthritis--old but important].
    Zeitschrift fur Rheumatologie, 2007, Volume: 66, Issue:4

    Topics: Anti-Inflammatory Agents; Gout; Gout Suppressants; Humans; Uric Acid

2007
Assessment of outcome in clinical trials of gout--a review of current measures.
    Rheumatology (Oxford, England), 2007, Volume: 46, Issue:12

    Topics: Arthritis, Gouty; Female; Gout; Humans; Male; Pain Measurement; Prognosis; Randomized Controlled Tri

2007
Elderly-onset gout: a review.
    Rheumatology international, 2007, Volume: 28, Issue:1

    Topics: Age Factors; Aged; Aged, 80 and over; Diuretics; Female; Gout; Humans; Immunosuppressive Agents; Inc

2007
Why is gout so poorly managed?
    Annals of the rheumatic diseases, 2007, Volume: 66, Issue:10

    Topics: Arthritis, Rheumatoid; Attitude of Health Personnel; Family Practice; Gout; Humans; Joints; Uric Aci

2007
Altered uric acid levels and disease states.
    The Journal of pharmacology and experimental therapeutics, 2008, Volume: 324, Issue:1

    Topics: Animals; Cardiovascular Diseases; Gout; Humans; Hypertension; Hyperuricemia; Inflammation; Kidney Di

2008
The role of interleukin-1 and the inflammasome in gout: implications for therapy.
    Arthritis and rheumatism, 2007, Volume: 56, Issue:10

    Topics: Animals; Arthritis, Gouty; Carrier Proteins; Colchicine; Gout; Gout Suppressants; Humans; Hyperurice

2007
Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?
    Arthritis and rheumatism, 2007, Oct-15, Volume: 57, Issue:7

    Topics: Allopurinol; Gout; Humans; Treatment Outcome; Uric Acid

2007
Hyperuricemia and gout: new insights into pathogenesis and treatment.
    Bulletin of the NYU hospital for joint diseases, 2007, Volume: 65, Issue:3

    Topics: Adrenal Cortex Hormones; Animals; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Febuxostat; G

2007
Update on gout: pathophysiology and potential treatments.
    Current pain and headache reports, 2007, Volume: 11, Issue:6

    Topics: Animals; Cardiovascular Diseases; Gout; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Immu

2007
Gout is a risk factor for cardiovascular disease.
    The Practitioner, 2007, Volume: 251, Issue:1701

    Topics: Acute Disease; Algorithms; Cardiovascular Diseases; Gout; Harm Reduction; Humans; Recurrence; Risk A

2007
Diagnosis of gout.
    Minerva medica, 2007, Volume: 98, Issue:6

    Topics: Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Synovial Fluid; Uric Acid

2007
We can make gout management more successful now.
    Current opinion in rheumatology, 2008, Volume: 20, Issue:2

    Topics: Evidence-Based Medicine; Gout; Humans; Patient Education as Topic; Practice Guidelines as Topic; Ris

2008
Establishing outcome domains for evaluating treatment of acute and chronic gout.
    Current opinion in rheumatology, 2008, Volume: 20, Issue:2

    Topics: Acute Disease; Chronic Disease; Clinical Trials as Topic; Endpoint Determination; Gout; Humans; Join

2008
Control of renal uric acid excretion and gout.
    Current opinion in rheumatology, 2008, Volume: 20, Issue:2

    Topics: Genetic Predisposition to Disease; Gout; Humans; Hyperuricemia; Kidney Tubules, Proximal; Organic An

2008
Aspiration of normal or asymptomatic pathological joints for diagnosis and research: indications, technique and success rate.
    Annals of the rheumatic diseases, 2009, Volume: 68, Issue:1

    Topics: Arthritis; Biopsy, Needle; Calcium Pyrophosphate; Case-Control Studies; Crystallization; Gout; Human

2009
[Historical review of gout and hyperuricemia investigations].
    Nihon rinsho. Japanese journal of clinical medicine, 2008, Volume: 66, Issue:4

    Topics: Gout; History, 17th Century; History, 18th Century; History, 19th Century; History, 20th Century; Hu

2008
[Physiology and dynamics of uric acid in hyperuricemia].
    Nihon rinsho. Japanese journal of clinical medicine, 2008, Volume: 66, Issue:4

    Topics: Gout; Humans; Hydrogen-Ion Concentration; Hyperuricemia; Solubility; Uric Acid

2008
[Idiopathic hyperuricemia with overproduction of uric acid].
    Nihon rinsho. Japanese journal of clinical medicine, 2008, Volume: 66, Issue:4

    Topics: Antihypertensive Agents; Gout; Humans; Hypertension; Hyperuricemia; Hypoxanthine; Muscle, Skeletal;

2008
[Increased activity of PRPP synthetase].
    Nihon rinsho. Japanese journal of clinical medicine, 2008, Volume: 66, Issue:4

    Topics: Chromosomes, Human, X; Genes, Dominant; Gout; Humans; Point Mutation; Ribose-Phosphate Pyrophosphoki

2008
[Urolithiasis and nephropathy complicated with gout].
    Nihon rinsho. Japanese journal of clinical medicine, 2008, Volume: 66, Issue:4

    Topics: Gout; Humans; Hydrogen-Ion Concentration; Metabolic Syndrome; Renal Insufficiency; Uric Acid; Urolit

2008
[Establishment of therapeutic goal and plan of gout and asymptomatic hyperuricemia].
    Nihon rinsho. Japanese journal of clinical medicine, 2008, Volume: 66, Issue:4

    Topics: Allopurinol; Benzbromarone; Cardiovascular Diseases; Gout; Gout Suppressants; Humans; Hyperuricemia;

2008
[Uricosuric agent].
    Nihon rinsho. Japanese journal of clinical medicine, 2008, Volume: 66, Issue:4

    Topics: Allopurinol; Benzbromarone; Gout; Humans; Hyperuricemia; Kidney Tubules, Proximal; Organic Anion Tra

2008
[Other antihyperuricemic agents].
    Nihon rinsho. Japanese journal of clinical medicine, 2008, Volume: 66, Issue:4

    Topics: Antihypertensive Agents; Cardiovascular Diseases; Drug Therapy, Combination; Fenofibrate; Gout; Gout

2008
Disorders associated with purine and pyrimidine metabolism.
    Special topics in endocrinology and metabolism, 1984, Volume: 6

    Topics: 5'-Nucleotidase; Adenine Phosphoribosyltransferase; Adenosine Deaminase; AMP Deaminase; Gout; Guanin

1984
[Kidneys in rheumatic diseases].
    Ryumachi. [Rheumatism], 1983, Volume: 23, Issue:1

    Topics: Animals; Anti-Inflammatory Agents; Antigen-Antibody Complex; Arteritis; Gout; Humans; Immune Complex

1983
Heberden oration 1979: human aberrations of purine metabolism and their significance for rheumatology.
    Annals of the rheumatic diseases, 1980, Volume: 39, Issue:2

    Topics: Adenosine Deaminase; Adult; Child; Female; Gout; Humans; Hypoxanthine Phosphoribosyltransferase; Imm

1980
[Etiology and risks of hyperuricemia].
    Medizinische Klinik, 1981, Feb-13, Volume: 76, Issue:4

    Topics: Alcoholism; Diuretics; Female; Gout; Humans; Hypoxanthine Phosphoribosyltransferase; Kidney Calculi;

1981
Human purine metabolism: some recent advances and relationships with immunodeficiency.
    Annals of the rheumatic diseases, 1983, Volume: 42 Suppl 1

    Topics: Adenine Phosphoribosyltransferase; Adenosine Deaminase; Glycogen Storage Disease Type I; Gout; Human

1983
Gout and hyperuricemia associated with sickle-cell anemia.
    Seminars in arthritis and rheumatism, 1983, Volume: 12, Issue:4

    Topics: Adolescent; Adult; Anemia, Sickle Cell; Arthritis; Female; Gout; Hemolysis; Humans; Male; Middle Age

1983
Gout.
    Annals of the rheumatic diseases, 1983, Volume: 42 Suppl 1

    Topics: Acute Disease; Adult; Arthritis; Crystallization; Gout; Humans; Male; Uric Acid

1983
Crystal deposition and inflammation.
    The Quarterly journal of medicine, 1984,Summer, Volume: 53, Issue:211

    Topics: Arthritis; Calcium Oxalate; Calcium Pyrophosphate; Cholesterol; Crystallization; Gout; Humans; Hydro

1984
Urate nephropathy.
    The American journal of the medical sciences, 1984, Volume: 288, Issue:5

    Topics: Allopurinol; Arthritis; Aspirin; Blood Urea Nitrogen; Glomerular Filtration Rate; Gout; Humans; Kidn

1984
[Adverse effect of diuretics: hyperuricosuria].
    Nihon rinsho. Japanese journal of clinical medicine, 1984, Volume: 42, Issue:9

    Topics: Diuretics; Gout; Humans; Kidney; Kidney Diseases; Middle Aged; Uric Acid

1984
Molecular mechanisms of gouty arthritis: new insights into an old disease.
    Survey and synthesis of pathology research, 1984, Volume: 3, Issue:5

    Topics: Arthritis; Blood Proteins; Gout; Humans; Inflammation; Neutrophils; Phagocytosis; Protein Binding; U

1984
[Animal model for gout].
    Jikken dobutsu. Experimental animals, 1982, Volume: 31, Issue:2

    Topics: Animals; Chickens; Disease Models, Animal; Female; Gout; Male; Mice; Oxonic Acid; Poultry Diseases;

1982
[Various pathophysiological, clinical and therapeutic problems of disorders of purine metabolism].
    Polski tygodnik lekarski (Warsaw, Poland : 1960), 1982, Oct-25, Volume: 37, Issue:40

    Topics: Acute Kidney Injury; Allopurinol; Diuretics; Gout; Humans; Kidney Calculi; Uric Acid

1982
Treatment of the gout and other forms of crystal-induced arthritis.
    Bulletin on the rheumatic diseases, 1982, Volume: 32, Issue:5

    Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Benzbromarone; Colchicine; Gout; Go

1982
Long-term management of gout and hyperuricaemia.
    British medical journal, 1980, Nov-01, Volume: 281, Issue:6249

    Topics: Allopurinol; Female; Gout; Humans; Long-Term Care; Male; Risk; Uric Acid; Uricosuric Agents

1980
Complete destruction of both femoral heads following idiopathic necrosis of the femoral heads in a diabetic patient with hyperuricemia and hyperlipoproteinemia.
    Archives of orthopaedic and traumatic surgery. Archiv fur orthopadische und Unfall-Chirurgie, 1980, Volume: 96, Issue:2

    Topics: Aged; Angiography; Diabetes Complications; Femur Head Necrosis; Gout; Heel; Hip; Humans; Hyperlipopr

1980
[Benzbromarone in the treatment of gout].
    Reumatologia, 1980, Volume: 18, Issue:1

    Topics: Benzbromarone; Benzofurans; Biological Availability; Chemical Phenomena; Chemistry; Gout; Half-Life;

1980
[Hyperuricemia, gout and gout-induced nephropathy].
    Terapevticheskii arkhiv, 1980, Volume: 52, Issue:4

    Topics: Allopurinol; Female; Gout; Humans; Kidney Calculi; Male; Nephritis, Interstitial; Purines; Uric Acid

1980
[Current theories on the role of hyperuricemia as one of the risk factors in ischemic heart disease].
    Terapevticheskii arkhiv, 1980, Volume: 52, Issue:10

    Topics: Carbohydrate Metabolism; Coronary Disease; Female; Gout; Humans; Hypercholesterolemia; Hypertension;

1980
Gout and pseudogout: crystal-induced arthropathies.
    Clinics in endocrinology and metabolism, 1981, Volume: 10, Issue:1

    Topics: Calcium Pyrophosphate; Chondrocalcinosis; Crystallization; Diuretics; Ethanol; Glycogen Storage Dise

1981
[Urate nephropathy].
    Recenti progressi in medicina, 1981, Volume: 70, Issue:6

    Topics: Allopurinol; Gout; Humans; Kidney Calculi; Kidney Diseases; Nephritis, Interstitial; Purines; Uric A

1981
Hyperuricemia and gout.
    The Journal of family practice, 1982, Volume: 14, Issue:5

    Topics: Allopurinol; Arthritis; Aspirin; Colchicine; Diuretics; Gout; Gout Suppressants; Humans; Indomethaci

1982
[Uric acid and arterial hypertension].
    Revista clinica espanola, 1981, Dec-31, Volume: 163, Issue:6

    Topics: Carbohydrate Metabolism; Cardiovascular Diseases; Endocrine System Diseases; Female; Gout; Humans; H

1981
[Double tunnel syndrome of the upper limb in tophaceous gout. Apropos of a case].
    Annales de chirurgie de la main et du membre superieur : organe officiel des societes de chirurgie de la main = Annals of hand and upper limb surgery, 1994, Volume: 13, Issue:1

    Topics: Aged; Carpal Tunnel Syndrome; Fingers; Gout; Hand; Humans; Male; Median Nerve; Nerve Compression Syn

1994
Gout, uric acid metabolism, and crystal-induced inflammation.
    Current opinion in rheumatology, 1995, Volume: 7, Issue:4

    Topics: Aged; Child; Female; Gout; Humans; Infant; Inflammation; Male; Uric Acid

1995
[Obesity and the related diseases: gout].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1995, Aug-10, Volume: 84, Issue:8

    Topics: Alcohol Drinking; Animals; Female; Gout; Humans; Hyperlipidemias; Male; Obesity; Uric Acid

1995
Prevention and management of gout.
    Drugs, 1993, Volume: 45, Issue:2

    Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Gout; Gout Suppressants; Humans; Incidence;

1993
Gout or 'pseudogout': how to differentiate crystal-induced arthropathies.
    Geriatrics, 1995, Volume: 50, Issue:4

    Topics: Adult; Arthritis, Gouty; Calcium Phosphates; Calcium Pyrophosphate; Chondrocalcinosis; Diagnosis, Di

1995
Urate and calcium oxalate stones: from repute to rhetoric to reality.
    Mineral and electrolyte metabolism, 1994, Volume: 20, Issue:6

    Topics: Allopurinol; Calcium Oxalate; Glycosaminoglycans; Gout; Humans; Hydrogen-Ion Concentration; Hyperoxa

1994
ABC of rheumatology. Gout, hyperuricaemia, and crystal arthritis.
    BMJ (Clinical research ed.), 1995, Feb-25, Volume: 310, Issue:6978

    Topics: Chondrocalcinosis; Gout; Humans; Kidney Diseases; Risk Factors; Uric Acid

1995
[Gout and hyperuricemia].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1994, Mar-10, Volume: 83, Issue:3

    Topics: Gout; Humans; Uric Acid

1994
[Hyperuricemia].
    Ugeskrift for laeger, 1994, Apr-18, Volume: 156, Issue:16

    Topics: Gout; Humans; Kidney Diseases; Uric Acid; Urinary Calculi

1994
Clinical and biochemical aspects of uric acid overproduction.
    Pharmacy world & science : PWS, 1994, Apr-15, Volume: 16, Issue:2

    Topics: Adenosine Triphosphate; Animals; Gout; Humans; Hypoxanthine Phosphoribosyltransferase; Nucleic Acids

1994
Hyperuricemia and gout.
    Current opinion in rheumatology, 1994, Volume: 6, Issue:4

    Topics: Arthritis, Gouty; Child; Child, Preschool; Crystallization; Gout; Humans; Inflammation; Kidney Trans

1994
[What remains of gout in 1993?].
    La Revue du praticien, 1994, Jan-15, Volume: 44, Issue:2

    Topics: Acute Disease; Adult; Chronic Disease; Female; Gout; Humans; Male; Middle Aged; Radiography; Sex Fac

1994
Optimal management of gout in older patients.
    Drugs & aging, 1994, Volume: 4, Issue:2

    Topics: Aged; Gout; Humans; Uric Acid

1994
Gout and 'pseudogout'. When are arthritic symptoms caused by crystal deposition?
    Postgraduate medicine, 1994, Feb-01, Volume: 95, Issue:2

    Topics: Calcium Pyrophosphate; Chondrocalcinosis; Diagnosis, Differential; Gout; Humans; Uric Acid

1994
Gout and mechanisms of crystal-induced inflammation.
    Current opinion in rheumatology, 1993, Volume: 5, Issue:4

    Topics: Aged; Animals; Arthritis, Gouty; Female; Gout; Humans; Infant; Kidney; Male; Mice; Uric Acid

1993
[Nutrition in gout].
    Medizinische Monatsschrift fur Pharmazeuten, 1993, Volume: 16, Issue:9

    Topics: Alcohol Drinking; Diet, Reducing; Food Analysis; Gout; Humans; Purines; Uric Acid

1993
Gout, uric acid and purine metabolism in paediatric nephrology.
    Pediatric nephrology (Berlin, Germany), 1993, Volume: 7, Issue:1

    Topics: Adolescent; Animals; Child; Child, Preschool; Gout; Humans; Infant; Infant, Newborn; Kidney Diseases

1993
[Osteo-articular complications of heart transplantation].
    Presse medicale (Paris, France : 1983), 1995, Dec-09, Volume: 24, Issue:38

    Topics: Bone Diseases; Bone Diseases, Metabolic; Gout; Heart Transplantation; Humans; Immunosuppressive Agen

1995
The management of gout.
    The New England journal of medicine, 1996, Feb-15, Volume: 334, Issue:7

    Topics: Acute Disease; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Diet;

1996
[Hyperuricemia].
    Der Internist, 1995, Volume: 36, Issue:12

    Topics: Adult; Aged; Combined Modality Therapy; Diagnosis, Differential; Female; Gout; Humans; Male; Middle

1995
[Hyperuricemia].
    Der Urologe. Ausg. A, 1996, Volume: 35, Issue:3

    Topics: Adult; Aged; Arthritis, Gouty; Combined Modality Therapy; Cross-Sectional Studies; Female; Germany;

1996
Rheumatoid arthritis preceding the onset of polyarticular tophaceous gout.
    Annals of the rheumatic diseases, 1996, Volume: 55, Issue:7

    Topics: Arthritis, Rheumatoid; Female; Gout; Humans; Middle Aged; Uric Acid

1996
The importance of uric acid examination.
    Sbornik lekarsky, 1994, Volume: 95, Issue:4

    Topics: Female; Gout; Humans; Hypoxanthine Phosphoribosyltransferase; Kidney; Male; Purine-Pyrimidine Metabo

1994
Uric acid stones.
    Seminars in nephrology, 1996, Volume: 16, Issue:5

    Topics: Gout; Humans; Uric Acid; Urinary Calculi

1996
Gout nodulosis: widespread subcutaneous deposits without gout.
    Arthritis care and research : the official journal of the Arthritis Health Professions Association, 1996, Volume: 9, Issue:1

    Topics: Adult; Biopsy, Needle; Gout; Humans; Male; Uric Acid

1996
[Metabolism of purine nucleotides and the production of uric acid].
    Nihon rinsho. Japanese journal of clinical medicine, 1996, Volume: 54, Issue:12

    Topics: Amidophosphoribosyltransferase; Gout; Humans; Purine Nucleotides; Ribose-Phosphate Pyrophosphokinase

1996
[Mammalian phosphoribosylpyrophosphate synthetase].
    Nihon rinsho. Japanese journal of clinical medicine, 1996, Volume: 54, Issue:12

    Topics: Amino Acid Sequence; Animals; Catalysis; Gout; Humans; Molecular Sequence Data; Phosphoribosyl Pyrop

1996
[Dynamics of uric acid metabolism in hyperuricemia].
    Nihon rinsho. Japanese journal of clinical medicine, 1996, Volume: 54, Issue:12

    Topics: Blood Proteins; Gout; Humans; Protein Binding; Uric Acid

1996
[Hyperuricosuria and urolithiasis].
    Nihon rinsho. Japanese journal of clinical medicine, 1996, Volume: 54, Issue:12

    Topics: Calcium Oxalate; Gout; Humans; Uric Acid; Urinary Calculi

1996
[Hyperuricemia and the kidney].
    Nihon rinsho. Japanese journal of clinical medicine, 1996, Volume: 54, Issue:12

    Topics: Acute Kidney Injury; Allopurinol; Gout; Humans; Hydrogen-Ion Concentration; Kidney; Renal Dialysis;

1996
[Gout and atherosclerosis].
    Nihon rinsho. Japanese journal of clinical medicine, 1996, Volume: 54, Issue:12

    Topics: Alcohol Drinking; Coronary Artery Disease; Gout; Humans; Hyperlipidemias; Hypertension; Obesity; Pla

1996
[PRPP synthetase superactivity].
    Nihon rinsho. Japanese journal of clinical medicine, 1996, Volume: 54, Issue:12

    Topics: Gout; Humans; Phosphoribosyl Pyrophosphate; Proteins; Purine Nucleotides; Purine-Pyrimidine Metaboli

1996
[Pharmacological agents affecting uric acid metabolism].
    Nihon rinsho. Japanese journal of clinical medicine, 1996, Volume: 54, Issue:12

    Topics: Allopurinol; Diuretics; Fructose; Gout; Gout Suppressants; Humans; Inosine; Kidney Diseases; Niacin;

1996
[Alcohol ingestion and hyperuricemia].
    Nihon rinsho. Japanese journal of clinical medicine, 1996, Volume: 54, Issue:12

    Topics: Adenosine Triphosphate; Alcohol Drinking; Aldehyde Dehydrogenase; Beer; Ethanol; Female; Genotype; G

1996
[Gout and hyperuricemia].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1996, Sep-10, Volume: 85, Issue:9

    Topics: Gout; Humans; Uric Acid

1996
Gout and other crystal arthropathies.
    The Medical journal of Australia, 1997, Jan-06, Volume: 166, Issue:1

    Topics: Aged; Arthritis, Gouty; Calcium Pyrophosphate; Chronic Disease; Crystallization; Female; Gout; Human

1997
[Uric acid and tubulointerstitial kidney diseases].
    Der Internist, 1996, Volume: 37, Issue:11

    Topics: Gout; Humans; Kidney Function Tests; Nephritis, Interstitial; Renal Dialysis; Uric Acid

1996
[Effects of alcohol on urate metabolism].
    Nihon rinsho. Japanese journal of clinical medicine, 1997, Volume: 55 Suppl

    Topics: Alcohol Drinking; Ethanol; Gout; Humans; Kidney; Lactic Acid; Purine Nucleotides; Uric Acid

1997
[Uric acid clearance].
    Nihon rinsho. Japanese journal of clinical medicine, 1997, Volume: 55 Suppl 1

    Topics: Creatinine; Female; Gout; Humans; Male; Uric Acid

1997
Crystal deposition disease.
    Current opinion in rheumatology, 1997, Volume: 9, Issue:3

    Topics: Antirheumatic Agents; Azathioprine; Chondrocalcinosis; Colchicine; Cyclosporine; Gout; Gout Suppress

1997
Gout and hyperuricemia.
    Current opinion in rheumatology, 1997, Volume: 9, Issue:3

    Topics: Crystallization; Epidemiologic Methods; Forecasting; Gout; Humans; Inflammation; Kidney; Kidney Calc

1997
Uric acid nephropathy and end-stage renal disease--review of a non-disease.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 1997, Volume: 12, Issue:9

    Topics: Gout; Humans; Kidney; Kidney Diseases; Kidney Failure, Chronic; Uric Acid

1997
[Therapy of hyperuricemia and gout].
    Wiener medizinische Wochenschrift (1946), 1997, Volume: 147, Issue:16

    Topics: Acute Disease; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; C

1997
[Gout due to disorder of urate binding proteins (the urate-binding alpha 1-2 globulin deficiency)].
    Ryoikibetsu shokogun shirizu, 1998, Issue:18 Pt 1

    Topics: Alpha-Globulins; Gout; Humans; Protein Binding; Uric Acid

1998
[Familial juvenile gouty nephropathy].
    Ryoikibetsu shokogun shirizu, 1998, Issue:18 Pt 1

    Topics: Adult; Diagnosis, Differential; Family Health; Female; Gout; Humans; Hypertension; Kidney Diseases;

1998
Gout: new questions for an ancient disease.
    Advances in experimental medicine and biology, 1998, Volume: 431

    Topics: Adult; Female; Gout; Humans; Kidney Failure, Chronic; Male; Microvascular Angina; Purine-Pyrimidine

1998
Broadsheet number 43: The role of the laboratory in the investigation and management of hyperuricemia.
    Pathology, 1998, Volume: 30, Issue:2

    Topics: Clinical Laboratory Techniques; Gout; Humans; Uric Acid

1998
Kelley-Seegmiller syndrome: a case report and review of the literature.
    British journal of rheumatology, 1998, Volume: 37, Issue:5

    Topics: Adult; Gout; Humans; Hypoxanthine Phosphoribosyltransferase; Kidney Diseases; Male; Syndrome; Uric A

1998
Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 1999, Volume: 33, Issue:2

    Topics: Cardiovascular Diseases; Gout; Humans; Hypertension; Kidney Diseases; Risk Factors; Uric Acid

1999
Gout and hyperuricemia.
    American family physician, 1999, Feb-15, Volume: 59, Issue:4

    Topics: Acute Disease; Algorithms; Female; Gout; Humans; Male; Sex Distribution; United States; Uric Acid

1999
Diagnosis and management of gout.
    American family physician, 1999, Apr-01, Volume: 59, Issue:7

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Diagnosis, Differential; Gout; Gout Suppressants; Humans; P

1999
[Physiopathology and treatment of gout and hyperuricemia].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1999, Apr-10, Volume: 88, Issue:4

    Topics: Adult; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Uric Acid

1999
Regulation of oxidant production in acute lung injury.
    Chest, 1999, Volume: 116, Issue:1 Suppl

    Topics: Animals; Gout; Humans; Lung; NADPH Oxidases; Reactive Oxygen Species; Respiratory Distress Syndrome;

1999
Gout.
    The Practitioner, 1998, Volume: 242, Issue:1588

    Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Gout; Gout Suppressants; Humans; U

1998
How well have diagnostic tests and therapies for gout been evaluated?
    Current opinion in rheumatology, 1999, Volume: 11, Issue:5

    Topics: Gout; Humans; Uric Acid

1999
Finger pad tophi.
    Cutis, 1999, Volume: 64, Issue:4

    Topics: Cyclosporine; Fingers; Follow-Up Studies; Gout; Gout Suppressants; Humans; Immunosuppressive Agents;

1999
[Treatment of gout].
    Revista clinica espanola, 1999, Volume: 199, Issue:12

    Topics: Acute Disease; Arthritis, Gouty; Gout; Humans; Uric Acid

1999
[Insulin sensitizer and urate metabolism].
    Nihon rinsho. Japanese journal of clinical medicine, 2000, Volume: 58, Issue:2

    Topics: Chromans; Diabetes Mellitus, Type 2; Female; Glucose; Gout; Humans; Hyperlipidemias; Hypertension; H

2000
Renal transplant-associated hyperuricemia and gout.
    Journal of the American Society of Nephrology : JASN, 2000, Volume: 11, Issue:5

    Topics: Cyclosporine; Drug Interactions; Gout; Humans; Immunosuppressive Agents; Kidney Transplantation; Ris

2000
Controlling hyperuricaemia in general practice.
    The Practitioner, 1999, Volume: 243, Issue:1605

    Topics: Arthritis; Causality; Family Practice; Female; Gout; Humans; Male; Uric Acid

1999
[Gout crisis].
    Klinicheskaia meditsina, 2000, Volume: 78, Issue:3

    Topics: Adult; Aged; Diagnosis, Differential; Gout; Humans; Male; Middle Aged; Nephritis, Interstitial; Uric

2000
Gout update: from lab to the clinic and back.
    Current opinion in rheumatology, 2000, Volume: 12, Issue:3

    Topics: Crystallization; Gout; Gout Suppressants; Humans; Organ Transplantation; Synovitis; Uric Acid

2000
What is new about crystals other than monosodium urate?
    Current opinion in rheumatology, 2000, Volume: 12, Issue:3

    Topics: Acute Disease; Calcium Pyrophosphate; Chondrocalcinosis; Crystallization; Durapatite; Gout; Humans;

2000
Clinical manifestations of gout and their management.
    The Medical journal of Australia, 2000, May-15, Volume: 172, Issue:10

    Topics: Adult; Aged; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Uric Acid

2000
[Synovial fluid analysis in gout].
    Harefuah, 1998, Dec-01, Volume: 135, Issue:11

    Topics: Arthritis, Gouty; Gout; Humans; Synovial Fluid; Uric Acid

1998
Gout and other crystal-associated arthropathies.
    Bailliere's best practice & research. Clinical rheumatology, 2000, Volume: 14, Issue:3

    Topics: Calcium; Calcium Phosphates; Calcium Pyrophosphate; Crystallization; Gout; Humans; Joint Diseases; U

2000
The spectrum of inherited mutations causing HPRT deficiency: 75 new cases and a review of 196 previously reported cases.
    Mutation research, 2000, Volume: 463, Issue:3

    Topics: Amino Acid Substitution; Cells, Cultured; Codon; DNA Mutational Analysis; DNA, Complementary; Exons;

2000
[Hyperuricemia in hypertension].
    Nihon rinsho. Japanese journal of clinical medicine, 2000, Volume: 58 Suppl 2

    Topics: Adolescent; Child; Female; Gout; Humans; Hypertension; Male; Uric Acid

2000
[Treatment of gout].
    Revue medicale de la Suisse romande, 2000, Volume: 120, Issue:10

    Topics: Acute Disease; Anti-Inflammatory Agents; Chronic Disease; Gout; Gout Suppressants; Humans; Patient S

2000
Difficult gout and new approaches for control of hyperuricemia in the allopurinol-allergic patient.
    Current rheumatology reports, 2001, Volume: 3, Issue:1

    Topics: Allopurinol; Drug Hypersensitivity; Gout; Gout Suppressants; Humans; Kidney; Transplantation, Homolo

2001
Pathogenesis of crystal-induced inflammation.
    Current rheumatology reports, 2001, Volume: 3, Issue:1

    Topics: Arthritis; Crystallization; Gout; Humans; Macrophages; Monocytes; Neutrophils; Synovial Fluid; Uric

2001
Gout: diagnosis, pathogenesis, and clinical manifestations.
    Current opinion in rheumatology, 2001, Volume: 13, Issue:3

    Topics: Arthritis, Gouty; Gout; Humans; Joints; Risk Factors; Uric Acid

2001
Gout: can management be improved?
    Current opinion in rheumatology, 2001, Volume: 13, Issue:3

    Topics: Acute Disease; Causality; Cyclosporine; Gout; Gout Suppressants; Humans; Immunosuppressive Agents; U

2001
[Hyperlipidemia in patients with hyperuricemia].
    Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59 Suppl 3

    Topics: Diagnosis, Differential; Diet, Fat-Restricted; Dietary Fiber; Exercise Therapy; Gout; Humans; Hydrox

2001
[Gout].
    Nederlands tijdschrift voor tandheelkunde, 2000, Volume: 107, Issue:8

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Glucocorticoids; Gout; Gout Suppressants; Humans; Incidence

2000
When, why, and how should we quantify the excretion rate of urinary uric acid?
    The Journal of rheumatology, 2001, Volume: 28, Issue:6

    Topics: Chemistry, Clinical; Gout; Humans; Uric Acid

2001
Dynamic videomicroscopy evaluation of synovial fluid in gout.
    The Journal of rheumatology, 2001, Volume: 28, Issue:8

    Topics: Crystallization; Gout; Humans; Microscopy, Video; Synovial Fluid; Uric Acid

2001
Medullary cystic kidney disease: past and present.
    Contributions to nephrology, 2001, Issue:136

    Topics: Gout; Humans; Kidney Diseases, Cystic; Kidney Medulla; Uric Acid

2001
Gout. A painful joint disorder.
    Mayo Clinic health letter (English ed.), 2001, Volume: 19, Issue:11

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Gout; Humans; Purines; Sex Factors; Uric Acid

2001
[Gout and hyperuricemia].
    Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59 Suppl 8

    Topics: Female; Gout; Humans; Male; Uric Acid

2001
[Gout: current views. Stage oriented treatment].
    Klinicheskaia meditsina, 2002, Volume: 80, Issue:2

    Topics: Acute Disease; Adult; Arthritis; Female; Gout; Humans; Male; Middle Aged; Severity of Illness Index;

2002
Gout and hyperuricemia.
    Current opinion in rheumatology, 2002, Volume: 14, Issue:3

    Topics: Africa; Arthritis, Gouty; Asia; Cardiovascular Diseases; Diet Therapy; Gout; Humans; Prevalence; Uri

2002
The value of synovial fluid assays in the diagnosis of joint disease: a literature survey.
    Annals of the rheumatic diseases, 2002, Volume: 61, Issue:6

    Topics: Acute Disease; Arthritis; Arthritis, Infectious; Calcium Pyrophosphate; Crystallization; Gout; Gram-

2002
Implications of disorders of purine metabolism for the kidney and the urinary tract.
    Ciba Foundation symposium, 1977, Issue:48

    Topics: Adenine Phosphoribosyltransferase; Allopurinol; Animals; Calcium; Gout; Humans; Hydrogen-Ion Concent

1977
New knowledge of the pathogenesis of gout.
    Journal of clinical pathology. Supplement (Royal College of Pathologists), 1978, Volume: 12

    Topics: Aging; Complement System Proteins; Crystallization; Endotoxins; Factor XII; Gout; Humans; Hydrogen-I

1978
[Hyperuricemia and arteriosclerosis].
    Klinicheskaia meditsina, 1978, Volume: 56, Issue:1

    Topics: Adult; Arteriosclerosis; Coronary Disease; Dehydroepiandrosterone; Female; Gout; Humans; Hyperlipide

1978
[Theory of pathogenesis in primary hyperuricamia].
    Medizinische Klinik, 1975, Jul-11, Volume: 70, Issue:28-29

    Topics: Adenosine Monophosphate; Adult; Child; Female; Glucosephosphates; Glycine; Gout; Humans; Kidney; Les

1975
Uric acid metabolism in man.
    Advances in clinical chemistry, 1976, Volume: 18

    Topics: Adenine Phosphoribosyltransferase; Adenosine; Adenosine Deaminase; Animals; Cells, Cultured; Gout; H

1976
Metabolic effects of fructose in the liver.
    Current topics in cellular regulation, 1978, Volume: 13

    Topics: Alcohols; AMP Deaminase; Animals; Child; Fructose; Fructose Intolerance; Fructosephosphates; Glucago

1978
Hyperuricemia and gout. Classification, complications and management.
    The New England journal of medicine, 1979, Jun-28, Volume: 300, Issue:26

    Topics: Acute Disease; Allopurinol; Arthritis; Aspirin; Colchicine; Coronary Disease; Diuretics; Gout; Human

1979
The pathogenesis of podagra.
    Annals of internal medicine, 1977, Volume: 86, Issue:2

    Topics: Adult; Age Factors; Aged; Crystallization; Gout; Humans; Middle Aged; Permeability; Radiography; Syn

1977
Hyperuricemia and gout.
    The Medical clinics of North America, 1977, Volume: 61, Issue:2

    Topics: Adult; Allopurinol; Colchicine; Diagnosis, Differential; Female; Gout; Humans; Indomethacin; Male; M

1977
Renal handling of uric acid.
    Advances in experimental medicine and biology, 1977, Volume: 76B

    Topics: Biological Transport; Glomerular Filtration Rate; Gout; Humans; Kidney; Kidney Tubules; Models, Biol

1977
[Primary hyperparathyroidism. Clinical aspects, diagnosis and surgical treatment].
    Fortschritte der Medizin, 1977, Nov-10, Volume: 95, Issue:42

    Topics: Adenoma; Aged; Bone Cysts; Female; Gout; Humans; Hypercalcemia; Hyperparathyroidism; Hypertension; K

1977
[Therapy of gout].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1977, Jul-15, Volume: 32, Issue:14

    Topics: Arteriosclerosis; Colchicine; Diabetes Mellitus; Diet; Gout; Humans; Hyperlipidemias; Kidney Calculi

1977
[Associated and secondary chondrocalcinosis].
    Revue du rhumatisme et des maladies osteo-articulaires, 1977, Volume: 44, Issue:10

    Topics: Arthritis, Rheumatoid; Chondrocalcinosis; Chondroma; Diabetes Complications; Female; Gout; Hemochrom

1977
Benzbromarone: a review of its pharmacological properties and therapeutic use in gout and hyperuricaemia.
    Drugs, 1977, Volume: 14, Issue:5

    Topics: Aspirin; Benzbromarone; Benzofurans; Drug Interactions; Fasting; Gout; Humans; Kidney Diseases; Kine

1977
[Gout. Diagnosis--pathogenesis--therapy].
    Fortschritte der Medizin, 1978, Mar-30, Volume: 96, Issue:12

    Topics: Allopurinol; Balneology; Benzofurans; Crystallization; Diagnosis, Differential; Exercise Therapy; Gl

1978
Drug control of gout and hyperuricaemia.
    Drugs, 1978, Volume: 16, Issue:2

    Topics: Allopurinol; Arthritis; Chronic Disease; Colchicine; Gout; Humans; Indomethacin; Naproxen; Phenylbut

1978
[Etiology of arteriosclerosis].
    Der Internist, 1978, Volume: 19, Issue:11

    Topics: Arteriosclerosis; Diabetes Complications; Gout; Humans; Hyperlipidemias; Hypertension; Risk; Smoking

1978
Use of the uricase-inhibited rat as an animal model in toxicology.
    Clinical toxicology, 1978, Volume: 13, Issue:1

    Topics: Aggression; Animals; Diet; Disease Models, Animal; Dogs; Embryo, Mammalian; Female; Gout; Humans; Ki

1978
Pathogenesis and clinical management of hyperuricemia and gout.
    The Journal of the Maine Medical Association, 1979, Volume: 70, Issue:3

    Topics: Allopurinol; Colchicine; Female; Gout; Humans; Kidney Calculi; Male; Uric Acid; Uricosuric Agents

1979
[Uric acid metabolism, specifically the effect of diuretics on the process].
    Nederlands tijdschrift voor geneeskunde, 1979, Aug-25, Volume: 123, Issue:34

    Topics: Allopurinol; Biological Transport; Diuretics; Glomerular Filtration Rate; Gout; Humans; Hypoxanthine

1979
Gout, a multi-faceted disease: Jan Van Breemen lecture, presented to the Dutch Society of Rheumatologists.
    The Netherlands journal of medicine, 1979, Volume: 22, Issue:3

    Topics: Child, Preschool; Colchicine; Crystallization; Gout; Humans; Netherlands; Phagocytosis; Societies, M

1979
Atherosclerosis and urate metabolism.
    Australian and New Zealand journal of medicine, 1979, Volume: 9, Issue:4

    Topics: Arteriosclerosis; Coronary Disease; Gout; Humans; Hyperlipidemias; Hyperlipoproteinemia Type IV; Hyp

1979
[Current aspects of pathogenesis of hyperuricemia and podagra].
    Terapevticheskii arkhiv, 1979, Volume: 51, Issue:12

    Topics: Female; Gout; Humans; Hypoxanthine Phosphoribosyltransferase; Kidney; Male; Middle Aged; Purines; Sy

1979
Choice of treatment in gout.
    The Practitioner, 1977, Volume: 219, Issue:1312

    Topics: Acute Disease; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Gout; Humans; Long-Term Care; U

1977
[The kidney and uric acid].
    L'union medicale du Canada, 1975, Volume: 104, Issue:12

    Topics: Acute Kidney Injury; Female; Gout; Humans; Hypertension; Kidney; Kidney Calculi; Kidney Diseases; Ki

1975
[Inborn errors of metabolism and their significance in urology and nephrology].
    Zeitschrift fur Urologie und Nephrologie, 1976, Volume: 69, Issue:5

    Topics: Acidosis, Renal Tubular; Alkaptonuria; Cystinuria; Diabetes Insipidus; Female; Glycine; Gout; Humans

1976
Uric acid biosynthesis and its disorders.
    Journal of the Royal College of Physicians of London, 1976, Volume: 11, Issue:1

    Topics: Adult; Child, Preschool; Female; Gout; Humans; Immunologic Deficiency Syndromes; Infant; Kidney Calc

1976
[Selected phsiopathological and clinical aspects of purine metabolism].
    Polski tygodnik lekarski (Warsaw, Poland : 1960), 1976, Oct-04, Volume: 31, Issue:40

    Topics: Alkalosis, Respiratory; Diabetes Mellitus; Diuresis; Female; Fructose Intolerance; Glomerular Filtra

1976
[Arterial hypertension and hyperuricemia].
    Semaine des hopitaux. Therapeutique, 1976, Volume: 52, Issue:10

    Topics: Female; Gout; Humans; Hypertension; Kidney; Male; Uric Acid

1976
The radiology of gout. Review article.
    Clinical radiology, 1975, Volume: 26, Issue:1

    Topics: Acute Disease; Aged; Alcoholism; BCG Vaccine; Bone Neoplasms; Chondrocalcinosis; Chronic Disease; Fe

1975
Pharmacologic approach to the maintenance of urate homeostasis.
    Nephron, 1975, Volume: 14, Issue:1

    Topics: Allopurinol; Diuresis; Gout; Homeostasis; Humans; Kidney Tubules; Probenecid; Sulfinpyrazone; Uric A

1975
Editorial: An evaluation of the pathogenesis of gouty kidney.
    Kidney international, 1975, Volume: 8, Issue:2

    Topics: Gout; Humans; Hypoxanthine Phosphoribosyltransferase; Kidney; Kidney Diseases; Kidney Failure, Chron

1975
Gout in Maoris.
    Seminars in arthritis and rheumatism, 1975, Volume: 5, Issue:2

    Topics: Adult; Diabetes Complications; Europe; Female; Gout; Hemoglobins; History, 18th Century; History, 19

1975
[Early recognition and treatment of diet-dependent diseases--gout].
    Bibliotheca nutritio et dieta, 1992, Issue:50

    Topics: Gout; Humans; Purines; Uric Acid

1992
[Hyperuricemia and gout].
    Zeitschrift fur arztliche Fortbildung, 1992, Sep-25, Volume: 86, Issue:18

    Topics: Arthritis, Gouty; Energy Metabolism; Gout; Humans; Kidney Calculi; Myocardial Ischemia; Risk Factors

1992
Gout and hyperuricemia.
    Current opinion in rheumatology, 1992, Volume: 4, Issue:4

    Topics: Crystallization; Gout; Humans; Uric Acid

1992
Tophi as the initial manifestation of gout. Report of six cases and review of the literature.
    Archives of internal medicine, 1992, Volume: 152, Issue:4

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Female; Gout; Humans; Kidney Failure, Chronic; Male; Mi

1992
Renal calculi: pathogenesis, diagnosis, and medical therapy.
    Seminars in nephrology, 1992, Volume: 12, Issue:2

    Topics: Calcium; Citrates; Citric Acid; Combined Modality Therapy; Diagnosis, Differential; Diuretics; Gout;

1992
Renal calculi: pathogenesis, diagnosis, and medical therapy.
    Seminars in nephrology, 1992, Volume: 12, Issue:2

    Topics: Calcium; Citrates; Citric Acid; Combined Modality Therapy; Diagnosis, Differential; Diuretics; Gout;

1992
Renal calculi: pathogenesis, diagnosis, and medical therapy.
    Seminars in nephrology, 1992, Volume: 12, Issue:2

    Topics: Calcium; Citrates; Citric Acid; Combined Modality Therapy; Diagnosis, Differential; Diuretics; Gout;

1992
Renal calculi: pathogenesis, diagnosis, and medical therapy.
    Seminars in nephrology, 1992, Volume: 12, Issue:2

    Topics: Calcium; Citrates; Citric Acid; Combined Modality Therapy; Diagnosis, Differential; Diuretics; Gout;

1992
[Neurological aspects of microcrystalline arthropathies].
    Sovetskaia meditsina, 1991, Issue:4

    Topics: Aged; Cervical Vertebrae; Chondrocalcinosis; Crystallization; Gout; Humans; Lumbar Vertebrae; Middle

1991
Gout and hyperuricemia.
    Current opinion in rheumatology, 1991, Volume: 3, Issue:4

    Topics: Adult; Animals; Female; Gout; Humans; Male; Purines; Uric Acid

1991
Strategies and controversies in the treatment of gout and hyperuricaemia.
    Bailliere's clinical rheumatology, 1990, Volume: 4, Issue:2

    Topics: Adrenal Cortex Hormones; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Col

1990
Gout and hyperuricemia.
    American family physician, 1991, Volume: 43, Issue:6

    Topics: Chronic Disease; Follow-Up Studies; Gout; Humans; Patient Compliance; Uric Acid

1991
The clinical management of gout.
    American pharmacy, 1991, Volume: NS31, Issue:5

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Diet; Gout; Humans; Uric Acid

1991
[New concept of the pathogenesis of gout and hyperuricemia].
    Nihon rinsho. Japanese journal of clinical medicine, 1991, Volume: 49, Issue:5

    Topics: Energy Metabolism; Gout; Purines; Uric Acid

1991
[The genetic basis of hyperuricemia due to a decrease in renal urate secretion].
    Nihon rinsho. Japanese journal of clinical medicine, 1991, Volume: 49, Issue:5

    Topics: Adolescent; Adult; Female; Gout; Humans; Kidney; Male; Metabolic Clearance Rate; Uric Acid

1991
[Clinical findings and pathogenesis of renal impairment in hyperuricemia].
    Nihon rinsho. Japanese journal of clinical medicine, 1991, Volume: 49, Issue:5

    Topics: Gout; Humans; Kidney Diseases; Uric Acid

1991
[Advances in drugs used to normalize hyperuricemia].
    Nihon rinsho. Japanese journal of clinical medicine, 1991, Volume: 49, Issue:5

    Topics: Gout; Humans; Uric Acid; Uricosuric Agents

1991
[Medical control of uric acid in patients with gout--desirable level of serum uric acid and the choice of drugs].
    Nihon rinsho. Japanese journal of clinical medicine, 1991, Volume: 49, Issue:5

    Topics: Allopurinol; Gout; Humans; Uric Acid

1991
[Dietary guidance for hyperuricemia and gout: its principle and practice].
    Nihon rinsho. Japanese journal of clinical medicine, 1991, Volume: 49, Issue:5

    Topics: Gout; Humans; Uric Acid

1991
[The prognosis of gout and hyperuricemia--the effect of the treatment on prognosis].
    Nihon rinsho. Japanese journal of clinical medicine, 1991, Volume: 49, Issue:5

    Topics: Gout; Humans; Prognosis; Uric Acid

1991
[Therapy of the gouty patients with ischemic heart diseases or cerebral vascular diseases].
    Nihon rinsho. Japanese journal of clinical medicine, 1991, Volume: 49, Issue:5

    Topics: Cerebrovascular Disorders; Coronary Disease; Gout; Humans; Uric Acid

1991
[Clinical management of obesity and diabetes with hyperuricemia].
    Nihon rinsho. Japanese journal of clinical medicine, 1991, Volume: 49, Issue:5

    Topics: Diabetes Complications; Diabetes Mellitus; Gout; Humans; Obesity; Uric Acid

1991
[The management of hyperuricemic patients associated with hypertension].
    Nihon rinsho. Japanese journal of clinical medicine, 1991, Volume: 49, Issue:5

    Topics: Gout; Humans; Hypertension; Uric Acid

1991
Drug-induced gout.
    Bailliere's clinical rheumatology, 1991, Volume: 5, Issue:1

    Topics: Cyclosporins; Cytotoxins; Diuretics; Drug-Related Side Effects and Adverse Reactions; Ethambutol; Et

1991
[Hyperuricemia: a laboratory finding needing treatment?].
    Verhandlungen der Deutschen Gesellschaft fur Innere Medizin, 1990, Volume: 96

    Topics: Diagnosis, Differential; Gout; Gout Suppressants; Humans; Uric Acid

1990
Gout and hyperuricemia.
    Rheumatic diseases clinics of North America, 1990, Volume: 16, Issue:3

    Topics: Gout; Humans; Prognosis; Risk Factors; Uric Acid

1990
Gout and hyperuricemia.
    Current opinion in rheumatology, 1990, Volume: 2, Issue:5

    Topics: Cyclosporins; Gout; Humans; Purines; Syndrome; Uric Acid

1990
[Is asymptomatic hyperuricemia in kidney-failure patients in need of therapy?].
    Deutsche medizinische Wochenschrift (1946), 1989, Jun-16, Volume: 114, Issue:24

    Topics: Allopurinol; Gout; Humans; Kidney; Kidney Failure, Chronic; Uric Acid

1989
[Genetic metabolic defects in adults].
    Der Internist, 1989, Volume: 30, Issue:9

    Topics: Arteriosclerosis; Gout; Humans; Hyperlipoproteinemias; Phenotype; Risk Factors; Uric Acid

1989
Observations with Rabenid in patients with locomotor disease.
    Therapia Hungarica (English edition), 1989, Volume: 37, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Clinical Trials as Topic; Female; Gout; Human

1989
Fungalbionics: a new concept of the etiology of gout, hyperuricemia and their related diseases.
    Advances in experimental medicine and biology, 1989, Volume: 253A

    Topics: Animals; Crystallization; Fungi; Gout; Humans; Purines; Uric Acid

1989
[Paraparesis due to gout].
    Arquivos de neuro-psiquiatria, 1989, Volume: 47, Issue:4

    Topics: Adult; Arthritis, Gouty; Crystallization; Gout; Humans; Male; Paraparesis, Tropical Spastic; Radiogr

1989
[Is gout correctly diagnosed?].
    Medicina clinica, 1988, Jun-25, Volume: 91, Issue:5

    Topics: Gout; Humans; Synovial Fluid; Uric Acid

1988
Crystal identification in human synovial fluids. Methods and interpretation.
    Rheumatic diseases clinics of North America, 1988, Volume: 14, Issue:2

    Topics: Arthritis; Calcium Oxalate; Calcium Phosphates; Calcium Pyrophosphate; Crystallography; Gout; Humans

1988
Pathology of crystal deposition diseases.
    Rheumatic diseases clinics of North America, 1988, Volume: 14, Issue:2

    Topics: Apatites; Calcium Phosphates; Calcium Pyrophosphate; Cartilage, Articular; Crystallography; Gout; Hu

1988
The inflammatory reaction to crystals.
    Rheumatic diseases clinics of North America, 1988, Volume: 14, Issue:2

    Topics: Antibody Formation; Arthritis, Gouty; Cell Membrane; Crystallization; Crystallography; Gout; Humans;

1988
Clinical aspects of monosodium urate monohydrate crystal deposition disease (gout).
    Rheumatic diseases clinics of North America, 1988, Volume: 14, Issue:2

    Topics: Adult; Child; Female; Gout; Humans; Kidney; Male; Uric Acid

1988
Mixed crystal deposition.
    Rheumatic diseases clinics of North America, 1988, Volume: 14, Issue:2

    Topics: Calcinosis; Calcium Pyrophosphate; Crystallization; Female; Gout; Humans; Joint Diseases; Middle Age

1988
Therapy in gout.
    Rheumatic diseases clinics of North America, 1988, Volume: 14, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Calculi; Colchicine; Gout; Humans; Recurrence; Uric Acid

1988
Gout: how presentation, diagnosis, and treatment differ in the elderly.
    Geriatrics, 1988, Volume: 43, Issue:11

    Topics: Adrenal Cortex Hormones; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Female; Gout; Hu

1988
Urate metabolism and gout--a perspective.
    Australian and New Zealand journal of medicine, 1988, Volume: 18, Issue:3

    Topics: Gout; Humans; Kidney Diseases; Uric Acid

1988
[Common sense and nonsense in diet therapy. Hyperuricemia and gout].
    Verhandlungen der Deutschen Gesellschaft fur Innere Medizin, 1988, Volume: 94

    Topics: Gout; Humans; Purines; Uric Acid

1988
Analytical reviews in clinical biochemistry: the measurement of urate.
    Annals of clinical biochemistry, 1988, Volume: 25 ( Pt 5)

    Topics: Blood Chemical Analysis; Gout; Humans; Uric Acid

1988
[Metabolism of uric acid and purines in leukocytes].
    Ryumachi. [Rheumatism], 1988, Volume: 28, Issue:1

    Topics: Adenosine Deaminase; Gout; Humans; Interleukin-1; Leukocytes; Purine-Nucleoside Phosphorylase; Purin

1988
Tubulo-interstitial nephritis associated with systemic disease and electrolyte abnormalities.
    Seminars in nephrology, 1988, Volume: 8, Issue:1

    Topics: Chronic Disease; Gout; Humans; Multiple Myeloma; Nephritis, Interstitial; Sarcoidosis; Sjogren's Syn

1988
[Unusual clinical syndrome: rheumatoid arthritis and gouty arthritis].
    Orvosi hetilap, 1987, Dec-20, Volume: 128, Issue:51

    Topics: Adult; Arthritis, Rheumatoid; Crystallization; Foot; Gout; Humans; Male; Metacarpus; Radiography; Rh

1987
Gout.
    Bailliere's clinical rheumatology, 1987, Volume: 1, Issue:3

    Topics: Arthritis; Cardiovascular Diseases; Diabetes Complications; Environment; Gout; Humans; Hyperlipidemi

1987
Hyperuricemia and gout.
    The Medical clinics of North America, 1986, Volume: 70, Issue:2

    Topics: Acute Disease; Adult; Allopurinol; Anti-Inflammatory Agents; Arthritis; Arthrography; Calcinosis; Ch

1986
[Hyperuricemia and essential arterial hypertension].
    Recenti progressi in medicina, 1985, Volume: 76, Issue:5

    Topics: Gout; Humans; Hypertension; Kidney; Renal Circulation; Uric Acid

1985
[Current aspects of the etiology and pathogenesis of primary gout].
    Vutreshni bolesti, 1985, Volume: 24, Issue:2

    Topics: Adult; Aging; Anaerobiosis; Female; Glycolysis; Gout; Humans; Kidney; Lysosomes; Male; Nutritional P

1985
Tophaceous gout of the spine in a patient with no peripheral tophi: case report and review of the literature.
    Arthritis and rheumatism, 1985, Volume: 28, Issue:11

    Topics: Aged; Crystallization; Electromyography; Female; Gout; Humans; Laminectomy; Lumbar Vertebrae; Radiog

1985
[Hyperuricemia: is treatment necessary or not?].
    Therapeutische Umschau. Revue therapeutique, 1985, Volume: 42, Issue:10

    Topics: Cardiovascular Diseases; Diuretics; Gout; Humans; Kidney Calculi; Uric Acid

1985
The 1968 interim scientific session of the American Rheumatism Association.
    Bulletin on the rheumatic diseases, 1969, Volume: 19, Issue:6

    Topics: Amyloidosis; Arthritis, Rheumatoid; Collagen Diseases; Fibroblasts; gamma-Globulins; Gout; Humans; L

1969
[Lipids and arteriosclerosis].
    Revista clinica espanola, 1973, Aug-15, Volume: 130, Issue:3

    Topics: Adult; Age Factors; Aged; Animals; Arteriosclerosis; Cats; Cholesterol; Coronary Disease; Dogs; Gout

1973
Hyperuricemia and gout.
    Advances in internal medicine, 1969, Volume: 15

    Topics: Biological Transport; Carbohydrate Metabolism, Inborn Errors; Down Syndrome; Fructose; Glucosyltrans

1969
[Hyperuricemia in childhood].
    Minerva pediatrica, 1973, Jun-30, Volume: 25, Issue:24

    Topics: Anemia, Hemolytic; Child; Down Syndrome; Glycogen Storage Disease; Gout; Humans; Kidney Calculi; Kid

1973
On the crystal deposition diseases.
    Disease-a-month : DM, 1970

    Topics: Adult; Aged; Arthritis; Calcinosis; Diphosphates; Female; Gout; Humans; Joint Diseases; Male; Middle

1970
Phosphoribosylpyrophosphate in man: biochemical and clinical significance.
    Annals of internal medicine, 1971, Volume: 74, Issue:3

    Topics: Adenine; Adrenocorticotropic Hormone; Allopurinol; Animals; Glycogen; Gout; Humans; Lesch-Nyhan Synd

1971
Pathophysiology of hyperuricemia in primary gout.
    Transactions of the American Clinical and Climatological Association, 1970, Volume: 81

    Topics: Adenosine Monophosphate; Adenosine Triphosphate; Culture Techniques; Diphosphates; Fibroblasts; Glut

1970
Ethanol metabolism and uric acid.
    Metabolism: clinical and experimental, 1972, Volume: 21, Issue:12

    Topics: Acetaldehyde; Alcoholism; Ethanol; Fasting; Gout; Humans; Hyperlipidemias; Ketone Bodies; Lactates;

1972
Editorial: The kidney and uric acid excretion in man.
    Kidney international, 1972, Volume: 2, Issue:3

    Topics: Angiotensin II; Animals; Biological Transport, Active; Blood Proteins; Diabetes Insipidus; Diet, Sod

1972
Crystal deposition joint disease.
    Annual review of medicine, 1974, Volume: 25

    Topics: Aged; Arthritis, Rheumatoid; Chondrocalcinosis; Colchicine; Crystallization; Diphosphates; Female; G

1974
Metabolic defects of primary hyperuricemia and gout.
    The American journal of medicine, 1974, Volume: 56, Issue:5

    Topics: Adenosine Monophosphate; Blood Proteins; Catalysis; Erythrocytes; Glutamine; Gout; Guanine; Guanine

1974
Medical management of the patient with arthritis.
    Clinical orthopaedics and related research, 1974, Issue:101

    Topics: Adrenocorticotropic Hormone; Arthritis; Arthritis, Infectious; Arthritis, Rheumatoid; Aspirin; Chond

1974
[Metabolic effects of diuretics].
    Duodecim; laaketieteellinen aikakauskirja, 1974, Volume: 90, Issue:14

    Topics: Angiotensin II; Depression, Chemical; Diuretics; Glucose; Gout; Humans; Hypokalemia; Magnesium; Pota

1974
Recent advances in rheumatic diseases: 1967 through 1969.
    Annals of internal medicine, 1970, Volume: 73, Issue:1

    Topics: Arthritis; Arthritis, Infectious; Arthritis, Reactive; Arthritis, Rheumatoid; Behcet Syndrome; Colla

1970
The physiologic approach to hyperuricemia.
    The New England journal of medicine, 1972, Mar-02, Volume: 286, Issue:9

    Topics: Allopurinol; Gout; Humans; Kidney; Purine-Pyrimidine Metabolism, Inborn Errors; Purines; Uric Acid;

1972
[Renal manifestations of hyperuricemia].
    Revue du rhumatisme et des maladies osteo-articulaires, 1972, Volume: 39, Issue:2

    Topics: Acute Kidney Injury; Albuminuria; Cortisone; Gout; Hematuria; Humans; Kidney Calculi; Kidney Disease

1972
Diabetes mellitus and gout.
    Seminars in arthritis and rheumatism, 1972,Fall, Volume: 2, Issue:2

    Topics: Benzothiadiazines; Blood Glucose; Carbohydrate Metabolism; Diabetes Complications; Diabetes Mellitus

1972
[Gout, archetype of diseases caused by deposits].
    Annales de biologie clinique, 1972, Volume: 30, Issue:6

    Topics: Gout; Humans; Kidney Calculi; Kinins; Lesch-Nyhan Syndrome; Metabolic Diseases; Nephritis, Interstit

1972
Views on the pathogenesis and management of primary gout--1971.
    The Journal of bone and joint surgery. American volume, 1972, Volume: 54, Issue:2

    Topics: Adenosine Triphosphate; Arthritis; Enzyme Precursors; Gout; Guanine Nucleotides; Humans; Hypoxanthin

1972
Renal mechanisms for regulation of uric acid excretion, with special reference to normal and gouty man.
    Seminars in arthritis and rheumatism, 1972,Summer, Volume: 2, Issue:1

    Topics: Allantoin; Animals; Birds; Dogs; Glomerular Filtration Rate; Gout; Guinea Pigs; Humans; Kidney; Kidn

1972
Epidemiology of coronary heart disease.
    The Medical clinics of North America, 1973, Volume: 57, Issue:1

    Topics: Adult; Aged; Arteriosclerosis; Cholesterol, Dietary; Coronary Disease; Diabetes Complications; Dieta

1973
[Effect of allopurinol on the metabolism of uric acid].
    Polskie Archiwum Medycyny Wewnetrznej, 1973, Volume: 50, Issue:4

    Topics: Allopurinol; Chemical Phenomena; Chemistry; Depression, Chemical; Feedback; Gout; Humans; Kidney; Pu

1973
Current concepts in the pathogenesis of hyperuricemia.
    Metabolism: clinical and experimental, 1973, Volume: 22, Issue:7

    Topics: Gout; Humans; Metabolic Diseases; Purine Nucleotides; Purines; Uric Acid

1973
[Coffee-drinking from the medical point of view].
    Schweizerische medizinische Wochenschrift, 1973, Volume: 103, Issue:43

    Topics: Adult; Blood Pressure; Caffeine; Coffee; Diabetes Mellitus; Feeding Behavior; Female; Gout; Health S

1973
Aetiology of gout.
    Scottish medical journal, 1973, Volume: 18

    Topics: Allopurinol; Creatinine; Diet Therapy; Erythrocytes; Gout; Humans; Hypoxanthines; Lesch-Nyhan Syndro

1973
Drug induced gout.
    Scottish medical journal, 1973, Volume: 18

    Topics: Absorption; Allopurinol; Aspirin; Benzothiadiazines; Diuretics; Ethanol; Gout; Humans; Kidney Calcul

1973
Crystals, lysosomes and gout.
    Advances in internal medicine, 1974, Volume: 19

    Topics: Cell Survival; Crystallization; Endocytosis; Gonadal Steroid Hormones; Gout; Hemolysis; Humans; Hydr

1974
Current management of polycythemia vera and related diseases.
    Postgraduate medicine, 1974, Volume: 55, Issue:5

    Topics: Allopurinol; Bloodletting; Chlorambucil; Erythropoiesis; Gout; Humans; Melphalan; Phosphorus Radiois

1974
Influence of the kidney upon urate homeostasis in health and disease.
    The American journal of medicine, 1974, Volume: 56, Issue:5

    Topics: Acute Kidney Injury; Female; Glomerular Filtration Rate; Gout; Homeostasis; Humans; Hypertension; Hy

1974
[Renal insufficiency and uric acid metabolism: harmful effect of uric acid and new interpretation of uric acid metabolism].
    Nihon rinsho. Japanese journal of clinical medicine, 1974, Volume: 32, Issue:3

    Topics: Female; Gout; Homeostasis; Humans; Kidney; Kidney Failure, Chronic; Male; Renal Dialysis; Uric Acid

1974
Genetic aspects of gout.
    Annual review of medicine, 1974, Volume: 25, Issue:0

    Topics: Adenine; Allopurinol; Carbon Radioisotopes; Erythrocytes; Fibroblasts; Glucosephosphate Dehydrogenas

1974
Milestones in the treatment of gout.
    The American journal of medicine, 1974, Volume: 56, Issue:5

    Topics: Allopurinol; Colchicine; Gout; Humans; Indomethacin; Kidney Calculi; Probenecid; Sulfinpyrazone; Uri

1974
[Threatening urate and gout].
    Nederlands tijdschrift voor geneeskunde, 1974, Dec-28, Volume: 118, Issue:52

    Topics: Diet; Gout; Humans; Urate Oxidase; Uric Acid

1974
Molecular variation in relation to purine metabolism.
    Journal of clinical pathology. Supplement (Royal College of Pathologists), 1974, Volume: 8

    Topics: Amidophosphoribosyltransferase; Chemical Phenomena; Chemistry; Glucosephosphate Dehydrogenase Defici

1974
Invitation to the gout. A consideration of the role of various predisposing and provocative factors in the genesis of acute gouty arthritis.
    Transactions & studies of the College of Physicians of Philadelphia, 1967, Volume: 35, Issue:2

    Topics: Acute Disease; Alcoholic Beverages; Arthritis; Fasting; Food; Gout; Humans; Mercury; Organomercury C

1967
Eighteenth rheumatism review. Review of American and English literature for the years 1965 and 1966.
    Arthritis and rheumatism, 1968, Volume: 11, Issue:3

    Topics: Adult; Animals; Arthritis, Infectious; Arthritis, Rheumatoid; Autoimmune Diseases; Bone Diseases; Ca

1968
Recent progress in the pathogenesis and treatment of gout.
    Medical times, 1969, Volume: 97, Issue:2

    Topics: Allopurinol; Gout; Humans; Uric Acid

1969
[Effects and side-effects of hypotensive diuretics].
    Nihon rinsho. Japanese journal of clinical medicine, 1968, Volume: 26, Issue:7

    Topics: Antihypertensive Agents; Benzothiadiazines; Chlorothiazide; Diabetes Mellitus; Diuretics; Gout; Huma

1968
Hypoxanthine-guanine phosphoribosyltransferase deficiency in gout.
    Annals of internal medicine, 1969, Volume: 70, Issue:1

    Topics: Adenine; Adolescent; Adult; Allopurinol; Azathioprine; Child; Child, Preschool; Female; Gout; Humans

1969
[On the biochemistry and pathogenesis of gout].
    Hippokrates, 1968, Feb-29, Volume: 39, Issue:4

    Topics: Alcoholism; Glomerular Filtration Rate; Gout; Humans; Kidney Tubules; Obesity; Purines; Uric Acid

1968
[The kidney in gout and gout of the kidney].
    Deutsches medizinisches Journal, 1968, Jun-05, Volume: 19, Issue:11

    Topics: Arteriosclerosis Obliterans; Carbohydrate Metabolism; Cerebrovascular Disorders; Diabetes Complicati

1968
Physiologic and biochemical basis for the treatment of gout and hyperuricemia.
    The Medical clinics of North America, 1969, Volume: 53, Issue:6

    Topics: Acute Disease; Adrenal Cortex Hormones; Arthritis; Chronic Disease; Colchicine; Glomerular Filtratio

1969
Epidemiology of serum uric acid and gout: an example of the complexities of multifactorial causation.
    Proceedings of the Royal Society of Medicine, 1970, Volume: 63, Issue:2

    Topics: ABO Blood-Group System; Adult; Aged; Altitude; Argentina; Brazil; Colombia; Female; Gout; Humans; Ma

1970
[Present status of gout in Japan].
    Geka chiryo. Surgical therapy, 1970, Volume: 22, Issue:3

    Topics: Diet Therapy; Gout; Health Education; Humans; Japan; Uric Acid

1970
Crystal-induced inflammation of the joints.
    Annual review of medicine, 1970, Volume: 21

    Topics: Animals; Arthritis; Colchicine; Dogs; Gout; Humans; Inflammation; Leukocytes; Phagocytosis; Uric Aci

1970
Uric acid excretion in the relatives of patients with gout.
    Annals of the rheumatic diseases, 1970, Volume: 29, Issue:4

    Topics: Creatinine; Female; Gout; Humans; Male; Sex Factors; Uric Acid

1970
Gout.
    Advances in metabolic disorders, 1965, Volume: 2

    Topics: Allopurinol; Arthritis; Carbon Isotopes; Colchicine; Glutamine; Gout; Humans; Kidney; Orotic Acid; P

1965
[Treatment of congenital purine-pyrimidine metabolism anomalies].
    Horumon to rinsho. Clinical endocrinology, 1971, Volume: 19, Issue:1

    Topics: Athetosis; Chorea; Compulsive Behavior; Gout; Humans; Intellectual Disability; Orotic Acid; Purine-P

1971
Control of uric acid excretion.
    The New England journal of medicine, 1971, May-27, Volume: 284, Issue:21

    Topics: Animals; Dogs; Glycine; Gout; Humans; Kidney; Kidney Diseases; Kidney Tubules; Pyrazinamide; Uric Ac

1971
[Gout. Clinical aspects, pathogenesis, current treatment].
    Les Cahiers de medecine, 1971, Apr-30, Volume: 12, Issue:6

    Topics: Calcinosis; Colchicine; Diagnosis, Differential; Diet Therapy; Female; Gout; Humans; Joint Diseases;

1971
[Drug therapy in gout].
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 1971, Jul-01, Volume: 24, Issue:13

    Topics: Allopurinol; Chemical Phenomena; Chemistry; Colchicine; Gout; Humans; Phagocytosis; Probenecid; Puri

1971
Treatment of gout.
    The New England journal of medicine, 1971, Dec-02, Volume: 285, Issue:23

    Topics: Adrenal Cortex Hormones; Allopurinol; Colchicine; Gout; Humans; Indomethacin; Phenylbutazone; Proben

1971
[What is certain in gout therapy?].
    Der Internist, 1971, Volume: 12, Issue:12

    Topics: Acute Disease; Allopurinol; Chronic Disease; Colchicine; Gout; Humans; Hydrogen-Ion Concentration; K

1971
Biochemical and genetic studies of an X-linked neurological disease (The Lesch-Nyhan syndrome).
    Harvey lectures, 1971, Volume: 65

    Topics: Animals; Athetosis; Cells, Cultured; Cerebral Palsy; Child; Disease Models, Animal; Feedback; Female

1971
[Gout].
    Schweizerische medizinische Wochenschrift, 1970, Feb-21, Volume: 100, Issue:8

    Topics: Allopurinol; Chondrocalcinosis; Colchicine; Diagnosis, Differential; Diet Therapy; Gout; Humans; Ino

1970
Allopurinol. A review.
    Le Journal medical libanais. The Lebanese medical journal, 1971, Volume: 24, Issue:5

    Topics: Adult; Allopurinol; Child; Drug Hypersensitivity; Drug Interactions; Gout; Humans; Iron; Kidney Dise

1971
Drug treatment of gout.
    Seminars in drug treatment, 1971, Volume: 1, Issue:2

    Topics: Acute Disease; Allopurinol; Arthritis; Colchicine; Gout; Humans; Orotic Acid; Probenecid; Structure-

1971
Selected aspects of the aetiology, pathogenesis and treatment of disorders of purine metabolism.
    Modern trends in rheumatology, 1971, Volume: 2

    Topics: Allopurinol; Colchicine; Glycogen Storage Disease Type I; Gout; Humans; Lesch-Nyhan Syndrome; Metabo

1971
Drugs and uric acid.
    Annual review of pharmacology, 1969, Volume: 9

    Topics: Allopurinol; Chemical Phenomena; Chemistry; Gout; Humans; Purines; Uric Acid; Xanthines

1969
[Hyperuricemia. IV. Theoretical mechanisms of hyperuricemia. Prinicipal causes of hyperuricemia: hereditary dyspurinia, overeating, renal insufficiency, blood diseases].
    Revue du rhumatisme et des maladies osteo-articulaires, 1966, Volume: 33, Issue:3

    Topics: Gout; Humans; In Vitro Techniques; Uric Acid

1966
Uric acid, gout, and the kidney.
    The Medical clinics of North America, 1966, Volume: 50, Issue:4

    Topics: Gout; Humans; Kidney Diseases; Uric Acid

1966
The study of human intermediary purine metabolism and its regulation.
    Proceedings of the Royal Society of Medicine, 1966, Volume: 59, Issue:4

    Topics: Gout; Humans; Purines; Uric Acid; Urine

1966
[Hyperuricemias].
    Rein et foie, maladies de la nutrition; actualites, 1966, Volume: 9

    Topics: Gout; Humans; Uric Acid

1966
Hyperuricemia, gout, and atherosclerosis.
    American heart journal, 1966, Volume: 72, Issue:4

    Topics: Arteriosclerosis; Gout; Humans; Uric Acid

1966
The biological significance of uric acid.
    Harvey lectures, 1966, Volume: 60

    Topics: Gout; Humans; Uric Acid

1966
[Gout and hyperuricemia].
    Archiv fur klinische Medizin, 1966, Volume: 212, Issue:2

    Topics: Diagnosis, Differential; Gout; Humans; Uric Acid

1966

Trials

229 trials available for uric acid and Gout

ArticleYear
Optimal uric acid levels by febuxostat treatment and cerebral, cardiorenovascular risks: post hoc analysis of a randomized controlled trial.
    Rheumatology (Oxford, England), 2022, 05-30, Volume: 61, Issue:6

    Topics: Aged; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome; Uric Acid

2022
Effect of alkalized urine on renal calculi in patients with gout: a protocol for a placebo-controlled, double-blinded randomized controlled trial.
    Trials, 2021, Oct-26, Volume: 22, Issue:1

    Topics: Double-Blind Method; Febuxostat; Gout; Gout Suppressants; Humans; Kidney Calculi; Randomized Control

2021
Denosumab did not improve computerized tomography erosion scores when added to intensive urate-lowering therapy in gout: Results from a pilot randomized controlled trial.
    Seminars in arthritis and rheumatism, 2021, Volume: 51, Issue:6

    Topics: Denosumab; Gout; Gout Suppressants; Humans; Pilot Projects; Tomography, X-Ray Computed; Uric Acid

2021
SToRytelling to Improve Disease outcomes in Gout (STRIDE-GO): a multicenter, randomized controlled trial in African American veterans with gout.
    BMC medicine, 2021, 11-09, Volume: 19, Issue:1

    Topics: Black or African American; Gout; Gout Suppressants; Humans; Male; Middle Aged; Quality of Life; Uric

2021
SToRytelliing to Improve Disease outcomes in Gout (STRIDE-GO) in African American veterans with gout: a trial study protocol.
    Trials, 2021, Dec-04, Volume: 22, Issue:1

    Topics: Black or African American; Ethnic and Racial Minorities; Gout; Gout Suppressants; Humans; Multicente

2021
Intensive Serum Urate Lowering With Oral Urate-Lowering Therapy for Erosive Gout: A Randomized Double-Blind Controlled Trial.
    Arthritis & rheumatology (Hoboken, N.J.), 2022, Volume: 74, Issue:6

    Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Quality of Life; Treatment Outcome; Uric A

2022
Design and implementation of a Pacific intervention to increase uptake of urate-lowering therapy for gout: a study protocol.
    International journal for equity in health, 2021, 12-23, Volume: 20, Issue:1

    Topics: Australia; Gout; Humans; Native Hawaiian or Other Pacific Islander; New Zealand; Symptom Flare Up; U

2021
Safety, Efficacy, and Pharmacokinetics of HP501 in Healthy Volunteers and Hyperuricemic Patients: A Phase I/IIa Study.
    The Journal of clinical endocrinology and metabolism, 2022, 05-17, Volume: 107, Issue:6

    Topics: Double-Blind Method; Gout; Healthy Volunteers; Humans; Hyperuricemia; Treatment Outcome; Uric Acid;

2022
Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial.
    Arthritis & rheumatology (Hoboken, N.J.), 2022, Volume: 74, Issue:9

    Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Treatment Outcom

2022
Zhengqing fengtongning sustained-release tablets prevents gout flares in the process of ULT: A randomized, positive control, double-blind, double-simulation, multicenter trial.
    Medicine, 2022, May-06, Volume: 101, Issue:18

    Topics: Arthritis, Gouty; Colchicine; Delayed-Action Preparations; Double-Blind Method; Drugs, Chinese Herba

2022
Effects of vitamin C supplementation on gout risk: results from the Physicians' Health Study II trial.
    The American journal of clinical nutrition, 2022, 09-02, Volume: 116, Issue:3

    Topics: Adult; Aged; Ascorbic Acid; Dietary Supplements; Double-Blind Method; Gout; Humans; Male; Middle Age

2022
Urate-lowering effect of calcium supplementation: Analyses of a randomized controlled trial.
    Clinical nutrition ESPEN, 2022, Volume: 49

    Topics: Adult; Calcium; Calcium Citrate; Calcium, Dietary; Dietary Supplements; Female; Gout; Humans; Uric A

2022
Evaluation of the safety and efficacy of a Fuling-Zexie decoction for people with asymptomatic hyperuricemia: protocol for a prospective, double-blinded, randomized, placebo-controlled clinical trial.
    Trials, 2022, Jun-20, Volume: 23, Issue:1

    Topics: Double-Blind Method; Gout; Humans; Hyperuricemia; Pilot Projects; Prospective Studies; Randomized Co

2022
Long-Term Follow-up of a Randomized Controlled Trial of Allopurinol Dose Escalation to Achieve Target Serum Urate in People With Gout.
    The Journal of rheumatology, 2022, Volume: 49, Issue:12

    Topics: Allopurinol; Follow-Up Studies; Gout; Gout Suppressants; Humans; Symptom Flare Up; Treatment Outcome

2022
Superiority of Low-Dose Benzbromarone to Low-Dose Febuxostat in a Prospective, Randomized Comparative Effectiveness Trial in Gout Patients With Renal Uric Acid Underexcretion.
    Arthritis & rheumatology (Hoboken, N.J.), 2022, Volume: 74, Issue:12

    Topics: Allopurinol; Benzbromarone; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Prospe

2022
The effects of aerobic exercise on body composition in overweight and obese patients with gout: a randomized, open-labeled, controlled trial.
    Trials, 2022, Sep-05, Volume: 23, Issue:1

    Topics: Adolescent; Adult; Body Composition; Cholesterol, HDL; Exercise; Exercise Therapy; Gout; Humans; Mid

2022
A Randomized, Placebo-Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings.
    Arthritis & rheumatology (Hoboken, N.J.), 2023, Volume: 75, Issue:2

    Topics: Adult; Anaphylaxis; Arthritis, Gouty; Double-Blind Method; Gout; Gout Suppressants; Humans; Methotre

2023
A Drug-Drug Interaction Study of a Novel Selective Urate Reabsorption Inhibitor, SHR4640, and Xanthine Oxidase Inhibitor, Febuxostat, in Patients With Primary Hyperuricemia.
    Journal of clinical pharmacology, 2023, Volume: 63, Issue:2

    Topics: Drug Interactions; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Tr

2023
Immersion in Water Between 20-30
    Biological research for nursing, 2023, Volume: 25, Issue:2

    Topics: Biomarkers; Gout; Humans; Immersion; Indonesia; Inflammasomes; Inflammation; Pain; Pain Management;

2023
Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial.
    Lancet (London, England), 2022, 10-08, Volume: 400, Issue:10359

    Topics: Aged; Allopurinol; Coronary Artery Disease; Female; Gout; Humans; Male; Myocardial Infarction; Myoca

2022
Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
    Journal of clinical pharmacy and therapeutics, 2022, Volume: 47, Issue:12

    Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni

2022
Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
    Journal of clinical pharmacy and therapeutics, 2022, Volume: 47, Issue:12

    Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni

2022
Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
    Journal of clinical pharmacy and therapeutics, 2022, Volume: 47, Issue:12

    Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni

2022
Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
    Journal of clinical pharmacy and therapeutics, 2022, Volume: 47, Issue:12

    Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni

2022
Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
    Journal of clinical pharmacy and therapeutics, 2022, Volume: 47, Issue:12

    Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni

2022
Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
    Journal of clinical pharmacy and therapeutics, 2022, Volume: 47, Issue:12

    Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni

2022
Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
    Journal of clinical pharmacy and therapeutics, 2022, Volume: 47, Issue:12

    Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni

2022
Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
    Journal of clinical pharmacy and therapeutics, 2022, Volume: 47, Issue:12

    Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni

2022
Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
    Journal of clinical pharmacy and therapeutics, 2022, Volume: 47, Issue:12

    Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni

2022
Early urate-lowering therapy in gouty arthritis with acute flares: a double-blind placebo controlled clinical trial.
    European journal of medical research, 2023, Jan-06, Volume: 28, Issue:1

    Topics: Arthritis, Gouty; Chronic Disease; Colchicine; Gout; Gout Suppressants; Humans; Probenecid; Symptom

2023
Serum Urate-Lowering Efficacy and Safety of Tigulixostat in Gout Patients With Hyperuricemia: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Trial.
    Arthritis & rheumatology (Hoboken, N.J.), 2023, Volume: 75, Issue:7

    Topics: Double-Blind Method; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Symptom Flare Up; T

2023
Hmong microbiome ANd Gout, Obesity, Vitamin C (HMANGO-C): A phase II clinical study protocol.
    PloS one, 2023, Volume: 18, Issue:2

    Topics: Adult; Ascorbic Acid; Clinical Trials, Phase II as Topic; COVID-19; Gout; Gout Suppressants; Humans;

2023
Febuxostat and renal outcomes: post-hoc analysis of a randomized trial.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2023, Volume: 46, Issue:6

    Topics: Aged; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment

2023
Urate-lowering therapy following a treat-to-target continuation strategy compared to a treat-to-avoid-symptoms discontinuation strategy in gout patients in remission (GO TEST Finale): study protocol of a multicentre pragmatic randomized superiority trial.
    Trials, 2023, Apr-19, Volume: 24, Issue:1

    Topics: Gout; Gout Suppressants; Humans; Kidney; Multicenter Studies as Topic; Pragmatic Clinical Trials as

2023
Pegloticase efficacy and safety in kidney transplant recipients; results of the phase IV, open-label PROTECT clinical trial.
    Clinical transplantation, 2023, Volume: 37, Issue:9

    Topics: Adult; COVID-19; Gout; Gout Suppressants; Humans; Kidney Transplantation; Middle Aged; Polyethylene

2023
Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial.
    Annals of the rheumatic diseases, 2023, Volume: 82, Issue:12

    Topics: Adult; Allopurinol; Colchicine; Gout; Gout Suppressants; Humans; Symptom Flare Up; Treatment Outcome

2023
Efficacy and safety of tart cherry supplementary citrate mixture on gout patients: a prospective, randomized, controlled study.
    Arthritis research & therapy, 2023, 09-07, Volume: 25, Issue:1

    Topics: C-Reactive Protein; Citrates; Citric Acid; Gout; Humans; Male; Metabolic Syndrome; Prospective Studi

2023
Effects of the DASH diet and losartan on serum urate among adults with hypertension: Results of a randomized trial.
    Journal of clinical hypertension (Greenwich, Conn.), 2023, Volume: 25, Issue:10

    Topics: Adult; Dietary Approaches To Stop Hypertension; Female; Gout; Humans; Hypertension; Hyperuricemia; L

2023
Efficacy of Aristolochia rotunda Linn in hyperuricemia: A randomised standard controlled study.
    Clinical nutrition ESPEN, 2023, Volume: 57

    Topics: Aristolochia; Gout; Humans; Hyperuricemia; Single-Blind Method; Uric Acid

2023
Evaluating the effectiveness and safety of acupuncture on serum uric acid in asymptomatic hyperuricemia population: a randomized controlled clinical trial study protocol.
    Frontiers in endocrinology, 2023, Volume: 14

    Topics: Acupuncture Therapy; Gout; Humans; Hyperuricemia; Randomized Controlled Trials as Topic; Single-Blin

2023
Relationships Between Allopurinol Dose, Oxypurinol Concentration and Urate-Lowering Response-In Search of a Minimum Effective Oxypurinol Concentration.
    Clinical and translational science, 2020, Volume: 13, Issue:1

    Topics: Aged; Allopurinol; ATP Binding Cassette Transporter, Subfamily G, Member 2; Body Mass Index; Creatin

2020
Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort.
    Arthritis research & therapy, 2019, 09-02, Volume: 21, Issue:1

    Topics: Benzbromarone; Biomarkers; China; Dose-Response Relationship, Drug; Febuxostat; Follow-Up Studies; G

2019
Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 stu
    Clinical and experimental nephrology, 2020, Volume: 24, Issue:Suppl 1

    Topics: Adult; Benzothiazoles; Double-Blind Method; Gout; Humans; Hyperuricemia; Japan; Male; Middle Aged; O

2020
Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study.
    Clinical and experimental nephrology, 2020, Volume: 24, Issue:Suppl 1

    Topics: Adult; Aged; Benzothiazoles; Dose-Response Relationship, Drug; Double-Blind Method; Female; Gout; Hu

2020
Open-label study of long-term administration of dotinurad in Japanese hyperuricemic patients with or without gout.
    Clinical and experimental nephrology, 2020, Volume: 24, Issue:Suppl 1

    Topics: Adult; Benzothiazoles; Female; Gout; Humans; Hyperuricemia; Japan; Male; Middle Aged; Organic Anion

2020
Lack of effect of tart cherry concentrate dose on serum urate in people with gout.
    Rheumatology (Oxford, England), 2020, 09-01, Volume: 59, Issue:9

    Topics: Adult; Aged; Allopurinol; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Phytotherapy;

2020
A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout.
    Clinical and experimental nephrology, 2020, Volume: 24, Issue:Suppl 1

    Topics: Adult; Aged; Benzothiazoles; Double-Blind Method; Febuxostat; Gout; Humans; Hyperuricemia; Japan; Ma

2020
Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study.
    Clinical and experimental nephrology, 2020, Volume: 24, Issue:Suppl 1

    Topics: Adult; Aged; Benzbromarone; Benzothiazoles; Double-Blind Method; Female; Gout; Humans; Hyperuricemia

2020
Effect of Curcumin on Serum Urate in Asymptomatic Hyperuricemia: A Randomized Placebo-Controlled Trial.
    Journal of dietary supplements, 2021, Volume: 18, Issue:3

    Topics: Curcumin; Female; Gout; Humans; Hyperuricemia; Male; Treatment Outcome; Uric Acid

2021
Pegloticase in Combination With Methotrexate in Patients With Uncontrolled Gout: A Multicenter, Open-label Study (MIRROR).
    The Journal of rheumatology, 2021, Volume: 48, Issue:5

    Topics: Adult; Gout; Gout Suppressants; Humans; Male; Methotrexate; Middle Aged; Polyethylene Glycols; Treat

2021
UltraSound evaluation in follow-up of urate-lowering therapy in gout phase 2 (USEFUL-2): Duration of flare prophylaxis.
    Joint bone spine, 2020, Volume: 87, Issue:6

    Topics: Aged; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Male; Middle Aged; Prospective Stu

2020
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
    Lancet (London, England), 2020, 11-28, Volume: 396, Issue:10264

    Topics: Aged; Allopurinol; Cardiovascular Diseases; Denmark; Febuxostat; Female; Gout; Gout Suppressants; Ho

2020
Initiation of febuxostat for acute gout flare does not prolong the current episode: a randomized clinical trial.
    Rheumatology (Oxford, England), 2021, 09-01, Volume: 60, Issue:9

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Febuxostat; Female; Gout; Gout Suppressa

2021
Effects of intensive urate lowering therapy with febuxostat in comparison with allopurinol on pulse wave velocity in patients with gout and increased cardiovascular risk: the FORWARD study.
    European heart journal. Cardiovascular pharmacotherapy, 2022, 05-05, Volume: 8, Issue:3

    Topics: Adult; Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Heart Disease Risk

2022
A Randomized Pilot Study of DASH Patterned Groceries on Serum Urate in Individuals with Gout.
    Nutrients, 2021, Feb-07, Volume: 13, Issue:2

    Topics: Cross-Over Studies; Dietary Approaches To Stop Hypertension; Eating; Female; Follow-Up Studies; Frui

2021
Effect of Serum Urate Lowering With Allopurinol on Blood Pressure in Young Adults: A Randomized, Controlled, Crossover Trial.
    Arthritis & rheumatology (Hoboken, N.J.), 2021, Volume: 73, Issue:8

    Topics: Adolescent; Adult; Allopurinol; Blood Pressure; C-Reactive Protein; Cross-Over Studies; Dilatation,

2021
Detection of intracellular monosodium urate crystals in gout synovial fluid using optical diffraction tomography.
    Scientific reports, 2021, 05-11, Volume: 11, Issue:1

    Topics: Cell Line; Gout; Humans; Imaging, Three-Dimensional; Macrophages; Refractometry; Synovial Fluid; Tom

2021
Early versus Late Allopurinol Initiation in Acute Gout Flare (ELAG): a randomized controlled trial.
    Clinical rheumatology, 2022, Volume: 41, Issue:1

    Topics: Allopurinol; Double-Blind Method; Gout; Gout Suppressants; Humans; Symptom Flare Up; Time-to-Treatme

2022
A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout.
    Annals of the rheumatic diseases, 2017, Volume: 76, Issue:9

    Topics: Aged; Alanine Transaminase; Alkaline Phosphatase; Allopurinol; Aspartate Aminotransferases; Chemical

2017
Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial.
    Arthritis & rheumatology (Hoboken, N.J.), 2017, Volume: 69, Issue:9

    Topics: Creatinine; Double-Blind Method; Drug Therapy, Combination; Febuxostat; Female; Gout; Gout Suppressa

2017
Ultrasonography and dual-energy computed tomography provide different quantification of urate burden in gout: results from a cross-sectional study.
    Arthritis research & therapy, 2017, 07-21, Volume: 19, Issue:1

    Topics: Aged; Cross-Sectional Studies; Female; Gout; Humans; Image Interpretation, Computer-Assisted; Male;

2017
Metoprolol Increases Uric Acid and Risk of Gout in African Americans With Chronic Kidney Disease Attributed to Hypertension.
    American journal of hypertension, 2017, Sep-01, Volume: 30, Issue:9

    Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Antihypertensive Agents; Biomarkers; Black or African

2017
Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension study.
    Annals of the rheumatic diseases, 2017, Volume: 76, Issue:12

    Topics: Aged; Allopurinol; Dose-Response Relationship, Drug; Female; Gout; Gout Suppressants; Humans; Male;

2017
Effects of Febuxostat in Early Gout: A Randomized, Double-Blind, Placebo-Controlled Study.
    Arthritis & rheumatology (Hoboken, N.J.), 2017, Volume: 69, Issue:12

    Topics: Adult; Double-Blind Method; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Join

2017
Effectiveness of an electronic patient-centred self-management tool for gout sufferers: a cluster randomised controlled trial protocol.
    BMJ open, 2017, 10-16, Volume: 7, Issue:10

    Topics: Allopurinol; Gout; Gout Suppressants; Humans; Internet; Patient Compliance; Prospective Studies; Qua

2017
Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study.
    Annals of the rheumatic diseases, 2018, Volume: 77, Issue:2

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Dose-Response Relationship, Drug; Febuxo

2018
The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial.
    Arthritis research & therapy, 2017, 12-21, Volume: 19, Issue:1

    Topics: Adult; Aged; Allopurinol; Creatinine; Dose-Response Relationship, Drug; Female; Gout; Gout Suppressa

2017
Ultrasonographic assessment of joint pathology in type 2 diabetes and hyperuricemia: The Fremantle Diabetes Study Phase II.
    Journal of diabetes and its complications, 2018, Volume: 32, Issue:4

    Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Gout; Humans; Hyperuricemia; Joints; Mal

2018
Metabolism and Disposition of Verinurad, a Uric Acid Reabsorption Inhibitor, in Humans.
    Drug metabolism and disposition: the biological fate of chemicals, 2018, Volume: 46, Issue:5

    Topics: Carbon Radioisotopes; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Feces; Gastrointestinal Tract

2018
Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study.
    The lancet. Diabetes & endocrinology, 2018, Volume: 6, Issue:4

    Topics: Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fenofibrate; Gout; Humans; Hypolipidem

2018
Design and Rationale for the Veterans Affairs "Cooperative Study Program 594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat" Trial.
    Contemporary clinical trials, 2018, Volume: 68

    Topics: Adult; Allopurinol; Dose-Response Relationship, Drug; Double-Blind Method; Drug Dosage Calculations;

2018
The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout.
    Journal of clinical pharmacology, 2018, Volume: 58, Issue:9

    Topics: Adult; Allopurinol; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination;

2018
Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout.
    Journal of clinical pharmacology, 2018, Volume: 58, Issue:9

    Topics: Adolescent; Adult; Aged; Allopurinol; Area Under Curve; Drug Administration Schedule; Gout; Gout Sup

2018
Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study.
    Rheumatology (Oxford, England), 2018, 09-01, Volume: 57, Issue:9

    Topics: Administration, Oral; Adult; Aged; Benzbromarone; Dose-Response Relationship, Drug; Drug Therapy, Co

2018
Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study.
    Arthritis & rheumatology (Hoboken, N.J.), 2019, Volume: 71, Issue:1

    Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Colchicine; Cough; Creatinine; Delay

2019
Can we predict inadequate response to allopurinol dose escalation? Analysis of a randomised controlled trial.
    Rheumatology (Oxford, England), 2018, 12-01, Volume: 57, Issue:12

    Topics: Allopurinol; Dose-Response Relationship, Drug; Female; Gout; Gout Suppressants; Humans; Male; Middle

2018
The efficacy of febuxostat and allopurinol in the treatment of gout with hyperuricemia.
    Pakistan journal of pharmaceutical sciences, 2018, Volume: 31, Issue:4(Special)

    Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Drug Therapy, Combination; Febuxos

2018
Multicenter, Open-Label Study of Long-Term Topiroxostat (FYX-051) Administration in Japanese Hyperuricemic Patients with or Without Gout.
    Clinical drug investigation, 2018, Volume: 38, Issue:12

    Topics: Administration, Oral; Adult; Aged; Drug Administration Schedule; Enzyme Inhibitors; Female; Gout; Go

2018
Relationship of Interleukin-1β Blockade With Incident Gout and Serum Uric Acid Levels: Exploratory Analysis of a Randomized Controlled Trial.
    Annals of internal medicine, 2018, 10-16, Volume: 169, Issue:8

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Data Interpretation, Statistical; F

2018
"Yellow-dragon Wonderful-seed Formula" for hyperuricemia in gout patients with dampness-heat pouring downward pattern: a pilot randomized controlled trial.
    Trials, 2018, Oct-11, Volume: 19, Issue:1

    Topics: Adult; Biomarkers; China; Down-Regulation; Drugs, Chinese Herbal; Gout; Gout Suppressants; Humans; H

2018
Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial.
    Lancet (London, England), 2018, 10-20, Volume: 392, Issue:10156

    Topics: Aged; Allopurinol; Cost-Benefit Analysis; Disease Management; England; Female; General Practice; Gou

2018
Implication of nurse intervention on engagement with urate-lowering drugs: A qualitative study of participants in a RCT of nurse led care.
    Joint bone spine, 2019, Volume: 86, Issue:3

    Topics: Allopurinol; Clinical Competence; Decision Making, Shared; Female; France; Gout; Gout Suppressants;

2019
Characterization of Stereoselective Metabolism, Inhibitory Effect on Uric Acid Uptake Transporters, and Pharmacokinetics of Lesinurad Atropisomers.
    Drug metabolism and disposition: the biological fate of chemicals, 2019, Volume: 47, Issue:2

    Topics: Administration, Oral; Adult; Gout; Healthy Volunteers; HEK293 Cells; Humans; Kidney; Male; Microsome

2019
How much allopurinol does it take to get to target urate? Comparison of actual dose with creatinine clearance-based dose.
    Arthritis research & therapy, 2018, Nov-16, Volume: 20, Issue:1

    Topics: Adult; Aged; Allopurinol; Creatinine; Dose-Response Relationship, Drug; Drug Delivery Systems; Femal

2018
Adherence and Outcomes with Urate-Lowering Therapy: A Site-Randomized Trial.
    The American journal of medicine, 2019, Volume: 132, Issue:3

    Topics: Adult; Aged; Allopurinol; Female; Gout; Gout Suppressants; Humans; Male; Medication Adherence; Middl

2019
Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare.
    Clinical rheumatology, 2019, Volume: 38, Issue:8

    Topics: Adult; Aged; C-Reactive Protein; Double-Blind Method; Female; Follow-Up Studies; Gout; Gout Suppress

2019
URC102, a potent and selective inhibitor of hURAT1, reduced serum uric acid in healthy volunteers.
    Rheumatology (Oxford, England), 2019, 11-01, Volume: 58, Issue:11

    Topics: Administration, Oral; Adult; Asian People; Double-Blind Method; Gout; Healthy Volunteers; Humans; Hy

2019
URC102, a potent and selective inhibitor of hURAT1, reduced serum uric acid in healthy volunteers.
    Rheumatology (Oxford, England), 2019, 11-01, Volume: 58, Issue:11

    Topics: Administration, Oral; Adult; Asian People; Double-Blind Method; Gout; Healthy Volunteers; Humans; Hy

2019
URC102, a potent and selective inhibitor of hURAT1, reduced serum uric acid in healthy volunteers.
    Rheumatology (Oxford, England), 2019, 11-01, Volume: 58, Issue:11

    Topics: Administration, Oral; Adult; Asian People; Double-Blind Method; Gout; Healthy Volunteers; Humans; Hy

2019
URC102, a potent and selective inhibitor of hURAT1, reduced serum uric acid in healthy volunteers.
    Rheumatology (Oxford, England), 2019, 11-01, Volume: 58, Issue:11

    Topics: Administration, Oral; Adult; Asian People; Double-Blind Method; Gout; Healthy Volunteers; Humans; Hy

2019
Effects of Allopurinol Dose Escalation on Bone Erosion and Urate Volume in Gout: A Dual-Energy Computed Tomography Imaging Study Within a Randomized, Controlled Trial.
    Arthritis & rheumatology (Hoboken, N.J.), 2019, Volume: 71, Issue:10

    Topics: Aged; Allopurinol; Bone Resorption; Dose-Response Relationship, Drug; Female; Foot Bones; Foot Joint

2019
Dissociation Between Clinical Benefit and Persistent Urate Lowering in Patients with Chronic Refractory Gout Treated with Pegloticase.
    The Journal of rheumatology, 2020, Volume: 47, Issue:4

    Topics: Chronic Disease; Gout; Gout Suppressants; Humans; Polyethylene Glycols; Urate Oxidase; Uric Acid

2020
Dissociation Between Clinical Benefit and Persistent Urate Lowering in Patients with Chronic Refractory Gout Treated with Pegloticase.
    The Journal of rheumatology, 2020, Volume: 47, Issue:4

    Topics: Chronic Disease; Gout; Gout Suppressants; Humans; Polyethylene Glycols; Urate Oxidase; Uric Acid

2020
Dissociation Between Clinical Benefit and Persistent Urate Lowering in Patients with Chronic Refractory Gout Treated with Pegloticase.
    The Journal of rheumatology, 2020, Volume: 47, Issue:4

    Topics: Chronic Disease; Gout; Gout Suppressants; Humans; Polyethylene Glycols; Urate Oxidase; Uric Acid

2020
Dissociation Between Clinical Benefit and Persistent Urate Lowering in Patients with Chronic Refractory Gout Treated with Pegloticase.
    The Journal of rheumatology, 2020, Volume: 47, Issue:4

    Topics: Chronic Disease; Gout; Gout Suppressants; Humans; Polyethylene Glycols; Urate Oxidase; Uric Acid

2020
Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial.
    Rheumatology (Oxford, England), 2013, Volume: 52, Issue:7

    Topics: Adult; Allopurinol; Double-Blind Method; Drug Therapy, Combination; Female; Gout; Gout Suppressants;

2013
Clinically insignificant effect of supplemental vitamin C on serum urate in patients with gout: a pilot randomized controlled trial.
    Arthritis and rheumatism, 2013, Volume: 65, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Ascorbic Acid; Creatinine; Dietary Supplements; Female;

2013
Ultrasound-detected musculoskeletal urate crystal deposition: which joints and what findings should be assessed for diagnosing gout?
    Annals of the rheumatic diseases, 2014, Volume: 73, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Cartilage, Articular; Case-Control Studies; Crystallization; Female;

2014
As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout.
    Rheumatology international, 2014, Volume: 34, Issue:1

    Topics: Aged; Allopurinol; Biomarkers; Chronic Disease; Enzyme Inhibitors; Febuxostat; Germany; Glomerular F

2014
Serum urate levels are unchanged with continuous positive airway pressure therapy for obstructive sleep apnea: a randomized controlled trial.
    Sleep medicine, 2013, Volume: 14, Issue:12

    Topics: Aged; Continuous Positive Airway Pressure; Diabetes Mellitus, Type 2; Gout; Humans; Hyperuricemia; M

2013
Impact of bariatric surgery on serum urate targets in people with morbid obesity and diabetes: a prospective longitudinal study.
    Annals of the rheumatic diseases, 2014, Volume: 73, Issue:5

    Topics: Adult; Bariatric Surgery; Diabetes Mellitus, Type 2; Female; Gout; Humans; Longitudinal Studies; Mal

2014
Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy.
    Arthritis research & therapy, 2013, Sep-26, Volume: 15, Issue:5

    Topics: Adult; Aged; Allopurinol; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Drug R

2013
Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy.
    Arthritis research & therapy, 2013, Sep-26, Volume: 15, Issue:5

    Topics: Adult; Aged; Allopurinol; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Drug R

2013
Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy.
    Arthritis research & therapy, 2013, Sep-26, Volume: 15, Issue:5

    Topics: Adult; Aged; Allopurinol; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Drug R

2013
Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy.
    Arthritis research & therapy, 2013, Sep-26, Volume: 15, Issue:5

    Topics: Adult; Aged; Allopurinol; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Drug R

2013
Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout.
    Clinical and experimental nephrology, 2014, Volume: 18, Issue:6

    Topics: Adiponectin; Aged; Albuminuria; Blood Pressure; Comorbidity; Creatinine; Double-Blind Method; Enzyme

2014
An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
    International journal of rheumatic diseases, 2014, Volume: 17, Issue:6

    Topics: Adult; Allopurinol; Biomarkers; China; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; G

2014
Influence of the ABCG2 gout risk 141 K allele on urate metabolism during a fructose challenge.
    Arthritis research & therapy, 2014, Jan-30, Volume: 16, Issue:1

    Topics: Adult; Alleles; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transp

2014
Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia.
    Rheumatology (Oxford, England), 2014, Volume: 53, Issue:12

    Topics: Adult; Aged; Colchicine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap

2014
Myeloperoxidase and oxidation of uric acid in gout: implications for the clinical consequences of hyperuricaemia.
    Rheumatology (Oxford, England), 2014, Volume: 53, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Enzyme-Linked Immunosorbent Assay; Female; Gout; Gout S

2014
Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study.
    The Journal of rheumatology, 2014, Volume: 41, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Dose-Response Relationship, Drug;

2014
Comprehensive dietary education in treated gout patients does not further improve serum urate.
    Internal medicine journal, 2015, Volume: 45, Issue:2

    Topics: Adult; Aged; Allopurinol; Australia; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Pat

2015
Population pharmacokinetics and exposure-uric acid analyses after single and multiple doses of ABT-639, a calcium channel blocker, in healthy volunteers.
    The AAPS journal, 2015, Volume: 17, Issue:2

    Topics: Adolescent; Adult; Aged; Calcium Channel Blockers; Computer Simulation; Dose-Response Relationship,

2015
Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus.
    Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:4

    Topics: Adult; Aged; Canagliflozin; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, D

2015
Does starting allopurinol prolong acute treated gout? A randomized clinical trial.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2015, Volume: 21, Issue:3

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Allopurinol; Cohort Studies; Disease Progression; Dos

2015
A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia.
    International journal of rheumatic diseases, 2015, Volume: 18, Issue:6

    Topics: Administration, Oral; Adult; Allopurinol; Biomarkers; China; Double-Blind Method; Febuxostat; Female

2015
Combination Therapies of Diacerein and Febuxostat Inhibit IL-1β Responses and Improve Clinical Symptoms in Patients With Refractory Gout.
    American journal of therapeutics, 2017, Volume: 24, Issue:3

    Topics: Adult; Anthraquinones; Anti-Inflammatory Agents; C-Reactive Protein; Case-Control Studies; Drug Ther

2017
An open-label, 6-month study of allopurinol safety in gout: The LASSO study.
    Seminars in arthritis and rheumatism, 2015, Volume: 45, Issue:2

    Topics: Adult; Aged; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Female; Gout; Gout Su

2015
Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study.
    Scandinavian journal of rheumatology, 2016, Volume: 45, Issue:4

    Topics: Administration, Oral; Adult; Alleles; Allopurinol; China; Febuxostat; Female; Gout; Gout Suppressant

2016
The effects of URAT1/SLC22A12 nonfunctional variants, R90H and W258X, on serum uric acid levels and gout/hyperuricemia progression.
    Scientific reports, 2016, Jan-29, Volume: 6

    Topics: Adult; Amino Acid Substitution; Female; Gout; Humans; Hyperuricemia; Male; Middle Aged; Mutation, Mi

2016
Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol.
    International journal of clinical oncology, 2016, Volume: 21, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hy

2016
Clinical efficacy and safety of topiroxostat in Japanese male hyperuricemic patients with or without gout: an exploratory, phase 2a, multicentre, randomized, double-blind, placebo-controlled study.
    Journal of clinical pharmacy and therapeutics, 2016, Volume: 41, Issue:3

    Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Follow-Up Studies; Gout; Gout Suppress

2016
Acute kidney injury observed during phase 1 clinical trials of a novel xanthine oxidase/URAT1 dual inhibitor PF-06743649.
    Clinical rheumatology, 2016, Volume: 35, Issue:8

    Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Double-Blind Method; Fe

2016
Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study.
    Journal of clinical pharmacy and therapeutics, 2016, Volume: 41, Issue:3

    Topics: Adult; Aged; Allopurinol; Double-Blind Method; Female; Follow-Up Studies; Gout; Gout Suppressants; H

2016
Patients with gout differ from healthy subjects in renal response to changes in serum uric acid.
    Joint bone spine, 2017, Volume: 84, Issue:2

    Topics: Adult; Aged; Female; Gout; Gout Suppressants; Healthy Volunteers; Humans; Hyperuricemia; Kidney; Mal

2017
A Pharmacist-Staffed, Virtual Gout Management Clinic for Achieving Target Serum Uric Acid Levels: A Randomized Clinical Trial.
    The Permanente journal, 2016,Summer, Volume: 20, Issue:3

    Topics: Female; Gout; Humans; Male; Middle Aged; Patient Education as Topic; Pharmacists; Professional Role;

2016
Rationale and design of the randomized evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-UP) Study.
    Contemporary clinical trials, 2016, Volume: 50

    Topics: Allopurinol; Ambulatory Care; Automation; Gout; Gout Suppressants; Humans; Patient Education as Topi

2016
Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney.
    Arthritis research & therapy, 2016, 10-03, Volume: 18, Issue:1

    Topics: Cell Line; Gout; Humans; Kidney; Male; Organic Anion Transporters; Organic Cation Transport Proteins

2016
Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).
    Annals of the rheumatic diseases, 2017, Volume: 76, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Creatinine; Double

2017
Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: a randomized, double-blinded, controlled phase 2b study.
    Clinical rheumatology, 2017, Volume: 36, Issue:3

    Topics: Adult; Allopurinol; Double-Blind Method; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Jap

2017
Allopurinol, benzbromarone and risk of coronary heart disease in gout patients: A population-based study.
    International journal of cardiology, 2017, Apr-15, Volume: 233

    Topics: Allopurinol; Benzbromarone; Coronary Disease; Dose-Response Relationship, Drug; Drug Administration

2017
Hypouricemic and arthritis relapse-reducing effects of compound tufuling oral-liquid in intercritical and chronic gout: A double-blind, placebo-controlled, multicenter randomized trial.
    Medicine, 2017, Volume: 96, Issue:11

    Topics: Adult; Aged; Arthritis, Gouty; Double-Blind Method; Drugs, Chinese Herbal; Female; Gout; Gout Suppre

2017
A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.
    Annals of the rheumatic diseases, 2009, Volume: 68, Issue:6

    Topics: Aged; Allopurinol; Benzbromarone; Confidence Intervals; Dose-Response Relationship, Drug; Drug Admin

2009
Clinical effect and action mechanism of Weicao Capsule in treating gout.
    Chinese journal of integrative medicine, 2008, Volume: 14, Issue:2

    Topics: Adult; Aged; beta 2-Microglobulin; Capsules; Drugs, Chinese Herbal; Female; Gout; Hemoglobins; Human

2008
Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.
    Arthritis and rheumatism, 2008, Volume: 58, Issue:9

    Topics: Adult; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gout; Humans; I

2008
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
    Arthritis and rheumatism, 2008, Nov-15, Volume: 59, Issue:11

    Topics: Adult; Aged; Allopurinol; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Febuxos

2008
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
    Arthritis and rheumatism, 2008, Nov-15, Volume: 59, Issue:11

    Topics: Adult; Aged; Allopurinol; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Febuxos

2008
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
    Arthritis and rheumatism, 2008, Nov-15, Volume: 59, Issue:11

    Topics: Adult; Aged; Allopurinol; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Febuxos

2008
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
    Arthritis and rheumatism, 2008, Nov-15, Volume: 59, Issue:11

    Topics: Adult; Aged; Allopurinol; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Febuxos

2008
Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study.
    Rheumatology (Oxford, England), 2009, Volume: 48, Issue:2

    Topics: Adult; Aged; Biomarkers; Clinical Trials, Phase II as Topic; Febuxostat; Female; Follow-Up Studies;

2009
Serum urate during acute gout.
    The Journal of rheumatology, 2009, Volume: 36, Issue:6

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Cyclooxygenase Inhibitors; Etoricoxib; Female; Gout;

2009
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.
    Arthritis research & therapy, 2010, Volume: 12, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Comorbidity; Dose-Response Relationship, Dr

2010
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.
    Arthritis research & therapy, 2010, Volume: 12, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Comorbidity; Dose-Response Relationship, Dr

2010
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.
    Arthritis research & therapy, 2010, Volume: 12, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Comorbidity; Dose-Response Relationship, Dr

2010
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.
    Arthritis research & therapy, 2010, Volume: 12, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Comorbidity; Dose-Response Relationship, Dr

2010
Acute effect of milk on serum urate concentrations: a randomised controlled crossover trial.
    Annals of the rheumatic diseases, 2010, Volume: 69, Issue:9

    Topics: Adult; Animals; Cross-Over Studies; Gout; Humans; Hypoxanthine; Male; Middle Aged; Milk; Purine Nucl

2010
More allopurinol is needed to get gout patients < 0.36 mmol/l: a gout audit in the form of a before-after trial.
    Journal of primary health care, 2009, Volume: 1, Issue:4

    Topics: Aged; Allopurinol; Benchmarking; Clinical Audit; Cultural Competency; Diagnosis, Differential; Gout;

2009
[Antihypertensive therapy optimization and endothelial function in patients with gout and chronic urate tubulointerstitial nephritis].
    Terapevticheskii arkhiv, 2010, Volume: 82, Issue:6

    Topics: Angiotensin II Type 2 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive

2010
Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment.
    Arthritis and rheumatism, 2011, Volume: 63, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Creatinine; Dose-Response Relationship, Drug; Drug Moni

2011
Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout.
    The Journal of rheumatology, 2011, Volume: 38, Issue:5

    Topics: Allopurinol; Drug Interactions; Drug Therapy, Combination; Gout; Gout Suppressants; Humans; Male; Mi

2011
Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
    Clinical therapeutics, 2010, Volume: 32, Issue:14

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Drug Administration Sc

2010
Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
    Clinical therapeutics, 2010, Volume: 32, Issue:14

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Drug Administration Sc

2010
Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
    Clinical therapeutics, 2010, Volume: 32, Issue:14

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Drug Administration Sc

2010
Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
    Clinical therapeutics, 2010, Volume: 32, Issue:14

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Drug Administration Sc

2010
Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
    Clinical therapeutics, 2010, Volume: 32, Issue:14

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Drug Administration Sc

2010
Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
    Clinical therapeutics, 2010, Volume: 32, Issue:14

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Drug Administration Sc

2010
Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
    Clinical therapeutics, 2010, Volume: 32, Issue:14

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Drug Administration Sc

2010
Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
    Clinical therapeutics, 2010, Volume: 32, Issue:14

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Drug Administration Sc

2010
Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
    Clinical therapeutics, 2010, Volume: 32, Issue:14

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Drug Administration Sc

2010
Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors.
    The Journal of rheumatology, 2011, Volume: 38, Issue:7

    Topics: Adult; Aged; Double-Blind Method; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle

2011
An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: p
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2011, Volume: 17, Issue:4 Suppl 2

    Topics: Administration, Oral; Allopurinol; Dose-Response Relationship, Drug; Double-Blind Method; Febuxostat

2011
Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2011, Volume: 17, Issue:4 Suppl 2

    Topics: Adult; Central Nervous System Diseases; Dental Enamel; Diabetes Mellitus, Type 2; Dose-Response Rela

2011
Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2011, Volume: 17, Issue:4 Suppl 2

    Topics: Administration, Oral; Dose-Response Relationship, Drug; Double-Blind Method; Febuxostat; Female; Fol

2011
An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phas
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2011, Volume: 17, Issue:4 Suppl 2

    Topics: Administration, Oral; Allopurinol; Dose-Response Relationship, Drug; Double-Blind Method; Febuxostat

2011
Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2011, Volume: 17, Issue:4 Suppl 2

    Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Febuxostat; Female; Follow-Up Studies

2011
Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
    JAMA, 2011, Aug-17, Volume: 306, Issue:7

    Topics: Allopurinol; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Drug Resistance; En

2011
Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
    JAMA, 2011, Aug-17, Volume: 306, Issue:7

    Topics: Allopurinol; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Drug Resistance; En

2011
Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
    JAMA, 2011, Aug-17, Volume: 306, Issue:7

    Topics: Allopurinol; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Drug Resistance; En

2011
Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
    JAMA, 2011, Aug-17, Volume: 306, Issue:7

    Topics: Allopurinol; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Drug Resistance; En

2011
Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
    JAMA, 2011, Aug-17, Volume: 306, Issue:7

    Topics: Allopurinol; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Drug Resistance; En

2011
Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
    JAMA, 2011, Aug-17, Volume: 306, Issue:7

    Topics: Allopurinol; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Drug Resistance; En

2011
Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
    JAMA, 2011, Aug-17, Volume: 306, Issue:7

    Topics: Allopurinol; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Drug Resistance; En

2011
Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
    JAMA, 2011, Aug-17, Volume: 306, Issue:7

    Topics: Allopurinol; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Drug Resistance; En

2011
Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
    JAMA, 2011, Aug-17, Volume: 306, Issue:7

    Topics: Allopurinol; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Drug Resistance; En

2011
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
    Arthritis care & research, 2012, Volume: 64, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux

2012
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
    Arthritis care & research, 2012, Volume: 64, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux

2012
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
    Arthritis care & research, 2012, Volume: 64, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux

2012
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
    Arthritis care & research, 2012, Volume: 64, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux

2012
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
    Arthritis care & research, 2012, Volume: 64, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux

2012
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
    Arthritis care & research, 2012, Volume: 64, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux

2012
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
    Arthritis care & research, 2012, Volume: 64, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux

2012
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
    Arthritis care & research, 2012, Volume: 64, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux

2012
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
    Arthritis care & research, 2012, Volume: 64, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux

2012
Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects.
    Nucleosides, nucleotides & nucleic acids, 2011, Volume: 30, Issue:12

    Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Allopurinol; Febuxostat; Gout; Gout Suppressants;

2011
The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.
    BMC geriatrics, 2012, Mar-21, Volume: 12

    Topics: Aged; Aged, 80 and over; Biomarkers; Cohort Studies; Double-Blind Method; Febuxostat; Female; Gout;

2012
Furosemide increases plasma oxypurinol without lowering serum urate--a complex drug interaction: implications for clinical practice.
    Rheumatology (Oxford, England), 2012, Volume: 51, Issue:9

    Topics: Adult; Aged; Allopurinol; Area Under Curve; Case-Control Studies; Diuretics; Drug Interactions; Drug

2012
Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.
    Arthritis care & research, 2012, Volume: 64, Issue:10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Drug Therapy, Combinat

2012
Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials.
    The Journal of rheumatology, 2012, Volume: 39, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Female; Gout; Gout Suppressants; Humans; Male; Midd

2012
Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study.
    Annals of the rheumatic diseases, 2013, Volume: 72, Issue:6

    Topics: Aged; Allopurinol; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Patient Compliance; P

2013
Fractional clearance of urate: validation of measurement in spot-urine samples in healthy subjects and gouty patients.
    Arthritis research & therapy, 2012, Aug-17, Volume: 14, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cross-Over Studies; Female; Gout; Healthy Volunteers; Hu

2012
Long-term safety of pegloticase in chronic gout refractory to conventional treatment.
    Annals of the rheumatic diseases, 2013, Sep-01, Volume: 72, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Drug Resistance; Enzymes, Immobilized; Female; Gout

2013
Preservation of renal function during gout treatment with febuxostat: a quantitative study.
    Postgraduate medicine, 2013, Volume: 125, Issue:1

    Topics: Adult; Aged; Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Kidney

2013
Hyperuricemia and gout in renal transplant recipients.
    Renal failure, 2002, Volume: 24, Issue:3

    Topics: Adult; Biomarkers; Causality; Creatinine; Cyclosporine; Dose-Response Relationship, Drug; Female; Fo

2002
Efficacy of benzbromarone compared to allopurinol in lowering serum uric acid level in hyperuricemic patients.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2002, Volume: 85 Suppl 1

    Topics: Adult; Aged; Allopurinol; Benzbromarone; Cross-Over Studies; Dose-Response Relationship, Drug; Drug

2002
Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.
    Arthritis and rheumatism, 2002, Volume: 47, Issue:4

    Topics: Adult; Aged; Allopurinol; Benzbromarone; Crystallization; Drug Therapy, Combination; Female; Gout; G

2002
Environmental lead exposure and urate excretion in the general population.
    The American journal of medicine, 2002, Volume: 113, Issue:7

    Topics: Adult; Aged; Body Burden; Chelating Agents; Cross-Sectional Studies; Edetic Acid; Environmental Expo

2002
Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout.
    Rheumatology (Oxford, England), 2003, Volume: 42, Issue:2

    Topics: Acute Disease; Adult; Aged; Alkaline Phosphatase; Allopurinol; Arthritis, Gouty; Chronic Disease; Cr

2003
Oxidized low-density lipoprotein autoantibodies in patients with primary gout: effect of urate-lowering therapy.
    Clinica chimica acta; international journal of clinical chemistry, 2004, Volume: 339, Issue:1-2

    Topics: Allopurinol; Antioxidants; Autoantibodies; Body Weight; Case-Control Studies; Cholesterol, HDL; Chol

2004
Clinical analysis for the acupuncture treatment in 42 cases of gouty renal damage.
    Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2004, Volume: 24, Issue:3

    Topics: Acupuncture Therapy; Adult; Aged; Arthritis, Gouty; Blood Urea Nitrogen; Creatinine; Female; Gout; H

2004
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
    Arthritis and rheumatism, 2005, Volume: 52, Issue:3

    Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female;

2005
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
    Arthritis and rheumatism, 2005, Volume: 52, Issue:3

    Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female;

2005
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
    Arthritis and rheumatism, 2005, Volume: 52, Issue:3

    Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female;

2005
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
    Arthritis and rheumatism, 2005, Volume: 52, Issue:3

    Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female;

2005
Benzbromarone therapy in management of refractory gout.
    The New Zealand medical journal, 2005, Jun-24, Volume: 118, Issue:1217

    Topics: Adult; Allopurinol; Benzbromarone; Creatinine; Female; Gout; Humans; Incidence; Male; Metabolic Clea

2005
Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
    The New England journal of medicine, 2005, Dec-08, Volume: 353, Issue:23

    Topics: Allopurinol; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Hu

2005
Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
    The New England journal of medicine, 2005, Dec-08, Volume: 353, Issue:23

    Topics: Allopurinol; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Hu

2005
Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
    The New England journal of medicine, 2005, Dec-08, Volume: 353, Issue:23

    Topics: Allopurinol; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Hu

2005
Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
    The New England journal of medicine, 2005, Dec-08, Volume: 353, Issue:23

    Topics: Allopurinol; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Hu

2005
Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase.
    Arthritis research & therapy, 2006, Volume: 8, Issue:1

    Topics: Adult; Aged; Carbon Radioisotopes; Female; Gout; Humans; Hyperuricemia; Immunoglobulin G; Male; Midd

2006
Clinicopathology of gout in growing layers induced by high calcium and high protein diets.
    British poultry science, 2005, Volume: 46, Issue:5

    Topics: Animal Feed; Animals; Calcium; Calcium, Dietary; Chickens; Diet; Dietary Proteins; Female; Gout; Mag

2005
[Use of metformin (siofor) in patients with gout and insulin resistance (pilot 6-month results)].
    Terapevticheskii arkhiv, 2005, Volume: 77, Issue:12

    Topics: Adult; Aged; Blood Glucose; Female; Follow-Up Studies; Gout; Humans; Hypoglycemic Agents; Insulin Re

2005
Photobiomodulation of pain and inflammation in microcrystalline arthropathies: experimental and clinical results.
    Photomedicine and laser surgery, 2006, Volume: 24, Issue:2

    Topics: Animals; Arthralgia; Arthritis, Experimental; Biomarkers; Calcium Pyrophosphate; Diclofenac; Dinopro

2006
Association between intronic SNP in urate-anion exchanger gene, SLC22A12, and serum uric acid levels in Japanese.
    Life sciences, 2006, Nov-02, Volume: 79, Issue:23

    Topics: Asian People; Creatinine; DNA Mutational Analysis; Female; Genetic Predisposition to Disease; Genoty

2006
Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients.
    Clinical rheumatology, 2007, Volume: 26, Issue:9

    Topics: Allopurinol; Benzbromarone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Gou

2007
Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout.
    Arthritis and rheumatism, 2007, Volume: 56, Issue:3

    Topics: Adult; Aged; Antibodies; Creatinine; Dose-Response Relationship, Drug; Female; Gout; Gout Suppressan

2007
Relationship between insulin resistance and low urinary pH in patients with gout, and effects of PPARalpha agonists on urine pH.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2007, Volume: 39, Issue:7

    Topics: Bezafibrate; Biomarkers; Body Mass Index; Fenofibrate; Gout; Humans; Hydrogen-Ion Concentration; Hyp

2007
Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.
    Annals of the rheumatic diseases, 2009, Volume: 68, Issue:1

    Topics: Aged; Allopurinol; Benzbromarone; Confidence Intervals; Dose-Response Relationship, Drug; Drug Admin

2009
Population pharmacokinetic and pharmacodynamic analysis of pegloticase in subjects with hyperuricemia and treatment-failure gout.
    Journal of clinical pharmacology, 2008, Volume: 48, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Body Weight; Dose-Response Relationship, Drug; Drug Administration S

2008
Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2008, Volume: 14, Issue:1

    Topics: Adult; Aged; Allopurinol; Dose-Response Relationship, Drug; Drug Monitoring; Female; Glomerular Filt

2008
[Spa Treatment of increased uric acid and cholesterol levels].
    Munchener medizinische Wochenschrift (1950), 1966, Mar-18, Volume: 108, Issue:11

    Topics: Balneology; Diet Therapy; Female; Gout; Humans; Hypercholesterolemia; Male; Mineral Waters; Uric Aci

1966
[Allopurinol in the treatment of gout and uric acid nephrolithiasis].
    Deutsche medizinische Wochenschrift (1946), 1967, Apr-04, Volume: 92, Issue:14

    Topics: Allopurinol; Enzyme Therapy; Gout; Humans; Kidney Calculi; Uric Acid; Urinary Calculi; Xanthine Oxid

1967
[Effect of benziodarone and benzbromarone on the uric acid level in the blood and urine and on the incidence of gout attacks].
    Reumatologia, 1980, Volume: 18, Issue:3

    Topics: Adult; Aged; Benzbromarone; Benzofurans; Clinical Trials as Topic; Gout; Humans; Male; Middle Aged;

1980
A controlled study of the effect of long term allopurinol treatment on renal function in gout.
    Advances in experimental medicine and biology, 1980, Volume: 122A

    Topics: Allopurinol; Clinical Trials as Topic; Colchicine; Female; Follow-Up Studies; Gout; Humans; Kidney;

1980
Benzbromarone as a long-term uricosuric agent.
    Advances in experimental medicine and biology, 1980, Volume: 122A

    Topics: Benzbromarone; Benzofurans; Clinical Trials as Topic; Follow-Up Studies; Gout; Humans; Uric Acid

1980
The action of benzbromarone in relation to age, sex and accompanying diseases.
    Advances in experimental medicine and biology, 1980, Volume: 122A

    Topics: Benzbromarone; Benzofurans; Body Height; Body Weight; Clinical Trials as Topic; Female; Follow-Up St

1980
[Mechanism of the action of allopurinol].
    Sovetskaia meditsina, 1981, Issue:10

    Topics: Adult; Aged; Allopurinol; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind M

1981
[The effect on uric acid and other laboratory parameters. A long-term study].
    ZFA. Zeitschrift fur Allgemeinmedizin, 1982, Feb-20, Volume: 58, Issue:5

    Topics: Allopurinol; Benzbromarone; Benzofurans; Clinical Trials as Topic; Gout; Humans; Uric Acid

1982
Azapropazone or allopurinol in the treatment of chronic gout and/or hyperuricaemia. A preliminary report.
    The British journal of clinical practice, 1982, Volume: 36, Issue:10

    Topics: Adult; Aged; Allopurinol; Apazone; Female; Gout; Humans; Kidney Function Tests; Male; Middle Aged; T

1982
[Therapeutic efficacy of slow-release allopurinol in gout and hyperuricaemia (author's transl)].
    Wiener klinische Wochenschrift, 1981, Jan-23, Volume: 93, Issue:2

    Topics: Allopurinol; Delayed-Action Preparations; Dose-Response Relationship, Drug; Gout; Humans; Uric Acid

1981
Free oxypurines in plasma and urine of gout patients before and after a purine-free diet.
    Advances in experimental medicine and biology, 1994, Volume: 370

    Topics: Adult; Aged; Chromatography, High Pressure Liquid; Creatinine; Diet Therapy; Female; Gout; Humans; H

1994
The effect of benzbromarone on allopurinol/oxypurinol kinetics in patients with gout.
    European journal of clinical pharmacology, 1993, Volume: 44, Issue:1

    Topics: Adult; Aged; Allopurinol; Benzbromarone; Gout; Humans; Male; Middle Aged; Oxypurinol; Uric Acid

1993
Effect of allopurinol and benzbromarone on the concentration of uridine in plasma.
    Metabolism: clinical and experimental, 1997, Volume: 46, Issue:12

    Topics: Adult; Allopurinol; Benzbromarone; Dose-Response Relationship, Drug; Gout; Gout Suppressants; Humans

1997
Determination of uric acid in scalp hair for non-invasive evaluation of uricemic controls in hyperuricemia.
    Biological & pharmaceutical bulletin, 1998, Volume: 21, Issue:4

    Topics: Adult; Allopurinol; Gout; Gout Suppressants; Hair; Humans; Hydroxides; Middle Aged; Potassium Compou

1998
Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.
    Annals of the rheumatic diseases, 1998, Volume: 57, Issue:9

    Topics: Adult; Aged; Allopurinol; Benzbromarone; Chronic Disease; Drug Administration Schedule; Gout; Gout S

1998
Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts.
    Nephron, 2000, Volume: 86, Issue:3

    Topics: Adult; Aged; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Benzbromarone; Creatinine; Drug T

2000
Increased visceral fat accumulation further aggravates the risks of insulin resistance in gout.
    Metabolism: clinical and experimental, 2001, Volume: 50, Issue:4

    Topics: Adult; Aged; Cluster Analysis; Creatinine; Eating; Gout; Humans; Insulin Resistance; Male; Middle Ag

2001
Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?
    The Journal of rheumatology, 2001, Volume: 28, Issue:3

    Topics: Allopurinol; Chronic Disease; Colchicine; Crystallization; Extracellular Space; Follow-Up Studies; G

2001
Spot urine uric acid to creatinine ratio used in the estimation of uric acid excretion in primary gout.
    The Journal of rheumatology, 2001, Volume: 28, Issue:6

    Topics: Chemistry, Clinical; Circadian Rhythm; Creatinine; Eating; Gout; Humans; Male; Middle Aged; Sensitiv

2001
Lead chelation therapy and urate excretion in patients with chronic renal diseases and gout.
    Kidney international, 2001, Volume: 60, Issue:1

    Topics: Adult; Aged; Body Burden; Chelating Agents; Cross-Sectional Studies; Edetic Acid; Female; Gout; Huma

2001
Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout.
    Journal of hypertension, 2001, Volume: 19, Issue:10

    Topics: Aged; Antihypertensive Agents; Biphenyl Compounds; Chronic Disease; Cross-Over Studies; Double-Blind

2001
[Treatment of hyperuricemia using daily doses of 50 and 25mg of benzbromarone].
    Fortschritte der Medizin, 1977, Jul-21, Volume: 95, Issue:27

    Topics: Benzbromarone; Clinical Trials as Topic; Drug Evaluation; Gout; Humans; Male; Uric Acid

1977
Ticrynafen and probenecid in hyperuricemic, hypertensive men.
    Clinical pharmacology and therapeutics, 1979, Volume: 26, Issue:2

    Topics: Blood Pressure; Blood Urea Nitrogen; Clinical Trials as Topic; Creatinine; Diuresis; Double-Blind Me

1979
A new potent hypouricemic drug. A clinical trial of the drug in a group of gouty patients.
    The Journal of the Egyptian Medical Association, 1979, Volume: 62, Issue:1-2

    Topics: Benzofurans; Clinical Trials as Topic; Gout; Humans; Male; Middle Aged; Uric Acid

1979
Urate kinetics in hypoxanthine-guanine phosphoribosyltransferase deficiency: their significance for the understanding of gout.
    The Quarterly journal of medicine, 1976, Volume: 45, Issue:177

    Topics: Adolescent; Adult; Arthritis; Clinical Trials as Topic; Creatinine; Female; Genetic Linkage; Glycine

1976
[Reducing the risks in the treatment of gout and hyperuricaemia (author's transl)].
    Deutsche medizinische Wochenschrift (1946), 1976, Aug-27, Volume: 101, Issue:35

    Topics: Adult; Allopurinol; Benzbromarone; Benzofurans; Clinical Trials as Topic; Drug Combinations; Female;

1976
[Therapy with alllopurinol and benzbromarone, single and combined. Renal elimination of lithogenous and colloid protective substances (author's transl)].
    Medizinische Klinik, 1977, Apr-15, Volume: 72, Issue:15

    Topics: Adult; Aged; Allopurinol; Benzbromarone; Benzofurans; Calcium; Citrates; Creatinine; Glomerular Filt

1977
Serum uric acid: its association with other risk factors and with mortality in coronary heart disease.
    Journal of chronic diseases, 1976, Volume: 29, Issue:9

    Topics: Adult; Aged; Diuretics; Follow-Up Studies; Gout; Humans; Male; Middle Aged; Myocardial Infarction; P

1976
[Benzbromarone in the treatment of hyperuricemias].
    Minerva medica, 1975, Mar-07, Volume: 66, Issue:17

    Topics: Adult; Aged; Benzofurans; Clinical Trials as Topic; Drug Evaluation; Drug Tolerance; Ethacrynic Acid

1975
[Uricolytic therapy. Value of urate oxidase in the treatment of hyperuricemias].
    La Nouvelle presse medicale, 1975, Apr-12, Volume: 4, Issue:15

    Topics: Acute Kidney Injury; Adult; Aged; Allantoin; Chemical Phenomena; Chemistry; Clinical Trials as Topic

1975
Single daily dose of allopurinol.
    Annals of the rheumatic diseases, 1975, Volume: 34, Issue:3

    Topics: Administration, Oral; Adult; Aged; Allopurinol; Clinical Trials as Topic; Gout; Humans; Middle Aged;

1975
Allopurinol and gouty hyperuricemia. Efficacy of a single daily dose.
    JAMA, 1975, Mar-17, Volume: 231, Issue:11

    Topics: Acute Disease; Adult; Aged; Allopurinol; Analysis of Variance; Chemical Phenomena; Chemistry; Gout;

1975
[Pathogenesis and treatment of fast-induced hyperuricemia using benzbromarone].
    Die Medizinische Welt, 1976, Mar-19, Volume: 27, Issue:12

    Topics: Adolescent; Adult; Benzbromarone; Benzofurans; Fasting; Female; Gout; Humans; Male; Middle Aged; Sta

1976
Hyperuricemia and gout in renal allograft recipients.
    Transplantation proceedings, 1992, Volume: 24, Issue:5

    Topics: Adult; Azathioprine; Cyclosporine; Gout; Humans; Kidney Transplantation; Risk Factors; Transplantati

1992
[Effectiveness and tolerance of long-term uricosuric treatment].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1990, Dec-01, Volume: 45, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Benzbromarone; Dose-Response Relationship, Drug; Drug C

1990
Gout and hyperuricemia.
    Current opinion in rheumatology, 1990, Volume: 2, Issue:5

    Topics: Cyclosporins; Gout; Humans; Purines; Syndrome; Uric Acid

1990
Intermittent control of hyperuricemia in the treatment of gout.
    The Journal of rheumatology, 1989, Volume: 16, Issue:9

    Topics: Allopurinol; Drug Administration Schedule; Gout; Humans; Male; Middle Aged; Randomized Controlled Tr

1989
Observations with Rabenid in patients with locomotor disease.
    Therapia Hungarica (English edition), 1989, Volume: 37, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Clinical Trials as Topic; Female; Gout; Human

1989
Hyperuricemia after renal transplantation.
    American journal of surgery, 1988, Volume: 156, Issue:5

    Topics: Antilymphocyte Serum; Azathioprine; Clinical Trials as Topic; Cyclosporins; Drug Therapy, Combinatio

1988
[The effect of allopurinol therapy on kidney processes concomitant with gout].
    Orvosi hetilap, 1987, Sep-13, Volume: 128, Issue:37

    Topics: Allopurinol; Clinical Trials as Topic; Drug Evaluation; Gout; Humans; Kidney Diseases; Kidney Tubule

1987
Comparative trial of azapropazone and indomethacin plus allopurinol in acute gout and hyperuricaemia.
    The Journal of the Royal College of General Practitioners, 1987, Volume: 37, Issue:302

    Topics: Adult; Aged; Allopurinol; Apazone; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; D

1987
Antihyperuricemic properties of amflutizole in gout.
    The Journal of rheumatology, 1985, Volume: 12, Issue:3

    Topics: Adult; Aged; Arthritis; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Tolerance;

1985
Fructose-induced hyperuricaemia.
    Lancet (London, England), 1971, Apr-17, Volume: 1, Issue:7703

    Topics: Fructose; Gout; Humans; Male; Uric Acid

1971
[Treatment of hyperuricemic and gouty patients with derivatives of benzofuran].
    La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1967, Apr-08, Volume: 43, Issue:17

    Topics: Benzofurans; Bromine; Clinical Trials as Topic; Gout; Humans; Iodine; Uric Acid; Uricosuric Agents;

1967
Renal excretion of ammonia and urate production: examination of Gutman-Yü hypothesis.
    Metabolism: clinical and experimental, 1972, Volume: 21, Issue:6

    Topics: Adult; Aged; Ammonia; Ammonium Chloride; Bicarbonates; Clinical Trials as Topic; Glutamine; Gout; Hu

1972
[Clinical trial of urate oxidase].
    Revue du rhumatisme et des maladies osteo-articulaires, 1972, Volume: 39, Issue:2

    Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Diet, Reducing; Female; Gout; Humans; Kidney Fail

1972
[Data on changes in blood and urinary uric acid induced by a urate oxidase].
    Revue du rhumatisme et des maladies osteo-articulaires, 1972, Volume: 39, Issue:2

    Topics: Adult; Aged; Clinical Trials as Topic; Female; Gout; Humans; Injections, Intramuscular; Male; Middle

1972
[Benziodarone in hyperuricemia due to renal insufficiency].
    Minerva medica, 1973, Jan-20, Volume: 64, Issue:4

    Topics: Acute Kidney Injury; Adult; Aged; Allopurinol; Benzofurans; Clinical Trials as Topic; Gout; Humans;

1973
[First clinical experiences in therapy of hyperuricemia and hyperlipidemia with the clofibrate derivative MK 185].
    Verhandlungen der Deutschen Gesellschaft fur Innere Medizin, 1973, Volume: 79

    Topics: Cholesterol; Clinical Trials as Topic; Glycolates; Gout; Halofenate; Humans; Hyperlipidemias; Hypoli

1973
Treatment of gout and hyperuricaemia by benzbromarone, ethyl 2 (dibromo-3,5 hydroxy-4 benzoyl)-3 benzofuran.
    Advances in experimental medicine and biology, 1974, Volume: 41

    Topics: Benzoates; Bromine; Clinical Trials as Topic; Creatinine; Gout; Humans; Hypoxanthines; Probenecid; P

1974
Uricosuric effect of glyceryl guaiacolate.
    The Journal of rheumatology, 1974, Volume: 1, Issue:1

    Topics: Clinical Trials as Topic; Gout; Guaifenesin; Humans; Male; Placebos; Uric Acid; Uricosuric Agents

1974
Effect of long-term allopurinol administration on serial GFR in normotensive and hypertensive hyperuricemic subjects.
    Advances in experimental medicine and biology, 1974, Volume: 41

    Topics: Adult; Allopurinol; Blood Pressure; Creatinine; Female; Follow-Up Studies; Glomerular Filtration Rat

1974
Effect of allopurinol on urinary ammonia excretion in patients with gout.
    Metabolism: clinical and experimental, 1969, Volume: 18, Issue:6

    Topics: Aged; Allopurinol; Ammonia; Ammonium Chloride; Clinical Trials as Topic; Computers; Female; Gout; Hu

1969
Renal function in gout. 3. Estimation of tubular secretion and reabsorption of uric acid by use of pyrazinamide (pyrazinoic acid).
    The American journal of medicine, 1969, Volume: 47, Issue:4

    Topics: Adult; Allopurinol; Clinical Trials as Topic; Gout; Humans; Kidney Tubules; Metabolic Clearance Rate

1969
A comparison of phenylbutazone and flufenamic acid in the treatment of acute gout.
    Annals of physical medicine, 1970, Volume: 10, Issue:6

    Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents; Clinical Trials as Topic; Female; Flufenamic A

1970
[Influence of aluminum nicotinate on serum lipids].
    Acta cardiologica, 1969, Volume: 24, Issue:6

    Topics: Adult; Alkaline Phosphatase; Aluminum; Arteriosclerosis; Blood Glucose; Cardiovascular Diseases; Cho

1969
[New trend in gout treatment. Clinical and biological study of urate oxidase].
    Lille medical : journal de la Faculte de medecine et de pharmacie de l'Universite de Lille, 1971, Volume: 16, Issue:9

    Topics: Adult; Aged; Clinical Trials as Topic; Female; Gout; Humans; Male; Middle Aged; Purines; Urate Oxida

1971
Clinical efficacy and lack of toxicity of allopurinol (NSC-1390) given intravenously.
    Cancer chemotherapy reports, 1970, Volume: 54, Issue:2

    Topics: Administration, Oral; Adolescent; Adult; Alkaline Phosphatase; Allopurinol; Blood Urea Nitrogen; Chi

1970
Comparison of allopurinol and probenecid.
    Annals of the rheumatic diseases, 1966, Volume: 25, Issue:6 Suppl

    Topics: Allopurinol; Clinical Trials as Topic; Colchicine; Enzyme Therapy; Follow-Up Studies; Gout; Humans;

1966
Treatment of gout with allopurinol. A study of 106 cases.
    Annals of the rheumatic diseases, 1966, Volume: 25, Issue:6 Suppl

    Topics: Allopurinol; Clinical Trials as Topic; Colchicine; Diuresis; Enzymes; Gout; Humans; Purines; Uric Ac

1966
Treatment of gout with allopurinol and sulphinpyrazone in combination and with allopurinol alone.
    Annals of the rheumatic diseases, 1966, Volume: 25, Issue:6 Suppl

    Topics: Acute Kidney Injury; Adult; Aged; Allopurinol; Arthritis, Rheumatoid; Clinical Trials as Topic; Duod

1966
Effect of drugs on urate binding to plasma proteins.
    British medical journal, 1969, Dec-06, Volume: 4, Issue:5683

    Topics: Adult; Allopurinol; Arthritis; Aspirin; Blood Proteins; Chromatography, DEAE-Cellulose; Colchicine;

1969
Allopurinol in treatment of gout.
    British medical journal, 1966, Aug-06, Volume: 2, Issue:5509

    Topics: Adult; Aged; Enzyme Therapy; Enzymes; Female; Gout; Humans; Liver Function Tests; Male; Middle Aged;

1966

Other Studies

3422 other studies available for uric acid and Gout

ArticleYear
Urate transport via human PAH transporter hOAT1 and its gene structure.
    Kidney international, 2003, Volume: 63, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Benzbromarone; Biological Transport; Blotting, Western; Car

2003
High MW polyethylene glycol prolongs circulation of pegloticase in mice with anti-PEG antibodies.
    Journal of controlled release : official journal of the Controlled Release Society, 2021, 10-10, Volume: 338

    Topics: Animals; Gout; Humans; Mice; Polyethylene Glycols; Tissue Distribution; Urate Oxidase; Uric Acid

2021
Using multiple Mendelian randomization approaches and genetic correlations to understand obesity, urate, and gout.
    Scientific reports, 2021, 09-07, Volume: 11, Issue:1

    Topics: Causality; Genome-Wide Association Study; Gout; Humans; Linkage Disequilibrium; Lipoproteins, HDL; L

2021
Incorporating gout guideline advice into urate reports is associated with reduced hospital admissions: results of an observational study.
    Rheumatology (Oxford, England), 2022, 05-05, Volume: 61, Issue:5

    Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Hospitals; Humans; Treatment Outcome; Uric Acid

2022
Triterpenoid acids from medicinal mushroom Inonotus obliquus (Chaga) alleviate hyperuricemia and inflammation in hyperuricemic mice: Possible inhibitory effects on xanthine oxidase activity.
    Journal of food biochemistry, 2022, Volume: 46, Issue:3

    Topics: Agaricales; Animals; Gout; Hyperuricemia; Inflammation; Inonotus; Mice; Triterpenes; Uric Acid; Xant

2022
X-ray dark-field radiography for in situ gout diagnosis by means of an ex vivo animal study.
    Scientific reports, 2021, 09-24, Volume: 11, Issue:1

    Topics: Animals; Biomarkers; Crystallization; Gout; Joints; Lizards; Panthera; Radiography; Sensitivity and

2021
Decrease in Serum Urate Level Is Associated With Loss of Visceral Fat in Male Gout Patients.
    Frontiers in endocrinology, 2021, Volume: 12

    Topics: Adult; Body Composition; Body Mass Index; China; Gout; Humans; Intra-Abdominal Fat; Male; Middle Age

2021
Epidemiology of gout and hyperuricemia in New Caledonia.
    Joint bone spine, 2022, Volume: 89, Issue:2

    Topics: Adolescent; Adult; Ethnicity; Female; Gout; Humans; Hyperuricemia; Male; Middle Aged; New Caledonia;

2022
Gout, urate-lowering drugs, and risk of cardiovascular disease: can we clinically trust in the adjusted real-life data?
    European heart journal, 2021, 11-21, Volume: 42, Issue:44

    Topics: Cardiovascular Diseases; Gout; Humans; Pharmaceutical Preparations; Trust; Uric Acid

2021
Guizhi-Shaoyao-Zhimu decoction attenuates monosodium urate crystal-induced inflammation through inactivation of NF-κB and NLRP3 inflammasome.
    Journal of ethnopharmacology, 2022, Jan-30, Volume: 283

    Topics: Animals; Caspase 1; Disease Models, Animal; Drugs, Chinese Herbal; Gout; Inflammasomes; Inflammation

2022
CD38 activation by monosodium urate crystals contributes to inflammatory responses in human and murine macrophages.
    Biochemical and biophysical research communications, 2021, 12-03, Volume: 581

    Topics: ADP-ribosyl Cyclase 1; Animals; Crystallization; Female; Gene Expression Regulation; Gout; Humans; H

2021
Pleiotropic Effects of Functional
    International journal of molecular sciences, 2021, Sep-30, Volume: 22, Issue:19

    Topics: Adult; Atherosclerosis; Blood Glucose; Blood Pressure; Blood Urea Nitrogen; Body Mass Index; DNA Met

2021
Should we be more aware of gender aspects in hyperuricemia? Analysis of the population-based German health interview and examination survey for adults (DEGS1).
    Maturitas, 2021, Volume: 153

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Comorbidity; Cross-Sectional St

2021
Pseudo-tumor of the patella due to gout tophi.
    Joint bone spine, 2022, Volume: 89, Issue:1

    Topics: Arthritis, Gouty; Gout; Humans; Neoplasms; Patella; Uric Acid

2022
Mechanosensitive TRPV4 is required for crystal-induced inflammation.
    Annals of the rheumatic diseases, 2021, Volume: 80, Issue:12

    Topics: Adult; Animals; Arthralgia; Arthritis; Arthritis, Gouty; Crystal Arthropathies; Gout; Humans; Inflam

2021
Gout-associated uric acid crystals induce tophi ulcerations and impair wound healing in a novel gouty ulcer model.
    Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society, 2022, Volume: 30, Issue:1

    Topics: Animals; Arthritis, Gouty; Gout; Rats; Ulcer; Uric Acid; Wound Healing

2022
Effect of integrated Traditional Chinese and Western Medicine on gout.
    Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2021, Volume: 41, Issue:5

    Topics: China; Drugs, Chinese Herbal; Gout; Humans; Medicine, Chinese Traditional; Uric Acid

2021
Distribution of bony erosions in feet and performance of two bone erosion scores: A dual-energy computed tomography study of 61 patients with gout.
    PloS one, 2021, Volume: 16, Issue:11

    Topics: Gout; Humans; Middle Aged; Uric Acid

2021
Comment on: Association between serum urate, gout and comorbidities: a case-control study using data from the UK Biobank.
    Rheumatology (Oxford, England), 2022, 03-02, Volume: 61, Issue:3

    Topics: Biological Specimen Banks; Case-Control Studies; Gout; Humans; United Kingdom; Uric Acid

2022
Comment on: Association between serum urate, gout and comorbidities: a case-control study using data from the UK Biobank: reply.
    Rheumatology (Oxford, England), 2022, 03-02, Volume: 61, Issue:3

    Topics: Biological Specimen Banks; Case-Control Studies; Gout; Humans; United Kingdom; Uric Acid

2022
Firm Nodule on the Ear.
    American family physician, 2021, 11-01, Volume: 104, Issue:5

    Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Diagnosis, Differen

2021
Regular pre-admission urate-lowering therapy and serum urate testing are associated with a shorter hospital length of stay in people with gout: A nation-wide population-based cohort study.
    International journal of rheumatic diseases, 2022, Volume: 25, Issue:2

    Topics: Aged; Female; Gout; Gout Suppressants; Humans; Length of Stay; Male; Middle Aged; Native Hawaiian or

2022
Gout during the SARS-CoV-2 pandemic: increased flares, urate levels and functional improvement.
    Clinical rheumatology, 2022, Volume: 41, Issue:3

    Topics: Allopurinol; COVID-19; Gout; Gout Suppressants; Humans; Male; Middle Aged; Pandemics; Prospective St

2022
Gout Storm.
    The American journal of case reports, 2021, Sep-20, Volume: 22

    Topics: Colchicine; Gout; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Symptom Flare Up; Uric Acid

2021
Effects of Washed Microbiota Transplantation on Serum Uric Acid Levels, Symptoms, and Intestinal Barrier Function in Patients with Acute and Recurrent Gout: A Pilot Study.
    Digestive diseases (Basel, Switzerland), 2022, Volume: 40, Issue:5

    Topics: Endotoxins; Gout; Humans; Lactic Acid; Microbiota; Pilot Projects; Uric Acid

2022
Epigenome-wide association study of serum urate reveals insights into urate co-regulation and the SLC2A9 locus.
    Nature communications, 2021, 12-09, Volume: 12, Issue:1

    Topics: Amino Acid Transport System y+; Cohort Studies; CpG Islands; DNA Methylation; Epigenome; Female; Gen

2021
Assessing causality between osteoarthritis with urate levels and gout: a bidirectional Mendelian randomization study.
    Osteoarthritis and cartilage, 2022, Volume: 30, Issue:4

    Topics: Genome-Wide Association Study; Gout; Humans; Mendelian Randomization Analysis; Osteoarthritis; Polym

2022
Things We Do for No Reason™: Discontinuing urate-lowering therapy on admission.
    Journal of hospital medicine, 2022, Volume: 17, Issue:5

    Topics: Gout; Humans; Uric Acid

2022
[Clinical characteristics of crystal deposits in joints and tendons in patients with gout].
    Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2021, Dec-18, Volume: 53, Issue:6

    Topics: Achilles Tendon; Gout; Humans; Knee Joint; Metatarsophalangeal Joint; Uric Acid

2021
Factors associated with bone erosion in patients with gout: A dual-energy gemstone spectral imaging computed tomography study.
    Modern rheumatology, 2022, Oct-15, Volume: 32, Issue:6

    Topics: Arthritis, Gouty; Bone and Bones; Gout; Humans; Tomography, X-Ray Computed; Uric Acid

2022
Urate-lowering therapy for gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database.
    BMC pediatrics, 2021, 12-18, Volume: 21, Issue:1

    Topics: Adolescent; Adult; Child; Cross-Sectional Studies; Gout; Gout Suppressants; Humans; Hyperuricemia; I

2021
Untreated Chronic Gout.
    The New England journal of medicine, 2021, Dec-30, Volume: 385, Issue:27

    Topics: Aged; Arthrocentesis; Chronic Disease; Gout; Gout Suppressants; Hand; Humans; Male; Metatarsophalang

2021
What Is Gout?
    JAMA, 2021, 12-28, Volume: 326, Issue:24

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Gout; Gout Suppressants; Humans; Risk Factors;

2021
Management of Gout.
    JAMA, 2021, Dec-28, Volume: 326, Issue:24

    Topics: Analgesics; Gout; Gout Suppressants; Humans; Practice Guidelines as Topic; Uric Acid; Uricosuric Age

2021
A Case of Spinal Infectious Osteomyelitis Versus Gout: Advanced Imaging with Dual Energy CT.
    The Yale journal of biology and medicine, 2021, Volume: 94, Issue:4

    Topics: Aged; Gout; Humans; Male; Osteomyelitis; Tomography, X-Ray Computed; Uric Acid

2021
Patients with severe gout treated in mixed settings.
    Danish medical journal, 2021, Oct-18, Volume: 68, Issue:11

    Topics: Aged; Female; Gout; Gout Suppressants; Humans; Male; Rheumatology; Treatment Outcome; Uric Acid

2021
Comparison of Rates of Lower Extremity Amputation in Patients With and Without Gout in the US Department of Veterans Affairs Health System.
    JAMA network open, 2022, 01-04, Volume: 5, Issue:1

    Topics: Aged; Amputation, Surgical; Cohort Studies; Female; Gout; Humans; Incidence; Lower Extremity; Male;

2022
Recombinant Human Proteoglycan 4 Regulates Phagocytic Activation of Monocytes and Reduces IL-1β Secretion by Urate Crystal Stimulated Gout PBMCs.
    Frontiers in immunology, 2021, Volume: 12

    Topics: Acetylcysteine; Adult; Aged; Aged, 80 and over; Animals; Anti-Inflammatory Agents; Female; Free Radi

2021
IL-37 blocks gouty inflammation by shaping macrophages into a non-inflammatory phagocytic phenotype.
    Rheumatology (Oxford, England), 2022, 08-30, Volume: 61, Issue:9

    Topics: Animals; Arthritis, Gouty; Glycogen Synthase Kinase 3 beta; Gout; Humans; Inflammation; Interleukin-

2022
Vascular deposition of monosodium urate crystals in gout: analysis of cadaveric tissue by dual-energy computed tomography and compensated polarizing light microscopy.
    Arthritis & rheumatology (Hoboken, N.J.), 2022, Volume: 74, Issue:7

    Topics: Cadaver; Gout; Humans; Microscopy, Polarization; Tomography, X-Ray Computed; Uric Acid

2022
Remission in Gout: Concepts From a Patient Perspective.
    The Journal of rheumatology, 2022, Volume: 49, Issue:3

    Topics: Gout; Gout Suppressants; Humans; Uric Acid

2022
Influence of Pinealectomy and Long-term Melatonin Administration on Inflammation and Oxidative Stress in Experimental Gouty Arthritis.
    Inflammation, 2022, Volume: 45, Issue:3

    Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Arthritis, Gouty; Gout; Inflammation; Melatonin; Ox

2022
The Anti-Inflammatory and Uric Acid Lowering Effects of Si-Miao-San on Gout.
    Frontiers in immunology, 2021, Volume: 12

    Topics: Animals; Anti-Inflammatory Agents; Chromones; Drugs, Chinese Herbal; Gout; Humans; Macrophages; Male

2021
Association of acidic urine pH with impaired renal function in primary gout patients: a Chinese population-based cross-sectional study.
    Arthritis research & therapy, 2022, 01-25, Volume: 24, Issue:1

    Topics: China; Cross-Sectional Studies; Gout; Humans; Hydrogen-Ion Concentration; Kidney; Kidney Calculi; Pr

2022
Evolving Role of Dual-Energy CT in the Clinical Workup of Gout: A Retrospective Study.
    AJR. American journal of roentgenology, 2022, Volume: 218, Issue:6

    Topics: Adult; Gout; Humans; Retrospective Studies; Tin; Tomography, X-Ray Computed; Uric Acid

2022
Discovery of Novel Bicyclic Imidazolopyridine-Containing Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Improved Efficacy and Favorable Druggability.
    Journal of medicinal chemistry, 2022, 03-10, Volume: 65, Issue:5

    Topics: Animals; Gout; Humans; Hyperuricemia; Mice; Organic Anion Transporters; Organic Cation Transport Pro

2022
Model-based cost-effectiveness analyses comparing combinations of urate lowering therapy and anti-inflammatory treatment in gout patients.
    PloS one, 2022, Volume: 17, Issue:1

    Topics: Anti-Inflammatory Agents; Cost-Benefit Analysis; Costs and Cost Analysis; Drug Therapy, Combination;

2022
Ocular manifestation in gout: an unusual presentation of gout.
    Clinical rheumatology, 2022, Volume: 41, Issue:5

    Topics: Eye; Gout; Humans; Uric Acid

2022
Is repeat serum urate testing superior to a single test to predict incident gout over time?
    PloS one, 2022, Volume: 17, Issue:2

    Topics: Adult; Area Under Curve; Female; Gout; Humans; Incidence; Longitudinal Studies; Male; Middle Aged; R

2022
EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome.
    Annals of the rheumatic diseases, 2022, Volume: 81, Issue:6

    Topics: Antiphospholipid Syndrome; Cardiovascular Diseases; Gout; Heart Disease Risk Factors; Humans; Lupus

2022
[Gout: an overview of diagnostics and treatment].
    Nederlands tijdschrift voor geneeskunde, 2022, 01-24, Volume: 166

    Topics: Gout; Humans; Hyperuricemia; Tomography, X-Ray Computed; Ultrasonography; Uric Acid

2022
Colchicine use and the risk of CKD progression: a multicentre nested case-control study.
    Rheumatology (Oxford, England), 2022, 11-02, Volume: 61, Issue:11

    Topics: Case-Control Studies; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal

2022
Green pixels on DECT: Is it gout?
    The American journal of the medical sciences, 2022, Volume: 364, Issue:3

    Topics: Gout; Humans; Uric Acid

2022
Why Do Patients With Gout Not Take Allopurinol?
    The Journal of rheumatology, 2022, Volume: 49, Issue:6

    Topics: Allopurinol; Gout; Gout Suppressants; Humans; Male; Rheumatology; Treatment Outcome; Uric Acid

2022
The shrinking toe sign in gout.
    Seminars in arthritis and rheumatism, 2022, Volume: 53

    Topics: Gout; Humans; Metatarsophalangeal Joint; Retrospective Studies; Toes; Uric Acid

2022
Development of a patient decision aid for the initiation of urate-lowering therapy in gout patients.
    RMD open, 2022, Volume: 8, Issue:1

    Topics: Cognition; Decision Support Techniques; Gout; Gout Suppressants; Humans; Uric Acid

2022
[Management of hyperuricemia in chronic kidney disease].
    Revue medicale suisse, 2022, Mar-02, Volume: 18, Issue:771

    Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Uric Acid

2022
Pegloticase causes prolonged improvement in multiple disease parameters in patients with chronic refractory gout who maintain low serum urate levels.
    Clinical and experimental rheumatology, 2022, Volume: 40, Issue:5

    Topics: Arthritis, Gouty; Chronic Disease; Gout; Gout Suppressants; Humans; Pain; Polyethylene Glycols; Trea

2022
Treating gout - can hypouricemia produced by moderate doses of combined oral treatment give early treatment success? Preliminary observations.
    Nucleosides, nucleotides & nucleic acids, 2022, Volume: 41, Issue:12

    Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Male; Treatment Outcome; Uric Acid

2022
What is the Place for Uricosuric Agents in Gout Management?
    Current rheumatology reviews, 2022, Volume: 18, Issue:4

    Topics: Gout; Humans; Uric Acid; Uricosuric Agents

2022
A machine learning-assisted model for renal urate underexcretion with genetic and clinical variables among Chinese men with gout.
    Arthritis research & therapy, 2022, 03-09, Volume: 24, Issue:1

    Topics: Asian People; Glucose Transport Proteins, Facilitative; Gout; Humans; Hyperuricemia; Machine Learnin

2022
Assessing the Causal Effects of Adipokines on Uric Acid and Gout: A Two-Sample Mendelian Randomization Study.
    Nutrients, 2022, Mar-05, Volume: 14, Issue:5

    Topics: Adipokines; Genome-Wide Association Study; Gout; Humans; Mendelian Randomization Analysis; Polymorph

2022
Hospitalizations for Acute Gout: Process Mapping the Inpatient Journey and Identifying Predictors of Admission.
    The Journal of rheumatology, 2022, Volume: 49, Issue:7

    Topics: Aftercare; Arthritis, Gouty; Gout; Gout Suppressants; Hospitalization; Humans; Inpatients; Patient D

2022
Dual-energy CT assessment of rapid monosodium urate depletion and bone erosion remodelling during pegloticase plus methotrexate co-therapy.
    Rheumatology (Oxford, England), 2022, 11-28, Volume: 61, Issue:12

    Topics: Adult; Arthritis, Gouty; Gout; Humans; Male; Methotrexate; Middle Aged; Tomography, X-Ray Computed;

2022
Natural antibodies and CRP drive anaphylatoxin production by urate crystals.
    Scientific reports, 2022, 03-16, Volume: 12, Issue:1

    Topics: Anaphylatoxins; C-Reactive Protein; Gout; Humans; Immunoglobulin M; Receptors, Immunologic; Uric Aci

2022
Retrospective longitudinal assessment of ultrasound gout lesions using the OMERACT semi-quantitative scoring system.
    Rheumatology (Oxford, England), 2022, 11-28, Volume: 61, Issue:12

    Topics: Arthritis, Gouty; Gout; Humans; Retrospective Studies; Ultrasonography; Uric Acid

2022
The correlation of uric acid levels with biochemical parameters and dietary factors in individuals with asymptomatic hyperuricemia and gouty arthritis.
    Nucleosides, nucleotides & nucleic acids, 2022, Volume: 41, Issue:5-6

    Topics: Arthritis, Gouty; Female; Gout; Humans; Hyperuricemia; Male; Triglycerides; Uric Acid; Vitamins

2022
Comparison of ultrasound attenuation by calcium pyrophosphate, hydroxyapatite and monosodium urate crystals: a proof-of-concept study.
    Annals of the rheumatic diseases, 2022, Volume: 81, Issue:8

    Topics: Calcium Pyrophosphate; Chondrocalcinosis; Durapatite; Gout; Humans; Uric Acid

2022
Improvement in hepatic fibrosis estimated by Fibrosis-4 index in pegloticase treated chronic refractory gout patients.
    Clinical and experimental rheumatology, 2023, Volume: 41, Issue:1

    Topics: Chronic Disease; Gout; Gout Suppressants; Humans; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease

2023
Association between serum uric acid and α-klotho protein levels in the middle-aged population.
    Aging, 2022, 03-29, Volume: 14, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Female; Gout; Humans; Hyperuricemia; Klotho Proteins; Male; Middle A

2022
Translation, internal consistency, reliability and validity of the Thai version of Gout Assessment Questionnaire version 2.0 (GAQ 2.0).
    Clinical rheumatology, 2022, Volume: 41, Issue:7

    Topics: Gout; Humans; Psychometrics; Quality of Life; Reproducibility of Results; Surveys and Questionnaires

2022
Kv1.5 channel mediates monosodium urate-induced activation of NLRP3 inflammasome in macrophages and arrhythmogenic effects of urate on cardiomyocytes.
    Molecular biology reports, 2022, Volume: 49, Issue:7

    Topics: Animals; Atrial Remodeling; Caspase 1; Gout; Humans; Inflammasomes; Interleukin-1beta; Kv1.5 Potassi

2022
The Negative Association Between NAFLD Severity and CKD in a Non-Diabetic Gouty Population.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2022, Volume: 54, Issue:5

    Topics: Cross-Sectional Studies; Female; Gout; Humans; Male; Non-alcoholic Fatty Liver Disease; Renal Insuff

2022
A fly GWAS for purine metabolites identifies human FAM214 homolog medusa, which acts in a conserved manner to enhance hyperuricemia-driven pathologies by modulating purine metabolism and the inflammatory response.
    GeroScience, 2022, Volume: 44, Issue:4

    Topics: Animals; Drosophila melanogaster; Drosophila Proteins; Genome-Wide Association Study; Gout; Humans;

2022
Development and usability of a web-based patient-tailored tool to support adherence to urate-lowering therapy in gout.
    BMC medical informatics and decision making, 2022, 04-07, Volume: 22, Issue:1

    Topics: Gout; Gout Suppressants; Humans; Internet; Motivation; Uric Acid

2022
Cardiovascular risk factors, ethnicity and infection stone are independent factors associated with reduced renal function in renal stone formers.
    PloS one, 2022, Volume: 17, Issue:4

    Topics: Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus; Ethnicity; Female; Gout; Heart

2022
Probiotic Characterization of
    Journal of medicinal food, 2022, Volume: 25, Issue:4

    Topics: Animals; Caco-2 Cells; Gout; Gout Suppressants; Humans; Hyperuricemia; Levilactobacillus brevis; Mic

2022
One- and 2-year flare rates after treat-to-target and tight-control therapy of gout: results from the NOR-Gout study.
    Arthritis research & therapy, 2022, 04-20, Volume: 24, Issue:1

    Topics: Allopurinol; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Symptom Flare Up; Uric Acid

2022
[Gout attack].
    MMW Fortschritte der Medizin, 2022, Volume: 164, Issue:8

    Topics: Gout; Humans; Uric Acid

2022
The Relationship between Alcohol Consumption and Gout: A Mendelian Randomization Study.
    Genes, 2022, 03-22, Volume: 13, Issue:4

    Topics: Alcohol Drinking; Gout; Humans; Hyperuricemia; Mendelian Randomization Analysis; Uric Acid

2022
Assessing the Sensitivity of Dual-Energy Computed Tomography 3-Material Decomposition for the Detection of Gout.
    Investigative radiology, 2022, 09-01, Volume: 57, Issue:9

    Topics: Gout; Humans; Phantoms, Imaging; Tomography, X-Ray Computed; Uric Acid

2022
Noninvasive and Individual-Centered Monitoring of Uric Acid for Precaution of Hyperuricemia via Optical Supramolecular Sensing.
    Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2022, Volume: 9, Issue:18

    Topics: Gout; Humans; Hyperuricemia; Kidney; Uric Acid

2022
Are we asking the right questions about urate-lowering therapy? Comment on the 2021 Asia-Pacific League of Associations for Rheumatology clinical practice guideline for treatment of gout.
    International journal of rheumatic diseases, 2022, Volume: 25, Issue:6

    Topics: Asia; Gout; Gout Suppressants; Humans; Rheumatology; Uric Acid

2022
Risk of Parkinson's disease in a gout Mediterranean population: A case-control study.
    Joint bone spine, 2022, Volume: 89, Issue:6

    Topics: Adult; Aged; Case-Control Studies; Cohort Studies; Female; Gout; Humans; Male; Neuroprotective Agent

2022
Anti-inflammatory and Antioxidant Effect of Poly-gallic Acid (PGAL) in an In Vitro Model of Synovitis Induced by Monosodium Urate Crystals.
    Inflammation, 2022, Volume: 45, Issue:5

    Topics: Anti-Inflammatory Agents; Antioxidants; Gallic Acid; Gout; Humans; Inflammation; Polyglutamic Acid;

2022
Differential gene expression of ABCG2, SLC22A12, IL-1β, and ALPK1 in peripheral blood leukocytes of primary gout patients with hyperuricemia and their comorbidities: a case-control study.
    European journal of medical research, 2022, May-03, Volume: 27, Issue:1

    Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Case-Control Studies; Gene Expression; Gout

2022
Prediction of the Uric Acid Component in Nephrolithiasis Using Simple Clinical Information about Metabolic Disorder and Obesity: A Machine Learning-Based Model.
    Nutrients, 2022, Apr-27, Volume: 14, Issue:9

    Topics: Female; Gout; Humans; Kidney Calculi; Machine Learning; Male; Obesity; Uric Acid

2022
Urate-lowering therapy for patients with gout on hemodialysis.
    International journal of rheumatic diseases, 2022, Volume: 25, Issue:7

    Topics: Aged; Female; Gout; Gout Suppressants; Humans; Kidney Failure, Chronic; Male; Renal Dialysis; Uric A

2022
Altered Gut Microbiota in Children With Hyperuricemia.
    Frontiers in endocrinology, 2022, Volume: 13

    Topics: Adult; Bacteria; Child; Gastrointestinal Microbiome; Gout; Humans; Hyperuricemia; RNA, Ribosomal, 16

2022
Cardiovascular risk and mortality in patients with hyperuricemia treated with febuxostat or allopurinol: a retrospective nation-wide cohort study in Austria 2014-2017.
    Rheumatology international, 2022, Volume: 42, Issue:9

    Topics: Aged; Allopurinol; Austria; Cardiovascular Diseases; Cohort Studies; Febuxostat; Female; Gout; Gout

2022
[Gout].
    Zeitschrift fur Rheumatologie, 2022, Volume: 81, Issue:5

    Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Symptom Flare Up; Uric Acid

2022
Distinct macrophage polarization in acute and chronic gout.
    Laboratory investigation; a journal of technical methods and pathology, 2022, Volume: 102, Issue:10

    Topics: Animals; Arginase; Gout; Humans; Inflammation; Macrophages; Mice; Nitric Oxide Synthase Type II; RNA

2022
What do we know about Toll-Like Receptors Involvement in Gout Arthritis?
    Endocrine, metabolic & immune disorders drug targets, 2023, Volume: 23, Issue:4

    Topics: Adaptor Proteins, Signal Transducing; Animals; Arthritis, Gouty; Gout; Humans; Mice; Toll-Like Recep

2023
Genetically predicted physical activity is associated with lower serum urate concentrations.
    Genes & genomics, 2022, Volume: 44, Issue:7

    Topics: Exercise; Genetic Predisposition to Disease; Genome-Wide Association Study; Gout; Humans; Mendelian

2022
Are polymorphisms affecting serum urate, renal urate handling and alcohol intake associated with co-morbidities in gout cases? A case-control study using data from the UK Biobank.
    Rheumatology international, 2022, Volume: 42, Issue:9

    Topics: Alcohol Drinking; Biological Specimen Banks; Case-Control Studies; Genetic Predisposition to Disease

2022
Early hearing loss detection in gout using extended high frequency audiometry.
    Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery, 2022, Volume: 47, Issue:5

    Topics: Audiometry; Audiometry, Pure-Tone; Auditory Threshold; Cross-Sectional Studies; Deafness; Gout; Hear

2022
Investigation on monosodium urate deposition in the first metatarsophalangeal joint and ankle of primary gout patients using dual-energy computed tomography.
    The Medical journal of Malaysia, 2022, Volume: 77, Issue:3

    Topics: Ankle; Cross-Sectional Studies; Gout; Humans; Metatarsophalangeal Joint; Tomography, X-Ray Computed;

2022
Phytochemicals in traditional Chinese medicine can treat gout by regulating intestinal flora through inactivating NLRP3 and inhibiting XOD activity.
    The Journal of pharmacy and pharmacology, 2022, Jul-15, Volume: 74, Issue:7

    Topics: Gastrointestinal Microbiome; Gout; Humans; Hyperuricemia; Inflammation; Lipopolysaccharides; Medicin

2022
Natural Adrenocorticotropic Hormone (ACTH) Relieves Acute Inflammation in Gout Patients by Changing the Function of Macrophages.
    Journal of healthcare engineering, 2022, Volume: 2022

    Topics: Adrenocorticotropic Hormone; Animals; Arthritis, Gouty; Dexamethasone; Gout; Humans; Hydrocortisone;

2022
The Inhibition of Osteoblast Viability by Monosodium Urate Crystal-Stimulated Neutrophil-Derived Exosomes.
    Frontiers in immunology, 2022, Volume: 13

    Topics: Exosomes; Gout; Humans; MicroRNAs; Neutrophils; Osteoblasts; Uric Acid

2022
Polysaccharide extract from Isatidis Radix inhibits multiple inflammasomes activation and alleviate gouty arthritis.
    Phytotherapy research : PTR, 2022, Volume: 36, Issue:8

    Topics: Animals; Arthritis, Gouty; Gout; Inflammasomes; Interleukin-1beta; Macrophages; Mice; NLR Family, Py

2022
The disproportionately large contribution of the Māori and Pacific Islander community to the healthcare burden of gout in Western Sydney.
    Internal medicine journal, 2023, Volume: 53, Issue:8

    Topics: Cost of Illness; Delivery of Health Care; Gout; Humans; Maori People; New South Wales; Pacific Islan

2023
Persistence with urate-lowering therapy in Australia: A longitudinal analysis of allopurinol prescriptions.
    British journal of clinical pharmacology, 2022, Volume: 88, Issue:11

    Topics: Allopurinol; Australia; Colchicine; Gout; Gout Suppressants; Humans; Male; Medication Adherence; Pha

2022
Association of the Quantity, Duration, and Type of Alcohol Consumption on the Development of Gouty Tophi.
    Arthritis care & research, 2023, Volume: 75, Issue:5

    Topics: Alcohol Drinking; Gout; Humans; Risk Factors; Uric Acid

2023
Taxifolin blocks monosodium urate crystal-induced gouty inflammation by regulating phagocytosis and autophagy.
    Inflammopharmacology, 2022, Volume: 30, Issue:4

    Topics: Arthritis, Gouty; Autophagy; Gout; Humans; Inflammation; Interleukin-1beta; Phagocytosis; Quercetin;

2022
TET2-mutant clonal hematopoiesis and risk of gout.
    Blood, 2022, 09-08, Volume: 140, Issue:10

    Topics: Animals; Clonal Hematopoiesis; Dioxygenases; DNA-Binding Proteins; Gout; Humans; Inflammasomes; Inte

2022
Birefringent crystals deposition and inflammasome expression in human atheroma plaques by levels of uricemia.
    Joint bone spine, 2022, Volume: 89, Issue:5

    Topics: Caspase 1; Ethanol; Gout; Humans; Hyperuricemia; Inflammasomes; Interleukin-1beta; NLR Family, Pyrin

2022
Upregulated expression of FFAR2 and SOC3 genes is associated with gout.
    Rheumatology (Oxford, England), 2023, 02-01, Volume: 62, Issue:2

    Topics: Cytokines; Gout; Humans; Hyperuricemia; Symptom Flare Up; Uric Acid

2023
Prevalence of Patients Receiving Urate-Lowering Medicine in Greenland and Denmark: A Cross-Sectional Case-Control Study.
    International journal of environmental research and public health, 2022, 06-13, Volume: 19, Issue:12

    Topics: Case-Control Studies; Cross-Sectional Studies; Female; Gout; Gout Suppressants; Greenland; Humans; H

2022
Genetic contributions to female gout and hyperuricaemia using genome-wide association study and polygenic risk score analyses.
    Rheumatology (Oxford, England), 2023, 02-01, Volume: 62, Issue:2

    Topics: Female; Genetic Predisposition to Disease; Genome-Wide Association Study; Glucose Transport Proteins

2023
Determination of total purine and free purine content in milk, soymilk, and enteral nutritional supplements to assist nutritional therapy for hyperuricemia and gout.
    Nucleosides, nucleotides & nucleic acids, 2022, Volume: 41, Issue:12

    Topics: Aged; Animals; Gout; Humans; Hyperuricemia; Milk; Purines; Uric Acid

2022
Serum urate outcomes of treat-to-target urate lowering treatment: results of a nationwide cohort study from 1997 to the COVID-19 pandemic using data from the Clinical Practice Research Datalink.
    Annals of the rheumatic diseases, 2022, Volume: 81, Issue:12

    Topics: Allopurinol; Cohort Studies; COVID-19; Gout; Gout Suppressants; Humans; Pandemics; Uric Acid

2022
Palpable tophi and more comorbidities associated with adherence to urate-lowering medical therapy in a Chinese gout cohort.
    Joint bone spine, 2022, Volume: 89, Issue:6

    Topics: China; Cohort Studies; Gout; Gout Suppressants; Humans; Male; Uric Acid

2022
Protective effects of corni fructus extract in mice with potassium oxonate-induced hyperuricemia.
    The Journal of veterinary medical science, 2022, Aug-19, Volume: 84, Issue:8

    Topics: Animals; Antioxidants; Cornus; Gout; Hyperuricemia; Mice; Oxonic Acid; Plant Extracts; Uric Acid; Xa

2022
[X-Ray Dark-field radiography: Does this carry potential for diagnosing gout in exotic pets?]
    Tierarztliche Praxis. Ausgabe K, Kleintiere/Heimtiere, 2022, Volume: 50, Issue:3

    Topics: Animals; Animals, Exotic; Gout; Radiography; Uric Acid; X-Rays

2022
Monosodium urate deposition in the lumbosacral spine of patients with gout compared with non-gout controls: A dual-energy CT study.
    Seminars in arthritis and rheumatism, 2022, Volume: 56

    Topics: Adult; Arthritis, Gouty; Case-Control Studies; Gout; Humans; Prevalence; Tomography, X-Ray Computed;

2022
The reality of treatment for hyperuricemia and gout in Japan: A historical cohort study using health insurance claims data.
    Journal of clinical hypertension (Greenwich, Conn.), 2022, Volume: 24, Issue:8

    Topics: Cohort Studies; Gout; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Insurance, Health; Jap

2022
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
    Seminars in arthritis and rheumatism, 2022, Volume: 56

    Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To

2022
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
    Seminars in arthritis and rheumatism, 2022, Volume: 56

    Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To

2022
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
    Seminars in arthritis and rheumatism, 2022, Volume: 56

    Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To

2022
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
    Seminars in arthritis and rheumatism, 2022, Volume: 56

    Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To

2022
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
    Seminars in arthritis and rheumatism, 2022, Volume: 56

    Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To

2022
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
    Seminars in arthritis and rheumatism, 2022, Volume: 56

    Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To

2022
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
    Seminars in arthritis and rheumatism, 2022, Volume: 56

    Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To

2022
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
    Seminars in arthritis and rheumatism, 2022, Volume: 56

    Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To

2022
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
    Seminars in arthritis and rheumatism, 2022, Volume: 56

    Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To

2022
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
    Seminars in arthritis and rheumatism, 2022, Volume: 56

    Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To

2022
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
    Seminars in arthritis and rheumatism, 2022, Volume: 56

    Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To

2022
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
    Seminars in arthritis and rheumatism, 2022, Volume: 56

    Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To

2022
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
    Seminars in arthritis and rheumatism, 2022, Volume: 56

    Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To

2022
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
    Seminars in arthritis and rheumatism, 2022, Volume: 56

    Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To

2022
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
    Seminars in arthritis and rheumatism, 2022, Volume: 56

    Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To

2022
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
    Seminars in arthritis and rheumatism, 2022, Volume: 56

    Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To

2022
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
    Seminars in arthritis and rheumatism, 2022, Volume: 56

    Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To

2022
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
    Seminars in arthritis and rheumatism, 2022, Volume: 56

    Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To

2022
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
    Seminars in arthritis and rheumatism, 2022, Volume: 56

    Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To

2022
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
    Seminars in arthritis and rheumatism, 2022, Volume: 56

    Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To

2022
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
    Seminars in arthritis and rheumatism, 2022, Volume: 56

    Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To

2022
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
    Seminars in arthritis and rheumatism, 2022, Volume: 56

    Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To

2022
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
    Seminars in arthritis and rheumatism, 2022, Volume: 56

    Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To

2022
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
    Seminars in arthritis and rheumatism, 2022, Volume: 56

    Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To

2022
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
    Seminars in arthritis and rheumatism, 2022, Volume: 56

    Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To

2022
Sodium-glucose cotransporter 1 inhibition and gout: Mendelian randomisation study.
    Seminars in arthritis and rheumatism, 2022, Volume: 56

    Topics: Genome-Wide Association Study; Glycated Hemoglobin; Gout; Humans; Polymorphism, Single Nucleotide; S

2022
Urate crystal deposition is associated with inflammatory markers and carotid artery pathology in patients with intercritical gout: results from the NOR-Gout study.
    RMD open, 2022, Volume: 8, Issue:2

    Topics: Adult; Aged; Biomarkers; Carotid Arteries; Carotid Intima-Media Thickness; Cross-Sectional Studies;

2022
Acute joint swelling in psoriatic arthritis: Flare or "psout"-A 10-year-monocentric study on synovial fluid.
    Experimental biology and medicine (Maywood, N.J.), 2022, Volume: 247, Issue:18

    Topics: Adult; Arthritis, Psoriatic; Female; Gout; Humans; Hyperuricemia; Male; Retrospective Studies; Synov

2022
Xanthine oxidase inhibitor urate-lowering therapy titration to target decreases serum free fatty acids in gout and suppresses lipolysis by adipocytes.
    Arthritis research & therapy, 2022, 07-25, Volume: 24, Issue:1

    Topics: Adipocytes; Allopurinol; Colchicine; Enzyme Inhibitors; Fatty Acids, Nonesterified; Febuxostat; Gout

2022
A rare presentation of a first gout flare.
    Rheumatology (Oxford, England), 2023, 03-01, Volume: 62, Issue:3

    Topics: Gout; Gout Suppressants; Humans; Symptom Flare Up; Uric Acid

2023
Monosodium urate crystals with controlled shape and aspect ratio for elucidating the pathological progress of acute gout.
    Biomaterials advances, 2022, Volume: 139

    Topics: Arthritis, Gouty; Gout; Humans; Inflammasomes; Macrophages; Uric Acid

2022
Protective effects of di-caffeoylquinic acids from Artemisia selengensis Turcz leaves against monosodium urate-induced inflammation via the modulation of NLRP3 inflammasome and Nrf2 signaling pathway in THP-1 macrophages.
    Journal of food biochemistry, 2022, Volume: 46, Issue:9

    Topics: Artemisia; Gout; Inflammasomes; Inflammation; Interleukin-1beta; Macrophages; NF-E2-Related Factor 2

2022
Study on the interaction mechanism between luteoloside and xanthine oxidase by multi-spectroscopic and molecular docking methods.
    Journal of molecular recognition : JMR, 2022, Volume: 35, Issue:12

    Topics: Enzyme Inhibitors; Gout; Humans; Molecular Docking Simulation; Spectrometry, Fluorescence; Uric Acid

2022
Should Low Serum Urate Be Exonerated? Untangling the Influence of Sarcopenia in Observational Studies.
    Arthritis & rheumatology (Hoboken, N.J.), 2023, Volume: 75, Issue:1

    Topics: Cardiovascular Diseases; Gout; Humans; Sarcopenia; Uric Acid

2023
Ultrasonography in the prediction of gout flares: a 12-month prospective observational study.
    Rheumatology (Oxford, England), 2023, 03-01, Volume: 62, Issue:3

    Topics: Gout; Humans; Inflammation; Prospective Studies; Symptom Flare Up; Ultrasonography; Uric Acid

2023
Purine content of hospital meals and its effect on serum uric acid, urine pH, and urinary uric acid excretion.
    Nucleosides, nucleotides & nucleic acids, 2022, Volume: 41, Issue:12

    Topics: Gout; Hospitals; Humans; Hydrogen-Ion Concentration; Hyperuricemia; Meals; Purines; Uric Acid

2022
Anti-inflammatory potential of stevia residue extract against uric acid-associated renal injury in mice.
    Journal of food biochemistry, 2022, Volume: 46, Issue:10

    Topics: Allopurinol; AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents; Colchicine; Creatinin

2022
Predictors of disease activity in gout: a 12-month analysis of the ATTACk (Achieving improvement in the management of crystal-induced arthritis) multicentre cohort study.
    Clinical and experimental rheumatology, 2023, Volume: 41, Issue:3

    Topics: Aged; Cohort Studies; Female; Gout; Gout Suppressants; Humans; Linear Models; Male; Middle Aged; Uri

2023
Correlation of obesity, dietary patterns, and blood pressure with uric acid: data from the NHANES 2017-2018.
    BMC endocrine disorders, 2022, Aug-05, Volume: 22, Issue:1

    Topics: Blood Pressure; Cross-Sectional Studies; Gout; Humans; Hyperuricemia; Nutrition Surveys; Obesity; Ri

2022
Genetic polymorphisms and decreased protein expression of ABCG2 urate transporters are associated with susceptibility to gout, disease severity and renal-overload hyperuricemia.
    Clinical and experimental medicine, 2023, Volume: 23, Issue:4

    Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Gout; Humans; Hyperuricemia; Neoplasm Prote

2023
Is febuxostat associated with higher risk of cardiovascular death than allopurinol in treating gout or asymptomatic hyperuricemia?
    Annals of palliative medicine, 2022, Volume: 11, Issue:8

    Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome; Uric Aci

2022
The Association of Serum Uric Acid Level, Gout, and Alzheimer's Disease: A Bidirectional Mendelian Randomization Study.
    Journal of Alzheimer's disease : JAD, 2022, Volume: 89, Issue:3

    Topics: Alzheimer Disease; Genome-Wide Association Study; Gout; Humans; Mendelian Randomization Analysis; Po

2022
The role of obesity, type 2 diabetes, and metabolic factors in gout: A Mendelian randomization study.
    Frontiers in endocrinology, 2022, Volume: 13

    Topics: Diabetes Mellitus, Type 2; Genome-Wide Association Study; Gout; Humans; Hypertension; Mendelian Rand

2022
A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an
    Arthritis research & therapy, 2022, 08-25, Volume: 24, Issue:1

    Topics: Gout; Gout Suppressants; Humans; Male; Methotrexate; Polyethylene Glycols; Symptom Flare Up; Treatme

2022
The paradoxical relation between serum uric acid and outcomes of hip fracture in older patients after surgery: A 1-year follow-up study.
    Surgery, 2022, Volume: 172, Issue:5

    Topics: Aged; Female; Follow-Up Studies; Gout; Hip Fractures; Humans; Hyperuricemia; Male; Risk Factors; Uri

2022
Monitoring and Achievement of Target Serum Urate Among Gout Patients Receiving Long-Term Urate-Lowering Therapy in the American College of Rheumatology RISE Registry.
    Arthritis care & research, 2023, Volume: 75, Issue:7

    Topics: Aged; Allopurinol; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Registries; Rheumatol

2023
Using Data-Driven Approaches to Classify and Predict Health Care Spending in Patients With Gout Using Urate-Lowering Therapy.
    Arthritis care & research, 2023, Volume: 75, Issue:6

    Topics: Aged; Aged, 80 and over; Female; Gout; Gout Suppressants; Health Expenditures; Humans; Male; Medicat

2023
Living with gout. Experiences, impact and challenges of the disease. Qualitative study through focus groups.
    Reumatologia clinica, 2023, Volume: 19, Issue:3

    Topics: Exercise; Female; Focus Groups; Gout; Humans; Male; Qualitative Research; Uric Acid

2023
Clinical Effect of the Guizhi Shaoyao Zhimu Decoction in the Treatment of Hyperuricemia.
    BioMed research international, 2022, Volume: 2022

    Topics: Gout; Humans; Hyperuricemia; Medicine, Chinese Traditional; Treatment Outcome; Uric Acid

2022
Modelling and assessing one- and two-drug dose titrations.
    Artificial intelligence in medicine, 2022, Volume: 131

    Topics: Allopurinol; Gout; Gout Suppressants; Humans; Hyperuricemia; Retrospective Studies; Uric Acid

2022
Isolation, identification, and pathogenicity of a goose astrovirus causing fatal gout in goslings.
    Veterinary microbiology, 2022, Volume: 274

    Topics: Amino Acids; Animals; Astroviridae Infections; Avastrovirus; Biological Products; China; Geese; Gout

2022
Type II collagen facilitates gouty arthritis by regulating MSU crystallisation and inflammatory cell recruitment.
    Annals of the rheumatic diseases, 2023, Volume: 82, Issue:3

    Topics: Arthritis, Gouty; Collagen Type II; Cytokines; Gout; Humans; Inflammation; Matrilin Proteins; Uric A

2023
Gout Flares and Intercritical Gout: Do they Play a Significant Role in Predicting Cardiovascular Events?
    Current vascular pharmacology, 2022, Volume: 20, Issue:6

    Topics: Cardiovascular Diseases; Chronic Disease; Gout; Humans; Symptom Flare Up; Uric Acid

2022
Assessing the causal associations of obstructive sleep apnea with serum uric acid levels and gout: a bidirectional two-sample Mendelian randomization study.
    Seminars in arthritis and rheumatism, 2022, Volume: 57

    Topics: Diabetes Mellitus, Type 2; Genome-Wide Association Study; Gout; Humans; Mendelian Randomization Anal

2022
Gouty sacroiliitis: A case report of an often-overlooked cause of inflammatory back pain.
    International journal of rheumatic diseases, 2023, Volume: 26, Issue:1

    Topics: Arthritis, Gouty; Back Pain; Gout; Humans; Sacroiliac Joint; Sacroiliitis; Uric Acid

2023
Outcomes of surgery for gouty tophi in the extremities.
    Polski przeglad chirurgiczny, 2022, Feb-17, Volume: 94, Issue:5

    Topics: Extremities; Female; Gout; Humans; Male; Middle Aged; Treatment Outcome; Uric Acid

2022
Long-Term Adherence to Urate-Lowering Therapy in Gout: A Glass Half Empty or a Glass Half Full?
    The Journal of rheumatology, 2022, Volume: 49, Issue:12

    Topics: Gout; Gout Suppressants; Humans; Uric Acid

2022
Changes in purine and uric acid content in edible insects during culinary processing.
    Food chemistry, 2023, Mar-01, Volume: 403

    Topics: Animals; Edible Insects; Gout; Gryllidae; Humans; Insecta; Purines; Uric Acid; Xanthine

2023
Surgical Treatment of Hand and Foot Gout Stone and Influence Factors on Prognosis.
    Computational and mathematical methods in medicine, 2022, Volume: 2022

    Topics: Calcium Carbonate; Gout; Humans; Prognosis; Retrospective Studies; Uric Acid

2022
Design, synthesis and activity evaluation of novel lesinurad analogues containing thienopyrimidinone or pyridine substructure as human urate transporter 1 inhibitors.
    European journal of medicinal chemistry, 2022, Dec-15, Volume: 244

    Topics: Animals; Gout; Humans; Hyperuricemia; Mice; Organic Anion Transporters; Organic Cation Transport Pro

2022
Polygenic risk score trend and new variants on chromosome 1 are associated with male gout in genome-wide association study.
    Arthritis research & therapy, 2022, 10-11, Volume: 24, Issue:1

    Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Chromosomes, Human, Pair 1; Female; Genetic

2022
Letter to the editor regarding "urate-lowering therapy for patients with gout on hemodialysis".
    International journal of rheumatic diseases, 2023, Volume: 26, Issue:1

    Topics: Gout; Gout Suppressants; Humans; Renal Dialysis; Uric Acid

2023
Predictors of Patient and Physician Assessments of Gout Control.
    Arthritis care & research, 2023, Volume: 75, Issue:6

    Topics: Allopurinol; Gout; Gout Suppressants; Humans; Symptom Flare Up; Uric Acid

2023
The Role of Ultrasound in Evaluating the Effect of Urate-lowering Drugs in Gout Patients.
    Current rheumatology reviews, 2022, Volume: 18, Issue:4

    Topics: Gout; Humans; Metatarsophalangeal Joint; Synovial Fluid; Ultrasonography; Uric Acid

2022
Prevalence of motor neuron diseases in gout patients: a nationwide population-based cohort study.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2023, Volume: 44, Issue:2

    Topics: Cohort Studies; Female; Gout; Humans; Motor Neuron Disease; Prevalence; Uric Acid

2023
The ultrasonographic pseudo-double contour sign in calcium pyrophosphate deposition disease: an anatomic explanation and how to distinguish it from gout.
    Arthritis & rheumatology (Hoboken, N.J.), 2023, Volume: 75, Issue:4

    Topics: Chondrocalcinosis; Gout; Humans; Ultrasonography; Uric Acid

2023
[Advantages of the use of metformin in patients with impaired uric acid metabolism].
    Terapevticheskii arkhiv, 2021, May-15, Volume: 93, Issue:5

    Topics: Anti-Inflammatory Agents; Diabetes Mellitus, Type 2; Gout; Humans; Hyperuricemia; Hypoglycemic Agent

2021
Gout in Dalarna, Sweden - a population-based study of gout occurrence and compliance to treatment guidelines.
    Scandinavian journal of rheumatology, 2023, Volume: 52, Issue:5

    Topics: Allopurinol; Gout; Gout Suppressants; Humans; Sweden; Treatment Outcome; Uric Acid

2023
Association between serum free fatty acid levels and tophus in patients with gout: a cross-sectional study.
    Clinical and experimental rheumatology, 2023, Volume: 41, Issue:3

    Topics: Cross-Sectional Studies; Fatty Acids, Nonesterified; Gout; Humans; Uric Acid

2023
Interplay between fat, muscle, bone mass, and oteophytes and risk for tophaceous gout.
    Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2023, Volume: 71, Issue:1

    Topics: Adipose Tissue; Aged; Bone Density; Case-Control Studies; Cross-Sectional Studies; Gout; Humans; Mal

2023
Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study.
    Clinical rheumatology, 2022, Volume: 41, Issue:12

    Topics: Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Prospective Studies; Surveys and Questio

2022
Cardiovascular risk of urate-lowering drugs: A study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan.
    Clinical and translational science, 2023, Volume: 16, Issue:2

    Topics: Allopurinol; Benzbromarone; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Heart Dise

2023
A retrospective observational study of the appropriate starting dose of febuxostat in patients with gout.
    The Korean journal of internal medicine, 2023, Volume: 38, Issue:3

    Topics: Adult; Aged; Allopurinol; Arthritis, Gouty; Febuxostat; Female; Gout; Gout Suppressants; Humans; Mal

2023
Orthopaedic Management of Gout.
    Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews, 2022, 11-01, Volume: 6, Issue:11

    Topics: Cartilage; Gout; Humans; Knee Joint; Orthopedics; Uric Acid

2022
Treat-to-target urate-lowering therapy and hospitalizations for gout: results from a nationwide cohort study in England.
    Rheumatology (Oxford, England), 2023, 07-05, Volume: 62, Issue:7

    Topics: Cohort Studies; Colchicine; England; Gout; Gout Suppressants; Hospitalization; Humans; Uric Acid

2023
Prevalence, Risk Factors, and Outcomes of Gout Flare in Patients Hospitalized for PCR-Confirmed COVID-19: A Multicenter Retrospective Cohort Study.
    The Journal of rheumatology, 2023, Volume: 50, Issue:4

    Topics: Adult; COVID-19; COVID-19 Testing; Gout; Gout Suppressants; Humans; Polymerase Chain Reaction; Preva

2023
Prevalence, Risk Factors, and Outcomes of Gout Flare in Patients Hospitalized for PCR-Confirmed COVID-19: A Multicenter Retrospective Cohort Study.
    The Journal of rheumatology, 2023, Volume: 50, Issue:4

    Topics: Adult; COVID-19; COVID-19 Testing; Gout; Gout Suppressants; Humans; Polymerase Chain Reaction; Preva

2023
Prevalence, Risk Factors, and Outcomes of Gout Flare in Patients Hospitalized for PCR-Confirmed COVID-19: A Multicenter Retrospective Cohort Study.
    The Journal of rheumatology, 2023, Volume: 50, Issue:4

    Topics: Adult; COVID-19; COVID-19 Testing; Gout; Gout Suppressants; Humans; Polymerase Chain Reaction; Preva

2023
Prevalence, Risk Factors, and Outcomes of Gout Flare in Patients Hospitalized for PCR-Confirmed COVID-19: A Multicenter Retrospective Cohort Study.
    The Journal of rheumatology, 2023, Volume: 50, Issue:4

    Topics: Adult; COVID-19; COVID-19 Testing; Gout; Gout Suppressants; Humans; Polymerase Chain Reaction; Preva

2023
Prevalence, Risk Factors, and Outcomes of Gout Flare in Patients Hospitalized for PCR-Confirmed COVID-19: A Multicenter Retrospective Cohort Study.
    The Journal of rheumatology, 2023, Volume: 50, Issue:4

    Topics: Adult; COVID-19; COVID-19 Testing; Gout; Gout Suppressants; Humans; Polymerase Chain Reaction; Preva

2023
Prevalence, Risk Factors, and Outcomes of Gout Flare in Patients Hospitalized for PCR-Confirmed COVID-19: A Multicenter Retrospective Cohort Study.
    The Journal of rheumatology, 2023, Volume: 50, Issue:4

    Topics: Adult; COVID-19; COVID-19 Testing; Gout; Gout Suppressants; Humans; Polymerase Chain Reaction; Preva

2023
Prevalence, Risk Factors, and Outcomes of Gout Flare in Patients Hospitalized for PCR-Confirmed COVID-19: A Multicenter Retrospective Cohort Study.
    The Journal of rheumatology, 2023, Volume: 50, Issue:4

    Topics: Adult; COVID-19; COVID-19 Testing; Gout; Gout Suppressants; Humans; Polymerase Chain Reaction; Preva

2023
Prevalence, Risk Factors, and Outcomes of Gout Flare in Patients Hospitalized for PCR-Confirmed COVID-19: A Multicenter Retrospective Cohort Study.
    The Journal of rheumatology, 2023, Volume: 50, Issue:4

    Topics: Adult; COVID-19; COVID-19 Testing; Gout; Gout Suppressants; Humans; Polymerase Chain Reaction; Preva

2023
Prevalence, Risk Factors, and Outcomes of Gout Flare in Patients Hospitalized for PCR-Confirmed COVID-19: A Multicenter Retrospective Cohort Study.
    The Journal of rheumatology, 2023, Volume: 50, Issue:4

    Topics: Adult; COVID-19; COVID-19 Testing; Gout; Gout Suppressants; Humans; Polymerase Chain Reaction; Preva

2023
The impact of genetic variability in urate transporters on oxypurinol pharmacokinetics.
    Clinical and translational science, 2023, Volume: 16, Issue:3

    Topics: Allopurinol; Glucose Transport Proteins, Facilitative; Gout; Humans; Organic Anion Transporters; Org

2023
The impact of genetic variability in urate transporters on oxypurinol pharmacokinetics.
    Clinical and translational science, 2023, Volume: 16, Issue:3

    Topics: Allopurinol; Glucose Transport Proteins, Facilitative; Gout; Humans; Organic Anion Transporters; Org

2023
The impact of genetic variability in urate transporters on oxypurinol pharmacokinetics.
    Clinical and translational science, 2023, Volume: 16, Issue:3

    Topics: Allopurinol; Glucose Transport Proteins, Facilitative; Gout; Humans; Organic Anion Transporters; Org

2023
The impact of genetic variability in urate transporters on oxypurinol pharmacokinetics.
    Clinical and translational science, 2023, Volume: 16, Issue:3

    Topics: Allopurinol; Glucose Transport Proteins, Facilitative; Gout; Humans; Organic Anion Transporters; Org

2023
The impact of genetic variability in urate transporters on oxypurinol pharmacokinetics.
    Clinical and translational science, 2023, Volume: 16, Issue:3

    Topics: Allopurinol; Glucose Transport Proteins, Facilitative; Gout; Humans; Organic Anion Transporters; Org

2023
The impact of genetic variability in urate transporters on oxypurinol pharmacokinetics.
    Clinical and translational science, 2023, Volume: 16, Issue:3

    Topics: Allopurinol; Glucose Transport Proteins, Facilitative; Gout; Humans; Organic Anion Transporters; Org

2023
The impact of genetic variability in urate transporters on oxypurinol pharmacokinetics.
    Clinical and translational science, 2023, Volume: 16, Issue:3

    Topics: Allopurinol; Glucose Transport Proteins, Facilitative; Gout; Humans; Organic Anion Transporters; Org

2023
The impact of genetic variability in urate transporters on oxypurinol pharmacokinetics.
    Clinical and translational science, 2023, Volume: 16, Issue:3

    Topics: Allopurinol; Glucose Transport Proteins, Facilitative; Gout; Humans; Organic Anion Transporters; Org

2023
The impact of genetic variability in urate transporters on oxypurinol pharmacokinetics.
    Clinical and translational science, 2023, Volume: 16, Issue:3

    Topics: Allopurinol; Glucose Transport Proteins, Facilitative; Gout; Humans; Organic Anion Transporters; Org

2023
Elevated serum CA72-4 predicts gout flares during urate lowering therapy initiation: a prospective cohort study.
    Rheumatology (Oxford, England), 2023, 07-05, Volume: 62, Issue:7

    Topics: Gout; Gout Suppressants; Humans; Male; Prospective Studies; Symptom Flare Up; Uric Acid

2023
Elevated serum CA72-4 predicts gout flares during urate lowering therapy initiation: a prospective cohort study.
    Rheumatology (Oxford, England), 2023, 07-05, Volume: 62, Issue:7

    Topics: Gout; Gout Suppressants; Humans; Male; Prospective Studies; Symptom Flare Up; Uric Acid

2023
Elevated serum CA72-4 predicts gout flares during urate lowering therapy initiation: a prospective cohort study.
    Rheumatology (Oxford, England), 2023, 07-05, Volume: 62, Issue:7

    Topics: Gout; Gout Suppressants; Humans; Male; Prospective Studies; Symptom Flare Up; Uric Acid

2023
Elevated serum CA72-4 predicts gout flares during urate lowering therapy initiation: a prospective cohort study.
    Rheumatology (Oxford, England), 2023, 07-05, Volume: 62, Issue:7

    Topics: Gout; Gout Suppressants; Humans; Male; Prospective Studies; Symptom Flare Up; Uric Acid

2023
Elevated serum CA72-4 predicts gout flares during urate lowering therapy initiation: a prospective cohort study.
    Rheumatology (Oxford, England), 2023, 07-05, Volume: 62, Issue:7

    Topics: Gout; Gout Suppressants; Humans; Male; Prospective Studies; Symptom Flare Up; Uric Acid

2023
Elevated serum CA72-4 predicts gout flares during urate lowering therapy initiation: a prospective cohort study.
    Rheumatology (Oxford, England), 2023, 07-05, Volume: 62, Issue:7

    Topics: Gout; Gout Suppressants; Humans; Male; Prospective Studies; Symptom Flare Up; Uric Acid

2023
Elevated serum CA72-4 predicts gout flares during urate lowering therapy initiation: a prospective cohort study.
    Rheumatology (Oxford, England), 2023, 07-05, Volume: 62, Issue:7

    Topics: Gout; Gout Suppressants; Humans; Male; Prospective Studies; Symptom Flare Up; Uric Acid

2023
Elevated serum CA72-4 predicts gout flares during urate lowering therapy initiation: a prospective cohort study.
    Rheumatology (Oxford, England), 2023, 07-05, Volume: 62, Issue:7

    Topics: Gout; Gout Suppressants; Humans; Male; Prospective Studies; Symptom Flare Up; Uric Acid

2023
Elevated serum CA72-4 predicts gout flares during urate lowering therapy initiation: a prospective cohort study.
    Rheumatology (Oxford, England), 2023, 07-05, Volume: 62, Issue:7

    Topics: Gout; Gout Suppressants; Humans; Male; Prospective Studies; Symptom Flare Up; Uric Acid

2023
Characterization of Urate Metabolism and Complications of Patients with Renal Hypouricemia.
    Internal medicine (Tokyo, Japan), 2023, Jul-01, Volume: 62, Issue:13

    Topics: beta 2-Microglobulin; Female; Gout; Humans; Male; Uric Acid; Urinary Calculi

2023
Characterization of Urate Metabolism and Complications of Patients with Renal Hypouricemia.
    Internal medicine (Tokyo, Japan), 2023, Jul-01, Volume: 62, Issue:13

    Topics: beta 2-Microglobulin; Female; Gout; Humans; Male; Uric Acid; Urinary Calculi

2023
Characterization of Urate Metabolism and Complications of Patients with Renal Hypouricemia.
    Internal medicine (Tokyo, Japan), 2023, Jul-01, Volume: 62, Issue:13

    Topics: beta 2-Microglobulin; Female; Gout; Humans; Male; Uric Acid; Urinary Calculi

2023
Characterization of Urate Metabolism and Complications of Patients with Renal Hypouricemia.
    Internal medicine (Tokyo, Japan), 2023, Jul-01, Volume: 62, Issue:13

    Topics: beta 2-Microglobulin; Female; Gout; Humans; Male; Uric Acid; Urinary Calculi

2023
Characterization of Urate Metabolism and Complications of Patients with Renal Hypouricemia.
    Internal medicine (Tokyo, Japan), 2023, Jul-01, Volume: 62, Issue:13

    Topics: beta 2-Microglobulin; Female; Gout; Humans; Male; Uric Acid; Urinary Calculi

2023
Characterization of Urate Metabolism and Complications of Patients with Renal Hypouricemia.
    Internal medicine (Tokyo, Japan), 2023, Jul-01, Volume: 62, Issue:13

    Topics: beta 2-Microglobulin; Female; Gout; Humans; Male; Uric Acid; Urinary Calculi

2023
Characterization of Urate Metabolism and Complications of Patients with Renal Hypouricemia.
    Internal medicine (Tokyo, Japan), 2023, Jul-01, Volume: 62, Issue:13

    Topics: beta 2-Microglobulin; Female; Gout; Humans; Male; Uric Acid; Urinary Calculi

2023
Characterization of Urate Metabolism and Complications of Patients with Renal Hypouricemia.
    Internal medicine (Tokyo, Japan), 2023, Jul-01, Volume: 62, Issue:13

    Topics: beta 2-Microglobulin; Female; Gout; Humans; Male; Uric Acid; Urinary Calculi

2023
Characterization of Urate Metabolism and Complications of Patients with Renal Hypouricemia.
    Internal medicine (Tokyo, Japan), 2023, Jul-01, Volume: 62, Issue:13

    Topics: beta 2-Microglobulin; Female; Gout; Humans; Male; Uric Acid; Urinary Calculi

2023
Characteristic alterations of gut microbiota in uncontrolled gout.
    Journal of microbiology (Seoul, Korea), 2022, Volume: 60, Issue:12

    Topics: Bacteria; Feces; Gastrointestinal Microbiome; Gout; Humans; RNA, Ribosomal, 16S; Uric Acid

2022
Characteristic alterations of gut microbiota in uncontrolled gout.
    Journal of microbiology (Seoul, Korea), 2022, Volume: 60, Issue:12

    Topics: Bacteria; Feces; Gastrointestinal Microbiome; Gout; Humans; RNA, Ribosomal, 16S; Uric Acid

2022
Characteristic alterations of gut microbiota in uncontrolled gout.
    Journal of microbiology (Seoul, Korea), 2022, Volume: 60, Issue:12

    Topics: Bacteria; Feces; Gastrointestinal Microbiome; Gout; Humans; RNA, Ribosomal, 16S; Uric Acid

2022
Characteristic alterations of gut microbiota in uncontrolled gout.
    Journal of microbiology (Seoul, Korea), 2022, Volume: 60, Issue:12

    Topics: Bacteria; Feces; Gastrointestinal Microbiome; Gout; Humans; RNA, Ribosomal, 16S; Uric Acid

2022
Characteristic alterations of gut microbiota in uncontrolled gout.
    Journal of microbiology (Seoul, Korea), 2022, Volume: 60, Issue:12

    Topics: Bacteria; Feces; Gastrointestinal Microbiome; Gout; Humans; RNA, Ribosomal, 16S; Uric Acid

2022
Characteristic alterations of gut microbiota in uncontrolled gout.
    Journal of microbiology (Seoul, Korea), 2022, Volume: 60, Issue:12

    Topics: Bacteria; Feces; Gastrointestinal Microbiome; Gout; Humans; RNA, Ribosomal, 16S; Uric Acid

2022
Characteristic alterations of gut microbiota in uncontrolled gout.
    Journal of microbiology (Seoul, Korea), 2022, Volume: 60, Issue:12

    Topics: Bacteria; Feces; Gastrointestinal Microbiome; Gout; Humans; RNA, Ribosomal, 16S; Uric Acid

2022
Characteristic alterations of gut microbiota in uncontrolled gout.
    Journal of microbiology (Seoul, Korea), 2022, Volume: 60, Issue:12

    Topics: Bacteria; Feces; Gastrointestinal Microbiome; Gout; Humans; RNA, Ribosomal, 16S; Uric Acid

2022
Characteristic alterations of gut microbiota in uncontrolled gout.
    Journal of microbiology (Seoul, Korea), 2022, Volume: 60, Issue:12

    Topics: Bacteria; Feces; Gastrointestinal Microbiome; Gout; Humans; RNA, Ribosomal, 16S; Uric Acid

2022
Increase in different peripheral effector T subsets in acute and chronic gout.
    Transplant immunology, 2023, Volume: 76

    Topics: Gout; Humans; T-Lymphocytes, Regulatory; Th1 Cells; Th17 Cells; Th2 Cells; Uric Acid

2023
Increase in different peripheral effector T subsets in acute and chronic gout.
    Transplant immunology, 2023, Volume: 76

    Topics: Gout; Humans; T-Lymphocytes, Regulatory; Th1 Cells; Th17 Cells; Th2 Cells; Uric Acid

2023
Increase in different peripheral effector T subsets in acute and chronic gout.
    Transplant immunology, 2023, Volume: 76

    Topics: Gout; Humans; T-Lymphocytes, Regulatory; Th1 Cells; Th17 Cells; Th2 Cells; Uric Acid

2023
Increase in different peripheral effector T subsets in acute and chronic gout.
    Transplant immunology, 2023, Volume: 76

    Topics: Gout; Humans; T-Lymphocytes, Regulatory; Th1 Cells; Th17 Cells; Th2 Cells; Uric Acid

2023
Increase in different peripheral effector T subsets in acute and chronic gout.
    Transplant immunology, 2023, Volume: 76

    Topics: Gout; Humans; T-Lymphocytes, Regulatory; Th1 Cells; Th17 Cells; Th2 Cells; Uric Acid

2023
Increase in different peripheral effector T subsets in acute and chronic gout.
    Transplant immunology, 2023, Volume: 76

    Topics: Gout; Humans; T-Lymphocytes, Regulatory; Th1 Cells; Th17 Cells; Th2 Cells; Uric Acid

2023
Increase in different peripheral effector T subsets in acute and chronic gout.
    Transplant immunology, 2023, Volume: 76

    Topics: Gout; Humans; T-Lymphocytes, Regulatory; Th1 Cells; Th17 Cells; Th2 Cells; Uric Acid

2023
Increase in different peripheral effector T subsets in acute and chronic gout.
    Transplant immunology, 2023, Volume: 76

    Topics: Gout; Humans; T-Lymphocytes, Regulatory; Th1 Cells; Th17 Cells; Th2 Cells; Uric Acid

2023
Increase in different peripheral effector T subsets in acute and chronic gout.
    Transplant immunology, 2023, Volume: 76

    Topics: Gout; Humans; T-Lymphocytes, Regulatory; Th1 Cells; Th17 Cells; Th2 Cells; Uric Acid

2023
Amplification of Inflammation by Lubricin Deficiency Implicated in Incident, Erosive Gout Independent of Hyperuricemia.
    Arthritis & rheumatology (Hoboken, N.J.), 2023, Volume: 75, Issue:5

    Topics: Animals; Arthritis, Gouty; Cathepsin G; Female; Gout; Humans; Hyperuricemia; Inflammation; Interleuk

2023
Amplification of Inflammation by Lubricin Deficiency Implicated in Incident, Erosive Gout Independent of Hyperuricemia.
    Arthritis & rheumatology (Hoboken, N.J.), 2023, Volume: 75, Issue:5

    Topics: Animals; Arthritis, Gouty; Cathepsin G; Female; Gout; Humans; Hyperuricemia; Inflammation; Interleuk

2023
Amplification of Inflammation by Lubricin Deficiency Implicated in Incident, Erosive Gout Independent of Hyperuricemia.
    Arthritis & rheumatology (Hoboken, N.J.), 2023, Volume: 75, Issue:5

    Topics: Animals; Arthritis, Gouty; Cathepsin G; Female; Gout; Humans; Hyperuricemia; Inflammation; Interleuk

2023
Amplification of Inflammation by Lubricin Deficiency Implicated in Incident, Erosive Gout Independent of Hyperuricemia.
    Arthritis & rheumatology (Hoboken, N.J.), 2023, Volume: 75, Issue:5

    Topics: Animals; Arthritis, Gouty; Cathepsin G; Female; Gout; Humans; Hyperuricemia; Inflammation; Interleuk

2023
HQL6 serves as a novel P2Y
    International immunopharmacology, 2023, Volume: 114

    Topics: Animals; Arthritis, Gouty; Gout; Macrophages; Pyroptosis; Rats; Uric Acid

2023
HQL6 serves as a novel P2Y
    International immunopharmacology, 2023, Volume: 114

    Topics: Animals; Arthritis, Gouty; Gout; Macrophages; Pyroptosis; Rats; Uric Acid

2023
HQL6 serves as a novel P2Y
    International immunopharmacology, 2023, Volume: 114

    Topics: Animals; Arthritis, Gouty; Gout; Macrophages; Pyroptosis; Rats; Uric Acid

2023
HQL6 serves as a novel P2Y
    International immunopharmacology, 2023, Volume: 114

    Topics: Animals; Arthritis, Gouty; Gout; Macrophages; Pyroptosis; Rats; Uric Acid

2023
An interesting tophus in gingiva.
    International journal of rheumatic diseases, 2023, Volume: 26, Issue:2

    Topics: Arthritis, Gouty; Gingiva; Gout; Humans; Uric Acid

2023
An interesting tophus in gingiva.
    International journal of rheumatic diseases, 2023, Volume: 26, Issue:2

    Topics: Arthritis, Gouty; Gingiva; Gout; Humans; Uric Acid

2023
An interesting tophus in gingiva.
    International journal of rheumatic diseases, 2023, Volume: 26, Issue:2

    Topics: Arthritis, Gouty; Gingiva; Gout; Humans; Uric Acid

2023
An interesting tophus in gingiva.
    International journal of rheumatic diseases, 2023, Volume: 26, Issue:2

    Topics: Arthritis, Gouty; Gingiva; Gout; Humans; Uric Acid

2023
The Therapeutic Effect of Phosphopeptide P140 Attenuates Inflammation Induced by Uric Acid Crystals in Gout Arthritis Mouse Model.
    Cells, 2022, Nov-22, Volume: 11, Issue:23

    Topics: Animals; Arthritis, Gouty; Disease Models, Animal; Gout; Humans; Inflammation; Mice; Neutrophils; Ph

2022
The Therapeutic Effect of Phosphopeptide P140 Attenuates Inflammation Induced by Uric Acid Crystals in Gout Arthritis Mouse Model.
    Cells, 2022, Nov-22, Volume: 11, Issue:23

    Topics: Animals; Arthritis, Gouty; Disease Models, Animal; Gout; Humans; Inflammation; Mice; Neutrophils; Ph

2022
The Therapeutic Effect of Phosphopeptide P140 Attenuates Inflammation Induced by Uric Acid Crystals in Gout Arthritis Mouse Model.
    Cells, 2022, Nov-22, Volume: 11, Issue:23

    Topics: Animals; Arthritis, Gouty; Disease Models, Animal; Gout; Humans; Inflammation; Mice; Neutrophils; Ph

2022
The Therapeutic Effect of Phosphopeptide P140 Attenuates Inflammation Induced by Uric Acid Crystals in Gout Arthritis Mouse Model.
    Cells, 2022, Nov-22, Volume: 11, Issue:23

    Topics: Animals; Arthritis, Gouty; Disease Models, Animal; Gout; Humans; Inflammation; Mice; Neutrophils; Ph

2022
Plasma adsorption in refractory chronic gouty arthritis flare: A case report.
    Frontiers in immunology, 2022, Volume: 13

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Cytokines; Gout; Humans; Infl

2022
Plasma adsorption in refractory chronic gouty arthritis flare: A case report.
    Frontiers in immunology, 2022, Volume: 13

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Cytokines; Gout; Humans; Infl

2022
Plasma adsorption in refractory chronic gouty arthritis flare: A case report.
    Frontiers in immunology, 2022, Volume: 13

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Cytokines; Gout; Humans; Infl

2022
Plasma adsorption in refractory chronic gouty arthritis flare: A case report.
    Frontiers in immunology, 2022, Volume: 13

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Cytokines; Gout; Humans; Infl

2022
Chalcone derivatives as xanthine oxidase inhibitors: synthesis, binding mode investigation, biological evaluation, and ADMET prediction.
    Bioorganic chemistry, 2023, Volume: 131

    Topics: Animals; Chalcone; Chalcones; Enzyme Inhibitors; Gout; Hyperuricemia; Rats; Structure-Activity Relat

2023
Chalcone derivatives as xanthine oxidase inhibitors: synthesis, binding mode investigation, biological evaluation, and ADMET prediction.
    Bioorganic chemistry, 2023, Volume: 131

    Topics: Animals; Chalcone; Chalcones; Enzyme Inhibitors; Gout; Hyperuricemia; Rats; Structure-Activity Relat

2023
Chalcone derivatives as xanthine oxidase inhibitors: synthesis, binding mode investigation, biological evaluation, and ADMET prediction.
    Bioorganic chemistry, 2023, Volume: 131

    Topics: Animals; Chalcone; Chalcones; Enzyme Inhibitors; Gout; Hyperuricemia; Rats; Structure-Activity Relat

2023
Chalcone derivatives as xanthine oxidase inhibitors: synthesis, binding mode investigation, biological evaluation, and ADMET prediction.
    Bioorganic chemistry, 2023, Volume: 131

    Topics: Animals; Chalcone; Chalcones; Enzyme Inhibitors; Gout; Hyperuricemia; Rats; Structure-Activity Relat

2023
Associations of metal exposure with hyperuricemia and gout in general adults.
    Frontiers in endocrinology, 2022, Volume: 13

    Topics: Cross-Sectional Studies; Gout; Humans; Hyperuricemia; Mercury; Nutrition Surveys; Selenium; Uric Aci

2022
Response to "Urate lowering therapy for patients with gout on hemodialysis".
    International journal of rheumatic diseases, 2023, Volume: 26, Issue:3

    Topics: Gout; Gout Suppressants; Humans; Renal Dialysis; Uric Acid

2023
Uricase-Deficient Larval Zebrafish with Elevated Urate Levels Demonstrate Suppressed Acute Inflammatory Response to Monosodium Urate Crystals and Prolonged Crystal Persistence.
    Genes, 2022, 11-22, Volume: 13, Issue:12

    Topics: Animals; Gout; Humans; Inflammation; Urate Oxidase; Uric Acid; Zebrafish

2022
Assessing tophaceous spinal gout treatment response using dual-energy CT as a point-of-care imaging modality: case report.
    Skeletal radiology, 2023, Volume: 52, Issue:8

    Topics: Aged; Febuxostat; Gout; Humans; Male; Point-of-Care Systems; Tomography, X-Ray Computed; Uric Acid

2023
Neutrophil extracellular traps induce the bone erosion of gout.
    BMC musculoskeletal disorders, 2022, Dec-26, Volume: 23, Issue:1

    Topics: Animals; Extracellular Traps; Gout; Sodium; Uric Acid

2022
Overnutrition-induced gout: An immune response to NLRP3 inflammasome dysregulation by XOD activity increased in quail.
    Frontiers in immunology, 2022, Volume: 13

    Topics: Animals; Arthritis, Gouty; Enzyme Inhibitors; Gout; Hyperuricemia; Immunity; Inflammasomes; NLR Fami

2022
Lipoxin A4 attenuates MSU-crystal-induced NLRP3 inflammasome activation through suppressing Nrf2 thereby increasing TXNRD2.
    Frontiers in immunology, 2022, Volume: 13

    Topics: Animals; Gout; Inflammasomes; Inflammation; Macrophages; NF-E2-Related Factor 2; NLR Family, Pyrin D

2022
Improved joint and patient-reported health assessments with pegloticase plus methotrexate co-therapy in patients with uncontrolled gout: 12-month exploratory outcomes of the MIRROR open-label trial.
    Arthritis research & therapy, 2022, 12-27, Volume: 24, Issue:1

    Topics: Adult; Gout; Gout Suppressants; Humans; Methotrexate; Polyethylene Glycols; Quality of Life; Treatme

2022
Neutrophil Extracellular Trap-Borne Elastase Prevents Inflammatory Relapse in Intercritical Gout.
    Arthritis & rheumatology (Hoboken, N.J.), 2023, Volume: 75, Issue:6

    Topics: Animals; Chronic Disease; Extracellular Traps; Gout; Inflammation; Leukocyte Elastase; Mice; Uric Ac

2023
Rutin ameliorates gout via reducing XOD activity, inhibiting ROS production and NLRP3 inflammasome activation in quail.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023, Volume: 158

    Topics: Animals; Gout; Inflammasomes; Inflammation; NLR Family, Pyrin Domain-Containing 3 Protein; Quail; Re

2023
Associations between serum urate and telomere length and inflammation markers: Evidence from UK Biobank cohort.
    Frontiers in immunology, 2022, Volume: 13

    Topics: Biological Specimen Banks; Biomarkers; Genome-Wide Association Study; Gout; Humans; Hyperuricemia; I

2022
[Clinical and ultrasonic characteristics of male gout patients with normal serum uric acid].
    Zhonghua yi xue za zhi, 2023, Jan-07, Volume: 103, Issue:1

    Topics: Gout; Gout Suppressants; Humans; Male; Retrospective Studies; Ultrasonics; Uric Acid

2023
Changes in Tophus Composition During Urate-Lowering Therapy: A Dual-Energy Computed Tomography Study.
    Arthritis care & research, 2023, Volume: 75, Issue:9

    Topics: Allopurinol; Gout; Gout Suppressants; Humans; Tomography, X-Ray Computed; Uric Acid

2023
Gout Flare and Cardiovascular Events-Reply.
    JAMA, 2023, 01-03, Volume: 329, Issue:1

    Topics: Cardiovascular Diseases; Gout; Gout Suppressants; Humans; Symptom Flare Up; Uric Acid

2023
Gout Flare and Cardiovascular Events.
    JAMA, 2023, 01-03, Volume: 329, Issue:1

    Topics: Cardiovascular Diseases; Gout; Gout Suppressants; Humans; Symptom Flare Up; Uric Acid

2023
Optimizing adherence to allopurinol for gout: patients' perspectives.
    British journal of clinical pharmacology, 2023, Volume: 89, Issue:7

    Topics: Allopurinol; Gout; Gout Suppressants; Humans; Medication Adherence; Uric Acid

2023
Cutting Edge: Negative Regulation of Inflammasome Activation by TRAF1 Can Limit Gout.
    Journal of immunology (Baltimore, Md. : 1950), 2023, 03-01, Volume: 210, Issue:5

    Topics: Adaptor Proteins, Signal Transducing; Animals; Cytokines; Gout; Humans; Inflammasomes; Interleukin-1

2023
Evaluation of ABCG2-mediated extra-renal urate excretion in hemodialysis patients.
    Scientific reports, 2023, 01-13, Volume: 13, Issue:1

    Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Gout; Humans; Hyperuricemia; Kidney; Neopla

2023
Nutrition Interventions for the Management of Gout.
    Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation, 2023, Volume: 33, Issue:2

    Topics: Gout; Humans; Uric Acid

2023
Global status and trends in gout research from 2012 to 2021: a bibliometric and visual analysis.
    Clinical rheumatology, 2023, Volume: 42, Issue:5

    Topics: Bibliometrics; Gout; Humans; Inflammasomes; NLR Family, Pyrin Domain-Containing 3 Protein; Uric Acid

2023
The risk of nonalcoholic fatty liver disease in gout patients with frequent flares: a retrospective cohort study.
    Clinical rheumatology, 2023, Volume: 42, Issue:5

    Topics: Gout; Humans; Non-alcoholic Fatty Liver Disease; Retrospective Studies; Risk Factors; Uric Acid

2023
Acute gout attacks during the perioperative period and risk factors of recurrence after orthopedic surgery among untreated gout patients.
    Journal of orthopaedic surgery and research, 2023, Jan-23, Volume: 18, Issue:1

    Topics: Arthritis, Gouty; Gout; Humans; Hyperuricemia; Orthopedic Procedures; Perioperative Period; Retrospe

2023
P2X7R Mediates the Synergistic Effect of ATP and MSU Crystals to Induce Acute Gouty Arthritis.
    Oxidative medicine and cellular longevity, 2023, Volume: 2023

    Topics: Adenosine Triphosphate; Animals; Arthritis, Gouty; Gout; Inflammasomes; Leukocytes, Mononuclear; NLR

2023
Gout of feet and ankles in different stages: The potentiality of a new semiquantitative DECT scoring system in monitoring urate deposition.
    Medicine, 2023, Jan-20, Volume: 102, Issue:3

    Topics: Ankle; Arthritis, Gouty; Foot; Gout; Humans; Uric Acid

2023
Single-Cell Analysis in Blood Reveals Distinct Immune Cell Profiles in Gouty Arthritis.
    Journal of immunology (Baltimore, Md. : 1950), 2023, 03-15, Volume: 210, Issue:6

    Topics: Arthritis, Gouty; Gout; Humans; Monocytes; Single-Cell Analysis; Uric Acid

2023
Inactivation of mitochondrial pyruvate carrier promotes NLRP3 inflammasome activation and gout development via metabolic reprogramming.
    Immunology, 2023, Volume: 169, Issue:3

    Topics: Animals; Diabetes Mellitus, Experimental; Gout; Hereditary Autoinflammatory Diseases; Inflammasomes;

2023
Musculoskeletal Ultrasound in Monitoring the Efficacy of Gout: A Prospective Study Based on Tophus and Double Contour Sign
    Balkan medical journal, 2023, 03-08, Volume: 40, Issue:2

    Topics: Gout; Humans; Prospective Studies; Ultrasonography; Uric Acid

2023
Using human genetics to understand the epidemiological association between obesity, serum urate, and gout.
    Rheumatology (Oxford, England), 2023, 10-03, Volume: 62, Issue:10

    Topics: Genome-Wide Association Study; Gout; Human Genetics; Humans; Obesity; Polymorphism, Single Nucleotid

2023
Dimethyl fumarate attenuates MSU-induced gouty arthritis by inhibiting NLRP3 inflammasome activation and oxidative stress.
    European review for medical and pharmacological sciences, 2023, Volume: 27, Issue:2

    Topics: Animals; Arthritis, Gouty; Caspases; Cytokines; Dimethyl Fumarate; Gout; Inflammasomes; Lipopolysacc

2023
The risk of ischemic cerebrovascular disease associated with benzbromarone use in gout people: A retrospective cohort study in Taiwan.
    Medicine, 2023, Feb-03, Volume: 102, Issue:5

    Topics: Benzbromarone; Cerebrovascular Disorders; Gout; Gout Suppressants; Humans; Retrospective Studies; Ta

2023
A metabonomic study to explore potential markers of asymptomatic hyperuricemia and acute gouty arthritis.
    Journal of orthopaedic surgery and research, 2023, Feb-13, Volume: 18, Issue:1

    Topics: Arthritis, Gouty; Biomarkers; Gout; Humans; Hyperuricemia; Metabolomics; Uric Acid

2023
Association between serum uric acid levels of patients with gout and their complications and examination fees: A cross-sectional analysis.
    International journal of rheumatic diseases, 2023, Volume: 26, Issue:4

    Topics: Cardiovascular Diseases; Cross-Sectional Studies; Female; Gout; Humans; Hyperuricemia; Kidney Diseas

2023
Scleroderma-like Disease Due to Diffuse Monosodium Urate Crystal Deposition.
    The Journal of rheumatology, 2023, Volume: 50, Issue:8

    Topics: Gout; Humans; Inflammation; Uric Acid

2023
Diallyl trisulfide inhibits monosodium urate-induced NLRP3 inflammasome activation via NOX3/4-dependent mitochondrial oxidative stress in RAW 264.7 and bone marrow-derived macrophages.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2023, Volume: 112

    Topics: Gout; Humans; Inflammasomes; Inflammation; Interleukin-1beta; Macrophages; NLR Family, Pyrin Domain-

2023
Gender difference in the association between gout at diagnosis and metabolic syndrome in African population: a retrospective cohort study.
    The Pan African medical journal, 2022, Volume: 43

    Topics: Aged; Cameroon; Female; Gout; Humans; Hypertension; Male; Metabolic Syndrome; Middle Aged; Obesity;

2022
TGF-β is elevated in hyperuricemic individuals and mediates urate-induced hyperinflammatory phenotype in human mononuclear cells.
    Arthritis research & therapy, 2023, 02-27, Volume: 25, Issue:1

    Topics: Gout; Humans; Hyperuricemia; Leukocytes; Leukocytes, Mononuclear; Transforming Growth Factor beta; U

2023
Risk Factors for Hyperuricemia or Gout in Men and Women: The Circulatory Risk in Communities Study (CIRCS).
    Journal of atherosclerosis and thrombosis, 2023, Oct-01, Volume: 30, Issue:10

    Topics: Diabetes Mellitus; Female; Gout; Humans; Hypercholesterolemia; Hypertension; Hypertriglyceridemia; H

2023
Pattern of gout and its association with chronic kidney disease in Maiduguri, northeastern Nigeria.
    Clinical rheumatology, 2023, Volume: 42, Issue:7

    Topics: Creatinine; Female; Glomerular Filtration Rate; Gout; Humans; Male; Nigeria; Renal Insufficiency, Ch

2023
Superiority of low-dose benzbromarone to low-dose febuxostat in gout patients with renal uric acid underexcretion: comment on the article by Yan et al.
    Arthritis & rheumatology (Hoboken, N.J.), 2023, Volume: 75, Issue:9

    Topics: Allopurinol; Benzbromarone; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Ou

2023
Lowering Serum Urate With Urate-Lowering Therapy to Target and Incident Fracture Among People With Gout.
    Arthritis & rheumatology (Hoboken, N.J.), 2023, Volume: 75, Issue:8

    Topics: Adult; Gout; Gout Suppressants; Hip Fractures; Humans; Hyperuricemia; Uric Acid

2023
Course and predictors of work productivity in gout - results from the NOR-Gout longitudinal 2-year treat-to-target study.
    Rheumatology (Oxford, England), 2023, 12-01, Volume: 62, Issue:12

    Topics: Absenteeism; Efficiency; Female; Gout; Humans; Male; Middle Aged; Quality of Life; Surveys and Quest

2023
Relationship between rs4349859 and rs116488202 polymorphisms close to MHC-I region and serum urate levels in patients with gout.
    Molecular biology reports, 2023, Volume: 50, Issue:5

    Topics: Genetic Predisposition to Disease; Genotype; Gout; Heterozygote; Humans; Polymorphism, Single Nucleo

2023
Comparative Safety of Gout Treatment Strategies on Cardiovascular Outcomes Using Observational Data: Clone-censor-weight Target Trial Emulation Approach.
    Epidemiology (Cambridge, Mass.), 2023, 07-01, Volume: 34, Issue:4

    Topics: Aged; Cardiovascular Diseases; Gout; Humans; Male; Medicare; United States; Uric Acid

2023
Unusual Cause of Cord Compression in a Patient with Chronic Lymphocytic Leukemia.
    The American journal of case reports, 2023, Mar-23, Volume: 24

    Topics: Aged; Gout; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Spinal Cord Compression; Symptom F

2023
Uric acid is independently associated with interleukin-1β levels in tear fluid of hyperuricemia and gout patients.
    Immunity, inflammation and disease, 2023, Volume: 11, Issue:3

    Topics: Gout; Humans; Hyperuricemia; Interleukin-1beta; Tumor Necrosis Factor-alpha; Uric Acid

2023
Sex specific serum uric acid levels are associated with ischemic changes on ECG and with 20-year all-cause mortality among older adults.
    PloS one, 2023, Volume: 18, Issue:3

    Topics: Aged; Biomarkers; Electrocardiography; Female; Gout; Humans; Male; Prospective Studies; Risk Factors

2023
Towards the Development of Dual Hypouricemic and Anti-inflammatory Candidates: Design, Synthesis, Stability Studies and Biological Evaluation of Some Mutual Ester Prodrugs of Febuxostat-NSAIDs.
    Bioorganic chemistry, 2023, Volume: 135

    Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Esters; Febuxostat; G

2023
Intestinal uric acid excretion contributes to serum uric acid decrease during acute gout attack.
    Rheumatology (Oxford, England), 2023, 12-01, Volume: 62, Issue:12

    Topics: Animals; Arthritis, Gouty; ATP-Binding Cassette Transporters; Caco-2 Cells; Gout; Humans; Hyperurice

2023
Prediagnostic Glycoprotein Acetyl Levels and Incident and Recurrent Flare Risk Accounting for Serum Urate Levels: A Population-Based, Prospective Study and Mendelian Randomization Analysis.
    Arthritis & rheumatology (Hoboken, N.J.), 2023, Volume: 75, Issue:9

    Topics: Glycoproteins; Gout; Humans; Mendelian Randomization Analysis; Prospective Studies; Risk Factors; Ur

2023
Prevalence and clinical association of hyperechoic crystal deposits on ultrasonography in patients with chronic kidney disease: a cross-sectional study from a single center.
    Journal of nephrology, 2023, Volume: 36, Issue:9

    Topics: Cross-Sectional Studies; Female; Glomerular Filtration Rate; Gout; Humans; Hyperuricemia; Male; Prev

2023
Dissecting the causal effect between gut microbiota, DHA, and urate metabolism: A large-scale bidirectional Mendelian randomization.
    Frontiers in immunology, 2023, Volume: 14

    Topics: Docosahexaenoic Acids; Gastrointestinal Microbiome; Gout; Humans; Mendelian Randomization Analysis;

2023
Lowering serum urate level to a guideline-based target is associated with a lower risk of incident fracture in people with gout: comment on the article by Wei et al.
    Arthritis & rheumatology (Hoboken, N.J.), 2023, Volume: 75, Issue:10

    Topics: Fractures, Bone; Gout; Gout Suppressants; Humans; Risk; Treatment Outcome; Uric Acid

2023
    MMW Fortschritte der Medizin, 2023, Volume: 165, Issue:8

    Topics: Gout; Humans; Uric Acid

2023
Trends in Prevalence of Gout Among US Asian Adults, 2011-2018.
    JAMA network open, 2023, 04-03, Volume: 6, Issue:4

    Topics: Adult; Aged; Asian; Cross-Sectional Studies; Female; Gout; Health Status Disparities; Humans; Male;

2023
The risk of venous thromboembolism increases within one month of gout flare: comment on the article by Cipolletta et al.
    Arthritis & rheumatology (Hoboken, N.J.), 2023, Volume: 75, Issue:10

    Topics: Gout; Gout Suppressants; Humans; Symptom Flare Up; Uric Acid; Venous Thromboembolism

2023
Exploring the mechanism underlying hyperuricemia using comprehensive research on multi-omics.
    Scientific reports, 2023, 05-03, Volume: 13, Issue:1

    Topics: Animals; Caffeine; Gout; Humans; Hyperuricemia; Mice; Multiomics; Tandem Mass Spectrometry; Uric Aci

2023
Detailed analysis of the association between urate deposition and bone erosion in gout: a dual-energy computed tomography study.
    Frontiers in endocrinology, 2023, Volume: 14

    Topics: Gout; Humans; Tomography, X-Ray Computed; Uric Acid

2023
Anaerobic purinolytic enzymes enable dietary purine clearance by engineered gut bacteria.
    Cell chemical biology, 2023, 09-21, Volume: 30, Issue:9

    Topics: Anaerobiosis; Animals; Drosophila melanogaster; Escherichia coli; Gout; Humans; Hydrolases; Hyperuri

2023
Effect of Dietary Counseling on Patients with Asymptomatic Hyperuricemia.
    The journal of medical investigation : JMI, 2023, Volume: 70, Issue:1.2

    Topics: Female; Glomerular Filtration Rate; Gout; Humans; Hyperuricemia; Male; Obesity; Uric Acid

2023
Development of a novel anti-inflammatory recombinant uricase with extended half-life for gout therapy.
    Biochemical and biophysical research communications, 2023, 07-23, Volume: 666

    Topics: Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Gout; Half-Life; Inflammasomes; Mice; Urate Oxi

2023
Model Informed Development of SIM0295 in Patients with Gout and Hyperuricemia and Healthy Volunteers Using a Population Pharmacokinetics/ Pharmacodynamics Approach.
    Expert opinion on investigational drugs, 2023, Volume: 32, Issue:5

    Topics: Gout; Gout Suppressants; Healthy Volunteers; Humans; Hyperuricemia; Uric Acid

2023
A wild rice-derived peptide R14 ameliorates monosodium urate crystals-induced IL-1β secretion through inhibition of NF-κB signaling and NLRP3 inflammasome activation.
    PeerJ, 2023, Volume: 11

    Topics: Gout; Humans; Inflammasomes; Inflammation; NF-kappa B; NLR Family, Pyrin Domain-Containing 3 Protein

2023
Polydatin ameliorates inflammation and oxidative stress associated with MSU-induced gouty arthritis in mice by regulating PPAR-γ and ferritin activation.
    Life sciences, 2023, Aug-01, Volume: 326

    Topics: Animals; Arthritis, Gouty; Cytokines; Gout; Humans; Inflammasomes; Inflammation; Mice; Mice, Inbred

2023
[ANMCO statement: Uric acid and cardiovascular disease: evidence and therapeutic approach].
    Giornale italiano di cardiologia (2006), 2023, Volume: 24, Issue:6

    Topics: Allopurinol; Cardiovascular Diseases; Gout; Gout Suppressants; Humans; Treatment Outcome; Uric Acid

2023
Comparison between the Effects of Allopurinol and Febuxostat on the Survival of Patients on Maintenance Hemodialysis.
    American journal of nephrology, 2023, Volume: 54, Issue:3-4

    Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Dialysis; Treatment O

2023
Monosodium urate crystals alter the circadian clock in macrophages leading to loss of NLRP3 inflammasome repression: Implications for timing of the gout flare.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2023, Volume: 37, Issue:6

    Topics: ARNTL Transcription Factors; Caspases; Circadian Clocks; Gout; Humans; Inflammasomes; Interleukin-1b

2023
Serum Urate Monitoring Among Older Adults With Gout: Initiating Urate-Lowering Therapy in Ontario, Canada.
    Arthritis care & research, 2023, Volume: 75, Issue:12

    Topics: Aged; Aged, 80 and over; Female; Gout; Gout Suppressants; Humans; Male; Ontario; Retrospective Studi

2023
Tailored hydrogel composite membrane for the regulated crystallization of monosodium urate monohydrate within coffee's metabolites system.
    Journal of colloid and interface science, 2023, Oct-15, Volume: 648

    Topics: Coffee; Crystallization; Gout; Humans; Hydrogels; Uric Acid

2023
The aftermath of Urate-Lowering TheRApy in gout (ULTRA) registry: The first prospective observational multicenter cohort of Korean patients with gout.
    International journal of rheumatic diseases, 2023, Volume: 26, Issue:6

    Topics: Gout; Humans; Registries; Republic of Korea; Uric Acid

2023
GLUT9 as a potential drug target for chronic kidney disease: Drug target validation by a Mendelian randomization study.
    Journal of human genetics, 2023, Volume: 68, Issue:10

    Topics: Glucose Transport Proteins, Facilitative; Gout; Humans; Mendelian Randomization Analysis; Organic An

2023
[The influence of uric acid on the course of amyotrophic lateral sclerosis].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2023, Volume: 123, Issue:5

    Topics: Amyotrophic Lateral Sclerosis; Antioxidants; Gout; Humans; Male; Neuroprotection; Uric Acid

2023
Safety update: febuxostat and CVD.
    Drug and therapeutics bulletin, 2023, Volume: 61, Issue:7

    Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Treatment Outcome

2023
Clec12a inhibits MSU-induced immune activation through lipid raft expulsion.
    Life science alliance, 2023, Volume: 6, Issue:9

    Topics: Gout; Humans; Immunity, Innate; Inflammation; Lipids; Uric Acid

2023
Association between serum uric acid and muscle strength in older adults with or without gout diagnosis: NHANES 2011-2014.
    Aging clinical and experimental research, 2023, Volume: 35, Issue:9

    Topics: Aged; Female; Gout; Hand Strength; Humans; Male; Muscle Strength; Nutrition Surveys; Uric Acid

2023
Preparation of PEGylated uricase attached magnetic nanowires and application for uric acid oxidation.
    Journal of biotechnology, 2023, Aug-20, Volume: 373

    Topics: Enzymes, Immobilized; Gout; Humans; Magnetic Phenomena; Nanowires; Polyethylene Glycols; Urate Oxida

2023
DECT: A Novel Window in Gout Imaging.
    The Journal of the Association of Physicians of India, 2023, Volume: 71, Issue:6

    Topics: Diagnostic Imaging; Gout; Humans; Uric Acid

2023
Factors affecting serum urate monitoring among older adults with gout initiating urate-lowering therapy: comment on the article by Kwok et al.
    Arthritis care & research, 2023, Volume: 75, Issue:12

    Topics: Aged; Gout; Gout Suppressants; Humans; Uric Acid

2023
Beliefs about medicines in gout patients: results from the NOR-Gout 2-year study.
    Scandinavian journal of rheumatology, 2023, Volume: 52, Issue:6

    Topics: Gout; Gout Suppressants; Health Knowledge, Attitudes, Practice; Humans; Longitudinal Studies; Medica

2023
Efficient Synergistic Cooperation of an Arginine-Rich Peptide and Copper Ions in Sodium Urate Crystallization Inhibition.
    Langmuir : the ACS journal of surfaces and colloids, 2023, 07-18, Volume: 39, Issue:28

    Topics: Copper; Crystallization; Gout; Humans; Ions; Peptides; Uric Acid

2023
14-3-3 η ETA protein as a potential marker of joint damage in gout.
    Clinical biochemistry, 2023, Volume: 118

    Topics: 14-3-3 Proteins; Cross-Sectional Studies; Gout; Humans; ROC Curve; Uric Acid

2023
Analysis of appropriate duration of colchicine prophylaxis to maximize the persistence of xanthine oxidase inhibitors as the first-line urate-lowering therapy in patients with gout using the Korean Health Insurance Review and Assessment Service database.
    International journal of rheumatic diseases, 2023, Volume: 26, Issue:9

    Topics: Adult; Allopurinol; Colchicine; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Humans; Insu

2023
Potential clinical value of serum interleukin-41 levels in patients with acute gout.
    International immunopharmacology, 2023, Volume: 122

    Topics: Arthritis, Gouty; C-Reactive Protein; Gout; Humans; Interleukins; Uric Acid

2023
Hyperuricemia and gout increased the risk of long-term mortality in patients with heart failure: insights from the National Health and Nutrition Examination Survey.
    Journal of translational medicine, 2023, 07-12, Volume: 21, Issue:1

    Topics: Gout; Heart Failure; Humans; Hyperuricemia; Nutrition Surveys; Uric Acid

2023
Test characteristics of Raman spectroscopy integrated with polarized light microscopy for the diagnosis of acute gouty arthritis.
    Joint bone spine, 2023, Volume: 90, Issue:6

    Topics: Arthritis, Gouty; Gout; Humans; Microscopy, Polarization; Prospective Studies; Sensitivity and Speci

2023
Sirt3 improves monosodium urate crystal-induced inflammation by suppressing Acod1 expression.
    Arthritis research & therapy, 2023, 07-19, Volume: 25, Issue:1

    Topics: Animals; Gout; Inflammation; Leukocytes, Mononuclear; Mice; Mice, Inbred C57BL; Sirtuin 3; Uric Acid

2023
Paeonia × suffruticosa Andrews leaf extract and its main component apigenin 7-O-glucoside ameliorate hyperuricemia by inhibiting xanthine oxidase activity and regulating renal urate transporters.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2023, Volume: 118

    Topics: Animals; Apigenin; Creatinine; Glucosides; Gout; Hyperuricemia; Kidney; Malondialdehyde; Mice; Molec

2023
Purine-ifying uric acid by gut microbes.
    Cell chemical biology, 2023, 07-20, Volume: 30, Issue:7

    Topics: Animals; Gastrointestinal Microbiome; Gout; Mammals; Purines; Uric Acid

2023
[Association between metabolism-related chronic disease combination and prevalence of non-alcoholic fatty liver disease in community residents in Shanghai].
    Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi, 2023, Jul-10, Volume: 44, Issue:7

    Topics: Adult; Body Mass Index; China; Chronic Disease; Diabetes Mellitus; Female; Gout; Humans; Hyperlipide

2023
Comparative Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for Recurrent Gout Flares and Gout-Primary Emergency Department Visits and Hospitalizations : A General Population Cohort Study.
    Annals of internal medicine, 2023, Volume: 176, Issue:8

    Topics: Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucose; Gout; Hospit

2023
Identification of tophi in ultrasound imaging based on transfer learning and clinical practice.
    Scientific reports, 2023, 08-02, Volume: 13, Issue:1

    Topics: Arthritis, Gouty; Gout; Humans; Inflammation; Machine Learning; Reproducibility of Results; Tomograp

2023
A widely distributed gene cluster compensates for uricase loss in hominids.
    Cell, 2023, 08-03, Volume: 186, Issue:16

    Topics: Adult; Animals; Evolution, Molecular; Gout; Hominidae; Humans; Hyperuricemia; Mammals; Mice; Urate O

2023
Comparison of the different monosodium urate crystals in the preparation process and pro-inflammation.
    Advances in rheumatology (London, England), 2023, 08-08, Volume: 63, Issue:1

    Topics: Animals; Gout; Humans; Inflammation; Interleukin-18; Tumor Necrosis Factor-alpha; Uric Acid

2023
Antihyperuricemic and Renal Protective Effect of Cordyceps chanhua (Ascomycetes) Fruiting Bodies in Acute Hyperuricemia and Chronic Gout Rodent Models.
    International journal of medicinal mushrooms, 2023, Volume: 25, Issue:8

    Topics: Animals; Cordyceps; Fruiting Bodies, Fungal; Gout; Gout Suppressants; Hyperuricemia; Kidney; Mice; R

2023
Asymptomatic hyperuricemia associated with increased risk of nephrolithiasis: a cross-sectional study.
    BMC public health, 2023, 08-10, Volume: 23, Issue:1

    Topics: China; Cross-Sectional Studies; Female; Gout; Humans; Hyperuricemia; Male; Nephrolithiasis; Risk Fac

2023
An interesting image of gout crystals with surrounding tophi.
    The American journal of the medical sciences, 2023, Volume: 366, Issue:6

    Topics: Gout; Humans; Uric Acid

2023
Validation of gout diagnosis in electronic primary care medical records: A population-based study.
    Joint bone spine, 2023, Volume: 90, Issue:6

    Topics: Cross-Sectional Studies; Electronic Health Records; Electronics; Gout; Gout Suppressants; Humans; Pr

2023
[Recommendations for the diagnosis and treatment of gout in China].
    Zhonghua nei ke za zhi, 2023, Sep-01, Volume: 62, Issue:9

    Topics: China; Gout; Humans; Practice Guidelines as Topic; Rheumatology; Uric Acid

2023
Reliability and Validity of the Korean Version of the Gout Impact Scale.
    Journal of Korean medical science, 2023, Sep-04, Volume: 38, Issue:35

    Topics: Female; Gout; Humans; Male; Quality of Life; Reproducibility of Results; Republic of Korea; Uric Aci

2023
Association between serum uric acid levels and peripheral artery disease in Chinese adults with hypertension.
    Frontiers in endocrinology, 2023, Volume: 14

    Topics: Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; East Asian People; Female; Gout; Humans; Hy

2023
Uric Acid and Risk of Cardiovascular Disease and Mortality: A Longitudinal Cohort Study.
    Journal of Korean medical science, 2023, Sep-25, Volume: 38, Issue:38

    Topics: Adult; Cardiovascular Diseases; Cohort Studies; Gout; Humans; Longitudinal Studies; Uric Acid

2023
MSU crystal deposition contributes to inflammation and immune responses in gout remission.
    Cell reports, 2023, 10-31, Volume: 42, Issue:10

    Topics: Chronic Disease; Gout; Humans; Inflammation; Leukocytes, Mononuclear; Monocytes; Uric Acid

2023
Prediction of renal and cardiometabolic outcomes in gout during urate-lowering therapy by sonography.
    International journal of rheumatic diseases, 2023, Volume: 26, Issue:12

    Topics: Gout; Gout Suppressants; Humans; Hypertension; Kidney; Prospective Studies; Uric Acid

2023
Safety of colchicine and NSAID prophylaxis when initiating urate-lowering therapy for gout: propensity score-matched cohort studies in the UK Clinical Practice Research Datalink.
    Annals of the rheumatic diseases, 2023, Volume: 82, Issue:12

    Topics: Adult; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Colchicine; Diarrhea; G

2023
Metabolomic analysis for asymptomatic hyperuricemia and gout based on a combination of dried blood spot sampling and mass spectrometry technology.
    Journal of orthopaedic surgery and research, 2023, Oct-11, Volume: 18, Issue:1

    Topics: Biomarkers; Gout; Humans; Hyperuricemia; Mass Spectrometry; Metabolomics; Uric Acid

2023
Interleukin-37: associations of plasma levels and genetic variants in gout.
    Arthritis research & therapy, 2023, 10-18, Volume: 25, Issue:1

    Topics: Arthritis, Gouty; Gout; Humans; Hyperuricemia; Interleukin-1beta; Uric Acid

2023
Molecular characteristic analysis of single-nucleotide polymorphisms in SLC16A9/hMCT9.
    Life sciences, 2023, Dec-01, Volume: 334

    Topics: Animals; Creatine; Gout; Humans; Hyperuricemia; Oocytes; Polymorphism, Single Nucleotide; Uric Acid;

2023
Diurnal Variations in Serum Uric Acid, Xanthine, and Xanthine Oxidoreductase Activity in Male Patients with Coronary Artery Disease.
    Nutrients, 2023, Oct-23, Volume: 15, Issue:20

    Topics: Coronary Artery Disease; Gout; Humans; Male; Uric Acid; Xanthine; Xanthine Dehydrogenase

2023
In patients with type 2 diabetes or HF, SGLT2 inhibitors reduce gout-related outcomes.
    Annals of internal medicine, 2023, Volume: 176, Issue:11

    Topics: Diabetes Mellitus, Type 2; Gout; Humans; Sodium-Glucose Transporter 2 Inhibitors; Uric Acid

2023
Factors influencing the kinetics of MSU crystal depletion measured with dual-energy CT in patients with gout.
    RMD open, 2023, Volume: 9, Issue:4

    Topics: Aged; Aged, 80 and over; Female; Foot; Gout; Humans; Male; Middle Aged; Tomography, X-Ray Computed;

2023
New animal model of chronic gout reproduces pathological features of the disease in humans.
    RMD open, 2023, Volume: 9, Issue:4

    Topics: Animals; Arthritis, Gouty; Disease Models, Animal; Gout; Gout Suppressants; Humans; Mice; Uric Acid

2023
Peptide NCTX15 derived from spider toxin gland effectively relieves hyperuricemia in mice.
    Biochemical and biophysical research communications, 2023, Dec-31, Volume: 689

    Topics: Animals; Gout; Hyperuricemia; Interleukin-6; Kidney; Mice; Uric Acid; Xanthine Oxidase

2023
Factors for achieving target serum uric acid levels after initiating urate-lowering therapy in patients with gout: results from the ULTRA registry.
    Scientific reports, 2023, Nov-22, Volume: 13, Issue:1

    Topics: Antihypertensive Agents; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Multivariate An

2023
Cohort study investigating gout flares and management in UK general practice.
    BMC primary care, 2023, Nov-22, Volume: 24, Issue:1

    Topics: Cohort Studies; General Practice; Gout; Gout Suppressants; Humans; Male; Symptom Flare Up; United Ki

2023
Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment.
    Arthritis research & therapy, 2023, Dec-02, Volume: 25, Issue:1

    Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Lipidomics; Uric Acid

2023
Lifestyle factors predict gout outcomes: Results from the NOR-Gout longitudinal 2-year treat-to-target study.
    RMD open, 2023, 12-01, Volume: 9, Issue:4

    Topics: Cholesterol, LDL; Female; Gout; Humans; Life Style; Male; Middle Aged; Symptom Flare Up; Uric Acid

2023
Role of immune system in development and progress of combined arterial hypertension and gout.
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 2019, Volume: 72, Issue:7

    Topics: Arthritis, Gouty; Gout; Humans; Hypertension; Immune System; Male; Middle Aged; Uric Acid

2019
Development and Pilot Testing of MyGoutCare: A Novel Web-Based Platform to Educate Patients With Gout.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2020, Volume: 26, Issue:8

    Topics: Gout; Gout Suppressants; Humans; Internet; Middle Aged; Patient Education as Topic; Pilot Projects;

2020
A conserved role of the insulin-like signaling pathway in diet-dependent uric acid pathologies in Drosophila melanogaster.
    PLoS genetics, 2019, Volume: 15, Issue:8

    Topics: Animals; Animals, Genetically Modified; Cohort Studies; Disease Models, Animal; Drosophila melanogas

2019
Factors Influencing the Effectiveness of Allopurinol in Achieving and Sustaining Target Serum Urate in a US Veterans Affairs Gout Cohort.
    The Journal of rheumatology, 2020, Volume: 47, Issue:3

    Topics: Age Factors; Aged; Aged, 80 and over; Allopurinol; Comorbidity; Female; Follow-Up Studies; Gout; Gou

2020
Risk of gout flares after vaccination.
    Annals of the rheumatic diseases, 2021, Volume: 80, Issue:8

    Topics: Gout; Gout Suppressants; Humans; Symptom Flare Up; Uric Acid; Vaccination

2021
Evaluation of Treatment Success Rate Among Antihyperuricemic Using Real-World Data.
    Studies in health technology and informatics, 2019, Aug-21, Volume: 264

    Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Treatment Outcome; Uric Acid

2019
Curcumin attenuates MSU crystal-induced inflammation by inhibiting the degradation of IκBα and blocking mitochondrial damage.
    Arthritis research & therapy, 2019, 08-27, Volume: 21, Issue:1

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blotting, Western; Curcumin; Cytokines; Disease Mo

2019
Pegloticase and lowering blood pressure in refractory gout; is it uric acid or hydrogen peroxide?
    European journal of internal medicine, 2019, Volume: 69

    Topics: Blood Pressure; Gout; Humans; Hydrogen Peroxide; Polyethylene Glycols; Urate Oxidase; Uric Acid

2019
The target uric acid level in multimorbid patients with gout is difficult to achieve: data from a longitudinal Swiss single-centre cohort.
    Swiss medical weekly, 2019, Aug-26, Volume: 149

    Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Female; Gout; Gout Suppressants; Humans; Longitudinal S

2019
The challenges of managing gout in primary care: Results of a best-practice audit.
    Australian journal of general practice, 2019, Volume: 48, Issue:9

    Topics: Aged; Allopurinol; Clinical Audit; Clinical Chemistry Tests; Clinical Protocols; Colchicine; Comorbi

2019
Postoperative Recurrent Gout Flares: A Cross-sectional Study From China.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2020, Volume: 26, Issue:5

    Topics: China; Cross-Sectional Studies; Gout; Gout Suppressants; Humans; Symptom Flare Up; Uric Acid

2020
Corneal Endothelial Morphology and Thickness Changes in Patients with Gout
    Turkish journal of ophthalmology, 2019, 09-03, Volume: 49, Issue:4

    Topics: Adult; Case-Control Studies; Cell Count; Endothelial Cells; Endothelium, Corneal; Female; Gout; Huma

2019
The performance of dual-energy CT in the classification criteria of gout: a prospective study in subjects with unclassified arthritis.
    Rheumatology (Oxford, England), 2020, 04-01, Volume: 59, Issue:4

    Topics: Aged; Area Under Curve; Arthritis, Gouty; Female; Gout; Humans; Male; Microscopy, Polarization; Midd

2020
Dual-Energy Computed Tomography Detection of Cardiovascular Monosodium Urate Deposits in Patients With Gout.
    JAMA cardiology, 2019, 10-01, Volume: 4, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Cadaver; Cardiovascular Diseases; Coronary Vessels; Fema

2019
Suppression of monosodium urate crystal-induced inflammation by inhibiting TGF-β-activated kinase 1-dependent signaling: role of the ubiquitin proteasome system.
    Cellular & molecular immunology, 2021, Volume: 18, Issue:1

    Topics: Animals; Antioxidants; Fibroblasts; Gout; Humans; Inflammation; Lactones; Male; MAP Kinase Kinase Ki

2021
Gout involved the cervical disc and adjacent vertebral endplates misdiagnosed infectious spondylodiscitis on imaging: case report and literature review.
    BMC musculoskeletal disorders, 2019, Sep-14, Volume: 20, Issue:1

    Topics: C-Reactive Protein; Cervical Vertebrae; Colchicine; Diagnostic Errors; Discitis; Gout; Humans; Inter

2019
Therapeutic potential of ethyl acetate fraction of Tephrosia purpurea Linn. leaves in a rat model of gout.
    Journal of integrative medicine, 2019, Volume: 17, Issue:6

    Topics: Acetates; Animals; Disease Models, Animal; Gout; Male; Plant Extracts; Plant Leaves; Rats; Rats, Spr

2019
Clinical features and risk factors for gout attacks during anti-tuberculosis treatment: A case-control study in South Korea.
    International journal of rheumatic diseases, 2019, Volume: 22, Issue:10

    Topics: Aged; Antitubercular Agents; Biomarkers; Case-Control Studies; Disease Progression; Female; Follow-U

2019
Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients.
    Arthritis research & therapy, 2019, 09-18, Volume: 21, Issue:1

    Topics: Allopurinol; Benzbromarone; Disease Progression; Febuxostat; Female; Glomerular Filtration Rate; Gou

2019
MSU crystals at-TAK!
    Nature reviews. Rheumatology, 2019, Volume: 15, Issue:11

    Topics: Gout; Humans; Inflammation; MAP Kinase Kinase Kinases; Proteasome Endopeptidase Complex; Ubiquitin;

2019
Target genes, variants, tissues and transcriptional pathways influencing human serum urate levels.
    Nature genetics, 2019, Volume: 51, Issue:10

    Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Cardiovascular Diseases; Cohort Studies; Ge

2019
Hyperuricemia and gout caused by missense mutation in d-lactate dehydrogenase.
    The Journal of clinical investigation, 2019, 12-02, Volume: 129, Issue:12

    Topics: Adult; Animals; Catalytic Domain; Child; DNA; Family Health; Female; Gout; HEK293 Cells; Heterozygot

2019
Treat-to-target (T2T) of serum urate (SUA) in gout: a clinical audit in real-world gout patients.
    Reumatismo, 2019, Oct-24, Volume: 71, Issue:3

    Topics: Adult; Aged; Female; Gout; Humans; Male; Medical Audit; Middle Aged; Practice Guidelines as Topic; R

2019
Predictive factors of tumour necrosis inhibitor treatment persistence for rheumatoid arthritis: An observational study in 8052 patients.
    Joint bone spine, 2020, Volume: 87, Issue:2

    Topics: Aged; Arthritis, Rheumatoid; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Necrosis; N

2020
Failure to reach uric acid target of <0.36 mmol/L in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality.
    RMD open, 2019, Volume: 5, Issue:2

    Topics: Aged; Biomarkers; Cardiovascular Diseases; Comorbidity; Female; Follow-Up Studies; Gout; Humans; Hyp

2019
Gout Management as Part of Secondary Cardiovascular Prevention: Comment on the Article by Stamp et al.
    Arthritis & rheumatology (Hoboken, N.J.), 2020, Volume: 72, Issue:2

    Topics: Cohort Studies; Coronary Disease; Gout; Gout Suppressants; Humans; Uric Acid

2020
Population-specific factors associated with fractional excretion of uric acid.
    Arthritis research & therapy, 2019, 11-12, Volume: 21, Issue:1

    Topics: Adult; Aged; Female; Gout; Humans; Hyperuricemia; Male; Middle Aged; Native Hawaiian or Other Pacifi

2019
Burden and management of gout in a multi-ethnic Asian cohort.
    Rheumatology international, 2020, Volume: 40, Issue:7

    Topics: Adult; Aged; Allopurinol; Comorbidity; Cross-Sectional Studies; Diabetes Mellitus; Dyslipidemias; Em

2020
A laser-engraved wearable sensor for sensitive detection of uric acid and tyrosine in sweat.
    Nature biotechnology, 2020, Volume: 38, Issue:2

    Topics: Adolescent; Adult; Aged; Equipment Design; Gout; Humans; Lasers; Microfluidics; Middle Aged; Reprodu

2020
Dysfunctional missense variant of
    Annals of the rheumatic diseases, 2020, Volume: 79, Issue:1

    Topics: Adult; Asian People; Case-Control Studies; Genetic Predisposition to Disease; Gout; Humans; Hyperuri

2020
Chronic tophaceous gout presenting as nonhealing ulcers.
    The journal of the Royal College of Physicians of Edinburgh, 2019, Volume: 49, Issue:4

    Topics: Adult; Allopurinol; Biopsy, Needle; Debridement; Foot Ulcer; Gout; Humans; Immunohistochemistry; Ind

2019
Appraisal of anti-gout potential of colchicine-loaded chitosan nanoparticle gel in uric acid-induced gout animal model.
    Archives of physiology and biochemistry, 2022, Volume: 128, Issue:2

    Topics: Animals; Chitosan; Colchicine; Disease Models, Animal; Gout; Nanoparticles; Uric Acid

2022
Relationship between urate within tophus and bone erosion according to the anatomic location of urate deposition in gout: A quantitative analysis using dual-energy CT volume measurements.
    Medicine, 2019, Volume: 98, Issue:51

    Topics: Adult; Bone Diseases; Gout; Humans; Male; Middle Aged; Retrospective Studies; Tomography, X-Ray Comp

2019
Serum urate goal attainment and associated factors in Chinese gout patients.
    Psychology, health & medicine, 2020, Volume: 25, Issue:8

    Topics: Adult; Aged; China; Cross-Sectional Studies; Female; Goals; Gout; Gout Suppressants; Humans; Male; M

2020
Eucalyptol alleviates inflammation and pain responses in a mouse model of gout arthritis.
    British journal of pharmacology, 2020, Volume: 177, Issue:9

    Topics: Animals; Eucalyptol; Gout; Humans; Inflammation; Macrophages; Mice; Pain; Quality of Life; Uric Acid

2020
The prevalence of gout and hyperuricemia in middle-aged and elderly people in Tibet Autonomous Region, China: A preliminary study.
    Medicine, 2020, Volume: 99, Issue:2

    Topics: Adult; Aged; China; Cross-Sectional Studies; Female; Gout; Humans; Hyperuricemia; Male; Middle Aged;

2020
Development of novel NLRP3-XOD dual inhibitors for the treatment of gout.
    Bioorganic & medicinal chemistry letters, 2020, 02-15, Volume: 30, Issue:4

    Topics: Animals; Benzimidazoles; Benzoxazoles; Cell Line; Disease Models, Animal; Gout; Humans; Hyperuricemi

2020
Does normouricemic status in acute gouty arthritis really reflect a normal status? Consider confounders of serum levels of urate.
    The Korean journal of internal medicine, 2020, Volume: 35, Issue:1

    Topics: Arthritis, Gouty; Gout; Humans; Uric Acid

2020
Review of gout clinic in a tertiary hospital setting.
    Internal medicine journal, 2020, Volume: 50, Issue:1

    Topics: Aged; Aged, 80 and over; Ambulatory Care; Australia; Disease Management; Female; Gout; Gout Suppress

2020
Genomic dissection of 43 serum urate-associated loci provides multiple insights into molecular mechanisms of urate control.
    Human molecular genetics, 2020, 04-15, Volume: 29, Issue:6

    Topics: Case-Control Studies; Genetic Markers; Genetic Predisposition to Disease; Genome-Wide Association St

2020
Systematic genetic analysis of early-onset gout: ABCG2 is the only associated locus.
    Rheumatology (Oxford, England), 2020, 09-01, Volume: 59, Issue:9

    Topics: Adult; Age of Onset; ATP Binding Cassette Transporter, Subfamily G, Member 2; Europe; Female; Geneti

2020
Epistatic interaction between PKD2 and ABCG2 influences the pathogenesis of hyperuricemia and gout.
    Hereditas, 2020, Jan-27, Volume: 157, Issue:1

    Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Body Mass Index; Epistasis, Genetic; Geneti

2020
Contribution of Rare Variants of the
    Genetics, 2020, Volume: 214, Issue:4

    Topics: Animals; Female; Gene-Environment Interaction; Gout; Humans; Male; Middle Aged; Organic Anion Transp

2020
Hyperuricemia as a potential plausible risk factor for periodontitis.
    Medical hypotheses, 2020, Volume: 137

    Topics: Animals; Gout; Humans; Hyperuricemia; Mice; Periodontitis; Risk Factors; Uric Acid

2020
Do Serum Urate-associated Genetic Variants Influence Gout Risk in People Taking Diuretics? Analysis of the UK Biobank.
    The Journal of rheumatology, 2020, 11-01, Volume: 47, Issue:11

    Topics: Biological Specimen Banks; Diuretics; Gout; Humans; United Kingdom; Uric Acid

2020
Cytokine Production and NET Formation by Monosodium Urate-Activated Human Neutrophils Involves Early and Late Events, and Requires Upstream TAK1 and Syk.
    Frontiers in immunology, 2019, Volume: 10

    Topics: Cytokines; Extracellular Traps; Gout; Humans; MAP Kinase Kinase Kinases; Neutrophil Activation; Neut

2019
Study on the relationship between FFA and gout flare.
    Clinical rheumatology, 2020, Volume: 39, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Arthritis, Gouty; Biomarkers; Cholesterol, LDL; Fatty Acids, Noneste

2020
Identification of Cardiovascular Monosodium Urate Crystal Deposition in Patients With Gout Using Dual-Energy Computed Tomography-Reply.
    JAMA cardiology, 2020, 04-01, Volume: 5, Issue:4

    Topics: Cardiovascular System; Gout; Humans; Tomography, X-Ray Computed; Uric Acid

2020
Identification of Cardiovascular Monosodium Urate Crystal Deposition in Patients With Gout Using Dual-Energy Computed Tomography.
    JAMA cardiology, 2020, 04-01, Volume: 5, Issue:4

    Topics: Cardiovascular System; Gout; Humans; Tomography, X-Ray Computed; Uric Acid

2020
Structured patient care pathway for gout.
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2020, 02-04, Volume: 140, Issue:2

    Topics: Allopurinol; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Patient Care; Uric Acid

2020
Efficacy and tolerability of febuxostat in gout patients on dialysis.
    Internal medicine journal, 2021, Volume: 51, Issue:3

    Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Dialysis; Retrospecti

2021
Risk factors of ultrasound-detected tophi in patients with gout.
    Clinical rheumatology, 2020, Volume: 39, Issue:6

    Topics: Adult; Aged; Ankle Joint; Female; Glomerular Filtration Rate; Gout; Humans; Knee Joint; Logistic Mod

2020
Gout in the Flexor Hallucis Longus Tendon Mimicking Cellulitis: A Case Report.
    Journal of the American Podiatric Medical Association, 2020, Volume: 110, Issue:1

    Topics: Aged; Ankle; Cellulitis; Diagnosis, Differential; Foot; Gout; Humans; Magnetic Resonance Imaging; Ma

2020
A negative association between urinary iodine concentration and the prevalence of hyperuricemia and gout: a cross-sectional and population-based study in Mainland China.
    European journal of nutrition, 2020, Volume: 59, Issue:8

    Topics: Adult; China; Cross-Sectional Studies; Female; Gout; Humans; Hyperuricemia; Iodine; Prevalence; Pros

2020
Better outcomes for patients with gout.
    Inflammopharmacology, 2020, Volume: 28, Issue:5

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Dose-Response Relationship, Drug; Drug Therapy,

2020
A mouse model of MSU-induced acute inflammation
    Theranostics, 2020, Volume: 10, Issue:5

    Topics: Acute Disease; Adjuvants, Immunologic; Administration, Topical; Animals; Antioxidants; Cytokines; Di

2020
The prevalence of the gout-associated polymorphism rs2231142 G>T in ABCG2 in a pregnant female Filipino cohort.
    Clinical rheumatology, 2020, Volume: 39, Issue:8

    Topics: Adolescent; Adult; Alleles; Asian People; ATP Binding Cassette Transporter, Subfamily G, Member 2; B

2020
The role of annexin A1 in the modulation of the NLRP3 inflammasome.
    Immunology, 2020, Volume: 160, Issue:1

    Topics: Administration, Intranasal; Animals; Annexin A1; Cartilage, Articular; Caspase 1; Cells, Cultured; D

2020
Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout.
    Annals of the rheumatic diseases, 2020, Volume: 79, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Animals; Case-Control Studies; Female; Genetic Predisposition to Dis

2020
Predictors of Success in Gout Treatment.
    The Journal of rheumatology, 2020, Volume: 47, Issue:3

    Topics: Allopurinol; Gout; Gout Suppressants; Humans; Uric Acid; Veterans

2020
The comparison of dyslipidemia and serum uric acid in patients with gout and asymptomatic hyperuricemia: a cross-sectional study.
    Lipids in health and disease, 2020, Mar-03, Volume: 19, Issue:1

    Topics: Cholesterol, HDL; Cholesterol, LDL; Cross-Sectional Studies; Dyslipidemias; Female; Gout; Humans; Hy

2020
Identification of the urine and serum metabolomics signature of gout.
    Rheumatology (Oxford, England), 2020, 10-01, Volume: 59, Issue:10

    Topics: Area Under Curve; Biomarkers; Carnitine; Case-Control Studies; Chromatography, High Pressure Liquid;

2020
Australian tertiary institutions are failing people with gout.
    Internal medicine journal, 2020, Volume: 50, Issue:3

    Topics: Australia; Gout; Humans; Rheumatology; Uric Acid

2020
Author reply.
    Internal medicine journal, 2020, Volume: 50, Issue:3

    Topics: Australia; Gout; Humans; Rheumatology; Uric Acid

2020
Uric acid-mediated inflammasome activation in IL-6 primed innate immune cells is regulated by baricitinib.
    Modern rheumatology, 2021, Volume: 31, Issue:1

    Topics: Azetidines; Cells, Cultured; Gout; Humans; Immunity, Innate; Inflammasomes; Interleukin-6; Neutrophi

2021
Pleiotropic effect of the ABCG2 gene in gout: involvement in serum urate levels and progression from hyperuricemia to gout.
    Arthritis research & therapy, 2020, 03-12, Volume: 22, Issue:1

    Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Disease Progression; Epistasis, Genetic; Eu

2020
Facilitating equitable prevention and management of gout for Māori in Northland, New Zealand, through a collaborative primary care approach.
    Journal of primary health care, 2019, Volume: 11, Issue:2

    Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Community Pharmacy Services; Cultural Co

2019
Effect of tart cherry juice on risk of gout attacks: protocol for a randomised controlled trial.
    BMJ open, 2020, 03-15, Volume: 10, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Pressure; Fruit and Vegetable Juices; Gout; Humans

2020
The effect of reducing systemic inflammation on serum urate.
    Rheumatology (Oxford, England), 2020, Oct-01, Volume: 59, Issue:10

    Topics: Adult; Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Blood Sedimentation; C-Rea

2020
Clinical observation of Qushi Xiezhuo formula in reducing monosodium urate crystal deposition in patients with axial spondyloarthritis.
    Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2019, Volume: 39, Issue:5

    Topics: Adult; Cohort Studies; Drug Compounding; Drugs, Chinese Herbal; Female; Gout; Humans; Male; Prospect

2019
IL-37 linked to gout pathogenesis and treatment.
    Nature reviews. Rheumatology, 2020, Volume: 16, Issue:5

    Topics: Anti-Inflammatory Agents; Cytokines; Gout; Humans; Interleukins; Uric Acid

2020
[Clinical study of staging operation for large gouty stone on the first metatarsophalangeal joint].
    Zhongguo gu shang = China journal of orthopaedics and traumatology, 2020, Mar-25, Volume: 33, Issue:3

    Topics: Aged; Arthrodesis; Gout; Humans; Male; Metatarsophalangeal Joint; Middle Aged; Treatment Outcome; Ur

2020
Goose astrovirus infection affects uric acid production and excretion in goslings.
    Poultry science, 2020, Volume: 99, Issue:4

    Topics: Animals; Astroviridae Infections; Avastrovirus; Avian Proteins; Carrier Proteins; Disease Models, An

2020
The Utility of the Random Urine Uric Acid-to-Creatinine Ratio for Patients with Gout Who Need Uricosuric Agents: Retrospective Cross-Sectional Study.
    Journal of Korean medical science, 2020, Apr-06, Volume: 35, Issue:13

    Topics: Adult; Aged; Creatinine; Cross-Sectional Studies; Female; Gout; Humans; Male; Middle Aged; Retrospec

2020
High-Protein Diet Induces Hyperuricemia in a New Animal Model for Studying Human Gout.
    International journal of molecular sciences, 2020, Mar-20, Volume: 21, Issue:6

    Topics: Allopurinol; Animal Structures; Animals; Chickens; Crystallization; Diet, High-Protein; Disease Mode

2020
X-ray Dark-Field Radiography: Potential for Visualization of Monosodium Urate Deposition.
    Investigative radiology, 2020, Volume: 55, Issue:8

    Topics: Animals; Disease Models, Animal; Gout; Humans; Mice; Photons; Radiography; Sensitivity and Specifici

2020
Understanding and perceptions of gout: an interdisciplinary assessment among patients, physicians and pharmacists in Italy.
    Reumatismo, 2020, Apr-10, Volume: 72, Issue:1

    Topics: Clinical Competence; Cross-Sectional Studies; General Practitioners; Gout; Health Knowledge, Attitud

2020
Gout management in Swiss primary care - a retrospective observational study.
    Swiss medical weekly, 2020, 04-20, Volume: 150

    Topics: Gout; Gout Suppressants; Humans; Primary Health Care; Switzerland; Uric Acid

2020
Using electronic visits (E-visits) to achieve goal serum urate levels in patients with gout in a rheumatology practice: A pilot study.
    Seminars in arthritis and rheumatism, 2020, Volume: 50, Issue:6

    Topics: Electronics; Goals; Gout; Gout Suppressants; Humans; Pilot Projects; Retrospective Studies; Rheumato

2020
The efficacy and tolerability of febuxostat treatment in a cohort of Chinese Han population with history of gout.
    The Journal of international medical research, 2020, Volume: 48, Issue:5

    Topics: Adult; Asian People; China; Cohort Studies; Double-Blind Method; Ethnicity; Febuxostat; Female; Gout

2020
Urate-lowering therapy exerts protective effects against hypertension development in patients with gout.
    Journal of human hypertension, 2021, Volume: 35, Issue:4

    Topics: Aged, 80 and over; Gout; Gout Suppressants; Humans; Hypertension; Retrospective Studies; Uric Acid

2021
A pharmacokinetic-pharmacodynamic study of a single dose of febuxostat in healthy subjects.
    British journal of clinical pharmacology, 2020, Volume: 86, Issue:12

    Topics: Adult; Febuxostat; Female; Gout; Gout Suppressants; Healthy Volunteers; Humans; Kidney; Male; Renal

2020
Comparison of Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction With Versus Without Hyperuricemia or Gout.
    The American journal of cardiology, 2020, 07-15, Volume: 127

    Topics: Aged; Cause of Death; Comorbidity; Echocardiography; Female; Follow-Up Studies; Gout; Heart Failure;

2020
Assessing the sensitivity to change of the OMERACT ultrasound structural gout lesions during urate-lowering therapy.
    RMD open, 2020, Volume: 6, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Female; Gout; Humans; Joints; Male; Middle Aged; Musculoskeletal Sys

2020
Treat-to-Target urate-lowering therapy in primary gout patients: A real-world retrospective study at a dedicated gout clinic in China.
    Technology and health care : official journal of the European Society for Engineering and Medicine, 2021, Volume: 29, Issue:1

    Topics: China; Gout; Gout Suppressants; Humans; Retrospective Studies; Uric Acid

2021
Management of gout by Moroccan rheumatologists: a Moroccan Society for Rheumatology National Survey.
    Rheumatology international, 2020, Volume: 40, Issue:9

    Topics: Allopurinol; Colchicine; Cross-Sectional Studies; Drug Therapy, Combination; Female; Gout; Gout Supp

2020
Patient Perceptions of Gout Management Goals: A Cross-sectional Internet Survey.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2020, Volume: 26, Issue:4

    Topics: Attitude to Health; Cross-Sectional Studies; Disease Management; Drug Monitoring; Female; Gout; Gout

2020
Comparison of persistence rates between allopurinol and febuxostat as first-line urate-lowering therapy in patients with gout: an 8-year retrospective cohort study.
    Clinical rheumatology, 2020, Volume: 39, Issue:12

    Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Middle Aged; Retrospective Studies; Uric A

2020
In Vivo Transmigrated Human Neutrophils Are Highly Primed for Intracellular Radical Production Induced by Monosodium Urate Crystals.
    International journal of molecular sciences, 2020, May-26, Volume: 21, Issue:11

    Topics: Adult; Aged; Cells, Cultured; Extracellular Traps; Female; Gout; Humans; Middle Aged; Neutrophils; P

2020
Mobile healthcare system based on the combination of a lateral flow pad and smartphone for rapid detection of uric acid in whole blood.
    Biosensors & bioelectronics, 2020, Sep-15, Volume: 164

    Topics: Biosensing Techniques; Delivery of Health Care; Gout; Humans; Smartphone; Uric Acid

2020
A nurse-led, rheumatologist-assisted telemedicine intervention for dose escalation of urate-lowering therapy in gout.
    International journal of rheumatic diseases, 2020, Volume: 23, Issue:9

    Topics: Adult; Aged; Allopurinol; Biomarkers; Down-Regulation; Female; Gout; Gout Suppressants; Humans; Male

2020
Blood glucose fluctuations detected by continuous glucose monitoring system in gout patients with normal glucose tolerance and the effect of urate-lowering therapy.
    International journal of rheumatic diseases, 2020, Volume: 23, Issue:9

    Topics: Adult; Aged; Allopurinol; Biomarkers; Blood Glucose; Blood Glucose Self-Monitoring; Down-Regulation;

2020
[Recommendations of diagnosis and treatment of gout in China].
    Zhonghua nei ke za zhi, 2020, Jun-01, Volume: 59, Issue:6

    Topics: China; Gout; Humans; Practice Guidelines as Topic; Uric Acid

2020
The ABCG2 Q141K hyperuricemia and gout associated variant illuminates the physiology of human urate excretion.
    Nature communications, 2020, 06-02, Volume: 11, Issue:1

    Topics: Alleles; Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Disease Models, Animal; E

2020
Gout Treatment in the USA from 2009 to 2016: A Repeated Cross-sectional Analysis.
    Journal of general internal medicine, 2021, Volume: 36, Issue:4

    Topics: Cross-Sectional Studies; Gout; Humans; United States; Uric Acid

2021
Cholesterol and Monosodium Urate Monohydrate Crystals in Synovial fluid From a Patient With Gout.
    Arthritis & rheumatology (Hoboken, N.J.), 2020, Volume: 72, Issue:10

    Topics: Aged; Cholesterol; Gout; Humans; Male; Synovial Fluid; Uric Acid

2020
RDP3, A Novel Antigout Peptide Derived from Water Extract of Rice.
    Journal of agricultural and food chemistry, 2020, Jul-08, Volume: 68, Issue:27

    Topics: Animals; Anti-Inflammatory Agents; Edema; Gout; Gout Suppressants; Humans; Hyperuricemia; Mice; Mice

2020
Spinal Urate Deposition in a Patient With Gout and Nonspecific Low Back Pain: Response to Initiation of Gout Therapy.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2021, Dec-01, Volume: 27, Issue:8S

    Topics: Arthritis, Gouty; Gout; Gout Suppressants; Humans; Low Back Pain; Uric Acid

2021
Serum Urate Levels of Hemodialyzed Renal Patients Revisited.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2021, Dec-01, Volume: 27, Issue:8

    Topics: Aged; Aged, 80 and over; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged;

2021
Urate-lowering therapy may mitigate the risks of hospitalized stroke and mortality in patients with gout.
    PloS one, 2020, Volume: 15, Issue:6

    Topics: Adult; Aged; Allopurinol; Female; Gout; Gout Suppressants; Hospital Mortality; Hospitalization; Huma

2020
Perfluoroalkyl acids, hyperuricemia and gout in adults: Analyses of NHANES 2009-2014.
    Chemosphere, 2020, Volume: 259

    Topics: Adult; Alkanesulfonic Acids; Caprylates; Cotinine; Cross-Sectional Studies; Decanoic Acids; Environm

2020
EPS8 regulates an NLRP3 inflammasome-independent caspase-1 activation pathway in monosodium urate crystal-treated RAW264.7 macrophages.
    Biochemical and biophysical research communications, 2020, 09-24, Volume: 530, Issue:3

    Topics: Adaptor Proteins, Signal Transducing; Animals; Caspase 1; Enzyme Activation; Gout; Inflammasomes; In

2020
[Comorbidity in gout and hyperuricemia: prevalence, causes, prospects of urate lowering therapy].
    Terapevticheskii arkhiv, 2019, May-15, Volume: 91, Issue:5

    Topics: Allopurinol; Comorbidity; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Prevalence; Ur

2019
Development of a multivariable improvement measure for gout.
    Arthritis research & therapy, 2020, 06-29, Volume: 22, Issue:1

    Topics: Arthritis, Gouty; Chronic Disease; Gout; Gout Suppressants; Humans; Polyethylene Glycols; Treatment

2020
Efficacy of febuxostat versus allopurinol and the predictors of achieving target serum urate in a cohort of Thai people with gout.
    Clinical rheumatology, 2021, Volume: 40, Issue:1

    Topics: Allopurinol; Cohort Studies; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Retrospecti

2021
Sex Differences in the Clinical Profile Among Patients With Gout: Cross-sectional Analyses of an Observational Study.
    The Journal of rheumatology, 2021, Volume: 48, Issue:2

    Topics: Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Gout; Humans; Male; Middle Aged; Sex Cha

2021
Long-Term Safety and Effectiveness of the Xanthine Oxidoreductase Inhibitor, Topiroxostat in Japanese Hyperuricemic Patients with or Without Gout: A 54-week Open-label, Multicenter, Post-marketing Observational Study.
    Clinical drug investigation, 2020, Volume: 40, Issue:9

    Topics: Adult; Enzyme Inhibitors; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Incidence; Japan;

2020
A leg ulcer with hard, yellow projections.
    Dermatology online journal, 2020, Apr-15, Volume: 26, Issue:4

    Topics: Aged, 80 and over; Gout; Humans; Leg Ulcer; Male; Obesity; Uric Acid

2020
Systemic Investigation of Promoter-wide Methylome and Genome Variations in Gout.
    International journal of molecular sciences, 2020, Jul-01, Volume: 21, Issue:13

    Topics: Adult; Aged; CpG Islands; DNA Methylation; Epigenesis, Genetic; Epigenome; Female; Gout; Humans; Hyp

2020
Gradual reduction of tophaceous deposits during urate-lowering therapy.
    Joint bone spine, 2021, Volume: 88, Issue:1

    Topics: Gout; Gout Suppressants; Humans; Uric Acid

2021
Rebranding Gout: Could a Name Change for Gout Improve Adherence to Urate-Lowering Therapy?
    Therapeutic innovation & regulatory science, 2021, Volume: 55, Issue:1

    Topics: Chronic Disease; Gout; Gout Suppressants; Humans; Male; Medication Adherence; Uric Acid

2021
Uric acid fluctuation had no effect on renal function among gout patients.
    Nutrition, metabolism, and cardiovascular diseases : NMCD, 2020, 09-24, Volume: 30, Issue:10

    Topics: Adult; Aged; Biomarkers; Electronic Health Records; Female; Glomerular Filtration Rate; Gout; Humans

2020
Associations of serum uric acid level and gout with cardiac structure, function and sex differences from large scale asymptomatic Asians.
    PloS one, 2020, Volume: 15, Issue:7

    Topics: Adult; Asian People; Asymptomatic Diseases; Echocardiography, Doppler; Female; Gout; Heart Atria; He

2020
Ultrasound for the diagnosis of gout-the value of gout lesions as defined by the Outcome Measures in Rheumatology ultrasound group.
    Rheumatology (Oxford, England), 2021, 01-05, Volume: 60, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; Female; Gout; Humans; Joints; Logistic Mode

2021
Gout and pseudo-gout-related crystals promote GLUT1-mediated glycolysis that governs NLRP3 and interleukin-1β activation on macrophages.
    Annals of the rheumatic diseases, 2020, Volume: 79, Issue:11

    Topics: Animals; Calcium Pyrophosphate; Glucose Transporter Type 1; Glycolysis; Gout; Humans; Interleukin-1b

2020
Achievement of the target serum urate level among patients with gout treated with allopurinol or febuxostat in an arthritis clinic in the Philippines.
    Modern rheumatology, 2021, Volume: 31, Issue:3

    Topics: Adult; Aged; Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Ph

2021
Latent Class Growth Analysis of Gout Flare Trajectories: A Three-Year Prospective Cohort Study in Primary Care.
    Arthritis & rheumatology (Hoboken, N.J.), 2020, Volume: 72, Issue:11

    Topics: Aged; Allopurinol; Disease Progression; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged;

2020
Association between Gout, Urate-Lowering Therapy, and Risk of Developing Type 2 Diabetes Mellitus: A Nationwide Population-Based Retrospective Cohort Study.
    BioMed research international, 2020, Volume: 2020

    Topics: Aged; Comorbidity; Diabetes Mellitus, Type 2; Female; Gout; Gout Suppressants; Humans; Male; Middle

2020
Trans-ancestral dissection of urate- and gout-associated major loci SLC2A9 and ABCG2 reveals primate-specific regulatory effects.
    Journal of human genetics, 2021, Volume: 66, Issue:2

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Evolution, Molecular; Genetic Pred

2021
A Study of Metabolic Parameters in Patients with Gout: A Single Center Study from Nepal.
    Endocrine, metabolic & immune disorders drug targets, 2021, Volume: 21, Issue:6

    Topics: Adult; Cross-Sectional Studies; Female; Gout; Humans; Male; Metabolic Syndrome; Middle Aged; Nepal;

2021
A novel mouse model of hyperuricemia and gouty nephropathy.
    Chinese medical journal, 2020, 08-20, Volume: 133, Issue:16

    Topics: Animals; Arthritis, Gouty; Disease Models, Animal; Gout; Hyperuricemia; Mice; Uric Acid

2020
[INDICATORS OF GOUT INTERLAYKINS AND THERMOGRAPHY OF JOINTS ON THE BACKGROUND OF ENTEROSORBTION THERAPY].
    Georgian medical news, 2020, Issue:303

    Topics: Cytokines; Gout; Humans; Interleukin-1beta; Thermography; Tumor Necrosis Factor-alpha; Uric Acid

2020
[ERRORS IN THE DIAGNOSTICS AND TREATMENT OF PATIENTS WITH GOUT AND THE ALGORITHM OF THERAPEUTIC TACTICS IN DIFFERENT PERIODS OF THE DISEASE (CLINICAL CASE)].
    Georgian medical news, 2020, Issue:303

    Topics: Algorithms; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Gout; Humans; Uric Acid

2020
Inpatient gout flare is multifactorial: comment on "clinical characteristics and risk factors for gout flare during the postsurgical period".
    Advances in rheumatology (London, England), 2020, 08-26, Volume: 60, Issue:1

    Topics: Gout; Humans; Inpatients; Risk Factors; Symptom Flare Up; Uric Acid

2020
[Consequences of Gout and Hyperuricemia].
    Lakartidningen, 2020, 08-25, Volume: 117

    Topics: Cardiovascular Diseases; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid

2020
[Large health benefits can be achieved by better treatment of gout].
    Lakartidningen, 2020, 08-25, Volume: 117

    Topics: Allopurinol; Colchicine; Gout; Gout Suppressants; Humans; Treatment Outcome; Uric Acid

2020
[Gout - a common and well known disease].
    Lakartidningen, 2020, 08-25, Volume: 117

    Topics: Gout; Humans; Hyperuricemia; Sweden; Ultrasonography; Uric Acid

2020
Allopurinol use and type 2 diabetes incidence among patients with gout: A VA retrospective cohort study.
    Medicine, 2020, Aug-28, Volume: 99, Issue:35

    Topics: Aged; Aged, 80 and over; Allopurinol; Colchicine; Diabetes Mellitus, Type 2; Female; Follow-Up Studi

2020
Association between hyperuricemia, gout, urate lowering therapy, and osteoarthritis: A protocol for a systematic review and meta-analysis.
    Medicine, 2020, Aug-14, Volume: 99, Issue:33

    Topics: Gout; Humans; Hyperuricemia; Meta-Analysis as Topic; Observational Studies as Topic; Osteoarthritis;

2020
Gout of ankle and foot: DECT versus US for crystal detection.
    Clinical rheumatology, 2021, Volume: 40, Issue:4

    Topics: Ankle; Arthritis, Gouty; Gout; Humans; Tomography, X-Ray Computed; Ultrasonography; Uric Acid

2021
Epidemiology of gout in Hong Kong: a population-based study from 2006 to 2016.
    Arthritis research & therapy, 2020, 09-04, Volume: 22, Issue:1

    Topics: Gout; Gout Suppressants; Hong Kong; Humans; Prevalence; Uric Acid

2020
Repair of Bone Erosion With Effective Urate-Lowering Therapy in a Patient With Tophaceous Gout.
    Arthritis & rheumatology (Hoboken, N.J.), 2021, Volume: 73, Issue:2

    Topics: Benzbromarone; Bone Resorption; Enzyme Inhibitors; Gout; Humans; Male; Metatarsal Bones; Metatarsoph

2021
A cross-sectional study of 502 patients found a diffuse hyperechoic kidney medulla pattern in patients with severe gout.
    Kidney international, 2021, Volume: 99, Issue:1

    Topics: Cross-Sectional Studies; Gout; Humans; Hyperuricemia; Kidney Medulla; Uric Acid

2021
Calcium Pyrophosphate Dihydrate Crystal Deposition in Gouty Tophi.
    Arthritis & rheumatology (Hoboken, N.J.), 2021, Volume: 73, Issue:2

    Topics: Adult; Age Factors; Aged; Calcium Pyrophosphate; Gout; Humans; Male; Microscopy, Electron, Scanning;

2021
Dual-energy CT in gout patients: Do all colour-coded lesions actually represent monosodium urate crystals?
    Arthritis research & therapy, 2020, 09-11, Volume: 22, Issue:1

    Topics: Color; Gout; Humans; Tendons; Tomography, X-Ray Computed; Uric Acid

2020
Coexistence of gout and chondrocalcinosis instead? Comment on: "Monosodium urate deposition in the articular cartilage and meniscus can mimic chondrocalcinosis" by Bousson et al. Joint Bone Spine 2020, 87:95-96.
    Joint bone spine, 2020, Volume: 87, Issue:6

    Topics: Cartilage, Articular; Chondrocalcinosis; Gout; Humans; Meniscus; Uric Acid

2020
Allopurinol: Good for Gout But Not for Preventing Loss of Kidney Function.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2021, Volume: 77, Issue:3

    Topics: Allopurinol; Diabetes Mellitus, Type 1; Gout; Gout Suppressants; Humans; Kidney; Uric Acid

2021
Use of electronic recruitment methods in a clinical trial of adults with gout.
    Clinical trials (London, England), 2021, Volume: 18, Issue:1

    Topics: Adult; Cross-Over Studies; Dietary Approaches To Stop Hypertension; Electronics; Female; Gout; Human

2021
Targeting uric acid levels in treating gout.
    Canadian family physician Medecin de famille canadien, 2020, Volume: 66, Issue:9

    Topics: Gout; Humans; Uric Acid

2020
Research in brief: Serum urate reduction and its effect on the progression of chronic kidney disease.
    Clinical medicine (London, England), 2020, Volume: 20, Issue:5

    Topics: Allopurinol; Diabetes Mellitus, Type 1; Disease Progression; Gout; Humans; Kidney; Renal Insufficien

2020
Factors associated with achieving target serum uric acid level and occurrence of gouty arthritis: A retrospective observational study of Japanese health insurance claims data.
    Pharmacoepidemiology and drug safety, 2021, Volume: 30, Issue:2

    Topics: Arthritis, Gouty; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Insurance, Health; Japan;

2021
Volumetric reduction and dissolution prediction of monosodium urate crystal during urate-lowering therapy - a study using dual-energy computed tomography.
    Modern rheumatology, 2021, Volume: 31, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Gout; Gout Suppressants; Humans; Male; Middle Aged; Polyethylene Gly

2021
Urate in fingernail represents the deposition of urate burden in gout patients.
    Scientific reports, 2020, 09-23, Volume: 10, Issue:1

    Topics: Adult; Chromatography, High Pressure Liquid; Female; Follow-Up Studies; Gout; Humans; Male; Middle A

2020
Variability in Urate-lowering Therapy Prescribing: A Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) Physician Survey.
    The Journal of rheumatology, 2021, 01-01, Volume: 48, Issue:1

    Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Physicians; Uric Acid

2021
Management of Gout-associated MSU crystals-induced NLRP3 inflammasome activation by procyanidin B2: targeting IL-1β and Cathepsin B in macrophages.
    Inflammopharmacology, 2020, Volume: 28, Issue:6

    Topics: Animals; Anti-Inflammatory Agents; Biflavonoids; Catechin; Cathepsin B; Cytokines; Dinoprostone; Gou

2020
Association of urate deposition shown by ultrasound and frequent gout attacks.
    Zeitschrift fur Rheumatologie, 2021, Volume: 80, Issue:6

    Topics: Arthritis, Gouty; Gout; Gout Suppressants; Humans; Ultrasonography; Uric Acid

2021
Pretreatment and Coadministration With Methotrexate Improved Durability of Pegloticase Response: An Observational, Proof-of-Concept Case Series.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2022, Jan-01, Volume: 28, Issue:1

    Topics: Gout; Gout Suppressants; Humans; Methotrexate; Polyethylene Glycols; Treatment Outcome; Urate Oxidas

2022
Prevalence of gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database.
    BMC pediatrics, 2020, 10-15, Volume: 20, Issue:1

    Topics: Adolescent; Child; Child, Preschool; Cross-Sectional Studies; Female; Gout; Humans; Hyperuricemia; I

2020
Rapid disappearance of gouty tophi of the foot by resection of massive gouty tophi of the opposite foot in a patient with hyperuricaemia: a case report.
    Modern rheumatology case reports, 2020, Volume: 4, Issue:1

    Topics: Adult; Arthritis, Gouty; Female; Gout; Humans; Hyperuricemia; Uric Acid

2020
Case with long-standing gout showing various ultrasonographic features caused by monosodium urate monohydrate crystal deposition.
    Modern rheumatology case reports, 2020, Volume: 4, Issue:1

    Topics: Gout; Humans; Hyaline Cartilage; Liquid Crystals; Synovial Fluid; Ultrasonography; Uric Acid

2020
Evaluation of the causal effects of blood lipid levels on gout with summary level GWAS data: two-sample Mendelian randomization and mediation analysis.
    Journal of human genetics, 2021, Volume: 66, Issue:5

    Topics: Age Factors; Causality; Cholesterol; Dyslipidemias; Genome-Wide Association Study; Gout; Humans; Hyp

2021
External validation of Gout-calculator performance on a cohort of acute arthritis (SYNOLACTATE) sparing distal joints such as hallux and midfoot. A cross-sectional study of 170 patients.
    Clinical rheumatology, 2021, Volume: 40, Issue:5

    Topics: Cross-Sectional Studies; Gout; Hallux; Humans; Male; Prospective Studies; Retrospective Studies; Syn

2021
Combined effects of MSU crystals injection and high fat-diet feeding on the establishment of a gout model in C57BL/6 mice.
    Advances in rheumatology (London, England), 2020, 11-04, Volume: 60, Issue:1

    Topics: Animals; Cytokines; Diet, High-Fat; Disease Models, Animal; Edema; Gout; Inflammation; Mice; Mice, I

2020
Discovery of a novel rice-derived peptide with significant anti-gout potency.
    Food & function, 2020, Dec-01, Volume: 11, Issue:12

    Topics: Animals; Edema; Female; Gout; Hyperuricemia; Inflammasomes; Inflammation; Interleukin-1beta; Kidney;

2020
IL-33/ST2 induces neutrophil-dependent reactive oxygen species production and mediates gout pain.
    Theranostics, 2020, Volume: 10, Issue:26

    Topics: Animals; Disease Models, Animal; Gout; Humans; Injections, Intra-Articular; Interleukin-1 Receptor-L

2020
Effects of Urate-Lowering Therapy on Risk of Hyperlipidemia in Gout by a Population-Based Cohort Study and on
    Mediators of inflammation, 2020, Volume: 2020

    Topics: Adult; Cohort Studies; Female; Gout; Hep G2 Cells; Humans; Hyperlipidemias; Incidence; Kaplan-Meier

2020
Real-world patterns of pegloticase use for treatment of gout: descriptive multidatabase cohort study.
    BMJ open, 2020, 12-07, Volume: 10, Issue:12

    Topics: Cohort Studies; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Polyethylene Glycols; Re

2020
Association between serum urate, gout and comorbidities: a case-control study using data from the UK Biobank.
    Rheumatology (Oxford, England), 2021, 07-01, Volume: 60, Issue:7

    Topics: Adult; Aged; Cardiovascular Diseases; Case-Control Studies; Comorbidity; Diabetes Mellitus; Female;

2021
Combining Model-Based Clinical Trial Simulation, Pharmacoeconomics, and Value of Information to Optimize Trial Design.
    CPT: pharmacometrics & systems pharmacology, 2021, Volume: 10, Issue:1

    Topics: Allopurinol; Bayes Theorem; Clinical Trials, Phase III as Topic; Computer Simulation; Decision Theor

2021
What is remission in gout and how should we measure it?
    Rheumatology (Oxford, England), 2021, 03-02, Volume: 60, Issue:3

    Topics: Biomarkers; Gout; Gout Suppressants; Humans; Remission Induction; Uric Acid

2021
Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease - Japanese Guideline on the Management of Asymptomatic Hyperuricemia.
    Circulation journal : official journal of the Japanese Circulation Society, 2021, 01-25, Volume: 85, Issue:2

    Topics: Allopurinol; Cardiovascular Diseases; Endothelial Cells; Febuxostat; Gout; Gout Suppressants; Humans

2021
[Evaluation of a 12-week allopurinol-lowering therapy in combination with the non-steroidal anti-inflammatory drug meloxicam in patients with gout].
    Terapevticheskii arkhiv, 2020, Jul-09, Volume: 92, Issue:6

    Topics: Allopurinol; Drug Therapy, Combination; Gout; Gout Suppressants; Humans; Hyperuricemia; Meloxicam; P

2020
Improved ultra-high performance liquid chromatographic method for simultaneous determination of five gout-related metabolites in human serum.
    Journal of separation science, 2021, Volume: 44, Issue:5

    Topics: Chromatography, High Pressure Liquid; Creatinine; Gout; Humans; Hypoxanthine; Inosine; Uric Acid; Xa

2021
Non-alcoholic fatty kidney disease (NAFKD): A novel disease that explains the etiology of hyperuricemia and gout in metabolic syndrome.
    Medical hypotheses, 2021, Volume: 146

    Topics: Adult; Female; Gout; Humans; Hyperuricemia; Kidney Diseases; Male; Metabolic Syndrome; Uric Acid

2021
Binding of Macrophage Receptor MARCO, LDL, and LDLR to Disease-Associated Crystalline Structures.
    Frontiers in immunology, 2020, Volume: 11

    Topics: Animals; Biomarkers; Carrier Proteins; Case-Control Studies; Cytokines; Disease Models, Animal; Dise

2020
A novel mouse model of hyperuricemia expressing a human functional ABCG2 variant.
    Kidney international, 2021, Volume: 99, Issue:1

    Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Gout; Humans; Hyperuricemia; Mice; Neoplasm

2021
Does gouty nephropathy exist, and is it more common than we think?
    Kidney international, 2021, Volume: 99, Issue:1

    Topics: Cross-Sectional Studies; Gout; Humans; Kidney Medulla; Ultrasonography; Uric Acid

2021
Effects of bariatric surgery on serum uric acid in people with obesity with or without hyperuricaemia and gout: a retrospective analysis.
    Rheumatology (Oxford, England), 2021, 08-02, Volume: 60, Issue:8

    Topics: Adult; Bariatric Surgery; Female; Gout; Humans; Hyperuricemia; Male; Middle Aged; Obesity; Retrospec

2021
Crystal deposition measured with dual-energy computed tomography: association with mortality and cardiovascular risks in gout.
    Rheumatology (Oxford, England), 2021, 10-02, Volume: 60, Issue:10

    Topics: Aged; Cardiovascular Diseases; Gout; Humans; Risk Factors; Tomography, X-Ray Computed; Uric Acid

2021
Effect of Topiroxostat on Brain Natriuretic Peptide Level in Patients with Heart Failure with Preserved Ejection Fraction: A Pilot Study.
    Journal of Nippon Medical School = Nippon Ika Daigaku zasshi, 2021, Nov-17, Volume: 88, Issue:5

    Topics: Aged; Aged, 80 and over; Biomarkers; Gout; Heart Failure; Humans; Hyperuricemia; Middle Aged; Natriu

2021
HSP60 Regulates Monosodium Urate Crystal-Induced Inflammation by Activating the TLR4-NF-
    Oxidative medicine and cellular longevity, 2020, Volume: 2020

    Topics: Adult; Animals; Antioxidants; Arthritis, Experimental; Case-Control Studies; Chaperonin 60; Gout; Hu

2020
How do dietary interventions affect serum urate and gout?
    Nature reviews. Rheumatology, 2021, Volume: 17, Issue:4

    Topics: Diet; Gout; Gout Suppressants; Humans; Hypertension; Uric Acid

2021
Expression, localization and metabolic function of "resurrected" human urate oxidase in human hepatocytes.
    International journal of biological macromolecules, 2021, Apr-01, Volume: 175

    Topics: Cell Proliferation; Gene Expression; Gout; HEK293 Cells; Hepatocytes; Humans; Hyperuricemia; Microsc

2021
Gout.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2021, Feb-01, Volume: 193, Issue:5

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Comorbidity; Gout; Gout Suppressants; Humans; Microscopy; P

2021
Limitations of dual-energy CT in the detection of monosodium urate deposition in dense liquid tophi and calcified tophi.
    Skeletal radiology, 2021, Volume: 50, Issue:8

    Topics: Arthritis, Gouty; Gout; Humans; Tomography, X-Ray Computed; Ultrasonography; Uric Acid

2021
Highly specific and label-free histological identification of microcrystals in fresh human gout tissues with stimulated Raman scattering.
    Theranostics, 2021, Volume: 11, Issue:7

    Topics: Animals; China; Disease Models, Animal; Gout; Histological Techniques; Humans; Male; Middle Aged; Ra

2021
Comorbidities and factors influencing frequent gout attacks in patients with gout: a cross-sectional study.
    Clinical rheumatology, 2021, Volume: 40, Issue:7

    Topics: Adult; Comorbidity; Cross-Sectional Studies; Female; Gout; Gout Suppressants; Humans; Male; Middle A

2021
Dual-Energy Computed Tomography for Detection and Characterization of Monosodium Urate, Calcium Pyrophosphate, and Hydroxyapatite: A Phantom Study on Diagnostic Performance.
    Investigative radiology, 2021, 07-01, Volume: 56, Issue:7

    Topics: Calcium Pyrophosphate; Durapatite; Gout; Humans; Tomography, X-Ray Computed; Uric Acid

2021
How Are We Managing Patients with Hyperuricemia and Gout: A Cross Sectional Study Assessing Knowledge and Attitudes of Primary Care Physicians?
    International journal of environmental research and public health, 2021, 01-30, Volume: 18, Issue:3

    Topics: Attitude; Cross-Sectional Studies; Gout; Humans; Hyperuricemia; Physicians, Primary Care; Uric Acid

2021
Synovial fluid analysis for the enhanced clinical diagnosis of crystal arthropathies in a tertiary care institution.
    Clinical rheumatology, 2021, Volume: 40, Issue:8

    Topics: Calcium Pyrophosphate; Gout; Humans; Synovial Fluid; Tertiary Healthcare; Uric Acid

2021
Genetic correlations between traits associated with hyperuricemia, gout, and comorbidities.
    European journal of human genetics : EJHG, 2021, Volume: 29, Issue:9

    Topics: Bayes Theorem; Blood Pressure; Cardiometabolic Risk Factors; Comorbidity; Creatinine; Genome-Wide As

2021
The comparative effect of exposure to various risk factors on the risk of hyperuricaemia: diet has a weak causal effect.
    Arthritis research & therapy, 2021, 03-04, Volume: 23, Issue:1

    Topics: Diet; Glucose Transport Proteins, Facilitative; Gout; Gout Suppressants; Humans; Hyperuricemia; Risk

2021
Loganin Alleviates Gout Inflammation by Suppressing NLRP3 Inflammasome Activation and Mitochondrial Damage.
    Molecules (Basel, Switzerland), 2021, Feb-18, Volume: 26, Issue:4

    Topics: Administration, Oral; Animals; Cells, Cultured; Disease Models, Animal; DNA, Mitochondrial; Gout; In

2021
Effects of fenofibrate therapy on renal function in primary gout patients.
    Rheumatology (Oxford, England), 2021, 11-03, Volume: 60, Issue:11

    Topics: Creatinine; Drug Monitoring; Electronic Health Records; Female; Fenofibrate; Gout; Humans; Hypolipid

2021
Presence of tophi is associated with a rapid decline in the renal function in patients with gout.
    Scientific reports, 2021, 03-11, Volume: 11, Issue:1

    Topics: Female; Follow-Up Studies; Glomerular Filtration Rate; Gout; Humans; Kidney; Kidney Function Tests;

2021
[Gout].
    Der Internist, 2021, Volume: 62, Issue:5

    Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Symptom Flare Up; Uric Acid

2021
Neutrophil extracellular trap clearance by synovial macrophages in gout.
    Arthritis research & therapy, 2021, 03-19, Volume: 23, Issue:1

    Topics: Arthritis, Gouty; Extracellular Traps; Gout; Humans; Macrophages; Uric Acid

2021
The URRAH study.
    Panminerva medica, 2021, Volume: 63, Issue:4

    Topics: Diabetes Mellitus, Type 2; Gout; Heart Failure; Humans; Hypertension; Retrospective Studies; Stroke;

2021
Genetic Predisposition to Type 2 Diabetes and Insulin Levels Is Positively Associated With Serum Urate Levels.
    The Journal of clinical endocrinology and metabolism, 2021, 06-16, Volume: 106, Issue:7

    Topics: Adult; Blood Glucose; Causality; Diabetes Mellitus, Type 2; Fasting; Female; Genetic Predisposition

2021
Drastic monosodium urate crystal dissolution with febuxostat and benzbromarone.
    Joint bone spine, 2021, Volume: 88, Issue:4

    Topics: Allopurinol; Benzbromarone; Febuxostat; Gout; Gout Suppressants; Humans; Solubility; Uric Acid

2021
Urate Lowering for Blood Pressure Control in Adults: Another Nail in the Coffin?
    Arthritis & rheumatology (Hoboken, N.J.), 2021, Volume: 73, Issue:8

    Topics: Adult; Blood Pressure; Gout; Gout Suppressants; Humans; Uric Acid

2021
12-month results from the real-life observational treat-to-target and tight-control therapy NOR-Gout study: achievements of the urate target levels and predictors of obtaining this target.
    RMD open, 2021, Volume: 7, Issue:1

    Topics: Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Symptom Flare Up; Treatment Outcome; Uri

2021
Ultrasound Evaluation of Three Outcome Domains in the Follow-up of Urate-Lowering Therapy in Gout: An Observational Study.
    Ultrasound in medicine & biology, 2021, Volume: 47, Issue:6

    Topics: Adult; Arthritis; Bone Diseases; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Hum

2021
Genetically predicted serum urate levels have no causal role on depression or other psychiatric disorders.
    Clinical rheumatology, 2021, Volume: 40, Issue:9

    Topics: Anxiety; Causality; Depression; Depressive Disorder, Major; Genome-Wide Association Study; Gout; Hum

2021
Temporal trends in hyperuricaemia among adults in Wuhan city, China, from 2010 to 2019: a cross-sectional study.
    BMJ open, 2021, 03-31, Volume: 11, Issue:3

    Topics: Adult; China; Cross-Sectional Studies; Female; Gout; Humans; Hyperuricemia; Male; Risk Factors; Uric

2021
Influence of Short-Term Consumption of
    Nutrients, 2021, Mar-21, Volume: 13, Issue:3

    Topics: Adult; Alkaline Phosphatase; Bacteria; Biomarkers; Creatinine; Fatty Acids, Volatile; Feces; Female;

2021
Substantial anti-gout effect conferred by common and rare dysfunctional variants of URAT1/SLC22A12.
    Rheumatology (Oxford, England), 2021, 11-03, Volume: 60, Issue:11

    Topics: Adult; Case-Control Studies; Genetic Variation; Gout; HEK293 Cells; Humans; Male; Middle Aged; Organ

2021
The inflammatory role of silent urate crystal deposition in intercritical gout.
    Rheumatology (Oxford, England), 2021, 11-03, Volume: 60, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Crystallization; Cytokines; Female; Gout; Huma

2021
Association between Anti-inflammatory Drug and Dementia in Patients with Gout: A Nationwide, Population-Based Nested Case-Control Study.
    International journal of medical sciences, 2021, Volume: 18, Issue:9

    Topics: Aged; Aged, 80 and over; Antirheumatic Agents; Case-Control Studies; Dementia; Female; Glucocorticoi

2021
Performance of Ultrasound in the Clinical Evaluation of Gout and Hyperuricemia.
    Journal of immunology research, 2021, Volume: 2021

    Topics: Adolescent; Adult; Aged; Arthritis, Gouty; Asymptomatic Diseases; Female; Gout; Humans; Hyperuricemi

2021
Polyarticular, ulcerated tophaceous gout.
    Journal of osteopathic medicine, 2021, 04-26, Volume: 121, Issue:6

    Topics: Gout; Humans; Ulcer; Uric Acid

2021
Real-world treatment of gout and asymptomatic hyperuricemia.
    Modern rheumatology, 2022, 02-28, Volume: 32, Issue:2

    Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid

2022
Cold-inducible RNA-binding protein (CIRP) potentiates uric acid-induced IL-1β production.
    Arthritis research & therapy, 2021, 04-26, Volume: 23, Issue:1

    Topics: Caspase 1; Gout; Humans; Inflammasomes; Interleukin-1beta; NLR Family, Pyrin Domain-Containing 3 Pro

2021
Association of urate-lowering drugs with the risk of future urolithiasis in patients with gout: A population-based nested case-control study.
    International journal of clinical practice, 2021, Volume: 75, Issue:8

    Topics: Case-Control Studies; Gout; Gout Suppressants; Humans; Male; Middle Aged; Pharmaceutical Preparation

2021
Gout-induced endothelial impairment: The role of SREBP2 transactivation of YAP.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2021, Volume: 35, Issue:6

    Topics: Animals; Cell Cycle Proteins; Gout; Human Umbilical Vein Endothelial Cells; Humans; Hyperuricemia; M

2021
Assessing the Causal Relationships Between Insulin Resistance and Hyperuricemia and Gout Using Bidirectional Mendelian Randomization.
    Arthritis & rheumatology (Hoboken, N.J.), 2021, Volume: 73, Issue:11

    Topics: Adult; Aged; Female; Genetic Loci; Gout; Humans; Hyperuricemia; Insulin; Insulin Resistance; Male; M

2021
CD300a contributes to the resolution of articular inflammation triggered by MSU crystals by controlling neutrophil apoptosis.
    Immunology, 2021, Volume: 164, Issue:2

    Topics: Animals; Antigens, CD; Apoptosis; Cells, Cultured; Gout; Humans; Inflammation; Interleukin-1beta; Jo

2021
Efficacy of subcutaneous tocilizumab in a patient with severe gout refractory to anakinra.
    Rheumatology (Oxford, England), 2021, 11-03, Volume: 60, Issue:11

    Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Drug Resistance; D

2021
Explaining the natural course of gout to people living in the tropics.
    International journal of rheumatic diseases, 2021, Volume: 24, Issue:6

    Topics: Gout; Gout Suppressants; Humans; Uric Acid

2021
Taxonomic variations in the gut microbiome of gout patients with and without tophi might have a functional impact on urate metabolism.
    Molecular medicine (Cambridge, Mass.), 2021, 05-24, Volume: 27, Issue:1

    Topics: Biodiversity; Computational Biology; Dysbiosis; Gastrointestinal Microbiome; Gout; Humans; Metagenom

2021
Melatonin Alleviates Acute Gouty Inflammation In Vivo and In Vitro.
    Current medical science, 2021, Volume: 41, Issue:4

    Topics: Acute Disease; Animals; Arthritis, Gouty; Disease Models, Animal; Gout; Humans; Inflammation; Interl

2021
Non-pharmacological treatment of gout.
    Vnitrni lekarstvi, 2021,Spring, Volume: 67, Issue:E-2

    Topics: Animals; Dairy Products; Diet; Gout; Humans; Hyperuricemia; Risk Factors; Uric Acid

2021
Urate levels and clearance in renal patients under peritoneal dialysis.
    Nucleosides, nucleotides & nucleic acids, 2021, Volume: 40, Issue:7

    Topics: Gout; Humans; Middle Aged; Peritoneal Dialysis; Uric Acid

2021
Tanshinones inhibit NLRP3 inflammasome activation by alleviating mitochondrial damage to protect against septic and gouty inflammation.
    International immunopharmacology, 2021, Volume: 97

    Topics: Abietanes; AMP-Activated Protein Kinases; Animals; Autophagy; Disease Models, Animal; Female; Furans

2021
Response to: 'Correspondence on 'Variants in urate transporters, ADH1B, GCKR and MEPE genes associated with transition from asymptomatic hyperuricaemia to gout: results of the first gout versus asymptomatic hyperuricaemia GWAS in Caucasians using data fro
    Annals of the rheumatic diseases, 2023, Volume: 82, Issue:7

    Topics: Adaptor Proteins, Signal Transducing; Biological Specimen Banks; Extracellular Matrix Proteins; Geno

2023
Correspondence on 'Variants in urate transporters,
    Annals of the rheumatic diseases, 2023, Volume: 82, Issue:7

    Topics: Adaptor Proteins, Signal Transducing; Biological Specimen Banks; Extracellular Matrix Proteins; Geno

2023
Highly permselective uric acid detection using kidney cell membrane-functionalized enzymatic biosensors.
    Biosensors & bioelectronics, 2021, Oct-15, Volume: 190

    Topics: Biosensing Techniques; Cell Membrane; Gout; Humans; Kidney; Uric Acid

2021
Gout of feet and ankles in different disease durations: diagnostic value of single-source DECT and evaluation of urate deposition with a novel semi-quantitative DECT scoring system.
    Advances in rheumatology (London, England), 2021, 06-12, Volume: 61, Issue:1

    Topics: Ankle; Arthritis, Gouty; Gout; Humans; Tomography, X-Ray Computed; Uric Acid

2021
Entheseal involvement of the lower extremities in gout: an ultrasonographic descriptive observational study.
    Clinical rheumatology, 2021, Volume: 40, Issue:11

    Topics: Achilles Tendon; Aged; Enthesopathy; Gout; Humans; Lower Extremity; Severity of Illness Index; Ultra

2021
Serum uric acid control for prevention of gout flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance claims and medical check-up data in Japan.
    Annals of the rheumatic diseases, 2021, Volume: 80, Issue:11

    Topics: Adolescent; Adult; Aged; Asymptomatic Diseases; Cohort Studies; Female; Gout; Gout Suppressants; Hum

2021
Cleroda-4(18),13-dien-15,16-olide as novel xanthine oxidase inhibitors: An integrated in silico and in vitro study.
    PloS one, 2021, Volume: 16, Issue:6

    Topics: Diterpenes, Clerodane; Enzyme Assays; Gout; Humans; Molecular Docking Simulation; Plant Extracts; Po

2021
Identification and characterization of peripheral vascular color-coded DECT lesions in gout and non-gout patients: The VASCURATE study.
    Seminars in arthritis and rheumatism, 2021, Volume: 51, Issue:4

    Topics: Arthritis, Gouty; Follow-Up Studies; Gout; Humans; Tomography, X-Ray Computed; Uric Acid

2021
Quercetin decreases the antinociceptive effect of diclofenac in an arthritic gout-pain model in rats.
    The Journal of pharmacy and pharmacology, 2021, Sep-07, Volume: 73, Issue:10

    Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Arthritis; Diclofenac; Dis

2021
Sonographic estimation of monosodium urate burden predicts the fulfillment of the 2016 remission criteria for gout: a 12-month study.
    Arthritis research & therapy, 2021, 07-09, Volume: 23, Issue:1

    Topics: Gout; Humans; Metatarsophalangeal Joint; Prospective Studies; Ultrasonography; Uric Acid

2021
Two-year reduction of dual-energy CT urate depositions during a treat-to-target strategy in gout in the NOR-Gout longitudinal study.
    Rheumatology (Oxford, England), 2022, 04-18, Volume: 61, Issue:SI

    Topics: Arthritis, Gouty; Gout; Gout Suppressants; Humans; Longitudinal Studies; Symptom Flare Up; Tomograph

2022
Simple metabolic markers associated with tophaceous gout.
    Clinical rheumatology, 2021, Volume: 40, Issue:12

    Topics: Glomerular Filtration Rate; Gout; Humans; Hyperuricemia; Uric Acid

2021
The GOUT-36 prediction rule for inpatient gout flare in people with comorbid gout: derivation and external validation.
    Rheumatology (Oxford, England), 2022, 04-11, Volume: 61, Issue:4

    Topics: Gout; Gout Suppressants; Humans; Inpatients; Prospective Studies; Symptom Flare Up; Uric Acid

2022
Factors Influencing Early Serum Uric Acid Fluctuation After Bariatric Surgery in Patients with Hyperuricemia.
    Obesity surgery, 2021, Volume: 31, Issue:10

    Topics: Bariatric Surgery; Gout; Humans; Hyperuricemia; Obesity, Morbid; Symptom Flare Up; Uric Acid

2021
Urate-induced epigenetic modifications in myeloid cells.
    Arthritis research & therapy, 2021, 07-28, Volume: 23, Issue:1

    Topics: Animals; Epigenesis, Genetic; Gout; Humans; Leukocytes, Mononuclear; Membrane Proteins; Mice; Monocy

2021
Factors Influencing the Serum Uric Acid in Gout with Cerebral Infarction.
    Mediators of inflammation, 2021, Volume: 2021

    Topics: Cerebral Infarction; Cross-Sectional Studies; Gout; Humans; Hypertension; Uric Acid

2021
Increased Systolic Blood Pressure Mediates the Relationship Between Urate and Gout Risk in Indonesia: A Novel Application of a Partial Least Squares-Structural Equation Model.
    Biological research for nursing, 2022, Volume: 24, Issue:1

    Topics: Adult; Blood Pressure; Case-Control Studies; Gout; Humans; Hyperuricemia; Indonesia; Least-Squares A

2022
Metagenomic analysis revealed the potential role of gut microbiome in gout.
    NPJ biofilms and microbiomes, 2021, 08-09, Volume: 7, Issue:1

    Topics: Adolescent; Adult; Aged; Arthritis; Bacteria; Butyrates; Diabetes Mellitus, Type 2; Dysbiosis; Fatty

2021
Gout-associated monosodium urate crystal-induced necrosis is independent of NLRP3 activity but can be suppressed by combined inhibitors for multiple signaling pathways.
    Acta pharmacologica Sinica, 2022, Volume: 43, Issue:5

    Topics: Animals; Arthritis, Gouty; Gout; Inflammasomes; Interleukin-1beta; Mice; Necrosis; NLR Family, Pyrin

2022
To Treat or Not to treat Asymptomatic Hyperuricemia.
    The Journal of the Association of Physicians of India, 2021, Volume: 69, Issue:7

    Topics: Asymptomatic Diseases; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid

2021
Lower Temperatures Exacerbate NLRP3 Inflammasome Activation by Promoting Monosodium Urate Crystallization, Causing Gout.
    Cells, 2021, 07-29, Volume: 10, Issue:8

    Topics: Animals; Caspase 1; Crystallization; Gout; Inflammasomes; Interleukin-1beta; Macrophages; Mice; NLR

2021
Acute Gout Following Dermofasciectomy in a Patient With Dupuytren Disease.
    The Journal of hand surgery, 2017, Volume: 42, Issue:1

    Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Dupuytren Contracture; Fasciotomy; Fingers;

2017
EULAR gout treatment guidelines by Richette
    Annals of the rheumatic diseases, 2018, Volume: 77, Issue:4

    Topics: Gout; Gout Suppressants; Humans; Uric Acid

2018
Performance of the 2015 American College of Rheumatology/European League Against Rheumatism gout classification criteria in Thai patients.
    Rheumatology international, 2017, Volume: 37, Issue:5

    Topics: Aged; Aged, 80 and over; Female; Gout; Humans; Male; Middle Aged; Rheumatology; Sensitivity and Spec

2017
Population-Specific Resequencing Associates the ATP-Binding Cassette Subfamily C Member 4 Gene With Gout in New Zealand Māori and Pacific Men.
    Arthritis & rheumatology (Hoboken, N.J.), 2017, Volume: 69, Issue:7

    Topics: Adult; Animals; Blotting, Western; Case-Control Studies; Female; Gout; Humans; Hyperuricemia; Logist

2017
Grape seed-derived procyanidins alleviate gout pain via NLRP3 inflammasome suppression.
    Journal of neuroinflammation, 2017, 04-04, Volume: 14, Issue:1

    Topics: Animals; Ankle; Anti-Inflammatory Agents; Antioxidants; Colchicine; Cytokines; Gout; Grape Seed Extr

2017
Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout.
    Scientific reports, 2017, 04-06, Volume: 7, Issue:1

    Topics: Adult; Animals; Benzbromarone; Biological Transport; Dose-Response Relationship, Drug; Gout; HEK293

2017
GOSPEL 3: Management of gout by primary-care physicians and office-based rheumatologists in France in the early 21st century - comparison with 2006 EULAR Recommendations.
    Joint bone spine, 2017, Volume: 84, Issue:4

    Topics: Allopurinol; Ambulatory Care; Colchicine; Female; France; Gout; Gout Suppressants; Health Behavior;

2017
SUA levels should not be maintained <3 mg/dL for several years. Response to 'EULAR gout treatment guidelines by Richette
    Annals of the rheumatic diseases, 2018, Volume: 77, Issue:4

    Topics: Gout; Gout Suppressants; Humans; Uric Acid

2018
The added value of synovial fluid centrifugation for monosodium urate and calcium pyrophosphate crystal detection.
    Clinical rheumatology, 2017, Volume: 36, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Calcium Pyrophosphate; Centrifugation; Chondrocalcinosis; Female; Go

2017
Performance of the 2015 ACR-EULAR classification criteria for gout in a primary care population presenting with monoarthritis.
    Rheumatology (Oxford, England), 2017, 08-01, Volume: 56, Issue:8

    Topics: Aged; Arthritis; Crystallization; Decision Support Techniques; Female; Gout; Humans; Male; Middle Ag

2017
An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome.
    American heart journal, 2017, Volume: 187

    Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; Cause of Death; Female; Gout; Humans; Male;

2017
Management of Gout and Hyperuricemia in CKD.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2017, Volume: 70, Issue:3

    Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Diet Therapy; Disease Management; Febuxostat;

2017
Previous Dosage of Allopurinol Is a Strong Determinant of Febuxostat Efficacy.
    Biological & pharmaceutical bulletin, 2017, Volume: 40, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Febuxostat; Glomerular Filtration Rate; Gout; Gout Supp

2017
Persistent clinical inertia in gout in 2014: An observational French longitudinal patient database study.
    Joint bone spine, 2018, Volume: 85, Issue:3

    Topics: Age Factors; Aged; Comorbidity; Databases, Factual; Female; France; General Practice; Gout; Gout Sup

2018
Uric acid priming in human monocytes is driven by the AKT-PRAS40 autophagy pathway.
    Proceedings of the National Academy of Sciences of the United States of America, 2017, 05-23, Volume: 114, Issue:21

    Topics: Adaptor Proteins, Signal Transducing; Animals; Autophagy; Disease Models, Animal; Gout; Granulomatou

2017
Metabolic characteristics and renal dysfunction in 65 patients with tophi prior to gout.
    Clinical rheumatology, 2017, Volume: 36, Issue:8

    Topics: Disease Progression; Female; Glomerular Filtration Rate; Gout; Humans; Kidney; Male; Middle Aged; Se

2017
First validation of the gout activity score against gout impact scale in a primary care based gout cohort.
    Joint bone spine, 2018, Volume: 85, Issue:3

    Topics: Adult; Age Factors; Aged; Cohort Studies; Cross-Sectional Studies; Female; Gout; Gout Suppressants;

2018
Cardiovascular Disease and Gout: Real-World Experience Evaluating Patient Characteristics, Treatment Patterns, and Health Care Utilization.
    Journal of managed care & specialty pharmacy, 2017, Volume: 23, Issue:6

    Topics: Cardiovascular Diseases; Female; Gout; Humans; Hyperuricemia; Logistic Models; Male; Middle Aged; Pa

2017
A survey on the beliefs and knowledge of gout management in new medical graduates - New South Wales, Australia.
    International journal of rheumatic diseases, 2018, Volume: 21, Issue:2

    Topics: Attitude of Health Personnel; Biomarkers; Clinical Competence; Clinical Decision-Making; Education,

2018
Response to: 'Is optimizing gout treatment the key to closing the mortality gap in gout patients?' by Brinck
    Annals of the rheumatic diseases, 2018, Volume: 77, Issue:1

    Topics: Gout; Humans; Mortality, Premature; Research Design; Uric Acid

2018
S100A9 potentiates the activation of neutrophils by the etiological agent of gout, monosodium urate crystals.
    Journal of leukocyte biology, 2017, Volume: 102, Issue:3

    Topics: Adult; Calcium; Calcium Signaling; Calgranulin B; Female; Gout; Humans; Interleukin-1; Interleukin-8

2017
The rate of adherence to urate-lowering therapy and associated factors in Chinese gout patients: a cross-sectional study.
    Rheumatology international, 2017, Volume: 37, Issue:7

    Topics: Adult; Aged; Asian People; Biomarkers; Chi-Square Distribution; China; Cross-Sectional Studies; Down

2017
The Economic Value of Genetic Testing for Tolerance of Allopurinol in Gout.
    The Journal of rheumatology, 2017, Volume: 44, Issue:6

    Topics: Allopurinol; Genetic Testing; Gout; Gout Suppressants; Humans; Uric Acid

2017
An optimal ultrasonographic diagnostic test for early gout: A prospective controlled study.
    The Journal of international medical research, 2017, Volume: 45, Issue:4

    Topics: Adult; Aged; Ankle Joint; Case-Control Studies; Early Diagnosis; Female; Gout; Humans; Knee Joint; M

2017
Comparison of dual-energy CT, ultrasound and surface measurement for assessing tophus dissolution during rapid urate debulking.
    Clinical rheumatology, 2017, Volume: 36, Issue:9

    Topics: Adult; Chronic Disease; Gout; Humans; Male; Physical Examination; Polyethylene Glycols; Quality of L

2017
Replication of Gout/Urate Concentrations GWAS Susceptibility Loci Associated with Gout in a Han Chinese Population.
    Scientific reports, 2017, 06-22, Volume: 7, Issue:1

    Topics: Alleles; Asian People; Biomarkers; China; Female; Genetic Loci; Genetic Predisposition to Disease; G

2017
The Impact of Eid Al-Fitr on Serum Uric Acid and Arthritis among Patients with Gout.
    The Israel Medical Association journal : IMAJ, 2017, Volume: 19, Issue:6

    Topics: Arthritis; Fasting; Gout; Humans; Islam; Uric Acid

2017
Clinically-evident tophi are associated with reduced muscle force in the foot and ankle in people with gout: a cross-sectional study.
    Journal of foot and ankle research, 2017, Volume: 10

    Topics: Achilles Tendon; Ankle Joint; Biomechanical Phenomena; Cross-Sectional Studies; Female; Foot; Gout;

2017
Interaction of the GCKR and A1CF loci with alcohol consumption to influence the risk of gout.
    Arthritis research & therapy, 2017, 07-05, Volume: 19, Issue:1

    Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Alcohol Drinking; Female; Gene-Environment Intera

2017
In Reply to 'Detection of Urate Crystals in Kidney Tissue'.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2017, Volume: 70, Issue:3

    Topics: Crystallization; Gout; Humans; Uric Acid

2017
Tophaceous Gout of the Lumbar Spine Mimicking Malignancy on FDG PET/CT.
    Clinical nuclear medicine, 2017, Volume: 42, Issue:9

    Topics: Diagnosis, Differential; Gout; Humans; Lumbar Vertebrae; Male; Middle Aged; Positron Emission Tomogr

2017
Clinical significance of delta neutrophil index in the differential diagnosis between septic arthritis and acute gout attack within 24 hours after hospitalization.
    Medicine, 2017, Volume: 96, Issue:30

    Topics: Aged; Arthritis, Infectious; Biomarkers; Diagnosis, Differential; Female; Gout; Hospitalization; Hum

2017
Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients.
    Rheumatology international, 2017, Volume: 37, Issue:9

    Topics: Aged; Aged, 80 and over; Biomarkers; Clinical Audit; Down-Regulation; Drug Therapy, Combination; Fem

2017
Uric acid and incident dementia over 12 years of follow-up: a population-based cohort study.
    Annals of the rheumatic diseases, 2018, Volume: 77, Issue:3

    Topics: Aged; Aged, 80 and over; Aging; Biomarkers; Brain; Cohort Studies; Dementia; Female; Follow-Up Studi

2018
Management of Gout in a Hospital Setting: A Lost Opportunity.
    The Journal of rheumatology, 2017, Volume: 44, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Disease Management; Female; Gout; Gout Suppressants; Guideline Adher

2017
My Treatment Approach to Gout.
    Mayo Clinic proceedings, 2017, Volume: 92, Issue:8

    Topics: Gout; Guideline Adherence; Humans; Tomography, X-Ray Computed; Ultrasonography; Uric Acid

2017
Performance of gout definitions for genetic epidemiological studies: analysis of UK Biobank.
    Arthritis research & therapy, 2017, 08-09, Volume: 19, Issue:1

    Topics: Adult; Aged; Biological Specimen Banks; Europe; Female; Genetic Predisposition to Disease; Gout; Gou

2017
Calcium pyrophosphate deposition disease: a frequent finding in patients with long-standing erosive gout.
    Scandinavian journal of rheumatology, 2018, Volume: 47, Issue:2

    Topics: Aged; Aged, 80 and over; Calcium Pyrophosphate; Chondrocalcinosis; Female; Gout; Humans; Male; Middl

2018
Allopurinol Medication Adherence as a Mediator of Optimal Outcomes in Gout Management.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2017, Volume: 23, Issue:6

    Topics: Aged; Allopurinol; Clinical Pharmacy Information Systems; Disease Management; Dose-Response Relation

2017
Prescription pattern of urate-lowering therapy in Korean gout patients: data from the national health claims database.
    The Korean journal of internal medicine, 2018, Volume: 33, Issue:1

    Topics: Allopurinol; Benzbromarone; Databases, Factual; Febuxostat; Gout; Gout Suppressants; Humans; Republi

2018
Dyslipidemia, Alcohol Consumption, and Obesity as Main Factors Associated With Poor Control of Urate Levels in Patients Receiving Urate-Lowering Therapy.
    Arthritis care & research, 2018, Volume: 70, Issue:6

    Topics: Aged; Alcohol Drinking; Comorbidity; Cross-Sectional Studies; Dyslipidemias; Female; France; Gout; G

2018
Impact of non-adherence on the safety and efficacy of uric acid-lowering therapies in the treatment of gout.
    British journal of clinical pharmacology, 2018, Volume: 84, Issue:1

    Topics: Computer Simulation; Drug Therapy, Combination; Febuxostat; Gout; Gout Suppressants; Humans; Male; M

2018
Elevated UMOD methylation level in peripheral blood is associated with gout risk.
    Scientific reports, 2017, 09-11, Volume: 7, Issue:1

    Topics: Adult; Aged; Blood Chemical Analysis; DNA Methylation; Gout; Humans; Male; Middle Aged; Real-Time Po

2017
Evaluating the urate-lowering effects of different microbial fermented extracts in hyperuricemic models accompanied with a safety study.
    Journal of food and drug analysis, 2017, Volume: 25, Issue:3

    Topics: Animals; Fermentation; Gout; Gout Suppressants; Hyperuricemia; Mice; Uric Acid; Xanthine Oxidase

2017
Role of serum urate in neurocognitive function and dementia: new evidence contradicts old thinking.
    Annals of the rheumatic diseases, 2018, Volume: 77, Issue:3

    Topics: Cohort Studies; Dementia; Gout; Humans; Research Design; Uric Acid

2018
The problem of cardio-renal diseases in patients with gout.
    Current medical research and opinion, 2017, Volume: 33, Issue:sup3

    Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Risk Factors; Ur

2017
[Dual-energy CT: new diagnostic possibilities].
    Nederlands tijdschrift voor geneeskunde, 2017, Volume: 161

    Topics: Absorptiometry, Photon; Gout; Humans; Sensitivity and Specificity; Tomography, X-Ray Computed; Uric

2017
A common variant of MAF/c-MAF, transcriptional factor gene in the kidney, is associated with gout susceptibility.
    Human cell, 2018, Volume: 31, Issue:1

    Topics: Adult; Asian People; Cell Differentiation; Gene Frequency; Genetic Association Studies; Genetic Pred

2018
Elderly Patients Exhibit Stronger Inflammatory Responses during Gout Attacks.
    Journal of Korean medical science, 2017, Volume: 32, Issue:12

    Topics: Adult; Age Factors; Aged; Blood Sedimentation; C-Reactive Protein; Female; Fever; Gout; Humans; Inte

2017
Lesinurad/allopurinol (Duzallo) for gout-associated hyperuricemia.
    The Medical letter on drugs and therapeutics, 2017, 11-06, Volume: 59, Issue:1533

    Topics: Allopurinol; Biomarkers; Drug Combinations; Gout; Gout Suppressants; Humans; Hyperuricemia; Thioglyc

2017
Use of urate-lowering therapies is not associated with an increased risk of incident dementia in older adults.
    Annals of the rheumatic diseases, 2018, Volume: 77, Issue:10

    Topics: Aged; Dementia; Gout; Humans; Uric Acid

2018
Response to: 'Uric acid and incident dementia: a population-based cohort study' by Lee and Song.
    Annals of the rheumatic diseases, 2018, Volume: 77, Issue:9

    Topics: Cohort Studies; Dementia; Gout; Humans; Research Design; Uric Acid

2018
Adherence to gout management recommendations of Chinese patients.
    Medicine, 2017, Volume: 96, Issue:45

    Topics: Adult; Age Factors; China; Gout; Gout Suppressants; Humans; Logistic Models; Male; Medication Adhere

2017
Response to: 'Use of urate-lowering therapies is not associated with an increase in the risk of incident dementia in older adults' by Lee and Song.
    Annals of the rheumatic diseases, 2018, Volume: 77, Issue:10

    Topics: Aged; Dementia; Gout; Humans; Hyperuricemia; Uric Acid

2018
Growth patterns of monosodium urate monohydrate (gouty and urinary) crystals in gel: An in vitro study.
    Pakistan journal of pharmaceutical sciences, 2017, Volume: 30, Issue:6

    Topics: Crystallization; Gels; Gout; Humans; Kidney Calculi; Microscopy, Electron, Scanning; Silicates; Spec

2017
Ultrasonographic detection of double contour sign and hyperechoic aggregates for diagnosis of gout: two sites examination is as good as six sites examination.
    International journal of rheumatic diseases, 2018, Volume: 21, Issue:2

    Topics: Adult; Ankle Joint; Biomarkers; Cartilage, Articular; Female; Gout; Humans; Knee Joint; Male; Metata

2018
Variability in the Reporting of Serum Urate and Flares in Gout Clinical Trials: Need for Minimum Reporting Requirements.
    The Journal of rheumatology, 2018, Volume: 45, Issue:3

    Topics: Biomarkers; Clinical Trials as Topic; Gout; Humans; Observational Studies as Topic; Outcome Assessme

2018
Treatment of gout: where are we now?
    Rheumatology (Oxford, England), 2018, 01-01, Volume: 57, Issue:suppl_1

    Topics: Gout; Gout Suppressants; Humans; Uric Acid

2018
Anorexia nervosa and uric acid beyond gout: An idea worth researching.
    The International journal of eating disorders, 2018, Volume: 51, Issue:2

    Topics: Anorexia Nervosa; Gout; Humans; Hyperuricemia; Research; Uric Acid

2018
Joint nociceptor nerve activity and pain in an animal model of acute gout and its modulation by intra-articular hyaluronan.
    Pain, 2018, Volume: 159, Issue:4

    Topics: Acute Pain; Adjuvants, Immunologic; Animals; Antioxidants; Disease Models, Animal; Flow Cytometry; G

2018
Suppression of NLRP3 inflammasome by oral treatment with sulforaphane alleviates acute gouty inflammation.
    Rheumatology (Oxford, England), 2018, 04-01, Volume: 57, Issue:4

    Topics: Acute Disease; Administration, Oral; Animals; Anticarcinogenic Agents; Cells, Cultured; Disease Mode

2018
Clinical characteristics associated with subcutaneous tophi formation in Chinese gout patients: a retrospective study.
    Clinical rheumatology, 2018, Volume: 37, Issue:5

    Topics: Adult; Age of Onset; Aged; Blood Pressure; China; Disease Progression; Female; Gout; Humans; Male; M

2018
Monosodium Urate Crystals Generate Nuclease-Resistant Neutrophil Extracellular Traps via a Distinct Molecular Pathway.
    Journal of immunology (Baltimore, Md. : 1950), 2018, 03-01, Volume: 200, Issue:5

    Topics: Extracellular Traps; Gout; Humans; Leukocyte Elastase; Male; Neutrophils; Synovial Fluid; Uric Acid

2018
Gouty arthritis: decision-making following dual-energy CT scan in clinical practice, a retrospective analysis.
    Clinical rheumatology, 2018, Volume: 37, Issue:7

    Topics: Adult; Aged; Arthritis, Gouty; Clinical Decision-Making; Female; Gout; Humans; Male; Middle Aged; Ne

2018
Effective uric acid reduction with probenecid and febuxostat in a patient with chronic kidney disease.
    BMJ case reports, 2018, Jan-31, Volume: 2018

    Topics: Adult; Chronic Disease; Drug Therapy, Combination; Febuxostat; Foot Deformities, Acquired; Gout; Gou

2018
Uric acid and cognitive decline: a double-edge sword?
    Current opinion in rheumatology, 2018, Volume: 30, Issue:2

    Topics: Cognitive Dysfunction; Cross-Sectional Studies; Dementia; Gout; Humans; Hyperuricemia; Oxidative Str

2018
Response to: "Monosodium urate crystal deposition associated with the progress of radiographic grade at the sacroiliac joint in axial SpA: a dual-energy CT study".
    Arthritis research & therapy, 2018, 02-12, Volume: 20, Issue:1

    Topics: Gout; Humans; Sacroiliac Joint; Sacroiliitis; Tomography, X-Ray Computed; Uric Acid

2018
MR-PheWAS: exploring the causal effect of SUA level on multiple disease outcomes by using genetic instruments in UK Biobank.
    Annals of the rheumatic diseases, 2018, Volume: 77, Issue:7

    Topics: Adult; Arthritis; Autoimmune Diseases; Biological Specimen Banks; Celiac Disease; Female; Genetic Pr

2018
Ultrasound scans and dual energy CT identify tendons as preferred anatomical location of MSU crystal depositions in gouty joints.
    Rheumatology international, 2018, Volume: 38, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ankle Joint; Crystallization; Female; Gout; Humans; Knee

2018
Management of gout by UK rheumatologists: a British Society for Rheumatology national audit.
    Rheumatology (Oxford, England), 2018, 05-01, Volume: 57, Issue:5

    Topics: Clinical Audit; Disease Management; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Outp

2018
The Cost-effectiveness of Biannual Serum Urate (SU) Monitoring after Reaching Target in Gout: A Health Economic Analysis Comparing SU Monitoring.
    The Journal of rheumatology, 2018, Volume: 45, Issue:5

    Topics: Australia; Cost-Benefit Analysis; Gout; Humans; Mass Screening; Quality-Adjusted Life Years; Uric Ac

2018
Impaired arterial responsiveness in untreated gout patients compared with healthy non-gout controls: association with serum urate and C-reactive protein.
    Clinical rheumatology, 2018, Volume: 37, Issue:7

    Topics: Adult; Aged; Brachial Artery; C-Reactive Protein; Case-Control Studies; Cross-Sectional Studies; End

2018
Levels of Cytokines and MicroRNAs in Individuals With Asymptomatic Hyperuricemia and Ultrasonographic Findings of Gout: A Bench-to-Bedside Approach.
    Arthritis care & research, 2018, Volume: 70, Issue:12

    Topics: Adult; Aged; Asymptomatic Diseases; Biomarkers; Case-Control Studies; Chronic Disease; Circulating M

2018
Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis.
    Annals of the rheumatic diseases, 2018, Volume: 77, Issue:7

    Topics: Adult; Age Distribution; Cohort Studies; Data Analysis; Disease Progression; Gout; Humans; Hyperuric

2018
    MMW Fortschritte der Medizin, 2018, Volume: 160, Issue:3

    Topics: Cohort Studies; Gout; Humans; Immune System; Infections; Uric Acid

2018
[Acid uric : key player in a recently recognized devastating nephropathy and in the development of chronic kidney disease.]
    Revue medicale suisse, 2018, Feb-21, Volume: 14, Issue:595

    Topics: Central America; Disease Progression; Gout; Humans; Renal Insufficiency, Chronic; Uric Acid

2018
Development of benzoxazole deoxybenzoin oxime and acyloxylamine derivatives targeting innate immune sensors and xanthine oxidase for treatment of gout.
    Bioorganic & medicinal chemistry, 2018, 05-01, Volume: 26, Issue:8

    Topics: Amines; Animals; Benzoin; Benzoxazoles; Cell Line; Dose-Response Relationship, Drug; Enzyme Inhibito

2018
An evaluation of longitudinal changes in serum uric acid levels and associated risk of cardio-metabolic events and renal function decline in gout.
    PloS one, 2018, Volume: 13, Issue:2

    Topics: Cardiovascular Diseases; Cohort Studies; Female; Follow-Up Studies; Gout; Humans; Kidney; Longitudin

2018
Coffee consumption and gout: a Mendelian randomisation study.
    Annals of the rheumatic diseases, 2018, Volume: 77, Issue:10

    Topics: Adult; Coffee; Female; Gout; Humans; Male; Mendelian Randomization Analysis; Polymorphism, Single Nu

2018
Genetic variants in two pathways influence serum urate levels and gout risk: a systematic pathway analysis.
    Scientific reports, 2018, 03-01, Volume: 8, Issue:1

    Topics: Asian People; Case-Control Studies; China; Female; Genetic Loci; Genetic Predisposition to Disease;

2018
Chronic Disease Approaches Needed to Curb Gout's Growing Burden.
    JAMA, 2018, Apr-03, Volume: 319, Issue:13

    Topics: Allopurinol; Chronic Disease; Diet; Drug Combinations; Febuxostat; Gout; Gout Suppressants; Healthy

2018
Improvement in OMERACT domains and renal function with regular treatment for gout: a 12-month follow-up cohort study.
    Clinical rheumatology, 2018, Volume: 37, Issue:7

    Topics: Adult; Allopurinol; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Kidney; Male; Mexico

2018
Reference level of serum urate for clinically evident incident gout.
    Annals of the rheumatic diseases, 2019, Volume: 78, Issue:5

    Topics: Data Analysis; Gout; Humans; Hyperuricemia; Uric Acid

2019
Response to: 'The reference levels of serum urate for clinically evident incident gout' by Chen and Ding.
    Annals of the rheumatic diseases, 2019, Volume: 78, Issue:5

    Topics: Data Analysis; Gout; Humans; Hyperuricemia; Uric Acid

2019
Could corneal densitometry be used as a diagnostic and screening tool for ocular involvement in patients with gout?
    International ophthalmology, 2019, Volume: 39, Issue:5

    Topics: Adult; Aged; Biomarkers; Cornea; Corneal Diseases; Corneal Topography; Densitometry; Female; Follow-

2019
Impact of diuretics on the urate lowering therapy in patients with gout: analysis of an inception cohort.
    Arthritis research & therapy, 2018, 03-22, Volume: 20, Issue:1

    Topics: Aged; Aged, 80 and over; Cohort Studies; Diuretics; Female; Follow-Up Studies; Gout; Gout Suppressan

2018
Blocking fatty acid-fueled mROS production within macrophages alleviates acute gouty inflammation.
    The Journal of clinical investigation, 2018, 05-01, Volume: 128, Issue:5

    Topics: Animals; Animals, Genetically Modified; Disease Models, Animal; Fatty Acids; Gout; Humans; Inflammat

2018
[Gout - a treatable condition].
    Laeknabladid, 2018, Volume: 104, Issue:4

    Topics: Biomarkers; Gout; Gout Suppressants; Humans; Life Style; Practice Guidelines as Topic; Risk Factors;

2018
4-(2-(4-chlorophenyl)-1-((4-chlorophenyl)amino)ethyl)benzene-1, 3-diol is a potential agent for gout therapy as a dual inhibitor of XOD and NLRP3.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2018, Mar-15, Volume: 42

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzene Derivatives; Enzyme Inhibitors; Gout; Huma

2018
Monosodium urate crystals induced ICAM-1 expression and cell-cell adhesion in renal mesangial cells: Implications for the pathogenesis of gouty nephropathy.
    Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2020, Volume: 53, Issue:1

    Topics: Cell Adhesion; Cell Line; Gout; Humans; Intercellular Adhesion Molecule-1; Kidney; Kidney Diseases;

2020
Crystal-proven Gout and Characteristic Gout Severity Factors Are Associated with Cardiovascular Disease.
    The Journal of rheumatology, 2018, Volume: 45, Issue:6

    Topics: Adult; Aged; Cardiovascular Diseases; Comorbidity; Cross-Sectional Studies; Female; Gout; Humans; Ma

2018
Mediators of the Effects of Gender on Uric Acid Nephrolithiasis: A Novel Application of Structural Equation Modeling.
    Scientific reports, 2018, 04-17, Volume: 8, Issue:1

    Topics: Adult; Aged; Female; Glomerular Filtration Rate; Gout; Humans; Likelihood Functions; Male; Middle Ag

2018
The nomenclature of the basic disease elements of gout: A content analysis of contemporary medical journals.
    Seminars in arthritis and rheumatism, 2018, Volume: 48, Issue:3

    Topics: Gout; Humans; Hyperuricemia; Terminology as Topic; Uric Acid

2018
Surprising safety outcomes of urate-lowering therapy.
    Nature reviews. Rheumatology, 2018, Volume: 14, Issue:6

    Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Uric Acid

2018
Accuracy of the HumaSens
    Arthritis research & therapy, 2018, 05-02, Volume: 20, Issue:1

    Topics: Blood Specimen Collection; Female; Gout; Humans; Hyperuricemia; Male; Middle Aged; Point-of-Care Sys

2018
Untangling the complex relationships between incident gout risk, serum urate, and its comorbidities.
    Arthritis research & therapy, 2018, 05-03, Volume: 20, Issue:1

    Topics: Adult; Aged; Black or African American; Comorbidity; Female; Gout; Humans; Hypertension; Incidence;

2018
Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout.
    Arthritis care & research, 2019, Volume: 71, Issue:3

    Topics: Consensus; Crystal Arthropathies; Delphi Technique; Gout; Humans; Hyperuricemia; Uric Acid

2019
Pharmacophore modeling, molecular docking and molecular dynamics studies on natural products database to discover novel skeleton as non-purine xanthine oxidase inhibitors.
    Journal of receptor and signal transduction research, 2018, Volume: 38, Issue:3

    Topics: Biological Products; Enzyme Inhibitors; Gout; Humans; Ligands; Molecular Docking Simulation; Molecul

2018
The lack of association between the burden of monosodium urate crystals assessed with dual-energy computed tomography or ultrasonography with cardiovascular risk in the commonly high-risk gout patient.
    Arthritis research & therapy, 2018, 05-29, Volume: 20, Issue:1

    Topics: Adult; Aged; Cardiovascular Diseases; Cross-Sectional Studies; Female; Gout; Humans; Male; Middle Ag

2018
Comorbidity in gout at the time of first diagnosis: sex differences that may have implications for dosing of urate lowering therapy.
    Arthritis research & therapy, 2018, 06-01, Volume: 20, Issue:1

    Topics: Aged; Aged, 80 and over; Case-Control Studies; Comorbidity; Dose-Response Relationship, Drug; Early

2018
GLUT9 influences uric acid concentration in patients with Lesch-Nyhan disease.
    International journal of rheumatic diseases, 2018, Volume: 21, Issue:6

    Topics: Adolescent; Adult; Allopurinol; ATP Binding Cassette Transporter, Subfamily G, Member 2; Biomarkers;

2018
Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD).
    Rheumatology (Oxford, England), 2018, 09-01, Volume: 57, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Biomarkers; Female; Follow-Up Studies; Gout; Gout Suppr

2018
[Analysis of serum ferritin and high sensitive C reactive protein in patients with gout].
    Wei sheng yan jiu = Journal of hygiene research, 2017, Volume: 46, Issue:2

    Topics: C-Reactive Protein; Ferritins; Gout; Humans; Hyperuricemia; Male; Uric Acid

2017
From hyperuricaemia to gout: what are the missing links?
    Nature reviews. Rheumatology, 2018, Volume: 14, Issue:8

    Topics: Data Analysis; Gout; Humans; Hyperuricemia; Risk Factors; Uric Acid

2018
Study on the expressions of NLRP3 gene transcript variants in peripheral blood monocytes of primary gout patients.
    Clinical rheumatology, 2018, Volume: 37, Issue:9

    Topics: Adult; Case-Control Studies; China; Cross-Sectional Studies; Gene Expression; Gout; Humans; Interleu

2018
Association of gout with osteoporotic fractures.
    International orthopaedics, 2018, Volume: 42, Issue:9

    Topics: Aged; Aged, 80 and over; Bone Density; Cross-Sectional Studies; Female; Gout; Humans; Male; Middle A

2018
Chronic gout: Barriers to effective management.
    Australian journal of general practice, 2018, Volume: 47, Issue:6

    Topics: Australia; Disease Management; Gout; Gout Suppressants; Humans; Primary Health Care; Rheumatology; U

2018
Mediation analysis to understand genetic relationships between habitual coffee intake and gout.
    Arthritis research & therapy, 2018, 07-05, Volume: 20, Issue:1

    Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Alleles; ATP Binding Cassette Transporter, Subfam

2018
Gouty arthritis: Can we avoid unnecessary dual-energy CT examinations using prior radiographs?
    PloS one, 2018, Volume: 13, Issue:7

    Topics: Adult; Aged; Algorithms; Arthritis, Gouty; False Negative Reactions; Female; Gout; Humans; Male; Mid

2018
Editorial Commentary: Prevention and treatment of atrial fibrillation: Is hyperuricemia the next target?
    Trends in cardiovascular medicine, 2019, Volume: 29, Issue:1

    Topics: Atrial Fibrillation; Gout; Humans; Hyperuricemia; Uric Acid

2019
Urate-lowering treatment and risk of total joint replacement in patients with gout.
    Rheumatology (Oxford, England), 2018, 12-01, Volume: 57, Issue:12

    Topics: Aged; Arthroplasty, Replacement; Databases, Factual; Female; Gout; Gout Suppressants; Humans; Incide

2018
Urate crystals induce macrophage PAF‑AH secretion which is differentially regulated by TGFβ1 and hydrocortisone.
    Molecular medicine reports, 2018, Volume: 18, Issue:3

    Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Colchicine; Cytokines; Gout; Humans; Hydrocortisone;

2018
Genetic Background of a Juvenile Onset Gout Patient.
    Chinese medical journal, 2018, 08-20, Volume: 131, Issue:16

    Topics: Adult; Genetic Background; Gout; Humans; Hyperuricemia; Kidney Diseases; Male; Uric Acid; Young Adul

2018
Genetic association between adiposity and gout: a Mendelian randomization study.
    Rheumatology (Oxford, England), 2018, 12-01, Volume: 57, Issue:12

    Topics: Adiposity; Adult; Body Mass Index; Female; Gout; Humans; Male; Mendelian Randomization Analysis; Mid

2018
The relationship between ferritin and urate levels and risk of gout.
    Arthritis research & therapy, 2018, 08-15, Volume: 20, Issue:1

    Topics: Black or African American; Female; Ferritins; Gout; Humans; Male; Middle Aged; Native Hawaiian or Ot

2018
Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout.
    Rheumatology (Oxford, England), 2019, 01-01, Volume: 58, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Clinical Trials, Phase III as T

2019
Long-term Treatment of Gout: New Opportunities for Improved Outcomes.
    The Journal of family practice, 2018, Volume: 67, Issue:8 suppl

    Topics: Adult; Aged; Aged, 80 and over; Curriculum; Education, Medical, Continuing; Female; Gout; Gout Suppr

2018
Plasma D-dimer is a Promising Indicator for the Treatment of Acute Gouty Attack.
    Annals of clinical and laboratory science, 2018, Volume: 48, Issue:4

    Topics: Acute Disease; Blood Sedimentation; C-Reactive Protein; Female; Fibrin Fibrinogen Degradation Produc

2018
The benchmark dose estimation of reference levels of serum urate for gout.
    Clinical rheumatology, 2018, Volume: 37, Issue:10

    Topics: Adult; Benchmarking; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Hyperuricemia; Male

2018
The risk of clinically diagnosed gout by serum urate levels: results from 30 years follow-up of the Malmö Preventive Project cohort in southern Sweden.
    Arthritis research & therapy, 2018, 08-29, Volume: 20, Issue:1

    Topics: Adult; Cohort Studies; Female; Follow-Up Studies; Gout; Humans; Hyperuricemia; Male; Mass Screening;

2018
Hyperuricemia and dementia - a case-control study.
    BMC neurology, 2018, Aug-31, Volume: 18, Issue:1

    Topics: Aged; Case-Control Studies; Dementia; Female; Gout; Humans; Hyperuricemia; Male; Middle Aged; Odds R

2018
Genetics of serum urate concentrations and gout in a high-risk population, patients with chronic kidney disease.
    Scientific reports, 2018, 09-04, Volume: 8, Issue:1

    Topics: Aged; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cohort Studies; Female; Genetic Predi

2018
Febuxostat in the treatment of gout patients with low serum uric acid level: 1-year finding of efficacy and safety study.
    Clinical rheumatology, 2018, Volume: 37, Issue:11

    Topics: Aged; Arthritis, Gouty; Creatinine; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middl

2018
Monosodium urate crystals reduce osteocyte viability and indirectly promote a shift in osteocyte function towards a proinflammatory and proresorptive state.
    Arthritis research & therapy, 2018, 09-10, Volume: 20, Issue:1

    Topics: Animals; Bone Resorption; Cell Survival; Gout; Humans; Inflammation Mediators; Male; Mice; Mice, Inb

2018
Urate crystals and inflammation. Cardiovascular impact of gout.
    International journal of cardiology, 2018, 11-15, Volume: 271

    Topics: Gout; Humans; Hyperuricemia; Inflammation; Uric Acid

2018
Monosodium urate burden assessed with dual-energy computed tomography predicts the risk of flares in gout: a 12-month observational study : MSU burden and risk of gout flare.
    Arthritis research & therapy, 2018, 09-17, Volume: 20, Issue:1

    Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Cost of Illness; Female; Follow-Up Studies; Gout; H

2018
Ultrasonographic Features of Lower-Limb Joints in Gout: Which Joints and Clinical Characteristics Would Provide More Information for Diagnosis?
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2020, Volume: 26, Issue:1

    Topics: Age Factors; Analysis of Variance; Ankle Joint; Cross-Sectional Studies; Female; Follow-Up Studies;

2020
Alternatives to specific uric acid lowering treatment in gout in patients with cardiovascular disease.
    BMJ (Clinical research ed.), 2018, Sep-20, Volume: 362

    Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Atorvastatin; Calcium Channel Blockers; Cardiov

2018
Coffee consumption and gout: a Mendelian randomisation study.
    Annals of the rheumatic diseases, 2019, Volume: 78, Issue:11

    Topics: Coffee; Gout; Humans; Uric Acid

2019
The role of diet in serum urate concentration.
    BMJ (Clinical research ed.), 2018, 10-10, Volume: 363

    Topics: Diet; Gout; Humans; Uric Acid

2018
Hyperferritinaemia and hyperuricaemia - a causal connection?
    Nature reviews. Rheumatology, 2018, Volume: 14, Issue:11

    Topics: Ferritins; Gout; Humans; Hyperuricemia; Uric Acid

2018
Noninvasive diagnosis of liquefied gouty tophus: Reflectance confocal microscopy as an alternative to polarizing light microscopy analysis.
    Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI), 2019, Volume: 25, Issue:2

    Topics: Female; Fingers; Gout; Granuloma; Humans; Microscopy, Confocal; Microscopy, Polarization; Middle Age

2019
Cardiovascular Safety of Febuxostat.
    The New England journal of medicine, 2018, 10-18, Volume: 379, Issue:16

    Topics: Cardiovascular System; Febuxostat; Gout; Humans; Thiazoles; Treatment Outcome; Uric Acid

2018
Cardiovascular Safety of Febuxostat.
    The New England journal of medicine, 2018, 10-18, Volume: 379, Issue:16

    Topics: Cardiovascular System; Febuxostat; Gout; Humans; Thiazoles; Treatment Outcome; Uric Acid

2018
Cardiovascular Safety of Febuxostat.
    The New England journal of medicine, 2018, 10-18, Volume: 379, Issue:16

    Topics: Cardiovascular System; Febuxostat; Gout; Humans; Thiazoles; Treatment Outcome; Uric Acid

2018
Cardiovascular Safety of Febuxostat.
    The New England journal of medicine, 2018, 10-18, Volume: 379, Issue:16

    Topics: Cardiovascular System; Febuxostat; Gout; Humans; Thiazoles; Treatment Outcome; Uric Acid

2018
Patient education and engagement in treat-to-target gout care.
    Lancet (London, England), 2018, 10-20, Volume: 392, Issue:10156

    Topics: Gout; Gout Suppressants; Humans; Patient Education as Topic; Uric Acid

2018
Renal excretion is a cause of decreased serum uric acid during acute gout.
    International journal of rheumatic diseases, 2018, Volume: 21, Issue:9

    Topics: Adult; Aged; Arthritis, Gouty; Biomarkers; Down-Regulation; Female; Gout; Humans; Hyperuricemia; Kid

2018
White Powder Over Palm: An Unusual Presentation of Hyperuricemia in Polyarticular Gout.
    The Journal of the Association of Physicians of India, 2018, Volume: 66, Issue:4

    Topics: Gout; Hand; Humans; Hyperuricemia; Uric Acid

2018
Association of solute carrier family 2, member 9 (SLC2A9) genetic variant rs3733591 with gout in a Malay sample set.
    The Medical journal of Malaysia, 2018, Volume: 73, Issue:5

    Topics: Adolescent; Adult; Aged; Asian People; Case-Control Studies; Creatinine; Female; Genetic Association

2018
Should our approach to diuretic using in patients with gout change?
    Arthritis research & therapy, 2018, 10-26, Volume: 20, Issue:1

    Topics: Diuretics; Gout; Humans; Hypertension; Uric Acid

2018
Urate-lowering therapy (ULT) reduces non-episodic foot pain in patients who fail to meet ACR/EULAR 2015 gout classification criteria: an effect predicted by ultrasound and potential rationale for reclassification.
    Annals of the rheumatic diseases, 2019, Volume: 78, Issue:4

    Topics: Case-Control Studies; Female; Foot Joints; Gout; Gout Suppressants; Humans; Male; Middle Aged; Pain;

2019
Infection of a tophaceous nodule of the wirst and hand.
    BMJ case reports, 2018, Oct-28, Volume: 2018

    Topics: Adult; Anti-Bacterial Agents; Arthritis, Gouty; Fingers; Gout; Hand; Humans; Male; Treatment Outcome

2018
Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study.
    Arthritis research & therapy, 2018, Oct-30, Volume: 20, Issue:1

    Topics: Adult; Aged; Cohort Studies; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Population

2018
Kelley-Seegmiller Syndrome: Urolithiasis, Renal Uric Acid Deposits, and Gout: What is the Role of the Urologist?
    Urologia internationalis, 2019, Volume: 102, Issue:2

    Topics: Adult; Conservative Treatment; Gout; Humans; Hypoxanthine Phosphoribosyltransferase; Kidney; Male; P

2019
LncRNA-Jak3:Jak3 coexpressed pattern regulates monosodium urate crystal-induced osteoclast differentiation through Nfatc1/Ctsk expression.
    Environmental toxicology, 2019, Volume: 34, Issue:2

    Topics: Animals; Cathepsin K; Cell Differentiation; Gene Expression Regulation; Gout; HEK293 Cells; Humans;

2019
Effect of fenofibrate on uric acid level in patients with gout.
    Scientific reports, 2018, 11-13, Volume: 8, Issue:1

    Topics: Adult; Aged; Drug Interactions; Enzyme Inhibitors; Female; Fenofibrate; Gout; Humans; Kidney; Liver;

2018
Serum urate levels and therapy in adults treated with long-term dialysis: a retrospective cross-sectional study.
    Internal medicine journal, 2019, Volume: 49, Issue:7

    Topics: Aged; Allopurinol; Cohort Studies; Cross-Sectional Studies; Female; Gout; Gout Suppressants; Humans;

2019
Antioxidant properties of citric acid interfere with the uricase-based measurement of circulating uric acid.
    Journal of pharmaceutical and biomedical analysis, 2019, Feb-05, Volume: 164

    Topics: Aged; Anticoagulants; Antioxidants; Biomarkers; Blood Specimen Collection; Citric Acid; Cohort Studi

2019
Urate-Lowering Therapy for Preventing Kidney Disease Progression: Are We There Yet?
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2018, Volume: 72, Issue:6

    Topics: Disease Progression; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency

2018
Characteristics of gout patients according to the laterality of nephrolithiasis: A cross-sectional study using helical computed tomography.
    International journal of rheumatic diseases, 2019, Volume: 22, Issue:4

    Topics: Adult; Aged; Biomarkers; Creatinine; Cross-Sectional Studies; Female; Glomerular Filtration Rate; Go

2019
[A woman with a white skin lesion of her toe].
    Nederlands tijdschrift voor geneeskunde, 2018, 11-27, Volume: 163

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Chronic Disease; Colchicine; Female

2018
Impact of Non-Adherence and Flare Resolution on the Cost-Effectiveness of Treatments for Gout: Application of a Linked Pharmacometric/Pharmacoeconomic Model.
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2018, Volume: 21, Issue:12

    Topics: Allopurinol; Cohort Studies; Cost-Benefit Analysis; Drug Therapy, Combination; Economics, Pharmaceut

2018
Resveratrol attenuates the MSU crystal-induced inflammatory response through the inhibition of TAK1 activity.
    International immunopharmacology, 2019, Volume: 67

    Topics: Animals; Anti-Inflammatory Agents; Cells, Cultured; Crystal Arthropathies; Down-Regulation; Extracel

2019
[A case of gout secondary to primary myelofibrosis].
    Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2018, Dec-18, Volume: 50, Issue:6

    Topics: Arthritis, Gouty; Febuxostat; Gout; Gout Suppressants; Humans; Male; Middle Aged; Primary Myelofibro

2018
A Case Report of Immunosuppressant Medication‒Associated Polyarticular Tophaceous Gout Successfully Treated Using the Polyethylene Glycol‒Conjugated Uricase Enzyme Pegloticase.
    Transplantation proceedings, 2018, Volume: 50, Issue:10

    Topics: Adult; Female; Gout; Gout Suppressants; Heart Transplantation; Humans; Immunocompromised Host; Immun

2018
Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase.
    Arthritis research & therapy, 2018, 12-29, Volume: 20, Issue:1

    Topics: Adult; Aged; Chronic Disease; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Polyethyle

2018
Associations between urate-lowering therapy and the risk of type 2 diabetes mellitus.
    PloS one, 2019, Volume: 14, Issue:1

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Allopurinol; Benzbromarone; Case-Control Studies; Diabe

2019
Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016.
    Arthritis & rheumatology (Hoboken, N.J.), 2019, Volume: 71, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hy

2019
Polymorphisms of
    Medicina (Kaunas, Lithuania), 2019, Jan-07, Volume: 55, Issue:1

    Topics: Adult; Aged; Alleles; ATP Binding Cassette Transporter, Subfamily G, Member 2; Blood Pressure; Case-

2019
Interactions between serum urate-associated genetic variants and sex on gout risk: analysis of the UK Biobank.
    Arthritis research & therapy, 2019, 01-09, Volume: 21, Issue:1

    Topics: Adult; Aged; Biological Specimen Banks; Female; Genetic Variation; Gout; Humans; Male; Middle Aged;

2019
Achievement of Target Serum Uric Acid Levels and Factors Associated with Therapeutic Failure among Japanese Men Treated for Hyperuricemia/Gout.
    Internal medicine (Tokyo, Japan), 2019, May-01, Volume: 58, Issue:9

    Topics: Adult; Aged; Anthropometry; Body Mass Index; Cross-Sectional Studies; Drug Monitoring; Dyslipidemias

2019
Evaluation of Turmeric Nanoparticles as Anti-Gout Agent: Modernization of a Traditional Drug.
    Medicina (Kaunas, Lithuania), 2019, Jan-11, Volume: 55, Issue:1

    Topics: Animals; Antioxidants; Cholesterol, HDL; Cholesterol, LDL; Curcuma; Disease Models, Animal; Drug Del

2019
Progress in Treatment of Gout Using Chinese and Western Medicine.
    Chinese journal of integrative medicine, 2020, Volume: 26, Issue:1

    Topics: Drugs, Chinese Herbal; Gout; Humans; Medicine, Chinese Traditional; Uric Acid

2020
Common variants in the
    Hereditas, 2019, Volume: 156

    Topics: Adult; Aged; Asian People; Case-Control Studies; China; Gout; Humans; Hyperuricemia; Male; Membrane

2019
Prevalence and treatment of gout among patients with chronic kidney disease in the Irish health system: A national study.
    PloS one, 2019, Volume: 14, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; Female; Glomerular Filtration Rate; Gout; G

2019
Clinical features and recurrent attack in gout patients according to serum urate levels during an acute attack.
    The Korean journal of internal medicine, 2020, Volume: 35, Issue:1

    Topics: Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Retrospective Studies; Uric Acid

2020
Clinical Utility of Multi-Energy Spectral Photon-Counting Computed Tomography in Crystal Arthritis.
    Arthritis & rheumatology (Hoboken, N.J.), 2019, Volume: 71, Issue:7

    Topics: Calcium Pyrophosphate; Chondrocalcinosis; Crystal Arthropathies; Diagnosis, Differential; Durapatite

2019
Secretion of IL-1β From Monocytes in Gout Is Redox Independent.
    Frontiers in immunology, 2019, Volume: 10

    Topics: Acetylcysteine; Antioxidants; Cell Survival; Furans; Gene Expression; Gout; Heterocyclic Compounds,

2019
Study on the diagnosis of gout with xanthine and hypoxanthine.
    Journal of clinical laboratory analysis, 2019, Volume: 33, Issue:5

    Topics: Blood Chemical Analysis; Chromatography, High Pressure Liquid; Gout; Humans; Hyperuricemia; Hypoxant

2019
mTOR inhibition by metformin impacts monosodium urate crystal-induced inflammation and cell death in gout: a prelude to a new add-on therapy?
    Annals of the rheumatic diseases, 2019, Volume: 78, Issue:5

    Topics: Cell Death; Cytokines; Gout; Humans; Inflammation; Metformin; Monocytes; Signal Transduction; TOR Se

2019
Hyperuricemia and acute gout after laparoscopic sleeve gastrectomy.
    Clinical obesity, 2019, Volume: 9, Issue:2

    Topics: Adult; Bariatric Surgery; Biomarkers; Body Composition; Body Water; Female; Gastrectomy; Gout; Greec

2019
[Gout with tophi].
    La Revue du praticien, 2018, Volume: 68, Issue:9

    Topics: Gout; Humans; Uric Acid

2018
Dual actions on gout flare and acute kidney injury along with enhanced renal transporter activities by Yokuininto, a Kampo medicine.
    BMC complementary and alternative medicine, 2019, Mar-12, Volume: 19, Issue:1

    Topics: Acute Kidney Injury; Animals; Cell Line; Cells, Cultured; Gout; HEK293 Cells; Humans; Male; Medicine

2019
Uric acid and xantine-oxidase inhibitors in patients with gout: A re-assessment and an update.
    Cardiology journal, 2019, Volume: 26, Issue:1

    Topics: Aged; Allopurinol; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Uri

2019
Urate Bulla: a Rare Manifestation of Gout.
    Journal of general internal medicine, 2019, Volume: 34, Issue:6

    Topics: Aged, 80 and over; Blister; Gout; Humans; Male; Uric Acid

2019
Hyperuricaemia and vascular risk: the debate continues.
    Current opinion in cardiology, 2019, Volume: 34, Issue:4

    Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Risk Factors; Uric Acid; Xanthine Oxidase

2019
Crystal-proven gout patients have an increased mortality due to cardiovascular diseases, cancer, and infectious diseases especially when having tophi and/or high serum uric acid levels: a prospective cohort study.
    Clinical rheumatology, 2019, Volume: 38, Issue:5

    Topics: Aged; Cardiovascular Diseases; Cause of Death; Communicable Diseases; Female; Gout; Humans; Hyperuri

2019
The Validity of Gout Diagnosis in Primary Care: Results from a Patient Survey.
    The Journal of rheumatology, 2019, Volume: 46, Issue:11

    Topics: Aged; Aged, 80 and over; Female; Gout; Humans; Inflammation; Male; Middle Aged; Primary Health Care;

2019
Alpha2B-Adrenergic Receptor Regulates Neutrophil Recruitment in MSU-Induced Peritoneal Inflammation.
    Frontiers in immunology, 2019, Volume: 10

    Topics: Animals; Disease Models, Animal; Gout; Inflammation; Interleukin-1beta; Macrophages; Male; Mice; Mic

2019
Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4-5 chronic kidney disease not yet on dialysis.
    The Korean journal of internal medicine, 2020, Volume: 35, Issue:4

    Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Dialysis; Renal Insuf

2020
Improving adherence to urate-lowering therapy in people living with gout.
    International journal of rheumatic diseases, 2019, Volume: 22, Issue:4

    Topics: Gout; Gout Suppressants; Humans; Uric Acid

2019
Integration of Pharmacometrics and Pharmacoeconomics to Quantify the Value of Improved Forgiveness to Nonadherence: A Case Study of Novel Xanthine Oxidase Inhibitors for Gout.
    Clinical pharmacology and therapeutics, 2019, Volume: 106, Issue:3

    Topics: Allopurinol; Computer Simulation; Cost-Benefit Analysis; Costs and Cost Analysis; Drug Monitoring; E

2019
Functional Characterization of Clinically-Relevant Rare Variants in
    Cells, 2019, 04-18, Volume: 8, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily G, Member 2;

2019
Protective effects of Rhizoma smilacis glabrae extracts on potassium oxonate- and monosodium urate-induced hyperuricemia and gout in mice.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2019, Volume: 59

    Topics: Animals; Antioxidants; Arthritis, Gouty; Disease Models, Animal; Drugs, Chinese Herbal; Edema; Flavo

2019
Diagnostic challenges of spinal gout: A case series.
    Medicine, 2019, Volume: 98, Issue:16

    Topics: Aged; Female; Gout; Humans; Male; Middle Aged; Retrospective Studies; Spinal Diseases; Uric Acid; Yo

2019
Chrysanthemum indicum extract inhibits NLRP3 and AIM2 inflammasome activation via regulating ASC phosphorylation.
    Journal of ethnopharmacology, 2019, Jul-15, Volume: 239

    Topics: Animals; Anti-Inflammatory Agents; CARD Signaling Adaptor Proteins; Chrysanthemum; DNA-Binding Prote

2019
Are Target Urate and Remission Possible in Severe Gout? A Five-year Cohort Study.
    The Journal of rheumatology, 2020, Volume: 47, Issue:1

    Topics: Adult; Female; Follow-Up Studies; Gout; Gout Suppressants; Health Surveys; Humans; Longitudinal Stud

2020
Partners and nurses' knowledge and representations of gout: A qualitative study.
    Joint bone spine, 2019, Volume: 86, Issue:6

    Topics: Adult; Aged, 80 and over; Attitude to Health; Disease Progression; Female; France; Gout; Grounded Th

2019
Point-of-care uric acid testing is useful in routine clinical care of gout.
    Arthritis research & therapy, 2019, 05-09, Volume: 21, Issue:1

    Topics: Gout; Humans; Hyperuricemia; Point-of-Care Systems; Punctures; Uric Acid

2019
Serum Urate, Uricase, and Blood Pressure Control in Gout.
    Hypertension (Dallas, Tex. : 1979), 2019, Volume: 74, Issue:1

    Topics: Blood Pressure; Gout; Humans; Polyethylene Glycols; Urate Oxidase; Uric Acid

2019
Pegloticase Treatment Significantly Decreases Blood Pressure in Patients With Chronic Gout.
    Hypertension (Dallas, Tex. : 1979), 2019, Volume: 74, Issue:1

    Topics: Adult; Aged; Blood Pressure Determination; Chronic Disease; Dose-Response Relationship, Drug; Drug A

2019
Sirt1 ameliorates monosodium urate crystal-induced inflammation by altering macrophage polarization via the PI3K/Akt/STAT6 pathway.
    Rheumatology (Oxford, England), 2019, 09-01, Volume: 58, Issue:9

    Topics: Acute Disease; Adult; Animals; Arthritis, Experimental; Arthritis, Gouty; Cell Polarity; Gout; Human

2019
Relationship of Interleukin-1β Blockade With Incident Gout and Serum Uric Acid Levels.
    Annals of internal medicine, 2019, 05-21, Volume: 170, Issue:10

    Topics: Gout; Humans; Interleukin-1beta; Uric Acid

2019
Level of Agreement with the Microscopic Analysis of Joint Aspirate for the Diagnosis of Gout in the Lower Extremity.
    Journal of the American Podiatric Medical Association, 2020, Jul-01, Volume: 110, Issue:4

    Topics: Gout; Humans; Lower Extremity; Reproducibility of Results; Retrospective Studies; Uric Acid

2020
Low-Dose Allopurinol Promotes Greater Serum Urate Lowering in Gout Patients with Chronic Kidney Disease Compared with Normal Kidney Function.
    Bulletin of the Hospital for Joint Disease (2013), 2019, Volume: 77, Issue:2

    Topics: Allopurinol; Dose-Response Relationship, Drug; Drug Monitoring; Female; Gout; Gout Suppressants; Hum

2019
Pharmacist-managed titration of urate-lowering therapy to streamline gout management.
    Rheumatology international, 2019, Volume: 39, Issue:9

    Topics: Adult; Aged; Biomarkers; Databases, Factual; Down-Regulation; Female; Gout; Gout Suppressants; Human

2019
Comparative Study of Real-Life Management Strategies in Gout: Data From Two Protocolized Gout Clinics.
    Arthritis care & research, 2020, Volume: 72, Issue:8

    Topics: Aged; Allopurinol; Clinical Decision Rules; Clinical Protocols; Female; Follow-Up Studies; Gout; Gou

2020
The Consequences of Untreated Gout: Is this a Tophus?
    The American journal of medicine, 2019, Volume: 132, Issue:11

    Topics: Aged, 80 and over; Fingers; Gout; Humans; Male; New Mexico; Uric Acid

2019
Venous thromboembolism in patients with gout and the impact of hospital admission, disease duration and urate-lowering therapy.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2019, 06-03, Volume: 191, Issue:22

    Topics: Aged; Case-Control Studies; Female; Gout; Gout Suppressants; Hospitalization; Humans; Length of Stay

2019
Associations of Gout and Baseline Serum Urate Level With Cardiovascular Outcomes: Analysis of the Coronary Disease Cohort Study.
    Arthritis & rheumatology (Hoboken, N.J.), 2019, Volume: 71, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Cardiovascular Diseases; Coronary Artery Disease;

2019
2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout.
    Annals of the rheumatic diseases, 2020, Volume: 79, Issue:1

    Topics: Gout; Humans; Hyperuricemia; Radiography; Risk Factors; Synovial Fluid; Tomography, X-Ray Computed;

2020
Epigallocatechin-3-Gallate Prevents Acute Gout by Suppressing NLRP3 Inflammasome Activation and Mitochondrial DNA Synthesis.
    Molecules (Basel, Switzerland), 2019, Jun-06, Volume: 24, Issue:11

    Topics: Animals; Caspase 1; Catechin; Disease Models, Animal; DNA, Mitochondrial; Gout; Humans; Inflammasome

2019
Anti-hyperuricemic effect of Alpinia oxyphylla seed extract by enhancing uric acid excretion in the kidney.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2019, Volume: 62

    Topics: Alpinia; Animals; China; Gout; Humans; Hyperuricemia; Kidney; Male; Organic Anion Transport Protein

2019
Pilot study: asymptomatic hyperuricemia patients with obesity and nonalcoholic fatty liver disease have increased risk of double contour sign.
    The Korean journal of internal medicine, 2020, Volume: 35, Issue:6

    Topics: Gout; Humans; Hyperuricemia; Non-alcoholic Fatty Liver Disease; Obesity; Pilot Projects; Ultrasonogr

2020
The Pyroptotic Cell Death Effector Gasdermin D Is Activated by Gout-Associated Uric Acid Crystals but Is Dispensable for Cell Death and IL-1β Release.
    Journal of immunology (Baltimore, Md. : 1950), 2019, 08-01, Volume: 203, Issue:3

    Topics: Acrylamides; Animals; Caspase 1; Cathepsins; Female; Gout; Interleukin-1beta; Intracellular Signalin

2019
DHA protects against monosodium urate-induced inflammation through modulation of oxidative stress.
    Food & function, 2019, Jul-17, Volume: 10, Issue:7

    Topics: Animals; Antioxidants; Catalase; Cell Survival; Cytokines; Docosahexaenoic Acids; Gout; Heme Oxygena

2019
Palm-Sized Uric Acid Test Lab Powered by Smartphone for Proactive Gout Management.
    IEEE transactions on biomedical circuits and systems, 2019, Volume: 13, Issue:5

    Topics: Biosensing Techniques; Gout; Humans; Point-of-Care Systems; Smartphone; Uric Acid

2019
Concurrent validity of provisional remission criteria for gout: a dual-energy CT study.
    Arthritis research & therapy, 2019, 06-21, Volume: 21, Issue:1

    Topics: Biomarkers; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Joints; Male; Middle Aged; P

2019
Downregulation of Transcription Factor T-Bet as a Protective Strategy in Monosodium Urate-Induced Gouty Inflammation.
    Frontiers in immunology, 2019, Volume: 10

    Topics: Adult; Animals; Body Fluids; Cytokines; Disease Models, Animal; Down-Regulation; Edema; Female; Foot

2019
[What is new on gout? : Report from ACR 2018].
    Zeitschrift fur Rheumatologie, 2019, Volume: 78, Issue:6

    Topics: Gout; Humans; Uric Acid

2019
Human Cartilage Homogenates Influence the Crystallization of Monosodium Urate and Inflammatory Response to Monosodium Urate Crystals: A Potential Link Between Osteoarthritis and Gout.
    Arthritis & rheumatology (Hoboken, N.J.), 2019, Volume: 71, Issue:12

    Topics: Cartilage; Crystallization; Cytokines; Gout; Humans; Inflammation; Knee Joint; Osteoarthritis; Uric

2019
Gout and hyperuricaemia: a worldwide health issue of joints and beyond.
    Rheumatology (Oxford, England), 2019, 12-01, Volume: 58, Issue:12

    Topics: Global Health; Gout; Humans; Hyperuricemia; Prevalence; United States; Uric Acid

2019
Primary Care Diagnosis of Gout Compared to a Primary Care Diagnostic Rule for Gout and to Classification Criteria.
    The Journal of rheumatology, 2019, Volume: 46, Issue:11

    Topics: Gout; Humans; Primary Health Care; Surveys and Questionnaires; Uric Acid

2019
Tophi reduction: ultrasound imaging and correlation with plasma levels of uric acid in patients undergoing treatment for tophaceous gout.
    Reumatismo, 2019, Jul-09, Volume: 71, Issue:2

    Topics: Adult; Aged; Correlation of Data; Gout; Humans; Male; Middle Aged; Prospective Studies; Uric Acid

2019
Decreased Expression of CD14 in MSU-Mediated Inflammation May Be Associated with Spontaneous Remission of Acute Gout.
    Journal of immunology research, 2019, Volume: 2019

    Topics: Adult; Aged; C-Reactive Protein; Female; Gout; Humans; Inflammation Mediators; Leukocytes, Mononucle

2019
Efficacy of uric acid-lowering therapy on hypercholesterolemia and hypertriglyceridemia in gouty patients.
    International journal of rheumatic diseases, 2019, Volume: 22, Issue:8

    Topics: Adult; Allopurinol; Benzbromarone; Biomarkers; Cholesterol; Febuxostat; Female; Gout; Gout Suppressa

2019
Evaluation of the chemical composition of nephrolithiasis using dual-energy CT in Southern Chinese gout patients.
    BMC nephrology, 2019, 07-19, Volume: 20, Issue:1

    Topics: Adult; Aged; China; Female; Gout; Humans; Kidney Calculi; Male; Middle Aged; Nephrolithiasis; Preval

2019
Monosodium urate deposition in the articular cartilage and meniscus can mimic chondrocalcinosis.
    Joint bone spine, 2020, Volume: 87, Issue:1

    Topics: Arthritis, Gouty; Cartilage, Articular; Chondrocalcinosis; Gout; Humans; Meniscus; Uric Acid

2020
Clinical characteristics and risk factors for gout flare during the postsurgical period.
    Advances in rheumatology (London, England), 2019, 07-25, Volume: 59, Issue:1

    Topics: Allopurinol; Blood Loss, Surgical; Female; Foot Joints; Gout; Gout Suppressants; Humans; Knee Joint;

2019
Effects of Conventional Uric Acid-Lowering Therapy on Monosodium Urate Crystal Deposits.
    Arthritis & rheumatology (Hoboken, N.J.), 2020, Volume: 72, Issue:1

    Topics: Aged; Alcohol Drinking; Allopurinol; Benzbromarone; Diet Therapy; Febuxostat; Female; Foot Joints; F

2020
Risk factors for the formation of double-contour sign and tophi in gout.
    Journal of orthopaedic surgery and research, 2019, Jul-29, Volume: 14, Issue:1

    Topics: Adult; Ankle Joint; Female; Gout; Humans; Knee Joint; Male; Metatarsophalangeal Joint; Middle Aged;

2019
Defining remission in patients with gout.
    Nature reviews. Rheumatology, 2019, Volume: 15, Issue:9

    Topics: Gout; Humans; Tomography, X-Ray Computed; Uric Acid

2019
Radiologic evidence of symmetric and polyarticular monosodium urate crystal deposition in gout - A cluster pattern analysis of dual-energy CT.
    Seminars in arthritis and rheumatism, 2020, Volume: 50, Issue:1

    Topics: Aged; Allopurinol; Female; Foot Joints; Gout; Gout Suppressants; Hand Joints; Humans; Knee Joint; Ma

2020
Management of patients with gout and achievement of target serum urate levels at a tertiary rheumatology service in Australia.
    Internal medicine journal, 2020, Volume: 50, Issue:3

    Topics: Allopurinol; Australia; Female; Gout; Gout Suppressants; Humans; Male; Rheumatology; Treatment Outco

2020
What can asymptomatic hyperuricaemia and systemic inflammation in the absence of gout tell us?
    Rheumatology (Oxford, England), 2013, Volume: 52, Issue:6

    Topics: Chemokine CCL2; Female; Gout; Humans; Hyperuricemia; Male; Monocytes; Uric Acid

2013
Gout and the risk of Parkinson's disease in Denmark.
    European journal of epidemiology, 2013, Volume: 28, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Denmark; Drug Prescriptions; Female; Gout; Gou

2013
Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population.
    The Journal of rheumatology, 2013, Volume: 40, Issue:6

    Topics: Adult; Aged; Female; Glomerular Filtration Rate; Gout; Gout Suppressants; Humans; Male; Middle Aged;

2013
Dose-response association of uncontrolled blood pressure and cardiovascular disease risk factors with hyperuricemia and gout.
    PloS one, 2013, Volume: 8, Issue:2

    Topics: Adult; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Dose-Response Relationship,

2013
Ultrasound learning curve in gout: a disease-oriented training program.
    Arthritis care & research, 2013, Volume: 65, Issue:8

    Topics: Gout; Humans; Joints; Learning Curve; Male; Middle Aged; Rheumatology; Ultrasonography; Uric Acid

2013
Anti-nociceptive and anti-edematogenic effects of glibenclamide in a model of acute gouty attack in rats.
    Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2013, Volume: 62, Issue:6

    Topics: Analgesics; Animals; Anti-Inflammatory Agents; Dinoprostone; Disease Models, Animal; Glyburide; Gout

2013
Italian Society of Rheumatology recommendations for the management of gout.
    Reumatismo, 2013, Mar-28, Volume: 65, Issue:1

    Topics: Adrenal Cortex Hormones; Advisory Committees; Alcoholic Beverages; Allopurinol; Anti-Inflammatory Ag

2013
Association of functional polymorphism rs2231142 (Q141K) in the ABCG2 gene with serum uric acid and gout in 4 US populations: the PAGE Study.
    American journal of epidemiology, 2013, May-01, Volume: 177, Issue:9

    Topics: Adult; Age Distribution; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Casset

2013
Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality.
    QJM : monthly journal of the Association of Physicians, 2013, Volume: 106, Issue:7

    Topics: Adult; Age Factors; Biomarkers; Cardiovascular Diseases; Female; Gout; Humans; Hyperuricemia; Incide

2013
ALPK1 genetic regulation and risk in relation to gout.
    International journal of epidemiology, 2013, Volume: 42, Issue:2

    Topics: Adult; Alleles; Asian People; Case-Control Studies; Gene Expression Regulation; Genetic Predispositi

2013
Relative and attributable diabetes risk associated with hyperuricemia in US veterans with gout.
    QJM : monthly journal of the Association of Physicians, 2013, Volume: 106, Issue:8

    Topics: Aged; Cohort Studies; Comorbidity; Diabetes Mellitus, Type 2; Female; Gout; Humans; Hyperuricemia; K

2013
Primary care providers' knowledge, beliefs and treatment practices for gout: results of a physician questionnaire.
    Rheumatology (Oxford, England), 2013, Volume: 52, Issue:9

    Topics: Female; Gout; Gout Suppressants; Health Care Surveys; Health Knowledge, Attitudes, Practice; Humans;

2013
The "gout of the Medici": making the modern diagnosis using paleopathology.
    Gene, 2013, Oct-01, Volume: 528, Issue:1

    Topics: Arthritis, Rheumatoid; Diet; Family Health; Gout; History, 15th Century; History, 16th Century; Hist

2013
Effect of bariatric surgery on the inflammatory response to monosodium urate crystals: a prospective study.
    Annals of the rheumatic diseases, 2013, Sep-01, Volume: 72, Issue:9

    Topics: Adult; Bariatric Surgery; Body Weight; Cells, Cultured; Cytokines; Female; Gout; Humans; Inflammatio

2013
Serum urate and incidence of kidney disease among veterans with gout.
    The Journal of rheumatology, 2013, Volume: 40, Issue:7

    Topics: Aged; Body Mass Index; Comorbidity; Gout; Humans; Hyperuricemia; Incidence; Kidney Diseases; Male; M

2013
Cost-effectiveness of febuxostat in chronic gout.
    The European journal of health economics : HEPAC : health economics in prevention and care, 2014, Volume: 15, Issue:5

    Topics: Cost-Benefit Analysis; Dose-Response Relationship, Drug; Febuxostat; Gout; Gout Suppressants; Humans

2014
Effect of genetic polymorphisms on development of gout.
    The Journal of rheumatology, 2013, Volume: 40, Issue:8

    Topics: Adult; Asian People; Case-Control Studies; Gene Frequency; Genetic Predisposition to Disease; Genome

2013
Type of uromodulin mutation and allelic status influence onset and severity of uromodulin-associated kidney disease in mice.
    Human molecular genetics, 2013, Oct-15, Volume: 22, Issue:20

    Topics: Age of Onset; Alleles; Animals; Body Weight; Cystatins; Disease Models, Animal; Disease Progression;

2013
Enzyme-entrapped mesoporous silica for treatment of uric acid disorders.
    Journal of biomedical nanotechnology, 2013, Volume: 9, Issue:5

    Topics: Administration, Cutaneous; Animals; Drug Delivery Systems; Enzyme Replacement Therapy; Enzymes, Immo

2013
Exploratory study of radiographic change in patients with tophaceous gout treated with intensive urate-lowering therapy.
    Arthritis care & research, 2014, Volume: 66, Issue:1

    Topics: Aged; Aged, 80 and over; Crystallization; Disease Progression; Female; Foot Joints; Gout; Gout Suppr

2014
Modulation of monosodium urate crystal-induced responses in neutrophils by the myeloid inhibitory C-type lectin-like receptor: potential therapeutic implications.
    Arthritis research & therapy, 2013, Jul-09, Volume: 15, Issue:4

    Topics: Blotting, Western; Cells, Cultured; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gout; Humans;

2013
Reversal of chronic refractory tophaceous gout with erosions with pegloticase.
    International journal of rheumatic diseases, 2013, Volume: 16, Issue:3

    Topics: Aged; Biomarkers; Chronic Disease; Disease Progression; Finger Joint; Gout; Gout Suppressants; Human

2013
Common missense variant of monocarboxylate transporter 9 (MCT9/SLC16A9) gene is associated with renal overload gout, but not with all gout susceptibility.
    Human cell, 2013, Volume: 26, Issue:4

    Topics: Aged; Female; Gene Expression; Gene Frequency; Genetic Predisposition to Disease; Genome-Wide Associ

2013
Transient receptor potential melastatin 2: a novel target for treatment of gout.
    Expert opinion on therapeutic targets, 2013, Volume: 17, Issue:11

    Topics: Gout; Humans; Inflammation; TRPM Cation Channels; Uric Acid

2013
Caspase-1 level in synovial fluid is high in patients with spondyloarthropathy but not in patients with gout.
    Journal of Korean medical science, 2013, Volume: 28, Issue:9

    Topics: Adult; Aged; Arthritis, Rheumatoid; Caspase 1; Female; Gout; Humans; Interleukin-18; Interleukin-1be

2013
[<> spondylodiscitis].
    Praxis, 2013, Sep-18, Volume: 102, Issue:19

    Topics: Aged, 80 and over; Biopsy; Diagnosis, Differential; Discitis; Female; Gout; Humans; Lumbar Vertebrae

2013
A common variant of organic anion transporter 4 (OAT4/SLC22A11) gene is associated with renal underexcretion type gout.
    Drug metabolism and pharmacokinetics, 2014, Volume: 29, Issue:2

    Topics: Asian People; Case-Control Studies; Chi-Square Distribution; Gene Frequency; Genetic Association Stu

2014
Sugar-sweetened beverage consumption: a risk factor for prevalent gout with SLC2A9 genotype-specific effects on serum urate and risk of gout.
    Annals of the rheumatic diseases, 2014, Volume: 73, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Beverages; Case-Control Studies; Dietary Sucrose; Female

2014
How to regulate neutrophils in gout.
    Arthritis research & therapy, 2013, Volume: 15, Issue:5

    Topics: Gout; Humans; Lectins, C-Type; Neutrophil Activation; Neutrophils; Receptors, Mitogen; Uric Acid

2013
Experiences of gout-related disability from the patients' perspective: a mixed methods study.
    Clinical rheumatology, 2014, Volume: 33, Issue:8

    Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; Disability Eval

2014
No association between gout and Alzheimer's disease: results of a case-control study in older people in Taiwan.
    International journal of geriatric psychiatry, 2013, Volume: 28, Issue:11

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Case-Control Studies; Comorbidity; Female; Gout; Humans;

2013
Molecular mechanisms of crystal-related kidney inflammation and injury. Implications for cholesterol embolism, crystalline nephropathies and kidney stone disease.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2014, Volume: 29, Issue:3

    Topics: Animals; Embolism, Cholesterol; Gout; Humans; Inflammasomes; Kidney; Kidney Calculi; Nephritis; Uric

2014
Workshop report: 4th European crystal network meeting.
    Arthritis research & therapy, 2013, Volume: 15, Issue:5

    Topics: Calcium; Calcium Phosphates; Crystallization; Gout; Humans; Hyperuricemia; Uric Acid

2013
Participation of the TRPV1 receptor in the development of acute gout attacks.
    Rheumatology (Oxford, England), 2014, Volume: 53, Issue:2

    Topics: Acute Disease; Anilides; Animals; Arthralgia; Cinnamates; Disease Models, Animal; Gout; Inflammation

2014
The effects of monosodium urate monohydrate crystals on chondrocyte viability and function: implications for development of cartilage damage in gout.
    The Journal of rheumatology, 2013, Volume: 40, Issue:12

    Topics: Aged; Apoptosis; Cartilage; Cell Survival; Chondrocytes; Crystallization; Dose-Response Relationship

2013
Crystal arthritis: Environment and genetics in gout: a maze for clinicians?
    Nature reviews. Rheumatology, 2014, Volume: 10, Issue:1

    Topics: Arthritis; Carbonated Beverages; Dietary Sucrose; Gout; Humans; Male; Uric Acid

2014
Improvement in the management of gout is vital and overdue: an audit from a UK primary care medical practice.
    BMC family practice, 2013, Nov-14, Volume: 14

    Topics: Aged; Blood Glucose; Diet Therapy; Disease Management; Female; Glomerular Filtration Rate; Gout; Gou

2013
Gout with auricular tophi following anti-tuberculosis treatment: a case report.
    BMC research notes, 2013, Nov-21, Volume: 6

    Topics: Antitubercular Agents; Biopsy; Carcinoma, Squamous Cell; Diagnosis, Differential; Ear Auricle; Epide

2013
An audit of a therapeutic drug monitoring service for allopurinol therapy.
    Therapeutic drug monitoring, 2013, Volume: 35, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Child; Child, Preschool; Creatinine; Drug M

2013
CaseBook challenges: Managing gout, hyperuricemia and comorbidities -- dialogue with the experts.
    The American journal of medicine, 2014, Volume: 127, Issue:1

    Topics: Allopurinol; Comorbidity; Disease Management; Drug Administration Schedule; Febuxostat; Gout; Gout S

2014
Citric acid treatment of chronic nonhealing ulcerated tophaceous gout with bursitis.
    The international journal of lower extremity wounds, 2013, Volume: 12, Issue:4

    Topics: Administration, Topical; Aged, 80 and over; Ankle Joint; Anti-Bacterial Agents; Anti-Infective Agent

2013
Lack of change in urate deposition by dual-energy computed tomography among clinically stable patients with long-standing tophaceous gout: a prospective longitudinal study.
    Arthritis research & therapy, 2013, Oct-23, Volume: 15, Issue:5

    Topics: Aged; Allopurinol; Female; Foot; Gout; Gout Suppressants; Humans; Male; Middle Aged; Prospective Stu

2013
Common variant of leucine-rich repeat-containing 16A (LRRC16A) gene is associated with gout susceptibility.
    Human cell, 2014, Volume: 27, Issue:1

    Topics: Actin Cytoskeleton; Actins; Carrier Proteins; Genetic Predisposition to Disease; Genetic Variation;

2014
High-density lipoproteins inhibit urate crystal-induced inflammation in mice.
    Annals of the rheumatic diseases, 2015, Volume: 74, Issue:3

    Topics: Animals; Back; Chemokine CCL2; Chemokine CXCL1; Disease Models, Animal; Gout; Inflammation; Interleu

2015
Late diagnosis of Lesch-Nyhan disease variant.
    BMJ case reports, 2013, Dec-10, Volume: 2013

    Topics: Adult; Allopurinol; Diuretics; Genetic Counseling; Gout; Gout Suppressants; Humans; Hyperuricemia; H

2013
Racial differences in gout incidence in a population-based cohort: Atherosclerosis Risk in Communities Study.
    American journal of epidemiology, 2014, Mar-01, Volume: 179, Issue:5

    Topics: Black People; Female; Gout; Humans; Incidence; Male; Middle Aged; Proportional Hazards Models; Risk

2014
Association of serum uric acid and incident nonspine fractures in elderly men: the Osteoporotic Fractures in Men (MrOS) study.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2014, Volume: 29, Issue:7

    Topics: Aged; Allopurinol; Bone Density; Cohort Studies; Gout; Hip Fractures; Humans; Incidence; Male; Osteo

2014
Reduced creatinine clearance is associated with early development of subcutaneous tophi in people with gout.
    BMC musculoskeletal disorders, 2013, Dec-21, Volume: 14

    Topics: Adult; Aged; Creatinine; Female; Foreign-Body Reaction; Gout; Humans; Logistic Models; Male; Middle

2013
Evaluating appropriate use of prophylactic colchicine for gout flare prevention.
    Arthritis care & research, 2014, Volume: 66, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Colchicine; Electronic Health Records; Female; Gout; Gout Suppressan

2014
The effects of gout on left atrial volume remodelling: a prospective echocardiographic study.
    Rheumatology (Oxford, England), 2014, Volume: 53, Issue:5

    Topics: Adult; Aged; Arthritis, Gouty; Atrial Remodeling; Cardiac Volume; Case-Control Studies; Cross-Sectio

2014
Effectiveness of a pharmacist-based gout care management programme in a large integrated health plan: results from a pilot study.
    BMJ open, 2014, Jan-10, Volume: 4, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Ambulatory Care Facilities; Chronic Disease; Feasibilit

2014
A customized Raman system for point-of-care detection of arthropathic crystals in the synovial fluid.
    The Analyst, 2014, Feb-21, Volume: 139, Issue:4

    Topics: Calcium Pyrophosphate; Crystallization; Gout; Humans; Limit of Detection; Microscopy, Electron, Scan

2014
Smilax riparia reduces hyperuricemia in mice as a potential treatment of gout.
    The American journal of Chinese medicine, 2014, Volume: 42, Issue:1

    Topics: Animals; Disease Models, Animal; Down-Regulation; Drugs, Chinese Herbal; Gout; Gout Suppressants; Hy

2014
Arthritis of the first metatarsophalangeal joint is not always gout: a prospective cohort study in primary care patients.
    Joint bone spine, 2014, Volume: 81, Issue:4

    Topics: Aged; Arthritis; Female; Gout; Humans; Male; Metatarsophalangeal Joint; Middle Aged; Primary Health

2014
Myeloid-related proteins 8 and 14 contribute to monosodium urate monohydrate crystal-induced inflammation in gout.
    Arthritis & rheumatology (Hoboken, N.J.), 2014, Volume: 66, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Animals; Calgranulin A; Calgranulin B; Cells, Cultured; Crystallizat

2014
Q: should patients with gout avoid thiazides for hypertension?
    Cleveland Clinic journal of medicine, 2014, Volume: 81, Issue:2

    Topics: Contraindications; Gout; Gout Suppressants; Humans; Hypertension; Thiazides; Uric Acid

2014
Additive value for ultrasonographic signal in a screening algorithm for patients presenting with acute mono-/oligoarthritis in whom gout is suspected.
    Clinical rheumatology, 2014, Volume: 33, Issue:4

    Topics: Adult; Aged; Algorithms; Calcium Pyrophosphate; Chondrocalcinosis; Female; Finger Joint; Gout; Human

2014
Relationship between structural joint damage and urate deposition in gout: a plain radiography and dual-energy CT study.
    Annals of the rheumatic diseases, 2015, Volume: 74, Issue:6

    Topics: Absorptiometry, Photon; Adolescent; Adult; Aged; Aged, 80 and over; Ankylosis; Female; Foot Joints;

2015
The degree of asymptomatic hyperuricemia and the risk of gout. A retrospective analysis of a large cohort.
    Clinical rheumatology, 2014, Volume: 33, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Asymptomatic Diseases; Cohort Studies; Female; Glo

2014
MANAGEMENT of gout; new views on uric acid metabolism.
    What's new, 1951, Volume: 161

    Topics: Disease Management; Gout; Humans; Uric Acid

1951
Association and interaction effect between VEGF receptor-2 (VEGFR-2) gene polymorphisms and dietary pattern on blood uric acid in Malays and Indians.
    Malaysian journal of nutrition, 2012, Volume: 18, Issue:3

    Topics: Adult; Animals; Body Mass Index; Diet; Dietary Proteins; Fast Foods; Female; Food; Fruit; Genotype;

2012
Systemic staging for urate crystal deposits with dual-energy CT and ultrasound in patients with suspected gout.
    Rheumatology international, 2014, Volume: 34, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Elbow Joint; Female; Foot Joints; Gout; Hand Joints;

2014
[A new application for well-known pharmaceutics--losartan and fenofibrate as potential remedies against gout?].
    Deutsche medizinische Wochenschrift (1946), 2014, Volume: 139, Issue:12

    Topics: Angiotensin II Type 1 Receptor Blockers; Fenofibrate; Gout; Gout Suppressants; Humans; Hypolipidemic

2014
Management of gout in a South Auckland general practice.
    Journal of primary health care, 2014, Mar-01, Volume: 6, Issue:1

    Topics: General Practice; Gout; Humans; Native Hawaiian or Other Pacific Islander; New Zealand; Practice Pat

2014
Dual-energy CT for the diagnosis of gout: an accuracy and diagnostic yield study.
    Annals of the rheumatic diseases, 2015, Volume: 74, Issue:6

    Topics: Absorptiometry, Photon; Adult; Aged; Arthritis; Case-Control Studies; Cohort Studies; Elbow Joint; F

2015
Dual-energy CT for the diagnosis of gout: an accuracy and diagnostic yield study.
    Annals of the rheumatic diseases, 2015, Volume: 74, Issue:6

    Topics: Absorptiometry, Photon; Adult; Aged; Arthritis; Case-Control Studies; Cohort Studies; Elbow Joint; F

2015
Dual-energy CT for the diagnosis of gout: an accuracy and diagnostic yield study.
    Annals of the rheumatic diseases, 2015, Volume: 74, Issue:6

    Topics: Absorptiometry, Photon; Adult; Aged; Arthritis; Case-Control Studies; Cohort Studies; Elbow Joint; F

2015
Dual-energy CT for the diagnosis of gout: an accuracy and diagnostic yield study.
    Annals of the rheumatic diseases, 2015, Volume: 74, Issue:6

    Topics: Absorptiometry, Photon; Adult; Aged; Arthritis; Case-Control Studies; Cohort Studies; Elbow Joint; F

2015
Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study.
    Arthritis research & therapy, 2014, Mar-29, Volume: 16, Issue:2

    Topics: Aged; Allopurinol; Black or African American; Evaluation Studies as Topic; Febuxostat; Female; Focus

2014
Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
    Postgraduate medicine, 2014, Volume: 126, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Biomarkers; Comparative Effectiveness Resea

2014
Interactions between tenocytes and monosodium urate monohydrate crystals: implications for tendon involvement in gout.
    Annals of the rheumatic diseases, 2014, Volume: 73, Issue:9

    Topics: Animals; Cell Survival; Cells, Cultured; Collagen; Crystallization; Dose-Response Relationship, Drug

2014
Aging, not menopause, is associated with higher prevalence of hyperuricemia among older women.
    Menopause (New York, N.Y.), 2014, Volume: 21, Issue:11

    Topics: Adult; Aged; Aging; Body Mass Index; Cross-Sectional Studies; Diuretics; Female; Glomerular Filtrati

2014
An unusual case of gout.
    BMJ case reports, 2014, Apr-11, Volume: 2014

    Topics: Acute Coronary Syndrome; Aged; Chest Pain; Diagnosis, Differential; Gout; Humans; Knee Joint; Male;

2014
Anakinra treatment in patients with gout and type 2 diabetes.
    Clinical rheumatology, 2015, Volume: 34, Issue:5

    Topics: Aged; Aged, 80 and over; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents;

2015
Cytospin preparations are superior to common smears in the detection of monosodium urate crystals in low-cellular synovial fluids.
    Clinical rheumatology, 2014, Volume: 33, Issue:12

    Topics: Adult; Aged; C-Reactive Protein; Calcium Pyrophosphate; Crystallization; Female; Gout; Humans; Leuko

2014
Crystal arthritis: Tendon damage in gout--a role for MSU crystals?
    Nature reviews. Rheumatology, 2014, Volume: 10, Issue:6

    Topics: Animals; Gout; Humans; Tendons; Uric Acid

2014
New gout test: enhanced ex vivo cytokine production from PBMCS in common gout patients and a gout patient with Kearns-Sayre syndrome.
    Clinical rheumatology, 2014, Volume: 33, Issue:9

    Topics: Adult; Cytokines; Gout; Humans; Kearns-Sayre Syndrome; Leukocytes, Mononuclear; Male; Uric Acid

2014
Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines.
    Nature medicine, 2014, Volume: 20, Issue:5

    Topics: Animals; Cell Aggregation; Chemokines; Cytokines; Gout; Humans; Inflammation; Mice; Neutrophils; Res

2014
Drugs for gout.
    The Medical letter on drugs and therapeutics, 2014, Mar-17, Volume: 56, Issue:1438

    Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Colchicine; Enzyme Inh

2014
An MRI assessment of chronic synovial-based inflammation in gout and its correlation with serum urate levels.
    Clinical rheumatology, 2015, Volume: 34, Issue:2

    Topics: Adult; Aged; Cross-Sectional Studies; Female; Gout; Humans; Inflammation; Knee Joint; Magnetic Reson

2015
In vitro xanthine oxidase inhibitory and in vivo hypouricemic activity of herbal coded formulation (Gouticin).
    Pakistan journal of pharmaceutical sciences, 2014, Volume: 27, Issue:3

    Topics: Allopurinol; Female; Gout; Humans; Male; Middle Aged; Phytotherapy; Plant Extracts; Plants, Medicina

2014
The methanol extract of Euonymus laxiflorus, Rubia lanceolata and Gardenia jasminoides inhibits xanthine oxidase and reduce serum uric acid level in rats.
    Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2014, Volume: 70

    Topics: Animals; Disease Models, Animal; Euonymus; Formaldehyde; Gardenia; Gout; Hyperuricemia; Nociception;

2014
Prevention of comorbidity and acute attack of gout by uric acid lowering therapy.
    Journal of Korean medical science, 2014, Volume: 29, Issue:5

    Topics: Adult; Allopurinol; Antimetabolites; Benzbromarone; Cardiovascular Diseases; Comorbidity; Diabetes M

2014
Common dysfunctional variants of ABCG2 have stronger impact on hyperuricemia progression than typical environmental risk factors.
    Scientific reports, 2014, Jun-09, Volume: 4

    Topics: Asian People; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transpor

2014
[A man with lung gout].
    MMW Fortschritte der Medizin, 2014, Mar-20, Volume: 156, Issue:5

    Topics: Bronchoscopy; Calculi; Crystallization; Gout; Humans; Lung Diseases; Male; Middle Aged; Uric Acid

2014
Physician adherence to ACR gout treatment guidelines: perception versus practice.
    Postgraduate medicine, 2014, Volume: 126, Issue:3

    Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Female; Gout; Gout Suppress

2014
Elevated serum homocysteine levels were not correlated with serum uric acid levels, but with decreased renal function in gouty patients.
    Journal of Korean medical science, 2014, Volume: 29, Issue:6

    Topics: Glomerular Filtration Rate; Gout; Homocysteine; Humans; Hyperhomocysteinemia; Male; Middle Aged; Ren

2014
Methods of assessment of tophus and bone erosions in gout using dual-energy CT: reproducibility analysis.
    Clinical rheumatology, 2015, Volume: 34, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Ankle; Arthritis, Gouty; Bone Diseases; C-Reactive Protein; Female;

2015
Efficacy and safety of a urate lowering regimen in primary gout.
    Nucleosides, nucleotides & nucleic acids, 2014, Volume: 33, Issue:4-6

    Topics: Adult; Aged; Aged, 80 and over; Female; Gout; Hospitals; Humans; Male; Middle Aged; Safety; Uric Aci

2014
Miliarial gout: a rare clinical presentation.
    Journal of the American Academy of Dermatology, 2014, Volume: 71, Issue:1

    Topics: Adult; Dermis; Gout; Humans; Male; Uric Acid

2014
Detection of uric acid depositing in tophaceous gout using a new dual energy spectral CT technology.
    Journal of X-ray science and technology, 2014, Volume: 22, Issue:4

    Topics: Adult; Aged; Analysis of Variance; Female; Foot; Gout; Humans; Male; Middle Aged; Tomography, X-Ray

2014
Clinical characteristics of and relationship between metabolic components and renal function among patients with early-onset juvenile tophaceous gout.
    The Journal of rheumatology, 2014, Volume: 41, Issue:9

    Topics: Adolescent; Adult; Age of Onset; Child; Female; Gout; Humans; Hyperuricemia; Kidney; Male; Uric Acid

2014
Monosodium urate crystals trigger Nrf2- and heme oxygenase-1-dependent inflammation in THP-1 cells.
    Cellular & molecular immunology, 2015, Volume: 12, Issue:4

    Topics: Carrier Proteins; Cell Line, Tumor; Gout; Heme Oxygenase-1; Humans; Inflammation; Interleukin-1beta;

2015
Development of a patient-reported outcome measure of tophus burden: the Tophus Impact Questionnaire (TIQ-20).
    Annals of the rheumatic diseases, 2015, Volume: 74, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Female; Gout; Humans; Male; Middle Aged; Patient Outcome Assessment;

2015
Tubular urate transporter gene polymorphisms differentiate patients with gout who have normal and decreased urinary uric acid excretion.
    The Journal of rheumatology, 2014, Volume: 41, Issue:9

    Topics: Aged; Alleles; Female; Gout; Humans; Hyperuricemia; Male; Middle Aged; Organic Anion Transporters; P

2014
A pilot study on dual-energy computed tomography for detection of urate deposits in renal transplant patients with asymptomatic hyperuricemia.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2014, Volume: 20, Issue:6

    Topics: Adult; Arthrography; Female; Follow-Up Studies; Gout; Humans; Hyperuricemia; Joints; Kidney; Kidney

2014
Current gout treatment and flare in South Korea: Prophylactic duration associated with fewer gout flares.
    International journal of rheumatic diseases, 2017, Volume: 20, Issue:4

    Topics: Adult; Aged; Biomarkers; Disease Progression; Drug Administration Schedule; Female; Gout; Gout Suppr

2017
Urate transporters: transforming the face of hyperuricemia and gout.
    The Journal of rheumatology, 2014, Volume: 41, Issue:10

    Topics: Female; Gout; Humans; Hyperuricemia; Male; Organic Anion Transporters; Polymorphism, Single Nucleoti

2014
Gout, urate-lowering therapy, and uric acid levels among adults in the United States.
    Arthritis care & research, 2015, Volume: 67, Issue:4

    Topics: Adult; Aged; Biomarkers; Cross-Sectional Studies; Female; Gout; Gout Suppressants; Humans; Male; Mid

2015
Gout: a curable disease that often is undertreated. Long-term treatment is proven and available, but most patients and their physicians continue to take a short-term approach.
    DukeMedicine healthnews, 2014, Volume: 20, Issue:8

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Diet; Gout; Gout Suppressants; Humans; Hyperuricemia; Patie

2014
The validation of a diagnostic rule for gout without joint fluid analysis: a prospective study.
    Rheumatology (Oxford, England), 2015, Volume: 54, Issue:4

    Topics: Aged; Cardiovascular Diseases; Decision Support Techniques; Erythema; Female; Gout; Humans; Hyperten

2015
The relationship between homocysteine and uric acid levels in gouty patients.
    Journal of Korean medical science, 2014, Volume: 29, Issue:9

    Topics: Gout; Homocysteine; Humans; Male; Uric Acid

2014
Impact of gout on left atrial function: a prospective speckle-tracking echocardiographic study.
    PloS one, 2014, Volume: 9, Issue:9

    Topics: Adult; Aged; Atrial Function, Left; Echocardiography, Doppler; Female; Gout; Humans; Male; Middle Ag

2014
NPT1/SLC17A1 is a renal urate exporter in humans and its common gain-of-function variant decreases the risk of renal underexcretion gout.
    Arthritis & rheumatology (Hoboken, N.J.), 2015, Volume: 67, Issue:1

    Topics: Amino Acid Sequence; Animals; Case-Control Studies; Female; Gene Frequency; Genetic Predisposition t

2015
Monosodium urate crystal induced macrophage inflammation is attenuated by chondroitin sulphate: pre-clinical model for gout prophylaxis?
    BMC musculoskeletal disorders, 2014, Sep-27, Volume: 15

    Topics: Cell Line; Chondroitin Sulfates; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Gou

2014
A comparative study of serum and synovial fluid levels of uric acid between patients with gout and other arthritides.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2014, Volume: 97, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Arthritis; Arthritis, Gouty; Arthritis, Infectious; Arthritis, Rheum

2014
The impact of Ramadan fast on patients with gout.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2014, Volume: 20, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Body Mass Index; Case-Control Studies; Colchicine; Crea

2014
[Gouty tophus].
    The Pan African medical journal, 2014, Volume: 17

    Topics: Aged; Diagnosis, Differential; Gout; Gout Suppressants; Humans; Male; Uric Acid

2014
Detection and characterization of crystal suspensions using single-source dual-energy computed tomography: a phantom model of crystal arthropathies.
    Investigative radiology, 2015, Volume: 50, Issue:4

    Topics: Calcium Pyrophosphate; Chondrocalcinosis; Feasibility Studies; Gout; Hand; Humans; Phantoms, Imaging

2015
The role of kinin B1 receptor and the effect of angiotensin I-converting enzyme inhibition on acute gout attacks in rodents.
    Annals of the rheumatic diseases, 2016, Volume: 75, Issue:1

    Topics: Acute Disease; Angiotensin-Converting Enzyme Inhibitors; Animals; Bradykinin B1 Receptor Antagonists

2016
Performance of classification criteria for gout in early and established disease.
    Annals of the rheumatic diseases, 2016, Volume: 75, Issue:1

    Topics: Adult; Aged; Biomarkers; Cross-Sectional Studies; Early Diagnosis; Female; Gout; Humans; Male; Middl

2016
AMP-activated protein kinase suppresses urate crystal-induced inflammation and transduces colchicine effects in macrophages.
    Annals of the rheumatic diseases, 2016, Volume: 75, Issue:1

    Topics: AMP-Activated Protein Kinases; Animals; Biphenyl Compounds; Cells, Cultured; Colchicine; Enzyme Acti

2016
The author response.
    Journal of Korean medical science, 2014, Volume: 29, Issue:9

    Topics: Gout; Homocysteine; Humans; Male; Uric Acid

2014
Influence of urate-lowering therapies on renal handling of uric acid.
    Clinical rheumatology, 2016, Volume: 35, Issue:1

    Topics: Adult; Antihypertensive Agents; Benzbromarone; Case-Control Studies; Creatinine; Glomerular Filtrati

2016
Study on the anti-gout activity of chlorogenic acid: improvement on hyperuricemia and gouty inflammation.
    The American journal of Chinese medicine, 2014, Volume: 42, Issue:6

    Topics: Animals; Chlorogenic Acid; Cytokines; Disease Models, Animal; Gout; Gout Suppressants; Hyperuricemia

2014
Distinguishing gouty arthritis from calcium pyrophosphate disease and other arthritides.
    The Journal of rheumatology, 2015, Volume: 42, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Gouty; Chondrocalcinosis; Female; Gout; Human

2015
Adherence and persistence to urate-lowering therapies in the Irish setting.
    Clinical rheumatology, 2016, Volume: 35, Issue:3

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Allopurinol; Databases, Factual; Febuxostat

2016
Gout, allopurinol intake and clinical outcomes in the hospitalized multimorbid elderly.
    European journal of internal medicine, 2014, Volume: 25, Issue:9

    Topics: Age Factors; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Chronic Disease; Comorbi

2014
Uric acid crystals.
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2014, Dec-09, Volume: 134, Issue:23-24

    Topics: Crystallization; Gout; Humans; Microscopy, Polarization; Synovial Fluid; Uric Acid

2014
Arsenic exposure, hyperuricemia, and gout in US adults.
    Environment international, 2015, Volume: 76

    Topics: Adult; Aged; Arsenic; Arsenicals; Cross-Sectional Studies; Environmental Exposure; Female; Gout; Hum

2015
Health literacy in patients dealing with gout: a qualitative study.
    Clinical rheumatology, 2015, Volume: 34, Issue:9

    Topics: Aged; Aged, 80 and over; Allopurinol; Female; Gout; Gout Suppressants; Health Literacy; Humans; Inte

2015
Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system.
    The Journal of rheumatology, 2015, Volume: 42, Issue:3

    Topics: Aged; Allopurinol; Databases, Factual; Delivery of Health Care, Integrated; Female; Gout; Gout Suppr

2015
Ultrasound in gout: a useful tool for following urate-lowering therapy.
    Joint bone spine, 2015, Volume: 82, Issue:1

    Topics: Adult; Aged; Gout; Humans; Male; Middle Aged; Prospective Studies; Ultrasonography; Uric Acid

2015
Allopurinol use and risk of non-fatal acute myocardial infarction.
    Heart (British Cardiac Society), 2015, Volume: 101, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Case-Control Studies; Female; Free Radical Scavengers;

2015
Patients with gout can be cured in primary care.
    The Practitioner, 2014, Volume: 258, Issue:1777

    Topics: Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthrography; Colchicine; Disease Manage

2014
Gout, tophi and the wonders of NETs.
    Arthritis research & therapy, 2014, Volume: 16, Issue:5

    Topics: Animals; Arthritis, Gouty; Extracellular Traps; Gout; Humans; Inflammation; Uric Acid

2014
The molecular insight into the antihyperuricemic and renoprotective effect of Shuang Qi gout capsule in mice.
    Journal of ethnopharmacology, 2015, Apr-02, Volume: 163

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters;

2015
Cost-effectiveness analysis of allopurinol versus febuxostat in chronic gout patients: a U.S. payer perspective.
    Journal of managed care & specialty pharmacy, 2015, Volume: 21, Issue:2

    Topics: Allopurinol; Chronic Disease; Cost-Benefit Analysis; Febuxostat; Gout; Gout Suppressants; Humans; Ma

2015
Images in clinical medicine. An unusual tophus.
    The New England journal of medicine, 2015, Jan-29, Volume: 372, Issue:5

    Topics: Aged; Crystallization; Gout; Humans; Male; Nail Diseases; Nails; Uric Acid

2015
Urate crystal deposition in asymptomatic hyperuricaemia and symptomatic gout: a dual energy CT study.
    Annals of the rheumatic diseases, 2015, Volume: 74, Issue:5

    Topics: Absorptiometry, Photon; Aged; Asymptomatic Diseases; Cross-Sectional Studies; Female; Foot; Foot Joi

2015
Role of miR-146a in regulation of the acute inflammatory response to monosodium urate crystals.
    Annals of the rheumatic diseases, 2015, Volume: 74, Issue:4

    Topics: Animals; Antioxidants; Case-Control Studies; Cell Line; Disease Models, Animal; Female; Gene Express

2015
Genome-wide association study of clinically defined gout identifies multiple risk loci and its association with clinical subtypes.
    Annals of the rheumatic diseases, 2016, Volume: 75, Issue:4

    Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Asian People; ATP Binding Cassette Transporter, S

2016
Soluble uric acid primes TLR-induced proinflammatory cytokine production by human primary cells via inhibition of IL-1Ra.
    Annals of the rheumatic diseases, 2016, Volume: 75, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Case-Control Studies; Cytokines; Enzyme-Linked Immunos

2016
Urate crystal induced inflammation and joint pain are reduced in transient receptor potential ankyrin 1 deficient mice--potential role for transient receptor potential ankyrin 1 in gout.
    PloS one, 2015, Volume: 10, Issue:2

    Topics: Acetanilides; Animals; Cytokines; Disease Models, Animal; Gout; Inflammation; Mice; Mice, Knockout;

2015
Smaller caliber renal arteries are a novel feature of uromodulin-associated kidney disease.
    Kidney international, 2015, Volume: 88, Issue:1

    Topics: Adolescent; Adult; Aged; Angiography; Child; Chronic Disease; Female; Genotype; Glomerular Filtratio

2015
Allopurinol adherence among patients with gout: an Italian general practice database study.
    International journal of clinical practice, 2015, Volume: 69, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Databases, Factual; Dose-Response Relations

2015
Plasma Urate and Risk of a Hospital Stay with AKI: The Atherosclerosis Risk in Communities Study.
    Clinical journal of the American Society of Nephrology : CJASN, 2015, May-07, Volume: 10, Issue:5

    Topics: Acute Kidney Injury; Aged; Female; Follow-Up Studies; Glomerular Filtration Rate; Gout; Hospitalizat

2015
Is the double contour sign specific for gout? Or only for crystal arthritis?
    The Journal of rheumatology, 2015, Volume: 42, Issue:3

    Topics: Arthritis, Gouty; Chondrocalcinosis; Female; Gout; Humans; Male; Uric Acid

2015
Characteristics and management of gout patients in Europe: data from a large cohort of patients.
    European review for medical and pharmacological sciences, 2015, Volume: 19, Issue:4

    Topics: Adult; Allopurinol; Cohort Studies; Comorbidity; Cross-Sectional Studies; Europe; Febuxostat; Female

2015
Renal clearance of uric acid is linked to insulin resistance and lower excretion of sodium in gout patients.
    Rheumatology international, 2015, Volume: 35, Issue:9

    Topics: Adult; Female; Gout; Humans; Hypertension; Hyperuricemia; Insulin Resistance; Kidney; Male; Middle A

2015
Hyperuricemia starts at 360 micromoles (6 mg/dL).
    Joint bone spine, 2015, Volume: 82, Issue:3

    Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Risk Factors; Uric Acid

2015
Urate crystal degradation for treatment of gout: a nanoparticulate combination therapy approach.
    Drug delivery and translational research, 2015, Volume: 5, Issue:3

    Topics: Absorption, Physiological; Administration, Cutaneous; Animals; Anti-Inflammatory Agents, Non-Steroid

2015
Ultrasound-guided dry-needle synovial tissue aspiration for diagnostic microscopy in gout patients presenting without synovial effusion or clinically detectable tophi.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2015, Volume: 21, Issue:3

    Topics: Adult; Aged; Biopsy, Fine-Needle; Diagnostic Imaging; Gout; Humans; Male; Middle Aged; Synovial Memb

2015
A network pharmacology approach to determine active ingredients and rationality of herb combinations of Modified-Simiaowan for treatment of gout.
    Journal of ethnopharmacology, 2015, Jun-20, Volume: 168

    Topics: Cells, Cultured; Drugs, Chinese Herbal; Gout; Human Umbilical Vein Endothelial Cells; Humans; Interc

2015
Ungoutedly time for a change.
    Annals of the rheumatic diseases, 2015, Volume: 74, Issue:9

    Topics: Female; Foot Joints; Gout; Humans; Hyperuricemia; Male; Radiography; Tendons; Uric Acid

2015
Inpatient management of gout in a New Zealand hospital: a retrospective audit.
    International journal of rheumatic diseases, 2016, Volume: 19, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Drug Therapy, Combination; Drug Utilization Review; Fema

2016
Clinical associations between gout and multiple sclerosis, Parkinson's disease and motor neuron disease: record-linkage studies.
    BMC neurology, 2015, Feb-28, Volume: 15

    Topics: Adult; Aged; Databases, Factual; England; Female; Gout; Hospitalization; Humans; Male; Middle Aged;

2015
Clinicopathologic characterization of visceral gout of various internal organs--a study of 2 cases from a venom and toxin research center.
    Diagnostic pathology, 2015, Apr-09, Volume: 10

    Topics: Animals; Animals, Laboratory; Autopsy; Biopsy; Cause of Death; Crystallization; Elapidae; Gout; Gran

2015
Gout and sickle cell disease: not all pain is sickle cell pain.
    British journal of haematology, 2015, Volume: 171, Issue:5

    Topics: Acute Disease; Adult; Age of Onset; Aged; Aged, 80 and over; Anemia, Sickle Cell; Female; Gout; Hemo

2015
A brief history of uric acid: From gout to cardiovascular risk factor.
    European journal of internal medicine, 2015, Volume: 26, Issue:5

    Topics: Cardiovascular Diseases; Gout; History, 18th Century; History, 19th Century; History, 20th Century;

2015
A Role for Gut Microbiota and the Metabolite-Sensing Receptor GPR43 in a Murine Model of Gout.
    Arthritis & rheumatology (Hoboken, N.J.), 2015, Volume: 67, Issue:6

    Topics: Animals; Cell Movement; Chemokine CXCL1; Disease Models, Animal; Fatty Acids, Volatile; Gout; Hypera

2015
The detection of monosodium urate crystals in synovial fluid after long-term and varying storage conditions.
    Joint bone spine, 2015, Volume: 82, Issue:6

    Topics: Gout; Humans; Microscopy, Polarization; Specimen Handling; Synovial Fluid; Temperature; Time Factors

2015
Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort.
    Arthritis research & therapy, 2015, May-12, Volume: 17

    Topics: Aged; Allopurinol; Cohort Studies; Cost-Benefit Analysis; Creatinine; Dose-Response Relationship, Dr

2015
Association of hormone therapy and incident gout: population-based case-control study.
    Menopause (New York, N.Y.), 2015, Volume: 22, Issue:12

    Topics: Age Factors; Aged; Aged, 80 and over; Alcohol Drinking; Body Mass Index; Case-Control Studies; Estro

2015
Cross-sectional analysis of nutrition and serum uric acid in two Caucasian cohorts: the AusDiab Study and the Tromsø study.
    Nutrition journal, 2015, May-14, Volume: 14

    Topics: Adult; Aged; Aged, 80 and over; Animals; Australia; Body Mass Index; Choice Behavior; Cholesterol; C

2015
Ticagrelor-related gout: An underestimated side effect.
    International journal of cardiology, 2015, Aug-01, Volume: 192

    Topics: Adenosine; Gout; Humans; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Ticagrelor; Uri

2015
Patient and clinical characteristics associated with gout flares in an integrated healthcare system.
    Rheumatology international, 2015, Volume: 35, Issue:11

    Topics: Aged; Biomarkers; California; Chi-Square Distribution; Delivery of Health Care, Integrated; Disease

2015
Hyperuricemia and tissue monourate deposits: prospective therapeutic considerations.
    European review for medical and pharmacological sciences, 2015, Volume: 19, Issue:9

    Topics: Asymptomatic Diseases; Cardiovascular Diseases; Cartilage; Gout; Humans; Hyperuricemia; Kidney Disea

2015
Gout: cartoonized and bagatellized and still left untreated. Time to change.
    Clinical rheumatology, 2015, Volume: 34, Issue:7

    Topics: Allopurinol; Arthritis; Cartoons as Topic; Gout; History, 19th Century; History, 20th Century; Histo

2015
Validity of gout diagnosis in Swedish primary and secondary care - a validation study.
    BMC musculoskeletal disorders, 2015, Jun-16, Volume: 16

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Crystallization; Female; Gout; Humans; Male; Medical Rec

2015
[Disturbance of uric acid metabolism].
    Nihon Jinzo Gakkai shi, 2015, Volume: 57, Issue:4

    Topics: Gout; Humans; Hyperuricemia; Kidney Diseases; Metabolism, Inborn Errors; Nucleic Acids; Renal Tubula

2015
Common Variants in LRP2 and COMT Genes Affect the Susceptibility of Gout in a Chinese Population.
    PloS one, 2015, Volume: 10, Issue:7

    Topics: Aged; Alleles; Asian People; Body Mass Index; Catechol O-Methyltransferase; China; Female; Gene Freq

2015
A method for counting monosodium urate crystals in synovial fluid.
    Reumatismo, 2015, Jun-30, Volume: 67, Issue:1

    Topics: Antioxidants; Biomarkers; Crystallization; Disease Progression; Feasibility Studies; Gout; Humans; L

2015
[Time course of changes in the clinical manifestations of gout in men: data of a 7-year retrospective follow-up].
    Terapevticheskii arkhiv, 2015, Volume: 87, Issue:5

    Topics: Adult; Aged; Allopurinol; Arthritis, Gouty; Follow-Up Studies; Gout; Gout Suppressants; Humans; Midd

2015
Treatment and prevention of gout.
    The Nurse practitioner, 2015, Aug-15, Volume: 40, Issue:8

    Topics: Adult; Diagnosis, Differential; Diagnostic Tests, Routine; Diet; Gout; Humans; Male; Nursing Diagnos

2015
Update on the diagnosis and management of gout.
    The Medical journal of Australia, 2015, Jul-20, Volume: 203, Issue:2

    Topics: Allopurinol; Anti-Inflammatory Agents; Diagnostic Imaging; Gout; Humans; Synovial Fluid; Uric Acid

2015
Hyperuricemia is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes.
    Journal of endocrinological investigation, 2016, Volume: 39, Issue:2

    Topics: Aged; Aged, 80 and over; Allopurinol; Atrial Fibrillation; Cross-Sectional Studies; Diabetes Mellitu

2016
The Positively Charged COOH-terminal Glycosaminoglycan-binding CXCL9(74-103) Peptide Inhibits CXCL8-induced Neutrophil Extravasation and Monosodium Urate Crystal-induced Gout in Mice.
    The Journal of biological chemistry, 2015, Aug-28, Volume: 290, Issue:35

    Topics: Amino Acid Sequence; Animals; Anti-Inflammatory Agents; Cell Migration Inhibition; Chemokine CXCL9;

2015
An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population.
    The Journal of rheumatology, 2015, Volume: 42, Issue:9

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Allopurinol; Australia; Electronic Health Records; Fema

2015
Ulcerated tophaceous gout.
    BMJ case reports, 2015, Aug-03, Volume: 2015

    Topics: Anemia; Anti-Bacterial Agents; Calculi; Clostridium Infections; Gout; Honey; Humans; Hyperuricemia;

2015
Positive association of tomato consumption with serum urate: support for tomato consumption as an anecdotal trigger of gout flares.
    BMC musculoskeletal disorders, 2015, Aug-19, Volume: 16

    Topics: Adolescent; Adult; Aged; Female; Gout; Humans; Hyperuricemia; Male; Middle Aged; Native Hawaiian or

2015
Monosodium urate crystal-induced triggering receptor expressed on myeloid cells 1 is associated with acute gouty inflammation.
    Rheumatology (Oxford, England), 2016, Volume: 55, Issue:1

    Topics: Acute Disease; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gene Expression Regulation; Gout;

2016
[Dual-energy computer tomography can be used for gout diagnostics].
    Ugeskrift for laeger, 2015, Aug-10, Volume: 177, Issue:33

    Topics: Allopurinol; Gout; Gout Suppressants; Humans; Male; Middle Aged; Radiography, Dual-Energy Scanned Pr

2015
Oral treatment with Bifidobacterium longum 51A reduced inflammation in a murine experimental model of gout.
    Beneficial microbes, 2015, Volume: 6, Issue:6

    Topics: Administration, Oral; Animals; Bifidobacterium; Cytokines; Disease Models, Animal; Gout; Gout Suppre

2015
Increase in thyroid stimulating hormone levels in patients with gout treated with inhibitors of xanthine oxidoreductase.
    Rheumatology international, 2015, Volume: 35, Issue:11

    Topics: Aged; Allopurinol; Biomarkers; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Human

2015
Gouty tophi in the bone marrow.
    British journal of haematology, 2016, Volume: 172, Issue:1

    Topics: Biopsy; Bone Marrow; Bone Marrow Diseases; Gout; Granuloma, Giant Cell; Humans; Male; Uric Acid

2016
Urate testing in gout: why, when and how.
    The New Zealand medical journal, 2015, Aug-21, Volume: 128, Issue:1420

    Topics: Biomarkers; Gout; Humans; Hyperuricemia; New Zealand; Quality of Health Care; Risk Factors; Uric Aci

2015
Body mass index modulates the relationship of sugar-sweetened beverage intake with serum urate concentrations and gout.
    Arthritis research & therapy, 2015, Sep-22, Volume: 17

    Topics: Adult; Aged; Analysis of Variance; Beverages; Body Mass Index; Cross-Sectional Studies; Female; Fruc

2015
Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises.
    Arthritis care & research, 2016, Volume: 68, Issue:5

    Topics: Consensus; Delphi Technique; Gout; Humans; Outcome Assessment, Health Care; Remission Induction; Sev

2016
The role of uric acid in the development of cardiovascular disease.
    Current medical research and opinion, 2015, Volume: 31 Suppl 2

    Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Risk Factors; Uric Acid

2015
Serum urate gene associations with incident gout, measured in the Framingham Heart Study, are modified by renal disease and not by body mass index.
    Rheumatology international, 2016, Volume: 36, Issue:2

    Topics: Age Factors; Aged; Aged, 80 and over; Biomarkers; Body Mass Index; Comorbidity; Female; Gene Frequen

2016
WDR1 and CLNK gene polymorphisms correlate with serum glucose and high-density lipoprotein levels in Tibetan gout patients.
    Rheumatology international, 2016, Volume: 36, Issue:3

    Topics: Adaptor Proteins, Signal Transducing; Adolescent; Adult; Aged; Asian People; Biomarkers; Blood Gluco

2016
Transmembrane TNF-α is sufficient for articular inflammation and hypernociception in a mouse model of gout.
    European journal of immunology, 2016, Volume: 46, Issue:1

    Topics: Animals; Disease Models, Animal; Gout; Hyperalgesia; Inflammation; Interleukin-1beta; Knee Joint; Ma

2016
Predicting allopurinol response in patients with gout.
    British journal of clinical pharmacology, 2016, Volume: 81, Issue:2

    Topics: Allopurinol; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Gout; Gout Suppress

2016
Gout and foot drop.
    Joint bone spine, 2016, Volume: 83, Issue:2

    Topics: Aged; Gait Disorders, Neurologic; Gout; Humans; Knee; Male; Peroneal Nerve; Peroneal Neuropathies; T

2016
Rebamipide Suppresses Monosodium Urate Crystal-Induced Interleukin-1β Production Through Regulation of Oxidative Stress and Caspase-1 in THP-1 Cells.
    Inflammation, 2016, Volume: 39, Issue:1

    Topics: Alanine; Ascorbic Acid; Caspase 1; Cell Line; Colchicine; Dexamethasone; Enzyme Activation; Gout; Hu

2016
Significance of the initiation time of urate-lowering therapy in gout patients: A retrospective research.
    Joint bone spine, 2015, Volume: 82, Issue:6

    Topics: Adult; Allopurinol; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Recur

2015
Development of a Dual-Energy Computed Tomography Scoring System for Measurement of Urate Deposition in Gout.
    Arthritis care & research, 2016, Volume: 68, Issue:6

    Topics: Aged; Female; Gout; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Tomography, X-Ra

2016
Is allopurinol use associated with an excess risk of osteoporotic fracture? A National Prescription Registry study.
    Archives of osteoporosis, 2015, Volume: 10

    Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Comorbidity; Denmark; Female; Gout; Gout Suppressants;

2015
[Not Available].
    Zeitschrift fur Rheumatologie, 2015, Volume: 74, Issue:6

    Topics: Animals; Gout; Humans; Tendons; Uric Acid

2015
Is urate crystal precipitation a predictor of cardiovascular risk in hyperuricemic patients? A Danish cohort study.
    Arthritis research & therapy, 2015, Oct-29, Volume: 17

    Topics: Cardiovascular Diseases; Cohort Studies; Crystallization; Denmark; Female; Gout; Humans; Hyperuricem

2015
Febuxostat in the management of gout: a cost-effectiveness analysis.
    Journal of medical economics, 2016, Volume: 19, Issue:3

    Topics: Adult; Aged; Allopurinol; Cost-Benefit Analysis; Disease Management; Febuxostat; Female; Gout; Gout

2016
Gout, not hyperuricemia alone, impairs left ventricular diastolic function.
    Arthritis research & therapy, 2015, Nov-14, Volume: 17

    Topics: Adult; Aged; Biomarkers; Cohort Studies; Diastole; Female; Gout; Humans; Hyperuricemia; Male; Middle

2015
A world of hurt: failure to achieve treatment goals in patients with gout requires a paradigm shift.
    Postgraduate medicine, 2016, Volume: 128, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Clinical Audit; Female; Gout; Gout Suppressants; Guideli

2016
A Real-World Study of Switching From Allopurinol to Febuxostat in a Health Plan Database.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2015, Volume: 21, Issue:8

    Topics: Adult; Aged; Allopurinol; Comparative Effectiveness Research; Drug Monitoring; Drug Substitution; Fe

2015
Management of gout in the real world: current practice versus guideline recommendations.
    Postgraduate medicine, 2016, Volume: 128, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Combined Modality Therapy; Cross-Sectional S

2016
Psoriasis and uric acid: a population-based cross-sectional study.
    Clinical and experimental dermatology, 2016, Volume: 41, Issue:3

    Topics: Adult; Case-Control Studies; Cross-Sectional Studies; Female; Gout; Humans; Hyperuricemia; Logistic

2016
A Tincture of Time-Latent Crystal Formation and Clinical Decision-Making in Acute Gout: A Teachable Moment.
    JAMA internal medicine, 2016, Volume: 176, Issue:2

    Topics: Arthritis, Infectious; Crystallization; Diagnosis, Differential; Gout; Humans; Male; Middle Aged; Sy

2016
[Compliance in intercriticalgout patients and its related factors].
    Zhonghua yi xue za zhi, 2015, Jul-21, Volume: 95, Issue:27

    Topics: Case-Control Studies; Gout; Humans; Patient Compliance; Surveys and Questionnaires; Uric Acid

2015
Gout in Older Adults: The Atherosclerosis Risk in Communities Study.
    The journals of gerontology. Series A, Biological sciences and medical sciences, 2016, Volume: 71, Issue:4

    Topics: Age Factors; Aged; Atherosclerosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Bin

2016
Low omega-3 fatty acid levels associate with frequent gout attacks: a case control study.
    Annals of the rheumatic diseases, 2016, Volume: 75, Issue:4

    Topics: Aged; Case-Control Studies; Disease Progression; Fatty Acids, Omega-3; Gout; Gout Suppressants; Huma

2016
rs3806268 of NLRP3 gene polymorphism is associated with the development of primary gout.
    International journal of clinical and experimental pathology, 2015, Volume: 8, Issue:10

    Topics: Adult; Alleles; Asian People; Biomarkers; Female; Gene Frequency; Genetic Predisposition to Disease;

2015
Prevalence of monosodium urate deposits in a population of rheumatoid arthritis patients with hyperuricemia.
    Seminars in arthritis and rheumatism, 2016, Volume: 45, Issue:6

    Topics: Age Distribution; Aged; Arthritis, Rheumatoid; Comorbidity; Female; Foot Joints; Gout; Hand Joints;

2016
Dual-Energy CT in Patients with Suspected Gouty Arthritis: Effects on Treatment Regimen and Clinical Outcome.
    Academic radiology, 2016, Volume: 23, Issue:3

    Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Ar

2016
Impact of Urate Level on Cardiovascular Risk in Allopurinol Treated Patients. A Nested Case-Control Study.
    PloS one, 2016, Volume: 11, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Case-Control Studies; Denmark;

2016
Prevalence and associations of gout and hyperuricaemia: results from an Australian population-based study.
    Internal medicine journal, 2016, Volume: 46, Issue:5

    Topics: Adult; Age Distribution; Aged; Australia; Comorbidity; Female; Gout; Gout Suppressants; Humans; Hype

2016
Effects of Pimenta pseudocaryophyllus extracts on gout: Anti-inflammatory activity and anti-hyperuricemic effect through xantine oxidase and uricosuric action.
    Journal of ethnopharmacology, 2016, Mar-02, Volume: 180

    Topics: Animals; Anti-Inflammatory Agents; Gout; Gout Suppressants; Hyperuricemia; Male; Mice; Phytotherapy;

2016
Target Serum Urate: Do Gout Patients Know Their Goal?
    Arthritis care & research, 2016, Volume: 68, Issue:7

    Topics: Aged; Cross-Sectional Studies; Female; Gout; Health Knowledge, Attitudes, Practice; Humans; Male; Mi

2016
ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout.
    The pharmacogenomics journal, 2017, Volume: 17, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Allopurinol; ATP Binding Cassette Transporter, Subfamily G, Member 2

2017
[Clinical value of toes periungual green-coloured voxels of dual-energy CT gout detecting technology].
    Zhonghua yi xue za zhi, 2015, Oct-20, Volume: 95, Issue:39

    Topics: Female; Gout; Humans; Male; Toes; Tomography, X-Ray Computed; Uric Acid

2015
Development and First Validation of a Disease Activity Score for Gout.
    Arthritis care & research, 2016, Volume: 68, Issue:10

    Topics: Aged; Arthralgia; Disease Progression; Factor Analysis, Statistical; Female; Follow-Up Studies; Gout

2016
Intestinal Microbiota Distinguish Gout Patients from Healthy Humans.
    Scientific reports, 2016, Feb-08, Volume: 6

    Topics: Adult; Aged; Area Under Curve; Bacteria; Bacteroides; Bifidobacterium pseudocatenulatum; Biomarkers;

2016
Association of Serum Uric Acid and Disease Duration With Frequent Gout Attacks: A Case-Control Study.
    Arthritis care & research, 2016, Volume: 68, Issue:10

    Topics: Aged; Case-Control Studies; Comorbidity; Disease Progression; Female; Gout; Humans; Logistic Models;

2016
Macrophage migration inhibitory factor drives neutrophil accumulation by facilitating IL-1β production in a murine model of acute gout.
    Journal of leukocyte biology, 2016, Volume: 99, Issue:6

    Topics: Acute Disease; Animals; Disease Models, Animal; Female; Gout; Humans; Inflammation; Injections; Inte

2016
Chronic tophaceous gout with unusual large tophi: case report.
    The Pan African medical journal, 2015, Volume: 22

    Topics: Aged; Chronic Disease; Gout; Humans; Joints; Male; Uric Acid

2015
Dual-energy computed tomography has limited sensitivity for non-tophaceous gout: a comparison study with tophaceous gout.
    BMC musculoskeletal disorders, 2016, Feb-18, Volume: 17

    Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Female; Gout; Humans; Male; Middle Aged; Tom

2016
Knowledge, illness perceptions and stated clinical practice behaviour in management of gout: a mixed methods study in general practice.
    Clinical rheumatology, 2016, Volume: 35, Issue:8

    Topics: Adult; Disease Management; Female; General Practice; General Practitioners; Gout; Health Knowledge,

2016
PDK2 and ABCG2 genes polymorphisms are correlated with blood glucose levels and uric acid in Tibetan gout patients.
    Genetics and molecular research : GMR, 2016, Feb-11, Volume: 15, Issue:1

    Topics: Asian People; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transpor

2016
Diagnostic Tool for Gout Without Need for Joint Fluid Aspiration.
    American family physician, 2016, Feb-15, Volume: 93, Issue:4

    Topics: Female; Gout; Humans; Male; Synovial Fluid; Unnecessary Procedures; Uric Acid

2016
A cross-sectional internet-based patient survey of the management strategies for gout.
    BMC complementary and alternative medicine, 2016, Mar-01, Volume: 16

    Topics: Adult; Aged; Aged, 80 and over; Attitude to Health; Complementary Therapies; Consumer Behavior; Cros

2016
Bone scintigraphy in tophaceous gout.
    European journal of nuclear medicine and molecular imaging, 2016, Volume: 43, Issue:7

    Topics: Aged; Bone and Bones; Gout; Humans; Male; Radionuclide Imaging; Uric Acid

2016
Hypercrosslinked strong cation-exchange polymers for selective extraction of serum purine metabolites associated with gout.
    Talanta, 2016, May-01, Volume: 151

    Topics: Cation Exchange Resins; Chromatography, High Pressure Liquid; Cross-Linking Reagents; Gout; Humans;

2016
Dual-Energy CT of Urate Deposits in Costal Cartilage and Intervertebral Disks of Patients With Tophaceous Gout and Age-Matched Controls.
    AJR. American journal of roentgenology, 2016, Volume: 206, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Costal Cartilage; Female; Gout; Humans; Intervertebral Disc; Male; M

2016
[Drug reduction of uric acid not just when symptoms appear].
    MMW Fortschritte der Medizin, 2016, Mar-17, Volume: 158, Issue:5

    Topics: Allopurinol; Clinical Trials as Topic; Febuxostat; Gout; Humans; Hyperuricemia; Uric Acid

2016
Urate crystals deposition in the feet of overweight juveniles and those with symptomatic hyperuricemia: a dual-energy CT study.
    Journal of pediatric endocrinology & metabolism : JPEM, 2016, May-01, Volume: 29, Issue:5

    Topics: Adolescent; Biomarkers; Child; Female; Follow-Up Studies; Gout; Humans; Hyperuricemia; Kidney Diseas

2016
Clinical and genetic features of diuretic-associated gout: a case-control study.
    Rheumatology (Oxford, England), 2016, Volume: 55, Issue:7

    Topics: Adult; Age of Onset; Aged; Alleles; ATP Binding Cassette Transporter, Subfamily G, Member 2; Biomark

2016
[Uric acid and kidneys – Physiological and pathophysiological aspects].
    Therapeutische Umschau. Revue therapeutique, 2016, Volume: 73, Issue:3

    Topics: Gout; Humans; Hyperuricemia; Kidney; Kidney Failure, Chronic; Kidney Tubules; Risk Factors; Uric Aci

2016
Survey Definitions of Gout for Epidemiologic Studies: Comparison With Crystal Identification as the Gold Standard.
    Arthritis care & research, 2016, Volume: 68, Issue:12

    Topics: Colchicine; Diagnostic Self Evaluation; Epidemiologic Studies; Female; Gout; Gout Suppressants; Huma

2016
Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease.
    Journal of managed care & specialty pharmacy, 2016, Volume: 22, Issue:4

    Topics: Aged; Aged, 80 and over; Allopurinol; Cohort Studies; Cost-Benefit Analysis; Febuxostat; Female; Gou

2016
Patients with Gout Treated with Conventional Urate-lowering Therapy: Association with Disease Control, Health-related Quality of Life, and Work Productivity.
    The Journal of rheumatology, 2016, Volume: 43, Issue:10

    Topics: Aged; Cross-Sectional Studies; Efficiency; Employment; Female; France; Germany; Gout; Gout Suppressa

2016
SHEsisPlus, a toolset for genetic studies on polyploid species.
    Scientific reports, 2016, Apr-06, Volume: 6

    Topics: Algorithms; Arthritis, Gouty; China; Computer Simulation; Diploidy; Epistasis, Genetic; Genetic Mark

2016
New therapeutic approach to hyperuricemia and gout in the light of recommendations.
    Joint bone spine, 2016, Volume: 83, Issue:4

    Topics: Europe; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Monitoring, Physiologic; Pract

2016
Replication of association of the apolipoprotein A1-C3-A4 gene cluster with the risk of gout.
    Rheumatology (Oxford, England), 2016, Volume: 55, Issue:8

    Topics: Adult; Apolipoprotein A-I; Apolipoprotein C-III; Apolipoproteins C; Case-Control Studies; Female; Ge

2016
Dual energy computed tomography: a novel technique for diagnosis of gout.
    International journal of rheumatic diseases, 2016, Volume: 19, Issue:9

    Topics: Adult; Aged; Biomarkers; Crystallization; Female; Foot Joints; Gout; Humans; Knee Joint; Male; Middl

2016
Spatiotemporal gait parameters and plantar pressure distribution during barefoot walking in people with gout and asymptomatic hyperuricemia: comparison with healthy individuals with normal serum urate concentrations.
    Journal of foot and ankle research, 2016, Volume: 9

    Topics: Adult; Aged; Body Mass Index; Case-Control Studies; Cross-Sectional Studies; Female; Foot; Gait; Gou

2016
A survey of the assessment and management of gout in general practitioners and medical officers within the Illawarra Network, Australia.
    International journal of rheumatic diseases, 2017, Volume: 20, Issue:8

    Topics: Attitude of Health Personnel; Biomarkers; Colchicine; Creatinine; Drug Administration Schedule; Gene

2017
ALPK1 phosphorylates myosin IIA modulating TNF-α trafficking in gout flares.
    Scientific reports, 2016, 05-12, Volume: 6

    Topics: Amino Acid Sequence; Cell Line; Colchicine; Cytokines; Down-Regulation; Gene Knockdown Techniques; G

2016
Synovial fluid proteins are required for the induction of interleukin-1β production by monosodium urate crystals.
    Scandinavian journal of rheumatology, 2016, Volume: 45, Issue:5

    Topics: Arthritis, Gouty; Case-Control Studies; Cell Line; Enzyme-Linked Immunosorbent Assay; Gout; Humans;

2016
Monosodium urate crystals induce oxidative stress in human synoviocytes.
    Arthritis research & therapy, 2016, 05-21, Volume: 18, Issue:1

    Topics: Apoptosis; Blotting, Western; Cell Survival; Cells, Cultured; Fibroblasts; Flow Cytometry; Fluoresce

2016
Febuxostat for Asymptomatic Hyperuricemia in CKD.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2016, Volume: 67, Issue:6

    Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Thiazoles;

2016
Febuxostat Renoprotection in CKD Patients With Asymptomatic Hyperuricemia.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2016, Volume: 67, Issue:6

    Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Thiazoles;

2016
In Reply to 'Febuxostat for Asymptomatic Hyperuricemia in CKD' and 'Febuxostat Renoprotection in CKD Patients With Asymptomatic Hyperuricemia'.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2016, Volume: 67, Issue:6

    Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Thiazoles;

2016
Gout Flare With a Draining Tophus.
    The Journal of the American Osteopathic Association, 2016, Jun-01, Volume: 116, Issue:6

    Topics: Aged, 80 and over; Chronic Disease; Female; Gout; Humans; Metatarsophalangeal Joint; Radiography; Ur

2016
Tendon involvement in patients with gout: an ultrasound study of prevalence.
    Clinical rheumatology, 2016, Volume: 35, Issue:8

    Topics: Achilles Tendon; Adult; Aged; Case-Control Studies; Comorbidity; Cross-Sectional Studies; Female; Go

2016
A joint effort over a period of time: factors affecting use of urate-lowering therapy for long-term treatment of gout.
    BMC musculoskeletal disorders, 2016, 06-06, Volume: 17

    Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Cooperative Behavior; Female; Gout; Gout Suppressants;

2016
The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed Care Pharmacy and Medical Costs Perspective.
    Clinical therapeutics, 2016, Volume: 38, Issue:7

    Topics: Adult; Aged; Allopurinol; Budgets; Chronic Disease; Febuxostat; Female; Gout; Gout Suppressants; Hea

2016
Enhanced p62 Is Responsible for Mitochondrial Pathway-Dependent Apoptosis and Interleukin-1β Production at the Early Phase by Monosodium Urate Crystals in Murine Macrophage.
    Inflammation, 2016, Volume: 39, Issue:5

    Topics: Animals; Apoptosis; Gout; Inflammation; Interleukin-1beta; Macrophages; Metabolic Networks and Pathw

2016
Febuxostat for Patients With Gout and Severe Chronic Kidney Disease: Which Is the Appropriate Dosage? Comment on the Article by Saag et al.
    Arthritis & rheumatology (Hoboken, N.J.), 2016, Volume: 68, Issue:10

    Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni

2016
Genetic background of uric acid metabolism in a patient with severe chronic tophaceous gout.
    Clinica chimica acta; international journal of clinical chemistry, 2016, Sep-01, Volume: 460

    Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Chronic Disease; Genetic Background; Gout;

2016
Allopurinol Dose Reductions Based on Creatinine Alert Redesign System.
    The American journal of medicine, 2016, Volume: 129, Issue:7

    Topics: Allopurinol; Creatinine; Gout; Gout Suppressants; Humans; Uric Acid

2016
[What do the guidelines say?].
    MMW Fortschritte der Medizin, 2016, Jun-23, Volume: 158, Issue:12

    Topics: Anti-Inflammatory Agents; Combined Modality Therapy; Drug Therapy, Combination; Evidence-Based Medic

2016
Serum uric acid, gout, and venous thromboembolism: The atherosclerosis risk in communities study.
    Thrombosis research, 2016, Volume: 144

    Topics: Atherosclerosis; Biomarkers; Female; Gout; Humans; Middle Aged; Prospective Studies; Risk Factors; U

2016
Coevolution of URAT1 and Uricase during Primate Evolution: Implications for Serum Urate Homeostasis and Gout.
    Molecular biology and evolution, 2016, Volume: 33, Issue:9

    Topics: Animals; Biological Evolution; Computer Simulation; Evolution, Molecular; Gout; HEK293 Cells; Homeos

2016
Wide-field imaging of birefringent synovial fluid crystals using lens-free polarized microscopy for gout diagnosis.
    Scientific reports, 2016, 06-30, Volume: 6

    Topics: Algorithms; Birefringence; Crystallization; Gout; Humans; Microscopy, Polarization; Point-of-Care Sy

2016
Adequacy of Online Patient Information Resources on Gout and Potentially Curative Urate-Lowering Treatment.
    Arthritis care & research, 2017, Volume: 69, Issue:5

    Topics: Australia; Canada; Comprehension; Consumer Health Information; Gout; Gout Suppressants; Humans; Pati

2017
The safety and efficacy of benzbromarone in gout in Aotearoa New Zealand.
    Internal medicine journal, 2016, Volume: 46, Issue:9

    Topics: Aged; Allopurinol; Benzbromarone; Comorbidity; Exanthema; Female; Gout; Gout Suppressants; Humans; K

2016
IMAGES IN CLINICAL MEDICINE. Milk of Urate Bulla.
    The New England journal of medicine, 2016, Jul-14, Volume: 375, Issue:2

    Topics: Aged; Blister; Crystallization; Fingers; Gout; Humans; Kidney Transplantation; Male; Uric Acid

2016
Tophaceous Gout in an Anorectic Patient Visualized by Dual Energy Computed Tomography (DECT).
    The American journal of case reports, 2016, Jul-15, Volume: 17

    Topics: Absorptiometry, Photon; Allopurinol; Anorexia Nervosa; Biomarkers; Biopsy; Colchicine; Drug Therapy,

2016
[New diagnostics and treatments in gout].
    Lakartidningen, 2016, 07-15, Volume: 113

    Topics: Algorithms; Gout; Gout Suppressants; Humans; Life Style; Tomography, X-Ray Computed; Uric Acid

2016
Clinical significance of SLC2A9/GLUT9 rs11722228 polymorphisms in gout.
    International journal of rheumatic diseases, 2018, Volume: 21, Issue:3

    Topics: Adult; Aged; Case-Control Studies; Chi-Square Distribution; Creatinine; Gene Frequency; Genetic Asso

2018
Dual-energy computed tomography as a diagnostic tool for gout during intercritical periods.
    International journal of rheumatic diseases, 2016, Volume: 19, Issue:12

    Topics: Adult; Aged; Asymptomatic Diseases; Biomarkers; Female; Gout; Gout Suppressants; Humans; Joints; Mal

2016
A qualitative study to explore health professionals' experience of treating gout: understanding perceived barriers to effective gout management.
    Journal of primary health care, 2016, Volume: 8, Issue:2

    Topics: Culture; Diet; Gout; Gout Suppressants; Health Knowledge, Attitudes, Practice; Health Personnel; Hum

2016
Temporal evolution of urate crystal deposition over articular cartilage after successful urate-lowering therapy in patients with gout: An ultrasonographic perspective.
    Modern rheumatology, 2017, Volume: 27, Issue:3

    Topics: Adult; Aged; Cartilage, Articular; Gout; Gout Suppressants; Humans; Male; Metatarsophalangeal Joint;

2017
Dietary fiber and the short-chain fatty acid acetate promote resolution of neutrophilic inflammation in a model of gout in mice.
    Journal of leukocyte biology, 2017, Volume: 101, Issue:1

    Topics: Acetates; Animals; Apoptosis; Caspases; Crystallization; Diet, High-Fat; Dietary Fiber; Disease Mode

2017
"From father to son": Early onset gout in Guidobaldo I da Montefeltro, Duke of Urbino (1472-1508).
    European journal of internal medicine, 2016, Volume: 36

    Topics: Age of Onset; Conjunctiva; Erectile Dysfunction; Gout; History, 15th Century; History, 16th Century;

2016
Usefulness of plain radiography for assessing hypouricemic treatment response in patients with tophaceous gout.
    International journal of rheumatic diseases, 2016, Volume: 19, Issue:11

    Topics: Aged; Arthrography; Biomarkers; Female; Gout; Gout Suppressants; Humans; Male; Metatarsophalangeal J

2016
Sensitivity and specificity of ultrasonographic features of gout in intercritical and chronic phase.
    International journal of rheumatic diseases, 2017, Volume: 20, Issue:7

    Topics: Adult; Biomarkers; Case-Control Studies; Chronic Disease; Cross-Sectional Studies; Female; Gout; Hum

2017
Gout and the Risk of Non-vertebral Fracture.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2017, Volume: 32, Issue:2

    Topics: Cohort Studies; Female; Fractures, Bone; Gout; Humans; Male; Middle Aged; Risk Factors; Uric Acid

2017
Poorly controlled gout: who is doing poorly?
    Singapore medical journal, 2016, Volume: 57, Issue:8

    Topics: Allopurinol; Arthritis; Comorbidity; Gout; Humans; Hyperuricemia; Inflammation; Medication Adherence

2016
Genetic Association for P2X7R rs3751142 and CARD8 rs2043211 Polymorphisms for Susceptibility of Gout in Korean Men: Multi-Center Study.
    Journal of Korean medical science, 2016, Volume: 31, Issue:10

    Topics: Adult; Age of Onset; Asian People; Body Mass Index; CARD Signaling Adaptor Proteins; Case-Control St

2016
Renal dosing of allopurinol results in suboptimal gout care.
    Annals of the rheumatic diseases, 2017, Volume: 76, Issue:1

    Topics: Allopurinol; Gout; Gout Suppressants; Humans; Kidney; Uric Acid

2017
Urate crystal deposition and bone erosion in gout: 'inside-out' or 'outside-in'? A dual-energy computed tomography study.
    Arthritis research & therapy, 2016, 09-15, Volume: 18, Issue:1

    Topics: Adult; Aged; Bone and Bones; Female; Gout; Humans; Male; Middle Aged; Tomography, X-Ray Computed; Ur

2016
Ultrasound Features of the First Metatarsophalangeal Joint in Gout and Asymptomatic Hyperuricemia: Comparison With Normouricemic Individuals.
    Arthritis care & research, 2017, Volume: 69, Issue:6

    Topics: Adult; Aged; Female; Gout; Humans; Hyperuricemia; Male; Metatarsophalangeal Joint; Middle Aged; Sing

2017
Risk of acute gout among active smokers: data from nationwide inpatient sample.
    Clinical rheumatology, 2016, Volume: 35, Issue:12

    Topics: Acute Disease; Adult; Aged; Arthritis, Gouty; Databases, Factual; Female; Gout; Hospitalization; Hum

2016
Treat-to-target (T2T) recommendations for gout.
    Annals of the rheumatic diseases, 2017, Volume: 76, Issue:4

    Topics: Chronic Disease; Gout; Guidelines as Topic; Humans; Kidney; Life Style; Medication Adherence; Patien

2017
Serum uric acid levels and the risk of flares among gout patients in a US managed care setting.
    Current medical research and opinion, 2017, Volume: 33, Issue:1

    Topics: Adult; Aged; Female; Gout; Humans; Male; Managed Care Programs; Middle Aged; Proportional Hazards Mo

2017
Miliarial gout: a rare presentation of extensive cutaneous tophi.
    QJM : monthly journal of the Association of Physicians, 2016, Volume: 109, Issue:12

    Topics: Fatal Outcome; Gout; Humans; Hyperuricemia; Male; Middle Aged; Sepsis; Skin Diseases; Uric Acid

2016
The management of gout in different clinical specialties in Turkey: a patient-based survey.
    Clinical rheumatology, 2016, Volume: 35, Issue:12

    Topics: Adult; Aged; Allopurinol; Colchicine; Female; Gout; Gout Suppressants; Humans; Internal Medicine; Li

2016
Metabolic syndrome: prevalence and risk factors in Korean gout patients.
    The Korean journal of internal medicine, 2018, Volume: 33, Issue:4

    Topics: Adult; Aged; Female; Gout; Humans; Insulin Resistance; Male; Metabolic Syndrome; Middle Aged; Preval

2018
Editorial: The Sound and the Fury: Musculoskeletal Ultrasound in the Diagnosis of Gout.
    Arthritis & rheumatology (Hoboken, N.J.), 2017, Volume: 69, Issue:2

    Topics: Gout; Humans; Ultrasonography; Uric Acid

2017
Performance of Ultrasound in the Diagnosis of Gout in a Multicenter Study: Comparison With Monosodium Urate Monohydrate Crystal Analysis as the Gold Standard.
    Arthritis & rheumatology (Hoboken, N.J.), 2017, Volume: 69, Issue:2

    Topics: Cross-Sectional Studies; Crystallization; Female; Gout; Humans; Male; Middle Aged; Sensitivity and S

2017
Decrystallization of Crystals Using Gold "Nano-Bullets" and the Metal-Assisted and Microwave-Accelerated Decrystallization Technique.
    Molecules (Basel, Switzerland), 2016, Oct-18, Volume: 21, Issue:10

    Topics: Alanine; Chemistry, Pharmaceutical; Crystallization; Gold; Gout; Humans; Metal Nanoparticles; Microw

2016
Familial juvenile hyperuricemic nephropathy as rare cause of dialysis-dependent chronic kidney disease-a series of cases in two families.
    Renal failure, 2016, Volume: 38, Issue:10

    Topics: Adolescent; Adult; Child; Child, Preschool; DNA Mutational Analysis; Female; Gout; Humans; Hyperuric

2016
Genomic sequencing of uric acid metabolizing and clearing genes in relationship to xanthine oxidase inhibitor dose.
    Rheumatology international, 2017, Volume: 37, Issue:3

    Topics: Acute Disease; Aged; Allopurinol; Cohort Studies; Febuxostat; Female; Gout; Gout Suppressants; Human

2017
Diagnosis of Acute Gout: A Clinical Practice Guideline From the American College of Physicians.
    Annals of internal medicine, 2017, 01-03, Volume: 166, Issue:1

    Topics: Adult; Algorithms; Gout; Humans; Synovial Fluid; Uric Acid

2017
Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians.
    Annals of internal medicine, 2017, 01-03, Volume: 166, Issue:1

    Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Adult; Anti-Inflammatory Agents, Non-Steroidal

2017
Relationship of bone erosion with the urate and soft tissue components of the tophus in gout: a dual energy computed tomography study.
    Rheumatology (Oxford, England), 2017, Volume: 56, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Resorption; Female; Foot Joints; Gout; Humans; Line

2017
Response: Renal dosing of allopurinol results in suboptimal gout care by T Neogi et al.
    Annals of the rheumatic diseases, 2017, Volume: 76, Issue:1

    Topics: Allopurinol; Gout; Gout Suppressants; Humans; Kidney; Uric Acid

2017
Gout: will the "King of Diseases" be the first rheumatic disease to be cured?
    BMC medicine, 2016, Nov-11, Volume: 14, Issue:1

    Topics: Adult; Arthritis, Rheumatoid; Chronic Disease; Gout; Gout Suppressants; Humans; Inflammation; Pain;

2016
Crystal identification of synovial fluid aspiration by polarized light microscopy. An online test suggesting that our traditional rheumatologic competence needs renewed attention and training.
    Clinical rheumatology, 2017, Volume: 36, Issue:3

    Topics: Calcium Pyrophosphate; Clinical Competence; Gout; Humans; Microscopy, Polarization; Rheumatology; Sy

2017
Macrophage-derived IL-1β enhances monosodium urate crystal-triggered NET formation.
    Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2017, Volume: 66, Issue:3

    Topics: Extracellular Traps; Gout; Humans; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Int

2017
Interleukin 37 limits monosodium urate crystal-induced innate immune responses in human and murine models of gout.
    Arthritis research & therapy, 2016, 11-18, Volume: 18, Issue:1

    Topics: Animals; Blotting, Western; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Female; Flow

2016
Effects of febuxostat on insulin resistance and expression of high-sensitivity C-reactive protein in patients with primary gout.
    Rheumatology international, 2017, Volume: 37, Issue:2

    Topics: Adult; Aged; C-Reactive Protein; Febuxostat; Female; Gout; Gout Suppressants; Humans; Insulin Resist

2017
Monitoring of Urate-Lowering Therapy Among US Veterans Following the 2012 American College of Rheumatology Guidelines for Management of Gout.
    The Annals of pharmacotherapy, 2017, Volume: 51, Issue:4

    Topics: Adult; Aged; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Drug Monitoring; Febuxostat; Fema

2017
P2Y6 Receptor Antagonist MRS2578 Inhibits Neutrophil Activation and Aggregated Neutrophil Extracellular Trap Formation Induced by Gout-Associated Monosodium Urate Crystals.
    Journal of immunology (Baltimore, Md. : 1950), 2017, 01-01, Volume: 198, Issue:1

    Topics: Chemotaxis, Leukocyte; Enzyme-Linked Immunosorbent Assay; Extracellular Traps; Fluorescent Antibody

2017
Ultrasonography in the diagnosis of asymptomatic hyperuricemia and gout.
    Nucleosides, nucleotides & nucleic acids, 2016, Volume: 35, Issue:10-12

    Topics: Gout; Humans; Hyperuricemia; Ultrasonography; Uric Acid

2016
Construct Validity of Radiographs of the Feet to Assess Joint Damage in Patients with Gout.
    The Journal of rheumatology, 2017, Volume: 44, Issue:1

    Topics: Age Factors; Aged; Disease Progression; Female; Foot; Foot Joints; Gout; Humans; Male; Middle Aged;

2017
The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States.
    Seminars in arthritis and rheumatism, 2017, Volume: 46, Issue:5

    Topics: Allopurinol; Asian; Black or African American; Cost-Benefit Analysis; Female; Genetic Markers; Genet

2017
Targeting ASC in NLRP3 inflammasome by caffeic acid phenethyl ester: a novel strategy to treat acute gout.
    Scientific reports, 2016, 12-09, Volume: 6

    Topics: Administration, Oral; Animals; Biomarkers; Caffeic Acids; CARD Signaling Adaptor Proteins; Disease M

2016
A study comparing the safety and efficacy of febuxostat, allopurinol, and benzbromarone in Chinese gout patients: a retrospective cohort study
.
    International journal of clinical pharmacology and therapeutics, 2017, Volume: 55, Issue:2

    Topics: Adult; Allopurinol; Asian People; Benzbromarone; Biomarkers; China; Drug Dosage Calculations; Febuxo

2017
Emerging uricosurics for gout.
    Expert review of clinical pharmacology, 2017, Volume: 10, Issue:3

    Topics: Drug Design; Gout; Humans; Hyperuricemia; Uric Acid; Uricosuric Agents

2017
Predictors of Mortality in People with Recent-onset Gout: A Prospective Observational Study.
    The Journal of rheumatology, 2017, Volume: 44, Issue:3

    Topics: Aged; Aged, 80 and over; Creatinine; Female; Gout; Humans; Male; Middle Aged; Mortality; Prospective

2017
Dietary Management of Gout: What is the Evidence?
    The American journal of medicine, 2017, Volume: 130, Issue:1

    Topics: Gout; Gout Suppressants; Humans; Uric Acid

2017
Annexin A1 promotes timely resolution of inflammation in murine gout.
    European journal of immunology, 2017, Volume: 47, Issue:3

    Topics: Animals; Annexin A1; Anti-Inflammatory Agents; Antibodies, Blocking; Apoptosis; Cell Movement; Disea

2017
AJKD Atlas of Renal Pathology: Gouty Nephropathy.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2017, Volume: 69, Issue:1

    Topics: Diagnosis, Differential; Gout; Humans; Kidney; Kidney Diseases; Microscopy; Uric Acid

2017
Chasing crystals out of the body: will treat to serum urate target for gout help us get there?
    Annals of the rheumatic diseases, 2017, Volume: 76, Issue:4

    Topics: Gout; Gout Suppressants; Humans; Uric Acid

2017
URAT1 inhibition by ALPK1 is associated with uric acid homeostasis.
    Rheumatology (Oxford, England), 2017, 04-01, Volume: 56, Issue:4

    Topics: Animals; Case-Control Studies; Cells, Cultured; Crystallization; Gout; Homeostasis; Humans; Hyperuri

2017
COX-2/mPGES-1/PGE2 cascade activation mediates uric acid-induced mesangial cell proliferation.
    Oncotarget, 2017, Feb-07, Volume: 8, Issue:6

    Topics: Aged; Animals; Case-Control Studies; Cell Line; Cell Proliferation; Cyclin A2; Cyclin D1; Cyclooxyge

2017
Plasma oxypurinol as a measure of adherence in clinical trials.
    Annals of the rheumatic diseases, 2018, Volume: 77, Issue:2

    Topics: Adult; Allopurinol; Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Medicat

2018
Oral delivery of allopurinol niosomes in treatment of gout in animal model.
    Journal of liposome research, 2017, Volume: 27, Issue:2

    Topics: Administration, Oral; Allopurinol; Animals; Disease Models, Animal; Drug Delivery Systems; Gout; Hex

2017
Effects of bariatric surgery on gout incidence in the Swedish Obese Subjects study: a non-randomised, prospective, controlled intervention trial.
    Annals of the rheumatic diseases, 2017, Volume: 76, Issue:4

    Topics: Adult; Bariatric Surgery; Body Mass Index; Case-Control Studies; Controlled Clinical Trials as Topic

2017
Clinical Inquiry: How do clinical prediction rules compare with joint fluid analysis in diagnosing gout?
    The Journal of family practice, 2016, Volume: 65, Issue:11

    Topics: Decision Support Techniques; Diagnostic Techniques and Procedures; Gout; Humans; Netherlands; Practi

2016
Delta neutrophil index contributes to the differential diagnosis between acute gout attack and cellulitis within 24 hours after hospitalization.
    Rheumatology (Oxford, England), 2017, 05-01, Volume: 56, Issue:5

    Topics: Acute Disease; Aged; Area Under Curve; Biomarkers; Cellulitis; Diagnosis, Differential; Female; Gout

2017
Achieving serum urate targets in gout: an audit in a gout-oriented rheumatology practice.
    International journal of rheumatic diseases, 2017, Volume: 20, Issue:7

    Topics: Aged; Allopurinol; Biomarkers; Drug Substitution; Febuxostat; Female; Gout; Gout Suppressants; Human

2017
A swollen red finger.
    BMJ (Clinical research ed.), 2017, Feb-16, Volume: 356

    Topics: Aged, 80 and over; Diagnosis, Differential; Female; Finger Joint; Fingers; Gout; Humans; Uric Acid

2017
Combining Hyperechoic Aggregates and the Double-Contour Sign Increases the Sensitivity of Sonography for Detection of Monosodium Urate Deposits in Gout.
    Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine, 2017, Volume: 36, Issue:5

    Topics: Adult; Female; Gout; Humans; Joints; Male; Middle Aged; Sensitivity and Specificity; Ultrasonography

2017
Evaluation of the Relationship Between Serum Uric Acid Levels and Cardiovascular Events in Patients With Gout: A Retrospective Analysis Using Electronic Medical Record Data.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2017, Volume: 23, Issue:3

    Topics: Adult; Electronic Health Records; Female; Gout; Heart Failure; Humans; Kidney Diseases; Male; Middle

2017
β-Hydroxybutyrate Deactivates Neutrophil NLRP3 Inflammasome to Relieve Gout Flares.
    Cell reports, 2017, 02-28, Volume: 18, Issue:9

    Topics: 3-Hydroxybutyric Acid; Adolescent; Adult; Aged; Animals; Diet, Ketogenic; Female; Gout; Humans; Infl

2017
Effects of multiple genetic loci on the pathogenesis from serum urate to gout.
    Scientific reports, 2017, 03-02, Volume: 7

    Topics: Alleles; Case-Control Studies; Disease Progression; Female; Gene Expression; Genetic Association Stu

2017
What is your diagnosis? Joint and associated tissue aspirates from a Bearded Dragon (Pogona vitticeps).
    Veterinary clinical pathology, 2017, Volume: 46, Issue:2

    Topics: Animals; Biopsy, Fine-Needle; Female; Gout; Joint Diseases; Lizards; Uric Acid

2017
Enhanced osteoclastogenesis in patients with tophaceous gout: urate crystals promote osteoclast development through interactions with stromal cells.
    Arthritis and rheumatism, 2008, Volume: 58, Issue:6

    Topics: Acid Phosphatase; Animals; Bone Resorption; Cell Differentiation; Cell Line; Cohort Studies; Fibrobl

2008
Crystal-induced neutrophil activation: X. Proinflammatory role of the tyrosine kinase Tec.
    Arthritis and rheumatism, 2008, Volume: 58, Issue:6

    Topics: Cells, Cultured; Gout; Gout Suppressants; Humans; Neutrophils; Protein-Tyrosine Kinases; Signal Tran

2008
An initial presentation of polyarticular gout with spinal involvement.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2008, Volume: 14, Issue:3

    Topics: Aged, 80 and over; Allopurinol; Anti-Inflammatory Agents; Diffusion Magnetic Resonance Imaging; Fema

2008
Fine needle aspiration of a subcutaneous gouty tophus.
    Diagnostic cytopathology, 2008, Volume: 36, Issue:7

    Topics: Adult; Biopsy, Fine-Needle; Crystallization; Diagnosis, Differential; Female; Gout; Histological Tec

2008
Gout in the spotlight.
    Arthritis research & therapy, 2008, Volume: 10, Issue:3

    Topics: Animals; Disease Models, Animal; Gout; Humans; Mice; Uric Acid

2008
Re: Gout and risk of Parkinson disease: a prospective study.
    Neurology, 2008, Jul-01, Volume: 71, Issue:1

    Topics: Comorbidity; Databases as Topic; Diagnostic Errors; Epidemiologic Studies; Gout; Humans; Parkinson D

2008
Re: Gout and risk of Parkinson disease: a prospective study.
    Neurology, 2008, Jul-01, Volume: 71, Issue:1

    Topics: Comorbidity; Dose-Response Relationship, Drug; Free Radical Scavengers; Gout; Gout Suppressants; Hum

2008
An unusual patient with hypothyroidism, tophaceous gout, and marked joint destruction.
    Nucleosides, nucleotides & nucleic acids, 2008, Volume: 27, Issue:6

    Topics: Aged; Gout; Humans; Hypothyroidism; Joints; Male; Uric Acid

2008
A survey of the management of gout in primary care.
    Irish medical journal, 2008, Volume: 101, Issue:5

    Topics: Gout; Health Care Surveys; Humans; Ireland; Physicians, Family; Prevalence; Primary Health Care; Ris

2008
Dietary and lifestyle changes associated with high prevalence of hyperuricemia and gout in the Shandong coastal cities of Eastern China.
    The Journal of rheumatology, 2008, Volume: 35, Issue:9

    Topics: Adult; Aged; China; Comorbidity; Feeding Behavior; Female; Gout; Humans; Hyperuricemia; Life Style;

2008
Ultrasonography for diagnosing atypical gout. Two case reports.
    Joint bone spine, 2008, Volume: 75, Issue:5

    Topics: Adult; Aged; Arthritis, Psoriatic; Cartilage, Articular; Colchicine; Diagnosis, Differential; Gout;

2008
Opportunities for improving medication use and monitoring in gout.
    Annals of the rheumatic diseases, 2009, Volume: 68, Issue:8

    Topics: Aged; Allopurinol; Biomarkers; Colchicine; Drug Administration Schedule; Drug Monitoring; Female; Go

2009
Mechanisms of bone erosion in gout: a quantitative analysis using plain radiography and computed tomography.
    Annals of the rheumatic diseases, 2009, Volume: 68, Issue:8

    Topics: Adult; Aged; Biomarkers; C-Reactive Protein; Chronic Disease; Female; Gout; Hand Joints; Humans; Mal

2009
Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile.
    Rheumatology (Oxford, England), 2008, Volume: 47, Issue:10

    Topics: Adult; Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diet; Epidemiologic Meth

2008
Febuxostat: a viewpoint by H. Ralph Schumacher Jr and Lan X. Chen.
    Drugs, 2008, Volume: 68, Issue:13

    Topics: Administration, Oral; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Uric Ac

2008
Febuxostat : a viewpoint by Naomi Schlesinger.
    Drugs, 2008, Volume: 68, Issue:13

    Topics: Administration, Oral; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Uric Ac

2008
Febuxostat : a viewpoint by N. Lawrence Edwards.
    Drugs, 2008, Volume: 68, Issue:13

    Topics: Administration, Oral; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Uric Ac

2008
Hyperuricemia, gout, and lifestyle factors.
    The Journal of rheumatology, 2008, Volume: 35, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; China; Comorbidity; Feeding Behavior; Gout; Humans; Hyperuricemia; L

2008
A little citrus might go a long way!
    The Journal of rheumatology, 2008, Volume: 35, Issue:9

    Topics: Antioxidants; Ascorbic Acid; Citrus; Gout; Humans; Phytotherapy; Randomized Controlled Trials as Top

2008
Confessions of a goutophile: Despite its treatability, gout remains a problem.
    Cleveland Clinic journal of medicine, 2008, Volume: 75 Suppl 5

    Topics: Diagnosis, Differential; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid

2008
How gout inhibits the development of cell-mediated autoimmune disease.
    Medical hypotheses, 2009, Volume: 72, Issue:1

    Topics: Arthritis, Rheumatoid; Autoimmune Diseases; Gout; Humans; Immunity, Cellular; Uric Acid

2009
How PCP education can impact gout management: the gout essentials.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2008, Volume: 14, Issue:5 Suppl

    Topics: Anti-Inflammatory Agents; Gout; Gout Suppressants; Humans; Hyperuricemia; Physicians, Family; Uric A

2008
Understanding deficient elimination of uric acid.
    Lancet (London, England), 2008, Dec-06, Volume: 372, Issue:9654

    Topics: Gout; Humans; Hyperuricemia; Kidney; Metabolic Clearance Rate; Uric Acid

2008
Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study.
    Lancet (London, England), 2008, Dec-06, Volume: 372, Issue:9654

    Topics: Alleles; Chromosomes, Human, 4-5; Chromosomes, Human, 6-12 and X; Cohort Studies; Female; Genetics,

2008
An unusual "gouty" case of back pain and fever.
    The Journal of rheumatology, 2008, Volume: 35, Issue:10

    Topics: Anti-Inflammatory Agents; Back Pain; Colchicine; Female; Gout; Gout Suppressants; Humans; Knee Joint

2008
Role of the adrenal cortex in urate metabolism and in gout.
    The Journal of laboratory and clinical medicine, 1948, Volume: 33, Issue:11

    Topics: Adrenal Cortex; Adrenal Glands; Adrenal Insufficiency; Cerebral Cortex; Gout; Humans; Uric Acid

1948
Resolution of gouty tophi after twelve weeks of pegloticase treatment.
    Arthritis and rheumatism, 2008, Volume: 58, Issue:11

    Topics: Aged; Gout; Humans; Male; Middle Aged; Polyethylene Glycols; Urate Oxidase; Uric Acid

2008
Gout and the risk of Parkinson's disease: a cohort study.
    Arthritis and rheumatism, 2008, Nov-15, Volume: 59, Issue:11

    Topics: Aged; Aged, 80 and over; Antioxidants; British Columbia; Case-Control Studies; Cohort Studies; Diure

2008
Gout management: let's get it right this time.
    Arthritis and rheumatism, 2008, Nov-15, Volume: 59, Issue:11

    Topics: Administration, Oral; Allopurinol; Dose-Response Relationship, Drug; Drug Evaluation; Europe; Febuxo

2008
Tophi as first clinical sign of gout.
    International journal of dermatology, 2008, Volume: 47 Suppl 1

    Topics: Aged, 80 and over; Crystallization; Female; Fingers; Gout; Humans; Skin; Skin Diseases; Uric Acid

2008
Persistent normalization of serum levels of uric acid in a gouty patient after administration of cyproterone acetate.
    Rheumatology international, 2009, Volume: 29, Issue:6

    Topics: Aged, 80 and over; Androgen Antagonists; Cyproterone Acetate; Dose-Response Relationship, Drug; Drug

2009
Hyperuricemia and its related factors in an urban population, Izmir, Turkey.
    Rheumatology international, 2009, Volume: 29, Issue:8

    Topics: Adult; Blood Glucose; Body Composition; Creatinine; Diabetes Mellitus; Female; Gout; Humans; Hyperte

2009
Dual energy computed tomography in tophaceous gout.
    Annals of the rheumatic diseases, 2009, Volume: 68, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Algorithms; Color; Female; Gout; Humans; Male; Middle Aged; Tissue D

2009
Adherence to urate-lowering therapy.
    Southern medical journal, 2009, Volume: 102, Issue:1

    Topics: Female; Gout; Gout Suppressants; Humans; Male; Medication Adherence; Uric Acid

2009
NALP3 inflammasome functional polymorphisms and gout susceptibility.
    Cell cycle (Georgetown, Tex.), 2009, Jan-01, Volume: 8, Issue:1

    Topics: Carrier Proteins; Genetic Predisposition to Disease; Gout; Humans; Inflammation; Interleukin-1beta;

2009
Resident macrophages initiating and driving inflammation in a monosodium urate monohydrate crystal-induced murine peritoneal model of acute gout.
    Arthritis and rheumatism, 2009, Volume: 60, Issue:1

    Topics: Acute Disease; Animals; Crystallization; Disease Models, Animal; Gout; Interleukin-1beta; Interleuki

2009
Clinical diagnostic criteria for gout: comparison with the gold standard of synovial fluid crystal analysis.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2009, Volume: 15, Issue:1

    Topics: Aged; Cohort Studies; Crystallization; Female; Gout; Humans; Hyperuricemia; Male; Middle Aged; Predi

2009
The role of diet in the management of gout: a comparison of knowledge and attitudes to current evidence.
    Journal of human nutrition and dietetics : the official journal of the British Dietetic Association, 2009, Volume: 22, Issue:1

    Topics: Aged; Aged, 80 and over; Alcohol Drinking; Attitude of Health Personnel; Cross-Sectional Studies; Di

2009
A role of IgM antibodies in monosodium urate crystal formation and associated adjuvanticity.
    Journal of immunology (Baltimore, Md. : 1950), 2009, Feb-15, Volume: 182, Issue:4

    Topics: Adjuvants, Immunologic; Animals; Antibodies, Monoclonal; B-Lymphocytes; Chromatography, High Pressur

2009
[Uric acid. Biology, biochemistry, and diagnostic value in the role of an integral test (a lecture)].
    Klinicheskaia laboratornaia diagnostika, 2009, Issue:1

    Topics: Animals; Cardiovascular Diseases; Female; Gout; Humans; Male; Portraits as Topic; Uric Acid

2009
Vitamin C intake and the risk of gout in men: a prospective study.
    Archives of internal medicine, 2009, Mar-09, Volume: 169, Issue:5

    Topics: Adult; Aged; Ascorbic Acid; Gout; Humans; Incidence; Male; Middle Aged; Prospective Studies; Risk Fa

2009
Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
    The Journal of rheumatology, 2009, Volume: 36, Issue:6

    Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Hyperuricemia; Thiazoles; Treatment Outcome; Uric

2009
New gout treatment approved.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2009, Apr-01, Volume: 66, Issue:7

    Topics: Administration, Oral; Drug Approval; Drug Interactions; Febuxostat; Gout; Gout Suppressants; Humans;

2009
High-resolution melting analysis for the rapid detection of an intronic single nucleotide polymorphism in SLC22A12 in male patients with primary gout in China.
    Scandinavian journal of rheumatology, 2009, Volume: 38, Issue:4

    Topics: Adult; Aged; Analysis of Variance; Case-Control Studies; China; DNA Mutational Analysis; Genetic Pre

2009
Adherence with urate-lowering therapies for the treatment of gout.
    Arthritis research & therapy, 2009, Volume: 11, Issue:2

    Topics: Age Factors; Allopurinol; Female; Gout; Gout Suppressants; Humans; Male; Medication Adherence; Middl

2009
Insulin resistance acts as an independent risk factor exacerbating high-purine diet induced renal injury and knee joint gouty lesions.
    Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2009, Volume: 58, Issue:10

    Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Gout; Homeostasis; Hyperuricemia; Hypogl

2009
What rheumatologists should know about gout and cardiovascular disease.
    The Journal of rheumatology, 2009, Volume: 36, Issue:4

    Topics: Cardiovascular Diseases; Gout; Humans; Metabolic Syndrome; Physicians; Rheumatology; Uric Acid

2009
Analysis of crystals leading to joint arthropathies by Raman spectroscopy: comparison with compensated polarized imaging.
    Applied spectroscopy, 2009, Volume: 63, Issue:4

    Topics: Calcium Pyrophosphate; Chondrocalcinosis; Crystallization; Gout; Humans; Lasers; Microscopy, Polariz

2009
Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter?
    The Journal of rheumatology, 2009, Volume: 36, Issue:5

    Topics: Aged; Aging; Blood Chemical Analysis; Female; Gout; Gout Suppressants; Health Expenditures; Humans;

2009
Fructose ingestion: dose-dependent responses in health research.
    The Journal of nutrition, 2009, Volume: 139, Issue:6

    Topics: Blood Glucose; Body Weight; Coronary Disease; Diabetes Mellitus, Type 2; Diet; Dose-Response Relatio

2009
Simple non-staining method to demonstrate urate crystals in formalin-fixed, paraffin-embedded skin biopsies.
    Journal of cutaneous pathology, 2009, Volume: 36, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Biopsy; Birefringence; Crystallization; Female; Formaldehyde; Gout;

2009
Clinical images: Pseudorheumatoid gout.
    Arthritis and rheumatism, 2009, Volume: 60, Issue:6

    Topics: Adult; Arthritis, Rheumatoid; Crystallization; Gout; Hand Joints; Humans; Male; Radiography; Uric Ac

2009
Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.
    Current medical research and opinion, 2009, Volume: 25, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Comorbidity; Drug Therapy, Combination; Female; Gout; H

2009
Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout.
    Proceedings of the National Academy of Sciences of the United States of America, 2009, Jun-23, Volume: 106, Issue:25

    Topics: Amino Acid Sequence; Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding C

2009
Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved.
    Rheumatology international, 2010, Volume: 30, Issue:4

    Topics: Aged; Aged, 80 and over; Allopurinol; Cartilage, Articular; Colchicine; Crystallization; Female; Gou

2010
Unusual case of gouty tophous within oral-maxillofacial region. Case report.
    The New York state dental journal, 2009, Volume: 75, Issue:3

    Topics: Diagnosis, Differential; Female; Gout; Granuloma, Foreign-Body; Humans; Middle Aged; Paranasal Sinus

2009
Gout Study Group: update on hyperuricemia and gout.
    Joint bone spine, 2009, Volume: 76, Issue:4

    Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Diet; Europe; Febuxostat; Gout;

2009
Adherence to treatment guidelines in two primary care populations with gout.
    Rheumatology international, 2010, Volume: 30, Issue:6

    Topics: Aged; Ambulatory Care Facilities; Biomarkers; Cohort Studies; Female; Gout; Guideline Adherence; Hum

2010
Acute gouty arthropathy mimicking infection after total knee arthroplasty.
    PM & R : the journal of injury, function, and rehabilitation, 2009, Volume: 1, Issue:3

    Topics: Adult; Arthroplasty, Replacement, Knee; Gout; Humans; Male; Reoperation; Synovial Fluid; Uric Acid

2009
Lower back pain caused by tophaceous gout of the spine.
    Neurology, 2009, Aug-04, Volume: 73, Issue:5

    Topics: Aged; Biopsy; Cauda Equina; Gout; Humans; Low Back Pain; Lumbar Vertebrae; Magnetic Resonance Imagin

2009
Gout: is a purine-restricted diet still recommended?
    Journal of the American Dietetic Association, 2009, Volume: 109, Issue:9

    Topics: Alcohol Drinking; Evidence-Based Medicine; Gout; Humans; Purines; Treatment Outcome; Uric Acid

2009
[Effect of metformin on the clinical course of gout and insulin resistance].
    Klinicheskaia meditsina, 2009, Volume: 87, Issue:7

    Topics: Adult; Female; Gout; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged;

2009
Identification of dairy fractions with anti-inflammatory properties in models of acute gout.
    Annals of the rheumatic diseases, 2010, Volume: 69, Issue:4

    Topics: Acute Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Caseins; Crystallization; Dairy Pro

2010
Identification of dairy fractions with anti-inflammatory properties in models of acute gout.
    Annals of the rheumatic diseases, 2010, Volume: 69, Issue:4

    Topics: Acute Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Caseins; Crystallization; Dairy Pro

2010
Identification of dairy fractions with anti-inflammatory properties in models of acute gout.
    Annals of the rheumatic diseases, 2010, Volume: 69, Issue:4

    Topics: Acute Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Caseins; Crystallization; Dairy Pro

2010
Identification of dairy fractions with anti-inflammatory properties in models of acute gout.
    Annals of the rheumatic diseases, 2010, Volume: 69, Issue:4

    Topics: Acute Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Caseins; Crystallization; Dairy Pro

2010
I've been diagnosed with gout and told that the elevated level of uric acid that brought it about may also increase my risk of heart attack. Is this true?
    DukeMedicine healthnews, 2009, Volume: 15, Issue:5

    Topics: Gout; Humans; Male; Myocardial Infarction; Risk Factors; Uric Acid

2009
A magic bullet for gout?
    Annals of the rheumatic diseases, 2009, Volume: 68, Issue:10

    Topics: Gout; Gout Suppressants; Humans; Interleukin-1beta; Recombinant Fusion Proteins; Uric Acid

2009
Calcium oxalate stone and gout.
    Urological research, 2009, Volume: 37, Issue:6

    Topics: Calcium; Calcium Oxalate; Case-Control Studies; Gout; Humans; Phosphorus; Uric Acid; Urinary Calculi

2009
Pancreatic gout masquerading as pancreatic cancer in a heart transplant candidate.
    The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2009, Volume: 28, Issue:10

    Topics: Diagnosis, Differential; Gout; Heart Failure; Heart Transplantation; Humans; Male; Middle Aged; Panc

2009
Melanocortin peptides inhibit urate crystal-induced activation of phagocytic cells.
    Arthritis research & therapy, 2009, Volume: 11, Issue:5

    Topics: Crystallization; Cytokines; Gout; Humans; Melanocortins; Monocytes; Neutrophil Activation; Neutrophi

2009
Progress in measurement instruments for acute and chronic gout studies.
    The Journal of rheumatology, 2009, Volume: 36, Issue:10

    Topics: Acute Disease; Arthralgia; Chronic Disease; Consensus; Consensus Development Conferences as Topic; D

2009
Outcome domains for studies of acute and chronic gout.
    The Journal of rheumatology, 2009, Volume: 36, Issue:10

    Topics: Acute Disease; Arthralgia; Chronic Disease; Consensus; Disability Evaluation; Gout; Humans; Outcome

2009
[Crystal-induced activation of the inflammasome: gout and pseudogout].
    Zeitschrift fur Rheumatologie, 2009, Volume: 68, Issue:9

    Topics: Anti-Inflammatory Agents; Cytokines; Gout; Hereditary Autoinflammatory Diseases; Humans; Immunologic

2009
Relationship between plasma uridine and urinary urea excretion.
    Metabolism: clinical and experimental, 2010, Volume: 59, Issue:3

    Topics: Adult; Creatinine; Diet; Dietary Carbohydrates; Dietary Fats; Dietary Proteins; Gout; Homeostasis; H

2010
[Dual energy CT--a new perspective in the diagnosis of gout].
    RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin, 2010, Volume: 182, Issue:3

    Topics: Arthrography; Cervical Vertebrae; Extremities; Gout; Humans; Lumbar Vertebrae; Radiography, Dual-Ene

2010
Common polymorphisms influencing serum uric acid levels contribute to susceptibility to gout, but not to coronary artery disease.
    PloS one, 2009, Nov-05, Volume: 4, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding

2009
Monoamine oxidase A gene polymorphisms and enzyme activity associated with risk of gout in Taiwan aborigines.
    Human genetics, 2010, Volume: 127, Issue:2

    Topics: Adult; Aged; Alleles; Asian People; Female; Gene Frequency; Genetic Predisposition to Disease; Genot

2010
Images in clinical medicine. Gouty tophi.
    The New England journal of medicine, 2009, Nov-19, Volume: 361, Issue:21

    Topics: Aged; Crystallization; Elbow Joint; Finger Joint; Gout; Humans; Male; Uric Acid

2009
[The High Priest of gout - Sir Alfred Baring Garrod (1819-1907)].
    Zeitschrift fur Rheumatologie, 2009, Volume: 68, Issue:10

    Topics: Arthritis, Rheumatoid; Gout; History, 19th Century; History, 20th Century; Humans; United Kingdom; U

2009
[Neutrophil bactericidal and absorptive function in gout].
    Terapevticheskii arkhiv, 2009, Volume: 81, Issue:10

    Topics: Adult; Aged; Antioxidants; Blood Bactericidal Activity; Gout; Humans; Indicators and Reagents; Male;

2009
Needle-shaped crystals are not always urate crystals: comment on the clinical image by Slobodin et al.
    Arthritis and rheumatism, 2009, Volume: 60, Issue:12

    Topics: Adult; Arthritis, Rheumatoid; Birefringence; Cholesterol; Crystallization; Gout; Hand Joints; Humans

2009
Medication trials in an imperfect world: gout and Parkinson's disease.
    Medicine and health, Rhode Island, 2009, Volume: 92, Issue:11

    Topics: Antiparkinson Agents; Cardiovascular Diseases; Clinical Trials as Topic; Disease Progression; Drug-R

2009
A case of isolated gouty tophus in a patient without a previous history of gouty arthritis.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2009, Volume: 15, Issue:7

    Topics: Arthritis, Gouty; Diagnosis, Differential; Gout; Humans; Joint Diseases; Magnetic Resonance Imaging;

2009
Dual energy computed tomography for quantification of tissue urate deposits in tophaceous gout: help from modern physics in the management of an ancient disease.
    Rheumatology international, 2012, Volume: 32, Issue:1

    Topics: Gout; Gout Suppressants; Hand Joints; Humans; Interleukin 1 Receptor Antagonist Protein; Interleukin

2012
Sex and age interaction with genetic association of atherogenic uric acid concentrations.
    Atherosclerosis, 2010, Volume: 210, Issue:2

    Topics: Age Factors; Aged; Atherosclerosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Bin

2010
Out with gout: opening the door on acute inflammation.
    Immunology and cell biology, 2010, Volume: 88, Issue:1

    Topics: Acute Disease; Adaptive Immunity; Gout; Humans; Inflammation; Uric Acid

2010
The dynamics of chronic gout treatment: medication gaps and return to therapy.
    The American journal of medicine, 2010, Volume: 123, Issue:1

    Topics: Age Factors; Aged; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Chi-Square Distribution; Ch

2010
Epidemiology of gout in women: Fifty-two-year followup of a prospective cohort.
    Arthritis and rheumatism, 2010, Volume: 62, Issue:4

    Topics: Adult; Alcohol Drinking; Blood Glucose; Cholesterol; Educational Status; Female; Follow-Up Studies;

2010
Cellular characterization of the gouty tophus: a quantitative analysis.
    Arthritis and rheumatism, 2010, Volume: 62, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Antigens, CD20; Antigens, Differentiation, Myelomonocy

2010
High-density lipoproteins downregulate CCL2 production in human fibroblast-like synoviocytes stimulated by urate crystals.
    Arthritis research & therapy, 2010, Volume: 12, Issue:1

    Topics: Cells, Cultured; Chemokine CCL2; Crystallization; Down-Regulation; Enzyme-Linked Immunosorbent Assay

2010
The uptake by blood-borne phagocytes of monosodium urate is dependent on heat-labile serum factor(s) and divalent cations.
    Autoimmunity, 2010, Volume: 43, Issue:3

    Topics: Cations, Divalent; Cytokines; Gout; Humans; Lupus Erythematosus, Systemic; Phagocytes; Uric Acid

2010
Gout masquerading as a triquetral fracture.
    The Journal of rheumatology, 2010, Volume: 37, Issue:3

    Topics: Adrenal Cortex Hormones; Diagnosis, Differential; Fractures, Bone; Gout; Humans; Male; Middle Aged;

2010
Gouty tophi presenting as medial patellar plica syndrome and patellofemoral disorder to limit knee range of motion.
    The Journal of rheumatology, 2010, Volume: 37, Issue:3

    Topics: Gout; Humans; Knee Joint; Male; Middle Aged; Patellofemoral Joint; Patellofemoral Pain Syndrome; Ran

2010
Simiao pill ameliorates urate underexcretion and renal dysfunction in hyperuricemic mice.
    Journal of ethnopharmacology, 2010, Apr-21, Volume: 128, Issue:3

    Topics: Allopurinol; Animals; Biological Transport; Gout; Hyperuricemia; Kidney; Male; Mice; Mice, Inbred St

2010
A survey on the management of gout in Malaysia.
    International journal of rheumatic diseases, 2009, Volume: 12, Issue:4

    Topics: Acute Disease; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Colchicine; Cr

2009
Differences in MSU-induced superoxide responses by neutrophils from gout subjects compared to healthy controls and a role for environmental inflammatory cytokines and hyperuricemia in neutrophil function and survival.
    The Journal of rheumatology, 2010, Volume: 37, Issue:6

    Topics: Aged; Antibodies, Blocking; Antioxidants; Apoptosis; Cell Survival; Crystallization; Culture Media,

2010
The rs2231142 variant of the ABCG2 gene is associated with uric acid levels and gout among Japanese people.
    Rheumatology (Oxford, England), 2010, Volume: 49, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Asian People; ATP Binding Cassette Transporter, Subfamily G, Member

2010
Comment on: Gout: an independent risk factor for all-cause and cardiovascular mortality.
    Rheumatology (Oxford, England), 2010, Volume: 49, Issue:7

    Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Iron; Risk Factors; Uric Acid

2010
The importance of urgent cytological examination of synovial fluids in differentiation inflammatory and non-inflammatory joint diseases.
    Collegium antropologicum, 2010, Volume: 34, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis; Child; Crystallization; Diagnosis, Differenti

2010
Treatment failure gout: failure to treat?
    Rheumatology (Oxford, England), 2010, Volume: 49, Issue:12

    Topics: Allopurinol; Drug Hypersensitivity; General Practice; Gout; Gout Suppressants; Guideline Adherence;

2010
On call. I've had gout for many years. I used to take Zyloprim without any problems, but I just had a severe allergic reaction, so my doctor switched me to Benemid. I'm doing okay, but the drug sometimes upsets my stomach. Do you have any suggestions?
    Harvard men's health watch, 2010, Volume: 14, Issue:6

    Topics: Allopurinol; Drug Hypersensitivity; Gastritis; Gout; Gout Suppressants; Humans; Male; Middle Aged; P

2010
Subconjunctival urate crystals: a case report.
    Cornea, 2010, Volume: 29, Issue:7

    Topics: Aged, 80 and over; Conjunctival Diseases; Crystallization; Female; Gout; Granuloma, Foreign-Body; Hu

2010
Risk factors associated with renal lithiasis during uricosuric treatment of hyperuricemia in patients with gout.
    Arthritis care & research, 2010, Volume: 62, Issue:9

    Topics: Allopurinol; Benzbromarone; Cohort Studies; Creatinine; Follow-Up Studies; Gout; Humans; Hyperuricem

2010
Computed tomography in tophaceous gout.
    The Journal of rheumatology, 2010, Volume: 37, Issue:6

    Topics: Gout; Hand Joints; Humans; Male; Middle Aged; Tomography, X-Ray Computed; Uric Acid

2010
An unusual soft tissue tumor.
    The Journal of rheumatology, 2010, Volume: 37, Issue:6

    Topics: Birefringence; Diagnosis, Differential; Foot; Gout; Humans; Male; Middle Aged; Soft Tissue Neoplasms

2010
Preventing and treating acute gout attacks across the clinical spectrum: a roundtable discussion.
    Cleveland Clinic journal of medicine, 2010, Volume: 77 Suppl 2

    Topics: Acute Disease; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Biopsy, Needle; Col

2010
Metabolic syndrome characteristics in gout patients.
    Nucleosides, nucleotides & nucleic acids, 2010, Volume: 29, Issue:4-6

    Topics: Aged; Blood Glucose; Blood Pressure; Female; Gout; Humans; Hyperuricemia; Male; Metabolic Syndrome;

2010
Uric acid metabolism in patients with primary gout and the metabolic syndrome.
    Nucleosides, nucleotides & nucleic acids, 2010, Volume: 29, Issue:4-6

    Topics: Female; Gout; Humans; Male; Metabolic Syndrome; Middle Aged; Uric Acid

2010
Diagnosis of chronic gout: evaluating the american college of rheumatology proposal, European league against rheumatism recommendations, and clinical judgment.
    The Journal of rheumatology, 2010, Aug-01, Volume: 37, Issue:8

    Topics: Chronic Disease; Cohort Studies; Cross-Sectional Studies; Crystallization; European Union; Female; G

2010
Gout and risk of non-alcoholic fatty liver disease.
    Scandinavian journal of rheumatology, 2010, Volume: 39, Issue:6

    Topics: Adult; Aged; Body Mass Index; Cross-Sectional Studies; Fatty Liver; Female; Glomerular Filtration Ra

2010
Type 1 sodium-dependent phosphate transporter (SLC17A1 Protein) is a Cl(-)-dependent urate exporter.
    The Journal of biological chemistry, 2010, Aug-20, Volume: 285, Issue:34

    Topics: Amino Acid Substitution; Animals; Biological Transport; Chlorides; Electrophysiology; Gout; Humans;

2010
Analyze multivariate phenotypes in genetic association studies by combining univariate association tests.
    Genetic epidemiology, 2010, Volume: 34, Issue:5

    Topics: Analysis of Variance; Genetic Linkage; Genetic Variation; Genome-Wide Association Study; Genome, Hum

2010
[Carbohydrate metabolic disorders in gout: incidence and clinical features].
    Terapevticheskii arkhiv, 2010, Volume: 82, Issue:5

    Topics: Anthropometry; Blood Glucose; Carbohydrate Metabolism; Cardiovascular Diseases; Cholesterol; Diabete

2010
Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo.
    Proceedings of the National Academy of Sciences of the United States of America, 2010, Aug-10, Volume: 107, Issue:32

    Topics: Antioxidants; Cells, Cultured; Erythrocytes; F2-Isoprostanes; Gout; Humans; Hydrogen Peroxide; Oxida

2010
Association of variants at UMOD with chronic kidney disease and kidney stones-role of age and comorbid diseases.
    PLoS genetics, 2010, Jul-29, Volume: 6, Issue:7

    Topics: Age Factors; Case-Control Studies; Comorbidity; Creatinine; Genetic Variation; Genome-Wide Associati

2010
Association of four genetic loci with uric acid levels and reduced renal function: the J-SHIPP Suita study.
    American journal of nephrology, 2010, Volume: 32, Issue:3

    Topics: Aged; Asian People; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Tr

2010
Panniculitis: another clinical expression of gout.
    Rheumatology international, 2011, Volume: 31, Issue:6

    Topics: Adult; Allopurinol; Colchicine; Crystallization; Gout; Gout Suppressants; Humans; Hyperuricemia; Mal

2011
Gout and coexisting pseudogout in the knee joint.
    Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA, 2011, Volume: 19, Issue:4

    Topics: Arthroscopy; Calcium Pyrophosphate; Chondrocalcinosis; Debridement; Emergency Service, Hospital; Fol

2011
The serum urate-lowering impact of weight loss among men with a high cardiovascular risk profile: the Multiple Risk Factor Intervention Trial.
    Rheumatology (Oxford, England), 2010, Volume: 49, Issue:12

    Topics: Body Weight; Cardiovascular Diseases; Cohort Studies; Follow-Up Studies; Gout; Humans; Hypertension;

2010
Gout as an early warning of concomitant sleep apnea.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2010, Volume: 16, Issue:6

    Topics: Gout; Humans; Hypoxia; Risk Factors; Sleep Apnea, Obstructive; Uric Acid

2010
Human sodium phosphate transporter 4 (hNPT4/SLC17A3) as a common renal secretory pathway for drugs and urate.
    The Journal of biological chemistry, 2010, Nov-05, Volume: 285, Issue:45

    Topics: Animals; Bumetanide; Diuretics; Furosemide; Genetic Predisposition to Disease; Glucose Transport Pro

2010
Disabling gout.
    Lancet (London, England), 2010, Sep-25, Volume: 376, Issue:9746

    Topics: Arthrodesis; Biomarkers; Foot; Gout; Hallux Valgus; Humans; Magnetic Resonance Imaging; Male; Metata

2010
Dietary intake and the risk of hyperuricemia, gout and chronic kidney disease in elderly Taiwanese men.
    The aging male : the official journal of the International Society for the Study of the Aging Male, 2011, Volume: 14, Issue:3

    Topics: Aged; Antihypertensive Agents; Chronic Disease; Comorbidity; Diet; Feeding Behavior; Glomerular Filt

2011
Managing hypertensive patients with gout who take thiazide.
    Journal of clinical hypertension (Greenwich, Conn.), 2010, Volume: 12, Issue:9

    Topics: Adult; Aged; Diuretics; Female; Gout; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged;

2010
Coincidence of calcium pyrophosphate and monosodium urate crystals in the synovial fluid of patients with gout determined by the cytocentrifugation technique.
    Annals of the rheumatic diseases, 2011, Volume: 70, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Calcium Pyrophosphate; Centrifugation; Crystallization; Female; Gout

2011
Association of an intronic SNP of SLC2A9 gene with serum uric acid levels in the Chinese male Han population by high-resolution melting method.
    Clinical rheumatology, 2011, Volume: 30, Issue:1

    Topics: Adult; Aged; China; Genotype; Glucose Transport Proteins, Facilitative; Gout; Homozygote; Humans; Hy

2011
Genome-wide study of familial juvenile hyperuricaemic (gouty) nephropathy (FJHN) indicates a new locus, FJHN3, linked to chromosome 2p22.1-p21.
    Human genetics, 2011, Volume: 129, Issue:1

    Topics: Chromosomes, Human, Pair 2; Female; Genetic Heterogeneity; Genetic Linkage; Genetic Loci; Genetic Pr

2011
Uric acid is not the cause of gout.
    Strasbourg medical, 1946, Volume: 106

    Topics: Gout; Humans; Uric Acid

1946
The current state of care in gout: Addressing the need for better understanding of an ancient disease.
    Journal of the American Academy of Nurse Practitioners, 2010, Volume: 22 Suppl 1

    Topics: Acute Disease; Aged; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Arthrit

2010
Fructose-rich beverages and risk of gout in women.
    JAMA, 2010, Nov-24, Volume: 304, Issue:20

    Topics: Adult; Beverages; Female; Fructose; Gout; Humans; Incidence; Middle Aged; Prospective Studies; Risk;

2010
Gout.
    BMJ (Clinical research ed.), 2010, Nov-15, Volume: 341

    Topics: Acute Disease; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Diagnosis, Differential;

2010
A new practical system for evaluating the pharmacological properties of uricase as a potential drug for hyperuricemia.
    Archives of pharmacal research, 2010, Volume: 33, Issue:11

    Topics: Animals; Bacillus; Gout; Half-Life; Hyperuricemia; Male; Polyethylene Glycols; Rabbits; Rats; Rats,

2010
Is metabolic syndrome related to uric acid metabolism in gout patients?
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2010, Volume: 16, Issue:8

    Topics: Gout; Humans; Metabolic Syndrome; Prevalence; Uric Acid

2010
Gout: nonsteroidal anti-inflammatory drugs and colchicine to prevent painful flares during early urate-lowering therapy.
    Journal of pain & palliative care pharmacotherapy, 2010, Volume: 24, Issue:4

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Gout; Gout Suppressants; Humans; Male; Pa

2010
Nonsteroidal anti-inflammatory drugs and colchicine to prevent gout flare during early urate-lowering therapy: perspectives on alternative therapies and costs.
    Journal of pain & palliative care pharmacotherapy, 2010, Volume: 24, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Drug Costs; Gout; Gout Suppressants; Humans; Pr

2010
Olea europaea leaf (Ph.Eur.) extract as well as several of its isolated phenolics inhibit the gout-related enzyme xanthine oxidase.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2011, May-15, Volume: 18, Issue:7

    Topics: Allopurinol; Animals; Apigenin; Chromatography, High Pressure Liquid; Dose-Response Relationship, Dr

2011
Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout.
    Rheumatology (Oxford, England), 2011, Volume: 50, Issue:4

    Topics: Aged; Chronic Disease; Cohort Studies; Colchicine; Disability Evaluation; Dose-Response Relationship

2011
[Epidemiological study on hyperuricemia and gout in Foshan areas, Guangdong province].
    Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi, 2010, Volume: 31, Issue:8

    Topics: Epidemiologic Studies; Gout; Humans; Hyperuricemia; Prevalence; Uric Acid

2010
Did The Captain only have gout?
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2010, Dec-16, Volume: 130, Issue:24

    Topics: Cardiovascular Diseases; Cartoons as Topic; Fructose; Gout; History, 19th Century; History, 20th Cen

2010
Large epidemiologic studies of gout: challenges in diagnosis and diagnostic criteria.
    Current rheumatology reports, 2011, Volume: 13, Issue:2

    Topics: Biomarkers; Epidemiologic Studies; Gout; Humans; Reproducibility of Results; Synovial Fluid; Uric Ac

2011
Non-invasive and transdermal measurement of blood uric acid level in human by electroporation and reverse iontophoresis.
    International journal of nanomedicine, 2010, Nov-19, Volume: 5

    Topics: Adult; Analysis of Variance; Diffusion; Electroporation; Female; Gout; Humans; Iontophoresis; Linear

2010
Role of ultrasound and other advanced imaging in the diagnosis and management of gout.
    Current rheumatology reports, 2011, Volume: 13, Issue:2

    Topics: Arthrography; Gout; Humans; Imaging, Three-Dimensional; Magnetic Resonance Imaging; Microscopy, Pola

2011
[Application of dual-energy computed tomography for detecting uric acid deposition in patients with gout].
    Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae, 2010, Volume: 32, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Arthrography; Extremities; Female; Gout; Humans; Male; Middle Aged;

2010
Treatment of gout.
    Internal medicine journal, 2011, Volume: 41, Issue:1a

    Topics: Aged; Allopurinol; Australia; Colchicine; Dose-Response Relationship, Drug; Drug Therapy, Combinatio

2011
Orange-colored diapers in infants from families with gout.
    Pediatric nephrology (Berlin, Germany), 2011, Volume: 26, Issue:6

    Topics: Color; Diagnostic Errors; Diapers, Infant; Family Health; Genetic Predisposition to Disease; Gout; H

2011
Application of a new method for GWAS in a related case/control sample with known pedigree structure: identification of new loci for nephrolithiasis.
    PLoS genetics, 2011, Jan-20, Volume: 7, Issue:1

    Topics: Carrier Proteins; Case-Control Studies; Cohort Studies; Data Interpretation, Statistical; Genetic Lo

2011
Positive correlation between Beta-3-Adrenergic Receptor (ADRB3) gene and gout in a Chinese male population.
    The Journal of rheumatology, 2011, Volume: 38, Issue:4

    Topics: Asian People; Case-Control Studies; Gene Frequency; Genotype; Gout; Humans; Male; Polymorphism, Sing

2011
A genome-wide association study of serum uric acid in African Americans.
    BMC medical genomics, 2011, Feb-04, Volume: 4

    Topics: Black or African American; Black People; Body Mass Index; Diabetes Mellitus, Type 2; Genome-Wide Ass

2011
I've been told to avoid "purines" because I have gout. What are purines, and what foods contain them?
    DukeMedicine healthnews, 2011, Volume: 17, Issue:1

    Topics: Diet; Gout; Humans; Purines; Uric Acid

2011
Uric acid and gout.
    The Nurse practitioner, 2011, Volume: 36, Issue:3

    Topics: Aged; Gout; Humans; Male; Nurse Practitioners; Physical Examination; Travel; Uric Acid

2011
Gout and chronic kidney disease.
    Cleveland Clinic journal of medicine, 2011, Volume: 78, Issue:2

    Topics: Gout; Humans; Hyperuricemia; Kidney Failure, Chronic; Uric Acid

2011
Impact of allopurinol use on urate concentration and cardiovascular outcome.
    British journal of clinical pharmacology, 2011, Volume: 71, Issue:4

    Topics: Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Cohort Studies; Female; Gout; Gout Su

2011
Osteoblast retraction induced by adherent neutrophils promotes osteoclast bone resorption: implication for altered bone remodeling in chronic gout.
    Laboratory investigation; a journal of technical methods and pathology, 2011, Volume: 91, Issue:6

    Topics: Analysis of Variance; Bone Remodeling; Bone Resorption; Cell Adhesion; Flow Cytometry; Gout; Humans;

2011
The nail plate biopsy may pick up gout crystals and other crystals.
    The American Journal of dermatopathology, 2011, Volume: 33, Issue:4

    Topics: Aged, 80 and over; Biopsy; Crystallization; Gout; Humans; Male; Nail Diseases; Nails; Uric Acid

2011
Monosodium urate monohydrate crystal-recruited noninflammatory monocytes differentiate into M1-like proinflammatory macrophages in a peritoneal murine model of gout.
    Arthritis and rheumatism, 2011, Volume: 63, Issue:5

    Topics: Animals; Blotting, Western; Cell Differentiation; Disease Models, Animal; Flow Cytometry; Gout; Infl

2011
Gout.
    The New England journal of medicine, 2011, 05-12, Volume: 364, Issue:19

    Topics: Allopurinol; Antihypertensive Agents; Gout; Gout Suppressants; Humans; Hydrochlorothiazide; Hyperten

2011
Diagnosis of crystal-associated disease: where do we stand?
    Bioanalysis, 2011, Volume: 3, Issue:10

    Topics: Calcium Phosphates; Calcium Pyrophosphate; Crystallization; Fluorescent Dyes; Gout; Humans; Light; S

2011
Potential of vitamin C in the prevention and treatment of gout.
    Nature reviews. Rheumatology, 2011, Volume: 7, Issue:6

    Topics: Antioxidants; Ascorbic Acid; Gout; Humans; Uric Acid

2011
Febuxostat efficacy in allopurinol-resistant tophaceous gout.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2011, Volume: 17, Issue:4

    Topics: Allopurinol; Dose-Response Relationship, Drug; Drug Resistance; Febuxostat; Female; Gout; Gout Suppr

2011
Monosodium urate monohydrate crystals inhibit osteoblast viability and function: implications for development of bone erosion in gout.
    Annals of the rheumatic diseases, 2011, Volume: 70, Issue:9

    Topics: Animals; Apoptosis; Bone and Bones; Bone Resorption; Cell Death; Cell Differentiation; Cell Survival

2011
Sonographic characterization of mixed crystal arthropathy due to monosodium urate and calcium pyrophosphate dihydrate: the triple-contour sign.
    Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine, 2011, Volume: 30, Issue:6

    Topics: Aged, 80 and over; Calcium Pyrophosphate; Gout; Humans; Male; Ultrasonography; Uric Acid; Wrist Join

2011
Trends in hyperuricemia and gout prevalence: Nutrition and Health Survey in Taiwan from 1993-1996 to 2005-2008.
    Asia Pacific journal of clinical nutrition, 2011, Volume: 20, Issue:2

    Topics: Adult; Age Distribution; Aged; Beverages; Coffee; Dairy Products; Diet; Female; Fruit; Glycine max;

2011
Reproducibility of musculoskeletal ultrasound for determining monosodium urate deposition: concordance between readers.
    Arthritis care & research, 2011, Volume: 63, Issue:10

    Topics: Aged; Aged, 80 and over; Asymptomatic Diseases; Crystallization; Gout; Hospitals, Veterans; Humans;

2011
Gout and hyperuricaemia in adults with cystic fibrosis.
    Journal of the Royal Society of Medicine, 2011, Volume: 104 Suppl 1

    Topics: Adult; Cystic Fibrosis; Female; Gout; Humans; Hyperuricemia; Male; Middle Aged; Prevalence; Uric Aci

2011
Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions.
    The Journal of rheumatology, 2011, Volume: 38, Issue:9

    Topics: Aged; Aged, 80 and over; Allopurinol; Drug Monitoring; Febuxostat; Female; Gout; Gout Suppressants;

2011
Serum urate in chronic gout--will it be the first validated soluble biomarker in rheumatology?
    The Journal of rheumatology, 2011, Volume: 38, Issue:7

    Topics: Biomarkers; Chronic Disease; Gout; Humans; Outcome Assessment, Health Care; Prognosis; Randomized Co

2011
Gender-specific risk factors for incident gout: a prospective cohort study.
    Clinical rheumatology, 2012, Volume: 31, Issue:2

    Topics: Adult; Comorbidity; Female; Follow-Up Studies; Gout; Humans; Hyperlipidemias; Hypertension; Incidenc

2012
Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.
    Clinical pharmacology and therapeutics, 2011, Volume: 90, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Arthritis, Gouty; Chronic Disease; Creatinine; Dose-Res

2011
Chronic kidney disease in gout in a managed care setting.
    BMC nephrology, 2011, Aug-03, Volume: 12

    Topics: Adult; Aged; Allopurinol; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Kidney Failure

2011
Lymphocyte α-kinase is a gout-susceptible gene involved in monosodium urate monohydrate-induced inflammatory responses.
    Journal of molecular medicine (Berlin, Germany), 2011, Volume: 89, Issue:12

    Topics: Cell Line, Tumor; Enzyme Induction; Gene Expression Profiling; Genetic Predisposition to Disease; Go

2011
Improving the use of allopurinol in chronic gout: monitoring oxypurinol levels to guide therapy.
    Clinical pharmacology and therapeutics, 2011, Volume: 90, Issue:3

    Topics: Allopurinol; Arthritis, Gouty; Enzyme Inhibitors; Female; Gout; Gout Suppressants; Humans; Male; Oxy

2011
Phenotype and outcome in hereditary tubulointerstitial nephritis secondary to UMOD mutations.
    Clinical journal of the American Society of Nephrology : CJASN, 2011, Volume: 6, Issue:10

    Topics: Adult; Belgium; Biomarkers; Central Nervous System Diseases; Chi-Square Distribution; Dental Enamel;

2011
Crystal deposition at elbow hyaline cartilage: the sonographic perspective.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2011, Volume: 17, Issue:6

    Topics: Aged; Calcium Pyrophosphate; Chondrocalcinosis; Crystallization; Elbow Joint; Female; Gout; Humans;

2011
A two-stage approach to the treatment of hyperuricemia in gout: the "dirty dish" hypothesis.
    Arthritis and rheumatism, 2011, Volume: 63, Issue:12

    Topics: Aged; Cohort Studies; Colchicine; Crystallization; Female; Fenofibrate; Follow-Up Studies; Gout; Gou

2011
[Hyperuricemia in sickle cell disease in France].
    La Revue de medecine interne, 2012, Volume: 33, Issue:1

    Topics: Adolescent; Adult; Aged; Anemia, Sickle Cell; Female; France; Gout; Humans; Hyperuricemia; Male; Mid

2012
Factors associated with acute gout attacks in normouricaemic gout patients receiving allopurinol: a retrospective study.
    Scandinavian journal of rheumatology, 2011, Volume: 40, Issue:6

    Topics: Acute Disease; Aged; Allopurinol; Arthritis, Gouty; Gout; Gout Suppressants; Humans; Male; Middle Ag

2011
Identification of intraarticular and periarticular uric acid crystals with dual-energy CT: initial evaluation.
    Radiology, 2011, Volume: 261, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Algorithms; Female; Gout; Humans; Male; Middle Aged; Reproducibility

2011
An audit of the variability of diagnosis and management of gout in the rheumatology setting: the gout evaluation and management study.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2011, Volume: 17, Issue:7

    Topics: Acute Disease; Adult; Aged; Cross-Sectional Studies; Europe; Female; Gout; Guideline Adherence; Huma

2011
Catastrophic axial gout causing paraplegia in a patient with glycogen storage disease.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2011, Volume: 17, Issue:7

    Topics: Adult; Catastrophic Illness; Drug Therapy, Combination; Febuxostat; Glycogen Storage Disease Type I;

2011
Hyperuricaemia and gout.
    The journal of the Royal College of Physicians of Edinburgh, 2011, Volume: 41, Issue:3

    Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Diet; Gout; Gout Suppressants; Hum

2011
NLRP3 inflammasome-mediated neutrophil recruitment and hypernociception depend on leukotriene B(4) in a murine model of gout.
    Arthritis and rheumatism, 2012, Volume: 64, Issue:2

    Topics: Animals; Carrier Proteins; Caspase 1; Cytokines; Gout; Hyperalgesia; Inflammasomes; Inflammation; In

2012
Monosodium urate (gout) crystals, an uncommon finding in ThinPrep synovial fluid cytology.
    Diagnostic cytopathology, 2013, Volume: 41, Issue:1

    Topics: Crystallization; Gout; Humans; Male; Middle Aged; Synovial Fluid; Uric Acid

2013
Identification of low-frequency variants associated with gout and serum uric acid levels.
    Nature genetics, 2011, Oct-09, Volume: 43, Issue:11

    Topics: Gout; Humans; Iceland; Mutation, Missense; Polymorphism, Single Nucleotide; Uric Acid

2011
Population heterogeneity in the genetic control of serum urate.
    Seminars in nephrology, 2011, Volume: 31, Issue:5

    Topics: Glucose Transport Proteins, Facilitative; Gout; Humans; Hyperuricemia; Racial Groups; Uric Acid; Whi

2011
Quantification of tissue uric acid levels in a Harris's hawk with visceral gout.
    Avian diseases, 2011, Volume: 55, Issue:3

    Topics: Animals; Bird Diseases; Gout; Hawks; Kidney; Louisiana; Muscle, Skeletal; Myocardium; Uric Acid

2011
Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension: the Atherosclerosis Risk in Communities cohort study.
    Arthritis and rheumatism, 2012, Volume: 64, Issue:1

    Topics: Community Medicine; Comorbidity; Diuretics; Female; Gout; Humans; Hypertension; Male; Middle Aged; P

2012
Giant gouty tophi of the hand and wrist.
    Orthopedics, 2011, Nov-09, Volume: 34, Issue:11

    Topics: Adult; Diet Therapy; Gout; Gout Suppressants; Hand Joints; Humans; Male; Plastic Surgery Procedures;

2011
Pegloticase and chronic gout.
    JAMA, 2011, Nov-09, Volume: 306, Issue:18

    Topics: Enzymes, Immobilized; Female; Gout; Humans; Male; Polyethylene Glycols; Urate Oxidase; Uric Acid

2011
[Exploration on the establishment of animal models for gouty nephropathy complicated with chronic renal failure].
    Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2011, Volume: 31, Issue:10

    Topics: Animals; Disease Models, Animal; Gout; Hyperuricemia; Kidney Failure, Chronic; Male; Rats; Rats, Wis

2011
High prevalence of gout with sleep apnea.
    Medical hypotheses, 2012, Volume: 78, Issue:2

    Topics: Glomerular Filtration Rate; Gout; Humans; Hypoxia; Prevalence; Sleep Apnea Syndromes; Uric Acid

2012
P2Y6 receptor signaling pathway mediates inflammatory responses induced by monosodium urate crystals.
    Journal of immunology (Baltimore, Md. : 1950), 2012, Jan-01, Volume: 188, Issue:1

    Topics: Animals; Antioxidants; Cell Line; Cytokines; Disease Models, Animal; Gout; Humans; Hyperuricemia; In

2012
ABCG2/BCRP dysfunction as a major cause of gout.
    Nucleosides, nucleotides & nucleic acids, 2011, Volume: 30, Issue:12

    Topics: Amino Acid Sequence; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette T

2011
Synthesis of [¹¹C]uric acid, using [¹¹C]phosgene, as a possible biomarker in PET imaging for diagnosis of gout.
    Bioorganic & medicinal chemistry letters, 2012, Jan-01, Volume: 22, Issue:1

    Topics: Animals; Automation; Biomarkers; Carbon Isotopes; Chromatography, High Pressure Liquid; Disease Mode

2012
Assessment of tophus size: a comparison between physical measurement methods and dual-energy computed tomography scanning.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2012, Volume: 18, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Female; Gout; Humans; Male; Middle Aged; Observer Variation; Physica

2012
[Contribution of the CoLaus study to decipher the determinants of serum uric acid].
    Revue medicale suisse, 2011, Nov-02, Volume: 7, Issue:315

    Topics: Biomarkers; Cardiovascular Diseases; Cohort Studies; Glucose Transport Proteins, Facilitative; Gout;

2011
Neutrophil extracellular trap formation is associated with IL-1β and autophagy-related signaling in gout.
    PloS one, 2011, Volume: 6, Issue:12

    Topics: Acute Disease; Autophagy; Crystallization; DNA; Endosomes; Extracellular Space; Gout; HMGB1 Protein;

2011
Interreader agreement in determining monosodium urate deposition using musculoskeletal ultrasound: comment on the article by Howard et al.
    Arthritis care & research, 2012, Volume: 64, Issue:5

    Topics: Gout; Humans; Hyperuricemia; Knee Joint; Male; Metatarsophalangeal Joint; Ultrasonography; Uric Acid

2012
Unknown: Multiple painful nodules - what is the diagnosis? Chronic tophaceous gout.
    Dermatology online journal, 2011, Dec-15, Volume: 17, Issue:12

    Topics: Alcoholics; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Chronic Disease; Colch

2011
Hyperuricemia and untreated gout are poor prognostic markers among those with a recent acute myocardial infarction.
    Arthritis research & therapy, 2012, Jan-17, Volume: 14, Issue:1

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cause of Death; Coronary Artery Disease; Co

2012
Evaluation of health care costs and utilization patterns for patients with gout.
    Clinical therapeutics, 2012, Volume: 34, Issue:3

    Topics: Cohort Studies; Drug Utilization; Female; Gout; Gout Suppressants; Health Care Costs; Health Service

2012
Dual energy CT in gout: a prospective validation study.
    Annals of the rheumatic diseases, 2012, Volume: 71, Issue:9

    Topics: Female; Gout; Humans; Male; Middle Aged; Observer Variation; Prospective Studies; Sensitivity and Sp

2012
Association between gout and polymorphisms in GCKR in male Han Chinese.
    Human genetics, 2012, Volume: 131, Issue:7

    Topics: Adaptor Proteins, Signal Transducing; Asian People; Blood Glucose; Case-Control Studies; China; Chol

2012
Gender-dependent associations of uric acid levels with a polymorphism in SLC2A9 in Han Chinese patients.
    Scandinavian journal of rheumatology, 2012, Volume: 41, Issue:2

    Topics: Asian People; China; Female; Glucose Transport Proteins, Facilitative; Gout; Humans; Hyperuricemia;

2012
False-negative dual-energy computed tomography in a patient with acute gout.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2012, Volume: 18, Issue:3

    Topics: Allopurinol; Arthralgia; Biopsy; False Negative Reactions; Gout; Gout Suppressants; Humans; Magnetic

2012
Relationship between serum allantoin and urate in healthy subjects and effects of benzbromarone in gout patients.
    International journal of clinical pharmacology and therapeutics, 2012, Volume: 50, Issue:4

    Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Allantoin; Benzbromarone; Biomarkers; Case-Control Studies; Crea

2012
Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol.
    Arthritis and rheumatism, 2012, Volume: 64, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Case-Control Studies; Dose-Response Relationship, Drug;

2012
Genetic architecture for susceptibility to gout in the KARE cohort study.
    Journal of human genetics, 2012, Volume: 57, Issue:6

    Topics: Binding Sites; Cohort Studies; Genetic Loci; Genetic Predisposition to Disease; Gout; Humans; Polymo

2012
Clinical study of ammonium acid urate urolithiasis.
    The Kaohsiung journal of medical sciences, 2012, Volume: 28, Issue:5

    Topics: Adult; Aged; Comorbidity; Female; Gout; Humans; Irritable Bowel Syndrome; Male; Middle Aged; Renal I

2012
Serum amyloid A triggers the mosodium urate -mediated mature interleukin-1β production from human synovial fibroblasts.
    Arthritis research & therapy, 2012, May-18, Volume: 14, Issue:3

    Topics: Antioxidants; Fibroblasts; Gout; Humans; Immunoblotting; Interleukin-1beta; Real-Time Polymerase Cha

2012
[Clinical significance of insulin resistance syndrome in development of endothelial dysfunction in patients with primary gout].
    Vestnik Rossiiskoi akademii meditsinskikh nauk, 2012, Issue:2

    Topics: Adult; Atherosclerosis; Blood Glucose; Brachial Artery; Carbohydrate Metabolism; Disease Progression

2012
The gout pipeline crystallizes.
    Nature reviews. Drug discovery, 2012, Jun-01, Volume: 11, Issue:6

    Topics: Allopurinol; Anti-Inflammatory Agents; Clinical Trials, Phase III as Topic; Drug Industry; Gout; Gou

2012
Gout mimicking psoriatic arthritis flare.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2012, Volume: 18, Issue:4

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Psoriatic; Diagnosi

2012
Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout.
    The Journal of rheumatology, 2012, Volume: 39, Issue:7

    Topics: Aged; Aged, 80 and over; Allopurinol; C-Reactive Protein; Colchicine; Female; Gout; Gout Suppressant

2012
The association of dietary intake of purine-rich vegetables, sugar-sweetened beverages and dairy with plasma urate, in a cross-sectional study.
    PloS one, 2012, Volume: 7, Issue:6

    Topics: Beverages; Calcium; Cohort Studies; Cross-Sectional Studies; Dairy Products; Diet; Female; Fructose;

2012
[Characteristics of carbohydrate metabolism changes in elderly patients with gout and metabolic syndrome].
    Advances in gerontology = Uspekhi gerontologii, 2012, Volume: 25, Issue:1

    Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Mass Index; Carbohydrate Metabolism; Dyslipidemias;

2012
Monosodium urate (MSU) crystals increase gout associated coronary heart disease (CHD) risk through the activation of NLRP3 inflammasome.
    International journal of cardiology, 2012, Sep-20, Volume: 160, Issue:1

    Topics: Carrier Proteins; Coronary Disease; Crystallization; Gout; Humans; Inflammasomes; NLR Family, Pyrin

2012
A urate gene-by-diuretic interaction and gout risk in participants with hypertension: results from the ARIC study.
    Annals of the rheumatic diseases, 2013, Volume: 72, Issue:5

    Topics: Databases, Factual; Diuretics; Drug Interactions; Female; Genotype; Glucose Transport Proteins, Faci

2013
Enhanced interleukin-1β production of PBMCs from patients with gout after stimulation with Toll-like receptor-2 ligands and urate crystals.
    Arthritis research & therapy, 2012, Jul-04, Volume: 14, Issue:4

    Topics: Adult; Aged; Crystallization; Female; Gout; Humans; Interleukin-1beta; Leukocytes, Mononuclear; Liga

2012
[Attack of gout].
    MMW Fortschritte der Medizin, 2012, Jun-11, Volume: 154, Issue:11

    Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Arthritis, Gouty; Diagnosis, Diffe

2012
Achieving treat to target in gout: a clinical practice improvement project.
    Scandinavian journal of rheumatology, 2012, Volume: 41, Issue:6

    Topics: Adult; Aged; Allopurinol; Diet; Evidence-Based Medicine; Female; Gout; Gout Suppressants; Humans; Li

2012
Casebook consults: improving outcomes in gout (multimedia activity).
    The American journal of medicine, 2012, Volume: 125, Issue:8

    Topics: Adrenal Cortex Hormones; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Febuxosta

2012
Crystal arthritis: a new 'package of care' strategy for effective gout management.
    Nature reviews. Rheumatology, 2012, Volume: 8, Issue:9

    Topics: Crystallization; Disease Management; Gout; Gout Suppressants; Humans; Nurse Clinicians; Rheumatology

2012
Gout and osteoarthritis: a pathogenetic link?
    Joint bone spine, 2012, Volume: 79, Issue:5

    Topics: Cartilage, Articular; Gout; Humans; Metatarsophalangeal Joint; Osteoarthritis; Uric Acid

2012
Reducing effect of mangiferin on serum uric acid levels in mice.
    Pharmaceutical biology, 2012, Volume: 50, Issue:9

    Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Gout;

2012
Low-level lead exposure and the prevalence of gout: an observational study.
    Annals of internal medicine, 2012, Aug-21, Volume: 157, Issue:4

    Topics: Adult; Age Factors; Aged; Cadmium; Creatinine; Cross-Sectional Studies; Diet; Environmental Exposure

2012
Summaries for patients. Low levels of lead in the blood and the occurrence of gout.
    Annals of internal medicine, 2012, Aug-21, Volume: 157, Issue:4

    Topics: Aged; Cadmium; Cross-Sectional Studies; Diet; Environmental Exposure; Female; Gout; Humans; Lead; Ma

2012
Longan seed extract reduces hyperuricemia via modulating urate transporters and suppressing xanthine oxidase activity.
    The American journal of Chinese medicine, 2012, Volume: 40, Issue:5

    Topics: Allopurinol; Animals; Glucose Transporter Type 1; Gout; Gout Suppressants; Hyperuricemia; Hypoxanthi

2012
Metabolite target analysis of human urine combined with pattern recognition techniques for the study of symptomatic gout.
    Molecular bioSystems, 2012, Volume: 8, Issue:11

    Topics: Animals; Chromatography, High Pressure Liquid; Gout; Guanosine; Humans; Hypoxanthine; Male; Mice; Ri

2012
Silkworms can be used as an animal model to screen and evaluate gouty therapeutic drugs.
    Journal of insect science (Online), 2012, Volume: 12

    Topics: Animals; Bombyx; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Fat Body; Gout; Gou

2012
Adherence to uric acid treatment guidelines in a rheumatology clinic.
    Clinical rheumatology, 2012, Volume: 31, Issue:12

    Topics: Aged; Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Guideline Adherence; Humans; Male; M

2012
[Therapy of gout. "Uric acid less than 6 mg/dl is the general consensus" (interview by Wiebke Kathmann)].
    MMW Fortschritte der Medizin, 2012, Jul-26, Volume: 154, Issue:13

    Topics: Anti-Inflammatory Agents; Arthritis, Gouty; Colchicine; Consensus; Gout; Gout Suppressants; Guidelin

2012
Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout.
    BMC musculoskeletal disorders, 2012, Sep-16, Volume: 13

    Topics: Adult; Aged; Allopurinol; Biomarkers; Cross-Sectional Studies; Down-Regulation; Drug Dosage Calculat

2012
Gout: the mechanism of urate crystal nucleation and growth. A hypothesis based in facts.
    Joint bone spine, 2013, Volume: 80, Issue:1

    Topics: Calculi; Crystallization; Gout; Humans; Lithiasis; Ultrasonography; Uric Acid

2013
DECT urate deposits: now you see them, now you don't.
    Annals of the rheumatic diseases, 2013, Volume: 72, Issue:3

    Topics: Absorptiometry, Photon; Gout; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Sensitivity and

2013
Uric Acid: a clearer focus.
    Advances in chronic kidney disease, 2012, Volume: 19, Issue:6

    Topics: Gout; Humans; Hyperuricemia; Uric Acid

2012
Gout: a step forward.
    Advances in chronic kidney disease, 2012, Volume: 19, Issue:6

    Topics: Gout; Humans; Uric Acid

2012
The experience and impact of gout in Māori and Pacific people: a prospective observational study.
    Clinical rheumatology, 2013, Volume: 32, Issue:2

    Topics: Adult; Aged; Female; Follow-Up Studies; Gout; Health Status; Humans; Hyperuricemia; Male; Middle Age

2013
Pegloticase and the patient with treatment-failure gout.
    Expert review of clinical pharmacology, 2012, Volume: 5, Issue:5

    Topics: Allopurinol; Enzymes, Immobilized; Female; Gout; Gout Suppressants; Humans; Infusions, Intravenous;

2012
Absence of the SLC22A12 gene mutation in Turkish population with primary gout disease.
    Rheumatology international, 2013, Volume: 33, Issue:11

    Topics: Adult; Female; Genetic Predisposition to Disease; Gout; Humans; Hyperuricemia; Male; Middle Aged; Mu

2013
Gout in women: differences in risk factors in young and older women.
    The New Zealand medical journal, 2012, Oct-12, Volume: 125, Issue:1363

    Topics: Adult; Age Factors; Aged; Body Mass Index; Comorbidity; Diuretics; Ethnicity; Female; Gout; Gout Sup

2012
Sack and sugar, and the aetiology of gout in England between 1650 and 1900.
    Rheumatology (Oxford, England), 2013, Volume: 52, Issue:3

    Topics: Dietary Sucrose; England; Fructose; Gout; History, 17th Century; History, 18th Century; History, 19t

2013
Management of gout: a 57-year-old man with a history of podagra, hyperuricemia, and mild renal insufficiency.
    JAMA, 2012, Nov-28, Volume: 308, Issue:20

    Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Gout

2012
JAMA patient page. Gout.
    JAMA, 2012, Nov-28, Volume: 308, Issue:20

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Gout; Gout Suppressants; Humans; Uric Acid

2012
Sonographic appearance of synovial crystal deposits in 2 patients with gout.
    The Journal of rheumatology, 2012, Volume: 39, Issue:12

    Topics: Arthroscopy; Crystallization; Gout; Humans; Male; Middle Aged; Synovial Fluid; Synovial Membrane; Ul

2012
Hyperuricaemia elevates circulating CCL2 levels and primes monocyte trafficking in subjects with inter-critical gout.
    Rheumatology (Oxford, England), 2013, Volume: 52, Issue:6

    Topics: Aged; Cell Movement; Chemokine CCL2; Female; Gout; Humans; Hyperuricemia; Lipopolysaccharide Recepto

2013
Reduced glomerular function and prevalence of gout: NHANES 2009-10.
    PloS one, 2012, Volume: 7, Issue:11

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Cross-Sectional Studies; Female; Glomerular

2012
Potential interest of dual-energy computed tomography in gout: focus on anatomical distribution and clinical association.
    Rheumatology (Oxford, England), 2013, Volume: 52, Issue:2

    Topics: Female; Foot Joints; Gout; Humans; Male; Retrospective Studies; Tomography, X-Ray Computed; Uric Aci

2013
Assessment of arterial stiffness in female and male gout patients.
    Clinical and experimental hypertension (New York, N.Y. : 1993), 2013, Volume: 35, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Case-Control Studies; Female; Gout; Humans; Male; Mi

2013
Gouty panniculitis also involving the bone marrow.
    Acta dermato-venereologica, 2013, Mar-27, Volume: 93, Issue:2

    Topics: Allopurinol; Biomarkers; Biopsy; Bone Marrow; Bone Marrow Examination; Colchicine; Crystallization;

2013
Insulin resistance and metabolic syndrome in primary gout: relation to punched-out erosions.
    International journal of rheumatic diseases, 2012, Volume: 15, Issue:6

    Topics: Adult; Biomarkers; Case-Control Studies; Gout; Humans; Insulin; Insulin Resistance; Male; Metabolic

2012
The effect of the systemic inflammatory response, as provoked by elective orthopaedic surgery, on serum uric acid in patients without gout: a prospective study.
    Rheumatology (Oxford, England), 2013, Volume: 52, Issue:4

    Topics: Aged; Albuminuria; C-Reactive Protein; Creatinine; Elective Surgical Procedures; Female; Gout; Human

2013
Neutrophil cannibalism triggers transforming growth factor β1 production and self regulation of neutrophil inflammatory function in monosodium urate monohydrate crystal-induced inflammation in mice.
    Arthritis and rheumatism, 2013, Volume: 65, Issue:3

    Topics: Animals; Antioxidants; Apoptosis; Cells, Cultured; Crystallization; Cytophagocytosis; Disease Models

2013
Allopurinol versus rilonacept for the prevention of gout flares: comment on the article by Schumacher et al.
    Arthritis care & research, 2013, Volume: 65, Issue:5

    Topics: Allopurinol; Female; Gout; Gout Suppressants; Humans; Male; Recombinant Fusion Proteins; Uric Acid

2013
Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout.
    Annals of the rheumatic diseases, 2014, Volume: 73, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Cohort Studies; Female; Follow-Up Studies;

2014
Unusual soft tissue mass of the left lower leg.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2013, Volume: 19, Issue:1

    Topics: Biopsy, Fine-Needle; Gout; Gout Suppressants; Humans; Leg; Male; Middle Aged; Muscular Diseases; Rad

2013
Gout treatment: should we aim for rapid crystal dissolution?
    Annals of the rheumatic diseases, 2013, Volume: 72, Issue:5

    Topics: Crystallization; Gout; Gout Suppressants; Humans; Hyperuricemia; Solubility; Time Factors; Uric Acid

2013
Tendon involvement in the feet of patients with gout: a dual-energy CT study.
    Annals of the rheumatic diseases, 2013, Sep-01, Volume: 72, Issue:9

    Topics: Absorptiometry, Photon; Achilles Tendon; Crystallization; Female; Gout; Humans; Ligaments; Male; Mid

2013
Population-specific influence of SLC2A9 genotype on the acute hyperuricaemic response to a fructose load.
    Annals of the rheumatic diseases, 2013, Volume: 72, Issue:11

    Topics: Adolescent; Adult; Female; Fructose; Genotype; Glucose Transport Proteins, Facilitative; Gout; Human

2013
Potential pitfalls in the diagnosis of crystal-induced arthritis and in the sonographic measurement of hyaline cartilage due to the presence of joint effusion.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2013, Volume: 19, Issue:2

    Topics: Adult; Aged; Cartilage, Articular; Chondrocalcinosis; Diagnosis, Differential; Elbow Joint; Female;

2013
Monosodium urate monohydrate crystal-induced inflammation in vivo: quantitative histomorphometric analysis of cellular events.
    Arthritis and rheumatism, 2002, Volume: 46, Issue:6

    Topics: Animals; Cell Count; Crystallization; Disease Models, Animal; Exudates and Transudates; Fibroblasts;

2002
[Gout].
    Duodecim; laaketieteellinen aikakauskirja, 2001, Volume: 117, Issue:18

    Topics: Diet; Glucocorticoids; Gout; Gout Suppressants; Humans; Injections, Intra-Articular; Uric Acid

2001
Hyperuricemia and gout: a reign of complacency.
    Cleveland Clinic journal of medicine, 2002, Volume: 69, Issue:8

    Topics: Allopurinol; Colchicine; Coronary Disease; Gout; Gout Suppressants; Humans; Kidney Failure, Chronic;

2002
The crystal, the gout, and the paradox.
    Cleveland Clinic journal of medicine, 2002, Volume: 69, Issue:9

    Topics: Adult; Aged; Bursa, Synovial; Gout; Humans; Male; Uric Acid

2002
A simple method of selecting gout patients for treatment with uricosuric agents, using spot urine and blood samples.
    The Journal of rheumatology, 2002, Volume: 29, Issue:9

    Topics: Adult; Analysis of Variance; Blood Chemical Analysis; Case-Control Studies; Chi-Square Distribution;

2002
[Progress in the study of allergy and collagen disease in the last 100 years: Gout].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2002, Sep-10, Volume: 91, Issue:9

    Topics: Gout; History, 19th Century; History, 20th Century; Humans; Uric Acid

2002
Gout and diabetes in Polynesia.
    Lancet (London, England), 1967, Oct-21, Volume: 2, Issue:7521

    Topics: Diabetes Mellitus; Dietary Sucrose; Gout; Humans; Native Hawaiian or Other Pacific Islander; New Zea

1967
Tophaceous gout.
    Annals of nuclear medicine, 2002, Volume: 16, Issue:6

    Topics: Aged; Arthralgia; Bone Neoplasms; Colonic Neoplasms; Diagnosis, Differential; Gout; Humans; Knee Joi

2002
Biochemical distinction between hyperuricosuric calcium urolithiasis and gouty diathesis.
    Urology, 2002, Volume: 60, Issue:5

    Topics: Adult; Aged; Calcium; Calcium Oxalate; Diagnosis, Differential; Female; Gout; Humans; Hydrogen-Ion C

2002
Clinical analysis of gouty patients with normouricaemia at diagnosis.
    Annals of the rheumatic diseases, 2003, Volume: 62, Issue:1

    Topics: Aged; Blood Urea Nitrogen; Creatinine; Disease Progression; Female; Follow-Up Studies; Gout; Humans;

2003
Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output.
    Arthritis and rheumatism, 2002, Dec-15, Volume: 47, Issue:6

    Topics: Adult; Allopurinol; Case-Control Studies; Gout; Gout Suppressants; Humans; Hyperuricemia; Middle Age

2002
Gout related upper limb cellulitis: an ultrasound study.
    The Journal of rheumatology, 2003, Volume: 30, Issue:2

    Topics: Aged; Aged, 80 and over; Cellulitis; Exudates and Transudates; Female; Gout; Hand; Humans; Ultrasono

2003
Long-term remission from gout associated with fenofibrate therapy.
    Clinical rheumatology, 2003, Volume: 22, Issue:1

    Topics: Fenofibrate; Gout; Humans; Hyperlipidemias; Hyperuricemia; Hypolipidemic Agents; Lipids; Male; Middl

2003
The elevated prevalence of apolipoprotein E2 in patients with gout is associated with reduced renal excretion of urates.
    Rheumatology (Oxford, England), 2003, Volume: 42, Issue:3

    Topics: Adult; Alleles; Apolipoprotein E2; Apolipoproteins E; Case-Control Studies; Genotype; Gout; Humans;

2003
Biochemical profile of stone-forming patients with diabetes mellitus.
    Urology, 2003, Volume: 61, Issue:3

    Topics: Adolescent; Adult; Age Factors; Aged; Blood Glucose; Calcium Oxalate; Comorbidity; Diabetes Mellitus

2003
Acute gout precipitated by total parenteral nutrition.
    The Journal of rheumatology, 2003, Volume: 30, Issue:4

    Topics: Acute Disease; Adenocarcinoma; Esophagectomy; Gastrectomy; Gastrointestinal Neoplasms; Gout; Humans;

2003
A comparison between pre- and posthibernation morphometry, hematology, and blood chemistry in viperid snakes.
    Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians, 2003, Volume: 34, Issue:1

    Topics: Animals; Animals, Zoo; Bile Acids and Salts; Blood Chemical Analysis; Drinking; Female; Gout; Hemato

2003
Clinical characterization of a family with a mutation in the uromodulin (Tamm-Horsfall glycoprotein) gene.
    Kidney international, 2003, Volume: 64, Issue:1

    Topics: Adolescent; Alleles; Base Pairing; Chronic Disease; Creatinine; Female; Gene Deletion; Genes, Domina

2003
Uric acid and urea in human sweat.
    The Chinese journal of physiology, 2002, Sep-30, Volume: 45, Issue:3

    Topics: Adult; Gout; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Sweat; Urea; Uric Acid

2002
Uric acid and urea in human sweat.
    The Chinese journal of physiology, 2002, Sep-30, Volume: 45, Issue:3

    Topics: Adult; Gout; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Sweat; Urea; Uric Acid

2002
Uric acid and urea in human sweat.
    The Chinese journal of physiology, 2002, Sep-30, Volume: 45, Issue:3

    Topics: Adult; Gout; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Sweat; Urea; Uric Acid

2002
Uric acid and urea in human sweat.
    The Chinese journal of physiology, 2002, Sep-30, Volume: 45, Issue:3

    Topics: Adult; Gout; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Sweat; Urea; Uric Acid

2002
Rush desensitization to allopurynol.
    Allergy, 2003, Volume: 58, Issue:7

    Topics: Adult; Allopurinol; Angioedema; Desensitization, Immunologic; Drug Administration Schedule; Drug Eru

2003
Phosphoribosylpyrophosphate synthetase overactivity as a cause of uric acid overproduction in a young woman.
    Arthritis and rheumatism, 2003, Volume: 48, Issue:7

    Topics: Adult; Female; Genes, Dominant; Gout; Humans; Hyperuricemia; Point Mutation; Ribose-Phosphate Pyroph

2003
Predictive value of kidney stone composition in the detection of metabolic abnormalities.
    The American journal of medicine, 2003, Volume: 115, Issue:1

    Topics: Acidosis, Renal Tubular; Adolescent; Adult; Aged; Ambulatory Care; Apatites; Calcium; Calcium Oxalat

2003
Limited knee joint range of motion due to invisible gouty tophi.
    Rheumatology (Oxford, England), 2004, Volume: 43, Issue:2

    Topics: Adult; Follow-Up Studies; Gout; Humans; Knee Joint; Magnetic Resonance Imaging; Male; Middle Aged; R

2004
[Diagnostic and therapeutic consequences from our knowledge of the uric acid metabolism to gout].
    Die Medizinische, 1952, Jun-28, Volume: 31, Issue:26

    Topics: Gout; Humans; Knowledge; Uric Acid

1952
Current concepts in gout.
    American practitioner and digest of treatment, 1953, Volume: 4, Issue:2

    Topics: Gout; Humans; Uric Acid

1953
Uric acid production in normal and gouty subjects, determined by N15 labeled glycine.
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1953, Volume: 82, Issue:1

    Topics: Biochemical Phenomena; Body Fluids; Glycine; Gout; Humans; Uric Acid; Urine

1953
A further study of the utilization of dietary glycine nitrogen for uric acid synthesis in gout.
    The Journal of clinical investigation, 1953, Volume: 32, Issue:8

    Topics: Diet; Glycine; Gout; Nitrogen; Uric Acid

1953
The relation of dietary nitrogen consumption to the rate of uric acid synthesis in normal and gouty man.
    The Journal of clinical investigation, 1953, Volume: 32, Issue:8

    Topics: Diet; Gout; Humans; Male; Nitrogen; Uric Acid

1953
Diagnosis and treatment of gouty arthritis.
    California medicine, 1953, Volume: 79, Issue:3

    Topics: Arthritis; Arthritis, Gouty; Colchicine; Gout; Humans; Hyperuricemia; Male; Middle Aged; Probenecid;

1953
Effect of phenylbutazone on uric acid excretion in patients with gout and rheumatoid arthritis.
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1953, Volume: 83, Issue:3

    Topics: Analgesics; Arthritis; Arthritis, Rheumatoid; Body Fluids; Gout; Humans; Phenylbutazone; Uric Acid;

1953
Ammonia, urea and uric acid content of toenails in renal insufficiency and gout.
    The Australian journal of experimental biology and medical science, 1953, Volume: 31, Issue:4

    Topics: Ammonia; Gout; Humans; Kidney Diseases; Nails; Renal Insufficiency; Urea; Uric Acid

1953
[Relations between cortisone and uricosuria in uratic disease (acute and chronic gout)].
    Reumatismo, 1953, Volume: 5, Issue:Suppl. 2

    Topics: Arthritis, Gouty; Chronic Disease; Cortisone; Gout; Humans; Uric Acid

1953
A simultaneous study of glycine-N15 incorporation into uric acid and heme, and of Fe59 utilization, in a case of gout associated with polycythemia secondary to congenital heart disease.
    The American journal of medicine, 1953, Volume: 15, Issue:6

    Topics: Blood; Cardiovascular Abnormalities; Cardiovascular System; Glycine; Gout; Heart Diseases; Heme; Hum

1953
Uric acid production in a case of myeloid metaplasia associated with gouty arthritis, studied with N15 labeled glycine.
    The American journal of medicine, 1953, Volume: 15, Issue:6

    Topics: Arthritis, Gouty; Glycine; Gout; Humans; Metaplasia; Primary Myelofibrosis; Research; Uric Acid

1953
Metabolism of uric acid and its relation to gout.
    Journal of the American Medical Association, 1954, Jan-16, Volume: 154, Issue:3

    Topics: Gout; Humans; Probenecid; Uric Acid

1954
Effect of phenylbutazone (3,5 dioxo-1,2-diphenyl-4-n-butylpyrazolidine) on renal clearance of urate and other discrete renal functions in gouty subjects.
    The Journal of clinical investigation, 1953, Volume: 32, Issue:11

    Topics: Analgesics; Biphenyl Compounds; Gout; Humans; Kidney; Phenylbutazone; Uric Acid

1953
Effect of ACTH and sodium salicylate on the urinary uric acid: creatinine ratio, and circulating eosinophils in man.
    Annals of the rheumatic diseases, 1953, Volume: 12, Issue:4

    Topics: Adrenocorticotropic Hormone; Arthritis; Arthritis, Rheumatoid; Creatinine; Eosinophils; Gout; Humans

1953
Effect of phenylbutazone on uric acid metabolism.
    British medical journal, 1954, Apr-03, Volume: 1, Issue:4865

    Topics: Analgesics; Gout; Humans; Phenylbutazone; Uric Acid

1954
[Citrosalicylate of piperazine in therapy of uric acid diathesis].
    Minerva medica, 1954, Jan-27, Volume: 45, Issue:8

    Topics: Aged; Disease Susceptibility; Gout; Humans; Piperazine; Piperazines; Uric Acid

1954
[Uric acid excretion after longacid administration in normal and in gouty persons].
    Klinische Wochenschrift, 1954, Jun-15, Volume: 32, Issue:23-24

    Topics: Biological Transport; Body Fluids; Gout; Humans; Sulfanilamide; Sulfanilamides; Sulfonamides; Uric A

1954
Urinary uric acid excretion after the ingestion of isotopic yeast nucleic acid in the normal and gouty human.
    The Journal of biological chemistry, 1954, Volume: 209, Issue:1

    Topics: Eating; Gout; Humans; Nucleic Acids; Saccharomyces cerevisiae; Uric Acid; Urine

1954
Sodium salicylate and probenecid in the treatment of chronic gout; assessment of their relative effects in lowering serum uric acid levels.
    Annals of the rheumatic diseases, 1954, Volume: 13, Issue:3

    Topics: Arthritis, Gouty; Blood; Chronic Disease; Gout; Humans; Probenecid; Salicylates; Sodium Salicylate;

1954
Further observation on the uricosuric effects of probenecid (benemid) in tophaceous gout.
    Transactions of the Association of American Physicians, 1954, Volume: 67

    Topics: Body Fluids; Gout; Humans; Probenecid; Uric Acid; Urine

1954
The conversion of uric acid to allantoin in the normal and gouty human.
    The Journal of biological chemistry, 1954, Volume: 211, Issue:2

    Topics: Allantoin; Gout; Humans; Hydantoins; Uric Acid

1954
Failure of folic acid to affect uric acid metabolism in a case of gout.
    Metabolism: clinical and experimental, 1955, Volume: 4, Issue:1

    Topics: Folic Acid; Gout; Humans; Uric Acid

1955
[The metabolic problem of gout].
    Schweizerische medizinische Wochenschrift, 1954, Dec-18, Volume: 84, Issue:51

    Topics: Biochemical Phenomena; Gout; Humans; Uric Acid

1954
Non-keratin uric acid determinations in gout.
    Australasian annals of medicine, 1955, Volume: 4, Issue:3

    Topics: Gout; Humans; Keratins; Uric Acid; Urologic Diseases

1955
Uricolysis in normal and gouty individuals.
    Annals of the rheumatic diseases, 1955, Volume: 14, Issue:4

    Topics: Aged; Gout; Humans; Uric Acid

1955
[Renal elimination of uric acid in gout patients with crystalluria or uric calculi].
    Archivos espanoles de urologia, 1955, Volume: 11, Issue:3

    Topics: Calculi; Gout; Humans; Renal Elimination; Uric Acid; Urinary Calculi; Urinary Tract; Urine; Urologic

1955
Heredity in gout and hyperuricemia.
    Acta medica Scandinavica, 1955, Nov-10, Volume: 152, Issue:4

    Topics: Blood; Gout; Heredity; Humans; Hyperuricemia; Uric Acid

1955
[Crystalluria, uric lithiasis and gout; physiopathological study].
    Revista clinica espanola, 1955, Nov-15, Volume: 59, Issue:3

    Topics: Calculi; Crystallization; Gout; Humans; Lithiasis; Uric Acid; Urine

1955
Effect of a phenylbutazone analog (4-[phenylthioethyl]-1, 2-diphenyl 3, 5-pyrazolidinedione) on urate clearance and other discrete renal functions in gouty subjects; evaluation as uricosuric agent.
    The Journal of clinical investigation, 1956, Volume: 35, Issue:4

    Topics: Biphenyl Compounds; Gout; Humans; Kidney; Phenylbutazone; Pyrazoles; Uric Acid; Uricosuric Agents

1956
[Effects of metacortandracin on clearance of urates].
    Reumatismo, 1956, Volume: 8, Issue:Suppl 1

    Topics: Gout; Humans; Prednisone; Steroids; Uric Acid

1956
[Studies on gout].
    Revue medicale de Liege, 1956, Oct-15, Volume: 11, Issue:20

    Topics: Aged; Gout; Humans; Uric Acid

1956
[Studies on gout].
    Revue medicale de Liege, 1956, Oct-15, Volume: 11, Issue:20

    Topics: Aged; Gout; Humans; Uric Acid

1956
[Studies on gout].
    Revue medicale de Liege, 1956, Oct-15, Volume: 11, Issue:20

    Topics: Aged; Gout; Humans; Uric Acid

1956
[Studies on gout].
    Revue medicale de Liege, 1956, Oct-15, Volume: 11, Issue:20

    Topics: Aged; Gout; Humans; Uric Acid

1956
Preliminary observation on the serum glutamic oxalacetic transaminase levels in gout and polycythemia vera.
    Ochsner Clinic reports, 1957, Volume: 3, Issue:2

    Topics: Gout; Humans; Polycythemia Vera; Transaminases; Uric Acid

1957
[Uric acid-eliminating drugs in gout].
    La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1957, May-30, Volume: 33, Issue:33/5

    Topics: Biological Transport; Gout; Humans; Uric Acid

1957
Renal function in gout; with a commentary on the renal regulation of urate excretion, and the role of the kidney in the pathogenesis of gout.
    The American journal of medicine, 1957, Volume: 23, Issue:4

    Topics: Gout; Humans; Kidney; Uric Acid

1957
Overproduction of uric acid as the cause of hyperuricemia in primary gout.
    The Journal of clinical investigation, 1957, Volume: 36, Issue:10

    Topics: Gout; Humans; Hyperuricemia; Uric Acid

1957
Uric acid and gout.
    Actualites biologiques, 1956, Volume: 3

    Topics: Gout; Humans; Uric Acid

1956
[Hepatic polycordia, hyperuricemia and gout].
    Archives francaises de pediatrie, 1957, Volume: 14, Issue:9

    Topics: Child; Gout; Humans; Infant; Liver Diseases; Uric Acid

1957
GOUT.
    British medical journal, 1958, Mar-29, Volume: 1, Issue:5073

    Topics: Body Fluids; Gout; Humans; Uric Acid; Urologic Diseases

1958
[Origin of hyperuricemia and urate deposition in tissues due to alloxan action; studies in pigeons and ducks].
    Archivio di fisiologia, 1957, Dec-12, Volume: 57, Issue:4

    Topics: Alloxan; Animals; Columbidae; Ducks; Gout; Hyperuricemia; Uric Acid

1957
Renal regulation of uric acid excretion in normal and gouty man; modification by uricosuric agents.
    Bulletin of the New York Academy of Medicine, 1958, Volume: 34, Issue:5

    Topics: Biological Transport; Body Fluids; Gout; Humans; Kidney; Male; Uric Acid; Uricosuric Agents

1958
Atypical manifestations of gout.
    California medicine, 1958, Volume: 88, Issue:5

    Topics: Female; Gout; Humans; Uric Acid

1958
On the mechanism of overproduction of uric acid in patients with primary gout.
    The Journal of clinical investigation, 1958, Volume: 37, Issue:4

    Topics: Gout; Humans; Hyperuricemia; Uric Acid

1958
[Diuresis in gout: effects of Evian therapy on uric acid clearance].
    Revue du rhumatisme et des maladies osteo-articulaires, 1958, Volume: 25, Issue:3

    Topics: Diuresis; Gout; Humans; Kidney; Kinetics; Mineral Waters; Uric Acid

1958
Gout and metabolism.
    Scientific American, 1958, Volume: 198, Issue:6

    Topics: Aged; Gout; Humans; Uric Acid

1958
Normal glycine-C14-incorporation into uric acid in primary gout.
    Metabolism: clinical and experimental, 1958, Volume: 7, Issue:4 Pt 1

    Topics: Glycine; Gout; Humans; Hyperuricemia; Uric Acid

1958
Failure to detect consistent overincorporation of glycine-1-C14 into uric acid in primary gout.
    Metabolism: clinical and experimental, 1958, Volume: 7, Issue:4 Pt 1

    Topics: Glycine; Gout; Humans; Hyperuricemia; Uric Acid

1958
[Note on uraturia in gout patients during benemid therapy].
    Revue du rhumatisme et des maladies osteo-articulaires, 1958, Volume: 25, Issue:4

    Topics: Body Fluids; Gout; Probenecid; Uric Acid

1958
Chlorothiazide (diuril) as a hyperuricaci'emic agent.
    Journal of the American Medical Association, 1958, Dec-20, Volume: 168, Issue:16

    Topics: Acetazolamide; Chlorothiazide; Gout; Uric Acid

1958
The diagnosis of gout; significance of an elevated serum uric acid value.
    The New England journal of medicine, 1958, Dec-04, Volume: 259, Issue:23

    Topics: Gout; Humans; Uric Acid

1958
[Incorporation of C14 formate in urinary uric acid in subjects of gout].
    Reumatismo, 1958, Volume: 10, Issue:Supp 2

    Topics: Formates; Gout; Humans; Uric Acid

1958
Incorporation of glycine-1-C14, glycine-2-C14 and glycine-N15 into uric acid in normal and gouty subjects.
    The American journal of medicine, 1958, Volume: 25, Issue:6

    Topics: Glycine; Gout; Humans; Uric Acid

1958
Studies in sialolithiasis. II. Uric acid calculus of the parotid gland; report of a case.
    The Annals of otology, rhinology, and laryngology, 1958, Volume: 67, Issue:4

    Topics: Calculi; Gout; Humans; Medical Records; Parotid Gland; Salivary Gland Calculi; Uric Acid

1958
Atypical gout and hyperuricemia.
    Medical times, 1959, Volume: 87, Issue:2

    Topics: Gout; Humans; Hyperuricemia; Uric Acid

1959
[New data on the metabolism of gout].
    Casopis lekaru ceskych, 1959, Feb-27, Volume: 98, Issue:9

    Topics: Aged; Gout; Humans; Uric Acid

1959
Dissolution of renal uric acid stones by oral alkalinization and large fluid intake in a patient suffering from gout.
    The American journal of medicine, 1959, Volume: 27, Issue:1

    Topics: Calculi; Gout; Humans; Kidney; Kidney Calculi; Solubility; Uric Acid

1959
[Hyperuricemia in the entero-arthrotic syndrome and in the etiology of colitis].
    Concours medical, 1961, Jun-10, Volume: 83

    Topics: Colitis; Gout; Humans; Hyperuricemia; Joint Diseases; Osteoarthritis; Syndrome; Uric Acid

1961
Hyperuricemia and acute gouty arthritis precipitated by thiazide derivatives.
    Canadian Medical Association journal, 1961, May-27, Volume: 84

    Topics: Antihypertensive Agents; Arthritis, Gouty; Chlorothiazide; Gout; Humans; Hyperuricemia; Uric Acid

1961
[The problem of uricolysis: clinico-experimental studies, results of the same and possible new method for the treatment of certain aspects of gout].
    Revista espanola de reumatismo y enfermedades osteoarticulares, 1960, Volume: 8

    Topics: Gout; Humans; Uric Acid

1960
[Theoretical concepts and practical applications of liver catalase in the treatment of chronic gout].
    Le Scalpel, 1961, May-06, Volume: 114

    Topics: Arthritis, Gouty; Catalase; Chronic Disease; Gout; Liver; Uric Acid

1961
Gout and serum cholesterol.
    Wisconsin medical journal, 1960, Volume: 59

    Topics: Cholesterol; Gout; Humans; Uric Acid

1960
Gout and the serum uric acid in diabetes mellitus.
    The Quarterly journal of medicine, 1960, Volume: 29

    Topics: Diabetes Complications; Diabetes Mellitus; Gout; Humans; Uric Acid

1960
Chlorothiazide-induced hyperuricemia: report of two cases.
    Metabolism: clinical and experimental, 1960, Volume: 9

    Topics: Chlorothiazide; Gout; Humans; Hyperuricemia; Uric Acid

1960
Uric acid production in gout.
    The Journal of clinical investigation, 1961, Volume: 40

    Topics: Aged; Gout; Humans; Uric Acid

1961
[Effects of sulfinpyrazone on uricemia and excretion of uric acid in 50 gouty hyperuricemic patients during diuretic thermal treatment. Comparison of its action in simple gout patients and in tophaceous gout patients].
    La Presse medicale, 1961, May-20, Volume: 69

    Topics: Biological Transport; Body Fluids; Diuretics; Gout; Humans; Hyperuricemia; Phenylbutazone; Sulfinpyr

1961
Identification of urate crystals in gouty synovial fluid.
    Annals of internal medicine, 1961, Volume: 54

    Topics: Gout; Humans; Synovial Fluid; Uric Acid

1961
[Considerations on the pathogenesis of hyperuricemia in the gout patient].
    Viata medicala, 1961, May-15, Volume: 8

    Topics: Gout; Humans; Hyperuricemia; Uric Acid

1961
On the dual etiology of hyperuricemia in primary gout.
    Arthritis and rheumatism, 1960, Volume: 3

    Topics: Arthritis, Gouty; Gout; Humans; Hyperuricemia; Uric Acid

1960
Suppression of uric acid synthesis in the gouty human by the use of 6-diazo-5-oxo-L-norleucine.
    The Journal of clinical investigation, 1960, Volume: 39

    Topics: Diazooxonorleucine; Gout; Humans; Leucine; Uric Acid

1960
Uricosuric agents in the treatment of gout.
    Annals of the rheumatic diseases, 1960, Volume: 19

    Topics: Gout; Uric Acid; Uricosuric Agents

1960
[A case of combined lipoid- and uric acid gout].
    Deutsche Zeitschrift fur Verdauungs- und Stoffwechselkrankheiten, 1959, Volume: 19

    Topics: Gout; Humans; Lipid Metabolism; Lipids; Medical Records; Nucleoproteins; Uric Acid

1959
[The renal regulation of urate excretion and its relationship to the etiology of gout].
    Archives of interamerican rheumatology : A.I.R, 1962, Volume: 5

    Topics: Gout; Humans; Kidney; Uric Acid

1962
Intramolecular distribution of uric acid-N15 after administration of glycine-N15 and ammonium-N15 chloride to goury and non-goury subjects.
    The Journal of clinical investigation, 1962, Volume: 41

    Topics: Ammonia; Ammonium Chloride; Glycine; Gout; Humans; Uric Acid

1962
[Hyperuricemia in Filipinos].
    Minerva medica, 1961, Oct-24, Volume: 52

    Topics: Gout; Humans; Hyperuricemia; Uric Acid

1961
The effect of colchicine on purine metabolism in gout.
    The Journal of the Kansas Medical Society, 1962, Volume: 63

    Topics: Biochemical Phenomena; Colchicine; Gout; Humans; Purines; Uric Acid

1962
Long term uricosuric therapy in gout.
    Arthritis and rheumatism, 1962, Volume: 5

    Topics: Gout; Phenylbutazone; Probenecid; Salicylates; Uric Acid; Zoxazolamine

1962
[From uric lithiasis to gout].
    Rein et foie, maladies de la nutrition; actualites, 1960, Volume: 1, Issue:4

    Topics: Gout; Humans; Lithiasis; Medical Records; Uric Acid

1960
Diagnosis of gouty arthritis. 18 months' experience with a pathognomonic test.
    Postgraduate medicine, 1963, Volume: 33

    Topics: Arthritis, Gouty; Gout; Humans; Synovial Fluid; Uric Acid

1963
Crystal-induced inflammation; syndromes of gout and pseudogout.
    Geriatrics, 1963, Volume: 18

    Topics: Chondrocalcinosis; Gout; Humans; Inflammation; Syndrome; Synovitis; Uric Acid

1963
X-ray diffraction studies of the tophaceous deposits in gout.
    Arthritis and rheumatism, 1963, Volume: 6

    Topics: Gout; Humans; Uric Acid; X-Ray Diffraction

1963
Gout and hyperuricemia after adrenalectomy for hypertension.
    The New England journal of medicine, 1963, May-16, Volume: 268

    Topics: Adrenalectomy; Gout; Humans; Hypertension; Hyperuricemia; Uric Acid

1963
[Uricosuria therapy of chronic gout].
    Orvosi hetilap, 1963, Mar-31, Volume: 104

    Topics: Arthritis; Chronic Disease; Gout; Humans; Probenecid; Uric Acid; Urologic Diseases

1963
[The use of uricosuric agents].
    Vie medicale (Paris, France : 1920), 1963, Volume: 44

    Topics: Gout; Humans; Probenecid; Uric Acid; Uricosuric Agents

1963
[The treatment of gout crises in patients with renal insufficiency].
    Vie medicale (Paris, France : 1920), 1963, Volume: 44

    Topics: Colchicine; Gout; Humans; Kidney Diseases; Phenylbutazone; Renal Insufficiency; Salicylates; Uric Ac

1963
Current concepts of gout and its treatment.
    The Medical clinics of North America, 1963, Volume: 47

    Topics: Gout; Humans; Uric Acid

1963
Arthritis after intrasynovial injection of sodium urate crystals.
    Lancet (London, England), 1962, Dec-29, Volume: 2, Issue:7270

    Topics: Arthritis; Gout; Humans; Injections; Uric Acid

1962
[The gouty kidney].
    Munchener medizinische Wochenschrift (1950), 1962, Nov-09, Volume: 104

    Topics: Gout; Humans; Kidney; Kidney Diseases; Uric Acid; Urinary Calculi

1962
Biochemistry of uric acid and its relation to gout.
    The New England journal of medicine, 1963, Mar-28, Volume: 268

    Topics: Gout; Humans; Uric Acid

1963
Biochemistry of uric acid and its relation to gout.
    The New England journal of medicine, 1963, Apr-11, Volume: 268

    Topics: Gout; Humans; Uric Acid

1963
Biochemistry of uric acid and its relation to gout.
    The New England journal of medicine, 1963, Apr-04, Volume: 268

    Topics: Gout; Humans; Uric Acid

1963
The relationship between gout and the kidney.
    Metabolism: clinical and experimental, 1963, Volume: 12

    Topics: Gout; Humans; Kidney; Kidney Diseases; Uric Acid

1963
Renal function in gout. II. Effect of uric acid loading on renal excretion of uric acid.
    The American journal of medicine, 1962, Volume: 33

    Topics: Gout; Humans; Kidney Function Tests; Renal Elimination; Uric Acid

1962
Significance of urate crystals in synovial fluids.
    Archives of internal medicine, 1963, Volume: 111

    Topics: Gout; Humans; Synovial Fluid; Uric Acid

1963
The effect of dietary fat on drug-induced uricosuria in gout.
    Current therapeutic research, clinical and experimental, 1962, Volume: 4

    Topics: Diet; Dietary Fats; Fats; Gout; Humans; Nutrition Assessment; Nutritional Status; Research; Uric Aci

1962
[1st results of D10-1C in the treatment of gout].
    Gazette medicale de France, 1963, Jul-10, Volume: 70

    Topics: Catalase; Gout; Humans; Uric Acid

1963
[The treatment of gout].
    Les Cahiers du College de medecine des hopitaux de Paris, 1963, Volume: 4

    Topics: Colchicine; Diet; Diet Therapy; Gout; Humans; Uric Acid

1963
[Biological supervision of the gout patient treated with uric acid eliminators with the aid of a simple test: the mean clearance of urea and uric acid].
    Revue du rhumatisme et des maladies osteo-articulaires, 1961, Volume: 28

    Topics: Gout; Humans; Kidney Function Tests; Kinetics; Urea; Uric Acid

1961
[Preliminary note on the effect of a hepatocatalase on gout and hyperuricemia. (Apropos of 40 cases)].
    Marseille medical, 1962, Volume: 99

    Topics: Catalase; Gout; Humans; Hyperuricemia; Liver Extracts; Oxidoreductases; Uric Acid

1962
[2-PHENYL-5-BROMO-1,3-INDANEDIONE IN THE URICOSURIC TREATMENT OF GOUT AND URIC ACID DIATHESIS].
    La Clinica terapeutica, 1963, Jul-15, Volume: 26

    Topics: Disease Susceptibility; Gout; Humans; Indans; Indenes; Phenindione; Uric Acid; Uricosuric Agents

1963
RENAL LESIONS RESULTING FROM INDUCED HYPERURICEMIA IN ANIMALS.
    Proceedings of the staff meetings. Mayo Clinic, 1963, Sep-11, Volume: 38

    Topics: Animals; Blood; Dogs; Gout; Hyperuricemia; Injections; Injections, Intravenous; Kidney; Kidney Disea

1963
RENAL EXCRETION OF URATE IN PATIENTS WITH GOUT.
    Archives of internal medicine, 1964, Volume: 113

    Topics: Blood; Gout; Humans; Kidney Function Tests; Metabolism; Renal Elimination; RNA; Uric Acid; Urine

1964
[EFFECT ON URICEMIA, URICOSURIA AND URIC ACID CLEARANCE OF THE ADMINISTRATION OF 2-ACETYLAMINO-5-CHLOROBENZOXAZOLE TO 47 GOUTY PATIENTS].
    Revue du rhumatisme et des maladies osteo-articulaires, 1963, Volume: 30

    Topics: Blood; Body Fluids; Gout; Humans; Oxazoles; Uric Acid; Uricosuric Agents; Urine; Urologic Diseases;

1963
[APROPOS OF THE REPORT: ACETYLZOXAZOLAMINE IN THE TREATMENT OF GOUT: INITIAL RESULTS].
    Revue du rhumatisme et des maladies osteo-articulaires, 1963, Volume: 30

    Topics: Blood; Geriatrics; Gout; Uric Acid; Uricosuric Agents; Zoxazolamine

1963
GOUT AMONG FILIPINOS.
    Journal of the Philippine Medical Association, 1963, Volume: 39

    Topics: Asian People; Colorimetry; Epidemiology; Gout; Humans; Philippines; Uric Acid; Uricosuric Agents

1963
[GOUT AND ARTERIOSCLEROSIS].
    Revista espanola de reumatismo y enfermedades osteoarticulares, 1963, Volume: 10

    Topics: Arteriosclerosis; Biometry; Gout; Humans; Hypercholesterolemia; Statistics as Topic; Uric Acid

1963
ANKYLOSING SPONDYLITIS, HYPERURICEMIA, AND ANOMALIES OF THE LUMBOSACRAL JUNCTION. A FAMILY STUDY.
    Annals of internal medicine, 1963, Volume: 59

    Topics: Blood Chemical Analysis; Genetics, Medical; Gout; Hyperuricemia; Lumbosacral Region; Research; Spine

1963
CHANGES IN SERUM AND URINARY URIC ACID WITH THE DEVELOPMENT OF SYMPTOMATIC GOUT.
    The Journal of clinical investigation, 1963, Volume: 42

    Topics: Blood Chemical Analysis; Body Fluids; Gout; Humans; Uric Acid; Urine

1963
BLOOD COAGULATION AND PLATELET ECONOMY IN SUBJECTS WITH PRIMARY GOUT.
    Canadian Medical Association journal, 1963, Dec-14, Volume: 89

    Topics: Arteriosclerosis; Arthritis, Gouty; Blood Coagulation; Blood Coagulation Tests; Blood Platelets; Gou

1963
[THE ACUTE INFLAMMATION OF GOUT].
    Revista espanola de reumatismo y enfermedades osteoarticulares, 1963, Volume: 10

    Topics: Colchicine; Gout; Humans; Inflammation; Pathology; Uric Acid; Uricosuric Agents

1963
[THE LIPIDS AND RHEUMATIC DISEASES. PRELIMINARY NOTE].
    Revista espanola de reumatismo y enfermedades osteoarticulares, 1963, Volume: 10

    Topics: Arthritis, Rheumatoid; Cholesterol; Gout; Humans; Lipid Metabolism; Lipids; Obesity; Phospholipids;

1963
A SURGERY OF RHEUMATISM IN A RURAL NEW ZEALAND MAORI COMMUNITY.
    Annals of the rheumatic diseases, 1963, Volume: 22

    Topics: Adolescent; Arthritis; Arthritis, Rheumatoid; Blood; Geriatrics; Gout; Humans; Joint Diseases; Latex

1963
AN ABNORMALITY OF GLUTAMINE METABOLISM IN PRIMARY GOUT.
    The American journal of medicine, 1963, Volume: 35

    Topics: Ammonia; Creatine; Creatinine; Glutamine; Glycine; Gout; Humans; Hyperuricemia; Kidney; Metabolism;

1963
[TREATMENT OF GOUT WITH URACIL-6-CARBOXYLIC ACID AND ITS DERIVATIVES].
    La Presse medicale, 1963, Sep-14, Volume: 71

    Topics: Blood; Body Fluids; Carboxylic Acids; Gout; Humans; Orotic Acid; Pharmacology; Toxicology; Uracil; U

1963
[HYPOURICEMIC ACTION OF COLCHICINE. IMPORTANCE OF URICEMIA IN GOUT].
    La Semana medica, 1963, Sep-19, Volume: 123

    Topics: Acid-Base Imbalance; Blood; Colchicine; Gout; Purine-Pyrimidine Metabolism, Inborn Errors; Uric Acid

1963
URIC ACID CALCULI.
    The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society, 1963, Volume: 115

    Topics: Blood Chemical Analysis; Geriatrics; Gout; Humans; Infant; Ureteral Calculi; Uric Acid; Urinary Cath

1963
MEDICAL GRAND ROUNDS FROM THE UNIVERSITY OF ALABAMA MEDICAL CENTER.
    Southern medical journal, 1964, Volume: 57

    Topics: Arthritis; Colchicine; Gout; Humans; Phenylbutazone; Probenecid; Teaching Rounds; Uric Acid

1964
[IS GRISEOFULVIN A URICO-ELIMINATOR?].
    Lyon medical, 1963, Dec-08, Volume: 210

    Topics: Gout; Griseofulvin; Metabolism; Uric Acid

1963
[TREATMENT OF URIC LITHIASIS].
    Rein et foie, maladies de la nutrition; actualites, 1963, Volume: 6

    Topics: Bicarbonates; Calcium Metabolism Disorders; Citrates; Diet; Diet Therapy; Diuresis; Gout; Humans; Hy

1963
ASSOCIATION OF HYPERURICAEMIA AND GOUT WITH HYPERPARATHYROIDISM.
    British medical journal, 1964, Apr-25, Volume: 1, Issue:5390

    Topics: Adenoma; Blood Chemical Analysis; Diagnosis; Gout; Humans; Hyperparathyroidism; Hyperuricemia; Nephr

1964
METABOLIC MALADIES IN NEW ZEALAND MAORIS.
    British medical journal, 1964, Apr-25, Volume: 1, Issue:5390

    Topics: Adolescent; Anthropometry; Blood Chemical Analysis; Cholesterol; Coronary Disease; Epidemiology; Eth

1964
POTENTIATION OF ANTICOAGULANTS CAUSED BY PYRAZOLE COMPOUNDS.
    JAMA, 1964, Apr-20, Volume: 188

    Topics: Anticoagulants; Blood Chemical Analysis; Chemical Phenomena; Chemistry; Coronary Disease; Gout; Hema

1964
MEDICAL GRAND ROUNDS OF THE METHODIST HOSPITAL HOUSTON, TEXAS. SUBJECT: GOUTY NEPHRITIS.
    Medical record and annals, 1964, Volume: 57

    Topics: Acetazolamide; Anuria; Blood Chemical Analysis; Body Fluids; Gout; Nephritis; Nephrosclerosis; Patho

1964
GOUT IN INFANCY MANIFESTED BY RENAL FAILURE.
    Pediatrics, 1964, Volume: 33

    Topics: Acute Kidney Injury; Adolescent; Blood Cell Count; Child; Citrates; Genetics, Medical; Glycine; Gout

1964
[CASE OF CHRONIC TOPHOCEOUS GOUT].
    Iryo, 1963, Volume: 17

    Topics: Arthritis, Gouty; Aspirin; Diet; Diet Therapy; Gout; Humans; Phenylbutazone; Prednisolone; Sulfinpyr

1963
"STUDIES ON THE NATURE OF GOUTY TOPHI" BY MAX FREUDWEILER, 1899. (AN INFLAMMATORY RESPONSE TO INJECTED SODIUM URATE, 1899). AN ABRIDGED TRANSLATION, WITH COMMENTS.
    Annals of internal medicine, 1964, Volume: 60

    Topics: Acid-Base Equilibrium; Animals; Calcium; Calcium, Dietary; Gout; History, 19th Century; History, 20t

1964
THE EPIDEMIOLOGY OF RHEUMATIC DISEASES.
    Annals of the rheumatic diseases, 1964, Volume: 23

    Topics: Arthritis; Arthritis, Rheumatoid; Blood; Colitis; Colitis, Ulcerative; Crohn Disease; Enteritis; Epi

1964
JOINT COMPLAINTS IN POLYCYTHAEMIA VERA.
    Annals of the rheumatic diseases, 1964, Volume: 23

    Topics: Arthritis; Arthritis, Rheumatoid; Blood; Blood Cell Count; Gout; Hemagglutination; Humans; Joints; L

1964
GOUT, HYPERURICAEMIA AND CARBOHYDRATE METABOLISM.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1964, Mar-14, Volume: 38

    Topics: Carbohydrate Metabolism; Cholesterol; Glucose Tolerance Test; Gout; Humans; Hypertension; Hyperurice

1964
HYPERTRIGLYCERIDEMIA IN GOUT.
    Circulation, 1964, Volume: 29

    Topics: Arteriosclerosis; Black People; Blood Chemical Analysis; Cholesterol; Genetics, Medical; Geriatrics;

1964
[THE KIDNEY IN CHRONIC LEAD POISONING].
    Revue francaise d'etudes cliniques et biologiques, 1964, Volume: 9

    Topics: Edetic Acid; Electrons; Gout; Humans; Hypertension; Kidney; Kidney Diseases; Kidney Function Tests;

1964
CLINICAL TRIAL OF TRIAMTERENE IN HYPERTENSIVE PATIENTS.
    The New Zealand medical journal, 1964, Volume: 63

    Topics: Biomedical Research; Blood Chemical Analysis; Blood Pressure Determination; Diuretics; Gout; Hyperal

1964
A FAMILIAL DISORDER OF URIC ACID METABOLISM AND CENTRAL NERVOUS SYSTEM FUNCTION.
    The American journal of medicine, 1964, Volume: 36

    Topics: Athetosis; Biomedical Research; Blood Chemical Analysis; Central Nervous System Diseases; Cerebral P

1964
RECURRENT ACUTE (?GOUTY) ARTHRITIS IN CHRONIC RENAL FAILURE TREATED WITH PERIODIC HEMODIALYSIS.
    The American journal of medicine, 1964, Volume: 36

    Topics: Alkaline Phosphatase; Arthritis; Blood Chemical Analysis; Calcinosis; Calcium; Colchicine; Fingers;

1964
[OUR EXPERIENCES WITH THE TREATMENT OF GOUT].
    Orvosi hetilap, 1964, Apr-26, Volume: 105

    Topics: Blood Chemical Analysis; Body Fluids; Colchicine; Dietary Carbohydrates; Dietary Fats; Dietary Prote

1964
[GOUT IN WOMEN].
    La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1964, May-20, Volume: 40

    Topics: Blood Chemical Analysis; Gout; Humans; Kidney Calculi; Kidney Diseases; Uric Acid; Women

1964
[ON CASES OF GOUT AND FAMILIAL HYPERURICEMIA].
    Nihon Seikeigeka Gakkai zasshi, 1964, Volume: 38

    Topics: Blood; Genetics, Medical; Gout; Humans; Hyperuricemia; Pathology; Uric Acid

1964
[URIC ACID METABOLISM AND SALIDIURETICS].
    Deutsche medizinische Wochenschrift (1946), 1964, Jun-05, Volume: 89

    Topics: Aged; Chlorothiazide; Chlorthalidone; Diagnosis; Gout; Humans; Hydrochlorothiazide; Metabolism; Toxi

1964
[ACUTE RECURRENT OLIGOARTICULAR GOUT. (STIMULATION OF RHEUMATOID ARTHRITIS)].
    El Dia medico, 1964, Apr-20, Volume: 36

    Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Arthritis, Rheumatoid; Classification; Clinica

1964
HYPERURICEMIA, GOUT AND CEREBROVASCULAR DISEASE.
    The West Virginia medical journal, 1964, Volume: 60

    Topics: Black People; Blood Chemical Analysis; Cerebrovascular Disorders; Cholesterol; Geriatrics; Gout; Hum

1964
[ON THE EFFECT OF ANTURAN AS A TREATMENT OF GOUT].
    [Sogo rinsho] Clinic all-round, 1964, Volume: 13

    Topics: Biomedical Research; Geriatrics; Gout; Sulfinpyrazone; Toxicology; Uric Acid; Uricosuric Agents

1964
MEASUREMENT OF SERUM URIC ACID IN GREAT BRITAIN IN 1963.
    Annals of the rheumatic diseases, 1964, Volume: 23

    Topics: Blood Chemical Analysis; Colorimetry; Female; Freeze Drying; Gout; Humans; Menopause; Sex; Spectroph

1964
POLYTHIAZIDE AND RESERPINE COMBINED IN THE OFFICE TREATMENT OF HYPERTENSION.
    Angiology, 1964, Volume: 15

    Topics: Antihypertensive Agents; Benzothiadiazines; Biomedical Research; Blood; Diuretics; Gastroenteritis;

1964
[A STUDY ON THE INHERITABLE FACTORS OF GOUT AND HYPERURICEMIA].
    Fukuoka igaku zasshi = Hukuoka acta medica, 1964, Volume: 55

    Topics: Blood; Genetics, Medical; Gout; Humans; Hyperuricemia; Japan; Pathology; Physiology; Statistics as T

1964
[ANEMIA AS A CONTRIBUTORY CAUSE OF URATIC ARTHRITIS].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1964, Jul-15, Volume: 84

    Topics: Anemia; Arthritis; Blood Transfusion; Gout; Humans; Uric Acid

1964
IN DEFENSE OF GOUT: THE IMPORTANCE OF URIC ACID IN DIAGNOSIS.
    Presbyterian-St. Luke's Hospital medical bulletin, 1964, Volume: 3

    Topics: Black People; Blood Chemical Analysis; Colchicine; Diagnosis; Geriatrics; Gout; Humans; Synovial Flu

1964
[LIVER CATALASE IN THE TREATMENT OF GOUT AND OTHER RHEUMATIC DISEASES].
    Revista medica de Chile, 1964, Volume: 92

    Topics: Biomedical Research; Catalase; Cholesterol; Dermatomyositis; Drug Therapy; Gout; Liver; Porphyrias;

1964
THE EFFECT OF GLUCOSE LOADS ON RENAL URIC ACID EXCRETION IN DIABETIC PATIENTS.
    Metabolism: clinical and experimental, 1964, Volume: 13

    Topics: Blood Glucose; Carbohydrate Metabolism; Creatine; Creatinine; Diabetes Mellitus; Glucose; Gout; Huma

1964
DIABETES MELLITUS IN PATIENTS WITH GOUTY ARTHRITIS.
    JAMA, 1964, Oct-26, Volume: 190

    Topics: Arthritis; Arthritis, Gouty; Blood; Diabetes Mellitus; Drug Therapy; Gout; Humans; Hyperglycemia; Ur

1964
BLOOD LIPID AND URIC ACID INTERRELATIONSHIPS.
    JAMA, 1964, Nov-30, Volume: 190

    Topics: Biomedical Research; Blood; Glycerides; Gout; Humans; Hypercholesterolemia; Hyperlipidemias; Lipid M

1964
[SECONDARY ASPECIFIC EFFECTS OF BENZOTHIAZINIC DIURETICS].
    Minerva medica, 1964, Sep-08, Volume: 55

    Topics: Agranulocytosis; Amylases; Blood Glucose; Chlorothiazide; Diabetes Mellitus; Diuretics; Drug Eruptio

1964
ARTICULAR AND FIBROCARTILAGE CALCIFICATION IN HYPERPARATHYROIDISM: ASSOCIATED HYPERURICEMIA.
    Radiology, 1964, Volume: 83

    Topics: Acetabulum; Blood; Calcinosis; Cartilage; Cartilage, Articular; Fibrocartilage; Gout; Humans; Hyperp

1964
NEW PROSPECTS IN THE TREATMENT OF GOUTY DYSPURINIA.
    Archives of interamerican rheumatology : A.I.R, 1964, Volume: 7

    Topics: Azaserine; Blood; Drug Therapy; Enzyme Inhibitors; Gout; Leucine; Metabolism; Orotic Acid; Oxidoredu

1964
THE TREATMENT OF GOUT.
    The New Zealand medical journal, 1964, Volume: 63

    Topics: Adolescent; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Colchicine; Diet; Diet Therapy; Dr

1964
SOLUBILITY OF SODIUM URATE IN THE PRESENCE OF CHONDROITIN-4-SULPHATE.
    Nature, 1964, Jun-27, Volume: 202

    Topics: Chondroitin; Chondroitin Sulfates; Connective Tissue; Dialysis; Gout; Humans; Ions; Renal Dialysis;

1964
THE PENDULUM OF PROGRESS IN GOUT: FROM CRYSTALS TO HYPERURICEMIA AND BACK.
    Arthritis and rheumatism, 1964, Volume: 7

    Topics: Blood; Chemical Precipitation; Crystallization; Exudates and Transudates; Geriatrics; Gout; Humans;

1964
GOUT.
    The Practitioner, 1964, Volume: 193

    Topics: Analgesics; Analgesics, Non-Narcotic; Antipyretics; Colchicine; Diagnosis, Differential; Diet; Diet

1964
[ON EXPERIMENTAL GOUT].
    Nihon Seikeigeka Gakkai zasshi, 1964, Volume: 38

    Topics: Animals; Arthritis, Experimental; Gout; Humans; Meat; Poultry; Research; Uric Acid

1964
[CORTICOSTEROID THERAPY OF GOUT].
    Minerva medica, 1964, Oct-17, Volume: 55

    Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Drug Therapy; Gout; Humans; Indoles; Indometha

1964
EFFECT OF SULFINPYRAZONE ON SERUM URIC ACID IN GOUT. A LONG-TERM STUDY.
    Geriatrics, 1964, Volume: 19

    Topics: Adolescent; Aging; Blood; Drug Therapy; Geriatrics; Gout; Longitudinal Studies; Metabolism; Phenylbu

1964
4-HYDROXYPYRAZOLO (3,4-D) PYRIMIDINE (HPP) IN THE TREATMENT OF GOUT: PRELIMINARY OBSERVATIONS.
    Annals of the rheumatic diseases, 1964, Volume: 23

    Topics: Blood; Colchicine; Diet; Diet Therapy; Drug Therapy; Enzyme Inhibitors; Geriatrics; Gout; Humans; Pr

1964
[CLINICAL CONSIDERATIONS ON THE RELATIONS THAT SEEM TO EXIST BETWEEN CERVICAL PAINS AND HYPERURICEMIA].
    La Presse thermale et climatique, 1964, Volume: 101

    Topics: Blood; Cervical Vertebrae; Gout; Humans; Hyperuricemia; Neck Pain; Neuralgia; Spinal Diseases; Torti

1964
[SECONDARY GOUT IN CHRONIC NEPHROPATHIES].
    La Presse medicale, 1965, Mar-06, Volume: 73

    Topics: Amyloidosis; Blood; Colchicine; Drug Therapy; Gout; Humans; Hypertension; Hypertension, Renal; Kidne

1965
SIGNIFICANCE OF THE RENAL CLEARANCE OF URIC ACID IN NORMAL AND GOUTY MAN.
    The American journal of medicine, 1964, Volume: 37

    Topics: Animals; Dogs; Fluids and Secretions; Glomerular Filtration Rate; Gout; Humans; Kidney Function Test

1964
OBSERVATIONS ON THE NATURAL HISTORY OF HYPERURICEMIA AND GOUT. I. AN EIGHTEEN YEAR FOLLOW-UP OF NINETEEN GOUTY FAMILIES.
    The American journal of medicine, 1964, Volume: 37

    Topics: Adolescent; Blood; Cerebrovascular Disorders; Colorimetry; Coronary Disease; Esophageal and Gastric

1964
EFFECT OF ALLOPURINOL (4-HYDROXYPYRAZOLO-(3,4-D)PYRIMIDINE) ON SERUM AND URINARY URIC ACID IN PRIMARY AND SECONDARY GOUT.
    The American journal of medicine, 1964, Volume: 37

    Topics: Allopurinol; Arthritis; Blood; Bone Marrow Diseases; Drug Therapy; Enzyme Inhibitors; Fluids and Sec

1964
HYPERURICAEMIA IN HYPERTENSION.
    Lancet (London, England), 1965, Mar-06, Volume: 1, Issue:7384

    Topics: Blood; Body Weight; Cholesterol; Creatine; Creatinine; Dehydroepiandrosterone; Fluids and Secretions

1965
STUDIES ON HYPERURICEMIA. II. A RECONSIDERATION OF THE DISTRIBUTION OF SERUM URIC ACID VALUES IN THE FAMILIES OF SMYTH, COTTERMAN, AND FREYBERG.
    American journal of human genetics, 1965, Volume: 17

    Topics: Blood; Genetics, Medical; Genetics, Population; Gout; Humans; Hyperuricemia; Metabolic Diseases; Mol

1965
TREATMENT OF CONGESTIVE HEART FAILURE WITH TRIAMTERENE.
    Canadian Medical Association journal, 1965, Feb-27, Volume: 92

    Topics: Blood; Diuresis; Diuretics; Drug Therapy; Gout; Heart Failure; Humans; Hydrochlorothiazide; Potassiu

1965
TOXICITY OF DIURETICS.
    The Practitioner, 1965, Volume: 194

    Topics: Blood; Diuretics; Gastrointestinal Diseases; Gout; Hematologic Diseases; Humans; Hyperglycemia; Hype

1965
URIC ACID IN HUMAN PLASMA. I. INVESTIGATIONS ON THE PRESENCE OF PURINES IN HUMAN BLOOD.
    Scandinavian journal of clinical and laboratory investigation, 1965, Volume: 17

    Topics: Blood; Colorimetry; Gout; Humans; Hypoxanthines; Leukemia; Liver Cirrhosis; Oxidoreductases; Purines

1965
URIC ACID IN HUMAN PLASMA. II. INVESTIGATIONS ON THE POSSIBLE PRESENCE OF URIC ACID COVALENTLY LINKED TO PLASMA MACROMOLECULES.
    Scandinavian journal of clinical and laboratory investigation, 1965, Volume: 17

    Topics: Arthritis; Arthritis, Rheumatoid; Blood; Chromatography; Chromatography, Gel; Female; Gout; Humans;

1965
URIC ACID, CALCIUM AND PHOSPHORUS CLEARANCES IN NORMAL SUBJECTS ON A LOW CALCIUM, LOW PHOSPHORUS DIET: URIC ACID, CALCIUM AND PHOSPHORUS CLEARANCES AFTER CLACIUM INFUSION IN NORMAL AND GOUTY PATIENTS.
    Metabolism: clinical and experimental, 1965, Volume: 14

    Topics: Absorption; Biological Transport; Calcium; Calcium, Dietary; Diet; Fluids and Secretions; Gout; Huma

1965
THE INFLAMMATORY PROCESS IN ACUTE GOUTY ARTHRITIS. I. ACTIVATION OF HAGEMAN FACTOR BY SODIUM URATE CRYSTALS.
    The Journal of laboratory and clinical medicine, 1965, Volume: 65

    Topics: Arthritis; Arthritis, Gouty; Blood Coagulation Factors; Factor XII; Gout; Humans; Inflammation; Phar

1965
PATHOGENIC AND THERAPEUTIC CONSIDERATIONS ON CHRONIC GOUT.
    Archives of interamerican rheumatology : A.I.R, 1964, Volume: 7

    Topics: Arthritis, Gouty; Drug Therapy; Gout; Physiology; Sulfinpyrazone; Toxicology; Uric Acid

1964
URINARY PH IN GOUT.
    Australasian annals of medicine, 1965, Volume: 14

    Topics: Ammonia; Gout; Humans; Hydrogen-Ion Concentration; Kidney Diseases; Periodicity; Phosphorus; Phospho

1965
THE EFFECTIVENESS OF THE XANTHINE OXIDASE INHIBITOR ALLOPURINOL IN THE TREATMENT OF GOUT.
    Annals of internal medicine, 1965, Volume: 62

    Topics: Allopurinol; Blood Chemical Analysis; Drug Therapy; Enzyme Inhibitors; Gout; Humans; Metabolism; Pur

1965
THE EFFECT OF PRETREATMENT WITH COLCHICINE ON THE INFLAMMATORY RESPONSE TO MICROCRYSTALLINE URATE: A MODEL FOR GOUTY INFLAMMATION.
    Annals of internal medicine, 1965, Volume: 62

    Topics: Biomedical Research; Blood Chemical Analysis; Colchicine; Dosage Forms; Drug Therapy; Gout; Humans;

1965
SERUM AND URINARY AMINO ACIDS IN NORMOURICEMIC AND HYPERURICEMIC SUBJECTS.
    Annals of internal medicine, 1965, Volume: 62

    Topics: Amino Acids; Blood; Blood Proteins; Chromatography; Gout; Humans; Kidney Function Tests; Uric Acid;

1965
THE RENAL LESION IN GOUT.
    Annals of internal medicine, 1965, Volume: 62

    Topics: Blood Chemical Analysis; Gout; Histological Techniques; Humans; Kidney; Kidney Diseases; Nephroscler

1965
EXPERIMENTAL INVESTIGATIONS INTO THE ORIGIN OF GOUTY TOPHI.
    Arthritis and rheumatism, 1965, Volume: 8

    Topics: Animals; Gout; History; Humans; Inflammation; Necrosis; Pathology; Poultry; Rabbits; Research; Uric

1965
THE INFLAMMATORY RESPONSE TO INJECTED MICROCRYSTALLINE MONOSODIUM URATE IN NORMAL, HYPERURICEMIC, GOUTY, AND UREMIC SUBJECTS.
    Arthritis and rheumatism, 1965, Volume: 8

    Topics: Blood Chemical Analysis; Blood Urea Nitrogen; Erythema; Geriatrics; Gout; Humans; Hyperuricemia; Inf

1965
SOME HAZARDS OF TOTAL FASTS IN THE CONTROL OF OBESITY AND DIABETES AND THEIR PREVENTION.
    Transactions of the American Clinical and Climatological Association, 1964, Volume: 76

    Topics: Anemia; Atrial Flutter; Blood; Diabetes Mellitus; Diet, Reducing; Fasting; Fatigue; Gout; Humans; Ne

1964
[GOUT, DIAGNOSIS AND TREATMENT].
    Belgisch tijdschrift voor geneeskunde, 1965, Jan-01, Volume: 21

    Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Colchicine; Diagnosis; Drug Therapy; Gout; Hum

1965
ASSOCIATION OF HYPERURICEMIA AND POLYCYSTIC KIDNEY DISEASE.
    Boletin de la Asociacion Medica de Puerto Rico, 1965, Volume: 57

    Topics: Genetics, Medical; Gout; Humans; Hyperuricemia; Kidney; Polycystic Kidney Diseases; Uric Acid

1965
CRYSTAL DEPOSITION DISEASES: SODIUM URATE (GOUT) AND CALCIUM PYROPHOSPHATE (CHONDROCALCINOSIS, PSEUDOGOUT).
    JAMA, 1965, Jul-12, Volume: 193

    Topics: Calcinosis; Calcium Phosphates; Calcium Pyrophosphate; Chondrocalcinosis; Crystallography; Diagnosis

1965
[ON THE PATHOGENESIS AND THERAPY OF GOUT].
    Schweizerische medizinische Wochenschrift, 1965, Jun-19, Volume: 95

    Topics: Drug Therapy; Gout; Humans; Metabolism; Uric Acid; Uricosuric Agents

1965
SYNOVIAL FLUID IN GOUT.
    British medical journal, 1965, Aug-21, Volume: 2, Issue:5459

    Topics: Blood; Cartilage; Cartilage, Articular; Diagnosis, Differential; Gout; Humans; Hyperparathyroidism;

1965
[ON URIC ACID CLEARANCE].
    Zeitschrift fur Rheumaforschung, 1964, Volume: 23

    Topics: Gout; Humans; Kidney Function Tests; Kinetics; Uric Acid

1964
URATE DIURETIC THERAPY IN CHRONIC GOUT; A COMPARATIVE STUDY OF PROBENECID AND SULFINPYRAZONE.
    Archives of internal medicine, 1965, Volume: 116

    Topics: Arthritis, Gouty; Biomedical Research; Blood; Diuretics; Drug Therapy; Gout; Humans; Kidney Calculi;

1965
THE DISTRIBUTION OF SERUM URIC ACID VALUES IN A POPULATION UNSELECTED AS TO GOUT OR HYPERURICEMIA: TECUMSEH, MICHIGAN 1959-1960.
    The American journal of medicine, 1965, Volume: 39

    Topics: Aging; Blood Chemical Analysis; Gout; Humans; Hyperuricemia; Mass Screening; Michigan; Sex; Uric Aci

1965
[HYPERURICEMIA AND GOUT WITH DIURETICS].
    Folia medica Neerlandica, 1965, Volume: 8

    Topics: Blood; Diuretics; Gout; Humans; Hyperuricemia; Toxicology; Uric Acid

1965
METHODS OF MEASURING GLOMERULAR-FILTRATION RATE: A COMPARISON OF INULIN, VITAMIN-B 12 AND CREATININE CLEARANCES.
    Lancet (London, England), 1965, Aug-07, Volume: 2, Issue:7406

    Topics: Cobalt Isotopes; Creatine; Creatinine; Diagnosis; Glomerular Filtration Rate; Gout; Humans; Hyperten

1965
GOUT IN THE ELDERLY. MODERN MANAGEMENT IN HISTORICAL PERSPECTIVE.
    Geriatrics, 1965, Volume: 20

    Topics: Aged; Colchicine; Diagnosis; Diet; Diet Therapy; Drug Therapy; Geriatrics; Gout; History; Humans; Ph

1965
[THE ROLE OF THE NORMAL KIDNEY AND THE PATHOLOGICAL KIDNEY IN THE GENESIS OF HYPERURICEMIA].
    Rein et foie, maladies de la nutrition; actualites, 1965, Volume: 7

    Topics: Blood; Diuresis; Gout; Humans; Hyperuricemia; Kidney; Kidney Diseases; Kidney Function Tests; Physio

1965
Gout.
    Journal of chronic diseases, 1955, Volume: 1, Issue:3

    Topics: Blood; Gout; Humans; Uric Acid

1955
Rate of conversion of isotopic glycine to uric acid in the normal and gouty human and how this is affected by vitamin E and folic acid.
    Metabolism: clinical and experimental, 1955, Volume: 4, Issue:2

    Topics: Folic Acid; Glycine; Gout; Humans; Uric Acid; Vitamin E

1955
Inhibition of the uricosuric action of benemid by salicylate.
    The Journal of laboratory and clinical medicine, 1955, Volume: 45, Issue:5

    Topics: Body Fluids; Gout; Probenecid; Salicylates; Uric Acid; Urine

1955
Osteogenesis imperfecta tarda with hyperuricemia and gout; report of three cases.
    The American journal of the medical sciences, 1955, Volume: 230, Issue:1

    Topics: Blood; Gout; Humans; Hyperuricemia; Osteogenesis Imperfecta; Uric Acid

1955
The fate of uric acid in the normal and gouty human being.
    Journal of chronic diseases, 1955, Volume: 2, Issue:1

    Topics: Gout; Humans; Uric Acid

1955
[The role of the kidney in hyperuricemia from the study of 390 clearances of uric acid].
    Revue du rhumatisme et des maladies osteo-articulaires, 1955, Volume: 22, Issue:4

    Topics: Blood; Gout; Humans; Hyperuricemia; Kidney; Uric Acid

1955
The renal excretion of uric acid in patients with gout and in nongouty subjects.
    The Journal of clinical investigation, 1959, Volume: 38

    Topics: Gout; Humans; Kidney Function Tests; Renal Elimination; Uric Acid

1959
The use of uricosuric agents in the management of gout.
    Medical record and annals, 1962, Volume: 55

    Topics: Disease Management; Gout; Uric Acid; Uricosuric Agents

1962
[The role of uric-elimination renal insufficiency in primary gout].
    Revue francaise d'etudes cliniques et biologiques, 1962, Volume: 7

    Topics: Gout; Humans; Hyperuricemia; Kidney; Renal Insufficiency; Uric Acid

1962
[Influence of hydrochlorothiazide on the mechanism of excretion of uric acid. Clinico-experimental observations].
    Archivio di patologia e clinica medica, 1961, Volume: 37

    Topics: Biological Transport; Body Fluids; Chlorothiazide; Gout; Humans; Hydrochlorothiazide; Leadership; Ur

1961
Uricosuric agents in the management of chronic tophaceous gout with renal impairment.
    The New Zealand medical journal, 1961, Volume: 60

    Topics: Arthritis, Gouty; Chronic Disease; Gout; Humans; Renal Insufficiency; Uric Acid; Uricosuric Agents

1961
[Gout and sweating. The effect of sweating on the metabolism of uric acid in gout patients].
    Rein et foie, maladies de la nutrition; actualites, 1960, Volume: 1, Issue:4

    Topics: Gout; Humans; Sweating; Uric Acid

1960
Renal excretion of uric acid in leukemia and gout.
    Archives of internal medicine, 1962, Volume: 109

    Topics: Aged; Gout; Humans; Leukemia; Renal Elimination; Uric Acid

1962
Gout and hyperuricaemia in rural and urban populations.
    Annals of the rheumatic diseases, 1962, Volume: 21

    Topics: Gout; Humans; Hyperuricemia; Urban Population; Uric Acid

1962
[Avoid purine-rich foods, drink a lot, reduce weight. The most important recipes against hyperuricemia].
    MMW Fortschritte der Medizin, 2003, Aug-07, Volume: 145, Issue:31-32

    Topics: Alcohol Drinking; Diet; Drinking; Exercise; Food; Gout; Humans; Hyperuricemia; Uric Acid; Weight Los

2003
New standards for uric acid excretion and evidence for an inducible transporter.
    Arthritis and rheumatism, 2003, Oct-15, Volume: 49, Issue:5

    Topics: Carrier Proteins; Gout; Humans; Hyperuricemia; Male; Reference Values; Uric Acid

2003
[Urate transporter and renal hypouricemia].
    Rinsho byori. The Japanese journal of clinical pathology, 2003, Volume: 51, Issue:9

    Topics: Carrier Proteins; Gout; Humans; Kidney; Kidney Diseases; Mutation; Organic Anion Transporters; Organ

2003
The effect of control and self-medication of chronic gout in a developing country. Outcome after 10 years.
    The Journal of rheumatology, 2003, Volume: 30, Issue:11

    Topics: Adult; Chronic Disease; Developing Countries; Gout; Humans; Indonesia; Joints; Malaysia; Male; Polyn

2003
The compliance-questionnaire-rheumatology compared with electronic medication event monitoring: a validation study.
    The Journal of rheumatology, 2003, Volume: 30, Issue:11

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Colchici

2003
Questions & answers. What's the difference between gout and pseudogout?
    Health news (Waltham, Mass.), 2003, Volume: 9, Issue:12

    Topics: Age Factors; Calcium Pyrophosphate; Chondrocalcinosis; Crystallization; Diagnosis, Differential; Fem

2003
Substance P immunoreactive nerve fibres in the domestic chick ankle joint before and after acute urate arthritis.
    Neuroscience letters, 2004, Jan-09, Volume: 354, Issue:2

    Topics: Animals; Arthralgia; Arthritis; Chickens; Disease Models, Animal; Down-Regulation; Female; Gout; Imm

2004
Association of biochemical values with morbidity in the elderly: a population-based Swedish study of persons aged 82 or more years.
    Scandinavian journal of clinical and laboratory investigation, 2003, Volume: 63, Issue:7-8

    Topics: Aged; Aged, 80 and over; Biomarkers; Blood Chemical Analysis; Body Mass Index; Cholesterol; Creatine

2003
Diclofenac residues as the cause of vulture population decline in Pakistan.
    Nature, 2004, Feb-12, Volume: 427, Issue:6975

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Autopsy; Bird Diseases; Cause of Death; Conservati

2004
Gout.
    The New England journal of medicine, 2004, Jan-29, Volume: 350, Issue:5

    Topics: Coronary Disease; Fenofibrate; Gout; Humans; Hypolipidemic Agents; Metabolic Syndrome; Risk Factors;

2004
Impressions of gout.
    Journal - Michigan State Medical Society, 1950, Volume: 49, Issue:11

    Topics: Gout; Humans; Purines; Social Behavior; Uric Acid

1950
URIC acid metabolism and gout.
    The American journal of medicine, 1950, Volume: 9, Issue:6

    Topics: Aged; Gout; Humans; Uric Acid

1950
Some recent advances in the study of uric acid metabolism and gout.
    Bulletin of the New York Academy of Medicine, 1951, Volume: 27, Issue:3

    Topics: Gout; Humans; Uric Acid

1951
Some observations on the blood uric acid levels in gout.
    Proceedings of the Royal Society of Medicine, 1951, Volume: 44, Issue:4

    Topics: Blood; Gout; Humans; Uric Acid

1951
A study of labeled uric acid in gouty and non-gouty subjects.
    Transactions of the Association of American Physicians, 1950, Volume: 63

    Topics: Gout; Humans; Uric Acid

1950
The effect of benemid (P-[DI-N-propylsulfamyl]-benzoic acid) on uric acid metabolism in one normal and one gouty subject.
    The Journal of clinical investigation, 1951, Volume: 30, Issue:8

    Topics: Benzoic Acid; Gout; Humans; Probenecid; Uric Acid

1951
Ultrafiltration of plasma uric acid.
    Journal of clinical pathology, 1951, Volume: 4, Issue:3

    Topics: Gout; Humans; Plasma; Ultrafiltration; Uric Acid

1951
Gout; observations on the effects of drugs on plasma uric acid and urinary uric acid.
    Annals of the rheumatic diseases, 1951, Volume: 10, Issue:3

    Topics: Gout; Humans; Uric Acid

1951
Benemid (p-di-n-propylsulfamyl)-benzoic acid) as uricosuric agent in chronic gouty arthritis.
    Transactions of the Association of American Physicians, 1951, Volume: 64

    Topics: Arthritis, Gouty; Benzoic Acid; Body Fluids; Chronic Disease; Gout; Probenecid; Uric Acid; Uricosuri

1951
The clinical and metabolic effects of benemid in patients with gout.
    Transactions of the Association of American Physicians, 1951, Volume: 64

    Topics: Body Fluids; Gout; Probenecid; Uric Acid

1951
Incorporation of glycine nitrogen into uric acid in normal and gouty man.
    Metabolism: clinical and experimental, 1952, Volume: 1, Issue:1

    Topics: Glycine; Gout; Humans; Male; Nitrogen; Uric Acid

1952
Experimental observations in acute and chronic gout.
    The Proceedings of the Institute of Medicine of Chicago, 1951, Nov-15, Volume: 18, Issue:17

    Topics: Arthritis, Gouty; Chronic Disease; Gout; Humans; Uric Acid

1951
[Gout-hyperuricacidemia; their therapy].
    Minerva medica, 1952, Feb-16, Volume: 43, Issue:14

    Topics: Aged; Gout; Humans; Piperazines; Uric Acid

1952
Effect of benemid (p-[di-n-propylsulfamyl]-benzoic acid) on urate clearance and other discrete renal functions in gouty subjects.
    The Journal of clinical investigation, 1952, Volume: 31, Issue:7

    Topics: Benzoic Acid; Gout; Humans; Kinetics; Probenecid; Uric Acid

1952
Uric acid and diet--insights into the epidemic of cardiovascular disease.
    The New England journal of medicine, 2004, Mar-11, Volume: 350, Issue:11

    Topics: Dairy Products; Diet; Dietary Proteins; Female; Gout; History, 17th Century; History, 18th Century;

2004
Synovial fluid from an African spur-thighed tortoise (Geochelone sulcata).
    Veterinary clinical pathology, 2004, Volume: 33, Issue:1

    Topics: Animals; Crystallization; Fatal Outcome; Gout; Kidney; Liver; Male; Synovial Fluid; Turtles; Uric Ac

2004
Drinking alcohol and gout.
    Lancet (London, England), 2004, Apr-17, Volume: 363, Issue:9417

    Topics: Alcohol Drinking; Alcoholic Beverages; Gout; Humans; Risk Factors; Uric Acid

2004
On call. I was recently diagnosed with gout. I'm feeling well with medication, but my doctor want me to take drugs for my cholesterol and blood pressure because gout will raise my risk of heart attack. I don't want to take more pills. What do you think?
    Harvard men's health watch, 2004, Volume: 8, Issue:10

    Topics: Anticholesteremic Agents; Antihypertensive Agents; Attitude to Health; Gout; Humans; Uric Acid

2004
Purine-rich foods and the risk of gout in men.
    The New England journal of medicine, 2004, Jun-10, Volume: 350, Issue:24

    Topics: Diet; Follow-Up Studies; Gout; Humans; Male; Sensitivity and Specificity; Synovial Fluid; Uric Acid

2004
Gout. Soothing a red-hot joint.
    Mayo Clinic women's healthsource, 2004, Volume: 8, Issue:7

    Topics: Benzothiadiazines; Diuretics; Female; Gout; Humans; Sodium Chloride Symporter Inhibitors; Uric Acid

2004
[Insulin resistance syndrome in patients with gout and its influence on formation of clinical characteristics of the disease].
    Terapevticheskii arkhiv, 2004, Volume: 76, Issue:5

    Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Gout; Humans;

2004
A (very) short history of diets for gout.
    Rheumatology (Oxford, England), 2004, Volume: 43, Issue:8

    Topics: Gout; History, 20th Century; History, Ancient; History, Medieval; Hordeum; Humans; Social Class; Uri

2004
Gout and alcohol.
    Rheumatology (Oxford, England), 2004, Volume: 43, Issue:10

    Topics: Alcohol Drinking; Diet; Female; Gout; Humans; Risk Factors; Uric Acid

2004
[Detection of sodium monourate crystals in biopsies of gastric mucosa in patients with gout].
    Terapevticheskii arkhiv, 2004, Volume: 76, Issue:6

    Topics: Adult; Aged; Biopsy; Endoscopy, Digestive System; Gastric Mucosa; Gout; Humans; Microscopy, Polariza

2004
Central role of complement membrane attack complex in monosodium urate crystal-induced neutrophilic rabbit knee synovitis.
    Arthritis and rheumatism, 2004, Volume: 50, Issue:8

    Topics: Animals; Complement C6; Complement Membrane Attack Complex; Crystallization; Gout; Interleukin-8; Kn

2004
[Diagnosis at a glance: painful awakening].
    MMW Fortschritte der Medizin, 2004, Apr-08, Volume: 146, Issue:15

    Topics: Alcohol Drinking; Arthralgia; Gout; Humans; Male; Metabolic Clearance Rate; Middle Aged; Toe Joint;

2004
The metabolism of uric acid in the normal and gouty human studied with the aid of isotopic uric acid.
    The Journal of biological chemistry, 1949, Volume: 181, Issue:1

    Topics: Gout; Research; Uric Acid

1949
Increased renal excretion of urate in young patients with gout.
    The American journal of medicine, 1950, Volume: 9, Issue:1

    Topics: Gout; Humans; Kidney; Renal Elimination; Urea; Uric Acid

1950
The rôle of glutamine in metabolism, with special regard to the formation of uric acid in gout.
    Acta medica Scandinavica, 1950, Volume: 138, Issue:2

    Topics: Blood; Glutamine; Gout; Humans; Uric Acid

1950
The effect of salicylates and adrenocorticotropic hormone upon the miscible pool of uric acid in gout.
    The Journal of clinical investigation, 1950, Volume: 29, Issue:8

    Topics: Adrenocorticotropic Hormone; Body Fluids; Gout; Humans; Salicylates; Uric Acid; Urine

1950
Ecology. Circling in on a vulture killer.
    Science (New York, N.Y.), 2004, Oct-08, Volume: 306, Issue:5694

    Topics: Animals; Animals, Domestic; Anti-Inflammatory Agents, Non-Steroidal; Bird Diseases; Conservation of

2004
[Uric acid, a neglected molecule--the value of imaging].
    Therapeutische Umschau. Revue therapeutique, 2004, Volume: 61, Issue:9

    Topics: Arthritis, Gouty; Diagnosis, Differential; Diagnostic Imaging; Gout; Humans; Hyperuricemia; Joints;

2004
[Gout and its differential diagnosis].
    Therapeutische Umschau. Revue therapeutique, 2004, Volume: 61, Issue:9

    Topics: Arthritis, Gouty; Crystallization; Diagnosis, Differential; Gout; Humans; Joints; Microscopy, Polari

2004
[Rasburicase (Fasturtec)].
    Therapeutische Umschau. Revue therapeutique, 2004, Volume: 61, Issue:9

    Topics: Crystallization; Glomerular Filtration Rate; Gout; Humans; Hyperuricemia; Kidney Failure, Chronic; K

2004
Peripheral involvement of the nitric oxide-cGMP pathway in the indomethacin-induced antinociception in rat.
    European journal of pharmacology, 2004, Oct-25, Volume: 503, Issue:1-3

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arginine; Chronic Disease; Cyclic GMP; Disease Mod

2004
The efficacy of combined low dose of Allopurinol and benzbromarone compared to standard dose of Allopurinol in hyperuricemia.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2004, Volume: 87, Issue:9

    Topics: Allopurinol; Benzbromarone; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug The

2004
[Diagnosis at a glance? Nodule of the ear].
    MMW Fortschritte der Medizin, 2004, Oct-14, Volume: 146, Issue:42

    Topics: Ear Diseases; Ear, External; Gout; Humans; Male; Middle Aged; Uric Acid

2004
Chyle and gout causing acute monoarthritis: some unusual findings.
    Clinical rheumatology, 2005, Volume: 24, Issue:1

    Topics: Acute Disease; Aged; Anti-Inflammatory Agents; Arthritis; Chyle; Diagnosis, Differential; Exudates a

2005
Determination of uric acid in human saliva by capillary electrophoresis with electrochemical detection: potential application in fast diagnosis of gout.
    Analytical and bioanalytical chemistry, 2004, Volume: 380, Issue:7-8

    Topics: Electrochemistry; Electrodes; Electrophoresis, Capillary; Gout; Humans; Hydrogen-Ion Concentration;

2004
My big toe has been extremely painful for some time. I thought it was a bunion, but I've been told I have gout. I thought gout was something only overweight men developed. What is it?
    Health news (Waltham, Mass.), 2005, Volume: 11, Issue:2

    Topics: Allopurinol; Drinking; Gout; Gout Suppressants; Humans; Male; Purines; Toes; Uric Acid

2005
[Xanthine oxidase inhibitory activity and hypouricemia effect of propolis in rats].
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2005, Volume: 125, Issue:3

    Topics: Animals; Anti-Infective Agents; Brazil; Caffeic Acids; China; Coumaric Acids; Disease Models, Animal

2005
Analysis for crystals in synovial fluid: training of the analysts results in high consistency.
    Annals of the rheumatic diseases, 2005, Volume: 64, Issue:4

    Topics: Arthritis; Biomarkers; Calcium Pyrophosphate; Chondrocalcinosis; Clinical Competence; Crystallizatio

2005
Intra-abdominal gout mimicking pelvic abscess.
    Skeletal radiology, 2005, Volume: 34, Issue:4

    Topics: Abdomen; Abdominal Pain; Abscess; Adult; Alcoholism; Biopsy, Needle; Contrast Media; Diagnosis, Diff

2005
TLR2 signaling in chondrocytes drives calcium pyrophosphate dihydrate and monosodium urate crystal-induced nitric oxide generation.
    Journal of immunology (Baltimore, Md. : 1950), 2005, Apr-15, Volume: 174, Issue:8

    Topics: Adaptor Proteins, Signal Transducing; Animals; Antigens, Differentiation; Base Sequence; Calcium Pyr

2005
Physicochemical metabolic characteristics for calcium oxalate stone formation in patients with gouty diathesis.
    The Journal of urology, 2005, Volume: 173, Issue:5

    Topics: Adult; Aged; Calcium Oxalate; Chemical Phenomena; Chemistry, Physical; Disease Susceptibility; Femal

2005
Inflammation and tissue damage in crystal deposition diseases.
    Current opinion in rheumatology, 2005, Volume: 17, Issue:3

    Topics: Calcium Phosphates; Calcium Pyrophosphate; Chondrocalcinosis; Disease Progression; Gout; Humans; Inf

2005
Cervical spine and crystal-associated diseases: imaging findings.
    European radiology, 2006, Volume: 16, Issue:2

    Topics: Adult; Calcinosis; Calcium Pyrophosphate; Cartilage, Articular; Cervical Vertebrae; Child; Chondroca

2006
Gout induced by intoxication of sodium bicarbonate in Korean native broilers.
    Drug and chemical toxicology, 2005, Volume: 28, Issue:2

    Topics: Animals; Chickens; Gout; Korea; Poultry Diseases; Sodium Bicarbonate; Uric Acid; Viscera

2005
Unusual imaging manifestations of intraosseous tophaceous gout of the patella.
    The Journal of rheumatology, 2005, Volume: 32, Issue:5

    Topics: Gout; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Patella; Uric Acid

2005
Spontaneous rupture of extensor pollicis longus tendon with tophaceous gout infiltration.
    Archives of orthopaedic and trauma surgery, 2005, Volume: 125, Issue:4

    Topics: Aged; Crystallization; Gout; Humans; Male; Rupture, Spontaneous; Tendon Injuries; Tendons; Uric Acid

2005
Ethnic background has minimal impact on the etiology of nephrolithiasis.
    The Journal of urology, 2005, Volume: 173, Issue:6

    Topics: Adult; Aged; Calcium; Citric Acid; Cross-Sectional Studies; Ethnicity; Female; Gout; Humans; Hyperox

2005
Confounders of uric acid levels.
    Archives of internal medicine, 2005, May-09, Volume: 165, Issue:9

    Topics: Alcohol Drinking; Cardiovascular Diseases; Gout; Humans; Male; Middle Aged; Uric Acid

2005
Optimal management of chronic gout: attempting to render the (t)issues crystal-clear.
    The New Zealand medical journal, 2005, Jun-24, Volume: 118, Issue:1217

    Topics: Allopurinol; Anti-Inflammatory Agents; Benzbromarone; Chronic Disease; Colchicine; Drug Hypersensiti

2005
A common mutation in an organic anion transporter gene, SLC22A12, is a suppressing factor for the development of gout.
    Arthritis and rheumatism, 2005, Volume: 52, Issue:8

    Topics: Adenine; Adult; Carrier Proteins; Case-Control Studies; Female; Gene Frequency; Genotype; Gout; Guan

2005
[Hyperuricemia and disorders in content of amino acids-purine precursors in patients with autoimmune diseases and gout].
    Likars'ka sprava, 2005, Issue:4

    Topics: Amino Acids; Autoimmune Diseases; Gout; Humans; Hyperuricemia; Lipid Peroxides; Purines; Uric Acid;

2005
I have gout, and my doctor told me not to take aspirin. Why?
    Health news (Waltham, Mass.), 2005, Volume: 11, Issue:9

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Contraindications; Gout; Humans; Kidney; Uric Acid

2005
Superficial collections of fluid tophaceous material as clinical presentation of anorexia nervosa.
    Annals of the rheumatic diseases, 2005, Volume: 64, Issue:11

    Topics: Adult; Anorexia Nervosa; Chronic Disease; Female; Gout; Hand Dermatoses; Humans; Uric Acid

2005
Effects of long-term beer ingestion on plasma concentrations and urinary excretion of purine bases.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2005, Volume: 37, Issue:10

    Topics: Adult; Alcohol Drinking; Beer; Ethanol; Gout; Humans; Hypoxanthine; Kidney Concentrating Ability; Ma

2005
Tophaceous gout: quantitative evaluation by direct physical measurement.
    The Journal of rheumatology, 2005, Volume: 32, Issue:12

    Topics: Crystallization; Disease Progression; Extremities; Female; Gout; Humans; Joints; Male; Middle Aged;

2005
Acute gouty inflammation of a cystic tophaceous lesion of a leg muscle associated with "urate milk".
    The Journal of rheumatology, 2005, Volume: 32, Issue:12

    Topics: Acute Disease; Adult; Crystallization; Cysts; Gout; Humans; Leg; Magnetic Resonance Imaging; Male; M

2005
Febuxostat--treatment for hyperuricemia and gout?
    The New England journal of medicine, 2005, Dec-08, Volume: 353, Issue:23

    Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Probenecid; Thiazoles; Uric

2005
Knee locking due to a single gouty tophus.
    The Journal of rheumatology, 2006, Volume: 33, Issue:1

    Topics: Gout; Granuloma, Foreign-Body; Humans; Joint Dislocations; Knee Joint; Male; Menisci, Tibial; Middle

2006
Gout-associated uric acid crystals activate the NALP3 inflammasome.
    Nature, 2006, Mar-09, Volume: 440, Issue:7081

    Topics: Animals; Calcium Pyrophosphate; Carrier Proteins; Caspase 1; Cell Line; Cells, Cultured; Chondrocalc

2006
New drugs for crystal deposition diseases.
    Current opinion in rheumatology, 2006, Volume: 18, Issue:2

    Topics: Calcinosis; Calcium Compounds; Citrates; Gout; Gout Suppressants; Humans; Joints; Osteoarthritis; Ur

2006
[Gout as an unusual cause of pelvic pain].
    Nederlands tijdschrift voor geneeskunde, 2006, Jan-21, Volume: 150, Issue:3

    Topics: Aged, 80 and over; Allopurinol; Colchicine; Crystallization; Drug Therapy, Combination; Female; Gout

2006
Clinical image: corneal tophus deposition in gout.
    Arthritis and rheumatism, 2006, Volume: 54, Issue:3

    Topics: Cornea; Crystallization; Gout; Humans; Male; Middle Aged; Uric Acid

2006
Urate deposition in the iris and anterior chamber.
    Ophthalmology, 2006, Volume: 113, Issue:3

    Topics: Aged; Anterior Chamber; Crystallization; Female; Gonioscopy; Gout; Humans; Iris; Microscopy, Electro

2006
[Diagnosis at a glance. This hand speaks volumes].
    MMW Fortschritte der Medizin, 2006, Feb-02, Volume: 148, Issue:5

    Topics: Arthritis, Gouty; Crystallization; Finger Joint; Gout; Hand Deformities, Acquired; Humans; Male; Per

2006
Serum-synovial gradient data of normouricemic patients with history of gout and acute knee effusion.
    Clinical rheumatology, 2006, Volume: 25, Issue:6

    Topics: Acute Disease; Aged; Crystallization; Gout; Humans; Hydrarthrosis; Knee Joint; Leukocytes; Male; Med

2006
I've had a couple of painful gout attacks. My doctor says they're related to high levels of uric acid in my blood. My doctor also says that increased uric acid might mean a higher risk of heart problems. Are uric acid levels usually checked?
    Mayo Clinic health letter (English ed.), 2006, Volume: 24, Issue:3

    Topics: Biomarkers; Gout; Heart Diseases; Humans; Risk; Uric Acid

2006
[Hyperuricemia and gout: diagnosis and therapy].
    Der Internist, 2006, Volume: 47, Issue:5

    Topics: Allopurinol; Anti-Inflammatory Agents; Colchicine; Diagnosis, Differential; Gout; Gout Suppressants;

2006
Serum urate levels and gout flares: analysis from managed care data.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2006, Volume: 12, Issue:2

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Allopurinol; Cohort Studies; Databases as T

2006
FNAC of gouty tophi--a case report.
    Indian journal of pathology & microbiology, 2006, Volume: 49, Issue:1

    Topics: Biopsy, Fine-Needle; Crystallization; Extremities; Giant Cells, Foreign-Body; Gout; Histocytochemist

2006
Sex differences in gout epidemiology: evaluation and treatment.
    Annals of the rheumatic diseases, 2006, Volume: 65, Issue:10

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Diuretics; Drug Monitoring; Drug Utilization; Epidemiol

2006
Gout--new insights into a forgotten disease.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2006, Volume: 38, Issue:3

    Topics: Carrier Proteins; Gout; Humans; Organic Anion Transporters; Organic Cation Transport Proteins; Uric

2006
[Badly managed gout for decades. Only then do the hands look this way].
    MMW Fortschritte der Medizin, 2006, May-04, Volume: 148, Issue:18

    Topics: Aged, 80 and over; Colchicine; Creatinine; Gout; Hand Deformities, Acquired; Humans; Male; Treatment

2006
Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout.
    The Journal of rheumatology, 2006, Volume: 33, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Creatinine; Dose-Response Relationship, Drug; Drug Moni

2006
Gout's not just for the gluttonous.
    The Johns Hopkins medical letter health after 50, 2006, Volume: 18, Issue:4

    Topics: Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Risk Factors; Sex Factors; S

2006
The prevalence of hyperuricemia in a population of the coastal city of Qingdao, China.
    The Journal of rheumatology, 2006, Volume: 33, Issue:7

    Topics: Adult; Aged; Alcohol Drinking; China; Cross-Sectional Studies; Female; Gout; Humans; Hypercholestero

2006
The severe gout of Holy Roman Emperor Charles V.
    The New England journal of medicine, 2006, Aug-03, Volume: 355, Issue:5

    Topics: Famous Persons; Finger Phalanges; Gout; Government; History, 16th Century; Humans; Male; Spain; Uric

2006
MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals.
    The Journal of clinical investigation, 2006, Volume: 116, Issue:8

    Topics: Adaptor Proteins, Signal Transducing; Animals; Gout; Inflammation; Mice; Mice, Inbred C57BL; Mice, K

2006
Effect of fenofibrate in combination with urate lowering agents in patients with gout.
    The Korean journal of internal medicine, 2006, Volume: 21, Issue:2

    Topics: Adult; Aged; Fenofibrate; Gout; Humans; Lipids; Male; Middle Aged; Uric Acid; Uricosuric Agents

2006
Fine needle aspiration of tophi in asymptomatic gout--a case report.
    Indian journal of pathology & microbiology, 2006, Volume: 49, Issue:2

    Topics: Ankle; Biopsy, Fine-Needle; Birefringence; Crystallization; Gout; Humans; Male; Middle Aged; Uric Ac

2006
Hyperuricemia and gout following pediatric renal transplantation.
    Pediatric nephrology (Berlin, Germany), 2006, Volume: 21, Issue:12

    Topics: Adolescent; Adult; Child; Child, Preschool; Female; Gout; Humans; Hyperuricemia; Immunosuppressive A

2006
Antihyperuricemic lignans from the leaves of Phyllanthus niruri.
    Planta medica, 2006, Volume: 72, Issue:14

    Topics: Animals; Dose-Response Relationship, Drug; Gout; Lignans; Male; Phyllanthus; Phytotherapy; Plant Ext

2006
Febuxostat for prevention of gout attacks.
    Issues in emerging health technologies, 2006, Issue:87

    Topics: Allopurinol; Canada; Clinical Trials, Phase III as Topic; Gout; Gout Suppressants; Humans; Hyperuric

2006
Transglutaminase 2 limits murine peritoneal acute gout-like inflammation by regulating macrophage clearance of apoptotic neutrophils.
    Arthritis and rheumatism, 2006, Volume: 54, Issue:10

    Topics: Animals; Apoptosis; Cells, Cultured; Female; Gene Expression Regulation; Gout; GTP-Binding Proteins;

2006
The management of gout: it should be crystal clear.
    The Journal of rheumatology, 2006, Volume: 33, Issue:10

    Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anti-Inflammatory Agents, Non-Steroidal; China

2006
The management of gout at an academic healthcare center in Beijing: a physician survey.
    The Journal of rheumatology, 2006, Volume: 33, Issue:10

    Topics: Academic Medical Centers; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Adult; China; Colchi

2006
A survey of current evaluation and treatment of gout.
    The Journal of rheumatology, 2006, Volume: 33, Issue:10

    Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anti-Inflammatory Agents, Non-Steroidal; Colch

2006
Excellent response to the clinical treatment of tophaceous gout.
    Clinical rheumatology, 2007, Volume: 26, Issue:9

    Topics: Aged; Allopurinol; Benzbromarone; Glomerular Filtration Rate; Gout; Gout Suppressants; Humans; Kidne

2007
Engagement of CD14 mediates the inflammatory potential of monosodium urate crystals.
    Journal of immunology (Baltimore, Md. : 1950), 2006, Nov-01, Volume: 177, Issue:9

    Topics: Animals; Caspase 1; Chemokines, CXC; CHO Cells; Cricetinae; Crystallization; Enzyme Activation; Gout

2006
Case 5: treatment options for acute gout.
    The American journal of medicine, 2006, Volume: 119, Issue:11 Suppl 1

    Topics: Acute Disease; Anti-Inflammatory Agents; Gout; Humans; Male; Middle Aged; Patient Compliance; Recurr

2006
Gout: finally, diagnosis and treatment guidelines. A European task force offers the first recommendations on dealing with this painful arthritic condition.
    Health news (Waltham, Mass.), 2006, Volume: 12, Issue:10

    Topics: Biomarkers; Colchicine; Gout; Gout Suppressants; Humans; Uric Acid

2006
Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout.
    Annals of the rheumatic diseases, 2007, Volume: 66, Issue:8

    Topics: Adult; Aged; Benzbromarone; Chronic Disease; Crystallization; Follow-Up Studies; Gout; Gout Suppress

2007
Does the presence of crystal arthritis rule out septic arthritis?
    The Journal of emergency medicine, 2007, Volume: 32, Issue:1

    Topics: Age Distribution; Aged; Arthritis, Infectious; Calcium Pyrophosphate; Chondrocalcinosis; Comorbidity

2007
[Gout and diuretics; still an issue].
    Nederlands tijdschrift voor geneeskunde, 2007, Feb-24, Volume: 151, Issue:8

    Topics: Cardiovascular Diseases; Case-Control Studies; Diuretics; Gout; Humans; Hypertension; Incidence; Uri

2007
[An unusual manifestation of osteo-articular, tendinous and nervous involvement secondary to tophaceous gout of the hand. A report of two cases].
    Chirurgie de la main, 2007, Volume: 26, Issue:1

    Topics: Carpal Tunnel Syndrome; Contracture; Crystallization; Cubital Tunnel Syndrome; Electromyography; Fin

2007
Diagnosis of gout by ultrasound.
    Rheumatology (Oxford, England), 2007, Volume: 46, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Cartilage, Articular; Crystallization; Female; Gout; Humans; Joints;

2007
Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations.
    Annals of the rheumatic diseases, 2007, Volume: 66, Issue:10

    Topics: Adult; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Colchicine; Diuretics;

2007
Quality of care for gout in the US needs improvement.
    Arthritis and rheumatism, 2007, Jun-15, Volume: 57, Issue:5

    Topics: Aged; Allopurinol; Blood Cell Count; Colchicine; Comorbidity; Creatine Kinase; Evidence-Based Medici

2007
Crystal-induced neutrophil activation. IX. Syk-dependent activation of class Ia phosphatidylinositol 3-kinase.
    Journal of leukocyte biology, 2007, Volume: 82, Issue:3

    Topics: Adult; Blotting, Western; Cells, Cultured; Crystallization; Gout; Humans; Immunoprecipitation; Intra

2007
Gout.
    Orthopedics, 2007, Volume: 30, Issue:5

    Topics: Bone and Bones; Gout; Humans; Male; Middle Aged; Radiography; Thumb; Uric Acid

2007
New treatments for gout.
    Joint bone spine, 2007, Volume: 74, Issue:4

    Topics: Allopurinol; Ascorbic Acid; Female; Fenofibrate; Gout; Gout Suppressants; Humans; Losartan; Male; Se

2007
Gouty panniculitis in a healthy male.
    Journal of the American Academy of Dermatology, 2007, Volume: 57, Issue:2 Suppl

    Topics: Adipose Tissue; Adult; Gout; Humans; Male; Panniculitis; Uric Acid

2007
Ultrasonographic measurement of tophi as an outcome measure for chronic gout.
    The Journal of rheumatology, 2007, Volume: 34, Issue:9

    Topics: Biopsy, Fine-Needle; Crystallization; Gout; Gout Suppressants; Humans; Joints; Sensitivity and Speci

2007
Homozygous frameshift mutation in the SLC22A12 gene in a patient with primary gout and high levels of serum uric acid.
    Journal of clinical pathology, 2007, Volume: 60, Issue:8

    Topics: Adult; Arthritis, Gouty; Frameshift Mutation; Gout; Homozygote; Humans; Hyperuricemia; Male; Mutagen

2007
Clinical image: Dual-energy computed tomographic molecular imaging of gout.
    Arthritis and rheumatism, 2007, Volume: 56, Issue:8

    Topics: Colchicine; Contrast Media; Gout; Gout Suppressants; Humans; Iodine Compounds; Male; Middle Aged; To

2007
Podagra, uric acid, and cardiovascular disease.
    Circulation, 2007, Aug-21, Volume: 116, Issue:8

    Topics: Cardiovascular Diseases; Gout; Humans; Prevalence; Uric Acid

2007
[European League Against Rheumatism evidence-based recommendations for diagnosis and management of gout].
    Zeitschrift fur Rheumatologie, 2007, Volume: 66, Issue:7

    Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Delphi Technique

2007
Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study.
    The Journal of rheumatology, 2007, Volume: 34, Issue:10

    Topics: Aged; Aged, 80 and over; Allopurinol; Contraindications; Female; Gout; Gout Suppressants; Humans; Ma

2007
Urate deposits.
    Ophthalmology, 2007, Volume: 114, Issue:10

    Topics: Anterior Chamber; Crystallization; Gonioscopy; Gout; Humans; Iris; Microscopy, Electron; Suction; Ur

2007
Information from your family doctor. Gout: what you should know.
    American family physician, 2007, Sep-15, Volume: 76, Issue:6

    Topics: Adult; Age Factors; Diagnosis, Differential; Diet; Exercise; Female; Gout; Gout Suppressants; Humans

2007
Carpal bone involvement in gout.
    Archives of orthopaedic and trauma surgery, 2007, Volume: 127, Issue:10

    Topics: Adult; Anti-Inflammatory Agents; Arthralgia; Carpal Bones; Gout; Humans; Male; Metatarsal Bones; Phy

2007
Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005.
    Annals of the rheumatic diseases, 2008, Volume: 67, Issue:7

    Topics: Aged; Allopurinol; Drug Administration Schedule; Drug Monitoring; Epidemiologic Methods; Family Prac

2008
Clinical features and risk factors of postsurgical gout.
    Annals of the rheumatic diseases, 2008, Volume: 67, Issue:9

    Topics: Aged; Case-Control Studies; Colchicine; Female; Gout; Gout Suppressants; Humans; Lower Extremity; Ma

2008
The genetics of gout and hyperuricaemia; an analysis of 19 families.
    The Journal of clinical investigation, 1948, Volume: 27, Issue:6

    Topics: Blood; Gout; Humans; Hyperuricemia; Uric Acid

1948
The transport and excretion of uric acid in man; a sex difference in urate metabolism; with a note on clinical and laboratory findings in gouty women.
    The Journal of clinical endocrinology and metabolism, 1949, Volume: 9, Issue:8

    Topics: Biological Transport; Body Fluids; Female; Gout; Humans; Male; Sex Characteristics; Uric Acid

1949
Tophaceous gout in a patient with rheumatoid arthritis.
    The Journal of the American Osteopathic Association, 2007, Volume: 107, Issue:12

    Topics: Anemia; Arthritis, Rheumatoid; Bone Diseases, Metabolic; Creatinine; Female; Fingers; Foot; Gout; Hu

2007
Gout: joint pain and more.
    Harvard men's health watch, 2007, Volume: 12, Issue:5

    Topics: Acute Disease; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Gout; Gout Suppressa

2007
Urate crystals, inflammation, and colchicine.
    Arthritis and rheumatism, 2008, Volume: 58, Issue:2 Suppl

    Topics: Animals; Arthritis, Gouty; Colchicine; Disease Models, Animal; Gout; Gout Suppressants; History, 20t

2008
Polymorphonuclear leukocyte motility in vitro: IV. Colchicine inhibition of chemotactic activity formation after phagocytosis of urate crystals.
    Arthritis and rheumatism, 2008, Volume: 58, Issue:2 Suppl

    Topics: Cell Movement; Cells, Cultured; Colchicine; Gout; Gout Suppressants; History, 20th Century; Humans;

2008
Advanced gout.
    QJM : monthly journal of the Association of Physicians, 2008, Volume: 101, Issue:5

    Topics: Aged, 80 and over; Diagnosis, Differential; Female; Gout; Humans; Uric Acid

2008
Management of recurrent gout: Professional guidelines differ.
    BMJ (Clinical research ed.), 2008, Mar-01, Volume: 336, Issue:7642

    Topics: Gout; Humans; Practice Guidelines as Topic; Recurrence; Uric Acid

2008
Widespread arterial calcification in a patient with gout.
    Internal medicine (Tokyo, Japan), 2008, Volume: 47, Issue:5

    Topics: Adult; Anti-Inflammatory Agents; Arteries; Calcinosis; Gout; Humans; Male; Methylprednisolone; Pelvi

2008
SLC2A9 influences uric acid concentrations with pronounced sex-specific effects.
    Nature genetics, 2008, Volume: 40, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Austria; Biomarkers; Case-Control Studies; Computational Biology; Fe

2008
SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout.
    Nature genetics, 2008, Volume: 40, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Biological Transport, Active; Biomarkers; Case-

2008
Disease-related and all-cause health care costs of elderly patients with gout.
    Journal of managed care pharmacy : JMCP, 2008, Volume: 14, Issue:2

    Topics: Adolescent; Aged; Biomarkers; Female; Gout; Gout Suppressants; Health Expenditures; Health Services;

2008
Uric acid: neuroprotective or neurotoxic?
    Stroke, 2008, Volume: 39, Issue:5

    Topics: Animals; Antioxidants; Brain Ischemia; Gout; Humans; Hyperuricemia; Lesch-Nyhan Syndrome; Neuroprote

2008
Haemoglobin A1c, fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels--the Third National Health and Nutrition Examination Survey.
    Rheumatology (Oxford, England), 2008, Volume: 47, Issue:5

    Topics: Adult; Biomarkers; Blood Glucose; C-Peptide; Diet; Fasting; Female; Glycated Hemoglobin; Gout; Healt

2008
Association of common polymorphisms in GLUT9 gene with gout but not with coronary artery disease in a large case-control study.
    PloS one, 2008, Apr-09, Volume: 3, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Coronary Artery Disease; Female; Genetic Predi

2008
Gout.
    Ear, nose, & throat journal, 2008, Volume: 87, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Gout; Humans; Uric Acid

2008
Vitamin C intake and serum uric acid concentration in men.
    The Journal of rheumatology, 2008, Volume: 35, Issue:9

    Topics: Adult; Aged; Antioxidants; Ascorbic Acid; Diet Surveys; Feeding Behavior; Gout; Humans; Hyperuricemi

2008
Asymptomatic hyperuricemia: perhaps not so benign?
    The Journal of rheumatology, 2008, Volume: 35, Issue:5

    Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Kidney Diseases; Risk Factors; Uric Acid

2008
Impact of childhood metabolic syndrome components on the risk of elevated uric acid in adulthood: the Bogalusa Heart Study.
    The American journal of the medical sciences, 2008, Volume: 335, Issue:5

    Topics: Adolescent; Child; Child, Preschool; Cholesterol, HDL; Cross-Sectional Studies; Female; Gout; Humans

2008
[Uric acid metabolism anomaly and its laboratory method--significance and limit of uric acid clearance].
    Rinsho byori. The Japanese journal of clinical pathology, 1966, Volume: 14, Issue:11

    Topics: Glomerular Filtration Rate; Gout; Humans; Uric Acid

1966
[On gout].
    Munchener medizinische Wochenschrift (1950), 1966, Jan-14, Volume: 108, Issue:2

    Topics: Adult; Ankle Joint; Diet Therapy; Female; Gout; Humans; Male; Middle Aged; Phenylbutazone; Sulfinpyr

1966
Epidemiology of gout and hyperuricemia. A long-term population study.
    The American journal of medicine, 1967, Volume: 42, Issue:1

    Topics: Adult; Aged; Arthritis, Rheumatoid; Diabetes Mellitus; Female; Gout; Humans; Male; Middle Aged; Samp

1967
Effect of food, fast and alcohol on serum uric acid and acute attacks of gout.
    The American journal of medicine, 1967, Volume: 42, Issue:1

    Topics: Adult; Aged; Butyrates; Dietary Proteins; Ethanol; Fasting; Female; Gout; Humans; Ketones; Lactates;

1967
Use of allopurinol in gout, hyperuricemia and uric acid lithiasis.
    Southern medical journal, 1967, Volume: 60, Issue:2

    Topics: Adult; Aged; Allopurinol; Blood Urea Nitrogen; Colchicine; Enzyme Therapy; Female; Gout; Humans; Ind

1967
Gout and the pathogenesis of its attacks.
    Acta medica Scandinavica, 1967, Volume: 181, Issue:2

    Topics: Adult; Aged; Diagnosis, Differential; Emotions; Female; Gout; Humans; Hypersensitivity; Kidney Disea

1967
The presence of a kinin in inflammatory synovial effusion from arthritides of varying etiologies.
    Arthritis and rheumatism, 1967, Volume: 10, Issue:1

    Topics: Adolescent; Adult; Animals; Arthritis; Arthritis, Rheumatoid; Bradykinin; Carboxypeptidases; Child;

1967
Hyperuricemia in Filipinos: interaction of heredity and environment.
    American journal of human genetics, 1967, Volume: 19, Issue:2

    Topics: Adult; Aged; Diet; Ethnology; Genetics, Medical; Gout; Humans; Kidney Tubules; Male; Middle Aged; Ph

1967
Regimen of indomethacin therapy in acute gouty arthritis.
    British medical journal, 1967, Apr-29, Volume: 2, Issue:5547

    Topics: Adult; Creatine; Female; Gout; Headache; Humans; Indomethacin; Male; Middle Aged; Nausea; Urea; Uric

1967
Allopurinol in the treatment of uraemic patients with gout.
    Annals of the rheumatic diseases, 1967, Volume: 26, Issue:2

    Topics: Allopurinol; Blood Urea Nitrogen; Enzyme Therapy; Gout; Humans; Purines; Uremia; Uric Acid; Xanthine

1967
Studies of uric acid metabolism in glycogen storage disease associated with gouty arthritis.
    Arthritis and rheumatism, 1967, Volume: 10, Issue:2

    Topics: Adolescent; Allopurinol; Body Height; Body Weight; Carbon Isotopes; Enzyme Therapy; Glucosephosphate

1967
Correlations of serum uric acid and lipid concentrations in normal, gouty, and atherosclerotic men.
    Annals of internal medicine, 1967, Volume: 66, Issue:5

    Topics: Adult; Arteriosclerosis; Black or African American; Blood Donors; Cholesterol; Ethnology; Female; Gl

1967
Non-traumatic aseptic necrosis of the femoral head.
    The Medical journal of Australia, 1967, Feb-18, Volume: 1, Issue:7

    Topics: Adrenal Cortex Hormones; Adult; Alcoholism; Fats; Female; Femoral Fractures; Femur Head; Gout; Hip D

1967
[Action of benziodarone on hyperuricemia in gout].
    La Presse medicale, 1967, May-27, Volume: 75, Issue:26

    Topics: Adult; Aged; Benzofurans; Female; Gout; Humans; Male; Middle Aged; Uric Acid; Vasodilator Agents

1967
[Place of hyperuricemia and gout in the etiology of retina vascular disorders].
    Angiology, 1967, Volume: 18, Issue:6

    Topics: Female; Gout; Humans; Male; Retinal Hemorrhage; Retinal Vessels; Thrombosis; Uric Acid

1967
The effect of indomethacin on urate metabolism.
    The Medical journal of Australia, 1967, May-27, Volume: 1, Issue:21

    Topics: Adult; Arthritis, Rheumatoid; Creatine; Gout; Humans; Indomethacin; Kidney; Kidney Function Tests; M

1967
Alcohol consumption and gout.
    The Medical journal of Australia, 1967, Jun-17, Volume: 1, Issue:24

    Topics: Adult; Alcoholic Beverages; Beer; Blood Pressure; Cardiovascular Diseases; Gout; Humans; Male; Middl

1967
Biochemical evidence for a distinct type of primary gout.
    Nature, 1967, Mar-18, Volume: 213, Issue:5081

    Topics: Adolescent; Allopurinol; Azathioprine; Carbon; Carbon Isotopes; Enzymes; Glycine; Gout; Humans; Hypo

1967
Treatment of gout.
    Pennsylvania medicine, 1967, Volume: 70, Issue:1

    Topics: Allopurinol; Enzyme Therapy; Gout; Humans; Uric Acid; Xanthine Oxidase

1967
Changes in some serum and urine laboratory indices in idiopathic uric acid lithiasis after administration of Eisenberg solution.
    Polish medical journal, 1967, Volume: 6, Issue:3

    Topics: Acid-Base Equilibrium; Adult; Ammonia; Androgens; Citrates; Creatine; Diagnosis, Differential; Diure

1967
[Primary gout].
    Lakartidningen, 1967, Mar-22, Volume: 64, Issue:12

    Topics: Gout; Humans; Purines; Uric Acid

1967
Birth order in gout.
    Arthritis and rheumatism, 1967, Volume: 10, Issue:4

    Topics: Adolescent; Adult; Aged; Birth Order; Black or African American; Female; Gout; Humans; Jews; Male; M

1967
Methotrexate in psoriasis. Precipitation of gout.
    Archives of dermatology, 1967, Volume: 96, Issue:4

    Topics: Colchicine; Female; Gout; Humans; Injections, Intravenous; Male; Methotrexate; Middle Aged; Psoriasi

1967
[Allopurinol treatment of hyperuricemia].
    Nordisk medicin, 1967, Oct-12, Volume: 78, Issue:41

    Topics: Adult; Aged; Allopurinol; Female; Gout; Humans; Iron; Male; Middle Aged; Nitrogen; Purines; Uric Aci

1967
The use of the xanthine oxidase inhibitor, allopurinol, in the control of hyperuricaemia, gout and uric acid calculi.
    Australasian annals of medicine, 1967, Volume: 16, Issue:3

    Topics: Adult; Aged; Allopurinol; Female; Gout; Humans; Hypoxanthines; Male; Metabolic Diseases; Middle Aged

1967
[Congenital hyperuricemia with neurologic, renal and blood disturbances].
    Archives francaises de pediatrie, 1967, Volume: 24, Issue:5

    Topics: Adolescent; Allopurinol; Anemia, Macrocytic; Athetosis; Chorea; Gout; Humans; Intellectual Disabilit

1967
[The importance of the lithiasis factor in chronic renal insufficiency in uricemia].
    Journal d'urologie et de nephrologie, 1967, Volume: 73, Issue:9

    Topics: Female; Gout; Humans; Kidney Calculi; Kidney Failure, Chronic; Male; Middle Aged; Uric Acid

1967
Uric acid nephrolithiasis in gout. Predisposing factors.
    Annals of internal medicine, 1967, Volume: 67, Issue:6

    Topics: Adolescent; Adult; Age Factors; Aged; Arthritis; Gout; Humans; Hydrogen-Ion Concentration; Kidney Ca

1967
[Survey of patients with uric arthritis in the Trogir region (Central Dalmatia)].
    Reumatizam, 1967, Volume: 14, Issue:5

    Topics: Gout; Humans; Uric Acid; Yugoslavia

1967
[On the simultaneous appearance of attacks of gout and coronary failure].
    Turk Tip Cemiyeti mecmuasi, 1967, Volume: 33, Issue:4

    Topics: Coronary Disease; Gout; Humans; Uric Acid

1967
[Gouty tophi in the renal medulla in chronic uremia. Study of 17 cases discovered from among 62 autopsies].
    Nephron, 1967, Volume: 4, Issue:6

    Topics: Adult; Aged; Female; Gout; Humans; Kidney Calculi; Male; Middle Aged; Uremia; Uric Acid

1967
[Gout and hyperuricemia].
    Nihon Ishikai zasshi. Journal of the Japan Medical Association, 1967, Mar-15, Volume: 57, Issue:6

    Topics: Adult; Gout; Hematologic Diseases; Humans; Male; Uric Acid

1967
Suppressive effects of indomethacin on crystal-induced inflammation in canine joints and on neutrophilic motility in vitro.
    The Journal of pharmacology and experimental therapeutics, 1967, Volume: 158, Issue:3

    Topics: Acute Disease; Animals; Anti-Inflammatory Agents; Arthritis; Blood Flow Velocity; Blood Pressure; Do

1967
[The behavior of uricemia during treatment with spironolactone and with other diuretics].
    Minerva medica, 1967, Nov-07, Volume: 58, Issue:89

    Topics: Acetazolamide; Adolescent; Adult; Aged; Chlorthalidone; Clopamide; Diuretics; Ethacrynic Acid; Femal

1967
[Data for the study of the gouty kidney].
    Rein et foie, maladies de la nutrition; actualites, 1967, Volume: 10

    Topics: Adolescent; Adult; Female; Glomerulonephritis; Gout; Humans; Kidney Calculi; Kidney Diseases, Cystic

1967
[Study of the effects of benziodarone in 100 gouty patients during a diuresis cure: effects on uric acid and oxalic acid].
    Rein et foie, maladies de la nutrition; actualites, 1967, Volume: 10

    Topics: Allopurinol; Benzofurans; Colchicine; Diuretics; Gout; Humans; Mineral Waters; Oxalates; Tromethamin

1967
The fever of gout: urate crystals activate endogenous pyrogen production from human and rabbit mononuclear phagocytes.
    Transactions of the Association of American Physicians, 1983, Volume: 96

    Topics: Animals; Colchicine; Crystallization; Cytochalasin B; Fever; Gout; Humans; Latex; Leukocytes; Monocy

1983
Oxygen radical production by horse and pig neutrophils induced by a range of crystals.
    The Journal of rheumatology, 1984, Volume: 11, Issue:6

    Topics: Animals; Arthritis; Crystallization; Gout; Horses; In Vitro Techniques; Neutrophils; Oxygen Consumpt

1984
[Pathogenetic mechanisms in joint diseases].
    Medizinische Klinik, 1981, May-08, Volume: 76, Issue:10

    Topics: Arthritis; Arthritis, Infectious; Arthritis, Reactive; Autoimmune Diseases; Chondrocalcinosis; Cryst

1981
Induction of collagenase and prostaglandin synthesis in synovial fibroblasts treated with monosodium urate crystals.
    The Journal of pharmacy and pharmacology, 1981, Volume: 33, Issue:6

    Topics: Animals; Cells, Cultured; Crystallization; Fibroblasts; Gout; Microbial Collagenase; Prostaglandins

1981
Leukotriene B4, an inflammatory mediator in gout.
    Lancet (London, England), 1982, Nov-20, Volume: 2, Issue:8308

    Topics: Acute Disease; Adult; Aged; Chemotactic Factors; Crystallization; Gout; Humans; Leukotriene B4; Male

1982
[Clinical aspects and prognosis of hyperuricemia and gout].
    Lebensversicherungs Medizin, 1983, Mar-22, Volume: 35, Issue:3

    Topics: Female; Gout; Humans; Male; Prognosis; Uric Acid

1983
IMP dehydrogenase mutants: cell culture model for hyperuricemia.
    Advances in experimental medicine and biology, 1984, Volume: 165 Pt A

    Topics: Animals; Cell Line; Disease Models, Animal; Gout; Humans; IMP Dehydrogenase; Ketone Oxidoreductases;

1984
Aspect of purine metabolic aberration associated with uric acid overproduction and gout.
    Advances in experimental medicine and biology, 1980, Volume: 122A

    Topics: Diphosphoglyceric Acids; Erythrocytes; Gout; Humans; Hypoxanthine Phosphoribosyltransferase; Kinetic

1980
Interpretation of synovial fluid data.
    Postgraduate medicine, 1980, Volume: 68, Issue:3

    Topics: Arthritis; Arthritis, Rheumatoid; Calcium Pyrophosphate; Cholesterol; Crystallization; Diagnosis, Di

1980
A hypothesis on the possible role of interferon in the initiation of acute gouty arthritis attack.
    Medical hypotheses, 1980, Volume: 6, Issue:8

    Topics: Acute Disease; Gout; Humans; Interferons; Macrophages; Models, Biological; Phagocytosis; Prostagland

1980
[Hyperuricemia].
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 1980, Aug-01, Volume: 33, Issue:15

    Topics: Female; Gout; Humans; Hypoxanthine Phosphoribosyltransferase; Male; Phosphoribosyl Pyrophosphate; Pu

1980
Gout with superactive phosphoribosylpyrophosphate synthetase due to increased enzyme catalytic rate.
    The Journal of laboratory and clinical medicine, 1982, Volume: 99, Issue:4

    Topics: Adult; Aged; Erythrocytes; Female; Gout; Humans; Kinetics; Male; Pedigree; Phosphoribosyl Pyrophosph

1982
Management of gout and hyperuricemia.
    Primary care, 1984, Volume: 11, Issue:2

    Topics: Allopurinol; Anti-Inflammatory Agents; Colchicine; Gout; Humans; Indomethacin; Kidney; Patient Educa

1984
Inherited disorders of purine metabolism--underlying molecular mechanisms.
    Klinische Wochenschrift, 1984, Oct-15, Volume: 62, Issue:20

    Topics: Adenine Phosphoribosyltransferase; Adenosine Deaminase; Gout; Humans; Hypoxanthine Phosphoribosyltra

1984
Hormonal aspects of human gout--excretion of adrenal hormone derivatives in gouty patients.
    Clinica chimica acta; international journal of clinical chemistry, 1983, Jun-15, Volume: 130, Issue:3

    Topics: Adrenal Cortex Hormones; Adult; Aged; Aging; Allopurinol; Androsterone; Dehydroepiandrosterone; Etio

1983
Uric acid metabolism in two patients with coexistent Down's syndrome and gout.
    Clinical rheumatology, 1984, Volume: 3, Issue:2

    Topics: Adult; Down Syndrome; Glomerular Filtration Rate; Gout; Humans; Male; Uric Acid

1984
[The effect of water with medium mineral content on various biohumoral parameters of uric acid metabolism].
    La Clinica terapeutica, 1984, Sep-30, Volume: 110, Issue:6

    Topics: Bicarbonates; Diuresis; Gout; Humans; Mineral Waters; Uric Acid

1984
The treatment of gout with azapropazone: clinical and experimental studies.
    European journal of rheumatology and inflammation, 1981, Volume: 4, Issue:3

    Topics: Animals; Apazone; Crystallization; Female; Gout; Humans; Male; Rats; Rats, Inbred Strains; Uric Acid

1981
Image alterations in the teaching microscope. A source of error in synovial fluid crystal identification.
    American journal of clinical pathology, 1980, Volume: 74, Issue:4

    Topics: Calcium Pyrophosphate; Chondrocalcinosis; Crystallization; Diagnosis, Differential; Diphosphates; Go

1980
Metabolic basis for disorders of purine nucleotide degradation.
    Metabolism: clinical and experimental, 1981, Volume: 30, Issue:6

    Topics: Adenosine Deaminase; Adenosine Monophosphate; Adenosine Triphosphate; AMP Deaminase; Anemia; Animals

1981
Stimulation of secretion of collagenase and prostaglandin E2 by synovial fibroblasts in response to crystals of monosodium urate monohydrate: a model for joint destruction in gout.
    Transactions of the Association of American Physicians, 1981, Volume: 94

    Topics: Animals; Crystallization; Dinoprostone; Disease Models, Animal; Fibroblasts; Gout; Microbial Collage

1981
Crystal-induced arthritis.
    Archives of physical medicine and rehabilitation, 1982, Volume: 63, Issue:9

    Topics: Adrenal Cortex Hormones; Aged; Anti-Inflammatory Agents; Arthritis; Calcium Pyrophosphate; Crystalli

1982
Stimulation of synovial fibroblasts by calcium oxalate and monosodium urate monohydrate. A mechanism of connective tissue degradation in oxalosis and gout.
    The Journal of laboratory and clinical medicine, 1982, Volume: 100, Issue:6

    Topics: Animals; Calcium Oxalate; Connective Tissue Diseases; Crystallization; Dinoprostone; Dose-Response R

1982
Inflammatory responses to intradermal crystals in healthy volunteers and patients with rheumatic diseases.
    Rheumatology international, 1982, Volume: 2, Issue:2

    Topics: Arthritis, Rheumatoid; Calcium Pyrophosphate; Diphosphates; Gout; Humans; Hydroxyapatites; Intraderm

1982
Phosphoribosyl pyrophosphate synthetase and glutathione reductase in erythrocytes from hyperuricaemic and gout patients.
    Clinica chimica acta; international journal of clinical chemistry, 1982, Dec-23, Volume: 126, Issue:3

    Topics: Erythrocytes; Female; Glutathione Reductase; Gout; Humans; Male; Phosphotransferases; Ribose-Phospha

1982
Radiology of the crystal-associated arthritides.
    Annals of the rheumatic diseases, 1983, Volume: 42 Suppl 1

    Topics: Arthritis; Calcium Pyrophosphate; Chondrocalcinosis; Crystallization; Durapatite; Gout; Humans; Hydr

1983
An autopsy study of the prevalence of monosodium urate and calcium pyrophosphate dihydrate crystal deposition in first metatarsophalangeal joints.
    Arthritis and rheumatism, 1983, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Autopsy; Biopsy, Needle; Calcium Pyrophosphate; Crystallization; Diphosphat

1983
Phagocytosis of sodium urate and calcium pyrophosphate crystals by leukocytes of gouty, pseudogouty and health donors.
    European journal of rheumatology and inflammation, 1983, Volume: 6, Issue:2

    Topics: Adult; Aged; Calcium Pyrophosphate; Chondrocalcinosis; Crystallization; Diphosphates; Glucose; Gout;

1983
Urinary cAMP excretion in gouty patients with and without nephrolithiasis.
    Advances in experimental medicine and biology, 1984, Volume: 165 Pt A

    Topics: Calcium; Cyclic AMP; Female; Gout; Humans; Kidney Calculi; Male; Phosphates; Uric Acid

1984
Diagnostic evaluation of phosphoribosylpyrophosphate synthetase activities in hemolysates.
    The Journal of laboratory and clinical medicine, 1984, Volume: 103, Issue:6

    Topics: Adenine Phosphoribosyltransferase; Adenosine Diphosphate; Clinical Enzyme Tests; Dialysis; Enzyme Ac

1984
Metabolic aspects in gout.
    Scandinavian journal of rheumatology. Supplement, 1984, Volume: 53

    Topics: Gout; Humans; Hypoxanthine Phosphoribosyltransferase; Purines; Ribose-Phosphate Pyrophosphokinase; U

1984
Drug-induced rheumatic diseases.
    Comprehensive therapy, 1984, Volume: 10, Issue:8

    Topics: Adrenal Cortex Hormones; Anticonvulsants; Antineoplastic Agents; Diuretics; Gout; Heparin; Humans; H

1984
Gouty nephropathy: fact or fiction?
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 1983, Volume: 2, Issue:5

    Topics: Gout; History, 16th Century; History, 19th Century; History, 20th Century; History, Ancient; Humans;

1983
The first era of lithium in medicine. An historical note.
    Pharmacopsychiatria, 1983, Volume: 16, Issue:2

    Topics: Chemistry; Depression; Gout; History, 19th Century; History, 20th Century; Humans; Lithium; Mineral

1983
[Cutaneous bullous tophaceous gout].
    Revista clinica espanola, 1983, Nov-15, Volume: 171, Issue:3

    Topics: Arthritis; Crystallization; Gout; Humans; Male; Middle Aged; Skin; Skin Diseases, Vesiculobullous; U

1983
[Diet therapy of gout and urate nephrolithiasis].
    Der Internist, 1984, Volume: 25, Issue:5

    Topics: Alcohol Drinking; Body Weight; Gout; Humans; Kidney Calculi; Purines; Uric Acid

1984
[Increase in blood uric acid induced by indomethacin in hens or chickens].
    Comptes rendus des seances de l'Academie des sciences. Serie III, Sciences de la vie, 1983, Volume: 296, Issue:8

    Topics: Animals; Chickens; Dose-Response Relationship, Drug; Female; Gout; Indomethacin; Uric Acid

1983
Purine metabolism in high- and low-uric acid lines of chickens: hypoxanthine/guanine phosphoribosyltransferase activities.
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1983, Volume: 173, Issue:1

    Topics: Animals; Chickens; Dietary Proteins; Female; Gout; Hypoxanthine Phosphoribosyltransferase; Hypoxanth

1983
Food, drink, and gout.
    British medical journal (Clinical research ed.), 1983, Jul-09, Volume: 287, Issue:6385

    Topics: Alcohol Drinking; Body Weight; Food; Gout; Humans; Purines; Uric Acid

1983
Moonshine and lead. Relationship to the pathogenesis of hyperuricemia in gout.
    Arthritis and rheumatism, 1983, Volume: 26, Issue:9

    Topics: Adult; Alcohol Drinking; Edetic Acid; Female; Gout; Humans; Kidney Diseases; Latex Fixation Tests; L

1983
Molecular genetics of the HPRT-deficiency syndromes.
    Hospital practice (Office ed.), 1984, Volume: 19, Issue:5

    Topics: Amino Acid Sequence; Female; Genetic Carrier Screening; Gout; Humans; Hypoxanthine Phosphoribosyltra

1984
Occult lead intoxication in patients with gout and kidney disease.
    The Journal of rheumatology, 1984, Volume: 11, Issue:4

    Topics: Adult; Aged; Alcohol Drinking; Creatinine; Edetic Acid; Female; Gout; Humans; Kidney Diseases; Lead;

1984
Gas-chromatographic evaluation of urinary 17-ketosteroids, etiocholanolone, and dehydroepiandrosterone in primary gout and hyperuricemia.
    Advances in experimental medicine and biology, 1980, Volume: 122A

    Topics: 17-Ketosteroids; Adult; Aged; Chromatography, Gas; Dehydroepiandrosterone; Etiocholanolone; Female;

1980
Musculoskeletal manifestations of Paget's disease of bone.
    Arthritis and rheumatism, 1980, Volume: 23, Issue:10

    Topics: Aged; Alkaline Phosphatase; Arthritis, Rheumatoid; Back Pain; Female; Gout; Hip Joint; Humans; Knee

1980
The differential diagnosis of septic arthritis in the elderly.
    Comprehensive therapy, 1984, Volume: 10, Issue:8

    Topics: Aged; Arthritis; Arthritis, Infectious; Arthritis, Rheumatoid; Cellulitis; Diabetic Neuropathies; Di

1984
[Gouty nephropathy (a review of the literature)].
    Vrachebnoe delo, 1984, Issue:7

    Topics: Animals; Gout; Humans; Kidney; Kidney Calculi; Kidney Diseases; Nephritis, Interstitial; Purines; Ra

1984
Juvenile gouty arthritis. Two cases associated with mild renal insufficiency.
    American journal of diseases of children (1960), 1984, Volume: 138, Issue:10

    Topics: Adolescent; Arthritis; Female; Gout; Humans; Kidney Diseases; Male; Recurrence; Synovial Fluid; Uric

1984
A case-control study of alcohol consumption and drinking behaviour in patients with acute gout.
    Canadian Medical Association journal, 1984, Sep-15, Volume: 131, Issue:6

    Topics: Acute Disease; Alcohol Drinking; Alcoholism; Diuretics; Female; Gout; Humans; Male; Middle Aged; Uri

1984
Crystal deposition in the knee and great toe joints of asymptomatic gout patients.
    Journal of the Royal Society of Medicine, 1984, Volume: 77, Issue:9

    Topics: Adult; Aged; Arthroscopy; Crystallization; Gout; Humans; Knee Joint; Male; Metatarsophalangeal Joint

1984
A study of the potential interactions between azapropazone and frusemide in man.
    British journal of clinical pharmacology, 1984, Volume: 18, Issue:4

    Topics: Adult; Apazone; Drug Interactions; Female; Furosemide; Gout; Humans; Male; Potassium; Sodium; Triazi

1984
Hyperuricaemia, gout and kidney function in New Zealand Maori men.
    British journal of rheumatology, 1984, Volume: 23, Issue:4

    Topics: Adult; Alcohol Drinking; Ethnicity; Gout; Humans; Kidney; Male; Middle Aged; New Zealand; Obesity; S

1984
An approach to hyperuricemia and gout.
    Geriatrics, 1984, Volume: 39, Issue:11

    Topics: Allopurinol; Anti-Inflammatory Agents; Colchicine; Female; Gout; Humans; Male; Naproxen; Phenylbutaz

1984
[Hyperuricemia in ischemic heart disease].
    Kardiologiia, 1984, Volume: 24, Issue:8

    Topics: Adult; Body Weight; Coronary Disease; Diuretics; Gout; Humans; Hyperlipoproteinemias; Hypertension;

1984
Prospective study of morphology and phagocytosis of synovial fluid monosodium urate crystals in gouty arthritis.
    The Journal of rheumatology, 1984, Volume: 11, Issue:6

    Topics: Arthritis; Crystallization; Gout; Humans; Leukocytes; Phagocytosis; Synovial Fluid; Uric Acid

1984
[Urate spherulite crystals in gouty synovial fluid].
    Harefuah, 1984, Nov-01, Volume: 107, Issue:9

    Topics: Gout; Humans; Synovial Fluid; Uric Acid

1984
Does benzbromarone in therapeutic doses raise renal excretion of oxipurinol?
    Klinische Wochenschrift, 1984, Dec-17, Volume: 62, Issue:24

    Topics: Adult; Aged; Allopurinol; Benzbromarone; Benzofurans; Creatinine; Drug Therapy, Combination; Glomeru

1984
Podagra is more than gout.
    Bulletin on the rheumatic diseases, 1984, Volume: 34, Issue:6

    Topics: Colchicine; Diagnosis, Differential; Gout; Humans; Metatarsophalangeal Joint; Toe Joint; Uric Acid

1984
Hypouricemic action of diflunisal in gouty patients: in vitro and in vivo studies.
    The Journal of rheumatology, 1984, Volume: 11, Issue:3

    Topics: Adult; Aged; Creatinine; Diflunisal; Enzyme Inhibitors; Gout; Humans; In Vitro Techniques; Middle Ag

1984
[Protein overload, hyperucemia, gout].
    Soins; la revue de reference infirmiere, 1983, Issue:406

    Topics: Adult; Diet; Female; Gout; Humans; Hyperlipoproteinemias; Male; Middle Aged; Uric Acid

1983
The approach to the acute joint and synovial fluid examination.
    Primary care, 1984, Volume: 11, Issue:2

    Topics: Acute Disease; Adult; Arthritis; Arthritis, Infectious; Calcium Pyrophosphate; Chondrocalcinosis; Fe

1984
[Hyperuricemia].
    L'Infirmiere francaise, 1984, Issue:260

    Topics: Gout; Humans; Uric Acid; Urinary Calculi

1984
The role of the laboratory in rheumatology. Uric acid and the interpretation of hyperuricaemia.
    Clinics in rheumatic diseases, 1983, Volume: 9, Issue:1

    Topics: Adolescent; Adult; Aged; Alcohol Drinking; Arthritis; Body Weight; Child; Female; Gout; Humans; Hype

1983
Polarised light microscopy: principles and practice for the rheumatologist.
    Annals of the rheumatic diseases, 1983, Volume: 42 Suppl 1

    Topics: Aged; Birefringence; Calcium Pyrophosphate; Crystallization; Gout; Humans; Microscopy, Polarization;

1983
T-cell leukaemia presenting with hyperuricaemia, acute renal failure and gout.
    Clinical and laboratory haematology, 1983, Volume: 5, Issue:4

    Topics: Acute Kidney Injury; Child; Gout; Humans; Leukemia, Lymphoid; Male; T-Lymphocytes; Uric Acid

1983
[Problems with xeroradiography].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1983, Jun-01, Volume: 38, Issue:11

    Topics: Adolescent; Adult; Arm; Female; Gout; Humans; Male; Middle Aged; Uric Acid; Xeroradiography

1983
Studies of urate crystallisation in relation to gout.
    Annals of the rheumatic diseases, 1983, Volume: 42 Suppl 1

    Topics: Chemical Phenomena; Chemistry; Crystallization; Gout; Humans; Macromolecular Substances; Neutral Red

1983
[The spine and polytopic hyperostoses in gout and hyperuricemia].
    Der Radiologe, 1983, Volume: 23, Issue:8

    Topics: Female; Gout; Humans; Male; Middle Aged; Spinal Osteophytosis; Uric Acid; Xeroradiography

1983
The diagnosis and management of gouty arthritis.
    Comprehensive therapy, 1983, Volume: 9, Issue:9

    Topics: Adult; Anti-Inflammatory Agents; Arthritis; Female; Gout; Gout Suppressants; Humans; Male; Middle Ag

1983
[Hyperuricemia and gout. Physiopathology, diagnosis and therapy].
    Die Medizinische Welt, 1983, Sep-09, Volume: 34, Issue:36

    Topics: Gout; Humans; Metabolic Clearance Rate; Uric Acid

1983
[The gouty kidney].
    La Revue du praticien, 1983, Oct-01, Volume: 33, Issue:43

    Topics: Gout; Humans; Kidney Diseases; Uric Acid

1983
[Metabolic disorders in hyperuricemia].
    La Revue du praticien, 1983, Oct-01, Volume: 33, Issue:43

    Topics: Diabetes Mellitus; Glycerides; Gout; Humans; Metabolic Diseases; Obesity; Uric Acid

1983
[Should asymptomatic hyperuricemia be treated?].
    La Revue du praticien, 1983, Oct-01, Volume: 33, Issue:43

    Topics: Gout; Humans; Metabolic Diseases; Uric Acid

1983
Mechanisms of vascular damage in gout and oxalosis: crystal induced, granulocyte mediated, endothelial injury.
    Thrombosis and haemostasis, 1983, Aug-30, Volume: 50, Issue:2

    Topics: Blood Physiological Phenomena; Blood Platelets; Calcium Oxalate; Cell Adhesion; Cell Aggregation; Co

1983
Oxipurinol therapy in allopurinol-allergic patients.
    American family physician, 1983, Volume: 28, Issue:5

    Topics: Aged; Allopurinol; Arthritis; Drug Hypersensitivity; Female; Gout; Humans; Oxypurinol; Pyrimidines;

1983
[Secondary gut].
    Zhonghua nei ke za zhi, 1983, Volume: 22, Issue:6

    Topics: Adult; Age Factors; Aged; Female; Gout; Humans; Lead Poisoning; Male; Middle Aged; Polycythemia; Uri

1983
Cutaneous gout in an Amazon dolphin.
    Journal of the American Veterinary Medical Association, 1983, Dec-01, Volume: 183, Issue:11

    Topics: Allopurinol; Animals; Animals, Zoo; Dolphins; Gout; Male; Skin; Skin Diseases; Uric Acid

1983
[Features differentiating between gout and asymptomatic hyperuricemias (1). Clinical study].
    Revista clinica espanola, 1983, Sep-15, Volume: 170, Issue:5

    Topics: Arthritis; Diagnosis, Differential; Female; Gout; Humans; Kidney Calculi; Male; Uric Acid

1983
Cholesterol "tophus".
    Arthritis and rheumatism, 1983, Volume: 26, Issue:12

    Topics: Ankle Joint; Biopsy, Needle; Cholesterol; Crystallization; Diagnosis, Differential; Gout; Granuloma;

1983
[Hyperuricemia and gout; treatment of an acute attack of gout].
    Nederlands tijdschrift voor geneeskunde, 1983, Dec-03, Volume: 127, Issue:49

    Topics: Adult; Colchicine; Female; Gout; Humans; Male; Middle Aged; Uric Acid; Uricosuric Agents

1983
[Features differentiating between gout and asymptomatic hyperuricemias. II. Laboratory data].
    Revista clinica espanola, 1983, Sep-30, Volume: 170, Issue:6

    Topics: Blood Proteins; Diagnosis, Differential; Gout; Humans; Lipids; Uric Acid

1983
[Features differentiating between gout and asymptomatic hyperuricemias. III. Correlations with metabolic parameters].
    Revista clinica espanola, 1983, Oct-15, Volume: 171, Issue:1

    Topics: Blood Proteins; Diagnosis, Differential; Gout; Humans; Lipids; Uric Acid

1983
[Therapy of gout and hyperuricemia].
    La Clinica terapeutica, 1983, Dec-15, Volume: 107, Issue:5

    Topics: Gout; Gout Suppressants; Humans; Uric Acid

1983
Preliminary studies with azapropazone in gout and hyperuricaemia.
    European journal of rheumatology and inflammation, 1983, Volume: 6, Issue:2

    Topics: Adult; Aged; Apazone; Drug Evaluation; Female; Gout; Humans; Male; Middle Aged; Triazines; Uric Acid

1983
The behavior of oxypurines in human primary gout.
    Quaderni Sclavo di diagnostica clinica e di laboratorio, 1983, Volume: 19, Issue:2

    Topics: Adult; Aged; Female; Gout; Humans; Hypoxanthines; Male; Middle Aged; Purines; Sex Factors; Uric Acid

1983
Effect of nonsteroidal anti-inflammatory drugs on the renal excretion of uric acid.
    Clinical rheumatology, 1983, Volume: 2, Issue:3

    Topics: Anti-Inflammatory Agents; Arthritis; Gout; Humans; ortho-Aminobenzoates; Piroxicam; Quinazolines; Th

1983
Gout and uric acid nephropathy: some new aspects in diagnosis and treatment.
    Klinische Wochenschrift, 1983, Dec-15, Volume: 61, Issue:24

    Topics: Adult; Diet; Female; Gout; Humans; Hypolipidemic Agents; Kidney Diseases; Male; Uric Acid; Uricosuri

1983
Azapropazone--a treatment for hyperuricaemia and gout?
    British journal of rheumatology, 1984, Volume: 23, Issue:1

    Topics: Adult; Aged; Allopurinol; Apazone; Creatinine; Gout; Humans; Middle Aged; Osmolar Concentration; Tri

1984
Does hyperuricemia protect from rheumatoid inflammation? A clinical study.
    Arthritis and rheumatism, 1984, Volume: 27, Issue:4

    Topics: Arthritis, Rheumatoid; Gout; Humans; Inflammation; Uric Acid

1984
[Urate gout in children].
    Pediatria polska, 1984, Volume: 59, Issue:2

    Topics: Adolescent; Child; Finger Joint; Gout; Humans; Male; Metatarsophalangeal Joint; Toe Joint; Uric Acid

1984
Clinical survey of 200 patients with gout.
    Advances in experimental medicine and biology, 1984, Volume: 165 Pt A

    Topics: Age Factors; Crystallization; Gout; Humans; Joints; Middle Aged; Retrospective Studies; Uric Acid

1984
Incorporation of 15N from glycine into uric acid in gout: a follow-up study.
    Advances in experimental medicine and biology, 1984, Volume: 165 Pt A

    Topics: Adult; Follow-Up Studies; Glycine; Gout; Humans; Male; Nitrogen Isotopes; Uric Acid

1984
Hyperuricaemia in young New Zealand Maori men.
    Advances in experimental medicine and biology, 1984, Volume: 165 Pt A

    Topics: Adult; Age Factors; Ethnicity; Gout; Humans; Male; Middle Aged; Native Hawaiian or Other Pacific Isl

1984
Lean dry gout patients.
    Advances in experimental medicine and biology, 1984, Volume: 165 Pt A

    Topics: Body Weight; Cholesterol; Cholesterol, HDL; Gout; Humans; Lipoproteins; Lipoproteins, HDL; Triglycer

1984
Urate deposits without gouty arthritis.
    Advances in experimental medicine and biology, 1984, Volume: 165 Pt A

    Topics: Aged; Arthritis; Arthritis, Rheumatoid; Gout; Humans; Male; Middle Aged; Osteoarthritis; Uric Acid

1984
HDL-cholesterol levels in gouty patients.
    Advances in experimental medicine and biology, 1984, Volume: 165 Pt A

    Topics: Cholesterol; Cholesterol, HDL; Gout; Humans; Lipoproteins, HDL; Lipoproteins, LDL; Middle Aged; Refe

1984
Gout resistant to allopurinol: poor compliance or non-response.
    Advances in experimental medicine and biology, 1984, Volume: 165 Pt A

    Topics: Allopurinol; Arthritis; Gout; Humans; Male; Middle Aged; Patient Compliance; Uric Acid

1984
Renal handling of uric acid in gout by means of the pyrazinamide and probenecid tests.
    Advances in experimental medicine and biology, 1984, Volume: 165 Pt A

    Topics: Adult; Gout; Humans; Kidney; Kidney Tubules; Probenecid; Pyrazinamide; Reference Values; Uric Acid

1984
The effect of beer ingestion on plasma and urine uric acid in gout and normouricaemic subjects.
    Advances in experimental medicine and biology, 1984, Volume: 165 Pt A

    Topics: Alcohol Drinking; Beer; Gout; Humans; Reference Values; Uric Acid

1984
Ethanol induced alterations of uric acid metabolism.
    Advances in experimental medicine and biology, 1984, Volume: 165 Pt A

    Topics: Alcohol Drinking; Creatinine; Ethanol; Gout; Humans; Uric Acid

1984
The management of hyperuricaemia.
    Journal of the Royal College of Physicians of London, 1984, Volume: 18, Issue:2

    Topics: Adult; Aged; Follow-Up Studies; Gout; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Myoc

1984
Diversity of clinical features in gouty arthritis.
    Seminars in arthritis and rheumatism, 1984, Volume: 13, Issue:4

    Topics: Adolescent; Adult; Age Factors; Aged; Arthritis; Child; Female; Gout; Humans; Hyperlipidemias; Hyper

1984
Mitral stenosis associated with valvular tophi.
    Mayo Clinic proceedings, 1984, Volume: 59, Issue:7

    Topics: Aged; Calcinosis; Female; Gout; Humans; Mitral Valve; Mitral Valve Stenosis; Uric Acid

1984
[When should hyperuricemia be treated?].
    Medicina clinica, 1984, May-12, Volume: 82, Issue:18

    Topics: Gout; Hematologic Diseases; Humans; Kidney Failure, Chronic; Uric Acid; Urinary Calculi

1984
Therapeutics of hyperuricaemia and gout.
    The Medical journal of Australia, 1984, Jul-07, Volume: 141, Issue:1

    Topics: Acute Disease; Allopurinol; Colchicine; Gout; Humans; Indomethacin; Uric Acid; Uricosuric Agents

1984
Gout in South African blacks.
    Annals of the rheumatic diseases, 1984, Volume: 43, Issue:3

    Topics: Adult; Black People; Female; Gout; Humans; Male; Middle Aged; Retrospective Studies; South Africa; U

1984
Beer drinking and its effect on uric acid.
    British journal of rheumatology, 1984, Volume: 23, Issue:3

    Topics: Alcohol Drinking; Beer; Gout; Humans; Lactates; Male; Uric Acid

1984
The rate of purine synthesis de nova in blood mononuclear cells in vitro from patients with familial hyperuricaemic nephropathy.
    Clinical science (London, England : 1979), 1984, Volume: 67, Issue:2

    Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Erythrocytes; Female; Gout; Humans; Kidney Disease

1984
Activation of the fifth component of human complement (C5) induced by monosodium urate crystals: C5 convertase assembly on the crystal surface.
    Clinical immunology and immunopathology, 1982, Volume: 24, Issue:2

    Topics: Arthritis; Chemotactic Factors; Complement Activating Enzymes; Complement Activation; Complement C3-

1982
The role of lead in gout nephropathy.
    The New England journal of medicine, 1981, Feb-26, Volume: 304, Issue:9

    Topics: Adult; Aged; Creatinine; Edetic Acid; Gout; Humans; Kidney; Kidney Diseases; Kidney Function Tests;

1981
[Urate-oxidase: a new therapy of cytotoxic-drug-induced hyperuricemia (author's transl)].
    Haematologica, 1981, Volume: 66, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Agents; Child; Female; Gout; Humans; Kidney Diseases; Leukemia; Ma

1981
Nonarticular gout: hyperuricemia and tophus formation without gouty arthritis.
    Arthritis and rheumatism, 1983, Volume: 26, Issue:1

    Topics: Aged; Arthritis, Rheumatoid; Ear; Gout; Humans; Kidney; Male; Middle Aged; Osteoarthritis; Synovial

1983
Tophaceous gout producing spinal cord compression. Case report.
    Journal of neurosurgery, 1983, Volume: 58, Issue:4

    Topics: Adult; Gout; Humans; Male; Paraplegia; Spinal Cord Compression; Uric Acid

1983
Lead nephropathy and gout.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 1983, Volume: 2, Issue:5

    Topics: Adolescent; Adult; Aged; Child, Preschool; Creatinine; Female; Glomerular Filtration Rate; Gout; Hum

1983
Calciuric effect of probenecid in gouty patients.
    Israel journal of medical sciences, 1983, Volume: 19, Issue:4

    Topics: Adult; Aged; Calcium; Creatinine; Gout; Humans; Male; Middle Aged; Probenecid; Uric Acid

1983
Familial nephropathy with hyperuricemia and gout.
    Nephron, 1983, Volume: 34, Issue:1

    Topics: Adult; Biopsy; Child; Female; Genes, Dominant; Glomerular Filtration Rate; Gout; Humans; Kidney; Kid

1983
[Current therapy: combined drug therapy of hyperuricemia, gout and alcohol induced fatty liver].
    Fortschritte der Medizin, 1983, May-12, Volume: 101, Issue:18

    Topics: Allopurinol; Benzbromarone; Benzofurans; Drug Therapy, Combination; Fatty Liver, Alcoholic; Gout; Hu

1983
Activation of the alternative pathway of complement by monosodium urate crystals.
    Clinical immunology and immunopathology, 1983, Volume: 26, Issue:2

    Topics: Complement Activation; Complement Pathway, Alternative; Crystallization; Gout; Humans; Uric Acid

1983
[Therapy of hyperuricemia and gout. Effect of a combination therapy of allopurinol with benzbromarone].
    Fortschritte der Medizin, 1983, May-26, Volume: 101, Issue:20

    Topics: Allopurinol; Benzbromarone; Benzofurans; Chemical Phenomena; Chemistry; Drug Therapy, Combination; G

1983
[Should asymptomatic hyperuricemia be treated?].
    Revue medicale de la Suisse romande, 1983, Volume: 103, Issue:5

    Topics: Arthritis; Gout; Humans; Kidney Calculi; Risk; Uric Acid; Uricosuric Agents

1983
Effect of IgG and C-reactive protein on complement depletion by monosodium urate crystals.
    The Journal of rheumatology, 1983, Volume: 10, Issue:3

    Topics: Acute Disease; Agammaglobulinemia; Arthritis; C-Reactive Protein; Complement Activation; Complement

1983
Tophaceous aortic valve: a case report.
    Pathology, 1983, Volume: 15, Issue:2

    Topics: Aortic Valve; Aortic Valve Stenosis; Gout; Humans; Male; Middle Aged; Uric Acid

1983
[Incidence of enthesopathic changes in gout and hyperuricemia].
    Fysiatricky a reumatologicky vestnik, 1982, Volume: 60, Issue:3

    Topics: Aged; Arthrography; Bone and Bones; Gout; Humans; Male; Periarthritis; Uric Acid

1982
Failure of folic acid (pteroylglutamic acid) to affect hyperuricemia.
    The Journal of laboratory and clinical medicine, 1980, Volume: 96, Issue:5

    Topics: Adult; Dose-Response Relationship, Drug; Female; Folic Acid; Gout; Humans; Hypoxanthines; Liver; Mal

1980
Clinical disorders of uric acid metabolism.
    The Medical clinics of North America, 1981, Volume: 65, Issue:2

    Topics: Amidophosphoribosyltransferase; Diet; Gout; Humans; Hypoxanthine Phosphoribosyltransferase; Kidney;

1981
Hyperuricemia and gout: an update.
    American family physician, 1981, Volume: 24, Issue:6

    Topics: Allopurinol; Female; Gout; Humans; Kidney; Kidney Diseases; Male; Metabolic Clearance Rate; Middle A

1981
[Nursing of gout patient (author's transl)].
    Hu li za zhi The journal of nursing, 1981, Volume: 28, Issue:1

    Topics: Gout; Gout Suppressants; Humans; Uric Acid

1981
Purine oversecretion in cultured murine lymphoma cells deficient in adenylosuccinate synthetase: genetic model for inherited hyperuricemia and gout.
    Proceedings of the National Academy of Sciences of the United States of America, 1982, Volume: 79, Issue:17

    Topics: Adenylosuccinate Synthase; Animals; Cell Line; Gout; Ligases; Lymphoma; Mice; Neoplasms, Experimenta

1982
Urate metabolism and renal calcium stone disease.
    Scandinavian journal of urology and nephrology. Supplementum, 1981, Volume: 62

    Topics: Acute Kidney Injury; Calcium Oxalate; Crystallization; Dietary Proteins; Feeding Behavior; Female; G

1981
Epidemiology of Rheumatic disorders in the Pacific with particular emphasis on hyperuricaemia and gout.
    Seminars in arthritis and rheumatism, 1981, Volume: 11, Issue:1

    Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Child, Preschool; Cross-Sectional Studies; Diabetes

1981
Type III glycogenosis with deposition of urate and amyloid.
    Acta pathologica japonica, 1980, Volume: 30, Issue:4

    Topics: Adult; Amyloid; Fructose Intolerance; Glycogen Storage Disease; Glycogen Storage Disease Type IV; Go

1980
[Serum urate and gout in a young male workforce (author's transl)].
    Pathologie-biologie, 1980, Volume: 28, Issue:7

    Topics: Adult; Age Factors; Body Weight; Diet; Gout; Humans; Male; Risk; Uric Acid

1980
Uric acid turnover in normals, in gout and in chronic renal failure using 14C-uric acid.
    Advances in experimental medicine and biology, 1980, Volume: 122A

    Topics: Carbon Radioisotopes; Gout; Humans; Kidney Failure, Chronic; Kinetics; Radioisotope Dilution Techniq

1980
[100 years of gout: from quackery and hypothesis to directed therapy].
    Fortschritte der Medizin, 1982, Apr-15, Volume: 100, Issue:14

    Topics: Europe; Gout; Gout Suppressants; History, 19th Century; History, 20th Century; Humans; Life Style; M

1982
The appropriate processing of tophi for microscopy.
    The American Journal of dermatopathology, 1982, Volume: 4, Issue:3

    Topics: Ethanol; Fixatives; Gout; Histological Techniques; Humans; Microscopy; Uric Acid

1982
[Asymptomatic hyperuricaemia: to treat or not to treat? (author's transl)].
    Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis, 1981, Nov-17, Volume: 70, Issue:47

    Topics: Adult; Diagnosis, Differential; Female; Gout; Humans; Kidney Calculi; Male; Uric Acid; Uricosuric Ag

1981
[Principles of treatment of gout and hyperuricemia].
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1982, Jan-09, Volume: 61, Issue:2

    Topics: Acute Disease; Adult; Gout; Humans; Male; Middle Aged; Uric Acid

1982
Aspiration of the asymptomatic metatarsophalangeal joint in gout patients and hyperuricemic controls.
    Arthritis and rheumatism, 1982, Volume: 25, Issue:2

    Topics: Arthritis; Biopsy, Needle; Gout; Humans; Kidney Failure, Chronic; Metatarsophalangeal Joint; Neutrop

1982
Surgical management of tophaceous gout: a literature review and case report.
    Journal of the American Podiatry Association, 1982, Volume: 72, Issue:4

    Topics: Aged; Female; Foot Dermatoses; Gout; Humans; Metatarsophalangeal Joint; Skin Ulcer; Toe Joint; Toes;

1982
[Treatment of acute gout attacks with tolmetin (author's transl)].
    Wiener medizinische Wochenschrift (1946), 1982, Jan-31, Volume: 132, Issue:2

    Topics: Acute Disease; Adult; Aged; Analgesia; Gout; Humans; Male; Middle Aged; Pyrroles; Tolmetin; Uric Aci

1982
[Uric acid load test. Proof of its value using the sequential probability ratio test].
    ZFA. Zeitschrift fur Allgemeinmedizin, 1982, Feb-28, Volume: 58, Issue:6

    Topics: Adenine; Adult; Female; Gout; Guanine; Humans; Male; Probability; Uric Acid

1982
Plasterer's tophi.
    Arthritis and rheumatism, 1982, Volume: 25, Issue:4

    Topics: Aged; Gout; Humans; Male; Occupational Diseases; Uric Acid

1982
Psoriasis and normouricemic gout.
    Dermatologica, 1982, Volume: 164, Issue:2

    Topics: Acute Disease; Gout; Humans; Male; Middle Aged; Psoriasis; Triamcinolone Acetonide; Uric Acid

1982
[Hallux rigidus arthrosis and gout].
    Fortschritte der Medizin, 1982, Mar-18, Volume: 100, Issue:11

    Topics: Calcium; Gout; Hallux; Humans; Obesity; Osteoarthritis; Uric Acid

1982
Tophaceous mitral value: Report of a case.
    The American journal of surgical pathology, 1982, Volume: 6, Issue:1

    Topics: Gout; Heart Valve Diseases; Humans; Male; Middle Aged; Mitral Valve; Mitral Valve Prolapse; Uric Aci

1982
[Treatment of cytostatic-induced hyperuricaemia with allopurinol (author's transl)].
    Deutsche medizinische Wochenschrift (1946), 1982, Jun-11, Volume: 107, Issue:23

    Topics: Adenocarcinoma; Allopurinol; Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Female; G

1982
[Medico-social problems of alcoholism].
    Minerva medica, 1982, May-19, Volume: 73, Issue:21

    Topics: Alcoholism; Breath Tests; Female; Gout; Humans; Liver Diseases, Alcoholic; Male; Melanocyte-Stimulat

1982
Gouty mammary tophus.
    Southern medical journal, 1982, Volume: 75, Issue:6

    Topics: Adult; Breast; Breast Neoplasms; Crystallization; Diagnosis, Differential; Gout; Humans; Male; Uric

1982
Family study of lipid and purine levels in gout patients.
    Annals of the rheumatic diseases, 1982, Volume: 41, Issue:3

    Topics: Female; Gout; Humans; Hyperlipoproteinemia Type IV; Lipids; Male; Middle Aged; Uric Acid

1982
Hyperuricemia.
    Minnesota medicine, 1982, Volume: 65, Issue:7

    Topics: Arthritis; Female; Gout; Humans; Hypertension; Kidney Calculi; Male; Uric Acid

1982
Heberden Oration 1981: epidemiology and the arthritides.
    Annals of the rheumatic diseases, 1982, Volume: 41, Issue:4

    Topics: Adolescent; Adult; Age Factors; Aged; Body Weight; Connecticut; Female; Gout; Hand; Humans; Male; Ma

1982
Frequency of chondrocalcinosis of the knees in asymptomatic hyperuricaemia and rheumatoid arthritis: a controlled study.
    Annals of the rheumatic diseases, 1982, Volume: 41, Issue:4

    Topics: Adult; Age Factors; Aged; Arthritis, Rheumatoid; Chondrocalcinosis; Female; Gout; Humans; Knee Joint

1982
Purine synthesis de novo in lymphocytes from patients with gout.
    Clinical science (London, England : 1979), 1982, Volume: 63, Issue:5

    Topics: Adult; Female; Gout; Humans; Lymphocytes; Male; Middle Aged; Purines; Uric Acid

1982
A population study of hyperuricaemia and gout in Japan--analysis of sex, age and occupational differences in thirty-four thousand people living in Nagano Prefecture.
    Ryumachi. [Rheumatism], 1982, Volume: 22, Issue:3

    Topics: Adolescent; Adult; Age Factors; Aged; Agriculture; Female; Gout; Humans; Japan; Male; Middle Aged; O

1982
Synovial fluid examination in hyperuricemic psoriatic patients.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 1982, Volume: 36, Issue:1

    Topics: Adult; Aged; Gout; Humans; Male; Middle Aged; Psoriasis; Synovial Fluid; Uric Acid

1982
[Uric acid and arthritis in Australia. Purified plant extract from meadow saffron is a good preparation against acute gout attacks].
    Lakartidningen, 1982, May-12, Volume: 79, Issue:19

    Topics: Arthritis; Australia; Colchicum; Gout; Humans; Plant Extracts; Plants, Medicinal; Uric Acid

1982
Gout and its manifestations in the head and neck.
    Otolaryngologic clinics of North America, 1982, Volume: 15, Issue:3

    Topics: Allopurinol; Arthritis; Colchicine; Ear, External; Gout; Head; Humans; Indomethacin; Laryngeal Carti

1982
[Microcrystal-induced joint diseases].
    La Nouvelle presse medicale, 1982, Aug-28, Volume: 11, Issue:33

    Topics: Chondrocalcinosis; Female; Gout; Humans; Hydroxyapatites; Male; Uric Acid

1982
[Epidemiology of hyperuricemia and gout].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1982, Jul-01, Volume: 37, Issue:13

    Topics: Body Weight; Chronic Disease; Female; Germany, East; Gout; Humans; Male; Purines; Sex Factors; Uric

1982
[Extraarticular diseases and findings in gout].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1982, Jul-01, Volume: 37, Issue:13

    Topics: Arteriosclerosis; Diabetes Complications; Female; Gout; Humans; Hyperlipoproteinemias; Hypertension;

1982
[Synovial milieu in gouty arthritis].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1982, Jul-01, Volume: 37, Issue:13

    Topics: Arthritis; Crystallization; Gout; Humans; Synovial Fluid; Uric Acid

1982
[Pathogenesis of gouty arthritis].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1982, Jul-01, Volume: 37, Issue:13

    Topics: Acute Disease; Arthritis; Demecolcine; Gout; Granulocytes; Humans; Lysosomes; Phagocytes; Uric Acid

1982
[Prognosis for disorders of purine metabolism].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1982, Jul-01, Volume: 37, Issue:13

    Topics: Age Factors; Arterial Occlusive Diseases; Diabetes Mellitus; Germany, East; Gout; Humans; Hyperlipop

1982
[Prevention and therapy of disorders of purine metabolism].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1982, Jul-01, Volume: 37, Issue:13

    Topics: Arteriosclerosis; Diabetes Mellitus; Gout; Gout Suppressants; Humans; Hyperlipoproteinemias; Metabol

1982
Thiazide-induced hyperuricemia and gout.
    Journal of the American Podiatry Association, 1982, Volume: 72, Issue:10

    Topics: Adult; Arthritis; Benzothiadiazines; Diuretics; Female; Gout; Humans; Male; Phenylbutazone; Sodium C

1982
Ethanol-induced hyperuricemia: evidence for increased urate production by activation of adenine nucleotide turnover.
    The New England journal of medicine, 1982, Dec-23, Volume: 307, Issue:26

    Topics: Adenine Nucleotides; Adenosine Triphosphate; Administration, Oral; Adult; Aged; Alcoholic Beverages;

1982
[Simultaneous incidence of systemic lupus erythematosus and gout].
    Orvosi hetilap, 1982, Aug-08, Volume: 123, Issue:32

    Topics: Crystallization; Female; Gout; Humans; Lupus Erythematosus, Systemic; Middle Aged; Uric Acid

1982
Idiopathic uric acid lithiasis: epidemiologic and metabolic aspects.
    The Journal of urology, 1982, Volume: 128, Issue:6

    Topics: Age Factors; Alcohol Drinking; Calcium Oxalate; Calcium Phosphates; Female; Gout; Humans; Hydrogen-I

1982
[Current treatment of hyperuricemia and gout].
    Medicinski pregled, 1982, Volume: 35, Issue:5-6

    Topics: Acute Disease; Anti-Inflammatory Agents; Arthritis; Gout; Gout Suppressants; Humans; Uric Acid

1982
[Dyslipoproteinemia and hyperuricemia in podagra and urinary calculi].
    Terapevticheskii arkhiv, 1982, Volume: 54, Issue:10

    Topics: Adult; Arteriosclerosis; Cholesterol; Foot Diseases; Gout; Humans; Hyperlipoproteinemias; Hypolipopr

1982
[Asymptomatic hyperuricemia-when should it be treated?].
    Zeitschrift fur arztliche Fortbildung, 1982, Sep-15, Volume: 76, Issue:18

    Topics: Arthritis; Cardiovascular Diseases; Gout; Humans; Kidney Calculi; Kidney Diseases; Patient Care Plan

1982
[Hyperuricemia, gout and ischemic disease of the coronary arteries of the heart].
    Srpski arhiv za celokupno lekarstvo, 1982, Volume: 110, Issue:9

    Topics: Coronary Disease; Gout; Humans; Hypertension; Lipids; Male; Middle Aged; Uric Acid

1982
[Gout and the hyperuricemic syndrome - comments on the differential diagnosis and therapy].
    Fysiatricky a reumatologicky vestnik, 1980, Volume: 58, Issue:4

    Topics: Adult; Diagnosis, Differential; Female; Gout; Humans; Male; Middle Aged; Uric Acid

1980
Urate spherulites in gouty synovia.
    JAMA, 1981, Apr-17, Volume: 245, Issue:15

    Topics: Acute Disease; Birefringence; Crystallization; Female; Gout; Humans; Leukocytes; Microscopy, Electro

1981
Long-term follow-up of incorporation of 15N from glycine into uric acid in gout.
    The American journal of medicine, 1981, Volume: 70, Issue:4

    Topics: Adult; Aged; Aging; Follow-Up Studies; Glycine; Gout; Humans; Male; Middle Aged; Nitrogen; Nitrogen

1981
Ten years' experience with benzbromarone in the management of gout and hyperuricaemia.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1981, May-09, Volume: 59, Issue:20

    Topics: Adult; Aged; Benzbromarone; Benzofurans; Female; Follow-Up Studies; Gout; Humans; Male; Middle Aged;

1981
[Effect of long-term base therapy on the clinical picture of gout].
    Terapevticheskii arkhiv, 1981, Volume: 53, Issue:2

    Topics: Adult; Allopurinol; Chronic Disease; Drug Evaluation; Drug Therapy, Combination; Female; Gout; Human

1981
[Cardiovascular risk factors among African populations. Gout].
    Dakar medical, 1980, Volume: 25, Issue:4

    Topics: Africa; Black or African American; Black People; Cardiovascular Diseases; Female; Gout; Humans; Male

1980
Treatment of gout.
    The New England journal of medicine, 1981, Jul-02, Volume: 305, Issue:1

    Topics: Gout; Humans; Probenecid; Uric Acid; Uricosuric Agents

1981
Effects of diuretics on urate and calcium excretion.
    Archives of internal medicine, 1981, Volume: 141, Issue:7

    Topics: Adult; Aged; Calcium; Chlorides; Furosemide; Glycolates; Gout; Humans; Hydrochlorothiazide; Middle A

1981
[Gout (author's transl)].
    Zhonghua nei ke za zhi, 1981, Volume: 20, Issue:1

    Topics: Gout; Humans; Purines; Uric Acid

1981
[The relation between gout and diabetes mellitus].
    Fortschritte der Medizin, 1981, Aug-06, Volume: 99, Issue:29

    Topics: Blood Glucose; Diabetes Complications; Diabetes Mellitus; Gout; Humans; Hyperlipoproteinemias; Metab

1981
Calculus disease of upper urinary tract in San Francisco Chinese.
    Urology, 1981, Volume: 18, Issue:2

    Topics: Adolescent; Adult; Aged; Calcium; California; Child; China; Diet; Female; Gout; Humans; Male; Middle

1981
Diagnostic and therapeutic aids in gout and hyperuricemia.
    Medical times, 1981, Volume: 109, Issue:8

    Topics: Acute Disease; Allopurinol; Arthritis, Rheumatoid; Colchicine; Diagnosis, Differential; Gout; Humans

1981
Effects of exercise performance on drugs used in musculoskeletal disorders.
    Medicine and science in sports and exercise, 1981, Volume: 13, Issue:4

    Topics: Allopurinol; Analgesics; Anti-Inflammatory Agents; Bone Diseases; Colchicine; Gout; Humans; Muscle R

1981
[Advances in the treatment of gout and hyperuricemia].
    Revista clinica espanola, 1981, May-31, Volume: 161, Issue:4

    Topics: Anti-Inflammatory Agents; Female; Gout; Humans; Hypertension; Kidney Calculi; Kidney Diseases; Male;

1981
[Comparative biochemical studies in asymptomatic hyperuricemia and manifest gout with special reference to renal change].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1981, May-01, Volume: 36, Issue:9

    Topics: Adolescent; Adult; Creatinine; Electrophoresis, Polyacrylamide Gel; Gout; Humans; Hyperlipoproteinem

1981
The diagnosis and management of acute and chronic gout.
    Australian family physician, 1981, Volume: 10, Issue:7

    Topics: Acute Disease; Arthritis; Chronic Disease; Diagnosis, Differential; Gout; Gout Suppressants; Humans;

1981
Urolithiasis in hyperuricemia and gout.
    The Journal of urology, 1981, Volume: 126, Issue:4

    Topics: Adult; Allopurinol; Child; Female; Gout; Humans; Hypoxanthine Phosphoribosyltransferase; Male; Myelo

1981
Management of asymptomatic hyperuricemia.
    JAMA, 1981, Nov-13, Volume: 246, Issue:19

    Topics: Acute Disease; Cardiovascular Diseases; Decision Making; Gout; Humans; Kidney Calculi; Risk; Uric Ac

1981
[Current methods of treating acute gouty arthritis].
    Terapevticheskii arkhiv, 1981, Volume: 53, Issue:7

    Topics: Acute Disease; Administration, Topical; Adult; Aged; Arthritis; Dimethyl Sulfoxide; Female; Gout; Hu

1981
Familial gout and renal failure.
    Archives of disease in childhood, 1981, Volume: 56, Issue:9

    Topics: Adult; Child; Creatinine; Female; Gout; Humans; Kidney Failure, Chronic; Male; Pedigree; Uric Acid

1981
[The serum uric acid level in the Viennese population (author's transl)].
    Wiener klinische Wochenschrift, 1981, Aug-07, Volume: 93, Issue:15

    Topics: Adult; Age Factors; Austria; Blood Glucose; Body Weight; Diabetes Mellitus; Female; Gout; Health Sur

1981
The effect of lead upon urate nucleation.
    Arthritis and rheumatism, 1981, Volume: 24, Issue:10

    Topics: Chemical Phenomena; Chemistry; Crystallization; Gout; Humans; Lead; Lead Poisoning; Uric Acid

1981
Uric acid crystal-induced nephropathy: evidence for a specific renal lesion in a gouty family.
    The Journal of pathology, 1981, Volume: 135, Issue:2

    Topics: Adenine; Adult; Animals; Child; Child, Preschool; Female; Gout; Humans; Kidney; Kidney Diseases; Swi

1981
[Elevated serum uric acid in a normal population and in patients (author's transl)].
    Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis, 1981, Nov-17, Volume: 70, Issue:47

    Topics: Adult; Female; Gout; Humans; Male; Middle Aged; Uric Acid

1981
Uric acid, gout and the kidney.
    Journal of clinical pathology, 1981, Volume: 34, Issue:11

    Topics: Acute Kidney Injury; Adult; Animals; Female; Gout; Humans; Kidney; Kidney Diseases; Male; Middle Age

1981
Urate deposits in the renal medulla. Prevalence and associations.
    Nephron, 1981, Volume: 29, Issue:5-6

    Topics: Female; Gout; Humans; Kidney Calculi; Kidney Medulla; Male; Uric Acid; Urodynamics

1981
Rheumatoid factor and monosodium urate crystal-neutrophil interactions in gouty inflammation.
    Inflammation, 1981, Volume: 5, Issue:4

    Topics: Adult; Cell Adhesion; Crystallization; Gout; Humans; Hydrolases; Inflammation; Kinetics; Lysosomes;

1981
Avian gout caused by oosporein, a mycotoxin produced by Caetomium trilaterale.
    Poultry science, 1981, Volume: 60, Issue:11

    Topics: Animals; Chickens; Gizzard, Avian; Gout; Kidney Tubules; Mycotoxins; Poultry; Poultry Diseases; Uric

1981
[Acute, massive urate crystal deposition into the subcutaneous tissues of patients with gout (author's transl)].
    Lijecnicki vjesnik, 1981, Volume: 103, Issue:9

    Topics: Acute Disease; Aged; Connective Tissue; Crystallization; Female; Finger Joint; Gout; Humans; Male; U

1981
[Diagnosis and therapy of gout and hyperuricemia].
    Revista medica de Chile, 1981, Volume: 109, Issue:12

    Topics: Colchicine; Diet; Gout; Gout Suppressants; Humans; Kidney; Uric Acid; Uricosuric Agents

1981
[Elements of risk of ischemic heart disease in patients with primary gout and its behavior as a function of the basic treatment].
    Reumatologia, 1981, Volume: 19, Issue:3-4

    Topics: Adult; Aged; Coronary Disease; Gout; Humans; Male; Middle Aged; Risk; Uric Acid

1981
[Acute attack of gout].
    Zeitschrift fur Alternsforschung, 1981, Volume: 36, Issue:4

    Topics: Acute Disease; Allopurinol; Bed Rest; Breathing Exercises; Colchicine; Female; Gout; Humans; Indomet

1981
Monosodium urate crystals in asymptomatic joints.
    Arthritis and rheumatism, 1980, Volume: 23, Issue:1

    Topics: Crystallization; Gout; Humans; Male; Synovial Fluid; Uric Acid

1980
High uric acid as an indicator of cardiovascular disease. Independence from obesity.
    The American journal of medicine, 1980, Volume: 68, Issue:3

    Topics: Aged; Body Weight; Cardiovascular Diseases; Coronary Disease; Female; Follow-Up Studies; Gout; Human

1980
Coexistent rheumatoid arthritis and chronic tophaceous gout.
    Arthritis and rheumatism, 1980, Volume: 23, Issue:2

    Topics: Aged; Arthritis, Rheumatoid; Chronic Disease; Foot; Gout; Hand; Humans; Immunosuppression Therapy; M

1980
Gouty arthritis: a disease for all ages.
    Geriatrics, 1980, Volume: 35, Issue:5

    Topics: Aged; Arthritis; Colchicine; Female; Gout; Humans; Kidney; Male; Middle Aged; Synovial Fluid; Uric A

1980
Current status of diagnosis and treatment of acute gouty arthritis.
    Australian family physician, 1980, Volume: 9, Issue:3

    Topics: Acute Disease; Adult; Arthritis; Female; Gout; Humans; Kidney Diseases; Male; Middle Aged; Synovial

1980
[The use of allopurinol in long-term treatments for optimal effect].
    Fortschritte der Medizin, 1980, Mar-13, Volume: 98, Issue:10

    Topics: Allopurinol; Biological Availability; Dose-Response Relationship, Drug; Gout; Half-Life; Humans; Kin

1980
[Uric acid-induced diseases. 1. Clinical picture, forms of manifestation].
    Fortschritte der Medizin, 1980, Apr-03, Volume: 98, Issue:13

    Topics: Animals; Arteriosclerosis; Gout; Humans; Kidney Calculi; Kidney Diseases; Pruritus; Rats; Risk; Syno

1980
[Uric acid-induced diseases. 2. Therapy].
    Fortschritte der Medizin, 1980, Apr-10, Volume: 98, Issue:14

    Topics: Allopurinol; Benzbromarone; Benzothiadiazines; Diuretics; Gout; Humans; Purines; Sodium Chloride Sym

1980
Studies on the nucleation of monosodium urate at 37 degrees c.
    Arthritis and rheumatism, 1980, Volume: 23, Issue:5

    Topics: Connective Tissue; Crystallization; Gout; Humans; Hydrogen-Ion Concentration; Sodium; Solubility; Sy

1980
Atraumatic avascular necrosis of the talus associated with hyperuricemia.
    Clinical orthopaedics and related research, 1980, Issue:148

    Topics: Black People; Female; Gout; Humans; Middle Aged; Osteonecrosis; Talus; Uric Acid

1980
[Attempt at normalizing the uricemia in gout].
    Vrachebnoe delo, 1980, Issue:4

    Topics: Adolescent; Adult; Aged; Chronic Disease; Drug Evaluation; Drug Therapy, Combination; Female; Gout;

1980
Renal handling of uric acid in normal and gouty subject: evidence for a 4-component system.
    Annals of the rheumatic diseases, 1980, Volume: 39, Issue:2

    Topics: Absorption; Benzbromarone; Blood Proteins; Female; Gout; Humans; In Vitro Techniques; Kidney; Kidney

1980
Determination of uric acid in serum using isotachophoresis.
    Journal of chromatography, 1980, Jun-13, Volume: 182, Issue:3-4

    Topics: Adult; Aged; Arthritis, Rheumatoid; Electrophoresis; Female; Gout; Humans; Male; Microchemistry; Mid

1980
[Hyperuricemia and gout].
    Die Medizinische Welt, 1980, Apr-18, Volume: 31, Issue:16

    Topics: Female; Gout; Humans; Male; Risk; Uric Acid; Urinary Calculi

1980
[Efficacy and tolerance of a new benzbromarone preparation].
    Die Medizinische Welt, 1980, May-23, Volume: 31, Issue:21

    Topics: Benzbromarone; Benzofurans; Gout; Humans; Hydrogen-Ion Concentration; Uric Acid; Urine

1980
Hereditary uricemia and articular gout in chickens.
    Poultry science, 1980, Volume: 59, Issue:5

    Topics: Animals; Chickens; Diet; Female; Gout; Male; Poultry Diseases; Uric Acid

1980
Primary overproduction of urate caused by a partial deficiency of hypoxanthine-guanine phosphoribosyl transferase.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1980, Jun-07, Volume: 57, Issue:23

    Topics: Adult; Gout; Humans; Hypoxanthine Phosphoribosyltransferase; Male; Uric Acid

1980
[Characteristics of the clinical course and diagnosis of gout under present-day conditions].
    Terapevticheskii arkhiv, 1980, Volume: 52, Issue:7

    Topics: Adult; Aged; Arthritis, Rheumatoid; Diagnosis, Differential; Gout; Humans; Male; Middle Aged; Synovi

1980
[Clinical picture and management of gout and hyperuricemia].
    Nihon Seikeigeka Gakkai zasshi, 1980, Volume: 54, Issue:6

    Topics: Adult; Female; Gout; Humans; Japan; Male; Middle Aged; Uric Acid

1980
[A case of primary hypouricosuric gout associated with mental retardation, self-mutilation and salt dependent hypertension (author's transl)].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1980, Jun-06, Volume: 69, Issue:6

    Topics: Adolescent; Gout; Humans; Hypertension; Intellectual Disability; Male; Self Mutilation; Uric Acid

1980
Psychosomatic aspects of gout.
    The Journal of general psychology, 1980, Volume: 103, Issue:1st Half

    Topics: Adult; Drive; Female; Gout; Humans; Male; Middle Aged; Psychophysiologic Disorders; Stress, Psycholo

1980
Indomethacin-induced hyperkalemia in three patients with gouty arthritis.
    JAMA, 1980, Sep-05, Volume: 244, Issue:10

    Topics: Acute Disease; Acute Kidney Injury; Aged; Diabetes Mellitus; Female; Gout; Humans; Hyperkalemia; Ind

1980
Changing trends of mortality in gout.
    Seminars in arthritis and rheumatism, 1980, Volume: 10, Issue:1

    Topics: Aged; Arteriosclerosis; Coronary Disease; Female; Gout; Humans; Kidney Diseases; Male; Middle Aged;

1980
Hyperuricemia in cyanotic congenital heart disease.
    American journal of diseases of children (1960), 1980, Volume: 134, Issue:9

    Topics: Adolescent; Adult; Allopurinol; Arthritis; Child; Child, Preschool; Gout; Heart Defects, Congenital;

1980
The natural history of hyperuricemia among asymptomatic relatives of patients with gout.
    Advances in experimental medicine and biology, 1980, Volume: 122A

    Topics: Amino Acids; Blood; Female; Glutamates; Glutamine; Gout; Humans; Hydrogen-Ion Concentration; Male; R

1980
Monosodium urate monohydrate as spherulites.
    Advances in experimental medicine and biology, 1980, Volume: 122A

    Topics: Birefringence; Crystallography; Gout; Humans; Microscopy, Electron, Scanning; Uric Acid

1980
Hereditary and environmental factors influencing on the serum uric acid throughout ten years population study in Japan.
    Advances in experimental medicine and biology, 1980, Volume: 122A

    Topics: Adolescent; Adult; Age Factors; Aged; Child; Child, Preschool; Environment; Female; Gout; Humans; In

1980
Family study of lipid and purine levels in gout patients and analysis of mortality.
    Advances in experimental medicine and biology, 1980, Volume: 122A

    Topics: Cholesterol; Female; Gout; Humans; Hyperlipidemias; Lipoproteins; Male; Sex Factors; Triglycerides;

1980
Tienilic acid in the treatment of gout and hypertension.
    Advances in experimental medicine and biology, 1980, Volume: 122A

    Topics: Adult; Blood Chemical Analysis; Blood Pressure; Creatinine; Glycolates; Gout; Humans; Hypertension;

1980
Erythrocyte adenosine-deaminase activity in gout and hyperuricemia.
    Advances in experimental medicine and biology, 1980, Volume: 122A

    Topics: Adenosine Deaminase; Erythrocytes; Female; Fructose; Gout; Humans; Kidney Diseases; Male; Nucleoside

1980
Clinical features of 4,000 gouty subjects in Japan.
    Advances in experimental medicine and biology, 1980, Volume: 122A

    Topics: Adult; Age Factors; Female; Gout; Humans; Hypertension; Japan; Kidney Failure, Chronic; Male; Middle

1980
Determination of tubular secretion of urate in healthy and gouty men.
    Advances in experimental medicine and biology, 1980, Volume: 122A

    Topics: Adult; Benzbromarone; Female; Gout; Humans; Kidney Tubules; Male; Reference Values; Uric Acid

1980
Familial gout and renal failure in young women.
    Clinical nephrology, 1980, Volume: 14, Issue:4

    Topics: Acute Kidney Injury; Adolescent; Adult; Allopurinol; Child; Female; Gout; Humans; Middle Aged; Uric

1980
Gout and achievement.
    JAMA, 1980, Nov-07, Volume: 244, Issue:18

    Topics: Achievement; Gout; Humans; Uric Acid

1980
[Case of uric acid gout].
    Ortopediia travmatologiia i protezirovanie, 1980, Issue:10

    Topics: Aged; Elbow Joint; Gout; Humans; Male; Uric Acid

1980
[Epidemiology and clinical aspects of hyperuricemia and gout].
    Zeitschrift fur arztliche Fortbildung, 1980, Jul-01, Volume: 74, Issue:13-14

    Topics: Aged; Alcohol Drinking; Blood Pressure; Body Weight; Diagnosis, Differential; Feeding Behavior; Gout

1980
Controlled inpatient study of tienilic acid in treatment of gout and hypertension.
    Annals of the rheumatic diseases, 1980, Volume: 39, Issue:4

    Topics: Blood Pressure; Drug Administration Schedule; Glycolates; Gout; Humans; Hypertension; Ticrynafen; Ur

1980
Tienilic acid: a single treatment for hyperuricaemia and hypertension?
    Annals of the rheumatic diseases, 1980, Volume: 39, Issue:4

    Topics: Adult; Aged; Blood Pressure; Glycolates; Gout; Humans; Hypertension; Male; Middle Aged; Ticrynafen;

1980
Gout secondary to chronic renal disease: studies on urate metabolism.
    Annals of the rheumatic diseases, 1980, Volume: 39, Issue:5

    Topics: Adult; Arthritis; Chronic Disease; Female; Gout; Humans; Kidney; Kidney Diseases; Male; Middle Aged;

1980
[Gout as a joint disease and as a generalized disease. Incidence, diagnosis and therapy].
    Fortschritte der Medizin, 1980, Aug-07, Volume: 98, Issue:29

    Topics: Allopurinol; Colchicine; Diabetes Complications; Gout; Humans; Hypertension; Indomethacin; Kidney Di

1980
Chronic gouty nephropathy: a vanishing syndrome?
    The New England journal of medicine, 1981, Feb-26, Volume: 304, Issue:9

    Topics: Animals; Gout; Humans; Kidney Diseases; Lead Poisoning; Lesch-Nyhan Syndrome; Lymphoproliferative Di

1981
[Study of the binding between uric acid and plasma proteins (author's transl)].
    Quaderni Sclavo di diagnostica clinica e di laboratorio, 1980, Volume: 15, Issue:4

    Topics: Blood Proteins; Electrophoresis, Agar Gel; Electrophoresis, Cellulose Acetate; Gout; Humans; Hyperli

1980
[Secondary hyperuricemia (author's transl)].
    Revue medicale de Bruxelles, 1980, Volume: 1, Issue:7

    Topics: Female; Gout; Humans; Male; Metabolic Diseases; Uric Acid

1980
Hyperuricaemia and gout in Western Samoans.
    Journal of chronic diseases, 1981, Volume: 34, Issue:2-3

    Topics: Adult; Aged; Epidemiologic Methods; Female; Gout; Humans; Independent State of Samoa; Life Style; Ma

1981
Uricosuric diuretics.
    Kidney international, 1980, Volume: 18, Issue:5

    Topics: Amiloride; Diuretics; Dose-Response Relationship, Drug; Drug Therapy, Combination; Gout; Humans; Ind

1980
[Value of uric acid clearance for the differential diagnosis and differential therapy of disorders of uric acid metabolism].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1980, Sep-01, Volume: 35, Issue:17

    Topics: Arthritis; Female; Gout; Humans; Male; Uric Acid

1980
Cyclosporine-induced hyperuricemia and gout in renal transplants.
    Transplantation proceedings, 1995, Volume: 27, Issue:5

    Topics: Adult; Allopurinol; Azathioprine; Cyclosporine; Drug Interactions; Gout; Gout Suppressants; Humans;

1995
Inflammatory microcrystals differentially regulate the secretion of macrophage inflammatory protein 1 and interleukin 8 by human neutrophils: a possible mechanism of neutrophil recruitment to sites of inflammation in synovitis.
    The Journal of experimental medicine, 1995, Dec-01, Volume: 182, Issue:6

    Topics: Calcium Pyrophosphate; Cells, Cultured; Chemokine CCL3; Chemokine CCL4; Chemokine CXCL1; Chemokines,

1995
A quantitative study of the phagocytosis of urate crystals in the synovial fluid of asymptomatic joints of patients with gout.
    British journal of rheumatology, 1995, Volume: 34, Issue:8

    Topics: Crystallization; Gout; Humans; Joints; Leukocyte Count; Monocytes; Neutrophils; Phagocytosis; Synovi

1995
The effects of alcoholic beverages on urate metabolism in gout sufferers.
    British journal of rheumatology, 1995, Volume: 34, Issue:8

    Topics: Alcohol Drinking; Alcoholic Beverages; Beer; Beverages; Citrus; Ethanol; Gout; Humans; Purines; Uric

1995
Clinical and biochemical presentation of gouty diathesis: comparison of uric acid versus pure calcium stone formation.
    The Journal of urology, 1995, Volume: 154, Issue:5

    Topics: Adult; Age Distribution; Alkalies; Body Mass Index; Calcium; Chemical Phenomena; Chemistry, Physical

1995
Gout in patients attending the rheumatology unit of Lomé Hospital.
    British journal of rheumatology, 1995, Volume: 34, Issue:9

    Topics: Adult; Female; Gout; Hospital Departments; Hospitals; Humans; Male; Middle Aged; Retrospective Studi

1995
Urate-oxidase for the treatment of tophaceous gout in heart transplant recipients. A report of three cases.
    Revue du rhumatisme (English ed.), 1995, Volume: 62, Issue:5

    Topics: Adult; Aged; Female; Gout; Heart Transplantation; Humans; Male; Middle Aged; Postoperative Complicat

1995
Renal urate hypoexcretion in Polynesian women is not as severe as in United Kingdom (UK) women with familial juvenile hyperuricaemic nephropathy (FJHN).
    Advances in experimental medicine and biology, 1994, Volume: 370

    Topics: Adult; Analysis of Variance; Creatinine; Female; Gout; Humans; Kidney Diseases; Middle Aged; Polynes

1994
Differential diagnosis of main rheumatic diseases in man.
    Advances in experimental medicine and biology, 1994, Volume: 370

    Topics: Arthritis, Psoriatic; Arthritis, Rheumatoid; Blood Glucose; Blood Sedimentation; Blood Urea Nitrogen

1994
Analysis of the genotypes for aldehyde dehydrogenase 2 in Japanese patients with primary gout.
    Advances in experimental medicine and biology, 1994, Volume: 370

    Topics: Alcohol Drinking; Aldehyde Dehydrogenase; Alleles; Genetic Carrier Screening; Gout; Homozygote; Huma

1994
Purine metabolism in female patients with primary gout.
    Advances in experimental medicine and biology, 1994, Volume: 370

    Topics: Adenine; Arthritis, Gouty; Creatinine; Female; Gout; Humans; Hypoxanthine; Hypoxanthines; Male; Puri

1994
Familial juvenile hyperuricaemic nephropathy in adolescents.
    Advances in experimental medicine and biology, 1994, Volume: 370

    Topics: Adolescent; Adult; Diagnosis, Differential; Erythrocytes; Female; Gout; Humans; Hypoxanthine Phospho

1994
Serum concentration of Lp(a) in patients with primary gout.
    Advances in experimental medicine and biology, 1994, Volume: 370

    Topics: Alanine Transaminase; Alcohol Drinking; Apolipoproteins; Aspartate Aminotransferases; Blood Glucose;

1994
Study on lipoprotein lipase and hepatic triglyceride lipase activities in patients with gout.
    Advances in experimental medicine and biology, 1994, Volume: 370

    Topics: Apolipoproteins B; Body Mass Index; Cholesterol; Cholesterol, HDL; Cohort Studies; Gout; Humans; Lip

1994
Benzbromarone and fenofibrate are lipid lowering and uricosuric: a possible key to metabolic syndrome?
    Advances in experimental medicine and biology, 1994, Volume: 370

    Topics: Benzbromarone; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Fenofibrate; Gout; Humans; Hyperlipi

1994
Determination of plasma purine nucleoside phosphorylase activity by high-performance liquid chromatography.
    Analytical biochemistry, 1995, May-01, Volume: 227, Issue:1

    Topics: Adult; Aged; Asthma; Calibration; Chromatography, High Pressure Liquid; Febuxostat; Female; Gout; Go

1995
How much do we know about hyperuricemia and gout? The expectations and the results.
    Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti, 1993, Volume: 47, Issue:1

    Topics: Clinical Competence; Educational Status; Gout; Humans; Internal Medicine; Uric Acid

1993
Gout and the gullible.
    The Journal of rheumatology, 1994, Volume: 21, Issue:12

    Topics: Crystallization; Gout; Humans; Solubility; Uric Acid

1994
Not water, but formalin, dissolves urate crystals in tophaceous tissue samples.
    The Journal of rheumatology, 1994, Volume: 21, Issue:12

    Topics: Crystallization; Ethanol; Formaldehyde; Gout; Humans; Solubility; Uric Acid; Water

1994
Gout: questions that still need to be answered.
    Annals of the rheumatic diseases, 1995, Volume: 54, Issue:2

    Topics: Animals; Crystallization; Disease Models, Animal; Gout; Humans; Mice; Mice, Mutant Strains; Synoviti

1995
Missed opportunity following diagnosis of gout.
    Annals of the rheumatic diseases, 1995, Volume: 54, Issue:2

    Topics: Adult; Allopurinol; Beer; Cardiovascular Diseases; Gout; Humans; Lipoproteins; Male; Risk Factors; U

1995
Gout and hyperuricaemia.
    Bailliere's clinical rheumatology, 1995, Volume: 9, Issue:1

    Topics: Acute Disease; Africa; Asia, Southeastern; Chronic Disease; Female; Gout; Humans; Male; New Zealand;

1995
[The frequency of gout and other disorders of uric acid metabolism in Dalmatia in comparison with these disorders in Croatia].
    Reumatizam, 1993, Volume: 40, Issue:2

    Topics: Croatia; Female; Gout; Humans; Male; Prevalence; Uric Acid; Urinary Calculi; Yugoslavia

1993
Effect of glucose infusion on the renal transport of purine bases and oxypurinol.
    Nephron, 1995, Volume: 69, Issue:4

    Topics: Adult; Allopurinol; Biological Transport, Active; Diabetes Complications; Diabetes Mellitus; Glucose

1995
Does renal impairment protect from gout?
    The Journal of rheumatology, 1995, Volume: 22, Issue:3

    Topics: Adult; Aged; Cohort Studies; Creatinine; Female; Gout; Humans; Kidney Diseases; Male; Middle Aged; R

1995
Molecular recognition. Crystallographic antibodies.
    Nature, 1995, Jan-12, Volume: 373, Issue:6510

    Topics: Allopurinol; Animals; Antibodies; Catalysis; Crystallization; Gout; Humans; Immunoglobulin G; Rabbit

1995
[Gout tophi and Heberden nodules in hyperuricemia].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1994, Volume: 45, Issue:11

    Topics: Aged; Aged, 80 and over; Arthritis, Gouty; Female; Fingers; Gout; Hand Deformities, Acquired; Humans

1994
Familial hyperuricemic nephropathy.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 1995, Volume: 25, Issue:2

    Topics: Adolescent; Adult; Child; Family Health; Female; Genes, Dominant; Gout; Humans; Hypertension; Kidney

1995
Community-based epidemiological study on hyperuricemia in Pu-Li, Taiwan.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 1993, Volume: 92, Issue:7

    Topics: Adult; Cross-Sectional Studies; Diet; Female; Gout; Humans; Male; Middle Aged; Prevalence; Risk Fact

1993
Polynesian women are also at risk for hyperuricaemia and gout because of a genetic defect in renal urate handling.
    British journal of rheumatology, 1994, Volume: 33, Issue:10

    Topics: Adult; Erythrocytes; Family; Female; Gout; Humans; Kidney Diseases; Male; Middle Aged; Pentosyltrans

1994
Purine metabolism in women with primary gout.
    The American journal of medicine, 1994, Volume: 97, Issue:4

    Topics: Aged; Creatinine; Female; Gout; Humans; Hypoxanthine; Hypoxanthines; Male; Middle Aged; Prospective

1994
Complexation of iron cation by sodium urate crystals and gouty inflammation.
    Archives of biochemistry and biophysics, 1994, Volume: 313, Issue:2

    Topics: Chemotaxis, Leukocyte; Chlorides; Complement Activation; Crystallization; Deferoxamine; Ferric Compo

1994
Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6720 in chimpanzees.
    European journal of pharmacology, 1993, Dec-21, Volume: 250, Issue:3

    Topics: Administration, Oral; Allopurinol; Animals; Dose-Response Relationship, Drug; Febuxostat; Female; Go

1993
[Spectrophotometric determination of uric acid in serum using a titanium (IV)-porphyrin complex].
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 1994, Volume: 114, Issue:1

    Topics: Gout; Humans; Porphyrins; Reagent Kits, Diagnostic; Spectrophotometry; Titanium; Urate Oxidase; Uric

1994
[The clinical manifestations of a purine metabolic disorder in the practice of the internist].
    Terapevticheskii arkhiv, 1994, Volume: 66, Issue:1

    Topics: Adult; Arthritis, Gouty; Glomerulonephritis; Gout; Humans; Liver Cirrhosis, Alcoholic; Middle Aged;

1994
[The use of Allomaron in treating hyperuricemia].
    Terapevticheskii arkhiv, 1994, Volume: 66, Issue:1

    Topics: Adult; Allopurinol; Arthritis, Gouty; Benzbromarone; Creatinine; Drug Combinations; Drug Evaluation;

1994
Lesch-Nyhan syndrome presenting with renal insufficiency in infancy and transient neonatal hypothyroidism.
    British journal of rheumatology, 1994, Volume: 33, Issue:4

    Topics: Acute Kidney Injury; Erythrocytes; Gout; Humans; Hypothyroidism; Hypoxanthine Phosphoribosyltransfer

1994
[Hyperuricemia and gout: therapeutic indications].
    La Revue du praticien, 1994, Jan-15, Volume: 44, Issue:2

    Topics: Acute Disease; Gout; Gout Suppressants; Humans; Uric Acid

1994
Thoracic myelopathy due to compression by the epidural tophus: a case report.
    Journal of spinal disorders, 1994, Volume: 7, Issue:1

    Topics: Constipation; Crystallization; Epidural Space; Gout; Humans; Laminectomy; Male; Middle Aged; Neuromu

1994
Changes in the proteins coating monosodium urate crystals during active and subsiding inflammation. Immunogold studies of synovial fluid from patients with gout and of fluid obtained using the rat subcutaneous air pouch model.
    Arthritis and rheumatism, 1993, Volume: 36, Issue:9

    Topics: Aged; Animals; Apolipoproteins B; Crystallization; Gout; Humans; Immunoglobulin G; Immunohistochemis

1993
Withdrawal of longterm antihyperuricemic therapy in tophaceous gout.
    The Journal of rheumatology, 1993, Volume: 20, Issue:8

    Topics: Adult; Allopurinol; Drug Administration Schedule; Gout; Humans; Middle Aged; Recurrence; Retrospecti

1993
Tophaceous gout of patella partita.
    The Journal of rheumatology, 1993, Volume: 20, Issue:8

    Topics: Adult; Arthrography; Gout; Humans; Male; Patella; Uric Acid

1993
Gout without hyperuricemia.
    JAMA, 1994, Jan-26, Volume: 271, Issue:4

    Topics: Acute Disease; Aged; Aged, 80 and over; Crystallization; Gout; Humans; Male; Reference Values; Tempe

1994
Gout: an experience from Zimbabwe.
    The Central African journal of medicine, 1993, Volume: 39, Issue:3

    Topics: Adult; Alcoholism; Comorbidity; Female; Follow-Up Studies; Gout; Humans; Male; Middle Aged; Risk Fac

1993
[Female gout disclosing Bartter pseudo-syndrome caused by vomiting].
    La Revue de medecine interne, 1993, Volume: 14, Issue:3

    Topics: Adult; Bartter Syndrome; Diagnosis, Differential; Female; Gout; Humans; Uric Acid; Vomiting

1993
[Hyperuricemia and atherosclerosis].
    Nihon rinsho. Japanese journal of clinical medicine, 1993, Volume: 51, Issue:8

    Topics: Aged; Arteriosclerosis; Diet, Atherogenic; Gout; Humans; Hyperinsulinism; Hyperlipidemias; Hypertens

1993
Hereditary nephropathy associated with hyperuricemia and gout.
    Archives of internal medicine, 1993, Feb-08, Volume: 153, Issue:3

    Topics: Adolescent; Adult; Child; Female; Follow-Up Studies; Gout; Humans; Kidney; Kidney Failure, Chronic;

1993
[Hyperuricemia].
    Nihon rinsho. Japanese journal of clinical medicine, 1993, Volume: 51 Suppl

    Topics: Adolescent; Adult; Aged; Female; Gout; Humans; Japan; Male; Middle Aged; Prognosis; Uric Acid

1993
Glycogenosis type V (McArdle's disease) with hyperuricemia. A case report and clinical investigation.
    European neurology, 1993, Volume: 33, Issue:3

    Topics: Adult; Biopsy; Enzymes; Exercise Test; Glycogen Storage Disease Type V; Gout; Humans; Male; Muscles;

1993
Rapid development of a tophus following ipsilateral hemiparesis.
    Annals of the rheumatic diseases, 1993, Volume: 52, Issue:4

    Topics: Acute Disease; Aged; Aged, 80 and over; Cerebrovascular Disorders; Foot Diseases; Gout; Hemiplegia;

1993
Tophaceous gout in patients with renal transplants treated with cyclosporine A.
    The Journal of rheumatology, 1993, Volume: 20, Issue:4

    Topics: Adult; Cyclosporine; Female; Gout; Humans; Kidney Transplantation; Male; Middle Aged; Postoperative

1993
Tophaceous gout in young patients with systemic lupus erythematosus.
    The Journal of rheumatology, 1993, Volume: 20, Issue:4

    Topics: Adult; Female; Glomerulonephritis; Gout; Humans; Lupus Erythematosus, Systemic; Male; Uric Acid

1993
Gout: modern management of an ancient malady.
    Journal of the South Carolina Medical Association (1975), 1993, Volume: 89, Issue:5

    Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Arthritis, Infectious; Gout;

1993
[Contraindication of ATP related drugs for therapy of gout and uric acidemia].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1995, Nov-10, Volume: 84, Issue:11

    Topics: Adenosine Triphosphate; Contraindications; Dipyridamole; Gout; Humans; Platelet Aggregation Inhibito

1995
[An epidemiologic study on pathogenesis of uric acid urolithiasis].
    Ryumachi. [Rheumatism], 1995, Volume: 35, Issue:5

    Topics: Alcohol Drinking; Female; Gout; Humans; Male; Sex Factors; Time Factors; Uric Acid; Urinary Calculi

1995
Management of gout.
    The New England journal of medicine, 1996, Jun-06, Volume: 334, Issue:23

    Topics: Gout; Humans; Uric Acid

1996
[Diagnosis and treatment of gout: not always simple].
    Nederlands tijdschrift voor geneeskunde, 1996, Jan-27, Volume: 140, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Arthritis, Rheumatoid; Biopsy; Colchicine; Diagnosis, D

1996
[Gout: current aspects of etiology, diagnosis and therapy].
    Nederlands tijdschrift voor geneeskunde, 1996, Jan-27, Volume: 140, Issue:4

    Topics: Aged; Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Female; Gout; Gou

1996
Compressive ulnar neuropathy in the proximal forearm caused by a gouty tophus.
    Muscle & nerve, 1996, Volume: 19, Issue:4

    Topics: Carpal Tunnel Syndrome; Diagnosis, Differential; Elbow; Electrodiagnosis; Gout; Humans; Male; Middle

1996
The diagnosis of gout and CPPD crystal arthropathy.
    British journal of rheumatology, 1996, Volume: 35, Issue:4

    Topics: Calcium Pyrophosphate; Chondrocalcinosis; Gout; Humans; Synovial Fluid; Uric Acid

1996
Characterization of E-selectin expression, leucocyte traffic and clinical sequelae in urate crystal-induced inflammation: an insight into gout.
    British journal of rheumatology, 1996, Volume: 35, Issue:4

    Topics: Albumins; Animals; Cell Movement; Disease Models, Animal; E-Selectin; Gout; Leukocytes, Mononuclear;

1996
Inhibition and prevention of monosodium urate monohydrate crystal-induced acute inflammation in vivo by transforming growth factor beta1.
    Arthritis and rheumatism, 1996, Volume: 39, Issue:7

    Topics: Acute Disease; Animals; Antibodies, Anti-Idiotypic; Disease Models, Animal; Dose-Response Relationsh

1996
[Kidney lesions in non-insulin dependent diabetes mellitus].
    Klinicheskaia meditsina, 1995, Volume: 73, Issue:6

    Topics: Adult; Aged; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; G

1995
Finger pad tophi in gout.
    The Journal of rheumatology, 1996, Volume: 23, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Creatinine; Female; Fingers; Gout; Hand Dermatoses;

1996
Gout in the cervical spine: MR pattern mimicking diskovertebral infection.
    AJNR. American journal of neuroradiology, 1996, Volume: 17, Issue:1

    Topics: Arthritis, Gouty; Cervical Vertebrae; Diagnosis, Differential; Discitis; Gout; Humans; Intervertebra

1996
[Microalbuminuria as one of the early diagnostic signs of kidney involvement in patients with a purine metabolic disorder].
    Terapevticheskii arkhiv, 1996, Volume: 68, Issue:6

    Topics: Adult; Albuminuria; Female; Gout; Hematuria; Humans; Kidney Diseases; Male; Purines; Recurrence; Tim

1996
Endogenous analgesia in the chicken.
    Neuroscience letters, 1995, Dec-15, Volume: 201, Issue:3

    Topics: Analgesia; Animals; Ankle Joint; Behavior, Animal; Chickens; Disease Models, Animal; Gout; Time Fact

1995
Gout, uric acid, albumin, and aging.
    Journal of the National Medical Association, 1996, Volume: 88, Issue:8

    Topics: Aging; Gout; Humans; Uric Acid

1996
Determination of human plasma xanthine oxidase activity by high-performance liquid chromatography.
    Journal of chromatography. B, Biomedical applications, 1996, Jun-07, Volume: 681, Issue:2

    Topics: Chromatography, High Pressure Liquid; Ethanol; Glycogen Storage Disease Type I; Gout; Heparin; Hepat

1996
Magnetic resonance imaging of tophaceous gout in the hands and wrists.
    Seminars in arthritis and rheumatism, 1996, Volume: 25, Issue:4

    Topics: Aged; Gout; Hand; Humans; Magnetic Resonance Imaging; Male; Radiography; Sensitivity and Specificity

1996
Unusual localisation of tophaceous gout. A report of four cases and review of the literature.
    Archives of orthopaedic and trauma surgery, 1996, Volume: 115, Issue:5

    Topics: Adult; Aged; Foot Diseases; Gout; Humans; Knee Joint; Male; Toes; Uric Acid

1996
Renal handling of urate in a patient with familial juvenile gouty nephropathy.
    Internal medicine (Tokyo, Japan), 1996, Volume: 35, Issue:7

    Topics: Adolescent; Benzbromarone; Female; Genes, Dominant; Gout; Gout Suppressants; Humans; Kidney; Kidney

1996
Hyperuricemia among Kuwaitis.
    Archives of internal medicine, 1996, Nov-11, Volume: 156, Issue:20

    Topics: Adult; Female; Gout; Hospitals, General; Humans; Kuwait; Life Style; Male; Middle Aged; Obesity; Pre

1996
Gout is on the increase in New Zealand.
    Annals of the rheumatic diseases, 1997, Volume: 56, Issue:1

    Topics: Adolescent; Adult; Age of Onset; Female; Gout; Humans; Male; Middle Aged; Native Hawaiian or Other P

1997
Demonstration of urate in formalin fixative as support for the histopathological diagnosis of gout.
    Histopathology, 1997, Volume: 30, Issue:2

    Topics: Crystallization; Elbow; Formaldehyde; Gout; Humans; Male; Middle Aged; Tissue Preservation; Uric Aci

1997
Purine metabolism in patients with gout: the role of lead.
    Nephron, 1997, Volume: 75, Issue:3

    Topics: Aged; Arteriosclerosis; Chelating Agents; Creatinine; Edetic Acid; Female; Gout; Humans; Hypoxanthin

1997
The perils of nontreatment of hyperuricemia.
    Cleveland Clinic journal of medicine, 1997, Volume: 64, Issue:4

    Topics: Aged; Gout; Gout Suppressants; Humans; Male; Staphylococcal Skin Infections; Uric Acid

1997
High prevalence of hyperuricaemia among Kuwaitis possibly without a proportionate increase in gout.
    British journal of rheumatology, 1997, Volume: 36, Issue:3

    Topics: Adult; Female; Gout; Humans; Kuwait; Male; Middle Aged; Prevalence; Uric Acid

1997
Gout: the last 50 years.
    Journal of the Royal Society of Medicine, 1996, Volume: 89, Issue:11

    Topics: Arthritis, Gouty; Colchicine; Crystallization; Gout; Gout Suppressants; History, 20th Century; Human

1996
Acute gout in a patient taking pefloxacin--a case report.
    Journal of the Indian Medical Association, 1996, Volume: 94, Issue:11

    Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Gout; Humans; Male; Pefloxacin; Respiratory Tract In

1996
Prepatellar bursitis: a unique presentation of tophaceous gout in an normouricemic patient.
    The Journal of rheumatology, 1997, Volume: 24, Issue:5

    Topics: Aged; Bursa, Synovial; Bursitis; Frail Elderly; Gout; Humans; Knee Joint; Magnetic Resonance Imaging

1997
Altered arachidonic acid metabolism in urate crystal induced inflammation.
    Inflammation, 1997, Volume: 21, Issue:2

    Topics: Animals; Arachidonic Acid; Arthritis, Gouty; Crystallization; Disease Models, Animal; Eicosanoids; F

1997
Is the plasma uridine level a marker of the overproduction of uric acid?
    Metabolism: clinical and experimental, 1997, Volume: 46, Issue:7

    Topics: Adult; Biomarkers; Gout; Humans; Male; Middle Aged; Osmolar Concentration; Purines; Triglycerides; U

1997
High prevalence of gout and related risk factors in Taiwan's Aborigines.
    The Journal of rheumatology, 1997, Volume: 24, Issue:7

    Topics: Age Distribution; Aged; Female; Gout; Humans; Logistic Models; Male; Middle Aged; Native Hawaiian or

1997
Thiazide diuretics and the initiation of anti-gout therapy.
    Journal of clinical epidemiology, 1997, Volume: 50, Issue:8

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Benzothiadiazines; Diuretics; Female; Gout; Humans

1997
Molecular determinants of monosodium urate crystal-induced murine peritonitis: a role for endogenous mast cells and a distinct requirement for endothelial-derived selectins.
    The Journal of pharmacology and experimental therapeutics, 1997, Volume: 283, Issue:1

    Topics: Animals; Cell Movement; Crystallization; Endothelium, Vascular; Gout; Histamine; Macrophage-1 Antige

1997
Gouty tophus simulating soft tissue tumor in a heart transplant recipient.
    Skeletal radiology, 1997, Volume: 26, Issue:10

    Topics: Adult; Diagnosis, Differential; Forearm; Gout; Heart Transplantation; Humans; Magnetic Resonance Ima

1997
Gout due to xanthine derivatives.
    British journal of rheumatology, 1997, Volume: 36, Issue:10

    Topics: Allopurinol; Aminophylline; Asthma; Benzbromarone; Bronchodilator Agents; Drug Therapy, Combination;

1997
The contribution of the Rabin Medical Center to the field of rheumatology.
    British journal of rheumatology, 1997, Volume: 36, Issue:10

    Topics: Gout; Humans; Israel; Publications; Rheumatic Diseases; Uric Acid

1997
[Determination of uric acid in scalp hair for non-invasive estimation of uricemic control in hyperuricemia].
    Rinsho byori. The Japanese journal of clinical pathology, 1997, Volume: 45, Issue:11

    Topics: Biomarkers; Gout; Hair; Humans; Sensitivity and Specificity; Uric Acid

1997
Analysis of abnormalities in purine metabolism leading to gout and to neurological dysfunctions in man.
    The Biochemical journal, 1998, Feb-01, Volume: 329 ( Pt 3)

    Topics: Adenylosuccinate Lyase; Aminoimidazole Carboxamide; AMP Deaminase; Gout; Humans; Hypoxanthine Phosph

1998
[Epidemiology, incidence and sex specific differences in primary gout].
    Wiener medizinische Wochenschrift (1946), 1997, Volume: 147, Issue:16

    Topics: Adult; Aged; Austria; Cross-Sectional Studies; Female; Gout; Health Behavior; Humans; Incidence; Lif

1997
Serum uric acid in acute gout.
    Annals of the rheumatic diseases, 1997, Volume: 56, Issue:11

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Biomarkers; Female; Gout; Humans; Male; Middle Aged;

1997
Tophaceous gout of the navicular bone as a cause of medial inflammatory tumor of the foot.
    Foot & ankle international, 1998, Volume: 19, Issue:1

    Topics: Adult; Alcoholism; Anorexia Nervosa; Crystallization; Female; Foot Diseases; Gout; Granuloma, Foreig

1998
[First-time standard setting for therapy of pulmonary tuberculosis after revision of the Medical Treatment Standard--special reference to results of questionnaire survey on reality of early stage short-term PZA therapy and occurrence of the adverse effect
    Kekkaku : [Tuberculosis], 1997, Volume: 72, Issue:11

    Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy; Gout; Humans; Japan; Li

1997
[Treatment of asymptomatic hyperuricemia].
    Der Internist, 1997, Volume: 38, Issue:12

    Topics: Allopurinol; Dose-Response Relationship, Drug; Drug Administration Schedule; Gout; Gout Suppressants

1997
Decreased serum concentrations of 1,25(OH)2-vitamin D3 in patients with gout.
    Metabolism: clinical and experimental, 1998, Volume: 47, Issue:3

    Topics: Adult; Allopurinol; Benzbromarone; Calcifediol; Calcitriol; Calcium; Gout; Gout Suppressants; Humans

1998
Disease-specific noncompliance with drug treatment as a cause of persistent hyperuricemia and gout in anorexia nervosa.
    European journal of medical research, 1998, Feb-21, Volume: 3, Issue:1-2

    Topics: Allopurinol; Anorexia Nervosa; Female; Gout; Humans; Middle Aged; Patient Compliance; Treatment Fail

1998
The epidemiology of hyperuricaemia and gout in Taiwan aborigines.
    British journal of rheumatology, 1998, Volume: 37, Issue:3

    Topics: Adult; Age Distribution; Aged; Asian People; Body Mass Index; Cholesterol; Female; Gout; Humans; Mal

1998
Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment.
    Advances in experimental medicine and biology, 1998, Volume: 431

    Topics: Biomarkers; Confidence Intervals; Drug Monitoring; Gout; Gout Suppressants; Humans; Male; Purine-Pyr

1998
How should we treat tophaceous gout in patients with allopurinol hypersensitivity?
    Advances in experimental medicine and biology, 1998, Volume: 431

    Topics: Adolescent; Adult; Aged; Allopurinol; Benzbromarone; Creatinine; Drug Hypersensitivity; Gout; Gout S

1998
Decreased serum concentrations of 1,25(OH)2-vitamin D3 in patients with gout.
    Advances in experimental medicine and biology, 1998, Volume: 431

    Topics: Allopurinol; Calcifediol; Calcitriol; Gout; Gout Suppressants; Humans; Male; Middle Aged; Parathyroi

1998
De novo purine synthesis is increased in the fibroblasts of purine autism patients.
    Advances in experimental medicine and biology, 1998, Volume: 431

    Topics: Autistic Disorder; Cells, Cultured; Fibroblasts; Gout; Humans; Lesch-Nyhan Syndrome; Purines; Refere

1998
Effect of Tofu (bean curd) ingestion and on uric acid metabolism in healthy and gouty subjects.
    Advances in experimental medicine and biology, 1998, Volume: 431

    Topics: Adult; Dietary Proteins; Food Handling; Glycine max; Gout; Humans; Male; Middle Aged; Reference Valu

1998
Demonstration of urate crystals after formalin fixation.
    Histopathology, 1998, Volume: 32, Issue:4

    Topics: Crystallization; Gout; Histological Techniques; Humans; Microscopy, Polarization; Specimen Handling;

1998
Medullary cystic kidney disease with hyperuricemia and gout in a large Cypriot family: no allelism with nephronophthisis type 1.
    American journal of medical genetics, 1998, May-01, Volume: 77, Issue:2

    Topics: Adult; Age of Onset; Aged; Cyprus; Female; Genes, Dominant; Genetic Linkage; Gout; Humans; Hypertens

1998
Quality control of synovial fluid crystal identification.
    Annals of the rheumatic diseases, 1998, Volume: 57, Issue:2

    Topics: Arthritis; Biomarkers; Crystallization; False Negative Reactions; False Positive Reactions; Gout; Hu

1998
Treatment of gout after transplantation.
    British journal of rheumatology, 1998, Volume: 37, Issue:5

    Topics: Allopurinol; Azathioprine; Cyclosporine; Diuretics; Drug Interactions; Furosemide; Gout; Gout Suppre

1998
Salivary urate in gout, exercise, and diurnal variation.
    Lancet (London, England), 1998, Jun-27, Volume: 351, Issue:9120

    Topics: Adult; Case-Control Studies; Circadian Rhythm; Exercise; Exercise Test; Female; Gout; Humans; Male;

1998
Apoptosis of tubular epithelial cells in familial juvenile gouty nephropathy.
    Nephron, 1998, Volume: 79, Issue:3

    Topics: Adult; Apoptosis; Benzbromarone; Biopsy; Biotin; Deoxyuracil Nucleotides; DNA Fragmentation; Family

1998
Presymptomatic detection of familial juvenile hyperuricaemic nephropathy in children.
    Pediatric nephrology (Berlin, Germany), 1998, Volume: 12, Issue:5

    Topics: Adolescent; Adult; Child; Child, Preschool; Female; Gout; Humans; Kidney Diseases; Kidney Failure, C

1998
Serum uric acid in acute gout.
    Annals of the rheumatic diseases, 1998, Volume: 57, Issue:7

    Topics: Acute Disease; Allopurinol; Gout; Gout Suppressants; Humans; Uric Acid

1998
Restoration of the uricosuric effect of probenecid after triglycylvasopressine administration in a gouty patient.
    Clinical nephrology, 1998, Volume: 50, Issue:4

    Topics: Absorption; Acute Kidney Injury; Adult; Anti-Inflammatory Agents; Benzbromarone; Fludrocortisone; Go

1998
Hyperlipidaemia in hyperuricaemia and gout.
    Annals of the rheumatic diseases, 1998, Volume: 57, Issue:9

    Topics: Gout; Humans; Hyperinsulinism; Hypertriglyceridemia; Insulin Resistance; Uric Acid

1998
Monosodium urate-crystal-stimulated phospholipase D in human neutrophils.
    The Biochemical journal, 1999, Jan-15, Volume: 337 ( Pt 2)

    Topics: ADP-Ribosylation Factors; Adult; Biological Transport; Cell Compartmentation; Cytochalasin B; Cytoso

1999
The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. 1956.
    Nutrition (Burbank, Los Angeles County, Calif.), 1999, Volume: 15, Issue:1

    Topics: Adrenal Cortex Hormones; Androgens; Arteriosclerosis; Body Constitution; Cholelithiasis; Diabetes Me

1999
Intradermal tophi in gout: a case-control study.
    The Journal of rheumatology, 1999, Volume: 26, Issue:1

    Topics: Adult; Aged; Case-Control Studies; Female; Glucocorticoids; Gout; Humans; Male; Middle Aged; Tissue

1999
[Gout: physiopathology, diagnosis, course, treatment].
    La Revue du praticien, 1998, Sep-01, Volume: 48, Issue:13

    Topics: Adult; Aged; Allopurinol; Arthritis, Gouty; Benzbromarone; Diagnosis, Differential; Female; Gout; Go

1998
[The central mechanisms regulating the blood circulation in hyperuricemia].
    Fiziolohichnyi zhurnal (Kiev, Ukraine : 1994), 1999, Volume: 45, Issue:1-2

    Topics: Adenosine; Animals; Blood Circulation; Brain; Brain Chemistry; Cyclic AMP; Cyclic GMP; Disease Model

1999
Identification of crystals in synovial fluid.
    Annals of the rheumatic diseases, 1999, Volume: 58, Issue:5

    Topics: Calcium Pyrophosphate; Crystallization; Gout; Humans; Microscopy, Polarization; Quality Control; Sen

1999
Serum uric acid: correlation with biological, clinical and behavioral factors in Japanese men.
    Journal of epidemiology, 1999, Volume: 9, Issue:2

    Topics: Adult; Alcohol Drinking; Cross-Sectional Studies; Diabetes Mellitus; Gout; Humans; Hypertension; Lif

1999
Displaced pathological patella fracture due to gout.
    Orthopedics, 1999, Volume: 22, Issue:5

    Topics: Biopsy; Debridement; Fractures, Spontaneous; Gout; Humans; Male; Middle Aged; Patella; Radiography;

1999
The epidemiology study of hyperuricemia and gout in a community population of Huangpu District in Shanghai.
    Chinese medical journal, 1998, Volume: 111, Issue:3

    Topics: Adolescent; Adult; Aged; China; Female; Gout; Humans; Male; Middle Aged; Prevalence; Risk Factors; S

1998
Contribution of a missense mutation (Trp64Arg) in beta3-adrenergic receptor gene to multiple risk factors in Japanese men with hyperuricemia.
    Endocrine journal, 1998, Volume: 45, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis; Gout; Humans; Insulin Resistance; Japan; Male; Mid

1998
[Disseminated skin abnormalities due to gout].
    Nederlands tijdschrift voor geneeskunde, 1999, Jun-19, Volume: 143, Issue:25

    Topics: Aged; Arthritis, Gouty; Biopsy; Crystallization; Gout; Humans; Male; Skin; Skin Diseases, Metabolic;

1999
Gout.
    Annals of the rheumatic diseases, 1999, Volume: 58, Issue:10

    Topics: Acute Disease; Aged; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Crystallizati

1999
Synovial fluid analysis for diagnosis of intercritical gout.
    Annals of internal medicine, 1999, Nov-16, Volume: 131, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; Crystallization; Female; Gout; Humans; Knee

1999
Kelley-Seegmiller syndrome due to a unique variant of hypoxanthine-guanine phosphoribosyltransferase: reduced affinity for 5-phosphoribosyl-1-pyrophosphate manifested only at low, physiological substrate concentrations.
    Biochimica et biophysica acta, 2000, Feb-21, Volume: 1500, Issue:2

    Topics: Acute Kidney Injury; Adenine; Cells, Cultured; Child, Preschool; Culture Media, Conditioned; DNA Mut

2000
Regulation of in vivo prostaglandin biosynthesis by glutathione.
    Advances in experimental medicine and biology, 1999, Volume: 469

    Topics: Animals; Cyclooxygenase 1; Cyclooxygenase 2; Fatty Acids, Unsaturated; Glutathione; Glyceraldehyde-3

1999
Localization of a gene for familial juvenile hyperuricemic nephropathy causing underexcretion-type gout to 16p12 by genome-wide linkage analysis of a large family.
    Arthritis and rheumatism, 2000, Volume: 43, Issue:4

    Topics: Chromosome Mapping; Chromosomes, Human, Pair 16; Family Health; Female; Genetic Linkage; Genotype; G

2000
Familial juvenile hyperuricemic nephropathy: localization of the gene on chromosome 16p11.2-and evidence for genetic heterogeneity.
    American journal of human genetics, 2000, Volume: 66, Issue:6

    Topics: Adolescent; Adult; Age of Onset; Carrier Proteins; Child; Chromosome Mapping; Chromosomes, Human, Pa

2000
Staining method to demonstrate urate crystals in formalin-fixed, paraffin-embedded tissue sections.
    Archives of pathology & laboratory medicine, 2000, Volume: 124, Issue:5

    Topics: Birefringence; Crystallization; Formaldehyde; Gout; Histocytological Preparation Techniques; Humans;

2000
Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kinmen.
    The Journal of rheumatology, 2000, Volume: 27, Issue:4

    Topics: Adult; Age Distribution; Cholesterol; Female; Gout; Humans; Logistic Models; Male; Middle Aged; Pred

2000
Clinical manifestations of Korean female gouty patients.
    Clinical rheumatology, 2000, Volume: 19, Issue:2

    Topics: Adolescent; Adult; Age of Onset; Aged; Aged, 80 and over; Cyclosporine; Diuretics; Female; Gout; Gra

2000
Reduced secretion of proinflammatory cytokines of monosodium urate crystal-stimulated monocytes in chronic renal failure: an explanation for infrequent gout episodes in chronic renal failure patients?
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2000, Volume: 15, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Crystallization; Cytokines; Cytological Techniques; Female; Gout; Hu

2000
Effect of urine storage on urinary uric acid concentrations.
    Annals of clinical biochemistry, 2000, Volume: 37 ( Pt 3)

    Topics: Gout; Humans; Male; Reference Values; Specimen Handling; Uric Acid

2000
Diagnosis of intercritical gout.
    Annals of internal medicine, 2000, May-16, Volume: 132, Issue:10

    Topics: Arthritis, Gouty; Crystallization; Gout; Humans; Synovial Fluid; Uric Acid

2000
The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study.
    The Journal of rheumatology, 2000, Volume: 27, Issue:6

    Topics: Adult; Alcohol Drinking; Diuretics; Follow-Up Studies; Gout; Humans; Hypertension; Incidence; Logist

2000
Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study.
    Annals of the rheumatic diseases, 2000, Volume: 59, Issue:7

    Topics: Adult; Body Mass Index; Diet, Reducing; Dietary Fats, Unsaturated; Dietary Proteins; Follow-Up Studi

2000
Effect of tea and coffee consumption on serum uric acid levels by liquid-chromatographic and uricase methods.
    Bulletin of environmental contamination and toxicology, 2000, Volume: 65, Issue:3

    Topics: Chromatography, High Pressure Liquid; Coffee; Diet; Female; Gout; Humans; Male; Tea; Urate Oxidase;

2000
Effect of low level lead exposure on hyperuricemia and gout among middle aged and elderly men: the normative aging study.
    The Journal of rheumatology, 2000, Volume: 27, Issue:7

    Topics: Age Factors; Aged; Alcohol Drinking; Blood Pressure; Body Mass Index; Bone Density; Cohort Studies;

2000
Carpal tunnel syndrome caused by tophaceous gout: CT and MR imaging features in 20 patients.
    AJR. American journal of roentgenology, 2000, Volume: 175, Issue:3

    Topics: Adult; Aged; Carpal Tunnel Syndrome; Female; Gout; Humans; Magnetic Resonance Imaging; Male; Middle

2000
[Tophaceous gout].
    Presse medicale (Paris, France : 1983), 2000, Sep-09, Volume: 29, Issue:25

    Topics: Aged; Aged, 80 and over; Diuretics; Female; Fingers; Gout; Humans; Hypertension; Uric Acid

2000
The optimal use of allopurinol: an audit of allopurinol use in South Auckland.
    Australian and New Zealand journal of medicine, 2000, Volume: 30, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Creatinine; Drug Evaluation; Female; Gout; Gout Suppres

2000
Flexor tendinitis and median nerve compression caused by gout in a patient with rheumatoid arthritis.
    Plastic and reconstructive surgery, 2000, Volume: 106, Issue:7

    Topics: Aged; Arthritis, Rheumatoid; Carpal Tunnel Syndrome; Female; Fingers; Giant Cells; Gout; Humans; Ten

2000
Syndrome X and gout: benefits of altered diet.
    Current rheumatology reports, 2001, Volume: 3, Issue:1

    Topics: Alcohol Drinking; Body Mass Index; Body Weight; Dietary Carbohydrates; Dietary Fats, Unsaturated; Di

2001
Hyperuricemia in Saudi Arabia.
    Rheumatology international, 2001, Volume: 20, Issue:2

    Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Female; Gout; Humans; Male; Middle Age

2001
Synthesis and structure-activity relationships of 1-phenylpyrazoles as xanthine oxidase inhibitors.
    Bioorganic & medicinal chemistry letters, 2001, Apr-09, Volume: 11, Issue:7

    Topics: Allopurinol; Animals; Area Under Curve; Gout; Gout Suppressants; Male; Metabolic Diseases; Models, A

2001
Diabetes insipidus in uricase-deficient mice: a model for evaluating therapy with poly(ethylene glycol)-modified uricase.
    Journal of the American Society of Nephrology : JASN, 2001, Volume: 12, Issue:5

    Topics: Animals; Body Water; Diabetes Insipidus; Disease Models, Animal; Gout; Humans; Kidney Concentrating

2001
[Therapeutic criteria in hyperuricemia].
    Revista clinica espanola, 2001, Volume: 201, Issue:2

    Topics: Acute Disease; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Colchicine; Gout; Go

2001
How should hyperuricemia be treated in a patient with allopurinol hypersensitivity?
    Cleveland Clinic journal of medicine, 2001, Volume: 68, Issue:7

    Topics: Antimetabolites; Desensitization, Immunologic; Drug Hypersensitivity; Gout; Gout Suppressants; Human

2001
Hyperuricemia and gout in Taiwan: results from the Nutritional and Health Survey in Taiwan (1993-96).
    The Journal of rheumatology, 2001, Volume: 28, Issue:7

    Topics: Adolescent; Adult; Aged; Asian People; Child; Child, Preschool; Female; Gout; Humans; Male; Middle A

2001
Biochemical profile of idiopathic uric acid nephrolithiasis.
    Kidney international, 2001, Volume: 60, Issue:2

    Topics: Adult; Female; Gout; Humans; Hydrogen-Ion Concentration; Hypertriglyceridemia; Kidney Calculi; Male;

2001
Laryngeal manifestation of gout: a case report of a subglottic gout tophus.
    Auris, nasus, larynx, 2001, Volume: 28, Issue:3

    Topics: Arytenoid Cartilage; Gout; Humans; Larynx; Male; Respiratory Mucosa; Uric Acid; Voice Disorders

2001
Evaluation of crystals in formalin-fixed, paraffin-embedded tissue sections for the differential diagnosis of pseudogout, gout, and tumoral calcinosis.
    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2001, Volume: 14, Issue:8

    Topics: Calcinosis; Calcium Pyrophosphate; Chondrocalcinosis; Crystallization; Diagnosis, Differential; Dura

2001
[Familial gout and nephropathy in a young woman. Report of one case].
    Revista medica de Chile, 2001, Volume: 129, Issue:6

    Topics: Adult; Allopurinol; Female; Genetic Counseling; Gout; Gout Suppressants; Humans; Kidney Diseases; Ur

2001
Gout: diet and uric acid revisited.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Dietary Proteins; Gout; Humans; Uric Acid

2001
[Urine fibrinolytic activity as an indicator of kidney damage in uric acid metabolic imbalance].
    Terapevticheskii arkhiv, 2001, Volume: 73, Issue:6

    Topics: Adolescent; Adult; Creatinine; Female; Glomerular Filtration Rate; Gout; Humans; Kidney Diseases; Ma

2001
[Interesting case no. 47. Gout tophus of the vocal cord].
    Laryngo- rhino- otologie, 2001, Volume: 80, Issue:8

    Topics: Diagnosis, Differential; Gout; Humans; Laryngeal Diseases; Laryngoscopy; Male; Middle Aged; Uric Aci

2001
Clinical features of familial gout and effects of probable genetic association between gout and its related disorders.
    Metabolism: clinical and experimental, 2001, Volume: 50, Issue:10

    Topics: Age of Onset; Alcohol Drinking; Body Mass Index; Comorbidity; Creatinine; Cross-Sectional Studies; D

2001
Crystal-induced neutrophil activation. VII. Involvement of Syk in the responses to monosodium urate crystals.
    Journal of leukocyte biology, 2001, Volume: 70, Issue:4

    Topics: Adult; Antibodies; Cells, Cultured; Crystallization; Enzyme Inhibitors; Enzyme Precursors; Gout; Hum

2001
[Upper limit value for uric acid much too high? Most frequent diagnostic error: arthritis instead if gout].
    MMW Fortschritte der Medizin, 2001, Sep-27, Volume: 143, Issue:39

    Topics: Arthritis, Rheumatoid; Diagnostic Errors; Gout; Humans; Uric Acid

2001
Hyperuricemia, gout, and renal function after liver transplantation.
    Transplantation, 2001, Nov-27, Volume: 72, Issue:10

    Topics: Adult; Aged; Allopurinol; Creatinine; Female; Gout; Humans; Kidney; Liver Transplantation; Male; Mid

2001
Tacrolimus for the treatment of gout in renal transplantation: two case reports and review of the literature.
    Transplantation, 2001, Nov-27, Volume: 72, Issue:10

    Topics: Adult; Cyclosporine; Female; Gout; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; M

2001
Src family protein tyrosine kinase signaling mediates monosodium urate crystal-induced IL-8 expression by monocytic THP-1 cells.
    Journal of leukocyte biology, 2001, Volume: 70, Issue:6

    Topics: Cell Line; Gout; Humans; I-kappa B Proteins; Interleukin-8; Monocytes; NF-kappa B; Ribosomal Protein

2001
[Pleural effusion of gout].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2000, Volume: 23, Issue:6

    Topics: Adult; Aged; Female; Fibrosis; Gout; Humans; Lung; Lung Diseases; Male; Middle Aged; Pleural Effusio

2000
Increased visceral fat accumulation in patients with primary gout.
    Advances in experimental medicine and biology, 2000, Volume: 486

    Topics: Fats; Gout; Humans; Incidence; Japan; Male; Obesity; Uric Acid

2000
Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout.
    Journal of hypertension, 2002, Volume: 20, Issue:2

    Topics: Antihypertensive Agents; Biphenyl Compounds; Gout; Humans; Hypertension; Irbesartan; Losartan; Tetra

2002
[Hyperuricemia and gout. Case report].
    Deutsche medizinische Wochenschrift (1946), 2002, Feb-01, Volume: 127, Issue:5

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Diagnosis, Differential; Diclofenac; Follow-Up

2002
[Hyperuricemia and gout--diagnosis].
    Deutsche medizinische Wochenschrift (1946), 2002, Feb-01, Volume: 127, Issue:5

    Topics: Adenine; Adult; Diagnosis, Differential; Drug-Related Side Effects and Adverse Reactions; Female; Go

2002
[Hyperuricemia and gout--treatment].
    Deutsche medizinische Wochenschrift (1946), 2002, Feb-01, Volume: 127, Issue:5

    Topics: Acute Disease; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Benzbromarone; Colchicine; Drug

2002
[The Dutch College of General Practitioners' "Gout" Standard: a response from rheumatologists].
    Nederlands tijdschrift voor geneeskunde, 2002, Feb-16, Volume: 146, Issue:7

    Topics: Attitude of Health Personnel; Family Practice; Gout; Humans; Netherlands; Practice Guidelines as Top

2002
[How to treat hyperuricemia and gout attacks in compensated kidney failure?].
    Deutsche medizinische Wochenschrift (1946), 2002, Mar-15, Volume: 127, Issue:11

    Topics: Aged; Aged, 80 and over; Allopurinol; Glucocorticoids; Gout; Gout Suppressants; Humans; Kidney Failu

2002
[Gout tophus].
    Annales de dermatologie et de venereologie, 2001, Volume: 128, Issue:11

    Topics: Aged; Aged, 80 and over; Arthritis, Gouty; Crystallization; Female; Gout; Humans; Uric Acid

2001
Is it gout? Tap the joint!
    Journal of the Medical Association of Georgia, 2002,Winter, Volume: 91, Issue:1

    Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Glucocorticoids; Gout; Gout Suppre

2002
High prevalence of hyperuricemia in adolescent Taiwan aborigines.
    The Journal of rheumatology, 2002, Volume: 29, Issue:4

    Topics: Adolescent; Asian People; Cholesterol; Creatinine; Female; Gout; Humans; Male; Native Hawaiian or Ot

2002
Delayed examination of synovial fluid by ordinary and polarised light microscopy to detect and identify crystals.
    Annals of the rheumatic diseases, 2002, Volume: 61, Issue:5

    Topics: Calcium Pyrophosphate; Case-Control Studies; Cryopreservation; Crystallization; Culture Media; Edeti

2002
Pathologic quiz case: a soft tissue mass with bone destruction. Gouty tophus.
    Archives of pathology & laboratory medicine, 2002, Volume: 126, Issue:5

    Topics: Aged; Biopsy; Elbow Joint; Gout; Humans; Male; Pain; Radiography; Uric Acid

2002
Kidney function: gateway to a long life?
    Nature, 2002, May-23, Volume: 417, Issue:6887

    Topics: Animals; Antioxidants; Biological Transport; Carrier Proteins; Gout; Humans; Kidney; Longevity; Orga

2002
Uric acid and the kidney.
    Perspectives in nephrology and hypertension, 1976, Volume: 3

    Topics: Acute Kidney Injury; Ammonia; Animals; Glomerular Filtration Rate; Glutamine; Gout; Humans; Hydrogen

1976
Dissolution of renal uric acid calculus with allopurinal and alkalization of urine: a case report.
    The Journal of urology, 1976, Volume: 115, Issue:6

    Topics: Acetazolamide; Allopurinol; Bicarbonates; Citrates; Drug Combinations; Gout; Humans; Hydrogen-Ion Co

1976
Physiological characteristics of various experimental models for the study of disorders in purine metabolism.
    Advances in experimental medicine and biology, 1977, Volume: 76B

    Topics: Acidosis; Alkalosis; Allopurinol; Animals; Cholesterol; Disease Models, Animal; Diuresis; Fructose;

1977
The effect of acid loading on renal excretion of uric acid and ammonium in gout.
    Advances in experimental medicine and biology, 1977, Volume: 76B

    Topics: Adult; Aged; Ammonia; Ammonium Chloride; Circadian Rhythm; Diet; Female; Gout; Humans; Hydrogen-Ion

1977
Urinary excretion of uricine.
    Investigative urology, 1977, Volume: 15, Issue:2

    Topics: Adult; Aged; Binding Sites; Calcium Phosphates; Female; Gout; Humans; Hydrogen-Ion Concentration; Ma

1977
[Drug therapy and metaphylaxis of urolithiasis].
    Zeitschrift fur arztliche Fortbildung, 1978, Oct-15, Volume: 72, Issue:20

    Topics: Alkalies; Citrates; Diuresis; Fluid Therapy; Gout; Humans; Hydrogen-Ion Concentration; Recurrence; U

1978
Gout and cardiovascular disease.
    Lancet (London, England), 1977, Apr-30, Volume: 1, Issue:8018

    Topics: Coronary Disease; Gout; Humans; Platelet Aggregation; Uric Acid

1977
Enzyme defect in primary gout.
    Lancet (London, England), 1979, Mar-17, Volume: 1, Issue:8116

    Topics: AMP Deaminase; Deamination; Gout; Humans; Inosine Monophosphate; Liver; Nucleotide Deaminases; Purin

1979
The gout-calcium-stone connection.
    Lancet (London, England), 1979, Jun-09, Volume: 1, Issue:8128

    Topics: Allopurinol; Calcium Oxalate; Gout; Humans; Kidney Calculi; Uric Acid

1979
[Spinal complaints of hyperuricemic patients].
    MMW, Munchener medizinische Wochenschrift, 1976, Jan-23, Volume: 118, Issue:4

    Topics: Back Pain; Female; Gout; Headache; Humans; Male; Neurologic Manifestations; Osteoarthritis; Pain; Sp

1976
A case of gouty arthritis associated with Down's syndrome.
    Journal of mental deficiency research, 1976, Volume: 20, Issue:4

    Topics: Adult; Down Syndrome; Gout; Humans; Karyotyping; Kidney Function Tests; Male; Metabolic Clearance Ra

1976
[Gout in young subjects].
    Minerva medica, 1977, Mar-30, Volume: 68, Issue:15

    Topics: Adolescent; Adult; Age Factors; Angina Pectoris; Back Pain; Diabetes Complications; Fatty Liver; Fem

1977
Stimulation of human purine synthesis de novo by fructose infusion.
    Metabolism: clinical and experimental, 1975, Volume: 24, Issue:7

    Topics: Adolescent; Adult; Creatinine; Erythrocytes; Fructose; Glycine; Gout; Humans; Male; Middle Aged; Ost

1975
An office technique for identifying crystal in synovial fluid.
    American family physician, 1975, Volume: 12, Issue:1

    Topics: Betamethasone; Calcium Phosphates; Cholesterol; Chondrocalcinosis; Color; Crystallography; Diphospha

1975
[Frequency and distribution of types of hyperlipoproteinemia with life-shortening risk factors among ambulant patients (author's transl)].
    Medizinische Klinik, 1975, Jul-11, Volume: 70, Issue:28-29

    Topics: Cholesterol; Diabetes Complications; Female; Germany, West; Gout; Humans; Hyperlipidemias; Hypertens

1975
[Diet in hyperuricemia (author's transl)].
    MMW, Munchener medizinische Wochenschrift, 1975, Aug-29, Volume: 117, Issue:35

    Topics: Adenosine Monophosphate; Diet Fads; Dietary Proteins; DNA; Ethanol; Fasting; Gout; Guanosine Monopho

1975
Mutant feedback-resistant phosphoribosylpyrophosphate synthetase associated with purine overproduction and gout. Phosphoribosylpyrophosphate and purine metabolism in cultured fibroblasts.
    The Journal of clinical investigation, 1975, Volume: 56, Issue:5

    Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Erythrocytes; Feedback; Female; Fibroblasts; Genes

1975
Patterns of phosphoribosylpyrophosphate and ribose-5-phosphate concentration and generation in fibroblasts from patients with gout and purine overproduction.
    The Journal of clinical investigation, 1976, Volume: 57, Issue:2

    Topics: Adenine Phosphoribosyltransferase; Adolescent; Adult; Cells, Cultured; Erythrocytes; Female; Fibrobl

1976
[Needle biopsy in gout and pseudogout (author's transl)].
    Beitrage zur Pathologie, 1976, Volume: 157, Issue:2

    Topics: Aged; Biopsy, Needle; Chondrocalcinosis; Diagnosis, Differential; Diphosphates; Female; Gout; Humans

1976
[Therapy of hyperlipemia and hyperuricemia with a combination of clofibrate and an extractive mucopolysaccharide complex].
    Reumatismo, 1975, Volume: 27, Issue:1

    Topics: Adult; Aged; Arthritis, Rheumatoid; Cholesterol; Clofibrate; Drug Therapy, Combination; Female; Glyc

1975
Evidence for X-linkage of phosphoribosylpyrophosphate synthetase in man. Studies with cultured fibroblasts from a gouty family with mutant feedback-resistant enzyme.
    Human heredity, 1977, Volume: 27, Issue:1

    Topics: Adolescent; Adult; Aged; Cells, Cultured; Child; Child, Preschool; Female; Fibroblasts; Genetic Link

1977
Fibroblast phosphoribosylpyrophosphate and ribose-5-phosphate concentration and generation in gout with purine overproduction.
    Advances in experimental medicine and biology, 1977, Volume: 76A

    Topics: Cells, Cultured; Erythrocytes; Fibroblasts; Gout; Humans; Hypoxanthine Phosphoribosyltransferase; Pe

1977
Familial distribution of increased erythrocyte PP-ribose-P levels.
    Advances in experimental medicine and biology, 1977, Volume: 76A

    Topics: Adult; Aged; Amidophosphoribosyltransferase; Erythrocytes; Gout; Humans; Hypoxanthine Phosphoribosyl

1977
Superactivity of phosphoribosylpyrophosphate synthetase, due to feedback resistance, causing purine overproduction and gout.
    Ciba Foundation symposium, 1977, Issue:48

    Topics: Adolescent; Adult; Aged; Amidophosphoribosyltransferase; Child; Child, Preschool; Erythrocytes; Feed

1977
Hyperuricemic nephropathy: pathologic features and factors influencing urate deposition.
    Nephron, 1975, Volume: 14, Issue:1

    Topics: Acute Kidney Injury; Animals; Binding Sites; Crystallization; Disease Models, Animal; Diuretics; Gou

1975
[Automatic dosage of uric acid by urate oxydase. Comparison with Praetorius' methods].
    Annales de biologie clinique, 1975, Volume: 33, Issue:2

    Topics: Autoanalysis; Coronary Disease; Gout; Humans; Hydrogen Peroxide; Hydrogen-Ion Concentration; Oxidati

1975
Nucleation of monosodium urate crystals.
    Annals of the rheumatic diseases, 1975, Volume: 34, Issue:4

    Topics: Acid-Base Equilibrium; Calcium; Collagen; Copper; Crystallization; Ethanol; Gout; Hydrogen-Ion Conce

1975
Acquired causes of hyperuricaemia.
    Australian and New Zealand journal of medicine, 1978, Volume: 8 Suppl 1

    Topics: Alcohol Drinking; Aspirin; Diet; Energy Intake; Gout; Humans; Kidney Diseases; Phenylbutazone; Uric

1978
[Interrelationship between purine, carbohydrate, lipid and aminoacid metabolism, in hyperuricaemia and gout (author's transl)].
    Quaderni Sclavo di diagnostica clinica e di laboratorio, 1978, Volume: 14, Issue:1

    Topics: Alcoholic Intoxication; Alcoholism; Amino Acids; Carbohydrate Metabolism; Diabetes Mellitus; Fructos

1978
Foibles and fallacies in the diagnosis of arthritis.
    Southern medical journal, 1977, Volume: 70, Issue:11

    Topics: Antibodies, Antinuclear; Arthritis; Arthritis, Infectious; Arthritis, Rheumatoid; Chondrocalcinosis;

1977
[Physiopathological bases for a rational therapy of gout].
    Minerva medica, 1978, Feb-04, Volume: 69, Issue:6

    Topics: Allopurinol; Benzofurans; Gout; Humans; Life Style; Phenylbutazone; Probenecid; Sulfinpyrazone; Uric

1978
[The relationship of uric acid, triglycerides, and cholesterol].
    Sbornik vedeckych praci Lekarske fakulty Karlovy univerzity v Hradci Kralove. Supplementum, 1978, Volume: 21, Issue:4

    Topics: Adult; Aged; Cholesterol; Gout; Humans; Middle Aged; Myocardial Infarction; Triglycerides; Uric Acid

1978
Bullous tophi in gout.
    Annals of the rheumatic diseases, 1977, Volume: 36, Issue:1

    Topics: Adrenal Cortex Hormones; Crystallization; Female; Gout; Humans; Male; Middle Aged; Skin Diseases, Ve

1977
History of gout. Including comments from an illustrious timeless gathering.
    Advances in experimental medicine and biology, 1977, Volume: 76A

    Topics: Famous Persons; Gout; History, Ancient; History, Medieval; History, Modern 1601-; Terminology as Top

1977
[Manifestation of gout. Observations concerning the combined effects of nutrition and biochemical individuality].
    Der Internist, 1977, Volume: 18, Issue:9

    Topics: Diet; DNA; Gout; Humans; Purines; RNA; Uric Acid

1977
Hyperuricemia and gout. A modern approach to diagnosis and treatment.
    Postgraduate medicine, 1979, Volume: 65, Issue:4

    Topics: Allopurinol; Anti-Inflammatory Agents; Colchicine; Gout; Humans; Uric Acid

1979
Recessive X-linked hyperuricemia with gout and renal damage, normal activity of hypoxanthine phosphoribosyltransferase and resistance to azaguanine.
    Acta medica Scandinavica, 1979, Volume: 205, Issue:3

    Topics: Adenine Phosphoribosyltransferase; Adolescent; Adult; Azaguanine; Azathioprine; Erythrocytes; Female

1979
[Infantile familial hyperuricemia with gouty manifestations].
    Orvosi hetilap, 1979, Mar-11, Volume: 120, Issue:10

    Topics: Autopsy; Gout; Humans; Infant; Kidney; Male; Uric Acid

1979
Drug therapy reviews: pathogenesis and clinical management of hyperuricemia and gout.
    American journal of hospital pharmacy, 1979, Volume: 36, Issue:4

    Topics: Acute Disease; Allopurinol; Anti-Inflammatory Agents; Arthritis; Chronic Disease; Colchicine; Gout;

1979
Management of gout.
    Annals of internal medicine, 1979, Volume: 90, Issue:5

    Topics: Adrenal Cortex Hormones; Allopurinol; Colchicine; Female; Gout; Humans; Indomethacin; Patient Educat

1979
Mechanism and treatment of hypertriglyceridaemia in gout.
    Annals of the rheumatic diseases, 1979, Volume: 38, Issue:1

    Topics: Alcohol Drinking; Allopurinol; Cholesterol; Gout; Humans; Hyperlipidemias; Male; Middle Aged; Obesit

1979
[Hyperuricemia].
    Die Medizinische Welt, 1979, Apr-20, Volume: 30, Issue:16

    Topics: Diagnosis, Differential; Gout; Humans; Models, Biological; Uric Acid

1979
Definitive diagnosis of gout by identification of urate crystals in asymptomatic metatarsophalangeal joints.
    Arthritis and rheumatism, 1979, Volume: 22, Issue:5

    Topics: Adult; Aged; Crystallization; Female; Gout; Humans; Male; Metatarsophalangeal Joint; Middle Aged; To

1979
Management of gout.
    JAMA, 1979, Jul-27, Volume: 242, Issue:4

    Topics: Acute Disease; Allopurinol; Gout; Gout Suppressants; Humans; Methods; Uric Acid; Uricosuric Agents

1979
Renal outcomes of gout and hyperuricemia.
    The American journal of medicine, 1979, Volume: 67, Issue:1

    Topics: Aged; Arthritis; California; Creatinine; Female; Follow-Up Studies; Gout; Humans; Kidney Calculi; Ki

1979
Uric acid excretion: quantitative assessment from spot, midmorning serum and urine samples.
    Annals of internal medicine, 1979, Volume: 91, Issue:1

    Topics: Gout; Humans; Male; Specimen Handling; Uric Acid

1979
Urate crystals in asymptomatic metatarsophalangeal joints.
    Annals of internal medicine, 1979, Volume: 91, Issue:1

    Topics: Crystallization; Gout; Humans; Male; Metatarsophalangeal Joint; Middle Aged; Synovial Fluid; Toe Joi

1979
Re-examination of effect of paracetamol on serum uric acid measured by phosphotungstic acid reduction.
    Annals of clinical biochemistry, 1979, Volume: 16, Issue:2

    Topics: Acetaminophen; False Positive Reactions; Gout; Humans; Methods; Oxidation-Reduction; Phosphotungstic

1979
Gout and crystal-related nephropathy.
    Contributions to nephrology, 1979, Volume: 16

    Topics: Adenine Phosphoribosyltransferase; Female; Gout; Humans; Kidney; Kidney Calculi; Kidney Diseases; Le

1979
Chronic gouty nephropathy treated by long-term hemodialysis and allopurinol.
    Mayo Clinic proceedings, 1979, Volume: 54, Issue:9

    Topics: Allopurinol; Gout; Humans; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Time Factors;

1979
Synovial fluid leukocytosis. A study of extremes.
    The American journal of medicine, 1979, Volume: 67, Issue:3

    Topics: Aged; Arthritis, Infectious; Arthritis, Rheumatoid; Calcium Pyrophosphate; Chondrocalcinosis; Crysta

1979
[Gout].
    Deutsche medizinische Wochenschrift (1946), 1979, Aug-31, Volume: 104, Issue:35

    Topics: Gout; Humans; Uric Acid

1979
[Therapy of gout].
    Fortschritte der Medizin, 1979, Aug-23, Volume: 97, Issue:32

    Topics: Allopurinol; Arteriosclerosis; Benzbromarone; Colchicine; Gout; Humans; Immobilization; Indomethacin

1979
[Uric acid clearance test].
    Nihon rinsho. Japanese journal of clinical medicine, 1979, Jun-29, Volume: Suppl

    Topics: Gout; Humans; Metabolic Clearance Rate; Methods; Uric Acid

1979
Uric acid metabolism in normal subjects and in gouty patients by chromatographic measurement of 14C-uric acid in plasma and urine.
    Metabolism: clinical and experimental, 1979, Volume: 28, Issue:11

    Topics: Adult; Carbon Radioisotopes; Gout; Humans; Kinetics; Male; Middle Aged; Reference Values; Uric Acid

1979
Acute arthralgia (gout?) after tricrynafen.
    The New England journal of medicine, 1979, Nov-08, Volume: 301, Issue:19

    Topics: Glycolates; Gout; Humans; Hypertension; Joint Diseases; Male; Middle Aged; Pain; Ticrynafen; Uric Ac

1979
Genetics of hyperuricemia in families with gout.
    American journal of medical genetics, 1979, Volume: 4, Issue:1

    Topics: Gene Frequency; Genetic Variation; Gout; Humans; Mathematics; Models, Genetic; Uric Acid

1979
Acute gouty bursitis: report of 15 cases.
    Annals of the rheumatic diseases, 1979, Volume: 38, Issue:4

    Topics: Acute Disease; Aged; Bursa, Synovial; Bursitis; Gout; Humans; Leukocyte Count; Male; Middle Aged; Sy

1979
Treatment of hyperuricemia and gout.
    The New England journal of medicine, 1979, Nov-29, Volume: 301, Issue:22

    Topics: Colchicine; Gout; Humans; Uric Acid

1979
Treatment of hyperuricemia and gout.
    The New England journal of medicine, 1979, Nov-29, Volume: 301, Issue:22

    Topics: Gout; Humans; Uric Acid

1979
Hypertension, renal function and gout.
    Postgraduate medical journal, 1979, Volume: 55 Suppl 3

    Topics: Adult; Glomerular Filtration Rate; Gout; Humans; Hypertension; Kidney; Kidney Diseases; Middle Aged;

1979
Uricosuric therapy and urate solubility in blood and urine.
    Postgraduate medical journal, 1979, Volume: 55 Suppl 3

    Topics: Gout; Humans; Solubility; Uric Acid; Uricosuric Agents

1979
Tienilic acid in hypertension with hyperuricaemia.
    Postgraduate medical journal, 1979, Volume: 55 Suppl 3

    Topics: Allopurinol; Bendroflumethiazide; Creatinine; Female; Glycolates; Gout; Humans; Hypertension; Male;

1979
Allopurinol toxicity.
    Southern medical journal, 1979, Volume: 72, Issue:11

    Topics: Allopurinol; Gout; Hematologic Diseases; Humans; Kidney Diseases; Uric Acid

1979
[Diagnosis of gout: problems caused by crystallization "in vitro" of sodium urate].
    L'union medicale du Canada, 1979, Volume: 108, Issue:7

    Topics: Crystallization; Diagnosis, Differential; Gout; Humans; Specimen Handling; Synovial Fluid; Uric Acid

1979
[Early diagnosis of gout].
    Zeitschrift fur arztliche Fortbildung, 1979, Jul-15, Volume: 73, Issue:13-14

    Topics: Adult; Allopurinol; Efficiency; Female; Gout; Humans; Kidney Diseases; Male; Middle Aged; Nephrocalc

1979
Renal function in gout. V. Factors influencing the renal hemodynamics.
    The American journal of medicine, 1979, Volume: 67, Issue:5

    Topics: Adult; Aged; Glomerular Filtration Rate; Gout; Humans; Inulin; Kidney; Kidney Function Tests; Middle

1979
[The effect of benzbromaron in gout patients with limited kidney function].
    Fortschritte der Medizin, 1979, Nov-22, Volume: 97, Issue:44

    Topics: Adult; Aged; Benzbromarone; Benzofurans; Creatinine; Drug Evaluation; Gout; Humans; Kidney Diseases;

1979
Evaluation of a new uricosuric diuretic--ticrynafen.
    JAMA, 1979, Dec-28, Volume: 242, Issue:26

    Topics: Diuretics; Drug Evaluation; Glycolates; Gout; Heart Failure; Humans; Hypertension; Ticrynafen; Uric

1979
Piroxicam in the treatment of acute gout: a multicentre open study in general practice.
    The Journal of international medical research, 1979, Volume: 7, Issue:6

    Topics: Acute Disease; Adult; Aged; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Pyridines; T

1979
[Allomaron in hyperuricemia and gout].
    ZFA. Zeitschrift fur Allgemeinmedizin, 1979, Aug-31, Volume: 55, Issue:24

    Topics: Adolescent; Adult; Aged; Allopurinol; Benzbromarone; Benzofurans; Drug Combinations; Drug Evaluation

1979
[Clinical chemistry diagnosis of uric-acid metabolism disorders].
    ZFA. Zeitschrift fur Allgemeinmedizin, 1978, Oct-20, Volume: 54, Issue:29

    Topics: Circadian Rhythm; Female; Gout; Humans; Male; Methods; Uric Acid

1978
Tophaceous gout. An unusual cause of bilateral carpal tunnel syndrome.
    JAMA, 1977, Jun-20, Volume: 237, Issue:25

    Topics: Adult; Carpal Tunnel Syndrome; Gout; Humans; Male; Paresthesia; Uric Acid

1977
[On the dose-effect relation of allopurinol (author's transl)].
    Arzneimittel-Forschung, 1977, Volume: 27, Issue:6

    Topics: Adult; Aged; Allopurinol; Delayed-Action Preparations; Dose-Response Relationship, Drug; Gout; Human

1977
Acute gouty arthritis. The diagnostic importance of aspirating more than one involved joint.
    JAMA, 1977, Dec-05, Volume: 238, Issue:23

    Topics: Acute Disease; Adult; Ankle Joint; Crystallization; Gout; Humans; Knee Joint; Male; Synovial Fluid;

1977
[Modern differential-therapeutic aspects of the drug therapy of chronic gout].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1979, Sep-15, Volume: 34, Issue:18

    Topics: Allopurinol; Arteriosclerosis; Citrates; Gout; Humans; Hypertension; Kidney Diseases; Obesity; Pheny

1979
Secondary gout in hemoglobinopathies: report of two cases and review of the literature.
    American journal of hematology, 1977, Volume: 2, Issue:4

    Topics: Adolescent; Female; Gout; Hemoglobinopathies; Humans; Kidney; Middle Aged; Uric Acid

1977
Gout and hyperuricaemia in Blacks.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1977, Nov-12, Volume: 52, Issue:21

    Topics: Black or African American; Black People; Democratic Republic of the Congo; Female; Gout; Humans; Mal

1977
Folic acid, xanthine oxidase, and uric acid.
    Annals of internal medicine, 1978, Volume: 88, Issue:2

    Topics: Folic Acid; Gout; Humans; Uric Acid; Xanthine Oxidase

1978
The workinghman's diet. II. Effect of weight reduction in obese patients with hypertension, diabetes, hyperuricemia and hyperlipidemia.
    Nutrition and metabolism, 1978, Volume: 22, Issue:3

    Topics: Body Weight; Diet, Diabetic; Diet, Reducing; Evaluation Studies as Topic; Female; Follow-Up Studies;

1978
Gout without crystals on initial synovial fluid analysis.
    Postgraduate medical journal, 1978, Volume: 54, Issue:628

    Topics: Adult; Arthritis; Gout; Humans; Male; Middle Aged; Synovial Fluid; Uric Acid

1978
[Uric acid diathesis in chickens].
    Veterinariia, 1978, Issue:2

    Topics: Animals; Chickens; Disease Susceptibility; Gout; Kidney Calculi; Poultry Diseases; Uric Acid

1978
The ultrastructure of urate crystals in gout.
    The Journal of rheumatology, 1978,Spring, Volume: 5, Issue:1

    Topics: Crystallization; Gout; Humans; Microscopy, Electron; Microscopy, Electron, Scanning; Synovial Fluid;

1978
Distinguishing gout from other types of arthritis.
    Postgraduate medicine, 1978, Volume: 63, Issue:5

    Topics: Acute Disease; Adult; Arthritis; Diagnosis, Differential; Female; Gout; Humans; Male; Synovial Fluid

1978
Role of the kidneys in the pathogenesis of gout.
    Postgraduate medicine, 1978, Volume: 63, Issue:5

    Topics: Absorption; Animals; Gout; Humans; Kidney; Kidney Tubules, Proximal; Models, Biological; Uric Acid

1978
Nephrolithiasis in patients with gout.
    Postgraduate medicine, 1978, Volume: 63, Issue:5

    Topics: Allopurinol; Gout; Humans; Kidney Calculi; Recurrence; Uric Acid

1978
[Diagnostic value of renal urate excretion].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1978, Mar-15, Volume: 33, Issue:6

    Topics: Adult; Female; Gout; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Time Factors; Uric Acid

1978
Asymptomatic hyperuricemia: the case for conservative management.
    Annals of internal medicine, 1978, Volume: 88, Issue:5

    Topics: Gout; Humans; Kidney Calculi; Risk; Uric Acid

1978
Immunoglobulin in tophi and on the surface of monosodium urate crystals.
    Arthritis and rheumatism, 1978, Volume: 21, Issue:3

    Topics: Agglutination; Blood; Gout; Humans; Immunoglobulin G; Immunoglobulin M; Immunoglobulins; Uric Acid

1978
High prevalence of hyperuricaemia and gout in an urbanised Micronesian population.
    British medical journal, 1978, May-13, Volume: 1, Issue:6122

    Topics: Adult; Aged; Female; Gout; Humans; Life Style; Male; Micronesia; Middle Aged; Sex Factors; Urban Pop

1978
Enhancement of urate solubility by connective tissue. I. Effect of proteoglycan aggregates and buffer cation.
    Arthritis and rheumatism, 1978, Volume: 21, Issue:4

    Topics: Animals; Buffers; Connective Tissue; Gout; Humans; Hyaluronoglucosaminidase; In Vitro Techniques; La

1978
Purine biosynthesis de novo by lymphocytes in gout.
    Clinical science and molecular medicine, 1978, Volume: 54, Issue:6

    Topics: Adult; Allopurinol; Female; Gout; Humans; In Vitro Techniques; Kidney Diseases; Lymphocytes; Male; M

1978
[Juvenile gout with decreased activity of hypoxanthine-guanine-phosphoribosyl transferase and pheochromocytoma: partial persistence of tophi despite uric-acid reducing treatment for 12 years (author's transl)].
    Deutsche medizinische Wochenschrift (1946), 1978, Jun-23, Volume: 103, Issue:25

    Topics: Adrenal Gland Neoplasms; Allopurinol; Gout; Humans; Hypertension, Malignant; Hypoxanthine Phosphorib

1978
[Effects and side effects of benzbromaron in the initial treatment of hyperuricemia and gout. Results of a field study on 3899 patients].
    Fortschritte der Medizin, 1978, Aug-24, Volume: 96, Issue:32

    Topics: Benzbromarone; Benzofurans; Diarrhea; Female; Gout; Humans; Kidney Calculi; Male; Nausea; Uric Acid

1978
[Uptake of 2-C14 urate by erythrocytes in hyperuricemia and in gout (author's transl)].
    Klinische Wochenschrift, 1978, Mar-15, Volume: 53, Issue:16

    Topics: Erythrocytes; Gout; Humans; Kinetics; Uric Acid

1978
[Gastric xanthelasma (author's transl)].
    Leber, Magen, Darm, 1978, Volume: 8, Issue:4

    Topics: Adult; Aged; Diabetes Mellitus; Female; Gastric Mucosa; Gastritis; Gastroscopy; Gout; Humans; Hypert

1978
Hepatic purine enzyme profiles and uric acid overproduction in muscular dystrophy and in inherited tophaceous gout.
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1978, Volume: 158, Issue:3

    Topics: Animals; Chickens; Gout; Liver; Muscular Dystrophy, Animal; Purines; Uric Acid

1978
[Xeroradiography in case of gout and hyperuricemic syndroms (author's transl)].
    Ceskoslovenska radiologie, 1978, Volume: 32, Issue:4

    Topics: Adult; Female; Foot; Gout; Humans; Male; Middle Aged; Syndrome; Uric Acid; Xeroradiography

1978
[Gout - a surgical problem].
    Handchirurgie, 1978, Volume: 10, Issue:1

    Topics: Allopurinol; Benzbromarone; Female; Gout; Hand; Humans; Middle Aged; Patient Care Team; Uric Acid

1978
Immobilized-enzyme nylon-tube reactor for routine determination of uric acid in serum.
    Clinical chemistry, 1978, Volume: 24, Issue:10

    Topics: Drug Stability; Enzymes, Immobilized; Gout; Humans; Urate Oxidase; Uric Acid

1978
Normouricemic acute polyarticular gout.
    The Journal of the Kansas Medical Society, 1978, Volume: 79, Issue:10

    Topics: Acute Disease; Aged; Gout; Humans; Male; Uric Acid

1978
Gout and serum uric acid levels in the Cotswolds.
    Rheumatology and rehabilitation, 1978, Volume: 17, Issue:3

    Topics: Adult; Aged; England; Female; Gout; Humans; Male; Middle Aged; Uric Acid

1978
Treatment of gout with alternate-day hypo-uricaemic drugs.
    Rheumatology and rehabilitation, 1978, Volume: 17, Issue:3

    Topics: Adult; Aged; Allopurinol; Benzbromarone; Benzofurans; Female; Gout; Humans; Male; Middle Aged; Sulfi

1978
[Various aspects of nephropathy in gout].
    Verhandlungen der Deutschen Gesellschaft fur Rheumatologie, 1978, Volume: 5

    Topics: Adult; Age Factors; Aged; Amyloidosis; Glomerular Filtration Rate; Gout; Humans; Hypertension, Renal

1978
Crystal induced arthritis: gout and pseudogout.
    Australian family physician, 1978, Volume: 7, Issue:8

    Topics: Acute Disease; Aged; Anti-Inflammatory Agents; Apatites; Arthritis; Calcium Hydroxide; Calcium Pyrop

1978
Hyperuricemia and gout: eminently treatable disorders.
    The Journal of the Kansas Medical Society, 1978, Volume: 79, Issue:11

    Topics: Gout; Humans; Uric Acid

1978
[Aseptic femoral head necrosis in patients with gouty arthritis].
    Zeitschrift fur arztliche Fortbildung, 1978, Aug-15, Volume: 72, Issue:16

    Topics: Adult; Femur Head Necrosis; Gout; Humans; Male; Radionuclide Imaging; Synovial Fluid; Synovial Membr

1978
A prospective study of gout in New Zealand Maoris.
    Annals of the rheumatic diseases, 1978, Volume: 37, Issue:5

    Topics: Adolescent; Adult; Aged; Ethnicity; Female; Gout; Humans; Male; Middle Aged; New Zealand; Prospectiv

1978
Familial occurrence of hyperuricemia, gout, and medullary cystic disease.
    Archives of internal medicine, 1978, Volume: 138, Issue:11

    Topics: Adolescent; Adult; Aged; Benzothiadiazines; Diuretics; Female; Gout; Humans; Kidney Medulla; Kidney

1978
Subclinical lead exposure: a possible cause of gout.
    British medical journal, 1978, Nov-18, Volume: 2, Issue:6149

    Topics: Adolescent; Adult; Aged; Female; Gout; Humans; Lead; Male; Middle Aged; Uric Acid

1978
Partial HGPRT deficiency: persistance of tophi after 12 years of therapeutic normouricemia and development of a pheochromocytoma.
    Monographs in human genetics, 1978, Volume: 10

    Topics: Adult; Gout; Humans; Hypoxanthine Phosphoribosyltransferase; Male; Middle Aged; Pheochromocytoma; Pu

1978
Nutritional aspects in the treatment of inborn errors.
    Monographs in human genetics, 1978, Volume: 10

    Topics: Diet; Gout; Humans; Male; Metabolism, Inborn Errors; Nutritional Physiological Phenomena; Uric Acid

1978
[Adenosine deaminase in hyperuricemic states].
    Bollettino della Societa italiana di biologia sperimentale, 1978, May-30, Volume: 54, Issue:10

    Topics: Acute Kidney Injury; Adenosine Deaminase; Adolescent; Adult; Aged; Erythrocytes; Female; Gout; Human

1978
Urate crystals in gout.
    The Journal of rheumatology, 1978,Fall, Volume: 5, Issue:3

    Topics: Crystallization; Gout; Humans; Synovial Fluid; Uric Acid

1978
[Relationship between uric acid and lipids in primary gout].
    Godisen zbornik na Medicinskiot fakultet vo Skopje, 1978, Volume: 24

    Topics: Adult; Aged; Female; Gout; Humans; Lipids; Male; Middle Aged; Uric Acid

1978
Uric acid excretion in patients with gout.
    Arthritis and rheumatism, 1979, Volume: 22, Issue:1

    Topics: Gout; Humans; Kidney; Male; Uric Acid

1979
[Hyperuricemia. Studies on the incidence of hyperuricemia and its therapeutic possibilities in general practice].
    ZFA. Zeitschrift fur Allgemeinmedizin, 1979, Jan-10, Volume: 55, Issue:1

    Topics: Diuretics; Family Practice; Female; Germany, West; Gout; Humans; Male; Uric Acid

1979
Asymptomatic hyperuricemia: pathogenic or innocent bystander?
    Archives of internal medicine, 1979, Volume: 139, Issue:1

    Topics: Gout; Humans; Kidney Diseases; Uric Acid

1979
[Uric-acid reduction with high allopurinol dosages (author's transl)].
    Deutsche medizinische Wochenschrift (1946), 1979, Mar-02, Volume: 104, Issue:9

    Topics: Aged; Allopurinol; Dose-Response Relationship, Drug; Female; Gout; Humans; Male; Middle Aged; Uric A

1979
[Hyperuricemia. An introduction].
    ZFA. Zeitschrift fur Allgemeinmedizin, 1976, Feb-10, Volume: 52, Issue:4

    Topics: Animals; Austria; Female; Gout; History, Ancient; History, Medieval; History, Modern 1601-; Humans;

1976
Gout.
    Nursing mirror and midwives journal, 1975, Jan-23, Volume: 140, Issue:4

    Topics: Adult; Anti-Inflammatory Agents; Female; Gout; Humans; Long-Term Care; Male; Middle Aged; Uric Acid

1975
[Chronic lead poisoning: Lead gout with giant tophi on the skin, nephrophathy and porphyrinopathy].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1975, Volume: 26, Issue:11

    Topics: Aged; Book Industry; Chronic Disease; Edetic Acid; Gout; Humans; Kidney Diseases; Lead; Lead Poisoni

1975
[Long-term therapy with benzbromarone in uric arthritis].
    Wiener medizinische Wochenschrift (1946), 1975, Sep-19, Volume: 125, Issue:28

    Topics: Adult; Aged; Benzbromarone; Benzofurans; Diarrhea; Female; Gout; Humans; Leukopenia; Long-Term Care;

1975
[Hyperuricemia in Parkinson's syndrome--by chance or probable?].
    MMW, Munchener medizinische Wochenschrift, 1976, Nov-12, Volume: 118, Issue:46

    Topics: Adult; Aged; Female; Gout; Humans; Hypertension; Levodopa; Male; Middle Aged; Obesity; Parkinson Dis

1976
[Occurrence of hyperuricemia in atrioventricular block. (Results of a study of 158 patients with isotopic pacemaker implantations)].
    Comptes rendus hebdomadaires des seances de l'Academie des sciences. Serie D: Sciences naturelles, 1976, Oct-27, Volume: 283, Issue:10

    Topics: Adolescent; Adult; Age Factors; Cardiac Surgical Procedures; Child; Female; Gout; Heart Block; Human

1976
[Definition and treatment requirements of uricemia].
    Fortschritte der Medizin, 1977, Jan-06, Volume: 95, Issue:1

    Topics: Adult; Aged; Chronic Disease; Diabetes Mellitus; Female; Gout; Humans; Hypertension, Renal; Liver Di

1977
Some unusual features of gouty arthritis in females.
    Seminars in arthritis and rheumatism, 1977, Volume: 6, Issue:3

    Topics: Adult; Age Factors; Aged; Black or African American; Female; Gout; Humans; Hypertension; Kidney Calc

1977
The gouty toe - a multifactorial condition.
    Annals of internal medicine, 1977, Volume: 86, Issue:2

    Topics: Calcium Pyrophosphate; Chemotaxis, Leukocyte; Gout; Humans; Immunoglobulin G; Leukocytes; Phagocytos

1977
Gout with normal serum urate concentration.
    British medical journal, 1977, Mar-12, Volume: 1, Issue:6062

    Topics: Aged; Gout; Humans; Male; Middle Aged; Uric Acid

1977
[Diagnosis of hyperuricemia].
    Hippokrates, 1977, Volume: 48, Issue:1

    Topics: Female; Gout; Humans; Pregnancy; Uric Acid

1977
Purine enzyme abnormalities: a four year experience.
    Advances in experimental medicine and biology, 1977, Volume: 76A

    Topics: Adenine Phosphoribosyltransferase; Adolescent; Adult; Child; Erythrocytes; Female; Gout; Humans; Hyp

1977
Xanthinuria, lithiasis and gout in the same family.
    Advances in experimental medicine and biology, 1977, Volume: 76A

    Topics: Adolescent; Adult; Age Factors; Aged; Child; Child, Preschool; Creatinine; Female; Genes, Recessive;

1977
Fatty acid composition of plasma lipid fractions in gout.
    Advances in experimental medicine and biology, 1977, Volume: 76A

    Topics: Cholesterol; Cholesterol Esters; Fatty Acids; Fatty Acids, Nonesterified; Fatty Acids, Unsaturated;

1977
A relationship between free urate, protein-bound urate, hyperuricemia and gout in Caucasians and Maoris.
    Advances in experimental medicine and biology, 1977, Volume: 76B

    Topics: Asian People; Gout; Humans; New Zealand; Protein Binding; Serum Albumin; Uric Acid; White People

1977
Protein binding to monosodium urate crystals and its effect on platelet degranulation. Influence of urate on connective tissue metabolism.
    Advances in experimental medicine and biology, 1977, Volume: 76B

    Topics: Acetylglucosaminidase; Benzbromarone; Connective Tissue; Glycosaminoglycans; Gout; Heparin; Hyaluron

1977
Hyperuricemia as a risk factor in coronary heart disease.
    Advances in experimental medicine and biology, 1977, Volume: 76B

    Topics: Age Factors; Black People; Coronary Disease; Female; Gout; Humans; Male; Myocardial Infarction; Sex

1977
Nutritional state and purine metabolism.
    Advances in experimental medicine and biology, 1977, Volume: 76B

    Topics: Adult; Age Factors; Aged; Alcohol Drinking; Body Weight; Coronary Disease; Diabetes Complications; D

1977
The effect of weight loss on plasma and urinary uric acid and lipid levels.
    Advances in experimental medicine and biology, 1977, Volume: 76B

    Topics: Body Weight; Cholesterol; Female; Gout; Humans; Male; Obesity; Triglycerides; Uric Acid

1977
Panel discussion: hyperuricemia as a risk factor.
    Advances in experimental medicine and biology, 1977, Volume: 76B

    Topics: Alcohol Drinking; Allopurinol; Blood Proteins; Body Weight; Coronary Disease; Diabetes Complications

1977
Urate excretion in normal and gouty men.
    Advances in experimental medicine and biology, 1977, Volume: 76B

    Topics: Asian People; Glomerular Filtration Rate; Gout; Humans; Kidney; Male; Uric Acid; White People

1977
Urinary excretion of uricine.
    Advances in experimental medicine and biology, 1977, Volume: 76B

    Topics: Bilirubin; Calcium; Chemical Precipitation; Gout; Humans; Kidney; Pigments, Biological; Pyrroles; Ur

1977
Preliminary criteria for the classification of the acute arthritis of primary gout.
    Arthritis and rheumatism, 1977, Volume: 20, Issue:3

    Topics: Acute Disease; Arthritis; Arthritis, Rheumatoid; Chondrocalcinosis; Diagnosis, Differential; Female;

1977
Gout disease. Its natural history based on 1,000 observations.
    Advances in experimental medicine and biology, 1977, Volume: 76B

    Topics: Calculi; Diabetes Complications; Female; Gout; Humans; Hypertension; Male; Sex Factors; Uric Acid

1977
Recurrent gouty phlebitis without articular gout.
    Advances in experimental medicine and biology, 1977, Volume: 76B

    Topics: Acute Disease; Colchicine; Gout; Humans; Male; Middle Aged; Phlebitis; Uric Acid

1977
Panniculitis of the legs with urate crystal deposition.
    Archives of dermatology, 1977, Volume: 113, Issue:5

    Topics: Aged; Arthritis; Diagnosis, Differential; Female; Furosemide; Gout; Heart Failure; Humans; Lipase; S

1977
[Allopurinol and gouty hyperuricemia : apropos of 30 cases treated by a single daily dose].
    Bruxelles medical, 1977, Volume: 57, Issue:3

    Topics: Allopurinol; Female; Gout; Humans; Male; Middle Aged; Uric Acid

1977
Crystal deposition disease. Diagnosis by electron microscopy.
    The American journal of medicine, 1977, Volume: 63, Issue:1

    Topics: Aged; Calcium Pyrophosphate; Chondrocalcinosis; Crystallization; Female; Gout; Humans; Male; Microsc

1977
[Experiences with uricotest, a simple device for the demonstration of birefringent cristals in tissue (author's transl)].
    Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis, 1977, May-17, Volume: 66, Issue:20

    Topics: Arthritis; Diagnosis, Differential; Gout; Humans; Synovial Fluid; Uric Acid

1977
Rheumatic disorders in the South African Negro. Part IV. Gout and hyperuricaemia.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1977, Jun-25, Volume: 51, Issue:26

    Topics: Adolescent; Adult; Age Factors; Aged; Black People; Ethnicity; Female; Gout; Humans; Male; Metabolic

1977
Kidney in patients with abnormalities in uric acid metabolism.
    Contributions to nephrology, 1977, Volume: 7

    Topics: Acute Disease; Aged; Animals; Dogs; Female; Gout; Humans; Kidney; Kidney Calculi; Kidney Diseases; R

1977
[Isolated or combined drug therapy of hyperuricemia?].
    Deutsche medizinische Wochenschrift (1946), 1977, Jul-29, Volume: 102, Issue:30

    Topics: Allopurinol; Benzbromarone; Drug Therapy, Combination; Gout; Humans; Uric Acid; Uricosuric Agents

1977
[Comparison of effects of various therapeutic methods of the urinary system in patients with gout. Observations on 195 patients with gout].
    Reumatologia, 1977, Volume: 15, Issue:2

    Topics: Adult; Aged; Allopurinol; Female; Gout; Humans; Male; Middle Aged; Probenecid; Uric Acid; Urinary Tr

1977
[De novo purine biosynthesis. In vitro measurement in hyperuricemia (author's transl)].
    La Nouvelle presse medicale, 1977, Sep-10, Volume: 6, Issue:29

    Topics: Adult; Allopurinol; Azaserine; Carbon Radioisotopes; Female; Formates; Gout; Humans; In Vitro Techni

1977
[Gouty attacks in hyperuricemic hypertensives. A follow-up study (author's transl)].
    Ryumachi. [Rheumatism], 1977, Volume: 17, Issue:3

    Topics: Adolescent; Adult; Aged; Female; Follow-Up Studies; Gout; Humans; Hypertension; Male; Middle Aged; U

1977
[Enzymopathies as a cause of hyperuricemia].
    Reumatologia, 1977, Volume: 15, Issue:3

    Topics: Adenine Phosphoribosyltransferase; Carbohydrate Metabolism; Feedback; Gout; Humans; Hypoxanthine Pho

1977
Uric acid, lean body weight, and creatinine interactions: results from regression analysis of 78 variables.
    Seminars in arthritis and rheumatism, 1977, Volume: 7, Issue:2

    Topics: Adult; Aged; Alcohol Drinking; Blood Glucose; Blood Pressure; Body Weight; Cholesterol; Creatinine;

1977
The gouty kidney.
    Seminars in arthritis and rheumatism, 1977, Volume: 7, Issue:2

    Topics: Animals; Disease Models, Animal; Glomerulosclerosis, Focal Segmental; Gout; Humans; Kidney; Kidney C

1977
[Diet therapy of hyperuricemia and gout].
    ZFA. Zeitschrift fur Allgemeinmedizin, 1977, Oct-31, Volume: 53, Issue:30

    Topics: Dietary Proteins; Ethanol; Fasting; Gout; Humans; Purines; Uric Acid

1977
[Secondary gout in chronic kidney failure].
    Orvosi hetilap, 1976, Jun-27, Volume: 117, Issue:26

    Topics: Aged; Chronic Disease; Female; Gout; Humans; Kidney; Kidney Failure, Chronic; Male; Middle Aged; Pye

1976
[Health maintenance despite health risks. III. 3 civilization diseases: hypertension, diabetes, and gout].
    ZFA. Zeitschrift fur Allgemeinmedizin, 1976, Jun-10, Volume: 52, Issue:16

    Topics: Adolescent; Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus; Female; Gout

1976
[Case of disabling form of gout with a 11-year follow-up].
    Reumatologia, 1976, Volume: 14, Issue:2

    Topics: Adult; Colchicine; Follow-Up Studies; Gout; Humans; Joints; Male; Uric Acid

1976
[Urate nephrolithiasis. Cause of consequence?].
    Fortschritte der Medizin, 1976, Jul-15, Volume: 94, Issue:20-21

    Topics: Calcium; Gout; Humans; Kidney Calculi; Oxalates; Uric Acid

1976
[Hyperuricemia].
    Hippokrates, 1976, Volume: 47, Issue:3

    Topics: Arteriosclerosis; Cholelithiasis; Female; Gout; Humans; Male; Sex Factors; Uric Acid

1976
Letter: Uric acid during phenylbutazone therapy.
    Medizinische Klinik, 1976, Sep-10, Volume: 71, Issue:37

    Topics: Dose-Response Relationship, Drug; Gout; Humans; Phenylbutazone; Uric Acid

1976
[Nutritional aspects in the treatment of hyperuricemia].
    Wiener medizinische Wochenschrift (1946), 1976, Feb-13, Volume: 126, Issue:7

    Topics: Body Weight; Dietary Carbohydrates; Gout; Humans; Uric Acid

1976
[Clinical aspects of gout].
    Zeitschrift fur arztliche Fortbildung, 1976, Aug-01, Volume: 70, Issue:15

    Topics: Adult; Age Factors; Aged; Female; Gout; Humans; Male; Middle Aged; Sex Factors; Uric Acid

1976
Platelet aggregation in rats made hyperuricaemic with nucleic adid-rich diets containing oxonate, and inhibitor of uricase [proceedings].
    The Proceedings of the Nutrition Society, 1976, Volume: 35, Issue:2

    Topics: Animals; Diet; Disease Models, Animal; Female; Fusarium; Gout; Nucleic Acids; Oxonic Acid; Platelet

1976
[Serum uric acid and uric acid elimination after benzbromarone therapy in patients with gout and hyperuricemia].
    Fortschritte der Medizin, 1976, Sep-16, Volume: 94, Issue:26

    Topics: Benzbromarone; Benzofurans; Gout; Humans; Uric Acid

1976
Pharmacokinetic and clinical studies of a new uricosuric agent - benzbromarone.
    The Journal of rheumatology, 1976, Volume: 3, Issue:3

    Topics: Adult; Aged; Arthritis; Benzbromarone; Benzofurans; Chemical Phenomena; Chemistry; Chronic Disease;

1976
Hereditary variation in uric acid transport by avian kidney slices.
    The American journal of physiology, 1976, Volume: 231, Issue:4

    Topics: Animals; Biological Transport; Chickens; Gout; Kidney; Male; Ouabain; Potassium; Poultry Diseases; S

1976
Paraparesis secondary to sodium urate deposits in the ligamentum flavum.
    Archives of neurology, 1976, Volume: 33, Issue:11

    Topics: Aged; Gout; Humans; Ligaments; Male; Paraplegia; Spinal Cord Compression; Uric Acid

1976
[Treatment of hyperuricaemia with a combination of allopurinol and benzbromaron (author's transl)].
    Deutsche medizinische Wochenschrift (1946), 1976, Oct-22, Volume: 101, Issue:43

    Topics: Allopurinol; Benzbromarone; Benzofurans; Drug Combinations; Gout; Humans; Time Factors; Uric Acid

1976
[Monitoring of therapy in hyperuricemia and gout].
    Das Medizinische Laboratorium, 1976, Volume: 29, Issue:10

    Topics: Adult; Child, Preschool; Female; Gout; Humans; Male; Middle Aged; Phenylbutazone; Salicylates; Uric

1976
[Physiologic bases of the treatment of gout].
    L'union medicale du Canada, 1976, Volume: 105, Issue:4

    Topics: Gout; Humans; Kidney; Kidney Diseases; Uric Acid; Uricosuric Agents

1976
[Diagnostic problems of gout].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1976, Aug-15, Volume: 31, Issue:16

    Topics: Adolescent; Adult; Age Factors; Child; Female; Gout; Humans; Male; Methods; Sex Factors; Uric Acid

1976
[Clinical effects of purine metabolism disorders in hematopoietic proliferative diseases].
    Polski tygodnik lekarski (Warsaw, Poland : 1960), 1976, Dec-06, Volume: 31, Issue:49

    Topics: Acute Disease; Calcium; Chronic Disease; Gout; Humans; Leukemia; Polycythemia Vera; Potassium; Progn

1976
Sparing effect of hemiplegia on tophaceous gout.
    Annals of the rheumatic diseases, 1976, Volume: 35, Issue:6

    Topics: Gout; Hemiplegia; Humans; Male; Middle Aged; Uric Acid

1976
Levels and significance of erythrocyte purine enzymes in hyperuricemia.
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1976, Volume: 153, Issue:3

    Topics: Adenine Phosphoribosyltransferase; Adenosine Deaminase; Adenosine Kinase; Adolescent; Adult; Erythro

1976
[Hyperuricemia and psoriasis].
    Annales de dermatologie et de syphiligraphie, 1976, Volume: 103, Issue:5-6

    Topics: Carbon Radioisotopes; Female; Glycine; Gout; Humans; Male; Metabolic Diseases; Psoriasis; Uric Acid

1976
Current therapy of gout and hyperuricemia.
    Hospital practice, 1976, Volume: 11, Issue:5

    Topics: Allopurinol; Colchicine; Drug Interactions; Gout; Humans; Indomethacin; Phenylbutazone; Probenecid;

1976
[Diet therapy in gout--experimental basis and practical application].
    Verhandlungen der Deutschen Gesellschaft fur Innere Medizin, 1976, Volume: 82 Pt 1

    Topics: Gout; Humans; Male; Purines; RNA; Uric Acid

1976
[Gout and hyperuricemia].
    Revue de l'infirmiere, 1975, Volume: 25, Issue:1

    Topics: Gout; Humans; Uric Acid

1975
[Diagnosis and therapy of gout].
    Schwestern Revue, 1976, Feb-15, Volume: 14, Issue:2

    Topics: Gout; Humans; Uric Acid

1976
[Uric acid concentration in serum in different types of hyperlipoproteinemia, myocardial infarction and primary gout].
    Klinische Wochenschrift, 1975, Apr-15, Volume: 53, Issue:8

    Topics: Adult; Blood Pressure; Body Weight; Cholesterol; Glucose Tolerance Test; Gout; Humans; Hyperlipidemi

1975
[Type I glycogenosis. Description of 2 cases with hyperuricemia].
    Minerva pediatrica, 1975, Jun-23, Volume: 27, Issue:22

    Topics: Biopsy; Child; Galactose; Glucagon; Glucose Tolerance Test; Glycogen Storage Disease Type I; Gout; H

1975
Adenine phosphoribosyltransferase deficiency: its inheritance and occurrence in a female with gout and renal disease.
    Australian and New Zealand journal of medicine, 1975, Volume: 5, Issue:5

    Topics: Adenine Phosphoribosyltransferase; Adolescent; Adult; Aged; Child; Child, Preschool; Erythrocytes; F

1975
Etiopathogenesis of the gouty arthritis.
    Scandinavian journal of rheumatology. Supplement, 1975, Volume: 12

    Topics: Arthritis; Gout; Humans; Obesity; Uric Acid

1975
Hyperuricemia and renal failure-presenting manifestations of occult hematologic malignancies.
    The Journal of pediatrics, 1976, Volume: 89, Issue:5

    Topics: Adolescent; Anuria; Child; Gout; Humans; Kidney; Kidney Failure, Chronic; Leukemia; Leukemia, Monocy

1976
Acute renal failure and gout as presenting features of acute lymphoblastic leukaemia.
    Archives of disease in childhood, 1976, Volume: 51, Issue:9

    Topics: Acute Kidney Injury; Allopurinol; Child, Preschool; Female; Gout; Humans; Leukemia, Lymphoid; Pancyt

1976
A contribution to the interrelation of lipid and uric acid metabolism.
    Sbornik vedeckych praci Lekarske fakulty Karlovy university v Hradci Kralove, 1976, Volume: 19, Issue:1

    Topics: Adult; Aged; Arteriosclerosis; Gout; Humans; Hyperlipidemias; Lipids; Middle Aged; Uric Acid

1976
[Clinical study of LC 75 (Ampliuril pH) in the states of hyperuricemia].
    Lille medical : journal de la Faculte de medecine et de pharmacie de l'Universite de Lille, 1975, Volume: 20, Issue:4

    Topics: Benzofurans; Carbonates; Coronary Disease; Diabetes Complications; Gout; Humans; Hypertension; Kidne

1975
Origin and extrarenal elimination of uric acid in man.
    Nephron, 1975, Volume: 14, Issue:1

    Topics: Amidophosphoribosyltransferase; Dietary Proteins; Glutamine; Gout; Humans; Hypoxanthine Phosphoribos

1975
Intrinsic renal disease leading to abnormal urate excretion.
    Nephron, 1975, Volume: 14, Issue:1

    Topics: Acute Kidney Injury; Gout; Humans; Kidney Diseases; Kidney Failure, Chronic; Kidney Tubules; Metabol

1975
Gouty arthritis in the black race.
    Seminars in arthritis and rheumatism, 1975, Volume: 4, Issue:3

    Topics: Adult; Aged; Anemia, Sickle Cell; Arthritis; Benzothiadiazines; Black People; Colchicine; Diuretics;

1975
Hyperuricaemia--to treat or not?
    Drugs, 1975, Volume: 9, Issue:2

    Topics: Alcohol Drinking; Diet; Endocrine System Diseases; Gout; Hematologic Diseases; Humans; Hyperlipidemi

1975
Letter: Gout.
    The Medical journal of Australia, 1975, Feb-01, Volume: 1, Issue:5

    Topics: Adult; Elbow Joint; Gout; Humans; Male; Tendinopathy; Uric Acid

1975
[The interrelation between obesity, hyperinsulinism and hyperuricemia].
    Minerva medica, 1975, Apr-11, Volume: 66, Issue:27

    Topics: Adolescent; Adult; Aged; Blood Glucose; Cholesterol; Diabetes Complications; Diabetes Mellitus; Fatt

1975
The Filipino and gout.
    Seminars in arthritis and rheumatism, 1975, Volume: 4, Issue:4

    Topics: Adolescent; Adult; Age Factors; Aged; Allopurinol; Cross-Cultural Comparison; Diet; Ethnicity; Femal

1975
[Deviations in purine metabolism].
    Vnitrni lekarstvi, 1975, Volume: 21, Issue:6

    Topics: Gout; Humans; Purine-Pyrimidine Metabolism, Inborn Errors; Purines; Uric Acid

1975
Proceedings: Single daily dose of allopurinol.
    Annals of the rheumatic diseases, 1975, Volume: 34, Issue:2

    Topics: Allopurinol; Gout; Humans; Time Factors; Uric Acid

1975
Letter: Fructose and hyperuricemia.
    Metabolism: clinical and experimental, 1975, Volume: 24, Issue:7

    Topics: Dietary Carbohydrates; Fructose; Gout; Humans; Uric Acid

1975
Long survival in sickle cell anemia.
    Tropical and geographical medicine, 1975, Volume: 27, Issue:1

    Topics: Age Factors; Aged; Anemia, Aplastic; Anemia, Sickle Cell; Chronic Disease; Electrophoresis, Starch G

1975
Hyperuricaemia in Sudanese.
    The Journal of tropical medicine and hygiene, 1975, Volume: 78, Issue:2

    Topics: Adult; Colorimetry; Female; Gout; Humans; Male; Middle Aged; Sex Factors; Sudan; Uric Acid; Urinary

1975
Letter: Gout.
    The Medical journal of Australia, 1975, Mar-29, Volume: 1, Issue:13

    Topics: Crystallization; Gout; Humans; Solubility; Uric Acid

1975
[25 years of arthritis treatment in the province of Groningen].
    Nederlands tijdschrift voor geneeskunde, 1975, Jun-07, Volume: 119, Issue:23

    Topics: Adolescent; Adult; Aged; Arthritis; Arthritis, Rheumatoid; Child; Child, Preschool; Female; Gout; Hu

1975
[On the hypouricemic action of an alkaline mineral water in the aged].
    Minerva medica, 1975, Apr-28, Volume: 66, Issue:32

    Topics: Aged; Alkalies; Gout; Humans; Mineral Waters; Purines; Uric Acid; Uricosuric Agents

1975
Gout as a complication of Bartter's syndrome. A possible role for alkalosis in the decreased clearance of uric acid.
    Annals of internal medicine, 1975, Volume: 83, Issue:1

    Topics: Acute Disease; Adolescent; Adult; Alkalosis; Bartter Syndrome; Bicarbonates; Child; Child, Preschool

1975
[Letter: Gout and alcohol].
    Deutsche medizinische Wochenschrift (1946), 1975, Aug-29, Volume: 100, Issue:35

    Topics: Alcohol Drinking; Ethanol; Gout; Humans; Uric Acid

1975
Chronic experimental hyperuricemic nephropathy.
    Laboratory investigation; a journal of technical methods and pathology, 1975, Volume: 33, Issue:3

    Topics: Animals; Disease Models, Animal; Gout; Kidney; Kidney Calculi; Nephritis, Interstitial; Oxonic Acid;

1975
[Clinical picture of gout and gouty (hyperuricemic) kidney].
    Vnitrni lekarstvi, 1975, Volume: 21, Issue:8

    Topics: Adult; Gout; Hematuria; Humans; Kidney Diseases; Male; Proteinuria; Uric Acid

1975
Gout: diagnosis and management.
    The British journal of clinical practice, 1975, Volume: 29, Issue:4

    Topics: Allopurinol; Anti-Inflammatory Agents; Gout; Humans; Probenecid; Uric Acid

1975
[Choice between uricosurics and inhibitors of uric acid synthesis in the treatment of gout].
    Nihon rinsho. Japanese journal of clinical medicine, 1975, Feb-10, Volume: 33, Issue:2

    Topics: Depression, Chemical; Gout; Gout Suppressants; Humans; Kidney Diseases; Uric Acid; Uricosuric Agents

1975
[Uric acid and gout].
    Das Medizinische Laboratorium, 1975, Volume: 28, Issue:4

    Topics: Chemical Phenomena; Chemistry; Gout; Humans; Purine Nucleotides; Purines; Uric Acid

1975
[Gout, hyperuricemia and femur head osteonecrosis (FHON)].
    Revue du rhumatisme et des maladies osteo-articulaires, 1975, Volume: 42, Issue:3

    Topics: Adrenal Cortex Hormones; Adult; Female; Femur Head Necrosis; France; Gout; Humans; Hypercholesterole

1975
Hypoxanthine-guanine phosphoribosyltransferase. Characterization of a mutant in a patient with gout.
    The Journal of clinical investigation, 1975, Volume: 56, Issue:5

    Topics: Adult; Erythrocytes; Female; Fibroblasts; Genes; Gout; Humans; Hypoxanthine Phosphoribosyltransferas

1975
[Hyperuricemia in the practice].
    Therapie der Gegenwart, 1975, Volume: 114, Issue:9

    Topics: Gout; Humans; Paraproteinemias; Polycythemia; Uric Acid

1975
Acute hyperuricemic nephropathy in rats. An electron microscopic study.
    The American journal of pathology, 1975, Volume: 81, Issue:2

    Topics: Animals; Disease Models, Animal; Gout; Kidney; Kidney Calculi; Kidney Diseases; Kidney Tubules; Male

1975
Uric acid, joint morbidity, and streptococcal antibodies in Maori and European teenagers. Rotorua Lakes study 3.
    Annals of the rheumatic diseases, 1975, Volume: 34, Issue:4

    Topics: Adolescent; Antibodies, Bacterial; Antistreptolysin; Female; Gout; Hemoglobins; Humans; Joint Diseas

1975
Drug-induced gout.
    Drug and therapeutics bulletin, 1975, Sep-12, Volume: 13, Issue:19

    Topics: Gout; Humans; Kidney; Nucleic Acids; Uric Acid

1975
Renal function in gout. IV. An analysis of 524 gouty subjects including long-term follow-up studies.
    The American journal of medicine, 1975, Volume: 59, Issue:5

    Topics: Adult; Aged; Aging; Calculi; Follow-Up Studies; Glomerular Filtration Rate; Gout; Humans; Inulin; Ki

1975
Avascular necrosis and its relation to lipid and purine metabolism.
    The Journal of rheumatology, 1975, Volume: 2, Issue:4

    Topics: Adrenal Cortex Hormones; Adult; Aged; Alcoholism; Cholesterol; Female; Femur Head Necrosis; Gout; Hu

1975
The pharmacology of hypouricemic effect of benzbromarone.
    The Journal of rheumatology, 1975, Volume: 2, Issue:4

    Topics: Adult; Aspirin; Benzbromarone; Benzofurans; Blood Proteins; Creatinine; Female; Gout; Humans; Male;

1975
[Proceedings: Normal values and samples of findings in kidney diseases].
    Medizinische Klinik, 1975, Jun-06, Volume: 70, Issue:23

    Topics: Bacteriuria; Creatinine; Female; Glomerular Filtration Rate; Gout; Hematuria; Humans; Inulin; Kidney

1975
[Clinical study of gout and hyperuricemia. (II) Physiopathology and diagnosis].
    Ryumachi. [Rheumatism], 1975, Volume: 15, Issue:2

    Topics: Adult; Aged; Gout; Humans; Middle Aged; Uric Acid

1975
Localization of renal tubular uric acid transport defect in gouty chickens.
    The American journal of physiology, 1975, Volume: 229, Issue:3

    Topics: Aminohippuric Acids; Animals; Biological Transport; Chickens; Gout; Guanine; Kidney Tubules; Uric Ac

1975
[The simultaneous occurrence of psoriasis, sarcoidosis and gout. Report of 3 cases].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1975, Volume: 26, Issue:7

    Topics: Adult; Female; Gout; Humans; Male; Middle Aged; Psoriasis; Sarcoidosis; Uric Acid

1975
[Hyperuricemia syndrome and blood coagulation disorder: effects of crenotherapy].
    La Clinica terapeutica, 1975, Sep-30, Volume: 74, Issue:6

    Topics: Blood Coagulation Disorders; Gout; Health Resorts; Humans; Mineral Waters; Syndrome; Uric Acid

1975
[Effect of thiopurinol on renal uric acid and oxypurine excretion in man under modified formula diet with a constant purine content].
    Verhandlungen der Deutschen Gesellschaft fur Innere Medizin, 1975, Volume: 81

    Topics: Allopurinol; Diet; Gout; Humans; Kidney; Purines; Uric Acid

1975
[Uric acid and gout].
    Das Medizinische Laboratorium, 1975, Volume: 28, Issue:5

    Topics: Chemical Phenomena; Chemistry; Gout; Humans; Uric Acid

1975
Uricosuric activity of suxibuzone, a new phenylbutazone derivative.
    Archivos de farmacologia y toxicologia, 1975, Volume: 1, Issue:1

    Topics: Adolescent; Adult; Drug Evaluation; Gout; Humans; Phenylbutazone; Sulfinpyrazone; Uric Acid; Uricosu

1975
[Behavior of 5-phosphoribosyl-1-pyrophosphate (PRPP) in erythrocytes, leukocytes and lymphocytes of normal and gouty subjects].
    Reumatismo, 1975, Volume: 27, Issue:1

    Topics: Adult; Aged; Allopurinol; Erythrocytes; Gout; Humans; Leukocytes; Lymphocytes; Middle Aged; Pentosep

1975
Monosodium urate monohydrate, the gout culprit.
    Journal of the American Chemical Society, 1976, Apr-14, Volume: 98, Issue:8

    Topics: Adult; Aged; Chemical Phenomena; Chemistry; Crystallography; Female; Gout; Humans; Hydrogen Bonding;

1976
[The hypoexcretors and hyperproducers of uric acid amomg juvenile gout patients].
    Die Medizinische Welt, 1976, Mar-19, Volume: 27, Issue:12

    Topics: Adolescent; Adult; Age Factors; Body Weight; Creatinine; Gout; Humans; Male; Uric Acid

1976
[Which uric acid value is in need of treatment?].
    Schweizerische medizinische Wochenschrift, 1976, Apr-03, Volume: 106, Issue:14

    Topics: Allopurinol; Benzbromarone; Citrates; Coronary Disease; Gout; Humans; Hyperlipidemias; Hypertension;

1976
[Hyperuricemia].
    ZFA. Zeitschrift fur Allgemeinmedizin, 1976, Feb-10, Volume: 52, Issue:4

    Topics: Gout; Humans; Uric Acid

1976
[Hyperuricemia and the kidney].
    ZFA. Zeitschrift fur Allgemeinmedizin, 1976, Feb-10, Volume: 52, Issue:4

    Topics: Gout; Humans; Kidney Diseases; Uric Acid; Uricosuric Agents

1976
Gout, uric acid and renal disease.
    The Medical journal of Australia, 1976, Mar-20, Volume: 1, Issue:12

    Topics: Arthritis; Gout; Humans; Kidney Diseases; Kidney Failure, Chronic; Metabolic Diseases; Uric Acid

1976
[Uric acid balance in radiotherapy].
    Strahlentherapie, 1976, Volume: 151, Issue:5

    Topics: Adenocarcinoma; Gout; Hodgkin Disease; Humans; Kidney; Kidney Neoplasms; Male; Radiotherapy; Radioth

1976
Clinical and family studies in Hungarian patients with gout.
    Rheumatology international, 1992, Volume: 12, Issue:5

    Topics: Adult; Arthritis, Gouty; Female; Gout; HLA Antigens; Humans; Male; Uric Acid

1992
[Hyperuricemia and its complications].
    Revue de l'infirmiere, 1992, Volume: 42, Issue:20

    Topics: Gout; Humans; Uric Acid

1992
[Long lasting normalization of uric acid after combination therapy with 300 mg allopurinol and 60 mg benzbromarone in patients with gout and hyperuricemia].
    Medizinische Klinik (Munich, Germany : 1983), 1992, Sep-15, Volume: 87, Issue:9

    Topics: Allopurinol; Benzbromarone; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug The

1992
Gout.
    Singapore medical journal, 1992, Volume: 33, Issue:4

    Topics: Adult; Aged; Arthritis, Gouty; Female; Gout; Humans; Male; Middle Aged; Uric Acid

1992
[Hyperuricemia and gout].
    Atencion primaria, 1992, Sep-01, Volume: 10, Issue:3

    Topics: Diagnosis, Differential; Education, Medical, Continuing; Gout; Humans; Spain; Uric Acid

1992
Acute gout after carpal tunnel release.
    The Journal of hand surgery, 1992, Volume: 17, Issue:6

    Topics: Acute Disease; Carpal Tunnel Syndrome; Gout; Gout Suppressants; Humans; Male; Middle Aged; Postopera

1992
Tophaceous gout as a fungating mass.
    Arthritis and rheumatism, 1992, Volume: 35, Issue:11

    Topics: Adult; Gout; Humans; Male; Mycoses; Recurrence; Uric Acid

1992
Gouty arthropathy and synovial uric acid.
    British journal of rheumatology, 1992, Volume: 31, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Animals; Female; Gout; Humans; Joint Diseases; Male; Middle Aged; Sy

1992
The epidemiology of gout and hyperuricemia in a rural population of Java.
    The Journal of rheumatology, 1992, Volume: 19, Issue:10

    Topics: Adolescent; Adult; Aged; Body Mass Index; Female; Gout; Humans; Indonesia; Life Expectancy; Male; Mi

1992
Surgical management of chronic tophaceous gout. A case report.
    Journal of the American Podiatric Medical Association, 1992, Volume: 82, Issue:10

    Topics: Aged; Chronic Disease; Ciprofloxacin; Foot Deformities, Acquired; Gout; Humans; Male; Metatarsophala

1992
[First indications of decrease in the incidence of hyperuricemia in North Germany].
    Versicherungsmedizin, 1992, Dec-01, Volume: 44, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; Feeding Behavior; Female; Germany; Gout; Hu

1992
Relation between creatinine and uric acid excretion.
    Annals of the rheumatic diseases, 1992, Volume: 51, Issue:1

    Topics: Adult; Creatinine; Gout; Humans; Male; Middle Aged; Time Factors; Uric Acid

1992
Hyperuricemia and gout among heart transplant recipients receiving cyclosporine.
    The American journal of medicine, 1992, Volume: 92, Issue:2

    Topics: Arthritis, Gouty; Chi-Square Distribution; Cyclosporine; Female; Gout; Heart Transplantation; Heart-

1992
Diuretic induced gout: a multifactorial condition.
    Annals of the rheumatic diseases, 1992, Volume: 51, Issue:2

    Topics: Aged; Aged, 80 and over; Creatinine; Diuretics; Female; Glomerular Filtration Rate; Gout; Humans; Ki

1992
[Secondary kidney diseases due to hyper-uric acidemia].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1992, Jan-10, Volume: 81, Issue:1

    Topics: Gout; Humans; Kidney; Kidney Diseases; Prognosis; Ultrasonography; Uric Acid

1992
What stops a gouty attack?
    The Journal of rheumatology, 1992, Volume: 19, Issue:1

    Topics: Anti-Inflammatory Agents; Crystallization; Cytokines; Gout; Humans; Joints; Neutrophils; Uric Acid

1992
Accelerated purine nucleotide degradation by anaerobic but not by aerobic ergometer muscle exercise.
    Metabolism: clinical and experimental, 1992, Volume: 41, Issue:4

    Topics: Adult; Aerobiosis; Anaerobiosis; Blood Pressure; Creatine Kinase; Gout; Heart Rate; Humans; Hypoxant

1992
The incidence of gout in patients with Dupuytren's disease.
    Journal of hand surgery (Edinburgh, Scotland), 1992, Volume: 17, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Arthritis, Gouty; Dupuytren Contracture; Female; Gout; Humans; Incid

1992
Antibodies against crystals.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 1992, Volume: 6, Issue:8

    Topics: Allopurinol; Animals; Antibody Formation; Arthritis, Rheumatoid; Crystallography; Electrophoresis, P

1992
Treatment with colchicine decreases white cell counts in synovial fluid of asymptomatic knees that contain monosodium urate crystals.
    The Journal of rheumatology, 1992, Volume: 19, Issue:4

    Topics: Colchicine; Crystallization; Gout; Humans; Knee Joint; Leukocyte Count; Neutrophils; Synovial Fluid;

1992
Subcutaneous pancreatic fat necrosis associated with acute arthritis.
    The Journal of rheumatology, 1992, Volume: 19, Issue:4

    Topics: Acute Disease; Aged; Arthritis; Crystallization; Diagnosis, Differential; Fat Necrosis; Gout; Humans

1992
Identification of distinct PRS1 mutations in two patients with X-linked phosphoribosylpyrophosphate synthetase superactivity.
    Advances in experimental medicine and biology, 1991, Volume: 309B

    Topics: Amino Acid Sequence; Base Sequence; DNA; DNA Mutational Analysis; Genetic Linkage; Gout; Humans; Mut

1991
Gout and uric acid excretion.
    American family physician, 1992, Volume: 45, Issue:1

    Topics: Gout; Humans; Uric Acid

1992
Ultrastructural studies of the reaction of urate crystals with a cultured renal tubular cell line.
    Nephron, 1991, Volume: 59, Issue:3

    Topics: Animals; Binding Sites; Cell Line; Crystallization; Gout; Kidney Diseases; Kidney Tubules; Microscop

1991
[Effects of alminoprofen on sodium urate crystal-induced inflammation].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 1991, Volume: 98, Issue:6

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Chemotaxis, Leukocyte; Depression, Chemical; Dinop

1991
Renal urate hypoexcretion preceding renal disease in a new kindred with familial juvenile gouty nephropathy (FJGN).
    Advances in experimental medicine and biology, 1991, Volume: 309A

    Topics: Adolescent; Adult; Child; Child, Preschool; Female; Gout; Humans; Kidney; Kidney Diseases; Male; Ped

1991
Familial nephropathy and gout: which comes first?
    Advances in experimental medicine and biology, 1991, Volume: 309A

    Topics: Adult; Creatinine; Female; Gout; Humans; Hypoxanthine; Hypoxanthines; Kidney Diseases; Kidney Failur

1991
Gout and main rheumatic diseases in man.
    Advances in experimental medicine and biology, 1991, Volume: 309A

    Topics: Adult; Arthritis; Arthritis, Psoriatic; Arthritis, Rheumatoid; Female; Gout; Humans; Male; Middle Ag

1991
Organic distribution and interrelationships of lesions occurring in laying hens suffering from gout and urolithiasis.
    Advances in experimental medicine and biology, 1991, Volume: 309A

    Topics: Animals; Chickens; Female; Gout; Kidney; Liver; Lung; Myocardium; Poultry Diseases; Spleen; Uric Aci

1991
A biochemical investigation on chicken gout observed in the Marmara region in Turkey.
    Advances in experimental medicine and biology, 1991, Volume: 309A

    Topics: Animals; Bicarbonates; Blood Proteins; Calcium; Chickens; Gout; Orotic Acid; Poultry Diseases; Refer

1991
Crystal arthritis: a clinician's view.
    Australian family physician, 1991, Volume: 20, Issue:12

    Topics: Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis,

1991
Familial juvenile gouty nephropathy with renal urate hypoexcretion preceding renal disease.
    Clinical nephrology, 1991, Volume: 35, Issue:6

    Topics: Adolescent; Adult; Child; Creatinine; Female; Glomerular Filtration Rate; Gout; Humans; Kidney; Kidn

1991
Evidence for a promoter of urate crystal formation in gouty synovial fluid.
    Annals of the rheumatic diseases, 1991, Volume: 50, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Calcium Pyrophosphate; Crystallization; Femal

1991
[Uric acid level in blood donors of southern Germany--almost constant since 1971].
    Fortschritte der Medizin, 1991, Jul-30, Volume: 109, Issue:22

    Topics: Adult; Arthritis, Gouty; Benzbromarone; Benzimidazoles; Blood Donors; Cross-Sectional Studies; Femal

1991
Precocious familial gout.
    Lancet (London, England), 1990, Sep-22, Volume: 336, Issue:8717

    Topics: Adult; Child; Family Health; Female; Gout; Humans; Kidney Diseases; Male; Patient Compliance; Uric A

1990
Apolipoprotein (apo) E inhibits the capacity of monosodium urate crystals to stimulate neutrophils. Characterization of intraarticular apo E and demonstration of apo E binding to urate crystals in vivo.
    The Journal of clinical investigation, 1991, Volume: 87, Issue:1

    Topics: Apolipoproteins E; Cartilage; Crystallization; Gout; Humans; Neutrophils; Synovial Fluid; Uric Acid

1991
Dupuytren's contracture and gouty tophi in a black patient.
    Journal of the National Medical Association, 1991, Volume: 83, Issue:1

    Topics: Dupuytren Contracture; Gout; Humans; Male; Middle Aged; Uric Acid

1991
Persistence of monosodium urate crystals and low-grade inflammation in the synovial fluid of patients with untreated gout.
    Arthritis and rheumatism, 1991, Volume: 34, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Gout; Humans; Inflammation; Leukocyte Count; Middle Aged; Neutrophil

1991
Urate and calcium stones--picking up a drop of mercury with one's fingers?
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 1991, Volume: 17, Issue:4

    Topics: Allopurinol; Animals; Calcium Oxalate; Glycosaminoglycans; Gout; Humans; Kidney Calculi; Uric Acid

1991
Urate crystals stimulate production of tumor necrosis factor alpha from human blood monocytes and synovial cells. Cytokine mRNA and protein kinetics, and cellular distribution.
    The Journal of clinical investigation, 1991, Volume: 87, Issue:4

    Topics: Blotting, Northern; Cell Survival; Cells, Cultured; Crystallography; Dose-Response Relationship, Dru

1991
Female gout. Clinical spectrum and uric acid metabolism.
    Archives of internal medicine, 1991, Volume: 151, Issue:4

    Topics: Adult; Age Factors; Diuretics; Female; Gout; Humans; Hypertension; Kidney Failure, Chronic; Male; Me

1991
Tophus-derived monosodium urate monohydrate crystals are biologically much more active than synthetic counterpart.
    Rheumatology international, 1991, Volume: 10, Issue:6

    Topics: Blood Proteins; Crystallization; Gout; Hemolysis; Humans; Inflammation; Knee Joint; Luminescent Meas

1991
[Epidemiology of hyperuricemia and gout: difference between Caucasians and Japanese].
    Nihon rinsho. Japanese journal of clinical medicine, 1991, Volume: 49, Issue:5

    Topics: Asian People; Gout; Humans; Japan; Uric Acid; White People

1991
Underexcretory-type hyperuricemia, disproportionate to the reduced glomerular filtration rate, in two boys with mild proteinuria.
    Nephron, 1990, Volume: 56, Issue:4

    Topics: Child; Creatinine; Glomerular Filtration Rate; Gout; Humans; Kidney; Male; Nephritis, Interstitial;

1990
[Changes in serum uric acid concentration after defined physical stress].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1990, Dec-15, Volume: 45, Issue:24

    Topics: Adult; Energy Metabolism; Gout; Humans; Male; Physical Exertion; Pilot Projects; Risk Factors; Uric

1990
An aberration of fructose metabolism in familial gout identified by 31P magnetic resonance spectroscopy of the liver.
    Transactions of the Association of American Physicians, 1990, Volume: 103

    Topics: Adult; Aged; Aged, 80 and over; Dietary Carbohydrates; Female; Fructose; Fructose-Bisphosphate Aldol

1990
[Metabolism of purine nucleotides in the central nervous system in patients with phosphoribosylpyrophosphate synthetase hyperactivity and neurosensory deafness].
    Neurologia (Barcelona, Spain), 1990, Volume: 5, Issue:1

    Topics: Adult; Brain; Child; Deafness; Female; Genetic Carrier Screening; Gout; Homozygote; Humans; Hypoxant

1990
Acute uric acid nephropathy in two gouty patients with moderate hyperuricemia and high urine acidity.
    Klinische Wochenschrift, 1990, Sep-03, Volume: 68, Issue:17

    Topics: Acute Kidney Injury; Benzbromarone; Glomerular Filtration Rate; Gout; Humans; Male; Middle Aged; Uri

1990
[Gout without hyperuricemia?].
    Deutsche medizinische Wochenschrift (1946), 1990, Nov-09, Volume: 115, Issue:45

    Topics: Diagnosis, Differential; Gout; Humans; Male; Middle Aged; Uric Acid

1990
Monosodium urate crystals stimulate phospholipase A2 enzyme activities and the synthesis of a phospholipase A2-activating protein.
    Journal of immunology (Baltimore, Md. : 1950), 1990, Nov-15, Volume: 145, Issue:10

    Topics: Cell Survival; Colchicine; Eicosanoids; Enzyme Activation; Gout; Humans; Phospholipases A; Phospholi

1990
Fructose-induced aberration of metabolism in familial gout identified by 31P magnetic resonance spectroscopy.
    Proceedings of the National Academy of Sciences of the United States of America, 1990, Volume: 87, Issue:21

    Topics: Diet; Female; Fructose; Gout; Humans; Liver; Magnetic Resonance Spectroscopy; Male; Phosphates; Phos

1990
[Clinical studies on hyperuricemia and gout after transplantation].
    Hinyokika kiyo. Acta urologica Japonica, 1990, Volume: 36, Issue:8

    Topics: Adult; Allopurinol; Analgesics; Benzbromarone; Female; Gout; Humans; Immunosuppressive Agents; Kidne

1990
Familial hyperuricemia and renal insufficiency.
    Child nephrology and urology, 1990, Volume: 10, Issue:2

    Topics: Adolescent; Adult; Allopurinol; Gout; Humans; Kidney Diseases; Kidney Failure, Chronic; Male; Pedigr

1990
Serum uric acid correlates in elderly men and women with special reference to body composition and dietary intake (Dutch Nutrition Surveillance System).
    Journal of clinical epidemiology, 1990, Volume: 43, Issue:12

    Topics: Aged; Alcohol Drinking; Anthropometry; Antihypertensive Agents; Body Mass Index; Body Weight; Diet;

1990
[Hyperuricemia--does modern therapy improve life expectancy?].
    Versicherungsmedizin, 1990, Oct-01, Volume: 42, Issue:5

    Topics: Cause of Death; Combined Modality Therapy; Gout; Humans; Life Expectancy; Uric Acid

1990
[The effect of oral calcium loading on the serum concentrations and urinary excretion of uric acid in patients with recurrent calcium nephrolithiasis and hypercalciuria].
    Vutreshni bolesti, 1990, Volume: 29, Issue:3

    Topics: Administration, Oral; Adolescent; Adult; Aged; Autoanalysis; Calcium; Chronic Disease; Female; Gout;

1990
Uric acid levels in southern Germany in 1989. A comparison with studies from 1962, 1971, and 1984.
    Klinische Wochenschrift, 1990, Dec-17, Volume: 68, Issue:24

    Topics: Adult; Aged; Aging; Female; Germany; Gout; Humans; Kidney Calculi; Male; Middle Aged; Population Sur

1990
Polyarticular symmetric tophaceous joint inflammation as the initial presentation of gout.
    The American journal of emergency medicine, 1990, Volume: 8, Issue:1

    Topics: Aged; Female; Finger Joint; Gout; Hand Deformities, Acquired; Humans; Synovial Fluid; Uric Acid

1990
Cyclosporine-induced hyperuricemia and gout.
    The New England journal of medicine, 1990, Feb-01, Volume: 322, Issue:5

    Topics: Allopurinol; Azathioprine; Cyclosporins; Drug Interactions; Gout; Humans; Transplantation, Homologou

1990
Is asteroid hyalosis ocular gout?
    Annals of ophthalmology, 1990, Volume: 22, Issue:2

    Topics: Age Factors; Aged; Aged, 80 and over; Black People; Eye Diseases; Female; Gout; Humans; Male; Medica

1990
Cyclosporin induced hyperuricemia and gout.
    Clinical nephrology, 1990, Volume: 33, Issue:3

    Topics: Adult; Cyclosporins; Female; Gout; Humans; Kidney Transplantation; Male; Middle Aged; Uric Acid; Uve

1990
Epidemiological study of urinary tract stones in a northern Italian city.
    British journal of urology, 1990, Volume: 65, Issue:3

    Topics: Adult; Calcium Oxalate; Colic; Diet; Drinking; Epidemiologic Methods; Female; Gout; Humans; Incidenc

1990
Intraarticular noninflammatory free urate suspension (urate milk) in 3 patients with painful joints.
    The Journal of rheumatology, 1990, Volume: 17, Issue:5

    Topics: Aged; Alcoholism; Crystallization; Exudates and Transudates; Female; Gout; Humans; Knee Joint; Neutr

1990
Quality control of the laboratory diagnosis of gout by synovial fluid microscopy.
    Scandinavian journal of rheumatology, 1990, Volume: 19, Issue:3

    Topics: Crystallization; False Positive Reactions; Gout; Humans; Quality Control; Synovial Fluid; Uric Acid

1990
Substituted cyclic imides as potential anti-gout agents.
    Life sciences, 1990, Volume: 46, Issue:26

    Topics: Allopurinol; Analysis of Variance; Animals; Dose-Response Relationship, Drug; Gout; Gout Suppressant

1990
Tophaceous neck mass presenting as a thyroglossal duct cyst.
    Arthritis and rheumatism, 1990, Volume: 33, Issue:6

    Topics: Diagnosis, Differential; Gout; Humans; Male; Middle Aged; Thyroglossal Cyst; Uric Acid

1990
Precocious familial gout with reduced fractional urate clearance and normal purine enzymes.
    The Quarterly journal of medicine, 1990, Volume: 75, Issue:277

    Topics: Adolescent; Adult; Age Factors; Creatinine; Family; Female; Glomerular Filtration Rate; Gout; Humans

1990
Alcohol and gout.
    BMJ (Clinical research ed.), 1989, Apr-22, Volume: 298, Issue:6680

    Topics: Alcohol Drinking; Alcoholic Intoxication; Gout; Humans; Uric Acid

1989
[Infratemporal gout tophus--a rare differential diagnosis in primary parotid gland disease].
    Laryngo- rhino- otologie, 1989, Volume: 68, Issue:11

    Topics: Aged; Diagnosis, Differential; Female; Gout; Humans; Ossification, Heterotopic; Parotid Diseases; Pa

1989
Inflammatory microcrystals stimulate interleukin-6 production and secretion by human monocytes and synoviocytes.
    Arthritis and rheumatism, 1989, Volume: 32, Issue:11

    Topics: Calcium Pyrophosphate; Cell Survival; Cells, Cultured; Chondrocalcinosis; Crystallization; Durapatit

1989
[Significance of uric acid analysis in clinical tests].
    Nihon rinsho. Japanese journal of clinical medicine, 1989, Volume: 48 Suppl

    Topics: Energy Metabolism; Female; Gout; Humans; Male; Purines; Reference Values; Uric Acid

1989
A model of gout nephropathy.
    Advances in experimental medicine and biology, 1989, Volume: 253A

    Topics: Animals; Cells, Cultured; Crystallization; Dogs; Gout; Kidney Diseases; Uric Acid

1989
Hyperuricemia, gout and idiopathic aseptic necrosis of bone.
    Advances in experimental medicine and biology, 1989, Volume: 253A

    Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Female; Femur Head Necrosis; Gout; Humans; Ma

1989
Is gout related to an alteration of the uric acid protein binding?
    Advances in experimental medicine and biology, 1989, Volume: 253A

    Topics: Arthritis, Gouty; Blood Proteins; Gout; Humans; Hypoxanthines; Kidney Diseases; Uric Acid

1989
Should dietary restrictions always be prescribed in the treatment of gout?
    Advances in experimental medicine and biology, 1989, Volume: 253A

    Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Diet; Female; Gout; Humans; Male; Middle Aged; Prevalen

1989
Intermittent control of hyperuricaemia in the treatment of gout.
    Advances in experimental medicine and biology, 1989, Volume: 253A

    Topics: Allopurinol; Arthritis, Gouty; Gout; Humans; Middle Aged; Uric Acid

1989
Impaired renal excretion of hypoxanthine and xanthine in primary gout.
    Advances in experimental medicine and biology, 1989, Volume: 253A

    Topics: Adult; Aged; Female; Gout; Humans; Hypoxanthine Phosphoribosyltransferase; Hypoxanthines; Kidney; Le

1989
Hyperuricemia and gout in cyclosporin A-treated renal transplant recipients.
    Advances in experimental medicine and biology, 1989, Volume: 253A

    Topics: Cyclosporins; Female; Gout; Humans; Kidney Transplantation; Male; Metabolic Clearance Rate; Uric Aci

1989
[Analysis of uric acid and oxypurines in normal subjects and in gout patients].
    Bollettino della Societa italiana di biologia sperimentale, 1989, Volume: 65, Issue:12

    Topics: Adult; Gout; Humans; Hypoxanthine; Hypoxanthines; Middle Aged; Uric Acid; Xanthine; Xanthines

1989
[Clearance of oxypurines in normal subjects and in gout patients subjected to a purine-free diet. Effects of allopurinol].
    Bollettino della Societa italiana di biologia sperimentale, 1989, Volume: 65, Issue:11

    Topics: Adult; Allopurinol; Creatinine; Diet; Gout; Humans; Hypoxanthine; Hypoxanthines; Middle Aged; Uric A

1989
Cyclosporine-induced hyperuricemia and gout.
    The New England journal of medicine, 1989, Aug-03, Volume: 321, Issue:5

    Topics: Adult; Arthritis, Gouty; Azathioprine; Creatinine; Cyclosporins; Drug Therapy, Combination; Female;

1989
A case of multiple urate deposition, without gouty attacks, in a patient with systemic lupus erythematosus.
    Cutis, 1989, Volume: 43, Issue:3

    Topics: Adult; Female; Gout; Humans; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Lupus Ne

1989
[Differential indications for uricosuric drugs and allopurinol].
    Klinische Wochenschrift, 1989, Mar-01, Volume: 67, Issue:5

    Topics: Allopurinol; Combined Modality Therapy; Dietary Proteins; Gout; Humans; Uric Acid; Uricosuric Agents

1989
Relationship between hypertriglyceridemia and uric acid production in primary gout.
    Metabolism: clinical and experimental, 1989, Volume: 38, Issue:7

    Topics: Alcohol Drinking; Cholesterol; Cholesterol, HDL; Gout; Humans; Hypertriglyceridemia; Male; Reference

1989
[Changes in uric acid and blood lipids in patients with asymptomatic hyperuricemia treated with diet therapy in a rehabilitation procedure].
    Die Rehabilitation, 1989, Volume: 28, Issue:3

    Topics: Adult; Aged; Combined Modality Therapy; Dietary Fats; Follow-Up Studies; Gout; Humans; Hyperlipidemi

1989
[Kidney tubular transport disorders. Disorders of renal urate transport].
    Nihon rinsho. Japanese journal of clinical medicine, 1989, Volume: 47, Issue:7

    Topics: Acid-Base Imbalance; Biological Transport; Extracellular Space; Gout; Humans; Kidney; Kidney Disease

1989
[Is it necessary to prescribe a diet for all patients with gout?].
    Medicina clinica, 1989, Sep-16, Volume: 93, Issue:7

    Topics: Female; Gout; Humans; Male; Uric Acid

1989
The "switch-off" mechanism of spontaneous resolution of acute gout attack.
    The Journal of rheumatology, 1988, Volume: 15, Issue:1

    Topics: Acute-Phase Reaction; Calorimetry; Crystallization; Gout; Humans; Inflammation; Lymphocytes; Microsc

1988
Calcium pyrophosphate crystal deposition: the effect of monosodium urate and apatite crystals in a kinetic study using a gelatin matrix model.
    Scanning microscopy, 1988, Volume: 2, Issue:2

    Topics: Apatites; Calcium Pyrophosphate; Diphosphates; Gelatin; Gout; Humans; Microscopy, Electron, Scanning

1988
Inherited superactivity of phosphoribosylpyrophosphate synthetase: association of uric acid overproduction and sensorineural deafness.
    The American journal of medicine, 1988, Volume: 85, Issue:3

    Topics: Adult; Child; Deafness; Female; Fibroblasts; Gout; Humans; Male; Phosphotransferases; Purine Nucleot

1988
[Cyclic nucleotides in gout].
    Vrachebnoe delo, 1988, Issue:6

    Topics: Adult; Cyclic AMP; Cyclic GMP; Female; Gout; Humans; Male; Middle Aged; Uric Acid

1988
Gout and hyperuricaemia in patients on cyclosporin and diuretics.
    Lancet (London, England), 1985, Feb-23, Volume: 1, Issue:8426

    Topics: Adult; Antilymphocyte Serum; Azathioprine; Cyclosporins; Diuretics; Female; Gout; Humans; Kidney Dis

1985
[Gamma-glutamyltransferase and alcohol consumption in primary gout].
    Quaderni Sclavo di diagnostica clinica e di laboratorio, 1986, Volume: 22, Issue:3

    Topics: Adult; Aged; Alcohol Drinking; Alcoholism; gamma-Glutamyltransferase; Gout; Humans; Middle Aged; Tri

1986
Study of hereditary fructose intolerance by use of 31P magnetic resonance spectroscopy.
    Lancet (London, England), 1987, Oct-24, Volume: 2, Issue:8565

    Topics: Carbohydrate Metabolism, Inborn Errors; Female; Fructose; Fructose Intolerance; Fructose-Bisphosphat

1987
A structural approach to pathological crystallizations. Gout: the possible role of albumin in sodium urate crystallization.
    Proceedings of the Royal Society of London. Series B, Biological sciences, 1988, Nov-22, Volume: 235, Issue:1279

    Topics: Crystallization; Fluorescence; Gout; Humans; Microscopy, Electron, Scanning; Ovalbumin; Peptides; Po

1988
Development of the gout tophus. An hypothesis.
    American journal of clinical pathology, 1989, Volume: 91, Issue:2

    Topics: Aged; Antibodies, Monoclonal; Crystallization; Gout; Humans; Macrophages; Male; Middle Aged; Models,

1989
Hyperuricemia, gout, and autosomal dominant polycystic kidney disease.
    The American journal of the medical sciences, 1989, Volume: 297, Issue:3

    Topics: Aged; Female; Gout; Humans; Hypoxanthine Phosphoribosyltransferase; Kidney Failure, Chronic; Male; M

1989
[Immune complex hyperuricemic nephritis: aspects of its morphology and pathogenesis].
    Terapevticheskii arkhiv, 1986, Volume: 58, Issue:8

    Topics: Biopsy, Needle; Glomerular Mesangium; Glomerulonephritis; Gout; Humans; Immune Complex Diseases; Kid

1986
Crystal-induced endogenous pyrogen production. A further look at gouty inflammation.
    Arthritis and rheumatism, 1985, Volume: 28, Issue:9

    Topics: Calcium Pyrophosphate; Crystallization; Diphosphates; Durapatite; Gout; Humans; Hydroxyapatites; Int

1985
[Hypothesis on the probable mechanism of auto-limitation of acute attacks of gout].
    Bollettino della Societa italiana di biologia sperimentale, 1986, Mar-31, Volume: 62, Issue:3

    Topics: Calorimetry; Crystallization; Free Radicals; Gout; Humans; Microscopy, Electron, Scanning; Models, B

1986
The "switch-off" mechanism of spontaneous resolution of acute gout attack.
    Advances in experimental medicine and biology, 1986, Volume: 195 Pt A

    Topics: Acute Disease; Allantoin; Crystallization; Durapatite; Gout; Humans; Hydroxyapatites; Kinetics; Lumi

1986
Products of polymorphonuclear cell injury inhibit IgG enhancement of monosodium urate-induced superoxide production.
    Arthritis and rheumatism, 1986, Volume: 29, Issue:12

    Topics: Animals; Crystallization; Gout; Humans; Immunoglobulin G; Microscopy, Electron; Neutrophils; Protein

1986
Articular oxalate crystals and the taxonomy of gout.
    JAMA, 1988, Sep-02, Volume: 260, Issue:9

    Topics: Calcium Oxalate; Crystallization; Gout; History, 19th Century; History, 20th Century; History, Medie

1988
Gout and hyperuricemia: diagnosis and management.
    Hospital practice (Office ed.), 1986, Nov-15, Volume: 21, Issue:11

    Topics: Adult; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Colchicine; Female; Gout; Hu

1986
Intractable gouty arthritis.
    Hospital practice (Office ed.), 1987, Jun-15, Volume: 22, Issue:6

    Topics: Allopurinol; Arthritis; Colchicine; Duodenal Ulcer; Gout; Humans; Hypertension; Indomethacin; Male;

1987
Migration and gout: the Tokelau Island migrant study.
    British medical journal (Clinical research ed.), 1987, Aug-22, Volume: 295, Issue:6596

    Topics: Adolescent; Adult; Age Factors; Aged; Cholesterol; Female; Gout; Humans; Male; Middle Aged; New Zeal

1987
Asymptomatic hyperuricaemia.
    British medical journal (Clinical research ed.), 1987, Apr-18, Volume: 294, Issue:6578

    Topics: Gout; Humans; Kidney Diseases; Male; Risk Factors; Uric Acid

1987
Studies on normal and abnormal excretion patterns of uric acid in Bahawalpur.
    JPMA. The Journal of the Pakistan Medical Association, 1987, Volume: 37, Issue:10

    Topics: Adolescent; Adult; Aged; Aging; Female; Gout; Humans; Male; Middle Aged; Pakistan; Urban Population;

1987
Altered fractional excretion of uric acid during total parenteral nutrition.
    The Journal of rheumatology, 1987, Volume: 14, Issue:5

    Topics: Adult; Aged; Amino Acids; Female; Gout; Humans; Male; Pancreatic Cyst; Pancreatic Pseudocyst; Parent

1987
Allopurinol hypersensitivity in a patient with coexistent systemic lupus erythematosus and tophaceous gout.
    The Journal of rheumatology, 1988, Volume: 15, Issue:5

    Topics: Adult; Allopurinol; Arthrography; Drug Hypersensitivity; Fingers; Gout; Humans; Klinefelter Syndrome

1988
[Dose response relations of allopurinol].
    Klinische Wochenschrift, 1988, Aug-15, Volume: 66, Issue:16

    Topics: Allopurinol; Dose-Response Relationship, Drug; Gout; Humans; Uric Acid

1988
Renal excretion of hypoxanthine and xanthine in primary gout.
    The American journal of medicine, 1988, Volume: 85, Issue:4

    Topics: Adult; Aged; Female; Gout; Humans; Hypoxanthine; Hypoxanthines; Kidney; Male; Middle Aged; Uric Acid

1988
[Medications against gout].
    Nederlands tijdschrift voor geneeskunde, 1988, Oct-01, Volume: 132, Issue:40

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Gout; Humans; Uric Acid; Uricosuric Agents; Xan

1988
[A case of partial deficiency of hypoxanthine-guanine phosphoribosyltransferase].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1988, Volume: 77, Issue:5

    Topics: Adolescent; Genes, Recessive; Gout; Humans; Hypoxanthine Phosphoribosyltransferase; Male; Purines; U

1988
[Uric acid metabolism disorders associated with alcoholism].
    Nihon rinsho. Japanese journal of clinical medicine, 1988, Volume: 46, Issue:8

    Topics: Adenosine Triphosphate; Alcoholism; Gout; Humans; Kidney; Uric Acid

1988
[Obesity as a risk factor in gout].
    Nihon rinsho. Japanese journal of clinical medicine, 1988, Volume: 46, Issue:11

    Topics: Diet; Female; Gout; Humans; Male; Middle Aged; Obesity; Risk Factors; Uric Acid

1988
[Prevalence of excess blood uric acid and gout in a sample of a rural Castillian population 40-50 years of age].
    Revista clinica espanola, 1988, Volume: 182, Issue:9

    Topics: Adult; Blood Glucose; Cross-Sectional Studies; Female; Gout; Humans; Lipids; Male; Middle Aged; Risk

1988
Concomitant gout and rheumatoid arthritis.
    The Journal of rheumatology, 1988, Volume: 15, Issue:8

    Topics: Adult; Arthritis, Rheumatoid; Crystallization; Ear; Gout; HLA-DR Antigens; HLA-DR4 Antigen; Humans;

1988
The incidence of gout in renal transplant recipients.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 1987, Volume: 10, Issue:5

    Topics: Azathioprine; Cyclosporins; Diuretics; Female; Gout; Humans; Kidney Transplantation; Male; Retrospec

1987
[The effect of inhibitor of angiotensin-converting enzyme on uric acid metabolism].
    Nihon Jinzo Gakkai shi, 1987, Volume: 29, Issue:10

    Topics: Adult; Aged; Captopril; Female; Gout; Humans; Hypertension; Male; Middle Aged; Uric Acid

1987
Ankle joint urate arthritis in rats provides a useful tool for the evaluation of analgesic and anti-arthritic agents.
    Pharmacology, biochemistry, and behavior, 1988, Volume: 29, Issue:3

    Topics: Analgesics; Animals; Ankle Joint; Anti-Inflammatory Agents; Arthritis; Disease Models, Animal; Drug

1988
[Hyperuricemia as a risk factor of nephropathy in gout].
    Terapevticheskii arkhiv, 1988, Volume: 60, Issue:1

    Topics: Adult; Aged; Female; Gout; Humans; Kidney Diseases; Male; Middle Aged; Risk Factors; Uric Acid

1988
[A family of hereditary xanthinuria: two siblings with peptic ulcer and hypouricemia due to xanthine oxidase deficiency, and a heterozygote (father) with gout].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1988, Volume: 77, Issue:1

    Topics: Adult; Gout; Heterozygote; Humans; Male; Peptic Ulcer; Purine-Pyrimidine Metabolism, Inborn Errors;

1988
[Therapeutic nutrition in gout].
    Fel'dsher i akusherka, 1988, Volume: 53, Issue:3

    Topics: Female; Gout; Humans; Kidney; Male; Middle Aged; Uric Acid

1988
[Uric acid concentrations of the kidney in primary gout].
    Nihon Jinzo Gakkai shi, 1988, Volume: 30, Issue:1

    Topics: Female; Gout; Humans; Kidney; Kidney Cortex; Kidney Failure, Chronic; Male; Middle Aged; Uric Acid

1988
[Hyperlipoproteinemia in primary gout and asymptomatic hyperuricemia].
    Wiener medizinische Wochenschrift (1946), 1988, May-31, Volume: 138, Issue:10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cholesterol; Creatinine; Gout; Humans; Hyperlipoproteine

1988
[Glomerular diseases secondary to gout].
    Nihon rinsho. Japanese journal of clinical medicine, 1988, Volume: 46, Issue:6

    Topics: Adult; Aged; Female; Glomerulonephritis; Gout; Humans; Kidney Glomerulus; Male; Middle Aged; Uric Ac

1988
[Clinical aspects and diagnosis of urinary calculi in patients with gout].
    Vrachebnoe delo, 1988, Issue:6

    Topics: Adult; Aged; Female; Gout; Humans; Kidney Calculi; Male; Middle Aged; Uric Acid

1988
[Intra-hospital acute arthritis. Prospective study of 50 cases].
    Revista clinica espanola, 1987, Volume: 181, Issue:6

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Arthritis; Calcinosis; Calcium Pyrophosphate; Crystal

1987
[The uric acid-lowering effect of diflunisal].
    Wiener klinische Wochenschrift, 1987, Nov-20, Volume: 99, Issue:22

    Topics: Adolescent; Adult; Aged; Arthritis; Diflunisal; Female; Gout; Humans; Male; Middle Aged; Salicylates

1987
Primary hyperparathyroidism and hyperuricaemia are associated but not correlated with indicators of bone turnover.
    Clinica chimica acta; international journal of clinical chemistry, 1987, Volume: 170, Issue:2-3

    Topics: Adult; Aged; Alkaline Phosphatase; Bone and Bones; Bone Regeneration; Female; Gout; Humans; Hydroxyp

1987
[Total purine content in selected foods].
    Zeitschrift fur Ernahrungswissenschaft, 1987, Volume: 26, Issue:4

    Topics: Food Analysis; Gout; Humans; Purines; Uric Acid

1987
[Use of sorption for the correction of hyperuricemia in the combined treatment of gout].
    Terapevticheskii arkhiv, 1987, Volume: 59, Issue:12

    Topics: Administration, Oral; Charcoal; Drug Therapy, Combination; Female; Gout; Humans; Male; Middle Aged;

1987
[Substantiation and effectiveness of the use of purine antagonists in gouty nephropathy].
    Terapevticheskii arkhiv, 1987, Volume: 59, Issue:12

    Topics: Adult; Azathioprine; Drug Therapy, Combination; Gout; Humans; Kidney Diseases; Mercaptopurine; Middl

1987
[The clinical picture of acute gout without hyperuricemia].
    Lijecnicki vjesnik, 1986, Volume: 108, Issue:9

    Topics: Acute Disease; Adult; Aged; Female; Gout; Humans; Male; Middle Aged; Pedigree; Uric Acid

1986
Gout and pseudogout of the temporomandibular joint.
    Oral surgery, oral medicine, and oral pathology, 1987, Volume: 63, Issue:5

    Topics: Adult; Arthritis; Calcium Pyrophosphate; Diagnosis, Differential; Female; Gout; Humans; Male; Middle

1987
[Uric acid levels of the serum of healthy persons and patients with various rheumatic diseases].
    Terapevticheskii arkhiv, 1987, Volume: 59, Issue:4

    Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Female; Gout; Humans; Male; Middle Aged; Osteoarthri

1987
Gout and hyperuricaemia.
    Australian family physician, 1987, Volume: 16, Issue:6

    Topics: Allopurinol; Colchicine; Cross-Sectional Studies; Family Practice; Female; Gout; Humans; Indomethaci

1987
[Evaluation of hyperuricemia caused by fructose in a status of altered uric acid metabolism].
    Quaderni Sclavo di diagnostica clinica e di laboratorio, 1987, Volume: 23, Issue:4

    Topics: Adult; Aged; Arthritis, Gouty; Diagnosis, Differential; Female; Fructose; Gout; Humans; Male; Metabo

1987
[Beta 2-microglobulin in the blood serum and urine of patients with interstitial kidney lesions].
    Terapevticheskii arkhiv, 1986, Volume: 58, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; beta 2-Microglobulin; Chronic Disease; Female; Gout; Hu

1986
Hyperuricemia and gout.
    Seminars in roentgenology, 1986, Volume: 21, Issue:4

    Topics: Adolescent; Age Factors; Arthritis; Arthrography; Bone Diseases; Child; Diagnosis, Differential; Fem

1986
[Observations on the effect of PZA, EB and RFP on uric acid metabolism].
    Zhonghua jie he he hu xi xi ji bing za zhi = Chinese journal of tuberculosis and respiratory diseases, 1986, Volume: 9, Issue:4

    Topics: Adolescent; Adult; Arthritis; Drug Therapy, Combination; Ethambutol; Female; Gout; Humans; Male; Mid

1986
Purine synthesis de novo in cultured lymphoblast cells derived from patients with gout.
    Rheumatology international, 1987, Volume: 7, Issue:1

    Topics: Adult; Cells, Cultured; Gout; Humans; Hypoxanthine Phosphoribosyltransferase; Lymphocytes; Male; Mid

1987
[Current clinical course of gout].
    Terapevticheskii arkhiv, 1987, Volume: 59, Issue:4

    Topics: Adult; Age Factors; Aged; Arthritis; Female; Gout; Humans; Male; Middle Aged; Sex Factors; Uric Acid

1987
[Epidemiology and pathogenesis of disorders of purine metabolism].
    Terapevticheskii arkhiv, 1987, Volume: 59, Issue:4

    Topics: Adolescent; Adult; Alcohol Drinking; Arthritis; Diet; Female; Gout; Humans; Male; Meat; Middle Aged;

1987
[Effect of decrease in hyperuricemia levels on joint, kidney and other symptoms in patients with gout].
    Terapevticheskii arkhiv, 1987, Volume: 59, Issue:4

    Topics: Adult; Aged; Allopurinol; Arthritis; Colchicine; Coronary Disease; Gout; Humans; Hypertension; Middl

1987
[Circadian rhythm of uric acid levels of the serum in gout].
    Terapevticheskii arkhiv, 1987, Volume: 59, Issue:4

    Topics: Adult; Arthritis, Rheumatoid; Circadian Rhythm; Gout; Humans; Kidney; Metabolic Clearance Rate; Uric

1987
[Rehabilitation of patients with gout during outpatient follow-up].
    Terapevticheskii arkhiv, 1987, Volume: 59, Issue:4

    Topics: Adult; Aged; Arthritis; Female; Follow-Up Studies; Gout; Gout Suppressants; Health Resorts; Humans;

1987
Comparison of the urate lowering effects of allopurinol and diflunisal.
    The Journal of rheumatology, 1987, Volume: 14, Issue:2

    Topics: Allopurinol; Diflunisal; Gout; Humans; Osmolar Concentration; Salicylates; Uric Acid; Xanthine; Xant

1987
Hyperuricemia and uric acid nephropathy.
    Archives of internal medicine, 1987, Volume: 147, Issue:7

    Topics: Aged; Allopurinol; Female; Gout; Humans; Kidney Diseases; Kidney Failure, Chronic; Nephritis, Inters

1987
Gout and hyperuricaemia in systemic lupus erythematosus.
    British journal of rheumatology, 1987, Volume: 26, Issue:4

    Topics: Adolescent; Adrenal Cortex Hormones; Adult; Age Factors; Diagnosis, Differential; Diuretics; Female;

1987
[Metabolic arthropathies with special reference to gout].
    Zeitschrift fur arztliche Fortbildung, 1987, Volume: 81, Issue:8

    Topics: Arthritis; Chondrocalcinosis; Gout; Humans; Prognosis; Uric Acid

1987
Evaluation of the renal mechanisms for urate homeostasis in uremic patients by probenecid and pyrazinamide test.
    Nephron, 1987, Volume: 46, Issue:3

    Topics: Absorption; Creatinine; Female; Glomerular Filtration Rate; Gout; Homeostasis; Humans; Kidney Failur

1987
Significance of single serum urate estimations in acutely hospitalized elderly patients.
    Age and ageing, 1987, Volume: 16, Issue:4

    Topics: Aged; Aged, 80 and over; Arthritis; Diuretics; Female; Gout; Humans; Male; Middle Aged; Predictive V

1987
[Diet therapy in gout].
    Meditsinskaia sestra, 1986, Volume: 45, Issue:3

    Topics: Gout; Humans; Menu Planning; Uric Acid

1986
Aseptic loosening of a total hip prosthesis secondary to tophaceous gout. A case report.
    The Journal of bone and joint surgery. American volume, 1987, Volume: 69, Issue:7

    Topics: Aged; Female; Gout; Hip Joint; Hip Prosthesis; Humans; Prosthesis Failure; Radiography; Reoperation;

1987
[Secondary gout and pseudo-Bartter syndrome in females with laxative abuse].
    Klinische Wochenschrift, 1987, Sep-01, Volume: 65, Issue:17

    Topics: Adult; Anorexia Nervosa; Bartter Syndrome; Cathartics; Dose-Response Relationship, Drug; Female; Gou

1987
Your CE topic this month (No. 26). Gout: medical management.
    The Journal of practical nursing, 1987, Volume: 37, Issue:3

    Topics: Diet, Reducing; Gout; Humans; Nursing, Practical; Uric Acid

1987
[Molecular genetic mechanisms of the pathogenesis of gout and gouty nephropathy].
    Terapevticheskii arkhiv, 1987, Volume: 59, Issue:8

    Topics: Adult; Aged; Creatine; DNA Repair; DNA Replication; Gout; Humans; Kidney Diseases; Male; Middle Aged

1987
Plasma oxipurinol concentrations during allopurinol therapy.
    British journal of rheumatology, 1987, Volume: 26, Issue:6

    Topics: Allopurinol; Creatine; Gout; Humans; Hypoxanthine; Hypoxanthines; Kidney Function Tests; Oxypurinol;

1987
Tophaceous gout presenting with bilateral hand contractures and carpal tunnel syndrome.
    The Journal of rheumatology, 1986, Volume: 13, Issue:1

    Topics: Aged; Carpal Tunnel Syndrome; Contracture; Gout; Hand; Humans; Male; Uric Acid

1986
[Clinical experience with a new uricolytic agent].
    Recenti progressi in medicina, 1986, Volume: 77, Issue:3

    Topics: Adolescent; Adult; Aged; Female; Gout; Humans; Kidney Failure, Chronic; Male; Middle Aged; Urate Oxi

1986
Immunochemical and ultrastructural characterization of serum proteins associated with monosodium urate crystals (MSU) in synovial fluid cells from patients with gout.
    Ultrastructural pathology, 1986, Volume: 10, Issue:3

    Topics: Arthritis; Blood Proteins; Gout; Humans; Immunochemistry; Immunoglobulin G; Microscopy, Electron; Ph

1986
Eye tophi deposition in gout.
    The Journal of rheumatology, 1986, Volume: 13, Issue:2

    Topics: Aged; Eye Diseases; Gout; Humans; Male; Sclera; Uric Acid

1986
[Arthropathies and nutrition: gout].
    Minerva medica, 1986, May-19, Volume: 77, Issue:21

    Topics: Adolescent; Adult; Arthritis; Colchicine; Diet; Dietary Fats; Dietary Proteins; Female; Gout; Humans

1986
[Hyperuricemia: explain, ignore or treat?].
    Schweizerische medizinische Wochenschrift, 1986, Jun-14, Volume: 116, Issue:24

    Topics: Coronary Disease; Female; Gout; Humans; Hypertension; Kidney Calculi; Male; Purines; Risk; Uric Acid

1986
Impact of associated medical conditions on clinical features of gout.
    Advances in experimental medicine and biology, 1986, Volume: 195 Pt A

    Topics: Adult; Gout; Humans; Kidney Calculi; Middle Aged; Proteinuria; United States; Uric Acid

1986
Corrected clearance identifies underexcretion of uric acid in a gouty kindred.
    Advances in experimental medicine and biology, 1986, Volume: 195 Pt A

    Topics: Gout; Humans; Kidney; Kinetics; Models, Biological; Uric Acid

1986
Diminished tubular secretion of urate in gout not dependent on serum urate levels.
    Advances in experimental medicine and biology, 1986, Volume: 195 Pt A

    Topics: Adult; Aged; Gout; Humans; Kidney Tubules; Kinetics; Male; Middle Aged; Nephrons; Probenecid; Refere

1986
Study of the effect of hypouricaemic therapy on serum lipid levels in gout patients.
    Advances in experimental medicine and biology, 1986, Volume: 195 Pt A

    Topics: Allopurinol; Cholesterol; Cholesterol, HDL; Gout; Humans; Lipids; Probenecid; Triglycerides; Uric Ac

1986
The sex steroids influence on uric acid binding to human plasma proteins.
    Advances in experimental medicine and biology, 1986, Volume: 195 Pt A

    Topics: Adolescent; Adult; Allopurinol; Blood Proteins; Child; Child, Preschool; Female; Gout; Humans; Male;

1986
Hypouricemic action of diflunisal in gouty patients.
    Clinical rheumatology, 1986, Volume: 5, Issue:2

    Topics: Adult; Aged; Diflunisal; Dose-Response Relationship, Drug; Female; Gout; Humans; Male; Middle Aged;

1986
Prevalence of rheumatoid arthritis, osteoarthritis, chondrocalcinosis and gouty arthritis at age 79.
    The Journal of rheumatology, 1986, Volume: 13, Issue:3

    Topics: Aged; Aging; Arthritis; Arthritis, Rheumatoid; Chondrocalcinosis; Female; Finger Joint; Gout; Hip Jo

1986
Carpal tunnel syndrome and gout: case report.
    Virginia medical, 1986, Volume: 113, Issue:7

    Topics: Aged; Carpal Tunnel Syndrome; Gout; Humans; Male; Uric Acid

1986
Preliminary evidence for the presence of an inhibitor on the surface of natural monosodium urate crystals.
    Arthritis and rheumatism, 1986, Volume: 29, Issue:9

    Topics: Gout; Humans; Uric Acid

1986
[Ketazone hepatosis--a possibility for the development of secondary hypouricemia].
    Zeitschrift fur arztliche Fortbildung, 1986, Volume: 80, Issue:1

    Topics: Adult; Arthritis; Chemical and Drug Induced Liver Injury; Gout; Humans; Liver Function Tests; Male;

1986
Requiem for gouty nephropathy.
    Kidney international, 1986, Volume: 30, Issue:2

    Topics: Acute Disease; Aged; Animals; Chronic Disease; Disease Models, Animal; Gout; Humans; Kidney; Kidney

1986
[Arterial hypertension in gouty nephropathy].
    Vutreshni bolesti, 1986, Volume: 25, Issue:3

    Topics: Adult; Aged; Blood Pressure; Female; Gout; Humans; Hypertension; Kidney Diseases; Male; Middle Aged;

1986
Coexistence of rheumatoid nodulosis and gout.
    The Journal of rheumatology, 1986, Volume: 13, Issue:4

    Topics: Adult; Gout; Humans; Male; Rheumatoid Nodule; Synovial Fluid; Uric Acid

1986
The clinical spectrum of gouty arthritis in women.
    Archives of internal medicine, 1986, Volume: 146, Issue:11

    Topics: Adult; Age Factors; Aged; Arthritis; Diuretics; Female; Gout; Humans; Kidney Diseases; Male; Menopau

1986
Paget's disease of bone in patients with gout.
    Archives of internal medicine, 1986, Volume: 146, Issue:12

    Topics: Aged; Aged, 80 and over; Gout; Humans; Male; Middle Aged; Osteitis Deformans; Radionuclide Imaging;

1986
Coexistent systemic lupus erythematosus and urate deposition.
    Journal of the American Academy of Dermatology, 1986, Volume: 15, Issue:5 Pt 1

    Topics: Adult; Female; Gout; Humans; Lupus Erythematosus, Systemic; Uric Acid

1986
Renal handling of uric acid in gout: impaired tubular transport of urate not dependent on serum urate levels.
    Metabolism: clinical and experimental, 1986, Volume: 35, Issue:12

    Topics: Adult; Aged; Biological Transport, Active; Gout; Humans; Kidney Tubules; Kinetics; Male; Middle Aged

1986
A comparison of gout in men and women. A 10-year experience.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1986, Dec-06, Volume: 70, Issue:12

    Topics: Adult; Age Factors; Aged; Arthritis; Female; Gout; Humans; Male; Middle Aged; Retrospective Studies;

1986
Monosodium urate crystals in the knee joints of patients with asymptomatic nontophaceous gout.
    Arthritis and rheumatism, 1986, Volume: 29, Issue:12

    Topics: Allopurinol; Crystallization; Female; Gout; Humans; Joints; Knee Joint; Male; Synovial Fluid; Uric A

1986
[Hyperuricemic nephropathy].
    Zhonghua nei ke za zhi, 1986, Volume: 25, Issue:9

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Gout; Humans; Kidney Diseases; Male; Middle Aged

1986
[Renal aspects of the pathogenesis of hyperuricemia].
    Verhandlungen der Deutschen Gesellschaft fur Innere Medizin, 1986, Volume: 92

    Topics: Glomerular Filtration Rate; Gout; Humans; Kidney Tubules; Uric Acid

1986
[Clinical picture and diagnosis of gout].
    Verhandlungen der Deutschen Gesellschaft fur Innere Medizin, 1986, Volume: 92

    Topics: Adult; Aged; Diagnosis, Differential; Female; Gout; Humans; Kidney Diseases; Male; Middle Aged; Uric

1986
[Diet therapy of hyperuricemia--scientific principles and practical consequences].
    Verhandlungen der Deutschen Gesellschaft fur Innere Medizin, 1986, Volume: 92

    Topics: Combined Modality Therapy; Gout; Humans; Purines; Uric Acid

1986
[Drug therapy of hyperuricemia].
    Verhandlungen der Deutschen Gesellschaft fur Innere Medizin, 1986, Volume: 92

    Topics: Allopurinol; Drug Therapy, Combination; Gout; Humans; Uric Acid; Uricosuric Agents

1986
When to treat hyperuricaemia.
    Verhandlungen der Deutschen Gesellschaft fur Innere Medizin, 1986, Volume: 92

    Topics: Female; Gout; Humans; Male; Risk; Uric Acid

1986
Gout in the elderly, a separate entity?
    Annals of the rheumatic diseases, 1987, Volume: 46, Issue:1

    Topics: Age Factors; Aged; Female; Gout; Humans; Male; Retrospective Studies; Sex Factors; Uric Acid

1987
[Adenosine deaminase activity in the lymphocytes of patients with gouty arthritis].
    Casopis lekaru ceskych, 1986, Nov-14, Volume: 125, Issue:46

    Topics: Adenosine Deaminase; Arthritis; Clinical Enzyme Tests; Female; Gout; Humans; Lymphocytes; Male; Midd

1986
[Hypouricemic effect of diflunisal in patients with gout].
    Casopis lekaru ceskych, 1986, Nov-14, Volume: 125, Issue:46

    Topics: Adult; Aged; Diflunisal; Female; Gout; Humans; Male; Middle Aged; Salicylates; Uric Acid

1986
[Alkalit in the treatment of hyperuricemic syndrome].
    Casopis lekaru ceskych, 1986, Nov-14, Volume: 125, Issue:46

    Topics: Adult; Aged; Citrates; Citric Acid; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Uric

1986
Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study.
    The American journal of medicine, 1987, Volume: 82, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Aging; Arthritis; Gout; Humans; Hypertension; Male; Massachusetts; M

1987
Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study.
    The American journal of medicine, 1987, Volume: 82, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Aging; Arthritis; Gout; Humans; Hypertension; Male; Massachusetts; M

1987
Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study.
    The American journal of medicine, 1987, Volume: 82, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Aging; Arthritis; Gout; Humans; Hypertension; Male; Massachusetts; M

1987
Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study.
    The American journal of medicine, 1987, Volume: 82, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Aging; Arthritis; Gout; Humans; Hypertension; Male; Massachusetts; M

1987
Tophaceous gout of the cervical spine without peripheral tophi.
    Arthritis and rheumatism, 1987, Volume: 30, Issue:2

    Topics: Aged; Cervical Vertebrae; Creatinine; Female; Gout; Humans; Male; Spinal Diseases; Uric Acid

1987
[A study on the prognosis of asymptomatic hyperuricemia--I].
    Ryumachi. [Rheumatism], 1985, Volume: 25, Issue:5

    Topics: Adult; Aged; Arthritis; Gout; Humans; Male; Middle Aged; Prognosis; Uric Acid; Urinary Calculi

1985
Case report: intraosseous gouty tophus.
    The Journal of the Medical Society of New Jersey, 1985, Volume: 82, Issue:1

    Topics: Aged; Clavicle; Female; Gout; Humans; Radiography; Uric Acid

1985
Adenosine triphosphate degradation in specific disease.
    The Journal of laboratory and clinical medicine, 1985, Volume: 106, Issue:2

    Topics: Adenine; Adenosine Triphosphate; Biotransformation; Carnitine O-Palmitoyltransferase; Ethanol; Fruct

1985
[Arresting an acute attack of gout. Open pilot study in 98 patients].
    Fortschritte der Medizin, 1985, Feb-26, Volume: 103, Issue:SPEC NO 7A

    Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Drug Evaluation; Female; Gout; Humans; Male;

1985
Elevated C3 anaphylatoxin levels in synovial fluids from patients with rheumatoid arthritis.
    Arthritis and rheumatism, 1985, Volume: 28, Issue:10

    Topics: Arthritis, Rheumatoid; Chondrocalcinosis; Complement C3; Complement C3a; Complement C5; Complement C

1985
The development of allopurinol.
    Archives of internal medicine, 1985, Volume: 145, Issue:8

    Topics: Allopurinol; Animals; Chemistry; Coronary Disease; Gout; History, 20th Century; Humans; Hypertension

1985
[Ultrasonography of the gouty kidney].
    Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica, 1985, Jul-25, Volume: 45, Issue:7

    Topics: Adult; Aged; Female; Gout; Humans; Kidney; Male; Middle Aged; Ultrasonography; Uric Acid

1985
Plasma follicle-stimulating hormone, luteinizing hormone, and sex hormones in patients with gout.
    Arthritis and rheumatism, 1985, Volume: 28, Issue:2

    Topics: Adult; Aged; Clomiphene; Estradiol; Female; Follicle Stimulating Hormone; Gonadal Steroid Hormones;

1985
Rational therapy for hyperuricaemia.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1986, Mar-15, Volume: 69, Issue:6

    Topics: Gout; Gout Suppressants; Humans; Uric Acid; Uricosuric Agents

1986
Hyperuricemia and gout.
    The Western journal of medicine, 1985, Volume: 142, Issue:1

    Topics: Allopurinol; Anti-Inflammatory Agents; Arthritis; Colchicine; Female; Gout; Humans; Indomethacin; Ki

1985
Gouty infiltration of a flexor tendon simulating rupture.
    Clinical orthopaedics and related research, 1985, Issue:194

    Topics: Adult; Fingers; Gout; Humans; Male; Rupture; Tendon Injuries; Tendons; Uric Acid

1985
Gouty tenosynovitis in the hand.
    The Journal of hand surgery, 1985, Volume: 10, Issue:2

    Topics: Adult; Aged; Arthritis; Carpal Tunnel Syndrome; Female; Gout; Hand; Humans; Male; Middle Aged; Tenos

1985
Asymptomatic hyperuricemia. The case for benign neglect.
    Postgraduate medicine, 1985, May-01, Volume: 77, Issue:6

    Topics: Age Factors; Female; Gout; Humans; Kidney Calculi; Leukemia; Lymphoma; Male; Reference Values; Risk;

1985
The treatment of hyperuricaemia and gout.
    Australian family physician, 1985, Volume: 14, Issue:3

    Topics: Arthritis; Gout; Gout Suppressants; Humans; Uric Acid

1985
Diuretic-induced gout in elderly women.
    British journal of rheumatology, 1985, Volume: 24, Issue:2

    Topics: Age Factors; Aged; Creatinine; Diuretics; Female; Gout; Humans; Sex Factors; Uric Acid

1985
Juvenile gouty arthritis.
    American journal of diseases of children (1960), 1985, Volume: 139, Issue:6

    Topics: Arthritis, Juvenile; Child; Child, Preschool; Gout; Humans; Uric Acid

1985
[Behavior of serum acid levels in children in comparison with adults and the incidence of purine metabolism disorders and concomitant diseases in children of families with gout].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1985, Apr-15, Volume: 40, Issue:8

    Topics: Adolescent; Adult; Child; Child, Preschool; Cholesterol; Female; Glomerular Filtration Rate; Gout; H

1985
Studies on the interaction of rheumatoid factor with monosodium urate crystals and case report of coexistent tophaceous gout and rheumatoid arthritis.
    Annals of the rheumatic diseases, 1985, Volume: 44, Issue:6

    Topics: Arthritis, Rheumatoid; Crystallization; Gout; Humans; Immunoglobulin G; Immunoglobulin M; In Vitro T

1985
Hyperuricemia and hypertriglyceridemia: metabolic basis for the association.
    Metabolism: clinical and experimental, 1985, Volume: 34, Issue:8

    Topics: Adult; Aged; Creatinine; Dietary Carbohydrates; Fat Emulsions, Intravenous; Female; Glucose; Gout; H

1985
Multiple microcrystal deposition within a family.
    Annals of the rheumatic diseases, 1985, Volume: 44, Issue:8

    Topics: Adult; Aged; Calcium Pyrophosphate; Chondrocalcinosis; Crystallization; Female; Gout; Humans; Joint

1985
Aortic valvular tophus: identification by X-ray diffraction of urate and calcium phosphates.
    Journal of clinical pathology, 1985, Volume: 38, Issue:8

    Topics: Aged; Aortic Valve; Calcium Phosphates; Gout; Heart Valve Diseases; Humans; Hydroxyapatites; Male; U

1985
Rapid development of gouty tophi after diuretic therapy.
    The Journal of rheumatology, 1985, Volume: 12, Issue:2

    Topics: Aged; Diuretics; Female; Furosemide; Gout; Heart Failure; Humans; Uric Acid

1985
[Illusion and reality in gout].
    Medicinski pregled, 1985, Volume: 38, Issue:3-4

    Topics: Arthritis; Arthritis, Rheumatoid; Diagnosis, Differential; Gout; Hallux; Humans; Rheumatic Nodule; U

1985
[Gout and urolithiasis].
    Ryumachi. [Rheumatism], 1985, Volume: 25, Issue:2

    Topics: Adult; Calcium Oxalate; Female; Gout; Humans; Male; Middle Aged; Uric Acid; Urinary Calculi

1985
[Lipoprotein patterns in gout and hyperuricemia].
    Fortschritte der Medizin, 1985, Jul-11, Volume: 103, Issue:26

    Topics: Aged; Arteriosclerosis; Chylomicrons; Female; Gout; Humans; Lipoproteins, LDL; Lipoproteins, VLDL; M

1985
Gout nephropathy and arterial hypertension.
    Przeglad lekarski, 1985, Volume: 42, Issue:3

    Topics: Female; Glomerular Filtration Rate; Gout; Humans; Hypertension; Kidney Diseases; Male; Middle Aged;

1985
Role of alcohol in clinical nephrology.
    Klinische Wochenschrift, 1985, Sep-16, Volume: 63, Issue:18

    Topics: Acute Kidney Injury; Alcoholism; Blood Glucose; Blood Proteins; Energy Metabolism; Female; Fetal Alc

1985
[Gout with giant tophi: description of a case].
    La Clinica terapeutica, 1985, Oct-31, Volume: 115, Issue:2

    Topics: Aged; Gout; Humans; Male; Radiography; Uric Acid

1985
Streptomycin induced acute hyperuricemia and podagra.
    The Journal of the Association of Physicians of India, 1985, Volume: 33, Issue:6

    Topics: Acute Disease; Adult; Gout; Humans; Male; Streptomycin; Uric Acid

1985
[Renal insufficiency and uric gout in a lead worker (clinicopathologic conference)].
    Revista clinica espanola, 1985, Volume: 177, Issue:7

    Topics: Aged; Gout; Humans; Hypertension; Kidney; Kidney Failure, Chronic; Lead Poisoning; Male; Myocardium;

1985
[Secondary hyperuricemia].
    Ryumachi. [Rheumatism], 1985, Volume: 25, Issue:4

    Topics: Cardiovascular Diseases; Diuretics; Endocrine System Diseases; Ethanol; Fructose; Gout; Hematologic

1985
[Criteria for the selection and evaluation of diagnostic tests].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1985, Nov-15, Volume: 40, Issue:22

    Topics: Blood Chemical Analysis; Clinical Laboratory Techniques; Creatinine; Diabetic Nephropathies; Glomeru

1985
[Attacks of gout and thromboembolic disease: role of heparin therapy].
    Annales de medecine interne, 1985, Volume: 136, Issue:7

    Topics: Acute Disease; Aged; Arthritis; Female; Gout; Heparin; Humans; Male; Middle Aged; Thromboembolism; U

1985
Apatite-type crystal deposition in arthritic cartilage.
    Scanning electron microscopy, 1985, Issue:Pt 4

    Topics: Apatites; Calcium Pyrophosphate; Cartilage, Articular; Electron Probe Microanalysis; Gout; Humans; M

1985
[Uricosuria after administration of benethazone].
    Sovetskaia meditsina, 1985, Issue:12

    Topics: Adult; Aged; Gout; Humans; Middle Aged; Phenylbutazone; Uric Acid

1985
Ambition and disease: the chicken or the egg?
    Lancet (London, England), 1970, Dec-19, Volume: 2, Issue:7686

    Topics: Cholesterol; Coronary Disease; Disease; Gout; Humans; Personality; Research; Uric Acid

1970
Fructose-induced hyperuricaemia.
    Lancet (London, England), 1970, Dec-19, Volume: 2, Issue:7686

    Topics: Administration, Oral; Adult; Age Factors; Carbohydrate Metabolism, Inborn Errors; Child; Female; Fru

1970
[The effect of animal protein and NaHCO3 on the occurrence of gout and on the protein content of the serum in chicks].
    Archiv fur experimentelle Veterinarmedizin, 1970, Volume: 24, Issue:1

    Topics: Animal Feed; Animals; Bicarbonates; Blood Proteins; Chickens; Cholinesterases; Dietary Proteins; gam

1970
Presence of ornithine in the urate-binding alpha-alpha2 globulin.
    Nature: New biology, 1971, May-26, Volume: 231, Issue:21

    Topics: Alpha-Globulins; Amino Acid Metabolism, Inborn Errors; Amino Acids; Arginase; Blood Protein Electrop

1971
Automated computerized metabolic profiles and subclinical tubular and glomerular nephropathy.
    The Alabama journal of medical sciences, 1968, Volume: 5, Issue:3

    Topics: Albumins; Alkaline Phosphatase; Amylases; Blood Glucose; Blood Urea Nitrogen; Calcium; Cholesterol;

1968
Plasma concentrations of the urate-binding alpha 1-2 -globulin in patients with different types of primary gout as compared to healthy control subjects.
    European journal of clinical investigation, 1972, Volume: 2, Issue:2

    Topics: Adult; Alpha-Globulins; Female; Gout; Humans; Hypoproteinemia; Immunodiffusion; Male; Middle Aged; P

1972
Laboratory investigations in connective tissue disease.
    Modern trends in orthopaedics, 1972, Volume: 5

    Topics: Antibodies, Antinuclear; Arthritis, Rheumatoid; Biopsy; Connective Tissue; Dermatomyositis; Diphosph

1972
Differential diagnosis of gout.
    Lancet (London, England), 1972, Sep-16, Volume: 2, Issue:7777

    Topics: Diagnosis, Differential; Fructose; Gout; Humans; Uric Acid

1972
Effect of weight-loss on plasma and urinary levels of uric acid.
    Lancet (London, England), 1972, Dec-09, Volume: 2, Issue:7789

    Topics: Adult; Aged; Body Weight; Diet Therapy; Dietary Carbohydrates; Female; Gout; Humans; Male; Middle Ag

1972
Urate--plasma protein interactions.
    Scandinavian journal of clinical and laboratory investigation, 1972, Volume: 30, Issue:4

    Topics: Alpha-Globulins; Blood Proteins; Gout; Humans; Protein Binding; Uric Acid

1972
[Arthritis uratica].
    Ceskoslovenska patologie, 1973, Volume: 9, Issue:1

    Topics: Autopsy; Cartilage, Articular; Gout; Humans; Macrophages; Microscopy, Electron; Staining and Labelin

1973
[Discussion on gout].
    Nihon rinsho. Japanese journal of clinical medicine, 1973, Volume: 31, Issue:5

    Topics: Alpha-Globulins; Gout; Humans; Purines; Uric Acid

1973
Local concentration of urate in the pathogenesis of gout.
    Lancet (London, England), 1973, Dec-08, Volume: 2, Issue:7841

    Topics: Carbon Radioisotopes; Crystallization; Diffusion; Extracellular Space; Gout; Humans; Injections, Sub

1973
[Glutamine synthetase activity in the liver in primary gout (author's transl)].
    Klinische Wochenschrift, 1974, Apr-15, Volume: 52, Issue:8

    Topics: Adult; Aged; Creatinine; Female; Glutamate-Ammonia Ligase; Gout; Humans; Liver; Male; Middle Aged; U

1974
Blood-uric-acid levels in familial hypercholesterolaemia.
    Lancet (London, England), 1966, Feb-05, Volume: 1, Issue:7432

    Topics: Blood; Female; Gout; Hypercholesterolemia; Hyperlipidemias; Male; Statistics as Topic; Uric Acid

1966
Hyperuricaemia, gout, and diabetic abnormality in Polynesian people.
    Lancet (London, England), 1966, Feb-12, Volume: 1, Issue:7433

    Topics: Adult; Aged; Blood; Blood Pressure; Diabetes Mellitus; Ethnology; Female; Glucose Tolerance Test; Gl

1966
Frequency-distribution curve of uric acid in the general population.
    Lancet (London, England), 1966, Jul-23, Volume: 2, Issue:7456

    Topics: Blood Chemical Analysis; Female; Gout; Humans; In Vitro Techniques; Male; Statistics as Topic; Uric

1966
Uric acid in human plasma. V. Isolation and identification of plasma proteins interacting with urate.
    Scandinavian journal of clinical and laboratory investigation, 1966, Volume: 18, Issue:2

    Topics: Adolescent; Adult; Aged; Alpha-Globulins; Blood Protein Electrophoresis; Chromatography, Gel; Chroma

1966
Fructose-induced hyperuricaemia.
    Lancet (London, England), 1967, Sep-09, Volume: 2, Issue:7515

    Topics: Adult; Aspartate Aminotransferases; Blood Glucose; Carbohydrate Metabolism, Inborn Errors; Child; Ch

1967
Uric acid in bone-marrow.
    Lancet (London, England), 1968, Mar-09, Volume: 1, Issue:7541

    Topics: Bone Marrow; Female; Gout; Humans; Middle Aged; Uric Acid

1968
Gout and the kidney.
    Lancet (London, England), 1968, May-04, Volume: 1, Issue:7549

    Topics: Allopurinol; Gout; Humans; Kidney Failure, Chronic; Uric Acid; Uricosuric Agents

1968
Genetic studies in primary gout. Investigations on the plasma levels of the urate-binding alpha 1-alpha 2-globulin in individuals from two gouty kindreds.
    The Journal of clinical investigation, 1968, Volume: 47, Issue:6

    Topics: Adult; Alpha-Globulins; Arthritis; Autoradiography; Chromatography, Gel; Epilepsy; Female; Gout; Het

1968
Serum-uric-acid and coronary heart-disease.
    Lancet (London, England), 1969, Feb-15, Volume: 1, Issue:7590

    Topics: Adult; Age Factors; Arteriosclerosis; Blood Glucose; Blood Pressure; Cholesterol; Coronary Disease;

1969
[Ultrastructural observations on gout-tophi].
    Verhandlungen der Deutschen Gesellschaft fur Pathologie, 1969, Volume: 53

    Topics: Capillaries; Connective Tissue; Gout; Histiocytes; Humans; Microscopy, Electron; Phagocytosis; Pinoc

1969
Gout.
    American family physician, 1973, Volume: 8, Issue:5

    Topics: Allopurinol; Arthritis, Rheumatoid; Chondrocalcinosis; Colchicine; Diagnosis, Differential; Gout; Hu

1973
[Homozygous inherited alpha1-antitrypsin deficiency with emphysema of the lung, cor pulmonale, and gout (author's transl)].
    Klinische Wochenschrift, 1974, Jan-15, Volume: 52, Issue:2

    Topics: Adult; alpha 1-Antitrypsin; Gout; Homozygote; Humans; Immunodiffusion; Male; Metabolism, Inborn Erro

1974
[Epidemiology and biochemistry of risk factors of gout (author's transl)].
    MMW, Munchener medizinische Wochenschrift, 1974, Feb-22, Volume: 116, Issue:8

    Topics: Arteriosclerosis; Carbohydrate Metabolism; Fatty Acids; Germany, West; Gout; Humans; Proteins; Purin

1974
[Nephrolithiasis within the framework of internal medicine (author's transl)].
    MMW, Munchener medizinische Wochenschrift, 1974, Feb-22, Volume: 116, Issue:8

    Topics: Antineoplastic Agents; Cystine; Gout; Humans; Kidney Calculi; Lesch-Nyhan Syndrome; Myeloproliferati

1974
[Fundamentals of gout research (author's transl)].
    MMW, Munchener medizinische Wochenschrift, 1974, Apr-26, Volume: 116, Issue:17

    Topics: Arthritis; Chemical Phenomena; Chemistry; Diet Therapy; Gout; Humans; Kidney Calculi; Kidney Disease

1974
[Incidence of primary hyperuricemia in ambulant patients (author's transl)].
    MMW, Munchener medizinische Wochenschrift, 1974, Apr-26, Volume: 116, Issue:17

    Topics: Adult; Age Factors; Aged; Ambulatory Care; Blood Protein Disorders; Diabetes Mellitus; Female; Germa

1974
[Simplification of allopurinol treatment].
    MMW, Munchener medizinische Wochenschrift, 1974, Sep-27, Volume: 116, Issue:39

    Topics: Allopurinol; Dosage Forms; Drug Evaluation; Gout; Half-Life; Humans; Uric Acid

1974
Drugs in the treatment of hyperuricemia.
    Advances in nephrology from the Necker Hospital, 1974, Volume: 3

    Topics: Allopurinol; Gout; Humans; Oxypurinol; Probenecid; Sulfinpyrazone; Uric Acid; Uricosuric Agents

1974
Hyperuricemia in children, with the exception of the Lesch-Nyhan syndrome.
    Advances in nephrology from the Necker Hospital, 1974, Volume: 3

    Topics: Acidosis; Acute Disease; Acute Kidney Injury; Adult; Child; Child, Preschool; Chronic Disease; Femal

1974
Studies in primary hyperuricaemia. I. Steroid and dehydroepiandrosterone excretion in primary hyperuricaemia and gout, renal clearances of uric acid and the incorporation of 14C from glycine-2-14C in urine uric acid.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1968, Mar-23, Volume: 42, Issue:12

    Topics: 17-Ketosteroids; Carbon Isotopes; Dehydroepiandrosterone; Glucocorticoids; Gout; Humans; Uric Acid

1968
The excretion of urinary dehydroepiandrosterone in gout.
    Arthritis and rheumatism, 1968, Volume: 11, Issue:3

    Topics: 17-Ketosteroids; Adult; Aged; Allopurinol; Arthritis; Dehydroepiandrosterone; Gout; Humans; Joint Di

1968
[Hyperuricemia and gout in childhood (Lesch-Nyhan syndrome)].
    Medizinische Klinik, 1971, Apr-23, Volume: 66, Issue:17

    Topics: Adolescent; Athetosis; Brain; Child; Child, Preschool; Compulsive Behavior; Gout; Humans; Huntington

1971
[Microscopic appearance and histogenesis of tophus in gout].
    Reumatologia, 1971, Volume: 9, Issue:4

    Topics: Acid-Base Equilibrium; Glycosaminoglycans; Gout; Histocytochemistry; Humans; Uric Acid

1971
Excess of ampicillin rashes associated with allopurinol or hyperuricemia. A report from the Boston Collaborative Drug Surveillance Program, Boston University Medical Center.
    The New England journal of medicine, 1972, Mar-09, Volume: 286, Issue:10

    Topics: Allopurinol; Ampicillin; Boston; Drug Eruptions; Drug Synergism; Female; Gout; Hospitalization; Huma

1972
Dehydroepiandrosterone (3 -hydroxy-5-androsten-17-one) metabolism in gout.
    Steroids, 1972, Volume: 19, Issue:4

    Topics: 17-Ketosteroids; Administration, Oral; Androstanes; Androsterone; Carbon Isotopes; Chromatography, G

1972
Microscopic appearance and histogenesis of gouty tophus.
    Polish medical journal, 1972, Volume: 11, Issue:5

    Topics: Connective Tissue; Crystallization; Ear; Extremities; Glycosaminoglycans; Gout; Humans; Necrosis; Sk

1972
[Organ findings in psoriasis].
    Deutsche medizinische Wochenschrift (1946), 1973, Aug-11, Volume: 98, Issue:33

    Topics: Dehydroepiandrosterone; Erythrocytes; Female; Gout; Humans; Intestinal Diseases; Joint Diseases; Liv

1973
[Juvenile gout of the hip-joints (author's transl)].
    Zeitschrift fur Orthopadie und ihre Grenzgebiete, 1973, Volume: 111, Issue:5

    Topics: Adolescent; Age Factors; Child; Gout; Hip; Hip Joint; Humans; Male; Pain; Radiography; Uric Acid

1973
[Gout and mongolism. Apropos of a case].
    Revue du rhumatisme et des maladies osteo-articulaires, 1974, Volume: 41, Issue:3

    Topics: Adolescent; Down Syndrome; Gout; Humans; Male; Purine-Pyrimidine Metabolism, Inborn Errors; Trisomy;

1974
[Multiple osteonecrosis with type IV hyperlipoproteinemia (author's transl)].
    Zeitschrift fur Orthopadie und ihre Grenzgebiete, 1974, Volume: 112, Issue:5

    Topics: Adult; Blood Protein Disorders; Bone Diseases; Glucose Tolerance Test; Gout; Hip Joint; Humans; Hype

1974
Etiologic varieties of hyperuricemia and gout.
    Advances in nephrology from the Necker Hospital, 1974, Volume: 3

    Topics: Acute Kidney Injury; Diabetic Ketoacidosis; Down Syndrome; Female; Gout; Hematologic Diseases; Human

1974
The use of certain immunosuppressive drugs in the clinical study of gout.
    Advances in nephrology from the Necker Hospital, 1974, Volume: 3

    Topics: Azathioprine; Erythrocytes; Gout; Humans; Immune Adherence Reaction; Lymphocyte Culture Test, Mixed;

1974
Dietary treatment of chronic renal failure. Experiences with a modified Giovannetti diet.
    Nephron, 1965, Volume: 2, Issue:3

    Topics: Acidosis; Acute Kidney Injury; Adolescent; Adult; Aged; Arteritis; Dietary Proteins; Edema; Female;

1965
[The hypo-uricemic action of oral benziodarone].
    La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1967, Jan-08, Volume: 43, Issue:2

    Topics: Benzofurans; Gout; Humans; Uric Acid; Xanthines

1967
A specific enzyme defect in gout associated with overproduction of uric acid.
    Proceedings of the National Academy of Sciences of the United States of America, 1967, Volume: 57, Issue:6

    Topics: Adult; Diphosphates; Erythrocytes; Glucosyltransferases; Gout; Guanine; Hot Temperature; Humans; Hyp

1967
[Female gout. (Analysis of 40 cases)].
    La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1967, Feb-26, Volume: 43, Issue:10

    Topics: Adolescent; Adult; Aged; Child; Female; Gout; Humans; Kidney Failure, Chronic; Male; Middle Aged; Se

1967
[Therapy of gout with allopurinol. (Study of 106 cases)].
    La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1967, Feb-26, Volume: 43, Issue:10

    Topics: Adult; Allopurinol; Gout; Humans; Male; Middle Aged; Uric Acid; Xanthine Oxidase

1967
[The effects of allopurinol in gout patients with uric urinary lithiasis or hyperuraturia].
    La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1967, Feb-26, Volume: 43, Issue:10

    Topics: Aged; Allopurinol; Female; Gout; Humans; Male; Middle Aged; Uric Acid; Urinary Calculi

1967
[The action of ethanol in gout and on the metabolism of uric acid].
    La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1967, Feb-26, Volume: 43, Issue:10

    Topics: Ethanol; Gout; Humans; Purines; Uric Acid; Xanthines

1967
[The level of oxypurines in the plasma and urine of control and gout patients. (Correlation with the level of uric acid)].
    La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1967, Apr-08, Volume: 43, Issue:17

    Topics: Adolescent; Adult; Aged; Female; Gout; Humans; Hypoxanthines; Male; Middle Aged; Spectrophotometry;

1967
[Value of the demonstration of crystalline formations in the synovial fluid: the morphologic and ultrastructural differentiation of the crystals].
    La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1967, Oct-14, Volume: 43, Issue:42

    Topics: Arthritis; Arthritis, Rheumatoid; Calcinosis; Calcium; Cytoplasmic Granules; Gout; Humans; Joint Dis

1967
Recent developments in the therapy of gout.
    Journal of the American Geriatrics Society, 1968, Volume: 16, Issue:5

    Topics: Acute Disease; Adrenocorticotropic Hormone; Allopurinol; Analgesics; Colchicine; Gout; Humans; Oxyph

1968
[Gout and myxedema].
    La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1967, Nov-26, Volume: 43, Issue:49

    Topics: Aged; Female; Gout; Humans; Male; Middle Aged; Myxedema; Thyroid Hormones; Uric Acid; Uricosuric Age

1967
[Diet therapy in gout].
    La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1969, Nov-14, Volume: 45, Issue:46

    Topics: Diet Therapy; Diuresis; Gout; Humans; Hypersensitivity; Kidney Diseases; Obesity; Purines; Uric Acid

1969
Depletion of erythrocyte phosphoribosylpyrophosphate in man.
    The New England journal of medicine, 1970, Nov-26, Volume: 283, Issue:22

    Topics: Administration, Oral; Adult; Allopurinol; Diphosphates; Erythrocytes; Female; Gout; Hemolysis; Human

1970
The purine revolution.
    The New England journal of medicine, 1970, Nov-26, Volume: 283, Issue:22

    Topics: Allopurinol; Diphosphates; Erythrocytes; Gout; Humans; Purine-Pyrimidine Metabolism, Inborn Errors;

1970
Corticosteroid crystals in synovial fluid.
    JAMA, 1970, Feb-02, Volume: 211, Issue:5

    Topics: Acetates; Arthritis; Arthritis, Rheumatoid; Betamethasone; Diagnosis, Differential; Diphosphates; Gl

1970
Differential membranolytic effects of microcrystalline sodium urate and calcium pyrophosphate dihydrate.
    The Journal of experimental medicine, 1971, Jan-01, Volume: 133, Issue:1

    Topics: Cell Membrane; Crystallization; Diphosphates; Erythrocytes; Gout; Hemolysis; Humans; Surface Propert

1971
[Uric acid inhibitors in the treatment of gout. Apropos of 126 cases].
    La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1970, Dec-08, Volume: 46, Issue:50

    Topics: Adult; Aged; Allopurinol; Colchicine; Drug Synergism; Female; Gout; Humans; Kidney Calculi; Kidney F

1970
Concentration and synthesis of phosphoribosylpyrophosphate in erythrocytes from normal, hyperuricemic, and gouty subjects.
    Metabolism: clinical and experimental, 1971, Volume: 20, Issue:8

    Topics: Adenosine Diphosphate; Allopurinol; Diphosphates; Erythrocytes; Feedback; Female; Glycerophosphates;

1971
[Differential diagnosis and therapy of gout and pseudo-gout].
    Arzneimittel-Forschung, 1971, Volume: 21, Issue:11

    Topics: Aged; Chondrocalcinosis; Crystallization; Diagnosis, Differential; Diphosphates; Female; Gout; Human

1971
Management of chronic and recurrent gout.
    Modern treatment, 1971, Volume: 8, Issue:4

    Topics: Adrenocorticotropic Hormone; Allopurinol; Chronic Disease; Colchicine; Dexamethasone; Diet Therapy;

1971
Medical Grand Rounds from the University of Alabama Medical Center. Lead poisoning.
    Southern medical journal, 1972, Volume: 65, Issue:3

    Topics: Adult; Aged; Alcoholism; Amyotrophic Lateral Sclerosis; Anemia, Macrocytic; Brain Diseases; Diagnosi

1972
Accelerated erythrocyte 5-phosphoribosyl-1-pyrophosphate synthesis. A familial abnormality associated with excessive uric acid production and gout.
    Biochemical medicine, 1972, Volume: 6, Issue:4

    Topics: Adult; Allopurinol; Diphosphates; Erythrocytes; Gout; Guanine; Humans; Hypoxanthines; Male; Nucleoti

1972
A comparison of the toxicity of ergocalciferol and cholecalciferol in rhesus monkeys (Macaca mulatta).
    The Journal of nutrition, 1972, Volume: 102, Issue:8

    Topics: Administration, Oral; Animals; Bone Diseases; Cholecalciferol; Diet; Ergocalciferols; Gout; Haplorhi

1972
[Uricoeliminating or urico-inhibiting agents? Reasons for a choice].
    La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1972, May-20, Volume: 48, Issue:24

    Topics: Allopurinol; Colchicine; Diet Therapy; Glomerular Filtration Rate; Gout; Humans; Long-Term Care; Oro

1972
Molecular basis of gouty inflammation: interaction of monosodium urate crystals with lysosomes and liposomes.
    Nature: New biology, 1972, Dec-06, Volume: 240, Issue:101

    Topics: Acid Phosphatase; Animals; Cholesterol; Chromates; Erythrocytes; Estradiol; Female; Glucuronidase; G

1972
Purine overproduction in man associated with increased phosphoribosylpyrophosphate synthetase activity.
    Science (New York, N.Y.), 1973, Mar-16, Volume: 179, Issue:4078

    Topics: Adenosine Triphosphate; Carbon Isotopes; Erythrocytes; Female; Fibroblasts; Glycine; Gout; Humans; M

1973
Complement as a mediator of inflammation in acute gouty arthritis. I. Studies on the reaction between human serum complement and sodium urate crystals.
    The Journal of laboratory and clinical medicine, 1973, Volume: 81, Issue:5

    Topics: Animals; Calcium; Complement System Proteins; Diphosphates; Erythrocytes; Factor XII; Gout; Hemolysi

1973
Gout.
    JAMA, 1973, Apr-30, Volume: 224, Issue:5 Suppl

    Topics: Adrenocorticotropic Hormone; Allopurinol; Colchicine; Diet; Extracellular Space; Gout; Humans; Indom

1973
Gout and pseudogout.
    Geriatrics, 1973, Volume: 28, Issue:6

    Topics: Adult; Aged; Arthritis; Calcium; Chondrocalcinosis; Crystallization; Diabetes Complications; Diet Th

1973
Mechanisms of the crystal deposition diseases--gout and pseudogout.
    Annals of internal medicine, 1973, Volume: 78, Issue:5

    Topics: Acid Phosphatase; Chondrocalcinosis; Diphosphates; Female; Gout; Hemolysis; Humans; Inflammation; Le

1973
Chronic lead nephropathy.
    Kidney international, 1973, Volume: 4, Issue:1

    Topics: Adult; Bone and Bones; Chelating Agents; Child; Child, Preschool; Edetic Acid; Environmental Exposur

1973
Familial gouty malignant uric acid lithiasis due to mutant phosphoribosylpyrophosphate synthetase.
    Der Urologe. Ausg. A, 1973, Volume: 12, Issue:4

    Topics: Adult; Allopurinol; Child; Child, Preschool; Diphosphates; Erythrocytes; Female; Gout; Humans; Infan

1973
The kinetics of intramolecular distribution of 15N in uric acid after administration of (15N) glycine. A reappraisal of the significance of preferential labeling of N-(3+9) of uric acid in primary gout.
    The Journal of clinical investigation, 1973, Volume: 52, Issue:10

    Topics: Adenosine Triphosphate; Adolescent; Adult; Carbon Isotopes; Glutamine; Glycine; Gout; Guanine; Hippu

1973
Gout and its relation to lipid metabolism. I. Serum uric acid, lipid, and lipoprotein levels in gout.
    Annals of the rheumatic diseases, 1973, Volume: 32, Issue:6

    Topics: Adolescent; Adult; Age Factors; Aged; Child; Cholesterol; Fatty Acids, Nonesterified; Female; Gout;

1973
Gout and its relation to lipid metabolism. II. Correlations between uric acid, lipid, and lipoprotein levels in gout.
    Annals of the rheumatic diseases, 1973, Volume: 32, Issue:6

    Topics: Adolescent; Adult; Aged; Child; Cholesterol; Fatty Acids, Nonesterified; Female; Gout; Humans; Lipid

1973
Pathology of gout.
    Scottish medical journal, 1973, Volume: 18

    Topics: Allopurinol; Arthritis; Calcium Phosphates; Cartilage, Articular; Chondrocalcinosis; Crystallization

1973
[Investigations concerning the incidence of disorders of lipid and carbohydrate metabolism in primary gout and symptomless hyperuricaemia (author's transl)].
    Wiener klinische Wochenschrift, 1974, May-03, Volume: 86, Issue:9

    Topics: Carbohydrate Metabolism; Cholesterol; Coronary Disease; Diabetes Complications; Female; Gout; Humans

1974
Increased PP-ribose-P synthetase activity: a genetic abnormality leading to excessive purine production and gout.
    Advances in experimental medicine and biology, 1973, Volume: 41

    Topics: Adenine; Carbon Radioisotopes; Cellulose; Creatinine; Electrophoresis; Enzyme Activation; Erythrocyt

1973
Observations of altered intracellular phosphoribosylpyrophosphate (PP-ribose-P) in human disease.
    Advances in experimental medicine and biology, 1974, Volume: 41

    Topics: Adenine; Carbon Radioisotopes; Erythrocytes; Fibroblasts; Formates; Gout; Guanine Nucleotides; Heter

1974
Evaluation of the role of 5-phosphoribosyl-alpha-1-pyrophosphate synthetase in congenital hyperuricemia and gout: a simple isotopic assay and an activity stain for the enzyme.
    Biochemical medicine, 1974, Volume: 10, Issue:3

    Topics: Cellulose; Chromatography, DEAE-Cellulose; Electrophoresis; Erythrocytes; Evaluation Studies as Topi

1974
Pharmacologic effects of nicotinic acid on human purine metabolism.
    The Journal of laboratory and clinical medicine, 1974, Volume: 84, Issue:2

    Topics: Adult; Aspirin; Creatinine; Erythrocytes; Female; Gout; Humans; Iopanoic Acid; Kidney Tubules; Male;

1974
Gout and pseudogout established by polarized light microscopy of synovial fluid. Methods and two case reports.
    Virginia medical monthly, 1970, Volume: 97, Issue:6

    Topics: Aged; Arthritis, Rheumatoid; Calcium; Chondrocalcinosis; Crystallization; Diphosphates; Gout; Humans

1970
Calcinosis.
    Proceedings of the Royal Society of Medicine, 1974, Volume: 67, Issue:6 Pt 1

    Topics: Adult; Calcinosis; Collagen; Diagnosis, Differential; Diphosphates; Gout; Hand; Humans; Knee; Male;

1974
[Microcrystalline arthropathies (gout and pseudo-gout)].
    La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1974, May-08, Volume: 50, Issue:22

    Topics: Calcium Phosphates; Chondrocalcinosis; Crystallization; Diphosphates; Gout; Humans; Joint Diseases;

1974
Ultrastructural evidence for leakage of lysosomal contents after phagocytosis of monosodium urate crystals. A mechanism of gouty inflammation.
    The American journal of pathology, 1974, Volume: 76, Issue:3

    Topics: Acid Phosphatase; Animals; Carbon; Cell Membrane; Cell Separation; Colloids; Cytoplasm; Ferritins; G

1974
["Articular and visceral gout" in armored lizards (Tomistoma schlegelii and Gavialis gangeticus) (reptilia, crocodylia)].
    Acta tropica, 1965, Volume: 22, Issue:3

    Topics: Animals; Gout; Histocytochemistry; Kidney; Liver; Lung; Myocardium; Pancreas; Reptiles; Spleen; Uric

1965
[On the action of antihistamincs in some cases of hyperuricemia].
    Minerva medica, 1968, Oct-06, Volume: 59, Issue:80

    Topics: Adult; Aged; Female; Gout; Histamine; Histamine H1 Antagonists; Humans; Male; Middle Aged; Uric Acid

1968
[A study of the value of Uralyt-U (Madaus) in the treatment of urinary calculi].
    Polski tygodnik lekarski (Warsaw, Poland : 1960), 1970, May-18, Volume: 25, Issue:20

    Topics: Adult; Female; Gout; Humans; Kidney Calculi; Male; Middle Aged; Piperazines; Quinolines; Uric Acid

1970
[Improvement of gout prognosis by suitable therapy].
    Lebensversicherungs Medizin, 1971, Volume: 23, Issue:6

    Topics: Adult; Female; Gout; Humans; Kidney Calculi; Male; Middle Aged; Prognosis; Uremia; Uric Acid

1971
[Metabolic arthropathies (uric acid gout and diffuse articular chondrocalcinosis].
    Therapeutische Umschau. Revue therapeutique, 1974, Volume: 31, Issue:7

    Topics: Chondrocalcinosis; Gout; Humans; Joint Diseases; Uric Acid

1974
[Metabolism of uric acid and lactic acid in essential arterial hypertension].
    Giornale di clinica medica, 1974, Volume: 55, Issue:1

    Topics: Adolescent; Adult; Age Factors; Diuretics; Female; Gout; Humans; Hypertension; Lactates; Male; Middl

1974
Factors affecting urate solubility in vitro.
    Annals of the rheumatic diseases, 1974, Volume: 33, Issue:4

    Topics: Blood; Gout; Humans; Hydrogen-Ion Concentration; Protein Binding; Serum Albumin; Sodium Chloride; So

1974
Gout and hyperlipidaemia.
    Annals of the rheumatic diseases, 1974, Volume: 33, Issue:4

    Topics: Adult; Aged; Alcohol Drinking; Allopurinol; Aspartate Aminotransferases; Body Height; Body Weight; C

1974
Proceedings: Metabolic studies of thiopurinol in man and pig.
    Annals of the rheumatic diseases, 1974, Volume: 33, Issue:4

    Topics: Allantoin; Animals; Carbon Radioisotopes; Gout; Humans; Hypoxanthines; Intestinal Absorption; Pyrazo

1974
Withdrawal of allopurinol in patients with gout.
    Annals of the rheumatic diseases, 1974, Volume: 33, Issue:4

    Topics: Adult; Aged; Allopurinol; Female; Gout; Humans; Male; Middle Aged; Recurrence; Substance Withdrawal

1974
[Effects of coffee during good health and in disease from the medical standpoint].
    Minerva medica, 1974, Jan-17, Volume: 65, Issue:3

    Topics: Acute Disease; Aged; Blood Pressure; Caffeine; Cerebrovascular Disorders; Coffee; Diabetes Mellitus;

1974
Letter: Drugs used in hyperuricaemia.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1974, Aug-31, Volume: 48, Issue:42

    Topics: Allopurinol; Anti-Inflammatory Agents; Gout; Humans; Metabolic Diseases; Uric Acid

1974
[Results obtained with long-term benzbromarone therapy (author's transl)].
    Wiener klinische Wochenschrift, 1974, May-17, Volume: 86, Issue:10

    Topics: Adult; Aged; Benzofurans; Cholesterol; Fatty Acids, Nonesterified; Gout; Humans; Lipids; Male; Middl

1974
[Prevention of renal lithiasis].
    Bruxelles medical, 1974, Volume: 54, Issue:12

    Topics: Calcium; Cystinuria; Diet; Gout; Humans; Kidney; Kidney Calculi; Kidney Failure, Chronic; Metabolism

1974
[Diabetes and hyperuricaemia (author's transl)].
    Deutsche medizinische Wochenschrift (1946), 1974, Dec-06, Volume: 99, Issue:49

    Topics: Adult; Blood Glucose; Blood Pressure; Body Weight; Cholesterol; Diabetes Complications; Diabetes Mel

1974
[Contribution to the study of hyperuricemia associated with essential hyperlipidemias. I].
    Revista clinica espanola, 1974, Jun-30, Volume: 133, Issue:6

    Topics: Adolescent; Adult; Female; Glucose Tolerance Test; Gout; Humans; Hyperlipidemias; Male; Middle Aged;

1974
Letter: A clinical impression of benzbromarone (Minuric).
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1974, Nov-16, Volume: 48, Issue:56

    Topics: Adult; Allopurinol; Benzoates; Benzofurans; Bromine; Gout; Gout Suppressants; Humans; Male; Metaboli

1974
[Biochemistry and clinical features of fructose-induced hyperuricamia (author's transl)].
    Wiener klinische Wochenschrift, 1974, Dec-13, Volume: 86, Issue:23

    Topics: Adenosine Triphosphate; Aminohydrolases; Fructose; Gout; Humans; Infusions, Parenteral; Liver; Nucle

1974
Abnormal regulation of carbohydrate metabolism in primary gout.
    Annals of the rheumatic diseases, 1974, Volume: 33, Issue:6

    Topics: Adult; Aged; Blood Glucose; Body Weight; Carbohydrate Metabolism; Cholesterol; Fatty Acids, Nonester

1974
Gout: new observations on an old disease.
    Journal of the Mississippi State Medical Association, 1974, Volume: 15, Issue:9

    Topics: Gout; Humans; Kidney; Uric Acid

1974
[Editorial: Therapy of gout nowadays (author's transl)].
    Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis, 1974, Oct-08, Volume: 63, Issue:40

    Topics: Allopurinol; Colchicine; Exercise Therapy; Gout; Humans; Uric Acid; Uricosuric Agents

1974
[The effect of daily single doses of 300 mg allopurinol on serum uric acid concentration and urate excretion in gouty patients (author's transl)].
    Deutsche medizinische Wochenschrift (1946), 1974, Nov-29, Volume: 99, Issue:48

    Topics: Allopurinol; Analysis of Variance; Gout; Humans; Metabolic Clearance Rate; Uric Acid

1974
[Clinical study of gout and hyperuricemia. (1) Epidemiological study on the development of gout].
    Ryumachi. [Rheumatism], 1974, Volume: 14, Issue:2

    Topics: Adolescent; Adult; Aged; Child; Female; Gout; Humans; Japan; Male; Middle Aged; Uric Acid

1974
[Incidence of partial deficiency of hypoxanthine-guanine phosphoribosyl-transferase in a gouty population. Study of the 1st affected Italian family].
    Schweizerische medizinische Wochenschrift, 1974, Oct-05, Volume: 104, Issue:40

    Topics: Adult; Aged; Erythrocytes; Genes, Recessive; Gout; Heterozygote; Humans; Italy; Male; Metabolism, In

1974
Renal excretion of urate in normal and gouty subjects at high, normal and low plasma urate levels.
    Biomedicine / [publiee pour l'A.A.I.C.I.G.], 1974, Sep-20, Volume: 21, Issue:9

    Topics: Adult; Allantoin; Gout; Humans; Inulin; Kidney; Kidney Function Tests; Kidney Tubules; Male; Metabol

1974
Urate binding: a clue to the pathogenesis of gout.
    The Journal of rheumatology, 1974, Volume: 1, Issue:2

    Topics: Binding, Competitive; Crystallization; Dialysis; Gout; Humans; Hydrogen-Ion Concentration; Jaundice;

1974
[Prevention of arteriosclerosis].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1974, Aug-15, Volume: 29, Issue:16

    Topics: Arteriosclerosis; Cholesterol; Diabetic Angiopathies; Diet Therapy; Female; Gout; Humans; Hyperglyce

1974
Microangiopathy in hyperlipidemia and gout.
    The American journal of the medical sciences, 1974, Volume: 268, Issue:5

    Topics: Adolescent; Adult; Age Factors; Aged; Basement Membrane; Biopsy, Needle; Blood Glucose; Body Weight;

1974
Urate crystal induced inflammation in dog joints: sequence of synovial changes.
    The Journal of rheumatology, 1974, Volume: 1, Issue:1

    Topics: Acid Phosphatase; Acute Disease; Animals; Chronic Disease; Crystallization; Dogs; Glucuronidase; Gou

1974
[Idiopathic necrosis of the femoral head and hyperuriciemia (author's transl)].
    Verhandlungen der Deutschen Gesellschaft fur Pathologie, 1974, Volume: 58

    Topics: Crystallization; Femur Head Necrosis; Gout; Humans; Male; Middle Aged; Uric Acid

1974
[Clearance of urates as a diagnostic tool in gout].
    Zeitschrift fur Urologie und Nephrologie, 1974, Volume: 67, Issue:11

    Topics: Adult; Age Factors; Aged; Blood Pressure; Creatine; Female; Gout; Humans; Kidney; Kidney Diseases; M

1974
Effect of allopurinol in gouty patients given long term corticotherapy.
    Biomedicine / [publiee pour l'A.A.I.C.I.G.], 1974, Nov-20, Volume: 21, Issue:11

    Topics: Adrenal Cortex Hormones; Allopurinol; Dose-Response Relationship, Drug; Gout; Humans; Purines; Uric

1974
Effect of Milurit on decreasing hyperuricaemia in hypertensive patients.
    Therapia Hungarica (English edition), 1974, Volume: 22, Issue:4

    Topics: Allopurinol; Glomerular Filtration Rate; Gout; Humans; Hypertension; Thiazines; Uric Acid

1974
[The effect of fructose on uric acid metabolism].
    Acta medica Academiae Scientiarum Hungaricae, 1974, Volume: 31, Issue:3-4

    Topics: Allopurinol; Animals; Diuresis; Fasting; Fructose; Gout; Humans; Male; Oxonic Acid; Rats; Urate Oxid

1974
[Chronic nephritis and hyperuricemia].
    Nihon Jinzo Gakkai shi, 1974, Volume: 16, Issue:7

    Topics: Adolescent; Adult; Chronic Disease; Female; Glomerulonephritis; Gout; Humans; Male; Middle Aged; Uri

1974
Current medical practice and the Food and Drug Administration. Some evidence for the existing gap.
    JAMA, 1974, Sep-23, Volume: 229, Issue:13

    Topics: Adult; Aged; Allopurinol; Angina Pectoris; Cephalexin; Child; Colchicine; Diuretics; Drug Labeling;

1974
Understanding hyperuricemia: nursing implications.
    The Nursing clinics of North America, 1972, Volume: 7, Issue:2

    Topics: Allopurinol; Diabetes Mellitus; Diet Therapy; Gout; Humans; Kidney Diseases; Metabolic Diseases; Uri

1972
Metabolic implications of the Lesch-Nyhan syndrome.
    Australian and New Zealand journal of medicine, 1972, Volume: 2, Issue:1

    Topics: Athetosis; Gout; Humans; Intellectual Disability; Lesch-Nyhan Syndrome; Mass Screening; Purine-Pyrim

1972
The health of leaders and policy-makers.
    IMS, Industrial medicine and surgery, 1972, Volume: 41, Issue:5

    Topics: Adult; Aged; Coronary Disease; Gout; Heart Diseases; Humans; Leadership; Longevity; Male; Middle Age

1972
Problems of diagnostic failure in gouty arthritis.
    Annals of clinical research, 1972, Volume: 4, Issue:2

    Topics: Adult; Aged; Arthritis, Rheumatoid; Colchicine; Diagnosis, Differential; Diagnostic Errors; Female;

1972
Coronary heart disease in young men: a study of seventy patients with a critical review of etiological factors.
    Australian and New Zealand journal of medicine, 1973, Volume: 3, Issue:1

    Topics: Adult; Australia; Body Height; Body Weight; Cholesterol, Dietary; Coronary Disease; Diabetes Complic

1973
Alteration of urate metabolism by weight reduction.
    Australian and New Zealand journal of medicine, 1973, Volume: 3, Issue:4

    Topics: Gout; Humans; Hypertension; Male; Metabolic Clearance Rate; Middle Aged; Obesity; Uric Acid

1973
Increasing excretion of urate with displacing agents in man.
    Annals of the New York Academy of Sciences, 1973, Nov-26, Volume: 226

    Topics: Anti-Inflammatory Agents; Binding Sites; Dansyl Compounds; Dialysis; Fatty Acids; Gout; Humans; Kidn

1973
Effects of alcohol on the kidney and blood electrolytes.
    The New Zealand medical journal, 1974, Jan-09, Volume: 79, Issue:506

    Topics: Acidosis; Alcoholism; Blood; Depression, Chemical; Diuresis; Ethanol; Gout; Humans; Lactates; Magnes

1974
Cardiovascular epidemiology in New Zealand and the Pacific.
    The New Zealand medical journal, 1974, Sep-25, Volume: 80, Issue:524

    Topics: Adult; Aged; Anthropometry; Blood Pressure; Cardiovascular Diseases; Cholesterol; Coronary Disease;

1974
Chondrocalcinosis articularis (pseudogout syndrome).
    Archives of internal medicine, 1973, Volume: 132, Issue:1

    Topics: Adrenal Cortex Hormones; Adult; Aged; Antibodies, Antinuclear; Arthritis, Rheumatoid; Aspirin; Blood

1973
[Uric acid clearance related to the use of an antirheumatic non-steroid drug].
    Minerva medica, 1973, Volume: 64, Issue:48

    Topics: Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Female; Glomerular Filtration Rate; Go

1973
[The prevalence of lipid metabolism disorders in rheumatological diseases].
    Wiener medizinische Wochenschrift (1946), 1974, Sep-14, Volume: 124, Issue:37

    Topics: Adult; Age Factors; Aged; Arthritis, Rheumatoid; Blood Glucose; Body Weight; Cholesterol; Diabetes M

1974
Some metabolic aspects of diseases of the locomotor system.
    Transactions of the Medical Society of London, 1973, Volume: 89

    Topics: Body Weight; Calcinosis; Calcium Phosphates; Cartilage; Chondrocalcinosis; Female; Gout; Humans; Mal

1973
[Gout and atherosclerosis].
    Bulletin de l'Academie nationale de medecine, 1972, Jan-25, Volume: 156, Issue:2

    Topics: Adult; Age Factors; Aged; Arteriosclerosis; Body Weight; Cholesterol; Female; Gout; Humans; Male; Mi

1972
Cover story: Sir Alfred Baring Garrod, FRS.
    JAMA, 1973, Apr-30, Volume: 224, Issue:5 Suppl

    Topics: Arthritis, Rheumatoid; England; Gout; History, 19th Century; History, 20th Century; Humans; Rheumati

1973
The scientific development of clinical chemistry to 1948.
    Clinical chemistry, 1973, Volume: 19, Issue:4

    Topics: Albuminuria; Animals; Biochemistry; Blood; Blood Glucose; Chemistry, Clinical; Colorimetry; Edema; E

1973
[Prevention of arteriosclerosis].
    Der Internist, 1973, Volume: 14, Issue:7

    Topics: Adult; Arteriosclerosis; Clofibrate; Germany, West; Gout; Humans; Hyperlipidemias; Male; Middle Aged

1973
Uric acid binding to serum proteins: differences among species.
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1972, Volume: 139, Issue:2

    Topics: Animals; Anura; Blood Proteins; Chickens; Dialysis; Dogs; Gout; Guinea Pigs; Haplorhini; Humans; Kid

1972
[Regression of gout tophi under long-term therapy with allopurinol].
    Medizinische Klinik, 1972, Apr-28, Volume: 67, Issue:17

    Topics: Aged; Allopurinol; Female; Fingers; Gout; Humans; Joint Diseases; Joints; Long-Term Care; Male; Midd

1972
Enzymatic uricolysis: a study of the effect of a fungal urate-oxydase.
    Revue europeenne d'etudes cliniques et biologiques. European journal of clinical and biological research, 1972, Volume: 17, Issue:9

    Topics: Allantoin; Aspergillus flavus; Gout; Humans; Injections, Intramuscular; Injections, Intravenous; Met

1972
[Urinary uric acid excretion in patients with gout].
    Reumatologia, 1972, Volume: 10, Issue:3

    Topics: Adult; Aged; Female; Gout; Humans; Kidney Tubules; Male; Middle Aged; Uric Acid

1972
Plasma lipid levels in gout.
    Annals of the rheumatic diseases, 1972, Volume: 31, Issue:6

    Topics: Cholesterol; Fatty Acids, Nonesterified; Female; Glycerides; Gout; Humans; Hyperlipidemias; Lipids;

1972
[Localization of gout in the hip joint].
    Archiv fur orthopadische und Unfall-Chirurgie, 1972, Volume: 73, Issue:4

    Topics: Aged; Female; Femur Head Necrosis; Gout; Hip; Hip Joint; Humans; Joint Prosthesis; Male; Middle Aged

1972
[Clinical aspects of gout].
    Zeitschrift fur arztliche Fortbildung, 1972, Aug-15, Volume: 66, Issue:16

    Topics: Adult; Age Factors; Aged; Body Weight; Diet Therapy; Female; Gout; Humans; Kidney Calculi; Male; Mid

1972
Hyperuricemia: when does it signify gout?
    Medical times, 1972, Volume: 100, Issue:11

    Topics: Gout; Humans; Kidney Tubules; Uric Acid

1972
Serum uric acid in 23,923 men and gout in a subsample of 4257 men in France.
    Journal of chronic diseases, 1972, Volume: 25, Issue:5

    Topics: Adult; Age Factors; France; Gout; Humans; Male; Middle Aged; Uric Acid

1972
[Comparative radiologic studies in gout].
    Orvosi hetilap, 1972, Dec-24, Volume: 113, Issue:52

    Topics: Adult; Aged; Female; Gout; Humans; Kidney Calculi; Male; Middle Aged; Sex Factors; Uric Acid; Urogra

1972
[Tophaceous gout and its surgical treatment].
    Acta chirurgiae orthopaedicae et traumatologiae Cechoslovaca, 1972, Volume: 39, Issue:6

    Topics: Colchicine; Gout; Humans; Methods; Middle Aged; Phenylbutazone; Uric Acid

1972
[The kidney and hyperuricemia].
    Les Cahiers de medecine, 1972, Sep-15, Volume: 13, Issue:10

    Topics: Female; Glomerular Filtration Rate; Gout; Humans; Hypertension; Kidney Diseases; Kidney Function Tes

1972
[Recognition of gout in a selected population pattern].
    Beitrage zur Rheumatologie, 1972, Volume: 18

    Topics: Adult; Age Factors; Ankle; C-Reactive Protein; Czechoslovakia; Elbow; Epidemiologic Methods; Female;

1972
Some contributions to metabolic relationships of uric acid.
    Beitrage zur Rheumatologie, 1972, Volume: 18

    Topics: Cholesterol; Female; Gout; Humans; Hypothyroidism; Lactates; Male; Menopause; Sex Factors; Thyroid H

1972
[Cytological and enzymatic studies of synovial fluid in the diagnosis of uric arthritis].
    Beitrage zur Rheumatologie, 1972, Volume: 18

    Topics: Acid Phosphatase; Alkaline Phosphatase; Aspartate Aminotransferases; Cytodiagnosis; Fructose-Bisphos

1972
[Sodium urate crystals in the diagnosis of uric arthritis].
    Beitrage zur Rheumatologie, 1972, Volume: 18

    Topics: Crystallization; Female; Gout; Humans; Hydrarthrosis; Male; Sodium; Synovial Fluid; Uric Acid

1972
[Urolithiasis in gout and hyperuricemic syndrome].
    Beitrage zur Rheumatologie, 1972, Volume: 18

    Topics: Allopurinol; Colchicine; Diabetes Complications; Diabetes Mellitus; Female; Gout; Humans; Male; Uric

1972
[Kidney involvement in gout].
    Beitrage zur Rheumatologie, 1972, Volume: 18

    Topics: Adolescent; Adult; Aged; Allopurinol; Anti-Bacterial Agents; Antihypertensive Agents; Female; Gout;

1972
[Reciprocal relationship between purine metabolism disorders and arteriosclerotic angioorganopathies].
    Beitrage zur Rheumatologie, 1972, Volume: 18

    Topics: Age Factors; Arm; Arterial Occlusive Diseases; Arteriosclerosis; Cholesterol; Diabetes Complications

1972
[Hyperuricemia and myocardial infarct].
    Beitrage zur Rheumatologie, 1972, Volume: 18

    Topics: Arteriosclerosis; Coronary Disease; Diabetes Complications; Female; Gout; Humans; Hypercholesterolem

1972
[Uric acid level and body weight].
    Beitrage zur Rheumatologie, 1972, Volume: 18

    Topics: Acidosis; Body Weight; Fasting; Female; Gout; Humans; Male; Obesity; Time Factors; Uric Acid

1972
[Gout in women].
    Beitrage zur Rheumatologie, 1972, Volume: 18

    Topics: Adult; Age Factors; Female; Gout; Humans; Kidney Diseases; Male; Menopause; Middle Aged; Obesity; Se

1972
[Prognosis and prevention of gout complications].
    Beitrage zur Rheumatologie, 1972, Volume: 18

    Topics: Adult; Aged; Arteriosclerosis; Diseases in Twins; Female; Gout; Humans; Kidney Calculi; Kidney Disea

1972
[Experience with benziodarone therapy in gout and hyperuricemic syndrome].
    Beitrage zur Rheumatologie, 1972, Volume: 18

    Topics: Administration, Oral; Adult; Benzofurans; Gout; Humans; Joint Diseases; Male; Psoriasis; Uric Acid

1972
[Current status of gout (physiopathological, morphological, clinical and therapeutic aspects)].
    Medicina interna, 1972, Volume: 24, Issue:9

    Topics: Anti-Inflammatory Agents; Colchicine; Diet Therapy; Gout; Humans; Joints; Purines; Urate Oxidase; Ur

1972
Rheumatology.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1972, Nov-04, Volume: 46, Issue:44

    Topics: Acute Disease; Aged; Analgesics; Arthritis, Rheumatoid; Chronic Disease; Diazepam; Female; Gout; Hum

1972
Management of gout.
    Drugs, 1972, Volume: 3, Issue:5

    Topics: Anti-Inflammatory Agents; Arthritis; Diet; Gout; Humans; Kidney Diseases; Phagocytes; Synovial Fluid

1972
[Aseptic, primary osteonecrosis of the femur head].
    Acta orthopaedica Belgica, 1972, Volume: 38, Issue:5

    Topics: Alcoholism; Femur Head; Femur Head Necrosis; Gout; Humans; Hyperlipidemias; Ischemia; Obesity; Osteo

1972
[Molecular bases of the treatment of Lesch-Nyhan syndrome, related syndromes and common gout].
    Biochimie, 1972, Volume: 54, Issue:5

    Topics: Adenine Nucleotides; Allopurinol; Feedback; Gout; Guanosine; Humans; Hypoxanthines; Lesch-Nyhan Synd

1972
Simultaneous measurement of plasma and erythrocyte oxypurines. II. Gouty patients with and without allopurinol medication.
    Gynecologic investigation, 1972, Volume: 3, Issue:5

    Topics: Allopurinol; Erythrocytes; Gout; Humans; Hypoxanthines; Male; Purinones; Stimulation, Chemical; Uric

1972
Effect of balneotherapy in Ciechocinek Spa on the occurrence of gouty attacks and the symptoms of chronic gouty arthropathy (observations of 112 cures).
    Polish medical journal, 1972, Volume: 11, Issue:6

    Topics: Adult; Aged; Allopurinol; Balneology; Blood Sedimentation; Colchicine; Female; Gout; Humans; Male; M

1972
[Lipid disorders in gout and in hyperuricemia with myalgia].
    Marseille medical, 1972, Volume: 109, Issue:10

    Topics: Adult; Aged; Cholesterol; Female; Gout; Humans; Hypercholesterolemia; Hyperlipidemias; Lipids; Lipop

1972
[Diagnosis and therapy of gout (uricopathy). Guide lines for daily practice].
    Fortschritte der Medizin, 1972, Dec-07, Volume: 90, Issue:34

    Topics: Allopurinol; Arthritis, Rheumatoid; Benzofurans; Diagnosis, Differential; Gout; Humans; Ketones; Pso

1972
[Mode of renal elimination of uric acid in patients with gout and normal subjects with comparable blood levels. Preliminary results].
    Journal d'urologie et de nephrologie, 1972, Volume: 78, Issue:9

    Topics: Adult; Glomerular Filtration Rate; Gout; Humans; Kidney; Kidney Concentrating Ability; Kidney Tubule

1972
Urate crystal induced inflammation in the rat: evidence for the combined actions of kinins, histamine and components of complement.
    Immunological communications, 1972, Volume: 1, Issue:2

    Topics: Animals; Carboxypeptidases; Colchicine; Complement System Proteins; Cyproheptadine; Edema; Female; G

1972
[Comparative studies on uric acid and phosphate levels in healthy subjects and patients with patent gout during several hours of intravenous fructose administration].
    Verhandlungen der Deutschen Gesellschaft fur Innere Medizin, 1972, Volume: 78

    Topics: Adult; Fructose; Gout; Humans; Injections, Intravenous; Middle Aged; Phosphates; Time Factors; Uric

1972
On the existence of a guanine nucleotide trap, the role of adenosine kinase and a possible cause of excessive purine production in mammalian cells.
    Journal of cell science, 1972, Volume: 11, Issue:1

    Topics: Adenosine; Adenosine Monophosphate; Animals; Cell Line; Fibroblasts; Gout; Guanine; Guanine Nucleoti

1972
[Hyperuricemia].
    Nihon rinsho. Japanese journal of clinical medicine, 1972, Volume: 30, Issue:6

    Topics: Gout; Humans; Kidney; Kidney Glomerulus; Kidney Tubules; Microscopy, Electron; Nephritis, Interstiti

1972
[Possible clinical use of benziodarone].
    Fysiatricky a reumatologicky vestnik, 1972, Volume: 50, Issue:6

    Topics: Benzofurans; Fatty Acids; Gout; Humans; Uric Acid

1972
[Relationship between metabolic diseases and the severity of coronary disease].
    Arzneimittel-Forschung, 1972, Volume: 22, Issue:10

    Topics: Angina Pectoris; Angiocardiography; Cholesterol; Diabetes Complications; Diabetic Angiopathies; Fema

1972
[Clinico-roentgenologic parallels in gout].
    Vutreshni bolesti, 1972, Volume: 11, Issue:2

    Topics: Foot; Gout; Hand; Humans; Radiography; Uric Acid

1972
Urate deposition disease. How is it regulated and how can it be modified?
    Annals of internal medicine, 1973, Volume: 78, Issue:1

    Topics: Animals; Blood Proteins; Disease Models, Animal; Gout; Humans; Hydrogen-Ion Concentration; Kidney; K

1973
[Changes between 1948 and 1970 in the epidemiology and clinical features of primary gout].
    Deutsche medizinische Wochenschrift (1946), 1973, Feb-02, Volume: 98, Issue:5

    Topics: Adult; Age Factors; Aged; Alcohol Drinking; Blood Protein Disorders; Diabetes Complications; Fatty L

1973
[Polycythemia, polyglobulia and gout].
    Medizinische Klinik, 1973, Jan-12, Volume: 68, Issue:2

    Topics: Cyanosis; Erythropoiesis; Female; Gout; Heart Defects, Congenital; Humans; Leukemia; Male; Nucleic A

1973
[The effect of spironolactone and thiabutazide on serum-uric acid and lipid levels in patients with gout and in healthy persons].
    Deutsche medizinische Wochenschrift (1946), 1973, Jan-05, Volume: 98, Issue:1

    Topics: Adult; Allopurinol; Benzothiadiazines; Cholesterol; Female; Follow-Up Studies; Gout; Humans; Lipids;

1973
[Current etiopathogenetic and therapeutic views concerning gout and hyperuremic syndromes].
    Minerva medica, 1973, Jan-20, Volume: 64, Issue:4

    Topics: Acute Disease; Aged; Antimetabolites; Chronic Disease; Colchicine; Female; Genetic Code; Gout; Human

1973
[Hyperuricemia due to diuretics].
    Minerva medica, 1973, Jan-20, Volume: 64, Issue:4

    Topics: Acetazolamide; Aged; Chlorothiazide; Chlorthalidone; Diuretics; Ethacrynic Acid; Furosemide; Gout; H

1973
[Arterial hypertension with convulsive seizures in a patient with right kidney hypoplasia and gout attacks and with a probable gouty kidney].
    Minerva medica, 1973, Jan-27, Volume: 64, Issue:6

    Topics: Electrocardiography; Gout; Headache; Heart; Humans; Hydronephrosis; Hypertension; Kidney; Kidney Dis

1973
[Use of enzymatic uricolysis in the treatment of hyperuricemia of renal origin].
    Schweizerische medizinische Wochenschrift, 1973, Mar-17, Volume: 103, Issue:11

    Topics: Gout; Humans; Injections, Intravenous; Kidney Failure, Chronic; Renal Dialysis; Urate Oxidase; Uric

1973
[Arthritis urica and L-dopa therapy].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1973, Jan-30, Volume: 93, Issue:3

    Topics: Dihydroxyphenylalanine; Gout; Humans; Parkinson Disease; Uric Acid

1973
[Gout and hyperuricemia during fasting. Action of associated thyroid hormone therapy].
    Revue du rhumatisme et des maladies osteo-articulaires, 1973, Volume: 40, Issue:1

    Topics: Adolescent; Adult; Fasting; Female; Gout; Humans; Male; Middle Aged; Obesity; Triiodothyronine; Uric

1973
Complement as a mediator of inflammation in acute gouty arthritis. II. Biological activities generated from complement by the interaction of serum complement and sodium urate crystals.
    The Journal of laboratory and clinical medicine, 1973, Volume: 81, Issue:5

    Topics: Animals; Chemotaxis; Complement System Proteins; Gout; Hot Temperature; Humans; Immunoelectrophoresi

1973
[Treatment with allopurinol in gout and hyperuricemic renal disease].
    Lakartidningen, 1973, Mar-28, Volume: 70, Issue:13

    Topics: Adult; Aged; Allopurinol; Creatinine; Female; Glomerular Filtration Rate; Gout; Humans; Hypertension

1973
Platelets and vascular disease in gout.
    Seminars in arthritis and rheumatism, 1973, Volume: 2, Issue:4

    Topics: Allopurinol; Analgesics; Arteriosclerosis; Blood Platelets; Colchicine; Diabetes Complications; Gout

1973
[Lipid disorders in gout and hyperuricemias].
    Revue du rhumatisme et des maladies osteo-articulaires, 1973, Volume: 40, Issue:2

    Topics: Cholesterol; Female; Gout; Humans; Hyperlipidemias; Lipids; Male; Metabolic Diseases; Phospholipids;

1973
Hyperglutamatemia in primary gout.
    The American journal of medicine, 1973, Volume: 54, Issue:6

    Topics: Adult; Aged; Alanine; Ammonia; Chromatography; Fasting; Glutamates; Glutamine; Glycine; Gout; Humans

1973
[Long-term therapy of gout and hyperuricemia].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1973, Mar-01, Volume: 28, Issue:5

    Topics: Allopurinol; Arteriosclerosis; Blood Protein Disorders; Citrates; Colchicine; Diabetes Mellitus; Die

1973
Sarcroilaic joints in primary gout. Clinical and roentgenographic study of 143 patients.
    The American journal of roentgenology, radium therapy, and nuclear medicine, 1973, Volume: 118, Issue:2

    Topics: Adolescent; Adult; Aged; Chronic Disease; Creatinine; Female; Gout; Humans; Male; Middle Aged; Osteo

1973
[Laboratory diagnosis of gout].
    Medizinische Monatsschrift, 1973, Volume: 27, Issue:1

    Topics: Gout; Humans; Methods; Uric Acid

1973
[Oxalate calculi formation in hyperuricemia].
    Deutsche medizinische Wochenschrift (1946), 1973, Jun-29, Volume: 98, Issue:26

    Topics: Gout; Humans; Oxalates; Uric Acid; Urinary Calculi

1973
Correlates and consequences of asymptomatic hyperuricemia.
    Archives of internal medicine, 1973, Volume: 132, Issue:1

    Topics: ABO Blood-Group System; Adult; Aspartate Aminotransferases; Blood Glucose; Calcium; Cholesterol; Cre

1973
[Gout treatment with a dibromine derivative of benzofuran].
    Revue du rhumatisme et des maladies osteo-articulaires, 1973, Volume: 40, Issue:4

    Topics: Benzofurans; Bromine; Gout; Humans; Uric Acid; Uricosuric Agents

1973
[Gout in an African university hospital].
    Annales de la Societe belge de medecine tropicale, 1973, Volume: 53, Issue:2

    Topics: Adult; Black People; Democratic Republic of the Congo; Gout; Humans; Male; Middle Aged; Rural Popula

1973
Gout with purine overproduction due to increased phosphoribosylpyrophosphate synthetase activity.
    The American journal of medicine, 1973, Volume: 55, Issue:2

    Topics: Adolescent; Adult; Carbon Isotopes; Child; Erythrocytes; Female; Fibroblasts; Glycine; Gout; Guanine

1973
Serum uric acid concentrations in a rural Tswana community in Southern Africa.
    Annals of the rheumatic diseases, 1973, Volume: 32, Issue:4

    Topics: Adolescent; Adult; Age Factors; Aged; Female; Gout; Humans; Male; Middle Aged; Obesity; Sex Factors;

1973
Comparison of indomethacin and phenylbutazone in acute gout.
    Annals of the rheumatic diseases, 1973, Volume: 32, Issue:4

    Topics: Acute Disease; Adult; Aged; Blood Sedimentation; Edema; Female; Gout; Humans; Indomethacin; Leukocyt

1973
A reappraisal of the concept of an abnormality of glutamine metabolism in primary gout.
    Transactions of the American Clinical and Climatological Association, 1973, Volume: 84

    Topics: Adolescent; Adult; Amino Acid Metabolism, Inborn Errors; Benzoates; Carbon Isotopes; Diet; Glutamine

1973
[Hyperuricacidemia: abnormal metabolism in biosynthesis--on Lesch-Nyhan syndrome].
    Nihon rinsho. Japanese journal of clinical medicine, 1973, Volume: 31, Issue:5

    Topics: Child, Preschool; Gout; Humans; Lesch-Nyhan Syndrome; Male; Purines; Uric Acid

1973
[Dynamics of uric acid metabolism in hyperuriacidemia].
    Nihon rinsho. Japanese journal of clinical medicine, 1973, Volume: 31, Issue:5

    Topics: Carbon Isotopes; Gout; Humans; Uric Acid

1973
[Renal factor in the development of hyperuricacidemia].
    Nihon rinsho. Japanese journal of clinical medicine, 1973, Volume: 31, Issue:5

    Topics: Gout; Humans; Kidney; Kidney Diseases; Uric Acid

1973
Hyperuricemia, gout, and the executive suite.
    JAMA, 1973, May-28, Volume: 224, Issue:9

    Topics: Achievement; Adolescent; Adult; Body Height; Body Weight; Drive; Feeding Behavior; Gout; Humans; Mal

1973
Studies with some novel uricosuric agents and their metabolites: correlation between clinical activity and drug-induced displacement of urate from its albumin-binding sites.
    The Journal of laboratory and clinical medicine, 1973, Volume: 82, Issue:3

    Topics: Adult; Aged; Benzophenones; Binding Sites; Binding, Competitive; Creatinine; Dansyl Compounds; Fluor

1973
Extradural spinal depositions of urates producing paraplegia. Case report.
    Journal of neurosurgery, 1973, Volume: 39, Issue:5

    Topics: Aged; Gout; Humans; Laminectomy; Ligaments; Male; Paraplegia; Radiography; Spinal Diseases; Spine; U

1973
An atypical case of hypoxanthine-guanine phosphoribosyltransferase deficiency (Lesch-Nyhan syndrome). I. Clinical studies.
    Clinical genetics, 1973, Volume: 4, Issue:4

    Topics: Adolescent; Adult; Bone Marrow Cells; Gout; Humans; Lesch-Nyhan Syndrome; Male; Neurologic Examinati

1973
Letter: Gouty arthritis and polycystic kidney disease.
    Annals of internal medicine, 1973, Volume: 79, Issue:4

    Topics: Gout; Humans; Polycystic Kidney Diseases; Uric Acid

1973
[New, special preparations registered in Austria].
    Wiener klinische Wochenschrift, 1973, Nov-16, Volume: 85, Issue:46

    Topics: Austria; Benzofurans; Chemical Phenomena; Chemistry; Gout; Humans; Ketones; Kidney Failure, Chronic;

1973
Hyperuricaemia and gout in Nigerians.
    Tropical and geographical medicine, 1973, Volume: 25, Issue:3

    Topics: Adolescent; Adult; Body Height; Body Weight; Child; Child, Preschool; Female; Gout; Hospitals; Human

1973
Editorial: Mechanism of gouty inflammation.
    British medical journal, 1973, Oct-20, Volume: 4, Issue:5885

    Topics: Gout; Humans; Inflammation; Leukocytes; Phagocytosis; Uric Acid

1973
[Gout, ideas on acquisition and problems to be solved].
    Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis, 1973, Oct-30, Volume: 62, Issue:44

    Topics: Gout; Humans; Kidney; Purines; Uric Acid

1973
[Renal complications of gout].
    Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis, 1973, Oct-30, Volume: 62, Issue:44

    Topics: Diet Therapy; Gout; Humans; Kidney Diseases; Uric Acid

1973
Letter: Mechanism of gouty inflammation.
    British medical journal, 1973, Dec-15, Volume: 4, Issue:5893

    Topics: Animals; Chemotaxis; Complement System Proteins; Gout; Joint Diseases; Uric Acid

1973
Familial hyperuricaemia and hypertriglyceridaemia.
    Annals of the rheumatic diseases, 1973, Volume: 32, Issue:6

    Topics: Adolescent; Adult; Alcohol Drinking; Blood Pressure; Cholesterol; Female; Gout; Humans; Hyperlipidem

1973
[The kidney and hyperuricemia].
    Minerva medica, 1973, Oct-31, Volume: 64, Issue:77

    Topics: Gout; Humans; Kidney; Kidney Calculi; Lesch-Nyhan Syndrome; Uric Acid

1973
[Surgery of gout].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 1973, Volume: 44, Issue:9

    Topics: Blood Vessels; Foot; Gout; Hand; Humans; Male; Methods; Microscopy, Electron; Microscopy, Polarizati

1973
Uric acid in alcoholics.
    Quarterly journal of studies on alcohol, 1973, Volume: 34, Issue:4

    Topics: Age Factors; Alcohol Drinking; Alcoholic Intoxication; Alcoholism; Female; Gout; Humans; Male; Middl

1973
The treatment of gout.
    Scottish medical journal, 1973, Volume: 18

    Topics: Acute Disease; Allopurinol; Aspirin; Colchicine; Drug Therapy, Combination; Gout; Indomethacin; Phen

1973
[When and how to treat hyperuricemia].
    Therapeutique (La Semaine des hopitaux), 1973, Volume: 49, Issue:4

    Topics: Gout; Humans; Uric Acid; Uricosuric Agents

1973
[Evaluation and treatment of hyperuricemia].
    Die Medizinische Welt, 1973, Dec-14, Volume: 24, Issue:50

    Topics: Adult; Arthritis; Female; Gout; Humans; Joint Diseases; Male; Middle Aged; Uric Acid; Uricosuric Age

1973
[The kidney and hyperuricemia].
    Les Cahiers de medecine, 1973, Oct-30, Volume: 14, Issue:11

    Topics: Gout; Humans; Kidney; Kidney Function Tests; Uric Acid; Urinary Calculi

1973
Urate metabolism in heterozygotes for HGPRTase deficiency.
    Advances in experimental medicine and biology, 1973, Volume: 41

    Topics: Adult; Aged; Body Weight; Carbon Radioisotopes; Creatinine; Erythrocytes; Glycine; Gout; Guanine Nuc

1973
Gout with adenine phosphoribosyl transferase deficiency.
    Advances in experimental medicine and biology, 1973, Volume: 41

    Topics: Adenine; Allopurinol; Carbon Radioisotopes; Erythrocytes; Female; Glycine; Gout; Humans; Male; Pedig

1973
Adenine phosphoribosyltransferase deficiency in a female with gout.
    Advances in experimental medicine and biology, 1973, Volume: 41

    Topics: Adenine; Adult; Carbon Radioisotopes; Creatinine; Erythrocytes; Female; Glycine; Gout; Humans; Pento

1973
[Studies on plasma protein binding of uric acid in gout].
    Acta medica Academiae Scientiarum Hungaricae, 1973, Volume: 30, Issue:4

    Topics: Allopurinol; Blood Protein Electrophoresis; Blood Proteins; Carbon Radioisotopes; Chromatography, Ge

1973
Urolithiasis and nephropathy in gout.
    The Journal of the Association of Physicians of India, 1973, Volume: 21, Issue:10

    Topics: Adult; Aged; Albuminuria; Female; Gout; Humans; Hypertension; Kidney Diseases; Male; Middle Aged; Ur

1973
[Diabetes mellitus, uricemia and gout].
    Acta diabetologica latina, 1973, Volume: 10, Issue:6

    Topics: Diabetes Complications; Diabetes Mellitus; Fructose; Glucose; Gout; Humans; Nucleoproteins; Nutritio

1973
[Diabetes mellitus, serum urate and gout. A study in 314 patients (author's transl)].
    Acta diabetologica latina, 1973, Volume: 10, Issue:6

    Topics: Adult; Age Factors; Aged; Alloxan; Blood Urea Nitrogen; Diabetes Complications; Diabetes Mellitus; F

1973
[Hyperuricemia. (Etiopathogenic and therapeutic concepts)].
    Medicina interna, 1973, Volume: 25, Issue:2

    Topics: Diuretics; Gout; Humans; Hypertension; Hypothyroidism; Kidney Diseases; Nicotinic Acids; Nucleoprote

1973
[Dyspurinia and atherosclerosis].
    Coeur et medecine interne, 1973, Volume: 12, Issue:4

    Topics: Adult; Aged; Arteriosclerosis; Arteritis; Coronary Disease; Female; Gout; Humans; Intracranial Arter

1973
[The kidney and hyperuricaemia (author's transl)].
    Munchener medizinische Wochenschrift (1950), 1973, Sep-21, Volume: 115, Issue:38

    Topics: Adult; Child; Female; Gout; Humans; Hydrogen-Ion Concentration; Kidney; Kidney Calculi; Male; Middle

1973
[Anuria due to bilateral ureteral uric acid lithiasis during a treatment with Amplivix].
    Journal d'urologie et de nephrologie, 1973, Volume: 79, Issue:12 Pt 2

    Topics: Anuria; Benzofurans; Gout; Humans; Male; Middle Aged; Ureteral Calculi; Uric Acid; Uricosuric Agents

1973
Uric acid and the kidney.
    Proceedings of the Royal Society of Medicine, 1973, Volume: 66, Issue:9

    Topics: Aged; Allopurinol; Animals; Diabetes Mellitus; Gout; Humans; Hydrogen-Ion Concentration; Hypercholes

1973
[Treatment of uric acid disorders].
    Die Medizinische Welt, 1973, Jan-26, Volume: 24, Issue:4

    Topics: Acute Disease; Allopurinol; Colchicine; Female; Gout; Humans; Male; Uric Acid

1973
[The action of allopurinol on uric acid transport].
    Turk Tip Cemiyeti mecmuasi, 1973, Volume: 39, Issue:7

    Topics: Allopurinol; Biological Transport, Active; Gout; Humans; Male; Middle Aged; Uremia; Uric Acid

1973
Use of Milurit in the treatment of gout.
    Therapia Hungarica (English edition), 1973, Volume: 21, Issue:3-4

    Topics: Aged; Allopurinol; Drug Administration Schedule; Drug Evaluation; Female; Gout; Humans; Male; Middle

1973
[Gout hazard as the price for development of intelligence?].
    Deutsche medizinische Wochenschrift (1946), 1974, Jan-04, Volume: 99, Issue:1

    Topics: Achievement; Age Factors; Feeding Behavior; Female; Gout; Humans; Intelligence; Leadership; Male; Mo

1974
Letter: Polycystic kidney disease and hyperuricemia.
    Annals of internal medicine, 1974, Volume: 80, Issue:1

    Topics: Adult; Female; Gout; Humans; Male; Polycystic Kidney Diseases; Uric Acid

1974
Erythrocytosis associated with chronic renal disease.
    Archives of internal medicine, 1974, Volume: 133, Issue:3

    Topics: Adult; Biopsy; Blood Urea Nitrogen; Blood Volume Determination; Creatinine; Erythrocyte Count; Glome

1974
Epidemiology of serum uric acid and gout in Frenchmen.
    Journal of chronic diseases, 1974, Volume: 27, Issue:1

    Topics: Adult; Age Factors; Body Constitution; Epidemiologic Methods; France; Gout; Humans; Male; Middle Age

1974
Gout: presentation as a popliteal cyst.
    Radiology, 1974, Volume: 111, Issue:1

    Topics: Drainage; Gout; Humans; Knee; Knee Joint; Male; Middle Aged; Radiography; Synovial Cyst; Synovial Fl

1974
[Diet in gout and hyperuricemia].
    Zeitschrift fur Allgemeinmedizin, 1974, Jan-20, Volume: 50, Issue:2

    Topics: Diet Therapy; Gout; Humans; Obesity; Purines; Uric Acid

1974
Gout.
    British medical journal, 1974, Mar-09, Volume: 1, Issue:5905

    Topics: Allopurinol; Blood Cell Count; Cell Movement; Colchicine; Diet; Drug Synergism; Gastrointestinal Dis

1974
[Fructose-induced hyperuricemia in healthy subjects and in patients with gout and secondary hyperuricemia].
    Die Medizinische Welt, 1974, Mar-08, Volume: 25, Issue:10

    Topics: Fructose; Gout; Humans; Infusions, Parenteral; Stimulation, Chemical; Uric Acid

1974
[Comparative study of uric acid renal elimination in the gout patients and normal patients in spontaneous or experimentally increased or decreased uricemia].
    Revue du rhumatisme et des maladies osteo-articulaires, 1974, Volume: 41, Issue:1

    Topics: Adult; Aged; Allantoin; Glomerular Filtration Rate; Gout; Humans; Injections, Intravenous; Kidney Fu

1974
The treatment of hyperuricemia in gout.
    Rational drug therapy, 1974, Volume: 8, Issue:3

    Topics: Allopurinol; Gout; Humans; Uric Acid; Uricosuric Agents

1974
Proceedings: Gout, hypertriglyceridaemia, and alcohol consumption.
    Annals of the rheumatic diseases, 1974, Volume: 33, Issue:1

    Topics: Alcohol Drinking; Fasting; Gout; Humans; Hyperlipidemias; Male; Obesity; Sulfobromophthalein; Trigly

1974
[New drugs: allopurinol. Foligan, Urosin, Zyloric].
    Der Urologe. Ausg. A, 1974, Volume: 13, Issue:1

    Topics: Allopurinol; Germany, West; Gout; Humans; Uric Acid; Uricosuric Agents

1974
Rheumatic manifestations of Paget's disease of bone.
    The American journal of medicine, 1974, Volume: 56, Issue:5

    Topics: Adult; Aged; Alkaline Phosphatase; Arthritis; Arthritis, Rheumatoid; Female; Finger Joint; Gout; Hum

1974
Diseases associated with calcium pyrophosphate dihydrate crystal deposition.
    The American journal of medicine, 1974, Volume: 56, Issue:5

    Topics: Adult; Aged; Calcium; Chondrocalcinosis; Creatinine; Diabetes Complications; Female; Gout; Hemochrom

1974
Acute polyarticular gout.
    The American journal of medicine, 1974, Volume: 56, Issue:5

    Topics: Aged; Ankle Joint; Elbow Joint; Female; Finger Joint; Gout; Hip Joint; Humans; Knee Joint; Male; Mid

1974
[Allopurinol treatment of gout with special reference to patients with gouty nephropathy].
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 1974, Volume: 27, Issue:8

    Topics: Adult; Aged; Allopurinol; Female; Gout; Humans; Kidney Diseases; Male; Middle Aged; Uric Acid

1974
The kinetics of intramolecular distribution of 15N in uric acid following administration of 15N-glycine: preferential labeling of N-(3+9) of uric acid in primary gout and a reappraisal of the "glutamine hypothesis".
    Advances in experimental medicine and biology, 1974, Volume: 41

    Topics: Adolescent; Adult; Chromatography, Ion Exchange; Glutamine; Glycine; Gout; Guanine Nucleotides; Hipp

1974
Hyperglutamatemia in primary gout.
    Advances in experimental medicine and biology, 1974, Volume: 41

    Topics: Administration, Oral; Alanine; Erythrocytes; Glutamates; Glutamine; Glycine; Gout; Humans; Male; Pub

1974
Effect of ribomononucleotides given orally on uric acid production in man.
    Advances in experimental medicine and biology, 1974, Volume: 41

    Topics: Adult; Ammonia; Blood Urea Nitrogen; Creatinine; Gout; Humans; Hydrogen-Ion Concentration; Kidney Ca

1974
The uptake of glycine-14C into the adenine and guanine of DNA and insoluble RNA of human leucocytes.
    Advances in experimental medicine and biology, 1974, Volume: 41

    Topics: Adenine; Autoanalysis; Carbon Radioisotopes; Chromatography, Paper; DNA; Female; Glycine; Gout; Guan

1974
On the problem of hyperuricemia in certain physiological stress conditions.
    Advances in experimental medicine and biology, 1974, Volume: 41

    Topics: Adolescent; Adult; Autoanalysis; Creatinine; Fasting; Female; Gout; Humans; Labor, Obstetric; Menstr

1974
The effect of weight reduction on urate metabolism.
    Advances in experimental medicine and biology, 1974, Volume: 41

    Topics: Blood Pressure; Body Weight; Carbon Radioisotopes; Creatinine; Diet Therapy; Glycine; Gout; Humans;

1974
Diet and gout.
    Advances in experimental medicine and biology, 1974, Volume: 41

    Topics: Body Weight; Calorimetry; Diet; DNA; Female; Food Analysis; Gout; Humans; Male; Nitrogen; Purines; R

1974
Relationship between gout and arterial hypertension.
    Advances in experimental medicine and biology, 1974, Volume: 41

    Topics: Acute Disease; Adult; Aged; Blood Pressure; Chronic Disease; Diabetes Complications; Female; Gout; H

1974
Observations concerning the incidence of disturbance of lipid and carbohydrate metabolism in gout.
    Advances in experimental medicine and biology, 1974, Volume: 41

    Topics: Arteriosclerosis; Blood Glucose; Body Weight; Cholesterol; Coronary Disease; Diabetes Complications;

1974
Gout and hyperlipidaemia.
    Advances in experimental medicine and biology, 1974, Volume: 41

    Topics: Adult; Aged; Alcohol Drinking; Alkaline Phosphatase; Aspartate Aminotransferases; Beer; Bilirubin; B

1974
An integrative hypothesis for the renal disease of urate overproduction.
    Advances in experimental medicine and biology, 1974, Volume: 41

    Topics: Acute Kidney Injury; Adult; Diagnosis, Differential; Erythrocytes; Female; Glomerular Filtration Rat

1974
Concentration of urate by differential diffusion: a hypothesis for initial urate deposition.
    Advances in experimental medicine and biology, 1974, Volume: 41

    Topics: Carbon Radioisotopes; Connective Tissue; Diffusion; Gout; Hallux; Humans; Synovial Fluid; Time Facto

1974
The binding of urate to plasma proteins.
    Advances in experimental medicine and biology, 1974, Volume: 41

    Topics: Allopurinol; Aspirin; Binding Sites; Blood Proteins; Colchicine; Dialysis; Evaluation Studies as Top

1974
Experimental hyperuricemia in rats.
    Advances in experimental medicine and biology, 1974, Volume: 41

    Topics: Animals; Dialysis; Diet; Female; Gout; Kidney; Male; Rats; Time Factors; Uric Acid

1974
Efficacy of single daily dose allopurinol in gouty hyperuricemia.
    Advances in experimental medicine and biology, 1974, Volume: 41

    Topics: Allopurinol; Evaluation Studies as Topic; Gout; Half-Life; Humans; Male; Time Factors; Uric Acid

1974
Withdrawal of allopurinol in patients with gout.
    Advances in experimental medicine and biology, 1974, Volume: 41

    Topics: Allopurinol; Evaluation Studies as Topic; Follow-Up Studies; Gout; Humans; Male; Middle Aged; Recurr

1974
Metabolic studies of thiopurinol in man and the pig.
    Advances in experimental medicine and biology, 1974, Volume: 41

    Topics: Adult; Alcohol Drinking; Allopurinol; Animals; Carbon Radioisotopes; Duodenum; Gout; Humans; Hypoxan

1974
Allopurinol and thiopurinol: effect in vivo on urinary oxypurine excretion and rate of synthesis of their ribonucleotides in different enzymatic deficiencies.
    Advances in experimental medicine and biology, 1974, Volume: 41

    Topics: Adenine; Allopurinol; Erythrocytes; Female; Gout; Guanine; Humans; Hypoxanthines; Lesch-Nyhan Syndro

1974
Influence of a uricosuric drug on connective tissue metabolism.
    Advances in experimental medicine and biology, 1974, Volume: 41

    Topics: Benzoates; Benzofurans; Benzyl Compounds; Bromine; Cartilage; Chondroitin; Creatinine; Gout; Humans;

1974
Uricosuric effect of an anticholinergic agent in hyperuricemic subjects.
    Advances in experimental medicine and biology, 1974, Volume: 41

    Topics: Creatinine; Cyclohexanes; Glycopyrrolate; Gout; Humans; Parasympatholytics; Propanolamines; Purine-P

1974
Hyperuricemia induced by ethambutol.
    Advances in experimental medicine and biology, 1974, Volume: 41

    Topics: Allopurinol; Creatinine; Diuretics; Ethambutol; Ethanol; Gout; Humans; Isoniazid; Lactates; Pyrazina

1974
A preliminary report of nephropathy in hyperuricemic rats.
    Laboratory investigation; a journal of technical methods and pathology, 1974, Volume: 30, Issue:6

    Topics: Animals; Body Weight; Disease Models, Animal; Gout; Kidney; Kidney Calculi; Kidney Diseases; Kidney

1974
[Hyperuricemia due to hypoxanthine-guanine-phosphoribosyltransferase deficiency].
    La Nouvelle presse medicale, 1974, Apr-20, Volume: 3, Issue:16

    Topics: Adult; Allopurinol; Anemia; Arthritis; Benzofurans; Gout; Humans; Hyperlipidemias; Hypothyroidism; H

1974
[Articular exudate in a case of gout with exceptionally profuse mass of sodium urate crystals].
    Reumatologia, 1974, Volume: 12, Issue:2

    Topics: Aged; Gout; Humans; Male; Synovial Fluid; Uric Acid

1974
[Renal tubular function in patients with gout].
    Reumatologia, 1974, Volume: 12, Issue:1

    Topics: Creatinine; Gout; Humans; Kidney Tubules; Uric Acid

1974
Specificity of the renal transport impairment in chickens having hyperuricemia and articular gout.
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1974, Volume: 146, Issue:3

    Topics: Aminohippuric Acids; Animals; Arginine; Biological Transport; Chickens; Creatinine; Female; Glomerul

1974
Pathophysiology of purine metabolism in man.
    Enzyme, 1974, Volume: 18, Issue:3

    Topics: Adenosine; Alkaline Phosphatase; Amidinotransferases; Amidohydrolases; Glomerular Filtration Rate; G

1974
[Mechanism of action and role of xanthine oxidoreductases (author's transl)].
    Postepy biochemii, 1974, Volume: 20, Issue:3

    Topics: Animals; Chemical Phenomena; Chemistry; Chickens; Electron Transport; Flavin-Adenine Dinucleotide; G

1974
Editorial: Drugs used in hyperuricaemia.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1974, Jun-22, Volume: 48, Issue:30

    Topics: Allopurinol; Gout; Humans; Metabolic Diseases; Uric Acid; Uricosuric Agents

1974
Gout with adenine phosphoribosyl transferase deficiency.
    Biomedicine / [publiee pour l'A.A.I.C.I.G.], 1974, Volume: 21, Issue:2

    Topics: Adenine; Adolescent; Adult; Aged; Allopurinol; Carbon Radioisotopes; Child; Child, Preschool; Chromo

1974
The Jewish Hospital of St. Louis. Therapeutic grand rounds number 7. An approach to disorders of uric acid metabolism.
    Archives of internal medicine, 1974, Volume: 134, Issue:3

    Topics: Allopurinol; Alloxan; Feedback; Gout; Guanine; Humans; Hypoxanthines; Kidney; Male; Metabolic Diseas

1974
Gout in the temporomandibular joint. Report on a case.
    ORL; journal for oto-rhino-laryngology and its related specialties, 1974, Volume: 36, Issue:1

    Topics: Aged; Diagnosis, Differential; Gout; Humans; Male; Radiography; Temporomandibular Joint; Uric Acid

1974
Genetics of hyperuricemia and achievement.
    JAMA, 1967, Nov-27, Volume: 202, Issue:9

    Topics: Achievement; Gout; History, 17th Century; History, 18th Century; History, 19th Century; History, 20t

1967
[Comparative study of triglyceridemia, lipemia, glycemia and weight index in patients with high and normal serum uric acid].
    Pathologie-biologie, 1969, Volume: 17, Issue:7

    Topics: Adult; Aged; Blood Glucose; Blood Urea Nitrogen; Body Weight; Cholesterol; Gout; Humans; Hyperlipide

1969
[Pathogenesis of gout].
    Der Internist, 1969, Volume: 10, Issue:7

    Topics: Gout; Humans; Purines; Transferases; Uric Acid

1969
Surgical management of tophaceous gout.
    Clinical orthopaedics and related research, 1970, Volume: 71

    Topics: Calculi; Colchicine; Gout; Hand; Hand Deformities, Acquired; Humans; Methods; Postoperative Care; Ra

1970
Diminished renal urate secretion per nephron as a basis for primary gout.
    Annals of internal medicine, 1970, Volume: 73, Issue:3

    Topics: Adult; Allopurinol; Carbon Isotopes; Computers; Dietary Proteins; Gout; Humans; Inulin; Kidney Funct

1970
[Clinical and biological aspects of dyspurinia with enzyme deficiency].
    Pathologie-biologie, 1970, Volume: 18, Issue:19

    Topics: Adult; Allopurinol; Gout; Guanine; Humans; Hypoxanthines; Joint Diseases; Kidney Calculi; Metabolism

1970
Tophectomy and bone-grafting for extensive tophi of the feet.
    The Journal of bone and joint surgery. American volume, 1971, Volume: 53, Issue:1

    Topics: Ankle; Bone Transplantation; Foot Diseases; Gout; Humans; Male; Metatarsus; Middle Aged; Radiography

1971
A study of familial aggregation of serum uric acid levels in the population of Tecumseh, Michigan, 1959-1960.
    American journal of epidemiology, 1967, Volume: 86, Issue:1

    Topics: Adolescent; Adult; Aged; Analysis of Variance; Child; Child, Preschool; Female; Gout; Humans; Male;

1967
The chronicity of inflammation and its significance in rheumatoid arthritis.
    Annals of the rheumatic diseases, 1968, Volume: 27, Issue:2

    Topics: Adjuvants, Immunologic; Animals; Antibodies; Antigens; Arthritis, Rheumatoid; Autoimmune Diseases; C

1968
[Retroaction effect of certain pyrazolopyrimidines on the metabolism of uric acid].
    Comptes rendus hebdomadaires des seances de l'Academie des sciences. Serie D: Sciences naturelles, 1968, Dec-16, Volume: 267, Issue:25

    Topics: Adult; Aged; Allopurinol; Child; Gout; Humans; Pyrimidines; Uric Acid; Xanthine Oxidase; Xanthines

1968
[Basic therapy of gout by benziodarone].
    La Presse medicale, 1969, Jul-05, Volume: 77, Issue:33

    Topics: Blood Urea Nitrogen; Colchicine; Gout; Humans; Long-Term Care; Uric Acid; Uricosuric Agents

1969
[Allopurinol in the prevention and treatment of urate complications in leukemia].
    Haematologica, 1969, Volume: 54, Issue:1

    Topics: Adolescent; Allopurinol; Gout; Humans; Leukemia; Male; Middle Aged; Uric Acid

1969
[Pathogenesis and therapy of gout].
    Medizinische Klinik, 1971, Apr-23, Volume: 66, Issue:17

    Topics: Allopurinol; Androsterone; Colchicine; Gout; Gymnastics; Humans; Indomethacin; Kinins; Long-Term Car

1971
Comparisons of serum lipid and uric acid content in white and Negro men.
    The American journal of the medical sciences, 1970, Volume: 260, Issue:6

    Topics: ABO Blood-Group System; Adult; Black or African American; Cholesterol; Culture; Diet; Gout; Humans;

1970
Treatment of hyperuricemia and gout.
    The New England journal of medicine, 1972, Feb-03, Volume: 286, Issue:5

    Topics: Colchicine; Female; Gout; Humans; Pregnancy; Pregnancy Complications; Uric Acid

1972
Juvenile gout.
    British medical journal, 1972, Jan-15, Volume: 1, Issue:5793

    Topics: Child; Female; Gout; Humans; Male; Uric Acid

1972
Gout and levodopa.
    The New England journal of medicine, 1972, Feb-17, Volume: 286, Issue:7

    Topics: Dihydroxyphenylalanine; Gout; Humans; Uric Acid

1972
Rarity of X-linked partial hypoxanthine-guanine phosphoribosyltransferase deficiency in a large gouty population.
    Annals of internal medicine, 1972, Volume: 76, Issue:2

    Topics: Adult; Aged; Erythrocytes; Female; Gout; Guanine; Humans; Hypoxanthines; Kidney Calculi; Male; Middl

1972
[Gout attacks and serum uric acid].
    Deutsche medizinische Wochenschrift (1946), 1972, Mar-10, Volume: 97, Issue:10

    Topics: Acute Disease; Gout; Humans; Uric Acid

1972
[Introduction to the study of uric acid crystals in peripheral blood].
    Revista espanola de reumatismo y enfermedades osteoarticulares, 1972, Volume: 15, Issue:1

    Topics: Crystallization; Gout; Humans; Uric Acid

1972
The treatment of gout.
    The Practitioner, 1972, Volume: 208, Issue:243

    Topics: Acute Disease; Allopurinol; Colchicine; Diagnosis, Differential; Female; Gout; Humans; Indomethacin;

1972
Comparison of urinary acidification and ammonium excretion in normal and gouty subjects.
    Metabolism: clinical and experimental, 1972, Volume: 21, Issue:5

    Topics: Acidosis; Acids; Adult; Aged; Ammonia; Ammonium Chloride; Creatinine; Diet; Gout; Humans; Hydrogen-I

1972
Organic acid excretion patterns in gout.
    Annals of the rheumatic diseases, 1972, Volume: 31, Issue:2

    Topics: Acids; Adult; Aged; Carbon Dioxide; Chromatography, Gas; Citrates; Citric Acid Cycle; Fumarates; Glo

1972
Azaguanine-resistance as a manifestation of a new form of metabolic overproduction of uric acid.
    The American journal of medicine, 1972, Volume: 52, Issue:4

    Topics: Adenine; Adolescent; Aminopterin; Azaguanine; Blood Urea Nitrogen; Carbon Isotopes; Cell Line; Creat

1972
The management of gout.
    The Medical journal of Australia, 1972, Mar-04, Volume: 1, Issue:10

    Topics: Acute Disease; Allopurinol; Colchicine; Diet Therapy; Gout; Humans; Indomethacin; Phenylbutazone; Pu

1972
Involvement of the spine in gout. A case report.
    Radiology, 1972, Volume: 103, Issue:2

    Topics: Arthritis, Rheumatoid; Biopsy; Cervical Vertebrae; Diagnosis, Differential; Gout; Humans; Interverte

1972
Medical management of gout.
    Postgraduate medicine, 1972, Volume: 51, Issue:6

    Topics: Adult; Allopurinol; Colchicine; Diet Therapy; Female; Gout; Humans; Kidney Diseases; Male; Middle Ag

1972
[Significance of hyperuricacidemia in psoriasis vulgaris and some other dermatoses].
    Dermatologische Monatschrift, 1972, Volume: 158, Issue:4

    Topics: Adolescent; Adult; Aged; Autoimmune Diseases; Clinical Enzyme Tests; Female; Gout; Humans; Hypersens

1972
Hyperuricemia--pathogenesis and treatment.
    California medicine, 1972, Volume: 116, Issue:6

    Topics: Diet Therapy; Gout; Humans; Kidney; Male; Middle Aged; Nucleotides; Purines; Uric Acid

1972
Uric acid excretion and surgery.
    Annals of the rheumatic diseases, 1972, Volume: 31, Issue:3

    Topics: Adult; Aged; Creatinine; Female; Gout; Humans; Kidney; Male; Metabolic Clearance Rate; Middle Aged;

1972
Gout in a New England town. A prevalence study in Sudbury, Massachusetts.
    Annals of the rheumatic diseases, 1972, Volume: 31, Issue:3

    Topics: Adolescent; Adult; Age Factors; Aged; Female; Gout; Humans; Male; Massachusetts; Middle Aged; New Yo

1972
Mechanism of allopurinol-mediated increase in enzyme activity in man.
    The Journal of clinical investigation, 1972, Volume: 51, Issue:7

    Topics: Allopurinol; Analysis of Variance; Carbon Isotopes; Carboxy-Lyases; Depression, Chemical; Drug Toler

1972
All hyperuricemia is not gout.
    Medical times, 1972, Volume: 100, Issue:5

    Topics: Colchicine; Gout; Humans; Uric Acid

1972
Some genetical aspects of hyperuricaemia and xanthinuria.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1972, Apr-29, Volume: 46, Issue:18

    Topics: Gout; Humans; Lesch-Nyhan Syndrome; Purine-Pyrimidine Metabolism, Inborn Errors; Sex Factors; Uric A

1972
Acute gout in the soft tissues. A case report.
    Journal of the American Podiatry Association, 1972, Volume: 62, Issue:5

    Topics: Acute Disease; Female; Gout; Humans; Middle Aged; Uric Acid

1972
Studies on the mechanism of fructose-induced hyperuricemia in man.
    Metabolism: clinical and experimental, 1972, Volume: 21, Issue:8

    Topics: Adenine; Adenosine Triphosphate; Aged; Allopurinol; Erythrocytes; Fasting; Fructose; Glucose; Gout;

1972
Biochemistry of the X-linked uric aciduria--enzyme defect and its genetic variants.
    Archives of internal medicine, 1972, Volume: 130, Issue:2

    Topics: Athetosis; Gout; Guanine; Humans; Hypoxanthines; Intellectual Disability; Lesch-Nyhan Syndrome; Phos

1972
Clinical features of patients with the "partial" deficiency of the X-linked uricaciduria enzyme.
    Archives of internal medicine, 1972, Volume: 130, Issue:2

    Topics: Adult; Athetosis; Female; Gout; Humans; Hypoxanthines; Intellectual Disability; Lesch-Nyhan Syndrome

1972
[Current status of the problem of gout and hyperuricemic states (clinical case report)].
    Rassegna internazionale di clinica e terapia, 1972, Jun-15, Volume: 52, Issue:11

    Topics: Aged; Foot; Gout; Hand; Humans; Male; Radiography; Uric Acid

1972
Abnormal regulation of glucose and fatty acid metabolism in gout.
    Israel journal of medical sciences, 1972, Volume: 8, Issue:6

    Topics: Dietary Carbohydrates; Fatty Acids; Fatty Acids, Nonesterified; Glucose; Glucose Tolerance Test; Gly

1972
Plasma lipoproteins, glucose tolerance and insulin response in primary gout.
    The American journal of medicine, 1972, Volume: 53, Issue:3

    Topics: Adult; Aged; Blood Protein Disorders; Body Weight; Carbohydrate Metabolism; Cholesterol; Electrophor

1972
Impaired renal clearance of uric acid in chickens having hyperuricemia and articular gout.
    The American journal of physiology, 1972, Volume: 223, Issue:3

    Topics: Animals; Chickens; Female; Gout; Kidney; Kidney Tubules; Secretory Rate; Uric Acid

1972
[Hyperuricemia].
    Nihon rinsho. Japanese journal of clinical medicine, 1972, Volume: 30, Issue:1

    Topics: Animals; Disease Models, Animal; Dogs; Gout; Mice; Uric Acid

1972
Gout while receiving levodopa for Parkinsonism.
    JAMA, 1972, Volume: 219, Issue:1

    Topics: Aged; Dihydroxyphenylalanine; Gout; Humans; Male; Middle Aged; Parkinson Disease; Uric Acid

1972
[Gout, diabetes mellitus and fatty liver].
    Munchener medizinische Wochenschrift (1950), 1972, Feb-04, Volume: 114, Issue:5

    Topics: Adult; Arteriosclerosis; Body Weight; Diabetes Complications; Fatty Liver; Female; Gout; Humans; Hyp

1972
[Gout and pregnancy. An unusual case with severe hyperlipoproteinaemia].
    Munchener medizinische Wochenschrift (1950), 1972, Apr-07, Volume: 114, Issue:14

    Topics: Adult; Blood Protein Electrophoresis; Cholesterol; Female; Gout; Humans; Hyperlipidemias; Lipids; Li

1972
[Missed gout].
    Munchener medizinische Wochenschrift (1950), 1972, Apr-07, Volume: 114, Issue:14

    Topics: Arteriosclerosis; Arthritis, Rheumatoid; Diagnosis, Differential; Gout; Humans; Hypertension; Kidney

1972
Gouty tophus. (Analysis of 132 cases of gout).
    Polish medical journal, 1972, Volume: 11, Issue:2

    Topics: Adult; Crystallization; Female; Gout; Granuloma; Humans; Male; Middle Aged; Tendons; Time Factors; U

1972
[Gout].
    Fortschritte der Medizin, 1972, Jul-20, Volume: 90, Issue:20

    Topics: Chronic Disease; Diet Therapy; Female; Gout; Humans; Male; Middle Aged; Radiography; Uric Acid; Uric

1972
Hyperuricaemia and myocardial infarction.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1972, Mar-25, Volume: 46, Issue:13

    Topics: Female; Gout; Humans; Male; Middle Aged; Myocardial Infarction; Uric Acid

1972
Diagnosis of gout.
    British medical journal, 1972, Oct-07, Volume: 4, Issue:5831

    Topics: Diagnosis, Differential; Female; Gout; Humans; Male; Radiography; Synovial Fluid; Uric Acid

1972
[Milky articular fluid in the course of gout].
    Polski tygodnik lekarski (Warsaw, Poland : 1960), 1972, Aug-28, Volume: 27, Issue:35

    Topics: Gout; Humans; Male; Middle Aged; Synovial Fluid; Uric Acid

1972
[Benziodarone in the basic treatment of gout].
    Revue du rhumatisme et des maladies osteo-articulaires, 1972, Volume: 39, Issue:1

    Topics: Adult; Aged; Benzofurans; Colchicine; Creatinine; Female; Gout; Humans; Kidney Function Tests; Male;

1972
Gouty tophus of the true vocal cord.
    Archives of otolaryngology (Chicago, Ill. : 1960), 1972, Volume: 96, Issue:2

    Topics: Calculi; Gout; Hoarseness; Humans; Laryngeal Diseases; Male; Middle Aged; Uric Acid; Vocal Cords

1972
Should asymptomatic hyperuricaemia be treated?
    The Medical journal of Australia, 1972, Aug-26, Volume: 2, Issue:9

    Topics: Allopurinol; Gout; Humans; Kidney Calculi; Metabolic Diseases; Multiphasic Screening; Uric Acid; Uri

1972
Surgery of tophaceous gout.
    Seminars in arthritis and rheumatism, 1972,Winter, Volume: 1, Issue:3

    Topics: Ankle Joint; Elbow Joint; Finger Joint; Gout; Hip Joint; Humans; Knee Joint; Radiography; Shoulder J

1972
Hyperuricemia in health and disease.
    Seminars in arthritis and rheumatism, 1972,Spring, Volume: 1, Issue:4

    Topics: Arteriosclerosis; Arthritis; Blood Group Antigens; Carbohydrate Metabolism; Diabetes Complications;

1972
Serum urate levels and gout in Australian males.
    The Medical journal of Australia, 1971, May-22, Volume: 1, Issue:21

    Topics: Adult; Alcohol Drinking; Analysis of Variance; Australia; Blood Pressure; Body Height; Body Weight;

1971
Notes on joint diseases. XI. Interpretation of the serum uric acid.
    Northwest medicine, 1971, Volume: 70, Issue:5

    Topics: Female; Gout; Humans; Male; Uric Acid

1971
[Clinical experience in long-term treatment of gout with benzofuran iodine and bromine derivatives].
    Lyon medical, 1971, Apr-25, Volume: 225, Issue:8

    Topics: Adult; Aged; Benzofurans; Bromine; Female; Gout; Humans; Iodine; Male; Middle Aged; Uric Acid; Urico

1971
Juvenile gout.
    Annals of the rheumatic diseases, 1971, Volume: 30, Issue:3

    Topics: Adolescent; Adult; Age Factors; Bacteriuria; Child; Child, Preschool; Creatinine; Female; Gout; Huma

1971
Uric acid clearance in patients with gout and normal subjects.
    Annals of the rheumatic diseases, 1971, Volume: 30, Issue:3

    Topics: Adult; Aged; Body Height; Body Weight; Creatinine; Female; Gout; Humans; Kidney; Male; Metabolic Cle

1971
Microscopic studies on skeletal muscle in gout patients treated with allopurinol.
    The Quarterly journal of medicine, 1971, Volume: 40, Issue:157

    Topics: Adult; Aged; Allopurinol; Biopsy; Birefringence; Female; Freezing; Gout; Histocytochemistry; Humans;

1971
[Is there a specific glomerulitis associated with gouty hyperuricemia? A case].
    Bruxelles medical, 1971, Volume: 51, Issue:5

    Topics: Glomerulonephritis; Gout; Humans; Kidney Failure, Chronic; Male; Middle Aged; Uric Acid

1971
[Etiology of hyperuricemia].
    Prensa medica argentina, 1971, Jun-11, Volume: 57, Issue:15

    Topics: Gout; Humans; Uric Acid

1971
[Uninterrupted therapy of hyperuricemia and gout].
    Reumatizam, 1971, Volume: 18, Issue:3

    Topics: Gout; Humans; Kidney Diseases; Uric Acid; Uricosuric Agents

1971
Renal handling of uric acid in homozygous haemoglobin C disease.
    The African journal of medical sciences, 1971, Volume: 2, Issue:1

    Topics: Africa, Western; Age Factors; Creatinine; Electrophoresis, Paper; Female; Genotype; Glomerular Filtr

1971
[Various types of arthritis associated with psoriasis].
    Seikeigeka. Orthopedic surgery, 1971, Volume: 22, Issue:7

    Topics: Adult; Arthritis; Female; Gout; Hand; Humans; Knee Joint; Male; Middle Aged; Psoriasis; Radiography;

1971
[Clinical symptoms and progress of gout complicated by urolithiasis].
    Fysiatricky a reumatologicky vestnik, 1971, Volume: 49, Issue:4

    Topics: Adult; Aged; Diabetes Complications; Female; Gout; Humans; Hypertension; Male; Middle Aged; Obesity;

1971
[Uric acid abnormalities in juveniles. Peculiarities of the clinical picture].
    Munchener medizinische Wochenschrift (1950), 1971, Mar-26, Volume: 113, Issue:13

    Topics: Adolescent; Adult; Diabetes Complications; Diagnosis, Differential; Fatty Liver; Gout; Humans; Hyper

1971
Plasma lipid levels and platelet adhesiveness in gout.
    Annals of the rheumatic diseases, 1971, Volume: 30, Issue:5

    Topics: Blood Group Antigens; Cholesterol; Fatty Acids, Nonesterified; Glycerides; Gout; Hemoglobinometry; H

1971
[Podagric arthropathy].
    Klinicheskaia meditsina, 1971, Volume: 49, Issue:9

    Topics: Adolescent; Adult; Albuminuria; Algeria; Cardiovascular Diseases; Child; Child, Preschool; Cholester

1971
[Serum uric acid levels and the occurrence of hyperuricemia].
    Zeitschrift fur arztliche Fortbildung, 1971, Jun-15, Volume: 65, Issue:12

    Topics: Adolescent; Adult; Age Factors; Aged; Blood Pressure Determination; Body Weight; Cerebrovascular Dis

1971
["Gout" and angioorganopathies].
    Das Deutsche Gesundheitswesen, 1971, Sep-02, Volume: 26, Issue:36

    Topics: Arteriosclerosis Obliterans; Female; Germany, East; Gout; Humans; Male; Uric Acid; Vascular Diseases

1971
[Severious azotemia and secondary gout in acute leukosis].
    Die Medizinische Welt, 1971, Oct-16, Volume: 42

    Topics: Adolescent; Gout; Humans; Leukemia; Male; Nitrogen; Uremia; Uric Acid

1971
Hyperuricemia and levodopa.
    The New England journal of medicine, 1971, Dec-23, Volume: 285, Issue:26

    Topics: Dihydroxyphenylalanine; Gout; Humans; Parkinson Disease; Uric Acid

1971
Determination of volatile constituents of human blood and tissue specimens by quantitative high resolution mass spectrometry.
    Analytical chemistry, 1971, Volume: 43, Issue:12

    Topics: Allopurinol; Gout; Humans; Hypoxanthines; Mass Spectrometry; Methods; Muscles; Purines; Pyrazoles; P

1971
[Xanthinoxidase inhibitors in hyperuricemia and gout].
    Casopis lekaru ceskych, 1971, Nov-12, Volume: 110, Issue:46

    Topics: Allopurinol; Female; Gout; Humans; Male; Phenylbutazone; Uric Acid

1971
Hyperuricemia and gout in an employee population.
    Journal of occupational medicine. : official publication of the Industrial Medical Association, 1971, Volume: 13, Issue:11

    Topics: Adult; Age Factors; Alcoholism; Coronary Disease; Diabetes Complications; Diuretics; Gout; Humans; H

1971
[Clinico-statistical studies on coronary insufficiency and heart rhythm changes in an aged patient with gout].
    Giornale di gerontologia, 1971, Volume: 19, Issue:4

    Topics: Adult; Aged; Arrhythmias, Cardiac; Arteriosclerosis; Coronary Disease; Gout; Humans; Middle Aged; Ur

1971
[Diet and pharmacologic therapy of hyperuricemias in the aged].
    Giornale di gerontologia, 1971, Volume: 19, Issue:3

    Topics: Aged; Allopurinol; Benzofurans; Diet Therapy; Gout; Humans; Uric Acid

1971
Results of surgical therapy in chronic gouty arthritis.
    Acta orthopaedica Belgica, 1971, Volume: 37, Issue:5

    Topics: Arthritis, Rheumatoid; Chronic Disease; Gout; Humans; Uric Acid

1971
[Physiopathology and treatment of hyperuricemia and gout].
    Rein et foie, maladies de la nutrition; actualites, 1971, Volume: 13

    Topics: Acidosis; Acute Disease; Gout; Humans; Kidney Failure, Chronic; Orotic Acid; Purines; Urate Oxidase;

1971
[Determination of uric acid in blood. Experimental determination; critical studies of the technics and results].
    Quaderni Sclavo di diagnostica clinica e di laboratorio, 1971, Volume: 7, Issue:2

    Topics: Adolescent; Adult; Aspirin; Autoanalysis; Female; Gout; Humans; Indicators and Reagents; Kidney Dise

1971
[Gouty arthropathy (presentation of 2 cases of exceptional seriousness)].
    La Chirurgia degli organi di movimento, 1971, Volume: 60, Issue:3

    Topics: Ear, External; Gout; Humans; Joints; Kidney; Male; Middle Aged; Time Factors; Uric Acid

1971
[Possibilities of the differential diagnosis of effusions from joints].
    Wiener medizinische Wochenschrift (1946), 1971, Oct-23, Volume: 121, Issue:43

    Topics: Acid Phosphatase; Arthritis, Rheumatoid; C-Reactive Protein; Diagnosis, Differential; Gout; Histiocy

1971
Alterations in the activity of hypoxanthine and adenine phosphoribosyltransferase in patients with hyperuricaemia and gout.
    The Quarterly journal of medicine, 1971, Volume: 40, Issue:160

    Topics: Adenine; Adult; Erythrocytes; Gout; Humans; Hypoxanthines; Lesch-Nyhan Syndrome; Pentosyltransferase

1971
[Current trends in gouty arthropathy (clinical correlations and possibilities of surgical treatment)].
    La Chirurgia degli organi di movimento, 1971, Volume: 60, Issue:6

    Topics: Aged; Arthritis, Rheumatoid; Diagnosis, Differential; Exercise Therapy; Gout; Humans; Joints; Lipid

1971
[Studies on uric acid metabolism in man. 2. Studies on uric acid metabolism in patients with hyperuricemia].
    Naika hokan. Japanese archives of internal medicine, 1971, Volume: 18, Issue:10

    Topics: Adolescent; Adult; Aged; Female; Gout; Humans; Male; Metabolic Diseases; Middle Aged; Nephritis; Uri

1971
[Gout].
    Nihon Seikeigeka Gakkai zasshi, 1971, Volume: 45, Issue:8

    Topics: Adolescent; Adult; Aged; Arthritis; Colchicine; Diet Therapy; Female; Gout; Griseofulvin; Humans; Ja

1971
[Coagulation factors in inflammation].
    Arzneimittel-Forschung, 1971, Volume: 21, Issue:11

    Topics: Blood Coagulation; Blood Coagulation Factors; Factor XII; Fibrin; Gout; Humans; Inflammation; Phagoc

1971
[Endocrine components in pathogenesis and clinico-metabolic evolution of dyspurinia in primary gout and its therapy].
    Recenti progressi in medicina, 1971, Volume: 51, Issue:4

    Topics: Anti-Inflammatory Agents; Diet Therapy; Endocrine Glands; Gout; Humans; Purines; Uric Acid; Uricosur

1971
[Hand in uric arthritis].
    Reumatizam, 1969, Volume: 16, Issue:4

    Topics: Aged; Gout; Hand; Humans; Male; Middle Aged; Radiography; Uric Acid

1969
[Uric arthritis and pseudo-uric syndrome. Diagnostic and pathogenetic significance in the study of crystals in synovial fluid].
    Reumatizam, 1969, Volume: 16, Issue:2

    Topics: Calcium; Crystallization; Gout; Humans; Synovial Fluid; Uric Acid

1969
Uric acid in human plasma. IV. Investigations on the interactions between urate and the macromolecular fraction in plasma from healthy individuals and patients with diseases associated with hyperuricemia.
    Scandinavian journal of clinical and laboratory investigation, 1965, Volume: 17, Issue:5

    Topics: Adolescent; Adult; Aged; Blood; Chemical Phenomena; Chemistry; Female; Gout; Hodgkin Disease; Humans

1965
Secondary gout associated with myeloproliferative diseases.
    Arthritis and rheumatism, 1965, Volume: 8, Issue:5

    Topics: Anemia, Hemolytic; Female; Gaucher Disease; Gout; Humans; Kidney Calculi; Leukemia, Myeloid; Male; N

1965
The interrelationship of glycogen storage disease and gout.
    Arthritis and rheumatism, 1965, Volume: 8, Issue:5

    Topics: Adult; Child; Glycogen Storage Disease Type I; Gout; Humans; Kidney Function Tests; Lactates; Uric A

1965
Contraindications and therapeutic results of fasting in obese patients.
    Annals of the New York Academy of Sciences, 1965, Oct-08, Volume: 131, Issue:1

    Topics: Anemia; Anuria; Atrial Flutter; Blood; Diabetes Mellitus; Diet, Sodium-Restricted; Fasting; Female;

1965
Uric acid, gout and public health in the South Pacific.
    The New Zealand medical journal, 1966, Volume: 65, Issue:405

    Topics: Adult; Ethnology; Female; Gout; Humans; Male; Mass Screening; Middle Aged; Pacific Islands; Public H

1966
Suppression of the shunt pathway in primary gout by azathioprine.
    Proceedings of the National Academy of Sciences of the United States of America, 1966, Volume: 55, Issue:3

    Topics: Adenine Nucleotides; Azathioprine; Blood; Enzyme Repression; Glycine; Gout; Guanine Nucleotides; Hum

1966
Lactic acid and hyperuricemia of faulty renal urate transport.
    JAMA, 1967, Jan-09, Volume: 199, Issue:2

    Topics: Female; Glycogen Storage Disease; Gout; Humans; Hypertension; Kidney Diseases; Lactates; Pre-Eclamps

1967
Relationships between glycogen storage disease and tophaceous gout.
    The American journal of medicine, 1967, Volume: 42, Issue:1

    Topics: Adult; Female; Glucose Tolerance Test; Glycogen Storage Disease Type I; Gout; Humans; Inulin; Lactat

1967
Metabolic effects of allopurinol and allo-xanthine.
    Annals of the rheumatic diseases, 1966, Volume: 25, Issue:6 Suppl

    Topics: Adult; Allopurinol; Drug Tolerance; Enzyme Therapy; Female; Gout; Humans; Leukemia, Myeloid, Acute;

1966
Biochemical considerations of the renal damage of gout.
    Annals of the rheumatic diseases, 1966, Volume: 25, Issue:6 Suppl

    Topics: Allopurinol; Gout; Humans; Hypoxanthines; Kidney Calculi; Leukemia, Lymphoid; Uric Acid; X-Ray Diffr

1966
Two rare causes of secondary gouty arthritis.
    The American journal of roentgenology, radium therapy, and nuclear medicine, 1967, Volume: 100, Issue:3

    Topics: Adult; Glomerulonephritis; Glycogen Storage Disease; Gout; Humans; Male; Phosphates; Radiography; Re

1967
The clinical significance of hyperuricemia.
    The Medical annals of the District of Columbia, 1967, Volume: 36, Issue:4

    Topics: Arthritis; Gout; Humans; Uric Acid; Uricosuric Agents

1967
Allopurinol in treatment of patients with gout and chronic renal failure.
    The New Zealand medical journal, 1967, Volume: 66, Issue:421

    Topics: Adult; Aged; Allopurinol; Female; Gout; Humans; Hypoxanthines; Kidney Failure, Chronic; Kidney Funct

1967
[Hyperuricemia with arthritis symptoms in the course of acute myeloid leukemia].
    Polski tygodnik lekarski (Warsaw, Poland : 1960), 1967, Dec-04, Volume: 22, Issue:49

    Topics: Gout; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Uric Acid

1967
Gout of the temporomandibular joint. Report of three cases.
    Oral surgery, oral medicine, and oral pathology, 1969, Volume: 27, Issue:2

    Topics: Colchicine; Diagnosis, Differential; Gout; Humans; Male; Middle Aged; Probenecid; Temporomandibular

1969
[Gout in the evolution of Von Gierke's disease].
    Minerva medica, 1969, May-12, Volume: 60, Issue:38

    Topics: Adolescent; Adult; Allopurinol; Child; Female; Glycogen Storage Disease; Glycogen Storage Disease Ty

1969
[Gout as a complication of adult glycogen storage disease].
    Archiv fur klinische Medizin, 1969, Volume: 216, Issue:2

    Topics: Adolescent; Adult; Blood Glucose; Female; Glycogen Storage Disease Type I; Gout; Humans; Lactates; M

1969
Allopurinol in the treatment of gout.
    The Nova Scotia medical bulletin, 1969, Volume: 48, Issue:4

    Topics: Adult; Aged; Allopurinol; Female; Gout; Humans; Male; Sulfinpyrazone; Uric Acid

1969
[Diagnostic value of hyperuricemia].
    La Presse medicale, 1968, Dec-14, Volume: 76, Issue:49

    Topics: Adult; Allopurinol; Child; Diabetes Mellitus; Female; Glycogen Storage Disease; Gout; Humans; Hypert

1968
Roentgenographic skeletal changes in the glycogen storage diseases.
    The American journal of roentgenology, radium therapy, and nuclear medicine, 1969, Volume: 107, Issue:4

    Topics: Adolescent; Adult; Age Factors; Body Height; Bone and Bones; Child; Child, Preschool; Female; Glycog

1969
Metabolic aberrations in gout.
    Clinical orthopaedics and related research, 1970, Volume: 71

    Topics: Female; Glycogen Storage Disease Type I; Gout; Humans; Kidney; Kidney Calculi; Kidney Diseases; Male

1970
Gout in Chinese patients.
    New York state journal of medicine, 1970, Dec-01, Volume: 70, Issue:23

    Topics: Adult; Aged; Asian People; China; Gout; Humans; Male; Middle Aged; Uric Acid

1970
Drug-induced hyperuricemia prevented by probenecid.
    Journal of medicine, 1971, Volume: 2, Issue:1

    Topics: Adult; Aged; Female; Gout; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Probenecid;

1971
[Serum and urine uric acid content in hemoblastoses and gout as well as its modification by allopurinol].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1971, Apr-01, Volume: 26, Issue:7

    Topics: Allopurinol; Bone Marrow Diseases; Gout; Hodgkin Disease; Humans; Leukemia; Leukemia, Myeloid; Plasm

1971
The relative contributions of tubular reabsorption and secretion to urate excretion in lead nephropathy.
    Australian and New Zealand journal of medicine, 1971, Volume: 1, Issue:4

    Topics: Absorption; Adult; Female; Glomerular Filtration Rate; Gout; Humans; Insulin; Kidney Failure, Chroni

1971
[Deposition of crystalline uric acid in the kidneys].
    Zentralblatt fur allgemeine Pathologie u. pathologische Anatomie, 1966, Volume: 109, Issue:5

    Topics: Aged; Gout; Humans; Hydronephrosis; Kidney Diseases, Cystic; Male; Pyelonephritis; Uremia; Uric Acid

1966
[Treatment of gout and of certain rheumatisms with hyperuricemia caused by benziodarone].
    Revue du rhumatisme et des maladies osteo-articulaires, 1968, Volume: 35, Issue:3

    Topics: Adult; Arthritis, Rheumatoid; Benzofurans; Female; Gout; Humans; Male; Rheumatic Diseases; Sulfinpyr

1968
[Comparative examinations of concrements of the human kidney by scanning electron microscopy].
    Virchows Archiv. A, Pathology. Pathologische Anatomie, 1969, Volume: 347, Issue:1

    Topics: Adult; Calcinosis; Crystallography; Gout; Humans; Infant, Newborn; Infant, Newborn, Diseases; Infarc

1969
[Early diagnosis of gout].
    Hospital (Rio de Janeiro, Brazil), 1969, Volume: 76, Issue:2

    Topics: Feeding Behavior; Gout; Humans; Uric Acid

1969
[Gout. Clinical analysis of 300 cases of urate gout].
    Rein et foie, maladies de la nutrition; actualites, 1968, Volume: 11

    Topics: Adult; Age Factors; Biopsy; Colchicine; Creatinine; Diagnosis, Differential; Diet; Diuretics; Female

1968
[Effects of benziodarone on hyperuricemia].
    AMB : revista da Associacao Medica Brasileira, 1969, Volume: 15, Issue:9

    Topics: Adult; Aged; Arthritis; Benzofurans; Female; Gout; Humans; Male; Middle Aged; Uric Acid

1969
[Basic concepts of physics for the interpretation of the curative effect of radioactive mineral waters].
    La Clinica terapeutica, 1969, Aug-15, Volume: 50, Issue:3

    Topics: Female; Genital Diseases, Female; Gout; Humans; Hypertension; Infertility, Female; Joint Diseases; M

1969
[Gout from the view of a special hospital for rheumatic patients].
    Wiener klinische Wochenschrift, 1971, Mar-19, Volume: 83, Issue:11

    Topics: Acute Disease; Adolescent; Adult; Aged; Austria; Child; Cholesterol; Colchicine; Colic; Diabetes Com

1971
Nephrotoxic effect of MSG (monosodium glutamate) in the chicken.
    Japanese journal of medical science & biology, 1971, Volume: 24, Issue:5

    Topics: Acute Kidney Injury; Animals; Atrophy; Body Weight; Chickens; Edema; Extremities; Gallbladder; Gluta

1971
The inflammatory reaction to microcrystalline sodium urate.
    Arthritis and rheumatism, 1965, Volume: 8, Issue:5

    Topics: Animals; Calcinosis; Crystallization; Dogs; Gout; History of Medicine; Humans; Inflammation; Leukocy

1965
Ultrastructural study of leucocytes and urates in gouty arthritis.
    Annals of the rheumatic diseases, 1967, Volume: 26, Issue:5

    Topics: Adult; Aged; Cytoplasm; Female; Gout; Humans; Leukocytes; Male; Microscopy, Electron; Microscopy, Fl

1967
[Orotic acid and hyperuricemia caused by fructose].
    Bollettino della Societa italiana di biologia sperimentale, 1969, Jan-31, Volume: 45, Issue:2

    Topics: Adult; Female; Fructose; Gout; Humans; Male; Orotic Acid; Uric Acid

1969
[Allpurinol in the treatment of hyperuricemia and chronic gout].
    Revista clinica espanola, 1969, Mar-31, Volume: 112, Issue:6

    Topics: Adult; Aged; Allopurinol; Arthritis; Female; Gout; Humans; Male; Middle Aged; Uric Acid; Xanthine Ox

1969
Nail changes in gout.
    British medical journal, 1969, Sep-27, Volume: 3, Issue:5673

    Topics: Adult; Aged; Gout; Humans; Middle Aged; Nails; Uric Acid

1969
Gout.
    The Journal of the Royal College of General Practitioners, 1969, Volume: 18, Issue:88 Suppl 3

    Topics: Anti-Inflammatory Agents; Gout; Humans; Uric Acid; Uricosuric Agents

1969
What to do about an elevated uric acid level.
    GP, 1969, Volume: 40, Issue:6

    Topics: Gout; Metabolic Diseases; Uric Acid

1969
Medical conference from the University of New Mexico School of Medicine. About gout.
    Rocky Mountain medical journal, 1969, Volume: 66, Issue:11

    Topics: Aged; Arthritis; Gout; Humans; Joints; Male; Metabolism, Inborn Errors; Uric Acid

1969
Gout and hyperuricemia in a Finnish rural population.
    Acta rheumatologica Scandinavica, 1969, Volume: 15, Issue:2

    Topics: Adolescent; Adult; Age Factors; Aged; Colchicine; Female; Finland; Gout; Humans; Male; Middle Aged;

1969
[Juvenile hyperuricemia, gout and cerebral palsy (Lesch-Nyhan syndrome)].
    Zeitschrift fur Kinderheilkunde, 1969, Oct-09, Volume: 107, Issue:1

    Topics: Adolescent; Allopurinol; Athetosis; Cerebral Palsy; Chorea; Gout; Humans; Male; Uric Acid

1969
[Apparently primary kidney disease revealing latent error of purine metabolism in 2 adolescents].
    Annales de pediatrie, 1969, Oct-02, Volume: 16, Issue:10

    Topics: Adolescent; Adult; Allopurinol; Diet Therapy; Diet, Sodium-Restricted; Diuretics; Gout; Humans; Kidn

1969
[Clinical findings and therapy of gout with special reference to the metabolic effects of sulfinpyrazone (Anturan) and allopurinol (Zyloric)].
    Wiener klinische Wochenschrift, 1969, Nov-07, Volume: 81, Issue:45

    Topics: Allopurinol; Diabetes Mellitus; Gout; Humans; Hypertension; Kidney Diseases; Male; Sulfinpyrazone; U

1969
[The daily rhythm of renal uric acid excretion in patients with gout].
    Wiener Zeitschrift fur innere Medizin und ihre Grenzgebiete, 1969, Volume: 50, Issue:9

    Topics: Adult; Calcium; Chlorides; Circadian Rhythm; Creatinine; Gout; Humans; Middle Aged; Natriuresis; Pho

1969
[Articular manifestations in hyperlipidemia].
    Revue du rhumatisme et des maladies osteo-articulaires, 1969, Volume: 36, Issue:10

    Topics: Adolescent; Adult; Aged; Arthritis; Arthritis, Rheumatoid; Child; Child, Preschool; Female; Gout; Hu

1969
[The hypouricemic effect of benziodarone].
    La Clinica terapeutica, 1969, Volume: 51, Issue:2

    Topics: Adult; Aged; Benzofurans; Female; Gout; Humans; Male; Middle Aged; Uric Acid

1969
[Uricemia in chronic arteriopathies of limbs].
    Revue de l'atherosclerose et des arteriopathies peripheriques, 1969, Volume: 11, Issue:1

    Topics: Arteries; Arteriosclerosis; Arteritis; Chronic Disease; Extremities; Female; Gout; Humans; Leg; Male

1969
Allopurinol and urolithiasis.
    The Journal of urology, 1969, Volume: 102, Issue:6

    Topics: Allopurinol; Female; Gout; Humans; Male; Uric Acid; Urinary Calculi

1969
[Xanthine oxidase activity in the jejunal mucosa of patients with gout].
    Bollettino della Societa italiana di biologia sperimentale, 1969, Jun-30, Volume: 45, Issue:12

    Topics: Gout; Humans; Intestinal Mucosa; Jejunum; Uric Acid; Xanthine Oxidase

1969
[Familial encephalopathy with hyperuricemia. A study of purine metabolism and therapeutic attempts].
    Archives francaises de pediatrie, 1969, Volume: 26, Issue:2

    Topics: Brain Diseases; Child, Preschool; Electroencephalography; Follow-Up Studies; Gout; Humans; Infant; K

1969
Total heart block as a complication of gout.
    Cardiologia, 1969, Volume: 54, Issue:6

    Topics: Electrocardiography; Gout; Heart Block; Heart Conduction System; Humans; Male; Middle Aged; Uric Aci

1969
[Proliferative synovitis after intra-articular injections of micro-crystals of sodium urate in rabbits. Preliminary note].
    Revue du rhumatisme et des maladies osteo-articulaires, 1969, Volume: 36, Issue:9

    Topics: Animals; Arthritis, Rheumatoid; Freund's Adjuvant; Gout; Injections, Intra-Articular; Male; Rabbits;

1969
[Renal scintiscanning and curves of urinary and hematic activity in the renal, peripheral and hepatic areas in presenile and senile gout].
    Giornale di gerontologia, 1969, Volume: 17, Issue:7

    Topics: Aged; Blood Circulation; Diuresis; Female; Gout; Humans; Kidney; Kidney Diseases; Kidney Function Te

1969
[Gout and trauma].
    Munchener medizinische Wochenschrift (1950), 1969, Aug-08, Volume: 111, Issue:32

    Topics: Adult; Athletic Injuries; Diagnosis, Differential; Female; Gout; Humans; Male; Middle Aged; Occupati

1969
[The uric acid contents of surgically excised gout nodes and bursae with gouty changes].
    Munchener medizinische Wochenschrift (1950), 1969, Aug-08, Volume: 111, Issue:32

    Topics: Aged; Bursa, Synovial; Bursitis; Elbow; Fingers; Gout; Humans; Male; Spectrophotometry; Toes; Uric A

1969
[Inhibition of endogenous synthesis of uric acid with allopurinol in patients with gout and urate diathesis].
    Munchener medizinische Wochenschrift (1950), 1969, Aug-08, Volume: 111, Issue:32

    Topics: Adult; Aged; Allopurinol; Disease Susceptibility; Gout; Humans; Kidney Calculi; Kidney Diseases; Kid

1969
[Clinical biochemistry of gout].
    Deutsches medizinisches Journal, 1969, May-27, Volume: 20, Issue:10

    Topics: Adenine Nucleotides; Benzofurans; Fatty Acids; Gout; Guanine; Humans; Hypoxanthines; Pentosephosphat

1969
Hyperuricaemia in northern Finland. An epidemiological study of serum uric acid in rural, urban and hospital populations.
    Annals of clinical research, 1969, Volume: 1

    Topics: Adolescent; Adult; Age Factors; Aged; Anemia; Body Weight; Cerebrovascular Disorders; Cholesterol; C

1969
[Gout and hyperuricemia associated with lead poisoning].
    Revue du rhumatisme et des maladies osteo-articulaires, 1969, Volume: 36, Issue:4

    Topics: Adult; Glomerular Filtration Rate; Gout; Humans; Kidney Failure, Chronic; Kidney Tubules; Lead Poiso

1969
[Clinical trial of L2214 in the treatment of gout or of rheumatologic syndromes associated with hyperuricemia].
    Journal belge de rhumatologie et de medecine physique = Belgisch tijdschrift voor reumatologie en fysische geneeskunde, 1969, Volume: 24, Issue:6

    Topics: Adult; Aged; Arthritis, Rheumatoid; Benzofurans; Female; Gout; Humans; Male; Middle Aged; Uric Acid;

1969
[Blood uric acid in chronic arteriopathies of the limbs. 3. Statistics on a continuous series of 200 personal cases. IV. Prospects of research].
    Revue de l'atherosclerose et des arteriopathies peripheriques, 1969, Volume: 11, Issue:3

    Topics: Adult; Age Factors; Aged; Arteriosclerosis; Arteritis; Body Weight; Cholesterol; Chronic Disease; Go

1969
[Clinical and biological effects of a new uric acid lowering substance (benziodaronum) in gout. Results of a 2-year-long study].
    Verhandlungen der Deutschen Gesellschaft fur Rheumatologie, 1969, Volume: 1

    Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents; Benzofurans; Chronic Disease; Gout; Humans; Ma

1969
[Uricemia in chronic arteriopathy of the extremities. 3. Statistical data on a continuous series of 200 personal cases. 4. Research perspectives].
    Revue de l'atherosclerose et des arteriopathies peripheriques, 1969, Volume: 11, Issue:3

    Topics: Adolescent; Adult; Aged; Arteritis; Gout; Humans; Leg; Male; Middle Aged; Uric Acid; Vascular Diseas

1969
[Recent progress in the knowledge of the mechanism of hyperuricemia and gout].
    Revista espanola de reumatismo y enfermedades osteoarticulares, 1969, Volume: 13, Issue:4

    Topics: Gout; Humans; Uric Acid

1969
Effects of allopurinol on hyperuricemia secondary to fasting.
    Metabolism: clinical and experimental, 1970, Volume: 19, Issue:1

    Topics: Allopurinol; Drug Tolerance; Fasting; Gout; Humans; Kidney; Uric Acid

1970
Reduction of serum uric acid in young men during physical training.
    The American journal of cardiology, 1970, Volume: 25, Issue:1

    Topics: Adolescent; Adult; Age Factors; Body Height; Body Surface Area; Body Weight; Coronary Disease; Gout;

1970
Notes on joint diseases. I. Gout is not hyperuricemia.
    Northwest medicine, 1970, Volume: 69, Issue:2

    Topics: Diagnosis, Differential; Gout; Humans; Uric Acid

1970
Long-term use of allopurinol in the treatment of gout.
    Annals of the rheumatic diseases, 1970, Volume: 29, Issue:1

    Topics: Adolescent; Aged; Allopurinol; Colic; Female; Gout; Humans; Kidney Diseases; Male; Middle Aged; Sulf

1970
Disorder of purine metabolism due to partial deficiency of hypoxanthine-guanine phosphoribosyltransferase. A study of a family.
    The American journal of medicine, 1970, Volume: 48, Issue:2

    Topics: Adolescent; Adult; Carbon Isotopes; Child; Child, Preschool; Female; Glucosyltransferases; Glutamina

1970
Benign symmetric lipomatosis (Launois-Bensaude adenolipomatosis) with gout and hyperlipoproteinemia.
    The American journal of medicine, 1970, Volume: 48, Issue:2

    Topics: Adult; Azathioprine; Blood Protein Electrophoresis; Carbon Isotopes; Female; Glucose Tolerance Test;

1970
The binding of urate to plasma proteins determined by means of equilibrium dialysis.
    The Journal of laboratory and clinical medicine, 1970, Volume: 75, Issue:3

    Topics: Aspirin; Blood Proteins; Dialysis; Gout; Humans; Hydrogen-Ion Concentration; Hypoxanthines; Kidney D

1970
[Benziodarone in the treatment of hyperuricemia].
    La Clinica terapeutica, 1970, Mar-15, Volume: 52, Issue:5

    Topics: Benzofurans; Gout; Humans; Purines; Uric Acid

1970
[Treatment of uric lithiasis].
    Therapeutique (La Semaine des hopitaux), 1970, Volume: 46, Issue:3

    Topics: Bicarbonates; Diet Therapy; Gout; Humans; Lactates; Uric Acid; Urinary Calculi

1970
[Dietetics in gout].
    Therapeutique (La Semaine des hopitaux), 1970, Volume: 46, Issue:4

    Topics: Diet Therapy; Gout; Humans; Uric Acid

1970
[Gout].
    Les Cahiers de medecine, 1970, Jun-15, Volume: 11, Issue:7

    Topics: Adolescent; Adult; Child; Child, Preschool; Chronic Disease; Female; Gout; Humans; Male; Middle Aged

1970
[At the borders of gout: procedure to follow in the case of isolated hyperuricemia].
    Les Cahiers de medecine, 1970, Jun-15, Volume: 11, Issue:7

    Topics: Gout; Humans; Uric Acid

1970
[Indications of basic treatment of gout].
    Les Cahiers de medecine, 1970, Jun-15, Volume: 11, Issue:7

    Topics: Gout; Uric Acid; Uricosuric Agents

1970
Uric acid lithiasis--a study of six hundred and twenty-two patients.
    Urologia internationalis, 1970, Volume: 25, Issue:1

    Topics: Adult; Ethnicity; Female; Gout; Humans; Hyperparathyroidism; Israel; Male; Myeloproliferative Disord

1970
[Gout].
    Naika. Internal medicine, 1970, Volume: 25, Issue:6

    Topics: Colchicine; Gout; Humans; Uric Acid; Uricosuric Agents

1970
Diagnosis of gout.
    Clinical orthopaedics and related research, 1970, Volume: 71

    Topics: Albuminuria; Arthritis; Arthritis, Rheumatoid; Colchicine; Colic; Diagnosis, Differential; Gout; Hum

1970
Pathogenesis and treatment of the acute attack of gout.
    Clinical orthopaedics and related research, 1970, Volume: 71

    Topics: Acute Disease; Animals; Calculi; Colchicine; Crystallization; Dogs; Gout; Humans; Inflammation; Leuk

1970
Pathogenesis and medical management of chronic gouty arthritis.
    Clinical orthopaedics and related research, 1970, Volume: 71

    Topics: Allopurinol; Chronic Disease; Colchicine; Gout; Humans; Joints; Kidney; Probenecid; Sulfinpyrazone;

1970
Visceral (nonarticular) manifestations associated with gout.
    Clinical orthopaedics and related research, 1970, Volume: 71

    Topics: Acute Kidney Injury; Arteriosclerosis; Gout; Humans; Hypertension; Kidney Calculi; Radiography; Uric

1970
Gouty arthritis of the spine.
    Clinical orthopaedics and related research, 1970, Volume: 71

    Topics: Autopsy; Biopsy; Calculi; Cervical Vertebrae; Colchicine; Female; Gout; Humans; Lumbar Vertebrae; Ma

1970
[Renal excretion of uric acid in various conditions inducing hyperuricemia].
    Il Policlinico. Sezione pratica, 1970, Feb-23, Volume: 77, Issue:8

    Topics: Adolescent; Adult; Aged; Female; Gout; Humans; Hydrochlorothiazide; Hypertension, Renal; Kidney Fail

1970
Non-traumatic necrosis of the femoral head. I. Relation of altered hemostasis to etiology.
    The Journal of bone and joint surgery. American volume, 1970, Volume: 52, Issue:2

    Topics: Alcohol Drinking; Blood Coagulation Disorders; Blood Coagulation Tests; Blood Platelet Disorders; Fe

1970
Chlorthalidone in the long term therapy of patients with hypertension.
    Internationale Zeitschrift fur klinische Pharmakologie, Therapie, und Toxikologie. International journal of clinical pharmacology, therapy, and toxicology, 1970, Volume: 3, Issue:1

    Topics: Adult; Aged; Blood Chemical Analysis; Blood Glucose; Blood Pressure; Carbohydrate Metabolism, Inborn

1970
Effects of colchicine in rats with urate crystal-induced inflammation.
    Pharmacology, 1970, Volume: 3, Issue:4

    Topics: Adrenal Glands; Animals; Body Weight; Colchicine; Crystallization; Edema; Gout; Inflammation; Male;

1970
[Biological manifestations of gout].
    Lille medical : journal de la Faculte de medecine et de pharmacie de l'Universite de Lille, 1970, Volume: 15, Issue:1

    Topics: Blood Sedimentation; Female; Fibrinogen; Gout; Humans; Male; Uric Acid

1970
Mechanism of excessive purine biosynthesis in hypoxanthine-guanine phosphoribosyltransferase deficiency.
    The Journal of clinical investigation, 1970, Volume: 49, Issue:5

    Topics: Adult; Allopurinol; Athetosis; Carbon Isotopes; Child; Chorea; Compulsive Behavior; Deficiency Disea

1970
Diuretics and hyperuricemia.
    The New England journal of medicine, 1970, Apr-30, Volume: 282, Issue:18

    Topics: Allopurinol; Diuretics; Gout; Humans; Hypertension; Uric Acid; Uricosuric Agents

1970
[On the hypouricemic and uricuric action of benziodarone].
    Minerva medica, 1970, Apr-25, Volume: 61, Issue:33

    Topics: Benzofurans; Gout; Humans; Middle Aged; Uric Acid

1970
[Enzymopathic gout. Dyspurinia due to hypoxanthine-guanine-phosphoribosyl-transferase deficiency. Occurrence and clinical characteristics of enzyme repression].
    La Presse medicale, 1970, Mar-28, Volume: 78, Issue:16

    Topics: Adenine; Adult; Age Factors; Allopurinol; Enzyme Repression; Female; Gout; Guanine; Humans; Hypoxant

1970
Allopurinol: alteration in pyrimidine metabolism in man.
    Science (New York, N.Y.), 1970, Jul-24, Volume: 169, Issue:3943

    Topics: Allopurinol; Carboxy-Lyases; Depression, Chemical; Erythrocytes; Gout; Humans; Hypoxanthines; Kineti

1970
[Circadian rhythm in uricemia].
    Prensa medica argentina, 1970, Apr-03, Volume: 57, Issue:5

    Topics: Circadian Rhythm; Female; Gout; Humans; Male; Sex Factors; Uric Acid

1970
[Gout and the excretion of uric acid in sweat].
    Revue du rhumatisme et des maladies osteo-articulaires, 1970, Volume: 37, Issue:5

    Topics: Gout; Hot Temperature; Humans; Sports; Sweat; Sweating; Uric Acid

1970
Effect of glycine loading on plasma and urinary uric acid and amino acids in normal and gouty subjects.
    The American journal of medicine, 1970, Volume: 49, Issue:3

    Topics: Adult; Aged; Amino Acids; Glycine; Gout; Humans; Hydrogen-Ion Concentration; Kidney; Male; Middle Ag

1970
The interaction of monosodium urate with connective tissue components.
    The Journal of clinical investigation, 1970, Volume: 49, Issue:10

    Topics: Animals; Binding Sites; Buffers; Cartilage; Cattle; Chondroitin; Crystallization; Dialysis; Gout; Hy

1970
Pitfalls in the diagnosis of hyperuricemic arthritis.
    Journal of the American Podiatry Association, 1970, Volume: 60, Issue:9

    Topics: Arthritis; Foot Diseases; Gout; Humans; Uric Acid

1970
[Symptomless hyperuricemia].
    Deutsche medizinische Wochenschrift (1946), 1970, Sep-25, Volume: 95, Issue:39

    Topics: Gout; Humans; Metabolic Diseases; Uric Acid

1970
Clinical significance of hyperuricemia in routinely screened hospitalized men.
    JAMA, 1970, Jan-12, Volume: 211, Issue:2

    Topics: Acidosis; Adult; Aged; Autoanalysis; Diuretics; Gout; Heart Failure; Hospitalization; Humans; Kidney

1970
[Biochemistry of gout, with special reference to the etiology of hyperuricemia].
    Geka chiryo. Surgical therapy, 1970, Volume: 22, Issue:3

    Topics: Gout; Humans; Nucleotides; Purines; Uric Acid

1970
[Determination of uric acid in gout].
    Geka chiryo. Surgical therapy, 1970, Volume: 22, Issue:3

    Topics: Adolescent; Adult; Age Factors; Aged; Child; Child, Preschool; Female; Gout; Humans; Male; Methods;

1970
[Heredity of gout and experimental gout].
    Geka chiryo. Surgical therapy, 1970, Volume: 22, Issue:3

    Topics: Adolescent; Adult; Age Factors; Aged; Animals; Birds; Child; Child, Preschool; Female; Gout; Humans;

1970
[Clinical studies of gout. Problems in the areas outside the cities].
    Geka chiryo. Surgical therapy, 1970, Volume: 22, Issue:3

    Topics: Adult; Diagnosis, Differential; Gout; Humans; Japan; Male; Rural Health; Uric Acid

1970
[Diagnosis of gout].
    Geka chiryo. Surgical therapy, 1970, Volume: 22, Issue:3

    Topics: Colchicine; Diagnosis, Differential; Gout; Humans; Joint Diseases; Uric Acid

1970
[Treatment of gout].
    Geka chiryo. Surgical therapy, 1970, Volume: 22, Issue:3

    Topics: Allopurinol; Analgesics; Gout; Humans; Uric Acid; Uricosuric Agents

1970
[Therapeutic agents for gout effecting the kidney].
    Geka chiryo. Surgical therapy, 1970, Volume: 22, Issue:3

    Topics: Allopurinol; Gout; Humans; Kidney; Phenylbutazone; Uric Acid; Uricosuric Agents

1970
[Physiopathology of articular manifestations of gout].
    La Presse thermale et climatique, 1970, Volume: 107, Issue:2

    Topics: Gout; Humans; Joint Diseases; Uric Acid

1970
[Treatment of hyperuricemia with benziodarone].
    La Presse thermale et climatique, 1970, Volume: 107, Issue:2

    Topics: Benzofurans; Gout; Humans; Male; Uric Acid; Uricosuric Agents

1970
[Crenotherapy of gout and hyperuricemia].
    La Presse thermale et climatique, 1970, Volume: 107, Issue:2

    Topics: Balneology; Diuresis; Gout; Humans; Mineral Waters; Uric Acid

1970
[Will the gout be eliminated?].
    La Presse thermale et climatique, 1970, Volume: 107, Issue:2

    Topics: Allopurinol; Gout; Humans; Uric Acid; Uricosuric Agents

1970
Serum uric acid and achievement--an explanation.
    JAMA, 1970, Jun-15, Volume: 212, Issue:11

    Topics: Achievement; Gout; Humans; Male; Personality; Social Class; Uric Acid

1970
The influence of allopurinol on the course of gout. A study of 28 cases.
    Reumatologia, 1970, Volume: 8, Issue:3

    Topics: Age Factors; Allopurinol; Colchicine; Drug Synergism; Gout; Humans; Probenecid; Uric Acid

1970
The epidemiology of hyperuricemia.
    Bulletin on the rheumatic diseases, 1970, Volume: 20, Issue:8

    Topics: Age Factors; Body Weight; Ethnicity; Female; Gout; Humans; Indians, North American; Male; Sex Factor

1970
[Diagnosis and therapy of uric arthritis].
    Wiener medizinische Wochenschrift (1946), 1970, Oct-31, Volume: 120, Issue:44

    Topics: Acute Disease; Adult; Allopurinol; Anti-Inflammatory Agents; Chronic Disease; Diagnosis, Differentia

1970
Preliminary results from high-resolution analyses of ultraviolet-absorbing and carbohydrate constituents in several pathologic body fluids.
    Clinical chemistry, 1970, Volume: 16, Issue:8

    Topics: Adolescent; Adult; Alkaptonuria; Allopurinol; Amniotic Fluid; Athetosis; Carbohydrates; Chorea; Chro

1970
Diuretics and hyperuricemia.
    The New England journal of medicine, 1970, Nov-19, Volume: 283, Issue:21

    Topics: Diuretics; Gout; Humans; Uric Acid

1970
[Further studies on the use of orotic acid in the treatment of gout].
    Rassegna internazionale di clinica e terapia, 1970, Apr-30, Volume: 50, Issue:8

    Topics: Gout; Humans; Orotic Acid; Uric Acid

1970
Clinical survey of 354 patients with gout.
    Annals of the rheumatic diseases, 1970, Volume: 29, Issue:5

    Topics: Adolescent; Adult; Age Factors; Aged; Alcohol Drinking; Blood Urea Nitrogen; Body Weight; Child; Com

1970
Uric acid metabolism in starvation.
    Annals of the rheumatic diseases, 1970, Volume: 29, Issue:5

    Topics: Allopurinol; Female; Gout; Humans; Male; Obesity; Starvation; Uric Acid

1970
A new assay method for hypoxanthine-guanine phosphoribosyltransferase.
    The Journal of laboratory and clinical medicine, 1970, Volume: 76, Issue:5

    Topics: Adenine; Adenine Nucleotides; Athetosis; Carbon Isotopes; Chorea; Chromatography; Compulsive Behavio

1970
[Effect of benzbromarone on serum uric acid level and uric acid excretion of patients with gout].
    Deutsche medizinische Wochenschrift (1946), 1970, Nov-27, Volume: 95, Issue:48

    Topics: Adult; Aged; Benzofurans; Creatinine; Female; Glomerular Filtration Rate; Gout; Humans; Kidney Funct

1970
Uricaemic pleurisy.
    The British journal of clinical practice, 1970, Volume: 24, Issue:10

    Topics: Adult; Aged; Analysis of Variance; Asthma; Gout; Humans; Male; Middle Aged; Pleurisy; Uric Acid

1970
[Role of carbohydrates in the diet of gout patients].
    Bollettino della Societa italiana di biologia sperimentale, 1970, May-30, Volume: 46, Issue:10

    Topics: Adult; Dietary Carbohydrates; Fructose; Glucose; Gout; Humans; Male; Sucrose; Uric Acid

1970
[Glucose and hyperuricemia caused by fructose].
    Bollettino della Societa italiana di biologia sperimentale, 1970, May-30, Volume: 46, Issue:10

    Topics: Adult; Fructose; Glucose; Gout; Humans; Male; Sucrose; Uric Acid

1970
Partial deficiency of hypoxanthine-guanine phosphoribosyltransferase associated with gout and uric acid lithiasis.
    Revue europeenne d'etudes cliniques et biologiques. European journal of clinical and biological research, 1970, Volume: 15, Issue:9

    Topics: Adult; Aged; Allopurinol; Calculi; Erythrocytes; Genes, Recessive; Gout; Guanine; Heterozygote; Huma

1970
[Dynamics of metabolism in gout].
    Medizinische Klinik, 1970, Apr-17, Volume: 65, Issue:16

    Topics: Adult; Aged; Blood Glucose; Carbohydrate Metabolism; Diabetes Mellitus; Fasting; Fatty Acids; Female

1970
[Uric acid in the diagnosis of gout].
    Revista brasileira de medicina, 1970, Volume: 27, Issue:12

    Topics: Colorimetry; Gout; Humans; Methods; Uric Acid

1970
[Allopurinol in the treatment of gout].
    Revista medica de Chile, 1970, Volume: 98, Issue:9

    Topics: Adult; Aged; Allopurinol; Female; Gout; Humans; Male; Middle Aged; Probenecid; Uric Acid

1970
[Metabolism relations between psoriasis vulgaris and secondary gout].
    Klinische Wochenschrift, 1970, Dec-15, Volume: 48, Issue:24

    Topics: Blood Glucose; Gout; Humans; Phosphates; Psoriasis; Uric Acid

1970
[Effect of allopurinol (Zyloric) on uric acid, creatinine, fasting blood sugar and plasma lipids in patients with gout].
    Wiener klinische Wochenschrift, 1970, Jan-30, Volume: 82, Issue:5

    Topics: Adult; Allopurinol; Blood Glucose; Cholesterol; Creatinine; Fasting; Fatty Acids, Nonesterified; Gou

1970
[Pre-senile and senile gout].
    Giornale di gerontologia, 1970, Volume: 18, Issue:9

    Topics: Age Factors; Aged; Female; Gout; Humans; Kidney; Male; Uric Acid

1970
[Benziodarone therapy in hyperuricemia in the aged].
    Giornale di gerontologia, 1970, Volume: 18, Issue:9

    Topics: Age Factors; Aged; Cardiovascular Diseases; Gout; Humans; Kidney Failure, Chronic; Respiratory Insuf

1970
[Current problems of gout].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1970, May-15, Volume: 25, Issue:10

    Topics: Blood Glucose; Cholesterol; Coronary Disease; Diabetes Complications; Female; Gout; Humans; Hypercho

1970
[Clinical experiences with the citrate granulate Blemaren in the prevention and therapy of uric acid lithiasis].
    Zeitschrift fur Urologie und Nephrologie, 1970, Volume: 63, Issue:1

    Topics: Bicarbonates; Calcium; Citrates; Female; Gout; Humans; Kidney Pelvis; Magnesium; Male; Middle Aged;

1970
[Treatment of gout by inhibitors of uric acid synthesis].
    Acquisitions medicales recentes, 1970

    Topics: Drug Synergism; Gout; Humans; Pyrazoles; Pyrimidines; Uric Acid; Uricosuric Agents

1970
[Etiopathogenesis of gout].
    Journal de medecine de Lyon, 1970, Jan-05, Volume: 51, Issue:178

    Topics: Female; Gout; Humans; Male; Uric Acid

1970
[Clinical, radiological and diagnostic study of articular gout].
    Journal de medecine de Lyon, 1970, Jan-05, Volume: 51, Issue:178

    Topics: Diagnosis, Differential; Female; Gout; Humans; Male; Uric Acid

1970
[Inhibition of endogenous uric acid synthesis with allopurinol in gout and urate diathesis. Remarks on E. Holländer and P. Schwarczmann, Münch. Med. Wschr. 3 (1969) 32, 1623-1626].
    Munchener medizinische Wochenschrift (1950), 1970, Dec-04, Volume: 112, Issue:49

    Topics: Allopurinol; Gout; Humans; Purine-Pyrimidine Metabolism, Inborn Errors; Urate Oxidase; Uric Acid

1970
[Diabetes mellitus, hyperlipemia, fatty liver, hypertension in primary gout and their influencing by benzbromaronum].
    Munchener medizinische Wochenschrift (1950), 1970, Feb-06, Volume: 112, Issue:6

    Topics: Adult; Benzofurans; Blood Glucose; Blood Sedimentation; Colchicine; Creatinine; Diabetes Mellitus; E

1970
Executive hyperuricemia.
    Journal of occupational medicine. : official publication of the Industrial Medical Association, 1971, Volume: 13, Issue:1

    Topics: Administrative Personnel; Arthritis; Gout; Humans; Male; Uric Acid; Urinary Calculi

1971
[Ocular findings in gout and hyperuricemia].
    Wiener klinische Wochenschrift, 1971, Jan-22, Volume: 83, Issue:3

    Topics: Adult; Eye Diseases; Gout; Humans; Hypertension; Male; Middle Aged; Uric Acid

1971
[Alterations of lipid metabolism in primary gout and hyperuircemia].
    Deutsche medizinische Wochenschrift (1946), 1971, Mar-19, Volume: 96, Issue:12

    Topics: Adult; Aged; Blood Glucose; Cholesterol; Diabetes Mellitus; Fatty Acids; Fatty Acids, Nonesterified;

1971
[The kidneys and hyperuricemia. Therapeutic problems].
    Therapeutique (La Semaine des hopitaux), 1971, Volume: 47, Issue:2

    Topics: Gout; Humans; Hypertension; Kidney Diseases; Uric Acid

1971
[Uricosuric effect of a phenylbutazone derivative, cetophenylbutazone].
    Revue du rhumatisme et des maladies osteo-articulaires, 1971, Volume: 38, Issue:1

    Topics: Female; Glomerular Filtration Rate; Gout; Humans; Male; Middle Aged; Phenylbutazone; Uric Acid; Uric

1971
[Microcrystalline arthritis: the gout crisis].
    Lyon medical, 1971, Jan-24, Volume: 225, Issue:2

    Topics: Acute Disease; Gout; Humans; Leukocytes; Synovial Fluid; Uric Acid

1971
[Ultrastructural study of intraleukocyte urates in the gout crisis].
    Lyon medical, 1971, Jan-24, Volume: 225, Issue:2

    Topics: Acute Disease; Gout; Humans; Leukocytes; Microscopy, Electron; Synovial Fluid; Uric Acid

1971
Phosphoribosyl transferase activity in normal subjects, gout patients, and children with mental retardation.
    Journal of neurology, neurosurgery, and psychiatry, 1971, Volume: 34, Issue:1

    Topics: Adenine; Adolescent; Adult; Child; Child, Preschool; Creatinine; Erythrocytes; Female; Gout; Guanine

1971
Hyperuricemia, a concomitant of congenital vasopressin-resistant diabetes insipidus in the adult.
    The New England journal of medicine, 1971, May-13, Volume: 284, Issue:19

    Topics: Adult; Aminohippuric Acids; Arginine; Child; Child, Preschool; Creatinine; Diabetes Insipidus; Diet;

1971
[Acute kidney failure and hyperuricemia].
    Die Medizinische Welt, 1971, Apr-24, Volume: 17

    Topics: Acidosis, Respiratory; Acute Kidney Injury; Allopurinol; Animals; Anuria; Dogs; Gout; Humans; Hypoxa

1971
An unusual form of renal disease associated with gout and hypertension.
    Journal of clinical pathology, 1971, Volume: 24, Issue:4

    Topics: Adolescent; Adult; Aged; Biopsy; Cerebrovascular Disorders; Chromosome Aberrations; Chromosome Disor

1971
Hyperuricemia and chronic renal disease.
    Journal of chronic diseases, 1971, Volume: 23, Issue:10

    Topics: Adult; Aged; Alcohol Drinking; Chronic Disease; Creatinine; Diabetes Mellitus; Diuretics; Female; Go

1971
[Genetic problems concerning gout].
    Les Cahiers de medecine, 1971, Apr-30, Volume: 12, Issue:6

    Topics: Adult; Aged; Female; Gout; Humans; Male; Metabolism, Inborn Errors; Middle Aged; Uric Acid

1971
Hyperuricaemia and gout.
    Reports on rheumatic diseases, 1971, Volume: 43

    Topics: Acute Disease; Adult; Arthritis; Chronic Disease; Diagnosis, Differential; Female; Gout; Humans; Mal

1971
[Gout in young patients].
    Les Cahiers de medecine, 1971, May-15, Volume: 12, Issue:7

    Topics: Adolescent; Adult; Age Factors; Diabetes Complications; Fatty Liver; Gout; Humans; Hyperlipidemias;

1971
A quantitative study of skeletal-muscle purines and pyrazolo(3,4-d)pyrimidines in gout patients treated with allopurinol.
    Clinical science, 1971, Volume: 41, Issue:2

    Topics: Allopurinol; Biopsy; Gout; Humans; Hypoxanthines; Mass Spectrometry; Muscles; Purines; Pyrazoles; Py

1971
[Gout].
    Zeitschrift fur Allgemeinmedizin, 1971, Feb-20, Volume: 47, Issue:5

    Topics: Dietary Fats; Gout; Humans; Indomethacin; Radiography; Uric Acid; Uricosuric Agents; Urinary Calculi

1971
The causes of nonazotemic hyperuricemia.
    American journal of clinical pathology, 1971, Volume: 55, Issue:6

    Topics: Adult; Age Factors; Animals; Arteriosclerosis; Blood Urea Nitrogen; Computers; Coronary Disease; Dia

1971
Triglyceride concentrations in primary gout and gout of chronic lead nephropathy.
    Metabolism: clinical and experimental, 1971, Volume: 20, Issue:8

    Topics: Adult; Aged; Alcoholic Beverages; Cholesterol; Gout; Humans; Kidney Failure, Chronic; Lead Poisoning

1971
[Renal manifestations of hyperuricemia].
    Les Cahiers de medecine, 1971, May-30, Volume: 12, Issue:8

    Topics: Gout; Humans; Kidney Diseases; Uric Acid

1971
Hyperlipoproteinaemia in gout.
    Annals of the rheumatic diseases, 1971, Volume: 30, Issue:2

    Topics: Adult; Aged; Allopurinol; Blood Protein Disorders; Blood Protein Electrophoresis; Cholesterol; Gout;

1971
[Too much and too little uric acid].
    Die Medizinische Welt, 1971, Aug-07, Volume: 31

    Topics: Gout; Humans; Uric Acid

1971
Hyperuricemia and levodopa.
    The New England journal of medicine, 1971, Oct-07, Volume: 285, Issue:15

    Topics: Aged; Dihydroxyphenylalanine; Female; Gout; Humans; Male; Parkinson Disease; Uric Acid

1971
[The kidney and hyperuricemia].
    La Presse medicale, 1971, Apr-17, Volume: 79, Issue:19

    Topics: Diuretics; Gout; Humans; Kidney Calculi; Kidney Diseases; Kidney Failure, Chronic; Kidney Function T

1971
[X-ray morphology of uric arthritis].
    Das Deutsche Gesundheitswesen, 1971, Mar-25, Volume: 26, Issue:13

    Topics: Adult; Aged; Chronic Disease; Female; Gout; Humans; Male; Middle Aged; Radiography; Uric Acid

1971
[Simple determination of purines by preparative thin-layer chromatography].
    Zeitschrift fur klinische Chemie und klinische Biochemie, 1971, Volume: 9, Issue:1

    Topics: Athetosis; Chorea; Chromatography, Thin Layer; Compulsive Behavior; Diagnosis, Differential; Gout; H

1971
[Liver pathology in gout].
    Medizinische Klinik, 1971, May-21, Volume: 66, Issue:21

    Topics: Adult; Biopsy; Blood Glucose; Blood Protein Electrophoresis; Body Weight; Cholesterol; Diabetes Comp

1971
High dose frusemide in the treatment of hypertension in chronic renal insufficiency and of terminal renal failure.
    Postgraduate medical journal, 1971, Volume: 47

    Topics: Adolescent; Adult; Creatine; Creatinine; Diuresis; Female; Furosemide; Gout; Humans; Hypertension, R

1971
Rheumatoid arthritis and gout in Hiroshima and Nagasaki, Japan. A prevalence and incidence study.
    Journal of chronic diseases, 1971, Volume: 23, Issue:9

    Topics: Adult; Age Factors; Aged; Arthritis, Rheumatoid; Blood Pressure; Educational Status; Environment; Fa

1971
[Synovial fluid in arthritis urica. Sodium urate crystals as a key to the diagnosis and pathogenesis].
    Bratislavske lekarske listy, 1971, Volume: 55, Issue:5

    Topics: Diagnosis, Differential; Female; Gout; Humans; Inflammation; Male; Synovial Fluid; Synovitis; Uric A

1971
[Gout and hyperlipemia].
    Wiener klinische Wochenschrift, 1967, Mar-24, Volume: 79, Issue:12

    Topics: Body Height; Body Weight; Cholesterol; Fatty Acids, Nonesterified; Gout; Humans; Hyperlipidemias; Ma

1967
[Secondary gout in skin diseases].
    Archiv fur klinische und experimentelle Dermatologie, 1967, Volume: 230, Issue:2

    Topics: Aged; Gout; Humans; Male; Middle Aged; Mycosis Fungoides; Nucleoproteins; Psoriasis; Uric Acid

1967
[The mechanism of urinary calculus formation from the internist's point of view].
    Urologia internationalis, 1967, Volume: 22, Issue:6

    Topics: Gout; Humans; Kidney Tubules; Leukemia; Uric Acid; Urinary Calculi

1967
Prophylaxis of idiopathic and gouty uric acid lithiasis by allopurinol.
    Urologia internationalis, 1967, Volume: 22, Issue:6

    Topics: Adult; Aged; Allopurinol; Female; Gout; Humans; Hyperparathyroidism; Kidney Tubules; Male; Middle Ag

1967
[Urate phagocytosis of granulocytes and its influencing by colchicine. Simultaneously a methodical contribution on the determination of their phagocytosis activity in vitro].
    Zeitschrift fur Rheumaforschung, 1967, Volume: 26, Issue:1

    Topics: Arthritis; Colchicine; Gout; Humans; In Vitro Techniques; Leukocytes; Neutrophils; Phagocytosis; Uri

1967
[Hints to the recognition of gout].
    Die Medizinische Welt, 1967, Feb-04, Volume: 5

    Topics: Age Factors; Arthritis; Diagnosis, Differential; Gout; Humans; Radiography; Sex Factors; Uric Acid

1967
[Allopurinol].
    Schweizerische medizinische Wochenschrift, 1967, Dec-09, Volume: 97, Issue:49

    Topics: Allopurinol; Gout; Humans; Kidney Diseases; Uric Acid; Xanthine Oxidase

1967
[Hyperuricemia. IX. Complications of hyperuricemia. On the treatment of hyperuricemia].
    Revue du rhumatisme et des maladies osteo-articulaires, 1967, Volume: 34, Issue:11

    Topics: Allopurinol; Gout; Humans; Joint Diseases; Kidney Calculi; Orotic Acid; Time Factors; Uric Acid; Uri

1967
[Allopurinol in hyperuricemia].
    Ugeskrift for laeger, 1967, Jul-27, Volume: 129, Issue:30

    Topics: Allopurinol; Gout; Humans; Male; Methods; Uric Acid

1967
[Ethamide--a drug for the therapy of gout and other conditions associated with accumulation of uric acid in the body].
    Sovetskaia meditsina, 1967, Volume: 30, Issue:2

    Topics: Adult; Aged; Female; Gout; Humans; Male; Probenecid; Toe Joint; Uric Acid

1967
[Treatment of the gouty diathesis with a xanthine oxidase inhibitor. A clinical trial of allopurinol].
    Ugeskrift for laeger, 1967, Feb-23, Volume: 129, Issue:8

    Topics: Aged; Allopurinol; Drug Synergism; Gout; Humans; Male; Middle Aged; Phenylbutazone; Sulfinpyrazone;

1967
[Renal function in uric gout. Analysis of 270 cases].
    Revista espanola de reumatismo y enfermedades osteoarticulares, 1967, Volume: 12, Issue:3

    Topics: Gout; Humans; Kidney; Uric Acid

1967
[Effects of allopurinol on plasma lipid fractions in gout patients].
    Atti della Accademia dei fisiocritici in Siena. Sezione medico-fisica, 1967, Volume: 16, Issue:2

    Topics: Adult; Aged; Allopurinol; Gout; Humans; Lipids; Male; Middle Aged; Uric Acid

1967
[Hypouricemizing effect of benzbromarone. Study of 24 cases (preliminary results)].
    Acta clinica Belgica, 1967, Volume: 22, Issue:5

    Topics: Adult; Aged; Allopurinol; Benzofurans; Female; Gout; Humans; Male; Middle Aged; Uric Acid

1967
[Treatment of hyperuricemia].
    Therapie der Gegenwart, 1967, Volume: 106, Issue:7

    Topics: Allopurinol; Gout; Humans; Male; Middle Aged; Uric Acid

1967
[Influence of Schroth's cure on the metabolism of uric acid].
    Fysiatricky a reumatologicky vestnik, 1967, Volume: 45, Issue:6

    Topics: Czechoslovakia; Diet Therapy; Folklore; Gout; History, 18th Century; History, 19th Century; Humans;

1967
[Acute kidney failure during drug-induced litholysis in urate calculi formation and in gout].
    Munchener medizinische Wochenschrift (1950), 1967, Jun-30, Volume: 109, Issue:26

    Topics: Acute Kidney Injury; Citrates; Drug Prescriptions; Gout; Humans; Male; Middle Aged; Solutions; Uric

1967
[Laboratory problems in gout].
    Fysiatricky a reumatologicky vestnik, 1967, Volume: 45, Issue:4

    Topics: Gout; Humans; Methods; Uric Acid

1967
Effects of azathiprine in a disorder of uric acid metabolism and cerebral function.
    The Journal of pediatrics, 1968, Volume: 72, Issue:1

    Topics: Adult; Azathioprine; Blood Platelets; Brain Diseases; Child; Gout; Hematocrit; Hemoglobinometry; Hum

1968
Modification of uricaemia and the excretion of uric acid nitrogen by an enzyme of fungal origin.
    Nature, 1968, Jan-06, Volume: 217, Issue:5123

    Topics: Allantoin; Aspergillus; Gout; Humans; Urate Oxidase; Uric Acid

1968
An enzymatic basis for variation in response to allopurinol. Hypoxanthine-guanine phosphoribosyltransferase deficiency.
    The New England journal of medicine, 1968, Feb-08, Volume: 278, Issue:6

    Topics: Adenine; Adolescent; Adult; Aged; Allopurinol; Child; Creatinine; Glucosyltransferases; Gout; Guanin

1968
Regulation of uric acid formation.
    The New England journal of medicine, 1968, Feb-08, Volume: 278, Issue:6

    Topics: Allopurinol; Glucosyltransferases; Gout; Humans; Hypoxanthines; Purines; Uric Acid; Xanthine Oxidase

1968
Hyperlipidemia in primary gout.
    Metabolism: clinical and experimental, 1968, Volume: 17, Issue:3

    Topics: Adult; Age Factors; Aged; Arteriosclerosis; Cholesterol; Fatty Acids; Female; Gout; Humans; Hyperlip

1968
Sulphobromophthalein retention in gout and asymptomatic hyperuricaemia.
    Annals of the rheumatic diseases, 1968, Volume: 27, Issue:1

    Topics: Adolescent; Adult; Age Factors; Aged; Alcoholic Beverages; Female; Gout; Humans; Liver; Liver Diseas

1968
An enzyme defect in metabolic gout.
    Annals of internal medicine, 1968, Volume: 68, Issue:3

    Topics: Feedback; Glucosyltransferases; Gout; Humans; Hypoxanthines; Purines; Uric Acid

1968
Chondrocalcinosis.
    British medical journal, 1968, Mar-02, Volume: 1, Issue:5591

    Topics: Calcinosis; Calcium Phosphates; Cartilage, Articular; Diagnosis, Differential; Female; Gout; Humans;

1968
Ultrastructural studies in hypertension. 3. Gouty nephropathy.
    Laboratory investigation; a journal of technical methods and pathology, 1968, Volume: 18, Issue:2

    Topics: Adult; Aged; Animals; Biopsy; Gout; Humans; Hypertension; Kidney; Kidney Glomerulus; Kidney Tubules;

1968
Comparison of uric acid levels in some Oriental and Caucasian groups unselected as to gout or hyperuricemia.
    Arthritis and rheumatism, 1968, Volume: 11, Issue:2

    Topics: Adolescent; Adult; Age Factors; Asian People; Colorimetry; Ethnicity; Female; Gout; Humans; Malaysia

1968
Suppression of glycine-15N incorporation into urinary uric acid by adenine-8-13C in normal and gouty subjects.
    The Journal of clinical investigation, 1968, Volume: 47, Issue:5

    Topics: Adenine Nucleotides; Carbon Isotopes; Glycine; Gout; Humans; Nitrogen; Purines; Uric Acid

1968
[Secondary gout, 6-years after acute renal failure].
    Deutsche medizinische Wochenschrift (1946), 1968, May-03, Volume: 93, Issue:18

    Topics: Accidents, Traffic; Acute Kidney Injury; Adult; Blood Pressure; Creatinine; Electrolytes; Erythrocyt

1968
Hypoglycemic and uricosuric properties of acetohexamide and hydroxyhexamide.
    Metabolism: clinical and experimental, 1968, Volume: 17, Issue:4

    Topics: Acetohexamide; Adolescent; Adult; Age Factors; Aged; Blood Glucose; Cyclohexanes; Diabetes Complicat

1968
Renal excretion of hydrogen in primarygout.
    Metabolism: clinical and experimental, 1968, Volume: 17, Issue:4

    Topics: Acidosis; Acids; Adult; Ammonia; Ammonium Chloride; Bicarbonates; Diet; Dietary Proteins; Gout; Huma

1968
Basic sciences in medicine: the example of gout.
    The New England journal of medicine, 1968, Jun-13, Volume: 278, Issue:24

    Topics: Allopurinol; Colchicine; Female; Gout; Humans; Male; Metabolism, Inborn Errors; Purines; Sex Factors

1968
Studies in primary hyperuricaemia. II. Glucose tolerance before and after prednisolone sensitization. IV. Tolbutamide response and fasting serum cholesterol and triglycerides.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1968, Apr-06, Volume: 42, Issue:14

    Topics: Adult; Aged; Cholesterol; Fatty Acids, Nonesterified; Glucose Tolerance Test; Gout; Humans; Middle A

1968
Long-term treatment of gout with "allopurinol".
    Acta rheumatologica Scandinavica, 1968, Volume: 14, Issue:1

    Topics: Allopurinol; Chronic Disease; Colchicine; Colorimetry; Female; Gout; Humans; Male; Purines; Sulfinpy

1968
Studies in primary hyperuricaemia. 3. The conversion of 14C to breath 14CO2 from glucose-1-14C and glucose-6-14C in hyperuricaemia and gout.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1968, May-11, Volume: 42, Issue:19

    Topics: Adult; Blood Glucose; Carbon Dioxide; Carbon Isotopes; Chromatography, Thin Layer; Diabetes Mellitus

1968
Defects in purine metabolism and neurologic disease.
    Bulletin of the Los Angeles neurological societies, 1968, Volume: 33, Issue:2

    Topics: Brain; Cerebellum; Child; Glucosyltransferases; Gout; Hemorrhage; Humans; Male; Necrosis; Nervous Sy

1968
Renal urate deposits in chronic renal insufficiency.
    Acta medica Scandinavica, 1968, Volume: 183, Issue:3

    Topics: Adult; Aged; Gout; Humans; Kidney; Kidney Failure, Chronic; Male; Uric Acid

1968
[Secondary gout, 6 years after acute renal failure].
    Deutsche medizinische Wochenschrift (1946), 1968, May-03, Volume: 93, Issue:18

    Topics: Accidents, Traffic; Acute Kidney Injury; Adult; Blood Pressure; Creatinine; Electrolytes; Erythrocyt

1968
Variations in purine metabolism of cultured skin fibroblasts from patients with gout.
    The Journal of clinical investigation, 1968, Volume: 47, Issue:7

    Topics: Adenine Nucleotides; Adolescent; Adult; Culture Techniques; Feedback; Fibroblasts; Gout; Humans; Pur

1968
Renal clearance of oxipurinol, the chief metabolite of allopurinol.
    The American journal of medicine, 1968, Volume: 45, Issue:1

    Topics: Allopurinol; Animals; Dogs; Gout; Humans; Kidney; Kidney Function Tests; Probenecid; Spectrophotomet

1968
Congenital hyperuricosuria. Associated radiologic features.
    Radiologic clinics of North America, 1968, Volume: 6, Issue:2

    Topics: Cerebral Palsy; Child; Finger Injuries; Gout; Hip Dislocation; Humans; Intellectual Disability; Male

1968
[Early diagnosis and early treatment of gout].
    Hippokrates, 1968, Jan-15, Volume: 39, Issue:1

    Topics: Adult; Allopurinol; Colchicine; Diagnosis, Differential; Female; Gout; Humans; Male; Middle Aged; Ur

1968
[Primary uratic gout in identical twins in the pathologic-anatomical picture].
    Bratislavske lekarske listy, 1968, Volume: 49, Issue:1

    Topics: Diseases in Twins; Gout; Humans; Male; Middle Aged; Uric Acid

1968
[Gout in women].
    Zeitschrift fur Rheumaforschung, 1968, Volume: 27, Issue:5

    Topics: Adolescent; Adult; Age Factors; Aged; Blood Pressure; Calculi; Female; Germany, West; Gout; Humans;

1968
Intranuclear urate crystals in corneal epithelium.
    Archives of ophthalmology (Chicago, Ill. : 1960), 1968, Volume: 80, Issue:3

    Topics: Aged; Body Temperature; Cell Nucleus; Cornea; Crystallization; Epithelium; Gout; Histocytochemistry;

1968
Asymptomatic hyperuricemia in flight personnel.
    Aerospace medicine, 1968, Volume: 39, Issue:8

    Topics: Adult; Aerospace Medicine; Arthritis; Gout; Humans; Male; Middle Aged; Preventive Medicine; United S

1968
Etiology and treatment of gout--modern concepts.
    Journal of the American Geriatrics Society, 1968, Volume: 16, Issue:6

    Topics: Allopurinol; Colchicine; Crystallization; Diagnosis, Differential; Diet Therapy; Gout; Humans; Indom

1968
Allopurinol and iron metabolism in man.
    Blood, 1968, Volume: 32, Issue:3

    Topics: Alkaline Phosphatase; Allopurinol; Arthritis, Rheumatoid; Blood Cell Count; Blood Protein Electropho

1968
C14 studies of uric acid turnover.
    Annals of the rheumatic diseases, 1968, Volume: 27, Issue:5

    Topics: Acute Kidney Injury; Allopurinol; Carbon Isotopes; Gout; Humans; Mathematics; Uric Acid

1968
Urine uric acid to creatinine rtio--a screening test for inherited disorders of purine metabolism. Phosphoribosyltransferase (PRT) deficiency in X-linked cerebral palsy and in a variant of gout.
    The Journal of pediatrics, 1968, Volume: 73, Issue:4

    Topics: Adolescent; Adult; Age Factors; Aged; Cerebral Palsy; Child; Child, Preschool; Creatinine; Diet; Fem

1968
The relationship of serum uric acid to risk factors in coronary heart disease.
    The American journal of medicine, 1968, Volume: 45, Issue:4

    Topics: Age Factors; Blood Glucose; Blood Pressure; Body Composition; Body Weight; Cholesterol; Coronary Dis

1968
Management of gouty arthritis and hyperuricemia.
    GP, 1968, Volume: 38, Issue:4

    Topics: Anti-Infective Agents, Urinary; Gout; Humans; Male; Middle Aged; Uric Acid; Uricosuric Agents

1968
The clinical differentiation of lead gout from primary gout.
    Arthritis and rheumatism, 1968, Volume: 11, Issue:5

    Topics: Alcohol Drinking; Body Height; Body Weight; Child Behavior Disorders; Diagnosis, Differential; Envir

1968
A short trial assessment of uricosuric therapy in gout.
    Australasian annals of medicine, 1968, Volume: 17, Issue:3

    Topics: Adult; Aged; Allopurinol; Female; Glomerular Filtration Rate; Gout; Humans; Male; Middle Aged; Probe

1968
Estimation of uricosuric activity of sulfinpyrazone in healthy adults.
    Zeitschrift fur Rheumaforschung, 1968, Volume: 27, Issue:3

    Topics: Adult; Creatinine; Gout; Humans; Sulfinpyrazone; Uric Acid

1968
[On the influence of Anturan on ric acid and plasma lipids in patients with gout].
    Wiener klinische Wochenschrift, 1968, Jun-14, Volume: 80, Issue:24

    Topics: Adult; Age Factors; Aged; Animals; Body Weight; Cholesterol; Diet Therapy; Fatty Acids, Nonesterifie

1968
Avascular necrosis of the femoral head in a patient with gout.
    JAMA, 1968, Jan-01, Volume: 203, Issue:1

    Topics: Adult; Amputation, Surgical; Bone Diseases; Femur Head; Gout; Hip Joint; Humans; Male; Necrosis; Rad

1968
Compensated polarized light microscopy. Identification of crystals in synovial fluids from gout and pseudogout.
    JAMA, 1968, Feb-12, Volume: 203, Issue:7

    Topics: Calcinosis; Calcium Phosphates; Cholesterol; Diagnosis, Differential; Gout; Humans; Joint Diseases;

1968
Sickle cell anemia and hyperuricemia.
    JAMA, 1968, Nov-11, Volume: 206, Issue:7

    Topics: Anemia, Sickle Cell; Erythropoiesis; Female; Gout; Humans; Middle Aged; Uric Acid

1968
Determination of uric acid levels in uraemia by enzymatic and colorimetric techniques.
    Journal of clinical pathology, 1968, Volume: 21, Issue:2

    Topics: Acute Kidney Injury; Colorimetry; Gout; Humans; Kidney Failure, Chronic; Methods; Phosphotungstic Ac

1968
[Gout and diabetes. II. Diabetes and its relation to saluretic-induced diabetes and hyperuricemia].
    Schweizerische medizinische Wochenschrift, 1968, Mar-02, Volume: 98, Issue:9

    Topics: Aged; Carbohydrate Metabolism; Chlorothiazide; Cholesterol; Diabetes Mellitus; Female; Gout; Humans;

1968
[Allopurinol in the treatment of gout: initial results].
    Revue du rhumatisme et des maladies osteo-articulaires, 1968, Volume: 35, Issue:6

    Topics: Adult; Aged; Allopurinol; Female; Gastrointestinal Diseases; Gout; Humans; Kidney Failure, Chronic;

1968
[Gout and development of urate calculi in the urinary tract].
    Wiener medizinische Wochenschrift (1946), 1968, May-04, Volume: 118, Issue:18

    Topics: Allopurinol; Citrus; Flavonoids; Gout; Humans; Male; Middle Aged; Piperazines; Purines; Uric Acid; U

1968
[Primary skin gout. Observations and contribution on the clinical course of gout].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1968, Volume: 19, Issue:7

    Topics: Acrodermatitis; Aged; Arthritis, Rheumatoid; Diagnosis, Differential; Erysipelas; Gout; Humans; Male

1968
[On clinical experiences with 2-ethyl-3(4-hydroxy-3,5-dibrombenzoyl)-benzofuran ("Benzbromaron") in the therapy of gout and hyperuricemia].
    Wiener medizinische Wochenschrift (1946), 1968, Nov-23, Volume: 118, Issue:47

    Topics: Adult; Aged; Benzofurans; Colchicine; Female; Gout; Humans; Male; Metabolism, Inborn Errors; Middle

1968
[Allopurinol in the treatment of gout].
    Duodecim; laaketieteellinen aikakauskirja, 1968, Volume: 84, Issue:17

    Topics: Adult; Aged; Allopurinol; Female; Gout; Humans; Male; Middle Aged; Uric Acid

1968
[On the therapy of gout].
    Wiener klinische Wochenschrift, 1968, Oct-04, Volume: 80, Issue:40

    Topics: Creatinine; Female; Gout; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Piperazines; Uric A

1968
[Gout and plasma lipid values].
    Wiener klinische Wochenschrift, 1968, Jul-19, Volume: 80, Issue:29

    Topics: Adult; Age Factors; Aged; Blood Sedimentation; Cholesterol; Fatty Acids, Nonesterified; Gout; Humans

1968
[Positive rheumatic serology in gouty arthritis].
    Zeitschrift fur Rheumaforschung, 1968, Volume: 27, Issue:11

    Topics: Agglutination Tests; Arthritis, Rheumatoid; Gout; Humans; Latex Fixation Tests; Male; Methods; Middl

1968
[Allopurinol in the treatment of gout].
    Zeitschrift fur Rheumaforschung, 1968, Volume: 27, Issue:11

    Topics: Adult; Allopurinol; Gout; Humans; Indomethacin; Male; Middle Aged; Probenecid; Uric Acid

1968
[Therapy of gout in surgical patients].
    Medizinische Klinik, 1968, Nov-22, Volume: 63, Issue:47

    Topics: Achilles Tendon; Allopurinol; Cortisone; Diagnosis, Differential; Gout; Humans; Joint Diseases; Male

1968
[Study of amplivix in gout patients and nongouty arthrosic hyperuricemics].
    Rhumatologie, 1968, Volume: 20, Issue:8

    Topics: Adult; Aged; Benzofurans; Female; Gout; Humans; Joint Diseases; Male; Middle Aged; Uric Acid

1968
[On pyelogram changes in gout].
    Wiener medizinische Wochenschrift (1946), 1968, Nov-30, Volume: 118, Issue:48

    Topics: Adult; Female; Gout; Humans; Kidney Pelvis; Male; Sex Factors; Uric Acid; Urography

1968
Gout in India. (A study of clinical features).
    The Journal of the Association of Physicians of India, 1968, Volume: 16, Issue:12

    Topics: Adolescent; Adult; Female; Gout; Humans; Hypertension; India; Male; Middle Aged; Uremia; Uric Acid

1968
Development of urate crystals in tophus.
    Yokohama medical bulletin, 1968, Volume: 19, Issue:4

    Topics: Animals; Cattle; Crystallization; Gallbladder; Gelatin; Gout; Guinea Pigs; Humans; Hydrogen-Ion Conc

1968
[The inhibition of uric acid synthesis with Allopurinol].
    Orvosi hetilap, 1968, Oct-13, Volume: 109, Issue:41

    Topics: Adult; Aged; Allopurinol; Arthritis, Rheumatoid; Female; Gout; Humans; Kidney Calculi; Male; Middle

1968
[Benziodarone in the treatment of primary hyperuricemias].
    Minerva medica, 1968, Dec-12, Volume: 59, Issue:99

    Topics: Adult; Aged; Benzofurans; Gout; Humans; Middle Aged; Uric Acid; Uricosuric Agents

1968
The interpretation of radioactive uric acid turnover data.
    Strahlentherapie. Sonderbande, 1968, Volume: 67

    Topics: Arthritis, Rheumatoid; Biological Assay; Carbon Isotopes; Gout; Humans; Hypertension; Myocardial Inf

1968
A comparative study of the xanthine oxidase inhibitors allopurinol and oxipurinol in man.
    Clinical science, 1968, Volume: 35, Issue:2

    Topics: Adult; Aged; Allopurinol; Gout; Humans; Hypoxanthines; Male; Middle Aged; Purines; Pyrazoles; Pyrimi

1968
Nyhan-Lesch syndrome and juvenile gout (2 cases).
    Proceedings of the Royal Society of Medicine, 1968, Volume: 61, Issue:11 Part 1

    Topics: Adult; Child, Preschool; Deficiency Diseases; Gout; Guanine; Humans; Hypoxanthines; Kidney Failure,

1968
[Purine metabolism and the possible pathogenesis of hyperuricemia and gout].
    Lakartidningen, 1968, Feb-07, Volume: 65, Issue:6

    Topics: Alanine Transaminase; Gout; Humans; Purines; Uric Acid

1968
[Kidneys, uric acid secretion and hyperuricemia].
    Lakartidningen, 1968, Feb-07, Volume: 65, Issue:6

    Topics: Glutaminase; Gout; Humans; Kidney; Pyelonephritis; Uric Acid

1968
[Therapy of hyperuricemia with allopurinol].
    Lakartidningen, 1968, Feb-07, Volume: 65, Issue:6

    Topics: Adult; Aged; Allopurinol; Female; Gout; Humans; Kidney Diseases; Kidney Function Tests; Male; Method

1968
Gout and uveitis. Report of a case.
    The British journal of ophthalmology, 1968, Volume: 52, Issue:9

    Topics: Adult; Colchicine; Gout; Humans; Male; Probenecid; Steroids; Uric Acid; Uveitis

1968
The pathophysiology of hyperuricemia and gout.
    University of Michigan Medical Center journal, 1968

    Topics: Gout; Humans; Purines; Uric Acid

1968
[Subacute rheumatoid arthritis in old age. II. Diseases under diagnostic exclusions].
    Acta rheumatologica Scandinavica, 1968, Volume: 14, Issue:2

    Topics: Aged; Antistreptolysin; Arthritis, Infectious; Arthritis, Reactive; Arthritis, Rheumatoid; Auscultat

1968
Idiopathic hyperlipemia and gout.
    Acta rheumatologica Scandinavica, 1968, Volume: 14, Issue:2

    Topics: Cholesterol; Colorimetry; Diet Therapy; Dietary Carbohydrates; Dietary Fats; Fatty Acids, Nonesterif

1968
Juvenile hyperuricemia with neurological manifestations. ACRH-29.
    ACRH [reports]. U.S. Atomic Energy Commission, 1968

    Topics: Adolescent; Carbon Isotopes; Child; Gout; Humans; Male; Neurologic Manifestations; Uric Acid

1968
Psoriasis and factors affecting the level of uricaemia.
    Acta Universitatis Carolinae. Medica, 1968, Volume: 14, Issue:1

    Topics: Female; Follow-Up Studies; Gout; Humans; Male; Obesity; Psoriasis; Respiratory Tract Infections; Sex

1968
[Allopurinol: its clinical use].
    Giornale di clinica medica, 1968, Volume: 49, Issue:10

    Topics: Adult; Aged; Allopurinol; Child; Diuretics; Female; Gout; Humans; Kidney Diseases; Kidney Failure, C

1968
[Curve of uricemia].
    Revista espanola de reumatismo y enfermedades osteoarticulares, 1968, Volume: 12, Issue:8

    Topics: Acetylcholinesterase; Gout; Humans; Uric Acid

1968
[Allopurinol in the treatment of hyperuricemia and chronic gout].
    La Clinica terapeutica, 1968, Apr-30, Volume: 45, Issue:2

    Topics: Adult; Aged; Allopurinol; Arthritis; Female; Gout; Humans; Male; Middle Aged; Uric Acid; Xanthine Ox

1968
[Uric acid and its metabolism].
    La Presse medicale, 1968, Dec-14, Volume: 76, Issue:49

    Topics: Allopurinol; Female; Glomerular Filtration Rate; Glutamine; Gout; Humans; Kidney Tubules; Male; Puri

1968
[Gout and pseudogout].
    La Presse medicale, 1968, Dec-14, Volume: 76, Issue:49

    Topics: Bradykinin; Calcinosis; Calcium; Female; Gout; Humans; Joint Diseases; Lysosomes; Male; Methods; Pep

1968
[Modalities of purine excretion during enzyme treatment of gout and other hyperuricemic conditions with urate oxidase].
    La Presse medicale, 1968, Dec-14, Volume: 76, Issue:49

    Topics: Aged; Allantoin; Antigen-Antibody Reactions; Complement Fixation Tests; Female; Gout; Humans; Immuni

1968
[Treatment of gouty purine metabolism disorder with mercapto-pyrazolo-pyrimidine (thiopurinol)].
    La Presse medicale, 1968, Dec-14, Volume: 76, Issue:49

    Topics: Allopurinol; Calculi; Drug Tolerance; Female; Gout; Guanine Nucleotides; Humans; Male; Purine-Pyrimi

1968
[Uricemia and uric acid excretion in normal patients].
    Arquivos brasileiros de endocrinologia e metabologia, 1968, Volume: 17, Issue:1

    Topics: Adolescent; Adult; Creatine; Female; Gout; Humans; Male; Periodicity; Uric Acid

1968
[Preliminary note on the hypourecemic effect of benzofuran (benziodarone)].
    Revista espanola de reumatismo y enfermedades osteoarticulares, 1968, Volume: 12, Issue:6

    Topics: Benzofurans; Gout; Humans; Uric Acid

1968
[Study of pH, of titrable acidity, and urinary buffer system in oxalate lithiasis, in gout and urate lithiasis].
    Rein et foie, maladies de la nutrition; actualites, 1968, Volume: 11

    Topics: Gout; Humans; Hydrogen-Ion Concentration; Oxalates; Phosphorus; Urea; Uric Acid; Urinary Calculi

1968
[Variations of uricemia during fasting by the obese].
    Lille medical : journal de la Faculte de medecine et de pharmacie de l'Universite de Lille, 1968, Volume: 13, Issue:1

    Topics: Fasting; Gout; Humans; Male; Middle Aged; Obesity; Uric Acid

1968
[Gout (pathogenesis and therapy)].
    Il Policlinico. Sezione pratica, 1968, Feb-05, Volume: 75, Issue:6

    Topics: Allopurinol; Colchicine; Diet Therapy; Gout; Humans; Indomethacin; Phenylbutazone; Uric Acid; Uricos

1968
[Polycythemia vera and secondary gout].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1968, May-10, Volume: 57, Issue:5

    Topics: Gout; Humans; Kidney; Male; Middle Aged; Polycythemia Vera; Uric Acid

1968
[New findings in the pathology and therapy of gout].
    Fysiatricky a reumatologicky vestnik, 1968, Volume: 46, Issue:6

    Topics: Colchicine; Diet Therapy; Gout; Humans; Hydrogen-Ion Concentration; Physical Exertion; Purines; Uric

1968
[Formation of a gout nodule].
    Rinsho byori. The Japanese journal of clinical pathology, 1968, Volume: 16, Issue:8

    Topics: Crystallization; Gelatin; Gout; Proteins; Uric Acid

1968
[Gout in advanced age].
    Munchener medizinische Wochenschrift (1950), 1968, Mar-15, Volume: 110, Issue:11

    Topics: Age Factors; Aged; Allopurinol; Bone and Bones; Cardiovascular Diseases; Colchicine; Female; Gout; H

1968
Treatment of gout and urate calculi with allopurinol.
    Cleveland Clinic quarterly, 1968, Volume: 35, Issue:3

    Topics: Allopurinol; Colchicine; Follow-Up Studies; Gout; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged;

1968
[Experimental studies of fructose overloading in normal subjects and in patients with gout].
    Atti della Accademia dei fisiocritici in Siena. Sezione medico-fisica, 1968, Volume: 17, Issue:2

    Topics: Adult; Fructose; Gout; Humans; Liver; Male; Nucleoproteins; Proteins; Purines; Uric Acid; Xanthine O

1968
Bilateral ureteral obstruction after the administration of allopurinol to a patient with renal pelvic urate calculi.
    Southern medical journal, 1969, Volume: 62, Issue:3

    Topics: Allopurinol; Colchicine; Creatinine; Gout; Humans; Kidney Calculi; Male; Middle Aged; Phenylbutazone

1969
Liver xanthine oxidase in gouty patients.
    Arthritis and rheumatism, 1969, Volume: 12, Issue:1

    Topics: Adult; Aged; Biopsy; Female; Gout; Humans; Liver; Liver Function Tests; Male; Middle Aged; Uric Acid

1969
Pathogenesis of hyperuricemia in saturnine gout.
    The New England journal of medicine, 1969, 05-29, Volume: 280, Issue:22

    Topics: Adult; Alcoholic Beverages; Alcoholism; Carbon Isotopes; Creatinine; Diet; Food Contamination; Glyci

1969
Saturnine gout--a moonshine malady.
    The New England journal of medicine, 1969, May-29, Volume: 280, Issue:22

    Topics: Alcoholic Beverages; Alcoholism; Gout; Humans; Kidney Diseases; Lead Poisoning; Uric Acid

1969
Medical memorandum: a case of pseudogout accompanying gout.
    Gerontologia clinica, 1969, Volume: 11, Issue:2

    Topics: Aged; Calcium Metabolism Disorders; Female; Finger Joint; Gout; Hallux; Humans; Joint Diseases; Knee

1969
Glycine-C-14 incorporation into nucleic acid purine by leucocytes obtained from normal and gouty subjects.
    Annals of the rheumatic diseases, 1969, Volume: 28, Issue:3

    Topics: Adenine; Carbon Isotopes; Cyanides; Depression, Chemical; DNA; Female; Glycine; Gout; Guanine; Human

1969
Deposition of urate crystals in man.
    Annals of the rheumatic diseases, 1969, Volume: 28, Issue:3

    Topics: Cartilage; Crystallization; Gout; Humans; Polysaccharides; Uric Acid

1969
Current concepts of hyperuricemia and gout.
    California medicine, 1969, Volume: 110, Issue:3

    Topics: Chemical Phenomena; Chemistry; Gout; Humans; Uric Acid

1969
The use of allopurinol in controlling hyperuricemia.
    Journal of the American Podiatry Association, 1969, Volume: 59, Issue:3

    Topics: Adult; Aged; Allopurinol; Female; Gout; Humans; Male; Middle Aged; Uric Acid

1969
Uric acid renal lithiasis: management by allopurinol.
    The Journal of urology, 1969, Volume: 101, Issue:5

    Topics: Adult; Allopurinol; Gout; Humans; Kidney Calculi; Male; Middle Aged; Uric Acid

1969
A new disorder of purine metabolism with behavioral manifestations.
    The Journal of pediatrics, 1969, Volume: 74, Issue:1

    Topics: Adenine; Allopurinol; Autistic Disorder; Carbon Isotopes; Child Behavior Disorders; Child, Preschool

1969
[Treatment of acute gouty attack with local infiltration of Kenacort-A and the study of gout and hyperuricemia at the Tanabe National Hospital during 1967].
    Iryo, 1969, Volume: 23, Issue:1

    Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Female; Gout; Humans; Injections; Japan; Male; Mid

1969
Polymorphonuclear leukocyte motility in vitro. II. Stimulatory effect of monosodium urate crystals and urate in solution; partial inhibition by colchicine and indomethacin.
    Arthritis and rheumatism, 1969, Volume: 12, Issue:3

    Topics: Anti-Inflammatory Agents; Cell Movement; Colchicine; Gout; Humans; In Vitro Techniques; Indomethacin

1969
Polymorphonuclear leukocyte motility in vitro. 3. Possible release of a chemotactic substance after phagocytosis of urate crystals by polymorphonuclear leukocytes.
    Arthritis and rheumatism, 1969, Volume: 12, Issue:3

    Topics: Cell Movement; Chemotaxis; Gout; Humans; In Vitro Techniques; Methods; Neutrophils; Phagocytosis; Se

1969
Studies of uric acid pool size and turnover rate.
    Annals of the rheumatic diseases, 1969, Volume: 28, Issue:4

    Topics: Adolescent; Adult; Aged; Allopurinol; Carbon Isotopes; Female; Gout; Humans; Hypertension; Male; Mat

1969
Dietes mellitus and gout. Blood sugar and plasma insulin responses to oral glucose in normal weight, overweight, and gouty patients.
    Annals of the rheumatic diseases, 1969, Volume: 28, Issue:4

    Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Complications; Diabetes Mellitus; Dietary Carbohyd

1969
Gouty tenosynovitis and the carpal tunnel syndrome.
    The Medical journal of Australia, 1969, May-17, Volume: 1, Issue:20

    Topics: Carpal Tunnel Syndrome; Diagnosis, Differential; Gout; Humans; Male; Median Nerve; Middle Aged; Radi

1969
[Benziodarone (Amplivix) in the treatment of hyperuricemia].
    Duodecim; laaketieteellinen aikakauskirja, 1969, Volume: 85, Issue:7

    Topics: Benzofurans; Female; Gout; Humans; Male; Middle Aged; Phenylbutazone; Purine-Pyrimidine Metabolism,

1969
[Hyperuricemia in therapy with saluretics].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1969, Jul-01, Volume: 89, Issue:13

    Topics: Diuretics; Gout; Humans; Kidney Diseases; Uric Acid

1969
[Are there characteristic x-ray findings in gout?].
    Deutsche medizinische Wochenschrift (1946), 1969, Sep-19, Volume: 94, Issue:38

    Topics: Arthritis, Rheumatoid; Chronic Disease; Gout; Humans; Radiography; Uric Acid

1969
Elevation of plasma glutamate in gout. Its possible role in the pathogenesis of hyperuricemia.
    The New England journal of medicine, 1969, Oct-02, Volume: 281, Issue:14

    Topics: Amino Acids; Caseins; Fasting; Glutamates; Glutamine; Gout; Humans; Male; Middle Aged; Nitrogen; Pur

1969
Causes of hyperuricaemia.
    Proceedings of the Royal Society of Medicine, 1969, Volume: 62, Issue:8

    Topics: Diet; Female; Gout; Hematopoiesis; Humans; Intellectual Disability; Male; Metabolic Diseases; Purine

1969
Management of gout.
    British medical journal, 1969, Aug-23, Volume: 3, Issue:5668

    Topics: Acute Disease; Allopurinol; Chronic Disease; Colchicine; Gout; Humans; Indomethacin; Metabolic Disea

1969
[Clinical findings and therapy of gout].
    Zeitschrift fur arztliche Fortbildung, 1969, Jun-15, Volume: 63, Issue:12

    Topics: Adult; Age Factors; Aged; Diabetes Complications; Diet Therapy; Female; Gout; Humans; Hypertension;

1969
[Hyperuricemia in internal diseases].
    Fysiatricky a reumatologicky vestnik, 1969, Volume: 47, Issue:2

    Topics: Anemia; Cardiovascular Diseases; Gout; Hematologic Diseases; Humans; Hydrochlorothiazide; Kidney Dis

1969
[Is there in gout a more frequent incidence of an astragalus spur?].
    Fysiatricky a reumatologicky vestnik, 1969, Volume: 47, Issue:2

    Topics: Adolescent; Adult; Aged; Female; Foot; Gout; Humans; Male; Middle Aged; Radiography; Talus; Uric Aci

1969
Plasma uric acid concentrations among Edinburgh business executives.
    JAMA, 1969, May-19, Volume: 208, Issue:7

    Topics: Achievement; Adult; Alcohol Drinking; Diet; Dietary Proteins; Gout; Humans; Male; Middle Aged; Occup

1969
Uric acid and the psyche.
    JAMA, 1969, May-19, Volume: 208, Issue:7

    Topics: Achievement; Gout; Humans; Male; Occupations; Personality; Uric Acid

1969
[Changes in the serum concentration of uric acid under the effect of benzbromaronum].
    Munchener medizinische Wochenschrift (1950), 1969, Feb-28, Volume: 111, Issue:9

    Topics: Adult; Allopurinol; Benzofurans; Depression, Chemical; Female; Gout; Humans; Male; Middle Aged; Uric

1969
[Fracture healing in hyperuricemia].
    Praxis, 1969, Jun-24, Volume: 58, Issue:25

    Topics: Adolescent; Adult; Aged; Female; Fractures, Bone; Gout; Humans; Male; Middle Aged; Uric Acid; Wound

1969
Total fasting, hyperuricaemia and gout.
    Postgraduate medical journal, 1969, Volume: 45, Issue:522

    Topics: Fasting; Female; Gout; Humans; Male; Middle Aged; Obesity; Uric Acid

1969
[Blood uric acid].
    Bibliotheca haematologica, 1969, Volume: 32

    Topics: Age Factors; Female; Gout; Humans; Male; Uric Acid

1969
Social class gradients and serum uric acid in males and females.
    British medical journal, 1969, Oct-11, Volume: 4, Issue:5675

    Topics: Adult; Age Factors; Connecticut; England; Female; Gout; Humans; Male; Middle Aged; Sex Factors; Soci

1969
Grand rounds at William Beaumont General Hospital. Gout and hyperuricemia.
    Southwestern medicine, 1965, Volume: 46, Issue:10

    Topics: Diagnosis, Differential; Gout; Humans; Uric Acid

1965
Acute gouty arthritis provoked by cerebrovascular disease.
    Acta medica Scandinavica, 1965, Volume: 178, Issue:4

    Topics: Aged; Anticoagulants; Blood; Electroencephalography; Gout; Hemiplegia; Humans; Intracranial Arterios

1965
Juvenile gout with brain involvement.
    Archives of neurology, 1965, Volume: 13, Issue:6

    Topics: Blood; Brain; Cerebral Palsy; Child; Demyelinating Diseases; Gout; Humans; Intellectual Disability;

1965
[Hyperuricemia. Apropos of a study dealing with 130 cases of articular gout and 1370 cases of various diseases].
    La Revue lyonnaise de medecine, 1965, Nov-30, Volume: 14, Issue:18

    Topics: Female; Gout; Humans; Male; Uric Acid

1965
Significance of joint fluid uric acid levels in gout.
    Annals of the rheumatic diseases, 1965, Volume: 24, Issue:6

    Topics: Gout; Humans; Knee Joint; Synovial Fluid; Uric Acid

1965
Effect of atromid and its components on uric acid excretion and on gout.
    Annals of the rheumatic diseases, 1965, Volume: 24, Issue:6

    Topics: Adult; Androsterone; Butyrates; Female; Gout; Humans; Male; Uric Acid; Uricosuric Agents; Urine

1965
[New method for the determination of uric acid in the blood].
    "Laboratorio;" analisis clinicos, bacteriologia, inmunologia, parasitologia, hematologia, anatomia patologica, quimica clinica, 1965, Volume: 40, Issue:240

    Topics: Blood Chemical Analysis; Gout; Humans; Uric Acid

1965
Heredity of gout and hyperuricemia.
    Arthritis and rheumatism, 1965, Volume: 8, Issue:5

    Topics: Blood; Ethnology; Gout; Humans; Purine-Pyrimidine Metabolism, Inborn Errors; Uric Acid

1965
The overproduction of uric acid in primary gout.
    Arthritis and rheumatism, 1965, Volume: 8, Issue:5

    Topics: Carbon Isotopes; Glycine; Gout; Humans; Nitrogen; Radioisotopes; Uric Acid

1965
Renal excretion of uric acid in normal and gouty man.
    Arthritis and rheumatism, 1965, Volume: 8, Issue:5

    Topics: Gout; Humans; Kidney; Uric Acid; Urine

1965
Renal urate excretion in gout studied by feeding ribonucleic acid.
    Arthritis and rheumatism, 1965, Volume: 8, Issue:5

    Topics: Blood; Gout; Humans; Kidney; RNA; Uric Acid; Urine

1965
Role of the intestinal tract in the elimination of uric acid.
    Arthritis and rheumatism, 1965, Volume: 8, Issue:5

    Topics: Allantoin; Ammonia; Carbon Dioxide; Carbon Isotopes; Digestive System Physiological Phenomena; Feces

1965
Pathology of gout.
    Arthritis and rheumatism, 1965, Volume: 8, Issue:5

    Topics: Arteriosclerosis; Gout; Humans; Kidney; Uric Acid

1965
Activation of Hageman factor by sodium urate crystals.
    Arthritis and rheumatism, 1965, Volume: 8, Issue:5

    Topics: Factor XII; Gout; In Vitro Techniques; Inflammation; Kinins; Leukocytes; Uric Acid

1965
The acute attack of gouty arthritis.
    Arthritis and rheumatism, 1965, Volume: 8, Issue:5

    Topics: Animals; Crystallization; Dogs; Gout; Humans; Kinins; Uric Acid

1965
Hyperuricemia induced by alcohol.
    Arthritis and rheumatism, 1965, Volume: 8, Issue:5

    Topics: Alcoholic Intoxication; Blood; Ethanol; Gout; Humans; Lactates; Uric Acid; Urine

1965
Hyperuricemia induced by high fat diets and starvation.
    Arthritis and rheumatism, 1965, Volume: 8, Issue:5

    Topics: Arthritis, Rheumatoid; Blood; Dietary Fats; Fasting; Gout; Humans; Ketone Bodies; Osteoarthritis; Ur

1965
Correlations among hyperuricemia, hypercholesterolemia, coronary disease and hypertension.
    Arthritis and rheumatism, 1965, Volume: 8, Issue:5

    Topics: Blood; Coronary Disease; Epidemiologic Methods; Gout; Humans; Hypercholesterolemia; Hypertension; Ur

1965
Hyperuricemia associated with uremia.
    Arthritis and rheumatism, 1965, Volume: 8, Issue:5

    Topics: Apatites; Blood; Calcinosis; Gout; Humans; Hydroxyapatites; Kidneys, Artificial; Uremia; Uric Acid

1965
The possible association of hyperuricemia and/or gout with diabetes mellitus.
    Arthritis and rheumatism, 1965, Volume: 8, Issue:5

    Topics: Blood; Diabetes Complications; Gout; Humans; Statistics as Topic; Uric Acid

1965
The renal excretion of urate in chronic lead nephropathy.
    Australasian annals of medicine, 1965, Volume: 14, Issue:4

    Topics: Adult; Creatine; Female; Gout; Humans; In Vitro Techniques; Kidney Diseases; Kidney Function Tests;

1965
Hyperuricemia, acute gout, renal insufficiency and urate nephrolithiasis due to starvation.
    Arthritis and rheumatism, 1965, Volume: 8, Issue:5

    Topics: Blood; Colchicine; Diet, Reducing; Fasting; Gout; Humans; Kidney Calculi; Kidney Diseases; Obesity;

1965
[Hyperuricemia and gout in retinal vascular accidents. New etiological and therapeutic data].
    L'Annee therapeutique et clinique en ophtalmologie, 1963, Volume: 14

    Topics: Adult; Aged; Female; Gout; Humans; Male; Middle Aged; Retinal Hemorrhage; Retinal Vessels; Thromboph

1963
Suppression of metabolic accompaniments of phagocytosis by colchicine.
    Arthritis and rheumatism, 1965, Volume: 8, Issue:6

    Topics: Carbon Isotopes; Colchicine; Gout; Humans; In Vitro Techniques; Leukocytes; Phagocytosis; Uric Acid

1965
Inhibition of monosodium urate needle crystal growth.
    Arthritis and rheumatism, 1965, Volume: 8, Issue:6

    Topics: Coloring Agents; Crystallization; Gout; In Vitro Techniques; Ions; Methylene Blue; Sodium; Solubilit

1965
[Recent views on gout].
    Naika. Internal medicine, 1965, Volume: 16, Issue:2

    Topics: Gout; Humans; Uric Acid

1965
[Secondary gout in renal insufficiency].
    Klinische Wochenschrift, 1965, Nov-01, Volume: 43, Issue:21

    Topics: Adult; Blood; Glomerulonephritis; Gout; Humans; Kidney Diseases; Kidney Failure, Chronic; Kidney Fun

1965
Gout in orthopaedic practice: review of 232 cases.
    Clinical orthopaedics and related research, 1963, Volume: 28

    Topics: Acute Disease; Adolescent; Aged; Bone Diseases; Chlorothiazide; Colchicine; Diagnosis, Differential;

1963
[On a family of persons with severe gout].
    Revue du rhumatisme et des maladies osteo-articulaires, 1965, Volume: 32, Issue:11

    Topics: Blood; Female; Gout; Hip Dislocation, Congenital; Humans; Male; Middle Aged; Nephritis, Interstitial

1965
Significance of uric acid as a nitrogenous waste in vertebrate evolution.
    Arthritis and rheumatism, 1965, Volume: 8, Issue:5

    Topics: Animals; Biological Evolution; Gout; Humans; Physiology, Comparative; Purines; Uric Acid; Vertebrate

1965
Gout: clinical and underwriting aspects.
    Transactions of the Association of Life Insurance Medical Directors of America, 1965, Volume: 49

    Topics: Female; Gout; Humans; Insurance, Life; Male; United States; Uric Acid

1965
[The kidneys in gout. Study of their interaction].
    Praxis, 1965, Aug-05, Volume: 54, Issue:31

    Topics: Adult; Gout; Humans; Kidney Diseases; Male; Uric Acid

1965
[Surgical treatment of hands severely deformed by gout].
    Munchener medizinische Wochenschrift (1950), 1965, Oct-29, Volume: 107, Issue:44

    Topics: Aged; Blood Vessels; Colchicine; Gout; Hand; Hand Deformities, Acquired; Humans; Male; Preoperative

1965
[Experiences with potassium orotate in hyperuricemic subjects].
    Acta vitaminologica, 1965, Volume: 19, Issue:5

    Topics: Adult; Aged; Blood; Gout; Humans; Middle Aged; Orotic Acid; Potassium; Uric Acid; Urine

1965
Selected aspects of gout and gouty arthritis.
    Maryland state medical journal, 1966, Volume: 15, Issue:2

    Topics: Adult; Aged; Gout; Humans; Middle Aged; Uric Acid; Uricosuric Agents

1966
Investigation of renal excretion of phosphate and urate.
    Clinical science, 1966, Volume: 31, Issue:1

    Topics: Adult; Gout; Humans; Middle Aged; Phosphates; Primary Myelofibrosis; Uric Acid; Urinary Calculi

1966
[Blood uric acid levels in gout patients].
    Rein et foie, maladies de la nutrition; actualites, 1966, Volume: 8

    Topics: Gout; Humans; Male; Uric Acid

1966
Serum uric acid in relation to body weight.
    Annals of the rheumatic diseases, 1966, Volume: 25, Issue:5

    Topics: Adolescent; Adult; Aged; Body Weight; Female; Gout; Humans; Male; Middle Aged; Obesity; Uric Acid

1966
[Uric acid gout. Pathogenetic considerations].
    Nordisk medicin, 1966, Sep-01, Volume: 76, Issue:35

    Topics: Gout; Humans; Hydrogen-Ion Concentration; Immunoelectrophoresis; Lipoproteins; Serum Albumin; Serum

1966
Allopurinol in the management of gout.
    Annals of physical medicine, 1966, Volume: 8, Issue:7

    Topics: Adult; Enzyme Therapy; Female; Gout; Humans; Male; Middle Aged; Uric Acid; Xanthine Oxidase

1966
Effect of anti-inflammatory agents on acute experimental synovitis in dogs.
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1966, Volume: 122, Issue:3

    Topics: Animals; Anti-Inflammatory Agents; Aspirin; Chlorpromazine; Codeine; Dogs; Gout; Hydrocortisone; Ind

1966
The treatment of gout and disorders of uric acid metabolism with allopurinol.
    Canadian Medical Association journal, 1966, Nov-26, Volume: 95, Issue:22

    Topics: Aged; Colchicine; Diet; Enzyme Therapy; Female; Gout; Humans; Male; Middle Aged; Sulfinpyrazone; Uri

1966
Use of allopurinol in preventing hyperuricemia in leukemia and lymphoma.
    Cancer, 1966, Volume: 19, Issue:11

    Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Enzyme Therapy; Female; Gout; Humans; Kidney Disea

1966
[On the combination of gouty arthritis and adenoma of the parathyroid gland].
    Schweizerische medizinische Wochenschrift, 1966, Oct-01, Volume: 96, Issue:39

    Topics: Adenoma; Angioedema; Diabetes Mellitus; Gout; Humans; Hyperparathyroidism; Male; Middle Aged; Parath

1966
Allopurinol in the treatment of hyperuricemia and gout.
    Northwest medicine, 1966, Volume: 65, Issue:5

    Topics: Adult; Blood; Child; Child, Preschool; Enzyme Therapy; Gout; Humans; Male; Middle Aged; Uric Acid; X

1966
Hyperuricaemia and gout in the Mariana Islands.
    Annals of the rheumatic diseases, 1966, Volume: 25, Issue:2

    Topics: Blood; Ethnology; Gout; Humans; In Vitro Techniques; Pacific Islands; Uric Acid

1966
[Action of ethanol in gout and on the metabolism of uric acid].
    La Presse medicale, 1966, Jun-18, Volume: 74, Issue:30

    Topics: Ethanol; Female; Gout; Humans; In Vitro Techniques; Middle Aged; Uric Acid

1966
Uric acid excretion in gouty and nongouty subjects.
    Mayo Clinic proceedings, 1966, Volume: 41, Issue:5

    Topics: Gout; Humans; Kidney Function Tests; Uric Acid; Urine

1966
Acute gout apparently precipitated by furosemide.
    British medical journal, 1966, Apr-23, Volume: 1, Issue:5494

    Topics: Blood; Diuretics; Furosemide; Gout; Humans; Male; Middle Aged; Pulmonary Edema; Uric Acid; Urine

1966
Uric acid production with particular reference to the role of xanthine oxidase and its inhibition.
    Proceedings of the Royal Society of Medicine, 1966, Volume: 59, Issue:4

    Topics: Enzymes; Gout; Humans; Pyrimidines; Uric Acid; Xanthine Oxidase

1966
Urates and kinin formation in synovial fluid.
    Proceedings of the Royal Society of Medicine, 1966, Volume: 59, Issue:4

    Topics: Gout; Humans; Kinins; Phagocytosis; Proteins; Synovial Fluid; Uric Acid

1966
Urate excretion.
    Proceedings of the Royal Society of Medicine, 1966, Volume: 59, Issue:4

    Topics: Blood; Gout; Humans; Kidney; Kidney Tubules; Uric Acid; Urine

1966
Factors inhibiting the excretion of uric acid.
    Proceedings of the Royal Society of Medicine, 1966, Volume: 59, Issue:4

    Topics: Blood; Gout; Humans; Uric Acid; Urine

1966
Population studies of serum uric acid.
    Proceedings of the Royal Society of Medicine, 1966, Volume: 59, Issue:4

    Topics: Black or African American; Blood; Ethnology; Gout; Humans; Obesity; Statistics as Topic; Uric Acid;

1966
Lipid metabolism in gout.
    Proceedings of the Royal Society of Medicine, 1966, Volume: 59, Issue:4

    Topics: Arteriosclerosis; Blood; Cholesterol; Gout; Humans; Lipid Metabolism; Lipids; Triglycerides; Uric Ac

1966
The pharmaceutical treatment of gout.
    Annals of physical medicine, 1966, Volume: 8, Issue:6

    Topics: Enzyme Therapy; Gout; Humans; Indomethacin; Phenylbutazone; Sulfinpyrazone; Uric Acid; Xanthine Oxid

1966
Effects of allopurinol, a xanthine oxidase inhibitor, and sulfinpyrazone upon the urinary and serum urate concentrations in eight patients with tophaceous gout.
    Arthritis and rheumatism, 1966, Volume: 9, Issue:3

    Topics: Aged; Blood; Drug Synergism; Enzyme Therapy; Gout; Humans; Middle Aged; Pyrimidines; Sulfinpyrazone;

1966
[Trial treatments of hyperuricemia in patients with chronic renal failure. I. Action of benziodarone].
    Revue francaise d'etudes cliniques et biologiques, 1966, Volume: 11, Issue:4

    Topics: Blood; Furans; Gout; Humans; Kidney Diseases; Kidney Failure, Chronic; Uremia; Uric Acid; Vasodilato

1966
The effects of allopurinol on serum and urinary uric acid.
    Archives of internal medicine, 1966, Volume: 118, Issue:3

    Topics: Adult; Aged; Blood; Enzymes; Female; Gout; Humans; Male; Probenecid; Uric Acid; Urinary Calculi; Uri

1966
Treatment of gout by reduction of uric acid production.
    Annals of the rheumatic diseases, 1966, Volume: 25, Issue:4

    Topics: Catalase; Drug Synergism; Enzyme Therapy; Gout; Humans; Kidney Calculi; Sulfinpyrazone; Uracil; Uric

1966
Serum urate concentrations among university professors; relation to drive, achievement, and leadership.
    JAMA, 1966, Feb-07, Volume: 195, Issue:6

    Topics: Achievement; Blood; Drive; Gout; Humans; Leadership; Motivation; Occupational Diseases; Psychology;

1966
Diabetes mellitus in patients with gout.
    JAMA, 1966, Jul-11, Volume: 197, Issue:2

    Topics: Adult; Aged; Animals; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Experimental; Female; Glu

1966
Coexistent rheumatoid arthritis and chronic tophaceous gout.
    JAMA, 1966, Sep-19, Volume: 197, Issue:12

    Topics: Arthritis, Rheumatoid; Colchicine; Foot; Gout; Hand Deformities, Acquired; Histocytochemistry; Human

1966
Allopurinol (xanthine oxidase inhibitor) in the treatment of resistant gout.
    JAMA, 1966, Nov-14, Volume: 198, Issue:7

    Topics: Adult; Aged; Colchicine; Enzyme Therapy; Enzymes; Female; Gout; Humans; Male; Middle Aged; Probeneci

1966
Allopurinol in primary gout with and after the administration of uricosuric agents.
    Annals of the rheumatic diseases, 1966, Volume: 25, Issue:6 Suppl

    Topics: Allopurinol; Drug Synergism; Enzyme Therapy; Female; Gout; Humans; Male; Sulfinpyrazone; Uric Acid;

1966
Effects of allopurinol on gouty and non-gouty uric acid nephropathy.
    Annals of the rheumatic diseases, 1966, Volume: 25, Issue:6 Suppl

    Topics: Allopurinol; Blood Urea Nitrogen; Enzyme Therapy; Female; Gout; Humans; Kidney Calculi; Kidney Disea

1966
Allopurinol in thiazide-induced hyperuricaemia.
    Annals of the rheumatic diseases, 1966, Volume: 25, Issue:6 Suppl

    Topics: Allopurinol; Clopamide; Enzyme Therapy; Gout; Hematologic Diseases; Humans; Hypertension; Kidney Fai

1966
Allopurinol in patients with impaired renal function.
    Annals of the rheumatic diseases, 1966, Volume: 25, Issue:6 Suppl

    Topics: Adolescent; Adult; Aged; Allopurinol; Child; Creatine; Enzyme Therapy; Female; Gout; Humans; Hydroge

1966
Allopurinol therapy of gout with renal complications.
    Annals of the rheumatic diseases, 1966, Volume: 25, Issue:6 Suppl

    Topics: Adult; Allopurinol; Calcium; Creatine; Enzyme Therapy; Gout; Humans; Kidney Failure, Chronic; Male;

1966
Allopurinol in the prophylaxis of uric acid stones.
    Annals of the rheumatic diseases, 1966, Volume: 25, Issue:6 Suppl

    Topics: Allopurinol; Enzyme Therapy; Female; Gout; Humans; Hydrogen-Ion Concentration; Kidney Calculi; Male;

1966
Lysosomes and gout.
    Nature, 1966, May-28, Volume: 210, Issue:5039

    Topics: Cell Membrane; Colchicine; Cytoplasmic Granules; Gout; Hydrolases; In Vitro Techniques; Leukocytes;

1966
The effects of estradiol-17 beta and/or progesterone on nitrogen balance values in studies on the castrated rooster.
    General and comparative endocrinology, 1966, Volume: 7, Issue:3

    Topics: Animals; Animals, Newborn; Blood Glucose; Blood Urea Nitrogen; Body Weight; Castration; Eating; Estr

1966
Gout and gouty arthritis. Current concepts and management.
    California medicine, 1966, Volume: 105, Issue:4

    Topics: Arthritis; Gout; Humans; Uric Acid

1966
[Clinical aspects of chronic gout].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1966, Sep-15, Volume: 21, Issue:18

    Topics: Adult; Aged; Allopurinol; Anemia; Arthritis; Bicarbonates; Blood Sedimentation; Chronic Disease; Fem

1966
[The kidney in gout].
    Beitrage zur pathologischen Anatomie und zur allgemeinen Pathologie, 1966, Volume: 133, Issue:4

    Topics: Aged; Arteriosclerosis; Gout; Humans; Kidney; Kidney Glomerulus; Male; Middle Aged; Uric Acid

1966
[Uricemia in the senile age].
    Giornale di gerontologia. Supplemento, 1966, Volume: 35

    Topics: Aged; Aging; Female; Gout; Humans; Male; Uric Acid

1966
[Contributions on the formation and dissolution of urinary calculi].
    Der Urologe, 1966, Volume: 5, Issue:4

    Topics: Carbohydrates; Carbonates; Citrates; Female; Gout; Humans; Male; Middle Aged; Potassium; Sodium; Sol

1966
[A rare form of podagra and its surgical treatment].
    Klinicheskaia meditsina, 1966, Volume: 44, Issue:2

    Topics: Crystallization; Foot; Gout; Humans; Male; Middle Aged; Rheumatic Nodule; Uric Acid

1966
[Our experience in the treatment of hyperuricemia with a xanthine oxidase inhibitor (HPP), Allopurinol].
    Revista espanola de reumatismo y enfermedades osteoarticulares, 1966, Volume: 11, Issue:8

    Topics: Allopurinol; Gout; Humans; Uric Acid; Xanthine Oxidase

1966